cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	16.01	7.38e-32	1.14e-24	1.05	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	15.98	8.29e-32	1.14e-24	1.05	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	15.98	8.29e-32	1.14e-24	1.05	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	15.53	8.76e-31	5.52e-24	1.1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	15.53	9.07e-31	5.52e-24	1.1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	15.53	9.07e-31	5.52e-24	1.1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	14.41	3.51e-28	4.7e-22	1	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	14.13	1.63e-27	1.9e-21	0.94	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	14.13	1.63e-27	1.9e-21	0.94	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	14.12	1.63e-27	1.9e-21	0.94	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	14.01	3.05e-27	2.66e-21	1	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	13.78	1.03e-26	4.87e-21	1.02	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	13.75	1.24e-26	5.56e-21	1.03	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	13.75	1.24e-26	5.56e-21	1.03	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	13.65	2.16e-26	9.05e-21	1.02	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	13.65	2.16e-26	9.05e-21	1.02	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	13.64	2.3e-26	9.55e-21	1.01	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	13.6	2.9e-26	1.17e-20	1.03	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	13.59	3.05e-26	1.21e-20	1.03	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	13.42	7.43e-26	2.79e-20	1.03	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	13.35	1.1e-25	4.08e-20	1.04	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	13.33	1.23e-25	4.5e-20	1.07	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	13.3	1.49e-25	5.34e-20	1.01	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	13.3	1.49e-25	5.34e-20	1.01	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	13.21	2.39e-25	8.18e-20	1.02	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	13.21	2.39e-25	8.18e-20	1.02	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	13.21	2.39e-25	8.18e-20	1.02	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
ESCA	cis	rs12439619	0.768	rs28694364	ENSG00000278603.1	RP13-608F4.5	13.15	3.28e-25	1.08e-19	1.22	0.76	Intelligence (multi-trait analysis);	chr15:82208119	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.81	rs28876157	ENSG00000278603.1	RP13-608F4.5	13.15	3.28e-25	1.08e-19	1.22	0.76	Intelligence (multi-trait analysis);	chr15:82216708	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	13.15	3.33e-25	1.08e-19	1.08	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	13.15	3.33e-25	1.08e-19	1.08	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	13.14	3.57e-25	1.13e-19	1.01	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	13.13	3.62e-25	1.14e-19	0.99	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	13.07	5.04e-25	1.53e-19	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	13.07	5.04e-25	1.53e-19	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	13.07	5.07e-25	1.53e-19	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	12.98	8.65e-25	2.5e-19	1.07	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
ESCA	cis	rs12439619	0.846	rs62012003	ENSG00000278603.1	RP13-608F4.5	12.93	1.09e-24	3.11e-19	1.2	0.76	Intelligence (multi-trait analysis);	chr15:82183236	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.846	rs62012004	ENSG00000278603.1	RP13-608F4.5	12.93	1.09e-24	3.11e-19	1.2	0.76	Intelligence (multi-trait analysis);	chr15:82183924	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	12.92	1.21e-24	3.44e-19	0.9	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	12.87	1.55e-24	4.27e-19	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	12.87	1.55e-24	4.27e-19	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	12.8	2.35e-24	6.37e-19	1.07	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	12.69	4.2e-24	1.1e-18	1.07	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	12.69	4.2e-24	1.1e-18	1.07	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	12.69	4.2e-24	1.1e-18	1.07	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-12.64	5.59e-24	1.42e-18	-1.01	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	12.64	5.67e-24	1.43e-18	1.03	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	12.63	5.76e-24	1.45e-18	1.06	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	12.61	6.44e-24	1.57e-18	0.89	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-12.46	1.51e-23	3.57e-18	-0.97	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	12.4	2.07e-23	4.86e-18	0.92	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	12.28	4.03e-23	9.01e-18	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	12.26	4.45e-23	9.57e-18	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	12.22	5.74e-23	1.2e-17	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	12.22	5.74e-23	1.2e-17	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	12.19	6.71e-23	1.37e-17	0.91	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	12.19	6.71e-23	1.37e-17	0.91	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
ESCA	cis	rs12439619	0.739	rs62012046	ENSG00000278603.1	RP13-608F4.5	12.19	6.83e-23	1.38e-17	1.18	0.74	Intelligence (multi-trait analysis);	chr15:82236824	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.774	rs62012047	ENSG00000278603.1	RP13-608F4.5	12.19	6.83e-23	1.38e-17	1.18	0.74	Intelligence (multi-trait analysis);	chr15:82236852	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.846	rs28470877	ENSG00000278603.1	RP13-608F4.5	12.19	6.83e-23	1.38e-17	1.18	0.74	Intelligence (multi-trait analysis);	chr15:82245797	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.846	rs62012056	ENSG00000278603.1	RP13-608F4.5	12.19	6.83e-23	1.38e-17	1.18	0.74	Intelligence (multi-trait analysis);	chr15:82247278	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	12.17	7.33e-23	1.47e-17	0.94	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-12.17	7.62e-23	1.52e-17	-1.06	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	12.13	9.12e-23	1.81e-17	0.91	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
ESCA	cis	rs12439619	0.846	rs62013464	ENSG00000278603.1	RP13-608F4.5	12.09	1.15e-22	2.26e-17	1.22	0.74	Intelligence (multi-trait analysis);	chr15:82288250	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.846	rs7496227	ENSG00000278603.1	RP13-608F4.5	12.09	1.2e-22	2.35e-17	1.22	0.74	Intelligence (multi-trait analysis);	chr15:82275241	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	12.07	1.33e-22	2.58e-17	0.91	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	12.07	1.35e-22	2.59e-17	0.93	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	11.93	2.84e-22	5.37e-17	0.96	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-11.92	3.07e-22	5.79e-17	-0.88	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	11.89	3.59e-22	6.69e-17	0.89	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
ESCA	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	11.87	4.06e-22	7.49e-17	0.9	0.73	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
ESCA	cis	rs12439619	0.81	rs62012049	ENSG00000278603.1	RP13-608F4.5	11.83	5.07e-22	9.26e-17	1.16	0.73	Intelligence (multi-trait analysis);	chr15:82237722	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-11.8	5.8e-22	1.06e-16	-1.01	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	11.79	6.11e-22	1.11e-16	0.91	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-11.7	1.02e-21	1.82e-16	-0.99	-0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	11.69	1.09e-21	1.93e-16	0.9	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	11.69	1.11e-21	1.96e-16	0.95	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	11.66	1.26e-21	2.21e-16	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-11.61	1.67e-21	2.91e-16	-1.05	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
ESCA	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	11.58	2.06e-21	3.56e-16	0.89	0.72	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	11.57	2.09e-21	3.6e-16	0.88	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
ESCA	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	11.55	2.4e-21	4.09e-16	0.89	0.72	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	11.51	3e-21	5.05e-16	0.97	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
ESCA	cis	rs12439619	0.846	rs62010071	ENSG00000278603.1	RP13-608F4.5	11.48	3.53e-21	5.94e-16	1.2	0.72	Intelligence (multi-trait analysis);	chr15:82289442	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs825754	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138796200	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.722	rs825751	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138798180	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825748	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800378	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825746	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800930	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825762	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138801981	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825761	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138802318	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.62	rs3789151	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138809771	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.722	rs4835649	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810534	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.587	rs6596450	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138810831	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs12517514	ENSG00000253404.1	AC034243.1	-11.42	4.79e-21	7.42e-16	-1.06	-0.72	Age-related hearing impairment (SNP x SNP interaction);	chr5:138814430	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	11.41	5.28e-21	8.09e-16	0.96	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
ESCA	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	11.4	5.52e-21	8.42e-16	1.14	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	11.38	6.08e-21	9.26e-16	0.89	0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
ESCA	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	11.37	6.6e-21	1e-15	1.16	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
ESCA	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	11.33	7.96e-21	1.2e-15	0.88	0.71	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-11.32	8.46e-21	1.27e-15	-0.9	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
ESCA	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	11.31	9.09e-21	1.36e-15	0.87	0.71	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	11.29	1.02e-20	1.52e-15	0.93	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
ESCA	cis	rs12439619	0.846	rs28697264	ENSG00000278603.1	RP13-608F4.5	11.26	1.18e-20	1.74e-15	1.19	0.71	Intelligence (multi-trait analysis);	chr15:82265559	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs825749	ENSG00000253404.1	AC034243.1	-11.21	1.55e-20	2.29e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800232	chr5:138744434~138753309:-
ESCA	cis	rs12439619	0.846	rs62011975	ENSG00000278603.1	RP13-608F4.5	11.21	1.61e-20	2.36e-15	1.18	0.71	Intelligence (multi-trait analysis);	chr15:82159213	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-11.19	1.76e-20	2.57e-15	-0.91	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
ESCA	cis	rs2882667	0.654	rs160406	ENSG00000253404.1	AC034243.1	-11.18	1.87e-20	2.72e-15	-1.02	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748032	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	11.17	1.99e-20	2.86e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	11.17	1.99e-20	2.86e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	11.17	1.99e-20	2.86e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	11.17	1.99e-20	2.86e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
ESCA	cis	rs12439619	0.774	rs2867649	ENSG00000278603.1	RP13-608F4.5	11.14	2.28e-20	3.24e-15	1.18	0.71	Intelligence (multi-trait analysis);	chr15:82262331	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.693	rs28689861	ENSG00000278603.1	RP13-608F4.5	11.13	2.49e-20	3.49e-15	1.05	0.71	Intelligence (multi-trait analysis);	chr15:82206369	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs700623	ENSG00000253404.1	AC034243.1	-11.13	2.54e-20	3.52e-15	-1.02	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762993	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.722	rs2011462	ENSG00000253404.1	AC034243.1	-11.13	2.54e-20	3.52e-15	-1.02	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827083	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	11.12	2.65e-20	3.65e-15	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	11.12	2.65e-20	3.65e-15	0.87	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
ESCA	cis	rs2882667	0.69	rs7714455	ENSG00000253404.1	AC034243.1	-11.1	2.99e-20	4.11e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818281	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	11.09	3.09e-20	4.24e-15	1.15	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
ESCA	cis	rs2882667	0.69	rs1828187	ENSG00000253404.1	AC034243.1	11.07	3.46e-20	4.69e-15	1.02	0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836531	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-11.07	3.47e-20	4.69e-15	-0.83	-0.71	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.654	rs1095374	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759517	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700620	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762247	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.659	rs700621	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762741	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700624	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763332	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700625	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138763908	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs2940595	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138765348	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.587	rs2174972	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138766229	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs851278	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767577	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs2693963	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138770637	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1567313	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138775013	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.589	rs825770	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779530	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825769	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138779666	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700627	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138783711	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825758	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138791288	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6873425	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819556	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs884470	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820236	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6877187	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138823655	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6860780	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138824367	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs3804199	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138826440	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs4835705	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138827887	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6884198	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138828618	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs4835706	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138829037	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6421921	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831581	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1039789	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835734	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1039788	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138835812	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1828188	ENSG00000253404.1	AC034243.1	-11.05	3.78e-20	4.69e-15	-1.04	-0.71	Age-related hearing impairment (SNP x SNP interaction);	chr5:138836307	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	11.05	3.96e-20	4.9e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
ESCA	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-11.04	4.13e-20	5.1e-15	-0.83	-0.71	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	11.03	4.22e-20	5.18e-15	1.19	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	11.03	4.22e-20	5.18e-15	1.19	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	11.03	4.4e-20	5.38e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	11.03	4.4e-20	5.38e-15	1.14	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	11.03	4.44e-20	5.42e-15	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
ESCA	cis	rs2882667	0.69	rs700629	ENSG00000253404.1	AC034243.1	-11.02	4.68e-20	5.7e-15	-1.01	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138788305	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	11.01	4.8e-20	5.82e-15	0.92	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
ESCA	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	11	5.01e-20	6.06e-15	1.17	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-11	5.15e-20	6.22e-15	-0.86	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
ESCA	cis	rs2882667	0.621	rs55901834	ENSG00000253404.1	AC034243.1	-10.99	5.46e-20	6.57e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844094	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	10.99	5.51e-20	6.6e-15	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
ESCA	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	10.99	5.57e-20	6.66e-15	1.16	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.591	rs56322405	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138837693	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs4835707	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138838831	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6887841	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840221	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs12656942	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138840769	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.686	rs62381196	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841000	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.72	rs56044552	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841265	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs7710288	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844049	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs4835708	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844204	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1976568	ENSG00000253404.1	AC034243.1	-10.98	5.84e-20	6.83e-15	-1.03	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138844627	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	10.97	5.92e-20	6.9e-15	1.14	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
ESCA	cis	rs12439619	0.693	rs17269819	ENSG00000278603.1	RP13-608F4.5	10.95	6.9e-20	7.99e-15	1.04	0.7	Intelligence (multi-trait analysis);	chr15:82174660	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.693	rs8034801	ENSG00000278603.1	RP13-608F4.5	10.95	6.9e-20	7.99e-15	1.04	0.7	Intelligence (multi-trait analysis);	chr15:82183996	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	10.9	8.91e-20	1.02e-14	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	10.9	8.91e-20	1.02e-14	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	10.9	8.91e-20	1.02e-14	0.88	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
ESCA	cis	rs2882667	0.654	rs884469	ENSG00000253404.1	AC034243.1	-10.89	9.22e-20	1.06e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138820270	chr5:138744434~138753309:-
ESCA	cis	rs12439619	0.705	rs4778665	ENSG00000278603.1	RP13-608F4.5	10.89	9.24e-20	1.06e-14	1.19	0.7	Intelligence (multi-trait analysis);	chr15:82144163	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs160405	ENSG00000253404.1	AC034243.1	10.88	9.8e-20	1.12e-14	1.02	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748387	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	10.86	1.12e-19	1.27e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	10.86	1.12e-19	1.27e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	10.86	1.12e-19	1.27e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	10.86	1.12e-19	1.27e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	10.85	1.2e-19	1.34e-14	1.16	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	10.84	1.27e-19	1.42e-14	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-10.83	1.3e-19	1.45e-14	-0.9	-0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
ESCA	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-10.83	1.3e-19	1.45e-14	-0.81	-0.7	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs6880786	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138845874	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs9327826	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846318	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.587	rs1848506	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846768	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1848505	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846841	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs1972072	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849604	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs6863054	ENSG00000253404.1	AC034243.1	-10.82	1.43e-19	1.57e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853166	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	10.8	1.54e-19	1.68e-14	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	10.8	1.54e-19	1.68e-14	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	10.8	1.54e-19	1.68e-14	1.13	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	10.8	1.55e-19	1.68e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	10.8	1.55e-19	1.68e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.69	rs274119	ENSG00000253404.1	AC034243.1	10.79	1.65e-19	1.78e-14	1	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138728530	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs274118	ENSG00000253404.1	AC034243.1	10.79	1.65e-19	1.78e-14	1	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729198	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs274117	ENSG00000253404.1	AC034243.1	10.79	1.65e-19	1.78e-14	1	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138729359	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	10.79	1.67e-19	1.79e-14	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	10.79	1.67e-19	1.79e-14	1.2	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.654	rs700626	ENSG00000253404.1	AC034243.1	-10.78	1.78e-19	1.91e-14	-1.01	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138782249	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700616	ENSG00000253404.1	AC034243.1	-10.76	1.96e-19	2.08e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752184	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs700617	ENSG00000253404.1	AC034243.1	-10.76	1.96e-19	2.08e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752290	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs700618	ENSG00000253404.1	AC034243.1	-10.76	1.96e-19	2.08e-14	-1.02	-0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138752429	chr5:138744434~138753309:-
ESCA	cis	rs12439619	0.846	rs62012059	ENSG00000278603.1	RP13-608F4.5	10.75	2.07e-19	2.19e-14	1.16	0.7	Intelligence (multi-trait analysis);	chr15:82251669	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs288033	ENSG00000253404.1	AC034243.1	10.73	2.29e-19	2.4e-14	0.98	0.7	Age-related hearing impairment (SNP x SNP interaction);	chr5:138878405	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	10.72	2.41e-19	2.52e-14	1.15	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	10.71	2.54e-19	2.65e-14	0.94	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
ESCA	cis	rs2882667	0.69	rs6596456	ENSG00000253404.1	AC034243.1	-10.7	2.81e-19	2.92e-14	-1.01	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831808	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	10.68	2.99e-19	3.1e-14	0.83	0.69	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	10.68	3.06e-19	3.16e-14	1.14	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	10.68	3.06e-19	3.16e-14	1.14	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	10.68	3.06e-19	3.16e-14	1.14	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
ESCA	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-10.68	3.09e-19	3.17e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-10.68	3.09e-19	3.17e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.659	rs311595	ENSG00000253404.1	AC034243.1	10.66	3.42e-19	3.5e-14	1.01	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736183	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	10.63	4e-19	4.06e-14	0.83	0.69	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	10.61	4.52e-19	4.52e-14	0.83	0.69	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	10.61	4.52e-19	4.52e-14	0.83	0.69	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	10.61	4.52e-19	4.52e-14	0.83	0.69	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs288016	ENSG00000253404.1	AC034243.1	-10.6	4.77e-19	4.77e-14	-1.03	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859299	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	10.59	4.94e-19	4.92e-14	0.85	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
ESCA	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-10.58	5.46e-19	5.37e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-10.58	5.46e-19	5.37e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-10.58	5.46e-19	5.37e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-10.58	5.46e-19	5.37e-14	-0.86	-0.69	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-10.57	5.62e-19	5.51e-14	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-10.56	6.11e-19	5.93e-14	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	10.56	6.11e-19	5.93e-14	0.82	0.69	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	10.56	6.11e-19	5.93e-14	0.82	0.69	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-10.54	6.6e-19	6.38e-14	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-10.54	6.87e-19	6.59e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-10.54	6.87e-19	6.59e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-10.54	6.88e-19	6.59e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs311602	ENSG00000253404.1	AC034243.1	10.51	8.1e-19	7.66e-14	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717370	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs930063	ENSG00000253404.1	AC034243.1	10.51	8.1e-19	7.66e-14	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717929	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs930062	ENSG00000253404.1	AC034243.1	10.51	8.1e-19	7.66e-14	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717934	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.658	rs172664	ENSG00000253404.1	AC034243.1	10.51	8.1e-19	7.66e-14	0.98	0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720617	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-10.5	8.6e-19	8.11e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
ESCA	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-10.49	8.76e-19	8.25e-14	-1.09	-0.69	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
ESCA	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-10.48	9.28e-19	8.64e-14	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	10.48	9.46e-19	8.79e-14	0.81	0.69	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs10038162	ENSG00000253404.1	AC034243.1	-10.46	1.08e-18	9.92e-14	-1.02	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901066	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-10.45	1.09e-18	1e-13	-0.82	-0.69	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000250470.1	AP000351.3	-10.45	1.11e-18	1.02e-13	-0.87	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23976904~23977585:-
ESCA	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-10.45	1.12e-18	1.02e-13	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-10.45	1.12e-18	1.02e-13	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-10.45	1.12e-18	1.02e-13	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	10.45	1.12e-18	1.02e-13	0.81	0.69	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	10.43	1.22e-18	1.1e-13	1.16	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
ESCA	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-10.43	1.26e-18	1.12e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs10043478	ENSG00000253404.1	AC034243.1	10.38	1.61e-18	1.42e-13	0.96	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138853022	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-10.38	1.64e-18	1.44e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000250470.1	AP000351.3	10.38	1.66e-18	1.45e-13	0.88	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	10.36	1.8e-18	1.57e-13	0.82	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	10.35	1.88e-18	1.64e-13	0.91	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
ESCA	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-10.34	2.01e-18	1.73e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-10.34	2.01e-18	1.73e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
ESCA	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	10.34	2.05e-18	1.75e-13	0.98	0.68	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	10.34	2.05e-18	1.75e-13	0.98	0.68	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
ESCA	cis	rs2882667	0.69	rs160402	ENSG00000253404.1	AC034243.1	10.34	2.08e-18	1.75e-13	0.98	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138723599	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs160398	ENSG00000253404.1	AC034243.1	10.34	2.08e-18	1.75e-13	0.98	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727750	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.658	rs311592	ENSG00000253404.1	AC034243.1	10.34	2.08e-18	1.75e-13	0.98	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138734506	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-10.31	2.35e-18	1.96e-13	-1.12	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.69	rs825669	ENSG00000253404.1	AC034243.1	-10.31	2.46e-18	2.05e-13	-0.94	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138731258	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	10.29	2.69e-18	2.24e-13	1.17	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	10.28	2.89e-18	2.39e-13	1.17	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
ESCA	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	10.27	2.98e-18	2.45e-13	0.83	0.68	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	10.27	2.98e-18	2.45e-13	0.83	0.68	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs160399	ENSG00000253404.1	AC034243.1	10.27	3e-18	2.46e-13	0.96	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727552	chr5:138744434~138753309:-
ESCA	cis	rs17507216	0.958	rs72751643	ENSG00000278603.1	RP13-608F4.5	10.26	3.11e-18	2.54e-13	1.1	0.68	Excessive daytime sleepiness;	chr15:82559444	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs311596	ENSG00000253404.1	AC034243.1	-10.26	3.11e-18	2.54e-13	-0.99	-0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138736393	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-10.26	3.16e-18	2.57e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-10.25	3.41e-18	2.77e-13	-1.09	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
ESCA	cis	rs3734266	0.639	rs7761391	ENSG00000186328.4	RP11-140K17.2	-10.25	3.43e-18	2.78e-13	-1.18	-0.68	Systemic lupus erythematosus;	chr6:34836427	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.69	rs311599	ENSG00000253404.1	AC034243.1	10.24	3.5e-18	2.82e-13	0.98	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138718994	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs311597	ENSG00000253404.1	AC034243.1	10.24	3.5e-18	2.82e-13	0.98	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138720212	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	10.24	3.51e-18	2.82e-13	0.98	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	10.21	4.29e-18	3.43e-13	0.84	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
ESCA	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-10.2	4.38e-18	3.49e-13	-0.8	-0.68	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-10.19	4.63e-18	3.67e-13	-0.81	-0.68	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs176382	ENSG00000253404.1	AC034243.1	10.18	5.08e-18	4.03e-13	0.99	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891078	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	10.18	5.1e-18	4.03e-13	0.82	0.68	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs160403	ENSG00000253404.1	AC034243.1	10.17	5.38e-18	4.24e-13	0.92	0.68	Age-related hearing impairment (SNP x SNP interaction);	chr5:138722793	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-10.16	5.64e-18	4.42e-13	-1.09	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
ESCA	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	10.15	5.96e-18	4.64e-13	0.97	0.68	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000250470.1	AP000351.3	10.13	6.62e-18	5.09e-13	0.85	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23976904~23977585:-
ESCA	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-10.12	6.93e-18	5.32e-13	-0.8	-0.67	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs160404	ENSG00000253404.1	AC034243.1	10.12	7.17e-18	5.49e-13	0.98	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138748580	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288014	ENSG00000253404.1	AC034243.1	-10.1	7.8e-18	5.94e-13	-1.01	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860104	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288022	ENSG00000253404.1	AC034243.1	10.09	8.25e-18	6.27e-13	1.01	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888586	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.598	rs288020	ENSG00000253404.1	AC034243.1	10.09	8.25e-18	6.27e-13	1.01	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888609	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-10.05	1.01e-17	7.63e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
ESCA	cis	rs2882667	0.69	rs160400	ENSG00000253404.1	AC034243.1	-10.04	1.08e-17	8.15e-13	-0.96	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138727330	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	10.04	1.09e-17	8.18e-13	0.82	0.67	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
ESCA	cis	rs12439619	0.693	rs7165536	ENSG00000278603.1	RP13-608F4.5	10.04	1.1e-17	8.18e-13	1.04	0.67	Intelligence (multi-trait analysis);	chr15:82273743	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.587	rs288015	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138859528	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288013	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860128	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs176381	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138861042	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288011	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864250	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288010	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864340	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs495638	ENSG00000253404.1	AC034243.1	-10.04	1.11e-17	8.18e-13	-1	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138865253	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288042	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138867345	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288041	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138868322	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288039	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138870511	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288038	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138871844	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288031	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880377	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288030	ENSG00000253404.1	AC034243.1	10.04	1.11e-17	8.18e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138880594	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	10.04	1.11e-17	8.19e-13	0.87	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
ESCA	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-10.03	1.14e-17	8.4e-13	-1.11	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.69	rs288025	ENSG00000253404.1	AC034243.1	10.03	1.16e-17	8.45e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887944	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288023	ENSG00000253404.1	AC034243.1	10.03	1.16e-17	8.45e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888359	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs7446631	ENSG00000253404.1	AC034243.1	10.02	1.21e-17	8.85e-13	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138891376	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-10.01	1.28e-17	9.18e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
ESCA	cis	rs2882667	0.654	rs1703211	ENSG00000253404.1	AC034243.1	-10.01	1.29e-17	9.22e-13	-0.98	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138740587	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1703212	ENSG00000253404.1	AC034243.1	-10.01	1.29e-17	9.22e-13	-0.98	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138742863	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-10.01	1.32e-17	9.31e-13	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-10	1.39e-17	9.82e-13	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
ESCA	cis	rs12439619	0.693	rs4778989	ENSG00000278603.1	RP13-608F4.5	9.98	1.51e-17	1.06e-12	1.03	0.67	Intelligence (multi-trait analysis);	chr15:82276963	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs288012	ENSG00000253404.1	AC034243.1	-9.98	1.53e-17	1.07e-12	-0.98	-0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138860584	chr5:138744434~138753309:-
ESCA	cis	rs3734266	0.646	rs2395605	ENSG00000186328.4	RP11-140K17.2	9.98	1.54e-17	1.08e-12	1.22	0.67	Systemic lupus erythematosus;	chr6:34810716	chr6:34715613~34715940:+
ESCA	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	9.96	1.68e-17	1.17e-12	0.84	0.67	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.659	rs12719515	ENSG00000253404.1	AC034243.1	9.96	1.7e-17	1.18e-12	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905629	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-9.94	1.85e-17	1.29e-12	-1.15	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
ESCA	cis	rs3734266	1	rs3734266	ENSG00000186328.4	RP11-140K17.2	9.94	1.86e-17	1.29e-12	1.19	0.67	Systemic lupus erythematosus;	chr6:34855410	chr6:34715613~34715940:+
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	9.94	1.92e-17	1.33e-12	0.86	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
ESCA	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-9.92	2.16e-17	1.49e-12	-1.13	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
ESCA	cis	rs2882667	0.599	rs288008	ENSG00000253404.1	AC034243.1	9.91	2.21e-17	1.52e-12	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138893632	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288004	ENSG00000253404.1	AC034243.1	9.91	2.21e-17	1.52e-12	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138895956	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs2662543	ENSG00000253404.1	AC034243.1	9.91	2.21e-17	1.52e-12	1	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898441	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-9.91	2.25e-17	1.55e-12	-0.92	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-9.91	2.29e-17	1.57e-12	-0.83	-0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
ESCA	cis	rs2882667	0.69	rs17207772	ENSG00000253404.1	AC034243.1	9.88	2.66e-17	1.81e-12	0.99	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138906131	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs13172507	ENSG00000253404.1	AC034243.1	9.88	2.66e-17	1.81e-12	0.99	0.67	Age-related hearing impairment (SNP x SNP interaction);	chr5:138907409	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-9.88	2.71e-17	1.84e-12	-0.77	-0.67	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
ESCA	cis	rs3734266	0.702	rs4646933	ENSG00000186328.4	RP11-140K17.2	9.83	3.55e-17	2.4e-12	1.11	0.66	Systemic lupus erythematosus;	chr6:34882883	chr6:34715613~34715940:+
ESCA	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	9.83	3.56e-17	2.4e-12	0.83	0.66	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
ESCA	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	9.82	3.7e-17	2.5e-12	0.99	0.66	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
ESCA	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	9.81	3.83e-17	2.57e-12	0.83	0.66	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs1627698	ENSG00000253404.1	AC034243.1	-9.8	4.12e-17	2.76e-12	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138741777	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1651032	ENSG00000253404.1	AC034243.1	-9.8	4.12e-17	2.76e-12	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138743151	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-9.79	4.46e-17	2.98e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs423469	ENSG00000253404.1	AC034243.1	9.77	5.02e-17	3.33e-12	0.97	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138898427	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.962	rs9688412	ENSG00000231760.4	RP11-350J20.5	-9.76	5.17e-17	3.42e-12	-0.8	-0.66	Lung cancer;	chr6:149803147	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	9.75	5.43e-17	3.59e-12	0.79	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
ESCA	cis	rs3734266	0.702	rs7743949	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34836738	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35940001	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34838763	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs11966100	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34839740	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs34480956	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34840324	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13196785	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34841044	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13213288	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34844683	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13213604	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34844764	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs34355573	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34849619	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6904996	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34852743	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35203657	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34853513	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13205210	ENSG00000186328.4	RP11-140K17.2	9.74	5.65e-17	3.67e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34864079	chr6:34715613~34715940:+
ESCA	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	9.74	5.72e-17	3.7e-12	1	0.66	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
ESCA	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-9.72	6.58e-17	4.25e-12	-0.88	-0.66	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
ESCA	cis	rs17507216	1	rs3850610	ENSG00000278603.1	RP13-608F4.5	-9.71	6.75e-17	4.35e-12	-0.94	-0.66	Excessive daytime sleepiness;	chr15:82552642	chr15:82472203~82472426:+
ESCA	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	9.7	7.06e-17	4.54e-12	0.84	0.66	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-9.69	7.75e-17	4.88e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs10515504	ENSG00000253404.1	AC034243.1	-9.68	7.9e-17	4.96e-12	-0.98	-0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138887305	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs12175504	ENSG00000231760.4	RP11-350J20.5	9.68	7.94e-17	4.96e-12	0.77	0.66	Lung cancer;	chr6:149664079	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs35443312	ENSG00000231760.4	RP11-350J20.5	9.68	7.94e-17	4.96e-12	0.77	0.66	Lung cancer;	chr6:149670625	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs62439843	ENSG00000231760.4	RP11-350J20.5	9.68	7.94e-17	4.96e-12	0.77	0.66	Lung cancer;	chr6:149676521	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs35031906	ENSG00000231760.4	RP11-350J20.5	9.68	7.94e-17	4.96e-12	0.77	0.66	Lung cancer;	chr6:149677438	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.702	rs16895659	ENSG00000186328.4	RP11-140K17.2	9.67	8.64e-17	5.37e-12	1.13	0.66	Systemic lupus erythematosus;	chr6:34923091	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs28360525	ENSG00000186328.4	RP11-140K17.2	9.67	8.64e-17	5.37e-12	1.13	0.66	Systemic lupus erythematosus;	chr6:34923261	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6457797	ENSG00000186328.4	RP11-140K17.2	9.67	8.64e-17	5.37e-12	1.13	0.66	Systemic lupus erythematosus;	chr6:34929397	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6457798	ENSG00000186328.4	RP11-140K17.2	9.67	8.64e-17	5.37e-12	1.13	0.66	Systemic lupus erythematosus;	chr6:34929422	chr6:34715613~34715940:+
ESCA	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-9.67	8.72e-17	5.41e-12	-0.89	-0.66	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
ESCA	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	9.66	8.81e-17	5.45e-12	1.03	0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	9.66	8.84e-17	5.47e-12	0.75	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
ESCA	cis	rs9322193	1	rs9322193	ENSG00000231760.4	RP11-350J20.5	9.66	9.04e-17	5.57e-12	0.77	0.66	Lung cancer;	chr6:149598007	chr6:149796151~149826294:-
ESCA	cis	rs9322193	1	rs9377229	ENSG00000231760.4	RP11-350J20.5	9.66	9.04e-17	5.57e-12	0.77	0.66	Lung cancer;	chr6:149607655	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9688858	ENSG00000231760.4	RP11-350J20.5	9.65	9.76e-17	5.99e-12	0.77	0.66	Lung cancer;	chr6:149637911	chr6:149796151~149826294:-
ESCA	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-9.65	9.79e-17	5.99e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-9.65	9.79e-17	5.99e-12	-0.83	-0.66	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.628	rs311606	ENSG00000253404.1	AC034243.1	9.64	9.82e-17	6e-12	0.96	0.66	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709551	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	9.64	1.02e-16	6.19e-12	0.86	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
ESCA	cis	rs9322193	0.923	rs9322197	ENSG00000231760.4	RP11-350J20.5	9.63	1.04e-16	6.32e-12	0.77	0.66	Lung cancer;	chr6:149622577	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.646	rs35369977	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34731564	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.591	rs35744142	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34737265	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.639	rs66672772	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34738160	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs71542490	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34740699	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35195182	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34741909	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs11961041	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34742132	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs11963234	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34754646	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs36026951	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34754984	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6934741	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34762272	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35141641	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34769175	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.639	rs11968972	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34773317	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs11968954	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34773397	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.697	rs67895864	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34774996	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35081279	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34776999	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.639	rs11967912	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34790076	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.536	rs35143960	ENSG00000186328.4	RP11-140K17.2	9.63	1.07e-16	6.32e-12	1.17	0.66	Systemic lupus erythematosus;	chr6:34793898	chr6:34715613~34715940:+
ESCA	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	9.61	1.21e-16	7.12e-12	0.83	0.65	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	9.61	1.21e-16	7.12e-12	0.83	0.65	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.962	rs3763162	ENSG00000231760.4	RP11-350J20.5	-9.61	1.21e-16	7.12e-12	-0.82	-0.65	Lung cancer;	chr6:149819674	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.628	rs311605	ENSG00000253404.1	AC034243.1	9.6	1.23e-16	7.16e-12	0.91	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138710150	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.962	rs9688750	ENSG00000231760.4	RP11-350J20.5	9.6	1.24e-16	7.22e-12	0.78	0.65	Lung cancer;	chr6:149657633	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-9.59	1.31e-16	7.66e-12	-0.89	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
ESCA	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-9.59	1.32e-16	7.67e-12	-0.88	-0.65	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	9.59	1.34e-16	7.82e-12	0.76	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	9.59	1.37e-16	7.95e-12	0.76	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
ESCA	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	9.58	1.39e-16	8.05e-12	1.04	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	9.58	1.4e-16	8.11e-12	1.1	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
ESCA	cis	rs3734266	0.639	rs9968782	ENSG00000186328.4	RP11-140K17.2	9.58	1.43e-16	8.2e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34769177	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs67622212	ENSG00000186328.4	RP11-140K17.2	9.58	1.43e-16	8.2e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34782255	chr6:34715613~34715940:+
ESCA	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	9.58	1.43e-16	8.22e-12	0.97	0.65	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
ESCA	cis	rs3734266	0.536	rs6925175	ENSG00000186328.4	RP11-140K17.2	9.57	1.45e-16	8.3e-12	1.18	0.65	Systemic lupus erythematosus;	chr6:34864518	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs7775947	ENSG00000186328.4	RP11-140K17.2	9.57	1.51e-16	8.61e-12	1.18	0.65	Systemic lupus erythematosus;	chr6:34747380	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs7776439	ENSG00000186328.4	RP11-140K17.2	9.57	1.51e-16	8.61e-12	1.18	0.65	Systemic lupus erythematosus;	chr6:34747671	chr6:34715613~34715940:+
ESCA	cis	rs9322193	0.886	rs4039600	ENSG00000231760.4	RP11-350J20.5	9.57	1.51e-16	8.61e-12	0.78	0.65	Lung cancer;	chr6:149576319	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	9.57	1.51e-16	8.61e-12	0.77	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
ESCA	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	9.56	1.56e-16	8.87e-12	0.76	0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
ESCA	cis	rs9322193	0.962	rs7818	ENSG00000231760.4	RP11-350J20.5	9.56	1.6e-16	9.07e-12	0.8	0.65	Lung cancer;	chr6:149810956	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.584	rs12111129	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34806671	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13213239	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34809715	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs7755354	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34814467	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6910824	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34818729	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs1018622	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34820454	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.646	rs912717	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34820790	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs7764126	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34821285	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs71567467	ENSG00000186328.4	RP11-140K17.2	9.54	1.72e-16	9.65e-12	1.16	0.65	Systemic lupus erythematosus;	chr6:34822832	chr6:34715613~34715940:+
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000231271.1	AP000350.8	-9.53	1.86e-16	1.04e-11	-0.81	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23949918~23954042:+
ESCA	cis	rs3734266	0.702	rs13196983	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34712698	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.646	rs111567516	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34720937	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs34261333	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34721763	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs4438945	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34722238	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs66926909	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34722933	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs72910167	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34728388	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs77208116	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34729376	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs34377413	ENSG00000186328.4	RP11-140K17.2	9.52	1.97e-16	1.08e-11	1.16	0.65	Systemic lupus erythematosus;	chr6:34730524	chr6:34715613~34715940:+
ESCA	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-9.52	1.97e-16	1.09e-11	-0.86	-0.65	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	9.51	2.02e-16	1.11e-11	0.66	0.65	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
ESCA	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-9.51	2.08e-16	1.14e-11	-0.89	-0.65	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
ESCA	cis	rs17507216	1	rs17507216	ENSG00000278603.1	RP13-608F4.5	-9.5	2.16e-16	1.18e-11	-1	-0.65	Excessive daytime sleepiness;	chr15:82558175	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.654	rs288019	ENSG00000253404.1	AC034243.1	-9.48	2.47e-16	1.34e-11	-0.98	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138855704	chr5:138744434~138753309:-
ESCA	cis	rs3734266	0.702	rs6941453	ENSG00000186328.4	RP11-140K17.2	9.47	2.58e-16	1.4e-11	1.17	0.65	Systemic lupus erythematosus;	chr6:34756118	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.639	rs7743724	ENSG00000186328.4	RP11-140K17.2	9.47	2.58e-16	1.4e-11	1.17	0.65	Systemic lupus erythematosus;	chr6:34757701	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs72892286	ENSG00000186328.4	RP11-140K17.2	9.47	2.58e-16	1.4e-11	1.17	0.65	Systemic lupus erythematosus;	chr6:34794400	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.69	rs9327827	ENSG00000253404.1	AC034243.1	9.44	2.98e-16	1.6e-11	0.93	0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138846639	chr5:138744434~138753309:-
ESCA	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	9.44	3.05e-16	1.63e-11	0.81	0.65	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-9.43	3.2e-16	1.69e-11	-0.91	-0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
ESCA	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-9.42	3.49e-16	1.84e-11	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	9.42	3.5e-16	1.85e-11	0.8	0.65	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
ESCA	cis	rs3734266	0.702	rs9469820	ENSG00000186328.4	RP11-140K17.2	9.41	3.69e-16	1.94e-11	1.15	0.65	Systemic lupus erythematosus;	chr6:34618986	chr6:34715613~34715940:+
ESCA	cis	rs9322193	0.961	rs9027	ENSG00000231760.4	RP11-350J20.5	9.4	3.85e-16	2.02e-11	0.76	0.65	Lung cancer;	chr6:149594921	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	9.4	3.89e-16	2.04e-11	1.1	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
ESCA	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-9.39	3.93e-16	2.06e-11	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-9.39	3.93e-16	2.06e-11	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-9.39	3.93e-16	2.06e-11	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs35830138	ENSG00000231760.4	RP11-350J20.5	9.39	3.97e-16	2.08e-11	0.78	0.65	Lung cancer;	chr6:149668635	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9322206	ENSG00000231760.4	RP11-350J20.5	9.39	4.04e-16	2.11e-11	0.77	0.65	Lung cancer;	chr6:149641481	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.651	rs9322188	ENSG00000231760.4	RP11-350J20.5	-9.39	4.05e-16	2.11e-11	-0.73	-0.65	Lung cancer;	chr6:149588355	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.887	rs3777949	ENSG00000231760.4	RP11-350J20.5	9.39	4.08e-16	2.12e-11	0.77	0.65	Lung cancer;	chr6:149596021	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.851	rs9322194	ENSG00000231760.4	RP11-350J20.5	9.39	4.08e-16	2.12e-11	0.77	0.65	Lung cancer;	chr6:149599113	chr6:149796151~149826294:-
ESCA	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-9.38	4.34e-16	2.25e-11	-0.85	-0.65	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
ESCA	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	9.38	4.37e-16	2.27e-11	0.75	0.65	Shingles;	chr7:38346957	chr7:38343894~38350022:-
ESCA	cis	rs9322193	0.962	rs7745915	ENSG00000231760.4	RP11-350J20.5	9.37	4.48e-16	2.32e-11	0.8	0.65	Lung cancer;	chr6:149834111	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.646	rs205266	ENSG00000186328.4	RP11-140K17.2	9.37	4.5e-16	2.33e-11	1.19	0.65	Systemic lupus erythematosus;	chr6:34592516	chr6:34715613~34715940:+
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000231271.1	AP000350.8	9.37	4.55e-16	2.35e-11	0.8	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23949918~23954042:+
ESCA	cis	rs9733	0.596	rs2867300	ENSG00000206931.1	RNU6-1042P	9.37	4.56e-16	2.35e-11	0.82	0.65	Tonsillectomy;	chr1:150694514	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-9.36	4.78e-16	2.46e-11	-0.85	-0.64	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
ESCA	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-9.34	5.4e-16	2.77e-11	-0.81	-0.64	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.962	rs10452626	ENSG00000231760.4	RP11-350J20.5	9.33	5.63e-16	2.84e-11	0.78	0.64	Lung cancer;	chr6:149767481	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs62441303	ENSG00000231760.4	RP11-350J20.5	9.33	5.63e-16	2.84e-11	0.78	0.64	Lung cancer;	chr6:149767547	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs13215691	ENSG00000231760.4	RP11-350J20.5	9.33	5.65e-16	2.84e-11	0.8	0.64	Lung cancer;	chr6:149792666	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-9.33	5.68e-16	2.84e-11	-0.94	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
ESCA	cis	rs9322193	0.923	rs11155683	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149779341	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9372044	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149780867	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs11155685	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149781649	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9322220	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149782897	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs10214845	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149783124	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9767122	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149783553	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs1413654	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149783956	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.683	rs113281309	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149787289	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9688809	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149787920	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9689242	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149787970	chr6:149796151~149826294:-
ESCA	cis	rs9322193	1	rs9767077	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149788479	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs9766562	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149788709	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9688938	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149788941	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9688940	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149788977	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9689447	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149789350	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.632	rs3828700	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149791033	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs3805751	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149791193	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9689269	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149791861	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs62441335	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149792658	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4816	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149793609	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs3805753	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149795662	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs952166	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149798774	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs952165	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149798900	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs10872656	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149799444	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs9285525	ENSG00000231760.4	RP11-350J20.5	9.33	5.75e-16	2.84e-11	0.79	0.64	Lung cancer;	chr6:149801253	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2184369	ENSG00000231760.4	RP11-350J20.5	9.32	5.79e-16	2.84e-11	0.8	0.64	Lung cancer;	chr6:149776681	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs2342861	ENSG00000231760.4	RP11-350J20.5	9.32	5.79e-16	2.84e-11	0.8	0.64	Lung cancer;	chr6:149777561	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs2342860	ENSG00000231760.4	RP11-350J20.5	9.32	5.79e-16	2.84e-11	0.8	0.64	Lung cancer;	chr6:149777641	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs10872653	ENSG00000231760.4	RP11-350J20.5	9.32	5.79e-16	2.84e-11	0.8	0.64	Lung cancer;	chr6:149778907	chr6:149796151~149826294:-
ESCA	cis	rs12439619	0.693	rs9944185	ENSG00000278603.1	RP13-608F4.5	9.32	5.96e-16	2.88e-11	0.92	0.64	Intelligence (multi-trait analysis);	chr15:82157927	chr15:82472203~82472426:+
ESCA	cis	rs9322193	0.884	rs2342858	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149805967	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs6914319	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149806304	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs2095375	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149807037	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4869730	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149808187	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs11155689	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149808470	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2151913	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149809506	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs933055	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149809701	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4869731	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149810072	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4552	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149811183	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs17673294	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149813857	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs6899661	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149818093	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs14314	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149820395	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs2151912	ENSG00000231760.4	RP11-350J20.5	9.32	6.03e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149831772	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs2275046	ENSG00000231760.4	RP11-350J20.5	9.32	6.06e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149835865	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9765929	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149769680	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs3805748	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149772542	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.736	rs10457851	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149775216	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.886	rs10872652	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149775303	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.886	rs12525871	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149775882	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.886	rs17672976	ENSG00000231760.4	RP11-350J20.5	9.32	6.08e-16	2.88e-11	0.79	0.64	Lung cancer;	chr6:149776207	chr6:149796151~149826294:-
ESCA	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-9.31	6.2e-16	2.93e-11	-0.78	-0.64	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-9.31	6.2e-16	2.93e-11	-0.78	-0.64	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-9.31	6.2e-16	2.93e-11	-0.78	-0.64	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
ESCA	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-9.3	6.6e-16	3.11e-11	-0.84	-0.64	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-9.3	6.64e-16	3.12e-11	-0.79	-0.64	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
ESCA	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-9.29	6.9e-16	3.19e-11	-0.78	-0.64	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	9.29	6.9e-16	3.19e-11	0.78	0.64	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-9.29	6.99e-16	3.22e-11	-0.78	-0.64	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
ESCA	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	9.29	6.99e-16	3.22e-11	1	0.64	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	9.29	6.99e-16	3.22e-11	1	0.64	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
ESCA	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-9.28	7.35e-16	3.38e-11	-0.75	-0.64	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
ESCA	cis	rs916888	0.821	rs199499	ENSG00000262500.1	RP11-259G18.2	9.27	7.85e-16	3.6e-11	1.16	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46243606~46245044:+
ESCA	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	9.27	7.97e-16	3.65e-11	0.78	0.64	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
ESCA	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-9.27	8.02e-16	3.66e-11	-0.78	-0.64	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-9.27	8.02e-16	3.66e-11	-0.78	-0.64	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
ESCA	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-9.27	8.02e-16	3.66e-11	-0.78	-0.64	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-9.27	8.02e-16	3.66e-11	-0.78	-0.64	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
ESCA	cis	rs3734266	0.702	rs34840245	ENSG00000186328.4	RP11-140K17.2	9.26	8.07e-16	3.68e-11	1.13	0.64	Systemic lupus erythematosus;	chr6:34844924	chr6:34715613~34715940:+
ESCA	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-9.25	8.69e-16	3.94e-11	-0.75	-0.64	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000231271.1	AP000350.8	9.25	8.73e-16	3.95e-11	0.81	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23949918~23954042:+
ESCA	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	9.25	8.81e-16	3.98e-11	1.1	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	9.25	8.81e-16	3.98e-11	1.1	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	9.25	8.81e-16	3.98e-11	1.1	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	9.25	8.81e-16	3.98e-11	1.1	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
ESCA	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	9.23	9.63e-16	4.34e-11	0.8	0.64	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
ESCA	cis	rs3734266	0.639	rs7739385	ENSG00000186328.4	RP11-140K17.2	9.23	9.69e-16	4.36e-11	1.09	0.64	Systemic lupus erythematosus;	chr6:34899701	chr6:34715613~34715940:+
ESCA	cis	rs9322193	0.923	rs2342857	ENSG00000231760.4	RP11-350J20.5	9.23	9.8e-16	4.4e-11	0.79	0.64	Lung cancer;	chr6:149809537	chr6:149796151~149826294:-
ESCA	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	9.21	1.06e-15	4.75e-11	0.86	0.64	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-9.21	1.07e-15	4.76e-11	-0.86	-0.64	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
ESCA	cis	rs3734266	0.702	rs9469814	ENSG00000186328.4	RP11-140K17.2	-9.2	1.12e-15	4.99e-11	-1.11	-0.64	Systemic lupus erythematosus;	chr6:34603868	chr6:34715613~34715940:+
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-9.19	1.24e-15	5.46e-11	-0.79	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	9.18	1.26e-15	5.57e-11	0.9	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
ESCA	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-9.18	1.32e-15	5.79e-11	-0.79	-0.64	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
ESCA	cis	rs3734266	0.702	rs1051115	ENSG00000186328.4	RP11-140K17.2	9.17	1.35e-15	5.92e-11	1.08	0.64	Systemic lupus erythematosus;	chr6:34887971	chr6:34715613~34715940:+
ESCA	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	9.17	1.37e-15	5.96e-11	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	9.17	1.37e-15	5.96e-11	0.9	0.64	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
ESCA	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-9.17	1.38e-15	5.97e-11	-0.82	-0.64	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-9.17	1.38e-15	5.98e-11	-0.85	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
ESCA	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	9.16	1.42e-15	6.15e-11	0.81	0.64	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.962	rs12175575	ENSG00000231760.4	RP11-350J20.5	9.16	1.45e-15	6.2e-11	0.77	0.64	Lung cancer;	chr6:149763351	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4869966	ENSG00000231760.4	RP11-350J20.5	9.16	1.45e-15	6.2e-11	0.77	0.64	Lung cancer;	chr6:149763714	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs1112730	ENSG00000231760.4	RP11-350J20.5	9.16	1.45e-15	6.2e-11	0.77	0.64	Lung cancer;	chr6:149766383	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs1112729	ENSG00000231760.4	RP11-350J20.5	9.16	1.45e-15	6.2e-11	0.77	0.64	Lung cancer;	chr6:149766491	chr6:149796151~149826294:-
ESCA	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	9.16	1.46e-15	6.22e-11	0.99	0.64	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	9.16	1.46e-15	6.22e-11	0.99	0.64	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	9.16	1.46e-15	6.22e-11	0.99	0.64	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
ESCA	cis	rs9322193	0.736	rs3828701	ENSG00000231760.4	RP11-350J20.5	9.15	1.48e-15	6.28e-11	0.8	0.64	Lung cancer;	chr6:149791063	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.736	rs3805750	ENSG00000231760.4	RP11-350J20.5	9.15	1.48e-15	6.28e-11	0.8	0.64	Lung cancer;	chr6:149791065	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	9.15	1.49e-15	6.31e-11	0.98	0.64	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
ESCA	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-9.15	1.53e-15	6.46e-11	-0.83	-0.64	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
ESCA	cis	rs17507216	0.681	rs28877110	ENSG00000278603.1	RP13-608F4.5	9.15	1.54e-15	6.52e-11	1.07	0.64	Excessive daytime sleepiness;	chr15:82672111	chr15:82472203~82472426:+
ESCA	cis	rs17507216	0.609	rs1431716	ENSG00000278603.1	RP13-608F4.5	9.15	1.54e-15	6.52e-11	1.07	0.64	Excessive daytime sleepiness;	chr15:82676180	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-9.14	1.56e-15	6.57e-11	-0.72	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-9.14	1.63e-15	6.86e-11	-0.84	-0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
ESCA	cis	rs9322193	0.924	rs9322189	ENSG00000231760.4	RP11-350J20.5	9.13	1.72e-15	7.19e-11	0.75	0.64	Lung cancer;	chr6:149588797	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	9.12	1.76e-15	7.36e-11	0.84	0.64	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
ESCA	cis	rs9733	0.596	rs2275236	ENSG00000206931.1	RNU6-1042P	-9.12	1.77e-15	7.37e-11	-0.83	-0.64	Tonsillectomy;	chr1:150697476	chr1:150701866~150701972:+
ESCA	cis	rs9322193	0.923	rs9767123	ENSG00000231760.4	RP11-350J20.5	9.12	1.77e-15	7.37e-11	0.77	0.64	Lung cancer;	chr6:149660323	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs62439836	ENSG00000231760.4	RP11-350J20.5	9.12	1.77e-15	7.37e-11	0.77	0.64	Lung cancer;	chr6:149669173	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4869812	ENSG00000231760.4	RP11-350J20.5	9.12	1.77e-15	7.37e-11	0.77	0.64	Lung cancer;	chr6:149669447	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4870267	ENSG00000231760.4	RP11-350J20.5	9.12	1.77e-15	7.37e-11	0.77	0.64	Lung cancer;	chr6:149671572	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs4380763	ENSG00000231760.4	RP11-350J20.5	9.12	1.77e-15	7.37e-11	0.77	0.64	Lung cancer;	chr6:149678086	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	9.12	1.78e-15	7.41e-11	0.77	0.64	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
ESCA	cis	rs3734266	0.702	rs36032186	ENSG00000186328.4	RP11-140K17.2	9.12	1.8e-15	7.48e-11	1.11	0.64	Systemic lupus erythematosus;	chr6:34606163	chr6:34715613~34715940:+
ESCA	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	9.12	1.83e-15	7.61e-11	0.79	0.63	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-9.11	1.86e-15	7.73e-11	-0.79	-0.63	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
ESCA	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	9.11	1.89e-15	7.81e-11	0.99	0.63	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
ESCA	cis	rs9322193	0.923	rs9800736	ENSG00000231760.4	RP11-350J20.5	9.11	1.9e-15	7.83e-11	0.77	0.63	Lung cancer;	chr6:149661281	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs3924871	ENSG00000231760.4	RP11-350J20.5	9.11	1.9e-15	7.83e-11	0.77	0.63	Lung cancer;	chr6:149662080	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs35961297	ENSG00000231760.4	RP11-350J20.5	9.11	1.9e-15	7.83e-11	0.77	0.63	Lung cancer;	chr6:149667929	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs35967444	ENSG00000231760.4	RP11-350J20.5	9.11	1.9e-15	7.83e-11	0.77	0.63	Lung cancer;	chr6:149675588	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs62439842	ENSG00000231760.4	RP11-350J20.5	9.11	1.9e-15	7.83e-11	0.77	0.63	Lung cancer;	chr6:149675847	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-9.1	1.94e-15	7.98e-11	-0.77	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
ESCA	cis	rs17507216	0.718	rs72751657	ENSG00000278603.1	RP13-608F4.5	9.09	2.11e-15	8.65e-11	1.07	0.63	Excessive daytime sleepiness;	chr15:82581259	chr15:82472203~82472426:+
ESCA	cis	rs9322193	0.961	rs2064520	ENSG00000231760.4	RP11-350J20.5	9.09	2.13e-15	8.7e-11	0.72	0.63	Lung cancer;	chr6:149603650	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	9.09	2.14e-15	8.72e-11	0.81	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
ESCA	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-9.08	2.2e-15	8.91e-11	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-9.08	2.2e-15	8.91e-11	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-9.08	2.2e-15	8.91e-11	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-9.08	2.2e-15	8.91e-11	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-9.08	2.24e-15	9.07e-11	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
ESCA	cis	rs12439619	0.883	rs62012045	ENSG00000278603.1	RP13-608F4.5	9.07	2.37e-15	9.58e-11	0.92	0.63	Intelligence (multi-trait analysis);	chr15:82229366	chr15:82472203~82472426:+
ESCA	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	9.07	2.4e-15	9.69e-11	0.77	0.63	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs12195866	ENSG00000231760.4	RP11-350J20.5	9.06	2.44e-15	9.83e-11	0.75	0.63	Lung cancer;	chr6:149693334	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.887	rs3734295	ENSG00000231760.4	RP11-350J20.5	9.06	2.45e-15	9.85e-11	0.76	0.63	Lung cancer;	chr6:149593917	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.628	rs13171173	ENSG00000253404.1	AC034243.1	-9.06	2.46e-15	9.88e-11	-1	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138706775	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	9.06	2.49e-15	1e-10	1.09	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	9.06	2.49e-15	1e-10	1.09	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
ESCA	cis	rs9322193	0.923	rs7753812	ENSG00000231760.4	RP11-350J20.5	9.06	2.51e-15	1e-10	0.75	0.63	Lung cancer;	chr6:149690150	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9285524	ENSG00000231760.4	RP11-350J20.5	9.06	2.51e-15	1e-10	0.75	0.63	Lung cancer;	chr6:149694122	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10872645	ENSG00000231760.4	RP11-350J20.5	9.06	2.51e-15	1e-10	0.75	0.63	Lung cancer;	chr6:149742840	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs12211511	ENSG00000231760.4	RP11-350J20.5	9.06	2.51e-15	1e-10	0.75	0.63	Lung cancer;	chr6:149745206	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9479810	ENSG00000231760.4	RP11-350J20.5	9.06	2.51e-15	1e-10	0.75	0.63	Lung cancer;	chr6:149751359	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2342765	ENSG00000231760.4	RP11-350J20.5	9.05	2.56e-15	1.02e-10	0.76	0.63	Lung cancer;	chr6:149858873	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9688861	ENSG00000231760.4	RP11-350J20.5	9.05	2.6e-15	1.04e-10	0.75	0.63	Lung cancer;	chr6:149637924	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	9.05	2.63e-15	1.05e-10	0.77	0.63	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs9505823	ENSG00000231760.4	RP11-350J20.5	9.05	2.67e-15	1.06e-10	0.75	0.63	Lung cancer;	chr6:149628899	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.847	rs62439808	ENSG00000231760.4	RP11-350J20.5	9.05	2.67e-15	1.06e-10	0.75	0.63	Lung cancer;	chr6:149629690	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-9.05	2.69e-15	1.07e-10	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-9.05	2.69e-15	1.07e-10	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.924	rs9498382	ENSG00000231760.4	RP11-350J20.5	9.04	2.77e-15	1.09e-10	0.74	0.63	Lung cancer;	chr6:149610982	chr6:149796151~149826294:-
ESCA	cis	rs9322193	1	rs9399693	ENSG00000231760.4	RP11-350J20.5	9.04	2.77e-15	1.09e-10	0.74	0.63	Lung cancer;	chr6:149612718	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	9.04	2.78e-15	1.1e-10	0.82	0.63	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.628	rs311607	ENSG00000253404.1	AC034243.1	9.04	2.78e-15	1.1e-10	0.86	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138709231	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.847	rs12191643	ENSG00000231760.4	RP11-350J20.5	9.04	2.81e-15	1.1e-10	0.75	0.63	Lung cancer;	chr6:149628912	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9377230	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149613607	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9404048	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149616188	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9767554	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149616860	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9505982	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149618465	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.886	rs9485408	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149618888	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322196	ENSG00000231760.4	RP11-350J20.5	9.03	2.88e-15	1.13e-10	0.75	0.63	Lung cancer;	chr6:149619645	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-9.03	2.92e-15	1.14e-10	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	9.03	2.93e-15	1.14e-10	0.84	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
ESCA	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	9.03	2.96e-15	1.14e-10	0.77	0.63	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
ESCA	cis	rs3734266	0.702	rs6908462	ENSG00000186328.4	RP11-140K17.2	-9.03	2.98e-15	1.14e-10	-1.11	-0.63	Systemic lupus erythematosus;	chr6:34705372	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13209544	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34620190	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9461992	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34621183	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9469832	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34635384	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6909637	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34645853	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9469837	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34647755	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs16892384	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34651226	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs16892386	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34651615	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9469838	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34655592	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9462002	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34691457	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9462003	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34692161	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs72910111	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34699627	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs7759985	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34703009	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6909393	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34705719	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.591	rs7749750	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34709268	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9469852	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34709999	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs13210470	ENSG00000186328.4	RP11-140K17.2	9.03	2.98e-15	1.14e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34834001	chr6:34715613~34715940:+
ESCA	cis	rs9322193	0.923	rs55993747	ENSG00000231760.4	RP11-350J20.5	9.02	3.04e-15	1.16e-10	0.75	0.63	Lung cancer;	chr6:149622016	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs1413655	ENSG00000231760.4	RP11-350J20.5	9.02	3.08e-15	1.17e-10	0.79	0.63	Lung cancer;	chr6:149821815	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs9383546	ENSG00000231760.4	RP11-350J20.5	9.02	3.08e-15	1.17e-10	0.79	0.63	Lung cancer;	chr6:149822743	chr6:149796151~149826294:-
ESCA	cis	rs9322193	1	rs9377228	ENSG00000231760.4	RP11-350J20.5	9.02	3.08e-15	1.17e-10	0.74	0.63	Lung cancer;	chr6:149600862	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	9.02	3.14e-15	1.19e-10	0.77	0.63	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	9.01	3.3e-15	1.24e-10	0.76	0.63	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
ESCA	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	9	3.43e-15	1.28e-10	1.09	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
ESCA	cis	rs9322193	0.962	rs9505974	ENSG00000231760.4	RP11-350J20.5	9	3.43e-15	1.28e-10	0.78	0.63	Lung cancer;	chr6:149779294	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.926	rs9689036	ENSG00000231760.4	RP11-350J20.5	9	3.43e-15	1.28e-10	0.78	0.63	Lung cancer;	chr6:149780563	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9322218	ENSG00000231760.4	RP11-350J20.5	9	3.43e-15	1.28e-10	0.78	0.63	Lung cancer;	chr6:149782183	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9322219	ENSG00000231760.4	RP11-350J20.5	9	3.43e-15	1.28e-10	0.78	0.63	Lung cancer;	chr6:149782263	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9322223	ENSG00000231760.4	RP11-350J20.5	9	3.43e-15	1.28e-10	0.78	0.63	Lung cancer;	chr6:149801509	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	9	3.51e-15	1.31e-10	0.8	0.63	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
ESCA	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.99	3.57e-15	1.33e-10	0.77	0.63	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
ESCA	cis	rs916888	0.821	rs199499	ENSG00000262539.1	RP11-259G18.3	8.99	3.59e-15	1.33e-10	1.16	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46259551~46260606:-
ESCA	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	8.99	3.62e-15	1.34e-10	0.84	0.63	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
ESCA	cis	rs9322193	0.962	rs9397022	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149812052	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9397357	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149812465	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs3763163	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149819770	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9478848	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149825080	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs1889473	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149825485	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs6903998	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149831357	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs1984111	ENSG00000231760.4	RP11-350J20.5	8.99	3.66e-15	1.35e-10	0.78	0.63	Lung cancer;	chr6:149831720	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.702	rs2296361	ENSG00000186328.4	RP11-140K17.2	-8.98	3.81e-15	1.4e-10	-1.02	-0.63	Systemic lupus erythematosus;	chr6:34835590	chr6:34715613~34715940:+
ESCA	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	8.98	3.86e-15	1.41e-10	0.85	0.63	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
ESCA	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	8.98	3.86e-15	1.41e-10	0.85	0.63	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
ESCA	cis	rs9322193	0.923	rs10782317	ENSG00000231760.4	RP11-350J20.5	-8.98	3.92e-15	1.43e-10	-0.75	-0.63	Lung cancer;	chr6:149753911	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-8.97	4.01e-15	1.46e-10	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	8.97	4.1e-15	1.46e-10	0.65	0.63	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-8.97	4.1e-15	1.46e-10	-0.65	-0.63	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
ESCA	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	8.96	4.33e-15	1.53e-10	1.09	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
ESCA	cis	rs3734266	0.702	rs7765969	ENSG00000186328.4	RP11-140K17.2	8.95	4.49e-15	1.58e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34667078	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6926373	ENSG00000186328.4	RP11-140K17.2	8.95	4.49e-15	1.58e-10	1.11	0.63	Systemic lupus erythematosus;	chr6:34833557	chr6:34715613~34715940:+
ESCA	cis	rs12439619	0.921	rs56042848	ENSG00000278603.1	RP13-608F4.5	8.95	4.56e-15	1.6e-10	0.92	0.63	Intelligence (multi-trait analysis);	chr15:82235244	chr15:82472203~82472426:+
ESCA	cis	rs3734266	0.702	rs205265	ENSG00000186328.4	RP11-140K17.2	8.95	4.61e-15	1.62e-10	1.14	0.63	Systemic lupus erythematosus;	chr6:34593808	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs205264	ENSG00000186328.4	RP11-140K17.2	8.95	4.61e-15	1.62e-10	1.14	0.63	Systemic lupus erythematosus;	chr6:34594419	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs205263	ENSG00000186328.4	RP11-140K17.2	8.95	4.61e-15	1.62e-10	1.14	0.63	Systemic lupus erythematosus;	chr6:34594746	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs205261	ENSG00000186328.4	RP11-140K17.2	8.95	4.61e-15	1.62e-10	1.14	0.63	Systemic lupus erythematosus;	chr6:34596110	chr6:34715613~34715940:+
ESCA	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	8.95	4.64e-15	1.62e-10	0.65	0.63	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-8.93	4.97e-15	1.73e-10	-0.64	-0.63	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
ESCA	cis	rs3734266	0.702	rs205267	ENSG00000186328.4	RP11-140K17.2	8.93	5.19e-15	1.8e-10	1.09	0.63	Systemic lupus erythematosus;	chr6:34591986	chr6:34715613~34715940:+
ESCA	cis	rs12439619	0.921	rs4778672	ENSG00000278603.1	RP13-608F4.5	-8.92	5.23e-15	1.81e-10	-0.91	-0.63	Intelligence (multi-trait analysis);	chr15:82245013	chr15:82472203~82472426:+
ESCA	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	8.92	5.4e-15	1.85e-10	0.64	0.63	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
ESCA	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	8.92	5.46e-15	1.87e-10	0.84	0.63	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
ESCA	cis	rs2882667	0.658	rs10076442	ENSG00000253404.1	AC034243.1	8.92	5.46e-15	1.87e-10	0.98	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941090	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.728	rs10037071	ENSG00000253404.1	AC034243.1	8.92	5.46e-15	1.87e-10	0.98	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942158	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.728	rs7722413	ENSG00000253404.1	AC034243.1	8.92	5.46e-15	1.87e-10	0.98	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138942562	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-8.91	5.7e-15	1.94e-10	-0.78	-0.63	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	8.9	5.92e-15	2.02e-10	1.09	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
ESCA	cis	rs875971	0.895	rs4145009	ENSG00000222364.1	RNU6-96P	8.9	6.01e-15	2.05e-10	0.66	0.63	Aortic root size;	chr7:66261628	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.69	rs1725335	ENSG00000253404.1	AC034243.1	-8.9	6.02e-15	2.05e-10	-0.99	-0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745541	chr5:138744434~138753309:-
ESCA	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	8.9	6.05e-15	2.05e-10	1.02	0.63	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
ESCA	cis	rs2882667	0.69	rs311601	ENSG00000253404.1	AC034243.1	8.9	6.09e-15	2.06e-10	0.97	0.63	Age-related hearing impairment (SNP x SNP interaction);	chr5:138717697	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.884	rs2064521	ENSG00000231760.4	RP11-350J20.5	-8.89	6.15e-15	2.08e-10	-0.75	-0.63	Lung cancer;	chr6:149625336	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	8.89	6.32e-15	2.13e-10	1.08	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	8.89	6.32e-15	2.13e-10	1.08	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	8.89	6.32e-15	2.13e-10	1.08	0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	8.88	6.54e-15	2.2e-10	0.72	0.63	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
ESCA	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-8.88	6.76e-15	2.27e-10	-0.8	-0.62	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-8.88	6.76e-15	2.27e-10	-0.8	-0.62	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	8.88	6.77e-15	2.27e-10	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.654	rs825760	ENSG00000253404.1	AC034243.1	-8.87	6.99e-15	2.33e-10	-1.02	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804285	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs4835703	ENSG00000253404.1	AC034243.1	-8.87	6.99e-15	2.33e-10	-1.02	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815048	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6596453	ENSG00000253404.1	AC034243.1	-8.87	6.99e-15	2.33e-10	-1.02	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816202	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.622	rs34645817	ENSG00000253404.1	AC034243.1	-8.87	6.99e-15	2.33e-10	-1.02	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138816944	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs9689084	ENSG00000231760.4	RP11-350J20.5	8.87	7.13e-15	2.36e-10	0.74	0.62	Lung cancer;	chr6:149639648	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs7740278	ENSG00000231760.4	RP11-350J20.5	8.87	7.13e-15	2.36e-10	0.74	0.62	Lung cancer;	chr6:149640116	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-8.87	7.15e-15	2.37e-10	-0.79	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-8.87	7.17e-15	2.37e-10	-0.64	-0.62	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	8.86	7.31e-15	2.38e-10	0.72	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
ESCA	cis	rs3734266	0.702	rs2296362	ENSG00000186328.4	RP11-140K17.2	8.86	7.31e-15	2.38e-10	1.1	0.62	Systemic lupus erythematosus;	chr6:34835222	chr6:34715613~34715940:+
ESCA	cis	rs9322193	0.847	rs12234128	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149627553	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs57012784	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149627691	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322200	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149630078	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9689599	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149631973	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9688794	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149632121	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9800580	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149632845	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs11155669	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149633501	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.887	rs9505824	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149633663	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9505826	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149633912	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322204	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149636047	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9766886	ENSG00000231760.4	RP11-350J20.5	8.86	7.32e-15	2.38e-10	0.74	0.62	Lung cancer;	chr6:149637048	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-8.86	7.36e-15	2.39e-10	-0.79	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-8.86	7.36e-15	2.39e-10	-0.79	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-8.86	7.36e-15	2.39e-10	-0.79	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-8.86	7.36e-15	2.39e-10	-0.79	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
ESCA	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	8.86	7.42e-15	2.41e-10	1.08	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	8.86	7.47e-15	2.41e-10	0.72	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
ESCA	cis	rs3734266	0.702	rs7764921	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34636558	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs9461994	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34643408	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6937428	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34662468	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35286877	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34673301	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs35987776	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34673447	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.639	rs9469842	ENSG00000186328.4	RP11-140K17.2	8.86	7.47e-15	2.41e-10	1.11	0.62	Systemic lupus erythematosus;	chr6:34676304	chr6:34715613~34715940:+
ESCA	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-8.86	7.49e-15	2.41e-10	-0.83	-0.62	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
ESCA	cis	rs9322193	0.923	rs66516768	ENSG00000231760.4	RP11-350J20.5	8.86	7.62e-15	2.44e-10	0.76	0.62	Lung cancer;	chr6:149671999	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	8.86	7.63e-15	2.45e-10	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-8.85	7.65e-15	2.45e-10	-0.8	-0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
ESCA	cis	rs17507216	0.718	rs4779034	ENSG00000278603.1	RP13-608F4.5	8.85	7.78e-15	2.49e-10	1.03	0.62	Excessive daytime sleepiness;	chr15:82576799	chr15:82472203~82472426:+
ESCA	cis	rs9322193	0.923	rs1080670	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149620161	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10782310	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149622458	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10782311	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149622592	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs10782312	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149622669	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10747275	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149622782	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.886	rs9322198	ENSG00000231760.4	RP11-350J20.5	8.85	7.81e-15	2.49e-10	0.74	0.62	Lung cancer;	chr6:149623772	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	8.85	7.86e-15	2.5e-10	0.65	0.62	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs1934534	ENSG00000231760.4	RP11-350J20.5	8.85	8e-15	2.54e-10	0.76	0.62	Lung cancer;	chr6:149711896	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-8.85	8.02e-15	2.55e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-8.85	8.02e-15	2.55e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-8.84	8.08e-15	2.56e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-8.84	8.45e-15	2.66e-10	-0.76	-0.62	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-8.84	8.45e-15	2.66e-10	-0.76	-0.62	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-8.84	8.45e-15	2.66e-10	-0.76	-0.62	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	8.83	8.55e-15	2.69e-10	0.73	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
ESCA	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	8.83	8.58e-15	2.7e-10	0.64	0.62	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
ESCA	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	8.83	8.99e-15	2.81e-10	0.95	0.62	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
ESCA	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-8.82	9.17e-15	2.86e-10	-0.76	-0.62	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.654	rs4835704	ENSG00000253404.1	AC034243.1	-8.82	9.21e-15	2.86e-10	-1.01	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138815636	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs12529698	ENSG00000231760.4	RP11-350J20.5	8.82	9.29e-15	2.88e-10	0.75	0.62	Lung cancer;	chr6:149650951	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	8.82	9.32e-15	2.89e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs11155671	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149650996	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9689716	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149655662	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9689723	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149655935	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322207	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149657185	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9968911	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149657419	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322208	ENSG00000231760.4	RP11-350J20.5	8.81	9.62e-15	2.97e-10	0.75	0.62	Lung cancer;	chr6:149658547	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	8.81	9.74e-15	2.99e-10	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	8.81	9.77e-15	3e-10	0.77	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
ESCA	cis	rs2882667	0.654	rs6862845	ENSG00000253404.1	AC034243.1	8.81	9.83e-15	3.01e-10	0.97	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937456	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	8.81	9.86e-15	3.02e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	8.81	1.01e-14	3.07e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	8.81	1.01e-14	3.07e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	8.81	1.01e-14	3.07e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	8.8	1.01e-14	3.07e-10	0.81	0.62	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	8.8	1.03e-14	3.13e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.654	rs10044432	ENSG00000253404.1	AC034243.1	8.8	1.03e-14	3.13e-10	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138939207	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-8.8	1.04e-14	3.15e-10	-0.75	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
ESCA	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-8.8	1.04e-14	3.15e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-8.8	1.04e-14	3.17e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-8.8	1.04e-14	3.17e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	8.8	1.05e-14	3.19e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
ESCA	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-8.79	1.1e-14	3.33e-10	-0.78	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
ESCA	cis	rs3734266	0.527	rs9462001	ENSG00000186328.4	RP11-140K17.2	8.78	1.12e-14	3.38e-10	1.09	0.62	Systemic lupus erythematosus;	chr6:34687786	chr6:34715613~34715940:+
ESCA	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-8.78	1.14e-14	3.4e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-8.78	1.14e-14	3.4e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-8.78	1.14e-14	3.4e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.886	rs4870055	ENSG00000231760.4	RP11-350J20.5	8.78	1.17e-14	3.51e-10	0.75	0.62	Lung cancer;	chr6:149848433	chr6:149796151~149826294:-
ESCA	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-8.77	1.21e-14	3.62e-10	-0.92	-0.62	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
ESCA	cis	rs2882667	0.654	rs7709770	ENSG00000253404.1	AC034243.1	-8.77	1.22e-14	3.65e-10	-1.02	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138813650	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	8.76	1.26e-14	3.74e-10	0.76	0.62	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
ESCA	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-8.76	1.27e-14	3.77e-10	-0.92	-0.62	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
ESCA	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.69	rs825747	ENSG00000253404.1	AC034243.1	-8.76	1.28e-14	3.77e-10	-0.99	-0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138800896	chr5:138744434~138753309:-
ESCA	cis	rs3734266	0.702	rs9469836	ENSG00000186328.4	RP11-140K17.2	-8.76	1.28e-14	3.77e-10	-1.11	-0.62	Systemic lupus erythematosus;	chr6:34647002	chr6:34715613~34715940:+
ESCA	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	8.76	1.28e-14	3.77e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs11155677	ENSG00000231760.4	RP11-350J20.5	8.75	1.33e-14	3.88e-10	0.78	0.62	Lung cancer;	chr6:149756953	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9480009	ENSG00000231760.4	RP11-350J20.5	8.75	1.33e-14	3.88e-10	0.78	0.62	Lung cancer;	chr6:149758502	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9480031	ENSG00000231760.4	RP11-350J20.5	8.75	1.33e-14	3.88e-10	0.78	0.62	Lung cancer;	chr6:149758875	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10872649	ENSG00000231760.4	RP11-350J20.5	8.75	1.33e-14	3.88e-10	0.78	0.62	Lung cancer;	chr6:149759454	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10872650	ENSG00000231760.4	RP11-350J20.5	8.75	1.33e-14	3.88e-10	0.78	0.62	Lung cancer;	chr6:149760959	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-8.75	1.35e-14	3.93e-10	-0.64	-0.62	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-8.75	1.35e-14	3.93e-10	-0.64	-0.62	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-8.75	1.35e-14	3.93e-10	-0.64	-0.62	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.659	rs10056014	ENSG00000253404.1	AC034243.1	8.75	1.35e-14	3.93e-10	1	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920329	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.598	rs10078179	ENSG00000253404.1	AC034243.1	8.75	1.35e-14	3.93e-10	1	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920410	chr5:138744434~138753309:-
ESCA	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-8.75	1.36e-14	3.94e-10	-0.92	-0.62	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
ESCA	cis	rs2882667	0.728	rs10068766	ENSG00000253404.1	AC034243.1	8.75	1.37e-14	3.96e-10	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941095	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs7709789	ENSG00000253404.1	AC034243.1	8.75	1.38e-14	3.98e-10	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138938762	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	8.75	1.38e-14	3.99e-10	1.12	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	8.75	1.38e-14	3.99e-10	1.12	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
ESCA	cis	rs2882667	0.69	rs11749163	ENSG00000253404.1	AC034243.1	8.75	1.38e-14	4e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926981	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	8.74	1.4e-14	4.02e-10	0.75	0.62	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.886	rs4870049	ENSG00000231760.4	RP11-350J20.5	8.74	1.4e-14	4.03e-10	0.79	0.62	Lung cancer;	chr6:149837058	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4870050	ENSG00000231760.4	RP11-350J20.5	8.74	1.4e-14	4.03e-10	0.79	0.62	Lung cancer;	chr6:149838917	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs7752089	ENSG00000231760.4	RP11-350J20.5	8.74	1.4e-14	4.03e-10	0.79	0.62	Lung cancer;	chr6:149839298	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4242279	ENSG00000231760.4	RP11-350J20.5	8.74	1.4e-14	4.03e-10	0.79	0.62	Lung cancer;	chr6:149839815	chr6:149796151~149826294:-
ESCA	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-8.74	1.41e-14	4.04e-10	-0.94	-0.62	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-8.74	1.44e-14	4.09e-10	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-8.74	1.44e-14	4.09e-10	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-8.74	1.44e-14	4.09e-10	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	8.73	1.55e-14	4.38e-10	0.64	0.62	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	8.73	1.55e-14	4.38e-10	0.64	0.62	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-8.72	1.56e-14	4.42e-10	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs9766037	ENSG00000231760.4	RP11-350J20.5	8.72	1.59e-14	4.48e-10	0.7	0.62	Lung cancer;	chr6:149616921	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-8.72	1.59e-14	4.48e-10	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs13174008	ENSG00000253404.1	AC034243.1	8.72	1.6e-14	4.5e-10	0.97	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922220	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs13158360	ENSG00000253404.1	AC034243.1	8.72	1.6e-14	4.5e-10	0.97	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138922488	chr5:138744434~138753309:-
ESCA	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-8.72	1.61e-14	4.53e-10	-0.82	-0.62	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
ESCA	cis	rs17507216	0.718	rs72751662	ENSG00000278603.1	RP13-608F4.5	8.71	1.71e-14	4.78e-10	1.04	0.62	Excessive daytime sleepiness;	chr15:82594705	chr15:82472203~82472426:+
ESCA	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	8.7	1.8e-14	5.02e-10	0.81	0.62	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
ESCA	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-8.7	1.8e-14	5.03e-10	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs10872644	ENSG00000231760.4	RP11-350J20.5	8.7	1.83e-14	5.1e-10	0.76	0.62	Lung cancer;	chr6:149741819	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs17745062	ENSG00000231760.4	RP11-350J20.5	8.69	1.86e-14	5.17e-10	0.76	0.62	Lung cancer;	chr6:149721079	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs62441279	ENSG00000231760.4	RP11-350J20.5	8.69	1.86e-14	5.17e-10	0.76	0.62	Lung cancer;	chr6:149721194	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4354168	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149696642	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4455682	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149700161	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4870529	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149716436	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9767309	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149716807	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9479494	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149739108	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9800806	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149740350	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9688517	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149740655	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs1572229	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149743841	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs10872646	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149746539	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs12528279	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149750892	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.809	rs9479808	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149751328	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs62441284	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149751542	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10782316	ENSG00000231760.4	RP11-350J20.5	8.69	1.92e-14	5.26e-10	0.76	0.62	Lung cancer;	chr6:149752755	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.628	rs10076629	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920272	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10078079	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920450	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.659	rs11750067	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138920589	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10054682	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923754	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs11953339	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923853	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs9327828	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925859	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10155636	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138926301	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10463975	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138927560	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs11954103	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138933459	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10045605	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936458	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.728	rs10068786	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.26e-10	0.98	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138941255	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1059110	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.27e-10	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138930857	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs13178601	ENSG00000253404.1	AC034243.1	8.69	1.93e-14	5.27e-10	0.99	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931688	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs9766004	ENSG00000231760.4	RP11-350J20.5	8.68	1.97e-14	5.38e-10	0.77	0.62	Lung cancer;	chr6:149754363	chr6:149796151~149826294:-
ESCA	cis	rs9733	0.596	rs11204704	ENSG00000206931.1	RNU6-1042P	8.68	1.98e-14	5.38e-10	0.79	0.62	Tonsillectomy;	chr1:150699154	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12077833	ENSG00000206931.1	RNU6-1042P	8.68	1.98e-14	5.38e-10	0.79	0.62	Tonsillectomy;	chr1:150701857	chr1:150701866~150701972:+
ESCA	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-8.68	1.98e-14	5.38e-10	-0.64	-0.62	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	8.68	2e-14	5.43e-10	0.83	0.62	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
ESCA	cis	rs9733	0.596	rs6587518	ENSG00000206931.1	RNU6-1042P	8.68	2.02e-14	5.45e-10	0.8	0.62	Tonsillectomy;	chr1:150689311	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs7529998	ENSG00000206931.1	RNU6-1042P	8.68	2.02e-14	5.45e-10	0.8	0.62	Tonsillectomy;	chr1:150690055	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702536	ENSG00000206931.1	RNU6-1042P	8.68	2.02e-14	5.45e-10	0.8	0.62	Tonsillectomy;	chr1:150690098	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs11803569	ENSG00000206931.1	RNU6-1042P	8.68	2.02e-14	5.45e-10	0.8	0.62	Tonsillectomy;	chr1:150691601	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs1336898	ENSG00000206931.1	RNU6-1042P	8.68	2.02e-14	5.45e-10	0.8	0.62	Tonsillectomy;	chr1:150692574	chr1:150701866~150701972:+
ESCA	cis	rs2882667	0.69	rs11750163	ENSG00000253404.1	AC034243.1	8.68	2.03e-14	5.47e-10	0.96	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138705920	chr5:138744434~138753309:-
ESCA	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-8.67	2.07e-14	5.56e-10	-0.92	-0.62	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-8.67	2.07e-14	5.56e-10	-0.92	-0.62	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
ESCA	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-8.67	2.14e-14	5.73e-10	-0.71	-0.62	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	8.66	2.17e-14	5.81e-10	0.73	0.62	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.961	rs4870144	ENSG00000231760.4	RP11-350J20.5	8.66	2.19e-14	5.87e-10	0.75	0.62	Lung cancer;	chr6:149575540	chr6:149796151~149826294:-
ESCA	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-8.66	2.26e-14	6.03e-10	-0.94	-0.62	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
ESCA	cis	rs9733	0.566	rs112967224	ENSG00000206931.1	RNU6-1042P	8.65	2.3e-14	6.11e-10	0.79	0.62	Tonsillectomy;	chr1:150704787	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702552	ENSG00000206931.1	RNU6-1042P	8.65	2.3e-14	6.11e-10	0.79	0.62	Tonsillectomy;	chr1:150704986	chr1:150701866~150701972:+
ESCA	cis	rs2882667	0.69	rs2351463	ENSG00000253404.1	AC034243.1	8.65	2.31e-14	6.12e-10	0.96	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138923113	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10068280	ENSG00000253404.1	AC034243.1	8.65	2.31e-14	6.12e-10	0.96	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138931394	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs9327830	ENSG00000253404.1	AC034243.1	8.65	2.31e-14	6.12e-10	0.96	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936560	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs9327831	ENSG00000253404.1	AC034243.1	8.65	2.31e-14	6.12e-10	0.96	0.62	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936597	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000273295.1	AP000350.5	8.65	2.36e-14	6.24e-10	0.83	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23901432~23907068:-
ESCA	cis	rs9733	0.596	rs72702585	ENSG00000206931.1	RNU6-1042P	8.64	2.52e-14	6.58e-10	0.79	0.61	Tonsillectomy;	chr1:150723951	chr1:150701866~150701972:+
ESCA	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-8.63	2.55e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-8.63	2.55e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs9800871	ENSG00000231760.4	RP11-350J20.5	8.63	2.56e-14	6.58e-10	0.74	0.61	Lung cancer;	chr6:149644540	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9800614	ENSG00000231760.4	RP11-350J20.5	8.63	2.56e-14	6.58e-10	0.74	0.61	Lung cancer;	chr6:149644604	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs11155670	ENSG00000231760.4	RP11-350J20.5	8.63	2.56e-14	6.58e-10	0.74	0.61	Lung cancer;	chr6:149644992	chr6:149796151~149826294:-
ESCA	cis	rs17507216	0.671	rs28582623	ENSG00000278603.1	RP13-608F4.5	8.63	2.61e-14	6.58e-10	1.02	0.61	Excessive daytime sleepiness;	chr15:82577381	chr15:82472203~82472426:+
ESCA	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	8.63	2.61e-14	6.58e-10	0.74	0.61	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
ESCA	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	8.63	2.61e-14	6.58e-10	0.64	0.61	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	8.63	2.61e-14	6.58e-10	0.64	0.61	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	8.63	2.61e-14	6.58e-10	0.64	0.61	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	8.63	2.61e-14	6.58e-10	0.64	0.61	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-8.63	2.61e-14	6.58e-10	-0.64	-0.61	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	8.63	2.62e-14	6.6e-10	0.79	0.61	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs12174716	ENSG00000231760.4	RP11-350J20.5	8.63	2.65e-14	6.66e-10	0.74	0.61	Lung cancer;	chr6:149644487	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.69	rs825672	ENSG00000253404.1	AC034243.1	-8.62	2.81e-14	7.04e-10	-1.02	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138759954	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	8.61	2.84e-14	7.1e-10	0.75	0.61	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	8.61	2.84e-14	7.1e-10	0.75	0.61	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	8.61	2.84e-14	7.1e-10	0.75	0.61	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
ESCA	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-8.61	2.93e-14	7.24e-10	-0.83	-0.61	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
ESCA	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	8.61	2.97e-14	7.34e-10	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	8.61	2.97e-14	7.34e-10	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	8.61	2.97e-14	7.34e-10	0.76	0.61	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
ESCA	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-8.6	3.03e-14	7.47e-10	-0.83	-0.61	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000218537.1	MIF-AS1	8.59	3.3e-14	8.07e-10	0.87	0.61	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23894426~23898930:-
ESCA	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	8.58	3.44e-14	8.39e-10	0.63	0.61	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	8.58	3.44e-14	8.39e-10	0.63	0.61	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	8.58	3.44e-14	8.39e-10	0.63	0.61	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	8.58	3.44e-14	8.39e-10	0.63	0.61	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	8.58	3.44e-14	8.39e-10	0.63	0.61	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
ESCA	cis	rs62229266	0.682	rs11700546	ENSG00000231106.2	LINC01436	8.58	3.47e-14	8.46e-10	0.69	0.61	Mitral valve prolapse;	chr21:35998841	chr21:36005338~36007838:+
ESCA	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	8.58	3.51e-14	8.53e-10	0.64	0.61	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
ESCA	cis	rs9733	0.596	rs3087960	ENSG00000206931.1	RNU6-1042P	8.58	3.52e-14	8.56e-10	0.8	0.61	Tonsillectomy;	chr1:150648093	chr1:150701866~150701972:+
ESCA	cis	rs2882667	0.69	rs13177415	ENSG00000253404.1	AC034243.1	8.57	3.58e-14	8.7e-10	0.97	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914251	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs13181762	ENSG00000253404.1	AC034243.1	8.57	3.58e-14	8.7e-10	0.97	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138914417	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	8.56	3.79e-14	9.18e-10	0.77	0.61	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	8.56	3.79e-14	9.18e-10	0.77	0.61	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
ESCA	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-8.56	3.8e-14	9.2e-10	-0.77	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-8.56	3.8e-14	9.2e-10	-0.77	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
ESCA	cis	rs3734266	0.646	rs79139175	ENSG00000186328.4	RP11-140K17.2	8.55	4e-14	9.62e-10	1.1	0.61	Systemic lupus erythematosus;	chr6:34601709	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.69	rs2016720	ENSG00000253404.1	AC034243.1	8.55	4.02e-14	9.66e-10	0.98	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138928369	chr5:138744434~138753309:-
ESCA	cis	rs3734266	0.702	rs34374374	ENSG00000186328.4	RP11-140K17.2	8.55	4.07e-14	9.75e-10	1.1	0.61	Systemic lupus erythematosus;	chr6:34600259	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.652	rs700622	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138762862	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs7722965	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138764766	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.587	rs825674	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138767031	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825677	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138769081	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs1976562	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138774905	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs825759	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138790250	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs7736925	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138818841	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs883333	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138819781	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6596455	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138831416	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs995177	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138833874	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.654	rs7710300	ENSG00000253404.1	AC034243.1	-8.55	4.1e-14	9.75e-10	-0.98	-0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138834793	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	8.54	4.16e-14	9.88e-10	0.73	0.61	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
ESCA	cis	rs3734266	0.639	rs6914714	ENSG00000186328.4	RP11-140K17.2	8.54	4.22e-14	9.97e-10	1.08	0.61	Systemic lupus erythematosus;	chr6:34676442	chr6:34715613~34715940:+
ESCA	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	8.54	4.22e-14	9.97e-10	0.64	0.61	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-8.54	4.33e-14	1.02e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
ESCA	cis	rs17507216	0.718	rs28587782	ENSG00000278603.1	RP13-608F4.5	8.54	4.35e-14	1.02e-09	1.01	0.61	Excessive daytime sleepiness;	chr15:82576881	chr15:82472203~82472426:+
ESCA	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-8.54	4.37e-14	1.03e-09	-0.77	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
ESCA	cis	rs17507216	0.718	rs17158403	ENSG00000278603.1	RP13-608F4.5	8.53	4.39e-14	1.03e-09	1.01	0.61	Excessive daytime sleepiness;	chr15:82572478	chr15:82472203~82472426:+
ESCA	cis	rs17507216	0.671	rs4779035	ENSG00000278603.1	RP13-608F4.5	8.53	4.47e-14	1.05e-09	1.03	0.61	Excessive daytime sleepiness;	chr15:82591686	chr15:82472203~82472426:+
ESCA	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-8.53	4.48e-14	1.05e-09	-0.79	-0.61	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.962	rs2065664	ENSG00000231760.4	RP11-350J20.5	8.53	4.54e-14	1.06e-09	0.73	0.61	Lung cancer;	chr6:149762485	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-8.53	4.61e-14	1.07e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.962	rs2342764	ENSG00000231760.4	RP11-350J20.5	8.52	4.67e-14	1.07e-09	0.79	0.61	Lung cancer;	chr6:149835068	chr6:149796151~149826294:-
ESCA	cis	rs17507216	0.718	rs7161977	ENSG00000278603.1	RP13-608F4.5	8.52	4.75e-14	1.09e-09	1.03	0.61	Excessive daytime sleepiness;	chr15:82646782	chr15:82472203~82472426:+
ESCA	cis	rs9322193	0.923	rs10747276	ENSG00000231760.4	RP11-350J20.5	8.51	4.9e-14	1.12e-09	0.77	0.61	Lung cancer;	chr6:149758739	chr6:149796151~149826294:-
ESCA	cis	rs17507216	0.718	rs72753931	ENSG00000278603.1	RP13-608F4.5	8.51	4.95e-14	1.13e-09	1.05	0.61	Excessive daytime sleepiness;	chr15:82721485	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.628	rs13154573	ENSG00000253404.1	AC034243.1	8.51	4.95e-14	1.13e-09	1.08	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138812375	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs12174035	ENSG00000231760.4	RP11-350J20.5	8.51	5.06e-14	1.15e-09	0.74	0.61	Lung cancer;	chr6:149763311	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322209	ENSG00000231760.4	RP11-350J20.5	8.5	5.36e-14	1.21e-09	0.77	0.61	Lung cancer;	chr6:149691226	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	8.49	5.48e-14	1.23e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	8.49	5.48e-14	1.23e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	8.49	5.48e-14	1.23e-09	0.74	0.61	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs10067361	ENSG00000253404.1	AC034243.1	8.49	5.52e-14	1.24e-09	0.97	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138905185	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs12186373	ENSG00000253404.1	AC034243.1	8.49	5.52e-14	1.24e-09	0.97	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138912885	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	8.49	5.52e-14	1.24e-09	0.75	0.61	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-8.48	5.9e-14	1.32e-09	-0.64	-0.61	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs4870052	ENSG00000231760.4	RP11-350J20.5	8.48	5.94e-14	1.33e-09	0.78	0.61	Lung cancer;	chr6:149839978	chr6:149796151~149826294:-
ESCA	cis	rs3734266	0.702	rs115531193	ENSG00000186328.4	RP11-140K17.2	8.47	6.15e-14	1.37e-09	1.05	0.61	Systemic lupus erythematosus;	chr6:34683534	chr6:34715613~34715940:+
ESCA	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-8.47	6.18e-14	1.37e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-8.47	6.26e-14	1.39e-09	-0.87	-0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
ESCA	cis	rs9322193	0.923	rs9478291	ENSG00000231760.4	RP11-350J20.5	8.46	6.48e-14	1.43e-09	0.74	0.61	Lung cancer;	chr6:149729434	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	8.46	6.53e-14	1.44e-09	1.09	0.61	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
ESCA	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	8.46	6.7e-14	1.47e-09	0.84	0.61	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
ESCA	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-8.46	6.72e-14	1.47e-09	-0.63	-0.61	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	8.46	6.76e-14	1.48e-09	0.75	0.61	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
ESCA	cis	rs7412746	0.597	rs868751	ENSG00000206931.1	RNU6-1042P	8.45	6.77e-14	1.48e-09	0.79	0.61	Melanoma;	chr1:150696938	chr1:150701866~150701972:+
ESCA	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	8.45	6.81e-14	1.49e-09	0.8	0.61	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-8.45	6.96e-14	1.52e-09	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
ESCA	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	8.44	7.32e-14	1.6e-09	1.01	0.61	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
ESCA	cis	rs2882667	0.69	rs10071381	ENSG00000253404.1	AC034243.1	8.44	7.33e-14	1.6e-09	0.93	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138937159	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	8.44	7.36e-14	1.6e-09	0.72	0.61	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
ESCA	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-8.44	7.41e-14	1.61e-09	-0.89	-0.61	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-8.44	7.41e-14	1.61e-09	-0.89	-0.61	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
ESCA	cis	rs9322193	0.884	rs9688699	ENSG00000231760.4	RP11-350J20.5	8.44	7.53e-14	1.63e-09	0.75	0.61	Lung cancer;	chr6:149733680	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs56397000	ENSG00000231760.4	RP11-350J20.5	8.44	7.53e-14	1.63e-09	0.75	0.61	Lung cancer;	chr6:149739347	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9689702	ENSG00000231760.4	RP11-350J20.5	8.44	7.53e-14	1.63e-09	0.75	0.61	Lung cancer;	chr6:149740720	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10782315	ENSG00000231760.4	RP11-350J20.5	8.44	7.53e-14	1.63e-09	0.75	0.61	Lung cancer;	chr6:149743093	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-8.43	7.58e-14	1.64e-09	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-8.43	7.58e-14	1.64e-09	-0.77	-0.61	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-8.43	7.58e-14	1.64e-09	-0.76	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.69	rs6890932	ENSG00000253404.1	AC034243.1	8.43	7.59e-14	1.64e-09	0.97	0.61	Age-related hearing impairment (SNP x SNP interaction);	chr5:138910639	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs2297928	ENSG00000231760.4	RP11-350J20.5	8.43	7.64e-14	1.64e-09	0.76	0.61	Lung cancer;	chr6:149718584	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs12526675	ENSG00000231760.4	RP11-350J20.5	-8.43	7.79e-14	1.67e-09	-0.74	-0.61	Lung cancer;	chr6:149729540	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs7450246	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149702517	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9383812	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149712355	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.847	rs9383844	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149716268	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2297930	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149718360	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9479094	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149725083	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9688350	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149730977	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9767652	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149734502	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs10782314	ENSG00000231760.4	RP11-350J20.5	8.43	7.88e-14	1.68e-09	0.75	0.6	Lung cancer;	chr6:149735527	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	8.43	7.92e-14	1.68e-09	0.72	0.6	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
ESCA	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-8.42	7.97e-14	1.68e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
ESCA	cis	rs62229266	0.682	rs2835224	ENSG00000231106.2	LINC01436	8.42	8.14e-14	1.71e-09	0.68	0.6	Mitral valve prolapse;	chr21:35997732	chr21:36005338~36007838:+
ESCA	cis	rs9322193	0.923	rs7767622	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149681766	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs3798761	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149683643	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9322210	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149695440	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs11155674	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149711111	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2185352	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149714640	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs12174349	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149718012	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2297932	ENSG00000231760.4	RP11-350J20.5	8.42	8.14e-14	1.71e-09	0.75	0.6	Lung cancer;	chr6:149718225	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs4869750	ENSG00000231760.4	RP11-350J20.5	8.42	8.31e-14	1.74e-09	0.74	0.6	Lung cancer;	chr6:149855996	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-8.41	8.47e-14	1.77e-09	-1.04	-0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
ESCA	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-8.41	8.77e-14	1.81e-09	-0.63	-0.6	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.962	rs4870048	ENSG00000231760.4	RP11-350J20.5	8.41	8.83e-14	1.82e-09	0.77	0.6	Lung cancer;	chr6:149834324	chr6:149796151~149826294:-
ESCA	cis	rs9733	0.519	rs2184833	ENSG00000206931.1	RNU6-1042P	8.4	8.9e-14	1.83e-09	0.77	0.6	Tonsillectomy;	chr1:150703007	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.565	rs7524620	ENSG00000206931.1	RNU6-1042P	-8.4	9.03e-14	1.86e-09	-0.77	-0.6	Tonsillectomy;	chr1:150644223	chr1:150701866~150701972:+
ESCA	cis	rs2882667	0.69	rs891996	ENSG00000253404.1	AC034243.1	8.39	9.46e-14	1.94e-09	0.92	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138932127	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.628	rs3749663	ENSG00000253404.1	AC034243.1	8.39	9.46e-14	1.94e-09	0.92	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935498	chr5:138744434~138753309:-
ESCA	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	8.39	9.58e-14	1.96e-09	1.01	0.6	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
ESCA	cis	rs2882667	0.628	rs13173618	ENSG00000253404.1	AC034243.1	8.39	9.64e-14	1.97e-09	1.06	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138804091	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs3763016	ENSG00000253404.1	AC034243.1	8.39	9.64e-14	1.97e-09	0.93	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935043	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.962	rs2275045	ENSG00000231760.4	RP11-350J20.5	8.39	9.64e-14	1.97e-09	0.79	0.6	Lung cancer;	chr6:149842775	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	8.39	9.66e-14	1.98e-09	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	8.39	9.68e-14	1.98e-09	0.77	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
ESCA	cis	rs2882667	0.554	rs1368425	ENSG00000253404.1	AC034243.1	8.39	9.75e-14	1.99e-09	1	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944528	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs3749664	ENSG00000253404.1	AC034243.1	8.39	9.83e-14	2.01e-09	0.93	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138935732	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs6872423	ENSG00000253404.1	AC034243.1	8.38	1.01e-13	2.06e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138911089	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	8.37	1.06e-13	2.15e-09	1.09	0.6	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000250470.1	AP000351.3	-8.37	1.08e-13	2.19e-09	-0.7	-0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23976904~23977585:-
ESCA	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	8.36	1.11e-13	2.25e-09	0.84	0.6	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	8.36	1.14e-13	2.3e-09	0.73	0.6	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs288007	ENSG00000253404.1	AC034243.1	8.36	1.14e-13	2.31e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894939	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	8.36	1.15e-13	2.32e-09	0.76	0.6	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-8.36	1.16e-13	2.32e-09	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	8.35	1.22e-13	2.41e-09	0.75	0.6	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.654	rs2351247	ENSG00000253404.1	AC034243.1	-8.35	1.22e-13	2.41e-09	-0.96	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138849456	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.619	rs6861556	ENSG00000253404.1	AC034243.1	-8.35	1.22e-13	2.41e-09	-0.96	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138852351	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288018	ENSG00000253404.1	AC034243.1	-8.35	1.22e-13	2.41e-09	-0.96	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138856727	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288017	ENSG00000253404.1	AC034243.1	-8.35	1.22e-13	2.41e-09	-0.96	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138857826	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs167009	ENSG00000253404.1	AC034243.1	-8.35	1.22e-13	2.41e-09	-0.96	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138864768	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288040	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138869205	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.659	rs288037	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138872752	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288036	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138875206	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288035	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138876728	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288032	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138879639	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288026	ENSG00000253404.1	AC034243.1	8.35	1.22e-13	2.41e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886905	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.887	rs11155662	ENSG00000231760.4	RP11-350J20.5	8.35	1.22e-13	2.41e-09	0.73	0.6	Lung cancer;	chr6:149592731	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.961	rs9285521	ENSG00000231760.4	RP11-350J20.5	8.34	1.25e-13	2.46e-09	0.71	0.6	Lung cancer;	chr6:149585576	chr6:149796151~149826294:-
ESCA	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	8.34	1.26e-13	2.48e-09	0.84	0.6	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
ESCA	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	8.34	1.27e-13	2.5e-09	0.84	0.6	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
ESCA	cis	rs2882667	0.69	rs288024	ENSG00000253404.1	AC034243.1	8.33	1.3e-13	2.53e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888103	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288021	ENSG00000253404.1	AC034243.1	8.33	1.3e-13	2.53e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138888594	chr5:138744434~138753309:-
ESCA	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	8.33	1.3e-13	2.55e-09	0.76	0.6	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-8.32	1.39e-13	2.7e-09	-0.89	-0.6	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
ESCA	cis	rs3734266	0.702	rs451603	ENSG00000186328.4	RP11-140K17.2	-8.32	1.39e-13	2.7e-09	-1.04	-0.6	Systemic lupus erythematosus;	chr6:34581330	chr6:34715613~34715940:+
ESCA	cis	rs3734266	0.702	rs6900426	ENSG00000186328.4	RP11-140K17.2	-8.32	1.39e-13	2.7e-09	-1.04	-0.6	Systemic lupus erythematosus;	chr6:34656371	chr6:34715613~34715940:+
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000225282.1	AP000350.6	8.32	1.43e-13	2.76e-09	0.76	0.6	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23926900~23929574:+
ESCA	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	8.31	1.45e-13	2.8e-09	0.78	0.6	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
ESCA	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	8.31	1.5e-13	2.88e-09	0.62	0.6	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	8.3	1.54e-13	2.95e-09	0.75	0.6	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	8.3	1.54e-13	2.95e-09	0.75	0.6	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.69	rs700619	ENSG00000253404.1	AC034243.1	-8.3	1.54e-13	2.95e-09	-0.97	-0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138753060	chr5:138744434~138753309:-
ESCA	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-8.3	1.54e-13	2.95e-09	-0.79	-0.6	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
ESCA	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	8.3	1.56e-13	2.99e-09	0.96	0.6	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
ESCA	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-8.3	1.59e-13	3.03e-09	-0.88	-0.6	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-8.3	1.59e-13	3.03e-09	-0.88	-0.6	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-8.3	1.59e-13	3.03e-09	-0.88	-0.6	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-8.3	1.59e-13	3.03e-09	-0.88	-0.6	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
ESCA	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-8.3	1.6e-13	3.05e-09	-0.63	-0.6	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
ESCA	cis	rs62229266	0.804	rs62230788	ENSG00000231106.2	LINC01436	8.29	1.62e-13	3.09e-09	0.67	0.6	Mitral valve prolapse;	chr21:36008039	chr21:36005338~36007838:+
ESCA	cis	rs3734266	0.639	rs9469813	ENSG00000186328.4	RP11-140K17.2	8.28	1.71e-13	3.23e-09	1.05	0.6	Systemic lupus erythematosus;	chr6:34602037	chr6:34715613~34715940:+
ESCA	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	8.28	1.73e-13	3.27e-09	1.02	0.6	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
ESCA	cis	rs2882667	0.69	rs288009	ENSG00000253404.1	AC034243.1	8.28	1.73e-13	3.27e-09	0.95	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138892973	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs185956	ENSG00000253404.1	AC034243.1	8.28	1.73e-13	3.27e-09	0.95	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138894574	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.658	rs288003	ENSG00000253404.1	AC034243.1	8.28	1.73e-13	3.27e-09	0.95	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896266	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs288002	ENSG00000253404.1	AC034243.1	8.28	1.73e-13	3.27e-09	0.95	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138896398	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.69	rs10044401	ENSG00000253404.1	AC034243.1	8.28	1.73e-13	3.27e-09	0.95	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138901868	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs9767105	ENSG00000231760.4	RP11-350J20.5	8.27	1.79e-13	3.37e-09	0.73	0.6	Lung cancer;	chr6:149659591	chr6:149796151~149826294:-
ESCA	cis	rs17507216	0.718	rs72751675	ENSG00000278603.1	RP13-608F4.5	8.27	1.86e-13	3.49e-09	1	0.6	Excessive daytime sleepiness;	chr15:82630452	chr15:82472203~82472426:+
ESCA	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-8.26	1.97e-13	3.68e-09	-0.76	-0.6	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
ESCA	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	8.26	1.98e-13	3.7e-09	0.83	0.6	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
ESCA	cis	rs9733	0.519	rs1336900	ENSG00000206931.1	RNU6-1042P	8.25	2.1e-13	3.9e-09	0.73	0.6	Tonsillectomy;	chr1:150706557	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-8.22	2.38e-13	4.4e-09	-0.76	-0.6	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	8.22	2.39e-13	4.41e-09	0.73	0.6	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
ESCA	cis	rs3734266	0.591	rs35684630	ENSG00000186328.4	RP11-140K17.2	8.22	2.39e-13	4.41e-09	0.98	0.6	Systemic lupus erythematosus;	chr6:34702567	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.69	rs288028	ENSG00000253404.1	AC034243.1	8.22	2.4e-13	4.43e-09	0.94	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138886300	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs7769101	ENSG00000231760.4	RP11-350J20.5	8.21	2.49e-13	4.58e-09	0.74	0.6	Lung cancer;	chr6:149848768	chr6:149796151~149826294:-
ESCA	cis	rs2882667	0.69	rs288029	ENSG00000253404.1	AC034243.1	8.21	2.5e-13	4.6e-09	0.96	0.6	Age-related hearing impairment (SNP x SNP interaction);	chr5:138881616	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	8.21	2.56e-13	4.7e-09	0.72	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
ESCA	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	8.21	2.58e-13	4.74e-09	0.82	0.59	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
ESCA	cis	rs17507216	0.628	rs28737193	ENSG00000278603.1	RP13-608F4.5	8.2	2.67e-13	4.87e-09	1.02	0.59	Excessive daytime sleepiness;	chr15:82701318	chr15:82472203~82472426:+
ESCA	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	8.2	2.67e-13	4.87e-09	1.04	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	8.2	2.67e-13	4.87e-09	1.04	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
ESCA	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	8.2	2.67e-13	4.87e-09	0.83	0.59	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
ESCA	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	8.2	2.7e-13	4.92e-09	1.04	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
ESCA	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	8.19	2.85e-13	5.17e-09	0.68	0.59	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
ESCA	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	8.19	2.85e-13	5.17e-09	0.68	0.59	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
ESCA	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	8.19	2.87e-13	5.2e-09	0.69	0.59	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
ESCA	cis	rs17507216	0.588	rs28864981	ENSG00000278603.1	RP13-608F4.5	8.19	2.87e-13	5.2e-09	1.02	0.59	Excessive daytime sleepiness;	chr15:82695420	chr15:82472203~82472426:+
ESCA	cis	rs17507216	0.628	rs8032321	ENSG00000278603.1	RP13-608F4.5	8.19	2.87e-13	5.2e-09	1.02	0.59	Excessive daytime sleepiness;	chr15:82698956	chr15:82472203~82472426:+
ESCA	cis	rs17507216	0.628	rs8040488	ENSG00000278603.1	RP13-608F4.5	8.19	2.87e-13	5.2e-09	1.02	0.59	Excessive daytime sleepiness;	chr15:82699081	chr15:82472203~82472426:+
ESCA	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	8.18	2.91e-13	5.28e-09	0.99	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
ESCA	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	8.18	3.04e-13	5.5e-09	0.69	0.59	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
ESCA	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-8.18	3.04e-13	5.5e-09	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-8.18	3.04e-13	5.5e-09	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
ESCA	cis	rs9322193	0.923	rs55849538	ENSG00000231760.4	RP11-350J20.5	8.18	3.05e-13	5.51e-09	0.7	0.59	Lung cancer;	chr6:149635330	chr6:149796151~149826294:-
ESCA	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-8.16	3.28e-13	5.88e-09	-0.62	-0.59	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs4421206	ENSG00000231760.4	RP11-350J20.5	8.16	3.33e-13	5.96e-09	0.73	0.59	Lung cancer;	chr6:149682891	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	8.16	3.41e-13	6.08e-09	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	8.16	3.41e-13	6.08e-09	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	8.16	3.41e-13	6.08e-09	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	8.16	3.41e-13	6.08e-09	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	8.16	3.41e-13	6.08e-09	0.71	0.59	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	8.15	3.59e-13	6.32e-09	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
ESCA	cis	rs9733	0.596	rs6587516	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150650745	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6678013	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150650809	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs2175615	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150651625	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.628	rs72700895	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150653553	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72700897	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150653562	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6661872	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150655881	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs11204687	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150657404	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs2867304	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150658519	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6690725	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150659846	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702504	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150662898	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6686525	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150663335	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.536	rs6661415	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150663393	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs11807058	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150667999	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs34140753	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150670107	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.569	rs11204691	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150671863	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12089731	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150675322	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs12095002	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150676773	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12085275	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150677789	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12086630	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150678479	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs2065900	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150679726	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.544	rs2867302	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150681174	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs2867301	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150681319	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs7538493	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150682945	chr1:150701866~150701972:+
ESCA	cis	rs4970988	0.64	rs7524734	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Urate levels;	chr1:150683210	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6685702	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150683831	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs7549795	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150684397	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs11204697	ENSG00000206931.1	RNU6-1042P	8.14	3.62e-13	6.32e-09	0.76	0.59	Tonsillectomy;	chr1:150686495	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	8.14	3.67e-13	6.39e-09	0.67	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
ESCA	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	8.14	3.69e-13	6.42e-09	0.62	0.59	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.69	rs9942422	ENSG00000253404.1	AC034243.1	8.14	3.7e-13	6.44e-09	0.94	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138936847	chr5:138744434~138753309:-
ESCA	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-8.14	3.74e-13	6.48e-09	-0.72	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-8.14	3.74e-13	6.48e-09	-0.72	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
ESCA	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	8.14	3.75e-13	6.49e-09	0.98	0.59	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
ESCA	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-8.13	3.94e-13	6.8e-09	-0.71	-0.59	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
ESCA	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-8.13	3.95e-13	6.81e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
ESCA	cis	rs9733	0.596	rs72702556	ENSG00000206931.1	RNU6-1042P	8.13	3.97e-13	6.85e-09	0.76	0.59	Tonsillectomy;	chr1:150707639	chr1:150701866~150701972:+
ESCA	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-8.12	4.04e-13	6.95e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-8.12	4.04e-13	6.95e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-8.12	4.04e-13	6.95e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
ESCA	cis	rs9733	0.566	rs72702554	ENSG00000206931.1	RNU6-1042P	8.12	4.1e-13	7.04e-09	0.75	0.59	Tonsillectomy;	chr1:150705758	chr1:150701866~150701972:+
ESCA	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	8.12	4.12e-13	7.06e-09	0.69	0.59	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	8.12	4.19e-13	7.16e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	8.12	4.19e-13	7.16e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	8.12	4.19e-13	7.16e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	8.12	4.19e-13	7.16e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	8.12	4.19e-13	7.16e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
ESCA	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	8.11	4.24e-13	7.23e-09	0.63	0.59	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
ESCA	cis	rs9733	0.596	rs11586422	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150706882	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702557	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150707654	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs17606613	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150710539	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.543	rs72702558	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150710775	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.628	rs11807409	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150710947	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.565	rs11804276	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150713285	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12072339	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150713623	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs34600506	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150715332	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702570	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150715720	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs11582840	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150716011	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.569	rs11588404	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150716053	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702573	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150716574	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs72702580	ENSG00000206931.1	RNU6-1042P	8.11	4.34e-13	7.36e-09	0.75	0.59	Tonsillectomy;	chr1:150718809	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs6700022	ENSG00000206931.1	RNU6-1042P	-8.11	4.36e-13	7.39e-09	-0.74	-0.59	Tonsillectomy;	chr1:150698008	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12063547	ENSG00000206931.1	RNU6-1042P	-8.11	4.39e-13	7.44e-09	-0.74	-0.59	Tonsillectomy;	chr1:150701577	chr1:150701866~150701972:+
ESCA	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	8.11	4.44e-13	7.49e-09	0.7	0.59	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
ESCA	cis	rs9733	0.525	rs11584184	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150723213	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6669369	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150723416	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6681990	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150723453	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs6692960	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150723489	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs12086472	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150725234	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.628	rs7540874	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150730187	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs1136808	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150730241	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs1415148	ENSG00000206931.1	RNU6-1042P	8.1	4.53e-13	7.6e-09	0.75	0.59	Tonsillectomy;	chr1:150733279	chr1:150701866~150701972:+
ESCA	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-8.09	4.71e-13	7.81e-09	-0.74	-0.59	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.772	rs7738696	ENSG00000231760.4	RP11-350J20.5	8.09	4.77e-13	7.9e-09	0.75	0.59	Lung cancer;	chr6:149848985	chr6:149796151~149826294:-
ESCA	cis	rs9733	0.596	rs56058687	ENSG00000206931.1	RNU6-1042P	8.09	4.85e-13	8.01e-09	0.76	0.59	Tonsillectomy;	chr1:150662590	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	8.09	4.91e-13	8.11e-09	0.62	0.59	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.523	rs1413724	ENSG00000203875.9	SNHG5	-8.09	4.92e-13	8.13e-09	-0.75	-0.59	Response to antipsychotic treatment;	chr6:86104831	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	8.08	5.18e-13	8.55e-09	0.81	0.59	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000250470.1	AP000351.3	8.07	5.25e-13	8.63e-09	0.69	0.59	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23976904~23977585:-
ESCA	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-8.07	5.33e-13	8.73e-09	-0.8	-0.59	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
ESCA	cis	rs6538678	0.746	rs1865736	ENSG00000258343.1	RP11-536G4.2	-8.07	5.51e-13	9.01e-09	-0.86	-0.59	Lupus nephritis in systemic lupus erythematosus;	chr12:95854051	chr12:95795345~95858839:-
ESCA	cis	rs9733	0.596	rs17658705	ENSG00000206931.1	RNU6-1042P	-8.06	5.61e-13	9.18e-09	-0.78	-0.59	Tonsillectomy;	chr1:150705595	chr1:150701866~150701972:+
ESCA	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-8.06	5.77e-13	9.41e-09	-0.61	-0.59	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
ESCA	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	8.05	6.02e-13	9.81e-09	1.03	0.59	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
ESCA	cis	rs4970988	0.501	rs11204713	ENSG00000206931.1	RNU6-1042P	8.04	6.18e-13	1.01e-08	0.75	0.59	Urate levels;	chr1:150722147	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.596	rs7418501	ENSG00000206931.1	RNU6-1042P	8.04	6.34e-13	1.03e-08	0.7	0.59	Tonsillectomy;	chr1:150739420	chr1:150701866~150701972:+
ESCA	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-8.04	6.37e-13	1.03e-08	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.961	rs9767713	ENSG00000231760.4	RP11-350J20.5	8.03	6.7e-13	1.07e-08	0.7	0.59	Lung cancer;	chr6:149588241	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-8.02	6.89e-13	1.1e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	8.02	7e-13	1.11e-08	0.61	0.59	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.967	rs387733	ENSG00000265828.1	MIR3939	8.02	7.07e-13	1.12e-08	0.63	0.59	Crohn's disease;	chr6:166996283	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs407515	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166994056	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs406095	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166995599	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.646	rs4710160	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166995753	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs388406	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166996074	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs433191	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166996174	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs430145	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166996881	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs425039	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166997039	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs376097	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166997390	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs424185	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166997419	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs400837	ENSG00000265828.1	MIR3939	-8.02	7.16e-13	1.13e-08	-0.64	-0.59	Crohn's disease;	chr6:166997520	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	8.01	7.23e-13	1.14e-08	0.61	0.59	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	8.01	7.23e-13	1.14e-08	0.61	0.59	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	8.01	7.23e-13	1.14e-08	0.61	0.59	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	8.01	7.23e-13	1.14e-08	0.61	0.59	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	8.01	7.23e-13	1.14e-08	0.61	0.59	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
ESCA	cis	rs9322193	1	rs58189451	ENSG00000231760.4	RP11-350J20.5	8.01	7.36e-13	1.16e-08	0.68	0.59	Lung cancer;	chr6:149600252	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-8.01	7.5e-13	1.18e-08	-0.7	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
ESCA	cis	rs9457247	1	rs416131	ENSG00000265828.1	MIR3939	8.01	7.56e-13	1.19e-08	0.64	0.59	Crohn's disease;	chr6:166993056	chr6:166997807~166997912:-
ESCA	cis	rs55794721	0.736	rs909832	ENSG00000261349.1	RP3-465N24.5	-7.99	8.22e-13	1.28e-08	-0.8	-0.58	Mean corpuscular volume;Plateletcrit;	chr1:25427534	chr1:25266102~25267136:-
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-7.98	8.59e-13	1.34e-08	-0.89	-0.58	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
ESCA	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	7.98	8.61e-13	1.34e-08	0.64	0.58	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	7.98	8.61e-13	1.34e-08	0.64	0.58	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
ESCA	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	7.98	8.65e-13	1.35e-08	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
ESCA	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-7.98	8.67e-13	1.35e-08	-0.72	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
ESCA	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	7.98	8.74e-13	1.36e-08	0.64	0.58	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	7.98	8.74e-13	1.36e-08	0.64	0.58	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
ESCA	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	7.98	8.75e-13	1.36e-08	0.72	0.58	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
ESCA	cis	rs9545047	0.935	rs7988601	ENSG00000227676.3	LINC01068	-7.98	8.88e-13	1.38e-08	-0.76	-0.58	Schizophrenia;	chr13:79475648	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs6563110	ENSG00000227676.3	LINC01068	-7.98	8.88e-13	1.38e-08	-0.76	-0.58	Schizophrenia;	chr13:79477137	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.901	rs7338530	ENSG00000227676.3	LINC01068	-7.98	8.88e-13	1.38e-08	-0.76	-0.58	Schizophrenia;	chr13:79477715	chr13:79566727~79571436:+
ESCA	cis	rs17507216	1	rs17356118	ENSG00000278603.1	RP13-608F4.5	7.97	9.1e-13	1.41e-08	0.91	0.58	Excessive daytime sleepiness;	chr15:82569149	chr15:82472203~82472426:+
ESCA	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	7.97	9.17e-13	1.41e-08	1.02	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
ESCA	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-7.96	9.46e-13	1.45e-08	-0.7	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
ESCA	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-7.96	9.5e-13	1.45e-08	-0.74	-0.58	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	7.96	9.53e-13	1.45e-08	0.62	0.58	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
ESCA	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	7.96	9.61e-13	1.46e-08	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	7.96	9.61e-13	1.46e-08	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	7.96	9.61e-13	1.46e-08	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	7.96	9.61e-13	1.46e-08	1.01	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
ESCA	cis	rs9322193	0.543	rs9371533	ENSG00000231760.4	RP11-350J20.5	7.96	9.62e-13	1.46e-08	0.73	0.58	Lung cancer;	chr6:149889545	chr6:149796151~149826294:-
ESCA	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	7.96	9.74e-13	1.48e-08	0.96	0.58	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
ESCA	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	7.95	1.01e-12	1.53e-08	1	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
ESCA	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-7.95	1.02e-12	1.54e-08	-0.69	-0.58	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
ESCA	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	7.95	1.04e-12	1.56e-08	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	7.95	1.04e-12	1.56e-08	0.7	0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
ESCA	cis	rs9457247	0.905	rs377232	ENSG00000265828.1	MIR3939	-7.95	1.05e-12	1.57e-08	-0.63	-0.58	Crohn's disease;	chr6:166996150	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	7.95	1.05e-12	1.57e-08	0.63	0.58	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	7.95	1.05e-12	1.57e-08	0.62	0.58	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	7.95	1.05e-12	1.57e-08	0.62	0.58	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	7.94	1.09e-12	1.63e-08	0.72	0.58	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
ESCA	cis	rs62229266	0.654	rs62230787	ENSG00000231106.2	LINC01436	7.94	1.09e-12	1.63e-08	0.64	0.58	Mitral valve prolapse;	chr21:36004182	chr21:36005338~36007838:+
ESCA	cis	rs9322193	0.923	rs12660304	ENSG00000231760.4	RP11-350J20.5	7.93	1.15e-12	1.71e-08	0.68	0.58	Lung cancer;	chr6:149739647	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	7.92	1.18e-12	1.74e-08	0.62	0.58	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-7.92	1.18e-12	1.74e-08	-0.62	-0.58	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.81	rs62439811	ENSG00000231760.4	RP11-350J20.5	7.92	1.18e-12	1.75e-08	0.68	0.58	Lung cancer;	chr6:149640416	chr6:149796151~149826294:-
ESCA	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	7.92	1.19e-12	1.75e-08	0.63	0.58	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	7.92	1.19e-12	1.75e-08	0.63	0.58	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
ESCA	cis	rs17507216	0.718	rs4779033	ENSG00000278603.1	RP13-608F4.5	-7.92	1.19e-12	1.75e-08	-0.93	-0.58	Excessive daytime sleepiness;	chr15:82576634	chr15:82472203~82472426:+
ESCA	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	7.92	1.2e-12	1.77e-08	0.61	0.58	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs9800686	ENSG00000231760.4	RP11-350J20.5	7.92	1.21e-12	1.77e-08	0.68	0.58	Lung cancer;	chr6:149634464	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-7.92	1.21e-12	1.77e-08	-0.69	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
ESCA	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	7.92	1.22e-12	1.78e-08	0.76	0.58	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
ESCA	cis	rs9733	0.544	rs72700902	ENSG00000206931.1	RNU6-1042P	7.92	1.22e-12	1.78e-08	0.75	0.58	Tonsillectomy;	chr1:150660871	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs10788792	ENSG00000206931.1	RNU6-1042P	7.92	1.22e-12	1.78e-08	0.75	0.58	Tonsillectomy;	chr1:150666096	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.527	rs11204694	ENSG00000206931.1	RNU6-1042P	7.92	1.22e-12	1.78e-08	0.75	0.58	Tonsillectomy;	chr1:150680915	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.526	rs11204696	ENSG00000206931.1	RNU6-1042P	7.92	1.22e-12	1.78e-08	0.75	0.58	Tonsillectomy;	chr1:150686245	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.526	rs11204698	ENSG00000206931.1	RNU6-1042P	7.92	1.22e-12	1.78e-08	0.75	0.58	Tonsillectomy;	chr1:150687069	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000250470.1	AP000351.3	7.91	1.27e-12	1.85e-08	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23976904~23977585:-
ESCA	cis	rs17507216	1	rs17158413	ENSG00000278603.1	RP13-608F4.5	7.91	1.28e-12	1.86e-08	0.96	0.58	Excessive daytime sleepiness;	chr15:82566658	chr15:82472203~82472426:+
ESCA	cis	rs9733	0.519	rs11807450	ENSG00000206931.1	RNU6-1042P	7.9	1.3e-12	1.88e-08	0.74	0.58	Tonsillectomy;	chr1:150705243	chr1:150701866~150701972:+
ESCA	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	7.9	1.31e-12	1.89e-08	0.66	0.58	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
ESCA	cis	rs62229266	0.773	rs878606	ENSG00000231106.2	LINC01436	7.9	1.33e-12	1.92e-08	0.64	0.58	Mitral valve prolapse;	chr21:36034394	chr21:36005338~36007838:+
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000250470.1	AP000351.3	7.89	1.37e-12	1.98e-08	0.68	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	7.89	1.4e-12	2.01e-08	0.79	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
ESCA	cis	rs9733	0.519	rs1336899	ENSG00000206931.1	RNU6-1042P	7.89	1.4e-12	2.02e-08	0.74	0.58	Tonsillectomy;	chr1:150706434	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs3768005	ENSG00000206931.1	RNU6-1042P	7.89	1.4e-12	2.02e-08	0.74	0.58	Tonsillectomy;	chr1:150708512	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs11803940	ENSG00000206931.1	RNU6-1042P	7.89	1.4e-12	2.02e-08	0.74	0.58	Melanoma;	chr1:150713359	chr1:150701866~150701972:+
ESCA	cis	rs9322193	0.923	rs9688452	ENSG00000231760.4	RP11-350J20.5	7.89	1.41e-12	2.03e-08	0.71	0.58	Lung cancer;	chr6:149658764	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	7.89	1.41e-12	2.03e-08	0.69	0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
ESCA	cis	rs2882667	0.628	rs13162420	ENSG00000253404.1	AC034243.1	7.89	1.43e-12	2.05e-08	1	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138839070	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.628	rs13167462	ENSG00000253404.1	AC034243.1	7.89	1.43e-12	2.05e-08	1	0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138841572	chr5:138744434~138753309:-
ESCA	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-7.88	1.46e-12	2.09e-08	-0.69	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-7.88	1.47e-12	2.1e-08	-0.61	-0.58	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
ESCA	cis	rs9733	0.519	rs7521898	ENSG00000206931.1	RNU6-1042P	7.88	1.49e-12	2.12e-08	0.74	0.58	Tonsillectomy;	chr1:150735120	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs7511673	ENSG00000206931.1	RNU6-1042P	7.88	1.49e-12	2.12e-08	0.74	0.58	Tonsillectomy;	chr1:150735160	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs72704603	ENSG00000206931.1	RNU6-1042P	7.88	1.49e-12	2.12e-08	0.74	0.58	Tonsillectomy;	chr1:150735516	chr1:150701866~150701972:+
ESCA	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-7.88	1.51e-12	2.14e-08	-0.61	-0.58	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
ESCA	cis	rs9457247	1	rs415890	ENSG00000265828.1	MIR3939	7.87	1.53e-12	2.16e-08	0.64	0.58	Crohn's disease;	chr6:166993145	chr6:166997807~166997912:-
ESCA	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-7.87	1.53e-12	2.16e-08	-0.72	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-7.87	1.59e-12	2.25e-08	-0.68	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-7.87	1.59e-12	2.25e-08	-0.68	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-7.87	1.59e-12	2.25e-08	-0.68	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-7.87	1.59e-12	2.25e-08	-0.68	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
ESCA	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	7.87	1.6e-12	2.26e-08	0.7	0.58	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
ESCA	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-7.86	1.65e-12	2.31e-08	-0.61	-0.58	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
ESCA	cis	rs9733	0.519	rs11204717	ENSG00000206931.1	RNU6-1042P	7.86	1.65e-12	2.31e-08	0.74	0.58	Tonsillectomy;	chr1:150736653	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	7.85	1.72e-12	2.41e-08	0.61	0.58	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.559	rs2223788	ENSG00000203875.9	SNHG5	-7.85	1.74e-12	2.42e-08	-0.75	-0.58	Response to antipsychotic treatment;	chr6:86102202	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	7.84	1.79e-12	2.49e-08	0.61	0.58	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000250470.1	AP000351.3	7.84	1.83e-12	2.55e-08	0.7	0.58	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23976904~23977585:-
ESCA	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-7.84	1.85e-12	2.58e-08	-0.69	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
ESCA	cis	rs1577917	0.559	rs7763210	ENSG00000203875.9	SNHG5	-7.83	1.93e-12	2.69e-08	-0.75	-0.58	Response to antipsychotic treatment;	chr6:86098900	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.884	rs7743823	ENSG00000231760.4	RP11-350J20.5	7.83	1.94e-12	2.7e-08	0.73	0.58	Lung cancer;	chr6:149849744	chr6:149796151~149826294:-
ESCA	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	7.83	1.98e-12	2.75e-08	0.61	0.58	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.69	rs9327829	ENSG00000253404.1	AC034243.1	-7.83	1.98e-12	2.75e-08	-0.95	-0.58	Age-related hearing impairment (SNP x SNP interaction);	chr5:138925982	chr5:138744434~138753309:-
ESCA	cis	rs9457247	1	rs932644	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166990699	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs10946198	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166990944	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs10946199	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991004	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs1794694	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991263	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs430293	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991470	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs430097	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991585	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs409356	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991738	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs447042	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166991947	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs402191	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992065	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs1794693	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992182	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs401260	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992400	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs422694	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992586	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs422780	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992721	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs400176	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166992750	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs415842	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166993193	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs389956	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166993766	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs389946	ENSG00000265828.1	MIR3939	-7.82	2.01e-12	2.77e-08	-0.64	-0.58	Crohn's disease;	chr6:166993780	chr6:166997807~166997912:-
ESCA	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-7.82	2.02e-12	2.78e-08	-0.69	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
ESCA	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-7.82	2.02e-12	2.78e-08	-0.69	-0.58	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
ESCA	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-7.81	2.12e-12	2.91e-08	-0.61	-0.58	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	7.81	2.12e-12	2.91e-08	0.61	0.58	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	7.81	2.12e-12	2.91e-08	0.61	0.58	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.884	rs7769115	ENSG00000231760.4	RP11-350J20.5	7.81	2.14e-12	2.94e-08	0.74	0.58	Lung cancer;	chr6:149848796	chr6:149796151~149826294:-
ESCA	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-7.8	2.33e-12	3.17e-08	-0.61	-0.58	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-7.8	2.33e-12	3.17e-08	-0.61	-0.58	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	7.8	2.33e-12	3.17e-08	0.61	0.58	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-7.79	2.34e-12	3.19e-08	-0.92	-0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.884	rs9383865	ENSG00000231760.4	RP11-350J20.5	7.79	2.35e-12	3.19e-08	0.72	0.57	Lung cancer;	chr6:149852043	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9397036	ENSG00000231760.4	RP11-350J20.5	7.79	2.39e-12	3.24e-08	0.72	0.57	Lung cancer;	chr6:149851787	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.884	rs9383864	ENSG00000231760.4	RP11-350J20.5	7.79	2.39e-12	3.24e-08	0.72	0.57	Lung cancer;	chr6:149851969	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-7.79	2.43e-12	3.3e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	7.78	2.46e-12	3.33e-08	0.69	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
ESCA	cis	rs9457247	1	rs408918	ENSG00000265828.1	MIR3939	-7.78	2.52e-12	3.41e-08	-0.63	-0.57	Crohn's disease;	chr6:166985794	chr6:166997807~166997912:-
ESCA	cis	rs6538678	0.784	rs7297403	ENSG00000258343.1	RP11-536G4.2	-7.78	2.54e-12	3.44e-08	-0.88	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95846683	chr12:95795345~95858839:-
ESCA	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	7.78	2.56e-12	3.47e-08	0.61	0.57	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
ESCA	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-7.77	2.63e-12	3.55e-08	-0.75	-0.57	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
ESCA	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	7.77	2.67e-12	3.59e-08	0.68	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
ESCA	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	7.77	2.68e-12	3.61e-08	1	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
ESCA	cis	rs172166	0.543	rs1150691	ENSG00000216901.1	AL022393.7	7.77	2.71e-12	3.65e-08	0.68	0.57	Cardiac Troponin-T levels;	chr6:28200255	chr6:28176188~28176674:+
ESCA	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-7.76	2.75e-12	3.69e-08	-0.61	-0.57	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-7.76	2.75e-12	3.69e-08	-0.61	-0.57	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-7.76	2.75e-12	3.69e-08	-0.61	-0.57	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
ESCA	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-7.76	2.76e-12	3.69e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
ESCA	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	7.76	2.76e-12	3.7e-08	0.64	0.57	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	7.76	2.76e-12	3.7e-08	0.64	0.57	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	7.76	2.76e-12	3.7e-08	0.64	0.57	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
ESCA	cis	rs9733	0.596	rs12403255	ENSG00000206931.1	RNU6-1042P	7.76	2.83e-12	3.78e-08	0.74	0.57	Tonsillectomy;	chr1:150687936	chr1:150701866~150701972:+
ESCA	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	7.76	2.85e-12	3.79e-08	0.61	0.57	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	7.76	2.85e-12	3.8e-08	0.68	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
ESCA	cis	rs9545047	0.935	rs9530922	ENSG00000227676.3	LINC01068	-7.75	2.96e-12	3.93e-08	-0.77	-0.57	Schizophrenia;	chr13:79469002	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs4885633	ENSG00000227676.3	LINC01068	-7.75	2.96e-12	3.93e-08	-0.77	-0.57	Schizophrenia;	chr13:79469720	chr13:79566727~79571436:+
ESCA	cis	rs1972460	0.506	rs62012050	ENSG00000278603.1	RP13-608F4.5	7.75	2.98e-12	3.96e-08	0.81	0.57	Intelligence (multi-trait analysis);	chr15:82239933	chr15:82472203~82472426:+
ESCA	cis	rs11155671	0.53	rs9371504	ENSG00000231760.4	RP11-350J20.5	7.75	3e-12	3.98e-08	0.7	0.57	Testicular germ cell tumor;	chr6:149862944	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9371505	ENSG00000231760.4	RP11-350J20.5	7.75	3e-12	3.98e-08	0.7	0.57	Testicular germ cell tumor;	chr6:149863012	chr6:149796151~149826294:-
ESCA	cis	rs9457247	1	rs2149090	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166959276	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2149091	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166959298	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs2149092	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166959490	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2013815	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166960324	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs4710147	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166960751	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs2757046	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166960865	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2757047	ENSG00000265828.1	MIR3939	7.75	3.03e-12	3.98e-08	0.63	0.57	Crohn's disease;	chr6:166961001	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs1819333	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166960059	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs393558	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166984262	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs394522	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166984583	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs408040	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166985415	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs413232	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166987484	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs86755	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166989620	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs382009	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166989633	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs428805	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166989644	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.934	rs2345571	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166989912	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.756	rs1811123	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166989955	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.902	rs366938	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166990050	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.871	rs1811121	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166990051	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs385460	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166990400	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs385113	ENSG00000265828.1	MIR3939	-7.75	3.03e-12	3.98e-08	-0.63	-0.57	Crohn's disease;	chr6:166990483	chr6:166997807~166997912:-
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	7.74	3.04e-12	4e-08	0.68	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
ESCA	cis	rs2882667	0.69	rs17031	ENSG00000253404.1	AC034243.1	7.74	3.13e-12	4.11e-08	0.93	0.57	Age-related hearing impairment (SNP x SNP interaction);	chr5:138934853	chr5:138744434~138753309:-
ESCA	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-7.74	3.15e-12	4.13e-08	-0.68	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-7.74	3.15e-12	4.13e-08	-0.68	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
ESCA	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	7.74	3.17e-12	4.16e-08	0.65	0.57	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
ESCA	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-7.74	3.2e-12	4.18e-08	-0.61	-0.57	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	7.74	3.2e-12	4.18e-08	0.61	0.57	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
ESCA	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	7.73	3.25e-12	4.24e-08	0.82	0.57	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-7.73	3.25e-12	4.24e-08	-0.61	-0.57	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-7.73	3.25e-12	4.24e-08	-0.61	-0.57	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-7.73	3.25e-12	4.24e-08	-0.77	-0.57	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
ESCA	cis	rs6538678	0.824	rs2367583	ENSG00000258343.1	RP11-536G4.2	-7.73	3.26e-12	4.25e-08	-0.83	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95856582	chr12:95795345~95858839:-
ESCA	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-7.73	3.35e-12	4.35e-08	-0.68	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
ESCA	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	7.72	3.38e-12	4.39e-08	0.78	0.57	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
ESCA	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	7.72	3.38e-12	4.39e-08	0.78	0.57	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
ESCA	cis	rs9457247	1	rs386548	ENSG00000265828.1	MIR3939	7.72	3.41e-12	4.42e-08	0.62	0.57	Crohn's disease;	chr6:166972045	chr6:166997807~166997912:-
ESCA	cis	rs9733	0.596	rs72702523	ENSG00000206931.1	RNU6-1042P	7.72	3.49e-12	4.48e-08	0.75	0.57	Tonsillectomy;	chr1:150677949	chr1:150701866~150701972:+
ESCA	cis	rs9457247	0.935	rs1187530	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166963324	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs2757050	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166963677	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs1590257	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166964294	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2769354	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166966283	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.846	rs2757052	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166966686	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs2015864	ENSG00000265828.1	MIR3939	7.72	3.5e-12	4.48e-08	0.63	0.57	Crohn's disease;	chr6:166967988	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs1211447	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166968491	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs1187532	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166968532	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs448060	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166969134	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs365189	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166971057	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs376551	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166971435	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs402749	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166972616	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs385863	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166973127	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs397713	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166973226	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.905	rs453184	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166973916	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs436707	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166975355	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs377753	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166976008	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs430477	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166976363	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs443570	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166976437	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs376574	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166976468	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs439553	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166977724	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs439237	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166977904	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs9457247	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166978686	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs405553	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166981570	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs1794697	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166981922	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.902	rs34560498	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166982374	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs422094	ENSG00000265828.1	MIR3939	-7.72	3.5e-12	4.48e-08	-0.63	-0.57	Crohn's disease;	chr6:166983545	chr6:166997807~166997912:-
ESCA	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-7.71	3.68e-12	4.71e-08	-0.62	-0.57	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
ESCA	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	7.7	3.88e-12	4.93e-08	0.96	0.57	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.887	rs2122290	ENSG00000217702.2	RP11-287D1.4	7.7	3.88e-12	4.93e-08	0.96	0.57	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.887	rs12478482	ENSG00000217702.2	RP11-287D1.4	7.7	3.88e-12	4.93e-08	0.96	0.57	Gestational age at birth (maternal effect);	chr2:74132293	chr2:74130583~74135395:+
ESCA	cis	rs9322193	0.923	rs57938011	ENSG00000231760.4	RP11-350J20.5	7.7	3.94e-12	5e-08	0.68	0.57	Lung cancer;	chr6:149642969	chr6:149796151~149826294:-
ESCA	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-7.69	3.98e-12	5.06e-08	-0.64	-0.57	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
ESCA	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	7.69	4.03e-12	5.11e-08	0.99	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	7.69	4.03e-12	5.11e-08	0.99	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	7.69	4.03e-12	5.11e-08	0.99	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
ESCA	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	7.69	4.03e-12	5.11e-08	0.83	0.57	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
ESCA	cis	rs9545047	0.901	rs314688	ENSG00000227676.3	LINC01068	7.69	4.09e-12	5.18e-08	0.74	0.57	Schizophrenia;	chr13:79449171	chr13:79566727~79571436:+
ESCA	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-7.69	4.11e-12	5.21e-08	-1.03	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
ESCA	cis	rs9457247	1	rs421214	ENSG00000265828.1	MIR3939	-7.69	4.12e-12	5.22e-08	-0.62	-0.57	Crohn's disease;	chr6:166983141	chr6:166997807~166997912:-
ESCA	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	7.68	4.25e-12	5.36e-08	0.81	0.57	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
ESCA	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	7.68	4.26e-12	5.37e-08	0.69	0.57	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
ESCA	cis	rs9457247	1	rs364283	ENSG00000265828.1	MIR3939	-7.68	4.28e-12	5.4e-08	-0.63	-0.57	Crohn's disease;	chr6:166970262	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs429083	ENSG00000265828.1	MIR3939	-7.68	4.28e-12	5.4e-08	-0.63	-0.57	Crohn's disease;	chr6:166970484	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs393727	ENSG00000265828.1	MIR3939	-7.67	4.43e-12	5.57e-08	-0.62	-0.57	Crohn's disease;	chr6:166985144	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs408087	ENSG00000265828.1	MIR3939	-7.67	4.43e-12	5.57e-08	-0.62	-0.57	Crohn's disease;	chr6:166985464	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	7.67	4.49e-12	5.63e-08	0.63	0.57	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	7.67	4.49e-12	5.63e-08	0.63	0.57	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	7.67	4.49e-12	5.63e-08	0.63	0.57	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
ESCA	cis	rs4747241	0.562	rs9416018	ENSG00000226163.1	RP11-167P22.3	-7.67	4.52e-12	5.66e-08	-0.63	-0.57	Heschl's gyrus morphology;	chr10:72340884	chr10:72501746~72502956:+
ESCA	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-7.67	4.58e-12	5.73e-08	-0.68	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
ESCA	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-7.66	4.63e-12	5.8e-08	-0.77	-0.57	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
ESCA	cis	rs17507216	0.958	rs28648832	ENSG00000278603.1	RP13-608F4.5	7.66	4.64e-12	5.8e-08	0.89	0.57	Excessive daytime sleepiness;	chr15:82567642	chr15:82472203~82472426:+
ESCA	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-7.66	4.71e-12	5.89e-08	-0.68	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
ESCA	cis	rs9322193	0.884	rs62439837	ENSG00000231760.4	RP11-350J20.5	7.66	4.77e-12	5.95e-08	0.68	0.57	Lung cancer;	chr6:149670380	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs62439840	ENSG00000231760.4	RP11-350J20.5	7.66	4.77e-12	5.95e-08	0.68	0.57	Lung cancer;	chr6:149674639	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs9393175	ENSG00000231760.4	RP11-350J20.5	7.66	4.77e-12	5.95e-08	0.68	0.57	Lung cancer;	chr6:149677587	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-7.66	4.81e-12	6e-08	-0.68	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	7.65	4.91e-12	6.11e-08	0.67	0.57	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
ESCA	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	7.65	5e-12	6.22e-08	0.62	0.57	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
ESCA	cis	rs9457247	1	rs400063	ENSG00000265828.1	MIR3939	-7.65	5.07e-12	6.29e-08	-0.62	-0.57	Crohn's disease;	chr6:166973104	chr6:166997807~166997912:-
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000228039.3	KB-1125A3.10	7.65	5.09e-12	6.33e-08	0.72	0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23963780~23964374:+
ESCA	cis	rs9457247	1	rs422562	ENSG00000265828.1	MIR3939	-7.65	5.1e-12	6.33e-08	-0.64	-0.57	Crohn's disease;	chr6:166992830	chr6:166997807~166997912:-
ESCA	cis	rs17507216	0.628	rs4627310	ENSG00000278603.1	RP13-608F4.5	7.65	5.14e-12	6.38e-08	0.98	0.57	Excessive daytime sleepiness;	chr15:82708330	chr15:82472203~82472426:+
ESCA	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	7.64	5.19e-12	6.43e-08	0.63	0.57	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	7.64	5.19e-12	6.43e-08	0.63	0.57	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
ESCA	cis	rs6538678	0.824	rs7299632	ENSG00000258343.1	RP11-536G4.2	-7.64	5.21e-12	6.45e-08	-0.87	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95838376	chr12:95795345~95858839:-
ESCA	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-7.64	5.31e-12	6.56e-08	-0.67	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
ESCA	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	7.64	5.38e-12	6.64e-08	0.77	0.57	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
ESCA	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-7.64	5.4e-12	6.66e-08	-0.76	-0.57	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
ESCA	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	7.63	5.59e-12	6.89e-08	0.63	0.57	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
ESCA	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-7.62	5.74e-12	7.07e-08	-0.81	-0.57	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
ESCA	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-7.62	5.76e-12	7.1e-08	-0.67	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-7.62	5.76e-12	7.1e-08	-0.67	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
ESCA	cis	rs6538678	0.746	rs4762630	ENSG00000258343.1	RP11-536G4.2	-7.62	5.95e-12	7.32e-08	-0.82	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95850631	chr12:95795345~95858839:-
ESCA	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	7.62	5.96e-12	7.32e-08	0.59	0.57	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.962	rs3805752	ENSG00000231760.4	RP11-350J20.5	7.61	6.04e-12	7.4e-08	0.73	0.57	Lung cancer;	chr6:149795490	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs12176034	ENSG00000231760.4	RP11-350J20.5	7.61	6.04e-12	7.4e-08	0.73	0.57	Lung cancer;	chr6:149800557	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-7.61	6.3e-12	7.7e-08	-0.66	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
ESCA	cis	rs6538678	0.824	rs2887026	ENSG00000258343.1	RP11-536G4.2	-7.6	6.37e-12	7.77e-08	-0.81	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95854713	chr12:95795345~95858839:-
ESCA	cis	rs6538678	0.824	rs4762631	ENSG00000258343.1	RP11-536G4.2	-7.6	6.37e-12	7.77e-08	-0.81	-0.57	Lupus nephritis in systemic lupus erythematosus;	chr12:95855698	chr12:95795345~95858839:-
ESCA	cis	rs9322193	0.847	rs868375	ENSG00000231760.4	RP11-350J20.5	7.6	6.57e-12	8e-08	0.74	0.57	Lung cancer;	chr6:149844905	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.847	rs56103941	ENSG00000231760.4	RP11-350J20.5	7.6	6.61e-12	8.04e-08	0.72	0.57	Lung cancer;	chr6:149816095	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.847	rs12210605	ENSG00000231760.4	RP11-350J20.5	7.6	6.61e-12	8.04e-08	0.72	0.57	Lung cancer;	chr6:149817267	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9371199	ENSG00000231760.4	RP11-350J20.5	7.6	6.61e-12	8.04e-08	0.72	0.57	Lung cancer;	chr6:149817526	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.962	rs7740784	ENSG00000231760.4	RP11-350J20.5	7.6	6.61e-12	8.04e-08	0.72	0.57	Lung cancer;	chr6:149833364	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-7.6	6.62e-12	8.05e-08	-0.68	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-7.6	6.62e-12	8.05e-08	-0.68	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
ESCA	cis	rs9322193	0.886	rs2065663	ENSG00000231760.4	RP11-350J20.5	7.59	6.79e-12	8.23e-08	0.71	0.56	Lung cancer;	chr6:149760331	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs12205092	ENSG00000231760.4	RP11-350J20.5	7.59	6.79e-12	8.23e-08	0.71	0.56	Lung cancer;	chr6:149761375	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-7.59	6.8e-12	8.24e-08	-0.67	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
ESCA	cis	rs9457247	1	rs2769347	ENSG00000265828.1	MIR3939	7.59	6.84e-12	8.29e-08	0.62	0.56	Crohn's disease;	chr6:166958249	chr6:166997807~166997912:-
ESCA	cis	rs9322193	0.962	rs3805749	ENSG00000231760.4	RP11-350J20.5	7.59	6.91e-12	8.36e-08	0.72	0.56	Lung cancer;	chr6:149772546	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.847	rs9505972	ENSG00000231760.4	RP11-350J20.5	7.59	6.91e-12	8.36e-08	0.72	0.56	Lung cancer;	chr6:149775255	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7758033	ENSG00000231760.4	RP11-350J20.5	7.59	7.02e-12	8.48e-08	0.71	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	7.59	7.05e-12	8.48e-08	0.8	0.56	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
ESCA	cis	rs9457247	0.967	rs2149083	ENSG00000265828.1	MIR3939	7.58	7.16e-12	8.61e-08	0.62	0.56	Crohn's disease;	chr6:166957483	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs2149084	ENSG00000265828.1	MIR3939	7.58	7.16e-12	8.61e-08	0.62	0.56	Crohn's disease;	chr6:166957500	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs2769346	ENSG00000265828.1	MIR3939	7.58	7.16e-12	8.61e-08	0.62	0.56	Crohn's disease;	chr6:166957511	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2149085	ENSG00000265828.1	MIR3939	7.58	7.16e-12	8.61e-08	0.62	0.56	Crohn's disease;	chr6:166957622	chr6:166997807~166997912:-
ESCA	cis	rs847845	0.535	rs72892238	ENSG00000186328.4	RP11-140K17.2	7.58	7.42e-12	8.88e-08	1.1	0.56	Non-small cell lung cancer;	chr6:34755359	chr6:34715613~34715940:+
ESCA	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-7.57	7.56e-12	9e-08	-0.8	-0.56	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
ESCA	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
ESCA	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	7.57	7.57e-12	9e-08	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	7.57	7.62e-12	9.05e-08	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs10782318	ENSG00000231760.4	RP11-350J20.5	7.57	7.67e-12	9.11e-08	0.69	0.56	Lung cancer;	chr6:149754137	chr6:149796151~149826294:-
ESCA	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-7.56	8.04e-12	9.51e-08	-0.97	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
ESCA	cis	rs7412746	0.611	rs111842513	ENSG00000206931.1	RNU6-1042P	7.56	8.25e-12	9.74e-08	0.71	0.56	Melanoma;	chr1:150740450	chr1:150701866~150701972:+
ESCA	cis	rs9322193	0.923	rs4870509	ENSG00000231760.4	RP11-350J20.5	7.55	8.27e-12	9.75e-08	0.69	0.56	Lung cancer;	chr6:149702212	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs9322214	ENSG00000231760.4	RP11-350J20.5	7.55	8.27e-12	9.75e-08	0.69	0.56	Lung cancer;	chr6:149703986	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.887	rs9767113	ENSG00000231760.4	RP11-350J20.5	7.55	8.27e-12	9.75e-08	0.69	0.56	Lung cancer;	chr6:149718157	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-7.55	8.48e-12	9.95e-08	-0.59	-0.56	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000099984.9	GSTT2	-7.55	8.53e-12	1e-07	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23980123~23983911:+
ESCA	cis	rs17608059	0.524	rs9897978	ENSG00000141028.6	CDRT15P1	7.55	8.58e-12	1.01e-07	0.62	0.56	Temperament;	chr17:13996939	chr17:14024514~14025488:+
ESCA	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	7.55	8.63e-12	1.01e-07	0.62	0.56	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
ESCA	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-7.54	8.98e-12	1.05e-07	-0.68	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
ESCA	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-7.54	9e-12	1.05e-07	-0.59	-0.56	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
ESCA	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-7.54	9.08e-12	1.06e-07	-0.56	-0.56	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
ESCA	cis	rs9457247	0.646	rs239934	ENSG00000265828.1	MIR3939	-7.54	9.16e-12	1.07e-07	-0.61	-0.56	Crohn's disease;	chr6:166998560	chr6:166997807~166997912:-
ESCA	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-7.53	9.21e-12	1.08e-07	-0.97	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
ESCA	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	7.53	9.3e-12	1.09e-07	0.94	0.56	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
ESCA	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	7.53	9.3e-12	1.09e-07	0.94	0.56	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
ESCA	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	7.53	9.35e-12	1.09e-07	0.65	0.56	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	7.53	9.41e-12	1.1e-07	0.65	0.56	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-7.53	9.44e-12	1.1e-07	-0.73	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
ESCA	cis	rs9322193	0.886	rs9767555	ENSG00000231760.4	RP11-350J20.5	7.53	9.62e-12	1.12e-07	0.67	0.56	Lung cancer;	chr6:149647022	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000228039.3	KB-1125A3.10	7.52	9.79e-12	1.14e-07	0.73	0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23963780~23964374:+
ESCA	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-7.52	9.89e-12	1.15e-07	-0.66	-0.56	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
ESCA	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-7.52	9.89e-12	1.15e-07	-0.66	-0.56	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
ESCA	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	7.51	1.02e-11	1.18e-07	0.73	0.56	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-7.51	1.02e-11	1.18e-07	-0.73	-0.56	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-7.51	1.02e-11	1.18e-07	-0.73	-0.56	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-7.51	1.02e-11	1.18e-07	-0.73	-0.56	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-7.51	1.02e-11	1.18e-07	-0.73	-0.56	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
ESCA	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	7.51	1.03e-11	1.18e-07	0.6	0.56	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-7.51	1.04e-11	1.19e-07	-0.6	-0.56	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
ESCA	cis	rs1336900	0.544	rs10888386	ENSG00000206931.1	RNU6-1042P	-7.51	1.04e-11	1.2e-07	-0.7	-0.56	Blood protein levels;	chr1:150639481	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000099984.9	GSTT2	-7.51	1.06e-11	1.21e-07	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23980123~23983911:+
ESCA	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-7.5	1.08e-11	1.23e-07	-0.68	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
ESCA	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-7.5	1.08e-11	1.23e-07	-0.74	-0.56	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
ESCA	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	7.5	1.08e-11	1.24e-07	0.8	0.56	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
ESCA	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	7.5	1.1e-11	1.25e-07	0.59	0.56	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-7.5	1.11e-11	1.26e-07	-0.6	-0.56	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
ESCA	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	7.5	1.11e-11	1.26e-07	0.65	0.56	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	7.5	1.11e-11	1.26e-07	0.68	0.56	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
ESCA	cis	rs9733	0.519	rs1134067	ENSG00000206931.1	RNU6-1042P	7.5	1.11e-11	1.26e-07	0.73	0.56	Tonsillectomy;	chr1:150748699	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs11587444	ENSG00000206931.1	RNU6-1042P	7.5	1.11e-11	1.26e-07	0.73	0.56	Tonsillectomy;	chr1:150750368	chr1:150701866~150701972:+
ESCA	cis	rs17507216	0.628	rs28607761	ENSG00000278603.1	RP13-608F4.5	7.5	1.11e-11	1.26e-07	0.97	0.56	Excessive daytime sleepiness;	chr15:82715317	chr15:82472203~82472426:+
ESCA	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	7.49	1.14e-11	1.29e-07	0.61	0.56	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	7.49	1.14e-11	1.29e-07	0.61	0.56	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-7.49	1.15e-11	1.3e-07	-0.6	-0.56	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-7.48	1.24e-11	1.39e-07	-0.6	-0.56	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-7.48	1.24e-11	1.39e-07	-0.6	-0.56	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-7.48	1.25e-11	1.4e-07	-0.6	-0.56	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
ESCA	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-7.47	1.27e-11	1.42e-07	-0.67	-0.56	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
ESCA	cis	rs1799949	1	rs8070085	ENSG00000198496.9	NBR2	7.47	1.28e-11	1.43e-07	0.63	0.56	Menopause (age at onset);	chr17:43189967	chr17:43125610~43153671:+
ESCA	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	7.47	1.28e-11	1.43e-07	0.61	0.56	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-7.47	1.29e-11	1.45e-07	-0.68	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	7.47	1.3e-11	1.45e-07	0.8	0.56	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
ESCA	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-7.46	1.33e-11	1.49e-07	-0.64	-0.56	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
ESCA	cis	rs9457247	0.967	rs2769355	ENSG00000265828.1	MIR3939	7.46	1.36e-11	1.51e-07	0.62	0.56	Crohn's disease;	chr6:166967005	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs2757054	ENSG00000265828.1	MIR3939	7.46	1.36e-11	1.51e-07	0.62	0.56	Crohn's disease;	chr6:166967013	chr6:166997807~166997912:-
ESCA	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-7.46	1.38e-11	1.54e-07	-0.6	-0.56	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
ESCA	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	7.45	1.39e-11	1.55e-07	0.63	0.56	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
ESCA	cis	rs9457247	0.756	rs2345572	ENSG00000265828.1	MIR3939	-7.45	1.41e-11	1.57e-07	-0.6	-0.56	Crohn's disease;	chr6:166989953	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs427824	ENSG00000265828.1	MIR3939	-7.45	1.41e-11	1.57e-07	-0.6	-0.56	Crohn's disease;	chr6:166990430	chr6:166997807~166997912:-
ESCA	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-7.45	1.44e-11	1.59e-07	-0.6	-0.56	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-7.44	1.47e-11	1.62e-07	-0.66	-0.56	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	7.44	1.47e-11	1.62e-07	0.67	0.56	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000099984.9	GSTT2	-7.44	1.48e-11	1.63e-07	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23980123~23983911:+
ESCA	cis	rs11155671	0.53	rs1334510	ENSG00000231760.4	RP11-350J20.5	7.44	1.51e-11	1.66e-07	0.7	0.56	Testicular germ cell tumor;	chr6:149880043	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	7.44	1.52e-11	1.67e-07	0.61	0.56	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	7.44	1.52e-11	1.67e-07	0.61	0.56	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	7.44	1.52e-11	1.67e-07	0.61	0.56	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	7.44	1.52e-11	1.67e-07	0.61	0.56	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
ESCA	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-7.44	1.54e-11	1.69e-07	-0.63	-0.56	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	7.43	1.55e-11	1.7e-07	0.59	0.56	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
ESCA	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-7.43	1.58e-11	1.73e-07	-0.9	-0.56	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
ESCA	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	7.43	1.58e-11	1.73e-07	0.65	0.56	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
ESCA	cis	rs9457247	1	rs364451	ENSG00000265828.1	MIR3939	-7.43	1.59e-11	1.73e-07	-0.6	-0.56	Crohn's disease;	chr6:166971268	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs9348211	ENSG00000265828.1	MIR3939	7.43	1.59e-11	1.73e-07	0.6	0.56	Crohn's disease;	chr6:166961685	chr6:166997807~166997912:-
ESCA	cis	rs6920364	1	rs6920364	ENSG00000265828.1	MIR3939	7.43	1.59e-11	1.73e-07	0.6	0.56	Lung cancer;	chr6:166962978	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs2769352	ENSG00000265828.1	MIR3939	7.43	1.59e-11	1.73e-07	0.6	0.56	Crohn's disease;	chr6:166965131	chr6:166997807~166997912:-
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000228039.3	KB-1125A3.10	-7.43	1.59e-11	1.74e-07	-0.71	-0.56	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23963780~23964374:+
ESCA	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-7.43	1.59e-11	1.74e-07	-0.67	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-7.43	1.6e-11	1.75e-07	-0.84	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-7.43	1.6e-11	1.75e-07	-0.84	-0.56	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
ESCA	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	7.43	1.62e-11	1.77e-07	0.64	0.56	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
ESCA	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-7.42	1.63e-11	1.78e-07	-0.59	-0.56	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs6913486	ENSG00000231760.4	RP11-350J20.5	-7.42	1.64e-11	1.79e-07	-0.66	-0.56	Lung cancer;	chr6:149705060	chr6:149796151~149826294:-
ESCA	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	7.42	1.66e-11	1.81e-07	0.58	0.56	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
ESCA	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-7.42	1.68e-11	1.83e-07	-0.87	-0.56	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
ESCA	cis	rs11155671	0.53	rs4870080	ENSG00000231760.4	RP11-350J20.5	7.42	1.68e-11	1.83e-07	0.71	0.56	Testicular germ cell tumor;	chr6:149881508	chr6:149796151~149826294:-
ESCA	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-7.41	1.72e-11	1.87e-07	-0.91	-0.56	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
ESCA	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	7.41	1.74e-11	1.88e-07	0.6	0.56	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
ESCA	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	7.41	1.76e-11	1.9e-07	0.62	0.56	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
ESCA	cis	rs6538678	0.824	rs1436120	ENSG00000258343.1	RP11-536G4.2	7.41	1.76e-11	1.9e-07	0.73	0.56	Lupus nephritis in systemic lupus erythematosus;	chr12:95826872	chr12:95795345~95858839:-
ESCA	cis	rs62229266	0.771	rs7280136	ENSG00000231106.2	LINC01436	-7.41	1.77e-11	1.91e-07	-0.62	-0.56	Mitral valve prolapse;	chr21:36060612	chr21:36005338~36007838:+
ESCA	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-7.4	1.88e-11	2.03e-07	-0.81	-0.55	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-7.4	1.88e-11	2.03e-07	-0.81	-0.55	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
ESCA	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-7.4	1.89e-11	2.04e-07	-0.6	-0.55	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.512	rs55788996	ENSG00000230658.1	KLHL7-AS1	7.4	1.9e-11	2.05e-07	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23153230	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.69	rs1651358	ENSG00000253404.1	AC034243.1	-7.39	1.93e-11	2.08e-07	-0.86	-0.55	Age-related hearing impairment (SNP x SNP interaction);	chr5:138745318	chr5:138744434~138753309:-
ESCA	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	7.39	1.96e-11	2.11e-07	0.63	0.55	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	7.39	1.96e-11	2.11e-07	0.64	0.55	Depression;	chr6:28301886	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	7.39	1.96e-11	2.11e-07	0.64	0.55	Depression;	chr6:28303421	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	7.39	1.98e-11	2.13e-07	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	7.39	1.98e-11	2.13e-07	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	7.39	1.98e-11	2.13e-07	0.78	0.55	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
ESCA	cis	rs9733	0.519	rs7529194	ENSG00000206931.1	RNU6-1042P	7.38	2.02e-11	2.17e-07	0.7	0.55	Tonsillectomy;	chr1:150650144	chr1:150701866~150701972:+
ESCA	cis	rs9322193	0.923	rs10872651	ENSG00000231760.4	RP11-350J20.5	7.38	2.07e-11	2.21e-07	0.7	0.55	Lung cancer;	chr6:149768273	chr6:149796151~149826294:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-7.38	2.09e-11	2.23e-07	-0.76	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000099984.9	GSTT2	-7.38	2.1e-11	2.25e-07	-0.7	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000099984.9	GSTT2	-7.38	2.1e-11	2.25e-07	-0.7	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23980123~23983911:+
ESCA	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-7.37	2.13e-11	2.27e-07	-0.85	-0.55	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
ESCA	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	7.37	2.19e-11	2.32e-07	0.68	0.55	Depression;	chr6:28327262	chr6:28176188~28176674:+
ESCA	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	7.36	2.24e-11	2.38e-07	0.63	0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
ESCA	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	7.36	2.28e-11	2.41e-07	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
ESCA	cis	rs1799949	1	rs4793194	ENSG00000198496.9	NBR2	-7.36	2.28e-11	2.41e-07	-0.61	-0.55	Menopause (age at onset);	chr17:43066316	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176234	ENSG00000198496.9	NBR2	-7.36	2.28e-11	2.41e-07	-0.61	-0.55	Menopause (age at onset);	chr17:43067763	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176233	ENSG00000198496.9	NBR2	-7.36	2.28e-11	2.41e-07	-0.61	-0.55	Menopause (age at onset);	chr17:43067787	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176220	ENSG00000198496.9	NBR2	-7.36	2.28e-11	2.41e-07	-0.61	-0.55	Menopause (age at onset);	chr17:43070445	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1799966	ENSG00000198496.9	NBR2	-7.36	2.28e-11	2.41e-07	-0.61	-0.55	Menopause (age at onset);	chr17:43071077	chr17:43125610~43153671:+
ESCA	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-7.36	2.31e-11	2.44e-07	-0.77	-0.55	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
ESCA	cis	rs9545047	0.901	rs7982263	ENSG00000227676.3	LINC01068	-7.36	2.32e-11	2.45e-07	-0.73	-0.55	Schizophrenia;	chr13:79486939	chr13:79566727~79571436:+
ESCA	cis	rs11155671	0.53	rs9397398	ENSG00000231760.4	RP11-350J20.5	7.36	2.33e-11	2.46e-07	0.71	0.55	Testicular germ cell tumor;	chr6:149872467	chr6:149796151~149826294:-
ESCA	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	7.35	2.36e-11	2.49e-07	0.63	0.55	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
ESCA	cis	rs6538678	0.857	rs4762626	ENSG00000258343.1	RP11-536G4.2	-7.35	2.43e-11	2.55e-07	-0.78	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95811383	chr12:95795345~95858839:-
ESCA	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	7.34	2.48e-11	2.61e-07	0.79	0.55	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
ESCA	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	7.34	2.51e-11	2.64e-07	0.64	0.55	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	7.34	2.55e-11	2.68e-07	0.61	0.55	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	7.34	2.55e-11	2.68e-07	0.61	0.55	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
ESCA	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	7.32	2.77e-11	2.89e-07	0.64	0.55	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
ESCA	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-7.32	2.77e-11	2.9e-07	-0.81	-0.55	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-7.32	2.77e-11	2.9e-07	-0.81	-0.55	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
ESCA	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-7.32	2.78e-11	2.9e-07	-0.52	-0.55	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
ESCA	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-7.32	2.81e-11	2.93e-07	-0.81	-0.55	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
ESCA	cis	rs17507216	0.628	rs4513065	ENSG00000278603.1	RP13-608F4.5	7.32	2.86e-11	2.98e-07	0.95	0.55	Excessive daytime sleepiness;	chr15:82712096	chr15:82472203~82472426:+
ESCA	cis	rs17507216	0.628	rs28371837	ENSG00000278603.1	RP13-608F4.5	7.32	2.86e-11	2.98e-07	0.95	0.55	Excessive daytime sleepiness;	chr15:82714435	chr15:82472203~82472426:+
ESCA	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	7.32	2.87e-11	2.99e-07	0.93	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
ESCA	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	7.32	2.88e-11	3e-07	0.65	0.55	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	7.31	2.9e-11	3.02e-07	0.69	0.55	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	7.3	3.07e-11	3.18e-07	0.74	0.55	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000099984.9	GSTT2	7.3	3.09e-11	3.19e-07	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23980123~23983911:+
ESCA	cis	rs7829975	0.536	rs2980439	ENSG00000253981.4	ALG1L13P	7.3	3.14e-11	3.24e-07	0.66	0.55	Mood instability;	chr8:8237348	chr8:8236003~8244667:-
ESCA	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-7.3	3.15e-11	3.25e-07	-0.72	-0.55	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
ESCA	cis	rs9545047	0.935	rs4885634	ENSG00000227676.3	LINC01068	-7.3	3.15e-11	3.25e-07	-0.72	-0.55	Schizophrenia;	chr13:79482772	chr13:79566727~79571436:+
ESCA	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	7.3	3.19e-11	3.28e-07	0.71	0.55	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	7.29	3.25e-11	3.35e-07	0.77	0.55	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
ESCA	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	7.29	3.27e-11	3.37e-07	0.73	0.55	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-7.28	3.38e-11	3.47e-07	-0.71	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
ESCA	cis	rs9322193	0.567	rs7742692	ENSG00000231760.4	RP11-350J20.5	7.28	3.42e-11	3.51e-07	0.7	0.55	Lung cancer;	chr6:149892363	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	7.28	3.53e-11	3.61e-07	0.78	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
ESCA	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	7.27	3.7e-11	3.77e-07	1.01	0.55	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-7.27	3.72e-11	3.79e-07	-0.78	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-7.27	3.72e-11	3.79e-07	-0.78	-0.55	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-7.27	3.73e-11	3.8e-07	-0.64	-0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
ESCA	cis	rs4970988	0.556	rs6695123	ENSG00000206931.1	RNU6-1042P	-7.26	3.84e-11	3.9e-07	-0.68	-0.55	Urate levels;	chr1:150591007	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000250470.1	AP000351.3	7.26	3.85e-11	3.91e-07	0.65	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23976904~23977585:-
ESCA	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-7.26	3.85e-11	3.91e-07	-0.78	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.754	rs28410083	ENSG00000278665.1	RP11-666O2.4	-7.26	3.85e-11	3.91e-07	-0.78	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.789	rs1968751	ENSG00000278665.1	RP11-666O2.4	-7.26	3.85e-11	3.91e-07	-0.78	-0.55	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28599241~28601881:-
ESCA	cis	rs847845	0.535	rs3734261	ENSG00000186328.4	RP11-140K17.2	-7.26	3.94e-11	3.98e-07	-0.99	-0.55	Non-small cell lung cancer;	chr6:34872621	chr6:34715613~34715940:+
ESCA	cis	rs11155671	0.53	rs9371215	ENSG00000231760.4	RP11-350J20.5	7.25	3.95e-11	4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149873162	chr6:149796151~149826294:-
ESCA	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-7.25	3.98e-11	4.02e-07	-0.68	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-7.25	3.98e-11	4.02e-07	-0.68	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
ESCA	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	7.25	3.99e-11	4.03e-07	0.7	0.55	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
ESCA	cis	rs6538678	0.895	rs7137751	ENSG00000258343.1	RP11-536G4.2	-7.25	4.1e-11	4.13e-07	-0.67	-0.55	Lupus nephritis in systemic lupus erythematosus;	chr12:95861806	chr12:95795345~95858839:-
ESCA	cis	rs12922317	0.681	rs2869492	ENSG00000260224.1	UBL5P4	7.24	4.25e-11	4.27e-07	0.6	0.55	Schizophrenia;	chr16:11977484	chr16:11968508~11968743:-
ESCA	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	7.24	4.27e-11	4.29e-07	0.59	0.55	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
ESCA	cis	rs11155671	0.53	rs9383912	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149885479	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9383577	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886059	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9383914	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886098	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.517	rs9397058	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886113	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7768626	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886826	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7768665	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886888	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7758020	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149886975	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9322228	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149888173	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7774787	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149888296	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs2342767	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149888581	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs7764376	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149889208	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs6933882	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149889666	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs6939761	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149889858	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs3823021	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149889863	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs4869763	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149890548	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs4869764	ENSG00000231760.4	RP11-350J20.5	7.23	4.42e-11	4.4e-07	0.69	0.55	Testicular germ cell tumor;	chr6:149890692	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	7.23	4.53e-11	4.52e-07	0.65	0.55	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
ESCA	cis	rs9457247	1	rs404222	ENSG00000265828.1	MIR3939	-7.23	4.54e-11	4.52e-07	-0.59	-0.55	Crohn's disease;	chr6:166988662	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.935	rs2149093	ENSG00000265828.1	MIR3939	7.23	4.54e-11	4.52e-07	0.59	0.55	Crohn's disease;	chr6:166959557	chr6:166997807~166997912:-
ESCA	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	7.23	4.54e-11	4.52e-07	0.61	0.55	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
ESCA	cis	rs7829975	0.536	rs2980439	ENSG00000173295.6	FAM86B3P	7.22	4.61e-11	4.58e-07	0.65	0.55	Mood instability;	chr8:8237348	chr8:8228595~8244865:+
ESCA	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-7.22	4.61e-11	4.59e-07	-0.67	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000099984.9	GSTT2	7.22	4.7e-11	4.67e-07	0.71	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23980123~23983911:+
ESCA	cis	rs9457247	0.935	rs1044059	ENSG00000265828.1	MIR3939	7.22	4.72e-11	4.69e-07	0.6	0.55	Crohn's disease;	chr6:166956409	chr6:166997807~166997912:-
ESCA	cis	rs9733	0.596	rs12089989	ENSG00000206931.1	RNU6-1042P	7.22	4.74e-11	4.7e-07	0.69	0.55	Tonsillectomy;	chr1:150743306	chr1:150701866~150701972:+
ESCA	cis	rs1799949	1	rs8176242	ENSG00000198496.9	NBR2	-7.22	4.77e-11	4.73e-07	-0.59	-0.55	Menopause (age at onset);	chr17:43065857	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs3092987	ENSG00000198496.9	NBR2	-7.22	4.77e-11	4.73e-07	-0.59	-0.55	Menopause (age at onset);	chr17:43070706	chr17:43125610~43153671:+
ESCA	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-7.22	4.77e-11	4.73e-07	-0.71	-0.55	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
ESCA	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	7.21	4.88e-11	4.83e-07	0.61	0.55	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
ESCA	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	7.21	4.88e-11	4.83e-07	0.61	0.55	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
ESCA	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	7.21	4.98e-11	4.92e-07	0.62	0.55	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
ESCA	cis	rs4747241	0.593	rs9415064	ENSG00000226163.1	RP11-167P22.3	-7.21	5.02e-11	4.96e-07	-0.6	-0.54	Heschl's gyrus morphology;	chr10:72329606	chr10:72501746~72502956:+
ESCA	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	7.21	5.04e-11	4.96e-07	0.71	0.54	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs9371504	ENSG00000216906.2	RP11-350J20.9	7.21	5.05e-11	4.96e-07	0.75	0.54	Testicular germ cell tumor;	chr6:149862944	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9371505	ENSG00000216906.2	RP11-350J20.9	7.21	5.05e-11	4.96e-07	0.75	0.54	Testicular germ cell tumor;	chr6:149863012	chr6:149904243~149906418:+
ESCA	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	7.2	5.16e-11	5.07e-07	0.63	0.54	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
ESCA	cis	rs9457247	1	rs398278	ENSG00000265828.1	MIR3939	-7.2	5.21e-11	5.12e-07	-0.59	-0.54	Crohn's disease;	chr6:166974681	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs444988	ENSG00000265828.1	MIR3939	-7.2	5.21e-11	5.12e-07	-0.59	-0.54	Crohn's disease;	chr6:166976186	chr6:166997807~166997912:-
ESCA	cis	rs9457247	1	rs408080	ENSG00000265828.1	MIR3939	-7.2	5.21e-11	5.12e-07	-0.59	-0.54	Crohn's disease;	chr6:166979034	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.967	rs1794696	ENSG00000265828.1	MIR3939	-7.2	5.21e-11	5.12e-07	-0.59	-0.54	Crohn's disease;	chr6:166982686	chr6:166997807~166997912:-
ESCA	cis	rs4970988	0.556	rs6681426	ENSG00000206931.1	RNU6-1042P	-7.2	5.26e-11	5.16e-07	-0.69	-0.54	Urate levels;	chr1:150614495	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-7.2	5.3e-11	5.19e-07	-0.79	-0.54	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-7.19	5.47e-11	5.33e-07	-0.82	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000099984.9	GSTT2	7.19	5.53e-11	5.39e-07	0.68	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23980123~23983911:+
ESCA	cis	rs1799949	1	rs8176109	ENSG00000198496.9	NBR2	-7.19	5.53e-11	5.39e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43113759	chr17:43125610~43153671:+
ESCA	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-7.19	5.55e-11	5.39e-07	-0.67	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-7.19	5.55e-11	5.39e-07	-0.67	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
ESCA	cis	rs1799949	1	rs8176103	ENSG00000198496.9	NBR2	-7.18	5.7e-11	5.54e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43115033	chr17:43125610~43153671:+
ESCA	cis	rs17507216	0.588	rs4778687	ENSG00000278603.1	RP13-608F4.5	7.18	5.76e-11	5.58e-07	0.98	0.54	Excessive daytime sleepiness;	chr15:82649085	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000099984.9	GSTT2	-7.18	5.78e-11	5.6e-07	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000099984.9	GSTT2	-7.18	5.78e-11	5.6e-07	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000099984.9	GSTT2	-7.18	5.78e-11	5.6e-07	-0.69	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23980123~23983911:+
ESCA	cis	rs9322193	0.504	rs7771014	ENSG00000231760.4	RP11-350J20.5	7.17	6.03e-11	5.83e-07	0.7	0.54	Lung cancer;	chr6:149884310	chr6:149796151~149826294:-
ESCA	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-7.17	6.17e-11	5.97e-07	-0.57	-0.54	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
ESCA	cis	rs1799949	0.965	rs8176087	ENSG00000198496.9	NBR2	-7.16	6.36e-11	6.14e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43118649	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs34942571	ENSG00000198496.9	NBR2	-7.16	6.36e-11	6.14e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43121362	chr17:43125610~43153671:+
ESCA	cis	rs9545047	0.935	rs8002042	ENSG00000227676.3	LINC01068	-7.16	6.37e-11	6.15e-07	-0.71	-0.54	Schizophrenia;	chr13:79486552	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs6563113	ENSG00000227676.3	LINC01068	-7.16	6.37e-11	6.15e-07	-0.71	-0.54	Schizophrenia;	chr13:79490000	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs9530925	ENSG00000227676.3	LINC01068	-7.16	6.37e-11	6.15e-07	-0.71	-0.54	Schizophrenia;	chr13:79492641	chr13:79566727~79571436:+
ESCA	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-7.16	6.38e-11	6.15e-07	-0.67	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-7.16	6.38e-11	6.15e-07	-0.67	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
ESCA	cis	rs6538678	0.824	rs4762633	ENSG00000258343.1	RP11-536G4.2	-7.16	6.44e-11	6.21e-07	-0.68	-0.54	Lupus nephritis in systemic lupus erythematosus;	chr12:95860295	chr12:95795345~95858839:-
ESCA	cis	rs9457247	1	rs2757042	ENSG00000265828.1	MIR3939	7.16	6.54e-11	6.29e-07	0.59	0.54	Crohn's disease;	chr6:166957746	chr6:166997807~166997912:-
ESCA	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	7.15	6.68e-11	6.41e-07	0.99	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
ESCA	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	7.15	6.71e-11	6.44e-07	0.73	0.54	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
ESCA	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-7.15	6.91e-11	6.61e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-7.15	6.91e-11	6.61e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-7.15	6.94e-11	6.62e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
ESCA	cis	rs4970988	0.556	rs2280078	ENSG00000206931.1	RNU6-1042P	-7.15	6.95e-11	6.63e-07	-0.65	-0.54	Urate levels;	chr1:150627705	chr1:150701866~150701972:+
ESCA	cis	rs1799949	0.965	rs8176161	ENSG00000198496.9	NBR2	-7.15	6.95e-11	6.63e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43089373	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.894	rs8176160	ENSG00000198496.9	NBR2	-7.15	6.95e-11	6.63e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43089486	chr17:43125610~43153671:+
ESCA	cis	rs847845	0.535	rs205284	ENSG00000186328.4	RP11-140K17.2	7.14	7.11e-11	6.78e-07	1.05	0.54	Non-small cell lung cancer;	chr6:34584135	chr6:34715613~34715940:+
ESCA	cis	rs1799949	1	rs3950989	ENSG00000198496.9	NBR2	-7.14	7.16e-11	6.82e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43085936	chr17:43125610~43153671:+
ESCA	cis	rs11155671	0.53	rs7757984	ENSG00000231760.4	RP11-350J20.5	7.14	7.2e-11	6.85e-07	0.69	0.54	Testicular germ cell tumor;	chr6:149887515	chr6:149796151~149826294:-
ESCA	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	7.14	7.22e-11	6.87e-07	0.64	0.54	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
ESCA	cis	rs2882667	0.893	rs7717375	ENSG00000253404.1	AC034243.1	7.14	7.29e-11	6.92e-07	0.78	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138955716	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.893	rs10054796	ENSG00000253404.1	AC034243.1	7.14	7.29e-11	6.92e-07	0.78	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958655	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.893	rs10069961	ENSG00000253404.1	AC034243.1	7.14	7.29e-11	6.92e-07	0.78	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138958879	chr5:138744434~138753309:-
ESCA	cis	rs1799949	0.965	rs8176323	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43043694	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs8176322	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43043756	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12516	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43044391	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793190	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43048092	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176297	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43051308	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176296	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43051574	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793191	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43052360	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793192	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43052373	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176289	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43054039	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs35330014	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43060530	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs3092994	ENSG00000198496.9	NBR2	-7.13	7.35e-11	6.96e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43063808	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176202	ENSG00000198496.9	NBR2	-7.13	7.53e-11	7.13e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43078211	chr17:43125610~43153671:+
ESCA	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-7.13	7.59e-11	7.17e-07	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
ESCA	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	7.12	7.86e-11	7.41e-07	0.6	0.54	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	7.12	7.94e-11	7.49e-07	0.59	0.54	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
ESCA	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	7.11	8.15e-11	7.66e-07	0.62	0.54	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-7.11	8.16e-11	7.66e-07	-0.74	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
ESCA	cis	rs11155671	0.53	rs9397420	ENSG00000231760.4	RP11-350J20.5	-7.11	8.2e-11	7.68e-07	-0.68	-0.54	Testicular germ cell tumor;	chr6:149885645	chr6:149796151~149826294:-
ESCA	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	7.11	8.38e-11	7.84e-07	0.72	0.54	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
ESCA	cis	rs1799949	1	rs8176083	ENSG00000198496.9	NBR2	-7.1	8.62e-11	8.06e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43123134	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs2271574	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43175631	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs33994002	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43176801	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs33920795	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43176993	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs33918839	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43177155	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11653231	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43179443	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1399323	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43180313	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs35954893	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43181769	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs4445938	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43185883	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8074136	ENSG00000198496.9	NBR2	-7.1	8.7e-11	8.11e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43190296	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs2070834	ENSG00000198496.9	NBR2	-7.1	8.78e-11	8.17e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43090268	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs16942	ENSG00000198496.9	NBR2	-7.1	8.93e-11	8.29e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43091983	chr17:43125610~43153671:+
ESCA	cis	rs2882667	0.964	rs12719517	ENSG00000253404.1	AC034243.1	7.1	8.96e-11	8.32e-07	0.78	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138969813	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000250470.1	AP000351.3	7.09	9.01e-11	8.36e-07	0.65	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23976904~23977585:-
ESCA	cis	rs1799949	1	rs2175957	ENSG00000198496.9	NBR2	-7.09	9.02e-11	8.36e-07	-0.6	-0.54	Menopause (age at onset);	chr17:43134805	chr17:43125610~43153671:+
ESCA	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	7.09	9.07e-11	8.4e-07	0.98	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	7.09	9.07e-11	8.4e-07	0.98	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
ESCA	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-7.09	9.07e-11	8.4e-07	-0.85	-0.54	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
ESCA	cis	rs8062405	0.755	rs62031607	ENSG00000278665.1	RP11-666O2.4	7.09	9.32e-11	8.63e-07	0.78	0.54	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28599241~28601881:-
ESCA	cis	rs916888	0.821	rs199499	ENSG00000214401.4	KANSL1-AS1	7.09	9.43e-11	8.72e-07	1.04	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46193576~46196723:+
ESCA	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-7.08	9.48e-11	8.76e-07	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	7.08	9.77e-11	8.99e-07	0.58	0.54	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	7.08	9.77e-11	8.99e-07	0.58	0.54	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	7.08	9.77e-11	8.99e-07	0.58	0.54	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	7.08	9.77e-11	8.99e-07	0.58	0.54	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.07	1.01e-10	9.29e-07	-0.76	-0.54	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
ESCA	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	7.07	1.01e-10	9.29e-07	0.63	0.54	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
ESCA	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	7.07	1.02e-10	9.34e-07	0.64	0.54	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
ESCA	cis	rs1336900	0.513	rs56253522	ENSG00000206931.1	RNU6-1042P	7.07	1.03e-10	9.43e-07	0.69	0.54	Blood protein levels;	chr1:150642393	chr1:150701866~150701972:+
ESCA	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-7.07	1.04e-10	9.46e-07	-0.6	-0.54	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
ESCA	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	7.06	1.07e-10	9.78e-07	0.66	0.54	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
ESCA	cis	rs1799949	0.896	rs35908185	ENSG00000198496.9	NBR2	-7.06	1.08e-10	9.8e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43103094	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs8176130	ENSG00000198496.9	NBR2	-7.06	1.08e-10	9.8e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43106026	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176120	ENSG00000198496.9	NBR2	-7.06	1.08e-10	9.8e-07	-0.59	-0.54	Menopause (age at onset);	chr17:43109216	chr17:43125610~43153671:+
ESCA	cis	rs4747241	0.556	rs4495815	ENSG00000226163.1	RP11-167P22.3	7.06	1.09e-10	9.94e-07	0.6	0.54	Heschl's gyrus morphology;	chr10:72309220	chr10:72501746~72502956:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000231271.1	AP000350.8	-7.06	1.1e-10	9.98e-07	-0.61	-0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23949918~23954042:+
ESCA	cis	rs1799949	1	rs8176145	ENSG00000198496.9	NBR2	-7.05	1.11e-10	1e-06	-0.59	-0.54	Menopause (age at onset);	chr17:43097077	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs8176140	ENSG00000198496.9	NBR2	-7.05	1.11e-10	1e-06	-0.59	-0.54	Menopause (age at onset);	chr17:43099629	chr17:43125610~43153671:+
ESCA	cis	rs4747241	0.626	rs9415061	ENSG00000226163.1	RP11-167P22.3	-7.05	1.12e-10	1.01e-06	-0.6	-0.54	Heschl's gyrus morphology;	chr10:72321425	chr10:72501746~72502956:+
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000250470.1	AP000351.3	7.05	1.13e-10	1.02e-06	0.64	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23976904~23977585:-
ESCA	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	7.05	1.13e-10	1.03e-06	0.62	0.54	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
ESCA	cis	rs2882667	0.893	rs10044672	ENSG00000253404.1	AC034243.1	7.04	1.17e-10	1.05e-06	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954790	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.893	rs13180851	ENSG00000253404.1	AC034243.1	7.04	1.17e-10	1.05e-06	0.77	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138954918	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-7.04	1.17e-10	1.06e-06	-0.65	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
ESCA	cis	rs1336900	0.637	rs35967040	ENSG00000206931.1	RNU6-1042P	-7.04	1.18e-10	1.06e-06	-0.66	-0.54	Blood protein levels;	chr1:150583112	chr1:150701866~150701972:+
ESCA	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-7.04	1.19e-10	1.07e-06	-0.57	-0.54	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	7.04	1.2e-10	1.07e-06	0.57	0.54	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	7.04	1.2e-10	1.07e-06	0.57	0.54	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
ESCA	cis	rs4970988	0.527	rs12067556	ENSG00000206931.1	RNU6-1042P	7.04	1.2e-10	1.07e-06	0.69	0.54	Urate levels;	chr1:150642059	chr1:150701866~150701972:+
ESCA	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-7.03	1.24e-10	1.11e-06	-0.57	-0.54	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
ESCA	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	7.03	1.27e-10	1.13e-06	0.67	0.54	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	7.03	1.27e-10	1.13e-06	0.67	0.54	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	7.03	1.27e-10	1.13e-06	0.67	0.54	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
ESCA	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-7.02	1.29e-10	1.15e-06	-0.56	-0.54	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
ESCA	cis	rs1799949	0.965	rs8176193	ENSG00000198496.9	NBR2	-7.02	1.3e-10	1.15e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43079499	chr17:43125610~43153671:+
ESCA	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	7.02	1.31e-10	1.16e-06	0.75	0.53	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9371207	ENSG00000231760.4	RP11-350J20.5	7.02	1.32e-10	1.17e-06	0.67	0.53	Lung cancer;	chr6:149858087	chr6:149796151~149826294:-
ESCA	cis	rs9322193	0.923	rs2880436	ENSG00000231760.4	RP11-350J20.5	7.02	1.32e-10	1.17e-06	0.67	0.53	Lung cancer;	chr6:149859123	chr6:149796151~149826294:-
ESCA	cis	rs1799949	0.896	rs8176098	ENSG00000198496.9	NBR2	-7.01	1.36e-10	1.2e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43116189	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000099984.9	GSTT2	-7.01	1.36e-10	1.2e-06	-0.67	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000099984.9	GSTT2	-7.01	1.36e-10	1.2e-06	-0.67	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23980123~23983911:+
ESCA	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	7	1.42e-10	1.26e-06	0.62	0.53	Depression;	chr6:28317705	chr6:28176188~28176674:+
ESCA	cis	rs9322193	0.847	rs880246	ENSG00000231760.4	RP11-350J20.5	7	1.44e-10	1.27e-06	0.68	0.53	Lung cancer;	chr6:149845972	chr6:149796151~149826294:-
ESCA	cis	rs1799949	1	rs3092988	ENSG00000198496.9	NBR2	-7	1.45e-10	1.27e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43049685	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176273	ENSG00000198496.9	NBR2	-7	1.45e-10	1.27e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43059636	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176269	ENSG00000198496.9	NBR2	-7	1.45e-10	1.27e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43061609	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176265	ENSG00000198496.9	NBR2	-7	1.45e-10	1.27e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43061979	chr17:43125610~43153671:+
ESCA	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-6.99	1.53e-10	1.34e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	6.98	1.59e-10	1.39e-06	0.7	0.53	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
ESCA	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	6.98	1.64e-10	1.44e-06	0.62	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
ESCA	cis	rs1799949	0.965	rs33925201	ENSG00000198496.9	NBR2	-6.98	1.65e-10	1.44e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43128665	chr17:43125610~43153671:+
ESCA	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-6.98	1.65e-10	1.44e-06	-0.83	-0.53	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-6.98	1.65e-10	1.44e-06	-0.83	-0.53	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
ESCA	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-6.97	1.67e-10	1.45e-06	-0.63	-0.53	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
ESCA	cis	rs9545047	0.901	rs1212082	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79552633	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs2760102	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79555193	chr13:79566727~79571436:+
ESCA	cis	rs9601248	0.508	rs9601240	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Major depressive disorder;	chr13:79558238	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.837	rs9601242	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79561543	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.901	rs73235963	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79562805	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.935	rs2484343	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79563587	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.868	rs2476173	ENSG00000227676.3	LINC01068	6.97	1.68e-10	1.45e-06	0.7	0.53	Schizophrenia;	chr13:79565740	chr13:79566727~79571436:+
ESCA	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-6.97	1.68e-10	1.45e-06	-0.65	-0.53	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
ESCA	cis	rs1799949	1	rs1060915	ENSG00000198496.9	NBR2	-6.97	1.72e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43082453	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11650132	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43174070	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11654731	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43174923	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11651623	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43177830	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11657883	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43178007	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11656945	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43178248	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12944430	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43178803	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11653460	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43179289	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11650913	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43179580	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12936831	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43179799	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11658499	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.48e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43182732	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs16941	ENSG00000198496.9	NBR2	-6.97	1.73e-10	1.49e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43092418	chr17:43125610~43153671:+
ESCA	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	6.96	1.75e-10	1.5e-06	0.71	0.53	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
ESCA	cis	rs2882667	0.964	rs12108892	ENSG00000253404.1	AC034243.1	6.96	1.75e-10	1.5e-06	0.75	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138963941	chr5:138744434~138753309:-
ESCA	cis	rs9368481	0.729	rs9379948	ENSG00000243307.2	POM121L6P	6.96	1.77e-10	1.51e-06	0.6	0.53	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26896952~26898777:+
ESCA	cis	rs11155671	0.53	rs7742993	ENSG00000231760.4	RP11-350J20.5	6.96	1.78e-10	1.52e-06	0.68	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149796151~149826294:-
ESCA	cis	rs1799949	1	rs16940	ENSG00000198496.9	NBR2	-6.96	1.78e-10	1.52e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43093220	chr17:43125610~43153671:+
ESCA	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-6.96	1.79e-10	1.53e-06	-0.65	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
ESCA	cis	rs1799949	1	rs8176126	ENSG00000198496.9	NBR2	6.96	1.8e-10	1.54e-06	0.59	0.53	Menopause (age at onset);	chr17:43107032	chr17:43125610~43153671:+
ESCA	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	6.96	1.81e-10	1.54e-06	0.71	0.53	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
ESCA	cis	rs9545047	0.905	rs9318644	ENSG00000227676.3	LINC01068	-6.96	1.82e-10	1.55e-06	-0.7	-0.53	Schizophrenia;	chr13:79510042	chr13:79566727~79571436:+
ESCA	cis	rs1799949	0.896	rs8176086	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43122761	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs3765640	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43124230	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176077	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43124331	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11655505	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43126360	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs4793204	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43127281	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs12947782	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43127865	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs33945274	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43128056	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11653069	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43131360	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs33988650	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43135863	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11656097	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43138596	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs2292595	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43138657	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11658754	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43140722	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs33968979	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43145975	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12952790	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43147590	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12950607	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43147911	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11079056	ENSG00000198496.9	NBR2	-6.95	1.84e-10	1.56e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43148782	chr17:43125610~43153671:+
ESCA	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.95	1.85e-10	1.56e-06	0.63	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000099984.9	GSTT2	-6.95	1.86e-10	1.57e-06	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23980123~23983911:+
ESCA	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	6.95	1.87e-10	1.58e-06	0.97	0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
ESCA	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	6.95	1.9e-10	1.6e-06	0.62	0.53	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
ESCA	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	6.95	1.9e-10	1.6e-06	0.62	0.53	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	6.95	1.91e-10	1.61e-06	0.7	0.53	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-6.95	1.92e-10	1.62e-06	-0.85	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-6.95	1.92e-10	1.62e-06	-0.85	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
ESCA	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	6.94	1.96e-10	1.65e-06	0.6	0.53	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
ESCA	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-6.94	1.99e-10	1.67e-06	-1.02	-0.53	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
ESCA	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-6.94	2.01e-10	1.68e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-6.94	2.01e-10	1.68e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-6.94	2.01e-10	1.68e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-6.94	2.01e-10	1.68e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
ESCA	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	6.94	2.01e-10	1.69e-06	0.62	0.53	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
ESCA	cis	rs3734266	0.591	rs9469812	ENSG00000186328.4	RP11-140K17.2	6.93	2.04e-10	1.7e-06	1.06	0.53	Systemic lupus erythematosus;	chr6:34599754	chr6:34715613~34715940:+
ESCA	cis	rs847845	0.535	rs1201872	ENSG00000186328.4	RP11-140K17.2	-6.93	2.07e-10	1.73e-06	-0.91	-0.53	Non-small cell lung cancer;	chr6:34587932	chr6:34715613~34715940:+
ESCA	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-6.93	2.09e-10	1.74e-06	-0.63	-0.53	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	6.93	2.12e-10	1.76e-06	0.63	0.53	Depression;	chr6:28323463	chr6:28176188~28176674:+
ESCA	cis	rs1799949	1	rs67060599	ENSG00000198496.9	NBR2	-6.92	2.14e-10	1.78e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43103085	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8176133	ENSG00000198496.9	NBR2	-6.92	2.14e-10	1.78e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43105441	chr17:43125610~43153671:+
ESCA	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-6.92	2.17e-10	1.8e-06	-0.82	-0.53	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
ESCA	cis	rs1799949	0.93	rs35292991	ENSG00000198496.9	NBR2	-6.92	2.18e-10	1.81e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43181999	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs66499067	ENSG00000198496.9	NBR2	-6.92	2.2e-10	1.83e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43096467	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	6.91	2.26e-10	1.88e-06	0.54	0.53	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-6.91	2.27e-10	1.88e-06	-0.77	-0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
ESCA	cis	rs4747241	0.626	rs10762510	ENSG00000226163.1	RP11-167P22.3	6.91	2.28e-10	1.89e-06	0.61	0.53	Heschl's gyrus morphology;	chr10:72307528	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.626	rs10762511	ENSG00000226163.1	RP11-167P22.3	6.91	2.28e-10	1.89e-06	0.61	0.53	Heschl's gyrus morphology;	chr10:72307554	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.591	rs10823913	ENSG00000226163.1	RP11-167P22.3	6.91	2.28e-10	1.89e-06	0.61	0.53	Heschl's gyrus morphology;	chr10:72307586	chr10:72501746~72502956:+
ESCA	cis	rs1799949	0.965	rs35521261	ENSG00000198496.9	NBR2	-6.91	2.31e-10	1.91e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43161595	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.896	rs33933393	ENSG00000198496.9	NBR2	-6.91	2.31e-10	1.91e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43165415	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs33946455	ENSG00000198496.9	NBR2	-6.91	2.31e-10	1.91e-06	-0.59	-0.53	Menopause (age at onset);	chr17:43169829	chr17:43125610~43153671:+
ESCA	cis	rs9462027	0.597	rs6940215	ENSG00000186328.4	RP11-140K17.2	6.91	2.32e-10	1.92e-06	0.63	0.53	Systemic lupus erythematosus;	chr6:34738581	chr6:34715613~34715940:+
ESCA	cis	rs9545047	0.935	rs1577416	ENSG00000227676.3	LINC01068	-6.9	2.39e-10	1.98e-06	-0.7	-0.53	Schizophrenia;	chr13:79500646	chr13:79566727~79571436:+
ESCA	cis	rs9368481	0.761	rs4358615	ENSG00000243307.2	POM121L6P	6.9	2.41e-10	1.99e-06	0.59	0.53	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26896952~26898777:+
ESCA	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-6.9	2.41e-10	1.99e-06	-0.69	-0.53	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
ESCA	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-6.9	2.43e-10	2e-06	-0.72	-0.53	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
ESCA	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	6.89	2.51e-10	2.07e-06	0.62	0.53	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
ESCA	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-6.89	2.52e-10	2.08e-06	-0.66	-0.53	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-6.89	2.52e-10	2.08e-06	-0.66	-0.53	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
ESCA	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	6.89	2.53e-10	2.08e-06	0.68	0.53	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
ESCA	cis	rs62229266	0.625	rs2051395	ENSG00000231106.2	LINC01436	-6.89	2.58e-10	2.11e-06	-0.59	-0.53	Mitral valve prolapse;	chr21:36058967	chr21:36005338~36007838:+
ESCA	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	6.89	2.59e-10	2.12e-06	0.59	0.53	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
ESCA	cis	rs62229266	0.633	rs743420	ENSG00000231106.2	LINC01436	6.89	2.59e-10	2.13e-06	0.58	0.53	Mitral valve prolapse;	chr21:36015104	chr21:36005338~36007838:+
ESCA	cis	rs1799949	0.93	rs8176194	ENSG00000198496.9	NBR2	-6.89	2.61e-10	2.14e-06	-0.58	-0.53	Menopause (age at onset);	chr17:43079204	chr17:43125610~43153671:+
ESCA	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-6.88	2.65e-10	2.17e-06	-0.92	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
ESCA	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-6.88	2.72e-10	2.22e-06	-0.56	-0.53	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
ESCA	cis	rs9457247	1	rs239935	ENSG00000265828.1	MIR3939	-6.87	2.79e-10	2.28e-06	-0.59	-0.53	Crohn's disease;	chr6:166998300	chr6:166997807~166997912:-
ESCA	cis	rs9733	0.596	rs7412396	ENSG00000206931.1	RNU6-1042P	6.87	2.84e-10	2.32e-06	0.72	0.53	Tonsillectomy;	chr1:150694321	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-6.87	2.85e-10	2.33e-06	-0.65	-0.53	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
ESCA	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.87	2.85e-10	2.33e-06	-0.65	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
ESCA	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-6.87	2.88e-10	2.34e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
ESCA	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	6.87	2.88e-10	2.35e-06	0.62	0.53	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
ESCA	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	6.87	2.9e-10	2.36e-06	0.67	0.53	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
ESCA	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	6.87	2.9e-10	2.36e-06	0.76	0.53	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
ESCA	cis	rs1799949	1	rs4793197	ENSG00000198496.9	NBR2	-6.86	2.9e-10	2.36e-06	-0.57	-0.53	Menopause (age at onset);	chr17:43079885	chr17:43125610~43153671:+
ESCA	cis	rs11235843	0.636	rs2140892	ENSG00000255928.1	RP11-456I15.2	-6.86	2.91e-10	2.37e-06	-0.7	-0.53	Hand grip strength;	chr11:73711834	chr11:73722349~73722694:+
ESCA	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-6.86	2.92e-10	2.37e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
ESCA	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-6.86	2.92e-10	2.37e-06	-0.65	-0.53	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-6.86	2.92e-10	2.37e-06	-0.65	-0.53	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-6.86	2.94e-10	2.38e-06	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000099984.9	GSTT2	-6.86	2.96e-10	2.4e-06	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000099984.9	GSTT2	-6.86	2.96e-10	2.4e-06	-0.66	-0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23980123~23983911:+
ESCA	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-6.86	2.98e-10	2.41e-06	-0.56	-0.53	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	6.86	2.98e-10	2.41e-06	0.54	0.53	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
ESCA	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	6.86	2.99e-10	2.41e-06	0.62	0.53	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
ESCA	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-6.86	3.02e-10	2.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-6.86	3.02e-10	2.44e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
ESCA	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-6.86	3.04e-10	2.45e-06	-0.49	-0.53	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
ESCA	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	6.86	3.05e-10	2.46e-06	0.64	0.53	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs7763849	ENSG00000231760.4	RP11-350J20.5	6.85	3.07e-10	2.47e-06	0.66	0.53	Testicular germ cell tumor;	chr6:149885244	chr6:149796151~149826294:-
ESCA	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	6.85	3.08e-10	2.47e-06	0.62	0.53	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
ESCA	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-6.85	3.14e-10	2.52e-06	-0.49	-0.53	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
ESCA	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	6.85	3.15e-10	2.53e-06	0.61	0.53	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
ESCA	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-6.85	3.15e-10	2.53e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-6.85	3.15e-10	2.53e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-6.85	3.15e-10	2.53e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-6.85	3.15e-10	2.53e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-6.85	3.15e-10	2.53e-06	-0.68	-0.53	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
ESCA	cis	rs1799949	1	rs8176318	ENSG00000198496.9	NBR2	-6.85	3.16e-10	2.53e-06	-0.57	-0.53	Menopause (age at onset);	chr17:43045257	chr17:43125610~43153671:+
ESCA	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-6.85	3.19e-10	2.56e-06	-0.65	-0.53	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
ESCA	cis	rs9368481	0.761	rs9379952	ENSG00000243307.2	POM121L6P	-6.84	3.26e-10	2.61e-06	-0.62	-0.53	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26896952~26898777:+
ESCA	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	6.84	3.34e-10	2.66e-06	0.63	0.52	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000250470.1	AP000351.3	6.84	3.36e-10	2.68e-06	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23976904~23977585:-
ESCA	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-6.83	3.38e-10	2.69e-06	-0.55	-0.52	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.964	rs2288824	ENSG00000253404.1	AC034243.1	6.83	3.41e-10	2.71e-06	0.76	0.52	Age-related hearing impairment (SNP x SNP interaction);	chr5:138962707	chr5:138744434~138753309:-
ESCA	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	6.83	3.45e-10	2.74e-06	0.62	0.52	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000099984.9	GSTT2	-6.83	3.48e-10	2.77e-06	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23980123~23983911:+
ESCA	cis	rs1799949	1	rs12936816	ENSG00000198496.9	NBR2	-6.83	3.52e-10	2.79e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43149692	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	6.83	3.54e-10	2.8e-06	0.55	0.52	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
ESCA	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	6.82	3.59e-10	2.84e-06	0.64	0.52	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
ESCA	cis	rs12439619	0.508	rs8023960	ENSG00000278603.1	RP13-608F4.5	6.82	3.59e-10	2.84e-06	0.67	0.52	Intelligence (multi-trait analysis);	chr15:82206704	chr15:82472203~82472426:+
ESCA	cis	rs1799949	0.965	rs33961729	ENSG00000198496.9	NBR2	-6.82	3.63e-10	2.86e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43135907	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11657835	ENSG00000198496.9	NBR2	-6.82	3.63e-10	2.86e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43139936	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1135214	ENSG00000198496.9	NBR2	-6.82	3.63e-10	2.86e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43140306	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11652332	ENSG00000198496.9	NBR2	-6.82	3.63e-10	2.86e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43143472	chr17:43125610~43153671:+
ESCA	cis	rs62229266	1	rs62229266	ENSG00000231106.2	LINC01436	6.82	3.66e-10	2.88e-06	0.59	0.52	Mitral valve prolapse;	chr21:36087973	chr21:36005338~36007838:+
ESCA	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	6.82	3.68e-10	2.89e-06	0.63	0.52	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
ESCA	cis	rs1799949	1	rs35668327	ENSG00000198496.9	NBR2	-6.82	3.69e-10	2.9e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43121078	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793215	ENSG00000198496.9	NBR2	-6.81	3.77e-10	2.95e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43166915	chr17:43125610~43153671:+
ESCA	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-6.81	3.77e-10	2.95e-06	-0.69	-0.52	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	6.81	3.77e-10	2.95e-06	0.55	0.52	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	6.81	3.77e-10	2.95e-06	0.55	0.52	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
ESCA	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-6.81	3.78e-10	2.96e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
ESCA	cis	rs1799949	1	rs2298862	ENSG00000198496.9	NBR2	-6.81	3.8e-10	2.97e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43024671	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs2298861	ENSG00000198496.9	NBR2	-6.81	3.8e-10	2.97e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43024814	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000250470.1	AP000351.3	6.81	3.82e-10	2.98e-06	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000250470.1	AP000351.3	6.81	3.82e-10	2.98e-06	0.64	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23976904~23977585:-
ESCA	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-6.81	3.83e-10	2.99e-06	-0.49	-0.52	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-6.81	3.83e-10	2.99e-06	-0.49	-0.52	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-6.81	3.87e-10	3.02e-06	-0.49	-0.52	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
ESCA	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	6.81	3.91e-10	3.04e-06	0.53	0.52	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	6.81	3.91e-10	3.04e-06	0.53	0.52	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	6.81	3.91e-10	3.04e-06	0.53	0.52	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
ESCA	cis	rs11235843	0.602	rs1830069	ENSG00000255928.1	RP11-456I15.2	-6.81	3.92e-10	3.05e-06	-0.69	-0.52	Hand grip strength;	chr11:73722184	chr11:73722349~73722694:+
ESCA	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-6.8	3.95e-10	3.07e-06	-0.52	-0.52	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
ESCA	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-6.8	3.96e-10	3.07e-06	-0.49	-0.52	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
ESCA	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	6.8	4.07e-10	3.15e-06	0.73	0.52	Depression;	chr6:28364057	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000231271.1	AP000350.8	6.8	4.07e-10	3.16e-06	0.6	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23949918~23954042:+
ESCA	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	6.8	4.1e-10	3.18e-06	0.56	0.52	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
ESCA	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-6.8	4.12e-10	3.19e-06	-0.49	-0.52	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
ESCA	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	6.79	4.19e-10	3.24e-06	0.55	0.52	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	6.79	4.19e-10	3.24e-06	0.55	0.52	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
ESCA	cis	rs11235843	0.602	rs7106773	ENSG00000255928.1	RP11-456I15.2	-6.79	4.21e-10	3.25e-06	-0.67	-0.52	Hand grip strength;	chr11:73672129	chr11:73722349~73722694:+
ESCA	cis	rs12922317	0.535	rs8051349	ENSG00000260224.1	UBL5P4	-6.79	4.24e-10	3.28e-06	-0.57	-0.52	Schizophrenia;	chr16:12011666	chr16:11968508~11968743:-
ESCA	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-6.79	4.3e-10	3.32e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
ESCA	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-6.78	4.45e-10	3.42e-06	-0.61	-0.52	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	6.78	4.48e-10	3.44e-06	0.53	0.52	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	6.78	4.48e-10	3.44e-06	0.53	0.52	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	6.78	4.49e-10	3.45e-06	0.68	0.52	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
ESCA	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-6.78	4.54e-10	3.48e-06	-0.63	-0.52	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
ESCA	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	6.78	4.56e-10	3.5e-06	0.53	0.52	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
ESCA	cis	rs9462027	1	rs6457796	ENSG00000186328.4	RP11-140K17.2	6.77	4.59e-10	3.52e-06	0.64	0.52	Systemic lupus erythematosus;	chr6:34860776	chr6:34715613~34715940:+
ESCA	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-6.77	4.59e-10	3.52e-06	-0.95	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000250470.1	AP000351.3	6.77	4.61e-10	3.53e-06	0.63	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000099984.9	GSTT2	6.77	4.62e-10	3.54e-06	0.68	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23980123~23983911:+
ESCA	cis	rs11235843	0.636	rs10736793	ENSG00000255928.1	RP11-456I15.2	-6.77	4.74e-10	3.63e-06	-0.67	-0.52	Hand grip strength;	chr11:73691531	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.636	rs1464908	ENSG00000255928.1	RP11-456I15.2	-6.77	4.74e-10	3.63e-06	-0.67	-0.52	Hand grip strength;	chr11:73691634	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.636	rs6592531	ENSG00000255928.1	RP11-456I15.2	-6.77	4.74e-10	3.63e-06	-0.67	-0.52	Hand grip strength;	chr11:73701309	chr11:73722349~73722694:+
ESCA	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-6.77	4.77e-10	3.65e-06	-0.64	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	6.77	4.78e-10	3.65e-06	0.68	0.52	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
ESCA	cis	rs950027	0.62	rs1145077	ENSG00000259520.4	CTD-2651B20.3	6.77	4.8e-10	3.66e-06	0.61	0.52	Response to fenofibrate (adiponectin levels);	chr15:45391597	chr15:45251580~45279251:-
ESCA	cis	rs9368481	0.761	rs9348746	ENSG00000243307.2	POM121L6P	-6.76	4.81e-10	3.67e-06	-0.62	-0.52	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26896952~26898777:+
ESCA	cis	rs9368481	0.761	rs9357030	ENSG00000243307.2	POM121L6P	-6.76	4.81e-10	3.67e-06	-0.62	-0.52	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26896952~26898777:+
ESCA	cis	rs1799949	1	rs33926631	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43152446	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1960605	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43153380	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs2037076	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43153866	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs12950779	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43154506	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.929	rs12937015	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43155456	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4340367	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43155755	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4792981	ENSG00000198496.9	NBR2	-6.76	4.83e-10	3.67e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43156257	chr17:43125610~43153671:+
ESCA	cis	rs62402013	1	rs62402013	ENSG00000243307.2	POM121L6P	6.76	4.91e-10	3.73e-06	0.6	0.52	Schizophrenia;	chr6:26947221	chr6:26896952~26898777:+
ESCA	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-6.76	4.92e-10	3.73e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.884	rs1108889	ENSG00000231760.4	RP11-350J20.5	6.76	4.93e-10	3.74e-06	0.67	0.52	Lung cancer;	chr6:149845433	chr6:149796151~149826294:-
ESCA	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-6.76	4.96e-10	3.76e-06	-0.64	-0.52	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-6.76	4.96e-10	3.76e-06	-0.64	-0.52	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.935	rs7339303	ENSG00000227676.3	LINC01068	-6.75	5.07e-10	3.84e-06	-0.69	-0.52	Schizophrenia;	chr13:79516730	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.905	rs7321953	ENSG00000227676.3	LINC01068	-6.75	5.07e-10	3.84e-06	-0.69	-0.52	Schizophrenia;	chr13:79517404	chr13:79566727~79571436:+
ESCA	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-6.75	5.09e-10	3.85e-06	-0.64	-0.52	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
ESCA	cis	rs1799949	1	rs2271573	ENSG00000198496.9	NBR2	-6.75	5.21e-10	3.94e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43175604	chr17:43125610~43153671:+
ESCA	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
ESCA	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-6.75	5.28e-10	3.97e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
ESCA	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-6.75	5.3e-10	3.98e-06	-0.79	-0.52	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
ESCA	cis	rs2929278	0.617	rs4617832	ENSG00000205771.5	CATSPER2P1	6.74	5.34e-10	4.01e-06	0.67	0.52	Schizophrenia;	chr15:43738381	chr15:43726918~43747094:-
ESCA	cis	rs2929278	0.589	rs2411284	ENSG00000205771.5	CATSPER2P1	6.74	5.34e-10	4.01e-06	0.67	0.52	Schizophrenia;	chr15:43746701	chr15:43726918~43747094:-
ESCA	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-6.74	5.35e-10	4.01e-06	-0.66	-0.52	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
ESCA	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	6.74	5.39e-10	4.04e-06	0.71	0.52	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	6.74	5.39e-10	4.04e-06	0.71	0.52	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
ESCA	cis	rs1799949	0.931	rs34410138	ENSG00000198496.9	NBR2	-6.74	5.44e-10	4.08e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43127753	chr17:43125610~43153671:+
ESCA	cis	rs17507216	0.591	rs7163848	ENSG00000278603.1	RP13-608F4.5	6.74	5.44e-10	4.08e-06	0.88	0.52	Excessive daytime sleepiness;	chr15:82729563	chr15:82472203~82472426:+
ESCA	cis	rs9368481	0.761	rs4713062	ENSG00000243307.2	POM121L6P	-6.74	5.45e-10	4.08e-06	-0.59	-0.52	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26896952~26898777:+
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000231271.1	AP000350.8	6.74	5.49e-10	4.1e-06	0.62	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23949918~23954042:+
ESCA	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	6.74	5.49e-10	4.1e-06	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
ESCA	cis	rs6538678	0.818	rs7976294	ENSG00000258343.1	RP11-536G4.2	-6.74	5.51e-10	4.11e-06	-0.67	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95876868	chr12:95795345~95858839:-
ESCA	cis	rs6538678	0.818	rs1036429	ENSG00000258343.1	RP11-536G4.2	-6.74	5.51e-10	4.11e-06	-0.67	-0.52	Lupus nephritis in systemic lupus erythematosus;	chr12:95877650	chr12:95795345~95858839:-
ESCA	cis	rs9457247	0.905	rs444210	ENSG00000265828.1	MIR3939	-6.74	5.55e-10	4.14e-06	-0.55	-0.52	Crohn's disease;	chr6:166976754	chr6:166997807~166997912:-
ESCA	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-6.74	5.57e-10	4.15e-06	-0.7	-0.52	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
ESCA	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-6.73	5.6e-10	4.17e-06	-0.64	-0.52	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-6.73	5.6e-10	4.17e-06	-0.64	-0.52	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-6.73	5.6e-10	4.17e-06	-0.64	-0.52	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.967	rs9318627	ENSG00000227676.3	LINC01068	6.73	5.63e-10	4.19e-06	0.68	0.52	Schizophrenia;	chr13:79355944	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	6.73	5.73e-10	4.26e-06	0.55	0.52	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
ESCA	cis	rs1799949	0.602	rs8176235	ENSG00000198496.9	NBR2	-6.73	5.79e-10	4.3e-06	-0.58	-0.52	Menopause (age at onset);	chr17:43067543	chr17:43125610~43153671:+
ESCA	cis	rs2980439	0.818	rs2948294	ENSG00000173295.6	FAM86B3P	6.73	5.85e-10	4.34e-06	0.59	0.52	Neuroticism;	chr8:8237439	chr8:8228595~8244865:+
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000099984.9	GSTT2	-6.73	5.87e-10	4.35e-06	-0.65	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23980123~23983911:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-6.73	5.87e-10	4.35e-06	-0.83	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-6.72	5.88e-10	4.35e-06	-0.62	-0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
ESCA	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	6.72	5.9e-10	4.37e-06	0.67	0.52	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	6.72	5.9e-10	4.37e-06	0.67	0.52	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	6.72	5.9e-10	4.37e-06	0.67	0.52	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
ESCA	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	6.72	5.95e-10	4.4e-06	0.57	0.52	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
ESCA	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-6.72	6.08e-10	4.49e-06	-0.94	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000250470.1	AP000351.3	6.72	6.09e-10	4.5e-06	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23976904~23977585:-
ESCA	cis	rs2929278	0.617	rs12908467	ENSG00000205771.5	CATSPER2P1	6.71	6.2e-10	4.56e-06	0.67	0.52	Schizophrenia;	chr15:43755232	chr15:43726918~43747094:-
ESCA	cis	rs9368481	0.645	rs10456350	ENSG00000243307.2	POM121L6P	6.71	6.23e-10	4.58e-06	0.58	0.52	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26896952~26898777:+
ESCA	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-6.71	6.23e-10	4.58e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-6.71	6.23e-10	4.58e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-6.71	6.23e-10	4.58e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-6.71	6.23e-10	4.58e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
ESCA	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	6.71	6.3e-10	4.62e-06	0.56	0.52	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
ESCA	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-6.71	6.31e-10	4.63e-06	-0.84	-0.52	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
ESCA	cis	rs12922317	0.556	rs8062691	ENSG00000260224.1	UBL5P4	-6.71	6.35e-10	4.66e-06	-0.55	-0.52	Schizophrenia;	chr16:11997972	chr16:11968508~11968743:-
ESCA	cis	rs9368481	0.761	rs12661756	ENSG00000243307.2	POM121L6P	6.71	6.36e-10	4.66e-06	0.62	0.52	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26896952~26898777:+
ESCA	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-6.71	6.49e-10	4.75e-06	-0.7	-0.52	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
ESCA	cis	rs1799949	1	rs1973646	ENSG00000198496.9	NBR2	-6.71	6.49e-10	4.75e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43158478	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12944458	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43028755	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs36036395	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43029280	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs72829113	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43029818	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11653253	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43030645	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12951869	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43035550	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11654452	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43037366	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793189	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43038698	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11657053	ENSG00000198496.9	NBR2	-6.7	6.59e-10	4.81e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43039112	chr17:43125610~43153671:+
ESCA	cis	rs9368481	0.761	rs3931464	ENSG00000243307.2	POM121L6P	6.7	6.64e-10	4.84e-06	0.6	0.52	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26896952~26898777:+
ESCA	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	6.7	6.72e-10	4.9e-06	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
ESCA	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	6.7	6.72e-10	4.9e-06	0.63	0.52	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
ESCA	cis	rs1799949	1	rs4793212	ENSG00000198496.9	NBR2	-6.7	6.73e-10	4.91e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43150733	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs34534709	ENSG00000198496.9	NBR2	-6.7	6.73e-10	4.91e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43150923	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs34059614	ENSG00000198496.9	NBR2	-6.7	6.73e-10	4.91e-06	-0.57	-0.52	Menopause (age at onset);	chr17:43151054	chr17:43125610~43153671:+
ESCA	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-6.69	6.85e-10	4.99e-06	-0.62	-0.52	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
ESCA	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-6.69	6.86e-10	4.99e-06	-0.64	-0.52	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
ESCA	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-6.69	6.88e-10	5.01e-06	-0.84	-0.52	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-6.69	6.94e-10	5.05e-06	-0.83	-0.52	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
ESCA	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	6.69	6.96e-10	5.06e-06	0.66	0.52	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
ESCA	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-6.69	6.97e-10	5.06e-06	-0.64	-0.52	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-6.69	6.97e-10	5.06e-06	-0.64	-0.52	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-6.69	6.97e-10	5.06e-06	-0.64	-0.52	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-6.69	6.97e-10	5.06e-06	-0.64	-0.52	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-6.69	6.97e-10	5.06e-06	-0.64	-0.52	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
ESCA	cis	rs62229266	0.659	rs7275820	ENSG00000231106.2	LINC01436	6.69	6.99e-10	5.07e-06	0.57	0.52	Mitral valve prolapse;	chr21:36037116	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.652	rs7280551	ENSG00000231106.2	LINC01436	6.69	6.99e-10	5.07e-06	0.57	0.52	Mitral valve prolapse;	chr21:36037311	chr21:36005338~36007838:+
ESCA	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-6.69	7.1e-10	5.15e-06	-0.54	-0.52	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	6.69	7.1e-10	5.15e-06	0.54	0.52	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
ESCA	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-6.69	7.12e-10	5.17e-06	-0.67	-0.52	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
ESCA	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	6.68	7.2e-10	5.22e-06	0.54	0.52	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
ESCA	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-6.68	7.22e-10	5.23e-06	-0.79	-0.52	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-6.68	7.25e-10	5.25e-06	-0.75	-0.52	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
ESCA	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-6.68	7.33e-10	5.3e-06	-0.55	-0.52	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	6.68	7.33e-10	5.3e-06	0.55	0.52	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	6.68	7.35e-10	5.32e-06	0.53	0.52	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	6.68	7.36e-10	5.32e-06	0.55	0.52	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
ESCA	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-6.68	7.39e-10	5.34e-06	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
ESCA	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-6.68	7.39e-10	5.34e-06	-0.65	-0.52	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
ESCA	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-6.68	7.44e-10	5.37e-06	-0.67	-0.52	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
ESCA	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	6.68	7.47e-10	5.4e-06	0.62	0.52	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000250470.1	AP000351.3	6.67	7.6e-10	5.49e-06	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000250470.1	AP000351.3	6.67	7.6e-10	5.49e-06	0.65	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23976904~23977585:-
ESCA	cis	rs62229266	0.659	rs2255734	ENSG00000231106.2	LINC01436	6.67	7.63e-10	5.5e-06	0.57	0.52	Mitral valve prolapse;	chr21:36039611	chr21:36005338~36007838:+
ESCA	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	6.67	7.64e-10	5.51e-06	0.53	0.52	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	6.67	7.64e-10	5.51e-06	0.53	0.52	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
ESCA	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-6.67	7.66e-10	5.52e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-6.67	7.66e-10	5.52e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-6.67	7.66e-10	5.52e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-6.67	7.66e-10	5.52e-06	-0.67	-0.52	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000250470.1	AP000351.3	6.67	7.66e-10	5.52e-06	0.61	0.52	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23976904~23977585:-
ESCA	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	6.67	7.76e-10	5.59e-06	0.52	0.52	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	6.67	7.76e-10	5.59e-06	0.52	0.52	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-6.67	7.76e-10	5.59e-06	-0.52	-0.52	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	6.67	7.9e-10	5.68e-06	0.67	0.52	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
ESCA	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	6.66	7.95e-10	5.72e-06	0.63	0.52	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
ESCA	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-6.66	7.97e-10	5.72e-06	-0.72	-0.52	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
ESCA	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-6.66	8.13e-10	5.83e-06	-0.54	-0.51	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-6.66	8.13e-10	5.83e-06	-0.54	-0.51	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-6.66	8.14e-10	5.83e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	6.66	8.17e-10	5.86e-06	0.56	0.51	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
ESCA	cis	rs11235843	0.565	rs1723840	ENSG00000255928.1	RP11-456I15.2	6.66	8.18e-10	5.86e-06	0.67	0.51	Hand grip strength;	chr11:73762840	chr11:73722349~73722694:+
ESCA	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	6.66	8.24e-10	5.9e-06	0.55	0.51	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
ESCA	cis	rs1336900	0.641	rs6587756	ENSG00000206931.1	RNU6-1042P	-6.66	8.26e-10	5.91e-06	-0.64	-0.51	Blood protein levels;	chr1:150574389	chr1:150701866~150701972:+
ESCA	cis	rs2980439	0.807	rs2980438	ENSG00000253981.4	ALG1L13P	6.66	8.34e-10	5.96e-06	0.63	0.51	Neuroticism;	chr8:8237303	chr8:8236003~8244667:-
ESCA	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-6.65	8.35e-10	5.97e-06	-0.54	-0.51	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-6.65	8.35e-10	5.97e-06	-0.54	-0.51	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	6.65	8.35e-10	5.97e-06	0.54	0.51	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	6.65	8.41e-10	6.01e-06	0.62	0.51	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
ESCA	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-6.65	8.43e-10	6.02e-06	-0.56	-0.51	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-6.65	8.43e-10	6.02e-06	-0.56	-0.51	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
ESCA	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	6.65	8.52e-10	6.08e-06	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
ESCA	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	6.65	8.55e-10	6.1e-06	0.66	0.51	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	6.65	8.55e-10	6.1e-06	0.66	0.51	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	6.65	8.55e-10	6.1e-06	0.66	0.51	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	6.65	8.55e-10	6.1e-06	0.66	0.51	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
ESCA	cis	rs62229266	0.625	rs62230813	ENSG00000231106.2	LINC01436	6.65	8.75e-10	6.22e-06	0.56	0.51	Mitral valve prolapse;	chr21:36031134	chr21:36005338~36007838:+
ESCA	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	6.64	8.87e-10	6.3e-06	0.53	0.51	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	6.64	8.87e-10	6.3e-06	0.53	0.51	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-6.64	8.89e-10	6.31e-06	-0.55	-0.51	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	6.64	8.94e-10	6.34e-06	0.55	0.51	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-6.64	8.94e-10	6.34e-06	-0.55	-0.51	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-6.64	8.94e-10	6.34e-06	-0.55	-0.51	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
ESCA	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-6.64	9.04e-10	6.41e-06	-0.61	-0.51	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
ESCA	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	6.64	9.06e-10	6.42e-06	0.54	0.51	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	6.64	9.06e-10	6.42e-06	0.54	0.51	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	6.64	9.14e-10	6.47e-06	0.53	0.51	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	6.64	9.14e-10	6.47e-06	0.53	0.51	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
ESCA	cis	rs9545047	0.868	rs1208049	ENSG00000227676.3	LINC01068	6.64	9.16e-10	6.48e-06	0.68	0.51	Schizophrenia;	chr13:79570220	chr13:79566727~79571436:+
ESCA	cis	rs62229266	0.659	rs62230814	ENSG00000231106.2	LINC01436	6.63	9.23e-10	6.53e-06	0.57	0.51	Mitral valve prolapse;	chr21:36031248	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.633	rs34259635	ENSG00000231106.2	LINC01436	6.63	9.23e-10	6.53e-06	0.57	0.51	Mitral valve prolapse;	chr21:36031272	chr21:36005338~36007838:+
ESCA	cis	rs1799949	1	rs2037075	ENSG00000198496.9	NBR2	-6.63	9.25e-10	6.53e-06	-0.57	-0.51	Menopause (age at onset);	chr17:43153809	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-6.63	9.36e-10	6.6e-06	-0.55	-0.51	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-6.63	9.36e-10	6.6e-06	-0.55	-0.51	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-6.63	9.36e-10	6.6e-06	-0.55	-0.51	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
ESCA	cis	rs1799949	0.827	rs74252763	ENSG00000198496.9	NBR2	-6.63	9.38e-10	6.61e-06	-0.57	-0.51	Menopause (age at onset);	chr17:43324652	chr17:43125610~43153671:+
ESCA	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-6.63	9.4e-10	6.61e-06	-0.55	-0.51	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-6.63	9.4e-10	6.61e-06	-0.55	-0.51	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-6.63	9.4e-10	6.61e-06	-0.55	-0.51	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-6.63	9.4e-10	6.61e-06	-0.55	-0.51	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	6.63	9.4e-10	6.61e-06	0.55	0.51	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
ESCA	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	6.63	9.4e-10	6.61e-06	0.7	0.51	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	6.63	9.4e-10	6.61e-06	0.7	0.51	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
ESCA	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	6.63	9.48e-10	6.66e-06	0.53	0.51	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
ESCA	cis	rs12439619	0.739	rs4778988	ENSG00000278603.1	RP13-608F4.5	6.63	9.5e-10	6.68e-06	0.76	0.51	Intelligence (multi-trait analysis);	chr15:82247996	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000250470.1	AP000351.3	6.63	9.53e-10	6.69e-06	0.65	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000250470.1	AP000351.3	6.63	9.53e-10	6.69e-06	0.65	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000231271.1	AP000350.8	6.63	9.6e-10	6.74e-06	0.6	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23949918~23954042:+
ESCA	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-6.63	9.66e-10	6.78e-06	-0.65	-0.51	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
ESCA	cis	rs9462027	1	rs6457792	ENSG00000186328.4	RP11-140K17.2	-6.62	9.72e-10	6.82e-06	-0.64	-0.51	Systemic lupus erythematosus;	chr6:34796666	chr6:34715613~34715940:+
ESCA	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-6.62	9.81e-10	6.88e-06	-0.55	-0.51	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
ESCA	cis	rs4747241	0.593	rs10740401	ENSG00000226163.1	RP11-167P22.3	6.62	9.83e-10	6.89e-06	0.59	0.51	Heschl's gyrus morphology;	chr10:72306639	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.593	rs3924190	ENSG00000226163.1	RP11-167P22.3	6.62	9.83e-10	6.89e-06	0.59	0.51	Heschl's gyrus morphology;	chr10:72308318	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.626	rs4275534	ENSG00000226163.1	RP11-167P22.3	6.62	9.83e-10	6.89e-06	0.59	0.51	Heschl's gyrus morphology;	chr10:72308393	chr10:72501746~72502956:+
ESCA	cis	rs9545047	0.935	rs2783119	ENSG00000227676.3	LINC01068	6.62	9.87e-10	6.92e-06	0.69	0.51	Schizophrenia;	chr13:79524983	chr13:79566727~79571436:+
ESCA	cis	rs1799949	1	rs11659028	ENSG00000198496.9	NBR2	-6.62	9.95e-10	6.97e-06	-0.57	-0.51	Menopause (age at onset);	chr17:43043008	chr17:43125610~43153671:+
ESCA	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-6.62	9.98e-10	6.99e-06	-0.62	-0.51	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
ESCA	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-6.62	1e-09	7.01e-06	-0.66	-0.51	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
ESCA	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-6.61	1.04e-09	7.21e-06	-0.55	-0.51	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
ESCA	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	6.61	1.04e-09	7.22e-06	0.78	0.51	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
ESCA	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-6.61	1.04e-09	7.22e-06	-0.55	-0.51	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
ESCA	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-6.61	1.04e-09	7.26e-06	-0.62	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.964	rs12055237	ENSG00000253404.1	AC034243.1	6.61	1.05e-09	7.29e-06	0.74	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138971617	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	6.61	1.05e-09	7.33e-06	0.62	0.51	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
ESCA	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	6.61	1.06e-09	7.35e-06	0.57	0.51	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
ESCA	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	6.61	1.06e-09	7.38e-06	0.63	0.51	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
ESCA	cis	rs7829975	0.564	rs2976855	ENSG00000253981.4	ALG1L13P	6.61	1.07e-09	7.42e-06	0.59	0.51	Mood instability;	chr8:8444284	chr8:8236003~8244667:-
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000250470.1	AP000351.3	6.61	1.07e-09	7.42e-06	0.64	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23976904~23977585:-
ESCA	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-6.61	1.07e-09	7.42e-06	-0.55	-0.51	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-6.61	1.07e-09	7.42e-06	-0.55	-0.51	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-6.61	1.07e-09	7.42e-06	-0.55	-0.51	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
ESCA	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	6.61	1.07e-09	7.42e-06	0.7	0.51	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
ESCA	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-6.6	1.07e-09	7.45e-06	-0.55	-0.51	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
ESCA	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	6.6	1.08e-09	7.46e-06	0.66	0.51	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
ESCA	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	6.6	1.09e-09	7.52e-06	0.53	0.51	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	6.6	1.09e-09	7.52e-06	0.53	0.51	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	6.6	1.09e-09	7.55e-06	0.64	0.51	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-6.6	1.1e-09	7.6e-06	-0.61	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
ESCA	cis	rs62229266	0.659	rs2835245	ENSG00000231106.2	LINC01436	6.6	1.1e-09	7.62e-06	0.57	0.51	Mitral valve prolapse;	chr21:36044410	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.609	rs12482541	ENSG00000231106.2	LINC01436	6.6	1.1e-09	7.62e-06	0.57	0.51	Mitral valve prolapse;	chr21:36047445	chr21:36005338~36007838:+
ESCA	cis	rs62229266	0.609	rs2835253	ENSG00000231106.2	LINC01436	6.6	1.1e-09	7.62e-06	0.57	0.51	Mitral valve prolapse;	chr21:36047447	chr21:36005338~36007838:+
ESCA	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-6.6	1.11e-09	7.64e-06	-0.56	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
ESCA	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	6.6	1.12e-09	7.71e-06	0.71	0.51	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
ESCA	cis	rs9368481	0.7	rs6911401	ENSG00000243307.2	POM121L6P	6.6	1.12e-09	7.72e-06	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26896952~26898777:+
ESCA	cis	rs9368481	0.729	rs10946881	ENSG00000243307.2	POM121L6P	6.6	1.12e-09	7.72e-06	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26896952~26898777:+
ESCA	cis	rs9368481	0.678	rs62402024	ENSG00000243307.2	POM121L6P	6.6	1.12e-09	7.72e-06	0.59	0.51	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26896952~26898777:+
ESCA	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-6.59	1.13e-09	7.76e-06	-0.54	-0.51	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
ESCA	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	6.59	1.13e-09	7.76e-06	0.68	0.51	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
ESCA	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-6.59	1.13e-09	7.76e-06	-0.65	-0.51	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-6.59	1.14e-09	7.81e-06	-0.61	-0.51	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
ESCA	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-6.59	1.14e-09	7.86e-06	-0.59	-0.51	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
ESCA	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-6.59	1.15e-09	7.88e-06	-0.68	-0.51	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	6.59	1.15e-09	7.91e-06	0.73	0.51	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	6.59	1.15e-09	7.91e-06	0.73	0.51	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	6.59	1.16e-09	7.96e-06	0.59	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
ESCA	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-6.59	1.17e-09	8.01e-06	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
ESCA	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-6.59	1.18e-09	8.12e-06	-0.53	-0.51	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
ESCA	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-6.58	1.18e-09	8.13e-06	-0.62	-0.51	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-6.58	1.18e-09	8.13e-06	-0.62	-0.51	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
ESCA	cis	rs1799949	1	rs915945	ENSG00000198496.9	NBR2	-6.58	1.19e-09	8.18e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43027847	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12944597	ENSG00000198496.9	NBR2	-6.58	1.19e-09	8.18e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43035667	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs12942277	ENSG00000198496.9	NBR2	-6.58	1.19e-09	8.18e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43035957	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs34616041	ENSG00000198496.9	NBR2	-6.58	1.19e-09	8.18e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43036769	chr17:43125610~43153671:+
ESCA	cis	rs9462027	1	rs9462027	ENSG00000186328.4	RP11-140K17.2	6.58	1.21e-09	8.29e-06	0.64	0.51	Systemic lupus erythematosus;	chr6:34829464	chr6:34715613~34715940:+
ESCA	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	6.58	1.21e-09	8.31e-06	0.62	0.51	Depression;	chr6:28363475	chr6:28176188~28176674:+
ESCA	cis	rs1563304	1	rs1563304	ENSG00000262539.1	RP11-259G18.3	6.58	1.22e-09	8.33e-06	0.86	0.51	Neuroticism;	chr17:46797087	chr17:46259551~46260606:-
ESCA	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-6.58	1.23e-09	8.42e-06	-0.49	-0.51	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
ESCA	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	6.58	1.24e-09	8.47e-06	0.69	0.51	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
ESCA	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-6.58	1.24e-09	8.47e-06	-0.54	-0.51	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-6.58	1.24e-09	8.47e-06	-0.54	-0.51	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
ESCA	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	6.57	1.25e-09	8.51e-06	0.82	0.51	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
ESCA	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	6.57	1.28e-09	8.73e-06	0.54	0.51	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	6.57	1.28e-09	8.73e-06	0.54	0.51	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000250470.1	AP000351.3	6.57	1.28e-09	8.73e-06	0.63	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23976904~23977585:-
ESCA	cis	rs62229266	0.659	rs2835243	ENSG00000231106.2	LINC01436	6.57	1.29e-09	8.81e-06	0.57	0.51	Mitral valve prolapse;	chr21:36041648	chr21:36005338~36007838:+
ESCA	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	6.57	1.29e-09	8.82e-06	0.55	0.51	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	6.57	1.3e-09	8.83e-06	0.55	0.51	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	6.57	1.3e-09	8.83e-06	0.55	0.51	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	6.57	1.3e-09	8.83e-06	0.55	0.51	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	6.57	1.3e-09	8.87e-06	0.63	0.51	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-6.57	1.3e-09	8.87e-06	-0.63	-0.51	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000099984.9	GSTT2	-6.56	1.31e-09	8.91e-06	-0.62	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23980123~23983911:+
ESCA	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-6.56	1.32e-09	8.96e-06	-0.63	-0.51	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
ESCA	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	6.56	1.32e-09	8.96e-06	0.54	0.51	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
ESCA	cis	rs1799949	0.501	rs2343819	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43332285	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.55	rs2343818	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43332406	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.501	rs35399157	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43334234	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.602	rs4600503	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43336956	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.526	rs4352088	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43337311	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.501	rs9675035	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43337648	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793229	ENSG00000198496.9	NBR2	6.56	1.33e-09	9e-06	0.56	0.51	Menopause (age at onset);	chr17:43340966	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs34633610	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43342017	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs11654051	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43342288	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11649954	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43342667	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1824889	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43344508	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs56729776	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43344763	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs35956818	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43345617	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs9646417	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43346885	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs1545764	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43347197	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs4584865	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43347551	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs9646412	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43348525	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4793231	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43350101	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs11651341	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43350693	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs34572725	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43351298	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs4534897	ENSG00000198496.9	NBR2	-6.56	1.33e-09	9e-06	-0.56	-0.51	Menopause (age at onset);	chr17:43354440	chr17:43125610~43153671:+
ESCA	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-6.56	1.33e-09	9e-06	-0.69	-0.51	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
ESCA	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-6.56	1.33e-09	9.02e-06	-0.55	-0.51	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
ESCA	cis	rs6456156	0.692	rs9457270	ENSG00000265828.1	MIR3939	-6.56	1.34e-09	9.04e-06	-0.57	-0.51	Primary biliary cholangitis;	chr6:167099440	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.565	rs12193698	ENSG00000265828.1	MIR3939	-6.56	1.35e-09	9.09e-06	-0.57	-0.51	Crohn's disease;	chr6:167098585	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.565	rs2239823	ENSG00000265828.1	MIR3939	-6.56	1.35e-09	9.09e-06	-0.57	-0.51	Crohn's disease;	chr6:167098643	chr6:166997807~166997912:-
ESCA	cis	rs4747241	0.774	rs10762507	ENSG00000226163.1	RP11-167P22.3	6.56	1.35e-09	9.12e-06	0.6	0.51	Heschl's gyrus morphology;	chr10:72298713	chr10:72501746~72502956:+
ESCA	cis	rs9462027	1	rs9689160	ENSG00000186328.4	RP11-140K17.2	6.56	1.35e-09	9.14e-06	0.64	0.51	Systemic lupus erythematosus;	chr6:34782072	chr6:34715613~34715940:+
ESCA	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	6.56	1.37e-09	9.25e-06	0.53	0.51	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
ESCA	cis	rs12439619	1	rs35152457	ENSG00000278603.1	RP13-608F4.5	6.55	1.39e-09	9.36e-06	0.74	0.51	Intelligence (multi-trait analysis);	chr15:82254207	chr15:82472203~82472426:+
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000099984.9	GSTT2	-6.55	1.39e-09	9.37e-06	-0.62	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23980123~23983911:+
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000099984.9	GSTT2	-6.55	1.39e-09	9.37e-06	-0.62	-0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23980123~23983911:+
ESCA	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	6.55	1.4e-09	9.41e-06	0.54	0.51	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
ESCA	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-6.55	1.41e-09	9.46e-06	-0.82	-0.51	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-6.55	1.41e-09	9.46e-06	-0.82	-0.51	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
ESCA	cis	rs9545047	0.935	rs1475797	ENSG00000227676.3	LINC01068	-6.55	1.42e-09	9.53e-06	-0.68	-0.51	Schizophrenia;	chr13:79519690	chr13:79566727~79571436:+
ESCA	cis	rs9368481	0.729	rs9379950	ENSG00000243307.2	POM121L6P	-6.55	1.42e-09	9.54e-06	-0.62	-0.51	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26896952~26898777:+
ESCA	cis	rs9368481	1	rs9368481	ENSG00000243307.2	POM121L6P	-6.55	1.42e-09	9.54e-06	-0.62	-0.51	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26896952~26898777:+
ESCA	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	6.55	1.43e-09	9.58e-06	0.64	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
ESCA	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	6.54	1.45e-09	9.68e-06	0.54	0.51	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
ESCA	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	6.54	1.45e-09	9.69e-06	0.65	0.51	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
ESCA	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-6.54	1.47e-09	9.8e-06	-0.48	-0.51	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
ESCA	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	6.54	1.47e-09	9.81e-06	0.61	0.51	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.964	rs67296915	ENSG00000253404.1	AC034243.1	6.54	1.48e-09	9.86e-06	0.71	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:138965910	chr5:138744434~138753309:-
ESCA	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	6.54	1.49e-09	9.91e-06	0.71	0.51	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
ESCA	cis	rs1799949	0.602	rs8176257	ENSG00000198496.9	NBR2	-6.54	1.49e-09	9.93e-06	-0.57	-0.51	Menopause (age at onset);	chr17:43064188	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.732	rs5760175	ENSG00000224205.1	AP000351.4	6.54	1.49e-09	9.94e-06	0.61	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24003209	chr22:23987320~23991421:-
ESCA	cis	rs4747241	0.626	rs4409753	ENSG00000226163.1	RP11-167P22.3	6.54	1.49e-09	9.94e-06	0.59	0.51	Heschl's gyrus morphology;	chr10:72309368	chr10:72501746~72502956:+
ESCA	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-6.54	1.49e-09	9.94e-06	-0.55	-0.51	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
ESCA	cis	rs9545047	0.735	rs314690	ENSG00000227676.3	LINC01068	6.54	1.5e-09	9.99e-06	0.68	0.51	Schizophrenia;	chr13:79434822	chr13:79566727~79571436:+
ESCA	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-6.54	1.5e-09	1e-05	-0.64	-0.51	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
ESCA	cis	rs11155671	0.53	rs9383940	ENSG00000231760.4	RP11-350J20.5	6.54	1.51e-09	1.01e-05	0.63	0.51	Testicular germ cell tumor;	chr6:149904923	chr6:149796151~149826294:-
ESCA	cis	rs9368481	0.554	rs2754603	ENSG00000243307.2	POM121L6P	-6.54	1.51e-09	1.01e-05	-0.62	-0.51	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26896952~26898777:+
ESCA	cis	rs9368481	0.761	rs9357028	ENSG00000243307.2	POM121L6P	-6.54	1.51e-09	1.01e-05	-0.62	-0.51	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26896952~26898777:+
ESCA	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-6.53	1.52e-09	1.01e-05	-0.63	-0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
ESCA	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-6.53	1.52e-09	1.01e-05	-0.55	-0.51	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-6.53	1.52e-09	1.01e-05	-0.54	-0.51	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-6.53	1.56e-09	1.03e-05	-0.56	-0.51	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
ESCA	cis	rs9368481	0.743	rs9368480	ENSG00000243307.2	POM121L6P	6.53	1.58e-09	1.05e-05	0.61	0.51	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26896952~26898777:+
ESCA	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-6.53	1.58e-09	1.05e-05	-0.68	-0.51	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-6.53	1.59e-09	1.05e-05	-0.7	-0.51	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
ESCA	cis	rs1799949	0.832	rs2070835	ENSG00000198496.9	NBR2	-6.52	1.61e-09	1.06e-05	-0.57	-0.51	Menopause (age at onset);	chr17:43022008	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	6.52	1.63e-09	1.07e-05	0.53	0.51	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
ESCA	cis	rs1799949	0.965	rs6503727	ENSG00000198496.9	NBR2	-6.52	1.63e-09	1.07e-05	-0.54	-0.51	Menopause (age at onset);	chr17:43160842	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	6.52	1.65e-09	1.09e-05	0.53	0.51	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
ESCA	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-6.52	1.65e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
ESCA	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-6.52	1.66e-09	1.09e-05	-0.55	-0.51	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
ESCA	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-6.52	1.67e-09	1.09e-05	-0.66	-0.51	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	6.52	1.67e-09	1.1e-05	0.53	0.51	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
ESCA	cis	rs12439619	0.53	rs7162177	ENSG00000278603.1	RP13-608F4.5	6.51	1.68e-09	1.1e-05	0.64	0.51	Intelligence (multi-trait analysis);	chr15:82181728	chr15:82472203~82472426:+
ESCA	cis	rs8062405	0.789	rs1968752	ENSG00000278665.1	RP11-666O2.4	6.51	1.68e-09	1.1e-05	0.7	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28599241~28601881:-
ESCA	cis	rs9457247	0.565	rs12178491	ENSG00000265828.1	MIR3939	-6.51	1.68e-09	1.1e-05	-0.57	-0.51	Crohn's disease;	chr6:167098986	chr6:166997807~166997912:-
ESCA	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-6.51	1.69e-09	1.1e-05	-0.54	-0.51	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
ESCA	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-6.51	1.69e-09	1.1e-05	-0.64	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000231271.1	AP000350.8	6.51	1.69e-09	1.11e-05	0.58	0.51	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23949918~23954042:+
ESCA	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-6.51	1.7e-09	1.11e-05	-0.55	-0.51	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-6.51	1.7e-09	1.11e-05	-0.55	-0.51	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-6.51	1.7e-09	1.11e-05	-0.53	-0.51	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
ESCA	cis	rs62229266	0.557	rs4817761	ENSG00000231106.2	LINC01436	6.51	1.71e-09	1.12e-05	0.56	0.51	Mitral valve prolapse;	chr21:36023258	chr21:36005338~36007838:+
ESCA	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	6.51	1.72e-09	1.12e-05	0.6	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
ESCA	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	6.51	1.72e-09	1.12e-05	0.81	0.51	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
ESCA	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	6.51	1.73e-09	1.12e-05	0.53	0.51	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	6.51	1.74e-09	1.13e-05	0.52	0.51	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	6.51	1.74e-09	1.13e-05	0.53	0.51	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	6.51	1.74e-09	1.13e-05	0.53	0.51	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	6.51	1.74e-09	1.13e-05	0.53	0.51	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
ESCA	cis	rs11155671	0.53	rs4458704	ENSG00000231760.4	RP11-350J20.5	6.51	1.74e-09	1.14e-05	0.64	0.51	Testicular germ cell tumor;	chr6:149911743	chr6:149796151~149826294:-
ESCA	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-6.51	1.75e-09	1.14e-05	-0.79	-0.51	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
ESCA	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	6.51	1.75e-09	1.14e-05	0.55	0.51	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
ESCA	cis	rs2929278	0.589	rs7174732	ENSG00000205771.5	CATSPER2P1	6.5	1.76e-09	1.15e-05	0.68	0.51	Schizophrenia;	chr15:43746265	chr15:43726918~43747094:-
ESCA	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	6.5	1.78e-09	1.16e-05	0.63	0.51	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
ESCA	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-6.5	1.78e-09	1.16e-05	-0.55	-0.51	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	6.5	1.78e-09	1.16e-05	0.52	0.51	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	6.5	1.78e-09	1.16e-05	0.52	0.51	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	6.5	1.78e-09	1.16e-05	0.52	0.51	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
ESCA	cis	rs748404	0.578	rs2584701	ENSG00000249839.1	AC011330.5	-6.5	1.79e-09	1.16e-05	-0.61	-0.51	Lung cancer;	chr15:43392741	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.578	rs2012467	ENSG00000249839.1	AC011330.5	-6.5	1.79e-09	1.16e-05	-0.61	-0.51	Lung cancer;	chr15:43398367	chr15:43663654~43684339:-
ESCA	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.5	1.79e-09	1.17e-05	-0.59	-0.51	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
ESCA	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	6.5	1.8e-09	1.17e-05	0.54	0.51	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
ESCA	cis	rs62229266	0.659	rs2835242	ENSG00000231106.2	LINC01436	6.5	1.8e-09	1.17e-05	0.56	0.51	Mitral valve prolapse;	chr21:36041234	chr21:36005338~36007838:+
ESCA	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	6.5	1.81e-09	1.18e-05	0.69	0.51	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
ESCA	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	6.5	1.84e-09	1.19e-05	0.54	0.51	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	6.5	1.84e-09	1.19e-05	0.54	0.51	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
ESCA	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	6.5	1.85e-09	1.19e-05	0.58	0.51	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
ESCA	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	6.5	1.85e-09	1.19e-05	0.61	0.51	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	6.49	1.85e-09	1.2e-05	0.69	0.51	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
ESCA	cis	rs17507216	0.667	rs72753916	ENSG00000278603.1	RP13-608F4.5	6.49	1.86e-09	1.2e-05	0.73	0.51	Excessive daytime sleepiness;	chr15:82684001	chr15:82472203~82472426:+
ESCA	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	6.49	1.86e-09	1.2e-05	0.53	0.51	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
ESCA	cis	rs2929278	0.617	rs11070410	ENSG00000205771.5	CATSPER2P1	6.49	1.86e-09	1.2e-05	0.68	0.51	Schizophrenia;	chr15:43764847	chr15:43726918~43747094:-
ESCA	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	6.49	1.87e-09	1.21e-05	0.55	0.51	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
ESCA	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	6.49	1.88e-09	1.21e-05	0.64	0.51	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
ESCA	cis	rs2658782	1	rs2658779	ENSG00000279684.1	RP11-755E23.2	6.49	1.89e-09	1.22e-05	0.76	0.51	Pulmonary function decline;	chr11:93429971	chr11:93286629~93288903:-
ESCA	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	6.49	1.9e-09	1.22e-05	0.55	0.51	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
ESCA	cis	rs9322193	0.884	rs880245	ENSG00000231760.4	RP11-350J20.5	-6.49	1.92e-09	1.24e-05	-0.65	-0.5	Lung cancer;	chr6:149846262	chr6:149796151~149826294:-
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000231271.1	AP000350.8	-6.49	1.93e-09	1.24e-05	-0.65	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23949918~23954042:+
ESCA	cis	rs1799949	0.965	rs2236762	ENSG00000198496.9	NBR2	-6.49	1.93e-09	1.24e-05	-0.55	-0.5	Menopause (age at onset);	chr17:43074658	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-6.49	1.94e-09	1.24e-05	-0.52	-0.5	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-6.49	1.94e-09	1.24e-05	-0.52	-0.5	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-6.49	1.94e-09	1.24e-05	-0.52	-0.5	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-6.49	1.94e-09	1.24e-05	-0.52	-0.5	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-6.49	1.94e-09	1.24e-05	-0.52	-0.5	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	6.49	1.94e-09	1.24e-05	0.52	0.5	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
ESCA	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	6.49	1.94e-09	1.24e-05	0.63	0.5	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
ESCA	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	6.48	1.95e-09	1.25e-05	0.55	0.5	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000099984.9	GSTT2	-6.48	1.96e-09	1.26e-05	-0.6	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23980123~23983911:+
ESCA	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-6.48	1.96e-09	1.26e-05	-0.55	-0.5	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
ESCA	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	6.48	1.97e-09	1.27e-05	0.7	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
ESCA	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	6.48	1.98e-09	1.27e-05	0.51	0.5	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	6.48	1.98e-09	1.27e-05	0.53	0.5	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
ESCA	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	6.48	1.99e-09	1.27e-05	0.64	0.5	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
ESCA	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-6.48	1.99e-09	1.28e-05	-0.53	-0.5	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
ESCA	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-6.48	2e-09	1.28e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-6.48	2e-09	1.28e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
ESCA	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-6.48	2e-09	1.28e-05	-0.63	-0.5	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
ESCA	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-6.48	2.01e-09	1.29e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-6.48	2.01e-09	1.29e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-6.48	2.01e-09	1.29e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
ESCA	cis	rs9462027	1	rs9296133	ENSG00000186328.4	RP11-140K17.2	6.48	2.02e-09	1.29e-05	0.63	0.5	Systemic lupus erythematosus;	chr6:34809756	chr6:34715613~34715940:+
ESCA	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	6.48	2.03e-09	1.3e-05	0.81	0.5	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
ESCA	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	6.48	2.03e-09	1.3e-05	0.71	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	6.48	2.03e-09	1.3e-05	0.71	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	6.48	2.03e-09	1.3e-05	0.71	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
ESCA	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	6.48	2.03e-09	1.3e-05	0.71	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
ESCA	cis	rs2929278	0.562	rs8033846	ENSG00000205771.5	CATSPER2P1	6.47	2.04e-09	1.3e-05	0.68	0.5	Schizophrenia;	chr15:43743165	chr15:43726918~43747094:-
ESCA	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-6.47	2.06e-09	1.32e-05	-0.52	-0.5	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
ESCA	cis	rs12922317	0.538	rs442234	ENSG00000260224.1	UBL5P4	6.47	2.06e-09	1.32e-05	0.55	0.5	Schizophrenia;	chr16:11978304	chr16:11968508~11968743:-
ESCA	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-6.47	2.07e-09	1.32e-05	-0.59	-0.5	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
ESCA	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-6.47	2.08e-09	1.32e-05	-0.62	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-6.47	2.08e-09	1.32e-05	-0.62	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-6.47	2.08e-09	1.32e-05	-0.62	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-6.47	2.08e-09	1.32e-05	-0.62	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
ESCA	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-6.47	2.09e-09	1.33e-05	-0.53	-0.5	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-6.47	2.09e-09	1.33e-05	-0.53	-0.5	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-6.47	2.09e-09	1.33e-05	-0.53	-0.5	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-6.47	2.09e-09	1.33e-05	-0.53	-0.5	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-6.47	2.09e-09	1.33e-05	-0.53	-0.5	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	6.47	2.09e-09	1.33e-05	0.53	0.5	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	6.47	2.13e-09	1.35e-05	0.52	0.5	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	6.46	2.2e-09	1.39e-05	0.52	0.5	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	6.46	2.2e-09	1.39e-05	0.52	0.5	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	6.46	2.2e-09	1.39e-05	0.52	0.5	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
ESCA	cis	rs10256972	0.539	rs2949174	ENSG00000229043.2	AC091729.9	-6.46	2.2e-09	1.39e-05	-0.47	-0.5	Endometriosis;Longevity;	chr7:1174287	chr7:1160374~1165267:+
ESCA	cis	rs6538678	0.895	rs1436124	ENSG00000258343.1	RP11-536G4.2	-6.46	2.22e-09	1.41e-05	-0.65	-0.5	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95795345~95858839:-
ESCA	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-6.46	2.23e-09	1.41e-05	-0.47	-0.5	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-6.46	2.23e-09	1.41e-05	-0.47	-0.5	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
ESCA	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-6.46	2.23e-09	1.41e-05	-0.64	-0.5	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
ESCA	cis	rs9457247	0.565	rs2239824	ENSG00000265828.1	MIR3939	-6.46	2.24e-09	1.41e-05	-0.57	-0.5	Crohn's disease;	chr6:167098311	chr6:166997807~166997912:-
ESCA	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	6.46	2.24e-09	1.41e-05	0.54	0.5	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
ESCA	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-6.45	2.26e-09	1.43e-05	-0.62	-0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
ESCA	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-6.45	2.26e-09	1.43e-05	-0.65	-0.5	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	6.45	2.26e-09	1.43e-05	0.52	0.5	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
ESCA	cis	rs62229266	0.839	rs11702763	ENSG00000231106.2	LINC01436	6.45	2.27e-09	1.43e-05	0.58	0.5	Mitral valve prolapse;	chr21:36098406	chr21:36005338~36007838:+
ESCA	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	6.45	2.27e-09	1.43e-05	0.65	0.5	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
ESCA	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	6.45	2.28e-09	1.44e-05	0.71	0.5	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
ESCA	cis	rs62229266	0.659	rs2835258	ENSG00000231106.2	LINC01436	6.45	2.31e-09	1.46e-05	0.57	0.5	Mitral valve prolapse;	chr21:36052067	chr21:36005338~36007838:+
ESCA	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	6.45	2.31e-09	1.46e-05	0.87	0.5	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
ESCA	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	6.45	2.32e-09	1.46e-05	0.61	0.5	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
ESCA	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-6.45	2.34e-09	1.47e-05	-0.62	-0.5	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
ESCA	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	6.45	2.34e-09	1.47e-05	0.51	0.5	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	6.45	2.34e-09	1.47e-05	0.51	0.5	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
ESCA	cis	rs1799949	0.894	rs36062488	ENSG00000198496.9	NBR2	6.45	2.35e-09	1.48e-05	0.56	0.5	Menopause (age at onset);	chr17:43185455	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	6.45	2.35e-09	1.48e-05	0.6	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
ESCA	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-6.45	2.36e-09	1.48e-05	-0.5	-0.5	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
ESCA	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-6.45	2.36e-09	1.48e-05	-0.52	-0.5	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
ESCA	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-6.44	2.4e-09	1.5e-05	-0.62	-0.5	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
ESCA	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-6.44	2.44e-09	1.53e-05	-0.78	-0.5	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
ESCA	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-6.43	2.49e-09	1.56e-05	-0.59	-0.5	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-6.43	2.49e-09	1.56e-05	-0.59	-0.5	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	6.43	2.5e-09	1.57e-05	0.6	0.5	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-6.43	2.5e-09	1.57e-05	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-6.43	2.51e-09	1.57e-05	-0.53	-0.5	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
ESCA	cis	rs12922317	0.521	rs378372	ENSG00000260224.1	UBL5P4	-6.43	2.53e-09	1.58e-05	-0.55	-0.5	Schizophrenia;	chr16:11985945	chr16:11968508~11968743:-
ESCA	cis	rs12922317	0.521	rs86428	ENSG00000260224.1	UBL5P4	-6.43	2.53e-09	1.58e-05	-0.55	-0.5	Schizophrenia;	chr16:11986538	chr16:11968508~11968743:-
ESCA	cis	rs950027	0.62	rs1145076	ENSG00000259520.4	CTD-2651B20.3	-6.43	2.54e-09	1.59e-05	-0.59	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45392310	chr15:45251580~45279251:-
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000099984.9	GSTT2	-6.43	2.55e-09	1.59e-05	-0.61	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23980123~23983911:+
ESCA	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-6.43	2.56e-09	1.6e-05	-0.54	-0.5	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.624	rs2239826	ENSG00000265828.1	MIR3939	-6.43	2.56e-09	1.6e-05	-0.55	-0.5	Crohn's disease;	chr6:167091392	chr6:166997807~166997912:-
ESCA	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	6.43	2.56e-09	1.6e-05	0.54	0.5	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	6.43	2.56e-09	1.6e-05	0.54	0.5	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	6.43	2.56e-09	1.6e-05	0.54	0.5	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
ESCA	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-6.43	2.57e-09	1.6e-05	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-6.43	2.57e-09	1.6e-05	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
ESCA	cis	rs7924176	0.521	rs10824137	ENSG00000236900.1	TIMM9P1	6.43	2.57e-09	1.6e-05	0.58	0.5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74273396	chr10:74344550~74344805:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000231271.1	AP000350.8	6.43	2.58e-09	1.61e-05	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23949918~23954042:+
ESCA	cis	rs2882667	0.898	rs13163536	ENSG00000253404.1	AC034243.1	6.43	2.6e-09	1.62e-05	0.71	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041530	chr5:138744434~138753309:-
ESCA	cis	rs7626444	0.625	rs843530	ENSG00000272359.1	U4	-6.42	2.63e-09	1.64e-05	-0.53	-0.5	Monocyte count;	chr3:196754153	chr3:196747192~196747324:-
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000250470.1	AP000351.3	6.42	2.64e-09	1.64e-05	0.63	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23976904~23977585:-
ESCA	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-6.42	2.64e-09	1.65e-05	-0.78	-0.5	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
ESCA	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-6.42	2.65e-09	1.65e-05	-0.63	-0.5	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-6.42	2.67e-09	1.66e-05	-0.63	-0.5	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
ESCA	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	6.42	2.68e-09	1.66e-05	0.64	0.5	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
ESCA	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	6.42	2.7e-09	1.68e-05	0.68	0.5	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
ESCA	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-6.42	2.71e-09	1.68e-05	-0.63	-0.5	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
ESCA	cis	rs1799949	1	rs4793236	ENSG00000198496.9	NBR2	-6.42	2.71e-09	1.68e-05	-0.56	-0.5	Menopause (age at onset);	chr17:43359072	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.761	rs5760176	ENSG00000224205.1	AP000351.4	-6.42	2.74e-09	1.7e-05	-0.59	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23987320~23991421:-
ESCA	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	6.41	2.77e-09	1.72e-05	0.55	0.5	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	6.41	2.81e-09	1.74e-05	0.54	0.5	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-6.41	2.81e-09	1.74e-05	-0.54	-0.5	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-6.41	2.81e-09	1.74e-05	-0.54	-0.5	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
ESCA	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-6.41	2.82e-09	1.74e-05	-0.72	-0.5	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
ESCA	cis	rs1799949	0.965	rs799916	ENSG00000198496.9	NBR2	6.41	2.83e-09	1.75e-05	0.52	0.5	Menopause (age at onset);	chr17:43091173	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	6.41	2.87e-09	1.77e-05	0.51	0.5	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.602	rs17615336	ENSG00000265828.1	MIR3939	-6.41	2.87e-09	1.77e-05	-0.56	-0.5	Crohn's disease;	chr6:167093246	chr6:166997807~166997912:-
ESCA	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	6.41	2.88e-09	1.77e-05	0.54	0.5	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-6.41	2.88e-09	1.77e-05	-0.54	-0.5	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-6.4	2.93e-09	1.8e-05	-0.53	-0.5	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-6.4	2.97e-09	1.82e-05	-0.52	-0.5	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
ESCA	cis	rs6964833	1	rs13227433	ENSG00000123965.13	PMS2P5	6.4	2.97e-09	1.83e-05	0.82	0.5	Menarche (age at onset);	chr7:74680386	chr7:74894116~74897835:+
ESCA	cis	rs6964833	1	rs6967152	ENSG00000123965.13	PMS2P5	6.4	2.97e-09	1.83e-05	0.82	0.5	Menarche (age at onset);	chr7:74684983	chr7:74894116~74897835:+
ESCA	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	6.4	2.97e-09	1.83e-05	0.82	0.5	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
ESCA	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	6.4	2.97e-09	1.83e-05	0.82	0.5	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
ESCA	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	6.4	3.01e-09	1.84e-05	0.53	0.5	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000231271.1	AP000350.8	-6.4	3.02e-09	1.85e-05	-0.64	-0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23949918~23954042:+
ESCA	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	6.4	3.02e-09	1.85e-05	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	6.4	3.02e-09	1.85e-05	0.61	0.5	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000099984.9	GSTT2	-6.39	3.05e-09	1.87e-05	-0.65	-0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23980123~23983911:+
ESCA	cis	rs950027	0.62	rs1719245	ENSG00000259520.4	CTD-2651B20.3	-6.39	3.05e-09	1.87e-05	-0.59	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45331584	chr15:45251580~45279251:-
ESCA	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-6.39	3.08e-09	1.88e-05	-0.66	-0.5	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	6.39	3.09e-09	1.89e-05	0.53	0.5	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-6.39	3.09e-09	1.89e-05	-0.62	-0.5	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
ESCA	cis	rs9457247	0.534	rs9347170	ENSG00000265828.1	MIR3939	6.39	3.1e-09	1.89e-05	0.56	0.5	Crohn's disease;	chr6:166991699	chr6:166997807~166997912:-
ESCA	cis	rs17507216	0.628	rs8028130	ENSG00000278603.1	RP13-608F4.5	6.39	3.1e-09	1.9e-05	0.83	0.5	Excessive daytime sleepiness;	chr15:82734974	chr15:82472203~82472426:+
ESCA	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-6.39	3.12e-09	1.9e-05	-0.67	-0.5	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
ESCA	cis	rs6964833	0.873	rs4717905	ENSG00000123965.13	PMS2P5	6.39	3.12e-09	1.91e-05	0.8	0.5	Menarche (age at onset);	chr7:74668903	chr7:74894116~74897835:+
ESCA	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	6.39	3.17e-09	1.93e-05	0.53	0.5	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
ESCA	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-6.39	3.17e-09	1.93e-05	-0.73	-0.5	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
ESCA	cis	rs875971	0.66	rs10229345	ENSG00000222364.1	RNU6-96P	-6.38	3.18e-09	1.93e-05	-0.54	-0.5	Aortic root size;	chr7:66517181	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.515	rs1951459	ENSG00000265828.1	MIR3939	6.38	3.18e-09	1.93e-05	0.55	0.5	Crohn's disease;	chr6:166989048	chr6:166997807~166997912:-
ESCA	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	6.38	3.19e-09	1.94e-05	0.63	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
ESCA	cis	rs1799949	0.894	rs71367985	ENSG00000198496.9	NBR2	-6.38	3.23e-09	1.96e-05	-0.56	-0.5	Menopause (age at onset);	chr17:43222443	chr17:43125610~43153671:+
ESCA	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	6.38	3.3e-09	1.99e-05	0.53	0.5	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-6.37	3.34e-09	2.01e-05	-0.53	-0.5	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-6.37	3.34e-09	2.01e-05	-0.53	-0.5	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-6.37	3.34e-09	2.01e-05	-0.53	-0.5	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.931	rs3749665	ENSG00000253404.1	AC034243.1	6.37	3.35e-09	2.02e-05	0.68	0.5	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021522	chr5:138744434~138753309:-
ESCA	cis	rs11155671	0.53	rs9371544	ENSG00000231760.4	RP11-350J20.5	6.37	3.37e-09	2.03e-05	0.61	0.5	Testicular germ cell tumor;	chr6:149896224	chr6:149796151~149826294:-
ESCA	cis	rs2980439	0.818	rs2948300	ENSG00000173295.6	FAM86B3P	6.37	3.38e-09	2.03e-05	0.59	0.5	Neuroticism;	chr8:8248986	chr8:8228595~8244865:+
ESCA	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-6.37	3.39e-09	2.04e-05	-0.86	-0.5	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
ESCA	cis	rs6597981	0.675	rs4963120	ENSG00000279672.1	CMB9-55F22.1	-6.37	3.4e-09	2.05e-05	-0.58	-0.5	Breast cancer;	chr11:825777	chr11:779617~780755:+
ESCA	cis	rs12922317	0.556	rs11648938	ENSG00000260224.1	UBL5P4	6.37	3.41e-09	2.05e-05	0.53	0.5	Schizophrenia;	chr16:12000292	chr16:11968508~11968743:-
ESCA	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-6.37	3.42e-09	2.05e-05	-0.7	-0.5	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
ESCA	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	6.37	3.42e-09	2.06e-05	0.87	0.5	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
ESCA	cis	rs9545047	1	rs2484345	ENSG00000227676.3	LINC01068	-6.37	3.44e-09	2.07e-05	-0.65	-0.5	Schizophrenia;	chr13:79427913	chr13:79566727~79571436:+
ESCA	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-6.37	3.46e-09	2.08e-05	-0.54	-0.5	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000250470.1	AP000351.3	6.37	3.49e-09	2.1e-05	0.64	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23976904~23977585:-
ESCA	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-6.37	3.5e-09	2.1e-05	-0.61	-0.5	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
ESCA	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-6.37	3.5e-09	2.1e-05	-0.64	-0.5	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
ESCA	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	6.36	3.51e-09	2.1e-05	0.52	0.5	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
ESCA	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-6.36	3.52e-09	2.1e-05	-0.53	-0.5	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-6.36	3.54e-09	2.12e-05	-0.53	-0.5	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
ESCA	cis	rs62229266	0.659	rs2026259	ENSG00000231106.2	LINC01436	6.36	3.54e-09	2.12e-05	0.58	0.5	Mitral valve prolapse;	chr21:36058329	chr21:36005338~36007838:+
ESCA	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	6.36	3.56e-09	2.12e-05	0.52	0.5	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
ESCA	cis	rs9549367	0.789	rs8001506	ENSG00000269125.1	RP11-98F14.11	-6.36	3.58e-09	2.13e-05	-0.53	-0.5	Platelet distribution width;	chr13:113212839	chr13:113165002~113165183:-
ESCA	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	6.36	3.62e-09	2.15e-05	0.71	0.5	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	6.36	3.62e-09	2.15e-05	0.52	0.5	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
ESCA	cis	rs9322193	0.567	rs7747457	ENSG00000231760.4	RP11-350J20.5	6.36	3.65e-09	2.17e-05	0.63	0.5	Lung cancer;	chr6:149892366	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.731	rs5751792	ENSG00000224205.1	AP000351.4	6.36	3.66e-09	2.17e-05	0.59	0.5	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23987320~23991421:-
ESCA	cis	rs7412746	0.587	rs11204722	ENSG00000206931.1	RNU6-1042P	-6.36	3.67e-09	2.17e-05	-0.63	-0.5	Melanoma;	chr1:150757708	chr1:150701866~150701972:+
ESCA	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-6.36	3.67e-09	2.17e-05	-0.69	-0.5	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
ESCA	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-6.36	3.67e-09	2.17e-05	-0.69	-0.5	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
ESCA	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-6.35	3.68e-09	2.17e-05	-0.52	-0.5	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	6.35	3.68e-09	2.17e-05	0.52	0.5	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	6.35	3.68e-09	2.17e-05	0.52	0.5	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	6.35	3.68e-09	2.17e-05	0.52	0.5	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	6.35	3.68e-09	2.17e-05	0.52	0.5	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
ESCA	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	6.35	3.69e-09	2.18e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
ESCA	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	6.35	3.69e-09	2.18e-05	0.55	0.5	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
ESCA	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-6.35	3.69e-09	2.18e-05	-0.52	-0.5	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
ESCA	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	6.35	3.7e-09	2.18e-05	0.6	0.5	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
ESCA	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	6.35	3.71e-09	2.18e-05	0.72	0.5	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
ESCA	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-6.35	3.71e-09	2.19e-05	-0.6	-0.5	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	6.35	3.73e-09	2.2e-05	0.62	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
ESCA	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-6.35	3.78e-09	2.22e-05	-0.52	-0.5	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
ESCA	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-6.35	3.8e-09	2.24e-05	-0.47	-0.5	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
ESCA	cis	rs9549367	0.826	rs2302755	ENSG00000269125.1	RP11-98F14.11	-6.34	3.89e-09	2.28e-05	-0.53	-0.5	Platelet distribution width;	chr13:113244104	chr13:113165002~113165183:-
ESCA	cis	rs977987	0.735	rs11149831	ENSG00000261783.1	RP11-252K23.2	-6.34	3.9e-09	2.28e-05	-0.64	-0.5	Dupuytren's disease;	chr16:75417563	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	6.34	3.99e-09	2.33e-05	0.52	0.5	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-6.34	4.01e-09	2.35e-05	-0.58	-0.5	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
ESCA	cis	rs11155671	0.53	rs6935829	ENSG00000231760.4	RP11-350J20.5	6.34	4.05e-09	2.36e-05	0.61	0.5	Testicular germ cell tumor;	chr6:149896675	chr6:149796151~149826294:-
ESCA	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-6.34	4.06e-09	2.37e-05	-0.52	-0.5	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-6.34	4.06e-09	2.37e-05	-0.52	-0.5	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-6.34	4.06e-09	2.37e-05	-0.52	-0.5	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.534	rs9366078	ENSG00000265828.1	MIR3939	6.34	4.06e-09	2.37e-05	0.55	0.5	Crohn's disease;	chr6:166986024	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.534	rs9356551	ENSG00000265828.1	MIR3939	6.34	4.06e-09	2.37e-05	0.55	0.5	Crohn's disease;	chr6:166986857	chr6:166997807~166997912:-
ESCA	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	6.33	4.06e-09	2.37e-05	0.61	0.5	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
ESCA	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	6.33	4.07e-09	2.37e-05	0.6	0.5	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
ESCA	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	6.33	4.09e-09	2.38e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
ESCA	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	6.33	4.1e-09	2.39e-05	0.54	0.5	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
ESCA	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-6.33	4.11e-09	2.39e-05	-0.65	-0.5	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
ESCA	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	6.33	4.13e-09	2.41e-05	0.52	0.5	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
ESCA	cis	rs62229266	0.557	rs4817760	ENSG00000231106.2	LINC01436	6.33	4.14e-09	2.41e-05	0.55	0.5	Mitral valve prolapse;	chr21:36023003	chr21:36005338~36007838:+
ESCA	cis	rs4747241	0.556	rs4433500	ENSG00000226163.1	RP11-167P22.3	6.33	4.16e-09	2.42e-05	0.52	0.5	Heschl's gyrus morphology;	chr10:72309240	chr10:72501746~72502956:+
ESCA	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	6.33	4.19e-09	2.44e-05	0.52	0.5	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
ESCA	cis	rs11155671	0.53	rs7756850	ENSG00000231760.4	RP11-350J20.5	6.33	4.2e-09	2.44e-05	0.62	0.5	Testicular germ cell tumor;	chr6:149891460	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9371542	ENSG00000231760.4	RP11-350J20.5	6.33	4.2e-09	2.44e-05	0.62	0.5	Testicular germ cell tumor;	chr6:149891949	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9371223	ENSG00000231760.4	RP11-350J20.5	6.33	4.2e-09	2.44e-05	0.62	0.5	Testicular germ cell tumor;	chr6:149893670	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs2342769	ENSG00000231760.4	RP11-350J20.5	6.33	4.2e-09	2.44e-05	0.62	0.5	Testicular germ cell tumor;	chr6:149895371	chr6:149796151~149826294:-
ESCA	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	6.32	4.29e-09	2.48e-05	0.78	0.5	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
ESCA	cis	rs9545047	0.967	rs9545097	ENSG00000227676.3	LINC01068	6.32	4.3e-09	2.49e-05	0.64	0.5	Schizophrenia;	chr13:79387352	chr13:79566727~79571436:+
ESCA	cis	rs9545047	1	rs9574418	ENSG00000227676.3	LINC01068	6.32	4.3e-09	2.49e-05	0.64	0.5	Schizophrenia;	chr13:79393874	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.967	rs9593396	ENSG00000227676.3	LINC01068	6.32	4.3e-09	2.49e-05	0.64	0.5	Schizophrenia;	chr13:79396164	chr13:79566727~79571436:+
ESCA	cis	rs9545047	1	rs9545101	ENSG00000227676.3	LINC01068	6.32	4.3e-09	2.49e-05	0.64	0.5	Schizophrenia;	chr13:79399806	chr13:79566727~79571436:+
ESCA	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.32	4.38e-09	2.53e-05	-0.58	-0.5	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
ESCA	cis	rs1799949	0.965	rs4793233	ENSG00000198496.9	NBR2	-6.32	4.38e-09	2.53e-05	-0.55	-0.5	Menopause (age at onset);	chr17:43358069	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.864	rs60309406	ENSG00000198496.9	NBR2	-6.32	4.38e-09	2.53e-05	-0.55	-0.5	Menopause (age at onset);	chr17:43358297	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs4793234	ENSG00000198496.9	NBR2	-6.32	4.38e-09	2.53e-05	-0.55	-0.5	Menopause (age at onset);	chr17:43358815	chr17:43125610~43153671:+
ESCA	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-6.32	4.43e-09	2.55e-05	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-6.32	4.43e-09	2.55e-05	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-6.32	4.43e-09	2.55e-05	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
ESCA	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	6.32	4.46e-09	2.57e-05	0.53	0.49	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	6.31	4.49e-09	2.58e-05	0.53	0.49	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-6.31	4.52e-09	2.6e-05	-0.65	-0.49	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	6.31	4.55e-09	2.61e-05	0.52	0.49	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-6.31	4.55e-09	2.61e-05	-0.52	-0.49	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-6.31	4.55e-09	2.61e-05	-0.52	-0.49	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-6.31	4.55e-09	2.61e-05	-0.52	-0.49	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-6.31	4.55e-09	2.61e-05	-0.52	-0.49	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	6.31	4.58e-09	2.63e-05	0.52	0.49	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
ESCA	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	6.31	4.6e-09	2.64e-05	0.81	0.49	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
ESCA	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	6.31	4.6e-09	2.64e-05	0.81	0.49	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
ESCA	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	6.31	4.6e-09	2.64e-05	0.81	0.49	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
ESCA	cis	rs1799949	0.86	rs8176279	ENSG00000198496.9	NBR2	-6.31	4.63e-09	2.65e-05	-0.54	-0.49	Menopause (age at onset);	chr17:43058379	chr17:43125610~43153671:+
ESCA	cis	rs748404	0.578	rs2244746	ENSG00000249839.1	AC011330.5	-6.31	4.66e-09	2.67e-05	-0.6	-0.49	Lung cancer;	chr15:43402885	chr15:43663654~43684339:-
ESCA	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.31	4.66e-09	2.67e-05	-0.58	-0.49	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
ESCA	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	6.31	4.68e-09	2.69e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000228039.3	KB-1125A3.10	6.3	4.72e-09	2.71e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23963780~23964374:+
ESCA	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-6.3	4.76e-09	2.72e-05	-0.52	-0.49	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
ESCA	cis	rs12439619	1	rs12439619	ENSG00000278603.1	RP13-608F4.5	6.3	4.81e-09	2.75e-05	0.71	0.49	Intelligence (multi-trait analysis);	chr15:82254605	chr15:82472203~82472426:+
ESCA	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	6.3	4.81e-09	2.75e-05	0.69	0.49	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
ESCA	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	6.3	4.83e-09	2.76e-05	0.63	0.49	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
ESCA	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	6.3	4.85e-09	2.77e-05	0.62	0.49	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
ESCA	cis	rs2882667	0.861	rs11242445	ENSG00000253404.1	AC034243.1	6.3	4.85e-09	2.77e-05	0.68	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139081365	chr5:138744434~138753309:-
ESCA	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-6.3	4.87e-09	2.78e-05	-0.64	-0.49	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
ESCA	cis	rs11155671	0.53	rs6557133	ENSG00000231760.4	RP11-350J20.5	6.3	4.87e-09	2.78e-05	0.63	0.49	Testicular germ cell tumor;	chr6:149874248	chr6:149796151~149826294:-
ESCA	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-6.3	4.87e-09	2.78e-05	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-6.3	4.87e-09	2.78e-05	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
ESCA	cis	rs8040855	0.557	rs9744503	ENSG00000259295.5	CSPG4P12	-6.3	4.88e-09	2.78e-05	-0.67	-0.49	Bulimia nervosa;	chr15:85180986	chr15:85191438~85213905:+
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000250470.1	AP000351.3	6.3	4.89e-09	2.79e-05	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000250470.1	AP000351.3	6.3	4.89e-09	2.79e-05	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23976904~23977585:-
ESCA	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-6.3	4.92e-09	2.8e-05	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-6.3	4.93e-09	2.81e-05	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
ESCA	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-6.3	4.93e-09	2.81e-05	-0.53	-0.49	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
ESCA	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-6.29	4.94e-09	2.81e-05	-0.68	-0.49	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
ESCA	cis	rs62229266	0.693	rs2835264	ENSG00000231106.2	LINC01436	6.29	4.96e-09	2.82e-05	0.57	0.49	Mitral valve prolapse;	chr21:36063667	chr21:36005338~36007838:+
ESCA	cis	rs1799949	0.773	rs2137990	ENSG00000198496.9	NBR2	6.29	5.01e-09	2.85e-05	0.55	0.49	Menopause (age at onset);	chr17:43165879	chr17:43125610~43153671:+
ESCA	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	6.29	5.04e-09	2.87e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	6.29	5.04e-09	2.87e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	6.29	5.04e-09	2.87e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	6.29	5.04e-09	2.87e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
ESCA	cis	rs11155671	0.53	rs2342770	ENSG00000231760.4	RP11-350J20.5	6.29	5.06e-09	2.88e-05	0.64	0.49	Testicular germ cell tumor;	chr6:149895549	chr6:149796151~149826294:-
ESCA	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	6.29	5.06e-09	2.88e-05	0.54	0.49	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	6.29	5.06e-09	2.88e-05	0.54	0.49	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	6.29	5.06e-09	2.88e-05	0.54	0.49	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	6.29	5.06e-09	2.88e-05	0.54	0.49	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
ESCA	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	6.29	5.09e-09	2.89e-05	0.64	0.49	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-6.29	5.13e-09	2.91e-05	-0.59	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
ESCA	cis	rs2929278	0.588	rs1975364	ENSG00000205771.5	CATSPER2P1	-6.29	5.13e-09	2.91e-05	-0.63	-0.49	Schizophrenia;	chr15:43857991	chr15:43726918~43747094:-
ESCA	cis	rs12439619	0.508	rs8042665	ENSG00000278603.1	RP13-608F4.5	6.29	5.14e-09	2.92e-05	0.63	0.49	Intelligence (multi-trait analysis);	chr15:82189008	chr15:82472203~82472426:+
ESCA	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	6.29	5.16e-09	2.93e-05	0.54	0.49	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
ESCA	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	6.29	5.18e-09	2.94e-05	0.78	0.49	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
ESCA	cis	rs2882667	0.861	rs10037106	ENSG00000253404.1	AC034243.1	6.28	5.2e-09	2.95e-05	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029801	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs4643949	ENSG00000253404.1	AC034243.1	6.28	5.2e-09	2.95e-05	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139036656	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs6867343	ENSG00000253404.1	AC034243.1	6.28	5.2e-09	2.95e-05	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038739	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs2882792	ENSG00000253404.1	AC034243.1	6.28	5.2e-09	2.95e-05	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044791	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs6882583	ENSG00000253404.1	AC034243.1	6.28	5.2e-09	2.95e-05	0.69	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139050107	chr5:138744434~138753309:-
ESCA	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-6.28	5.22e-09	2.96e-05	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
ESCA	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-6.28	5.22e-09	2.96e-05	-0.52	-0.49	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
ESCA	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	6.28	5.25e-09	2.97e-05	0.86	0.49	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
ESCA	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-6.28	5.29e-09	2.99e-05	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
ESCA	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	6.28	5.29e-09	2.99e-05	0.53	0.49	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
ESCA	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-6.28	5.33e-09	3.01e-05	-0.68	-0.49	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
ESCA	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.28	5.35e-09	3.02e-05	0.56	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
ESCA	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	6.28	5.42e-09	3.06e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	6.28	5.42e-09	3.06e-05	0.77	0.49	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
ESCA	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-6.27	5.47e-09	3.08e-05	-0.52	-0.49	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
ESCA	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-6.27	5.47e-09	3.08e-05	-0.52	-0.49	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000250470.1	AP000351.3	-6.27	5.49e-09	3.09e-05	-0.61	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23976904~23977585:-
ESCA	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	6.27	5.5e-09	3.1e-05	0.55	0.49	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
ESCA	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	6.27	5.51e-09	3.1e-05	0.58	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
ESCA	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	6.27	5.54e-09	3.12e-05	0.49	0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
ESCA	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	6.27	5.55e-09	3.12e-05	0.67	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	6.27	5.57e-09	3.13e-05	0.52	0.49	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	6.27	5.57e-09	3.13e-05	0.52	0.49	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.534	rs7750593	ENSG00000265828.1	MIR3939	6.27	5.62e-09	3.16e-05	0.55	0.49	Crohn's disease;	chr6:166973871	chr6:166997807~166997912:-
ESCA	cis	rs1799949	1	rs35070007	ENSG00000198496.9	NBR2	6.27	5.65e-09	3.17e-05	0.54	0.49	Menopause (age at onset);	chr17:43164730	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000231271.1	AP000350.8	6.27	5.68e-09	3.19e-05	0.59	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23949918~23954042:+
ESCA	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-6.27	5.7e-09	3.2e-05	-0.52	-0.49	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
ESCA	cis	rs9457247	0.765	rs1322077	ENSG00000265828.1	MIR3939	-6.26	5.71e-09	3.21e-05	-0.54	-0.49	Crohn's disease;	chr6:167010805	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9457249	ENSG00000265828.1	MIR3939	-6.26	5.71e-09	3.21e-05	-0.54	-0.49	Crohn's disease;	chr6:167012950	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9457251	ENSG00000265828.1	MIR3939	-6.26	5.71e-09	3.21e-05	-0.54	-0.49	Crohn's disease;	chr6:167013219	chr6:166997807~166997912:-
ESCA	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	6.26	5.72e-09	3.21e-05	0.55	0.49	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
ESCA	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-6.26	5.75e-09	3.22e-05	-0.58	-0.49	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
ESCA	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	6.26	5.78e-09	3.24e-05	0.69	0.49	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
ESCA	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-6.26	5.79e-09	3.25e-05	-0.63	-0.49	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	6.26	5.8e-09	3.25e-05	0.69	0.49	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	6.26	5.8e-09	3.25e-05	0.69	0.49	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
ESCA	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	6.26	5.81e-09	3.26e-05	0.7	0.49	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
ESCA	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	6.26	5.81e-09	3.26e-05	0.7	0.49	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
ESCA	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-6.26	5.85e-09	3.28e-05	-0.6	-0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
ESCA	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-6.26	5.86e-09	3.28e-05	-0.58	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
ESCA	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-6.26	5.88e-09	3.29e-05	-0.82	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-6.26	5.88e-09	3.29e-05	-0.82	-0.49	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
ESCA	cis	rs4970988	0.787	rs1532770	ENSG00000206931.1	RNU6-1042P	6.26	5.89e-09	3.3e-05	0.64	0.49	Urate levels;	chr1:150752859	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000250470.1	AP000351.3	6.26	5.9e-09	3.3e-05	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000250470.1	AP000351.3	6.26	5.9e-09	3.3e-05	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23976904~23977585:-
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000250470.1	AP000351.3	6.26	5.9e-09	3.3e-05	0.63	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23976904~23977585:-
ESCA	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-6.26	5.92e-09	3.31e-05	-0.52	-0.49	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-6.26	5.92e-09	3.31e-05	-0.52	-0.49	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	6.26	5.94e-09	3.32e-05	0.52	0.49	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.894	rs10054478	ENSG00000253404.1	AC034243.1	6.26	5.94e-09	3.32e-05	0.67	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018386	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.931	rs10075951	ENSG00000253404.1	AC034243.1	6.26	5.94e-09	3.32e-05	0.67	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020274	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	6.26	5.95e-09	3.32e-05	0.55	0.49	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-6.25	6e-09	3.35e-05	-0.54	-0.49	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
ESCA	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.25	6.03e-09	3.35e-05	-0.58	-0.49	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
ESCA	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-6.25	6.06e-09	3.37e-05	-0.6	-0.49	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-6.25	6.06e-09	3.37e-05	-0.6	-0.49	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-6.25	6.06e-09	3.37e-05	-0.6	-0.49	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-6.25	6.06e-09	3.37e-05	-0.6	-0.49	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
ESCA	cis	rs1799949	0.965	rs7212284	ENSG00000198496.9	NBR2	-6.25	6.08e-09	3.38e-05	-0.53	-0.49	Menopause (age at onset);	chr17:43053924	chr17:43125610~43153671:+
ESCA	cis	rs1799949	1	rs8077486	ENSG00000198496.9	NBR2	-6.25	6.08e-09	3.38e-05	-0.53	-0.49	Menopause (age at onset);	chr17:43060788	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.929	rs799906	ENSG00000198496.9	NBR2	-6.25	6.12e-09	3.4e-05	-0.54	-0.49	Menopause (age at onset);	chr17:43126099	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs799908	ENSG00000198496.9	NBR2	-6.25	6.12e-09	3.4e-05	-0.54	-0.49	Menopause (age at onset);	chr17:43126899	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.93	rs1554063	ENSG00000198496.9	NBR2	-6.25	6.12e-09	3.4e-05	-0.54	-0.49	Menopause (age at onset);	chr17:43135128	chr17:43125610~43153671:+
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000231271.1	AP000350.8	6.25	6.13e-09	3.41e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000231271.1	AP000350.8	6.25	6.13e-09	3.41e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23949918~23954042:+
ESCA	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-6.25	6.16e-09	3.42e-05	-0.82	-0.49	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
ESCA	cis	rs2882667	0.898	rs10058347	ENSG00000253404.1	AC034243.1	6.25	6.22e-09	3.45e-05	0.68	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025669	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.931	rs10038799	ENSG00000253404.1	AC034243.1	6.25	6.22e-09	3.45e-05	0.68	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139026594	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-6.25	6.24e-09	3.46e-05	-0.64	-0.49	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-6.25	6.25e-09	3.46e-05	-0.54	-0.49	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000228039.3	KB-1125A3.10	-6.25	6.28e-09	3.48e-05	-0.57	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23963780~23964374:+
ESCA	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	6.24	6.33e-09	3.5e-05	0.52	0.49	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	6.24	6.33e-09	3.5e-05	0.52	0.49	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
ESCA	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	6.24	6.33e-09	3.5e-05	0.61	0.49	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	6.24	6.34e-09	3.51e-05	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	6.24	6.34e-09	3.51e-05	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
ESCA	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	6.24	6.34e-09	3.51e-05	0.61	0.49	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
ESCA	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	6.24	6.35e-09	3.51e-05	0.7	0.49	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
ESCA	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-6.24	6.38e-09	3.52e-05	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
ESCA	cis	rs9368481	0.761	rs7775041	ENSG00000243307.2	POM121L6P	-6.24	6.39e-09	3.52e-05	-0.59	-0.49	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26896952~26898777:+
ESCA	cis	rs1563304	1	rs1563304	ENSG00000214401.4	KANSL1-AS1	6.24	6.44e-09	3.55e-05	0.86	0.49	Neuroticism;	chr17:46797087	chr17:46193576~46196723:+
ESCA	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	6.24	6.45e-09	3.56e-05	0.51	0.49	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
ESCA	cis	rs1799949	0.628	rs4474733	ENSG00000198496.9	NBR2	-6.24	6.48e-09	3.57e-05	-0.56	-0.49	Menopause (age at onset);	chr17:43356292	chr17:43125610~43153671:+
ESCA	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	6.24	6.49e-09	3.58e-05	0.84	0.49	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
ESCA	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	6.24	6.49e-09	3.58e-05	0.84	0.49	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
ESCA	cis	rs6479891	1	rs2893922	ENSG00000235816.3	PRELID1P3	-6.24	6.49e-09	3.58e-05	-0.66	-0.49	Arthritis (juvenile idiopathic);	chr10:63487259	chr10:63427297~63427939:+
ESCA	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-6.24	6.51e-09	3.58e-05	-0.51	-0.49	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
ESCA	cis	rs6479891	0.908	rs61853639	ENSG00000235816.3	PRELID1P3	6.24	6.6e-09	3.63e-05	0.64	0.49	Arthritis (juvenile idiopathic);	chr10:63545353	chr10:63427297~63427939:+
ESCA	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	6.23	6.63e-09	3.65e-05	0.54	0.49	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	6.23	6.63e-09	3.65e-05	0.54	0.49	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	6.23	6.64e-09	3.65e-05	0.52	0.49	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
ESCA	cis	rs62229266	0.563	rs6517325	ENSG00000231106.2	LINC01436	6.23	6.72e-09	3.7e-05	0.57	0.49	Mitral valve prolapse;	chr21:36062680	chr21:36005338~36007838:+
ESCA	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-6.23	6.72e-09	3.7e-05	-0.52	-0.49	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	6.23	6.72e-09	3.7e-05	0.52	0.49	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
ESCA	cis	rs7412746	0.611	rs3768018	ENSG00000206931.1	RNU6-1042P	6.23	6.74e-09	3.7e-05	0.64	0.49	Melanoma;	chr1:150751271	chr1:150701866~150701972:+
ESCA	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	6.23	6.8e-09	3.73e-05	0.53	0.49	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
ESCA	cis	rs9457247	0.534	rs4710149	ENSG00000265828.1	MIR3939	6.23	6.86e-09	3.77e-05	0.55	0.49	Crohn's disease;	chr6:166972858	chr6:166997807~166997912:-
ESCA	cis	rs2882667	0.898	rs12719519	ENSG00000253404.1	AC034243.1	6.23	6.88e-09	3.77e-05	0.68	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139039998	chr5:138744434~138753309:-
ESCA	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	6.23	6.91e-09	3.79e-05	0.5	0.49	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000231271.1	AP000350.8	6.22	6.99e-09	3.83e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23949918~23954042:+
ESCA	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-6.22	7e-09	3.84e-05	-0.61	-0.49	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
ESCA	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-6.22	7.02e-09	3.84e-05	-0.66	-0.49	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
ESCA	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	6.22	7.05e-09	3.86e-05	0.7	0.49	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
ESCA	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-6.22	7.09e-09	3.88e-05	-0.66	-0.49	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
ESCA	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	6.22	7.13e-09	3.9e-05	0.52	0.49	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	6.22	7.16e-09	3.92e-05	0.53	0.49	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	6.22	7.16e-09	3.92e-05	0.53	0.49	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
ESCA	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-6.22	7.17e-09	3.92e-05	-0.51	-0.49	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
ESCA	cis	rs2929278	0.617	rs575082	ENSG00000205771.5	CATSPER2P1	6.22	7.2e-09	3.93e-05	0.64	0.49	Schizophrenia;	chr15:43817944	chr15:43726918~43747094:-
ESCA	cis	rs2929278	0.617	rs2955969	ENSG00000205771.5	CATSPER2P1	6.22	7.2e-09	3.93e-05	0.64	0.49	Schizophrenia;	chr15:43822329	chr15:43726918~43747094:-
ESCA	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-6.22	7.22e-09	3.94e-05	-0.79	-0.49	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
ESCA	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-6.22	7.24e-09	3.95e-05	-0.49	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
ESCA	cis	rs2882667	0.931	rs13153618	ENSG00000253404.1	AC034243.1	6.22	7.24e-09	3.95e-05	0.67	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139017087	chr5:138744434~138753309:-
ESCA	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	6.22	7.25e-09	3.96e-05	0.64	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
ESCA	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-6.22	7.26e-09	3.96e-05	-0.53	-0.49	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
ESCA	cis	rs9457247	0.534	rs4710154	ENSG00000265828.1	MIR3939	6.22	7.27e-09	3.96e-05	0.54	0.49	Crohn's disease;	chr6:166981146	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.597	rs11771318	ENSG00000222364.1	RNU6-96P	6.21	7.33e-09	4e-05	0.54	0.49	Aortic root size;	chr7:66597493	chr7:66395191~66395286:+
ESCA	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-6.21	7.35e-09	4e-05	-0.51	-0.49	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.569	rs35070132	ENSG00000179406.6	LINC00174	-6.21	7.37e-09	4.01e-05	-0.55	-0.49	Aortic root size;	chr7:66773096	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-6.21	7.39e-09	4.01e-05	-0.51	-0.49	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	6.21	7.49e-09	4.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	6.21	7.49e-09	4.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	6.21	7.49e-09	4.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	6.21	7.49e-09	4.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	6.21	7.49e-09	4.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-6.21	7.51e-09	4.07e-05	-0.5	-0.49	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
ESCA	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-6.21	7.56e-09	4.1e-05	-0.61	-0.49	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
ESCA	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	6.21	7.59e-09	4.11e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	6.21	7.59e-09	4.11e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	6.21	7.59e-09	4.11e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	6.21	7.59e-09	4.11e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
ESCA	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	6.21	7.59e-09	4.11e-05	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
ESCA	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	6.21	7.59e-09	4.12e-05	0.63	0.49	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
ESCA	cis	rs801193	0.548	rs6975044	ENSG00000179406.6	LINC00174	-6.21	7.64e-09	4.14e-05	-0.55	-0.49	Aortic root size;	chr7:66762495	chr7:66376044~66401338:-
ESCA	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	6.2	7.66e-09	4.15e-05	0.53	0.49	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	6.2	7.69e-09	4.16e-05	0.54	0.49	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
ESCA	cis	rs9457247	0.534	rs933243	ENSG00000265828.1	MIR3939	-6.2	7.71e-09	4.17e-05	-0.53	-0.49	Crohn's disease;	chr6:166990385	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.534	rs9355610	ENSG00000265828.1	MIR3939	6.2	7.74e-09	4.19e-05	0.54	0.49	Crohn's disease;	chr6:166969587	chr6:166997807~166997912:-
ESCA	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-6.2	7.77e-09	4.2e-05	-0.53	-0.49	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	6.2	7.79e-09	4.21e-05	0.51	0.49	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	6.2	7.79e-09	4.21e-05	0.51	0.49	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	6.2	7.79e-09	4.21e-05	0.51	0.49	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	6.2	7.79e-09	4.21e-05	0.51	0.49	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	6.2	7.79e-09	4.21e-05	0.51	0.49	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
ESCA	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.2	7.79e-09	4.21e-05	-0.58	-0.49	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
ESCA	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	6.2	7.86e-09	4.24e-05	0.52	0.49	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	6.2	7.86e-09	4.24e-05	0.52	0.49	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	6.2	7.86e-09	4.24e-05	0.52	0.49	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	6.2	7.86e-09	4.24e-05	0.52	0.49	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	6.2	7.86e-09	4.24e-05	0.52	0.49	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
ESCA	cis	rs2929278	0.561	rs62018952	ENSG00000205771.5	CATSPER2P1	6.2	7.87e-09	4.24e-05	0.66	0.49	Schizophrenia;	chr15:43788539	chr15:43726918~43747094:-
ESCA	cis	rs847845	0.541	rs61732793	ENSG00000186328.4	RP11-140K17.2	6.2	7.9e-09	4.26e-05	1.17	0.49	Non-small cell lung cancer;	chr6:34859144	chr6:34715613~34715940:+
ESCA	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	6.2	7.93e-09	4.27e-05	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	6.2	7.93e-09	4.27e-05	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	6.2	7.93e-09	4.27e-05	0.79	0.49	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
ESCA	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	6.2	7.94e-09	4.27e-05	0.58	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	6.2	7.94e-09	4.27e-05	0.58	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
ESCA	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-6.2	8.01e-09	4.31e-05	-0.67	-0.49	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
ESCA	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	6.2	8.02e-09	4.31e-05	0.57	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
ESCA	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-6.19	8.03e-09	4.32e-05	-0.51	-0.49	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
ESCA	cis	rs6964833	0.935	rs34762099	ENSG00000123965.13	PMS2P5	6.19	8.07e-09	4.34e-05	0.8	0.49	Menarche (age at onset);	chr7:74636378	chr7:74894116~74897835:+
ESCA	cis	rs6538678	1	rs6538678	ENSG00000258343.1	RP11-536G4.2	-6.19	8.17e-09	4.39e-05	-0.62	-0.49	Lupus nephritis in systemic lupus erythematosus;	chr12:95867790	chr12:95795345~95858839:-
ESCA	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	6.19	8.18e-09	4.39e-05	0.53	0.49	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
ESCA	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	6.19	8.2e-09	4.4e-05	0.69	0.49	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000231271.1	AP000350.8	6.19	8.3e-09	4.45e-05	0.56	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23949918~23954042:+
ESCA	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	6.19	8.31e-09	4.45e-05	0.64	0.49	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
ESCA	cis	rs748404	0.66	rs2467738	ENSG00000249839.1	AC011330.5	-6.19	8.39e-09	4.49e-05	-0.6	-0.49	Lung cancer;	chr15:43447738	chr15:43663654~43684339:-
ESCA	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	6.18	8.5e-09	4.55e-05	0.51	0.49	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
ESCA	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	6.18	8.54e-09	4.56e-05	0.51	0.49	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	6.18	8.54e-09	4.56e-05	0.51	0.49	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	6.18	8.54e-09	4.56e-05	0.51	0.49	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	6.18	8.54e-09	4.56e-05	0.51	0.49	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
ESCA	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	6.18	8.56e-09	4.57e-05	0.58	0.49	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
ESCA	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-6.18	8.75e-09	4.66e-05	-0.53	-0.49	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000250470.1	AP000351.3	6.18	8.79e-09	4.68e-05	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23976904~23977585:-
ESCA	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	6.17	8.89e-09	4.73e-05	0.52	0.49	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	6.17	8.98e-09	4.77e-05	0.5	0.49	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
ESCA	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-6.17	8.98e-09	4.77e-05	-0.6	-0.49	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-6.17	8.98e-09	4.77e-05	-0.6	-0.49	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-6.17	8.98e-09	4.77e-05	-0.6	-0.49	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-6.17	8.98e-09	4.77e-05	-0.6	-0.49	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
ESCA	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-6.17	9.02e-09	4.79e-05	-0.49	-0.49	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
ESCA	cis	rs950027	0.62	rs1346267	ENSG00000259520.4	CTD-2651B20.3	-6.17	9.03e-09	4.79e-05	-0.55	-0.49	Response to fenofibrate (adiponectin levels);	chr15:45398791	chr15:45251580~45279251:-
ESCA	cis	rs12439619	0.53	rs28883606	ENSG00000278603.1	RP13-608F4.5	6.17	9.04e-09	4.79e-05	0.62	0.49	Intelligence (multi-trait analysis);	chr15:82216713	chr15:82472203~82472426:+
ESCA	cis	rs12439619	0.693	rs28665836	ENSG00000278603.1	RP13-608F4.5	6.17	9.04e-09	4.79e-05	0.62	0.49	Intelligence (multi-trait analysis);	chr15:82218955	chr15:82472203~82472426:+
ESCA	cis	rs7412746	0.611	rs10788794	ENSG00000206931.1	RNU6-1042P	6.17	9.05e-09	4.8e-05	0.63	0.49	Melanoma;	chr1:150756200	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs10888391	ENSG00000206931.1	RNU6-1042P	6.17	9.05e-09	4.8e-05	0.63	0.49	Melanoma;	chr1:150757507	chr1:150701866~150701972:+
ESCA	cis	rs2929278	0.617	rs694461	ENSG00000205771.5	CATSPER2P1	6.17	9.13e-09	4.84e-05	0.65	0.49	Schizophrenia;	chr15:43803865	chr15:43726918~43747094:-
ESCA	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	6.17	9.15e-09	4.85e-05	0.53	0.49	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
ESCA	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-6.17	9.16e-09	4.85e-05	-0.69	-0.49	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
ESCA	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	6.17	9.22e-09	4.88e-05	0.52	0.49	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	6.17	9.22e-09	4.88e-05	0.52	0.49	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	6.17	9.22e-09	4.88e-05	0.52	0.49	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	6.17	9.22e-09	4.88e-05	0.52	0.49	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
ESCA	cis	rs6782228	1	rs12495411	ENSG00000277250.1	Metazoa_SRP	6.16	9.28e-09	4.91e-05	0.63	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128673681~128674021:-
ESCA	cis	rs6782228	1	rs6775011	ENSG00000277250.1	Metazoa_SRP	6.16	9.28e-09	4.91e-05	0.63	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128673681~128674021:-
ESCA	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-6.16	9.29e-09	4.92e-05	-0.65	-0.49	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
ESCA	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	6.16	9.3e-09	4.92e-05	0.52	0.49	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
ESCA	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	6.16	9.33e-09	4.93e-05	0.66	0.49	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000250470.1	AP000351.3	6.16	9.35e-09	4.95e-05	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23976904~23977585:-
ESCA	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	6.16	9.37e-09	4.95e-05	0.54	0.49	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
ESCA	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	6.16	9.42e-09	4.98e-05	0.62	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
ESCA	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-6.16	9.45e-09	4.99e-05	-0.48	-0.49	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
ESCA	cis	rs9545047	0.967	rs9545087	ENSG00000227676.3	LINC01068	6.16	9.49e-09	5.02e-05	0.63	0.49	Schizophrenia;	chr13:79364440	chr13:79566727~79571436:+
ESCA	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-6.16	9.5e-09	5.02e-05	-0.52	-0.49	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	6.16	9.54e-09	5.04e-05	0.52	0.49	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	6.16	9.54e-09	5.04e-05	0.52	0.49	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
ESCA	cis	rs2882667	0.931	rs10044736	ENSG00000253404.1	AC034243.1	-6.16	9.56e-09	5.05e-05	-0.68	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:138985120	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	6.16	9.58e-09	5.06e-05	0.53	0.49	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-6.16	9.58e-09	5.06e-05	-0.66	-0.49	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-6.16	9.63e-09	5.08e-05	-0.5	-0.49	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-6.16	9.63e-09	5.08e-05	-0.5	-0.49	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
ESCA	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-6.16	9.65e-09	5.09e-05	-0.59	-0.49	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
ESCA	cis	rs1799949	0.683	rs55737636	ENSG00000198496.9	NBR2	-6.15	9.85e-09	5.19e-05	-0.54	-0.49	Menopause (age at onset);	chr17:43112722	chr17:43125610~43153671:+
ESCA	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	6.15	9.92e-09	5.22e-05	0.66	0.49	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
ESCA	cis	rs6964833	1	rs3846966	ENSG00000123965.13	PMS2P5	6.15	9.99e-09	5.26e-05	0.81	0.48	Menarche (age at onset);	chr7:74698811	chr7:74894116~74897835:+
ESCA	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	6.15	9.99e-09	5.26e-05	0.81	0.48	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
ESCA	cis	rs9545047	1	rs9545086	ENSG00000227676.3	LINC01068	6.15	1e-08	5.26e-05	0.63	0.48	Schizophrenia;	chr13:79364233	chr13:79566727~79571436:+
ESCA	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	6.15	1e-08	5.27e-05	0.51	0.48	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	6.15	1e-08	5.27e-05	0.5	0.48	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	6.15	1e-08	5.27e-05	0.5	0.48	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
ESCA	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-6.15	1e-08	5.27e-05	-0.5	-0.48	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
ESCA	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-6.15	1e-08	5.27e-05	-0.61	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
ESCA	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	6.15	1.01e-08	5.3e-05	0.78	0.48	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	6.15	1.01e-08	5.3e-05	0.78	0.48	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	6.15	1.01e-08	5.3e-05	0.78	0.48	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
ESCA	cis	rs9549367	0.789	rs2287253	ENSG00000269125.1	RP11-98F14.11	6.15	1.01e-08	5.3e-05	0.54	0.48	Platelet distribution width;	chr13:113236761	chr13:113165002~113165183:-
ESCA	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	6.15	1.01e-08	5.31e-05	0.66	0.48	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
ESCA	cis	rs12922317	0.538	rs446289	ENSG00000260224.1	UBL5P4	-6.15	1.01e-08	5.32e-05	-0.55	-0.48	Schizophrenia;	chr16:11976629	chr16:11968508~11968743:-
ESCA	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	6.15	1.02e-08	5.33e-05	0.52	0.48	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-6.14	1.03e-08	5.37e-05	-0.48	-0.48	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-6.14	1.03e-08	5.37e-05	-0.48	-0.48	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-6.14	1.03e-08	5.37e-05	-0.48	-0.48	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-6.14	1.03e-08	5.37e-05	-0.48	-0.48	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-6.14	1.03e-08	5.37e-05	-0.48	-0.48	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	6.14	1.03e-08	5.37e-05	0.52	0.48	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
ESCA	cis	rs2882667	0.931	rs10075039	ENSG00000253404.1	AC034243.1	6.14	1.04e-08	5.43e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002165	chr5:138744434~138753309:-
ESCA	cis	rs950027	0.62	rs1426932	ENSG00000259520.4	CTD-2651B20.3	-6.14	1.04e-08	5.43e-05	-0.55	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45395058	chr15:45251580~45279251:-
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000231271.1	AP000350.8	6.14	1.05e-08	5.46e-05	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000231271.1	AP000350.8	6.14	1.05e-08	5.46e-05	0.6	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23949918~23954042:+
ESCA	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	6.14	1.05e-08	5.49e-05	0.53	0.48	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
ESCA	cis	rs4747241	0.626	rs4262652	ENSG00000226163.1	RP11-167P22.3	-6.14	1.05e-08	5.49e-05	-0.5	-0.48	Heschl's gyrus morphology;	chr10:72368095	chr10:72501746~72502956:+
ESCA	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-6.14	1.05e-08	5.49e-05	-0.8	-0.48	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
ESCA	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	6.14	1.06e-08	5.5e-05	0.58	0.48	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
ESCA	cis	rs4747241	0.738	rs4747244	ENSG00000226163.1	RP11-167P22.3	6.14	1.06e-08	5.52e-05	0.57	0.48	Heschl's gyrus morphology;	chr10:72291884	chr10:72501746~72502956:+
ESCA	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	6.14	1.06e-08	5.52e-05	0.71	0.48	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.53e-05	0.5	0.48	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
ESCA	cis	rs62229266	0.839	rs11088335	ENSG00000231106.2	LINC01436	6.14	1.06e-08	5.53e-05	0.55	0.48	Mitral valve prolapse;	chr21:36098037	chr21:36005338~36007838:+
ESCA	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	6.14	1.06e-08	5.54e-05	0.51	0.48	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
ESCA	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	6.14	1.07e-08	5.55e-05	0.51	0.48	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.898	rs6862393	ENSG00000253404.1	AC034243.1	6.14	1.07e-08	5.57e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139029009	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs3925110	ENSG00000253404.1	AC034243.1	6.14	1.07e-08	5.57e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035676	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs6882330	ENSG00000253404.1	AC034243.1	6.14	1.07e-08	5.57e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046493	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs6882526	ENSG00000253404.1	AC034243.1	6.14	1.07e-08	5.57e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139046679	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000231271.1	AP000350.8	6.13	1.07e-08	5.58e-05	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23949918~23954042:+
ESCA	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-6.13	1.07e-08	5.58e-05	-0.69	-0.48	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
ESCA	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-6.13	1.08e-08	5.6e-05	-0.49	-0.48	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-6.13	1.08e-08	5.62e-05	-0.53	-0.48	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	6.13	1.08e-08	5.62e-05	0.5	0.48	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
ESCA	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-6.13	1.09e-08	5.63e-05	-0.59	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
ESCA	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-6.13	1.09e-08	5.64e-05	-0.51	-0.48	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.931	rs10069528	ENSG00000253404.1	AC034243.1	6.13	1.09e-08	5.65e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139018338	chr5:138744434~138753309:-
ESCA	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-6.13	1.09e-08	5.65e-05	-0.64	-0.48	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000231271.1	AP000350.8	6.13	1.09e-08	5.67e-05	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23949918~23954042:+
ESCA	cis	rs2882667	0.931	rs10077896	ENSG00000253404.1	AC034243.1	6.13	1.1e-08	5.69e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021067	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	6.13	1.1e-08	5.7e-05	0.53	0.48	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
ESCA	cis	rs9549367	0.756	rs2302756	ENSG00000269125.1	RP11-98F14.11	6.13	1.1e-08	5.71e-05	0.54	0.48	Platelet distribution width;	chr13:113245883	chr13:113165002~113165183:-
ESCA	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-6.13	1.11e-08	5.73e-05	-0.65	-0.48	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-6.13	1.11e-08	5.73e-05	-0.65	-0.48	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-6.13	1.11e-08	5.73e-05	-0.65	-0.48	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-6.13	1.11e-08	5.73e-05	-0.65	-0.48	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
ESCA	cis	rs977987	0.806	rs1109342	ENSG00000261783.1	RP11-252K23.2	6.13	1.11e-08	5.75e-05	0.58	0.48	Dupuytren's disease;	chr16:75411777	chr16:75379818~75381260:-
ESCA	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	6.13	1.11e-08	5.76e-05	0.61	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
ESCA	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	6.13	1.12e-08	5.8e-05	0.68	0.48	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
ESCA	cis	rs1799949	0.965	rs4239149	ENSG00000198496.9	NBR2	6.12	1.13e-08	5.84e-05	0.53	0.48	Menopause (age at onset);	chr17:43176078	chr17:43125610~43153671:+
ESCA	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-6.12	1.13e-08	5.84e-05	-0.49	-0.48	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.528	rs7784607	ENSG00000229043.2	AC091729.9	-6.12	1.13e-08	5.84e-05	-0.49	-0.48	Endometriosis;Longevity;	chr7:1139058	chr7:1160374~1165267:+
ESCA	cis	rs875971	0.895	rs4145009	ENSG00000226824.5	RP4-756H11.3	6.12	1.15e-08	5.92e-05	0.51	0.48	Aortic root size;	chr7:66261628	chr7:66654538~66669855:+
ESCA	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	6.12	1.15e-08	5.95e-05	0.68	0.48	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
ESCA	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	6.12	1.16e-08	5.96e-05	0.51	0.48	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
ESCA	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-6.12	1.16e-08	5.97e-05	-0.59	-0.48	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-6.12	1.16e-08	5.99e-05	-0.5	-0.48	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.765	rs2237276	ENSG00000265828.1	MIR3939	-6.12	1.17e-08	6.01e-05	-0.53	-0.48	Crohn's disease;	chr6:167028627	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.74	rs13195812	ENSG00000265828.1	MIR3939	-6.12	1.17e-08	6.01e-05	-0.53	-0.48	Crohn's disease;	chr6:167030414	chr6:166997807~166997912:-
ESCA	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	6.12	1.17e-08	6.02e-05	0.7	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
ESCA	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	6.12	1.17e-08	6.02e-05	0.5	0.48	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-6.12	1.17e-08	6.02e-05	-0.5	-0.48	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.867	rs11749045	ENSG00000253404.1	AC034243.1	6.12	1.17e-08	6.02e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085271	chr5:138744434~138753309:-
ESCA	cis	rs1799949	0.536	rs4793227	ENSG00000198496.9	NBR2	-6.12	1.18e-08	6.03e-05	-0.54	-0.48	Menopause (age at onset);	chr17:43334882	chr17:43125610~43153671:+
ESCA	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.03e-05	0.52	0.48	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.03e-05	0.52	0.48	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.66	rs2659897	ENSG00000179406.6	LINC00174	6.12	1.18e-08	6.04e-05	0.54	0.48	Aortic root size;	chr7:66722728	chr7:66376044~66401338:-
ESCA	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	6.12	1.18e-08	6.04e-05	0.53	0.48	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
ESCA	cis	rs7924176	0.601	rs10824107	ENSG00000236900.1	TIMM9P1	-6.11	1.18e-08	6.05e-05	-0.59	-0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74202041	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.564	rs11000920	ENSG00000236900.1	TIMM9P1	-6.11	1.18e-08	6.05e-05	-0.59	-0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74208443	chr10:74344550~74344805:-
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000231271.1	AP000350.8	6.11	1.18e-08	6.05e-05	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000231271.1	AP000350.8	6.11	1.18e-08	6.05e-05	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23949918~23954042:+
ESCA	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-6.11	1.18e-08	6.06e-05	-0.57	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
ESCA	cis	rs4948102	0.551	rs4275190	ENSG00000273720.1	RP11-613E4.4	-6.11	1.19e-08	6.08e-05	-0.59	-0.48	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55743073~55743457:+
ESCA	cis	rs7924176	0.564	rs6480727	ENSG00000236900.1	TIMM9P1	-6.11	1.19e-08	6.11e-05	-0.58	-0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74243315	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.58	rs12360119	ENSG00000236900.1	TIMM9P1	-6.11	1.19e-08	6.11e-05	-0.58	-0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74255558	chr10:74344550~74344805:-
ESCA	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	6.11	1.2e-08	6.12e-05	0.5	0.48	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.534	rs12055488	ENSG00000265828.1	MIR3939	6.11	1.2e-08	6.12e-05	0.54	0.48	Crohn's disease;	chr6:166966082	chr6:166997807~166997912:-
ESCA	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-6.11	1.2e-08	6.12e-05	-0.78	-0.48	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-6.11	1.2e-08	6.12e-05	-0.78	-0.48	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
ESCA	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-6.11	1.21e-08	6.16e-05	-0.51	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
ESCA	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-6.11	1.21e-08	6.16e-05	-0.53	-0.48	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.75	rs4888414	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75413335	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs6564258	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75413465	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs6564259	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75413495	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8056236	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75414375	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8051407	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75414761	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888416	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75415278	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs7199132	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75416141	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs7188604	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75417272	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs12149063	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75417860	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11642572	ENSG00000261783.1	RP11-252K23.2	-6.11	1.21e-08	6.16e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75418884	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000231271.1	AP000350.8	6.11	1.22e-08	6.18e-05	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23949918~23954042:+
ESCA	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	6.11	1.23e-08	6.25e-05	0.6	0.48	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
ESCA	cis	rs4747241	0.7	rs7099642	ENSG00000226163.1	RP11-167P22.3	6.11	1.23e-08	6.26e-05	0.57	0.48	Heschl's gyrus morphology;	chr10:72292255	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.771	rs7075993	ENSG00000226163.1	RP11-167P22.3	6.11	1.23e-08	6.26e-05	0.57	0.48	Heschl's gyrus morphology;	chr10:72294832	chr10:72501746~72502956:+
ESCA	cis	rs9457247	0.73	rs9459841	ENSG00000265828.1	MIR3939	-6.11	1.24e-08	6.28e-05	-0.52	-0.48	Crohn's disease;	chr6:167018461	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs6900701	ENSG00000265828.1	MIR3939	-6.11	1.24e-08	6.28e-05	-0.52	-0.48	Crohn's disease;	chr6:167020624	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.715	rs6923582	ENSG00000265828.1	MIR3939	-6.11	1.24e-08	6.28e-05	-0.52	-0.48	Crohn's disease;	chr6:167023674	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs10484531	ENSG00000265828.1	MIR3939	-6.1	1.24e-08	6.31e-05	-0.53	-0.48	Crohn's disease;	chr6:167040946	chr6:166997807~166997912:-
ESCA	cis	rs2882667	0.931	rs10068237	ENSG00000253404.1	AC034243.1	6.1	1.25e-08	6.33e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139002271	chr5:138744434~138753309:-
ESCA	cis	rs9457247	0.534	rs2757053	ENSG00000265828.1	MIR3939	6.1	1.25e-08	6.34e-05	0.54	0.48	Crohn's disease;	chr6:166966850	chr6:166997807~166997912:-
ESCA	cis	rs2221894	0.922	rs7018244	ENSG00000273710.1	Metazoa_SRP	6.1	1.26e-08	6.36e-05	0.53	0.48	Obesity-related traits;	chr8:29037474	chr8:28915579~28915864:-
ESCA	cis	rs2221894	0.881	rs2035644	ENSG00000273710.1	Metazoa_SRP	6.1	1.26e-08	6.36e-05	0.53	0.48	Obesity-related traits;	chr8:29042180	chr8:28915579~28915864:-
ESCA	cis	rs2221894	0.881	rs1948132	ENSG00000273710.1	Metazoa_SRP	6.1	1.26e-08	6.36e-05	0.53	0.48	Obesity-related traits;	chr8:29042570	chr8:28915579~28915864:-
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000099984.9	GSTT2	-6.1	1.26e-08	6.36e-05	-0.57	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23980123~23983911:+
ESCA	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	6.1	1.26e-08	6.38e-05	0.68	0.48	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
ESCA	cis	rs2221894	0.881	rs6994074	ENSG00000273710.1	Metazoa_SRP	6.1	1.26e-08	6.38e-05	0.53	0.48	Obesity-related traits;	chr8:29035376	chr8:28915579~28915864:-
ESCA	cis	rs977987	0.806	rs4887824	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75407715	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11864102	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75408462	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888411	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75409285	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs4888412	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75409298	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs4888413	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75409325	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs8057849	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75409918	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs72787160	ENSG00000261783.1	RP11-252K23.2	-6.1	1.27e-08	6.45e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75411264	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	6.1	1.28e-08	6.45e-05	0.51	0.48	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.861	rs13176902	ENSG00000253404.1	AC034243.1	6.1	1.28e-08	6.46e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139057640	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs2116789	ENSG00000253404.1	AC034243.1	6.1	1.28e-08	6.46e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058573	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.931	rs12719518	ENSG00000253404.1	AC034243.1	6.1	1.29e-08	6.5e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139005287	chr5:138744434~138753309:-
ESCA	cis	rs875971	1	rs10244498	ENSG00000179406.6	LINC00174	-6.1	1.29e-08	6.51e-05	-0.56	-0.48	Aortic root size;	chr7:66651069	chr7:66376044~66401338:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000228039.3	KB-1125A3.10	6.1	1.29e-08	6.51e-05	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23963780~23964374:+
ESCA	cis	rs6479891	1	rs4746195	ENSG00000235816.3	PRELID1P3	6.1	1.29e-08	6.52e-05	0.63	0.48	Arthritis (juvenile idiopathic);	chr10:63547893	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4469774	ENSG00000235816.3	PRELID1P3	6.1	1.29e-08	6.52e-05	0.63	0.48	Arthritis (juvenile idiopathic);	chr10:63550017	chr10:63427297~63427939:+
ESCA	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	6.1	1.3e-08	6.54e-05	0.6	0.48	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
ESCA	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-6.09	1.3e-08	6.57e-05	-0.58	-0.48	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
ESCA	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	6.09	1.3e-08	6.58e-05	0.52	0.48	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	6.09	1.3e-08	6.58e-05	0.52	0.48	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	6.09	1.3e-08	6.58e-05	0.52	0.48	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	6.09	1.3e-08	6.58e-05	0.52	0.48	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	6.09	1.3e-08	6.58e-05	0.52	0.48	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	6.09	1.31e-08	6.59e-05	0.64	0.48	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000228039.3	KB-1125A3.10	6.09	1.31e-08	6.59e-05	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23963780~23964374:+
ESCA	cis	rs2980439	0.818	rs2948294	ENSG00000253981.4	ALG1L13P	6.09	1.31e-08	6.61e-05	0.55	0.48	Neuroticism;	chr8:8237439	chr8:8236003~8244667:-
ESCA	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	6.09	1.31e-08	6.62e-05	0.5	0.48	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.645	rs10871311	ENSG00000261783.1	RP11-252K23.2	-6.09	1.32e-08	6.63e-05	-0.59	-0.48	Dupuytren's disease;	chr16:75417014	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	6.09	1.32e-08	6.64e-05	0.53	0.48	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	6.09	1.32e-08	6.65e-05	0.69	0.48	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
ESCA	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-6.09	1.32e-08	6.67e-05	-0.48	-0.48	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
ESCA	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	6.09	1.33e-08	6.69e-05	0.49	0.48	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
ESCA	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-6.09	1.33e-08	6.7e-05	-0.71	-0.48	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
ESCA	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	6.09	1.34e-08	6.76e-05	0.52	0.48	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
ESCA	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-6.09	1.34e-08	6.76e-05	-0.47	-0.48	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000228039.3	KB-1125A3.10	6.09	1.35e-08	6.78e-05	0.57	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23963780~23964374:+
ESCA	cis	rs7924176	0.521	rs12415957	ENSG00000236900.1	TIMM9P1	6.09	1.35e-08	6.78e-05	0.58	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74342225	chr10:74344550~74344805:-
ESCA	cis	rs6479891	0.818	rs2393976	ENSG00000235816.3	PRELID1P3	6.09	1.35e-08	6.78e-05	0.65	0.48	Arthritis (juvenile idiopathic);	chr10:63493679	chr10:63427297~63427939:+
ESCA	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	6.09	1.35e-08	6.78e-05	0.51	0.48	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	6.09	1.35e-08	6.78e-05	0.51	0.48	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	6.09	1.36e-08	6.83e-05	0.5	0.48	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
ESCA	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	6.08	1.37e-08	6.9e-05	0.54	0.48	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
ESCA	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	6.08	1.39e-08	6.97e-05	0.47	0.48	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	6.08	1.4e-08	7.02e-05	0.53	0.48	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
ESCA	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-6.08	1.4e-08	7.04e-05	-0.76	-0.48	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
ESCA	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.08	1.41e-08	7.07e-05	-0.57	-0.48	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
ESCA	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-6.08	1.42e-08	7.1e-05	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
ESCA	cis	rs2882667	0.898	rs2043272	ENSG00000253404.1	AC034243.1	6.08	1.42e-08	7.1e-05	0.67	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054942	chr5:138744434~138753309:-
ESCA	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	6.08	1.42e-08	7.11e-05	0.61	0.48	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
ESCA	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-6.08	1.42e-08	7.11e-05	-0.56	-0.48	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-6.08	1.42e-08	7.11e-05	-0.56	-0.48	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
ESCA	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-6.08	1.42e-08	7.13e-05	-0.51	-0.48	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.765	rs9459849	ENSG00000265828.1	MIR3939	-6.08	1.43e-08	7.15e-05	-0.52	-0.48	Crohn's disease;	chr6:167030672	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9457259	ENSG00000265828.1	MIR3939	-6.08	1.43e-08	7.15e-05	-0.52	-0.48	Crohn's disease;	chr6:167030793	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs10946203	ENSG00000265828.1	MIR3939	-6.08	1.43e-08	7.15e-05	-0.52	-0.48	Crohn's disease;	chr6:167033247	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs10455982	ENSG00000265828.1	MIR3939	-6.08	1.43e-08	7.15e-05	-0.52	-0.48	Crohn's disease;	chr6:167035240	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.74	rs10946204	ENSG00000265828.1	MIR3939	-6.08	1.43e-08	7.15e-05	-0.52	-0.48	Crohn's disease;	chr6:167037641	chr6:166997807~166997912:-
ESCA	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	6.07	1.43e-08	7.16e-05	0.51	0.48	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.931	rs7706391	ENSG00000253404.1	AC034243.1	6.07	1.43e-08	7.17e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139013475	chr5:138744434~138753309:-
ESCA	cis	rs7927771	0.864	rs10838724	ENSG00000280615.1	Y_RNA	-6.07	1.44e-08	7.2e-05	-0.49	-0.48	Subjective well-being;	chr11:47505500	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-6.07	1.44e-08	7.21e-05	-0.48	-0.48	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
ESCA	cis	rs1563304	1	rs1563304	ENSG00000262500.1	RP11-259G18.2	6.07	1.44e-08	7.21e-05	0.79	0.48	Neuroticism;	chr17:46797087	chr17:46243606~46245044:+
ESCA	cis	rs11155671	0.53	rs9968871	ENSG00000231760.4	RP11-350J20.5	6.07	1.44e-08	7.22e-05	0.61	0.48	Testicular germ cell tumor;	chr6:149888060	chr6:149796151~149826294:-
ESCA	cis	rs11155671	0.53	rs9969044	ENSG00000231760.4	RP11-350J20.5	6.07	1.44e-08	7.22e-05	0.61	0.48	Testicular germ cell tumor;	chr6:149888068	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs73146609	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66302477	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs2173571	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66305392	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs11770063	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66318029	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs3936065	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66325577	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs4718335	ENSG00000222364.1	RNU6-96P	-6.07	1.45e-08	7.25e-05	-0.65	-0.48	Aortic root size;	chr7:66339619	chr7:66395191~66395286:+
ESCA	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	6.07	1.47e-08	7.31e-05	0.68	0.48	Depression;	chr6:28386473	chr6:28176188~28176674:+
ESCA	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-6.07	1.47e-08	7.32e-05	-0.83	-0.48	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
ESCA	cis	rs1799949	0.93	rs34210004	ENSG00000198496.9	NBR2	-6.07	1.48e-08	7.35e-05	-0.53	-0.48	Menopause (age at onset);	chr17:43218318	chr17:43125610~43153671:+
ESCA	cis	rs2929278	0.561	rs2927071	ENSG00000205771.5	CATSPER2P1	-6.07	1.48e-08	7.36e-05	-0.63	-0.48	Schizophrenia;	chr15:43626883	chr15:43726918~43747094:-
ESCA	cis	rs9457247	0.765	rs4710171	ENSG00000265828.1	MIR3939	-6.07	1.48e-08	7.36e-05	-0.52	-0.48	Crohn's disease;	chr6:167016698	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-6.07	1.48e-08	7.38e-05	-0.59	-0.48	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
ESCA	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	6.07	1.48e-08	7.38e-05	0.62	0.48	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-6.07	1.48e-08	7.39e-05	-0.56	-0.48	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
ESCA	cis	rs2980439	0.818	rs2948300	ENSG00000253981.4	ALG1L13P	6.07	1.49e-08	7.39e-05	0.57	0.48	Neuroticism;	chr8:8248986	chr8:8236003~8244667:-
ESCA	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	6.07	1.49e-08	7.39e-05	0.68	0.48	Depression;	chr6:28379133	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	6.07	1.49e-08	7.39e-05	0.68	0.48	Depression;	chr6:28379168	chr6:28176188~28176674:+
ESCA	cis	rs2980439	0.807	rs2980438	ENSG00000173295.6	FAM86B3P	6.07	1.49e-08	7.39e-05	0.58	0.48	Neuroticism;	chr8:8237303	chr8:8228595~8244865:+
ESCA	cis	rs9457247	0.765	rs1060404	ENSG00000265828.1	MIR3939	-6.06	1.51e-08	7.5e-05	-0.52	-0.48	Crohn's disease;	chr6:167015979	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs3752520	ENSG00000265828.1	MIR3939	-6.06	1.51e-08	7.5e-05	-0.52	-0.48	Crohn's disease;	chr6:167022671	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9457256	ENSG00000265828.1	MIR3939	-6.06	1.51e-08	7.5e-05	-0.52	-0.48	Crohn's disease;	chr6:167022973	chr6:166997807~166997912:-
ESCA	cis	rs1799949	0.965	rs7223952	ENSG00000198496.9	NBR2	-6.06	1.53e-08	7.58e-05	-0.53	-0.48	Menopause (age at onset);	chr17:43042868	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	6.06	1.53e-08	7.59e-05	0.52	0.48	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	6.06	1.53e-08	7.6e-05	0.52	0.48	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	6.06	1.53e-08	7.6e-05	0.52	0.48	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
ESCA	cis	rs2412819	0.599	rs2470120	ENSG00000205771.5	CATSPER2P1	-6.06	1.53e-08	7.6e-05	-0.62	-0.48	Lung cancer;	chr15:43636872	chr15:43726918~43747094:-
ESCA	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-6.06	1.54e-08	7.61e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-6.06	1.54e-08	7.61e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-6.06	1.54e-08	7.61e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-6.06	1.54e-08	7.61e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-6.06	1.54e-08	7.61e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
ESCA	cis	rs9549367	0.789	rs9549695	ENSG00000269125.1	RP11-98F14.11	6.06	1.54e-08	7.62e-05	0.54	0.48	Platelet distribution width;	chr13:113220500	chr13:113165002~113165183:-
ESCA	cis	rs1799949	0.965	rs1842147	ENSG00000198496.9	NBR2	-6.06	1.54e-08	7.63e-05	-0.53	-0.48	Menopause (age at onset);	chr17:43357824	chr17:43125610~43153671:+
ESCA	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-6.06	1.54e-08	7.63e-05	-0.48	-0.48	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-6.06	1.54e-08	7.63e-05	-0.48	-0.48	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
ESCA	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-6.06	1.55e-08	7.66e-05	-0.57	-0.48	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
ESCA	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	6.06	1.55e-08	7.66e-05	0.64	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
ESCA	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	6.06	1.55e-08	7.66e-05	0.64	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
ESCA	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-6.06	1.56e-08	7.72e-05	-0.51	-0.48	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
ESCA	cis	rs9457247	0.765	rs12212247	ENSG00000265828.1	MIR3939	-6.06	1.56e-08	7.72e-05	-0.52	-0.48	Crohn's disease;	chr6:167000051	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9459836	ENSG00000265828.1	MIR3939	-6.06	1.56e-08	7.72e-05	-0.52	-0.48	Crohn's disease;	chr6:167005617	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.765	rs9459838	ENSG00000265828.1	MIR3939	-6.06	1.56e-08	7.72e-05	-0.52	-0.48	Crohn's disease;	chr6:167013111	chr6:166997807~166997912:-
ESCA	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-6.06	1.57e-08	7.75e-05	-0.58	-0.48	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
ESCA	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-6.06	1.57e-08	7.76e-05	-0.51	-0.48	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	6.05	1.58e-08	7.8e-05	0.5	0.48	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000099984.9	GSTT2	-6.05	1.59e-08	7.86e-05	-0.58	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23980123~23983911:+
ESCA	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	6.05	1.59e-08	7.86e-05	0.68	0.48	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
ESCA	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	6.05	1.6e-08	7.88e-05	0.59	0.48	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
ESCA	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-6.05	1.6e-08	7.89e-05	-0.59	-0.48	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-6.05	1.61e-08	7.94e-05	-0.59	-0.48	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-6.05	1.62e-08	7.98e-05	-0.51	-0.48	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
ESCA	cis	rs9322193	0.961	rs4870144	ENSG00000216906.2	RP11-350J20.9	6.05	1.62e-08	8e-05	0.66	0.48	Lung cancer;	chr6:149575540	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-6.05	1.62e-08	8e-05	-0.65	-0.48	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
ESCA	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-6.05	1.62e-08	8e-05	-0.48	-0.48	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
ESCA	cis	rs950027	0.596	rs2467853	ENSG00000259520.4	CTD-2651B20.3	-6.05	1.65e-08	8.11e-05	-0.54	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45406595	chr15:45251580~45279251:-
ESCA	cis	rs950027	0.595	rs2486288	ENSG00000259520.4	CTD-2651B20.3	-6.05	1.65e-08	8.11e-05	-0.54	-0.48	Response to fenofibrate (adiponectin levels);	chr15:45420141	chr15:45251580~45279251:-
ESCA	cis	rs2486288	0.539	rs2433601	ENSG00000259520.4	CTD-2651B20.3	-6.05	1.65e-08	8.11e-05	-0.54	-0.48	Glomerular filtration rate;	chr15:45424227	chr15:45251580~45279251:-
ESCA	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-6.05	1.65e-08	8.12e-05	-0.62	-0.48	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-6.04	1.65e-08	8.12e-05	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-6.04	1.65e-08	8.12e-05	-0.64	-0.48	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
ESCA	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-6.04	1.66e-08	8.14e-05	-0.48	-0.48	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-6.04	1.66e-08	8.14e-05	-0.48	-0.48	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
ESCA	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-6.04	1.66e-08	8.15e-05	-0.53	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
ESCA	cis	rs9355610	0.892	rs2247314	ENSG00000265828.1	MIR3939	6.04	1.66e-08	8.16e-05	0.55	0.48	Graves' disease;	chr6:166956742	chr6:166997807~166997912:-
ESCA	cis	rs2882667	0.898	rs2351465	ENSG00000253404.1	AC034243.1	6.04	1.66e-08	8.17e-05	0.66	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028162	chr5:138744434~138753309:-
ESCA	cis	rs2439831	0.85	rs2957637	ENSG00000249839.1	AC011330.5	-6.04	1.67e-08	8.19e-05	-0.88	-0.48	Lung cancer in ever smokers;	chr15:43658920	chr15:43663654~43684339:-
ESCA	cis	rs7924176	0.521	rs7899920	ENSG00000236900.1	TIMM9P1	6.04	1.67e-08	8.19e-05	0.57	0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74329365	chr10:74344550~74344805:-
ESCA	cis	rs1075265	0.548	rs2542575	ENSG00000235937.1	AC008280.1	6.04	1.67e-08	8.21e-05	0.57	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.568	rs2542577	ENSG00000235937.1	AC008280.1	6.04	1.67e-08	8.21e-05	0.57	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54029552~54030682:-
ESCA	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.25e-05	0.51	0.48	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	6.04	1.68e-08	8.26e-05	0.52	0.48	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	6.04	1.69e-08	8.28e-05	0.52	0.48	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.632	rs34481394	ENSG00000248280.1	RP11-33B1.2	6.04	1.69e-08	8.28e-05	0.52	0.48	Educational attainment;	chr4:119327219	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.666	rs35231872	ENSG00000248280.1	RP11-33B1.2	6.04	1.69e-08	8.28e-05	0.52	0.48	Educational attainment;	chr4:119327221	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.7	rs35653026	ENSG00000248280.1	RP11-33B1.2	6.04	1.69e-08	8.28e-05	0.52	0.48	Educational attainment;	chr4:119327223	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	6.04	1.7e-08	8.32e-05	0.51	0.48	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	6.04	1.71e-08	8.34e-05	0.52	0.48	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	6.04	1.71e-08	8.34e-05	0.66	0.48	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
ESCA	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.04	1.71e-08	8.36e-05	-0.65	-0.48	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
ESCA	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-6.04	1.71e-08	8.36e-05	-0.65	-0.48	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
ESCA	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	6.04	1.72e-08	8.39e-05	0.52	0.48	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	6.04	1.72e-08	8.39e-05	0.52	0.48	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	6.04	1.72e-08	8.39e-05	0.52	0.48	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
ESCA	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	6.04	1.72e-08	8.41e-05	0.66	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
ESCA	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	6.04	1.73e-08	8.41e-05	0.63	0.48	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
ESCA	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.04	1.73e-08	8.42e-05	-0.57	-0.48	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.04	1.73e-08	8.42e-05	-0.57	-0.48	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.04	1.73e-08	8.42e-05	-0.57	-0.48	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
ESCA	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	6.03	1.73e-08	8.45e-05	0.68	0.48	Depression;	chr6:28391932	chr6:28176188~28176674:+
ESCA	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-6.03	1.73e-08	8.45e-05	-0.56	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
ESCA	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-6.03	1.73e-08	8.45e-05	-0.56	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
ESCA	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	6.03	1.74e-08	8.46e-05	0.52	0.48	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	6.03	1.74e-08	8.46e-05	0.52	0.48	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	6.03	1.74e-08	8.5e-05	0.63	0.48	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
ESCA	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-6.03	1.75e-08	8.51e-05	-0.8	-0.48	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
ESCA	cis	rs2929278	0.588	rs688009	ENSG00000205771.5	CATSPER2P1	-6.03	1.76e-08	8.55e-05	-0.63	-0.48	Schizophrenia;	chr15:43864104	chr15:43726918~43747094:-
ESCA	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	6.03	1.76e-08	8.57e-05	0.52	0.48	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
ESCA	cis	rs9549367	0.789	rs3764124	ENSG00000269125.1	RP11-98F14.11	-6.03	1.76e-08	8.58e-05	-0.53	-0.48	Platelet distribution width;	chr13:113243006	chr13:113165002~113165183:-
ESCA	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-6.03	1.77e-08	8.59e-05	-0.59	-0.48	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
ESCA	cis	rs7924176	0.521	rs61863363	ENSG00000236900.1	TIMM9P1	-6.03	1.77e-08	8.62e-05	-0.57	-0.48	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380493	chr10:74344550~74344805:-
ESCA	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-6.03	1.77e-08	8.62e-05	-0.59	-0.48	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-6.03	1.77e-08	8.62e-05	-0.59	-0.48	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
ESCA	cis	rs6538678	0.824	rs7307510	ENSG00000258343.1	RP11-536G4.2	-6.03	1.78e-08	8.63e-05	-0.79	-0.48	Lupus nephritis in systemic lupus erythematosus;	chr12:95843792	chr12:95795345~95858839:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000250470.1	AP000351.3	-6.03	1.78e-08	8.67e-05	-0.62	-0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23976904~23977585:-
ESCA	cis	rs1799949	0.965	rs9911630	ENSG00000198496.9	NBR2	-6.03	1.8e-08	8.73e-05	-0.52	-0.48	Menopause (age at onset);	chr17:43036325	chr17:43125610~43153671:+
ESCA	cis	rs13217239	0.646	rs10946888	ENSG00000243307.2	POM121L6P	6.03	1.81e-08	8.77e-05	0.54	0.48	Schizophrenia;	chr6:26983899	chr6:26896952~26898777:+
ESCA	cis	rs875971	0.545	rs6969224	ENSG00000222364.1	RNU6-96P	-6.02	1.82e-08	8.81e-05	-0.64	-0.48	Aortic root size;	chr7:66370011	chr7:66395191~66395286:+
ESCA	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	6.02	1.82e-08	8.85e-05	0.52	0.48	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-6.02	1.83e-08	8.88e-05	-0.48	-0.48	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000228039.3	KB-1125A3.10	6.02	1.83e-08	8.89e-05	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000231271.1	AP000350.8	6.02	1.83e-08	8.89e-05	0.59	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23949918~23954042:+
ESCA	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-6.02	1.84e-08	8.92e-05	-0.56	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-6.02	1.84e-08	8.92e-05	-0.56	-0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
ESCA	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	6.02	1.85e-08	8.94e-05	0.52	0.48	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
ESCA	cis	rs17608059	0.545	rs9915045	ENSG00000141028.6	CDRT15P1	-6.02	1.85e-08	8.97e-05	-0.48	-0.48	Temperament;	chr17:13999319	chr17:14024514~14025488:+
ESCA	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	6.02	1.86e-08	8.97e-05	0.52	0.48	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
ESCA	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-6.02	1.86e-08	8.98e-05	-0.56	-0.48	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
ESCA	cis	rs12439619	0.508	rs11856561	ENSG00000278603.1	RP13-608F4.5	6.02	1.87e-08	9.03e-05	0.59	0.48	Intelligence (multi-trait analysis);	chr15:82161415	chr15:82472203~82472426:+
ESCA	cis	rs9457247	0.508	rs6941355	ENSG00000265828.1	MIR3939	-6.02	1.88e-08	9.06e-05	-0.52	-0.48	Crohn's disease;	chr6:167092750	chr6:166997807~166997912:-
ESCA	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-6.02	1.9e-08	9.17e-05	-0.48	-0.48	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
ESCA	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	6.01	1.92e-08	9.23e-05	0.61	0.48	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
ESCA	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	6.01	1.92e-08	9.24e-05	0.51	0.48	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	6.01	1.92e-08	9.24e-05	0.51	0.48	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	6.01	1.92e-08	9.24e-05	0.51	0.48	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	6.01	1.92e-08	9.24e-05	0.51	0.48	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	6.01	1.92e-08	9.25e-05	0.52	0.48	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-6.01	1.95e-08	9.39e-05	-0.52	-0.48	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
ESCA	cis	rs2882667	0.861	rs7703288	ENSG00000253404.1	AC034243.1	6.01	1.96e-08	9.43e-05	0.65	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139030850	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000231271.1	AP000350.8	6.01	1.97e-08	9.48e-05	0.58	0.48	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23949918~23954042:+
ESCA	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	6.01	1.97e-08	9.48e-05	0.52	0.48	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	6.01	1.97e-08	9.48e-05	0.52	0.48	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	6.01	1.97e-08	9.48e-05	0.52	0.48	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
ESCA	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-6.01	1.97e-08	9.49e-05	-0.49	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
ESCA	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	6.01	1.97e-08	9.49e-05	0.55	0.48	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
ESCA	cis	rs17507216	0.667	rs13379724	ENSG00000278603.1	RP13-608F4.5	6.01	1.98e-08	9.51e-05	0.69	0.48	Excessive daytime sleepiness;	chr15:82619892	chr15:82472203~82472426:+
ESCA	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	6.01	1.98e-08	9.52e-05	0.51	0.48	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	6.01	1.98e-08	9.52e-05	0.51	0.48	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
ESCA	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-6.01	1.98e-08	9.52e-05	-0.63	-0.48	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
ESCA	cis	rs977987	0.806	rs7202596	ENSG00000261783.1	RP11-252K23.2	-6.01	1.99e-08	9.52e-05	-0.58	-0.48	Dupuytren's disease;	chr16:75457174	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	6.01	1.99e-08	9.52e-05	0.51	0.48	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-6.01	1.99e-08	9.52e-05	-0.51	-0.48	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
ESCA	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	6.01	2e-08	9.56e-05	0.63	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
ESCA	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	6	2.02e-08	9.66e-05	0.63	0.48	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
ESCA	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	6	2.03e-08	9.71e-05	0.52	0.48	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
ESCA	cis	rs2929278	0.617	rs693919	ENSG00000205771.5	CATSPER2P1	6	2.03e-08	9.73e-05	0.63	0.48	Schizophrenia;	chr15:43810130	chr15:43726918~43747094:-
ESCA	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	6	2.04e-08	9.73e-05	0.51	0.48	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	6	2.04e-08	9.73e-05	0.51	0.48	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	6	2.04e-08	9.73e-05	0.51	0.48	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	6	2.04e-08	9.73e-05	0.51	0.48	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
ESCA	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	6	2.04e-08	9.74e-05	0.63	0.48	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
ESCA	cis	rs2882667	0.931	rs10077796	ENSG00000253404.1	AC034243.1	-6	2.04e-08	9.74e-05	-0.62	-0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139021086	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	6	2.04e-08	9.77e-05	0.51	0.48	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
ESCA	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6	2.05e-08	9.77e-05	-0.64	-0.48	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
ESCA	cis	rs9545047	0.613	rs79774056	ENSG00000227676.3	LINC01068	6	2.06e-08	9.86e-05	0.62	0.48	Schizophrenia;	chr13:79421486	chr13:79566727~79571436:+
ESCA	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	6	2.07e-08	9.87e-05	0.65	0.48	Depression;	chr6:28430971	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	6	2.07e-08	9.87e-05	0.65	0.48	Depression;	chr6:28432562	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	6	2.07e-08	9.89e-05	0.49	0.48	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
ESCA	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	6	2.09e-08	9.97e-05	0.67	0.48	Depression;	chr6:28428413	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	6	2.09e-08	9.97e-05	0.67	0.48	Depression;	chr6:28431469	chr6:28176188~28176674:+
ESCA	cis	rs801193	0.548	rs2659904	ENSG00000179406.6	LINC00174	-5.99	2.1e-08	9.98e-05	-0.54	-0.48	Aortic root size;	chr7:66713615	chr7:66376044~66401338:-
ESCA	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-5.99	2.1e-08	1e-04	-0.53	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
ESCA	cis	rs875971	0.545	rs2279757	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66363676	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs11766183	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66374173	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs1065265	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66376216	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs7811204	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66387213	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.571	rs78668714	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66474464	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs73150604	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66480545	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs7810213	ENSG00000222364.1	RNU6-96P	-5.99	2.1e-08	1e-04	-0.64	-0.48	Aortic root size;	chr7:66481592	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.602	rs2157388	ENSG00000265828.1	MIR3939	-5.99	2.11e-08	1e-04	-0.52	-0.48	Crohn's disease;	chr6:167068424	chr6:166997807~166997912:-
ESCA	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-5.99	2.12e-08	0.000101	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-5.99	2.12e-08	0.000101	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
ESCA	cis	rs977987	0.843	rs11641801	ENSG00000261783.1	RP11-252K23.2	-5.99	2.13e-08	0.000101	-0.57	-0.48	Dupuytren's disease;	chr16:75421550	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11648176	ENSG00000261783.1	RP11-252K23.2	-5.99	2.13e-08	0.000101	-0.57	-0.48	Dupuytren's disease;	chr16:75422525	chr16:75379818~75381260:-
ESCA	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	5.99	2.14e-08	0.000102	0.62	0.48	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
ESCA	cis	rs977987	0.806	rs12444589	ENSG00000261783.1	RP11-252K23.2	5.99	2.14e-08	0.000102	0.57	0.48	Dupuytren's disease;	chr16:75420506	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.99	2.15e-08	0.000102	0.69	0.48	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
ESCA	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-5.99	2.15e-08	0.000102	-0.48	-0.48	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
ESCA	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-5.99	2.16e-08	0.000102	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
ESCA	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	5.99	2.17e-08	0.000103	0.74	0.48	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
ESCA	cis	rs9457247	0.515	rs2757039	ENSG00000265828.1	MIR3939	5.99	2.18e-08	0.000103	0.54	0.48	Crohn's disease;	chr6:166956865	chr6:166997807~166997912:-
ESCA	cis	rs916888	0.821	rs199499	ENSG00000261575.2	RP11-259G18.1	5.99	2.18e-08	0.000103	0.92	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:46267037~46268694:+
ESCA	cis	rs9549367	0.713	rs3024761	ENSG00000269125.1	RP11-98F14.11	5.99	2.19e-08	0.000104	0.52	0.47	Platelet distribution width;	chr13:113169776	chr13:113165002~113165183:-
ESCA	cis	rs7412746	0.611	rs111905669	ENSG00000206931.1	RNU6-1042P	5.98	2.2e-08	0.000104	0.63	0.47	Melanoma;	chr1:150805089	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-5.98	2.2e-08	0.000104	-0.5	-0.47	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-5.98	2.2e-08	0.000104	-0.5	-0.47	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-5.98	2.2e-08	0.000104	-0.5	-0.47	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
ESCA	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-5.98	2.2e-08	0.000104	-0.61	-0.47	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
ESCA	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-5.98	2.21e-08	0.000104	-0.48	-0.47	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
ESCA	cis	rs2882667	0.861	rs10043676	ENSG00000253404.1	AC034243.1	5.98	2.21e-08	0.000104	0.65	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053872	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs10038121	ENSG00000253404.1	AC034243.1	5.98	2.21e-08	0.000104	0.65	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139053913	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.861	rs10075541	ENSG00000253404.1	AC034243.1	5.98	2.21e-08	0.000104	0.65	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139054629	chr5:138744434~138753309:-
ESCA	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-5.98	2.21e-08	0.000104	-0.48	-0.47	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-5.98	2.21e-08	0.000104	-0.48	-0.47	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-5.98	2.21e-08	0.000104	-0.48	-0.47	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
ESCA	cis	rs17361889	0.766	rs1918260	ENSG00000224683.1	RPL36AP29	5.98	2.22e-08	0.000105	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16205510	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.806	rs7778438	ENSG00000224683.1	RPL36AP29	5.98	2.22e-08	0.000105	0.6	0.47	Pediatric bone mineral content (hip);	chr7:16207624	chr7:16208945~16209265:+
ESCA	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	5.98	2.22e-08	0.000105	0.76	0.47	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
ESCA	cis	rs2882667	0.898	rs13182437	ENSG00000253404.1	AC034243.1	5.98	2.22e-08	0.000105	0.65	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051460	chr5:138744434~138753309:-
ESCA	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	5.98	2.23e-08	0.000105	0.58	0.47	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
ESCA	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	5.98	2.24e-08	0.000106	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	5.98	2.24e-08	0.000106	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	5.98	2.24e-08	0.000106	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	5.98	2.24e-08	0.000106	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	5.98	2.24e-08	0.000106	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
ESCA	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	5.98	2.24e-08	0.000106	0.64	0.47	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	5.98	2.24e-08	0.000106	0.64	0.47	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
ESCA	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-5.98	2.25e-08	0.000106	-0.49	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
ESCA	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	5.98	2.27e-08	0.000107	0.51	0.47	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000231271.1	AP000350.8	5.98	2.28e-08	0.000107	0.59	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23949918~23954042:+
ESCA	cis	rs61160187	0.582	rs1460961	ENSG00000215032.2	GNL3LP1	5.98	2.29e-08	0.000107	0.58	0.47	Educational attainment (years of education);Educational attainment (college completion);	chr5:61116005	chr5:60891935~60893577:-
ESCA	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	5.98	2.3e-08	0.000107	0.51	0.47	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.806	rs1030262	ENSG00000261783.1	RP11-252K23.2	-5.98	2.3e-08	0.000107	-0.58	-0.47	Dupuytren's disease;	chr16:75457429	chr16:75379818~75381260:-
ESCA	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	5.98	2.3e-08	0.000107	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
ESCA	cis	rs7924176	0.521	rs12359775	ENSG00000236900.1	TIMM9P1	-5.98	2.3e-08	0.000107	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74330115	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs11000999	ENSG00000236900.1	TIMM9P1	-5.98	2.3e-08	0.000107	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74332933	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs10762599	ENSG00000236900.1	TIMM9P1	-5.98	2.3e-08	0.000107	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339162	chr10:74344550~74344805:-
ESCA	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	5.97	2.3e-08	0.000107	0.51	0.47	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
ESCA	cis	rs6538678	0.895	rs4762637	ENSG00000258343.1	RP11-536G4.2	-5.97	2.31e-08	0.000107	-0.61	-0.47	Lupus nephritis in systemic lupus erythematosus;	chr12:95888877	chr12:95795345~95858839:-
ESCA	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	5.97	2.31e-08	0.000107	0.64	0.47	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
ESCA	cis	rs7924176	0.521	rs11000986	ENSG00000236900.1	TIMM9P1	-5.97	2.31e-08	0.000107	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74312877	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs10824147	ENSG00000236900.1	TIMM9P1	-5.97	2.31e-08	0.000107	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74317528	chr10:74344550~74344805:-
ESCA	cis	rs6479891	0.908	rs61853655	ENSG00000235816.3	PRELID1P3	5.97	2.31e-08	0.000107	0.63	0.47	Arthritis (juvenile idiopathic);	chr10:63570645	chr10:63427297~63427939:+
ESCA	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-5.97	2.32e-08	0.000107	-0.63	-0.47	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
ESCA	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	5.97	2.34e-08	0.000108	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
ESCA	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-5.97	2.34e-08	0.000109	-0.6	-0.47	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
ESCA	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-5.97	2.35e-08	0.000109	-0.47	-0.47	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
ESCA	cis	rs6782228	1	rs11718130	ENSG00000277250.1	Metazoa_SRP	5.97	2.36e-08	0.000109	0.64	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128673681~128674021:-
ESCA	cis	rs7924176	0.54	rs61866073	ENSG00000236900.1	TIMM9P1	-5.97	2.37e-08	0.00011	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74347856	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs11516630	ENSG00000236900.1	TIMM9P1	-5.97	2.37e-08	0.00011	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74351195	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs10509347	ENSG00000236900.1	TIMM9P1	-5.97	2.37e-08	0.00011	-0.58	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74358782	chr10:74344550~74344805:-
ESCA	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-5.97	2.37e-08	0.00011	-0.49	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
ESCA	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-5.97	2.39e-08	0.00011	-0.49	-0.47	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
ESCA	cis	rs7924176	0.521	rs7098200	ENSG00000236900.1	TIMM9P1	5.97	2.39e-08	0.000111	0.57	0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74339799	chr10:74344550~74344805:-
ESCA	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-5.97	2.39e-08	0.000111	-0.66	-0.47	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
ESCA	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	5.97	2.41e-08	0.000111	0.49	0.47	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
ESCA	cis	rs7412746	0.571	rs12402939	ENSG00000206931.1	RNU6-1042P	5.96	2.42e-08	0.000112	0.62	0.47	Melanoma;	chr1:150642618	chr1:150701866~150701972:+
ESCA	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-5.96	2.42e-08	0.000112	-0.58	-0.47	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
ESCA	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-5.96	2.43e-08	0.000112	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
ESCA	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	5.96	2.43e-08	0.000112	0.92	0.47	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
ESCA	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-5.96	2.44e-08	0.000113	-0.57	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
ESCA	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	5.96	2.45e-08	0.000113	0.62	0.47	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-5.96	2.45e-08	0.000113	-0.52	-0.47	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
ESCA	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-5.96	2.45e-08	0.000113	-0.57	-0.47	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
ESCA	cis	rs4747241	0.662	rs9415068	ENSG00000226163.1	RP11-167P22.3	-5.96	2.47e-08	0.000114	-0.48	-0.47	Heschl's gyrus morphology;	chr10:72353575	chr10:72501746~72502956:+
ESCA	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	5.96	2.47e-08	0.000114	0.53	0.47	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
ESCA	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	5.96	2.47e-08	0.000114	0.51	0.47	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	5.96	2.47e-08	0.000114	0.51	0.47	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-5.96	2.47e-08	0.000114	-0.51	-0.47	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
ESCA	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-5.96	2.48e-08	0.000114	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-5.96	2.48e-08	0.000114	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-5.96	2.48e-08	0.000114	-0.63	-0.47	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
ESCA	cis	rs9549260	0.632	rs7323267	ENSG00000229456.1	RLIMP1	5.96	2.5e-08	0.000114	0.57	0.47	Red blood cell count;	chr13:40629878	chr13:40618738~40621348:+
ESCA	cis	rs9355610	0.727	rs2247315	ENSG00000265828.1	MIR3939	5.96	2.51e-08	0.000115	0.54	0.47	Graves' disease;	chr6:166956723	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.534	rs1130033	ENSG00000265828.1	MIR3939	-5.96	2.52e-08	0.000115	-0.53	-0.47	Crohn's disease;	chr6:166972135	chr6:166997807~166997912:-
ESCA	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	5.95	2.54e-08	0.000116	0.58	0.47	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000228039.3	KB-1125A3.10	5.95	2.55e-08	0.000117	0.57	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23963780~23964374:+
ESCA	cis	rs977987	0.788	rs7184525	ENSG00000261783.1	RP11-252K23.2	-5.95	2.56e-08	0.000117	-0.58	-0.47	Dupuytren's disease;	chr16:75403288	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12051326	ENSG00000261783.1	RP11-252K23.2	-5.95	2.56e-08	0.000117	-0.58	-0.47	Dupuytren's disease;	chr16:75403989	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs12443834	ENSG00000261783.1	RP11-252K23.2	-5.95	2.56e-08	0.000117	-0.58	-0.47	Dupuytren's disease;	chr16:75404571	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12924920	ENSG00000261783.1	RP11-252K23.2	-5.95	2.56e-08	0.000117	-0.58	-0.47	Dupuytren's disease;	chr16:75406235	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	5.95	2.58e-08	0.000118	0.51	0.47	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
ESCA	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-5.95	2.58e-08	0.000118	-0.48	-0.47	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-5.95	2.58e-08	0.000118	-0.48	-0.47	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
ESCA	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	5.95	2.59e-08	0.000118	0.67	0.47	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	5.95	2.59e-08	0.000118	0.67	0.47	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	5.95	2.59e-08	0.000118	0.67	0.47	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	5.95	2.59e-08	0.000118	0.67	0.47	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
ESCA	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-5.95	2.59e-08	0.000118	-0.48	-0.47	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
ESCA	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	5.95	2.6e-08	0.000119	0.57	0.47	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	5.95	2.61e-08	0.000119	0.61	0.47	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	5.95	2.61e-08	0.000119	0.51	0.47	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	5.95	2.61e-08	0.000119	0.51	0.47	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	5.95	2.61e-08	0.000119	0.51	0.47	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
ESCA	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-5.95	2.61e-08	0.000119	-0.58	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-5.95	2.61e-08	0.000119	-0.58	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
ESCA	cis	rs7412746	0.611	rs4509581	ENSG00000206931.1	RNU6-1042P	5.95	2.62e-08	0.000119	0.62	0.47	Melanoma;	chr1:150801989	chr1:150701866~150701972:+
ESCA	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	5.95	2.62e-08	0.000119	0.6	0.47	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
ESCA	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.95	2.63e-08	0.000119	0.69	0.47	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.95	2.63e-08	0.000119	0.69	0.47	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
ESCA	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	5.95	2.64e-08	0.00012	0.51	0.47	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
ESCA	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-5.95	2.64e-08	0.00012	-0.48	-0.47	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-5.95	2.64e-08	0.00012	-0.48	-0.47	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
ESCA	cis	rs9368481	0.547	rs2093303	ENSG00000243307.2	POM121L6P	5.95	2.65e-08	0.00012	0.54	0.47	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26896952~26898777:+
ESCA	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-5.94	2.66e-08	0.000121	-0.54	-0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
ESCA	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-5.94	2.66e-08	0.000121	-0.48	-0.47	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
ESCA	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	5.94	2.66e-08	0.000121	0.51	0.47	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
ESCA	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-5.94	2.67e-08	0.000121	-0.62	-0.47	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
ESCA	cis	rs2455601	0.638	rs11042148	ENSG00000254860.4	TMEM9B-AS1	5.94	2.67e-08	0.000121	0.71	0.47	Schizophrenia;	chr11:8987127	chr11:8964675~8977527:+
ESCA	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	5.94	2.68e-08	0.000121	0.52	0.47	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	5.94	2.71e-08	0.000123	0.51	0.47	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
ESCA	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	5.94	2.73e-08	0.000123	0.74	0.47	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
ESCA	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-5.94	2.73e-08	0.000123	-0.46	-0.47	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
ESCA	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	5.94	2.73e-08	0.000123	0.58	0.47	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
ESCA	cis	rs9457247	0.602	rs12209395	ENSG00000265828.1	MIR3939	-5.94	2.74e-08	0.000124	-0.52	-0.47	Crohn's disease;	chr6:167050426	chr6:166997807~166997912:-
ESCA	cis	rs7924176	0.564	rs12569971	ENSG00000236900.1	TIMM9P1	-5.94	2.75e-08	0.000124	-0.59	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74194617	chr10:74344550~74344805:-
ESCA	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	5.94	2.75e-08	0.000124	0.5	0.47	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
ESCA	cis	rs7924176	0.564	rs12359146	ENSG00000236900.1	TIMM9P1	-5.94	2.75e-08	0.000125	-0.59	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74205914	chr10:74344550~74344805:-
ESCA	cis	rs2882667	0.898	rs10079634	ENSG00000253404.1	AC034243.1	5.94	2.77e-08	0.000125	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077364	chr5:138744434~138753309:-
ESCA	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	5.93	2.79e-08	0.000126	0.67	0.47	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.806	rs2865530	ENSG00000261783.1	RP11-252K23.2	-5.93	2.79e-08	0.000126	-0.56	-0.47	Dupuytren's disease;	chr16:75380478	chr16:75379818~75381260:-
ESCA	cis	rs7924176	0.668	rs7895133	ENSG00000236900.1	TIMM9P1	-5.93	2.79e-08	0.000126	-0.57	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74247697	chr10:74344550~74344805:-
ESCA	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-5.93	2.8e-08	0.000127	-0.65	-0.47	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
ESCA	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-5.93	2.81e-08	0.000127	-0.57	-0.47	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
ESCA	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	5.93	2.83e-08	0.000128	0.61	0.47	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
ESCA	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	5.93	2.83e-08	0.000128	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
ESCA	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	5.93	2.83e-08	0.000128	0.51	0.47	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
ESCA	cis	rs1799949	0.965	rs8176310	ENSG00000198496.9	NBR2	-5.93	2.84e-08	0.000128	-0.5	-0.47	Menopause (age at onset);	chr17:43047896	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs8070179	ENSG00000198496.9	NBR2	-5.93	2.84e-08	0.000128	-0.5	-0.47	Menopause (age at onset);	chr17:43050671	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.929	rs799905	ENSG00000198496.9	NBR2	-5.93	2.84e-08	0.000128	-0.51	-0.47	Menopause (age at onset);	chr17:43125170	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.965	rs799910	ENSG00000198496.9	NBR2	-5.93	2.84e-08	0.000128	-0.51	-0.47	Menopause (age at onset);	chr17:43127544	chr17:43125610~43153671:+
ESCA	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	5.93	2.85e-08	0.000128	0.58	0.47	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	5.93	2.85e-08	0.000128	0.58	0.47	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
ESCA	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-5.93	2.89e-08	0.00013	-0.78	-0.47	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
ESCA	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	5.93	2.89e-08	0.00013	0.51	0.47	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	5.93	2.89e-08	0.00013	0.51	0.47	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	5.93	2.9e-08	0.000131	0.51	0.47	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
ESCA	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-5.93	2.92e-08	0.000131	-0.64	-0.47	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
ESCA	cis	rs1799949	0.965	rs6503726	ENSG00000198496.9	NBR2	-5.92	2.92e-08	0.000131	-0.52	-0.47	Menopause (age at onset);	chr17:43132725	chr17:43125610~43153671:+
ESCA	cis	rs13217239	0.646	rs6937880	ENSG00000243307.2	POM121L6P	5.92	2.93e-08	0.000131	0.51	0.47	Schizophrenia;	chr6:27032457	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.621	rs12527231	ENSG00000243307.2	POM121L6P	5.92	2.93e-08	0.000131	0.51	0.47	Schizophrenia;	chr6:27033509	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs12523820	ENSG00000243307.2	POM121L6P	5.92	2.93e-08	0.000131	0.51	0.47	Schizophrenia;	chr6:27033723	chr6:26896952~26898777:+
ESCA	cis	rs9549367	0.789	rs9549699	ENSG00000269125.1	RP11-98F14.11	-5.92	2.94e-08	0.000132	-0.52	-0.47	Platelet distribution width;	chr13:113223949	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs7999579	ENSG00000269125.1	RP11-98F14.11	-5.92	2.94e-08	0.000132	-0.52	-0.47	Platelet distribution width;	chr13:113225043	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs6577035	ENSG00000269125.1	RP11-98F14.11	-5.92	2.94e-08	0.000132	-0.52	-0.47	Platelet distribution width;	chr13:113225683	chr13:113165002~113165183:-
ESCA	cis	rs9368481	0.594	rs2636425	ENSG00000243307.2	POM121L6P	5.92	2.94e-08	0.000132	0.56	0.47	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26896952~26898777:+
ESCA	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	5.92	2.95e-08	0.000132	0.52	0.47	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
ESCA	cis	rs2882667	0.898	rs4380651	ENSG00000253404.1	AC034243.1	5.92	2.95e-08	0.000132	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139055383	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.92	2.95e-08	0.000132	-0.62	-0.47	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
ESCA	cis	rs1799949	0.965	rs9897425	ENSG00000198496.9	NBR2	-5.92	2.98e-08	0.000134	-0.52	-0.47	Menopause (age at onset);	chr17:43352811	chr17:43125610~43153671:+
ESCA	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	5.92	2.99e-08	0.000134	0.74	0.47	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
ESCA	cis	rs9545047	1	rs9545047	ENSG00000227676.3	LINC01068	5.92	3e-08	0.000134	0.64	0.47	Schizophrenia;	chr13:79285321	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.862	rs10256544	ENSG00000179406.6	LINC00174	-5.92	3e-08	0.000134	-0.53	-0.47	Aortic root size;	chr7:66210141	chr7:66376044~66401338:-
ESCA	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-5.92	3e-08	0.000134	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
ESCA	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-5.92	3e-08	0.000134	-0.59	-0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
ESCA	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-5.92	3.03e-08	0.000135	-0.78	-0.47	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
ESCA	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	5.92	3.03e-08	0.000135	0.51	0.47	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	5.92	3.03e-08	0.000135	0.51	0.47	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
ESCA	cis	rs1799949	0.965	rs9646418	ENSG00000198496.9	NBR2	-5.92	3.05e-08	0.000136	-0.51	-0.47	Menopause (age at onset);	chr17:43348533	chr17:43125610~43153671:+
ESCA	cis	rs950027	0.62	rs1153860	ENSG00000259520.4	CTD-2651B20.3	5.92	3.05e-08	0.000136	0.55	0.47	Response to fenofibrate (adiponectin levels);	chr15:45344386	chr15:45251580~45279251:-
ESCA	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-5.92	3.05e-08	0.000136	-0.5	-0.47	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	5.92	3.06e-08	0.000136	0.51	0.47	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	5.92	3.06e-08	0.000136	0.51	0.47	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.636	rs2659895	ENSG00000179406.6	LINC00174	-5.91	3.08e-08	0.000137	-0.54	-0.47	Aortic root size;	chr7:66731484	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.66	rs974239	ENSG00000179406.6	LINC00174	-5.91	3.09e-08	0.000137	-0.54	-0.47	Aortic root size;	chr7:66748504	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs1129531	ENSG00000179406.6	LINC00174	5.91	3.1e-08	0.000138	0.54	0.47	Aortic root size;	chr7:66154117	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.924	rs9322189	ENSG00000216906.2	RP11-350J20.9	5.91	3.11e-08	0.000138	0.63	0.47	Lung cancer;	chr6:149588797	chr6:149904243~149906418:+
ESCA	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	5.91	3.12e-08	0.000139	0.51	0.47	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	5.91	3.12e-08	0.000139	0.53	0.47	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
ESCA	cis	rs6782228	1	rs11711038	ENSG00000277250.1	Metazoa_SRP	5.91	3.13e-08	0.000139	0.61	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128673681~128674021:-
ESCA	cis	rs801193	0.613	rs2659900	ENSG00000179406.6	LINC00174	-5.91	3.13e-08	0.000139	-0.54	-0.47	Aortic root size;	chr7:66719456	chr7:66376044~66401338:-
ESCA	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	5.91	3.13e-08	0.000139	0.67	0.47	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
ESCA	cis	rs801193	0.66	rs2659914	ENSG00000179406.6	LINC00174	-5.91	3.14e-08	0.000139	-0.54	-0.47	Aortic root size;	chr7:66691927	chr7:66376044~66401338:-
ESCA	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	5.91	3.14e-08	0.000139	0.47	0.47	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	5.91	3.14e-08	0.000139	0.47	0.47	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	5.91	3.14e-08	0.000139	0.47	0.47	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.806	rs17696696	ENSG00000261783.1	RP11-252K23.2	5.91	3.14e-08	0.00014	0.56	0.47	Dupuytren's disease;	chr16:75359454	chr16:75379818~75381260:-
ESCA	cis	rs7412746	0.658	rs7526489	ENSG00000206931.1	RNU6-1042P	5.91	3.16e-08	0.00014	0.6	0.47	Melanoma;	chr1:150753762	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs12068264	ENSG00000206931.1	RNU6-1042P	5.91	3.16e-08	0.00014	0.6	0.47	Melanoma;	chr1:150754853	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs2230061	ENSG00000206931.1	RNU6-1042P	5.91	3.16e-08	0.00014	0.6	0.47	Melanoma;	chr1:150755063	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-5.91	3.17e-08	0.000141	-0.59	-0.47	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
ESCA	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-5.91	3.17e-08	0.000141	-0.57	-0.47	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
ESCA	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-5.91	3.17e-08	0.000141	-0.46	-0.47	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
ESCA	cis	rs7829975	0.564	rs2976855	ENSG00000173295.6	FAM86B3P	5.91	3.17e-08	0.000141	0.54	0.47	Mood instability;	chr8:8444284	chr8:8228595~8244865:+
ESCA	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	5.91	3.19e-08	0.000141	0.5	0.47	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	5.91	3.2e-08	0.000142	0.51	0.47	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
ESCA	cis	rs801193	0.66	rs1016265	ENSG00000179406.6	LINC00174	-5.91	3.21e-08	0.000142	-0.54	-0.47	Aortic root size;	chr7:66749580	chr7:66376044~66401338:-
ESCA	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-5.9	3.26e-08	0.000144	-0.47	-0.47	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-5.9	3.26e-08	0.000144	-0.47	-0.47	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-5.9	3.26e-08	0.000144	-0.47	-0.47	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
ESCA	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	5.9	3.27e-08	0.000144	0.6	0.47	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
ESCA	cis	rs7924176	0.564	rs4564273	ENSG00000236900.1	TIMM9P1	-5.9	3.28e-08	0.000145	-0.57	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74230154	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs11000959	ENSG00000236900.1	TIMM9P1	-5.9	3.32e-08	0.000146	-0.56	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74287053	chr10:74344550~74344805:-
ESCA	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	5.9	3.33e-08	0.000147	0.54	0.47	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	5.9	3.33e-08	0.000147	0.54	0.47	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	5.9	3.33e-08	0.000147	0.54	0.47	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
ESCA	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	5.9	3.33e-08	0.000147	0.66	0.47	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	5.9	3.33e-08	0.000147	0.66	0.47	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
ESCA	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	5.9	3.33e-08	0.000147	0.59	0.47	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
ESCA	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-5.9	3.33e-08	0.000147	-0.57	-0.47	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
ESCA	cis	rs9549367	0.789	rs3764125	ENSG00000269125.1	RP11-98F14.11	5.9	3.34e-08	0.000147	0.54	0.47	Platelet distribution width;	chr13:113243334	chr13:113165002~113165183:-
ESCA	cis	rs801193	0.66	rs4610622	ENSG00000179406.6	LINC00174	-5.89	3.41e-08	0.00015	-0.54	-0.47	Aortic root size;	chr7:66759510	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.66	rs10950049	ENSG00000179406.6	LINC00174	-5.89	3.41e-08	0.00015	-0.54	-0.47	Aortic root size;	chr7:66765873	chr7:66376044~66401338:-
ESCA	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	5.89	3.41e-08	0.00015	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
ESCA	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-5.89	3.42e-08	0.00015	-0.62	-0.47	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
ESCA	cis	rs2882667	0.894	rs1433008	ENSG00000253404.1	AC034243.1	5.89	3.47e-08	0.000152	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138997975	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.931	rs1433009	ENSG00000253404.1	AC034243.1	5.89	3.47e-08	0.000152	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998095	chr5:138744434~138753309:-
ESCA	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-5.89	3.48e-08	0.000153	-0.63	-0.47	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-5.89	3.48e-08	0.000153	-0.63	-0.47	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
ESCA	cis	rs2739330	0.627	rs9608219	ENSG00000099984.9	GSTT2	-5.89	3.48e-08	0.000153	-0.56	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23980123~23983911:+
ESCA	cis	rs801193	0.636	rs10233806	ENSG00000179406.6	LINC00174	5.89	3.49e-08	0.000154	0.54	0.47	Aortic root size;	chr7:66653261	chr7:66376044~66401338:-
ESCA	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	5.89	3.5e-08	0.000154	0.5	0.47	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.735	rs166013	ENSG00000261783.1	RP11-252K23.2	5.89	3.51e-08	0.000154	0.6	0.47	Dupuytren's disease;	chr16:75400248	chr16:75379818~75381260:-
ESCA	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	5.88	3.53e-08	0.000155	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
ESCA	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-5.88	3.54e-08	0.000155	-0.64	-0.47	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
ESCA	cis	rs9545047	1	rs9574422	ENSG00000227676.3	LINC01068	5.88	3.55e-08	0.000155	0.62	0.47	Schizophrenia;	chr13:79415246	chr13:79566727~79571436:+
ESCA	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-5.88	3.55e-08	0.000156	-0.47	-0.47	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
ESCA	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	5.88	3.55e-08	0.000156	0.61	0.47	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
ESCA	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	5.88	3.55e-08	0.000156	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
ESCA	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	5.88	3.56e-08	0.000156	0.61	0.47	Depression;	chr6:28402301	chr6:28176188~28176674:+
ESCA	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-5.88	3.56e-08	0.000156	-0.6	-0.47	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
ESCA	cis	rs2799081	1	rs2799081	ENSG00000216901.1	AL022393.7	5.88	3.56e-08	0.000156	0.54	0.47	Myopia;	chr6:28302807	chr6:28176188~28176674:+
ESCA	cis	rs17361889	0.806	rs6961874	ENSG00000224683.1	RPL36AP29	5.88	3.59e-08	0.000157	0.59	0.47	Pediatric bone mineral content (hip);	chr7:16207299	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.766	rs1527221	ENSG00000224683.1	RPL36AP29	5.88	3.59e-08	0.000157	0.59	0.47	Pediatric bone mineral content (hip);	chr7:16207470	chr7:16208945~16209265:+
ESCA	cis	rs9457247	0.602	rs12208359	ENSG00000265828.1	MIR3939	-5.88	3.61e-08	0.000158	-0.51	-0.47	Crohn's disease;	chr6:167044967	chr6:166997807~166997912:-
ESCA	cis	rs7412746	0.611	rs12085336	ENSG00000206931.1	RNU6-1042P	5.88	3.61e-08	0.000158	0.58	0.47	Melanoma;	chr1:150803304	chr1:150701866~150701972:+
ESCA	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-5.88	3.61e-08	0.000158	-0.61	-0.47	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
ESCA	cis	rs7924176	0.601	rs7093532	ENSG00000236900.1	TIMM9P1	-5.88	3.62e-08	0.000158	-0.57	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74178282	chr10:74344550~74344805:-
ESCA	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-5.88	3.63e-08	0.000159	-0.5	-0.47	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-5.88	3.63e-08	0.000159	-0.5	-0.47	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
ESCA	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	5.88	3.64e-08	0.000159	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	5.88	3.64e-08	0.000159	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	5.88	3.64e-08	0.000159	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	5.88	3.64e-08	0.000159	0.61	0.47	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	5.88	3.64e-08	0.000159	0.63	0.47	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
ESCA	cis	rs6479891	1	rs12412012	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63556003	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs61579729	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63559553	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs16918599	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63560319	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.73	rs16918600	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63560690	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs11812934	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63560970	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs16918601	ENSG00000235816.3	PRELID1P3	5.88	3.67e-08	0.00016	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63561291	chr10:63427297~63427939:+
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000250470.1	AP000351.3	5.88	3.67e-08	0.00016	0.54	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23976904~23977585:-
ESCA	cis	rs6782228	1	rs12635488	ENSG00000277250.1	Metazoa_SRP	5.87	3.7e-08	0.000161	0.63	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128673681~128674021:-
ESCA	cis	rs2882667	0.931	rs10075893	ENSG00000253404.1	AC034243.1	-5.87	3.71e-08	0.000162	-0.65	-0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139020182	chr5:138744434~138753309:-
ESCA	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	5.87	3.71e-08	0.000162	0.56	0.47	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
ESCA	cis	rs7924176	0.521	rs11001022	ENSG00000236900.1	TIMM9P1	-5.87	3.74e-08	0.000163	-0.57	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74380110	chr10:74344550~74344805:-
ESCA	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-5.87	3.77e-08	0.000164	-0.48	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
ESCA	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.87	3.8e-08	0.000166	0.63	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
ESCA	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-5.87	3.8e-08	0.000166	-0.61	-0.47	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
ESCA	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-5.87	3.83e-08	0.000167	-0.57	-0.47	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-5.87	3.83e-08	0.000167	-0.57	-0.47	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-5.87	3.83e-08	0.000167	-0.57	-0.47	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
ESCA	cis	rs7412746	0.563	rs3768013	ENSG00000206931.1	RNU6-1042P	5.87	3.85e-08	0.000167	0.61	0.47	Melanoma;	chr1:150842935	chr1:150701866~150701972:+
ESCA	cis	rs801193	0.591	rs2707839	ENSG00000179406.6	LINC00174	-5.87	3.85e-08	0.000168	-0.53	-0.47	Aortic root size;	chr7:66728097	chr7:66376044~66401338:-
ESCA	cis	rs1799949	0.794	rs116409325	ENSG00000198496.9	NBR2	-5.87	3.87e-08	0.000168	-0.51	-0.47	Menopause (age at onset);	chr17:43368092	chr17:43125610~43153671:+
ESCA	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	5.87	3.87e-08	0.000168	0.47	0.47	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
ESCA	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	5.86	3.89e-08	0.000169	0.61	0.47	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
ESCA	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-5.86	3.91e-08	0.00017	-0.64	-0.47	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
ESCA	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-5.86	3.94e-08	0.000171	-0.48	-0.47	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
ESCA	cis	rs7924176	0.564	rs10762588	ENSG00000236900.1	TIMM9P1	-5.86	3.94e-08	0.000171	-0.57	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226087	chr10:74344550~74344805:-
ESCA	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	5.86	3.96e-08	0.000172	0.55	0.47	Depression;	chr6:28314871	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	5.86	3.99e-08	0.000173	0.52	0.47	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	5.86	3.99e-08	0.000173	0.52	0.47	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	5.86	3.99e-08	0.000173	0.52	0.47	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.898	rs6890272	ENSG00000253404.1	AC034243.1	5.86	4e-08	0.000173	0.64	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:139035427	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	5.86	4.01e-08	0.000173	0.51	0.47	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
ESCA	cis	rs6479891	0.908	rs16918603	ENSG00000235816.3	PRELID1P3	5.86	4.02e-08	0.000174	0.62	0.47	Arthritis (juvenile idiopathic);	chr10:63561712	chr10:63427297~63427939:+
ESCA	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	5.86	4.02e-08	0.000174	0.51	0.47	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	5.86	4.02e-08	0.000174	0.51	0.47	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	5.86	4.02e-08	0.000174	0.51	0.47	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	5.86	4.02e-08	0.000174	0.51	0.47	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	5.86	4.02e-08	0.000174	0.51	0.47	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
ESCA	cis	rs12439619	0.508	rs17354842	ENSG00000278603.1	RP13-608F4.5	-5.86	4.02e-08	0.000174	-0.57	-0.47	Intelligence (multi-trait analysis);	chr15:82177259	chr15:82472203~82472426:+
ESCA	cis	rs1799949	0.965	rs799917	ENSG00000198496.9	NBR2	-5.86	4.04e-08	0.000175	-0.51	-0.47	Menopause (age at onset);	chr17:43092919	chr17:43125610~43153671:+
ESCA	cis	rs9368849	0.536	rs1880090	ENSG00000186328.4	RP11-140K17.2	5.86	4.05e-08	0.000175	0.65	0.47	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35023191	chr6:34715613~34715940:+
ESCA	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	5.86	4.05e-08	0.000175	0.71	0.47	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	5.86	4.05e-08	0.000175	0.71	0.47	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
ESCA	cis	rs2439831	0.85	rs8042868	ENSG00000249839.1	AC011330.5	-5.86	4.05e-08	0.000175	-0.82	-0.47	Lung cancer in ever smokers;	chr15:43647444	chr15:43663654~43684339:-
ESCA	cis	rs2221894	0.922	rs11136054	ENSG00000273710.1	Metazoa_SRP	-5.85	4.07e-08	0.000176	-0.5	-0.47	Obesity-related traits;	chr8:28997585	chr8:28915579~28915864:-
ESCA	cis	rs2221894	0.922	rs11136055	ENSG00000273710.1	Metazoa_SRP	-5.85	4.07e-08	0.000176	-0.5	-0.47	Obesity-related traits;	chr8:28998009	chr8:28915579~28915864:-
ESCA	cis	rs2221894	0.922	rs11136056	ENSG00000273710.1	Metazoa_SRP	-5.85	4.07e-08	0.000176	-0.5	-0.47	Obesity-related traits;	chr8:29006558	chr8:28915579~28915864:-
ESCA	cis	rs2221894	0.922	rs7837237	ENSG00000273710.1	Metazoa_SRP	5.85	4.07e-08	0.000176	0.5	0.47	Obesity-related traits;	chr8:29018704	chr8:28915579~28915864:-
ESCA	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-5.85	4.07e-08	0.000176	-0.48	-0.47	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
ESCA	cis	rs7924176	0.601	rs12414280	ENSG00000236900.1	TIMM9P1	-5.85	4.07e-08	0.000176	-0.56	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74174642	chr10:74344550~74344805:-
ESCA	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	5.85	4.08e-08	0.000176	0.56	0.47	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
ESCA	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-5.85	4.1e-08	0.000177	-0.48	-0.47	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	5.85	4.14e-08	0.000178	0.49	0.47	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	5.85	4.14e-08	0.000178	0.49	0.47	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	5.85	4.14e-08	0.000178	0.72	0.47	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
ESCA	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-5.85	4.18e-08	0.00018	-0.49	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
ESCA	cis	rs9457247	0.508	rs9457268	ENSG00000265828.1	MIR3939	-5.85	4.18e-08	0.00018	-0.51	-0.47	Crohn's disease;	chr6:167090151	chr6:166997807~166997912:-
ESCA	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-5.85	4.19e-08	0.00018	-0.74	-0.47	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-5.85	4.19e-08	0.00018	-0.74	-0.47	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
ESCA	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	5.85	4.19e-08	0.00018	0.56	0.47	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
ESCA	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-5.85	4.2e-08	0.00018	-0.47	-0.47	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-5.85	4.2e-08	0.00018	-0.47	-0.47	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
ESCA	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-5.85	4.2e-08	0.00018	-0.47	-0.47	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
ESCA	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	5.85	4.2e-08	0.000181	0.59	0.47	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
ESCA	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-5.85	4.23e-08	0.000181	-0.63	-0.47	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
ESCA	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	5.85	4.23e-08	0.000182	0.47	0.47	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
ESCA	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	5.84	4.26e-08	0.000183	0.58	0.47	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
ESCA	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	5.84	4.27e-08	0.000183	0.58	0.47	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
ESCA	cis	rs2929278	0.617	rs524908	ENSG00000205771.5	CATSPER2P1	5.84	4.28e-08	0.000183	0.6	0.47	Schizophrenia;	chr15:43895793	chr15:43726918~43747094:-
ESCA	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-5.84	4.28e-08	0.000184	-0.76	-0.47	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
ESCA	cis	rs801193	0.591	rs4506088	ENSG00000179406.6	LINC00174	5.84	4.34e-08	0.000186	0.53	0.47	Aortic root size;	chr7:66670470	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2659908	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66695835	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2659907	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66699045	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs7782587	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66701485	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs4717315	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66713338	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.527	rs2707837	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66716086	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2659893	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66735006	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2659892	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66735318	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.548	rs2659891	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66736127	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2707847	ENSG00000179406.6	LINC00174	-5.84	4.34e-08	0.000186	-0.53	-0.47	Aortic root size;	chr7:66737884	chr7:66376044~66401338:-
ESCA	cis	rs9549367	0.789	rs12584813	ENSG00000269125.1	RP11-98F14.11	-5.84	4.36e-08	0.000187	-0.51	-0.47	Platelet distribution width;	chr13:113241129	chr13:113165002~113165183:-
ESCA	cis	rs875971	0.862	rs10274883	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66651104	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs881285	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66654433	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs3846973	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66655048	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs2013908	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66656082	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs13242290	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66656898	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.548	rs2109297	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66657397	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs6978178	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66658097	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.591	rs721717	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66665305	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs6951302	ENSG00000179406.6	LINC00174	5.84	4.37e-08	0.000187	0.53	0.47	Aortic root size;	chr7:66667525	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.548	rs7805152	ENSG00000179406.6	LINC00174	-5.84	4.37e-08	0.000187	-0.53	-0.47	Aortic root size;	chr7:66744266	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs11761542	ENSG00000179406.6	LINC00174	-5.84	4.37e-08	0.000187	-0.53	-0.47	Aortic root size;	chr7:66753209	chr7:66376044~66401338:-
ESCA	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.84	4.38e-08	0.000187	0.46	0.47	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
ESCA	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	5.84	4.39e-08	0.000188	0.61	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
ESCA	cis	rs9457247	0.765	rs9457252	ENSG00000265828.1	MIR3939	5.84	4.4e-08	0.000188	0.51	0.47	Crohn's disease;	chr6:167020437	chr6:166997807~166997912:-
ESCA	cis	rs9601248	0.529	rs2783126	ENSG00000227676.3	LINC01068	5.84	4.43e-08	0.000189	0.61	0.47	Major depressive disorder;	chr13:79584566	chr13:79566727~79571436:+
ESCA	cis	rs9601248	0.529	rs9545142	ENSG00000227676.3	LINC01068	5.84	4.43e-08	0.000189	0.61	0.47	Major depressive disorder;	chr13:79588420	chr13:79566727~79571436:+
ESCA	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	5.84	4.44e-08	0.000189	0.58	0.47	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
ESCA	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	5.84	4.44e-08	0.00019	0.57	0.47	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
ESCA	cis	rs977987	0.843	rs6564260	ENSG00000261783.1	RP11-252K23.2	-5.84	4.45e-08	0.00019	-0.57	-0.47	Dupuytren's disease;	chr16:75413528	chr16:75379818~75381260:-
ESCA	cis	rs2882667	0.931	rs10070021	ENSG00000253404.1	AC034243.1	5.83	4.48e-08	0.000191	0.63	0.47	Age-related hearing impairment (SNP x SNP interaction);	chr5:138989017	chr5:138744434~138753309:-
ESCA	cis	rs2980439	0.607	rs2980419	ENSG00000253981.4	ALG1L13P	5.83	4.49e-08	0.000191	0.58	0.47	Neuroticism;	chr8:8256619	chr8:8236003~8244667:-
ESCA	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	5.83	4.49e-08	0.000191	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	5.83	4.49e-08	0.000191	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	5.83	4.49e-08	0.000191	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
ESCA	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-5.83	4.49e-08	0.000192	-0.54	-0.47	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
ESCA	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	5.83	4.5e-08	0.000192	0.56	0.47	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
ESCA	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	5.83	4.51e-08	0.000192	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	5.83	4.51e-08	0.000192	0.51	0.47	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
ESCA	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-5.83	4.51e-08	0.000192	-0.75	-0.47	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
ESCA	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-5.83	4.51e-08	0.000192	-0.63	-0.47	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-5.83	4.51e-08	0.000192	-0.63	-0.47	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-5.83	4.51e-08	0.000192	-0.63	-0.47	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-5.83	4.51e-08	0.000192	-0.63	-0.47	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
ESCA	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-5.83	4.51e-08	0.000192	-0.63	-0.47	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
ESCA	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	5.83	4.54e-08	0.000193	0.58	0.47	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	5.83	4.54e-08	0.000193	0.54	0.47	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
ESCA	cis	rs7924176	0.601	rs10824091	ENSG00000236900.1	TIMM9P1	-5.83	4.54e-08	0.000193	-0.56	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74169750	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.549	rs2395076	ENSG00000236900.1	TIMM9P1	-5.83	4.54e-08	0.000193	-0.56	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74172081	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.601	rs7089391	ENSG00000236900.1	TIMM9P1	-5.83	4.54e-08	0.000193	-0.56	-0.47	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74177762	chr10:74344550~74344805:-
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	5.83	4.57e-08	0.000194	0.56	0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
ESCA	cis	rs801193	0.569	rs11772819	ENSG00000179406.6	LINC00174	-5.83	4.57e-08	0.000194	-0.53	-0.47	Aortic root size;	chr7:66752983	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs7800620	ENSG00000179406.6	LINC00174	-5.83	4.57e-08	0.000194	-0.53	-0.47	Aortic root size;	chr7:66758701	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.569	rs13226966	ENSG00000179406.6	LINC00174	-5.83	4.57e-08	0.000194	-0.53	-0.47	Aortic root size;	chr7:66768636	chr7:66376044~66401338:-
ESCA	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	5.83	4.63e-08	0.000196	0.73	0.47	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
ESCA	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	5.83	4.64e-08	0.000197	0.59	0.47	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
ESCA	cis	rs1799949	0.965	rs799912	ENSG00000198496.9	NBR2	-5.83	4.66e-08	0.000197	-0.51	-0.47	Menopause (age at onset);	chr17:43105117	chr17:43125610~43153671:+
ESCA	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	5.83	4.66e-08	0.000198	0.5	0.47	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
ESCA	cis	rs12439619	0.508	rs8032033	ENSG00000278603.1	RP13-608F4.5	5.83	4.67e-08	0.000198	0.58	0.47	Intelligence (multi-trait analysis);	chr15:82165555	chr15:82472203~82472426:+
ESCA	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-5.82	4.68e-08	0.000198	-0.66	-0.46	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
ESCA	cis	rs6479891	1	rs12411988	ENSG00000235816.3	PRELID1P3	-5.82	4.7e-08	0.000199	-0.63	-0.46	Arthritis (juvenile idiopathic);	chr10:63555637	chr10:63427297~63427939:+
ESCA	cis	rs7412746	0.611	rs10888394	ENSG00000206931.1	RNU6-1042P	5.82	4.71e-08	0.000199	0.61	0.46	Melanoma;	chr1:150777437	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-5.82	4.71e-08	0.000199	-0.61	-0.46	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
ESCA	cis	rs9457247	0.565	rs2038580	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167043002	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.602	rs10484530	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167048074	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.544	rs6920858	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167051142	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.602	rs9459854	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167052394	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.582	rs9459855	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167052662	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.624	rs9457260	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167053177	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.624	rs17524252	ENSG00000265828.1	MIR3939	-5.82	4.76e-08	0.000201	-0.51	-0.46	Crohn's disease;	chr6:167053490	chr6:166997807~166997912:-
ESCA	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	5.82	4.76e-08	0.000201	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
ESCA	cis	rs694739	1	rs694739	ENSG00000236935.1	AP003774.1	5.82	4.78e-08	0.000202	0.57	0.46	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64329761	chr11:64325050~64329504:-
ESCA	cis	rs2455601	0.573	rs2653573	ENSG00000254860.4	TMEM9B-AS1	5.82	4.8e-08	0.000203	0.62	0.46	Schizophrenia;	chr11:8968327	chr11:8964675~8977527:+
ESCA	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	5.82	4.83e-08	0.000204	0.73	0.46	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
ESCA	cis	rs1005277	0.602	rs1831315	ENSG00000276805.1	RP11-291L22.6	5.82	4.85e-08	0.000204	0.59	0.46	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38451030~38451785:+
ESCA	cis	rs9545047	0.967	rs3903388	ENSG00000227676.3	LINC01068	5.82	4.9e-08	0.000206	0.62	0.46	Schizophrenia;	chr13:79330686	chr13:79566727~79571436:+
ESCA	cis	rs9545047	1	rs9545073	ENSG00000227676.3	LINC01068	5.82	4.9e-08	0.000206	0.62	0.46	Schizophrenia;	chr13:79334872	chr13:79566727~79571436:+
ESCA	cis	rs9549367	0.789	rs9549715	ENSG00000269125.1	RP11-98F14.11	-5.81	4.92e-08	0.000207	-0.51	-0.46	Platelet distribution width;	chr13:113253926	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs2302757	ENSG00000269125.1	RP11-98F14.11	-5.81	4.92e-08	0.000207	-0.51	-0.46	Platelet distribution width;	chr13:113255025	chr13:113165002~113165183:-
ESCA	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-5.81	4.94e-08	0.000208	-0.66	-0.46	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
ESCA	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	5.81	4.96e-08	0.000209	0.76	0.46	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
ESCA	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.81	4.96e-08	0.000209	0.48	0.46	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
ESCA	cis	rs9545047	0.716	rs643778	ENSG00000227676.3	LINC01068	-5.81	4.97e-08	0.000209	-0.61	-0.46	Schizophrenia;	chr13:79423937	chr13:79566727~79571436:+
ESCA	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	5.81	5.01e-08	0.000211	0.72	0.46	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
ESCA	cis	rs7714584	1	rs59043558	ENSG00000197083.10	ZNF300P1	5.81	5.04e-08	0.000212	0.83	0.46	Crohn's disease;	chr5:150955100	chr5:150930645~150946289:-
ESCA	cis	rs9457247	0.602	rs2239827	ENSG00000265828.1	MIR3939	-5.81	5.05e-08	0.000212	-0.52	-0.46	Crohn's disease;	chr6:167077457	chr6:166997807~166997912:-
ESCA	cis	rs9545047	1	rs9545078	ENSG00000227676.3	LINC01068	5.81	5.09e-08	0.000214	0.62	0.46	Schizophrenia;	chr13:79339216	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.869	rs3742119	ENSG00000227676.3	LINC01068	5.81	5.09e-08	0.000214	0.62	0.46	Schizophrenia;	chr13:79342859	chr13:79566727~79571436:+
ESCA	cis	rs9545047	1	rs9318626	ENSG00000227676.3	LINC01068	5.81	5.09e-08	0.000214	0.62	0.46	Schizophrenia;	chr13:79351820	chr13:79566727~79571436:+
ESCA	cis	rs9545047	1	rs56911077	ENSG00000227676.3	LINC01068	5.81	5.09e-08	0.000214	0.62	0.46	Schizophrenia;	chr13:79354126	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	5.81	5.1e-08	0.000214	0.51	0.46	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
ESCA	cis	rs2929278	0.561	rs3099045	ENSG00000205771.5	CATSPER2P1	-5.81	5.1e-08	0.000214	-0.61	-0.46	Schizophrenia;	chr15:43631757	chr15:43726918~43747094:-
ESCA	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-5.81	5.11e-08	0.000214	-0.48	-0.46	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-5.81	5.11e-08	0.000214	-0.48	-0.46	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
ESCA	cis	rs4747241	0.626	rs4300326	ENSG00000226163.1	RP11-167P22.3	-5.81	5.11e-08	0.000215	-0.5	-0.46	Heschl's gyrus morphology;	chr10:72308938	chr10:72501746~72502956:+
ESCA	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	5.81	5.12e-08	0.000215	0.68	0.46	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
ESCA	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	5.8	5.16e-08	0.000216	0.59	0.46	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
ESCA	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-5.8	5.17e-08	0.000217	-0.57	-0.46	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
ESCA	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-5.8	5.22e-08	0.000219	-0.56	-0.46	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-5.8	5.22e-08	0.000219	-0.56	-0.46	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-5.8	5.22e-08	0.000219	-0.56	-0.46	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
ESCA	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	5.8	5.26e-08	0.00022	0.48	0.46	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	5.8	5.26e-08	0.00022	0.51	0.46	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
ESCA	cis	rs7412746	0.611	rs16827671	ENSG00000206931.1	RNU6-1042P	5.8	5.26e-08	0.00022	0.61	0.46	Melanoma;	chr1:150766283	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs11204726	ENSG00000206931.1	RNU6-1042P	5.8	5.26e-08	0.00022	0.61	0.46	Melanoma;	chr1:150771016	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.553	rs59337856	ENSG00000206931.1	RNU6-1042P	5.8	5.26e-08	0.00022	0.61	0.46	Melanoma;	chr1:150773930	chr1:150701866~150701972:+
ESCA	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-5.8	5.27e-08	0.000221	-0.62	-0.46	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
ESCA	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-5.8	5.3e-08	0.000221	-0.46	-0.46	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-5.8	5.3e-08	0.000221	-0.46	-0.46	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
ESCA	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-5.8	5.3e-08	0.000222	-0.55	-0.46	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-5.8	5.3e-08	0.000222	-0.55	-0.46	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-5.8	5.3e-08	0.000222	-0.55	-0.46	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-5.8	5.3e-08	0.000222	-0.55	-0.46	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-5.8	5.3e-08	0.000222	-0.55	-0.46	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
ESCA	cis	rs2882667	0.931	rs6596457	ENSG00000253404.1	AC034243.1	5.8	5.31e-08	0.000222	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138987690	chr5:138744434~138753309:-
ESCA	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-5.8	5.33e-08	0.000222	-0.53	-0.46	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
ESCA	cis	rs9457247	0.561	rs916331	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Crohn's disease;	chr6:167057071	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.602	rs13204839	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Crohn's disease;	chr6:167057631	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.602	rs6456152	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Crohn's disease;	chr6:167058574	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.602	rs9457262	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Crohn's disease;	chr6:167060197	chr6:166997807~166997912:-
ESCA	cis	rs3093024	0.595	rs4412174	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Rheumatoid arthritis;	chr6:167062578	chr6:166997807~166997912:-
ESCA	cis	rs3093024	0.595	rs4458654	ENSG00000265828.1	MIR3939	-5.8	5.33e-08	0.000222	-0.51	-0.46	Rheumatoid arthritis;	chr6:167062580	chr6:166997807~166997912:-
ESCA	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-5.8	5.36e-08	0.000223	-0.58	-0.46	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
ESCA	cis	rs7412746	0.611	rs6660084	ENSG00000206931.1	RNU6-1042P	5.8	5.36e-08	0.000224	0.61	0.46	Melanoma;	chr1:150776327	chr1:150701866~150701972:+
ESCA	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	5.8	5.37e-08	0.000224	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000099984.9	GSTT2	-5.79	5.4e-08	0.000225	-0.54	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23980123~23983911:+
ESCA	cis	rs2882667	0.931	rs10074461	ENSG00000253404.1	AC034243.1	5.79	5.41e-08	0.000225	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138984126	chr5:138744434~138753309:-
ESCA	cis	rs950880	0.71	rs66566526	ENSG00000234389.1	AC007278.3	-5.79	5.41e-08	0.000225	-0.43	-0.46	Serum protein levels (sST2);	chr2:102431342	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs56331791	ENSG00000234389.1	AC007278.3	-5.79	5.41e-08	0.000225	-0.43	-0.46	Serum protein levels (sST2);	chr2:102431697	chr2:102438713~102440475:+
ESCA	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-5.79	5.43e-08	0.000226	-0.55	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
ESCA	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.43e-08	0.000226	-0.58	-0.46	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
ESCA	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-5.79	5.47e-08	0.000227	-0.49	-0.46	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.569	rs2707824	ENSG00000179406.6	LINC00174	-5.79	5.47e-08	0.000227	-0.52	-0.46	Aortic root size;	chr7:66724256	chr7:66376044~66401338:-
ESCA	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-5.79	5.48e-08	0.000228	-0.58	-0.46	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
ESCA	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
ESCA	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.54	-0.46	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-5.79	5.49e-08	0.000228	-0.55	-0.46	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
ESCA	cis	rs1799949	0.965	rs9646413	ENSG00000198496.9	NBR2	-5.79	5.51e-08	0.000229	-0.51	-0.46	Menopause (age at onset);	chr17:43348789	chr17:43125610~43153671:+
ESCA	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-5.79	5.51e-08	0.000229	-0.49	-0.46	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
ESCA	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	5.79	5.52e-08	0.000229	0.47	0.46	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
ESCA	cis	rs977987	0.806	rs4146809	ENSG00000261783.1	RP11-252K23.2	5.79	5.52e-08	0.000229	0.55	0.46	Dupuytren's disease;	chr16:75381877	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000228039.3	KB-1125A3.10	5.79	5.54e-08	0.00023	0.55	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23963780~23964374:+
ESCA	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-5.79	5.54e-08	0.00023	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-5.79	5.54e-08	0.00023	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
ESCA	cis	rs2882667	0.898	rs11749944	ENSG00000253404.1	AC034243.1	5.79	5.55e-08	0.00023	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139077090	chr5:138744434~138753309:-
ESCA	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	5.79	5.6e-08	0.000232	0.61	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
ESCA	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	5.79	5.6e-08	0.000232	0.63	0.46	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
ESCA	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	5.79	5.6e-08	0.000232	0.53	0.46	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
ESCA	cis	rs1799949	0.965	rs8071278	ENSG00000198496.9	NBR2	-5.79	5.6e-08	0.000232	-0.5	-0.46	Menopause (age at onset);	chr17:43041893	chr17:43125610~43153671:+
ESCA	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	5.79	5.61e-08	0.000232	0.63	0.46	Depression;	chr6:28399846	chr6:28176188~28176674:+
ESCA	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	5.79	5.62e-08	0.000233	0.5	0.46	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	5.79	5.63e-08	0.000233	0.51	0.46	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	5.79	5.64e-08	0.000233	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
ESCA	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-5.78	5.65e-08	0.000234	-0.48	-0.46	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
ESCA	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	5.78	5.68e-08	0.000235	0.53	0.46	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000250470.1	AP000351.3	-5.78	5.68e-08	0.000235	-0.61	-0.46	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23976904~23977585:-
ESCA	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-5.78	5.68e-08	0.000235	-0.54	-0.46	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
ESCA	cis	rs6479891	0.818	rs9415700	ENSG00000235816.3	PRELID1P3	5.78	5.68e-08	0.000235	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63385805	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9415701	ENSG00000235816.3	PRELID1P3	5.78	5.68e-08	0.000235	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63391749	chr10:63427297~63427939:+
ESCA	cis	rs9549367	0.789	rs2302754	ENSG00000269125.1	RP11-98F14.11	5.78	5.7e-08	0.000236	0.53	0.46	Platelet distribution width;	chr13:113244071	chr13:113165002~113165183:-
ESCA	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-5.78	5.71e-08	0.000236	-0.56	-0.46	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-5.78	5.72e-08	0.000236	-0.54	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
ESCA	cis	rs7924176	0.521	rs1904062	ENSG00000236900.1	TIMM9P1	-5.78	5.72e-08	0.000236	-0.57	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74309665	chr10:74344550~74344805:-
ESCA	cis	rs9549367	0.774	rs9549696	ENSG00000269125.1	RP11-98F14.11	-5.78	5.73e-08	0.000237	-0.52	-0.46	Platelet distribution width;	chr13:113220748	chr13:113165002~113165183:-
ESCA	cis	rs7924176	0.521	rs7477710	ENSG00000236900.1	TIMM9P1	-5.78	5.73e-08	0.000237	-0.56	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74275444	chr10:74344550~74344805:-
ESCA	cis	rs9457247	0.566	rs10946207	ENSG00000265828.1	MIR3939	-5.78	5.75e-08	0.000238	-0.51	-0.46	Crohn's disease;	chr6:167042548	chr6:166997807~166997912:-
ESCA	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-5.78	5.76e-08	0.000238	-0.41	-0.46	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
ESCA	cis	rs13217239	0.646	rs4403259	ENSG00000243307.2	POM121L6P	5.78	5.77e-08	0.000238	0.5	0.46	Schizophrenia;	chr6:27029838	chr6:26896952~26898777:+
ESCA	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-5.78	5.79e-08	0.000239	-0.58	-0.46	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
ESCA	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	5.78	5.79e-08	0.000239	0.51	0.46	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
ESCA	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-5.78	5.8e-08	0.000239	-0.5	-0.46	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
ESCA	cis	rs2221894	0.959	rs2129784	ENSG00000273710.1	Metazoa_SRP	5.78	5.84e-08	0.000241	0.54	0.46	Obesity-related traits;	chr8:29042480	chr8:28915579~28915864:-
ESCA	cis	rs2929278	0.546	rs686666	ENSG00000205771.5	CATSPER2P1	-5.78	5.85e-08	0.000241	-0.6	-0.46	Schizophrenia;	chr15:43869352	chr15:43726918~43747094:-
ESCA	cis	rs977987	0.806	rs56343285	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75375899	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs1544810	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75377265	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs11858992	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75377547	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4993970	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75377721	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.736	rs4888392	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75378364	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11860284	ENSG00000261783.1	RP11-252K23.2	-5.78	5.87e-08	0.000241	-0.55	-0.46	Dupuytren's disease;	chr16:75379009	chr16:75379818~75381260:-
ESCA	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-5.78	5.88e-08	0.000242	-0.46	-0.46	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
ESCA	cis	rs977987	0.843	rs4888415	ENSG00000261783.1	RP11-252K23.2	-5.77	5.93e-08	0.000244	-0.57	-0.46	Dupuytren's disease;	chr16:75415023	chr16:75379818~75381260:-
ESCA	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-5.77	5.93e-08	0.000244	-0.56	-0.46	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
ESCA	cis	rs9457247	0.663	rs1894603	ENSG00000265828.1	MIR3939	5.77	5.94e-08	0.000244	0.48	0.46	Crohn's disease;	chr6:167021198	chr6:166997807~166997912:-
ESCA	cis	rs2929278	0.617	rs533143	ENSG00000205771.5	CATSPER2P1	-5.77	5.94e-08	0.000244	-0.61	-0.46	Schizophrenia;	chr15:43896656	chr15:43726918~43747094:-
ESCA	cis	rs9457247	0.765	rs6904946	ENSG00000265828.1	MIR3939	5.77	5.96e-08	0.000245	0.51	0.46	Crohn's disease;	chr6:167020460	chr6:166997807~166997912:-
ESCA	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	5.77	5.97e-08	0.000245	0.73	0.46	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
ESCA	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	5.77	5.97e-08	0.000245	0.48	0.46	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
ESCA	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-5.77	5.97e-08	0.000245	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-5.77	5.97e-08	0.000245	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-5.77	5.97e-08	0.000245	-0.62	-0.46	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
ESCA	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-5.77	5.99e-08	0.000246	-0.47	-0.46	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
ESCA	cis	rs748404	0.697	rs1095389	ENSG00000249839.1	AC011330.5	-5.77	6.03e-08	0.000247	-0.58	-0.46	Lung cancer;	chr15:43274473	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs473554	ENSG00000249839.1	AC011330.5	-5.77	6.03e-08	0.000247	-0.58	-0.46	Lung cancer;	chr15:43276009	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs530683	ENSG00000249839.1	AC011330.5	5.77	6.03e-08	0.000247	0.58	0.46	Lung cancer;	chr15:43276801	chr15:43663654~43684339:-
ESCA	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	5.77	6.04e-08	0.000248	0.46	0.46	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	5.77	6.04e-08	0.000248	0.46	0.46	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
ESCA	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	5.77	6.05e-08	0.000248	0.59	0.46	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
ESCA	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-5.77	6.06e-08	0.000248	-0.46	-0.46	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
ESCA	cis	rs13217239	0.646	rs10946897	ENSG00000243307.2	POM121L6P	5.77	6.07e-08	0.000249	0.5	0.46	Schizophrenia;	chr6:27027472	chr6:26896952~26898777:+
ESCA	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	5.77	6.07e-08	0.000249	0.61	0.46	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
ESCA	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	5.77	6.07e-08	0.000249	0.61	0.46	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
ESCA	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-5.77	6.1e-08	0.00025	-0.93	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
ESCA	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	5.77	6.12e-08	0.00025	0.51	0.46	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
ESCA	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-5.77	6.14e-08	0.000251	-0.74	-0.46	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
ESCA	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-5.77	6.15e-08	0.000251	-0.76	-0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-5.77	6.16e-08	0.000252	-0.59	-0.46	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
ESCA	cis	rs977987	0.843	rs62062564	ENSG00000261783.1	RP11-252K23.2	-5.77	6.17e-08	0.000252	-0.57	-0.46	Dupuytren's disease;	chr16:75408724	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs62062568	ENSG00000261783.1	RP11-252K23.2	-5.77	6.17e-08	0.000252	-0.57	-0.46	Dupuytren's disease;	chr16:75411426	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-5.77	6.18e-08	0.000252	-0.51	-0.46	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
ESCA	cis	rs847845	0.614	rs4646947	ENSG00000186328.4	RP11-140K17.2	5.76	6.2e-08	0.000253	1.11	0.46	Non-small cell lung cancer;	chr6:34878500	chr6:34715613~34715940:+
ESCA	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-5.76	6.22e-08	0.000254	-0.61	-0.46	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs1617484	ENSG00000179406.6	LINC00174	-5.76	6.22e-08	0.000254	-0.54	-0.46	Aortic root size;	chr7:65998108	chr7:66376044~66401338:-
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-5.76	6.25e-08	0.000255	-0.56	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
ESCA	cis	rs2439831	0.702	rs8033995	ENSG00000249839.1	AC011330.5	-5.76	6.3e-08	0.000257	-0.79	-0.46	Lung cancer in ever smokers;	chr15:43721311	chr15:43663654~43684339:-
ESCA	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	5.76	6.31e-08	0.000257	0.49	0.46	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	5.76	6.34e-08	0.000258	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	5.76	6.34e-08	0.000258	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	5.76	6.34e-08	0.000258	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	5.76	6.34e-08	0.000258	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	5.76	6.34e-08	0.000258	0.7	0.46	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
ESCA	cis	rs2221894	0.959	rs28679662	ENSG00000273710.1	Metazoa_SRP	5.76	6.35e-08	0.000258	0.54	0.46	Obesity-related traits;	chr8:29033270	chr8:28915579~28915864:-
ESCA	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-5.76	6.4e-08	0.00026	-0.52	-0.46	Breast cancer;	chr11:743813	chr11:779617~780755:+
ESCA	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	5.76	6.4e-08	0.00026	0.66	0.46	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	5.76	6.4e-08	0.00026	0.66	0.46	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
ESCA	cis	rs2882667	0.931	rs7720150	ENSG00000253404.1	AC034243.1	5.76	6.43e-08	0.000261	0.62	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:138998380	chr5:138744434~138753309:-
ESCA	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	5.76	6.43e-08	0.000261	0.61	0.46	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
ESCA	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-5.76	6.44e-08	0.000262	-0.56	-0.46	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-5.76	6.44e-08	0.000262	-0.56	-0.46	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
ESCA	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-5.76	6.45e-08	0.000262	-0.59	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
ESCA	cis	rs6940638	0.531	rs12211984	ENSG00000243307.2	POM121L6P	5.76	6.45e-08	0.000262	0.5	0.46	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs10456351	ENSG00000243307.2	POM121L6P	5.76	6.45e-08	0.000262	0.5	0.46	Schizophrenia;	chr6:27019013	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs10456352	ENSG00000243307.2	POM121L6P	5.76	6.45e-08	0.000262	0.5	0.46	Schizophrenia;	chr6:27022579	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs4583981	ENSG00000243307.2	POM121L6P	5.76	6.45e-08	0.000262	0.5	0.46	Schizophrenia;	chr6:27024244	chr6:26896952~26898777:+
ESCA	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-5.76	6.46e-08	0.000262	-0.55	-0.46	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
ESCA	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	5.76	6.47e-08	0.000262	0.7	0.46	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
ESCA	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	5.76	6.47e-08	0.000262	0.64	0.46	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
ESCA	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-5.76	6.48e-08	0.000263	-0.55	-0.46	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
ESCA	cis	rs9549367	0.789	rs9549711	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113246243	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.756	rs2316463	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113247092	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.737	rs9549712	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113248041	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.774	rs9549364	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113249431	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.737	rs11619691	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113250322	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.826	rs9549713	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113250994	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs3850451	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113251498	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs3861720	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113251783	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.865	rs3861721	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113251994	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs7994324	ENSG00000269125.1	RP11-98F14.11	-5.76	6.48e-08	0.000263	-0.52	-0.46	Platelet distribution width;	chr13:113252183	chr13:113165002~113165183:-
ESCA	cis	rs10875746	0.855	rs12296244	ENSG00000240399.1	RP1-228P16.1	-5.75	6.5e-08	0.000264	-0.57	-0.46	Longevity (90 years and older);	chr12:48047696	chr12:48054813~48055591:-
ESCA	cis	rs13217239	0.646	rs10946898	ENSG00000243307.2	POM121L6P	5.75	6.51e-08	0.000264	0.5	0.46	Schizophrenia;	chr6:27036105	chr6:26896952~26898777:+
ESCA	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.53e-08	0.000265	-0.56	-0.46	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.53e-08	0.000265	-0.56	-0.46	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.53e-08	0.000265	-0.56	-0.46	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
ESCA	cis	rs7924176	0.502	rs12784355	ENSG00000236900.1	TIMM9P1	-5.75	6.54e-08	0.000265	-0.54	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74386487	chr10:74344550~74344805:-
ESCA	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-5.75	6.54e-08	0.000265	-0.6	-0.46	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
ESCA	cis	rs950880	0.71	rs55645612	ENSG00000234389.1	AC007278.3	-5.75	6.58e-08	0.000266	-0.43	-0.46	Serum protein levels (sST2);	chr2:102439201	chr2:102438713~102440475:+
ESCA	cis	rs6782228	0.565	rs67445542	ENSG00000277250.1	Metazoa_SRP	-5.75	6.59e-08	0.000267	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.585	rs9841161	ENSG00000277250.1	Metazoa_SRP	-5.75	6.59e-08	0.000267	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs2712405	ENSG00000277250.1	Metazoa_SRP	-5.75	6.59e-08	0.000267	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs9828893	ENSG00000277250.1	Metazoa_SRP	-5.75	6.59e-08	0.000267	-0.53	-0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128673681~128674021:-
ESCA	cis	rs9457247	0.663	rs2282861	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167026640	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs2282860	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167026756	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.579	rs2181059	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167028136	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs2237277	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167028619	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs9457258	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167030766	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs10946205	ENSG00000265828.1	MIR3939	-5.75	6.61e-08	0.000268	-0.49	-0.46	Crohn's disease;	chr6:167037823	chr6:166997807~166997912:-
ESCA	cis	rs2739330	0.791	rs9612520	ENSG00000099984.9	GSTT2	-5.75	6.63e-08	0.000268	-0.56	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23980123~23983911:+
ESCA	cis	rs2729354	0.779	rs2511984	ENSG00000265566.2	RN7SL605P	-5.75	6.64e-08	0.000268	-0.65	-0.46	Blood protein levels;	chr11:57511260	chr11:57528085~57528365:-
ESCA	cis	rs1005277	0.579	rs1780130	ENSG00000276805.1	RP11-291L22.6	5.75	6.67e-08	0.00027	0.59	0.46	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38451030~38451785:+
ESCA	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	5.75	6.68e-08	0.00027	0.59	0.46	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
ESCA	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-5.75	6.68e-08	0.00027	-0.56	-0.46	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
ESCA	cis	rs1577917	1	rs6933377	ENSG00000203875.9	SNHG5	5.75	6.69e-08	0.00027	0.53	0.46	Response to antipsychotic treatment;	chr6:85995537	chr6:85660950~85678736:-
ESCA	cis	rs7829975	0.514	rs2920983	ENSG00000253981.4	ALG1L13P	5.75	6.73e-08	0.000272	0.53	0.46	Mood instability;	chr8:8410553	chr8:8236003~8244667:-
ESCA	cis	rs9457247	0.508	rs2285147	ENSG00000265828.1	MIR3939	-5.75	6.73e-08	0.000272	-0.49	-0.46	Crohn's disease;	chr6:167092060	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.508	rs6902119	ENSG00000265828.1	MIR3939	-5.75	6.73e-08	0.000272	-0.49	-0.46	Crohn's disease;	chr6:167092303	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.508	rs6918286	ENSG00000265828.1	MIR3939	-5.75	6.73e-08	0.000272	-0.49	-0.46	Crohn's disease;	chr6:167092341	chr6:166997807~166997912:-
ESCA	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-5.75	6.75e-08	0.000272	-0.47	-0.46	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
ESCA	cis	rs7924176	0.601	rs10824073	ENSG00000236900.1	TIMM9P1	-5.75	6.76e-08	0.000273	-0.54	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74115458	chr10:74344550~74344805:-
ESCA	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	5.75	6.77e-08	0.000273	0.48	0.46	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-5.75	6.77e-08	0.000273	-0.46	-0.46	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-5.74	6.8e-08	0.000274	-0.46	-0.46	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
ESCA	cis	rs875971	1	rs709597	ENSG00000179406.6	LINC00174	5.74	6.86e-08	0.000276	0.51	0.46	Aortic root size;	chr7:66360996	chr7:66376044~66401338:-
ESCA	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-5.74	6.86e-08	0.000276	-0.56	-0.46	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
ESCA	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	5.74	6.86e-08	0.000277	0.49	0.46	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
ESCA	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	5.74	6.94e-08	0.000279	0.5	0.46	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	5.74	6.94e-08	0.000279	0.5	0.46	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
ESCA	cis	rs2221894	0.922	rs4407834	ENSG00000273710.1	Metazoa_SRP	-5.74	6.94e-08	0.000279	-0.5	-0.46	Obesity-related traits;	chr8:28984304	chr8:28915579~28915864:-
ESCA	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-5.74	6.96e-08	0.00028	-0.65	-0.46	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
ESCA	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-5.74	6.98e-08	0.00028	-0.56	-0.46	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
ESCA	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	5.74	7.03e-08	0.000282	0.58	0.46	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.862	rs6460302	ENSG00000179406.6	LINC00174	-5.74	7.03e-08	0.000282	-0.51	-0.46	Aortic root size;	chr7:66495270	chr7:66376044~66401338:-
ESCA	cis	rs9457247	0.508	rs7760495	ENSG00000265828.1	MIR3939	-5.74	7.05e-08	0.000283	-0.5	-0.46	Crohn's disease;	chr6:167093307	chr6:166997807~166997912:-
ESCA	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	5.74	7.07e-08	0.000283	0.56	0.46	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
ESCA	cis	rs10875746	0.951	rs10875748	ENSG00000240399.1	RP1-228P16.1	-5.74	7.1e-08	0.000284	-0.58	-0.46	Longevity (90 years and older);	chr12:48132577	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.951	rs2286021	ENSG00000240399.1	RP1-228P16.1	-5.74	7.1e-08	0.000284	-0.58	-0.46	Longevity (90 years and older);	chr12:48134437	chr12:48054813~48055591:-
ESCA	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	5.73	7.18e-08	0.000288	0.48	0.46	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
ESCA	cis	rs7412746	0.622	rs11552229	ENSG00000206931.1	RNU6-1042P	5.73	7.25e-08	0.00029	0.6	0.46	Melanoma;	chr1:150811509	chr1:150701866~150701972:+
ESCA	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	5.73	7.29e-08	0.000292	0.58	0.46	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
ESCA	cis	rs875971	0.597	rs11771318	ENSG00000226824.5	RP4-756H11.3	5.73	7.34e-08	0.000293	0.51	0.46	Aortic root size;	chr7:66597493	chr7:66654538~66669855:+
ESCA	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-5.73	7.34e-08	0.000293	-0.74	-0.46	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
ESCA	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	5.73	7.36e-08	0.000294	0.55	0.46	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
ESCA	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-5.73	7.4e-08	0.000296	-0.6	-0.46	Depression;	chr6:28422360	chr6:28176188~28176674:+
ESCA	cis	rs7412746	0.658	rs10305714	ENSG00000206931.1	RNU6-1042P	-5.73	7.41e-08	0.000296	-0.58	-0.46	Melanoma;	chr1:150828179	chr1:150701866~150701972:+
ESCA	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-5.73	7.42e-08	0.000296	-0.54	-0.46	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-5.73	7.42e-08	0.000296	-0.54	-0.46	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-5.73	7.42e-08	0.000296	-0.54	-0.46	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
ESCA	cis	rs875971	1	rs6945843	ENSG00000179406.6	LINC00174	5.73	7.42e-08	0.000296	0.51	0.46	Aortic root size;	chr7:66269796	chr7:66376044~66401338:-
ESCA	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	5.73	7.44e-08	0.000297	0.55	0.46	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
ESCA	cis	rs977987	0.806	rs4888383	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75352451	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8050769	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75354536	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8050059	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75354833	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs6564252	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75355042	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs2113232	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75357287	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs35263058	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75358039	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs1895490	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75358908	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888388	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75360250	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs7185640	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75360501	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11640674	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75361046	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888389	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75361330	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11865004	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75361879	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs1364077	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75363093	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs4887820	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75363389	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs34222958	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75364354	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs4887821	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75364676	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11640473	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75369391	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8057203	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75371076	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs35552529	ENSG00000261783.1	RP11-252K23.2	-5.73	7.45e-08	0.000297	-0.55	-0.46	Dupuytren's disease;	chr16:75371981	chr16:75379818~75381260:-
ESCA	cis	rs13217239	0.646	rs35691005	ENSG00000243307.2	POM121L6P	5.72	7.47e-08	0.000297	0.5	0.46	Schizophrenia;	chr6:27004291	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs10946891	ENSG00000243307.2	POM121L6P	5.72	7.47e-08	0.000297	0.5	0.46	Schizophrenia;	chr6:27005436	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs12201393	ENSG00000243307.2	POM121L6P	5.72	7.47e-08	0.000297	0.5	0.46	Schizophrenia;	chr6:27007911	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs12209886	ENSG00000243307.2	POM121L6P	5.72	7.47e-08	0.000297	0.5	0.46	Schizophrenia;	chr6:27016978	chr6:26896952~26898777:+
ESCA	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-5.72	7.48e-08	0.000298	-0.47	-0.46	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
ESCA	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	5.72	7.53e-08	0.000299	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	5.72	7.53e-08	0.000299	0.58	0.46	Depression;	chr6:28399886	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	5.72	7.53e-08	0.000299	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	5.72	7.53e-08	0.000299	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	5.72	7.53e-08	0.000299	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
ESCA	cis	rs17361889	0.806	rs1918259	ENSG00000224683.1	RPL36AP29	5.72	7.53e-08	0.000299	0.56	0.46	Pediatric bone mineral content (hip);	chr7:16205732	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.766	rs1527220	ENSG00000224683.1	RPL36AP29	5.72	7.53e-08	0.000299	0.56	0.46	Pediatric bone mineral content (hip);	chr7:16206354	chr7:16208945~16209265:+
ESCA	cis	rs6782228	1	rs35871360	ENSG00000277250.1	Metazoa_SRP	5.72	7.57e-08	0.000301	0.59	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128673681~128674021:-
ESCA	cis	rs6940638	0.513	rs4424065	ENSG00000243307.2	POM121L6P	-5.72	7.6e-08	0.000302	-0.5	-0.46	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26896952~26898777:+
ESCA	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-5.72	7.61e-08	0.000302	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
ESCA	cis	rs9545047	0.967	rs9574402	ENSG00000227676.3	LINC01068	5.72	7.61e-08	0.000302	0.59	0.46	Schizophrenia;	chr13:79298392	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	5.72	7.64e-08	0.000303	0.49	0.46	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
ESCA	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.72	7.66e-08	0.000303	0.68	0.46	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
ESCA	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-5.72	7.7e-08	0.000305	-0.46	-0.46	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-5.72	7.7e-08	0.000305	-0.46	-0.46	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
ESCA	cis	rs2221894	0.96	rs1487970	ENSG00000273710.1	Metazoa_SRP	5.72	7.73e-08	0.000306	0.51	0.46	Obesity-related traits;	chr8:29031649	chr8:28915579~28915864:-
ESCA	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	5.72	7.74e-08	0.000306	0.59	0.46	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
ESCA	cis	rs181553	0.504	rs7237062	ENSG00000266696.1	RP11-30L3.2	5.72	7.77e-08	0.000307	0.51	0.46	Hip circumference adjusted for BMI;	chr18:49200883	chr18:49205912~49208781:+
ESCA	cis	rs9549367	0.826	rs9549710	ENSG00000269125.1	RP11-98F14.11	-5.72	7.79e-08	0.000307	-0.52	-0.46	Platelet distribution width;	chr13:113243750	chr13:113165002~113165183:-
ESCA	cis	rs9545047	0.716	rs9545053	ENSG00000227676.3	LINC01068	5.72	7.81e-08	0.000308	0.6	0.46	Schizophrenia;	chr13:79296079	chr13:79566727~79571436:+
ESCA	cis	rs9457247	0.663	rs6456143	ENSG00000265828.1	MIR3939	-5.72	7.81e-08	0.000308	-0.49	-0.46	Crohn's disease;	chr6:167001952	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs9459835	ENSG00000265828.1	MIR3939	-5.72	7.81e-08	0.000308	-0.49	-0.46	Crohn's disease;	chr6:167004063	chr6:166997807~166997912:-
ESCA	cis	rs950880	0.71	rs56117144	ENSG00000234389.1	AC007278.3	-5.71	7.82e-08	0.000308	-0.42	-0.46	Serum protein levels (sST2);	chr2:102458191	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs57081652	ENSG00000234389.1	AC007278.3	-5.71	7.82e-08	0.000308	-0.42	-0.46	Serum protein levels (sST2);	chr2:102458921	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.614	rs60038017	ENSG00000234389.1	AC007278.3	-5.71	7.82e-08	0.000308	-0.42	-0.46	Serum protein levels (sST2);	chr2:102459541	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs17027230	ENSG00000234389.1	AC007278.3	-5.71	7.82e-08	0.000308	-0.42	-0.46	Serum protein levels (sST2);	chr2:102462870	chr2:102438713~102440475:+
ESCA	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-5.71	7.85e-08	0.00031	-0.4	-0.46	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
ESCA	cis	rs1799949	0.859	rs11657004	ENSG00000198496.9	NBR2	-5.71	7.89e-08	0.000311	-0.5	-0.46	Menopause (age at onset);	chr17:43365383	chr17:43125610~43153671:+
ESCA	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-5.71	7.92e-08	0.000312	-0.65	-0.46	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000231271.1	AP000350.8	5.71	7.93e-08	0.000312	0.57	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23949918~23954042:+
ESCA	cis	rs977987	0.806	rs4888390	ENSG00000261783.1	RP11-252K23.2	-5.71	7.94e-08	0.000313	-0.55	-0.46	Dupuytren's disease;	chr16:75366422	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888391	ENSG00000261783.1	RP11-252K23.2	-5.71	7.94e-08	0.000313	-0.55	-0.46	Dupuytren's disease;	chr16:75366848	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs8054769	ENSG00000261783.1	RP11-252K23.2	-5.71	7.94e-08	0.000313	-0.55	-0.46	Dupuytren's disease;	chr16:75367215	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs35415181	ENSG00000261783.1	RP11-252K23.2	-5.71	7.94e-08	0.000313	-0.55	-0.46	Dupuytren's disease;	chr16:75369226	chr16:75379818~75381260:-
ESCA	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
ESCA	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-5.71	7.97e-08	0.000313	-0.48	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
ESCA	cis	rs950880	0.71	rs56166614	ENSG00000234389.1	AC007278.3	-5.71	8e-08	0.000314	-0.42	-0.46	Serum protein levels (sST2);	chr2:102439636	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs17027179	ENSG00000234389.1	AC007278.3	-5.71	8e-08	0.000314	-0.42	-0.46	Serum protein levels (sST2);	chr2:102440699	chr2:102438713~102440475:+
ESCA	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-5.71	8e-08	0.000314	-0.56	-0.46	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
ESCA	cis	rs7924176	0.521	rs11000960	ENSG00000236900.1	TIMM9P1	-5.71	8.01e-08	0.000314	-0.55	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74288349	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs10824142	ENSG00000236900.1	TIMM9P1	-5.71	8.01e-08	0.000314	-0.55	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74290249	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs11000965	ENSG00000236900.1	TIMM9P1	-5.71	8.01e-08	0.000314	-0.55	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74294019	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.521	rs12357370	ENSG00000236900.1	TIMM9P1	-5.71	8.01e-08	0.000314	-0.55	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74296329	chr10:74344550~74344805:-
ESCA	cis	rs875971	0.54	rs1723268	ENSG00000179406.6	LINC00174	-5.71	8.01e-08	0.000314	-0.53	-0.46	Aortic root size;	chr7:66008093	chr7:66376044~66401338:-
ESCA	cis	rs1005277	0.579	rs2749616	ENSG00000276805.1	RP11-291L22.6	5.71	8.03e-08	0.000315	0.61	0.46	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780146	ENSG00000276805.1	RP11-291L22.6	5.71	8.03e-08	0.000315	0.61	0.46	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38451030~38451785:+
ESCA	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	5.71	8.07e-08	0.000316	0.5	0.46	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
ESCA	cis	rs6782228	1	rs7429360	ENSG00000277250.1	Metazoa_SRP	5.71	8.07e-08	0.000316	0.59	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128673681~128674021:-
ESCA	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	5.71	8.07e-08	0.000316	0.6	0.46	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-5.71	8.09e-08	0.000317	-0.5	-0.46	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-5.71	8.09e-08	0.000317	-0.5	-0.46	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
ESCA	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-5.71	8.1e-08	0.000317	-0.47	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
ESCA	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-5.71	8.17e-08	0.000319	-0.58	-0.46	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
ESCA	cis	rs1799949	0.931	rs9912203	ENSG00000198496.9	NBR2	5.71	8.17e-08	0.00032	0.49	0.46	Menopause (age at onset);	chr17:43367777	chr17:43125610~43153671:+
ESCA	cis	rs1799949	0.931	rs34474989	ENSG00000198496.9	NBR2	-5.71	8.17e-08	0.00032	-0.49	-0.46	Menopause (age at onset);	chr17:43368042	chr17:43125610~43153671:+
ESCA	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
ESCA	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	5.7	8.19e-08	0.00032	0.49	0.46	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
ESCA	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-5.7	8.2e-08	0.00032	-0.62	-0.46	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
ESCA	cis	rs2455601	0.529	rs2653569	ENSG00000254860.4	TMEM9B-AS1	5.7	8.2e-08	0.00032	0.61	0.46	Schizophrenia;	chr11:8965431	chr11:8964675~8977527:+
ESCA	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	5.7	8.31e-08	0.000324	0.49	0.46	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
ESCA	cis	rs6479891	0.915	rs2616628	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63460197	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs2393980	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63464750	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.818	rs59215788	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63474074	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs59246603	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63474182	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12414159	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63479017	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs10995543	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63479787	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4746138	ENSG00000235816.3	PRELID1P3	5.7	8.31e-08	0.000324	0.62	0.46	Arthritis (juvenile idiopathic);	chr10:63481981	chr10:63427297~63427939:+
ESCA	cis	rs801193	0.967	rs34356500	ENSG00000179406.6	LINC00174	-5.7	8.33e-08	0.000325	-0.5	-0.46	Aortic root size;	chr7:66771620	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.904	rs4718405	ENSG00000179406.6	LINC00174	-5.7	8.33e-08	0.000325	-0.5	-0.46	Aortic root size;	chr7:66789659	chr7:66376044~66401338:-
ESCA	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-5.7	8.34e-08	0.000325	-0.76	-0.46	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
ESCA	cis	rs977987	0.806	rs4993969	ENSG00000261783.1	RP11-252K23.2	-5.7	8.34e-08	0.000325	-0.53	-0.46	Dupuytren's disease;	chr16:75377623	chr16:75379818~75381260:-
ESCA	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	5.7	8.35e-08	0.000325	0.59	0.46	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
ESCA	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-5.7	8.35e-08	0.000325	-0.54	-0.46	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000231271.1	AP000350.8	-5.7	8.36e-08	0.000325	-0.56	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23949918~23954042:+
ESCA	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	5.7	8.37e-08	0.000325	0.47	0.46	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	5.7	8.37e-08	0.000325	0.47	0.46	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
ESCA	cis	rs7924176	0.601	rs11000882	ENSG00000236900.1	TIMM9P1	-5.7	8.38e-08	0.000326	-0.54	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74130145	chr10:74344550~74344805:-
ESCA	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	5.7	8.42e-08	0.000327	0.57	0.46	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
ESCA	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	5.7	8.46e-08	0.000329	0.5	0.46	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
ESCA	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	5.7	8.46e-08	0.000329	0.61	0.46	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
ESCA	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-5.7	8.47e-08	0.000329	-0.55	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
ESCA	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-5.7	8.48e-08	0.000329	-0.47	-0.46	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-5.7	8.48e-08	0.000329	-0.47	-0.46	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
ESCA	cis	rs2739330	0.731	rs4822450	ENSG00000231271.1	AP000350.8	5.7	8.48e-08	0.000329	0.53	0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23949918~23954042:+
ESCA	cis	rs875971	0.862	rs10282433	ENSG00000179406.6	LINC00174	5.7	8.49e-08	0.000329	0.51	0.46	Aortic root size;	chr7:66256452	chr7:66376044~66401338:-
ESCA	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-5.7	8.5e-08	0.00033	-0.57	-0.46	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
ESCA	cis	rs10875746	0.903	rs12313404	ENSG00000240399.1	RP1-228P16.1	-5.7	8.5e-08	0.00033	-0.57	-0.46	Longevity (90 years and older);	chr12:48098265	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.855	rs73102065	ENSG00000240399.1	RP1-228P16.1	-5.7	8.5e-08	0.00033	-0.57	-0.46	Longevity (90 years and older);	chr12:48098824	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.855	rs73102067	ENSG00000240399.1	RP1-228P16.1	-5.7	8.5e-08	0.00033	-0.57	-0.46	Longevity (90 years and older);	chr12:48100643	chr12:48054813~48055591:-
ESCA	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.7	8.55e-08	0.000332	0.45	0.46	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
ESCA	cis	rs6456156	0.586	rs4710176	ENSG00000265828.1	MIR3939	-5.7	8.55e-08	0.000332	-0.5	-0.46	Primary biliary cholangitis;	chr6:167078151	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.508	rs9459874	ENSG00000265828.1	MIR3939	5.7	8.56e-08	0.000332	0.49	0.46	Crohn's disease;	chr6:167090639	chr6:166997807~166997912:-
ESCA	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	5.7	8.57e-08	0.000333	0.63	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-5.69	8.59e-08	0.000333	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-5.69	8.59e-08	0.000333	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-5.69	8.59e-08	0.000333	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
ESCA	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.69	8.61e-08	0.000333	0.45	0.46	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	5.69	8.62e-08	0.000334	0.49	0.46	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
ESCA	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-5.69	8.62e-08	0.000334	-0.71	-0.46	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
ESCA	cis	rs801193	1	rs2659915	ENSG00000179406.6	LINC00174	-5.69	8.65e-08	0.000335	-0.51	-0.46	Aortic root size;	chr7:66688114	chr7:66376044~66401338:-
ESCA	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-5.69	8.67e-08	0.000336	-0.65	-0.46	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
ESCA	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	5.69	8.7e-08	0.000337	0.6	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
ESCA	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-5.69	8.7e-08	0.000337	-0.53	-0.46	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
ESCA	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	5.69	8.72e-08	0.000337	0.58	0.46	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
ESCA	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-5.69	8.73e-08	0.000338	-0.64	-0.46	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
ESCA	cis	rs7829975	0.514	rs2979139	ENSG00000253981.4	ALG1L13P	5.69	8.83e-08	0.000341	0.53	0.46	Mood instability;	chr8:8410803	chr8:8236003~8244667:-
ESCA	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-5.69	8.87e-08	0.000343	-0.61	-0.46	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
ESCA	cis	rs2882667	0.898	rs11956089	ENSG00000253404.1	AC034243.1	-5.69	8.91e-08	0.000344	-0.61	-0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139058915	chr5:138744434~138753309:-
ESCA	cis	rs977987	0.806	rs2903033	ENSG00000261783.1	RP11-252K23.2	-5.69	8.94e-08	0.000345	-0.55	-0.46	Dupuytren's disease;	chr16:75355708	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.771	rs4888387	ENSG00000261783.1	RP11-252K23.2	-5.69	8.94e-08	0.000345	-0.55	-0.46	Dupuytren's disease;	chr16:75355857	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs2865531	ENSG00000261783.1	RP11-252K23.2	-5.69	8.94e-08	0.000345	-0.55	-0.46	Dupuytren's disease;	chr16:75356418	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000250470.1	AP000351.3	-5.69	8.95e-08	0.000345	-0.6	-0.46	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23976904~23977585:-
ESCA	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-5.69	8.95e-08	0.000345	-0.62	-0.46	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
ESCA	cis	rs7924176	0.564	rs34868542	ENSG00000236900.1	TIMM9P1	-5.69	8.97e-08	0.000346	-0.56	-0.46	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74226399	chr10:74344550~74344805:-
ESCA	cis	rs7412746	0.611	rs2864873	ENSG00000206931.1	RNU6-1042P	5.68	9e-08	0.000347	0.59	0.46	Melanoma;	chr1:150841698	chr1:150701866~150701972:+
ESCA	cis	rs9545047	0.645	rs9635027	ENSG00000227676.3	LINC01068	5.68	9.02e-08	0.000348	0.59	0.46	Schizophrenia;	chr13:79295538	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.862	rs10276077	ENSG00000179406.6	LINC00174	5.68	9.02e-08	0.000348	0.51	0.46	Aortic root size;	chr7:66263424	chr7:66376044~66401338:-
ESCA	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	5.68	9.05e-08	0.000349	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	5.68	9.05e-08	0.000349	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	5.68	9.05e-08	0.000349	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	5.68	9.05e-08	0.000349	0.58	0.46	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
ESCA	cis	rs9549367	0.789	rs9549361	ENSG00000269125.1	RP11-98F14.11	5.68	9.06e-08	0.000349	0.51	0.46	Platelet distribution width;	chr13:113244015	chr13:113165002~113165183:-
ESCA	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	5.68	9.08e-08	0.00035	0.81	0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-5.68	9.08e-08	0.00035	-0.93	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-5.68	9.08e-08	0.00035	-0.93	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-5.68	9.08e-08	0.00035	-0.93	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
ESCA	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	5.68	9.11e-08	0.000351	0.47	0.46	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
ESCA	cis	rs950880	0.71	rs11678975	ENSG00000234389.1	AC007278.3	-5.68	9.11e-08	0.000351	-0.43	-0.46	Serum protein levels (sST2);	chr2:102427279	chr2:102438713~102440475:+
ESCA	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	5.68	9.13e-08	0.000351	0.58	0.46	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
ESCA	cis	rs6538678	0.777	rs10745736	ENSG00000258343.1	RP11-536G4.2	-5.68	9.19e-08	0.000354	-0.61	-0.46	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95795345~95858839:-
ESCA	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	5.68	9.21e-08	0.000354	0.51	0.46	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	5.68	9.21e-08	0.000354	0.51	0.46	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
ESCA	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	5.68	9.24e-08	0.000355	0.59	0.46	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
ESCA	cis	rs950880	0.677	rs17027087	ENSG00000234389.1	AC007278.3	-5.68	9.34e-08	0.000358	-0.43	-0.46	Serum protein levels (sST2);	chr2:102399458	chr2:102438713~102440475:+
ESCA	cis	rs747650	0.699	rs4237547	ENSG00000271350.1	CTD-2384B9.1	-5.68	9.34e-08	0.000358	-0.53	-0.46	Acne (severe);	chr11:47214854	chr11:47041027~47041945:-
ESCA	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-5.68	9.35e-08	0.000359	-0.92	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-5.68	9.35e-08	0.000359	-0.92	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-5.68	9.35e-08	0.000359	-0.92	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-5.68	9.35e-08	0.000359	-0.92	-0.46	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
ESCA	cis	rs1075265	0.704	rs10181999	ENSG00000235937.1	AC008280.1	5.68	9.36e-08	0.000359	0.51	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54029552~54030682:-
ESCA	cis	rs950880	0.71	rs10490204	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102440074	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11123927	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102442343	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs10490203	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102442777	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs4851583	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102443840	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3771150	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102444391	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11694360	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102444687	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11123928	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102444826	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs7597017	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102445656	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.677	rs4851585	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102446294	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11123929	ENSG00000234389.1	AC007278.3	-5.68	9.38e-08	0.000359	-0.42	-0.46	Serum protein levels (sST2);	chr2:102450683	chr2:102438713~102440475:+
ESCA	cis	rs2221894	0.959	rs8180944	ENSG00000273710.1	Metazoa_SRP	5.68	9.4e-08	0.00036	0.53	0.46	Obesity-related traits;	chr8:29046569	chr8:28915579~28915864:-
ESCA	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-5.67	9.42e-08	0.000361	-0.51	-0.46	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
ESCA	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-5.67	9.53e-08	0.000365	-0.53	-0.46	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
ESCA	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	5.67	9.53e-08	0.000365	0.59	0.46	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
ESCA	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-5.67	9.54e-08	0.000365	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
ESCA	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-5.67	9.54e-08	0.000365	-0.61	-0.46	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	5.67	9.61e-08	0.000367	0.58	0.46	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.895	rs4145009	ENSG00000179406.6	LINC00174	5.67	9.78e-08	0.000373	0.51	0.45	Aortic root size;	chr7:66261628	chr7:66376044~66401338:-
ESCA	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	5.67	9.79e-08	0.000374	0.71	0.45	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
ESCA	cis	rs977987	0.778	rs2865528	ENSG00000261783.1	RP11-252K23.2	-5.67	9.8e-08	0.000374	-0.56	-0.45	Dupuytren's disease;	chr16:75422044	chr16:75379818~75381260:-
ESCA	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	5.67	9.85e-08	0.000376	0.56	0.45	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
ESCA	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	5.66	9.87e-08	0.000377	0.45	0.45	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
ESCA	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-5.66	9.9e-08	0.000378	-0.4	-0.45	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
ESCA	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-5.66	9.91e-08	0.000378	-0.46	-0.45	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
ESCA	cis	rs1075265	0.589	rs2542571	ENSG00000235937.1	AC008280.1	5.66	9.94e-08	0.000379	0.54	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54029552~54030682:-
ESCA	cis	rs6782228	0.876	rs34198449	ENSG00000277250.1	Metazoa_SRP	5.66	9.94e-08	0.000379	0.6	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128673681~128674021:-
ESCA	cis	rs1075265	0.589	rs2253760	ENSG00000235937.1	AC008280.1	5.66	9.94e-08	0.000379	0.54	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54029552~54030682:-
ESCA	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	5.66	9.97e-08	0.00038	0.57	0.45	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	5.66	9.97e-08	0.00038	0.57	0.45	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
ESCA	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-5.66	9.98e-08	0.00038	-0.46	-0.45	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
ESCA	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	5.66	1e-07	0.000382	0.59	0.45	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
ESCA	cis	rs7924176	0.601	rs7896660	ENSG00000236900.1	TIMM9P1	-5.66	1e-07	0.000382	-0.55	-0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74170399	chr10:74344550~74344805:-
ESCA	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	5.66	1.01e-07	0.000383	0.49	0.45	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	5.66	1.01e-07	0.000383	0.49	0.45	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
ESCA	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	5.66	1.01e-07	0.000384	0.67	0.45	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	5.66	1.01e-07	0.000384	0.67	0.45	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	5.66	1.01e-07	0.000384	0.67	0.45	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	5.66	1.01e-07	0.000384	0.67	0.45	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
ESCA	cis	rs950880	0.71	rs1474309	ENSG00000234389.1	AC007278.3	-5.66	1.01e-07	0.000385	-0.42	-0.45	Serum protein levels (sST2);	chr2:102474542	chr2:102438713~102440475:+
ESCA	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-5.66	1.02e-07	0.000386	-0.55	-0.45	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
ESCA	cis	rs7829975	0.514	rs2976926	ENSG00000253981.4	ALG1L13P	5.66	1.02e-07	0.000387	0.52	0.45	Mood instability;	chr8:8404114	chr8:8236003~8244667:-
ESCA	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	5.66	1.02e-07	0.000388	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
ESCA	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	5.66	1.03e-07	0.000389	0.4	0.45	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	5.66	1.03e-07	0.000389	0.4	0.45	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
ESCA	cis	rs801193	1	rs2707856	ENSG00000179406.6	LINC00174	-5.66	1.03e-07	0.000389	-0.51	-0.45	Aortic root size;	chr7:66746023	chr7:66376044~66401338:-
ESCA	cis	rs7829975	0.623	rs10087493	ENSG00000253981.4	ALG1L13P	-5.66	1.03e-07	0.00039	-0.54	-0.45	Mood instability;	chr8:8516047	chr8:8236003~8244667:-
ESCA	cis	rs9549367	0.789	rs9549708	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113237573	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs3794422	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113239415	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs34568744	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240250	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs57747440	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240436	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs34989271	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240452	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs71446679	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240507	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.737	rs71446680	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240532	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs71446682	ENSG00000269125.1	RP11-98F14.11	-5.66	1.03e-07	0.00039	-0.51	-0.45	Platelet distribution width;	chr13:113240594	chr13:113165002~113165183:-
ESCA	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-5.66	1.03e-07	0.000391	-0.51	-0.45	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
ESCA	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	5.66	1.03e-07	0.000391	0.71	0.45	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	5.66	1.03e-07	0.000391	0.71	0.45	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
ESCA	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	5.66	1.03e-07	0.000391	0.71	0.45	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
ESCA	cis	rs9322193	0.961	rs9027	ENSG00000216906.2	RP11-350J20.9	5.65	1.03e-07	0.000391	0.6	0.45	Lung cancer;	chr6:149594921	chr6:149904243~149906418:+
ESCA	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	5.65	1.04e-07	0.000392	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	5.65	1.04e-07	0.000392	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
ESCA	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-5.65	1.04e-07	0.000392	-0.47	-0.45	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
ESCA	cis	rs13217239	0.646	rs9379956	ENSG00000243307.2	POM121L6P	-5.65	1.04e-07	0.000393	-0.5	-0.45	Schizophrenia;	chr6:27065956	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs7747454	ENSG00000243307.2	POM121L6P	-5.65	1.04e-07	0.000393	-0.5	-0.45	Schizophrenia;	chr6:27066474	chr6:26896952~26898777:+
ESCA	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	5.65	1.04e-07	0.000394	0.57	0.45	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
ESCA	cis	rs10875746	0.903	rs12306451	ENSG00000240399.1	RP1-228P16.1	-5.65	1.05e-07	0.000396	-0.56	-0.45	Longevity (90 years and older);	chr12:48089458	chr12:48054813~48055591:-
ESCA	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-5.65	1.05e-07	0.000396	-0.63	-0.45	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
ESCA	cis	rs6782228	1	rs35604103	ENSG00000277250.1	Metazoa_SRP	5.65	1.05e-07	0.000398	0.59	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128673681~128674021:-
ESCA	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	5.65	1.05e-07	0.000398	0.4	0.45	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
ESCA	cis	rs35160687	0.862	rs13023154	ENSG00000273080.1	RP11-301O19.1	-5.65	1.06e-07	0.000398	-0.56	-0.45	Night sleep phenotypes;	chr2:86289861	chr2:86195590~86196049:+
ESCA	cis	rs1005277	0.579	rs1780137	ENSG00000276805.1	RP11-291L22.6	5.65	1.06e-07	0.000399	0.6	0.45	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38451030~38451785:+
ESCA	cis	rs748404	0.65	rs518234	ENSG00000249839.1	AC011330.5	-5.65	1.06e-07	0.000399	-0.58	-0.45	Lung cancer;	chr15:43281223	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.65	rs518261	ENSG00000249839.1	AC011330.5	-5.65	1.06e-07	0.000399	-0.58	-0.45	Lung cancer;	chr15:43281231	chr15:43663654~43684339:-
ESCA	cis	rs1799949	0.965	rs11080034	ENSG00000198496.9	NBR2	-5.65	1.06e-07	0.000399	-0.49	-0.45	Menopause (age at onset);	chr17:43365646	chr17:43125610~43153671:+
ESCA	cis	rs7924176	0.502	rs10824134	ENSG00000236900.1	TIMM9P1	-5.65	1.06e-07	4e-04	-0.55	-0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74261866	chr10:74344550~74344805:-
ESCA	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-5.65	1.06e-07	4e-04	-0.48	-0.45	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	5.65	1.06e-07	4e-04	0.61	0.45	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
ESCA	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-5.65	1.07e-07	0.000403	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-5.65	1.07e-07	0.000403	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-5.65	1.07e-07	0.000403	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
ESCA	cis	rs977987	0.966	rs6564261	ENSG00000261783.1	RP11-252K23.2	-5.65	1.07e-07	0.000403	-0.54	-0.45	Dupuytren's disease;	chr16:75458344	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	5.65	1.07e-07	0.000403	0.49	0.45	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	5.65	1.07e-07	0.000403	0.49	0.45	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	5.65	1.07e-07	0.000403	0.49	0.45	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	5.65	1.07e-07	0.000403	0.49	0.45	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	5.65	1.07e-07	0.000403	0.49	0.45	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-5.65	1.07e-07	0.000404	-0.46	-0.45	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
ESCA	cis	rs977987	0.778	rs11149825	ENSG00000261783.1	RP11-252K23.2	-5.65	1.07e-07	0.000404	-0.56	-0.45	Dupuytren's disease;	chr16:75400980	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12599361	ENSG00000261783.1	RP11-252K23.2	-5.65	1.07e-07	0.000404	-0.56	-0.45	Dupuytren's disease;	chr16:75401075	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12051136	ENSG00000261783.1	RP11-252K23.2	-5.65	1.07e-07	0.000404	-0.56	-0.45	Dupuytren's disease;	chr16:75401833	chr16:75379818~75381260:-
ESCA	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-5.65	1.07e-07	0.000405	-0.58	-0.45	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
ESCA	cis	rs13217239	0.646	rs11756275	ENSG00000243307.2	POM121L6P	-5.64	1.09e-07	0.000409	-0.49	-0.45	Schizophrenia;	chr6:27039334	chr6:26896952~26898777:+
ESCA	cis	rs17608059	0.566	rs17676459	ENSG00000141028.6	CDRT15P1	-5.64	1.09e-07	0.000411	-0.45	-0.45	Temperament;	chr17:14007198	chr17:14024514~14025488:+
ESCA	cis	rs17608059	0.566	rs5005684	ENSG00000141028.6	CDRT15P1	-5.64	1.09e-07	0.000411	-0.45	-0.45	Temperament;	chr17:14007316	chr17:14024514~14025488:+
ESCA	cis	rs9549260	0.753	rs10507486	ENSG00000229456.1	RLIMP1	-5.64	1.1e-07	0.000412	-0.52	-0.45	Red blood cell count;	chr13:40612364	chr13:40618738~40621348:+
ESCA	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	5.64	1.1e-07	0.000412	0.5	0.45	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs1612452	ENSG00000179406.6	LINC00174	5.64	1.1e-07	0.000412	0.53	0.45	Aortic root size;	chr7:66108909	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1167390	ENSG00000179406.6	LINC00174	5.64	1.1e-07	0.000412	0.53	0.45	Aortic root size;	chr7:66110906	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs35034167	ENSG00000179406.6	LINC00174	5.64	1.1e-07	0.000412	0.53	0.45	Aortic root size;	chr7:66115179	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	5.64	1.1e-07	0.000414	0.65	0.45	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
ESCA	cis	rs10875746	0.951	rs2228500	ENSG00000240399.1	RP1-228P16.1	5.64	1.1e-07	0.000414	0.58	0.45	Longevity (90 years and older);	chr12:48132929	chr12:48054813~48055591:-
ESCA	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-5.64	1.11e-07	0.000415	-0.56	-0.45	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
ESCA	cis	rs875971	0.522	rs1701760	ENSG00000179406.6	LINC00174	-5.64	1.11e-07	0.000416	-0.52	-0.45	Aortic root size;	chr7:66008701	chr7:66376044~66401338:-
ESCA	cis	rs9549367	0.789	rs12584981	ENSG00000269125.1	RP11-98F14.11	-5.64	1.11e-07	0.000417	-0.51	-0.45	Platelet distribution width;	chr13:113226871	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs2025247	ENSG00000269125.1	RP11-98F14.11	-5.64	1.11e-07	0.000417	-0.51	-0.45	Platelet distribution width;	chr13:113228250	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs34448227	ENSG00000269125.1	RP11-98F14.11	-5.64	1.11e-07	0.000417	-0.51	-0.45	Platelet distribution width;	chr13:113230440	chr13:113165002~113165183:-
ESCA	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	5.64	1.11e-07	0.000418	0.39	0.45	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
ESCA	cis	rs875971	0.862	rs28470208	ENSG00000179406.6	LINC00174	5.64	1.12e-07	0.000418	0.53	0.45	Aortic root size;	chr7:66119713	chr7:66376044~66401338:-
ESCA	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	5.64	1.12e-07	0.00042	0.48	0.45	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	5.64	1.12e-07	0.00042	0.48	0.45	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	5.64	1.12e-07	0.00042	0.48	0.45	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.697	rs574065	ENSG00000249839.1	AC011330.5	5.64	1.12e-07	0.000421	0.57	0.45	Lung cancer;	chr15:43258457	chr15:43663654~43684339:-
ESCA	cis	rs977987	0.751	rs56004344	ENSG00000261783.1	RP11-252K23.2	-5.64	1.12e-07	0.000421	-0.56	-0.45	Dupuytren's disease;	chr16:75440291	chr16:75379818~75381260:-
ESCA	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	5.64	1.12e-07	0.000421	0.62	0.45	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000228039.3	KB-1125A3.10	5.64	1.13e-07	0.000422	0.54	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23963780~23964374:+
ESCA	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	5.64	1.13e-07	0.000422	0.54	0.45	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
ESCA	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	5.64	1.13e-07	0.000422	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
ESCA	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	5.64	1.13e-07	0.000423	0.7	0.45	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
ESCA	cis	rs5758659	0.716	rs5758661	ENSG00000182057.4	OGFRP1	5.64	1.13e-07	0.000423	0.52	0.45	Cognitive function;	chr22:42228439	chr22:42269753~42275196:+
ESCA	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-5.64	1.13e-07	0.000423	-0.55	-0.45	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
ESCA	cis	rs17507216	0.628	rs17158396	ENSG00000278603.1	RP13-608F4.5	5.63	1.13e-07	0.000424	0.66	0.45	Excessive daytime sleepiness;	chr15:82615688	chr15:82472203~82472426:+
ESCA	cis	rs875971	0.825	rs6951503	ENSG00000179406.6	LINC00174	5.63	1.13e-07	0.000424	0.51	0.45	Aortic root size;	chr7:66253949	chr7:66376044~66401338:-
ESCA	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	5.63	1.14e-07	0.000425	0.54	0.45	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
ESCA	cis	rs801193	0.569	rs10950050	ENSG00000179406.6	LINC00174	-5.63	1.14e-07	0.000426	-0.51	-0.45	Aortic root size;	chr7:66774601	chr7:66376044~66401338:-
ESCA	cis	rs9549367	0.789	rs912012	ENSG00000269125.1	RP11-98F14.11	-5.63	1.14e-07	0.000426	-0.51	-0.45	Platelet distribution width;	chr13:113231838	chr13:113165002~113165183:-
ESCA	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-5.63	1.14e-07	0.000427	-0.7	-0.45	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
ESCA	cis	rs2739330	0.828	rs2877178	ENSG00000228039.3	KB-1125A3.10	5.63	1.14e-07	0.000427	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23963780~23964374:+
ESCA	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	5.63	1.14e-07	0.000427	0.5	0.45	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	5.63	1.14e-07	0.000427	0.5	0.45	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	5.63	1.14e-07	0.000427	0.5	0.45	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
ESCA	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.63	1.15e-07	0.00043	0.84	0.45	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
ESCA	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
ESCA	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
ESCA	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-5.63	1.15e-07	0.000431	-0.46	-0.45	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
ESCA	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	5.63	1.16e-07	0.000433	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
ESCA	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	5.63	1.17e-07	0.000435	0.45	0.45	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-5.63	1.17e-07	0.000436	-0.49	-0.45	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-5.63	1.17e-07	0.000436	-0.49	-0.45	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
ESCA	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	5.63	1.17e-07	0.000437	0.67	0.45	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	5.63	1.17e-07	0.000438	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
ESCA	cis	rs2006771	0.846	rs6518754	ENSG00000236132.1	CTA-440B3.1	-5.63	1.18e-07	0.000439	-0.53	-0.45	Nonsyndromic cleft lip with cleft palate;	chr22:31701789	chr22:31816379~31817491:-
ESCA	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-5.63	1.18e-07	0.00044	-0.61	-0.45	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
ESCA	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-5.63	1.19e-07	0.000441	-0.73	-0.45	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-5.63	1.19e-07	0.000441	-0.73	-0.45	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
ESCA	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	5.62	1.19e-07	0.000441	0.57	0.45	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
ESCA	cis	rs6479891	0.908	rs11817901	ENSG00000235816.3	PRELID1P3	5.62	1.19e-07	0.000443	0.6	0.45	Arthritis (juvenile idiopathic);	chr10:63580123	chr10:63427297~63427939:+
ESCA	cis	rs9549367	0.789	rs9549705	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113234111	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs7338235	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113234373	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs2287248	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113234912	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.826	rs2287249	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113235041	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs2287251	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113235185	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs9549718	ENSG00000269125.1	RP11-98F14.11	-5.62	1.19e-07	0.000443	-0.51	-0.45	Platelet distribution width;	chr13:113255508	chr13:113165002~113165183:-
ESCA	cis	rs977987	0.843	rs12443904	ENSG00000261783.1	RP11-252K23.2	-5.62	1.21e-07	0.000447	-0.56	-0.45	Dupuytren's disease;	chr16:75404872	chr16:75379818~75381260:-
ESCA	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-5.62	1.21e-07	0.000448	-0.41	-0.45	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-5.62	1.21e-07	0.000448	-0.41	-0.45	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
ESCA	cis	rs977987	0.843	rs10431974	ENSG00000261783.1	RP11-252K23.2	-5.62	1.22e-07	0.000451	-0.55	-0.45	Dupuytren's disease;	chr16:75401563	chr16:75379818~75381260:-
ESCA	cis	rs2882667	0.867	rs6868085	ENSG00000253404.1	AC034243.1	5.62	1.22e-07	0.000451	0.6	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139096757	chr5:138744434~138753309:-
ESCA	cis	rs694739	0.796	rs479777	ENSG00000236935.1	AP003774.1	5.62	1.22e-07	0.000452	0.54	0.45	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340005	chr11:64325050~64329504:-
ESCA	cis	rs9457247	0.663	rs9459839	ENSG00000265828.1	MIR3939	-5.62	1.22e-07	0.000452	-0.47	-0.45	Crohn's disease;	chr6:167018341	chr6:166997807~166997912:-
ESCA	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	5.62	1.23e-07	0.000453	0.58	0.45	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	5.62	1.23e-07	0.000453	0.58	0.45	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	5.62	1.23e-07	0.000453	0.58	0.45	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
ESCA	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	5.62	1.23e-07	0.000453	0.76	0.45	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	5.62	1.23e-07	0.000453	0.76	0.45	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
ESCA	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	5.62	1.23e-07	0.000453	0.59	0.45	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
ESCA	cis	rs1799949	0.965	rs4793230	ENSG00000198496.9	NBR2	-5.62	1.23e-07	0.000453	-0.49	-0.45	Menopause (age at onset);	chr17:43350035	chr17:43125610~43153671:+
ESCA	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-5.62	1.23e-07	0.000453	-0.52	-0.45	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
ESCA	cis	rs10875746	0.855	rs12310999	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48053875	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs61918774	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48054351	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.807	rs12297004	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48060037	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs58952582	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48064665	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs10875735	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48070023	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.855	rs17122620	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48070692	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.859	rs4760680	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48072914	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs11168386	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48074194	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.807	rs12313300	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48076934	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs12315625	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48078670	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs10875738	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48079956	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs12301339	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48081450	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs886588	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48083639	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs11168401	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48087736	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs12304476	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48088370	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs3782911	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48089709	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.859	rs3782910	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48089724	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs989144	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48090190	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs61918806	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48090650	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs11168403	ENSG00000240399.1	RP1-228P16.1	-5.62	1.23e-07	0.000453	-0.56	-0.45	Longevity (90 years and older);	chr12:48091175	chr12:48054813~48055591:-
ESCA	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	5.62	1.23e-07	0.000453	0.58	0.45	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
ESCA	cis	rs977987	0.778	rs1109341	ENSG00000261783.1	RP11-252K23.2	-5.62	1.23e-07	0.000454	-0.55	-0.45	Dupuytren's disease;	chr16:75411707	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	5.62	1.24e-07	0.000454	0.67	0.45	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
ESCA	cis	rs9545047	0.716	rs6563096	ENSG00000227676.3	LINC01068	-5.62	1.24e-07	0.000455	-0.6	-0.45	Schizophrenia;	chr13:79284100	chr13:79566727~79571436:+
ESCA	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	5.62	1.24e-07	0.000456	0.6	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
ESCA	cis	rs977987	0.806	rs2285225	ENSG00000261783.1	RP11-252K23.2	-5.61	1.24e-07	0.000456	-0.55	-0.45	Dupuytren's disease;	chr16:75395354	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.527	rs62059844	ENSG00000261783.1	RP11-252K23.2	-5.61	1.24e-07	0.000456	-0.55	-0.45	Dupuytren's disease;	chr16:75395839	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.585	rs62059845	ENSG00000261783.1	RP11-252K23.2	-5.61	1.24e-07	0.000456	-0.55	-0.45	Dupuytren's disease;	chr16:75396815	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs62059846	ENSG00000261783.1	RP11-252K23.2	-5.61	1.24e-07	0.000456	-0.55	-0.45	Dupuytren's disease;	chr16:75396911	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs11149824	ENSG00000261783.1	RP11-252K23.2	-5.61	1.24e-07	0.000456	-0.55	-0.45	Dupuytren's disease;	chr16:75397932	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.862	rs11773628	ENSG00000179406.6	LINC00174	5.61	1.24e-07	0.000456	0.49	0.45	Aortic root size;	chr7:66517644	chr7:66376044~66401338:-
ESCA	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
ESCA	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-5.61	1.24e-07	0.000456	-0.53	-0.45	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
ESCA	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	5.61	1.25e-07	0.000458	0.9	0.45	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
ESCA	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	5.61	1.25e-07	0.000459	0.67	0.45	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
ESCA	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-5.61	1.25e-07	0.00046	-0.63	-0.45	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
ESCA	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	5.61	1.26e-07	0.00046	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	5.61	1.26e-07	0.00046	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	5.61	1.26e-07	0.00046	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
ESCA	cis	rs9322193	0.887	rs3734295	ENSG00000216906.2	RP11-350J20.9	5.61	1.27e-07	0.000463	0.61	0.45	Lung cancer;	chr6:149593917	chr6:149904243~149906418:+
ESCA	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-5.61	1.27e-07	0.000463	-0.53	-0.45	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
ESCA	cis	rs950880	0.71	rs56043441	ENSG00000234389.1	AC007278.3	-5.61	1.27e-07	0.000464	-0.42	-0.45	Serum protein levels (sST2);	chr2:102470923	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs4140785	ENSG00000234389.1	AC007278.3	-5.61	1.27e-07	0.000464	-0.42	-0.45	Serum protein levels (sST2);	chr2:102472057	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs4851011	ENSG00000234389.1	AC007278.3	5.61	1.27e-07	0.000464	0.42	0.45	Serum protein levels (sST2);	chr2:102473219	chr2:102438713~102440475:+
ESCA	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	5.61	1.27e-07	0.000464	0.56	0.45	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	5.61	1.27e-07	0.000464	0.56	0.45	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	5.61	1.27e-07	0.000464	0.56	0.45	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
ESCA	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-5.61	1.27e-07	0.000465	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-5.61	1.27e-07	0.000465	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-5.61	1.27e-07	0.000465	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
ESCA	cis	rs7829975	0.633	rs2979181	ENSG00000253981.4	ALG1L13P	5.61	1.27e-07	0.000465	0.55	0.45	Mood instability;	chr8:8465578	chr8:8236003~8244667:-
ESCA	cis	rs9595066	0.941	rs9533777	ENSG00000227258.4	SMIM2-AS1	-5.61	1.28e-07	0.000466	-0.61	-0.45	Schizophrenia;	chr13:44134584	chr13:44110451~44240517:+
ESCA	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	5.61	1.28e-07	0.000466	0.49	0.45	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000250470.1	AP000351.3	-5.61	1.28e-07	0.000467	-0.59	-0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23976904~23977585:-
ESCA	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-5.61	1.28e-07	0.000468	-0.6	-0.45	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	5.61	1.28e-07	0.000468	0.48	0.45	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
ESCA	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-5.61	1.28e-07	0.000468	-0.53	-0.45	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000231271.1	AP000350.8	5.61	1.29e-07	0.000469	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000231271.1	AP000350.8	5.61	1.29e-07	0.000469	0.55	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23949918~23954042:+
ESCA	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-5.61	1.29e-07	0.00047	-0.46	-0.45	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
ESCA	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-5.61	1.29e-07	0.00047	-0.46	-0.45	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
ESCA	cis	rs875971	0.502	rs1796227	ENSG00000222364.1	RNU6-96P	5.61	1.29e-07	0.000471	0.59	0.45	Aortic root size;	chr7:66622032	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.675	rs6947132	ENSG00000179406.6	LINC00174	5.61	1.29e-07	0.000472	0.53	0.45	Calcium levels;	chr7:65808508	chr7:66376044~66401338:-
ESCA	cis	rs977987	0.806	rs2161684	ENSG00000261783.1	RP11-252K23.2	-5.61	1.3e-07	0.000473	-0.55	-0.45	Dupuytren's disease;	chr16:75445255	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs34996006	ENSG00000261783.1	RP11-252K23.2	-5.61	1.3e-07	0.000473	-0.55	-0.45	Dupuytren's disease;	chr16:75445536	chr16:75379818~75381260:-
ESCA	cis	rs2307394	0.964	rs13008838	ENSG00000223911.1	AC009480.3	5.61	1.3e-07	0.000474	0.53	0.45	Urate levels;	chr2:147997256	chr2:147899401~147902956:-
ESCA	cis	rs6782228	1	rs6801509	ENSG00000277250.1	Metazoa_SRP	5.6	1.31e-07	0.000477	0.58	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128673681~128674021:-
ESCA	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	5.6	1.31e-07	0.000477	0.64	0.45	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
ESCA	cis	rs9457247	0.663	rs2301436	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167024500	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs9459845	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167027013	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs9457257	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167027248	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.637	rs9459846	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167027535	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs2237274	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167029507	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.612	rs2237273	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167029529	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.663	rs9295384	ENSG00000265828.1	MIR3939	-5.6	1.31e-07	0.000477	-0.47	-0.45	Crohn's disease;	chr6:167034625	chr6:166997807~166997912:-
ESCA	cis	rs9545047	0.541	rs36152718	ENSG00000227676.3	LINC01068	5.6	1.31e-07	0.000478	0.6	0.45	Schizophrenia;	chr13:79306069	chr13:79566727~79571436:+
ESCA	cis	rs950880	0.645	rs56044378	ENSG00000234389.1	AC007278.3	-5.6	1.31e-07	0.000478	-0.42	-0.45	Serum protein levels (sST2);	chr2:102448907	chr2:102438713~102440475:+
ESCA	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	5.6	1.32e-07	0.000479	0.63	0.45	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
ESCA	cis	rs2882667	0.861	rs11959727	ENSG00000253404.1	AC034243.1	5.6	1.32e-07	0.000479	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061276	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs11950819	ENSG00000253404.1	AC034243.1	5.6	1.32e-07	0.000479	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061411	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs10045761	ENSG00000253404.1	AC034243.1	5.6	1.32e-07	0.000479	0.61	0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139061600	chr5:138744434~138753309:-
ESCA	cis	rs9545047	0.704	rs3742120	ENSG00000227676.3	LINC01068	5.6	1.32e-07	0.00048	0.58	0.45	Schizophrenia;	chr13:79386700	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs3742122	ENSG00000227676.3	LINC01068	5.6	1.32e-07	0.00048	0.58	0.45	Schizophrenia;	chr13:79387061	chr13:79566727~79571436:+
ESCA	cis	rs801193	0.875	rs13227951	ENSG00000222364.1	RNU6-96P	5.6	1.33e-07	0.000482	0.51	0.45	Aortic root size;	chr7:66748121	chr7:66395191~66395286:+
ESCA	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-5.6	1.33e-07	0.000484	-0.59	-0.45	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
ESCA	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	5.6	1.33e-07	0.000485	0.68	0.45	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	5.6	1.33e-07	0.000485	0.68	0.45	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	5.6	1.33e-07	0.000485	0.68	0.45	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
ESCA	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	5.6	1.34e-07	0.000485	0.62	0.45	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
ESCA	cis	rs10875746	0.951	rs7485355	ENSG00000240399.1	RP1-228P16.1	-5.6	1.34e-07	0.000487	-0.57	-0.45	Longevity (90 years and older);	chr12:48154559	chr12:48054813~48055591:-
ESCA	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	5.6	1.35e-07	0.000488	0.48	0.45	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
ESCA	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	5.6	1.35e-07	0.000489	0.67	0.45	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
ESCA	cis	rs875971	0.79	rs10257911	ENSG00000179406.6	LINC00174	5.6	1.35e-07	0.00049	0.52	0.45	Aortic root size;	chr7:66278783	chr7:66376044~66401338:-
ESCA	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-5.6	1.35e-07	0.000491	-0.89	-0.45	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
ESCA	cis	rs875971	0.929	rs4122249	ENSG00000179406.6	LINC00174	-5.6	1.35e-07	0.000491	-0.51	-0.45	Aortic root size;	chr7:66455949	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	5.6	1.36e-07	0.000491	0.61	0.45	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	5.6	1.36e-07	0.000491	0.61	0.45	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	5.6	1.36e-07	0.000491	0.61	0.45	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	5.6	1.36e-07	0.000491	0.61	0.45	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	5.6	1.36e-07	0.000491	0.61	0.45	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
ESCA	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	5.6	1.36e-07	0.000492	0.56	0.45	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
ESCA	cis	rs977987	0.778	rs11862719	ENSG00000261783.1	RP11-252K23.2	-5.6	1.36e-07	0.000493	-0.55	-0.45	Dupuytren's disease;	chr16:75397810	chr16:75379818~75381260:-
ESCA	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	5.59	1.36e-07	0.000493	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	5.59	1.36e-07	0.000493	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
ESCA	cis	rs2921073	0.51	rs2976944	ENSG00000253981.4	ALG1L13P	5.59	1.36e-07	0.000494	0.52	0.45	Parkinson's disease;	chr8:8413404	chr8:8236003~8244667:-
ESCA	cis	rs977987	0.806	rs4887823	ENSG00000261783.1	RP11-252K23.2	-5.59	1.37e-07	0.000495	-0.55	-0.45	Dupuytren's disease;	chr16:75399176	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.828	rs2154593	ENSG00000228039.3	KB-1125A3.10	5.59	1.37e-07	0.000496	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.828	rs5760108	ENSG00000228039.3	KB-1125A3.10	5.59	1.37e-07	0.000496	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23963780~23964374:+
ESCA	cis	rs950880	0.71	rs11681718	ENSG00000234389.1	AC007278.3	-5.59	1.38e-07	0.000498	-0.42	-0.45	Serum protein levels (sST2);	chr2:102434684	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs4851582	ENSG00000234389.1	AC007278.3	-5.59	1.38e-07	0.000498	-0.42	-0.45	Serum protein levels (sST2);	chr2:102435098	chr2:102438713~102440475:+
ESCA	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	5.59	1.38e-07	0.000499	0.61	0.45	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
ESCA	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-5.59	1.39e-07	0.000501	-0.45	-0.45	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
ESCA	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	5.59	1.39e-07	0.000503	0.61	0.45	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	5.59	1.39e-07	0.000503	0.61	0.45	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	5.59	1.39e-07	0.000503	0.61	0.45	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	5.59	1.39e-07	0.000503	0.61	0.45	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	5.59	1.39e-07	0.000503	0.61	0.45	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
ESCA	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	5.59	1.39e-07	0.000503	0.67	0.45	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
ESCA	cis	rs977987	0.778	rs7203157	ENSG00000261783.1	RP11-252K23.2	-5.59	1.4e-07	0.000506	-0.54	-0.45	Dupuytren's disease;	chr16:75384022	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.771	rs8048527	ENSG00000261783.1	RP11-252K23.2	-5.59	1.4e-07	0.000506	-0.54	-0.45	Dupuytren's disease;	chr16:75388156	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.815	rs11149821	ENSG00000261783.1	RP11-252K23.2	-5.59	1.4e-07	0.000506	-0.54	-0.45	Dupuytren's disease;	chr16:75388919	chr16:75379818~75381260:-
ESCA	cis	rs9549367	0.789	rs12869947	ENSG00000269125.1	RP11-98F14.11	-5.59	1.4e-07	0.000506	-0.51	-0.45	Platelet distribution width;	chr13:113241842	chr13:113165002~113165183:-
ESCA	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-5.59	1.4e-07	0.000506	-0.52	-0.45	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	5.59	1.4e-07	0.000506	0.52	0.45	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.756	rs4718328	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66228350	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4718330	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66250256	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.658	rs2275235	ENSG00000206931.1	RNU6-1042P	5.59	1.41e-07	0.000506	0.58	0.45	Melanoma;	chr1:150757803	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs11204723	ENSG00000206931.1	RNU6-1042P	5.59	1.41e-07	0.000506	0.58	0.45	Melanoma;	chr1:150759142	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs4537557	ENSG00000206931.1	RNU6-1042P	5.59	1.41e-07	0.000506	0.58	0.45	Melanoma;	chr1:150761960	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs2864869	ENSG00000206931.1	RNU6-1042P	5.59	1.41e-07	0.000506	0.58	0.45	Melanoma;	chr1:150762179	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.893	rs62465470	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66136231	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4368860	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66143495	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1983372	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66146364	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs908915	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66149664	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7809814	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66150410	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7786892	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66163889	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2420174	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66180374	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2420173	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66180412	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4718319	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66187797	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.723	rs28391294	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66189328	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs6967708	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66192326	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs7782806	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66192910	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs880166	ENSG00000179406.6	LINC00174	5.59	1.41e-07	0.000506	0.51	0.45	Aortic root size;	chr7:66205775	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.621	rs72704656	ENSG00000206931.1	RNU6-1042P	5.59	1.41e-07	0.000508	0.59	0.45	Melanoma;	chr1:150855831	chr1:150701866~150701972:+
ESCA	cis	rs6479891	0.908	rs16918638	ENSG00000235816.3	PRELID1P3	5.59	1.42e-07	0.00051	0.6	0.45	Arthritis (juvenile idiopathic);	chr10:63583371	chr10:63427297~63427939:+
ESCA	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-5.58	1.43e-07	0.000512	-0.58	-0.45	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
ESCA	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-5.58	1.43e-07	0.000514	-0.46	-0.45	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	5.58	1.43e-07	0.000514	0.51	0.45	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
ESCA	cis	rs748404	0.697	rs498227	ENSG00000249839.1	AC011330.5	-5.58	1.44e-07	0.000515	-0.57	-0.45	Lung cancer;	chr15:43280854	chr15:43663654~43684339:-
ESCA	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-5.58	1.44e-07	0.000515	-0.46	-0.45	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
ESCA	cis	rs977987	0.736	rs11865296	ENSG00000261783.1	RP11-252K23.2	-5.58	1.44e-07	0.000516	-0.56	-0.45	Dupuytren's disease;	chr16:75439795	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs34021527	ENSG00000261783.1	RP11-252K23.2	-5.58	1.44e-07	0.000516	-0.56	-0.45	Dupuytren's disease;	chr16:75440192	chr16:75379818~75381260:-
ESCA	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	5.58	1.44e-07	0.000516	0.53	0.45	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
ESCA	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-5.58	1.45e-07	0.000519	-0.46	-0.45	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
ESCA	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-5.58	1.45e-07	0.000519	-0.46	-0.45	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
ESCA	cis	rs13217239	0.608	rs6930508	ENSG00000243307.2	POM121L6P	-5.58	1.45e-07	0.00052	-0.49	-0.45	Schizophrenia;	chr6:27085363	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs2142685	ENSG00000243307.2	POM121L6P	-5.58	1.45e-07	0.00052	-0.49	-0.45	Schizophrenia;	chr6:27086718	chr6:26896952~26898777:+
ESCA	cis	rs6782228	0.883	rs11712115	ENSG00000277250.1	Metazoa_SRP	5.58	1.45e-07	0.000521	0.57	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128673681~128674021:-
ESCA	cis	rs875971	0.66	rs10229345	ENSG00000226824.5	RP4-756H11.3	-5.58	1.46e-07	0.000523	-0.49	-0.45	Aortic root size;	chr7:66517181	chr7:66654538~66669855:+
ESCA	cis	rs6479901	0.512	rs11817169	ENSG00000235816.3	PRELID1P3	5.58	1.46e-07	0.000524	0.64	0.45	Intelligence (multi-trait analysis);	chr10:63596549	chr10:63427297~63427939:+
ESCA	cis	rs10875746	0.903	rs17122666	ENSG00000240399.1	RP1-228P16.1	-5.58	1.46e-07	0.000524	-0.56	-0.45	Longevity (90 years and older);	chr12:48108791	chr12:48054813~48055591:-
ESCA	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-5.58	1.47e-07	0.000525	-0.55	-0.45	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
ESCA	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-5.58	1.47e-07	0.000525	-0.53	-0.45	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-5.58	1.47e-07	0.000525	-0.53	-0.45	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-5.58	1.47e-07	0.000525	-0.53	-0.45	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-5.58	1.47e-07	0.000525	-0.53	-0.45	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
ESCA	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	5.58	1.47e-07	0.000525	0.48	0.45	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
ESCA	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	5.58	1.48e-07	0.000528	0.48	0.45	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
ESCA	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-5.58	1.48e-07	0.000528	-0.54	-0.45	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
ESCA	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-5.58	1.48e-07	0.000529	-0.58	-0.45	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
ESCA	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	5.58	1.49e-07	0.000531	0.53	0.45	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
ESCA	cis	rs9549367	0.789	rs2316442	ENSG00000269125.1	RP11-98F14.11	-5.57	1.49e-07	0.000533	-0.5	-0.45	Platelet distribution width;	chr13:113223173	chr13:113165002~113165183:-
ESCA	cis	rs10875746	0.903	rs11168427	ENSG00000240399.1	RP1-228P16.1	-5.57	1.5e-07	0.000535	-0.57	-0.45	Longevity (90 years and older);	chr12:48145196	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.951	rs61918826	ENSG00000240399.1	RP1-228P16.1	-5.57	1.5e-07	0.000535	-0.57	-0.45	Longevity (90 years and older);	chr12:48150195	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.904	rs10875750	ENSG00000240399.1	RP1-228P16.1	-5.57	1.5e-07	0.000535	-0.57	-0.45	Longevity (90 years and older);	chr12:48151847	chr12:48054813~48055591:-
ESCA	cis	rs9457247	0.602	rs4710175	ENSG00000265828.1	MIR3939	-5.57	1.5e-07	0.000535	-0.5	-0.45	Crohn's disease;	chr6:167054312	chr6:166997807~166997912:-
ESCA	cis	rs6782228	1	rs6782407	ENSG00000277250.1	Metazoa_SRP	5.57	1.51e-07	0.000537	0.59	0.45	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128673681~128674021:-
ESCA	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-5.57	1.51e-07	0.000537	-0.56	-0.45	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
ESCA	cis	rs13217239	0.646	rs7451149	ENSG00000243307.2	POM121L6P	-5.57	1.51e-07	0.000537	-0.49	-0.45	Schizophrenia;	chr6:27089739	chr6:26896952~26898777:+
ESCA	cis	rs9457247	0.588	rs35171809	ENSG00000265828.1	MIR3939	-5.57	1.51e-07	0.000537	-0.47	-0.45	Crohn's disease;	chr6:167019278	chr6:166997807~166997912:-
ESCA	cis	rs2439831	0.85	rs3862142	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43772608	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.702	rs2788	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43772688	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs2277531	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43776871	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28891769	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43780662	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28578398	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43782848	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs60883262	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43784305	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs8023458	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43788741	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs16963953	ENSG00000249839.1	AC011330.5	-5.57	1.51e-07	0.000537	-0.87	-0.45	Lung cancer in ever smokers;	chr15:43789521	chr15:43663654~43684339:-
ESCA	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-5.57	1.52e-07	0.000539	-0.5	-0.45	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	5.57	1.52e-07	0.000541	0.7	0.45	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
ESCA	cis	rs9457247	0.765	rs9295385	ENSG00000265828.1	MIR3939	-5.57	1.53e-07	0.000542	-0.52	-0.45	Crohn's disease;	chr6:167034693	chr6:166997807~166997912:-
ESCA	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	5.57	1.53e-07	0.000542	0.68	0.45	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
ESCA	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	5.57	1.53e-07	0.000543	0.5	0.45	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
ESCA	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-5.57	1.53e-07	0.000544	-0.58	-0.45	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-5.57	1.53e-07	0.000544	-0.58	-0.45	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
ESCA	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-5.57	1.54e-07	0.000546	-0.53	-0.45	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
ESCA	cis	rs9549367	0.826	rs35306827	ENSG00000269125.1	RP11-98F14.11	-5.57	1.54e-07	0.000546	-0.52	-0.45	Platelet distribution width;	chr13:113214731	chr13:113165002~113165183:-
ESCA	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	5.57	1.54e-07	0.000546	0.62	0.45	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	5.57	1.54e-07	0.000546	0.63	0.45	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
ESCA	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.57	1.54e-07	0.000546	-0.6	-0.45	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.965	rs10267430	ENSG00000179406.6	LINC00174	5.57	1.54e-07	0.000546	0.5	0.45	Aortic root size;	chr7:66278036	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs10257427	ENSG00000179406.6	LINC00174	5.57	1.54e-07	0.000546	0.5	0.45	Aortic root size;	chr7:66278221	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs10215948	ENSG00000179406.6	LINC00174	5.57	1.54e-07	0.000546	0.5	0.45	Aortic root size;	chr7:66282799	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.838	rs2173570	ENSG00000179406.6	LINC00174	5.57	1.54e-07	0.000546	0.5	0.45	Aortic root size;	chr7:66297976	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs55748098	ENSG00000179406.6	LINC00174	5.57	1.54e-07	0.000546	0.5	0.45	Aortic root size;	chr7:66298631	chr7:66376044~66401338:-
ESCA	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	5.57	1.55e-07	0.000548	0.45	0.45	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	5.57	1.55e-07	0.000548	0.45	0.45	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	5.57	1.56e-07	0.00055	0.49	0.45	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
ESCA	cis	rs875971	1	rs937495	ENSG00000179406.6	LINC00174	5.57	1.56e-07	0.00055	0.5	0.45	Aortic root size;	chr7:66314811	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.965	rs9969301	ENSG00000179406.6	LINC00174	5.57	1.56e-07	0.00055	0.5	0.45	Aortic root size;	chr7:66316668	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2036264	ENSG00000179406.6	LINC00174	5.57	1.56e-07	0.00055	0.5	0.45	Aortic root size;	chr7:66334917	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs7783613	ENSG00000179406.6	LINC00174	5.57	1.56e-07	0.00055	0.5	0.45	Aortic root size;	chr7:66340274	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs778735	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66349822	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs709595	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66352346	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs811880	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66353659	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778726	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66363744	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs778723	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66364510	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.767	rs1695815	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66366357	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778685	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66371189	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs778682	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66372947	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs11765965	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66377234	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs1643388	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66379575	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778722	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66379841	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs778721	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66380410	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs778712	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66384991	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778710	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66389847	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs778708	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66391332	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778706	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66395437	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs778700	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66401463	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778699	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66403303	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778696	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66405826	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs778694	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66406571	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs778692	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66407462	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs4718343	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66409301	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs4718344	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66409394	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs1968225	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66409786	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.737	rs7803424	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66415618	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs7799834	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66415707	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6460295	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66417741	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs6978721	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66418217	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6979382	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66421388	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6961990	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66423583	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs3857684	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66473171	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs6978429	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66494889	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs4718357	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66495891	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs12535036	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66499076	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs12533997	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66500390	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs12532998	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66502472	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs12698523	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66503126	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6970030	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66503692	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.928	rs6970357	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66503891	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs3735148	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66506022	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs60193905	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66506273	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs4718358	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66508681	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs10950041	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66508888	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs6970860	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66511647	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6957199	ENSG00000179406.6	LINC00174	-5.57	1.56e-07	0.00055	-0.5	-0.45	Aortic root size;	chr7:66513532	chr7:66376044~66401338:-
ESCA	cis	rs9545047	0.704	rs9530904	ENSG00000227676.3	LINC01068	5.56	1.56e-07	0.00055	0.57	0.45	Schizophrenia;	chr13:79370157	chr13:79566727~79571436:+
ESCA	cis	rs6479891	1	rs16918575	ENSG00000235816.3	PRELID1P3	-5.56	1.56e-07	0.000551	-0.56	-0.45	Arthritis (juvenile idiopathic);	chr10:63541565	chr10:63427297~63427939:+
ESCA	cis	rs1799949	0.965	rs4793237	ENSG00000198496.9	NBR2	-5.56	1.56e-07	0.000551	-0.49	-0.45	Menopause (age at onset);	chr17:43359227	chr17:43125610~43153671:+
ESCA	cis	rs13217239	0.646	rs4269366	ENSG00000243307.2	POM121L6P	5.56	1.57e-07	0.000553	0.49	0.45	Schizophrenia;	chr6:27048634	chr6:26896952~26898777:+
ESCA	cis	rs9457247	0.663	rs12526548	ENSG00000265828.1	MIR3939	-5.56	1.58e-07	0.000555	-0.47	-0.45	Crohn's disease;	chr6:167017659	chr6:166997807~166997912:-
ESCA	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.56	1.58e-07	0.000556	0.68	0.45	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
ESCA	cis	rs2739330	0.828	rs5751770	ENSG00000228039.3	KB-1125A3.10	5.56	1.59e-07	0.000558	0.57	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23963780~23964374:+
ESCA	cis	rs3747113	1	rs3747113	ENSG00000128262.7	POM121L9P	5.56	1.59e-07	0.000559	0.54	0.45	Gut microbiome composition (summer);	chr22:24321550	chr22:24251828~24265525:+
ESCA	cis	rs5758659	0.729	rs134866	ENSG00000182057.4	OGFRP1	5.56	1.59e-07	0.00056	0.51	0.45	Cognitive function;	chr22:42254657	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.679	rs134870	ENSG00000182057.4	OGFRP1	5.56	1.59e-07	0.00056	0.51	0.45	Cognitive function;	chr22:42256311	chr22:42269753~42275196:+
ESCA	cis	rs10875746	0.951	rs10875747	ENSG00000240399.1	RP1-228P16.1	-5.56	1.59e-07	0.00056	-0.57	-0.45	Longevity (90 years and older);	chr12:48132078	chr12:48054813~48055591:-
ESCA	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	5.56	1.6e-07	0.00056	0.5	0.45	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	5.56	1.6e-07	0.00056	0.71	0.45	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
ESCA	cis	rs977987	0.806	rs4888418	ENSG00000261783.1	RP11-252K23.2	-5.56	1.6e-07	0.00056	-0.55	-0.45	Dupuytren's disease;	chr16:75426408	chr16:75379818~75381260:-
ESCA	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-5.56	1.6e-07	0.00056	-0.53	-0.45	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
ESCA	cis	rs7412746	0.634	rs3754212	ENSG00000206931.1	RNU6-1042P	5.56	1.6e-07	0.00056	0.58	0.45	Melanoma;	chr1:150765724	chr1:150701866~150701972:+
ESCA	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-5.56	1.6e-07	0.000561	-0.39	-0.45	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
ESCA	cis	rs875971	0.862	rs12537823	ENSG00000179406.6	LINC00174	-5.56	1.6e-07	0.000561	-0.49	-0.45	Aortic root size;	chr7:66255897	chr7:66376044~66401338:-
ESCA	cis	rs61160187	0.582	rs17419290	ENSG00000215032.2	GNL3LP1	-5.56	1.61e-07	0.000564	-0.57	-0.45	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012077	chr5:60891935~60893577:-
ESCA	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-5.56	1.63e-07	0.000569	-0.45	-0.45	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000231271.1	AP000350.8	5.56	1.63e-07	0.00057	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000231271.1	AP000350.8	5.56	1.63e-07	0.00057	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23949918~23954042:+
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000231271.1	AP000350.8	5.56	1.63e-07	0.00057	0.56	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23949918~23954042:+
ESCA	cis	rs875971	1	rs6961717	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66122550	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2087647	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66128201	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6958484	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66134459	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs4718307	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66146001	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs7801282	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66148700	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs55962648	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66160764	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs11971949	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66161027	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2420168	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66165644	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs11974219	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66182423	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs11974264	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66182595	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs1540651	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66185134	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs1565531	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66198126	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6963646	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66220780	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.965	rs28682868	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66224822	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.898	rs6977501	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66228355	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs9986696	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66239589	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.965	rs6971509	ENSG00000179406.6	LINC00174	5.56	1.63e-07	0.00057	0.51	0.45	Aortic root size;	chr7:66249983	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.658	rs6657388	ENSG00000206931.1	RNU6-1042P	5.55	1.63e-07	0.00057	0.58	0.45	Melanoma;	chr1:150776310	chr1:150701866~150701972:+
ESCA	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	5.55	1.64e-07	0.000572	0.48	0.45	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
ESCA	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	5.55	1.64e-07	0.000572	0.54	0.45	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
ESCA	cis	rs13217239	0.646	rs62401067	ENSG00000243307.2	POM121L6P	5.55	1.65e-07	0.000574	0.49	0.45	Schizophrenia;	chr6:27050322	chr6:26896952~26898777:+
ESCA	cis	rs10875746	0.855	rs2269936	ENSG00000240399.1	RP1-228P16.1	-5.55	1.65e-07	0.000574	-0.56	-0.45	Longevity (90 years and older);	chr12:48031452	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.855	rs10875730	ENSG00000240399.1	RP1-228P16.1	-5.55	1.65e-07	0.000574	-0.56	-0.45	Longevity (90 years and older);	chr12:48034092	chr12:48054813~48055591:-
ESCA	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	5.55	1.65e-07	0.000576	0.4	0.45	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	5.55	1.65e-07	0.000576	0.4	0.45	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	5.55	1.65e-07	0.000576	0.4	0.45	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
ESCA	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-5.55	1.65e-07	0.000576	-0.52	-0.45	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-5.55	1.65e-07	0.000576	-0.52	-0.45	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-5.55	1.65e-07	0.000576	-0.52	-0.45	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.862	rs6460282	ENSG00000179406.6	LINC00174	5.55	1.65e-07	0.000576	0.52	0.45	Aortic root size;	chr7:66226259	chr7:66376044~66401338:-
ESCA	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	5.55	1.65e-07	0.000576	0.52	0.45	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	5.55	1.65e-07	0.000576	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
ESCA	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	5.55	1.66e-07	0.000579	0.39	0.45	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
ESCA	cis	rs977987	0.843	rs35737321	ENSG00000261783.1	RP11-252K23.2	-5.55	1.66e-07	0.000579	-0.56	-0.45	Dupuytren's disease;	chr16:75405287	chr16:75379818~75381260:-
ESCA	cis	rs950880	0.71	rs17027258	ENSG00000234389.1	AC007278.3	-5.55	1.66e-07	0.000579	-0.41	-0.45	Serum protein levels (sST2);	chr2:102475081	chr2:102438713~102440475:+
ESCA	cis	rs875971	0.522	rs709604	ENSG00000179406.6	LINC00174	5.55	1.67e-07	0.00058	0.51	0.45	Aortic root size;	chr7:66032447	chr7:66376044~66401338:-
ESCA	cis	rs977987	0.843	rs4146810	ENSG00000261783.1	RP11-252K23.2	-5.55	1.67e-07	0.000581	-0.54	-0.45	Dupuytren's disease;	chr16:75381933	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	5.55	1.67e-07	0.000582	0.67	0.45	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	5.55	1.67e-07	0.000582	0.67	0.45	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
ESCA	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	5.55	1.68e-07	0.000583	0.59	0.45	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
ESCA	cis	rs4747241	0.892	rs11593212	ENSG00000226163.1	RP11-167P22.3	5.55	1.68e-07	0.000583	0.52	0.45	Heschl's gyrus morphology;	chr10:72268948	chr10:72501746~72502956:+
ESCA	cis	rs8059260	0.736	rs16957835	ENSG00000274038.1	RP11-66H6.4	-5.55	1.68e-07	0.000584	-0.84	-0.45	Alcohol consumption over the past year;	chr16:10958198	chr16:11056556~11057034:+
ESCA	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	5.55	1.68e-07	0.000584	0.59	0.45	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
ESCA	cis	rs9322193	0.923	rs1934534	ENSG00000216906.2	RP11-350J20.9	5.55	1.68e-07	0.000585	0.61	0.45	Lung cancer;	chr6:149711896	chr6:149904243~149906418:+
ESCA	cis	rs10875746	0.903	rs11168414	ENSG00000240399.1	RP1-228P16.1	-5.55	1.68e-07	0.000585	-0.57	-0.45	Longevity (90 years and older);	chr12:48118548	chr12:48054813~48055591:-
ESCA	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	5.55	1.69e-07	0.000587	0.6	0.45	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
ESCA	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	5.55	1.69e-07	0.000587	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
ESCA	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-5.55	1.69e-07	0.000587	-0.44	-0.45	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
ESCA	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	5.55	1.7e-07	0.000588	0.69	0.45	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
ESCA	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-5.55	1.7e-07	0.000589	-0.52	-0.45	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
ESCA	cis	rs9549367	0.713	rs2476328	ENSG00000269125.1	RP11-98F14.11	5.55	1.7e-07	0.000589	0.53	0.45	Platelet distribution width;	chr13:113175036	chr13:113165002~113165183:-
ESCA	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-5.55	1.7e-07	0.000591	-0.4	-0.45	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-5.55	1.7e-07	0.000591	-0.4	-0.45	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
ESCA	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-5.55	1.7e-07	0.000591	-0.53	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
ESCA	cis	rs1075265	0.554	rs10168293	ENSG00000235937.1	AC008280.1	5.55	1.71e-07	0.000593	0.49	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.567	rs66773232	ENSG00000235937.1	AC008280.1	5.55	1.71e-07	0.000593	0.49	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.633	rs10183655	ENSG00000235937.1	AC008280.1	5.55	1.71e-07	0.000593	0.49	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54029552~54030682:-
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000231271.1	AP000350.8	-5.55	1.71e-07	0.000593	-0.56	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23949918~23954042:+
ESCA	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	5.54	1.72e-07	0.000595	0.54	0.45	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
ESCA	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	5.54	1.72e-07	0.000596	0.67	0.45	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
ESCA	cis	rs13217239	0.646	rs12527111	ENSG00000243307.2	POM121L6P	5.54	1.75e-07	0.000603	0.5	0.45	Schizophrenia;	chr6:27038696	chr6:26896952~26898777:+
ESCA	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-5.54	1.76e-07	0.000603	-0.39	-0.45	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
ESCA	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	5.54	1.76e-07	0.000603	0.39	0.45	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
ESCA	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	5.54	1.76e-07	0.000605	0.59	0.45	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
ESCA	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	5.54	1.76e-07	0.000605	0.59	0.45	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.806	rs4888404	ENSG00000261783.1	RP11-252K23.2	-5.54	1.76e-07	0.000606	-0.54	-0.45	Dupuytren's disease;	chr16:75394199	chr16:75379818~75381260:-
ESCA	cis	rs2739330	0.76	rs5760095	ENSG00000099984.9	GSTT2	-5.54	1.77e-07	0.000606	-0.52	-0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23980123~23983911:+
ESCA	cis	rs875971	1	rs2420591	ENSG00000179406.6	LINC00174	-5.54	1.77e-07	0.000607	-0.5	-0.45	Aortic root size;	chr7:66447394	chr7:66376044~66401338:-
ESCA	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	5.54	1.77e-07	0.000608	0.67	0.45	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	5.54	1.77e-07	0.000608	0.67	0.45	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
ESCA	cis	rs17711722	1	rs17711722	ENSG00000179406.6	LINC00174	5.54	1.78e-07	0.000611	0.52	0.45	Calcium levels;	chr7:65806210	chr7:66376044~66401338:-
ESCA	cis	rs1005277	0.579	rs2749616	ENSG00000263064.2	RP11-291L22.7	5.54	1.78e-07	0.000612	0.61	0.45	Extrinsic epigenetic age acceleration;	chr10:38222065	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780146	ENSG00000263064.2	RP11-291L22.7	5.54	1.78e-07	0.000612	0.61	0.45	Extrinsic epigenetic age acceleration;	chr10:38228946	chr10:38448689~38448949:+
ESCA	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	5.54	1.78e-07	0.000612	0.59	0.45	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
ESCA	cis	rs62229266	0.626	rs2835268	ENSG00000231106.2	LINC01436	5.54	1.79e-07	0.000613	0.51	0.45	Mitral valve prolapse;	chr21:36076838	chr21:36005338~36007838:+
ESCA	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000613	0.39	0.45	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
ESCA	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	5.53	1.8e-07	0.000614	0.67	0.45	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
ESCA	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	5.53	1.8e-07	0.000615	0.39	0.45	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
ESCA	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	5.53	1.8e-07	0.000615	0.62	0.45	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	5.53	1.8e-07	0.000615	0.62	0.45	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	5.53	1.8e-07	0.000615	0.62	0.45	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	5.53	1.8e-07	0.000615	0.62	0.45	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
ESCA	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-5.53	1.8e-07	0.000615	-0.72	-0.45	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
ESCA	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-5.53	1.81e-07	0.000617	-0.45	-0.45	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
ESCA	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-5.53	1.81e-07	0.000617	-0.45	-0.45	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000099984.9	GSTT2	5.53	1.82e-07	0.000621	0.51	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23980123~23983911:+
ESCA	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	5.53	1.82e-07	0.000621	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	5.53	1.82e-07	0.000621	0.49	0.45	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
ESCA	cis	rs8059260	0.551	rs7187539	ENSG00000274038.1	RP11-66H6.4	-5.53	1.82e-07	0.000621	-0.84	-0.45	Alcohol consumption over the past year;	chr16:10964900	chr16:11056556~11057034:+
ESCA	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-5.53	1.83e-07	0.000624	-0.46	-0.45	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
ESCA	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	5.53	1.84e-07	0.000625	0.59	0.45	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
ESCA	cis	rs1005277	0.579	rs1614236	ENSG00000276805.1	RP11-291L22.6	5.53	1.84e-07	0.000625	0.59	0.45	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38451030~38451785:+
ESCA	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-5.53	1.85e-07	0.000628	-0.47	-0.45	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	5.53	1.85e-07	0.000629	0.6	0.45	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
ESCA	cis	rs1075265	0.568	rs3095756	ENSG00000235937.1	AC008280.1	5.53	1.85e-07	0.00063	0.52	0.45	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54029552~54030682:-
ESCA	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	5.53	1.87e-07	0.000636	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
ESCA	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	5.52	1.88e-07	0.000637	0.49	0.45	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000228039.3	KB-1125A3.10	5.52	1.88e-07	0.000638	0.52	0.45	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23963780~23964374:+
ESCA	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	5.52	1.88e-07	0.000638	0.39	0.45	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
ESCA	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	5.52	1.88e-07	0.000639	0.52	0.45	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.54	rs4717275	ENSG00000179406.6	LINC00174	5.52	1.88e-07	0.000639	0.52	0.45	Aortic root size;	chr7:65800193	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs10807697	ENSG00000179406.6	LINC00174	-5.52	1.88e-07	0.000639	-0.51	-0.45	Aortic root size;	chr7:65951183	chr7:66376044~66401338:-
ESCA	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	5.52	1.88e-07	0.00064	0.39	0.45	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	5.52	1.88e-07	0.00064	0.39	0.45	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	5.52	1.88e-07	0.00064	0.39	0.45	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
ESCA	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	5.52	1.88e-07	0.00064	0.39	0.45	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
ESCA	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-5.52	1.89e-07	0.00064	-0.62	-0.45	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
ESCA	cis	rs977987	0.778	rs4888400	ENSG00000261783.1	RP11-252K23.2	-5.52	1.89e-07	0.00064	-0.54	-0.45	Dupuytren's disease;	chr16:75391698	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.836	rs7198873	ENSG00000261783.1	RP11-252K23.2	-5.52	1.89e-07	0.000641	-0.55	-0.45	Dupuytren's disease;	chr16:75440856	chr16:75379818~75381260:-
ESCA	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.52	1.89e-07	0.000642	-0.44	-0.45	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	5.52	1.9e-07	0.000643	0.64	0.45	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.516	rs6945322	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Aortic root size;	chr7:65871069	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.701	rs55773927	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Calcium levels;	chr7:65872915	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.727	rs35850374	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Calcium levels;	chr7:65892789	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs2008188	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Aortic root size;	chr7:65964026	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.505	rs6955582	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Aortic root size;	chr7:65966699	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.727	rs1880555	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Calcium levels;	chr7:65967580	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.701	rs781143	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Calcium levels;	chr7:65974892	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.727	rs2658585	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Calcium levels;	chr7:65996954	chr7:66376044~66401338:-
ESCA	cis	rs6479891	0.908	rs7078456	ENSG00000235816.3	PRELID1P3	-5.52	1.9e-07	0.000643	-0.6	-0.45	Arthritis (juvenile idiopathic);	chr10:63509719	chr10:63427297~63427939:+
ESCA	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	5.52	1.9e-07	0.000643	0.72	0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.862	rs778734	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66349862	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs709596	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66360926	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778724	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66364304	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778686	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66370923	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.767	rs1643394	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66371107	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778684	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66371416	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778680	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66375427	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs11769079	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66377141	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1695820	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66379576	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs778715	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66384222	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs809025	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66384832	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778702	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66399848	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1643375	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66407690	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6962717	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66418748	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.798	rs6460304	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66499741	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6945775	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66503987	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.798	rs57739047	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66507579	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs6950137	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66511623	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs11763189	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.49	-0.45	Aortic root size;	chr7:66518542	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.928	rs2036263	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66335210	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10240949	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66339430	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7782704	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66340379	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6460290	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66344119	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6959268	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66347979	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778720	ENSG00000179406.6	LINC00174	5.52	1.9e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66381288	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs3778909	ENSG00000179406.6	LINC00174	-5.52	1.9e-07	0.000643	-0.51	-0.45	Aortic root size;	chr7:66790659	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs4587224	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66271195	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.792	rs6971752	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66272999	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10950033	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66274686	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs11760844	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66274896	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4149461	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66279745	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4236208	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66284091	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10261398	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66285177	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10224872	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66294786	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs949930	ENSG00000179406.6	LINC00174	5.52	1.91e-07	0.000643	0.49	0.45	Aortic root size;	chr7:66301835	chr7:66376044~66401338:-
ESCA	cis	rs9549367	0.789	rs12866090	ENSG00000269125.1	RP11-98F14.11	-5.52	1.91e-07	0.000643	-0.51	-0.45	Platelet distribution width;	chr13:113215096	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs7317558	ENSG00000269125.1	RP11-98F14.11	-5.52	1.91e-07	0.000644	-0.48	-0.45	Platelet distribution width;	chr13:113239311	chr13:113165002~113165183:-
ESCA	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	5.52	1.91e-07	0.000644	0.61	0.45	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
ESCA	cis	rs9322193	0.923	rs10872644	ENSG00000216906.2	RP11-350J20.9	5.52	1.91e-07	0.000644	0.62	0.45	Lung cancer;	chr6:149741819	chr6:149904243~149906418:+
ESCA	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	5.52	1.91e-07	0.000645	0.57	0.45	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
ESCA	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-5.52	1.91e-07	0.000645	-0.58	-0.45	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
ESCA	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	5.52	1.92e-07	0.000647	0.47	0.45	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
ESCA	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.52	1.93e-07	0.000648	-0.45	-0.45	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	5.52	1.93e-07	0.000648	0.59	0.45	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	5.52	1.93e-07	0.000648	0.59	0.45	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	5.52	1.93e-07	0.000648	0.59	0.45	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	5.52	1.93e-07	0.000648	0.59	0.45	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.825	rs1000464	ENSG00000179406.6	LINC00174	5.52	1.93e-07	0.000649	0.49	0.45	Aortic root size;	chr7:66312922	chr7:66376044~66401338:-
ESCA	cis	rs977987	0.778	rs4888409	ENSG00000261783.1	RP11-252K23.2	-5.52	1.93e-07	0.00065	-0.55	-0.45	Dupuytren's disease;	chr16:75402333	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs7206541	ENSG00000261783.1	RP11-252K23.2	-5.52	1.93e-07	0.00065	-0.55	-0.45	Dupuytren's disease;	chr16:75402815	chr16:75379818~75381260:-
ESCA	cis	rs7412746	0.611	rs10888395	ENSG00000206931.1	RNU6-1042P	5.52	1.94e-07	0.000652	0.59	0.45	Melanoma;	chr1:150789695	chr1:150701866~150701972:+
ESCA	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	5.52	1.94e-07	0.000653	0.62	0.45	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	5.52	1.94e-07	0.000653	0.62	0.45	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.522	rs4718285	ENSG00000179406.6	LINC00174	-5.52	1.95e-07	0.000654	-0.51	-0.45	Aortic root size;	chr7:65827018	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs4718286	ENSG00000179406.6	LINC00174	-5.52	1.95e-07	0.000654	-0.51	-0.45	Aortic root size;	chr7:65827777	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs4502988	ENSG00000179406.6	LINC00174	-5.52	1.95e-07	0.000654	-0.51	-0.45	Aortic root size;	chr7:65832759	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.585	rs6942660	ENSG00000179406.6	LINC00174	-5.52	1.95e-07	0.000654	-0.51	-0.45	Calcium levels;	chr7:65837419	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.64	rs13237956	ENSG00000179406.6	LINC00174	-5.52	1.95e-07	0.000654	-0.51	-0.45	Calcium levels;	chr7:65853042	chr7:66376044~66401338:-
ESCA	cis	rs11763147	1	rs11763147	ENSG00000179406.6	LINC00174	5.52	1.95e-07	0.000654	0.51	0.45	Corneal structure;	chr7:65861834	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs2949690	ENSG00000179406.6	LINC00174	5.52	1.95e-07	0.000654	0.51	0.45	Aortic root size;	chr7:66018255	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.887	rs3777949	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000655	0.6	0.45	Lung cancer;	chr6:149596021	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.851	rs9322194	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000655	0.6	0.45	Lung cancer;	chr6:149599113	chr6:149904243~149906418:+
ESCA	cis	rs748404	0.723	rs573169	ENSG00000249839.1	AC011330.5	-5.52	1.95e-07	0.000656	-0.56	-0.45	Lung cancer;	chr15:43258383	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs524547	ENSG00000249839.1	AC011330.5	-5.52	1.95e-07	0.000656	-0.56	-0.45	Lung cancer;	chr15:43258825	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.723	rs565658	ENSG00000249839.1	AC011330.5	-5.52	1.95e-07	0.000656	-0.56	-0.45	Lung cancer;	chr15:43264109	chr15:43663654~43684339:-
ESCA	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	5.52	1.95e-07	0.000656	0.66	0.45	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
ESCA	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	5.52	1.95e-07	0.000656	0.6	0.45	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
ESCA	cis	rs3747113	0.954	rs2298378	ENSG00000128262.7	POM121L9P	-5.52	1.95e-07	0.000656	-0.55	-0.45	Gut microbiome composition (summer);	chr22:24323637	chr22:24251828~24265525:+
ESCA	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	5.51	1.96e-07	0.000658	0.66	0.45	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
ESCA	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-5.51	1.96e-07	0.000658	-0.53	-0.45	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
ESCA	cis	rs977987	0.843	rs11860231	ENSG00000261783.1	RP11-252K23.2	-5.51	1.97e-07	0.00066	-0.54	-0.45	Dupuytren's disease;	chr16:75351261	chr16:75379818~75381260:-
ESCA	cis	rs2439831	0.85	rs10438303	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43724219	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs12441127	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43728977	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.702	rs7171750	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43733660	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs11070408	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43742590	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28718261	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43751595	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28595038	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43752661	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs10163054	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43755440	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs7168158	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43758178	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs7174208	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43760484	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs12101756	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43761689	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs12442129	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43763658	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.702	rs7175032	ENSG00000249839.1	AC011330.5	-5.51	1.98e-07	0.000661	-0.85	-0.45	Lung cancer in ever smokers;	chr15:43768038	chr15:43663654~43684339:-
ESCA	cis	rs977987	0.843	rs12927562	ENSG00000261783.1	RP11-252K23.2	-5.51	1.98e-07	0.000661	-0.55	-0.45	Dupuytren's disease;	chr16:75448962	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs59155720	ENSG00000261783.1	RP11-252K23.2	-5.51	1.98e-07	0.000661	-0.55	-0.45	Dupuytren's disease;	chr16:75449908	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	5.51	1.98e-07	0.000661	0.49	0.45	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.564	rs313804	ENSG00000179406.6	LINC00174	-5.51	1.98e-07	0.000661	-0.51	-0.45	Aortic root size;	chr7:66049635	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.662	rs448725	ENSG00000179406.6	LINC00174	-5.51	1.98e-07	0.000661	-0.51	-0.45	Aortic root size;	chr7:66049641	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.658	rs432667	ENSG00000179406.6	LINC00174	-5.51	1.98e-07	0.000661	-0.51	-0.45	Aortic root size;	chr7:66049646	chr7:66376044~66401338:-
ESCA	cis	rs7924176	0.58	rs7912162	ENSG00000236900.1	TIMM9P1	-5.51	1.98e-07	0.000662	-0.53	-0.45	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74162005	chr10:74344550~74344805:-
ESCA	cis	rs9322193	0.923	rs9505823	ENSG00000216906.2	RP11-350J20.9	5.51	1.99e-07	0.000662	0.59	0.45	Lung cancer;	chr6:149628899	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.847	rs62439808	ENSG00000216906.2	RP11-350J20.9	5.51	1.99e-07	0.000662	0.59	0.45	Lung cancer;	chr6:149629690	chr6:149904243~149906418:+
ESCA	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-5.51	1.99e-07	0.000665	-0.55	-0.45	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-5.51	1.99e-07	0.000665	-0.55	-0.45	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-5.51	1.99e-07	0.000665	-0.55	-0.45	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
ESCA	cis	rs8046696	1	rs8046696	ENSG00000261783.1	RP11-252K23.2	-5.51	2e-07	0.000668	-0.55	-0.44	Coronary artery disease;	chr16:75408245	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.737	rs8046697	ENSG00000261783.1	RP11-252K23.2	-5.51	2e-07	0.000668	-0.55	-0.44	Dupuytren's disease;	chr16:75408246	chr16:75379818~75381260:-
ESCA	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-5.51	2.01e-07	0.000669	-0.55	-0.44	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
ESCA	cis	rs9322193	0.923	rs9688861	ENSG00000216906.2	RP11-350J20.9	5.51	2.02e-07	0.000672	0.59	0.44	Lung cancer;	chr6:149637924	chr6:149904243~149906418:+
ESCA	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-5.51	2.02e-07	0.000673	-0.58	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
ESCA	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	5.51	2.03e-07	0.000675	0.45	0.44	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
ESCA	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	5.51	2.03e-07	0.000675	0.49	0.44	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9479494	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149739108	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9800806	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149740350	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9688517	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149740655	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs1572229	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149743841	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs10872646	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149746539	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs12528279	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149750892	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.809	rs9479808	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149751328	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10782316	ENSG00000216906.2	RP11-350J20.9	5.51	2.03e-07	0.000676	0.61	0.44	Lung cancer;	chr6:149752755	chr6:149904243~149906418:+
ESCA	cis	rs6456156	0.586	rs2285148	ENSG00000265828.1	MIR3939	-5.51	2.04e-07	0.000677	-0.48	-0.44	Primary biliary cholangitis;	chr6:167077511	chr6:166997807~166997912:-
ESCA	cis	rs858239	0.669	rs10950940	ENSG00000230042.1	AK3P3	5.51	2.04e-07	0.000677	0.48	0.44	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23129178~23129841:+
ESCA	cis	rs875971	1	rs6958271	ENSG00000179406.6	LINC00174	-5.51	2.04e-07	0.000677	-0.5	-0.44	Aortic root size;	chr7:66514344	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6958277	ENSG00000179406.6	LINC00174	-5.51	2.04e-07	0.000677	-0.5	-0.44	Aortic root size;	chr7:66514362	chr7:66376044~66401338:-
ESCA	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-5.51	2.04e-07	0.000678	-0.48	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-5.51	2.04e-07	0.000678	-0.48	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-5.51	2.04e-07	0.000678	-0.48	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
ESCA	cis	rs9549260	0.712	rs9532564	ENSG00000229456.1	RLIMP1	5.51	2.04e-07	0.000678	0.56	0.44	Red blood cell count;	chr13:40586442	chr13:40618738~40621348:+
ESCA	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	5.51	2.04e-07	0.000678	0.67	0.44	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	5.51	2.04e-07	0.000678	0.67	0.44	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	5.51	2.04e-07	0.000678	0.67	0.44	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	5.51	2.04e-07	0.000678	0.67	0.44	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
ESCA	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	5.51	2.04e-07	0.000679	0.59	0.44	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
ESCA	cis	rs6867032	0.917	rs10474734	ENSG00000249731.1	RP11-259O2.3	5.51	2.05e-07	0.000679	0.34	0.44	Gut microbiome composition (winter);	chr5:2004094	chr5:1968094~1969013:+
ESCA	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	5.51	2.05e-07	0.000679	0.55	0.44	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
ESCA	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-5.51	2.05e-07	0.00068	-0.55	-0.44	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
ESCA	cis	rs875971	0.522	rs1880556	ENSG00000179406.6	LINC00174	-5.51	2.05e-07	0.000681	-0.52	-0.44	Aortic root size;	chr7:65967557	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs781144	ENSG00000179406.6	LINC00174	-5.51	2.05e-07	0.000681	-0.52	-0.44	Aortic root size;	chr7:65975357	chr7:66376044~66401338:-
ESCA	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-5.5	2.06e-07	0.000683	-0.55	-0.44	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-5.5	2.06e-07	0.000683	-0.55	-0.44	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
ESCA	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	5.5	2.07e-07	0.000686	0.6	0.44	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
ESCA	cis	rs2280018	0.963	rs12928424	ENSG00000260735.1	RP11-72I8.1	-5.5	2.07e-07	0.000688	-0.45	-0.44	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056916	chr16:15094411~15109197:+
ESCA	cis	rs2439831	0.85	rs28504496	ENSG00000249839.1	AC011330.5	-5.5	2.08e-07	0.000688	-0.85	-0.44	Lung cancer in ever smokers;	chr15:43724685	chr15:43663654~43684339:-
ESCA	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	5.5	2.08e-07	0.000688	0.64	0.44	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
ESCA	cis	rs4747241	0.962	rs11000248	ENSG00000226163.1	RP11-167P22.3	5.5	2.08e-07	0.00069	0.52	0.44	Heschl's gyrus morphology;	chr10:72282843	chr10:72501746~72502956:+
ESCA	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-5.5	2.09e-07	0.000692	-0.44	-0.44	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
ESCA	cis	rs9322193	0.884	rs9688858	ENSG00000216906.2	RP11-350J20.9	5.5	2.1e-07	0.000695	0.59	0.44	Lung cancer;	chr6:149637911	chr6:149904243~149906418:+
ESCA	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	5.5	2.1e-07	0.000696	0.58	0.44	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
ESCA	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	5.5	2.1e-07	0.000696	0.67	0.44	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
ESCA	cis	rs875971	1	rs7781698	ENSG00000179406.6	LINC00174	-5.5	2.1e-07	0.000696	-0.5	-0.44	Aortic root size;	chr7:66431325	chr7:66376044~66401338:-
ESCA	cis	rs5758659	0.716	rs2143138	ENSG00000182057.4	OGFRP1	5.5	2.1e-07	0.000696	0.51	0.44	Cognitive function;	chr22:42222334	chr22:42269753~42275196:+
ESCA	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	5.5	2.11e-07	0.000698	0.5	0.44	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
ESCA	cis	rs875971	1	rs4717300	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66482393	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2077593	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66427543	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6460296	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66430152	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs4717292	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66430611	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs4718349	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66444024	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs10755833	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66448930	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs12668936	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66449417	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs7788984	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66450629	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs12698520	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66453720	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs1833495	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66456608	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs6945019	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66457471	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs6945032	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66457499	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs12673810	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66458866	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs35149210	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66464938	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.929	rs34406470	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66464969	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2042133	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66466935	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs2161065	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66467918	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6961155	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66468308	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs7789768	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66473993	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs12698521	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66474502	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs1363055	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66478288	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs9691480	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66479319	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs7789554	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66481051	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs1974769	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66485627	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs6460300	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66487937	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7803416	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66489212	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs1981798	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66489916	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1981799	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66490572	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.964	rs2277911	ENSG00000179406.6	LINC00174	-5.5	2.11e-07	0.000698	-0.5	-0.44	Aortic root size;	chr7:66493638	chr7:66376044~66401338:-
ESCA	cis	rs2882667	0.838	rs11958529	ENSG00000253404.1	AC034243.1	5.5	2.11e-07	0.000698	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059379	chr5:138744434~138753309:-
ESCA	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-5.5	2.11e-07	0.000698	-0.53	-0.44	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
ESCA	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	5.5	2.12e-07	0.000699	0.59	0.44	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
ESCA	cis	rs6538678	0.864	rs10777749	ENSG00000258343.1	RP11-536G4.2	-5.5	2.12e-07	7e-04	-0.55	-0.44	Lupus nephritis in systemic lupus erythematosus;	chr12:95883182	chr12:95795345~95858839:-
ESCA	cis	rs7924176	0.601	rs4638254	ENSG00000236900.1	TIMM9P1	-5.5	2.12e-07	7e-04	-0.53	-0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74152974	chr10:74344550~74344805:-
ESCA	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-5.5	2.13e-07	0.000701	-0.48	-0.44	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-5.5	2.13e-07	0.000701	-0.48	-0.44	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-5.5	2.13e-07	0.000702	-0.47	-0.44	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.586	rs12920883	ENSG00000261783.1	RP11-252K23.2	-5.5	2.13e-07	0.000702	-0.56	-0.44	Dupuytren's disease;	chr16:75398783	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.624	rs59867374	ENSG00000261783.1	RP11-252K23.2	-5.5	2.13e-07	0.000702	-0.56	-0.44	Dupuytren's disease;	chr16:75398784	chr16:75379818~75381260:-
ESCA	cis	rs1075265	0.633	rs3731967	ENSG00000235937.1	AC008280.1	-5.5	2.13e-07	0.000702	-0.49	-0.44	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54029552~54030682:-
ESCA	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-5.5	2.13e-07	0.000702	-0.45	-0.44	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
ESCA	cis	rs977987	0.806	rs766521	ENSG00000261783.1	RP11-252K23.2	5.5	2.13e-07	0.000703	0.54	0.44	Dupuytren's disease;	chr16:75390256	chr16:75379818~75381260:-
ESCA	cis	rs6479891	1	rs16918567	ENSG00000235816.3	PRELID1P3	5.5	2.13e-07	0.000703	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63534910	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs16918573	ENSG00000235816.3	PRELID1P3	5.5	2.13e-07	0.000703	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63541045	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12414796	ENSG00000235816.3	PRELID1P3	5.5	2.13e-07	0.000703	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63543327	chr10:63427297~63427939:+
ESCA	cis	rs9733	0.818	rs12403609	ENSG00000206931.1	RNU6-1042P	-5.5	2.14e-07	0.000706	-0.56	-0.44	Tonsillectomy;	chr1:150704009	chr1:150701866~150701972:+
ESCA	cis	rs2739330	0.753	rs4822452	ENSG00000228039.3	KB-1125A3.10	5.5	2.15e-07	0.000707	0.55	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23963780~23964374:+
ESCA	cis	rs875971	1	rs3981131	ENSG00000179406.6	LINC00174	-5.49	2.15e-07	0.000708	-0.5	-0.44	Aortic root size;	chr7:66486690	chr7:66376044~66401338:-
ESCA	cis	rs3747113	1	rs9624447	ENSG00000128262.7	POM121L9P	-5.49	2.18e-07	0.000715	-0.55	-0.44	Gut microbiome composition (summer);	chr22:24285587	chr22:24251828~24265525:+
ESCA	cis	rs801193	0.935	rs3800820	ENSG00000179406.6	LINC00174	5.49	2.21e-07	0.000724	0.51	0.44	Aortic root size;	chr7:66682191	chr7:66376044~66401338:-
ESCA	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	5.49	2.22e-07	0.000726	0.54	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
ESCA	cis	rs2921073	0.51	rs2976945	ENSG00000253981.4	ALG1L13P	5.49	2.22e-07	0.000728	0.5	0.44	Parkinson's disease;	chr8:8413361	chr8:8236003~8244667:-
ESCA	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	5.49	2.22e-07	0.000728	0.59	0.44	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.00073	0.59	0.44	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.00073	0.59	0.44	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.00073	0.59	0.44	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.00073	0.59	0.44	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.00073	0.59	0.44	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
ESCA	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	5.49	2.23e-07	0.000732	0.49	0.44	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.000732	0.6	0.44	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.000732	0.6	0.44	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	5.49	2.23e-07	0.000732	0.6	0.44	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
ESCA	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-5.49	2.24e-07	0.000732	-0.46	-0.44	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
ESCA	cis	rs875971	0.862	rs6952182	ENSG00000179406.6	LINC00174	5.49	2.24e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66218330	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6964437	ENSG00000179406.6	LINC00174	5.49	2.24e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66221457	chr7:66376044~66401338:-
ESCA	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.49	2.24e-07	0.000733	-0.59	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
ESCA	cis	rs2221894	0.959	rs1487969	ENSG00000273710.1	Metazoa_SRP	5.49	2.24e-07	0.000733	0.5	0.44	Obesity-related traits;	chr8:29028144	chr8:28915579~28915864:-
ESCA	cis	rs6479891	1	rs10437345	ENSG00000235816.3	PRELID1P3	-5.49	2.24e-07	0.000733	-0.59	-0.44	Arthritis (juvenile idiopathic);	chr10:63443186	chr10:63427297~63427939:+
ESCA	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-5.49	2.25e-07	0.000733	-0.59	-0.44	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-5.49	2.25e-07	0.000733	-0.59	-0.44	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-5.49	2.25e-07	0.000733	-0.59	-0.44	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	5.49	2.25e-07	0.000733	0.59	0.44	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	5.49	2.25e-07	0.000733	0.59	0.44	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.895	rs6460278	ENSG00000179406.6	LINC00174	5.48	2.25e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66197749	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6460279	ENSG00000179406.6	LINC00174	5.48	2.25e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66197774	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs28491091	ENSG00000179406.6	LINC00174	5.48	2.25e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66204077	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6944374	ENSG00000179406.6	LINC00174	5.48	2.25e-07	0.000733	0.51	0.44	Aortic root size;	chr7:66221942	chr7:66376044~66401338:-
ESCA	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	5.48	2.26e-07	0.000735	0.67	0.44	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
ESCA	cis	rs9322193	0.923	rs11155677	ENSG00000216906.2	RP11-350J20.9	5.48	2.26e-07	0.000735	0.63	0.44	Lung cancer;	chr6:149756953	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs9480009	ENSG00000216906.2	RP11-350J20.9	5.48	2.26e-07	0.000735	0.63	0.44	Lung cancer;	chr6:149758502	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9480031	ENSG00000216906.2	RP11-350J20.9	5.48	2.26e-07	0.000735	0.63	0.44	Lung cancer;	chr6:149758875	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10872649	ENSG00000216906.2	RP11-350J20.9	5.48	2.26e-07	0.000735	0.63	0.44	Lung cancer;	chr6:149759454	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10872650	ENSG00000216906.2	RP11-350J20.9	5.48	2.26e-07	0.000735	0.63	0.44	Lung cancer;	chr6:149760959	chr6:149904243~149906418:+
ESCA	cis	rs748404	0.697	rs572959	ENSG00000249839.1	AC011330.5	-5.48	2.26e-07	0.000736	-0.56	-0.44	Lung cancer;	chr15:43258304	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs554001	ENSG00000249839.1	AC011330.5	-5.48	2.26e-07	0.000736	-0.56	-0.44	Lung cancer;	chr15:43259721	chr15:43663654~43684339:-
ESCA	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-5.48	2.26e-07	0.000736	-0.48	-0.44	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs11984115	ENSG00000179406.6	LINC00174	5.48	2.26e-07	0.000736	0.5	0.44	Aortic root size;	chr7:66308872	chr7:66376044~66401338:-
ESCA	cis	rs1005277	0.579	rs1780137	ENSG00000263064.2	RP11-291L22.7	5.48	2.27e-07	0.000737	0.61	0.44	Extrinsic epigenetic age acceleration;	chr10:38212547	chr10:38448689~38448949:+
ESCA	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-5.48	2.27e-07	0.000737	-0.51	-0.44	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-5.48	2.27e-07	0.000737	-0.51	-0.44	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-5.48	2.27e-07	0.000737	-0.51	-0.44	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
ESCA	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-5.48	2.27e-07	0.000738	-0.71	-0.44	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
ESCA	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-5.48	2.27e-07	0.000739	-0.87	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-5.48	2.27e-07	0.000739	-0.87	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-5.48	2.27e-07	0.000739	-0.87	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-5.48	2.27e-07	0.000739	-0.87	-0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
ESCA	cis	rs6456156	0.565	rs6921588	ENSG00000265828.1	MIR3939	-5.48	2.28e-07	0.000739	-0.51	-0.44	Primary biliary cholangitis;	chr6:167080909	chr6:166997807~166997912:-
ESCA	cis	rs453301	0.686	rs6601280	ENSG00000253981.4	ALG1L13P	5.48	2.28e-07	0.00074	0.54	0.44	Joint mobility (Beighton score);	chr8:9051726	chr8:8236003~8244667:-
ESCA	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	5.48	2.28e-07	0.00074	0.48	0.44	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
ESCA	cis	rs9545047	0.604	rs7332367	ENSG00000227676.3	LINC01068	-5.48	2.29e-07	0.000743	-0.56	-0.44	Schizophrenia;	chr13:79339816	chr13:79566727~79571436:+
ESCA	cis	rs9322193	0.923	rs10782317	ENSG00000216906.2	RP11-350J20.9	-5.48	2.29e-07	0.000745	-0.6	-0.44	Lung cancer;	chr6:149753911	chr6:149904243~149906418:+
ESCA	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-5.48	2.3e-07	0.000745	-0.52	-0.44	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
ESCA	cis	rs9549367	0.789	rs12584008	ENSG00000269125.1	RP11-98F14.11	-5.48	2.3e-07	0.000746	-0.51	-0.44	Platelet distribution width;	chr13:113226914	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs9549701	ENSG00000269125.1	RP11-98F14.11	-5.48	2.3e-07	0.000746	-0.51	-0.44	Platelet distribution width;	chr13:113227438	chr13:113165002~113165183:-
ESCA	cis	rs7714584	1	rs931058	ENSG00000197083.10	ZNF300P1	5.48	2.3e-07	0.000746	0.86	0.44	Crohn's disease;	chr5:150954136	chr5:150930645~150946289:-
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000231271.1	AP000350.8	5.48	2.3e-07	0.000746	0.5	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23949918~23954042:+
ESCA	cis	rs801193	1	rs2659909	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66695292	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2707836	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66695448	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.844	rs7779971	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66696803	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2659906	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66700323	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.935	rs11772264	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66711400	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs1553610	ENSG00000179406.6	LINC00174	-5.48	2.3e-07	0.000747	-0.5	-0.44	Aortic root size;	chr7:66732246	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.658	rs6669855	ENSG00000206931.1	RNU6-1042P	5.48	2.31e-07	0.000748	0.57	0.44	Melanoma;	chr1:150888753	chr1:150701866~150701972:+
ESCA	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	5.48	2.31e-07	0.00075	0.74	0.44	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
ESCA	cis	rs801193	1	rs11773829	ENSG00000179406.6	LINC00174	5.48	2.31e-07	0.000751	0.5	0.44	Aortic root size;	chr7:66676087	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs62466793	ENSG00000179406.6	LINC00174	-5.48	2.31e-07	0.000751	-0.5	-0.44	Aortic root size;	chr7:66726530	chr7:66376044~66401338:-
ESCA	cis	rs977987	0.836	rs7200053	ENSG00000261783.1	RP11-252K23.2	-5.48	2.32e-07	0.000751	-0.55	-0.44	Dupuytren's disease;	chr16:75440720	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs7204984	ENSG00000261783.1	RP11-252K23.2	-5.48	2.32e-07	0.000751	-0.55	-0.44	Dupuytren's disease;	chr16:75441622	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs35214308	ENSG00000261783.1	RP11-252K23.2	-5.48	2.32e-07	0.000751	-0.55	-0.44	Dupuytren's disease;	chr16:75442190	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888425	ENSG00000261783.1	RP11-252K23.2	-5.48	2.32e-07	0.000751	-0.55	-0.44	Dupuytren's disease;	chr16:75442465	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs4888426	ENSG00000261783.1	RP11-252K23.2	-5.48	2.32e-07	0.000751	-0.55	-0.44	Dupuytren's disease;	chr16:75442553	chr16:75379818~75381260:-
ESCA	cis	rs2301436	0.512	rs6925969	ENSG00000265828.1	MIR3939	-5.48	2.33e-07	0.000754	-0.48	-0.44	Crohn's disease;	chr6:167088250	chr6:166997807~166997912:-
ESCA	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	5.48	2.33e-07	0.000754	0.66	0.44	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
ESCA	cis	rs977987	0.902	rs34539062	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75459381	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.866	rs17696831	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75459400	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.898	rs12918797	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75459912	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.931	rs11641430	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75461378	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.931	rs7195161	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75461674	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.931	rs1424013	ENSG00000261783.1	RP11-252K23.2	-5.48	2.33e-07	0.000755	-0.54	-0.44	Dupuytren's disease;	chr16:75462088	chr16:75379818~75381260:-
ESCA	cis	rs801193	0.935	rs2659916	ENSG00000179406.6	LINC00174	-5.48	2.34e-07	0.000758	-0.5	-0.44	Aortic root size;	chr7:66686365	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs6958520	ENSG00000179406.6	LINC00174	-5.48	2.34e-07	0.000758	-0.5	-0.44	Aortic root size;	chr7:66686466	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.967	rs2707849	ENSG00000179406.6	LINC00174	-5.48	2.34e-07	0.000758	-0.5	-0.44	Aortic root size;	chr7:66687725	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2659912	ENSG00000179406.6	LINC00174	-5.48	2.34e-07	0.000758	-0.5	-0.44	Aortic root size;	chr7:66693012	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs7788576	ENSG00000179406.6	LINC00174	5.48	2.34e-07	0.000758	0.5	0.44	Aortic root size;	chr7:66683315	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6946143	ENSG00000179406.6	LINC00174	-5.48	2.34e-07	0.000758	-0.51	-0.44	Aortic root size;	chr7:66114735	chr7:66376044~66401338:-
ESCA	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-5.47	2.36e-07	0.000763	-0.58	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-5.47	2.36e-07	0.000763	-0.58	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.638	rs7793569	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66651646	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs6975195	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66659787	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs3857688	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66662819	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2286684	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66664843	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.935	rs2286683	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66664856	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2420824	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66666129	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs10274773	ENSG00000179406.6	LINC00174	5.47	2.36e-07	0.000763	0.5	0.44	Aortic root size;	chr7:66668591	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.923	rs12174716	ENSG00000216906.2	RP11-350J20.9	5.47	2.36e-07	0.000764	0.6	0.44	Lung cancer;	chr6:149644487	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.872	rs2161648	ENSG00000261783.1	RP11-252K23.2	-5.47	2.36e-07	0.000764	-0.53	-0.44	Dupuytren's disease;	chr16:75280731	chr16:75379818~75381260:-
ESCA	cis	rs5758659	0.716	rs86669	ENSG00000182057.4	OGFRP1	5.47	2.36e-07	0.000764	0.5	0.44	Cognitive function;	chr22:42284794	chr22:42269753~42275196:+
ESCA	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-5.47	2.37e-07	0.000766	-0.55	-0.44	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
ESCA	cis	rs9322193	0.847	rs12234128	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149627553	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs57012784	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149627691	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322200	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149630078	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9689599	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149631973	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9800580	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149632845	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs11155669	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149633501	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.887	rs9505824	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149633663	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9505826	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149633912	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322204	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149636047	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9766886	ENSG00000216906.2	RP11-350J20.9	5.47	2.39e-07	0.000771	0.59	0.44	Lung cancer;	chr6:149637048	chr6:149904243~149906418:+
ESCA	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	5.47	2.4e-07	0.000774	0.49	0.44	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	5.47	2.4e-07	0.000774	0.49	0.44	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	5.47	2.4e-07	0.000774	0.49	0.44	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
ESCA	cis	rs6479891	1	rs7087279	ENSG00000235816.3	PRELID1P3	-5.47	2.41e-07	0.000776	-0.56	-0.44	Arthritis (juvenile idiopathic);	chr10:63532176	chr10:63427297~63427939:+
ESCA	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-5.47	2.41e-07	0.000777	-0.57	-0.44	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
ESCA	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-5.47	2.41e-07	0.000777	-0.57	-0.44	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
ESCA	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	5.47	2.42e-07	0.00078	0.49	0.44	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
ESCA	cis	rs9322193	0.923	rs9689084	ENSG00000216906.2	RP11-350J20.9	5.47	2.43e-07	0.000781	0.59	0.44	Lung cancer;	chr6:149639648	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs7740278	ENSG00000216906.2	RP11-350J20.9	5.47	2.43e-07	0.000781	0.59	0.44	Lung cancer;	chr6:149640116	chr6:149904243~149906418:+
ESCA	cis	rs801193	1	rs4717310	ENSG00000179406.6	LINC00174	-5.47	2.43e-07	0.000781	-0.5	-0.44	Aortic root size;	chr7:66696020	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs7782320	ENSG00000179406.6	LINC00174	-5.47	2.43e-07	0.000781	-0.5	-0.44	Aortic root size;	chr7:66712111	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs1553609	ENSG00000179406.6	LINC00174	-5.47	2.43e-07	0.000781	-0.5	-0.44	Aortic root size;	chr7:66732152	chr7:66376044~66401338:-
ESCA	cis	rs9457247	0.529	rs6907666	ENSG00000265828.1	MIR3939	5.47	2.44e-07	0.000784	0.48	0.44	Crohn's disease;	chr6:167109907	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	5.47	2.44e-07	0.000784	0.48	0.44	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	5.47	2.44e-07	0.000784	0.48	0.44	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	5.47	2.44e-07	0.000784	0.48	0.44	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	5.47	2.44e-07	0.000784	0.48	0.44	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-5.47	2.44e-07	0.000784	-0.51	-0.44	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
ESCA	cis	rs9549367	0.774	rs2287246	ENSG00000269125.1	RP11-98F14.11	-5.47	2.44e-07	0.000785	-0.49	-0.44	Platelet distribution width;	chr13:113234813	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.789	rs2287247	ENSG00000269125.1	RP11-98F14.11	-5.47	2.44e-07	0.000785	-0.49	-0.44	Platelet distribution width;	chr13:113234898	chr13:113165002~113165183:-
ESCA	cis	rs875971	0.54	rs781152	ENSG00000179406.6	LINC00174	-5.47	2.45e-07	0.000787	-0.52	-0.44	Aortic root size;	chr7:66014585	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.727	rs781151	ENSG00000179406.6	LINC00174	-5.47	2.45e-07	0.000787	-0.52	-0.44	Calcium levels;	chr7:66014891	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	5.47	2.46e-07	0.000789	0.59	0.44	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
ESCA	cis	rs801193	0.935	rs2659899	ENSG00000179406.6	LINC00174	-5.47	2.46e-07	0.00079	-0.5	-0.44	Aortic root size;	chr7:66721734	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs62466794	ENSG00000179406.6	LINC00174	-5.47	2.46e-07	0.00079	-0.5	-0.44	Aortic root size;	chr7:66726592	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs7785213	ENSG00000179406.6	LINC00174	5.47	2.46e-07	0.00079	0.5	0.44	Aortic root size;	chr7:66673991	chr7:66376044~66401338:-
ESCA	cis	rs6479891	1	rs11814792	ENSG00000235816.3	PRELID1P3	5.47	2.46e-07	0.00079	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63157799	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12413415	ENSG00000235816.3	PRELID1P3	5.47	2.46e-07	0.00079	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63159751	chr10:63427297~63427939:+
ESCA	cis	rs977987	0.868	rs10871313	ENSG00000261783.1	RP11-252K23.2	-5.46	2.47e-07	0.000791	-0.57	-0.44	Dupuytren's disease;	chr16:75473196	chr16:75379818~75381260:-
ESCA	cis	rs801193	0.967	rs2707841	ENSG00000179406.6	LINC00174	-5.46	2.47e-07	0.000792	-0.5	-0.44	Aortic root size;	chr7:66692033	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs13536	ENSG00000179406.6	LINC00174	5.46	2.47e-07	0.000792	0.5	0.44	Aortic root size;	chr7:66554203	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs801209	ENSG00000179406.6	LINC00174	5.46	2.47e-07	0.000792	0.5	0.44	Aortic root size;	chr7:66554403	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs801206	ENSG00000179406.6	LINC00174	5.46	2.47e-07	0.000792	0.5	0.44	Aortic root size;	chr7:66556979	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs801204	ENSG00000179406.6	LINC00174	5.46	2.47e-07	0.000792	0.5	0.44	Aortic root size;	chr7:66557934	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs801203	ENSG00000179406.6	LINC00174	5.46	2.47e-07	0.000792	0.5	0.44	Aortic root size;	chr7:66558025	chr7:66376044~66401338:-
ESCA	cis	rs9287719	0.625	rs7567304	ENSG00000234818.1	AC092687.5	-5.46	2.47e-07	0.000793	-0.41	-0.44	Prostate cancer;	chr2:10649903	chr2:10589166~10604830:+
ESCA	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.46	2.48e-07	0.000794	-0.56	-0.44	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
ESCA	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	5.46	2.48e-07	0.000794	0.48	0.44	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	5.46	2.48e-07	0.000794	0.48	0.44	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
ESCA	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-5.46	2.48e-07	0.000795	-0.57	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
ESCA	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	5.46	2.48e-07	0.000795	0.6	0.44	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	5.46	2.48e-07	0.000795	0.6	0.44	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	5.46	2.48e-07	0.000795	0.6	0.44	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	5.46	2.48e-07	0.000795	0.6	0.44	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
ESCA	cis	rs7924176	0.601	rs7099026	ENSG00000236900.1	TIMM9P1	-5.46	2.5e-07	0.000801	-0.52	-0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74128770	chr10:74344550~74344805:-
ESCA	cis	rs875971	0.83	rs6976714	ENSG00000179406.6	LINC00174	-5.46	2.5e-07	0.000801	-0.49	-0.44	Aortic root size;	chr7:66426474	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.651	rs2420596	ENSG00000179406.6	LINC00174	-5.46	2.5e-07	0.000801	-0.49	-0.44	Aortic root size;	chr7:66450996	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.52	rs2420597	ENSG00000179406.6	LINC00174	-5.46	2.5e-07	0.000801	-0.49	-0.44	Aortic root size;	chr7:66450999	chr7:66376044~66401338:-
ESCA	cis	rs2882667	1	rs10064201	ENSG00000253404.1	AC034243.1	5.46	2.51e-07	0.000802	0.6	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973716	chr5:138744434~138753309:-
ESCA	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	5.46	2.51e-07	0.000804	0.39	0.44	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	5.46	2.51e-07	0.000804	0.39	0.44	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
ESCA	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-5.46	2.52e-07	0.000805	-0.57	-0.44	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
ESCA	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	5.46	2.52e-07	0.000805	0.56	0.44	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
ESCA	cis	rs875971	1	rs7792762	ENSG00000179406.6	LINC00174	-5.46	2.53e-07	0.000809	-0.51	-0.44	Aortic root size;	chr7:66539151	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.66	rs1962050	ENSG00000179406.6	LINC00174	5.46	2.54e-07	0.000811	0.5	0.44	Aortic root size;	chr7:66775021	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs875971	ENSG00000179406.6	LINC00174	5.46	2.54e-07	0.000812	0.49	0.44	Aortic root size;	chr7:66152608	chr7:66376044~66401338:-
ESCA	cis	rs6479891	1	rs4746149	ENSG00000235816.3	PRELID1P3	-5.46	2.54e-07	0.000812	-0.55	-0.44	Arthritis (juvenile idiopathic);	chr10:63497633	chr10:63427297~63427939:+
ESCA	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	5.46	2.54e-07	0.000812	0.72	0.44	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
ESCA	cis	rs7412746	0.611	rs1889740	ENSG00000206931.1	RNU6-1042P	5.46	2.55e-07	0.000812	0.57	0.44	Melanoma;	chr1:150827279	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.519	rs11800855	ENSG00000206931.1	RNU6-1042P	5.46	2.55e-07	0.000812	0.57	0.44	Tonsillectomy;	chr1:150828519	chr1:150701866~150701972:+
ESCA	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-5.46	2.55e-07	0.000812	-0.54	-0.44	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-5.46	2.55e-07	0.000812	-0.54	-0.44	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
ESCA	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-5.46	2.55e-07	0.000812	-0.54	-0.44	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
ESCA	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-5.46	2.56e-07	0.000813	-0.47	-0.44	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
ESCA	cis	rs801193	1	rs2707845	ENSG00000179406.6	LINC00174	-5.46	2.56e-07	0.000814	-0.5	-0.44	Aortic root size;	chr7:66733811	chr7:66376044~66401338:-
ESCA	cis	rs6456156	0.583	rs7748224	ENSG00000265828.1	MIR3939	-5.46	2.56e-07	0.000814	-0.47	-0.44	Primary biliary cholangitis;	chr6:167043372	chr6:166997807~166997912:-
ESCA	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	5.46	2.56e-07	0.000815	0.59	0.44	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
ESCA	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	5.46	2.57e-07	0.000816	0.45	0.44	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
ESCA	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-5.46	2.57e-07	0.000817	-0.54	-0.44	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
ESCA	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	5.46	2.57e-07	0.000817	0.57	0.44	Depression;	chr6:28407125	chr6:28176188~28176674:+
ESCA	cis	rs17711722	0.701	rs4467826	ENSG00000179406.6	LINC00174	-5.46	2.57e-07	0.000817	-0.5	-0.44	Calcium levels;	chr7:65903721	chr7:66376044~66401338:-
ESCA	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-5.45	2.58e-07	0.000819	-0.52	-0.44	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000228039.3	KB-1125A3.10	-5.45	2.58e-07	0.00082	-0.61	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23963780~23964374:+
ESCA	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	5.45	2.58e-07	0.000821	0.66	0.44	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
ESCA	cis	rs875971	0.862	rs6460307	ENSG00000179406.6	LINC00174	-5.45	2.58e-07	0.000821	-0.49	-0.44	Aortic root size;	chr7:66595884	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.961	rs9767713	ENSG00000216906.2	RP11-350J20.9	5.45	2.59e-07	0.000822	0.59	0.44	Lung cancer;	chr6:149588241	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.806	rs11643410	ENSG00000261783.1	RP11-252K23.2	-5.45	2.59e-07	0.000823	-0.53	-0.44	Dupuytren's disease;	chr16:75394408	chr16:75379818~75381260:-
ESCA	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-5.45	2.59e-07	0.000823	-0.52	-0.44	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-5.45	2.59e-07	0.000823	-0.52	-0.44	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-5.45	2.59e-07	0.000823	-0.52	-0.44	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
ESCA	cis	rs801193	1	rs2707850	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66738883	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.967	rs1110414	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66740595	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs7783924	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66744070	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs7789184	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66745208	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2707854	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66747610	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs3800812	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66758474	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs4279493	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66761633	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.761	rs2659888	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66765184	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs4717319	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66777606	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.904	rs4718403	ENSG00000179406.6	LINC00174	-5.45	2.6e-07	0.000824	-0.5	-0.44	Aortic root size;	chr7:66777742	chr7:66376044~66401338:-
ESCA	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	5.45	2.6e-07	0.000825	0.63	0.44	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
ESCA	cis	rs12594515	0.694	rs2068295	ENSG00000273972.1	CTD-2306A12.1	-5.45	2.61e-07	0.000827	-0.55	-0.44	Weight;Waist circumference;	chr15:45693348	chr15:45702640~45703183:+
ESCA	cis	rs12594515	0.694	rs2068294	ENSG00000273972.1	CTD-2306A12.1	-5.45	2.61e-07	0.000827	-0.55	-0.44	Weight;Waist circumference;	chr15:45693350	chr15:45702640~45703183:+
ESCA	cis	rs10875746	0.903	rs10875740	ENSG00000240399.1	RP1-228P16.1	-5.45	2.61e-07	0.000827	-0.55	-0.44	Longevity (90 years and older);	chr12:48095334	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.903	rs2158516	ENSG00000240399.1	RP1-228P16.1	-5.45	2.61e-07	0.000827	-0.55	-0.44	Longevity (90 years and older);	chr12:48097051	chr12:48054813~48055591:-
ESCA	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	5.45	2.63e-07	0.000832	0.56	0.44	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
ESCA	cis	rs1005277	0.579	rs1740737	ENSG00000276805.1	RP11-291L22.6	5.45	2.63e-07	0.000832	0.58	0.44	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780116	ENSG00000276805.1	RP11-291L22.6	5.45	2.63e-07	0.000832	0.58	0.44	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780121	ENSG00000276805.1	RP11-291L22.6	5.45	2.63e-07	0.000832	0.58	0.44	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780122	ENSG00000276805.1	RP11-291L22.6	5.45	2.63e-07	0.000832	0.58	0.44	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780145	ENSG00000276805.1	RP11-291L22.6	5.45	2.63e-07	0.000832	0.58	0.44	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38451030~38451785:+
ESCA	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	5.45	2.63e-07	0.000833	0.49	0.44	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
ESCA	cis	rs950880	0.71	rs17027071	ENSG00000234389.1	AC007278.3	-5.45	2.64e-07	0.000835	-0.42	-0.44	Serum protein levels (sST2);	chr2:102396214	chr2:102438713~102440475:+
ESCA	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-5.45	2.64e-07	0.000835	-0.61	-0.44	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
ESCA	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-5.45	2.65e-07	0.000837	-0.39	-0.44	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
ESCA	cis	rs977987	0.931	rs8057084	ENSG00000261783.1	RP11-252K23.2	5.45	2.65e-07	0.000839	0.53	0.44	Dupuytren's disease;	chr16:75458808	chr16:75379818~75381260:-
ESCA	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-5.45	2.66e-07	0.000839	-0.45	-0.44	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-5.45	2.66e-07	0.000839	-0.45	-0.44	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-5.45	2.66e-07	0.000839	-0.45	-0.44	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
ESCA	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	5.45	2.66e-07	0.000839	0.49	0.44	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
ESCA	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-5.45	2.66e-07	0.000841	-0.62	-0.44	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
ESCA	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	5.45	2.67e-07	0.000842	0.39	0.44	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
ESCA	cis	rs5758659	0.633	rs762995	ENSG00000182057.4	OGFRP1	5.45	2.67e-07	0.000842	0.5	0.44	Cognitive function;	chr22:42276118	chr22:42269753~42275196:+
ESCA	cis	rs875971	0.862	rs6971059	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66602045	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.789	rs7808013	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66606209	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs7384021	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66612917	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs66981195	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66614048	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs3926380	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66615658	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs1860472	ENSG00000179406.6	LINC00174	5.45	2.68e-07	0.000844	0.49	0.44	Aortic root size;	chr7:66617736	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2003301	ENSG00000179406.6	LINC00174	5.44	2.7e-07	0.000848	0.5	0.44	Aortic root size;	chr7:66682669	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.658	rs3768016	ENSG00000206931.1	RNU6-1042P	5.44	2.71e-07	0.00085	0.57	0.44	Melanoma;	chr1:150837443	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs1027699	ENSG00000206931.1	RNU6-1042P	5.44	2.71e-07	0.00085	0.57	0.44	Melanoma;	chr1:150839236	chr1:150701866~150701972:+
ESCA	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	5.44	2.71e-07	0.000851	0.57	0.44	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
ESCA	cis	rs977987	0.836	rs4888376	ENSG00000261783.1	RP11-252K23.2	-5.44	2.71e-07	0.000852	-0.53	-0.44	Dupuytren's disease;	chr16:75288675	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-5.44	2.72e-07	0.000853	-0.48	-0.44	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.862	rs2024192	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66576460	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6955837	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66578155	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs10281499	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66583979	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4718377	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66584691	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10278014	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66586277	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1968126	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66592017	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6460306	ENSG00000179406.6	LINC00174	5.44	2.72e-07	0.000853	0.49	0.44	Aortic root size;	chr7:66595806	chr7:66376044~66401338:-
ESCA	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	5.44	2.72e-07	0.000853	0.44	0.44	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	5.44	2.72e-07	0.000853	0.44	0.44	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	5.44	2.72e-07	0.000853	0.44	0.44	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	5.44	2.72e-07	0.000853	0.44	0.44	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	5.44	2.72e-07	0.000853	0.44	0.44	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
ESCA	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	5.44	2.72e-07	0.000854	0.54	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
ESCA	cis	rs17711722	0.701	rs781145	ENSG00000179406.6	LINC00174	-5.44	2.73e-07	0.000856	-0.51	-0.44	Calcium levels;	chr7:65975383	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.967	rs2707853	ENSG00000179406.6	LINC00174	-5.44	2.74e-07	0.000859	-0.5	-0.44	Aortic root size;	chr7:66749023	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2659889	ENSG00000179406.6	LINC00174	-5.44	2.74e-07	0.000859	-0.5	-0.44	Aortic root size;	chr7:66752125	chr7:66376044~66401338:-
ESCA	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	5.44	2.75e-07	0.000861	0.54	0.44	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	5.44	2.75e-07	0.000861	0.54	0.44	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
ESCA	cis	rs9545047	0.74	rs9574409	ENSG00000227676.3	LINC01068	5.44	2.75e-07	0.000862	0.57	0.44	Schizophrenia;	chr13:79341844	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.68	rs7987769	ENSG00000227676.3	LINC01068	5.44	2.75e-07	0.000862	0.57	0.44	Schizophrenia;	chr13:79343965	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs7327386	ENSG00000227676.3	LINC01068	5.44	2.75e-07	0.000862	0.57	0.44	Schizophrenia;	chr13:79347901	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.644	rs9318624	ENSG00000227676.3	LINC01068	5.44	2.75e-07	0.000862	0.57	0.44	Schizophrenia;	chr13:79350915	chr13:79566727~79571436:+
ESCA	cis	rs17361889	0.645	rs17285792	ENSG00000224683.1	RPL36AP29	5.44	2.75e-07	0.000862	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16086578	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	5.44	2.75e-07	0.000862	0.57	0.44	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
ESCA	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	5.44	2.75e-07	0.000863	0.63	0.44	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
ESCA	cis	rs42490	0.868	rs12675281	ENSG00000251136.7	RP11-37B2.1	5.44	2.76e-07	0.000863	0.45	0.44	Leprosy;	chr8:89681561	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.868	rs4961158	ENSG00000251136.7	RP11-37B2.1	5.44	2.76e-07	0.000863	0.45	0.44	Leprosy;	chr8:89685607	chr8:89609409~89757727:-
ESCA	cis	rs977987	0.815	rs11646677	ENSG00000261783.1	RP11-252K23.2	-5.44	2.76e-07	0.000864	-0.54	-0.44	Dupuytren's disease;	chr16:75375083	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs8056080	ENSG00000261783.1	RP11-252K23.2	-5.44	2.76e-07	0.000864	-0.54	-0.44	Dupuytren's disease;	chr16:75376900	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	5.44	2.77e-07	0.000866	0.47	0.44	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
ESCA	cis	rs2221894	0.96	rs10093622	ENSG00000273710.1	Metazoa_SRP	-5.44	2.79e-07	0.00087	-0.51	-0.44	Obesity-related traits;	chr8:29005420	chr8:28915579~28915864:-
ESCA	cis	rs2221894	1	rs7842492	ENSG00000273710.1	Metazoa_SRP	-5.44	2.79e-07	0.00087	-0.51	-0.44	Obesity-related traits;	chr8:29012120	chr8:28915579~28915864:-
ESCA	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	5.44	2.79e-07	0.00087	0.57	0.44	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
ESCA	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	5.44	2.79e-07	0.000871	0.47	0.44	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	5.44	2.79e-07	0.000871	0.47	0.44	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
ESCA	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-5.44	2.8e-07	0.000871	-0.51	-0.44	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-5.44	2.8e-07	0.000871	-0.51	-0.44	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
ESCA	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-5.44	2.81e-07	0.000875	-0.39	-0.44	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
ESCA	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-5.44	2.81e-07	0.000876	-0.44	-0.44	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
ESCA	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	5.44	2.82e-07	0.000876	0.58	0.44	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
ESCA	cis	rs42490	0.837	rs218916	ENSG00000251136.7	RP11-37B2.1	-5.44	2.82e-07	0.000877	-0.45	-0.44	Leprosy;	chr8:89688709	chr8:89609409~89757727:-
ESCA	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-5.43	2.82e-07	0.000879	-0.57	-0.44	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
ESCA	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-5.43	2.83e-07	0.00088	-0.38	-0.44	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
ESCA	cis	rs2627019	0.528	rs4972322	ENSG00000223911.1	AC009480.3	5.43	2.84e-07	0.000885	0.49	0.44	Neuroticism;	chr2:148056861	chr2:147899401~147902956:-
ESCA	cis	rs858239	0.699	rs955187	ENSG00000230042.1	AK3P3	5.43	2.85e-07	0.000885	0.47	0.44	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23129178~23129841:+
ESCA	cis	rs6456156	0.586	rs13195158	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167067904	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs9457266	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167069067	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs7750209	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167069407	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs7746628	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167069747	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs2345753	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167070856	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.603	rs2345754	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167070873	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs7761977	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167072190	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs7742305	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167072235	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs7762156	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167072343	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs2001115	ENSG00000265828.1	MIR3939	-5.43	2.85e-07	0.000886	-0.47	-0.44	Primary biliary cholangitis;	chr6:167072730	chr6:166997807~166997912:-
ESCA	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	5.43	2.86e-07	0.000887	0.66	0.44	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
ESCA	cis	rs875971	0.862	rs1875057	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66266868	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6960446	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66268272	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.789	rs10260426	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66271055	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7796162	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66280771	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2901152	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66300017	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10263690	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66301466	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10250544	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66301574	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs12531677	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66304099	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7798630	ENSG00000179406.6	LINC00174	5.43	2.86e-07	0.000887	0.5	0.44	Aortic root size;	chr7:66306492	chr7:66376044~66401338:-
ESCA	cis	rs1005277	0.579	rs1740732	ENSG00000276805.1	RP11-291L22.6	5.43	2.86e-07	0.000888	0.56	0.44	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38451030~38451785:+
ESCA	cis	rs9549367	0.662	rs3818334	ENSG00000269125.1	RP11-98F14.11	-5.43	2.87e-07	0.000891	-0.52	-0.44	Platelet distribution width;	chr13:113170860	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.713	rs9549681	ENSG00000269125.1	RP11-98F14.11	-5.43	2.87e-07	0.000891	-0.52	-0.44	Platelet distribution width;	chr13:113175559	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.713	rs9549682	ENSG00000269125.1	RP11-98F14.11	-5.43	2.87e-07	0.000891	-0.52	-0.44	Platelet distribution width;	chr13:113175867	chr13:113165002~113165183:-
ESCA	cis	rs875971	0.755	rs10228885	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66315542	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs3893216	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66325720	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6958294	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66329809	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2088655	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66330724	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.895	rs10447522	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66331087	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs7783779	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66331639	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2088653	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66343621	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6460293	ENSG00000179406.6	LINC00174	5.43	2.88e-07	0.000893	0.5	0.44	Aortic root size;	chr7:66345205	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778736	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66348861	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2909688	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66376625	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs778711	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66386670	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs1083554	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66387354	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778707	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66392040	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778705	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66396128	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs778697	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66405439	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.798	rs7789615	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66413674	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6978028	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66421313	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.798	rs12698522	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66502354	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs28714531	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66503250	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs12698526	ENSG00000179406.6	LINC00174	-5.43	2.88e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66504118	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs6947339	ENSG00000179406.6	LINC00174	-5.43	2.89e-07	0.000893	-0.5	-0.44	Aortic root size;	chr7:66423483	chr7:66376044~66401338:-
ESCA	cis	rs748404	0.723	rs512431	ENSG00000249839.1	AC011330.5	5.43	2.89e-07	0.000894	0.54	0.44	Lung cancer;	chr15:43249741	chr15:43663654~43684339:-
ESCA	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
ESCA	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	5.43	2.89e-07	0.000894	0.47	0.44	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
ESCA	cis	rs6479891	1	rs61853589	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63427351	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9414803	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63428309	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9415707	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63428530	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12413029	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63429366	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9415708	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63430282	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs72837025	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63434731	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12784772	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63435695	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs77494594	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63437549	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs2466128	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63448561	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs2719815	ENSG00000235816.3	PRELID1P3	5.43	2.9e-07	0.000895	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63450534	chr10:63427297~63427939:+
ESCA	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-5.43	2.91e-07	0.000897	-0.45	-0.44	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
ESCA	cis	rs10875746	0.81	rs10875732	ENSG00000240399.1	RP1-228P16.1	-5.43	2.92e-07	9e-04	-0.55	-0.44	Longevity (90 years and older);	chr12:48048322	chr12:48054813~48055591:-
ESCA	cis	rs977987	0.933	rs4888431	ENSG00000261783.1	RP11-252K23.2	-5.43	2.92e-07	9e-04	-0.55	-0.44	Dupuytren's disease;	chr16:75466801	chr16:75379818~75381260:-
ESCA	cis	rs977987	1	rs62060550	ENSG00000261783.1	RP11-252K23.2	-5.43	2.92e-07	9e-04	-0.55	-0.44	Dupuytren's disease;	chr16:75468354	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.966	rs62060551	ENSG00000261783.1	RP11-252K23.2	-5.43	2.92e-07	9e-04	-0.55	-0.44	Dupuytren's disease;	chr16:75468414	chr16:75379818~75381260:-
ESCA	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	5.43	2.93e-07	0.000903	0.57	0.44	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
ESCA	cis	rs875971	0.545	rs2420612	ENSG00000222364.1	RNU6-96P	-5.43	2.94e-07	0.000906	-0.58	-0.44	Aortic root size;	chr7:66536825	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	5.43	2.94e-07	0.000907	0.61	0.44	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
ESCA	cis	rs6456156	0.586	rs9459853	ENSG00000265828.1	MIR3939	-5.43	2.94e-07	0.000908	-0.47	-0.44	Primary biliary cholangitis;	chr6:167052286	chr6:166997807~166997912:-
ESCA	cis	rs9733	0.818	rs4970924	ENSG00000206931.1	RNU6-1042P	-5.42	2.95e-07	0.00091	-0.55	-0.44	Tonsillectomy;	chr1:150660603	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.818	rs11204695	ENSG00000206931.1	RNU6-1042P	-5.42	2.95e-07	0.00091	-0.55	-0.44	Tonsillectomy;	chr1:150684535	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.818	rs11204702	ENSG00000206931.1	RNU6-1042P	-5.42	2.95e-07	0.00091	-0.55	-0.44	Tonsillectomy;	chr1:150691031	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.818	rs4970926	ENSG00000206931.1	RNU6-1042P	-5.42	2.95e-07	0.00091	-0.55	-0.44	Tonsillectomy;	chr1:150701208	chr1:150701866~150701972:+
ESCA	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-5.42	2.96e-07	0.000913	-0.46	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
ESCA	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	5.42	2.98e-07	0.000919	0.66	0.44	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	5.42	2.98e-07	0.000919	0.66	0.44	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
ESCA	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	5.42	2.98e-07	0.000919	0.53	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
ESCA	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-5.42	2.99e-07	0.000921	-0.49	-0.44	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
ESCA	cis	rs3136516	0.772	rs7947747	ENSG00000271350.1	CTD-2384B9.1	-5.42	2.99e-07	0.000921	-0.51	-0.44	Venous thromboembolism;	chr11:46831288	chr11:47041027~47041945:-
ESCA	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-5.42	3e-07	0.000923	-0.45	-0.44	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
ESCA	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-5.42	3e-07	0.000924	-0.63	-0.44	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
ESCA	cis	rs875971	0.862	rs13232191	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66521661	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs35378740	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66522725	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs10950043	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66523623	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs17747530	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66529742	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs13226170	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66534311	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs2420611	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66534333	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.767	rs61348003	ENSG00000179406.6	LINC00174	-5.42	3.01e-07	0.000927	-0.5	-0.44	Aortic root size;	chr7:66540947	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.861	rs801215	ENSG00000179406.6	LINC00174	5.42	3.01e-07	0.000927	0.5	0.44	Aortic root size;	chr7:66546951	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.825	rs801202	ENSG00000179406.6	LINC00174	5.42	3.01e-07	0.000927	0.5	0.44	Aortic root size;	chr7:66558942	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.867	rs1002053	ENSG00000179406.6	LINC00174	5.42	3.02e-07	0.000929	0.49	0.44	Aortic root size;	chr7:66333558	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs6460292	ENSG00000179406.6	LINC00174	5.42	3.02e-07	0.000929	0.49	0.44	Aortic root size;	chr7:66345088	chr7:66376044~66401338:-
ESCA	cis	rs7582403	0.51	rs13015655	ENSG00000223911.1	AC009480.3	5.42	3.02e-07	0.00093	0.48	0.44	Neuroticism;	chr2:148115763	chr2:147899401~147902956:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000231271.1	AP000350.8	5.42	3.04e-07	0.000934	0.51	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23949918~23954042:+
ESCA	cis	rs6782228	0.606	rs2712404	ENSG00000277250.1	Metazoa_SRP	5.42	3.05e-07	0.000936	0.51	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128673681~128674021:-
ESCA	cis	rs9549367	0.789	rs9549698	ENSG00000269125.1	RP11-98F14.11	-5.42	3.05e-07	0.000936	-0.5	-0.44	Platelet distribution width;	chr13:113223387	chr13:113165002~113165183:-
ESCA	cis	rs1005277	0.579	rs1780133	ENSG00000276805.1	RP11-291L22.6	5.42	3.05e-07	0.000938	0.57	0.44	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38451030~38451785:+
ESCA	cis	rs10875746	0.855	rs11168369	ENSG00000240399.1	RP1-228P16.1	-5.42	3.07e-07	0.000942	-0.53	-0.44	Longevity (90 years and older);	chr12:48037385	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.855	rs10875731	ENSG00000240399.1	RP1-228P16.1	-5.42	3.07e-07	0.000942	-0.53	-0.44	Longevity (90 years and older);	chr12:48038960	chr12:48054813~48055591:-
ESCA	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	5.42	3.07e-07	0.000943	0.64	0.44	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000228039.3	KB-1125A3.10	5.42	3.07e-07	0.000943	0.53	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23963780~23964374:+
ESCA	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	5.42	3.08e-07	0.000946	0.5	0.44	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	5.42	3.08e-07	0.000946	0.5	0.44	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
ESCA	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	5.42	3.09e-07	0.000947	0.39	0.44	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	5.42	3.09e-07	0.000947	0.39	0.44	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	5.42	3.09e-07	0.000947	0.39	0.44	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	5.42	3.09e-07	0.000947	0.39	0.44	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	5.42	3.09e-07	0.000947	0.39	0.44	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
ESCA	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000947	-0.55	-0.44	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000947	-0.55	-0.44	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000947	-0.55	-0.44	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000947	-0.55	-0.44	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-5.41	3.09e-07	0.000947	-0.55	-0.44	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
ESCA	cis	rs9322193	0.887	rs11155662	ENSG00000216906.2	RP11-350J20.9	5.41	3.09e-07	0.000948	0.6	0.44	Lung cancer;	chr6:149592731	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.54	rs736270	ENSG00000179406.6	LINC00174	-5.41	3.11e-07	0.000953	-0.51	-0.44	Aortic root size;	chr7:65963835	chr7:66376044~66401338:-
ESCA	cis	rs7582403	0.528	rs7569780	ENSG00000223911.1	AC009480.3	5.41	3.13e-07	0.000958	0.49	0.44	Neuroticism;	chr2:148053129	chr2:147899401~147902956:-
ESCA	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-5.41	3.13e-07	0.000958	-0.5	-0.44	Migraine;	chr4:56879851	chr4:56960927~56961373:-
ESCA	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-5.41	3.13e-07	0.000958	-0.5	-0.44	Migraine;	chr4:56880007	chr4:56960927~56961373:-
ESCA	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-5.41	3.13e-07	0.000958	-0.5	-0.44	Migraine;	chr4:56880190	chr4:56960927~56961373:-
ESCA	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-5.41	3.13e-07	0.000958	-0.5	-0.44	Migraine;	chr4:56880659	chr4:56960927~56961373:-
ESCA	cis	rs875971	0.522	rs7784623	ENSG00000179406.6	LINC00174	-5.41	3.13e-07	0.000958	-0.5	-0.44	Aortic root size;	chr7:65930047	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs34973832	ENSG00000179406.6	LINC00174	-5.41	3.13e-07	0.000958	-0.5	-0.44	Aortic root size;	chr7:65931217	chr7:66376044~66401338:-
ESCA	cis	rs17711722	0.74	rs7809991	ENSG00000179406.6	LINC00174	-5.41	3.13e-07	0.000958	-0.5	-0.44	Calcium levels;	chr7:65941231	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs6960048	ENSG00000179406.6	LINC00174	-5.41	3.13e-07	0.000958	-0.5	-0.44	Aortic root size;	chr7:65943052	chr7:66376044~66401338:-
ESCA	cis	rs6479891	0.908	rs12412946	ENSG00000235816.3	PRELID1P3	5.41	3.15e-07	0.000964	0.55	0.44	Arthritis (juvenile idiopathic);	chr10:63529792	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs59035163	ENSG00000235816.3	PRELID1P3	5.41	3.15e-07	0.000964	0.55	0.44	Arthritis (juvenile idiopathic);	chr10:63532283	chr10:63427297~63427939:+
ESCA	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-5.41	3.16e-07	0.000966	-0.6	-0.44	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
ESCA	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-5.41	3.16e-07	0.000967	-0.38	-0.44	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
ESCA	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-5.41	3.17e-07	0.000968	-0.44	-0.44	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-5.41	3.17e-07	0.000968	-0.44	-0.44	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-5.41	3.17e-07	0.000969	-0.46	-0.44	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
ESCA	cis	rs5758659	0.692	rs5751251	ENSG00000182057.4	OGFRP1	5.41	3.18e-07	0.000972	0.51	0.44	Cognitive function;	chr22:42244600	chr22:42269753~42275196:+
ESCA	cis	rs8040855	0.93	rs6496767	ENSG00000259295.5	CSPG4P12	-5.41	3.18e-07	0.000972	-0.72	-0.44	Bulimia nervosa;	chr15:85159522	chr15:85191438~85213905:+
ESCA	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	5.41	3.18e-07	0.000972	0.52	0.44	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
ESCA	cis	rs13217239	0.646	rs7768407	ENSG00000243307.2	POM121L6P	5.41	3.19e-07	0.000974	0.49	0.44	Schizophrenia;	chr6:27049016	chr6:26896952~26898777:+
ESCA	cis	rs1816752	0.583	rs6490918	ENSG00000273628.1	RP11-756A22.7	-5.41	3.2e-07	0.000975	-0.42	-0.44	Obesity-related traits;	chr13:24427977	chr13:24933006~24936796:+
ESCA	cis	rs6479891	1	rs2616630	ENSG00000235816.3	PRELID1P3	5.41	3.2e-07	0.000975	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63453579	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs2616629	ENSG00000235816.3	PRELID1P3	5.41	3.2e-07	0.000975	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63454056	chr10:63427297~63427939:+
ESCA	cis	rs875971	0.862	rs801194	ENSG00000179406.6	LINC00174	5.41	3.21e-07	0.000978	0.5	0.44	Aortic root size;	chr7:66563508	chr7:66376044~66401338:-
ESCA	cis	rs7412746	0.611	rs7532045	ENSG00000206931.1	RNU6-1042P	5.41	3.21e-07	0.000979	0.57	0.44	Melanoma;	chr1:150849371	chr1:150701866~150701972:+
ESCA	cis	rs977987	0.872	rs4887816	ENSG00000261783.1	RP11-252K23.2	-5.41	3.23e-07	0.000982	-0.52	-0.44	Dupuytren's disease;	chr16:75285818	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs4243112	ENSG00000261783.1	RP11-252K23.2	-5.41	3.23e-07	0.000982	-0.52	-0.44	Dupuytren's disease;	chr16:75287133	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.836	rs34673655	ENSG00000261783.1	RP11-252K23.2	-5.41	3.23e-07	0.000982	-0.52	-0.44	Dupuytren's disease;	chr16:75289661	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs1011121	ENSG00000261783.1	RP11-252K23.2	-5.41	3.23e-07	0.000982	-0.52	-0.44	Dupuytren's disease;	chr16:75292035	chr16:75379818~75381260:-
ESCA	cis	rs950880	0.71	rs11693955	ENSG00000234389.1	AC007278.3	-5.41	3.23e-07	0.000982	-0.41	-0.44	Serum protein levels (sST2);	chr2:102412705	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.744	rs3771156	ENSG00000234389.1	AC007278.3	-5.41	3.23e-07	0.000982	-0.41	-0.44	Serum protein levels (sST2);	chr2:102420217	chr2:102438713~102440475:+
ESCA	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	5.41	3.23e-07	0.000982	0.47	0.44	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.806	rs11862582	ENSG00000261783.1	RP11-252K23.2	-5.41	3.23e-07	0.000982	-0.54	-0.44	Dupuytren's disease;	chr16:75397397	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	5.4	3.23e-07	0.000984	0.48	0.44	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
ESCA	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	5.4	3.23e-07	0.000984	0.53	0.44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
ESCA	cis	rs7412746	0.658	rs10305704	ENSG00000206931.1	RNU6-1042P	5.4	3.26e-07	0.000992	0.56	0.44	Melanoma;	chr1:150831953	chr1:150701866~150701972:+
ESCA	cis	rs7829975	0.511	rs2948286	ENSG00000253981.4	ALG1L13P	5.4	3.27e-07	0.000992	0.53	0.44	Mood instability;	chr8:8272638	chr8:8236003~8244667:-
ESCA	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	5.4	3.27e-07	0.000992	0.67	0.44	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	5.4	3.27e-07	0.000992	0.67	0.44	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
ESCA	cis	rs875971	1	rs6956179	ENSG00000179406.6	LINC00174	5.4	3.31e-07	0.001	0.49	0.44	Aortic root size;	chr7:66341672	chr7:66376044~66401338:-
ESCA	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	5.4	3.32e-07	0.00101	0.48	0.44	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
ESCA	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-5.4	3.32e-07	0.00101	-0.44	-0.44	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
ESCA	cis	rs6456156	0.528	rs6936261	ENSG00000265828.1	MIR3939	-5.4	3.32e-07	0.00101	-0.47	-0.44	Primary biliary cholangitis;	chr6:167056188	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs13210649	ENSG00000265828.1	MIR3939	-5.4	3.32e-07	0.00101	-0.47	-0.44	Primary biliary cholangitis;	chr6:167059705	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12213801	ENSG00000265828.1	MIR3939	-5.4	3.32e-07	0.00101	-0.47	-0.44	Primary biliary cholangitis;	chr6:167060596	chr6:166997807~166997912:-
ESCA	cis	rs7924176	0.601	rs2131957	ENSG00000236900.1	TIMM9P1	-5.4	3.33e-07	0.00101	-0.51	-0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107171	chr10:74344550~74344805:-
ESCA	cis	rs2739330	0.76	rs5751760	ENSG00000099984.9	GSTT2	-5.4	3.33e-07	0.00101	-0.52	-0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23980123~23983911:+
ESCA	cis	rs2627019	0.546	rs6430286	ENSG00000223911.1	AC009480.3	5.4	3.33e-07	0.00101	0.49	0.44	Neuroticism;	chr2:148076795	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.528	rs12691772	ENSG00000223911.1	AC009480.3	5.4	3.33e-07	0.00101	0.49	0.44	Neuroticism;	chr2:148048864	chr2:147899401~147902956:-
ESCA	cis	rs7412746	0.658	rs11589458	ENSG00000206931.1	RNU6-1042P	5.4	3.34e-07	0.00101	0.56	0.44	Melanoma;	chr1:150820140	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs17660092	ENSG00000206931.1	RNU6-1042P	5.4	3.34e-07	0.00101	0.56	0.44	Melanoma;	chr1:150825272	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs2089082	ENSG00000206931.1	RNU6-1042P	5.4	3.34e-07	0.00101	0.56	0.44	Melanoma;	chr1:150827614	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs10305711	ENSG00000206931.1	RNU6-1042P	5.4	3.34e-07	0.00101	0.56	0.44	Melanoma;	chr1:150830520	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.505	rs1723275	ENSG00000179406.6	LINC00174	5.4	3.34e-07	0.00101	0.5	0.44	Aortic root size;	chr7:66039646	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.505	rs2462573	ENSG00000179406.6	LINC00174	5.4	3.34e-07	0.00101	0.5	0.44	Aortic root size;	chr7:66042405	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.505	rs1167386	ENSG00000179406.6	LINC00174	5.4	3.34e-07	0.00101	0.5	0.44	Aortic root size;	chr7:66048109	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.505	rs1167385	ENSG00000179406.6	LINC00174	5.4	3.34e-07	0.00101	0.5	0.44	Aortic root size;	chr7:66048321	chr7:66376044~66401338:-
ESCA	cis	rs748404	0.697	rs493177	ENSG00000249839.1	AC011330.5	-5.4	3.36e-07	0.00101	-0.53	-0.44	Lung cancer;	chr15:43251060	chr15:43663654~43684339:-
ESCA	cis	rs42490	0.903	rs7824932	ENSG00000251136.7	RP11-37B2.1	5.4	3.38e-07	0.00102	0.45	0.44	Leprosy;	chr8:89703848	chr8:89609409~89757727:-
ESCA	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	5.4	3.38e-07	0.00102	0.56	0.44	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
ESCA	cis	rs875971	0.825	rs1129531	ENSG00000226824.5	RP4-756H11.3	5.4	3.38e-07	0.00102	0.47	0.44	Aortic root size;	chr7:66154117	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	5.39	3.38e-07	0.00102	0.47	0.44	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	5.39	3.38e-07	0.00102	0.47	0.44	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	5.39	3.38e-07	0.00102	0.47	0.44	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	5.39	3.38e-07	0.00102	0.47	0.44	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
ESCA	cis	rs977987	0.836	rs11646044	ENSG00000261783.1	RP11-252K23.2	-5.39	3.39e-07	0.00102	-0.52	-0.44	Dupuytren's disease;	chr16:75278650	chr16:75379818~75381260:-
ESCA	cis	rs2882667	0.929	rs17207828	ENSG00000253404.1	AC034243.1	5.39	3.39e-07	0.00102	0.59	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:138964146	chr5:138744434~138753309:-
ESCA	cis	rs6479891	0.908	rs4746201	ENSG00000235816.3	PRELID1P3	5.39	3.39e-07	0.00102	0.56	0.44	Arthritis (juvenile idiopathic);	chr10:63562621	chr10:63427297~63427939:+
ESCA	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-5.39	3.4e-07	0.00102	-0.57	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	5.39	3.41e-07	0.00102	0.6	0.44	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	5.39	3.41e-07	0.00102	0.6	0.44	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
ESCA	cis	rs6456156	0.586	rs10946209	ENSG00000265828.1	MIR3939	-5.39	3.41e-07	0.00102	-0.47	-0.44	Primary biliary cholangitis;	chr6:167067503	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12198816	ENSG00000265828.1	MIR3939	-5.39	3.41e-07	0.00102	-0.47	-0.44	Primary biliary cholangitis;	chr6:167070058	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs2001114	ENSG00000265828.1	MIR3939	-5.39	3.41e-07	0.00102	-0.47	-0.44	Primary biliary cholangitis;	chr6:167073090	chr6:166997807~166997912:-
ESCA	cis	rs977987	0.762	rs1364079	ENSG00000261783.1	RP11-252K23.2	-5.39	3.41e-07	0.00102	-0.53	-0.44	Dupuytren's disease;	chr16:75359233	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs2059256	ENSG00000261783.1	RP11-252K23.2	-5.39	3.41e-07	0.00102	-0.53	-0.44	Dupuytren's disease;	chr16:75361937	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.815	rs1364078	ENSG00000261783.1	RP11-252K23.2	-5.39	3.41e-07	0.00102	-0.53	-0.44	Dupuytren's disease;	chr16:75362983	chr16:75379818~75381260:-
ESCA	cis	rs1005277	0.579	rs1740735	ENSG00000276805.1	RP11-291L22.6	5.39	3.42e-07	0.00103	0.56	0.44	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38451030~38451785:+
ESCA	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	5.39	3.42e-07	0.00103	0.62	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
ESCA	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-5.39	3.42e-07	0.00103	-0.44	-0.44	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-5.39	3.42e-07	0.00103	-0.44	-0.44	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
ESCA	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-5.39	3.44e-07	0.00103	-0.52	-0.44	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
ESCA	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-5.39	3.45e-07	0.00104	-0.45	-0.44	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
ESCA	cis	rs2221894	0.922	rs11136052	ENSG00000273710.1	Metazoa_SRP	-5.39	3.46e-07	0.00104	-0.47	-0.44	Obesity-related traits;	chr8:28945558	chr8:28915579~28915864:-
ESCA	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	5.39	3.46e-07	0.00104	0.61	0.44	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.806	rs11862095	ENSG00000261783.1	RP11-252K23.2	-5.39	3.47e-07	0.00104	-0.53	-0.44	Dupuytren's disease;	chr16:75351520	chr16:75379818~75381260:-
ESCA	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-5.39	3.47e-07	0.00104	-0.55	-0.44	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
ESCA	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-5.39	3.48e-07	0.00105	-0.52	-0.44	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.522	rs1917563	ENSG00000179406.6	LINC00174	5.39	3.49e-07	0.00105	0.48	0.44	Aortic root size;	chr7:65950660	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	5.39	3.5e-07	0.00105	0.64	0.44	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
ESCA	cis	rs9549367	0.713	rs3024776	ENSG00000269125.1	RP11-98F14.11	5.39	3.5e-07	0.00105	0.5	0.44	Platelet distribution width;	chr13:113172761	chr13:113165002~113165183:-
ESCA	cis	rs6479901	0.557	rs4746125	ENSG00000235816.3	PRELID1P3	5.39	3.51e-07	0.00105	0.55	0.44	Intelligence (multi-trait analysis);	chr10:63393125	chr10:63427297~63427939:+
ESCA	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-5.39	3.51e-07	0.00105	-0.54	-0.44	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
ESCA	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	5.39	3.51e-07	0.00105	0.55	0.44	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
ESCA	cis	rs7829975	0.511	rs2955578	ENSG00000253981.4	ALG1L13P	5.39	3.52e-07	0.00106	0.54	0.44	Mood instability;	chr8:8279561	chr8:8236003~8244667:-
ESCA	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	5.39	3.52e-07	0.00106	0.63	0.44	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
ESCA	cis	rs7829975	0.593	rs2921051	ENSG00000253981.4	ALG1L13P	5.39	3.53e-07	0.00106	0.53	0.44	Mood instability;	chr8:8462594	chr8:8236003~8244667:-
ESCA	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-5.39	3.53e-07	0.00106	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-5.39	3.53e-07	0.00106	-0.53	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
ESCA	cis	rs7924176	0.601	rs767809	ENSG00000236900.1	TIMM9P1	-5.39	3.53e-07	0.00106	-0.51	-0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74105307	chr10:74344550~74344805:-
ESCA	cis	rs9399135	0.636	rs4646871	ENSG00000232876.1	CTA-212D2.2	5.38	3.56e-07	0.00107	0.5	0.44	Red blood cell count;	chr6:134944479	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	5.38	3.57e-07	0.00107	0.56	0.44	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	5.38	3.57e-07	0.00107	0.56	0.44	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
ESCA	cis	rs9549367	0.713	rs11620600	ENSG00000269125.1	RP11-98F14.11	-5.38	3.57e-07	0.00107	-0.51	-0.44	Platelet distribution width;	chr13:113174776	chr13:113165002~113165183:-
ESCA	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-5.38	3.58e-07	0.00107	-0.47	-0.44	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
ESCA	cis	rs9549367	0.713	rs9549352	ENSG00000269125.1	RP11-98F14.11	-5.38	3.59e-07	0.00107	-0.52	-0.44	Platelet distribution width;	chr13:113178907	chr13:113165002~113165183:-
ESCA	cis	rs7412746	0.658	rs3768015	ENSG00000206931.1	RNU6-1042P	5.38	3.62e-07	0.00108	0.57	0.44	Melanoma;	chr1:150840478	chr1:150701866~150701972:+
ESCA	cis	rs2929278	0.617	rs663214	ENSG00000205771.5	CATSPER2P1	5.38	3.62e-07	0.00108	0.55	0.44	Schizophrenia;	chr15:43821584	chr15:43726918~43747094:-
ESCA	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	5.38	3.64e-07	0.00108	0.61	0.44	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.843	rs17696749	ENSG00000261783.1	RP11-252K23.2	-5.38	3.64e-07	0.00108	-0.53	-0.44	Dupuytren's disease;	chr16:75369164	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	5.38	3.67e-07	0.00109	0.65	0.44	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
ESCA	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	5.38	3.68e-07	0.00109	0.48	0.44	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	5.38	3.68e-07	0.00109	0.48	0.44	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	5.38	3.68e-07	0.00109	0.48	0.44	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	5.38	3.68e-07	0.00109	0.48	0.44	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
ESCA	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-5.38	3.69e-07	0.0011	-0.51	-0.44	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
ESCA	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	5.38	3.69e-07	0.0011	0.61	0.44	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.502	rs6460311	ENSG00000222364.1	RNU6-96P	5.38	3.69e-07	0.0011	0.58	0.44	Aortic root size;	chr7:66646886	chr7:66395191~66395286:+
ESCA	cis	rs3136516	0.503	rs17787966	ENSG00000271350.1	CTD-2384B9.1	5.38	3.7e-07	0.0011	0.5	0.44	Venous thromboembolism;	chr11:47048874	chr11:47041027~47041945:-
ESCA	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.37	3.7e-07	0.0011	0.6	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.37	3.7e-07	0.0011	0.6	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
ESCA	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.37	3.7e-07	0.0011	0.6	0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.767	rs12668005	ENSG00000179406.6	LINC00174	-5.37	3.71e-07	0.0011	-0.5	-0.44	Aortic root size;	chr7:66444034	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs11765791	ENSG00000179406.6	LINC00174	-5.37	3.71e-07	0.0011	-0.5	-0.44	Aortic root size;	chr7:66471587	chr7:66376044~66401338:-
ESCA	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	5.37	3.71e-07	0.0011	0.53	0.44	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
ESCA	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-5.37	3.75e-07	0.00111	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-5.37	3.75e-07	0.00111	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-5.37	3.75e-07	0.00111	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
ESCA	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-5.37	3.75e-07	0.00111	-0.48	-0.44	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000231271.1	AP000350.8	-5.37	3.76e-07	0.00112	-0.59	-0.44	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23949918~23954042:+
ESCA	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-5.37	3.76e-07	0.00112	-0.56	-0.44	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
ESCA	cis	rs6479891	1	rs72837056	ENSG00000235816.3	PRELID1P3	5.37	3.77e-07	0.00112	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63500718	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.818	rs11815969	ENSG00000235816.3	PRELID1P3	5.37	3.77e-07	0.00112	0.58	0.44	Arthritis (juvenile idiopathic);	chr10:63506095	chr10:63427297~63427939:+
ESCA	cis	rs9549367	0.713	rs56002882	ENSG00000269125.1	RP11-98F14.11	-5.37	3.8e-07	0.00112	-0.52	-0.44	Platelet distribution width;	chr13:113176380	chr13:113165002~113165183:-
ESCA	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	5.37	3.81e-07	0.00113	0.6	0.44	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
ESCA	cis	rs1005277	0.563	rs2505215	ENSG00000276805.1	RP11-291L22.6	5.37	3.81e-07	0.00113	0.56	0.44	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.563	rs2505216	ENSG00000276805.1	RP11-291L22.6	5.37	3.81e-07	0.00113	0.56	0.44	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.563	rs2800550	ENSG00000276805.1	RP11-291L22.6	5.37	3.81e-07	0.00113	0.56	0.44	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38451030~38451785:+
ESCA	cis	rs8040855	0.894	rs6496770	ENSG00000259295.5	CSPG4P12	-5.37	3.81e-07	0.00113	-0.71	-0.44	Bulimia nervosa;	chr15:85161890	chr15:85191438~85213905:+
ESCA	cis	rs453301	0.624	rs330056	ENSG00000253981.4	ALG1L13P	-5.37	3.81e-07	0.00113	-0.54	-0.44	Joint mobility (Beighton score);	chr8:9232185	chr8:8236003~8244667:-
ESCA	cis	rs453301	0.624	rs330058	ENSG00000253981.4	ALG1L13P	-5.37	3.81e-07	0.00113	-0.54	-0.44	Joint mobility (Beighton score);	chr8:9232299	chr8:8236003~8244667:-
ESCA	cis	rs7412746	0.658	rs6660845	ENSG00000206931.1	RNU6-1042P	5.37	3.83e-07	0.00113	0.56	0.44	Melanoma;	chr1:150868590	chr1:150701866~150701972:+
ESCA	cis	rs6456156	0.586	rs6456149	ENSG00000265828.1	MIR3939	-5.37	3.83e-07	0.00113	-0.46	-0.44	Primary biliary cholangitis;	chr6:167050414	chr6:166997807~166997912:-
ESCA	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-5.37	3.84e-07	0.00113	-0.45	-0.44	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
ESCA	cis	rs1816752	0.679	rs7999480	ENSG00000273628.1	RP11-756A22.7	-5.37	3.85e-07	0.00114	-0.42	-0.44	Obesity-related traits;	chr13:24397865	chr13:24933006~24936796:+
ESCA	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	5.37	3.85e-07	0.00114	0.83	0.44	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
ESCA	cis	rs1799949	0.965	rs8067269	ENSG00000198496.9	NBR2	-5.37	3.86e-07	0.00114	-0.49	-0.44	Menopause (age at onset);	chr17:43083782	chr17:43125610~43153671:+
ESCA	cis	rs7412746	0.611	rs4319334	ENSG00000206931.1	RNU6-1042P	5.37	3.86e-07	0.00114	0.56	0.44	Melanoma;	chr1:150794346	chr1:150701866~150701972:+
ESCA	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-5.37	3.87e-07	0.00114	-0.45	-0.44	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
ESCA	cis	rs7412746	0.611	rs2228099	ENSG00000206931.1	RNU6-1042P	5.36	3.87e-07	0.00114	0.54	0.44	Melanoma;	chr1:150836413	chr1:150701866~150701972:+
ESCA	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-5.36	3.87e-07	0.00114	-0.44	-0.44	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
ESCA	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	5.36	3.88e-07	0.00114	0.45	0.44	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
ESCA	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-5.36	3.88e-07	0.00115	-0.51	-0.44	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
ESCA	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-5.36	3.89e-07	0.00115	-0.53	-0.44	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
ESCA	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-5.36	3.89e-07	0.00115	-0.54	-0.44	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
ESCA	cis	rs42490	0.903	rs184302	ENSG00000251136.7	RP11-37B2.1	-5.36	3.9e-07	0.00115	-0.44	-0.44	Leprosy;	chr8:89704396	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.903	rs218948	ENSG00000251136.7	RP11-37B2.1	-5.36	3.9e-07	0.00115	-0.44	-0.44	Leprosy;	chr8:89705617	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.873	rs218895	ENSG00000251136.7	RP11-37B2.1	-5.36	3.9e-07	0.00115	-0.44	-0.44	Leprosy;	chr8:89714320	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.903	rs218899	ENSG00000251136.7	RP11-37B2.1	-5.36	3.9e-07	0.00115	-0.44	-0.44	Leprosy;	chr8:89717279	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.844	rs444078	ENSG00000251136.7	RP11-37B2.1	-5.36	3.92e-07	0.00116	-0.44	-0.44	Leprosy;	chr8:89701558	chr8:89609409~89757727:-
ESCA	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-5.36	3.94e-07	0.00116	-0.48	-0.44	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
ESCA	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-5.36	3.95e-07	0.00116	-0.51	-0.44	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
ESCA	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	5.36	3.95e-07	0.00117	0.65	0.44	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
ESCA	cis	rs2739330	0.828	rs5760107	ENSG00000228039.3	KB-1125A3.10	5.36	3.96e-07	0.00117	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.789	rs5760109	ENSG00000228039.3	KB-1125A3.10	5.36	3.96e-07	0.00117	0.56	0.44	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23963780~23964374:+
ESCA	cis	rs9322193	0.962	rs7818	ENSG00000216906.2	RP11-350J20.9	5.36	3.98e-07	0.00117	0.6	0.44	Lung cancer;	chr6:149810956	chr6:149904243~149906418:+
ESCA	cis	rs977987	0.806	rs4888386	ENSG00000261783.1	RP11-252K23.2	-5.36	3.98e-07	0.00117	-0.53	-0.44	Dupuytren's disease;	chr16:75355842	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	5.36	4e-07	0.00118	0.64	0.43	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
ESCA	cis	rs6921919	0.697	rs12180820	ENSG00000216901.1	AL022393.7	-5.36	4e-07	0.00118	-0.52	-0.43	Autism spectrum disorder or schizophrenia;	chr6:28348701	chr6:28176188~28176674:+
ESCA	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	5.36	4.01e-07	0.00118	0.53	0.43	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	5.36	4.01e-07	0.00118	0.53	0.43	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
ESCA	cis	rs7412746	0.658	rs72704652	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150846994	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.634	rs7521592	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150849215	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.622	rs72704654	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150853934	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs11582281	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150854355	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.634	rs72704658	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150860534	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.588	rs10305664	ENSG00000206931.1	RNU6-1042P	5.36	4.01e-07	0.00118	0.56	0.43	Melanoma;	chr1:150867210	chr1:150701866~150701972:+
ESCA	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-5.36	4.02e-07	0.00118	-0.54	-0.43	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
ESCA	cis	rs3820716	0.507	rs7583759	ENSG00000223911.1	AC009480.3	5.36	4.03e-07	0.00118	0.51	0.43	Glomerular filtration rate (creatinine);	chr2:148084810	chr2:147899401~147902956:-
ESCA	cis	rs977987	0.902	rs4888430	ENSG00000261783.1	RP11-252K23.2	-5.36	4.03e-07	0.00118	-0.54	-0.43	Dupuytren's disease;	chr16:75460526	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.931	rs1834013	ENSG00000261783.1	RP11-252K23.2	-5.36	4.03e-07	0.00118	-0.54	-0.43	Dupuytren's disease;	chr16:75462265	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.645	rs34904236	ENSG00000261783.1	RP11-252K23.2	-5.36	4.03e-07	0.00118	-0.54	-0.43	Dupuytren's disease;	chr16:75464355	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.933	rs1834014	ENSG00000261783.1	RP11-252K23.2	-5.36	4.03e-07	0.00118	-0.54	-0.43	Dupuytren's disease;	chr16:75467376	chr16:75379818~75381260:-
ESCA	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	5.35	4.05e-07	0.00119	0.63	0.43	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
ESCA	cis	rs2739330	0.828	rs4822451	ENSG00000228039.3	KB-1125A3.10	5.35	4.08e-07	0.0012	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.828	rs5760099	ENSG00000228039.3	KB-1125A3.10	5.35	4.08e-07	0.0012	0.55	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23963780~23964374:+
ESCA	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-5.35	4.08e-07	0.0012	-0.51	-0.43	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
ESCA	cis	rs950880	0.71	rs2270298	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102375619	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs17027037	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102378424	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs2080289	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102378560	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11683700	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102380345	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3771162	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102380714	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs11465633	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102381273	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs56258475	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102382852	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs1035130	ENSG00000234389.1	AC007278.3	-5.35	4.09e-07	0.0012	-0.41	-0.43	Serum protein levels (sST2);	chr2:102384942	chr2:102438713~102440475:+
ESCA	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-5.35	4.1e-07	0.0012	-0.73	-0.43	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-5.35	4.1e-07	0.0012	-0.73	-0.43	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
ESCA	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-5.35	4.11e-07	0.0012	-0.61	-0.43	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
ESCA	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-5.35	4.11e-07	0.0012	-0.68	-0.43	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
ESCA	cis	rs7829975	0.688	rs7827182	ENSG00000253981.4	ALG1L13P	5.35	4.12e-07	0.0012	0.5	0.43	Mood instability;	chr8:8522961	chr8:8236003~8244667:-
ESCA	cis	rs9549367	0.707	rs9549353	ENSG00000269125.1	RP11-98F14.11	-5.35	4.12e-07	0.00121	-0.52	-0.43	Platelet distribution width;	chr13:113189113	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.664	rs9549689	ENSG00000269125.1	RP11-98F14.11	-5.35	4.12e-07	0.00121	-0.52	-0.43	Platelet distribution width;	chr13:113194073	chr13:113165002~113165183:-
ESCA	cis	rs9549367	0.713	rs9549356	ENSG00000269125.1	RP11-98F14.11	-5.35	4.12e-07	0.00121	-0.52	-0.43	Platelet distribution width;	chr13:113197319	chr13:113165002~113165183:-
ESCA	cis	rs394563	0.591	rs11155641	ENSG00000231760.4	RP11-350J20.5	-5.35	4.12e-07	0.00121	-0.5	-0.43	Dupuytren's disease;	chr6:149327459	chr6:149796151~149826294:-
ESCA	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-5.35	4.13e-07	0.00121	-0.52	-0.43	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
ESCA	cis	rs2221894	1	rs12674777	ENSG00000273710.1	Metazoa_SRP	-5.35	4.14e-07	0.00121	-0.5	-0.43	Obesity-related traits;	chr8:28986204	chr8:28915579~28915864:-
ESCA	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-5.35	4.14e-07	0.00121	-0.43	-0.43	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
ESCA	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-5.35	4.16e-07	0.00122	-0.48	-0.43	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
ESCA	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-5.35	4.16e-07	0.00122	-0.51	-0.43	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
ESCA	cis	rs9322193	0.923	rs9478291	ENSG00000216906.2	RP11-350J20.9	5.35	4.16e-07	0.00122	0.6	0.43	Lung cancer;	chr6:149729434	chr6:149904243~149906418:+
ESCA	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-5.35	4.16e-07	0.00122	-0.55	-0.43	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
ESCA	cis	rs1005277	0.579	rs1614236	ENSG00000263064.2	RP11-291L22.7	5.35	4.17e-07	0.00122	0.6	0.43	Extrinsic epigenetic age acceleration;	chr10:38214068	chr10:38448689~38448949:+
ESCA	cis	rs950880	0.71	rs55742125	ENSG00000234389.1	AC007278.3	-5.35	4.2e-07	0.00123	-0.41	-0.43	Serum protein levels (sST2);	chr2:102403322	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs2287034	ENSG00000234389.1	AC007278.3	5.35	4.2e-07	0.00123	0.41	0.43	Serum protein levels (sST2);	chr2:102394128	chr2:102438713~102440475:+
ESCA	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	5.35	4.2e-07	0.00123	0.62	0.43	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
ESCA	cis	rs8059260	0.673	rs7188928	ENSG00000274038.1	RP11-66H6.4	-5.35	4.2e-07	0.00123	-0.81	-0.43	Alcohol consumption over the past year;	chr16:10964896	chr16:11056556~11057034:+
ESCA	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-5.35	4.2e-07	0.00123	-0.81	-0.43	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
ESCA	cis	rs1005277	0.602	rs1831315	ENSG00000263064.2	RP11-291L22.7	5.35	4.21e-07	0.00123	0.57	0.43	Extrinsic epigenetic age acceleration;	chr10:38184425	chr10:38448689~38448949:+
ESCA	cis	rs9322193	0.884	rs2064521	ENSG00000216906.2	RP11-350J20.9	-5.35	4.23e-07	0.00123	-0.58	-0.43	Lung cancer;	chr6:149625336	chr6:149904243~149906418:+
ESCA	cis	rs9399135	0.684	rs1135205	ENSG00000232876.1	CTA-212D2.2	-5.34	4.25e-07	0.00124	-0.51	-0.43	Red blood cell count;	chr6:134960657	chr6:135055033~135060550:+
ESCA	cis	rs950880	0.71	rs4851570	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102389927	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs17027060	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102391107	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs66919607	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102392509	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.668	rs3732126	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102397502	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3732125	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102397503	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs1135354	ENSG00000234389.1	AC007278.3	-5.34	4.26e-07	0.00124	-0.41	-0.43	Serum protein levels (sST2);	chr2:102397842	chr2:102438713~102440475:+
ESCA	cis	rs9733	0.791	rs11800059	ENSG00000206931.1	RNU6-1042P	-5.34	4.29e-07	0.00124	-0.55	-0.43	Tonsillectomy;	chr1:150678699	chr1:150701866~150701972:+
ESCA	cis	rs9545047	0.604	rs1324870	ENSG00000227676.3	LINC01068	-5.34	4.31e-07	0.00125	-0.54	-0.43	Schizophrenia;	chr13:79297911	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-5.34	4.31e-07	0.00125	-0.46	-0.43	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
ESCA	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-5.34	4.31e-07	0.00125	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
ESCA	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	5.34	4.32e-07	0.00125	0.52	0.43	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	5.34	4.32e-07	0.00125	0.52	0.43	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	5.34	4.32e-07	0.00125	0.52	0.43	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
ESCA	cis	rs2712381	0.797	rs62270806	ENSG00000277250.1	Metazoa_SRP	-5.34	4.34e-07	0.00126	-0.51	-0.43	Monocyte count;	chr3:128657426	chr3:128673681~128674021:-
ESCA	cis	rs6456156	0.586	rs9459862	ENSG00000265828.1	MIR3939	5.34	4.36e-07	0.00126	0.45	0.43	Primary biliary cholangitis;	chr6:167073523	chr6:166997807~166997912:-
ESCA	cis	rs9545047	0.669	rs2095477	ENSG00000227676.3	LINC01068	-5.34	4.38e-07	0.00127	-0.57	-0.43	Schizophrenia;	chr13:79427869	chr13:79566727~79571436:+
ESCA	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-5.34	4.39e-07	0.00127	-0.85	-0.43	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
ESCA	cis	rs950880	0.71	rs55883125	ENSG00000234389.1	AC007278.3	-5.34	4.4e-07	0.00127	-0.41	-0.43	Serum protein levels (sST2);	chr2:102407871	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.645	rs4851006	ENSG00000234389.1	AC007278.3	-5.34	4.4e-07	0.00127	-0.41	-0.43	Serum protein levels (sST2);	chr2:102408278	chr2:102438713~102440475:+
ESCA	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	5.33	4.43e-07	0.00128	0.65	0.43	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
ESCA	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	5.33	4.48e-07	0.00129	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	5.33	4.48e-07	0.00129	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	5.33	4.48e-07	0.00129	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	5.33	4.48e-07	0.00129	0.54	0.43	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
ESCA	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	5.33	4.49e-07	0.00129	0.47	0.43	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	5.33	4.49e-07	0.00129	0.47	0.43	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	5.33	4.49e-07	0.00129	0.47	0.43	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	5.33	4.49e-07	0.00129	0.47	0.43	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.756	rs2901210	ENSG00000179406.6	LINC00174	5.33	4.49e-07	0.0013	0.5	0.43	Aortic root size;	chr7:66552518	chr7:66376044~66401338:-
ESCA	cis	rs7582403	0.51	rs12691773	ENSG00000223911.1	AC009480.3	5.33	4.5e-07	0.0013	0.48	0.43	Neuroticism;	chr2:148071753	chr2:147899401~147902956:-
ESCA	cis	rs2627019	0.51	rs6714672	ENSG00000223911.1	AC009480.3	5.33	4.5e-07	0.0013	0.48	0.43	Neuroticism;	chr2:148074595	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs10199458	ENSG00000223911.1	AC009480.3	5.33	4.5e-07	0.0013	0.48	0.43	Neuroticism;	chr2:148079781	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs7595067	ENSG00000223911.1	AC009480.3	5.33	4.5e-07	0.0013	0.48	0.43	Neuroticism;	chr2:148087922	chr2:147899401~147902956:-
ESCA	cis	rs1005277	0.579	rs2103938	ENSG00000276805.1	RP11-291L22.6	5.33	4.51e-07	0.0013	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38451030~38451785:+
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000231271.1	AP000350.8	-5.33	4.52e-07	0.0013	-0.55	-0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23949918~23954042:+
ESCA	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-5.33	4.53e-07	0.0013	-0.51	-0.43	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
ESCA	cis	rs9322193	0.886	rs4870049	ENSG00000216906.2	RP11-350J20.9	5.33	4.53e-07	0.0013	0.62	0.43	Lung cancer;	chr6:149837058	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	5.33	4.53e-07	0.0013	0.62	0.43	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	5.33	4.53e-07	0.0013	0.62	0.43	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	5.33	4.53e-07	0.0013	0.62	0.43	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
ESCA	cis	rs6782228	0.606	rs2811497	ENSG00000277250.1	Metazoa_SRP	-5.33	4.56e-07	0.00131	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs2811500	ENSG00000277250.1	Metazoa_SRP	-5.33	4.56e-07	0.00131	-0.51	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128673681~128674021:-
ESCA	cis	rs7924176	0.601	rs17676126	ENSG00000236900.1	TIMM9P1	-5.33	4.56e-07	0.00131	-0.52	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74145440	chr10:74344550~74344805:-
ESCA	cis	rs7826238	0.566	rs2945886	ENSG00000253981.4	ALG1L13P	5.33	4.58e-07	0.00132	0.54	0.43	Systolic blood pressure;	chr8:8290748	chr8:8236003~8244667:-
ESCA	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-5.33	4.58e-07	0.00132	-0.54	-0.43	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-5.33	4.58e-07	0.00132	-0.54	-0.43	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-5.33	4.58e-07	0.00132	-0.54	-0.43	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
ESCA	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-5.33	4.59e-07	0.00132	-0.48	-0.43	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.742	rs34624768	ENSG00000261783.1	RP11-252K23.2	-5.33	4.59e-07	0.00132	-0.51	-0.43	Dupuytren's disease;	chr16:75297674	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs4888378	ENSG00000261783.1	RP11-252K23.2	-5.33	4.59e-07	0.00132	-0.51	-0.43	Dupuytren's disease;	chr16:75298143	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs12935787	ENSG00000261783.1	RP11-252K23.2	-5.33	4.59e-07	0.00132	-0.51	-0.43	Dupuytren's disease;	chr16:75298437	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs3784935	ENSG00000261783.1	RP11-252K23.2	-5.33	4.59e-07	0.00132	-0.51	-0.43	Dupuytren's disease;	chr16:75302532	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs11645329	ENSG00000261783.1	RP11-252K23.2	-5.33	4.59e-07	0.00132	-0.51	-0.43	Dupuytren's disease;	chr16:75302781	chr16:75379818~75381260:-
ESCA	cis	rs748404	0.697	rs555001	ENSG00000249839.1	AC011330.5	-5.33	4.6e-07	0.00132	-0.54	-0.43	Lung cancer;	chr15:43253530	chr15:43663654~43684339:-
ESCA	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	5.33	4.61e-07	0.00132	0.52	0.43	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
ESCA	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-5.33	4.61e-07	0.00132	-0.5	-0.43	Migraine;	chr4:56852029	chr4:56960927~56961373:-
ESCA	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-5.33	4.62e-07	0.00132	-0.44	-0.43	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-5.33	4.62e-07	0.00132	-0.44	-0.43	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
ESCA	cis	rs6479891	0.908	rs2616631	ENSG00000235816.3	PRELID1P3	5.32	4.64e-07	0.00133	0.57	0.43	Arthritis (juvenile idiopathic);	chr10:63448154	chr10:63427297~63427939:+
ESCA	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	5.32	4.64e-07	0.00133	0.48	0.43	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
ESCA	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-5.32	4.65e-07	0.00133	-0.46	-0.43	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
ESCA	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-5.32	4.65e-07	0.00133	-0.52	-0.43	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
ESCA	cis	rs950880	0.71	rs3732123	ENSG00000234389.1	AC007278.3	-5.32	4.65e-07	0.00133	-0.4	-0.43	Serum protein levels (sST2);	chr2:102401617	chr2:102438713~102440475:+
ESCA	cis	rs42490	0.8	rs56291556	ENSG00000251136.7	RP11-37B2.1	5.32	4.65e-07	0.00133	0.44	0.43	Leprosy;	chr8:89662546	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.868	rs4961155	ENSG00000251136.7	RP11-37B2.1	5.32	4.65e-07	0.00133	0.44	0.43	Leprosy;	chr8:89666035	chr8:89609409~89757727:-
ESCA	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	5.32	4.65e-07	0.00133	0.45	0.43	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
ESCA	cis	rs7412746	0.658	rs57818453	ENSG00000206931.1	RNU6-1042P	5.32	4.67e-07	0.00133	0.56	0.43	Melanoma;	chr1:150790663	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.566	rs2864871	ENSG00000206931.1	RNU6-1042P	5.32	4.67e-07	0.00133	0.56	0.43	Melanoma;	chr1:150794488	chr1:150701866~150701972:+
ESCA	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-5.32	4.68e-07	0.00134	-0.48	-0.43	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
ESCA	cis	rs9545047	0.716	rs9545063	ENSG00000227676.3	LINC01068	5.32	4.68e-07	0.00134	0.56	0.43	Schizophrenia;	chr13:79316989	chr13:79566727~79571436:+
ESCA	cis	rs747650	0.892	rs7937101	ENSG00000271350.1	CTD-2384B9.1	-5.32	4.69e-07	0.00134	-0.53	-0.43	Acne (severe);	chr11:47204937	chr11:47041027~47041945:-
ESCA	cis	rs62229266	0.605	rs11701331	ENSG00000231106.2	LINC01436	5.32	4.69e-07	0.00134	0.49	0.43	Mitral valve prolapse;	chr21:36086094	chr21:36005338~36007838:+
ESCA	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	5.32	4.69e-07	0.00134	0.66	0.43	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	5.32	4.69e-07	0.00134	0.66	0.43	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	5.32	4.69e-07	0.00134	0.66	0.43	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	5.32	4.69e-07	0.00134	0.66	0.43	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
ESCA	cis	rs1005277	0.579	rs1621040	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780136	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780138	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.602	rs1780141	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.541	rs1740741	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.528	rs2057228	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1740742	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.602	rs1740743	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1740745	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1740747	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1740749	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1780115	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.529	rs1780125	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.502	rs2800484	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2800485	ENSG00000276805.1	RP11-291L22.6	5.32	4.71e-07	0.00134	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38451030~38451785:+
ESCA	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-5.32	4.73e-07	0.00135	-0.53	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-5.32	4.73e-07	0.00135	-0.53	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
ESCA	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	5.32	4.75e-07	0.00135	0.49	0.43	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
ESCA	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	5.32	4.75e-07	0.00135	0.49	0.43	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-5.32	4.76e-07	0.00136	-0.44	-0.43	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-5.32	4.76e-07	0.00136	-0.44	-0.43	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
ESCA	cis	rs801193	0.844	rs2244022	ENSG00000179406.6	LINC00174	-5.32	4.78e-07	0.00136	-0.48	-0.43	Aortic root size;	chr7:66737443	chr7:66376044~66401338:-
ESCA	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	5.32	4.8e-07	0.00136	0.51	0.43	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	5.32	4.8e-07	0.00137	0.47	0.43	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.843	rs11649638	ENSG00000261783.1	RP11-252K23.2	-5.32	4.81e-07	0.00137	-0.54	-0.43	Dupuytren's disease;	chr16:75454387	chr16:75379818~75381260:-
ESCA	cis	rs748404	0.697	rs546170	ENSG00000249839.1	AC011330.5	-5.32	4.82e-07	0.00137	-0.53	-0.43	Lung cancer;	chr15:43272651	chr15:43663654~43684339:-
ESCA	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	5.31	4.85e-07	0.00138	0.45	0.43	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
ESCA	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	5.31	4.86e-07	0.00138	0.55	0.43	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
ESCA	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	5.31	4.88e-07	0.00138	0.44	0.43	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	5.31	4.88e-07	0.00138	0.44	0.43	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	5.31	4.88e-07	0.00138	0.44	0.43	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	5.31	4.91e-07	0.00139	0.47	0.43	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
ESCA	cis	rs42490	0.868	rs1605996	ENSG00000251136.7	RP11-37B2.1	5.31	4.91e-07	0.00139	0.44	0.43	Leprosy;	chr8:89655674	chr8:89609409~89757727:-
ESCA	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	5.31	4.92e-07	0.0014	0.58	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
ESCA	cis	rs3136516	0.935	rs4506602	ENSG00000271350.1	CTD-2384B9.1	-5.31	4.93e-07	0.0014	-0.53	-0.43	Venous thromboembolism;	chr11:46794083	chr11:47041027~47041945:-
ESCA	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	5.31	4.95e-07	0.0014	0.48	0.43	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
ESCA	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	5.31	4.95e-07	0.0014	0.55	0.43	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
ESCA	cis	rs875971	0.755	rs76288834	ENSG00000179406.6	LINC00174	5.31	4.98e-07	0.00141	0.49	0.43	Aortic root size;	chr7:66604815	chr7:66376044~66401338:-
ESCA	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-5.31	4.98e-07	0.00141	-0.61	-0.43	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
ESCA	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	5.31	4.98e-07	0.00141	0.47	0.43	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
ESCA	cis	rs7684253	0.526	rs34112167	ENSG00000269949.1	RP11-738E22.3	-5.31	4.98e-07	0.00141	-0.49	-0.43	Migraine;	chr4:56853383	chr4:56960927~56961373:-
ESCA	cis	rs2882667	1	rs2060222	ENSG00000253404.1	AC034243.1	5.31	4.99e-07	0.00141	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138972777	chr5:138744434~138753309:-
ESCA	cis	rs2882667	1	rs10064130	ENSG00000253404.1	AC034243.1	5.31	4.99e-07	0.00141	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:138973618	chr5:138744434~138753309:-
ESCA	cis	rs977987	0.832	rs37597	ENSG00000261783.1	RP11-252K23.2	5.31	5.01e-07	0.00142	0.54	0.43	Dupuytren's disease;	chr16:75466377	chr16:75379818~75381260:-
ESCA	cis	rs1005277	0.579	rs1740735	ENSG00000263064.2	RP11-291L22.7	5.31	5.01e-07	0.00142	0.57	0.43	Extrinsic epigenetic age acceleration;	chr10:38208849	chr10:38448689~38448949:+
ESCA	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-5.31	5.02e-07	0.00142	-0.62	-0.43	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
ESCA	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-5.31	5.03e-07	0.00142	-0.84	-0.43	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
ESCA	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-5.31	5.03e-07	0.00142	-0.45	-0.43	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
ESCA	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-5.31	5.04e-07	0.00143	-0.45	-0.43	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	5.3	5.06e-07	0.00143	0.47	0.43	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
ESCA	cis	rs1005277	0.557	rs2983338	ENSG00000276805.1	RP11-291L22.6	5.3	5.07e-07	0.00143	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38451030~38451785:+
ESCA	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-5.3	5.08e-07	0.00144	-0.42	-0.43	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
ESCA	cis	rs9733	0.621	rs6669122	ENSG00000206931.1	RNU6-1042P	-5.3	5.08e-07	0.00144	-0.51	-0.43	Tonsillectomy;	chr1:150619256	chr1:150701866~150701972:+
ESCA	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-5.3	5.09e-07	0.00144	-0.46	-0.43	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.965	rs7794930	ENSG00000179406.6	LINC00174	5.3	5.12e-07	0.00144	0.48	0.43	Aortic root size;	chr7:66313559	chr7:66376044~66401338:-
ESCA	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	5.3	5.14e-07	0.00145	0.55	0.43	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
ESCA	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	5.3	5.14e-07	0.00145	0.55	0.43	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
ESCA	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-5.3	5.15e-07	0.00145	-0.49	-0.43	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
ESCA	cis	rs2742234	0.794	rs17153156	ENSG00000273008.1	RP11-351D16.3	5.3	5.16e-07	0.00145	0.47	0.43	Hirschsprung disease;	chr10:43209189	chr10:43136824~43138334:-
ESCA	cis	rs2439831	0.867	rs2447208	ENSG00000249839.1	AC011330.5	-5.3	5.16e-07	0.00145	-0.74	-0.43	Lung cancer in ever smokers;	chr15:43641697	chr15:43663654~43684339:-
ESCA	cis	rs6456156	0.586	rs6909180	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167047049	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12213683	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167047230	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12529876	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167048013	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12528323	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167048157	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12528689	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167048258	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs13208636	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167048477	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs2181058	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167051842	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs12529238	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167052088	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.524	rs6932740	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167052951	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.524	rs6934043	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167052961	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs1358882	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167053613	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs9457261	ENSG00000265828.1	MIR3939	-5.3	5.18e-07	0.00146	-0.46	-0.43	Primary biliary cholangitis;	chr6:167054191	chr6:166997807~166997912:-
ESCA	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-5.3	5.19e-07	0.00146	-0.43	-0.43	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-5.3	5.19e-07	0.00146	-0.43	-0.43	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-5.3	5.19e-07	0.00146	-0.43	-0.43	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-5.3	5.19e-07	0.00146	-0.43	-0.43	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
ESCA	cis	rs1005277	0.579	rs2749612	ENSG00000276805.1	RP11-291L22.6	5.3	5.19e-07	0.00146	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38451030~38451785:+
ESCA	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-5.3	5.2e-07	0.00146	-0.44	-0.43	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-5.3	5.2e-07	0.00146	-0.44	-0.43	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
ESCA	cis	rs7829975	0.56	rs6994131	ENSG00000253981.4	ALG1L13P	-5.3	5.2e-07	0.00146	-0.51	-0.43	Mood instability;	chr8:8693448	chr8:8236003~8244667:-
ESCA	cis	rs950880	0.71	rs17027255	ENSG00000234389.1	AC007278.3	-5.3	5.23e-07	0.00147	-0.41	-0.43	Serum protein levels (sST2);	chr2:102473668	chr2:102438713~102440475:+
ESCA	cis	rs3747113	0.865	rs9620384	ENSG00000128262.7	POM121L9P	-5.3	5.25e-07	0.00147	-0.54	-0.43	Gut microbiome composition (summer);	chr22:24379380	chr22:24251828~24265525:+
ESCA	cis	rs977987	0.806	rs1549306	ENSG00000261783.1	RP11-252K23.2	-5.3	5.25e-07	0.00147	-0.51	-0.43	Dupuytren's disease;	chr16:75381443	chr16:75379818~75381260:-
ESCA	cis	rs2439831	0.85	rs16950562	ENSG00000249839.1	AC011330.5	-5.3	5.27e-07	0.00148	-0.81	-0.43	Lung cancer in ever smokers;	chr15:43744166	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs12441861	ENSG00000249839.1	AC011330.5	-5.3	5.27e-07	0.00148	-0.81	-0.43	Lung cancer in ever smokers;	chr15:43768685	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs9944216	ENSG00000249839.1	AC011330.5	5.3	5.28e-07	0.00148	0.86	0.43	Lung cancer in ever smokers;	chr15:43868575	chr15:43663654~43684339:-
ESCA	cis	rs7826238	0.601	rs2976907	ENSG00000253981.4	ALG1L13P	5.3	5.28e-07	0.00148	0.56	0.43	Systolic blood pressure;	chr8:8487658	chr8:8236003~8244667:-
ESCA	cis	rs7826238	0.601	rs2979206	ENSG00000253981.4	ALG1L13P	5.3	5.28e-07	0.00148	0.56	0.43	Systolic blood pressure;	chr8:8488071	chr8:8236003~8244667:-
ESCA	cis	rs7412746	0.646	rs10399947	ENSG00000206931.1	RNU6-1042P	5.29	5.32e-07	0.00149	0.55	0.43	Melanoma;	chr1:150889484	chr1:150701866~150701972:+
ESCA	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-5.29	5.32e-07	0.00149	-0.43	-0.43	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
ESCA	cis	rs6479891	1	rs4746974	ENSG00000235816.3	PRELID1P3	5.29	5.38e-07	0.0015	0.55	0.43	Arthritis (juvenile idiopathic);	chr10:63132292	chr10:63427297~63427939:+
ESCA	cis	rs748404	0.697	rs530188	ENSG00000249839.1	AC011330.5	-5.29	5.4e-07	0.00151	-0.53	-0.43	Lung cancer;	chr15:43253116	chr15:43663654~43684339:-
ESCA	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	5.29	5.41e-07	0.00151	0.57	0.43	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
ESCA	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-5.29	5.41e-07	0.00151	-0.57	-0.43	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
ESCA	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-5.29	5.42e-07	0.00152	-0.52	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-5.29	5.42e-07	0.00152	-0.52	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
ESCA	cis	rs5758659	0.819	rs134871	ENSG00000182057.4	OGFRP1	5.29	5.43e-07	0.00152	0.49	0.43	Cognitive function;	chr22:42256710	chr22:42269753~42275196:+
ESCA	cis	rs7829975	0.593	rs2979241	ENSG00000253981.4	ALG1L13P	5.29	5.44e-07	0.00152	0.49	0.43	Mood instability;	chr8:8445843	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.623	rs7010753	ENSG00000253981.4	ALG1L13P	5.29	5.44e-07	0.00152	0.53	0.43	Mood instability;	chr8:8516446	chr8:8236003~8244667:-
ESCA	cis	rs977987	0.898	rs12918974	ENSG00000261783.1	RP11-252K23.2	-5.29	5.47e-07	0.00153	-0.53	-0.43	Dupuytren's disease;	chr16:75460045	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.866	rs12932606	ENSG00000261783.1	RP11-252K23.2	-5.29	5.47e-07	0.00153	-0.53	-0.43	Dupuytren's disease;	chr16:75460046	chr16:75379818~75381260:-
ESCA	cis	rs17711722	0.583	rs11768292	ENSG00000222364.1	RNU6-96P	5.29	5.47e-07	0.00153	0.47	0.43	Calcium levels;	chr7:66009814	chr7:66395191~66395286:+
ESCA	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	5.29	5.48e-07	0.00153	0.66	0.43	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
ESCA	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	5.29	5.49e-07	0.00153	0.38	0.43	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
ESCA	cis	rs1005277	0.579	rs1780133	ENSG00000263064.2	RP11-291L22.7	5.29	5.5e-07	0.00153	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38210581	chr10:38448689~38448949:+
ESCA	cis	rs16828019	0.704	rs35071528	ENSG00000235358.1	RP11-399E6.1	5.29	5.5e-07	0.00153	0.95	0.43	Intelligence (multi-trait analysis);	chr1:41146985	chr1:41242373~41284861:+
ESCA	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-5.29	5.5e-07	0.00154	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
ESCA	cis	rs6456156	0.586	rs12203510	ENSG00000265828.1	MIR3939	-5.28	5.56e-07	0.00155	-0.46	-0.43	Primary biliary cholangitis;	chr6:167059518	chr6:166997807~166997912:-
ESCA	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-5.28	5.57e-07	0.00155	-0.66	-0.43	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
ESCA	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-5.28	5.57e-07	0.00155	-0.49	-0.43	Migraine;	chr4:56851192	chr4:56960927~56961373:-
ESCA	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-5.28	5.57e-07	0.00155	-0.49	-0.43	Migraine;	chr4:56852087	chr4:56960927~56961373:-
ESCA	cis	rs977987	0.843	rs4888427	ENSG00000261783.1	RP11-252K23.2	-5.28	5.58e-07	0.00155	-0.54	-0.43	Dupuytren's disease;	chr16:75444549	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs35683383	ENSG00000261783.1	RP11-252K23.2	-5.28	5.58e-07	0.00155	-0.54	-0.43	Dupuytren's disease;	chr16:75445379	chr16:75379818~75381260:-
ESCA	cis	rs2882667	0.824	rs13189485	ENSG00000253404.1	AC034243.1	5.28	5.58e-07	0.00155	0.61	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139139712	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.898	rs11952020	ENSG00000253404.1	AC034243.1	5.28	5.59e-07	0.00156	0.58	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139059467	chr5:138744434~138753309:-
ESCA	cis	rs9545047	0.716	rs9565500	ENSG00000227676.3	LINC01068	-5.28	5.59e-07	0.00156	-0.56	-0.43	Schizophrenia;	chr13:79433416	chr13:79566727~79571436:+
ESCA	cis	rs7829975	0.56	rs4841013	ENSG00000253981.4	ALG1L13P	-5.28	5.6e-07	0.00156	-0.51	-0.43	Mood instability;	chr8:8694503	chr8:8236003~8244667:-
ESCA	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-5.28	5.6e-07	0.00156	-0.85	-0.43	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
ESCA	cis	rs6456156	0.792	rs4710183	ENSG00000265828.1	MIR3939	5.28	5.66e-07	0.00157	0.47	0.43	Primary biliary cholangitis;	chr6:167100595	chr6:166997807~166997912:-
ESCA	cis	rs6782228	0.606	rs7627549	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.585	rs2811492	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs1697	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs6439135	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.509	rs2811495	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.565	rs2811496	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.585	rs3122175	ENSG00000277250.1	Metazoa_SRP	-5.28	5.66e-07	0.00157	-0.5	-0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128673681~128674021:-
ESCA	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-5.28	5.68e-07	0.00158	-0.53	-0.43	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
ESCA	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-5.28	5.68e-07	0.00158	-0.46	-0.43	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
ESCA	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	5.28	5.69e-07	0.00158	0.38	0.43	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
ESCA	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	5.28	5.69e-07	0.00158	0.38	0.43	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
ESCA	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-5.28	5.69e-07	0.00158	-0.46	-0.43	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
ESCA	cis	rs977987	0.843	rs60730309	ENSG00000261783.1	RP11-252K23.2	-5.28	5.71e-07	0.00158	-0.54	-0.43	Dupuytren's disease;	chr16:75397871	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.75	rs4888406	ENSG00000261783.1	RP11-252K23.2	-5.28	5.71e-07	0.00158	-0.54	-0.43	Dupuytren's disease;	chr16:75398436	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.75	rs4888407	ENSG00000261783.1	RP11-252K23.2	-5.28	5.71e-07	0.00158	-0.54	-0.43	Dupuytren's disease;	chr16:75398492	chr16:75379818~75381260:-
ESCA	cis	rs3762637	1	rs11932	ENSG00000272758.4	RP11-299J3.8	5.28	5.72e-07	0.00159	0.53	0.43	LDL cholesterol levels;	chr3:122422288	chr3:122416207~122443180:+
ESCA	cis	rs875971	0.862	rs801195	ENSG00000179406.6	LINC00174	5.28	5.73e-07	0.00159	0.49	0.43	Aortic root size;	chr7:66561128	chr7:66376044~66401338:-
ESCA	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	5.28	5.74e-07	0.00159	0.82	0.43	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
ESCA	cis	rs977987	0.835	rs7200616	ENSG00000261783.1	RP11-252K23.2	-5.28	5.75e-07	0.00159	-0.52	-0.43	Dupuytren's disease;	chr16:75332191	chr16:75379818~75381260:-
ESCA	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-5.28	5.75e-07	0.00159	-0.43	-0.43	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
ESCA	cis	rs6538678	0.746	rs12820313	ENSG00000258343.1	RP11-536G4.2	-5.28	5.75e-07	0.00159	-0.5	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95861926	chr12:95795345~95858839:-
ESCA	cis	rs7829975	0.514	rs2976929	ENSG00000253981.4	ALG1L13P	5.28	5.76e-07	0.00159	0.48	0.43	Mood instability;	chr8:8401202	chr8:8236003~8244667:-
ESCA	cis	rs1075265	0.597	rs11694711	ENSG00000235937.1	AC008280.1	5.28	5.77e-07	0.0016	0.48	0.43	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54029552~54030682:-
ESCA	cis	rs6479891	0.915	rs10761744	ENSG00000235816.3	PRELID1P3	-5.28	5.78e-07	0.0016	-0.53	-0.43	Arthritis (juvenile idiopathic);	chr10:63341266	chr10:63427297~63427939:+
ESCA	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-5.27	5.8e-07	0.0016	-0.53	-0.43	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-5.27	5.8e-07	0.0016	-0.53	-0.43	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-5.27	5.8e-07	0.0016	-0.53	-0.43	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
ESCA	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-5.27	5.81e-07	0.0016	-0.6	-0.43	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
ESCA	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-5.27	5.81e-07	0.00161	-0.52	-0.43	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-5.27	5.81e-07	0.00161	-0.52	-0.43	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
ESCA	cis	rs2882667	0.755	rs55650316	ENSG00000253404.1	AC034243.1	5.27	5.83e-07	0.00161	0.61	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139131603	chr5:138744434~138753309:-
ESCA	cis	rs9733	0.791	rs11204693	ENSG00000206931.1	RNU6-1042P	-5.27	5.85e-07	0.00161	-0.54	-0.43	Tonsillectomy;	chr1:150675511	chr1:150701866~150701972:+
ESCA	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-5.27	5.85e-07	0.00161	-0.53	-0.43	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
ESCA	cis	rs2307394	0.964	rs13035475	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:147997293	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13014936	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:147997668	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13022962	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:147999055	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13028348	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:147999575	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs1598207	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148000301	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.963	rs6724719	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148007321	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs6732463	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148008906	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs12997165	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148011304	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13032810	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148012485	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs6746415	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148014122	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs12989250	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148018869	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs1975748	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148019290	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs897172	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148020703	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs1015096	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148024789	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs11886876	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148026238	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13007770	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148026755	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs57627012	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148026957	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.963	rs61274111	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148026958	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs4972321	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148027415	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs7560425	ENSG00000223911.1	AC009480.3	5.27	5.86e-07	0.00161	0.51	0.43	Urate levels;	chr2:148027743	chr2:147899401~147902956:-
ESCA	cis	rs42490	0.934	rs218946	ENSG00000251136.7	RP11-37B2.1	-5.27	5.86e-07	0.00162	-0.43	-0.43	Leprosy;	chr8:89704478	chr8:89609409~89757727:-
ESCA	cis	rs7829975	0.514	rs2920991	ENSG00000253981.4	ALG1L13P	5.27	5.87e-07	0.00162	0.48	0.43	Mood instability;	chr8:8401607	chr8:8236003~8244667:-
ESCA	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-5.27	5.87e-07	0.00162	-0.43	-0.43	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
ESCA	cis	rs6456156	0.586	rs1407315	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167055171	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs12527827	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167055783	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs12529959	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167055804	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs911632	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167057973	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs2017338	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167058226	chr6:166997807~166997912:-
ESCA	cis	rs9457247	0.51	rs6456151	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Crohn's disease;	chr6:167058363	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs6456153	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167058679	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.586	rs6456154	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167058768	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.565	rs12525345	ENSG00000265828.1	MIR3939	-5.27	5.89e-07	0.00162	-0.46	-0.43	Primary biliary cholangitis;	chr6:167065387	chr6:166997807~166997912:-
ESCA	cis	rs2280018	1	rs2280018	ENSG00000260735.1	RP11-72I8.1	-5.27	5.9e-07	0.00162	-0.43	-0.43	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15056976	chr16:15094411~15109197:+
ESCA	cis	rs42490	0.903	rs218944	ENSG00000251136.7	RP11-37B2.1	-5.27	5.9e-07	0.00162	-0.43	-0.43	Leprosy;	chr8:89701839	chr8:89609409~89757727:-
ESCA	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-5.27	5.9e-07	0.00162	-0.5	-0.43	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
ESCA	cis	rs2307394	1	rs12990262	ENSG00000223911.1	AC009480.3	5.27	5.94e-07	0.00163	0.51	0.43	Urate levels;	chr2:147980260	chr2:147899401~147902956:-
ESCA	cis	rs6479891	1	rs10761745	ENSG00000235816.3	PRELID1P3	-5.27	5.94e-07	0.00163	-0.55	-0.43	Arthritis (juvenile idiopathic);	chr10:63341311	chr10:63427297~63427939:+
ESCA	cis	rs12480328	1	rs6096186	ENSG00000228663.1	PSMD10P1	-5.27	5.94e-07	0.00163	-0.49	-0.43	Prostate cancer;	chr20:50917412	chr20:50913731~50914411:+
ESCA	cis	rs7829975	0.782	rs6990746	ENSG00000253981.4	ALG1L13P	-5.27	5.95e-07	0.00164	-0.5	-0.43	Mood instability;	chr8:8690301	chr8:8236003~8244667:-
ESCA	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	5.27	5.95e-07	0.00164	0.57	0.43	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
ESCA	cis	rs9545047	0.584	rs7995243	ENSG00000227676.3	LINC01068	-5.27	5.95e-07	0.00164	-0.55	-0.43	Schizophrenia;	chr13:79358645	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9601217	ENSG00000227676.3	LINC01068	-5.27	5.95e-07	0.00164	-0.55	-0.43	Schizophrenia;	chr13:79359797	chr13:79566727~79571436:+
ESCA	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-5.27	5.95e-07	0.00164	-0.56	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-5.27	5.95e-07	0.00164	-0.56	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-5.27	5.95e-07	0.00164	-0.56	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	5.27	5.96e-07	0.00164	0.44	0.43	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
ESCA	cis	rs6538678	0.864	rs10777747	ENSG00000258343.1	RP11-536G4.2	-5.27	5.97e-07	0.00164	-0.51	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95870192	chr12:95795345~95858839:-
ESCA	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	5.27	5.97e-07	0.00164	0.47	0.43	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	5.27	5.97e-07	0.00164	0.47	0.43	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
ESCA	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-5.27	5.97e-07	0.00164	-0.43	-0.43	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
ESCA	cis	rs10875746	0.951	rs4760689	ENSG00000240399.1	RP1-228P16.1	-5.27	5.98e-07	0.00164	-0.56	-0.43	Longevity (90 years and older);	chr12:48169861	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.951	rs4760690	ENSG00000240399.1	RP1-228P16.1	-5.27	5.98e-07	0.00164	-0.56	-0.43	Longevity (90 years and older);	chr12:48169870	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.951	rs58865997	ENSG00000240399.1	RP1-228P16.1	-5.27	5.98e-07	0.00164	-0.56	-0.43	Longevity (90 years and older);	chr12:48173090	chr12:48054813~48055591:-
ESCA	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	5.27	6e-07	0.00165	0.6	0.43	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
ESCA	cis	rs6479891	1	rs72837070	ENSG00000235816.3	PRELID1P3	5.27	6.01e-07	0.00165	0.55	0.43	Arthritis (juvenile idiopathic);	chr10:63514919	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs61853635	ENSG00000235816.3	PRELID1P3	5.27	6.01e-07	0.00165	0.55	0.43	Arthritis (juvenile idiopathic);	chr10:63516750	chr10:63427297~63427939:+
ESCA	cis	rs875971	0.8	rs427557	ENSG00000179406.6	LINC00174	-5.27	6.02e-07	0.00165	-0.48	-0.43	Aortic root size;	chr7:66054263	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.83	rs587360	ENSG00000179406.6	LINC00174	-5.27	6.02e-07	0.00165	-0.48	-0.43	Aortic root size;	chr7:66057711	chr7:66376044~66401338:-
ESCA	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-5.27	6.04e-07	0.00166	-0.54	-0.43	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
ESCA	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-5.26	6.05e-07	0.00166	-0.62	-0.43	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
ESCA	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-5.26	6.07e-07	0.00166	-0.49	-0.43	Migraine;	chr4:56879297	chr4:56960927~56961373:-
ESCA	cis	rs10875746	0.859	rs11558768	ENSG00000240399.1	RP1-228P16.1	-5.26	6.1e-07	0.00167	-0.52	-0.43	Longevity (90 years and older);	chr12:48184006	chr12:48054813~48055591:-
ESCA	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-5.26	6.1e-07	0.00167	-0.6	-0.43	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
ESCA	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	5.26	6.12e-07	0.00167	0.56	0.43	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
ESCA	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	5.26	6.13e-07	0.00168	0.46	0.43	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
ESCA	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	5.26	6.13e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	5.26	6.13e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	5.26	6.13e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	5.26	6.13e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	5.26	6.13e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
ESCA	cis	rs8040855	0.794	rs4843024	ENSG00000259295.5	CSPG4P12	-5.26	6.13e-07	0.00168	-0.75	-0.43	Bulimia nervosa;	chr15:85162669	chr15:85191438~85213905:+
ESCA	cis	rs7924176	0.601	rs10824071	ENSG00000236900.1	TIMM9P1	-5.26	6.15e-07	0.00168	-0.5	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74113881	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.601	rs10824072	ENSG00000236900.1	TIMM9P1	-5.26	6.15e-07	0.00168	-0.5	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74114134	chr10:74344550~74344805:-
ESCA	cis	rs2921073	0.51	rs2976944	ENSG00000173295.6	FAM86B3P	5.26	6.16e-07	0.00168	0.49	0.43	Parkinson's disease;	chr8:8413404	chr8:8228595~8244865:+
ESCA	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	5.26	6.16e-07	0.00168	0.38	0.43	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
ESCA	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
ESCA	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	5.26	6.17e-07	0.00168	0.6	0.43	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
ESCA	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-5.26	6.2e-07	0.00169	-0.52	-0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
ESCA	cis	rs2006771	0.81	rs2006648	ENSG00000236132.1	CTA-440B3.1	5.26	6.2e-07	0.00169	0.49	0.43	Nonsyndromic cleft lip with cleft palate;	chr22:31685943	chr22:31816379~31817491:-
ESCA	cis	rs748404	0.697	rs475261	ENSG00000249839.1	AC011330.5	-5.26	6.21e-07	0.00169	-0.53	-0.43	Lung cancer;	chr15:43254258	chr15:43663654~43684339:-
ESCA	cis	rs1816752	0.74	rs6490924	ENSG00000273628.1	RP11-756A22.7	-5.26	6.22e-07	0.00169	-0.41	-0.43	Obesity-related traits;	chr13:24432914	chr13:24933006~24936796:+
ESCA	cis	rs9545047	0.564	rs7336186	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79385497	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.547	rs1590465	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79393998	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2182009	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79397781	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4605023	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79398700	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9565496	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79398751	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs12877507	ENSG00000227676.3	LINC01068	-5.26	6.24e-07	0.0017	-0.55	-0.43	Schizophrenia;	chr13:79401822	chr13:79566727~79571436:+
ESCA	cis	rs977987	0.815	rs11149818	ENSG00000261783.1	RP11-252K23.2	-5.26	6.25e-07	0.0017	-0.52	-0.43	Dupuytren's disease;	chr16:75385475	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs11149820	ENSG00000261783.1	RP11-252K23.2	-5.26	6.25e-07	0.0017	-0.52	-0.43	Dupuytren's disease;	chr16:75388862	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs10514396	ENSG00000261783.1	RP11-252K23.2	-5.26	6.25e-07	0.0017	-0.52	-0.43	Dupuytren's disease;	chr16:75389005	chr16:75379818~75381260:-
ESCA	cis	rs4747241	0.739	rs11596698	ENSG00000226163.1	RP11-167P22.3	5.26	6.25e-07	0.0017	0.48	0.43	Heschl's gyrus morphology;	chr10:72309687	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.739	rs4074609	ENSG00000226163.1	RP11-167P22.3	5.26	6.25e-07	0.0017	0.48	0.43	Heschl's gyrus morphology;	chr10:72310024	chr10:72501746~72502956:+
ESCA	cis	rs801193	1	rs17566701	ENSG00000179406.6	LINC00174	-5.26	6.25e-07	0.0017	-0.49	-0.43	Aortic root size;	chr7:66728196	chr7:66376044~66401338:-
ESCA	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	5.26	6.25e-07	0.0017	0.47	0.43	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
ESCA	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-5.26	6.25e-07	0.0017	-0.52	-0.43	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
ESCA	cis	rs1538970	0.739	rs4660863	ENSG00000280836.1	AL355480.1	-5.26	6.26e-07	0.0017	-0.55	-0.43	Platelet count;	chr1:45490196	chr1:45581219~45581321:-
ESCA	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-5.26	6.26e-07	0.0017	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
ESCA	cis	rs7826238	0.594	rs2948285	ENSG00000253981.4	ALG1L13P	5.26	6.28e-07	0.00171	0.52	0.43	Systolic blood pressure;	chr8:8273016	chr8:8236003~8244667:-
ESCA	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	5.26	6.28e-07	0.00171	0.5	0.43	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
ESCA	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-5.26	6.29e-07	0.00171	-0.43	-0.43	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
ESCA	cis	rs6456156	0.586	rs10946208	ENSG00000265828.1	MIR3939	-5.26	6.3e-07	0.00171	-0.45	-0.43	Primary biliary cholangitis;	chr6:167046108	chr6:166997807~166997912:-
ESCA	cis	rs6479901	0.588	rs10740105	ENSG00000235816.3	PRELID1P3	-5.26	6.3e-07	0.00171	-0.49	-0.43	Intelligence (multi-trait analysis);	chr10:63129957	chr10:63427297~63427939:+
ESCA	cis	rs10256972	0.681	rs12702016	ENSG00000229043.2	AC091729.9	-5.26	6.3e-07	0.00171	-0.42	-0.43	Endometriosis;Longevity;	chr7:1089756	chr7:1160374~1165267:+
ESCA	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-5.25	6.32e-07	0.00172	-0.44	-0.43	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
ESCA	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	5.25	6.33e-07	0.00172	0.65	0.43	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	5.25	6.34e-07	0.00172	0.65	0.43	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
ESCA	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	5.25	6.34e-07	0.00172	0.47	0.43	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
ESCA	cis	rs2307394	0.964	rs9789434	ENSG00000223911.1	AC009480.3	5.25	6.35e-07	0.00172	0.51	0.43	Urate levels;	chr2:147991824	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13021605	ENSG00000223911.1	AC009480.3	5.25	6.35e-07	0.00172	0.51	0.43	Urate levels;	chr2:148028767	chr2:147899401~147902956:-
ESCA	cis	rs875971	0.508	rs10258739	ENSG00000179406.6	LINC00174	5.25	6.35e-07	0.00172	0.47	0.43	Aortic root size;	chr7:66597948	chr7:66376044~66401338:-
ESCA	cis	rs7924176	0.564	rs12572820	ENSG00000236900.1	TIMM9P1	-5.25	6.36e-07	0.00172	-0.5	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74117387	chr10:74344550~74344805:-
ESCA	cis	rs7924176	0.601	rs3180427	ENSG00000236900.1	TIMM9P1	-5.25	6.36e-07	0.00172	-0.5	-0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74121589	chr10:74344550~74344805:-
ESCA	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-5.25	6.36e-07	0.00173	-0.5	-0.43	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-5.25	6.36e-07	0.00173	-0.5	-0.43	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
ESCA	cis	rs9545047	0.716	rs314692	ENSG00000227676.3	LINC01068	-5.25	6.37e-07	0.00173	-0.56	-0.43	Schizophrenia;	chr13:79433091	chr13:79566727~79571436:+
ESCA	cis	rs1075265	0.73	rs11893270	ENSG00000235937.1	AC008280.1	5.25	6.38e-07	0.00173	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.704	rs10084374	ENSG00000235937.1	AC008280.1	5.25	6.38e-07	0.00173	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54029552~54030682:-
ESCA	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-5.25	6.4e-07	0.00173	-0.52	-0.43	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000231271.1	AP000350.8	-5.25	6.4e-07	0.00173	-0.6	-0.43	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23949918~23954042:+
ESCA	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	5.25	6.4e-07	0.00173	0.64	0.43	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
ESCA	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	5.25	6.42e-07	0.00174	0.51	0.43	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
ESCA	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	5.25	6.45e-07	0.00174	0.6	0.43	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
ESCA	cis	rs3747113	1	rs11703914	ENSG00000128262.7	POM121L9P	-5.25	6.46e-07	0.00175	-0.53	-0.43	Gut microbiome composition (summer);	chr22:24371634	chr22:24251828~24265525:+
ESCA	cis	rs1075265	0.73	rs6711105	ENSG00000235937.1	AC008280.1	5.25	6.47e-07	0.00175	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.704	rs6711217	ENSG00000235937.1	AC008280.1	5.25	6.47e-07	0.00175	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54029552~54030682:-
ESCA	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-5.25	6.47e-07	0.00175	-0.5	-0.43	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
ESCA	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	5.25	6.47e-07	0.00175	0.57	0.43	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
ESCA	cis	rs1005277	0.579	rs1780130	ENSG00000263064.2	RP11-291L22.7	5.25	6.48e-07	0.00175	0.57	0.43	Extrinsic epigenetic age acceleration;	chr10:38196450	chr10:38448689~38448949:+
ESCA	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-5.25	6.48e-07	0.00175	-0.44	-0.43	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
ESCA	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	5.25	6.49e-07	0.00175	0.57	0.43	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.61	0.43	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9478848	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149825080	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	5.25	6.52e-07	0.00176	0.6	0.43	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
ESCA	cis	rs1075265	0.73	rs7597188	ENSG00000235937.1	AC008280.1	5.25	6.53e-07	0.00176	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.704	rs9631059	ENSG00000235937.1	AC008280.1	5.25	6.53e-07	0.00176	0.46	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54029552~54030682:-
ESCA	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	5.25	6.53e-07	0.00176	0.56	0.43	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
ESCA	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-5.25	6.55e-07	0.00177	-0.5	-0.43	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
ESCA	cis	rs1005277	0.579	rs1740737	ENSG00000263064.2	RP11-291L22.7	5.25	6.56e-07	0.00177	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38210437	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780116	ENSG00000263064.2	RP11-291L22.7	5.25	6.56e-07	0.00177	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38237693	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780121	ENSG00000263064.2	RP11-291L22.7	5.25	6.56e-07	0.00177	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38240509	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780122	ENSG00000263064.2	RP11-291L22.7	5.25	6.56e-07	0.00177	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38240581	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780145	ENSG00000263064.2	RP11-291L22.7	5.25	6.56e-07	0.00177	0.58	0.43	Extrinsic epigenetic age acceleration;	chr10:38248142	chr10:38448689~38448949:+
ESCA	cis	rs977987	0.835	rs3863445	ENSG00000261783.1	RP11-252K23.2	-5.25	6.58e-07	0.00177	-0.52	-0.43	Dupuytren's disease;	chr16:75337846	chr16:75379818~75381260:-
ESCA	cis	rs9549367	0.713	rs2146750	ENSG00000269125.1	RP11-98F14.11	5.25	6.6e-07	0.00178	0.51	0.43	Platelet distribution width;	chr13:113168216	chr13:113165002~113165183:-
ESCA	cis	rs977987	0.843	rs67409275	ENSG00000261783.1	RP11-252K23.2	-5.24	6.61e-07	0.00178	-0.53	-0.43	Dupuytren's disease;	chr16:75423314	chr16:75379818~75381260:-
ESCA	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-5.24	6.62e-07	0.00178	-0.49	-0.43	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
ESCA	cis	rs748404	0.697	rs531910	ENSG00000249839.1	AC011330.5	-5.24	6.63e-07	0.00179	-0.53	-0.43	Lung cancer;	chr15:43268409	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs491804	ENSG00000249839.1	AC011330.5	-5.24	6.63e-07	0.00179	-0.53	-0.43	Lung cancer;	chr15:43268627	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs492743	ENSG00000249839.1	AC011330.5	-5.24	6.63e-07	0.00179	-0.53	-0.43	Lung cancer;	chr15:43268747	chr15:43663654~43684339:-
ESCA	cis	rs10875746	0.951	rs10875756	ENSG00000240399.1	RP1-228P16.1	-5.24	6.66e-07	0.00179	-0.55	-0.43	Longevity (90 years and older);	chr12:48168521	chr12:48054813~48055591:-
ESCA	cis	rs9545047	0.716	rs9545108	ENSG00000227676.3	LINC01068	5.24	6.66e-07	0.00179	0.55	0.43	Schizophrenia;	chr13:79411175	chr13:79566727~79571436:+
ESCA	cis	rs977987	0.843	rs28655617	ENSG00000261783.1	RP11-252K23.2	-5.24	6.67e-07	0.0018	-0.54	-0.43	Dupuytren's disease;	chr16:75455744	chr16:75379818~75381260:-
ESCA	cis	rs9733	0.818	rs7520022	ENSG00000206931.1	RNU6-1042P	-5.24	6.69e-07	0.0018	-0.53	-0.43	Tonsillectomy;	chr1:150686697	chr1:150701866~150701972:+
ESCA	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-5.24	6.7e-07	0.0018	-0.54	-0.43	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-5.24	6.7e-07	0.0018	-0.54	-0.43	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
ESCA	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	5.24	6.74e-07	0.00181	0.59	0.43	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-5.24	6.77e-07	0.00181	-0.46	-0.43	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
ESCA	cis	rs9322193	0.923	rs9766004	ENSG00000216906.2	RP11-350J20.9	5.24	6.78e-07	0.00181	0.6	0.43	Lung cancer;	chr6:149754363	chr6:149904243~149906418:+
ESCA	cis	rs2439831	0.867	rs2447211	ENSG00000249839.1	AC011330.5	-5.24	6.78e-07	0.00182	-0.74	-0.43	Lung cancer in ever smokers;	chr15:43644153	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.571	rs2470121	ENSG00000249839.1	AC011330.5	-5.24	6.78e-07	0.00182	-0.74	-0.43	Lung cancer in ever smokers;	chr15:43645420	chr15:43663654~43684339:-
ESCA	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	5.24	6.79e-07	0.00182	0.64	0.43	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
ESCA	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	5.24	6.79e-07	0.00182	0.51	0.43	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
ESCA	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-5.24	6.79e-07	0.00182	-0.54	-0.43	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
ESCA	cis	rs10256972	0.63	rs13235747	ENSG00000229043.2	AC091729.9	-5.24	6.81e-07	0.00182	-0.42	-0.43	Endometriosis;Longevity;	chr7:1089487	chr7:1160374~1165267:+
ESCA	cis	rs6456156	0.586	rs6456150	ENSG00000265828.1	MIR3939	-5.24	6.82e-07	0.00182	-0.45	-0.43	Primary biliary cholangitis;	chr6:167055434	chr6:166997807~166997912:-
ESCA	cis	rs7829975	0.511	rs1543238	ENSG00000253981.4	ALG1L13P	5.24	6.83e-07	0.00183	0.53	0.43	Mood instability;	chr8:8277287	chr8:8236003~8244667:-
ESCA	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-5.24	6.84e-07	0.00183	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
ESCA	cis	rs7829975	0.623	rs10092965	ENSG00000253981.4	ALG1L13P	5.24	6.85e-07	0.00183	0.51	0.43	Mood instability;	chr8:8515975	chr8:8236003~8244667:-
ESCA	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	5.24	6.86e-07	0.00183	0.61	0.43	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
ESCA	cis	rs7582403	0.51	rs4001	ENSG00000223911.1	AC009480.3	5.24	6.86e-07	0.00184	0.46	0.43	Neuroticism;	chr2:148118074	chr2:147899401~147902956:-
ESCA	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-5.24	6.87e-07	0.00184	-0.44	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-5.24	6.87e-07	0.00184	-0.44	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-5.24	6.87e-07	0.00184	-0.44	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-5.24	6.87e-07	0.00184	-0.44	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-5.24	6.87e-07	0.00184	-0.44	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
ESCA	cis	rs801193	0.967	rs3800823	ENSG00000179406.6	LINC00174	5.24	6.88e-07	0.00184	0.49	0.43	Aortic root size;	chr7:66682123	chr7:66376044~66401338:-
ESCA	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	5.24	6.89e-07	0.00184	0.54	0.43	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
ESCA	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	5.23	6.9e-07	0.00184	0.59	0.43	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
ESCA	cis	rs9287719	0.649	rs58633964	ENSG00000234818.1	AC092687.5	5.23	6.93e-07	0.00185	0.37	0.43	Prostate cancer;	chr2:10596256	chr2:10589166~10604830:+
ESCA	cis	rs977987	0.835	rs3851733	ENSG00000261783.1	RP11-252K23.2	-5.23	6.94e-07	0.00185	-0.52	-0.43	Dupuytren's disease;	chr16:75336365	chr16:75379818~75381260:-
ESCA	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-5.23	6.98e-07	0.00186	-0.51	-0.43	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
ESCA	cis	rs3136516	0.935	rs11038993	ENSG00000271350.1	CTD-2384B9.1	5.23	6.98e-07	0.00186	0.52	0.43	Venous thromboembolism;	chr11:46789366	chr11:47041027~47041945:-
ESCA	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-5.23	7e-07	0.00187	-0.58	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-5.23	7e-07	0.00187	-0.58	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
ESCA	cis	rs7582403	0.51	rs7604592	ENSG00000223911.1	AC009480.3	5.23	7.01e-07	0.00187	0.48	0.43	Neuroticism;	chr2:148132966	chr2:147899401~147902956:-
ESCA	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-5.23	7.05e-07	0.00188	-0.57	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
ESCA	cis	rs9545047	0.604	rs35476664	ENSG00000227676.3	LINC01068	-5.23	7.08e-07	0.00189	-0.55	-0.43	Schizophrenia;	chr13:79375462	chr13:79566727~79571436:+
ESCA	cis	rs6538678	0.712	rs10777748	ENSG00000258343.1	RP11-536G4.2	-5.23	7.09e-07	0.00189	-0.54	-0.43	Lupus nephritis in systemic lupus erythematosus;	chr12:95880227	chr12:95795345~95858839:-
ESCA	cis	rs6456156	0.586	rs12525855	ENSG00000265828.1	MIR3939	-5.23	7.09e-07	0.00189	-0.45	-0.43	Primary biliary cholangitis;	chr6:167066525	chr6:166997807~166997912:-
ESCA	cis	rs2455601	0.507	rs2568044	ENSG00000254860.4	TMEM9B-AS1	-5.23	7.12e-07	0.0019	-0.55	-0.43	Schizophrenia;	chr11:8980930	chr11:8964675~8977527:+
ESCA	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	5.23	7.13e-07	0.0019	0.37	0.43	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
ESCA	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	5.23	7.13e-07	0.0019	0.5	0.43	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
ESCA	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	5.23	7.15e-07	0.0019	0.52	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
ESCA	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	5.23	7.15e-07	0.0019	0.52	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
ESCA	cis	rs10256972	0.641	rs12702017	ENSG00000229043.2	AC091729.9	-5.23	7.16e-07	0.0019	-0.42	-0.43	Endometriosis;Longevity;	chr7:1089777	chr7:1160374~1165267:+
ESCA	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	5.23	7.16e-07	0.0019	0.54	0.43	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
ESCA	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-5.23	7.16e-07	0.00191	-0.69	-0.43	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
ESCA	cis	rs1439620	0.686	rs7167859	ENSG00000258647.4	LINC00930	5.23	7.18e-07	0.00191	0.57	0.43	Body mass index;	chr15:92957805	chr15:92567818~92572042:-
ESCA	cis	rs3820716	0.545	rs12469509	ENSG00000223911.1	AC009480.3	5.23	7.18e-07	0.00191	0.5	0.43	Glomerular filtration rate (creatinine);	chr2:148095531	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs13006721	ENSG00000223911.1	AC009480.3	5.23	7.18e-07	0.00191	0.5	0.43	Glomerular filtration rate (creatinine);	chr2:148097048	chr2:147899401~147902956:-
ESCA	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	5.23	7.2e-07	0.00191	0.45	0.43	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
ESCA	cis	rs2627019	0.546	rs6430289	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148100666	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs1901014	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148101012	chr2:147899401~147902956:-
ESCA	cis	rs2627019	0.528	rs11902430	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148103023	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs12470955	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148106316	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs4436897	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148110619	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs13001416	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148114073	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs12691774	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148116504	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs12691775	ENSG00000223911.1	AC009480.3	5.23	7.21e-07	0.00192	0.47	0.43	Neuroticism;	chr2:148116521	chr2:147899401~147902956:-
ESCA	cis	rs7829975	0.846	rs7005216	ENSG00000253981.4	ALG1L13P	-5.22	7.22e-07	0.00192	-0.5	-0.43	Mood instability;	chr8:8689600	chr8:8236003~8244667:-
ESCA	cis	rs1439620	0.686	rs4778061	ENSG00000258647.4	LINC00930	5.22	7.22e-07	0.00192	0.58	0.43	Body mass index;	chr15:92958168	chr15:92567818~92572042:-
ESCA	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	5.22	7.24e-07	0.00192	0.53	0.43	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
ESCA	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-5.22	7.26e-07	0.00193	-0.54	-0.43	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
ESCA	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-5.22	7.29e-07	0.00193	-0.46	-0.43	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
ESCA	cis	rs116927879	1	rs116927879	ENSG00000272556.1	RP11-638I8.1	-5.22	7.3e-07	0.00193	-0.85	-0.43	Subjective response to lithium treatment in bipolar disorder;	chr7:45825128	chr7:45814602~45815263:+
ESCA	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-5.22	7.3e-07	0.00193	-0.56	-0.43	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
ESCA	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	5.22	7.32e-07	0.00194	0.51	0.43	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
ESCA	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	5.22	7.33e-07	0.00194	0.57	0.43	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
ESCA	cis	rs801193	1	rs10234018	ENSG00000179406.6	LINC00174	5.22	7.34e-07	0.00194	0.46	0.43	Aortic root size;	chr7:66681297	chr7:66376044~66401338:-
ESCA	cis	rs801193	1	rs2055682	ENSG00000179406.6	LINC00174	-5.22	7.34e-07	0.00194	-0.49	-0.43	Aortic root size;	chr7:66795302	chr7:66376044~66401338:-
ESCA	cis	rs748404	0.697	rs475227	ENSG00000249839.1	AC011330.5	-5.22	7.39e-07	0.00195	-0.52	-0.43	Lung cancer;	chr15:43254248	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.692	rs314694	ENSG00000227676.3	LINC01068	-5.22	7.39e-07	0.00195	-0.56	-0.43	Schizophrenia;	chr13:79432467	chr13:79566727~79571436:+
ESCA	cis	rs2221894	0.96	rs1877501	ENSG00000273710.1	Metazoa_SRP	-5.22	7.43e-07	0.00196	-0.46	-0.43	Obesity-related traits;	chr8:28952434	chr8:28915579~28915864:-
ESCA	cis	rs6479891	0.915	rs9415699	ENSG00000235816.3	PRELID1P3	-5.22	7.43e-07	0.00197	-0.55	-0.43	Arthritis (juvenile idiopathic);	chr10:63383798	chr10:63427297~63427939:+
ESCA	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-5.22	7.44e-07	0.00197	-0.45	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
ESCA	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	5.22	7.47e-07	0.00197	0.56	0.43	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
ESCA	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-5.22	7.47e-07	0.00197	-0.52	-0.43	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
ESCA	cis	rs2505998	0.957	rs1864408	ENSG00000273008.1	RP11-351D16.3	-5.22	7.49e-07	0.00198	-0.47	-0.43	Hirschsprung disease;	chr10:43080435	chr10:43136824~43138334:-
ESCA	cis	rs1005277	0.579	rs1740732	ENSG00000263064.2	RP11-291L22.7	5.22	7.49e-07	0.00198	0.56	0.43	Extrinsic epigenetic age acceleration;	chr10:38202457	chr10:38448689~38448949:+
ESCA	cis	rs7582403	0.51	rs6430292	ENSG00000223911.1	AC009480.3	5.22	7.5e-07	0.00198	0.47	0.43	Neuroticism;	chr2:148117438	chr2:147899401~147902956:-
ESCA	cis	rs2627019	0.546	rs1823447	ENSG00000223911.1	AC009480.3	5.22	7.5e-07	0.00198	0.47	0.43	Neuroticism;	chr2:148119034	chr2:147899401~147902956:-
ESCA	cis	rs2882667	0.858	rs13177503	ENSG00000253404.1	AC034243.1	5.21	7.54e-07	0.00199	0.63	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139097070	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs13170388	ENSG00000253404.1	AC034243.1	5.21	7.54e-07	0.00199	0.63	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139101176	chr5:138744434~138753309:-
ESCA	cis	rs748404	0.697	rs579651	ENSG00000249839.1	AC011330.5	-5.21	7.55e-07	0.00199	-0.53	-0.43	Lung cancer;	chr15:43266178	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs473016	ENSG00000249839.1	AC011330.5	-5.21	7.55e-07	0.00199	-0.53	-0.43	Lung cancer;	chr15:43266625	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.604	rs2057573	ENSG00000227676.3	LINC01068	-5.21	7.58e-07	0.002	-0.55	-0.43	Schizophrenia;	chr13:79357736	chr13:79566727~79571436:+
ESCA	cis	rs977987	0.843	rs7499872	ENSG00000261783.1	RP11-252K23.2	-5.21	7.58e-07	0.002	-0.52	-0.43	Dupuytren's disease;	chr16:75392631	chr16:75379818~75381260:-
ESCA	cis	rs9545047	0.604	rs7319212	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79365404	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7319252	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79365471	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9318633	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79369113	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9318634	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79369303	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs12872328	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79370489	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2182010	ENSG00000227676.3	LINC01068	-5.21	7.6e-07	0.002	-0.54	-0.43	Schizophrenia;	chr13:79370618	chr13:79566727~79571436:+
ESCA	cis	rs8040855	0.86	rs6496775	ENSG00000259295.5	CSPG4P12	-5.21	7.62e-07	0.00201	-0.75	-0.43	Bulimia nervosa;	chr15:85164910	chr15:85191438~85213905:+
ESCA	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-5.21	7.63e-07	0.00201	-0.85	-0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-5.21	7.63e-07	0.00201	-0.85	-0.43	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
ESCA	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-5.21	7.65e-07	0.00201	-0.52	-0.43	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-5.21	7.65e-07	0.00201	-0.52	-0.43	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-5.21	7.65e-07	0.00201	-0.52	-0.43	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-5.21	7.65e-07	0.00201	-0.52	-0.43	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
ESCA	cis	rs9457247	0.638	rs239933	ENSG00000265828.1	MIR3939	-5.21	7.66e-07	0.00202	-0.46	-0.43	Crohn's disease;	chr6:166999742	chr6:166997807~166997912:-
ESCA	cis	rs977987	0.654	rs8054194	ENSG00000261783.1	RP11-252K23.2	-5.21	7.69e-07	0.00202	-0.54	-0.43	Dupuytren's disease;	chr16:75463262	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.581	rs8056141	ENSG00000261783.1	RP11-252K23.2	-5.21	7.69e-07	0.00202	-0.54	-0.43	Dupuytren's disease;	chr16:75463264	chr16:75379818~75381260:-
ESCA	cis	rs42490	0.903	rs218900	ENSG00000251136.7	RP11-37B2.1	-5.21	7.69e-07	0.00202	-0.44	-0.43	Leprosy;	chr8:89718678	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.903	rs218901	ENSG00000251136.7	RP11-37B2.1	-5.21	7.69e-07	0.00202	-0.44	-0.43	Leprosy;	chr8:89719089	chr8:89609409~89757727:-
ESCA	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	5.21	7.69e-07	0.00202	0.45	0.43	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
ESCA	cis	rs748404	0.697	rs1814323	ENSG00000249839.1	AC011330.5	5.21	7.7e-07	0.00202	0.52	0.43	Lung cancer;	chr15:43271039	chr15:43663654~43684339:-
ESCA	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-5.21	7.73e-07	0.00203	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-5.21	7.73e-07	0.00203	-0.53	-0.43	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	5.21	7.73e-07	0.00203	0.53	0.43	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
ESCA	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-5.21	7.75e-07	0.00204	-0.56	-0.43	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
ESCA	cis	rs9545047	0.716	rs8001795	ENSG00000227676.3	LINC01068	5.21	7.76e-07	0.00204	0.55	0.43	Schizophrenia;	chr13:79421402	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs8002838	ENSG00000227676.3	LINC01068	5.21	7.76e-07	0.00204	0.55	0.43	Schizophrenia;	chr13:79421681	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.669	rs9545113	ENSG00000227676.3	LINC01068	5.21	7.76e-07	0.00204	0.55	0.43	Schizophrenia;	chr13:79422017	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.68	rs9545114	ENSG00000227676.3	LINC01068	5.21	7.76e-07	0.00204	0.55	0.43	Schizophrenia;	chr13:79423744	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs586219	ENSG00000227676.3	LINC01068	-5.21	7.76e-07	0.00204	-0.55	-0.43	Schizophrenia;	chr13:79425177	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs2265377	ENSG00000227676.3	LINC01068	-5.21	7.76e-07	0.00204	-0.55	-0.43	Schizophrenia;	chr13:79425485	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs2265378	ENSG00000227676.3	LINC01068	-5.21	7.76e-07	0.00204	-0.55	-0.43	Schizophrenia;	chr13:79425581	chr13:79566727~79571436:+
ESCA	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-5.21	7.76e-07	0.00204	-0.56	-0.43	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
ESCA	cis	rs2882667	0.858	rs6882112	ENSG00000253404.1	AC034243.1	-5.21	7.77e-07	0.00204	-0.59	-0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078046	chr5:138744434~138753309:-
ESCA	cis	rs694739	0.628	rs538147	ENSG00000236935.1	AP003774.1	5.21	7.78e-07	0.00204	0.53	0.43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64362250	chr11:64325050~64329504:-
ESCA	cis	rs1005277	0.579	rs2103938	ENSG00000263064.2	RP11-291L22.7	5.21	7.79e-07	0.00204	0.57	0.43	Extrinsic epigenetic age acceleration;	chr10:38205070	chr10:38448689~38448949:+
ESCA	cis	rs7582403	0.51	rs4972329	ENSG00000223911.1	AC009480.3	5.21	7.81e-07	0.00205	0.47	0.42	Neuroticism;	chr2:148122244	chr2:147899401~147902956:-
ESCA	cis	rs6479891	1	rs6479899	ENSG00000235816.3	PRELID1P3	-5.21	7.81e-07	0.00205	-0.55	-0.42	Arthritis (juvenile idiopathic);	chr10:63379287	chr10:63427297~63427939:+
ESCA	cis	rs1538970	0.816	rs3790583	ENSG00000280836.1	AL355480.1	-5.21	7.83e-07	0.00205	-0.54	-0.42	Platelet count;	chr1:45491156	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.816	rs11211123	ENSG00000280836.1	AL355480.1	-5.21	7.83e-07	0.00205	-0.54	-0.42	Platelet count;	chr1:45491937	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.816	rs10789464	ENSG00000280836.1	AL355480.1	-5.21	7.83e-07	0.00205	-0.54	-0.42	Platelet count;	chr1:45493430	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.816	rs11211124	ENSG00000280836.1	AL355480.1	-5.21	7.83e-07	0.00205	-0.54	-0.42	Platelet count;	chr1:45496737	chr1:45581219~45581321:-
ESCA	cis	rs2627019	0.51	rs13015552	ENSG00000223911.1	AC009480.3	5.21	7.83e-07	0.00205	0.5	0.42	Neuroticism;	chr2:148085803	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs2122386	ENSG00000223911.1	AC009480.3	5.21	7.83e-07	0.00205	0.5	0.42	Glomerular filtration rate (creatinine);	chr2:148089118	chr2:147899401~147902956:-
ESCA	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	5.21	7.85e-07	0.00206	0.5	0.42	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
ESCA	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-5.21	7.85e-07	0.00206	-0.43	-0.42	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-5.21	7.85e-07	0.00206	-0.42	-0.42	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
ESCA	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-5.21	7.85e-07	0.00206	-0.45	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
ESCA	cis	rs1816752	1	rs7999554	ENSG00000273628.1	RP11-756A22.7	5.21	7.88e-07	0.00206	0.41	0.42	Obesity-related traits;	chr13:24435631	chr13:24933006~24936796:+
ESCA	cis	rs1005277	0.579	rs1621040	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38208304	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780136	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38212525	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780138	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38212726	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.602	rs1780141	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38215371	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.541	rs1740741	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38226406	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.528	rs2057228	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38226838	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1740742	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38229932	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.602	rs1740743	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38230294	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1740745	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38231128	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1740747	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38231537	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1740749	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38232718	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1780115	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38235845	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.529	rs1780125	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38242448	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.502	rs2800484	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38253487	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2800485	ENSG00000263064.2	RP11-291L22.7	5.2	7.91e-07	0.00207	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38253660	chr10:38448689~38448949:+
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000231271.1	AP000350.8	-5.2	7.91e-07	0.00207	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23949918~23954042:+
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000231271.1	AP000350.8	-5.2	7.91e-07	0.00207	-0.6	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23949918~23954042:+
ESCA	cis	rs6456156	0.586	rs720325	ENSG00000265828.1	MIR3939	-5.2	7.92e-07	0.00207	-0.46	-0.42	Primary biliary cholangitis;	chr6:167053861	chr6:166997807~166997912:-
ESCA	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	5.2	7.95e-07	0.00208	0.59	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
ESCA	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-5.2	8.01e-07	0.00209	-0.45	-0.42	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
ESCA	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-5.2	8.01e-07	0.00209	-0.45	-0.42	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
ESCA	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	5.2	8.02e-07	0.00209	0.5	0.42	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
ESCA	cis	rs2221894	0.922	rs2203209	ENSG00000273710.1	Metazoa_SRP	-5.2	8.04e-07	0.0021	-0.45	-0.42	Obesity-related traits;	chr8:28930516	chr8:28915579~28915864:-
ESCA	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-5.2	8.06e-07	0.0021	-0.49	-0.42	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
ESCA	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-5.2	8.06e-07	0.0021	-0.49	-0.42	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-5.2	8.06e-07	0.0021	-0.49	-0.42	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-5.2	8.06e-07	0.0021	-0.49	-0.42	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
ESCA	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-5.2	8.06e-07	0.0021	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
ESCA	cis	rs977987	0.806	rs4638613	ENSG00000261783.1	RP11-252K23.2	-5.2	8.11e-07	0.00211	-0.52	-0.42	Dupuytren's disease;	chr16:75391655	chr16:75379818~75381260:-
ESCA	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	5.2	8.15e-07	0.00212	0.46	0.42	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
ESCA	cis	rs977987	0.806	rs7188231	ENSG00000261783.1	RP11-252K23.2	-5.2	8.17e-07	0.00213	-0.54	-0.42	Dupuytren's disease;	chr16:75402663	chr16:75379818~75381260:-
ESCA	cis	rs2439831	0.85	rs7169988	ENSG00000249839.1	AC011330.5	-5.2	8.17e-07	0.00213	-0.78	-0.42	Lung cancer in ever smokers;	chr15:43768237	chr15:43663654~43684339:-
ESCA	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	5.2	8.19e-07	0.00213	0.73	0.42	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
ESCA	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-5.2	8.21e-07	0.00213	-0.56	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
ESCA	cis	rs2980439	0.607	rs2980419	ENSG00000173295.6	FAM86B3P	5.2	8.21e-07	0.00213	0.53	0.42	Neuroticism;	chr8:8256619	chr8:8228595~8244865:+
ESCA	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-5.2	8.23e-07	0.00214	-0.61	-0.42	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
ESCA	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-5.2	8.23e-07	0.00214	-0.49	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
ESCA	cis	rs875971	0.66	rs79009421	ENSG00000179406.6	LINC00174	5.19	8.24e-07	0.00214	0.47	0.42	Aortic root size;	chr7:66603522	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.638	rs6960778	ENSG00000179406.6	LINC00174	5.19	8.24e-07	0.00214	0.47	0.42	Aortic root size;	chr7:66606610	chr7:66376044~66401338:-
ESCA	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	5.19	8.26e-07	0.00214	0.45	0.42	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	5.19	8.26e-07	0.00214	0.45	0.42	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-5.19	8.26e-07	0.00214	-0.45	-0.42	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-5.19	8.26e-07	0.00214	-0.45	-0.42	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-5.19	8.26e-07	0.00214	-0.45	-0.42	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-5.19	8.26e-07	0.00214	-0.45	-0.42	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-5.19	8.26e-07	0.00214	-0.45	-0.42	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
ESCA	cis	rs2742234	0.656	rs1864400	ENSG00000273008.1	RP11-351D16.3	-5.19	8.32e-07	0.00216	-0.51	-0.42	Hirschsprung disease;	chr10:43114918	chr10:43136824~43138334:-
ESCA	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	5.19	8.32e-07	0.00216	0.6	0.42	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	5.19	8.32e-07	0.00216	0.6	0.42	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
ESCA	cis	rs1563304	1	rs1563304	ENSG00000261575.2	RP11-259G18.1	5.19	8.34e-07	0.00216	0.75	0.42	Neuroticism;	chr17:46797087	chr17:46267037~46268694:+
ESCA	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-5.19	8.35e-07	0.00216	-0.52	-0.42	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
ESCA	cis	rs13217239	0.572	rs9379958	ENSG00000243307.2	POM121L6P	-5.19	8.37e-07	0.00217	-0.47	-0.42	Schizophrenia;	chr6:27098384	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs9393789	ENSG00000243307.2	POM121L6P	-5.19	8.37e-07	0.00217	-0.47	-0.42	Schizophrenia;	chr6:27099249	chr6:26896952~26898777:+
ESCA	cis	rs13217239	0.646	rs6456767	ENSG00000243307.2	POM121L6P	-5.19	8.37e-07	0.00217	-0.47	-0.42	Schizophrenia;	chr6:27102764	chr6:26896952~26898777:+
ESCA	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	5.19	8.39e-07	0.00217	0.45	0.42	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
ESCA	cis	rs1005277	0.557	rs2983338	ENSG00000263064.2	RP11-291L22.7	5.19	8.4e-07	0.00217	0.57	0.42	Extrinsic epigenetic age acceleration;	chr10:38261806	chr10:38448689~38448949:+
ESCA	cis	rs8059260	1	rs6498139	ENSG00000274038.1	RP11-66H6.4	-5.19	8.4e-07	0.00217	-0.79	-0.42	Alcohol consumption over the past year;	chr16:10954066	chr16:11056556~11057034:+
ESCA	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-5.19	8.4e-07	0.00217	-0.79	-0.42	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
ESCA	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-5.19	8.4e-07	0.00217	-0.55	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.66	rs6460308	ENSG00000179406.6	LINC00174	5.19	8.4e-07	0.00217	0.47	0.42	Aortic root size;	chr7:66619753	chr7:66376044~66401338:-
ESCA	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-5.19	8.41e-07	0.00217	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs13438188	ENSG00000230042.1	AK3P3	5.19	8.41e-07	0.00217	0.43	0.42	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23129178~23129841:+
ESCA	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	5.19	8.43e-07	0.00218	0.61	0.42	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
ESCA	cis	rs765787	0.53	rs1648285	ENSG00000259520.4	CTD-2651B20.3	5.19	8.45e-07	0.00218	0.49	0.42	Uric acid levels;	chr15:45225307	chr15:45251580~45279251:-
ESCA	cis	rs9322193	0.962	rs2275045	ENSG00000216906.2	RP11-350J20.9	5.19	8.45e-07	0.00218	0.63	0.42	Lung cancer;	chr6:149842775	chr6:149904243~149906418:+
ESCA	cis	rs12822507	1	rs12822507	ENSG00000275560.1	RP11-180M15.7	5.19	8.45e-07	0.00218	0.43	0.42	Systemic lupus erythematosus;	chr12:12620587	chr12:12718973~12719521:+
ESCA	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-5.19	8.47e-07	0.00219	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
ESCA	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	5.19	8.49e-07	0.00219	0.53	0.42	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
ESCA	cis	rs977987	0.843	rs12928036	ENSG00000261783.1	RP11-252K23.2	-5.19	8.49e-07	0.00219	-0.53	-0.42	Dupuytren's disease;	chr16:75449234	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs59465235	ENSG00000261783.1	RP11-252K23.2	-5.19	8.49e-07	0.00219	-0.53	-0.42	Dupuytren's disease;	chr16:75449912	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.815	rs4887829	ENSG00000261783.1	RP11-252K23.2	-5.19	8.49e-07	0.00219	-0.53	-0.42	Dupuytren's disease;	chr16:75455037	chr16:75379818~75381260:-
ESCA	cis	rs2307394	0.964	rs13033589	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147945430	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs1531032	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147945741	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs10460259	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147947152	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs1030317	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147947363	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13012311	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147949463	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs11888152	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147957469	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs12463798	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147958530	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs2307394	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147958859	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs4972317	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147961351	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs34539489	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147965308	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs6729465	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147965557	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.927	rs11901963	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147969202	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.929	rs1020653	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147974841	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13027706	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147975134	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs7594075	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147982254	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs4972318	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147983018	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13031064	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:147984409	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs4417662	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:148031817	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.963	rs11896010	ENSG00000223911.1	AC009480.3	5.19	8.51e-07	0.00219	0.5	0.42	Urate levels;	chr2:148032161	chr2:147899401~147902956:-
ESCA	cis	rs7829975	0.624	rs7823056	ENSG00000253981.4	ALG1L13P	5.19	8.53e-07	0.0022	0.52	0.42	Mood instability;	chr8:8525195	chr8:8236003~8244667:-
ESCA	cis	rs748404	0.697	rs564946	ENSG00000249839.1	AC011330.5	-5.19	8.55e-07	0.0022	-0.52	-0.42	Lung cancer;	chr15:43264074	chr15:43663654~43684339:-
ESCA	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-5.19	8.55e-07	0.0022	-0.51	-0.42	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
ESCA	cis	rs2739330	0.828	rs2330635	ENSG00000228039.3	KB-1125A3.10	5.19	8.58e-07	0.00221	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23963780~23964374:+
ESCA	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	5.18	8.64e-07	0.00222	0.46	0.42	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.858	rs11957633	ENSG00000253404.1	AC034243.1	5.18	8.65e-07	0.00223	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139028705	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs35812969	ENSG00000253404.1	AC034243.1	5.18	8.65e-07	0.00223	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139041861	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs11242442	ENSG00000253404.1	AC034243.1	5.18	8.65e-07	0.00223	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139044800	chr5:138744434~138753309:-
ESCA	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	5.18	8.68e-07	0.00223	0.41	0.42	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
ESCA	cis	rs9549367	0.713	rs9549691	ENSG00000269125.1	RP11-98F14.11	-5.18	8.7e-07	0.00224	-0.48	-0.42	Platelet distribution width;	chr13:113207292	chr13:113165002~113165183:-
ESCA	cis	rs7924176	0.502	rs1874151	ENSG00000236900.1	TIMM9P1	-5.18	8.71e-07	0.00224	-0.51	-0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74107856	chr10:74344550~74344805:-
ESCA	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	5.18	8.73e-07	0.00224	0.51	0.42	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
ESCA	cis	rs9545047	0.604	rs9574419	ENSG00000227676.3	LINC01068	-5.18	8.74e-07	0.00225	-0.55	-0.42	Schizophrenia;	chr13:79402337	chr13:79566727~79571436:+
ESCA	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	5.18	8.78e-07	0.00225	0.59	0.42	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
ESCA	cis	rs875971	0.638	rs6460305	ENSG00000179406.6	LINC00174	5.18	8.78e-07	0.00225	0.47	0.42	Aortic root size;	chr7:66595421	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs10272357	ENSG00000179406.6	LINC00174	5.18	8.78e-07	0.00225	0.47	0.42	Aortic root size;	chr7:66598087	chr7:66376044~66401338:-
ESCA	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-5.18	8.8e-07	0.00226	-0.48	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
ESCA	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	5.18	8.82e-07	0.00226	0.46	0.42	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
ESCA	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-5.18	8.85e-07	0.00227	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
ESCA	cis	rs6538678	0.929	rs10735336	ENSG00000258343.1	RP11-536G4.2	-5.18	8.86e-07	0.00227	-0.51	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95869661	chr12:95795345~95858839:-
ESCA	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-5.18	8.88e-07	0.00228	-0.43	-0.42	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
ESCA	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-5.18	8.89e-07	0.00228	-0.45	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
ESCA	cis	rs6432860	0.545	rs1841546	ENSG00000232411.1	AC009495.3	5.18	8.89e-07	0.00228	0.47	0.42	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166052594	chr2:165833048~165839098:-
ESCA	cis	rs7829975	0.514	rs2920983	ENSG00000173295.6	FAM86B3P	5.18	8.89e-07	0.00228	0.49	0.42	Mood instability;	chr8:8410553	chr8:8228595~8244865:+
ESCA	cis	rs9399135	0.744	rs9402677	ENSG00000232876.1	CTA-212D2.2	-5.18	8.92e-07	0.00229	-0.5	-0.42	Red blood cell count;	chr6:135049570	chr6:135055033~135060550:+
ESCA	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	5.18	8.99e-07	0.0023	0.44	0.42	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
ESCA	cis	rs7582403	0.51	rs10178849	ENSG00000223911.1	AC009480.3	5.17	8.99e-07	0.0023	0.47	0.42	Neuroticism;	chr2:148063372	chr2:147899401~147902956:-
ESCA	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	5.17	9.04e-07	0.00231	0.57	0.42	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs62439840	ENSG00000216906.2	RP11-350J20.9	5.17	9.04e-07	0.00231	0.57	0.42	Lung cancer;	chr6:149674639	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs9393175	ENSG00000216906.2	RP11-350J20.9	5.17	9.04e-07	0.00231	0.57	0.42	Lung cancer;	chr6:149677587	chr6:149904243~149906418:+
ESCA	cis	rs10256972	0.684	rs2363279	ENSG00000229043.2	AC091729.9	-5.17	9.05e-07	0.00231	-0.43	-0.42	Endometriosis;Longevity;	chr7:1056507	chr7:1160374~1165267:+
ESCA	cis	rs853679	0.657	rs1778483	ENSG00000216901.1	AL022393.7	5.17	9.05e-07	0.00231	0.49	0.42	Depression;	chr6:28273214	chr6:28176188~28176674:+
ESCA	cis	rs853679	0.657	rs1778482	ENSG00000216901.1	AL022393.7	5.17	9.05e-07	0.00231	0.49	0.42	Depression;	chr6:28273215	chr6:28176188~28176674:+
ESCA	cis	rs765787	0.53	rs2554454	ENSG00000259520.4	CTD-2651B20.3	5.17	9.07e-07	0.00232	0.48	0.42	Uric acid levels;	chr15:45229338	chr15:45251580~45279251:-
ESCA	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	5.17	9.07e-07	0.00232	0.43	0.42	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
ESCA	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	5.17	9.08e-07	0.00232	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
ESCA	cis	rs112158604	1	rs112158604	ENSG00000206931.1	RNU6-1042P	-5.17	9.1e-07	0.00232	-0.53	-0.42	Lymphocyte counts;	chr1:150724325	chr1:150701866~150701972:+
ESCA	cis	rs2882667	0.929	rs34846849	ENSG00000253404.1	AC034243.1	5.17	9.1e-07	0.00232	0.6	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139024889	chr5:138744434~138753309:-
ESCA	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	5.17	9.12e-07	0.00233	0.46	0.42	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
ESCA	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-5.17	9.12e-07	0.00233	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-5.17	9.12e-07	0.00233	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
ESCA	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-5.17	9.13e-07	0.00233	-0.56	-0.42	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
ESCA	cis	rs7582403	0.51	rs7592576	ENSG00000223911.1	AC009480.3	-5.17	9.14e-07	0.00233	-0.47	-0.42	Neuroticism;	chr2:148081978	chr2:147899401~147902956:-
ESCA	cis	rs2882667	0.824	rs1560656	ENSG00000253404.1	AC034243.1	-5.17	9.18e-07	0.00234	-0.58	-0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135100	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.923	rs10782318	ENSG00000216906.2	RP11-350J20.9	5.17	9.19e-07	0.00234	0.59	0.42	Lung cancer;	chr6:149754137	chr6:149904243~149906418:+
ESCA	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	5.17	9.21e-07	0.00235	0.65	0.42	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	5.17	9.21e-07	0.00235	0.65	0.42	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000250470.1	AP000351.3	-5.17	9.21e-07	0.00235	-0.58	-0.42	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23976904~23977585:-
ESCA	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-5.17	9.22e-07	0.00235	-0.51	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
ESCA	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	5.17	9.23e-07	0.00235	0.58	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.638	rs6895690	ENSG00000253404.1	AC034243.1	5.17	9.23e-07	0.00235	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139130162	chr5:138744434~138753309:-
ESCA	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	5.17	9.28e-07	0.00236	0.53	0.42	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	5.17	9.28e-07	0.00236	0.53	0.42	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	5.17	9.28e-07	0.00236	0.53	0.42	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
ESCA	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	5.17	9.28e-07	0.00236	0.59	0.42	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	5.17	9.28e-07	0.00236	0.59	0.42	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	5.17	9.28e-07	0.00236	0.59	0.42	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
ESCA	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-5.17	9.29e-07	0.00237	-0.71	-0.42	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-5.17	9.29e-07	0.00237	-0.46	-0.42	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-5.17	9.29e-07	0.00237	-0.46	-0.42	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
ESCA	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	5.17	9.29e-07	0.00237	0.47	0.42	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
ESCA	cis	rs9545047	0.604	rs2025913	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79357315	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545082	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79358994	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7332913	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79359149	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545083	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79360695	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7322756	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79361120	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7324006	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79361225	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7322673	ENSG00000227676.3	LINC01068	5.17	9.3e-07	0.00237	0.54	0.42	Schizophrenia;	chr13:79361266	chr13:79566727~79571436:+
ESCA	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-5.17	9.3e-07	0.00237	-0.53	-0.42	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
ESCA	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	5.17	9.33e-07	0.00237	0.43	0.42	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
ESCA	cis	rs7829975	0.511	rs1401390	ENSG00000253981.4	ALG1L13P	5.17	9.34e-07	0.00238	0.52	0.42	Mood instability;	chr8:8278888	chr8:8236003~8244667:-
ESCA	cis	rs10875746	0.951	rs2269935	ENSG00000240399.1	RP1-228P16.1	-5.17	9.34e-07	0.00238	-0.54	-0.42	Longevity (90 years and older);	chr12:48122681	chr12:48054813~48055591:-
ESCA	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-5.17	9.34e-07	0.00238	-0.72	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
ESCA	cis	rs1075265	0.568	rs805416	ENSG00000235937.1	AC008280.1	-5.17	9.38e-07	0.00239	-0.46	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54029552~54030682:-
ESCA	cis	rs4747241	0.828	rs3998474	ENSG00000226163.1	RP11-167P22.3	5.17	9.4e-07	0.00239	0.49	0.42	Heschl's gyrus morphology;	chr10:72259918	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.859	rs10823910	ENSG00000226163.1	RP11-167P22.3	5.17	9.4e-07	0.00239	0.49	0.42	Heschl's gyrus morphology;	chr10:72262594	chr10:72501746~72502956:+
ESCA	cis	rs6867032	0.874	rs4975786	ENSG00000249731.1	RP11-259O2.3	-5.16	9.44e-07	0.0024	-0.32	-0.42	Gut microbiome composition (winter);	chr5:2004610	chr5:1968094~1969013:+
ESCA	cis	rs1075265	0.756	rs809280	ENSG00000235937.1	AC008280.1	5.16	9.47e-07	0.00241	0.45	0.42	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54029552~54030682:-
ESCA	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-5.16	9.47e-07	0.00241	-0.56	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
ESCA	cis	rs977987	0.864	rs40446	ENSG00000261783.1	RP11-252K23.2	5.16	9.48e-07	0.00241	0.54	0.42	Dupuytren's disease;	chr16:75462760	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.864	rs37592	ENSG00000261783.1	RP11-252K23.2	5.16	9.48e-07	0.00241	0.54	0.42	Dupuytren's disease;	chr16:75462893	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.864	rs37593	ENSG00000261783.1	RP11-252K23.2	5.16	9.48e-07	0.00241	0.54	0.42	Dupuytren's disease;	chr16:75463009	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.864	rs37594	ENSG00000261783.1	RP11-252K23.2	5.16	9.48e-07	0.00241	0.54	0.42	Dupuytren's disease;	chr16:75463045	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.864	rs37595	ENSG00000261783.1	RP11-252K23.2	5.16	9.48e-07	0.00241	0.54	0.42	Dupuytren's disease;	chr16:75463065	chr16:75379818~75381260:-
ESCA	cis	rs9545047	0.716	rs9545061	ENSG00000227676.3	LINC01068	5.16	9.48e-07	0.00241	0.55	0.42	Schizophrenia;	chr13:79310695	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.716	rs9545067	ENSG00000227676.3	LINC01068	5.16	9.48e-07	0.00241	0.55	0.42	Schizophrenia;	chr13:79323429	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.68	rs9574405	ENSG00000227676.3	LINC01068	5.16	9.48e-07	0.00241	0.55	0.42	Schizophrenia;	chr13:79328943	chr13:79566727~79571436:+
ESCA	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-5.16	9.51e-07	0.00241	-0.5	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-5.16	9.51e-07	0.00241	-0.5	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
ESCA	cis	rs61160187	0.582	rs12655209	ENSG00000215032.2	GNL3LP1	-5.16	9.53e-07	0.00242	-0.52	-0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:61010225	chr5:60891935~60893577:-
ESCA	cis	rs2221894	0.96	rs4732893	ENSG00000273710.1	Metazoa_SRP	5.16	9.54e-07	0.00242	0.48	0.42	Obesity-related traits;	chr8:28937161	chr8:28915579~28915864:-
ESCA	cis	rs977987	0.836	rs17685540	ENSG00000261783.1	RP11-252K23.2	-5.16	9.57e-07	0.00243	-0.51	-0.42	Dupuytren's disease;	chr16:75289942	chr16:75379818~75381260:-
ESCA	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-5.16	9.58e-07	0.00243	-0.84	-0.42	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
ESCA	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	5.16	9.59e-07	0.00243	0.52	0.42	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
ESCA	cis	rs9545047	0.588	rs9530913	ENSG00000227676.3	LINC01068	5.16	9.59e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79384539	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7329331	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79384986	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7330479	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79385058	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs6563104	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79389718	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7981500	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79391461	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7986306	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79392530	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs57821487	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79392810	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7323246	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79392903	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7331766	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79394076	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530915	ENSG00000227676.3	LINC01068	5.16	9.6e-07	0.00243	0.55	0.42	Schizophrenia;	chr13:79396512	chr13:79566727~79571436:+
ESCA	cis	rs6479891	1	rs9415696	ENSG00000235816.3	PRELID1P3	5.16	9.66e-07	0.00245	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63374588	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9415697	ENSG00000235816.3	PRELID1P3	5.16	9.66e-07	0.00245	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63375377	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs724553	ENSG00000235816.3	PRELID1P3	5.16	9.66e-07	0.00245	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63380624	chr10:63427297~63427939:+
ESCA	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	5.16	9.67e-07	0.00245	0.61	0.42	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
ESCA	cis	rs977987	0.806	rs11644306	ENSG00000261783.1	RP11-252K23.2	-5.16	9.68e-07	0.00245	-0.53	-0.42	Dupuytren's disease;	chr16:75456155	chr16:75379818~75381260:-
ESCA	cis	rs10256972	0.706	rs12701969	ENSG00000229043.2	AC091729.9	-5.16	9.72e-07	0.00246	-0.42	-0.42	Endometriosis;Longevity;	chr7:1082213	chr7:1160374~1165267:+
ESCA	cis	rs9545047	0.716	rs943710	ENSG00000227676.3	LINC01068	5.16	9.73e-07	0.00246	0.56	0.42	Schizophrenia;	chr13:79282987	chr13:79566727~79571436:+
ESCA	cis	rs2739330	0.796	rs5760097	ENSG00000228039.3	KB-1125A3.10	5.16	9.73e-07	0.00246	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.828	rs5760098	ENSG00000228039.3	KB-1125A3.10	5.16	9.73e-07	0.00246	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.828	rs5760102	ENSG00000228039.3	KB-1125A3.10	5.16	9.73e-07	0.00246	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23963780~23964374:+
ESCA	cis	rs2882667	0.931	rs11955952	ENSG00000253404.1	AC034243.1	5.16	9.76e-07	0.00247	0.58	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138993430	chr5:138744434~138753309:-
ESCA	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	5.16	9.76e-07	0.00247	0.5	0.42	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
ESCA	cis	rs9399135	0.66	rs9389248	ENSG00000232876.1	CTA-212D2.2	-5.16	9.77e-07	0.00247	-0.51	-0.42	Red blood cell count;	chr6:134961518	chr6:135055033~135060550:+
ESCA	cis	rs1538970	0.748	rs11211137	ENSG00000280836.1	AL355480.1	-5.16	9.77e-07	0.00247	-0.56	-0.42	Platelet count;	chr1:45548220	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.781	rs11211139	ENSG00000280836.1	AL355480.1	-5.16	9.77e-07	0.00247	-0.56	-0.42	Platelet count;	chr1:45550079	chr1:45581219~45581321:-
ESCA	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-5.16	9.78e-07	0.00247	-0.53	-0.42	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
ESCA	cis	rs2221894	1	rs10111019	ENSG00000273710.1	Metazoa_SRP	-5.15	9.83e-07	0.00248	-0.49	-0.42	Obesity-related traits;	chr8:28972783	chr8:28915579~28915864:-
ESCA	cis	rs1005277	0.579	rs1780139	ENSG00000276805.1	RP11-291L22.6	5.15	9.83e-07	0.00248	0.55	0.42	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38451030~38451785:+
ESCA	cis	rs977987	0.966	rs11643207	ENSG00000261783.1	RP11-252K23.2	-5.15	9.83e-07	0.00248	-0.53	-0.42	Dupuytren's disease;	chr16:75464895	chr16:75379818~75381260:-
ESCA	cis	rs9549260	0.753	rs9549246	ENSG00000229456.1	RLIMP1	5.15	9.83e-07	0.00248	0.53	0.42	Red blood cell count;	chr13:40646618	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.712	rs1334241	ENSG00000229456.1	RLIMP1	5.15	9.83e-07	0.00248	0.53	0.42	Red blood cell count;	chr13:40648973	chr13:40618738~40621348:+
ESCA	cis	rs2221894	0.922	rs4732894	ENSG00000273710.1	Metazoa_SRP	-5.15	9.87e-07	0.00249	-0.45	-0.42	Obesity-related traits;	chr8:28965534	chr8:28915579~28915864:-
ESCA	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-5.15	9.87e-07	0.00249	-0.5	-0.42	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
ESCA	cis	rs10256972	0.568	rs1133043	ENSG00000229043.2	AC091729.9	-5.15	9.91e-07	0.0025	-0.42	-0.42	Endometriosis;Longevity;	chr7:1093669	chr7:1160374~1165267:+
ESCA	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	5.15	9.92e-07	0.0025	0.58	0.42	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
ESCA	cis	rs9733	0.65	rs1971378	ENSG00000206931.1	RNU6-1042P	-5.15	9.94e-07	0.00251	-0.49	-0.42	Tonsillectomy;	chr1:150624785	chr1:150701866~150701972:+
ESCA	cis	rs6538678	0.864	rs7308921	ENSG00000258343.1	RP11-536G4.2	5.15	9.94e-07	0.00251	0.5	0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95870757	chr12:95795345~95858839:-
ESCA	cis	rs7582403	0.51	rs6730641	ENSG00000223911.1	AC009480.3	5.15	9.97e-07	0.00251	0.46	0.42	Neuroticism;	chr2:148075187	chr2:147899401~147902956:-
ESCA	cis	rs9545047	0.604	rs2876740	ENSG00000227676.3	LINC01068	-5.15	1e-06	0.00253	-0.55	-0.42	Schizophrenia;	chr13:79409829	chr13:79566727~79571436:+
ESCA	cis	rs7924176	0.601	rs3750862	ENSG00000236900.1	TIMM9P1	-5.15	1.01e-06	0.00253	-0.51	-0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74091491	chr10:74344550~74344805:-
ESCA	cis	rs748404	0.697	rs501884	ENSG00000249839.1	AC011330.5	-5.15	1.01e-06	0.00253	-0.52	-0.42	Lung cancer;	chr15:43261784	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.697	rs504417	ENSG00000249839.1	AC011330.5	-5.15	1.01e-06	0.00253	-0.52	-0.42	Lung cancer;	chr15:43262028	chr15:43663654~43684339:-
ESCA	cis	rs748404	0.723	rs560134	ENSG00000249839.1	AC011330.5	-5.15	1.01e-06	0.00253	-0.52	-0.42	Lung cancer;	chr15:43263501	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.604	rs9574416	ENSG00000227676.3	LINC01068	-5.15	1.01e-06	0.00254	-0.55	-0.42	Schizophrenia;	chr13:79388577	chr13:79566727~79571436:+
ESCA	cis	rs7412746	0.611	rs12410869	ENSG00000206931.1	RNU6-1042P	5.15	1.01e-06	0.00254	0.54	0.42	Melanoma;	chr1:150883677	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs36008098	ENSG00000206931.1	RNU6-1042P	5.15	1.01e-06	0.00254	0.54	0.42	Melanoma;	chr1:150884330	chr1:150701866~150701972:+
ESCA	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-5.15	1.01e-06	0.00254	-0.84	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
ESCA	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	5.15	1.01e-06	0.00254	0.46	0.42	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
ESCA	cis	rs7714584	1	rs3900064	ENSG00000197083.10	ZNF300P1	-5.15	1.01e-06	0.00255	-0.68	-0.42	Crohn's disease;	chr5:150884852	chr5:150930645~150946289:-
ESCA	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	5.15	1.01e-06	0.00255	0.44	0.42	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
ESCA	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-5.15	1.02e-06	0.00257	-0.5	-0.42	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
ESCA	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-5.15	1.02e-06	0.00257	-0.5	-0.42	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
ESCA	cis	rs847845	0.614	rs17703197	ENSG00000186328.4	RP11-140K17.2	5.14	1.03e-06	0.00258	0.96	0.42	Non-small cell lung cancer;	chr6:34875173	chr6:34715613~34715940:+
ESCA	cis	rs977987	0.741	rs10514393	ENSG00000261783.1	RP11-252K23.2	-5.14	1.03e-06	0.00259	-0.51	-0.42	Dupuytren's disease;	chr16:75310578	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.545	rs1796219	ENSG00000222364.1	RNU6-96P	5.14	1.03e-06	0.00259	0.58	0.42	Aortic root size;	chr7:66645977	chr7:66395191~66395286:+
ESCA	cis	rs9322193	0.886	rs2065663	ENSG00000216906.2	RP11-350J20.9	5.14	1.03e-06	0.00259	0.6	0.42	Lung cancer;	chr6:149760331	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	5.14	1.03e-06	0.00259	0.6	0.42	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
ESCA	cis	rs28830936	1	rs17734856	ENSG00000250379.1	RP11-23P13.4	5.14	1.04e-06	0.0026	0.49	0.42	Diastolic blood pressure;	chr15:41752962	chr15:41825099~41827936:-
ESCA	cis	rs61160187	0.548	rs68104763	ENSG00000215032.2	GNL3LP1	5.14	1.04e-06	0.00261	0.53	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:61107016	chr5:60891935~60893577:-
ESCA	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
ESCA	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
ESCA	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-5.14	1.04e-06	0.00261	-0.49	-0.42	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
ESCA	cis	rs977987	0.528	rs9926933	ENSG00000261783.1	RP11-252K23.2	5.14	1.05e-06	0.00262	0.66	0.42	Dupuytren's disease;	chr16:75467669	chr16:75379818~75381260:-
ESCA	cis	rs2221894	0.922	rs9792190	ENSG00000273710.1	Metazoa_SRP	-5.14	1.05e-06	0.00262	-0.46	-0.42	Obesity-related traits;	chr8:28970874	chr8:28915579~28915864:-
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000228039.3	KB-1125A3.10	5.14	1.05e-06	0.00262	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23963780~23964374:+
ESCA	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-5.14	1.05e-06	0.00263	-0.81	-0.42	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-5.14	1.05e-06	0.00263	-0.81	-0.42	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
ESCA	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	5.14	1.05e-06	0.00263	0.57	0.42	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
ESCA	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	5.14	1.05e-06	0.00263	0.45	0.42	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
ESCA	cis	rs3747113	1	rs34949904	ENSG00000128262.7	POM121L9P	-5.14	1.06e-06	0.00264	-0.53	-0.42	Gut microbiome composition (summer);	chr22:24299330	chr22:24251828~24265525:+
ESCA	cis	rs3747113	1	rs1041748	ENSG00000128262.7	POM121L9P	-5.14	1.06e-06	0.00264	-0.53	-0.42	Gut microbiome composition (summer);	chr22:24304886	chr22:24251828~24265525:+
ESCA	cis	rs6456156	0.792	rs9366089	ENSG00000265828.1	MIR3939	-5.14	1.06e-06	0.00264	-0.47	-0.42	Primary biliary cholangitis;	chr6:167099408	chr6:166997807~166997912:-
ESCA	cis	rs977987	0.872	rs1559339	ENSG00000261783.1	RP11-252K23.2	-5.14	1.06e-06	0.00264	-0.51	-0.42	Dupuytren's disease;	chr16:75284748	chr16:75379818~75381260:-
ESCA	cis	rs1075265	0.73	rs7597189	ENSG00000235937.1	AC008280.1	5.14	1.06e-06	0.00264	0.46	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54029552~54030682:-
ESCA	cis	rs7829975	0.514	rs2979139	ENSG00000173295.6	FAM86B3P	5.14	1.06e-06	0.00264	0.48	0.42	Mood instability;	chr8:8410803	chr8:8228595~8244865:+
ESCA	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-5.14	1.06e-06	0.00265	-0.61	-0.42	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
ESCA	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-5.14	1.06e-06	0.00265	-0.61	-0.42	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
ESCA	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-5.14	1.06e-06	0.00265	-0.61	-0.42	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
ESCA	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-5.14	1.07e-06	0.00266	-0.5	-0.42	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
ESCA	cis	rs2412819	0.559	rs8040336	ENSG00000205771.5	CATSPER2P1	-5.14	1.07e-06	0.00267	-0.49	-0.42	Lung cancer;	chr15:43761419	chr15:43726918~43747094:-
ESCA	cis	rs7829975	0.56	rs56094035	ENSG00000253981.4	ALG1L13P	-5.13	1.08e-06	0.00268	-0.5	-0.42	Mood instability;	chr8:8694112	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.539	rs4841012	ENSG00000253981.4	ALG1L13P	-5.13	1.08e-06	0.00268	-0.5	-0.42	Mood instability;	chr8:8694200	chr8:8236003~8244667:-
ESCA	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-5.13	1.08e-06	0.00268	-0.45	-0.42	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
ESCA	cis	rs10875746	0.951	rs11168433	ENSG00000240399.1	RP1-228P16.1	-5.13	1.08e-06	0.00269	-0.53	-0.42	Longevity (90 years and older);	chr12:48164281	chr12:48054813~48055591:-
ESCA	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-5.13	1.08e-06	0.00269	-0.7	-0.42	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
ESCA	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-5.13	1.08e-06	0.00269	-0.7	-0.42	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
ESCA	cis	rs7582403	0.51	rs1449959	ENSG00000223911.1	AC009480.3	5.13	1.09e-06	0.0027	0.46	0.42	Neuroticism;	chr2:148100120	chr2:147899401~147902956:-
ESCA	cis	rs7829975	0.501	rs2980769	ENSG00000253981.4	ALG1L13P	5.13	1.09e-06	0.0027	0.5	0.42	Mood instability;	chr8:8462781	chr8:8236003~8244667:-
ESCA	cis	rs6952407	1	rs6952407	ENSG00000179406.6	LINC00174	5.13	1.09e-06	0.00271	0.49	0.42	Cotinine glucuronidation;	chr7:66580525	chr7:66376044~66401338:-
ESCA	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-5.13	1.1e-06	0.00272	-0.35	-0.42	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
ESCA	cis	rs9545047	0.584	rs1619669	ENSG00000227676.3	LINC01068	5.13	1.1e-06	0.00273	0.54	0.42	Schizophrenia;	chr13:79378363	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs6563100	ENSG00000227676.3	LINC01068	5.13	1.1e-06	0.00273	0.54	0.42	Schizophrenia;	chr13:79382978	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7322901	ENSG00000227676.3	LINC01068	5.13	1.1e-06	0.00273	0.54	0.42	Schizophrenia;	chr13:79383505	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-5.13	1.1e-06	0.00273	-0.46	-0.42	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
ESCA	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	5.13	1.1e-06	0.00273	0.71	0.42	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	5.13	1.1e-06	0.00273	0.71	0.42	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
ESCA	cis	rs7582403	0.51	rs6430295	ENSG00000223911.1	AC009480.3	5.13	1.1e-06	0.00273	0.46	0.42	Neuroticism;	chr2:148140212	chr2:147899401~147902956:-
ESCA	cis	rs2627019	0.526	rs2084578	ENSG00000223911.1	AC009480.3	5.13	1.1e-06	0.00273	0.46	0.42	Neuroticism;	chr2:148155073	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs12691778	ENSG00000223911.1	AC009480.3	5.13	1.1e-06	0.00273	0.46	0.42	Neuroticism;	chr2:148157325	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs12691779	ENSG00000223911.1	AC009480.3	5.13	1.1e-06	0.00273	0.46	0.42	Glomerular filtration rate (creatinine);	chr2:148157394	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.51	rs10207309	ENSG00000223911.1	AC009480.3	5.13	1.1e-06	0.00273	0.46	0.42	Neuroticism;	chr2:148157621	chr2:147899401~147902956:-
ESCA	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	5.13	1.1e-06	0.00273	0.5	0.42	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
ESCA	cis	rs1816752	0.87	rs73469543	ENSG00000273628.1	RP11-756A22.7	5.13	1.1e-06	0.00273	0.4	0.42	Obesity-related traits;	chr13:24424832	chr13:24933006~24936796:+
ESCA	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-5.13	1.1e-06	0.00274	-0.47	-0.42	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
ESCA	cis	rs42490	0.873	rs218903	ENSG00000251136.7	RP11-37B2.1	-5.13	1.11e-06	0.00274	-0.43	-0.42	Leprosy;	chr8:89721458	chr8:89609409~89757727:-
ESCA	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-5.13	1.11e-06	0.00274	-0.82	-0.42	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
ESCA	cis	rs6456156	0.792	rs4710178	ENSG00000265828.1	MIR3939	-5.13	1.11e-06	0.00274	-0.47	-0.42	Primary biliary cholangitis;	chr6:167100044	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.792	rs4710179	ENSG00000265828.1	MIR3939	-5.13	1.11e-06	0.00274	-0.47	-0.42	Primary biliary cholangitis;	chr6:167100204	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.792	rs4710181	ENSG00000265828.1	MIR3939	-5.13	1.11e-06	0.00274	-0.47	-0.42	Primary biliary cholangitis;	chr6:167100510	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.755	rs4710182	ENSG00000265828.1	MIR3939	-5.13	1.11e-06	0.00274	-0.47	-0.42	Primary biliary cholangitis;	chr6:167100573	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	5.13	1.12e-06	0.00276	0.46	0.42	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
ESCA	cis	rs1864400	0.605	rs12360493	ENSG00000273008.1	RP11-351D16.3	5.12	1.12e-06	0.00277	0.48	0.42	Hirschsprung disease;	chr10:43223165	chr10:43136824~43138334:-
ESCA	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-5.12	1.12e-06	0.00277	-0.53	-0.42	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
ESCA	cis	rs9545047	0.716	rs9318638	ENSG00000227676.3	LINC01068	-5.12	1.12e-06	0.00278	-0.55	-0.42	Schizophrenia;	chr13:79412018	chr13:79566727~79571436:+
ESCA	cis	rs7829975	0.511	rs2976906	ENSG00000253981.4	ALG1L13P	5.12	1.13e-06	0.00278	0.53	0.42	Mood instability;	chr8:8484905	chr8:8236003~8244667:-
ESCA	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-5.12	1.13e-06	0.00279	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-5.12	1.13e-06	0.00279	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-5.12	1.13e-06	0.00279	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
ESCA	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	5.12	1.13e-06	0.00279	0.59	0.42	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	5.12	1.13e-06	0.00279	0.59	0.42	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
ESCA	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	5.12	1.13e-06	0.00279	0.53	0.42	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
ESCA	cis	rs2739330	0.828	rs2186366	ENSG00000228039.3	KB-1125A3.10	-5.12	1.14e-06	0.0028	-0.53	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23963780~23964374:+
ESCA	cis	rs6479891	1	rs4745729	ENSG00000235816.3	PRELID1P3	5.12	1.14e-06	0.0028	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63517323	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs12416349	ENSG00000235816.3	PRELID1P3	5.12	1.14e-06	0.0028	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63517783	chr10:63427297~63427939:+
ESCA	cis	rs61160187	0.582	rs62367903	ENSG00000215032.2	GNL3LP1	5.12	1.14e-06	0.00281	0.53	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023146	chr5:60891935~60893577:-
ESCA	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	5.12	1.15e-06	0.00282	0.54	0.42	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-5.12	1.15e-06	0.00282	-0.54	-0.42	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
ESCA	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-5.12	1.15e-06	0.00283	-0.47	-0.42	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
ESCA	cis	rs747650	0.859	rs4567413	ENSG00000271350.1	CTD-2384B9.1	-5.12	1.15e-06	0.00283	-0.49	-0.42	Acne (severe);	chr11:47210633	chr11:47041027~47041945:-
ESCA	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-5.12	1.15e-06	0.00283	-0.81	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-5.12	1.15e-06	0.00283	-0.81	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
ESCA	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-5.12	1.15e-06	0.00283	-0.81	-0.42	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
ESCA	cis	rs7829975	0.514	rs2976926	ENSG00000173295.6	FAM86B3P	5.12	1.15e-06	0.00284	0.48	0.42	Mood instability;	chr8:8404114	chr8:8228595~8244865:+
ESCA	cis	rs801193	0.901	rs4273746	ENSG00000179406.6	LINC00174	5.12	1.16e-06	0.00284	0.49	0.42	Aortic root size;	chr7:66836124	chr7:66376044~66401338:-
ESCA	cis	rs1816752	0.633	rs9578729	ENSG00000273628.1	RP11-756A22.7	5.12	1.16e-06	0.00285	0.4	0.42	Obesity-related traits;	chr13:24425106	chr13:24933006~24936796:+
ESCA	cis	rs7412746	0.634	rs12409208	ENSG00000206931.1	RNU6-1042P	5.12	1.17e-06	0.00286	0.54	0.42	Melanoma;	chr1:150887579	chr1:150701866~150701972:+
ESCA	cis	rs977987	1	rs977985	ENSG00000261783.1	RP11-252K23.2	-5.12	1.17e-06	0.00287	-0.52	-0.42	Dupuytren's disease;	chr16:75473049	chr16:75379818~75381260:-
ESCA	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-5.11	1.17e-06	0.00287	-0.44	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
ESCA	cis	rs9457247	0.663	rs7749278	ENSG00000265828.1	MIR3939	5.11	1.18e-06	0.00288	0.45	0.42	Crohn's disease;	chr6:167021837	chr6:166997807~166997912:-
ESCA	cis	rs6479891	1	rs10740117	ENSG00000235816.3	PRELID1P3	-5.11	1.18e-06	0.00289	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63338517	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs6479894	ENSG00000235816.3	PRELID1P3	-5.11	1.18e-06	0.00289	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63338981	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs10733790	ENSG00000235816.3	PRELID1P3	-5.11	1.18e-06	0.00289	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63340574	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs7091664	ENSG00000235816.3	PRELID1P3	-5.11	1.18e-06	0.00289	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63342040	chr10:63427297~63427939:+
ESCA	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-5.11	1.18e-06	0.00289	-0.45	-0.42	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
ESCA	cis	rs6479891	1	rs9414793	ENSG00000235816.3	PRELID1P3	-5.11	1.18e-06	0.00289	-0.53	-0.42	Arthritis (juvenile idiopathic);	chr10:63315349	chr10:63427297~63427939:+
ESCA	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-5.11	1.18e-06	0.00289	-0.62	-0.42	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
ESCA	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-5.11	1.18e-06	0.00289	-0.51	-0.42	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
ESCA	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	5.11	1.18e-06	0.0029	0.56	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
ESCA	cis	rs9545047	0.604	rs7327603	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79366676	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.589	rs9545090	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79367276	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530902	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79367748	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545092	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79369809	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.611	rs9545093	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79371969	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530906	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79372401	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs8001392	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79374211	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4146473	ENSG00000227676.3	LINC01068	5.11	1.19e-06	0.0029	0.54	0.42	Schizophrenia;	chr13:79374548	chr13:79566727~79571436:+
ESCA	cis	rs9733	0.65	rs4970923	ENSG00000206931.1	RNU6-1042P	-5.11	1.19e-06	0.0029	-0.51	-0.42	Tonsillectomy;	chr1:150635824	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.65	rs11204684	ENSG00000206931.1	RNU6-1042P	-5.11	1.19e-06	0.0029	-0.51	-0.42	Tonsillectomy;	chr1:150636418	chr1:150701866~150701972:+
ESCA	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	5.11	1.19e-06	0.00291	0.52	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
ESCA	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	5.11	1.19e-06	0.00291	0.59	0.42	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
ESCA	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-5.11	1.19e-06	0.00292	-0.67	-0.42	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000228039.3	KB-1125A3.10	5.11	1.2e-06	0.00293	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23963780~23964374:+
ESCA	cis	rs2742234	0.915	rs2742233	ENSG00000273008.1	RP11-351D16.3	-5.11	1.2e-06	0.00293	-0.47	-0.42	Hirschsprung disease;	chr10:43115110	chr10:43136824~43138334:-
ESCA	cis	rs1816752	0.905	rs9511249	ENSG00000273628.1	RP11-756A22.7	5.11	1.2e-06	0.00294	0.4	0.42	Obesity-related traits;	chr13:24425457	chr13:24933006~24936796:+
ESCA	cis	rs977987	0.835	rs4888380	ENSG00000261783.1	RP11-252K23.2	-5.11	1.2e-06	0.00294	-0.5	-0.42	Dupuytren's disease;	chr16:75313792	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.835	rs8057535	ENSG00000261783.1	RP11-252K23.2	-5.11	1.2e-06	0.00294	-0.5	-0.42	Dupuytren's disease;	chr16:75314043	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.8	rs12922951	ENSG00000261783.1	RP11-252K23.2	-5.11	1.2e-06	0.00294	-0.5	-0.42	Dupuytren's disease;	chr16:75321198	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4887818	ENSG00000261783.1	RP11-252K23.2	-5.11	1.2e-06	0.00294	-0.5	-0.42	Dupuytren's disease;	chr16:75328097	chr16:75379818~75381260:-
ESCA	cis	rs2882667	0.858	rs11948429	ENSG00000253404.1	AC034243.1	5.11	1.2e-06	0.00294	0.59	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139122895	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs2043271	ENSG00000253404.1	AC034243.1	5.11	1.2e-06	0.00294	0.59	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139123419	chr5:138744434~138753309:-
ESCA	cis	rs61160187	0.582	rs62367872	ENSG00000215032.2	GNL3LP1	5.1	1.22e-06	0.00298	0.54	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60976943	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.556	rs55738840	ENSG00000215032.2	GNL3LP1	5.1	1.22e-06	0.00298	0.54	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977587	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs58646987	ENSG00000215032.2	GNL3LP1	5.1	1.22e-06	0.00298	0.54	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60979867	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs11739952	ENSG00000215032.2	GNL3LP1	5.1	1.22e-06	0.00298	0.54	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60980150	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs4642318	ENSG00000215032.2	GNL3LP1	5.1	1.22e-06	0.00298	0.54	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996931	chr5:60891935~60893577:-
ESCA	cis	rs9322193	0.923	rs9800686	ENSG00000216906.2	RP11-350J20.9	5.1	1.23e-06	0.00298	0.55	0.42	Lung cancer;	chr6:149634464	chr6:149904243~149906418:+
ESCA	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-5.1	1.23e-06	0.00299	-0.37	-0.42	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
ESCA	cis	rs950880	0.71	rs3821203	ENSG00000234389.1	AC007278.3	-5.1	1.23e-06	0.00299	-0.4	-0.42	Serum protein levels (sST2);	chr2:102380412	chr2:102438713~102440475:+
ESCA	cis	rs6479901	0.639	rs10995448	ENSG00000235816.3	PRELID1P3	-5.1	1.23e-06	0.003	-0.48	-0.42	Intelligence (multi-trait analysis);	chr10:63127299	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.639	rs7082200	ENSG00000235816.3	PRELID1P3	-5.1	1.23e-06	0.003	-0.48	-0.42	Intelligence (multi-trait analysis);	chr10:63128561	chr10:63427297~63427939:+
ESCA	cis	rs7829975	0.511	rs2921028	ENSG00000253981.4	ALG1L13P	5.1	1.24e-06	0.003	0.53	0.42	Mood instability;	chr8:8482967	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.511	rs2976902	ENSG00000253981.4	ALG1L13P	5.1	1.24e-06	0.003	0.53	0.42	Mood instability;	chr8:8483595	chr8:8236003~8244667:-
ESCA	cis	rs2739330	0.76	rs1007888	ENSG00000099984.9	GSTT2	-5.1	1.24e-06	0.00301	-0.48	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23980123~23983911:+
ESCA	cis	rs875971	1	rs1544549	ENSG00000179406.6	LINC00174	5.1	1.24e-06	0.00301	0.49	0.42	Aortic root size;	chr7:66625676	chr7:66376044~66401338:-
ESCA	cis	rs875971	1	rs2420820	ENSG00000179406.6	LINC00174	5.1	1.24e-06	0.00301	0.49	0.42	Aortic root size;	chr7:66626920	chr7:66376044~66401338:-
ESCA	cis	rs2638953	0.541	rs10843209	ENSG00000247934.4	RP11-967K21.1	-5.1	1.24e-06	0.00301	-0.47	-0.42	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28573702	chr12:28163298~28190738:-
ESCA	cis	rs9322193	0.81	rs62439811	ENSG00000216906.2	RP11-350J20.9	5.1	1.25e-06	0.00302	0.55	0.42	Lung cancer;	chr6:149640416	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.545	rs1796222	ENSG00000222364.1	RNU6-96P	5.1	1.25e-06	0.00303	0.55	0.42	Aortic root size;	chr7:66592167	chr7:66395191~66395286:+
ESCA	cis	rs2307394	0.896	rs12992412	ENSG00000223911.1	AC009480.3	5.1	1.25e-06	0.00303	0.46	0.42	Urate levels;	chr2:148035096	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.896	rs12992231	ENSG00000223911.1	AC009480.3	5.1	1.25e-06	0.00303	0.46	0.42	Urate levels;	chr2:148042141	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.858	rs6430285	ENSG00000223911.1	AC009480.3	5.1	1.25e-06	0.00303	0.46	0.42	Urate levels;	chr2:148042519	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.896	rs12995413	ENSG00000223911.1	AC009480.3	5.1	1.25e-06	0.00303	0.46	0.42	Urate levels;	chr2:148044083	chr2:147899401~147902956:-
ESCA	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-5.1	1.25e-06	0.00303	-0.51	-0.42	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
ESCA	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	5.1	1.26e-06	0.00304	0.62	0.42	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
ESCA	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-5.1	1.26e-06	0.00305	-0.43	-0.42	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
ESCA	cis	rs9322193	0.923	rs57938011	ENSG00000216906.2	RP11-350J20.9	5.1	1.26e-06	0.00305	0.56	0.42	Lung cancer;	chr6:149642969	chr6:149904243~149906418:+
ESCA	cis	rs9545047	0.716	rs314693	ENSG00000227676.3	LINC01068	-5.1	1.26e-06	0.00306	-0.55	-0.42	Schizophrenia;	chr13:79432792	chr13:79566727~79571436:+
ESCA	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	5.1	1.27e-06	0.00306	0.45	0.42	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
ESCA	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-5.1	1.27e-06	0.00306	-0.54	-0.42	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-5.1	1.27e-06	0.00306	-0.54	-0.42	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-5.1	1.27e-06	0.00306	-0.54	-0.42	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
ESCA	cis	rs2739330	0.828	rs4822454	ENSG00000228039.3	KB-1125A3.10	5.1	1.27e-06	0.00307	0.54	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23963780~23964374:+
ESCA	cis	rs2882667	0.858	rs11957527	ENSG00000253404.1	AC034243.1	5.1	1.27e-06	0.00307	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139069206	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000228039.3	KB-1125A3.10	5.1	1.27e-06	0.00307	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23963780~23964374:+
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000228039.3	KB-1125A3.10	5.1	1.27e-06	0.00307	0.51	0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23963780~23964374:+
ESCA	cis	rs2882667	0.754	rs11746434	ENSG00000253404.1	AC034243.1	5.09	1.28e-06	0.00309	0.61	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139099614	chr5:138744434~138753309:-
ESCA	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	5.09	1.28e-06	0.00309	0.37	0.42	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
ESCA	cis	rs801193	0.875	rs13227951	ENSG00000226824.5	RP4-756H11.3	5.09	1.28e-06	0.00309	0.48	0.42	Aortic root size;	chr7:66748121	chr7:66654538~66669855:+
ESCA	cis	rs977987	0.843	rs4888372	ENSG00000261783.1	RP11-252K23.2	-5.09	1.28e-06	0.00309	-0.51	-0.42	Dupuytren's disease;	chr16:75279587	chr16:75379818~75381260:-
ESCA	cis	rs9545047	0.553	rs7332004	ENSG00000227676.3	LINC01068	-5.09	1.28e-06	0.0031	-0.54	-0.42	Schizophrenia;	chr13:79364128	chr13:79566727~79571436:+
ESCA	cis	rs977987	0.872	rs4243111	ENSG00000261783.1	RP11-252K23.2	-5.09	1.28e-06	0.0031	-0.51	-0.42	Dupuytren's disease;	chr16:75286929	chr16:75379818~75381260:-
ESCA	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-5.09	1.28e-06	0.0031	-0.43	-0.42	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
ESCA	cis	rs61160187	0.576	rs10805374	ENSG00000215032.2	GNL3LP1	5.09	1.29e-06	0.0031	0.53	0.42	Educational attainment (years of education);Educational attainment (college completion);	chr5:61004078	chr5:60891935~60893577:-
ESCA	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	5.09	1.3e-06	0.00312	0.5	0.42	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
ESCA	cis	rs7412746	0.658	rs12410394	ENSG00000206931.1	RNU6-1042P	5.09	1.3e-06	0.00313	0.54	0.42	Melanoma;	chr1:150887710	chr1:150701866~150701972:+
ESCA	cis	rs1816752	0.905	rs11839006	ENSG00000273628.1	RP11-756A22.7	5.09	1.3e-06	0.00313	0.41	0.42	Obesity-related traits;	chr13:24435893	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs2033955	ENSG00000273628.1	RP11-756A22.7	5.09	1.3e-06	0.00313	0.41	0.42	Obesity-related traits;	chr13:24436406	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs2033954	ENSG00000273628.1	RP11-756A22.7	5.09	1.3e-06	0.00313	0.41	0.42	Obesity-related traits;	chr13:24436429	chr13:24933006~24936796:+
ESCA	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	5.09	1.3e-06	0.00313	0.45	0.42	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
ESCA	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	5.09	1.3e-06	0.00313	0.52	0.42	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000099984.9	GSTT2	-5.09	1.3e-06	0.00314	-0.49	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23980123~23983911:+
ESCA	cis	rs748404	0.697	rs471122	ENSG00000249839.1	AC011330.5	5.09	1.31e-06	0.00314	0.52	0.42	Lung cancer;	chr15:43266376	chr15:43663654~43684339:-
ESCA	cis	rs1538970	0.781	rs34768551	ENSG00000280836.1	AL355480.1	-5.09	1.31e-06	0.00315	-0.55	-0.42	Platelet count;	chr1:45554736	chr1:45581219~45581321:-
ESCA	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-5.09	1.31e-06	0.00315	-0.48	-0.42	Migraine;	chr4:56850720	chr4:56960927~56961373:-
ESCA	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	5.09	1.32e-06	0.00318	0.65	0.42	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
ESCA	cis	rs6479891	1	rs7099425	ENSG00000235816.3	PRELID1P3	-5.09	1.32e-06	0.00318	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63200957	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.908	rs11819167	ENSG00000235816.3	PRELID1P3	5.09	1.32e-06	0.00318	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63216409	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.512	rs7082090	ENSG00000235816.3	PRELID1P3	5.09	1.32e-06	0.00318	0.54	0.42	Intelligence (multi-trait analysis);	chr10:63239252	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs1904295	ENSG00000235816.3	PRELID1P3	-5.09	1.32e-06	0.00318	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63223116	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.512	rs6415875	ENSG00000235816.3	PRELID1P3	-5.09	1.32e-06	0.00318	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:63226657	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs4281380	ENSG00000235816.3	PRELID1P3	-5.09	1.32e-06	0.00318	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63227938	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.512	rs4439410	ENSG00000235816.3	PRELID1P3	-5.09	1.32e-06	0.00318	-0.54	-0.42	Intelligence (multi-trait analysis);	chr10:63239012	chr10:63427297~63427939:+
ESCA	cis	rs9545047	0.716	rs418150	ENSG00000227676.3	LINC01068	-5.09	1.33e-06	0.00319	-0.54	-0.42	Schizophrenia;	chr13:79432675	chr13:79566727~79571436:+
ESCA	cis	rs801193	0.839	rs6968619	ENSG00000179406.6	LINC00174	5.09	1.33e-06	0.00319	0.45	0.42	Aortic root size;	chr7:66603880	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.839	rs12534943	ENSG00000179406.6	LINC00174	5.09	1.33e-06	0.00319	0.45	0.42	Aortic root size;	chr7:66605533	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.805	rs12532355	ENSG00000179406.6	LINC00174	5.09	1.33e-06	0.00319	0.45	0.42	Aortic root size;	chr7:66605597	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-5.09	1.33e-06	0.0032	-0.46	-0.42	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-5.09	1.33e-06	0.0032	-0.46	-0.42	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
ESCA	cis	rs9987353	0.518	rs4841110	ENSG00000253981.4	ALG1L13P	5.08	1.34e-06	0.0032	0.52	0.42	Recombination measurement;	chr8:9228513	chr8:8236003~8244667:-
ESCA	cis	rs9309711	0.621	rs12993215	ENSG00000225234.1	TRAPPC12-AS1	-5.08	1.34e-06	0.0032	-0.53	-0.42	Neurofibrillary tangles;	chr2:3469956	chr2:3481242~3482409:-
ESCA	cis	rs875971	0.508	rs10950045	ENSG00000179406.6	LINC00174	5.08	1.34e-06	0.0032	0.45	0.42	Aortic root size;	chr7:66601386	chr7:66376044~66401338:-
ESCA	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-5.08	1.34e-06	0.0032	-0.81	-0.42	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
ESCA	cis	rs977987	0.872	rs10781976	ENSG00000261783.1	RP11-252K23.2	-5.08	1.34e-06	0.00321	-0.5	-0.42	Dupuytren's disease;	chr16:75280940	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	5.08	1.34e-06	0.00321	0.45	0.42	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
ESCA	cis	rs1816752	0.716	rs9553289	ENSG00000273628.1	RP11-756A22.7	-5.08	1.35e-06	0.00322	-0.41	-0.42	Obesity-related traits;	chr13:24400640	chr13:24933006~24936796:+
ESCA	cis	rs6479891	1	rs9415692	ENSG00000235816.3	PRELID1P3	5.08	1.35e-06	0.00323	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63355392	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9414799	ENSG00000235816.3	PRELID1P3	5.08	1.35e-06	0.00323	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63369842	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4746119	ENSG00000235816.3	PRELID1P3	5.08	1.35e-06	0.00323	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63370157	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9414800	ENSG00000235816.3	PRELID1P3	5.08	1.35e-06	0.00323	0.54	0.42	Arthritis (juvenile idiopathic);	chr10:63371522	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs7081275	ENSG00000235816.3	PRELID1P3	-5.08	1.35e-06	0.00323	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63346791	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs7895348	ENSG00000235816.3	PRELID1P3	-5.08	1.35e-06	0.00323	-0.54	-0.42	Arthritis (juvenile idiopathic);	chr10:63349781	chr10:63427297~63427939:+
ESCA	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-5.08	1.36e-06	0.00324	-0.37	-0.42	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
ESCA	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	5.08	1.36e-06	0.00325	0.53	0.42	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
ESCA	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	5.08	1.36e-06	0.00325	0.53	0.42	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
ESCA	cis	rs9399135	0.66	rs9376072	ENSG00000232876.1	CTA-212D2.2	-5.08	1.36e-06	0.00325	-0.49	-0.42	Red blood cell count;	chr6:134959381	chr6:135055033~135060550:+
ESCA	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-5.08	1.36e-06	0.00325	-0.45	-0.42	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
ESCA	cis	rs7826238	0.535	rs2979179	ENSG00000253981.4	ALG1L13P	5.08	1.37e-06	0.00326	0.49	0.42	Systolic blood pressure;	chr8:8462519	chr8:8236003~8244667:-
ESCA	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-5.08	1.37e-06	0.00328	-0.52	-0.42	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
ESCA	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-5.08	1.37e-06	0.00328	-0.57	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-5.08	1.37e-06	0.00328	-0.57	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
ESCA	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-5.08	1.38e-06	0.00328	-0.61	-0.42	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
ESCA	cis	rs2307394	0.964	rs2303392	ENSG00000223911.1	AC009480.3	5.08	1.38e-06	0.00329	0.49	0.42	Urate levels;	chr2:147922858	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs1345994	ENSG00000223911.1	AC009480.3	5.08	1.38e-06	0.00329	0.49	0.42	Urate levels;	chr2:147937557	chr2:147899401~147902956:-
ESCA	cis	rs1061377	1	rs9990742	ENSG00000249685.1	RP11-360F5.3	5.08	1.38e-06	0.00329	0.45	0.42	Uric acid levels;	chr4:39119794	chr4:39133913~39135608:+
ESCA	cis	rs9733	0.818	rs6694531	ENSG00000206931.1	RNU6-1042P	-5.08	1.38e-06	0.00329	-0.52	-0.42	Tonsillectomy;	chr1:150711036	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.818	rs10888388	ENSG00000206931.1	RNU6-1042P	-5.08	1.38e-06	0.00329	-0.52	-0.42	Tonsillectomy;	chr1:150714820	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.818	rs12130363	ENSG00000206931.1	RNU6-1042P	-5.08	1.38e-06	0.00329	-0.52	-0.42	Tonsillectomy;	chr1:150716120	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.508	rs10242423	ENSG00000179406.6	LINC00174	5.08	1.38e-06	0.00329	0.45	0.42	Aortic root size;	chr7:66594188	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.508	rs10253883	ENSG00000179406.6	LINC00174	5.08	1.38e-06	0.00329	0.45	0.42	Aortic root size;	chr7:66596151	chr7:66376044~66401338:-
ESCA	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-5.08	1.38e-06	0.00329	-0.61	-0.42	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
ESCA	cis	rs10995505	0.578	rs1533068	ENSG00000235816.3	PRELID1P3	-5.08	1.38e-06	0.00329	-0.47	-0.42	Intelligence (multi-trait analysis);	chr10:63132407	chr10:63427297~63427939:+
ESCA	cis	rs1061377	1	rs12646251	ENSG00000249685.1	RP11-360F5.3	5.08	1.38e-06	0.00329	0.47	0.42	Uric acid levels;	chr4:39132751	chr4:39133913~39135608:+
ESCA	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-5.08	1.38e-06	0.00329	-0.48	-0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
ESCA	cis	rs394563	0.663	rs415434	ENSG00000231760.4	RP11-350J20.5	5.08	1.39e-06	0.00331	0.5	0.42	Dupuytren's disease;	chr6:149451509	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	5.08	1.39e-06	0.00331	0.46	0.42	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
ESCA	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	5.07	1.4e-06	0.00334	0.48	0.42	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
ESCA	cis	rs6538678	0.929	rs10777744	ENSG00000258343.1	RP11-536G4.2	-5.07	1.4e-06	0.00334	-0.5	-0.42	Lupus nephritis in systemic lupus erythematosus;	chr12:95864561	chr12:95795345~95858839:-
ESCA	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	5.07	1.41e-06	0.00334	0.35	0.42	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
ESCA	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-5.07	1.41e-06	0.00335	-0.37	-0.42	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
ESCA	cis	rs858239	0.511	rs10256996	ENSG00000230042.1	AK3P3	5.07	1.41e-06	0.00335	0.46	0.42	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23129178~23129841:+
ESCA	cis	rs7412746	0.634	rs12096831	ENSG00000206931.1	RNU6-1042P	5.07	1.41e-06	0.00336	0.54	0.42	Melanoma;	chr1:150891637	chr1:150701866~150701972:+
ESCA	cis	rs2742234	1	rs2742234	ENSG00000273008.1	RP11-351D16.3	5.07	1.42e-06	0.00337	0.47	0.42	Hirschsprung disease;	chr10:43117161	chr10:43136824~43138334:-
ESCA	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	5.07	1.42e-06	0.00337	0.45	0.42	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	5.07	1.42e-06	0.00337	0.45	0.42	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	5.07	1.42e-06	0.00337	0.45	0.42	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	5.07	1.42e-06	0.00337	0.45	0.42	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
ESCA	cis	rs875971	0.638	rs10249404	ENSG00000179406.6	LINC00174	5.07	1.43e-06	0.00339	0.46	0.42	Aortic root size;	chr7:66581737	chr7:66376044~66401338:-
ESCA	cis	rs62229266	0.626	rs7280896	ENSG00000231106.2	LINC01436	5.07	1.43e-06	0.00339	0.47	0.42	Mitral valve prolapse;	chr21:36088608	chr21:36005338~36007838:+
ESCA	cis	rs9322193	0.962	rs4870048	ENSG00000216906.2	RP11-350J20.9	5.07	1.44e-06	0.00341	0.59	0.42	Lung cancer;	chr6:149834324	chr6:149904243~149906418:+
ESCA	cis	rs9545047	0.604	rs7983344	ENSG00000227676.3	LINC01068	-5.07	1.45e-06	0.00342	-0.54	-0.42	Schizophrenia;	chr13:79299295	chr13:79566727~79571436:+
ESCA	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	5.07	1.45e-06	0.00343	0.46	0.42	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
ESCA	cis	rs394563	0.591	rs237026	ENSG00000231760.4	RP11-350J20.5	5.07	1.45e-06	0.00344	0.49	0.42	Dupuytren's disease;	chr6:149399545	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.622	rs237024	ENSG00000231760.4	RP11-350J20.5	5.07	1.45e-06	0.00344	0.49	0.42	Dupuytren's disease;	chr6:149400829	chr6:149796151~149826294:-
ESCA	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-5.06	1.46e-06	0.00344	-0.45	-0.42	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-5.06	1.46e-06	0.00344	-0.45	-0.42	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-5.06	1.46e-06	0.00344	-0.45	-0.42	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-5.06	1.46e-06	0.00344	-0.45	-0.42	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-5.06	1.46e-06	0.00344	-0.45	-0.42	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
ESCA	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	5.06	1.46e-06	0.00344	0.45	0.42	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	5.06	1.46e-06	0.00344	0.45	0.42	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.706	rs1643374	ENSG00000179406.6	LINC00174	-5.06	1.46e-06	0.00345	-0.49	-0.42	Aortic root size;	chr7:66407695	chr7:66376044~66401338:-
ESCA	cis	rs28830936	0.966	rs62002090	ENSG00000250379.1	RP11-23P13.4	5.06	1.46e-06	0.00345	0.48	0.42	Diastolic blood pressure;	chr15:41800128	chr15:41825099~41827936:-
ESCA	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	5.06	1.46e-06	0.00346	0.46	0.42	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
ESCA	cis	rs977987	0.843	rs10459859	ENSG00000261783.1	RP11-252K23.2	-5.06	1.46e-06	0.00346	-0.52	-0.42	Dupuytren's disease;	chr16:75348052	chr16:75379818~75381260:-
ESCA	cis	rs4713118	0.715	rs200480	ENSG00000216901.1	AL022393.7	5.06	1.46e-06	0.00346	0.47	0.42	Parkinson's disease;	chr6:27805886	chr6:28176188~28176674:+
ESCA	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	5.06	1.46e-06	0.00346	0.46	0.42	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
ESCA	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	5.06	1.47e-06	0.00346	0.51	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
ESCA	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	5.06	1.47e-06	0.00346	0.51	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
ESCA	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	5.06	1.47e-06	0.00346	0.51	0.42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
ESCA	cis	rs2638953	0.79	rs4357727	ENSG00000247934.4	RP11-967K21.1	5.06	1.47e-06	0.00347	0.46	0.42	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28291989	chr12:28163298~28190738:-
ESCA	cis	rs8059260	0.668	rs16957839	ENSG00000274038.1	RP11-66H6.4	-5.06	1.47e-06	0.00347	-0.82	-0.42	Alcohol consumption over the past year;	chr16:10962521	chr16:11056556~11057034:+
ESCA	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	5.06	1.47e-06	0.00347	0.46	0.42	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
ESCA	cis	rs1075265	0.68	rs6715488	ENSG00000235937.1	AC008280.1	5.06	1.47e-06	0.00347	0.45	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54029552~54030682:-
ESCA	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-5.06	1.47e-06	0.00347	-0.57	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-5.06	1.47e-06	0.00347	-0.57	-0.42	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
ESCA	cis	rs7847628	0.587	rs12684934	ENSG00000226752.6	PSMD5-AS1	-5.06	1.47e-06	0.00347	-0.37	-0.42	Birth weight;	chr9:120830881	chr9:120824828~120854385:+
ESCA	cis	rs3747113	0.913	rs34999116	ENSG00000128262.7	POM121L9P	-5.06	1.47e-06	0.00348	-0.53	-0.42	Gut microbiome composition (summer);	chr22:24418657	chr22:24251828~24265525:+
ESCA	cis	rs2173763	1	rs2173763	ENSG00000272758.4	RP11-299J3.8	-5.06	1.48e-06	0.00349	-0.54	-0.42	Major depressive disorder;	chr3:122610313	chr3:122416207~122443180:+
ESCA	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-5.06	1.48e-06	0.00349	-0.48	-0.42	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-5.06	1.48e-06	0.00349	-0.48	-0.42	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
ESCA	cis	rs4747241	0.81	rs6480615	ENSG00000226163.1	RP11-167P22.3	5.06	1.48e-06	0.00349	0.48	0.42	Heschl's gyrus morphology;	chr10:72297884	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.774	rs6480616	ENSG00000226163.1	RP11-167P22.3	5.06	1.48e-06	0.00349	0.48	0.42	Heschl's gyrus morphology;	chr10:72298086	chr10:72501746~72502956:+
ESCA	cis	rs4747241	0.774	rs10762508	ENSG00000226163.1	RP11-167P22.3	5.06	1.48e-06	0.00349	0.48	0.42	Heschl's gyrus morphology;	chr10:72298753	chr10:72501746~72502956:+
ESCA	cis	rs7829975	0.56	rs17154599	ENSG00000173295.6	FAM86B3P	-5.06	1.49e-06	0.0035	-0.48	-0.42	Mood instability;	chr8:8693908	chr8:8228595~8244865:+
ESCA	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	5.06	1.49e-06	0.0035	0.46	0.42	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
ESCA	cis	rs7924176	0.564	rs2270551	ENSG00000236900.1	TIMM9P1	-5.06	1.49e-06	0.0035	-0.5	-0.42	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74109307	chr10:74344550~74344805:-
ESCA	cis	rs765787	0.53	rs4514617	ENSG00000259520.4	CTD-2651B20.3	5.06	1.49e-06	0.00351	0.47	0.42	Uric acid levels;	chr15:45243241	chr15:45251580~45279251:-
ESCA	cis	rs875971	0.66	rs10281080	ENSG00000179406.6	LINC00174	5.06	1.49e-06	0.00352	0.46	0.41	Aortic root size;	chr7:66577454	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs10950044	ENSG00000179406.6	LINC00174	5.06	1.49e-06	0.00352	0.46	0.41	Aortic root size;	chr7:66577989	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.522	rs1968127	ENSG00000179406.6	LINC00174	5.06	1.49e-06	0.00352	0.46	0.41	Aortic root size;	chr7:66591816	chr7:66376044~66401338:-
ESCA	cis	rs977987	0.836	rs7199062	ENSG00000261783.1	RP11-252K23.2	-5.06	1.49e-06	0.00352	-0.52	-0.41	Dupuytren's disease;	chr16:75440929	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.872	rs7206665	ENSG00000261783.1	RP11-252K23.2	-5.06	1.49e-06	0.00352	-0.52	-0.41	Dupuytren's disease;	chr16:75441389	chr16:75379818~75381260:-
ESCA	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	5.06	1.5e-06	0.00352	0.45	0.41	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	5.06	1.5e-06	0.00352	0.45	0.41	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	5.06	1.5e-06	0.00352	0.45	0.41	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	5.06	1.5e-06	0.00352	0.45	0.41	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
ESCA	cis	rs7829975	0.564	rs2921057	ENSG00000253981.4	ALG1L13P	5.06	1.5e-06	0.00353	0.52	0.41	Mood instability;	chr8:8461157	chr8:8236003~8244667:-
ESCA	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-5.06	1.5e-06	0.00353	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
ESCA	cis	rs7412746	0.552	rs4970980	ENSG00000206931.1	RNU6-1042P	5.06	1.51e-06	0.00354	0.53	0.41	Melanoma;	chr1:150892516	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.66	rs10215132	ENSG00000179406.6	LINC00174	5.06	1.51e-06	0.00355	0.46	0.41	Aortic root size;	chr7:66589419	chr7:66376044~66401338:-
ESCA	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-5.06	1.51e-06	0.00355	-0.5	-0.41	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
ESCA	cis	rs9545047	0.604	rs9574406	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79338982	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9574410	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79343091	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2274555	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79344188	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9318623	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79346913	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.564	rs7998837	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79349190	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9574411	ENSG00000227676.3	LINC01068	-5.06	1.51e-06	0.00356	-0.54	-0.41	Schizophrenia;	chr13:79354342	chr13:79566727~79571436:+
ESCA	cis	rs10875746	0.68	rs4760610	ENSG00000240399.1	RP1-228P16.1	-5.05	1.52e-06	0.00358	-0.52	-0.41	Longevity (90 years and older);	chr12:48024442	chr12:48054813~48055591:-
ESCA	cis	rs2439831	0.867	rs2447196	ENSG00000249839.1	AC011330.5	5.05	1.53e-06	0.00358	0.74	0.41	Lung cancer in ever smokers;	chr15:43601620	chr15:43663654~43684339:-
ESCA	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-5.05	1.53e-06	0.00358	-0.57	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
ESCA	cis	rs732716	0.785	rs34080966	ENSG00000267980.1	AC007292.6	5.05	1.53e-06	0.00359	0.57	0.41	Mean corpuscular volume;	chr19:4417848	chr19:4363789~4364640:+
ESCA	cis	rs875971	0.619	rs2302918	ENSG00000179406.6	LINC00174	-5.05	1.53e-06	0.00359	-0.46	-0.41	Aortic root size;	chr7:66535945	chr7:66376044~66401338:-
ESCA	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-5.05	1.54e-06	0.0036	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
ESCA	cis	rs875971	0.66	rs7807930	ENSG00000179406.6	LINC00174	5.05	1.54e-06	0.0036	0.46	0.41	Aortic root size;	chr7:66622178	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs7807944	ENSG00000179406.6	LINC00174	5.05	1.54e-06	0.0036	0.46	0.41	Aortic root size;	chr7:66622208	chr7:66376044~66401338:-
ESCA	cis	rs2439831	0.867	rs2260160	ENSG00000249839.1	AC011330.5	-5.05	1.55e-06	0.00362	-0.68	-0.41	Lung cancer in ever smokers;	chr15:43603445	chr15:43663654~43684339:-
ESCA	cis	rs10875746	0.768	rs4760676	ENSG00000240399.1	RP1-228P16.1	-5.05	1.55e-06	0.00362	-0.53	-0.41	Longevity (90 years and older);	chr12:48027880	chr12:48054813~48055591:-
ESCA	cis	rs858239	0.665	rs858305	ENSG00000230042.1	AK3P3	5.05	1.55e-06	0.00363	0.48	0.41	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23129178~23129841:+
ESCA	cis	rs977987	0.966	rs8055490	ENSG00000261783.1	RP11-252K23.2	-5.05	1.55e-06	0.00363	-0.53	-0.41	Dupuytren's disease;	chr16:75463237	chr16:75379818~75381260:-
ESCA	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	5.05	1.55e-06	0.00363	0.6	0.41	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
ESCA	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	5.05	1.56e-06	0.00364	0.57	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
ESCA	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	5.05	1.56e-06	0.00365	0.5	0.41	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
ESCA	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-5.05	1.57e-06	0.00367	-0.53	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
ESCA	cis	rs732716	0.74	rs62129356	ENSG00000267980.1	AC007292.6	-5.05	1.58e-06	0.00368	-0.58	-0.41	Mean corpuscular volume;	chr19:4400317	chr19:4363789~4364640:+
ESCA	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	5.04	1.59e-06	0.0037	0.45	0.41	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
ESCA	cis	rs9545047	0.716	rs416660	ENSG00000227676.3	LINC01068	-5.04	1.59e-06	0.00371	-0.54	-0.41	Schizophrenia;	chr13:79432726	chr13:79566727~79571436:+
ESCA	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-5.04	1.59e-06	0.00371	-0.54	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
ESCA	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-5.04	1.6e-06	0.00372	-0.47	-0.41	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
ESCA	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-5.04	1.6e-06	0.00372	-0.54	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
ESCA	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	5.04	1.6e-06	0.00373	0.54	0.41	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.66	rs2013222	ENSG00000179406.6	LINC00174	5.04	1.6e-06	0.00373	0.46	0.41	Aortic root size;	chr7:66570949	chr7:66376044~66401338:-
ESCA	cis	rs2739330	0.828	rs4820572	ENSG00000228039.3	KB-1125A3.10	5.04	1.61e-06	0.00374	0.53	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23963780~23964374:+
ESCA	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-5.04	1.61e-06	0.00374	-0.49	-0.41	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
ESCA	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	5.04	1.61e-06	0.00375	0.6	0.41	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs12176034	ENSG00000216906.2	RP11-350J20.9	5.04	1.61e-06	0.00375	0.6	0.41	Lung cancer;	chr6:149800557	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.66	rs801217	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66545590	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.638	rs801216	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66546680	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs801211	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66550702	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.638	rs801205	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66557157	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.617	rs810400	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66557902	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs801192	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66566965	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs801190	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66568046	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs3857686	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66571204	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.638	rs3898855	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66571411	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.638	rs10278816	ENSG00000179406.6	LINC00174	5.04	1.61e-06	0.00375	0.46	0.41	Aortic root size;	chr7:66572000	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.619	rs12533585	ENSG00000179406.6	LINC00174	-5.04	1.61e-06	0.00375	-0.46	-0.41	Aortic root size;	chr7:66519618	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs12698534	ENSG00000179406.6	LINC00174	-5.04	1.61e-06	0.00375	-0.46	-0.41	Aortic root size;	chr7:66521858	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs28698552	ENSG00000179406.6	LINC00174	-5.04	1.61e-06	0.00375	-0.46	-0.41	Aortic root size;	chr7:66540031	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs62465434	ENSG00000179406.6	LINC00174	-5.04	1.61e-06	0.00375	-0.46	-0.41	Aortic root size;	chr7:66540165	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs13224319	ENSG00000179406.6	LINC00174	-5.04	1.61e-06	0.00375	-0.46	-0.41	Aortic root size;	chr7:66542376	chr7:66376044~66401338:-
ESCA	cis	rs1538970	0.816	rs12029322	ENSG00000280836.1	AL355480.1	-5.04	1.61e-06	0.00375	-0.53	-0.41	Platelet count;	chr1:45504774	chr1:45581219~45581321:-
ESCA	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-5.04	1.62e-06	0.00376	-0.48	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-5.04	1.62e-06	0.00376	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-5.04	1.62e-06	0.00376	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
ESCA	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-5.04	1.62e-06	0.00377	-0.51	-0.41	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-5.04	1.62e-06	0.00377	-0.45	-0.41	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
ESCA	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	5.04	1.63e-06	0.00378	0.49	0.41	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
ESCA	cis	rs6479891	1	rs12413730	ENSG00000235816.3	PRELID1P3	5.04	1.63e-06	0.00378	0.54	0.41	Arthritis (juvenile idiopathic);	chr10:63204388	chr10:63427297~63427939:+
ESCA	cis	rs950880	0.71	rs2287035	ENSG00000234389.1	AC007278.3	-5.04	1.63e-06	0.00379	-0.39	-0.41	Serum protein levels (sST2);	chr2:102394070	chr2:102438713~102440475:+
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000250470.1	AP000351.3	5.04	1.64e-06	0.00381	0.54	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23976904~23977585:-
ESCA	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-5.04	1.64e-06	0.00382	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
ESCA	cis	rs10875746	0.903	rs11168420	ENSG00000240399.1	RP1-228P16.1	-5.04	1.65e-06	0.00382	-0.53	-0.41	Longevity (90 years and older);	chr12:48122113	chr12:48054813~48055591:-
ESCA	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-5.04	1.65e-06	0.00382	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-5.04	1.65e-06	0.00382	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
ESCA	cis	rs2882667	0.756	rs11957953	ENSG00000253404.1	AC034243.1	5.04	1.65e-06	0.00383	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139143688	chr5:138744434~138753309:-
ESCA	cis	rs9355610	0.609	rs7772112	ENSG00000265828.1	MIR3939	5.04	1.65e-06	0.00384	0.52	0.41	Graves' disease;	chr6:166995408	chr6:166997807~166997912:-
ESCA	cis	rs9549260	0.753	rs61963264	ENSG00000229456.1	RLIMP1	5.04	1.66e-06	0.00384	0.5	0.41	Red blood cell count;	chr13:40580655	chr13:40618738~40621348:+
ESCA	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-5.03	1.66e-06	0.00385	-0.48	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
ESCA	cis	rs1799949	0.965	rs8176198	ENSG00000198496.9	NBR2	-5.03	1.67e-06	0.00387	-0.43	-0.41	Menopause (age at onset);	chr17:43078520	chr17:43125610~43153671:+
ESCA	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-5.03	1.67e-06	0.00387	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
ESCA	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-5.03	1.68e-06	0.00389	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
ESCA	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-5.03	1.68e-06	0.00389	-0.48	-0.41	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
ESCA	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-5.03	1.68e-06	0.00389	-0.48	-0.41	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
ESCA	cis	rs7208859	0.673	rs999796	ENSG00000263531.1	RP13-753N3.1	5.03	1.68e-06	0.0039	0.59	0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832386	chr17:30863921~30864940:-
ESCA	cis	rs977987	0.843	rs28558946	ENSG00000261783.1	RP11-252K23.2	-5.03	1.7e-06	0.00392	-0.52	-0.41	Dupuytren's disease;	chr16:75455424	chr16:75379818~75381260:-
ESCA	cis	rs61160187	0.582	rs4700407	ENSG00000215032.2	GNL3LP1	-5.03	1.7e-06	0.00392	-0.51	-0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61070701	chr5:60891935~60893577:-
ESCA	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	5.03	1.7e-06	0.00393	0.83	0.41	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
ESCA	cis	rs1426063	0.8	rs28861517	ENSG00000248165.1	RP11-44F21.2	5.03	1.7e-06	0.00394	0.57	0.41	QT interval;	chr4:75092995	chr4:74993877~75034824:-
ESCA	cis	rs1005277	0.579	rs1780139	ENSG00000263064.2	RP11-291L22.7	5.03	1.7e-06	0.00394	0.55	0.41	Extrinsic epigenetic age acceleration;	chr10:38214090	chr10:38448689~38448949:+
ESCA	cis	rs10875746	0.768	rs10875724	ENSG00000240399.1	RP1-228P16.1	-5.03	1.71e-06	0.00395	-0.53	-0.41	Longevity (90 years and older);	chr12:48026470	chr12:48054813~48055591:-
ESCA	cis	rs977987	0.806	rs12933281	ENSG00000261783.1	RP11-252K23.2	-5.03	1.71e-06	0.00395	-0.51	-0.41	Dupuytren's disease;	chr16:75449166	chr16:75379818~75381260:-
ESCA	cis	rs1061377	1	rs9996285	ENSG00000249685.1	RP11-360F5.3	5.03	1.71e-06	0.00395	0.46	0.41	Uric acid levels;	chr4:39130556	chr4:39133913~39135608:+
ESCA	cis	rs6479891	1	rs12415038	ENSG00000235816.3	PRELID1P3	5.03	1.71e-06	0.00395	0.53	0.41	Arthritis (juvenile idiopathic);	chr10:63401098	chr10:63427297~63427939:+
ESCA	cis	rs2921073	0.51	rs2976945	ENSG00000173295.6	FAM86B3P	5.03	1.71e-06	0.00395	0.46	0.41	Parkinson's disease;	chr8:8413361	chr8:8228595~8244865:+
ESCA	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-5.03	1.72e-06	0.00397	-0.48	-0.41	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
ESCA	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-5.03	1.72e-06	0.00397	-0.49	-0.41	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
ESCA	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-5.03	1.72e-06	0.00397	-0.49	-0.41	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
ESCA	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-5.03	1.72e-06	0.00397	-0.57	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
ESCA	cis	rs2455601	0.786	rs11042127	ENSG00000254860.4	TMEM9B-AS1	5.03	1.72e-06	0.00397	0.64	0.41	Schizophrenia;	chr11:8926039	chr11:8964675~8977527:+
ESCA	cis	rs2455601	0.786	rs3763913	ENSG00000254860.4	TMEM9B-AS1	5.03	1.72e-06	0.00397	0.64	0.41	Schizophrenia;	chr11:8929683	chr11:8964675~8977527:+
ESCA	cis	rs2455601	0.766	rs1109304	ENSG00000254860.4	TMEM9B-AS1	5.03	1.72e-06	0.00397	0.64	0.41	Schizophrenia;	chr11:8933908	chr11:8964675~8977527:+
ESCA	cis	rs817565	0.506	rs817546	ENSG00000278972.1	CTD-3022L24.1	-5.03	1.72e-06	0.00397	-0.42	-0.41	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);	chr17:69417262	chr17:69433084~69435533:+
ESCA	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	5.03	1.72e-06	0.00398	0.54	0.41	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
ESCA	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	5.03	1.72e-06	0.00398	0.52	0.41	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	5.03	1.72e-06	0.00398	0.52	0.41	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	5.03	1.72e-06	0.00398	0.52	0.41	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
ESCA	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-5.02	1.73e-06	0.004	-0.53	-0.41	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
ESCA	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	5.02	1.73e-06	0.004	0.46	0.41	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
ESCA	cis	rs6479891	1	rs4745706	ENSG00000235816.3	PRELID1P3	5.02	1.74e-06	0.00401	0.54	0.41	Arthritis (juvenile idiopathic);	chr10:63399820	chr10:63427297~63427939:+
ESCA	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	5.02	1.74e-06	0.00401	0.45	0.41	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
ESCA	cis	rs9494142	0.592	rs1547247	ENSG00000232876.1	CTA-212D2.2	-5.02	1.74e-06	0.00402	-0.54	-0.41	Mean corpuscular hemoglobin;Mean corpuscular volume;Lymphocyte counts;	chr6:135069698	chr6:135055033~135060550:+
ESCA	cis	rs1439620	0.686	rs10152428	ENSG00000258647.4	LINC00930	5.02	1.75e-06	0.00404	0.52	0.41	Body mass index;	chr15:92967013	chr15:92567818~92572042:-
ESCA	cis	rs7849270	1	rs2541164	ENSG00000268707.1	RP11-247A12.7	-5.02	1.75e-06	0.00404	-0.48	-0.41	Blood metabolite ratios;	chr9:129114629	chr9:129170434~129170940:+
ESCA	cis	rs9545047	0.604	rs9601226	ENSG00000227676.3	LINC01068	-5.02	1.76e-06	0.00405	-0.54	-0.41	Schizophrenia;	chr13:79403400	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs9574420	ENSG00000227676.3	LINC01068	-5.02	1.76e-06	0.00405	-0.54	-0.41	Schizophrenia;	chr13:79404342	chr13:79566727~79571436:+
ESCA	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-5.02	1.76e-06	0.00407	-0.7	-0.41	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
ESCA	cis	rs2221894	0.922	rs1858462	ENSG00000273710.1	Metazoa_SRP	-5.02	1.77e-06	0.00407	-0.44	-0.41	Obesity-related traits;	chr8:28903220	chr8:28915579~28915864:-
ESCA	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-5.02	1.78e-06	0.0041	-0.59	-0.41	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
ESCA	cis	rs6538678	0.929	rs10745733	ENSG00000258343.1	RP11-536G4.2	-5.02	1.78e-06	0.00411	-0.51	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95868728	chr12:95795345~95858839:-
ESCA	cis	rs6538678	0.926	rs10745734	ENSG00000258343.1	RP11-536G4.2	-5.02	1.78e-06	0.00411	-0.51	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95868936	chr12:95795345~95858839:-
ESCA	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-5.02	1.79e-06	0.00412	-0.48	-0.41	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
ESCA	cis	rs3820716	0.527	rs10497026	ENSG00000223911.1	AC009480.3	5.02	1.8e-06	0.00413	0.48	0.41	Glomerular filtration rate (creatinine);	chr2:148060868	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs12472459	ENSG00000223911.1	AC009480.3	5.02	1.8e-06	0.00413	0.48	0.41	Glomerular filtration rate (creatinine);	chr2:148065286	chr2:147899401~147902956:-
ESCA	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	5.02	1.8e-06	0.00414	0.51	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
ESCA	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	5.02	1.8e-06	0.00414	0.51	0.41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
ESCA	cis	rs977987	0.835	rs1010630	ENSG00000261783.1	RP11-252K23.2	-5.02	1.8e-06	0.00414	-0.5	-0.41	Dupuytren's disease;	chr16:75294693	chr16:75379818~75381260:-
ESCA	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	5.02	1.8e-06	0.00414	0.6	0.41	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	5.02	1.8e-06	0.00414	0.6	0.41	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	5.02	1.8e-06	0.00414	0.6	0.41	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	5.02	1.8e-06	0.00414	0.6	0.41	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
ESCA	cis	rs858239	0.601	rs6966776	ENSG00000234800.2	PCMTD1P3	-5.02	1.8e-06	0.00414	-0.47	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23721311~23721782:-
ESCA	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	5.02	1.8e-06	0.00415	0.59	0.41	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
ESCA	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	5.02	1.8e-06	0.00415	0.49	0.41	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
ESCA	cis	rs6538678	0.929	rs7962359	ENSG00000258343.1	RP11-536G4.2	-5.01	1.81e-06	0.00415	-0.49	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95862566	chr12:95795345~95858839:-
ESCA	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-5.01	1.81e-06	0.00415	-0.8	-0.41	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
ESCA	cis	rs61160187	0.61	rs4700397	ENSG00000215032.2	GNL3LP1	-5.01	1.81e-06	0.00416	-0.53	-0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840135	chr5:60891935~60893577:-
ESCA	cis	rs847845	0.614	rs17647222	ENSG00000186328.4	RP11-140K17.2	5.01	1.81e-06	0.00416	0.9	0.41	Non-small cell lung cancer;	chr6:34912692	chr6:34715613~34715940:+
ESCA	cis	rs1075265	0.563	rs2542588	ENSG00000235937.1	AC008280.1	-5.01	1.81e-06	0.00416	-0.46	-0.41	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54029552~54030682:-
ESCA	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	5.01	1.82e-06	0.00417	0.43	0.41	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
ESCA	cis	rs394563	0.775	rs412894	ENSG00000231760.4	RP11-350J20.5	5.01	1.82e-06	0.00418	0.47	0.41	Dupuytren's disease;	chr6:149460039	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.717	rs548848	ENSG00000231760.4	RP11-350J20.5	5.01	1.82e-06	0.00418	0.47	0.41	Dupuytren's disease;	chr6:149460873	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.775	rs399673	ENSG00000231760.4	RP11-350J20.5	5.01	1.82e-06	0.00418	0.47	0.41	Dupuytren's disease;	chr6:149462085	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.775	rs420430	ENSG00000231760.4	RP11-350J20.5	5.01	1.82e-06	0.00418	0.47	0.41	Dupuytren's disease;	chr6:149464403	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.775	rs448420	ENSG00000231760.4	RP11-350J20.5	5.01	1.82e-06	0.00418	0.47	0.41	Dupuytren's disease;	chr6:149464666	chr6:149796151~149826294:-
ESCA	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-5.01	1.82e-06	0.00418	-0.69	-0.41	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-5.01	1.82e-06	0.00418	-0.69	-0.41	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
ESCA	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-5.01	1.82e-06	0.00418	-0.69	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
ESCA	cis	rs7412746	0.611	rs2256355	ENSG00000206931.1	RNU6-1042P	5.01	1.82e-06	0.00418	0.5	0.41	Melanoma;	chr1:150839318	chr1:150701866~150701972:+
ESCA	cis	rs801193	1	rs10252765	ENSG00000179406.6	LINC00174	-5.01	1.82e-06	0.00418	-0.47	-0.41	Aortic root size;	chr7:66763745	chr7:66376044~66401338:-
ESCA	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-5.01	1.83e-06	0.00419	-0.43	-0.41	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
ESCA	cis	rs765787	0.53	rs11636440	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45243784	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs28414644	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45244523	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs28396110	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45244711	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775834	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45245313	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775835	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45245355	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775836	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45245466	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775837	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45245486	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs12917187	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45246099	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11639403	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45246152	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2413782	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45246292	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2413780	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45246668	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11636018	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45246939	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.556	rs2413778	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45247199	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs28756676	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45248162	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs55771002	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45249368	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs55920042	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45249379	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4238376	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45249689	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4238377	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45249783	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775844	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45249850	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4774550	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45250114	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs3759893	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45250752	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs16941017	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45251083	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2413776	ENSG00000259520.4	CTD-2651B20.3	5.01	1.83e-06	0.0042	0.47	0.41	Uric acid levels;	chr15:45251972	chr15:45251580~45279251:-
ESCA	cis	rs1816752	0.638	rs9578730	ENSG00000273628.1	RP11-756A22.7	5.01	1.84e-06	0.00421	0.4	0.41	Obesity-related traits;	chr13:24425545	chr13:24933006~24936796:+
ESCA	cis	rs977987	0.835	rs11641532	ENSG00000261783.1	RP11-252K23.2	-5.01	1.85e-06	0.00423	-0.5	-0.41	Dupuytren's disease;	chr16:75295582	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs35937717	ENSG00000261783.1	RP11-252K23.2	-5.01	1.85e-06	0.00423	-0.5	-0.41	Dupuytren's disease;	chr16:75297669	chr16:75379818~75381260:-
ESCA	cis	rs2439831	0.85	rs28509275	ENSG00000249839.1	AC011330.5	-5.01	1.85e-06	0.00423	-0.83	-0.41	Lung cancer in ever smokers;	chr15:43805907	chr15:43663654~43684339:-
ESCA	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-5.01	1.87e-06	0.00426	-0.49	-0.41	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
ESCA	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-5.01	1.87e-06	0.00426	-0.55	-0.41	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	5.01	1.88e-06	0.00428	0.59	0.41	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
ESCA	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-5	1.89e-06	0.0043	-0.49	-0.41	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
ESCA	cis	rs394563	0.69	rs372205	ENSG00000231760.4	RP11-350J20.5	5	1.89e-06	0.0043	0.49	0.41	Dupuytren's disease;	chr6:149454131	chr6:149796151~149826294:-
ESCA	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	5	1.89e-06	0.00431	0.46	0.41	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	5	1.89e-06	0.00431	0.46	0.41	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
ESCA	cis	rs10875746	0.768	rs12305182	ENSG00000240399.1	RP1-228P16.1	-5	1.9e-06	0.00431	-0.53	-0.41	Longevity (90 years and older);	chr12:48027624	chr12:48054813~48055591:-
ESCA	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	5	1.9e-06	0.00432	0.45	0.41	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
ESCA	cis	rs2439831	0.85	rs2228368	ENSG00000249839.1	AC011330.5	-5	1.9e-06	0.00432	-0.77	-0.41	Lung cancer in ever smokers;	chr15:43809812	chr15:43663654~43684339:-
ESCA	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-5	1.9e-06	0.00433	-0.47	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
ESCA	cis	rs977987	1	rs977987	ENSG00000261783.1	RP11-252K23.2	-5	1.91e-06	0.00434	-0.52	-0.41	Dupuytren's disease;	chr16:75472695	chr16:75379818~75381260:-
ESCA	cis	rs9322193	0.923	rs55849538	ENSG00000216906.2	RP11-350J20.9	5	1.91e-06	0.00434	0.54	0.41	Lung cancer;	chr6:149635330	chr6:149904243~149906418:+
ESCA	cis	rs2221894	0.959	rs6558089	ENSG00000273710.1	Metazoa_SRP	5	1.91e-06	0.00435	0.48	0.41	Obesity-related traits;	chr8:29036720	chr8:28915579~28915864:-
ESCA	cis	rs6479901	0.639	rs10995450	ENSG00000235816.3	PRELID1P3	5	1.91e-06	0.00435	0.47	0.41	Intelligence (multi-trait analysis);	chr10:63129151	chr10:63427297~63427939:+
ESCA	cis	rs10256972	0.616	rs3802141	ENSG00000229043.2	AC091729.9	-5	1.91e-06	0.00435	-0.42	-0.41	Endometriosis;Longevity;	chr7:1091720	chr7:1160374~1165267:+
ESCA	cis	rs1723838	0.826	rs1792194	ENSG00000255928.1	RP11-456I15.2	5	1.92e-06	0.00436	0.93	0.41	Obesity-related traits;	chr11:73849569	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs2511262	ENSG00000255928.1	RP11-456I15.2	5	1.92e-06	0.00436	0.93	0.41	Obesity-related traits;	chr11:73855295	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs1792186	ENSG00000255928.1	RP11-456I15.2	5	1.92e-06	0.00436	0.93	0.41	Obesity-related traits;	chr11:73860295	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs1792197	ENSG00000255928.1	RP11-456I15.2	5	1.92e-06	0.00436	0.93	0.41	Obesity-related traits;	chr11:73874815	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs1466218	ENSG00000255928.1	RP11-456I15.2	5	1.92e-06	0.00436	0.93	0.41	Obesity-related traits;	chr11:73878139	chr11:73722349~73722694:+
ESCA	cis	rs2227564	0.794	rs2633320	ENSG00000229990.3	RP11-574K11.8	-5	1.92e-06	0.00436	-0.46	-0.41	Crohn's disease;Inflammatory bowel disease;	chr10:73933548	chr10:73841833~73847115:+
ESCA	cis	rs6538678	0.864	rs4762249	ENSG00000258343.1	RP11-536G4.2	5	1.92e-06	0.00436	0.51	0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95884183	chr12:95795345~95858839:-
ESCA	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	5	1.92e-06	0.00437	0.53	0.41	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
ESCA	cis	rs9545047	0.604	rs9565497	ENSG00000227676.3	LINC01068	-5	1.93e-06	0.00438	-0.55	-0.41	Schizophrenia;	chr13:79406330	chr13:79566727~79571436:+
ESCA	cis	rs3747113	1	rs13056719	ENSG00000128262.7	POM121L9P	-5	1.93e-06	0.00438	-0.51	-0.41	Gut microbiome composition (summer);	chr22:24328131	chr22:24251828~24265525:+
ESCA	cis	rs1061377	0.965	rs1046655	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39126127	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7694760	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39126481	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs35116118	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39127293	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs34771104	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39127432	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.932	rs35464499	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39127670	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs11728058	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39128224	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs13144374	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39128859	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs17508864	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39129025	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1897136	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39131242	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1897137	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39131387	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs35437629	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39131712	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7657926	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39132443	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7681116	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39133015	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs11096982	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39133247	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs11727875	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39133699	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs10018622	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39133944	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.76	rs7678457	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39136041	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs28607301	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39136460	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs36090629	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39137195	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.87	rs73238544	ENSG00000249685.1	RP11-360F5.3	5	1.93e-06	0.00438	0.46	0.41	Uric acid levels;	chr4:39137343	chr4:39133913~39135608:+
ESCA	cis	rs765787	0.53	rs11636367	ENSG00000259520.4	CTD-2651B20.3	5	1.93e-06	0.00438	0.47	0.41	Uric acid levels;	chr15:45243664	chr15:45251580~45279251:-
ESCA	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	5	1.93e-06	0.00438	0.59	0.41	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
ESCA	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	5	1.93e-06	0.00438	0.59	0.41	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000228039.3	KB-1125A3.10	-5	1.94e-06	0.00438	-0.54	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23963780~23964374:+
ESCA	cis	rs9545047	0.604	rs9545052	ENSG00000227676.3	LINC01068	5	1.94e-06	0.00439	0.54	0.41	Schizophrenia;	chr13:79294875	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2147566	ENSG00000227676.3	LINC01068	5	1.94e-06	0.00439	0.54	0.41	Schizophrenia;	chr13:79296580	chr13:79566727~79571436:+
ESCA	cis	rs2221894	0.881	rs2693	ENSG00000273710.1	Metazoa_SRP	5	1.94e-06	0.00439	0.44	0.41	Obesity-related traits;	chr8:29067341	chr8:28915579~28915864:-
ESCA	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-5	1.94e-06	0.0044	-0.69	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
ESCA	cis	rs10954779	0.511	rs2725356	ENSG00000253579.1	SUMO2P16	-5	1.95e-06	0.0044	-0.45	-0.41	Intelligence (multi-trait analysis);	chr8:31130566	chr8:31131539~31131802:-
ESCA	cis	rs950880	0.71	rs11693204	ENSG00000234389.1	AC007278.3	-5	1.95e-06	0.00441	-0.38	-0.41	Serum protein levels (sST2);	chr2:102319514	chr2:102438713~102440475:+
ESCA	cis	rs6456156	0.792	rs7775443	ENSG00000265828.1	MIR3939	5	1.95e-06	0.00441	0.45	0.41	Primary biliary cholangitis;	chr6:167099764	chr6:166997807~166997912:-
ESCA	cis	rs748404	0.697	rs505249	ENSG00000249839.1	AC011330.5	-5	1.95e-06	0.00441	-0.51	-0.41	Lung cancer;	chr15:43267762	chr15:43663654~43684339:-
ESCA	cis	rs2505998	1	rs2506006	ENSG00000273008.1	RP11-351D16.3	-5	1.95e-06	0.00441	-0.47	-0.41	Hirschsprung disease;	chr10:43086053	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.957	rs2506005	ENSG00000273008.1	RP11-351D16.3	-5	1.95e-06	0.00441	-0.47	-0.41	Hirschsprung disease;	chr10:43086532	chr10:43136824~43138334:-
ESCA	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-5	1.95e-06	0.00442	-0.69	-0.41	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
ESCA	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	5	1.95e-06	0.00442	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
ESCA	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	5	1.96e-06	0.00443	0.44	0.41	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
ESCA	cis	rs950880	0.71	rs873022	ENSG00000234389.1	AC007278.3	-5	1.96e-06	0.00443	-0.39	-0.41	Serum protein levels (sST2);	chr2:102339223	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3771177	ENSG00000234389.1	AC007278.3	-5	1.96e-06	0.00443	-0.39	-0.41	Serum protein levels (sST2);	chr2:102339400	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3732129	ENSG00000234389.1	AC007278.3	-5	1.96e-06	0.00443	-0.39	-0.41	Serum protein levels (sST2);	chr2:102341072	chr2:102438713~102440475:+
ESCA	cis	rs1061377	1	rs13182	ENSG00000249685.1	RP11-360F5.3	5	1.96e-06	0.00443	0.46	0.41	Uric acid levels;	chr4:39121293	chr4:39133913~39135608:+
ESCA	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5	1.96e-06	0.00443	0.52	0.41	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5	1.96e-06	0.00443	0.52	0.41	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
ESCA	cis	rs2439831	0.867	rs12443102	ENSG00000249839.1	AC011330.5	-5	1.96e-06	0.00444	-0.72	-0.41	Lung cancer in ever smokers;	chr15:43639905	chr15:43663654~43684339:-
ESCA	cis	rs2882667	0.858	rs66839813	ENSG00000253404.1	AC034243.1	5	1.96e-06	0.00444	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106633	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs11242448	ENSG00000253404.1	AC034243.1	5	1.96e-06	0.00444	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139107465	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs13174479	ENSG00000253404.1	AC034243.1	5	1.96e-06	0.00444	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139108481	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs13176497	ENSG00000253404.1	AC034243.1	5	1.96e-06	0.00444	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139110385	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.858	rs11959803	ENSG00000253404.1	AC034243.1	5	1.96e-06	0.00444	0.6	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139115626	chr5:138744434~138753309:-
ESCA	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	5	1.97e-06	0.00444	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
ESCA	cis	rs1061377	1	rs1061377	ENSG00000249685.1	RP11-360F5.3	4.99	1.97e-06	0.00445	0.46	0.41	Uric acid levels;	chr4:39123130	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1982009	ENSG00000249685.1	RP11-360F5.3	4.99	1.97e-06	0.00445	0.46	0.41	Uric acid levels;	chr4:39123253	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs1138494	ENSG00000249685.1	RP11-360F5.3	4.99	1.97e-06	0.00445	0.46	0.41	Uric acid levels;	chr4:39123315	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs13109200	ENSG00000249685.1	RP11-360F5.3	4.99	1.97e-06	0.00445	0.46	0.41	Uric acid levels;	chr4:39124396	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs2890659	ENSG00000249685.1	RP11-360F5.3	4.99	1.97e-06	0.00445	0.46	0.41	Uric acid levels;	chr4:39125401	chr4:39133913~39135608:+
ESCA	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-4.99	1.97e-06	0.00445	-0.49	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.508	rs10242104	ENSG00000230042.1	AK3P3	-4.99	1.97e-06	0.00445	-0.49	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23129178~23129841:+
ESCA	cis	rs801193	0.967	rs2420827	ENSG00000179406.6	LINC00174	4.99	1.97e-06	0.00445	0.47	0.41	Aortic root size;	chr7:66682114	chr7:66376044~66401338:-
ESCA	cis	rs1075265	0.597	rs10490471	ENSG00000235937.1	AC008280.1	4.99	1.97e-06	0.00446	0.45	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54029552~54030682:-
ESCA	cis	rs6782228	0.606	rs2811490	ENSG00000277250.1	Metazoa_SRP	-4.99	1.97e-06	0.00446	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.606	rs7650156	ENSG00000277250.1	Metazoa_SRP	-4.99	1.97e-06	0.00446	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128673681~128674021:-
ESCA	cis	rs8059260	0.736	rs7200623	ENSG00000274038.1	RP11-66H6.4	-4.99	1.98e-06	0.00447	-0.79	-0.41	Alcohol consumption over the past year;	chr16:11001188	chr16:11056556~11057034:+
ESCA	cis	rs9545047	0.604	rs9545085	ENSG00000227676.3	LINC01068	4.99	1.98e-06	0.00447	0.53	0.41	Schizophrenia;	chr13:79363969	chr13:79566727~79571436:+
ESCA	cis	rs2505998	0.833	rs2505536	ENSG00000273008.1	RP11-351D16.3	4.99	1.98e-06	0.00447	0.45	0.41	Hirschsprung disease;	chr10:43096756	chr10:43136824~43138334:-
ESCA	cis	rs2638953	0.64	rs1511548	ENSG00000247934.4	RP11-967K21.1	-4.99	1.98e-06	0.00447	-0.46	-0.41	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28579057	chr12:28163298~28190738:-
ESCA	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	4.99	1.98e-06	0.00448	0.51	0.41	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
ESCA	cis	rs1528149	0.93	rs2389581	ENSG00000224683.1	RPL36AP29	4.99	1.98e-06	0.00448	0.51	0.41	Sitting height ratio;	chr7:16078546	chr7:16208945~16209265:+
ESCA	cis	rs1528149	0.856	rs6952865	ENSG00000224683.1	RPL36AP29	4.99	1.98e-06	0.00448	0.51	0.41	Sitting height ratio;	chr7:16082239	chr7:16208945~16209265:+
ESCA	cis	rs1816752	0.837	rs7139748	ENSG00000273628.1	RP11-756A22.7	4.99	1.99e-06	0.0045	0.39	0.41	Obesity-related traits;	chr13:24411531	chr13:24933006~24936796:+
ESCA	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	4.99	2e-06	0.0045	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	4.99	2e-06	0.0045	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	4.99	2e-06	0.0045	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
ESCA	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-4.99	2e-06	0.00451	-0.49	-0.41	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
ESCA	cis	rs1061377	1	rs7685468	ENSG00000249685.1	RP11-360F5.3	4.99	2e-06	0.00451	0.44	0.41	Uric acid levels;	chr4:39116649	chr4:39133913~39135608:+
ESCA	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-4.99	2e-06	0.00451	-0.49	-0.41	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
ESCA	cis	rs61160187	0.556	rs10939881	ENSG00000215032.2	GNL3LP1	4.99	2.01e-06	0.00452	0.53	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61087146	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs7713481	ENSG00000215032.2	GNL3LP1	4.99	2.01e-06	0.00452	0.53	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61093038	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs7737276	ENSG00000215032.2	GNL3LP1	4.99	2.01e-06	0.00452	0.53	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61102467	chr5:60891935~60893577:-
ESCA	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	4.99	2.02e-06	0.00454	0.51	0.41	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	4.99	2.02e-06	0.00454	0.51	0.41	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
ESCA	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	4.99	2.02e-06	0.00454	0.51	0.41	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
ESCA	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-4.99	2.03e-06	0.00456	-0.8	-0.41	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
ESCA	cis	rs9545047	0.604	rs7331872	ENSG00000227676.3	LINC01068	-4.99	2.03e-06	0.00456	-0.53	-0.41	Schizophrenia;	chr13:79388717	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7331867	ENSG00000227676.3	LINC01068	-4.99	2.03e-06	0.00456	-0.53	-0.41	Schizophrenia;	chr13:79418791	chr13:79566727~79571436:+
ESCA	cis	rs2505998	0.833	rs2742243	ENSG00000273008.1	RP11-351D16.3	-4.99	2.03e-06	0.00456	-0.45	-0.41	Hirschsprung disease;	chr10:43106301	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs2565204	ENSG00000273008.1	RP11-351D16.3	-4.99	2.03e-06	0.00456	-0.45	-0.41	Hirschsprung disease;	chr10:43107725	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs2742244	ENSG00000273008.1	RP11-351D16.3	-4.99	2.03e-06	0.00456	-0.45	-0.41	Hirschsprung disease;	chr10:43108144	chr10:43136824~43138334:-
ESCA	cis	rs7826238	0.564	rs2921053	ENSG00000253981.4	ALG1L13P	4.99	2.03e-06	0.00456	0.48	0.41	Systolic blood pressure;	chr8:8462453	chr8:8236003~8244667:-
ESCA	cis	rs765787	0.53	rs1706832	ENSG00000259520.4	CTD-2651B20.3	4.99	2.03e-06	0.00456	0.47	0.41	Uric acid levels;	chr15:45224975	chr15:45251580~45279251:-
ESCA	cis	rs6456156	0.586	rs1358883	ENSG00000265828.1	MIR3939	4.99	2.03e-06	0.00457	0.44	0.41	Primary biliary cholangitis;	chr6:167053945	chr6:166997807~166997912:-
ESCA	cis	rs2742234	0.614	rs3026750	ENSG00000273008.1	RP11-351D16.3	-4.99	2.03e-06	0.00457	-0.47	-0.41	Hirschsprung disease;	chr10:43112308	chr10:43136824~43138334:-
ESCA	cis	rs67180937	0.882	rs2378584	ENSG00000272750.1	RP11-378J18.8	-4.99	2.03e-06	0.00457	-0.5	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620290	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.733	rs34767248	ENSG00000272750.1	RP11-378J18.8	-4.99	2.03e-06	0.00457	-0.5	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620428	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.882	rs17163301	ENSG00000272750.1	RP11-378J18.8	-4.99	2.03e-06	0.00457	-0.5	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222620749	chr1:222658867~222661512:-
ESCA	cis	rs7412746	0.524	rs58304714	ENSG00000206931.1	RNU6-1042P	4.99	2.04e-06	0.00458	0.53	0.41	Melanoma;	chr1:150859085	chr1:150701866~150701972:+
ESCA	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-4.99	2.04e-06	0.00458	-0.48	-0.41	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
ESCA	cis	rs2221894	1	rs6985217	ENSG00000273710.1	Metazoa_SRP	-4.99	2.04e-06	0.00459	-0.47	-0.41	Obesity-related traits;	chr8:28955638	chr8:28915579~28915864:-
ESCA	cis	rs2882667	0.824	rs11748097	ENSG00000253404.1	AC034243.1	4.99	2.05e-06	0.00461	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144198	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.824	rs12173085	ENSG00000253404.1	AC034243.1	4.99	2.05e-06	0.00461	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139144336	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.788	rs11959691	ENSG00000253404.1	AC034243.1	4.99	2.05e-06	0.00461	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139145399	chr5:138744434~138753309:-
ESCA	cis	rs9322193	0.886	rs9767555	ENSG00000216906.2	RP11-350J20.9	4.98	2.06e-06	0.00463	0.55	0.41	Lung cancer;	chr6:149647022	chr6:149904243~149906418:+
ESCA	cis	rs765787	0.53	rs2899381	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45237432	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2413785	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45238183	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2413784	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45238318	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs7165889	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45239442	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11070451	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45241343	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs28897155	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45241776	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775831	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45242524	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4775832	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45242630	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4442750	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45243130	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4444275	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45243149	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4270107	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45243152	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs4544188	ENSG00000259520.4	CTD-2651B20.3	4.98	2.07e-06	0.00464	0.47	0.41	Uric acid levels;	chr15:45243195	chr15:45251580~45279251:-
ESCA	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	4.98	2.07e-06	0.00464	0.52	0.41	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	4.98	2.07e-06	0.00464	0.52	0.41	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
ESCA	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	4.98	2.07e-06	0.00464	0.52	0.41	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
ESCA	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-4.98	2.07e-06	0.00464	-0.83	-0.41	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
ESCA	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	4.98	2.08e-06	0.00464	0.51	0.41	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
ESCA	cis	rs765787	0.53	rs7167389	ENSG00000259520.4	CTD-2651B20.3	4.98	2.08e-06	0.00465	0.47	0.41	Uric acid levels;	chr15:45243485	chr15:45251580~45279251:-
ESCA	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-4.98	2.08e-06	0.00466	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
ESCA	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-4.98	2.08e-06	0.00466	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
ESCA	cis	rs2882667	0.858	rs11242444	ENSG00000253404.1	AC034243.1	4.98	2.09e-06	0.00467	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070690	chr5:138744434~138753309:-
ESCA	cis	rs394563	0.559	rs7752555	ENSG00000231760.4	RP11-350J20.5	-4.98	2.1e-06	0.00467	-0.48	-0.41	Dupuytren's disease;	chr6:149349980	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.559	rs7753269	ENSG00000231760.4	RP11-350J20.5	-4.98	2.1e-06	0.00467	-0.48	-0.41	Dupuytren's disease;	chr6:149350224	chr6:149796151~149826294:-
ESCA	cis	rs2439831	0.618	rs8023508	ENSG00000249839.1	AC011330.5	4.98	2.1e-06	0.00468	0.72	0.41	Lung cancer in ever smokers;	chr15:43883905	chr15:43663654~43684339:-
ESCA	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-4.98	2.1e-06	0.00468	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
ESCA	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	4.98	2.1e-06	0.00469	0.45	0.41	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
ESCA	cis	rs9287719	0.747	rs1534400	ENSG00000234818.1	AC092687.5	4.98	2.1e-06	0.00469	0.36	0.41	Prostate cancer;	chr2:10556707	chr2:10589166~10604830:+
ESCA	cis	rs2882667	0.858	rs11741150	ENSG00000253404.1	AC034243.1	4.98	2.11e-06	0.0047	0.59	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095768	chr5:138744434~138753309:-
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000250470.1	AP000351.3	4.98	2.11e-06	0.0047	0.48	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23976904~23977585:-
ESCA	cis	rs2439831	0.867	rs11856184	ENSG00000249839.1	AC011330.5	-4.98	2.12e-06	0.00471	-0.77	-0.41	Lung cancer in ever smokers;	chr15:43626964	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2927072	ENSG00000249839.1	AC011330.5	-4.98	2.12e-06	0.00471	-0.77	-0.41	Lung cancer in ever smokers;	chr15:43630200	chr15:43663654~43684339:-
ESCA	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-4.98	2.12e-06	0.00471	-0.54	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
ESCA	cis	rs6538678	0.833	rs1898178	ENSG00000258343.1	RP11-536G4.2	-4.98	2.12e-06	0.00472	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887554	chr12:95795345~95858839:-
ESCA	cis	rs6538678	0.833	rs1898177	ENSG00000258343.1	RP11-536G4.2	-4.98	2.12e-06	0.00472	-0.52	-0.41	Lupus nephritis in systemic lupus erythematosus;	chr12:95887568	chr12:95795345~95858839:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000228039.3	KB-1125A3.10	-4.98	2.12e-06	0.00472	-0.59	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23963780~23964374:+
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000228039.3	KB-1125A3.10	-4.98	2.12e-06	0.00472	-0.59	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23963780~23964374:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000228039.3	KB-1125A3.10	-4.98	2.12e-06	0.00472	-0.6	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23963780~23964374:+
ESCA	cis	rs10875746	0.859	rs12305647	ENSG00000240399.1	RP1-228P16.1	-4.98	2.13e-06	0.00474	-0.5	-0.41	Longevity (90 years and older);	chr12:48189178	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.859	rs4760695	ENSG00000240399.1	RP1-228P16.1	-4.98	2.13e-06	0.00474	-0.5	-0.41	Longevity (90 years and older);	chr12:48198065	chr12:48054813~48055591:-
ESCA	cis	rs7829975	0.688	rs7826654	ENSG00000253981.4	ALG1L13P	4.98	2.13e-06	0.00474	0.48	0.41	Mood instability;	chr8:8521596	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.688	rs7826660	ENSG00000253981.4	ALG1L13P	4.98	2.13e-06	0.00474	0.48	0.41	Mood instability;	chr8:8521597	chr8:8236003~8244667:-
ESCA	cis	rs1075265	0.553	rs2692532	ENSG00000235937.1	AC008280.1	4.98	2.13e-06	0.00474	0.44	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54029552~54030682:-
ESCA	cis	rs801193	0.875	rs13227951	ENSG00000179406.6	LINC00174	4.98	2.13e-06	0.00474	0.5	0.41	Aortic root size;	chr7:66748121	chr7:66376044~66401338:-
ESCA	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	4.98	2.13e-06	0.00474	0.59	0.41	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
ESCA	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	4.98	2.13e-06	0.00474	0.59	0.41	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
ESCA	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	4.98	2.13e-06	0.00474	0.59	0.41	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
ESCA	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	4.98	2.13e-06	0.00474	0.59	0.41	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
ESCA	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-4.98	2.14e-06	0.00475	-0.47	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
ESCA	cis	rs12480328	1	rs2870025	ENSG00000228663.1	PSMD10P1	4.98	2.14e-06	0.00475	0.49	0.41	Prostate cancer;	chr20:50922521	chr20:50913731~50914411:+
ESCA	cis	rs2307394	1	rs2890915	ENSG00000223911.1	AC009480.3	-4.98	2.14e-06	0.00475	-0.48	-0.41	Urate levels;	chr2:148031974	chr2:147899401~147902956:-
ESCA	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-4.98	2.14e-06	0.00476	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	4.97	2.15e-06	0.00478	0.52	0.41	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
ESCA	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	4.97	2.15e-06	0.00478	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
ESCA	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-4.97	2.16e-06	0.00479	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
ESCA	cis	rs8059260	0.736	rs76818150	ENSG00000274038.1	RP11-66H6.4	-4.97	2.16e-06	0.00479	-0.88	-0.41	Alcohol consumption over the past year;	chr16:10955006	chr16:11056556~11057034:+
ESCA	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-4.97	2.16e-06	0.00479	-0.48	-0.41	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
ESCA	cis	rs394563	0.726	rs6906384	ENSG00000231760.4	RP11-350J20.5	-4.97	2.16e-06	0.00479	-0.47	-0.41	Dupuytren's disease;	chr6:149343404	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.81	rs480870	ENSG00000231760.4	RP11-350J20.5	4.97	2.16e-06	0.00479	0.47	0.41	Dupuytren's disease;	chr6:149463682	chr6:149796151~149826294:-
ESCA	cis	rs1075265	0.587	rs2949811	ENSG00000235937.1	AC008280.1	4.97	2.17e-06	0.0048	0.45	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54029552~54030682:-
ESCA	cis	rs9368849	0.512	rs942373	ENSG00000186328.4	RP11-140K17.2	-4.97	2.17e-06	0.00481	-0.59	-0.41	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35185211	chr6:34715613~34715940:+
ESCA	cis	rs2439831	0.85	rs694985	ENSG00000249839.1	AC011330.5	-4.97	2.17e-06	0.00481	-0.62	-0.41	Lung cancer in ever smokers;	chr15:43521189	chr15:43663654~43684339:-
ESCA	cis	rs42490	0.903	rs393891	ENSG00000251136.7	RP11-37B2.1	-4.97	2.17e-06	0.00481	-0.42	-0.41	Leprosy;	chr8:89701556	chr8:89609409~89757727:-
ESCA	cis	rs875971	0.619	rs10278371	ENSG00000179406.6	LINC00174	4.97	2.18e-06	0.00481	0.47	0.41	Aortic root size;	chr7:66586553	chr7:66376044~66401338:-
ESCA	cis	rs6479891	0.841	rs7085869	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63310403	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.818	rs9299455	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63313841	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs7899715	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63318695	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4525102	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63326513	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.841	rs7092504	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63329679	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4133250	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63332645	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs10995506	ENSG00000235816.3	PRELID1P3	-4.97	2.18e-06	0.00481	-0.53	-0.41	Arthritis (juvenile idiopathic);	chr10:63334706	chr10:63427297~63427939:+
ESCA	cis	rs1075232	1	rs72722829	ENSG00000270055.1	CTD-3092A11.2	-4.97	2.18e-06	0.00481	-0.91	-0.41	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs16956707	ENSG00000270055.1	CTD-3092A11.2	-4.97	2.18e-06	0.00481	-0.91	-0.41	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30487963~30490313:+
ESCA	cis	rs2742234	0.541	rs10793426	ENSG00000273008.1	RP11-351D16.3	4.97	2.18e-06	0.00482	0.49	0.41	Hirschsprung disease;	chr10:43249832	chr10:43136824~43138334:-
ESCA	cis	rs9545047	0.604	rs9565491	ENSG00000227676.3	LINC01068	-4.97	2.19e-06	0.00483	-0.53	-0.41	Schizophrenia;	chr13:79346037	chr13:79566727~79571436:+
ESCA	cis	rs4747241	0.739	rs10740400	ENSG00000226163.1	RP11-167P22.3	4.97	2.19e-06	0.00484	0.47	0.41	Heschl's gyrus morphology;	chr10:72300772	chr10:72501746~72502956:+
ESCA	cis	rs61160187	0.582	rs12516995	ENSG00000215032.2	GNL3LP1	4.97	2.2e-06	0.00486	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61012447	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs55814394	ENSG00000215032.2	GNL3LP1	4.97	2.2e-06	0.00486	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61014107	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs10939879	ENSG00000215032.2	GNL3LP1	4.97	2.2e-06	0.00486	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61019996	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs1479645	ENSG00000215032.2	GNL3LP1	4.97	2.2e-06	0.00486	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61023904	chr5:60891935~60893577:-
ESCA	cis	rs9733	0.65	rs6698495	ENSG00000206931.1	RNU6-1042P	-4.97	2.21e-06	0.00487	-0.49	-0.41	Tonsillectomy;	chr1:150592000	chr1:150701866~150701972:+
ESCA	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	4.97	2.21e-06	0.00488	0.6	0.41	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
ESCA	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-4.97	2.22e-06	0.00488	-0.49	-0.41	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
ESCA	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-4.97	2.22e-06	0.00488	-0.44	-0.41	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
ESCA	cis	rs2439831	0.702	rs3759791	ENSG00000249839.1	AC011330.5	-4.97	2.23e-06	0.0049	-0.81	-0.41	Lung cancer in ever smokers;	chr15:43798600	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.567	rs7321186	ENSG00000227676.3	LINC01068	4.97	2.23e-06	0.0049	0.53	0.41	Schizophrenia;	chr13:79383403	chr13:79566727~79571436:+
ESCA	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	4.97	2.23e-06	0.00491	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	4.97	2.23e-06	0.00491	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	4.97	2.23e-06	0.00491	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
ESCA	cis	rs1075265	0.633	rs28653587	ENSG00000235937.1	AC008280.1	4.96	2.24e-06	0.00493	0.44	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.633	rs7564912	ENSG00000235937.1	AC008280.1	4.96	2.24e-06	0.00493	0.44	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54029552~54030682:-
ESCA	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-4.96	2.24e-06	0.00493	-0.69	-0.41	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-4.96	2.24e-06	0.00493	-0.69	-0.41	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
ESCA	cis	rs12712135	0.706	rs6543114	ENSG00000234389.1	AC007278.3	-4.96	2.25e-06	0.00494	-0.4	-0.41	Blood protein levels;	chr2:102309534	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs12470867	ENSG00000234389.1	AC007278.3	-4.96	2.25e-06	0.00494	-0.4	-0.41	Serum protein levels (sST2);	chr2:102309906	chr2:102438713~102440475:+
ESCA	cis	rs4888378	0.576	rs8050367	ENSG00000261783.1	RP11-252K23.2	4.96	2.26e-06	0.00496	0.58	0.41	Coronary artery disease;	chr16:75279360	chr16:75379818~75381260:-
ESCA	cis	rs394563	0.591	rs11964335	ENSG00000231760.4	RP11-350J20.5	-4.96	2.26e-06	0.00496	-0.48	-0.41	Dupuytren's disease;	chr6:149336965	chr6:149796151~149826294:-
ESCA	cis	rs2221894	0.922	rs983365	ENSG00000273710.1	Metazoa_SRP	-4.96	2.26e-06	0.00496	-0.44	-0.41	Obesity-related traits;	chr8:28892912	chr8:28915579~28915864:-
ESCA	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	4.96	2.26e-06	0.00496	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	4.96	2.26e-06	0.00496	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
ESCA	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-4.96	2.26e-06	0.00496	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-4.96	2.26e-06	0.00496	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-4.96	2.26e-06	0.00496	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-4.96	2.26e-06	0.00496	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-4.96	2.26e-06	0.00496	-0.42	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
ESCA	cis	rs8059260	0.736	rs80079627	ENSG00000274038.1	RP11-66H6.4	-4.96	2.27e-06	0.00498	-0.81	-0.41	Alcohol consumption over the past year;	chr16:10948741	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.736	rs77920180	ENSG00000274038.1	RP11-66H6.4	-4.96	2.27e-06	0.00498	-0.81	-0.41	Alcohol consumption over the past year;	chr16:10949041	chr16:11056556~11057034:+
ESCA	cis	rs977987	0.806	rs11643209	ENSG00000261783.1	RP11-252K23.2	-4.96	2.27e-06	0.00498	-0.5	-0.41	Dupuytren's disease;	chr16:75297146	chr16:75379818~75381260:-
ESCA	cis	rs61160187	0.582	rs2898309	ENSG00000215032.2	GNL3LP1	4.96	2.27e-06	0.00498	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60981546	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.549	rs62367879	ENSG00000215032.2	GNL3LP1	4.96	2.27e-06	0.00498	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60996384	chr5:60891935~60893577:-
ESCA	cis	rs1075232	0.826	rs12437800	ENSG00000270055.1	CTD-3092A11.2	-4.96	2.27e-06	0.00499	-0.95	-0.41	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30487963~30490313:+
ESCA	cis	rs6772849	0.708	rs12491942	ENSG00000242551.2	POU5F1P6	-4.96	2.27e-06	0.00499	-0.56	-0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128674735~128677005:-
ESCA	cis	rs2882667	0.66	rs11951084	ENSG00000253404.1	AC034243.1	4.96	2.28e-06	0.005	0.54	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139125858	chr5:138744434~138753309:-
ESCA	cis	rs17711722	0.583	rs11768292	ENSG00000179406.6	LINC00174	4.96	2.28e-06	0.005	0.48	0.41	Calcium levels;	chr7:66009814	chr7:66376044~66401338:-
ESCA	cis	rs6772849	0.768	rs4521246	ENSG00000242551.2	POU5F1P6	4.96	2.28e-06	0.005	0.56	0.41	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128674735~128677005:-
ESCA	cis	rs732716	0.785	rs62129354	ENSG00000267980.1	AC007292.6	-4.96	2.28e-06	0.00501	-0.57	-0.41	Mean corpuscular volume;	chr19:4396508	chr19:4363789~4364640:+
ESCA	cis	rs394563	0.726	rs6942381	ENSG00000231760.4	RP11-350J20.5	-4.96	2.29e-06	0.00502	-0.47	-0.41	Dupuytren's disease;	chr6:149341855	chr6:149796151~149826294:-
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	4.96	2.3e-06	0.00504	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
ESCA	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	4.96	2.3e-06	0.00505	0.46	0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
ESCA	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	4.96	2.31e-06	0.00506	0.56	0.41	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
ESCA	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	4.96	2.31e-06	0.00507	0.51	0.41	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
ESCA	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	4.96	2.31e-06	0.00507	0.51	0.41	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
ESCA	cis	rs950880	0.677	rs56224165	ENSG00000234389.1	AC007278.3	-4.96	2.32e-06	0.00507	-0.4	-0.41	Serum protein levels (sST2);	chr2:102308763	chr2:102438713~102440475:+
ESCA	cis	rs875971	0.508	rs6947808	ENSG00000179406.6	LINC00174	4.96	2.32e-06	0.00508	0.45	0.41	Aortic root size;	chr7:66580095	chr7:66376044~66401338:-
ESCA	cis	rs61160187	0.582	rs976631	ENSG00000215032.2	GNL3LP1	4.96	2.32e-06	0.00508	0.53	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60920216	chr5:60891935~60893577:-
ESCA	cis	rs12480328	1	rs41274692	ENSG00000228663.1	PSMD10P1	4.96	2.32e-06	0.00508	0.49	0.41	Prostate cancer;	chr20:50914391	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs2870024	ENSG00000228663.1	PSMD10P1	4.96	2.32e-06	0.00508	0.49	0.41	Prostate cancer;	chr20:50922384	chr20:50913731~50914411:+
ESCA	cis	rs6456156	0.846	rs204293	ENSG00000265828.1	MIR3939	-4.96	2.33e-06	0.00509	-0.46	-0.41	Primary biliary cholangitis;	chr6:167100993	chr6:166997807~166997912:-
ESCA	cis	rs150992	0.673	rs330419	ENSG00000248489.1	CTD-2007H13.3	-4.95	2.34e-06	0.00511	-0.58	-0.41	Body mass index;	chr5:98857460	chr5:98929171~98995013:+
ESCA	cis	rs9545047	0.604	rs7981067	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79341254	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7996652	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79341474	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9565488	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79341604	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.625	rs9565489	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79342106	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs3742117	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79342498	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.647	rs3742118	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79342838	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.625	rs7319320	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79343072	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs3752994	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79345076	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs4884129	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79346448	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs1410336	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79347598	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9565492	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79348554	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9318625	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79351429	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530899	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79352461	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7338677	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79352580	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7322744	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79354070	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530900	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79355048	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530901	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79355191	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4328330	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79355503	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs4497554	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79355651	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2182873	ENSG00000227676.3	LINC01068	4.95	2.34e-06	0.00511	0.53	0.41	Schizophrenia;	chr13:79356846	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs11620233	ENSG00000227676.3	LINC01068	-4.95	2.35e-06	0.00512	-0.53	-0.41	Schizophrenia;	chr13:79373871	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	4.95	2.36e-06	0.00514	0.51	0.41	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
ESCA	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-4.95	2.37e-06	0.00515	-0.57	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
ESCA	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	4.95	2.38e-06	0.00517	0.46	0.41	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
ESCA	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	4.95	2.38e-06	0.00518	0.45	0.41	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
ESCA	cis	rs9532580	0.778	rs34373380	ENSG00000229456.1	RLIMP1	4.95	2.38e-06	0.00518	0.39	0.41	Mean corpuscular hemoglobin;	chr13:40670080	chr13:40618738~40621348:+
ESCA	cis	rs9532580	0.778	rs61963319	ENSG00000229456.1	RLIMP1	4.95	2.38e-06	0.00518	0.39	0.41	Mean corpuscular hemoglobin;	chr13:40670083	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.599	rs12870023	ENSG00000229456.1	RLIMP1	4.95	2.38e-06	0.00518	0.39	0.41	Red blood cell count;	chr13:40670085	chr13:40618738~40621348:+
ESCA	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	4.95	2.38e-06	0.00519	0.48	0.41	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
ESCA	cis	rs6867032	0.527	rs4975777	ENSG00000249731.1	RP11-259O2.3	-4.95	2.39e-06	0.00519	-0.36	-0.41	Gut microbiome composition (winter);	chr5:1973210	chr5:1968094~1969013:+
ESCA	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-4.95	2.39e-06	0.0052	-0.7	-0.41	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
ESCA	cis	rs10875746	0.904	rs11168422	ENSG00000240399.1	RP1-228P16.1	-4.95	2.39e-06	0.0052	-0.5	-0.41	Longevity (90 years and older);	chr12:48125722	chr12:48054813~48055591:-
ESCA	cis	rs7826238	0.623	rs2976893	ENSG00000253981.4	ALG1L13P	-4.95	2.4e-06	0.00521	-0.53	-0.41	Systolic blood pressure;	chr8:8480709	chr8:8236003~8244667:-
ESCA	cis	rs1723838	0.826	rs1670571	ENSG00000255928.1	RP11-456I15.2	4.95	2.42e-06	0.00525	0.95	0.41	Obesity-related traits;	chr11:73838981	chr11:73722349~73722694:+
ESCA	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-4.95	2.42e-06	0.00526	-0.36	-0.41	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
ESCA	cis	rs801193	0.844	rs732465	ENSG00000179406.6	LINC00174	-4.95	2.43e-06	0.00527	-0.44	-0.41	Aortic root size;	chr7:66533463	chr7:66376044~66401338:-
ESCA	cis	rs801193	0.773	rs801207	ENSG00000179406.6	LINC00174	4.95	2.43e-06	0.00527	0.44	0.41	Aortic root size;	chr7:66555603	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.543	rs801191	ENSG00000179406.6	LINC00174	4.95	2.43e-06	0.00527	0.44	0.41	Aortic root size;	chr7:66567968	chr7:66376044~66401338:-
ESCA	cis	rs1075232	1	rs12439239	ENSG00000270055.1	CTD-3092A11.2	-4.95	2.43e-06	0.00527	-0.91	-0.41	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30487963~30490313:+
ESCA	cis	rs2283792	0.745	rs5756306	ENSG00000228050.1	TOP3BP1	-4.95	2.44e-06	0.00529	-0.51	-0.41	Multiple sclerosis;	chr22:21978846	chr22:22223187~22224566:-
ESCA	cis	rs1005277	0.563	rs2505215	ENSG00000263064.2	RP11-291L22.7	4.94	2.44e-06	0.0053	0.54	0.41	Extrinsic epigenetic age acceleration;	chr10:38192345	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.563	rs2505216	ENSG00000263064.2	RP11-291L22.7	4.94	2.44e-06	0.0053	0.54	0.41	Extrinsic epigenetic age acceleration;	chr10:38193902	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.563	rs2800550	ENSG00000263064.2	RP11-291L22.7	4.94	2.44e-06	0.0053	0.54	0.41	Extrinsic epigenetic age acceleration;	chr10:38194001	chr10:38448689~38448949:+
ESCA	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	4.94	2.45e-06	0.00531	0.35	0.41	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
ESCA	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	4.94	2.45e-06	0.00531	0.53	0.41	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
ESCA	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	4.94	2.46e-06	0.00533	0.51	0.41	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
ESCA	cis	rs2307394	1	rs57679331	ENSG00000223911.1	AC009480.3	4.94	2.47e-06	0.00534	0.48	0.41	Urate levels;	chr2:147979756	chr2:147899401~147902956:-
ESCA	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	4.94	2.47e-06	0.00534	0.49	0.41	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	4.94	2.47e-06	0.00534	0.49	0.41	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
ESCA	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-4.94	2.47e-06	0.00534	-0.46	-0.41	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
ESCA	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-4.94	2.48e-06	0.00535	-0.43	-0.41	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
ESCA	cis	rs765787	0.53	rs4331289	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45223140	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2433228	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45223173	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11854690	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45223818	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs28733848	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45223849	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11854689	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45223854	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1706830	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45224031	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1706831	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45224032	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2433227	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45224921	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2668751	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45225095	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1648286	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45225188	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1706835	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45225686	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1631533	ENSG00000259520.4	CTD-2651B20.3	4.94	2.48e-06	0.00535	0.48	0.41	Uric acid levels;	chr15:45226430	chr15:45251580~45279251:-
ESCA	cis	rs1681630	0.545	rs1228001	ENSG00000280615.1	Y_RNA	-4.94	2.49e-06	0.00538	-0.44	-0.41	Height;	chr11:47965442	chr11:47614898~47614994:-
ESCA	cis	rs1816752	0.905	rs9581026	ENSG00000273628.1	RP11-756A22.7	4.94	2.49e-06	0.00538	0.39	0.41	Obesity-related traits;	chr13:24423788	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs1050112	ENSG00000273628.1	RP11-756A22.7	4.94	2.5e-06	0.00539	0.4	0.41	Obesity-related traits;	chr13:24435159	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs13428	ENSG00000273628.1	RP11-756A22.7	4.94	2.5e-06	0.00539	0.4	0.41	Obesity-related traits;	chr13:24435303	chr13:24933006~24936796:+
ESCA	cis	rs61160187	0.582	rs72757187	ENSG00000215032.2	GNL3LP1	4.94	2.5e-06	0.0054	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967939	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs67490467	ENSG00000215032.2	GNL3LP1	4.94	2.5e-06	0.0054	0.52	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:60967991	chr5:60891935~60893577:-
ESCA	cis	rs9545047	0.567	rs9530896	ENSG00000227676.3	LINC01068	4.94	2.51e-06	0.00542	0.53	0.41	Schizophrenia;	chr13:79335507	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530897	ENSG00000227676.3	LINC01068	4.94	2.51e-06	0.00542	0.53	0.41	Schizophrenia;	chr13:79336420	chr13:79566727~79571436:+
ESCA	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-4.94	2.52e-06	0.00543	-0.47	-0.41	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
ESCA	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-4.94	2.52e-06	0.00543	-0.47	-0.41	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
ESCA	cis	rs9898641	1	rs9898641	ENSG00000266992.1	DHX40P1	4.94	2.52e-06	0.00543	0.49	0.41	Interleukin-1-beta levels;	chr17:59493672	chr17:59976009~60002384:-
ESCA	cis	rs1061377	1	rs9997089	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39119263	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs28465556	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39119569	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs10027813	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39119818	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs9990755	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39119819	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7675782	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120048	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7676008	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120154	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs7677729	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120370	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7655122	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120396	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3796511	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120586	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3733274	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39120957	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs3733275	ENSG00000249685.1	RP11-360F5.3	4.94	2.52e-06	0.00543	0.44	0.41	Uric acid levels;	chr4:39121077	chr4:39133913~39135608:+
ESCA	cis	rs1816752	0.87	rs9581025	ENSG00000273628.1	RP11-756A22.7	4.94	2.53e-06	0.00545	0.39	0.41	Obesity-related traits;	chr13:24423687	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs9581027	ENSG00000273628.1	RP11-756A22.7	4.94	2.53e-06	0.00545	0.39	0.41	Obesity-related traits;	chr13:24423790	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs9318529	ENSG00000273628.1	RP11-756A22.7	4.94	2.53e-06	0.00545	0.39	0.41	Obesity-related traits;	chr13:24424190	chr13:24933006~24936796:+
ESCA	cis	rs765787	0.53	rs2413786	ENSG00000259520.4	CTD-2651B20.3	4.94	2.53e-06	0.00546	0.48	0.41	Uric acid levels;	chr15:45233196	chr15:45251580~45279251:-
ESCA	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	4.94	2.53e-06	0.00546	0.57	0.41	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	4.94	2.53e-06	0.00546	0.57	0.41	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	4.94	2.53e-06	0.00546	0.57	0.41	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	4.94	2.53e-06	0.00546	0.57	0.41	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
ESCA	cis	rs10954779	0.702	rs2737334	ENSG00000253579.1	SUMO2P16	-4.94	2.55e-06	0.00548	-0.45	-0.41	Intelligence (multi-trait analysis);	chr8:31135951	chr8:31131539~31131802:-
ESCA	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-4.93	2.55e-06	0.00548	-0.56	-0.41	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
ESCA	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-4.93	2.55e-06	0.0055	-0.43	-0.41	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
ESCA	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-4.93	2.56e-06	0.00551	-0.6	-0.41	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-4.93	2.56e-06	0.00551	-0.6	-0.41	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
ESCA	cis	rs2221894	1	rs2221894	ENSG00000273710.1	Metazoa_SRP	-4.93	2.56e-06	0.00551	-0.46	-0.41	Obesity-related traits;	chr8:28933642	chr8:28915579~28915864:-
ESCA	cis	rs8059260	1	rs6498138	ENSG00000274038.1	RP11-66H6.4	4.93	2.57e-06	0.00552	0.74	0.41	Alcohol consumption over the past year;	chr16:10951421	chr16:11056556~11057034:+
ESCA	cis	rs9677476	0.516	rs6437001	ENSG00000201574.1	RNU1-93P	-4.93	2.57e-06	0.00553	-0.47	-0.41	Food antigen IgG levels;	chr2:231148590	chr2:231133462~231133630:+
ESCA	cis	rs9549260	0.753	rs9532563	ENSG00000229456.1	RLIMP1	4.93	2.58e-06	0.00554	0.48	0.41	Red blood cell count;	chr13:40586133	chr13:40618738~40621348:+
ESCA	cis	rs61160187	0.582	rs726824	ENSG00000215032.2	GNL3LP1	4.93	2.58e-06	0.00554	0.51	0.41	Educational attainment (years of education);Educational attainment (college completion);	chr5:61036989	chr5:60891935~60893577:-
ESCA	cis	rs7829975	0.714	rs11784052	ENSG00000253981.4	ALG1L13P	4.93	2.58e-06	0.00554	0.45	0.41	Mood instability;	chr8:8814452	chr8:8236003~8244667:-
ESCA	cis	rs2307394	1	rs1128919	ENSG00000223911.1	AC009480.3	4.93	2.59e-06	0.00556	0.48	0.41	Urate levels;	chr2:147899548	chr2:147899401~147902956:-
ESCA	cis	rs7826238	0.653	rs2979202	ENSG00000253981.4	ALG1L13P	4.93	2.6e-06	0.00559	0.52	0.41	Systolic blood pressure;	chr8:8486617	chr8:8236003~8244667:-
ESCA	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	4.93	2.6e-06	0.00559	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
ESCA	cis	rs1816752	0.875	rs1050110	ENSG00000273628.1	RP11-756A22.7	4.93	2.61e-06	0.0056	0.4	0.41	Obesity-related traits;	chr13:24435347	chr13:24933006~24936796:+
ESCA	cis	rs2882667	0.858	rs17207870	ENSG00000253404.1	AC034243.1	4.93	2.61e-06	0.00561	0.57	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139052048	chr5:138744434~138753309:-
ESCA	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	4.93	2.61e-06	0.00561	0.56	0.41	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
ESCA	cis	rs1816752	0.905	rs9511260	ENSG00000273628.1	RP11-756A22.7	4.93	2.62e-06	0.00561	0.39	0.41	Obesity-related traits;	chr13:24437038	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.935	rs4770676	ENSG00000273628.1	RP11-756A22.7	4.93	2.62e-06	0.00561	0.4	0.41	Obesity-related traits;	chr13:24429745	chr13:24933006~24936796:+
ESCA	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	4.93	2.62e-06	0.00562	0.44	0.41	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
ESCA	cis	rs7829975	0.564	rs2921060	ENSG00000253981.4	ALG1L13P	-4.93	2.62e-06	0.00562	-0.51	-0.41	Mood instability;	chr8:8460307	chr8:8236003~8244667:-
ESCA	cis	rs2439831	0.85	rs28513374	ENSG00000249839.1	AC011330.5	-4.93	2.62e-06	0.00562	-0.81	-0.41	Lung cancer in ever smokers;	chr15:43833297	chr15:43663654~43684339:-
ESCA	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-4.93	2.63e-06	0.00564	-0.47	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
ESCA	cis	rs1439620	0.54	rs8042437	ENSG00000271763.1	RP11-386M24.9	4.93	2.63e-06	0.00564	0.41	0.41	Body mass index;	chr15:93004345	chr15:92602910~92620015:+
ESCA	cis	rs2412819	0.571	rs2729494	ENSG00000249839.1	AC011330.5	4.93	2.63e-06	0.00564	0.71	0.41	Lung cancer;	chr15:43837395	chr15:43663654~43684339:-
ESCA	cis	rs6479891	1	rs6479891	ENSG00000235816.3	PRELID1P3	4.93	2.64e-06	0.00565	0.54	0.41	Arthritis (juvenile idiopathic);	chr10:63246696	chr10:63427297~63427939:+
ESCA	cis	rs747650	0.892	rs7111764	ENSG00000271350.1	CTD-2384B9.1	-4.93	2.64e-06	0.00566	-0.47	-0.41	Acne (severe);	chr11:47211658	chr11:47041027~47041945:-
ESCA	cis	rs747650	0.892	rs2029298	ENSG00000271350.1	CTD-2384B9.1	-4.93	2.64e-06	0.00566	-0.47	-0.41	Acne (severe);	chr11:47213167	chr11:47041027~47041945:-
ESCA	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-4.93	2.64e-06	0.00567	-0.48	-0.41	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-4.93	2.64e-06	0.00567	-0.48	-0.41	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-4.93	2.64e-06	0.00567	-0.48	-0.41	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
ESCA	cis	rs9545047	0.604	rs9601227	ENSG00000227676.3	LINC01068	-4.93	2.65e-06	0.00567	-0.53	-0.41	Schizophrenia;	chr13:79420805	chr13:79566727~79571436:+
ESCA	cis	rs61990749	0.597	rs2299930	ENSG00000239272.1	RPL21P10	-4.93	2.65e-06	0.00568	-0.48	-0.41	Fibroblast growth factor basic levels;	chr14:77697379	chr14:77683202~77683989:-
ESCA	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	4.93	2.66e-06	0.00569	0.45	0.41	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
ESCA	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	4.92	2.66e-06	0.00569	0.34	0.41	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
ESCA	cis	rs1816752	0.719	rs11843470	ENSG00000273628.1	RP11-756A22.7	4.92	2.66e-06	0.0057	0.39	0.41	Obesity-related traits;	chr13:24423561	chr13:24933006~24936796:+
ESCA	cis	rs875971	0.825	rs28480509	ENSG00000179406.6	LINC00174	4.92	2.66e-06	0.0057	0.48	0.41	Aortic root size;	chr7:66634237	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs9791712	ENSG00000179406.6	LINC00174	4.92	2.66e-06	0.0057	0.48	0.41	Aortic root size;	chr7:66640176	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs9791713	ENSG00000179406.6	LINC00174	4.92	2.66e-06	0.0057	0.48	0.41	Aortic root size;	chr7:66640211	chr7:66376044~66401338:-
ESCA	cis	rs9322193	0.923	rs6913486	ENSG00000216906.2	RP11-350J20.9	-4.92	2.66e-06	0.0057	-0.54	-0.41	Lung cancer;	chr6:149705060	chr6:149904243~149906418:+
ESCA	cis	rs1061377	1	rs7685082	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39116472	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7664078	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39116583	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.722	rs34803689	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39116665	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs7669376	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39116717	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs9998481	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39117215	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs9998867	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39117542	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs2381284	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39117976	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.803	rs6857761	ENSG00000249685.1	RP11-360F5.3	4.92	2.66e-06	0.0057	0.44	0.41	Uric acid levels;	chr4:39118353	chr4:39133913~39135608:+
ESCA	cis	rs1816752	0.87	rs9581029	ENSG00000273628.1	RP11-756A22.7	4.92	2.66e-06	0.0057	0.39	0.41	Obesity-related traits;	chr13:24425147	chr13:24933006~24936796:+
ESCA	cis	rs10954779	0.537	rs2553277	ENSG00000253579.1	SUMO2P16	-4.92	2.66e-06	0.0057	-0.45	-0.41	Intelligence (multi-trait analysis);	chr8:31134494	chr8:31131539~31131802:-
ESCA	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-4.92	2.67e-06	0.0057	-0.55	-0.41	QT interval;	chr16:28877088	chr16:28700294~28701540:-
ESCA	cis	rs2439831	0.85	rs3736180	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43814426	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28684672	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43815464	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs7183809	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43828670	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs3759790	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43828832	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs7179388	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43831747	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28524541	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43832633	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28564774	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43833277	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs12441984	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43834087	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs7169322	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43838816	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28707214	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43839425	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs61390361	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43867644	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs11856795	ENSG00000249839.1	AC011330.5	-4.92	2.67e-06	0.00571	-0.82	-0.41	Lung cancer in ever smokers;	chr15:43868384	chr15:43663654~43684339:-
ESCA	cis	rs2455601	0.638	rs3815991	ENSG00000254860.4	TMEM9B-AS1	-4.92	2.67e-06	0.00571	-0.64	-0.41	Schizophrenia;	chr11:8986122	chr11:8964675~8977527:+
ESCA	cis	rs9545047	0.604	rs9545104	ENSG00000227676.3	LINC01068	4.92	2.68e-06	0.00573	0.53	0.41	Schizophrenia;	chr13:79404000	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545106	ENSG00000227676.3	LINC01068	4.92	2.68e-06	0.00573	0.53	0.41	Schizophrenia;	chr13:79404130	chr13:79566727~79571436:+
ESCA	cis	rs6479891	1	rs4747045	ENSG00000235816.3	PRELID1P3	4.92	2.68e-06	0.00573	0.52	0.41	Arthritis (juvenile idiopathic);	chr10:63166722	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4466712	ENSG00000235816.3	PRELID1P3	4.92	2.68e-06	0.00573	0.52	0.41	Arthritis (juvenile idiopathic);	chr10:63173508	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs72829170	ENSG00000235816.3	PRELID1P3	4.92	2.68e-06	0.00573	0.52	0.41	Arthritis (juvenile idiopathic);	chr10:63180529	chr10:63427297~63427939:+
ESCA	cis	rs2882667	0.858	rs11951899	ENSG00000253404.1	AC034243.1	4.92	2.68e-06	0.00573	0.58	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139038621	chr5:138744434~138753309:-
ESCA	cis	rs12822507	0.868	rs34051318	ENSG00000275560.1	RP11-180M15.7	-4.92	2.69e-06	0.00574	-0.42	-0.41	Systemic lupus erythematosus;	chr12:12645404	chr12:12718973~12719521:+
ESCA	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	4.92	2.69e-06	0.00575	0.44	0.41	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
ESCA	cis	rs1816752	0.905	rs9511242	ENSG00000273628.1	RP11-756A22.7	4.92	2.7e-06	0.00576	0.38	0.41	Obesity-related traits;	chr13:24419261	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs7317850	ENSG00000273628.1	RP11-756A22.7	4.92	2.7e-06	0.00576	0.38	0.41	Obesity-related traits;	chr13:24419899	chr13:24933006~24936796:+
ESCA	cis	rs1816752	1	rs7326932	ENSG00000273628.1	RP11-756A22.7	4.92	2.7e-06	0.00577	0.39	0.41	Obesity-related traits;	chr13:24430355	chr13:24933006~24936796:+
ESCA	cis	rs6782228	0.527	rs2811491	ENSG00000277250.1	Metazoa_SRP	-4.92	2.7e-06	0.00577	-0.48	-0.41	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128673681~128674021:-
ESCA	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.92	2.7e-06	0.00577	0.5	0.41	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
ESCA	cis	rs2439831	0.867	rs3101443	ENSG00000249839.1	AC011330.5	-4.92	2.71e-06	0.00579	-0.76	-0.41	Lung cancer in ever smokers;	chr15:43620174	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2614811	ENSG00000249839.1	AC011330.5	-4.92	2.71e-06	0.00579	-0.76	-0.41	Lung cancer in ever smokers;	chr15:43621289	chr15:43663654~43684339:-
ESCA	cis	rs9545047	0.604	rs9318640	ENSG00000227676.3	LINC01068	-4.92	2.72e-06	0.0058	-0.53	-0.41	Schizophrenia;	chr13:79426527	chr13:79566727~79571436:+
ESCA	cis	rs950880	0.71	rs67723747	ENSG00000234389.1	AC007278.3	-4.92	2.73e-06	0.00582	-0.38	-0.41	Serum protein levels (sST2);	chr2:102353347	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs56386507	ENSG00000234389.1	AC007278.3	-4.92	2.73e-06	0.00582	-0.38	-0.41	Serum protein levels (sST2);	chr2:102354705	chr2:102438713~102440475:+
ESCA	cis	rs10875746	0.951	rs8804	ENSG00000240399.1	RP1-228P16.1	-4.92	2.74e-06	0.00583	-0.48	-0.41	Longevity (90 years and older);	chr12:48147974	chr12:48054813~48055591:-
ESCA	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-4.92	2.75e-06	0.00585	-0.43	-0.41	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-4.92	2.75e-06	0.00585	-0.43	-0.41	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-4.92	2.75e-06	0.00585	-0.43	-0.41	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-4.92	2.75e-06	0.00585	-0.43	-0.41	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
ESCA	cis	rs2882667	0.858	rs11956159	ENSG00000253404.1	AC034243.1	4.92	2.76e-06	0.00586	0.58	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139072879	chr5:138744434~138753309:-
ESCA	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-4.92	2.76e-06	0.00587	-0.6	-0.41	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
ESCA	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	4.92	2.76e-06	0.00588	0.43	0.41	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000228039.3	KB-1125A3.10	-4.92	2.77e-06	0.00588	-0.54	-0.41	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23963780~23964374:+
ESCA	cis	rs9595066	0.712	rs4391951	ENSG00000227258.4	SMIM2-AS1	-4.92	2.77e-06	0.00589	-0.58	-0.41	Schizophrenia;	chr13:44180935	chr13:44110451~44240517:+
ESCA	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	4.92	2.77e-06	0.00589	0.41	0.41	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-4.92	2.77e-06	0.00589	-0.4	-0.41	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
ESCA	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-4.92	2.77e-06	0.00589	-0.4	-0.41	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
ESCA	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-4.92	2.77e-06	0.00589	-0.43	-0.41	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-4.92	2.77e-06	0.00589	-0.43	-0.41	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
ESCA	cis	rs7829975	0.593	rs2921077	ENSG00000173295.6	FAM86B3P	4.91	2.77e-06	0.00589	0.43	0.41	Mood instability;	chr8:8446992	chr8:8228595~8244865:+
ESCA	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-4.91	2.78e-06	0.0059	-0.49	-0.41	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-4.91	2.78e-06	0.0059	-0.49	-0.41	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
ESCA	cis	rs67180937	0.844	rs4846384	ENSG00000272750.1	RP11-378J18.8	-4.91	2.78e-06	0.00591	-0.47	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222624272	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.882	rs17163313	ENSG00000272750.1	RP11-378J18.8	-4.91	2.78e-06	0.00591	-0.47	-0.41	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222626283	chr1:222658867~222661512:-
ESCA	cis	rs1061377	1	rs10026775	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115155	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3733276	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115291	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3733277	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115483	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3733278	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115615	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs3733279	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115625	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs10018049	ENSG00000249685.1	RP11-360F5.3	4.91	2.78e-06	0.00591	0.44	0.41	Uric acid levels;	chr4:39115781	chr4:39133913~39135608:+
ESCA	cis	rs2221894	1	rs2137471	ENSG00000273710.1	Metazoa_SRP	-4.91	2.78e-06	0.00591	-0.46	-0.41	Obesity-related traits;	chr8:28948132	chr8:28915579~28915864:-
ESCA	cis	rs2221894	1	rs2292478	ENSG00000273710.1	Metazoa_SRP	-4.91	2.78e-06	0.00591	-0.46	-0.41	Obesity-related traits;	chr8:28949839	chr8:28915579~28915864:-
ESCA	cis	rs6479891	1	rs11817689	ENSG00000235816.3	PRELID1P3	-4.91	2.78e-06	0.00591	-0.51	-0.41	Arthritis (juvenile idiopathic);	chr10:63164457	chr10:63427297~63427939:+
ESCA	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	4.91	2.79e-06	0.00593	0.44	0.41	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
ESCA	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	4.91	2.8e-06	0.00593	0.47	0.41	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	4.91	2.8e-06	0.00593	0.47	0.41	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	4.91	2.8e-06	0.00594	0.5	0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
ESCA	cis	rs2742234	0.759	rs12241923	ENSG00000273008.1	RP11-351D16.3	4.91	2.8e-06	0.00595	0.44	0.4	Hirschsprung disease;	chr10:43217599	chr10:43136824~43138334:-
ESCA	cis	rs765787	0.53	rs2433229	ENSG00000259520.4	CTD-2651B20.3	4.91	2.8e-06	0.00595	0.48	0.4	Uric acid levels;	chr15:45223037	chr15:45251580~45279251:-
ESCA	cis	rs7829975	0.846	rs1879957	ENSG00000253981.4	ALG1L13P	-4.91	2.81e-06	0.00596	-0.47	-0.4	Mood instability;	chr8:8687298	chr8:8236003~8244667:-
ESCA	cis	rs2627019	0.51	rs13013887	ENSG00000223911.1	AC009480.3	4.91	2.81e-06	0.00597	0.48	0.4	Neuroticism;	chr2:148068211	chr2:147899401~147902956:-
ESCA	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.91	2.81e-06	0.00597	0.57	0.4	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
ESCA	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	4.91	2.81e-06	0.00597	0.57	0.4	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
ESCA	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-4.91	2.82e-06	0.00598	-0.49	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
ESCA	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	4.91	2.83e-06	0.00599	0.47	0.4	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
ESCA	cis	rs1816752	1	rs7988810	ENSG00000273628.1	RP11-756A22.7	4.91	2.83e-06	0.006	0.39	0.4	Obesity-related traits;	chr13:24444958	chr13:24933006~24936796:+
ESCA	cis	rs858239	0.636	rs28706766	ENSG00000230042.1	AK3P3	-4.91	2.85e-06	0.00603	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23129178~23129841:+
ESCA	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-4.91	2.85e-06	0.00604	-0.49	-0.4	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
ESCA	cis	rs1816752	0.905	rs4769348	ENSG00000273628.1	RP11-756A22.7	4.91	2.85e-06	0.00604	0.39	0.4	Obesity-related traits;	chr13:24400975	chr13:24933006~24936796:+
ESCA	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-4.91	2.86e-06	0.00604	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
ESCA	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	4.91	2.86e-06	0.00606	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
ESCA	cis	rs1816752	0.905	rs4770666	ENSG00000273628.1	RP11-756A22.7	4.91	2.87e-06	0.00608	0.38	0.4	Obesity-related traits;	chr13:24414891	chr13:24933006~24936796:+
ESCA	cis	rs9987353	0.566	rs34389718	ENSG00000253981.4	ALG1L13P	-4.91	2.88e-06	0.00609	-0.53	-0.4	Recombination measurement;	chr8:9208015	chr8:8236003~8244667:-
ESCA	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	4.91	2.88e-06	0.00609	0.52	0.4	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
ESCA	cis	rs2307394	1	rs3768689	ENSG00000223911.1	AC009480.3	4.91	2.89e-06	0.0061	0.47	0.4	Urate levels;	chr2:147912205	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs3768687	ENSG00000223911.1	AC009480.3	4.91	2.89e-06	0.0061	0.47	0.4	Urate levels;	chr2:147914451	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13026650	ENSG00000223911.1	AC009480.3	4.91	2.89e-06	0.0061	0.47	0.4	Urate levels;	chr2:147916632	chr2:147899401~147902956:-
ESCA	cis	rs6479891	0.524	rs10740107	ENSG00000235816.3	PRELID1P3	-4.91	2.89e-06	0.0061	-0.52	-0.4	Arthritis (juvenile idiopathic);	chr10:63184557	chr10:63427297~63427939:+
ESCA	cis	rs11169552	0.51	rs4768912	ENSG00000200428.1	Y_RNA	4.91	2.89e-06	0.00611	0.5	0.4	Colorectal cancer;	chr12:50742157	chr12:50743568~50743684:+
ESCA	cis	rs2739330	0.796	rs5760106	ENSG00000228039.3	KB-1125A3.10	-4.9	2.89e-06	0.00611	-0.52	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23963780~23964374:+
ESCA	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	4.9	2.9e-06	0.00612	0.72	0.4	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
ESCA	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-4.9	2.9e-06	0.00612	-0.43	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
ESCA	cis	rs950880	0.71	rs3771172	ENSG00000234389.1	AC007278.3	-4.9	2.9e-06	0.00613	-0.38	-0.4	Serum protein levels (sST2);	chr2:102369352	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3771171	ENSG00000234389.1	AC007278.3	-4.9	2.9e-06	0.00613	-0.38	-0.4	Serum protein levels (sST2);	chr2:102369490	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs2160202	ENSG00000234389.1	AC007278.3	-4.9	2.9e-06	0.00613	-0.38	-0.4	Serum protein levels (sST2);	chr2:102369694	chr2:102438713~102440475:+
ESCA	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	4.9	2.91e-06	0.00613	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
ESCA	cis	rs12480328	1	rs78860779	ENSG00000228663.1	PSMD10P1	4.9	2.91e-06	0.00615	0.48	0.4	Prostate cancer;	chr20:50910834	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs12480328	ENSG00000228663.1	PSMD10P1	4.9	2.91e-06	0.00615	0.48	0.4	Prostate cancer;	chr20:50911385	chr20:50913731~50914411:+
ESCA	cis	rs950880	0.71	rs12905	ENSG00000234389.1	AC007278.3	-4.9	2.92e-06	0.00615	-0.38	-0.4	Serum protein levels (sST2);	chr2:102343547	chr2:102438713~102440475:+
ESCA	cis	rs765787	0.53	rs3759895	ENSG00000259520.4	CTD-2651B20.3	4.9	2.92e-06	0.00617	0.46	0.4	Uric acid levels;	chr15:45251672	chr15:45251580~45279251:-
ESCA	cis	rs1061377	0.965	rs6833654	ENSG00000249685.1	RP11-360F5.3	4.9	2.93e-06	0.00617	0.44	0.4	Uric acid levels;	chr4:39110701	chr4:39133913~39135608:+
ESCA	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	4.9	2.94e-06	0.00619	0.51	0.4	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
ESCA	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	4.9	2.94e-06	0.0062	0.45	0.4	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	4.9	2.94e-06	0.0062	0.45	0.4	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	4.9	2.94e-06	0.0062	0.45	0.4	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
ESCA	cis	rs9549260	0.753	rs2297628	ENSG00000229456.1	RLIMP1	4.9	2.94e-06	0.0062	0.5	0.4	Red blood cell count;	chr13:40659768	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.753	rs9532578	ENSG00000229456.1	RLIMP1	4.9	2.94e-06	0.0062	0.5	0.4	Red blood cell count;	chr13:40662270	chr13:40618738~40621348:+
ESCA	cis	rs2505998	0.957	rs2435366	ENSG00000273008.1	RP11-351D16.3	-4.9	2.95e-06	0.00621	-0.46	-0.4	Hirschsprung disease;	chr10:43076540	chr10:43136824~43138334:-
ESCA	cis	rs2505998	1	rs1864410	ENSG00000273008.1	RP11-351D16.3	-4.9	2.95e-06	0.00621	-0.46	-0.4	Hirschsprung disease;	chr10:43080177	chr10:43136824~43138334:-
ESCA	cis	rs875971	0.666	rs13242072	ENSG00000179406.6	LINC00174	4.9	2.95e-06	0.00622	0.47	0.4	Aortic root size;	chr7:66301001	chr7:66376044~66401338:-
ESCA	cis	rs1031391	0.716	rs10772416	ENSG00000247157.5	LINC01252	-4.9	2.95e-06	0.00622	-0.53	-0.4	Bitter taste perception;	chr12:11017488	chr12:11548030~11590369:+
ESCA	cis	rs67180937	0.844	rs4846770	ENSG00000272750.1	RP11-378J18.8	-4.9	2.96e-06	0.00623	-0.5	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222622227	chr1:222658867~222661512:-
ESCA	cis	rs394563	0.591	rs6570963	ENSG00000231760.4	RP11-350J20.5	-4.9	2.96e-06	0.00623	-0.47	-0.4	Dupuytren's disease;	chr6:149370219	chr6:149796151~149826294:-
ESCA	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	4.9	2.97e-06	0.00625	0.43	0.4	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
ESCA	cis	rs7714584	1	rs1428555	ENSG00000197083.10	ZNF300P1	-4.9	2.97e-06	0.00626	-0.64	-0.4	Crohn's disease;	chr5:150877829	chr5:150930645~150946289:-
ESCA	cis	rs4535700	0.501	rs2135116	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55923451	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.543	rs2174459	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55923600	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs57153841	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55927400	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.504	rs66528253	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55929070	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs11765577	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55930245	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs28678267	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55941797	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs11765531	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55942594	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs10227764	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55944729	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs60517461	ENSG00000273720.1	RP11-613E4.4	4.9	2.99e-06	0.00627	0.5	0.4	Macular telangiectasia type 2;	chr7:55949952	chr7:55743073~55743457:+
ESCA	cis	rs11169552	0.51	rs12231309	ENSG00000200428.1	Y_RNA	4.9	2.99e-06	0.00628	0.49	0.4	Colorectal cancer;	chr12:50647279	chr12:50743568~50743684:+
ESCA	cis	rs1577917	0.687	rs34618171	ENSG00000203875.9	SNHG5	-4.9	2.99e-06	0.00628	-0.57	-0.4	Response to antipsychotic treatment;	chr6:86101447	chr6:85660950~85678736:-
ESCA	cis	rs4535700	0.501	rs2135116	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55923451	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.543	rs2174459	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55923600	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs57153841	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55927400	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.504	rs66528253	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55929070	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs11765577	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55930245	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs28678267	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55941797	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs11765531	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55942594	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs10227764	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55944729	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs60517461	ENSG00000226278.1	PSPHP1	4.9	2.99e-06	0.00629	0.53	0.4	Macular telangiectasia type 2;	chr7:55949952	chr7:55764797~55773288:+
ESCA	cis	rs6479901	0.639	rs871690	ENSG00000235816.3	PRELID1P3	-4.9	2.99e-06	0.00629	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:63134299	chr10:63427297~63427939:+
ESCA	cis	rs2439831	0.764	rs2447193	ENSG00000249839.1	AC011330.5	-4.9	3e-06	0.00629	-0.7	-0.4	Lung cancer in ever smokers;	chr15:43637535	chr15:43663654~43684339:-
ESCA	cis	rs12480328	1	rs16995626	ENSG00000228663.1	PSMD10P1	4.9	3e-06	0.00629	0.48	0.4	Prostate cancer;	chr20:50924388	chr20:50913731~50914411:+
ESCA	cis	rs10754283	0.967	rs6663363	ENSG00000231613.1	RP5-943J3.1	4.9	3e-06	0.00629	0.44	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89651295	chr1:89788914~89790492:+
ESCA	cis	rs2108622	0.527	rs67617968	ENSG00000267453.5	AC004791.2	-4.9	3e-06	0.0063	-0.48	-0.4	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866755	chr19:15851993~15864904:-
ESCA	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-4.9	3.01e-06	0.0063	-0.44	-0.4	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-4.9	3.01e-06	0.0063	-0.44	-0.4	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
ESCA	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-4.9	3.01e-06	0.00631	-0.52	-0.4	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
ESCA	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-4.89	3.02e-06	0.00633	-0.5	-0.4	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
ESCA	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	4.89	3.02e-06	0.00634	0.58	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
ESCA	cis	rs10995505	0.589	rs1553789	ENSG00000235816.3	PRELID1P3	4.89	3.03e-06	0.00634	0.43	0.4	Intelligence (multi-trait analysis);	chr10:63119469	chr10:63427297~63427939:+
ESCA	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-4.89	3.04e-06	0.00637	-0.6	-0.4	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
ESCA	cis	rs4535700	0.501	rs9642405	ENSG00000226278.1	PSPHP1	4.89	3.04e-06	0.00637	0.52	0.4	Macular telangiectasia type 2;	chr7:55910473	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs57251705	ENSG00000226278.1	PSPHP1	4.89	3.04e-06	0.00637	0.52	0.4	Macular telangiectasia type 2;	chr7:55913390	chr7:55764797~55773288:+
ESCA	cis	rs4535700	0.501	rs28828764	ENSG00000226278.1	PSPHP1	4.89	3.04e-06	0.00637	0.52	0.4	Macular telangiectasia type 2;	chr7:55920986	chr7:55764797~55773288:+
ESCA	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	4.89	3.05e-06	0.00638	0.44	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
ESCA	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	4.89	3.05e-06	0.00639	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	4.89	3.05e-06	0.00639	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
ESCA	cis	rs6479901	0.696	rs931972	ENSG00000235816.3	PRELID1P3	-4.89	3.06e-06	0.0064	-0.45	-0.4	Intelligence (multi-trait analysis);	chr10:63150467	chr10:63427297~63427939:+
ESCA	cis	rs875971	0.628	rs6974355	ENSG00000179406.6	LINC00174	-4.89	3.08e-06	0.00644	-0.47	-0.4	Aortic root size;	chr7:66376994	chr7:66376044~66401338:-
ESCA	cis	rs6538678	0.746	rs703693	ENSG00000258343.1	RP11-536G4.2	-4.89	3.08e-06	0.00644	-0.49	-0.4	Lupus nephritis in systemic lupus erythematosus;	chr12:95866214	chr12:95795345~95858839:-
ESCA	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-4.89	3.08e-06	0.00644	-0.47	-0.4	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
ESCA	cis	rs9545047	0.519	rs8001281	ENSG00000227676.3	LINC01068	4.89	3.09e-06	0.00645	0.53	0.4	Schizophrenia;	chr13:79410707	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.511	rs1624537	ENSG00000227676.3	LINC01068	4.89	3.09e-06	0.00645	0.53	0.4	Schizophrenia;	chr13:79411686	chr13:79566727~79571436:+
ESCA	cis	rs1816752	0.837	rs7324645	ENSG00000273628.1	RP11-756A22.7	4.89	3.1e-06	0.00646	0.39	0.4	Obesity-related traits;	chr13:24426717	chr13:24933006~24936796:+
ESCA	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-4.89	3.1e-06	0.00647	-0.44	-0.4	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
ESCA	cis	rs9545047	0.625	rs9545109	ENSG00000227676.3	LINC01068	4.89	3.1e-06	0.00647	0.53	0.4	Schizophrenia;	chr13:79413480	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.518	rs7328494	ENSG00000227676.3	LINC01068	4.89	3.1e-06	0.00647	0.53	0.4	Schizophrenia;	chr13:79414673	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2147568	ENSG00000227676.3	LINC01068	4.89	3.1e-06	0.00647	0.53	0.4	Schizophrenia;	chr13:79417091	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530917	ENSG00000227676.3	LINC01068	4.89	3.1e-06	0.00647	0.53	0.4	Schizophrenia;	chr13:79417719	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7990321	ENSG00000227676.3	LINC01068	4.89	3.1e-06	0.00647	0.53	0.4	Schizophrenia;	chr13:79418066	chr13:79566727~79571436:+
ESCA	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-4.89	3.11e-06	0.00649	-0.48	-0.4	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
ESCA	cis	rs765787	0.53	rs28526629	ENSG00000259520.4	CTD-2651B20.3	4.89	3.11e-06	0.00649	0.45	0.4	Uric acid levels;	chr15:45248264	chr15:45251580~45279251:-
ESCA	cis	rs6479891	1	rs9415705	ENSG00000235816.3	PRELID1P3	4.89	3.11e-06	0.0065	0.52	0.4	Arthritis (juvenile idiopathic);	chr10:63401790	chr10:63427297~63427939:+
ESCA	cis	rs950880	0.645	rs11679889	ENSG00000234389.1	AC007278.3	-4.89	3.12e-06	0.00651	-0.38	-0.4	Serum protein levels (sST2);	chr2:102324549	chr2:102438713~102440475:+
ESCA	cis	rs1816752	1	rs9511265	ENSG00000273628.1	RP11-756A22.7	4.89	3.13e-06	0.00652	0.39	0.4	Obesity-related traits;	chr13:24438221	chr13:24933006~24936796:+
ESCA	cis	rs394563	0.559	rs13219868	ENSG00000231760.4	RP11-350J20.5	-4.89	3.13e-06	0.00653	-0.47	-0.4	Dupuytren's disease;	chr6:149365382	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.591	rs6570964	ENSG00000231760.4	RP11-350J20.5	-4.89	3.13e-06	0.00653	-0.47	-0.4	Dupuytren's disease;	chr6:149370723	chr6:149796151~149826294:-
ESCA	cis	rs1816752	0.935	rs3816219	ENSG00000273628.1	RP11-756A22.7	4.89	3.13e-06	0.00653	0.39	0.4	Obesity-related traits;	chr13:24442995	chr13:24933006~24936796:+
ESCA	cis	rs1075265	0.749	rs805379	ENSG00000235937.1	AC008280.1	4.89	3.14e-06	0.00653	0.46	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54029552~54030682:-
ESCA	cis	rs2439831	0.717	rs28495368	ENSG00000249839.1	AC011330.5	-4.89	3.14e-06	0.00654	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43603444	chr15:43663654~43684339:-
ESCA	cis	rs7829975	0.511	rs2980426	ENSG00000253981.4	ALG1L13P	4.89	3.14e-06	0.00655	0.53	0.4	Mood instability;	chr8:8288087	chr8:8236003~8244667:-
ESCA	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	4.89	3.15e-06	0.00655	0.43	0.4	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
ESCA	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	4.88	3.15e-06	0.00657	0.54	0.4	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
ESCA	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-4.88	3.16e-06	0.00657	-0.47	-0.4	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
ESCA	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-4.88	3.17e-06	0.00659	-0.46	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
ESCA	cis	rs6538678	0.963	rs11108310	ENSG00000258343.1	RP11-536G4.2	-4.88	3.17e-06	0.00659	-0.47	-0.4	Lupus nephritis in systemic lupus erythematosus;	chr12:95864164	chr12:95795345~95858839:-
ESCA	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	4.88	3.17e-06	0.00659	0.56	0.4	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
ESCA	cis	rs4713675	0.584	rs560111	ENSG00000186328.4	RP11-140K17.2	-4.88	3.17e-06	0.0066	-0.49	-0.4	Plateletcrit;	chr6:33738500	chr6:34715613~34715940:+
ESCA	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	4.88	3.18e-06	0.00662	0.39	0.4	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
ESCA	cis	rs9733	0.65	rs12125672	ENSG00000206931.1	RNU6-1042P	-4.88	3.19e-06	0.00663	-0.48	-0.4	Tonsillectomy;	chr1:150581994	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.65	rs61820165	ENSG00000206931.1	RNU6-1042P	-4.88	3.19e-06	0.00663	-0.48	-0.4	Tonsillectomy;	chr1:150583511	chr1:150701866~150701972:+
ESCA	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	4.88	3.19e-06	0.00663	0.7	0.4	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
ESCA	cis	rs7829975	0.742	rs7832968	ENSG00000253981.4	ALG1L13P	4.88	3.2e-06	0.00665	0.48	0.4	Mood instability;	chr8:8795379	chr8:8236003~8244667:-
ESCA	cis	rs7849270	1	rs6478867	ENSG00000268707.1	RP11-247A12.7	4.88	3.21e-06	0.00666	0.46	0.4	Blood metabolite ratios;	chr9:129141644	chr9:129170434~129170940:+
ESCA	cis	rs765787	0.53	rs28815867	ENSG00000259520.4	CTD-2651B20.3	4.88	3.22e-06	0.00668	0.47	0.4	Uric acid levels;	chr15:45234607	chr15:45251580~45279251:-
ESCA	cis	rs2505998	0.787	rs28502801	ENSG00000273008.1	RP11-351D16.3	-4.88	3.22e-06	0.00668	-0.45	-0.4	Hirschsprung disease;	chr10:43088591	chr10:43136824~43138334:-
ESCA	cis	rs950880	0.71	rs17027006	ENSG00000234389.1	AC007278.3	4.88	3.22e-06	0.00669	0.38	0.4	Serum protein levels (sST2);	chr2:102348872	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs3821204	ENSG00000234389.1	AC007278.3	-4.88	3.22e-06	0.00669	-0.38	-0.4	Serum protein levels (sST2);	chr2:102343821	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.71	rs12469506	ENSG00000234389.1	AC007278.3	-4.88	3.22e-06	0.00669	-0.38	-0.4	Serum protein levels (sST2);	chr2:102349411	chr2:102438713~102440475:+
ESCA	cis	rs875971	0.558	rs4433015	ENSG00000179406.6	LINC00174	4.88	3.23e-06	0.00669	0.47	0.4	Aortic root size;	chr7:66174736	chr7:66376044~66401338:-
ESCA	cis	rs2882667	0.858	rs11949916	ENSG00000253404.1	AC034243.1	4.88	3.24e-06	0.00672	0.58	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139060588	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.822	rs11738376	ENSG00000253404.1	AC034243.1	4.88	3.24e-06	0.00672	0.58	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139062483	chr5:138744434~138753309:-
ESCA	cis	rs2882667	0.822	rs13187096	ENSG00000253404.1	AC034243.1	4.88	3.24e-06	0.00672	0.58	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139068399	chr5:138744434~138753309:-
ESCA	cis	rs9549260	0.755	rs4941987	ENSG00000229456.1	RLIMP1	4.88	3.27e-06	0.00676	0.37	0.4	Red blood cell count;	chr13:40621855	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.683	rs4941988	ENSG00000229456.1	RLIMP1	4.88	3.27e-06	0.00676	0.37	0.4	Red blood cell count;	chr13:40621869	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.64	rs4943796	ENSG00000229456.1	RLIMP1	4.88	3.27e-06	0.00676	0.37	0.4	Red blood cell count;	chr13:40621879	chr13:40618738~40621348:+
ESCA	cis	rs12682352	0.715	rs332039	ENSG00000253981.4	ALG1L13P	4.88	3.28e-06	0.00678	0.5	0.4	Neuroticism;	chr8:8866141	chr8:8236003~8244667:-
ESCA	cis	rs1723838	1	rs1792164	ENSG00000255928.1	RP11-456I15.2	4.88	3.28e-06	0.00679	0.94	0.4	Obesity-related traits;	chr11:73837625	chr11:73722349~73722694:+
ESCA	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-4.88	3.29e-06	0.00679	-0.48	-0.4	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
ESCA	cis	rs12822507	0.868	rs12580006	ENSG00000275560.1	RP11-180M15.7	-4.87	3.29e-06	0.0068	-0.41	-0.4	Systemic lupus erythematosus;	chr12:12636712	chr12:12718973~12719521:+
ESCA	cis	rs2505998	0.833	rs2565203	ENSG00000273008.1	RP11-351D16.3	-4.87	3.29e-06	0.00681	-0.44	-0.4	Hirschsprung disease;	chr10:43108287	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs1864405	ENSG00000273008.1	RP11-351D16.3	-4.87	3.29e-06	0.00681	-0.44	-0.4	Hirschsprung disease;	chr10:43108700	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs1864404	ENSG00000273008.1	RP11-351D16.3	-4.87	3.29e-06	0.00681	-0.44	-0.4	Hirschsprung disease;	chr10:43108942	chr10:43136824~43138334:-
ESCA	cis	rs2739330	0.892	rs5751776	ENSG00000272787.1	KB-226F1.2	-4.87	3.3e-06	0.00682	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23969211~23969873:+
ESCA	cis	rs2739330	0.929	rs5751777	ENSG00000272787.1	KB-226F1.2	-4.87	3.3e-06	0.00682	-0.48	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23969211~23969873:+
ESCA	cis	rs2439831	0.85	rs68079546	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43844759	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs56909447	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43845420	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28476182	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43847445	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28696802	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43848197	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28413704	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43856229	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.702	rs16977724	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43859101	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.702	rs9989313	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43860619	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs28858500	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43864744	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs3742982	ENSG00000249839.1	AC011330.5	-4.87	3.31e-06	0.00684	-0.8	-0.4	Lung cancer in ever smokers;	chr15:43884483	chr15:43663654~43684339:-
ESCA	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-4.87	3.31e-06	0.00684	-0.47	-0.4	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
ESCA	cis	rs11169552	0.51	rs10783382	ENSG00000200428.1	Y_RNA	4.87	3.32e-06	0.00685	0.48	0.4	Colorectal cancer;	chr12:50661167	chr12:50743568~50743684:+
ESCA	cis	rs67180937	0.774	rs3748626	ENSG00000272750.1	RP11-378J18.8	-4.87	3.32e-06	0.00686	-0.46	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222629461	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.882	rs17163345	ENSG00000272750.1	RP11-378J18.8	-4.87	3.32e-06	0.00686	-0.46	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632876	chr1:222658867~222661512:-
ESCA	cis	rs2439831	0.85	rs16950562	ENSG00000205771.5	CATSPER2P1	-4.87	3.33e-06	0.00687	-0.73	-0.4	Lung cancer in ever smokers;	chr15:43744166	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs12441861	ENSG00000205771.5	CATSPER2P1	-4.87	3.33e-06	0.00687	-0.73	-0.4	Lung cancer in ever smokers;	chr15:43768685	chr15:43726918~43747094:-
ESCA	cis	rs9545047	0.625	rs7338170	ENSG00000227676.3	LINC01068	-4.87	3.33e-06	0.00687	-0.53	-0.4	Schizophrenia;	chr13:79286030	chr13:79566727~79571436:+
ESCA	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-4.87	3.34e-06	0.00688	-0.47	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
ESCA	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-4.87	3.34e-06	0.00688	-0.47	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
ESCA	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-4.87	3.34e-06	0.00688	-0.47	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
ESCA	cis	rs2638953	0.64	rs1511549	ENSG00000247934.4	RP11-967K21.1	-4.87	3.34e-06	0.00689	-0.46	-0.4	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28578968	chr12:28163298~28190738:-
ESCA	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	4.87	3.34e-06	0.00689	0.43	0.4	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
ESCA	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-4.87	3.34e-06	0.00689	-0.68	-0.4	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
ESCA	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	4.87	3.35e-06	0.0069	0.43	0.4	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
ESCA	cis	rs2179367	0.959	rs9373589	ENSG00000216906.2	RP11-350J20.9	4.87	3.35e-06	0.00691	0.51	0.4	Dupuytren's disease;	chr6:149386152	chr6:149904243~149906418:+
ESCA	cis	rs9545047	0.604	rs2265381	ENSG00000227676.3	LINC01068	-4.87	3.35e-06	0.00691	-0.53	-0.4	Schizophrenia;	chr13:79425903	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2265382	ENSG00000227676.3	LINC01068	-4.87	3.35e-06	0.00691	-0.53	-0.4	Schizophrenia;	chr13:79426196	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2477395	ENSG00000227676.3	LINC01068	-4.87	3.35e-06	0.00691	-0.53	-0.4	Schizophrenia;	chr13:79427679	chr13:79566727~79571436:+
ESCA	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-4.87	3.37e-06	0.00694	-0.47	-0.4	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
ESCA	cis	rs1075265	0.62	rs2542584	ENSG00000235937.1	AC008280.1	4.87	3.37e-06	0.00694	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54029552~54030682:-
ESCA	cis	rs2739330	0.929	rs5751775	ENSG00000272787.1	KB-226F1.2	-4.87	3.37e-06	0.00694	-0.47	-0.4	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23969211~23969873:+
ESCA	cis	rs9545047	0.604	rs9565483	ENSG00000227676.3	LINC01068	-4.87	3.38e-06	0.00696	-0.53	-0.4	Schizophrenia;	chr13:79294001	chr13:79566727~79571436:+
ESCA	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	4.87	3.38e-06	0.00696	0.37	0.4	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
ESCA	cis	rs9545047	0.532	rs9545079	ENSG00000227676.3	LINC01068	4.87	3.38e-06	0.00697	0.52	0.4	Schizophrenia;	chr13:79346044	chr13:79566727~79571436:+
ESCA	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-4.87	3.39e-06	0.00698	-0.47	-0.4	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
ESCA	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	4.87	3.4e-06	0.00699	0.59	0.4	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
ESCA	cis	rs2882667	0.858	rs11242447	ENSG00000253404.1	AC034243.1	4.87	3.4e-06	0.007	0.58	0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139090484	chr5:138744434~138753309:-
ESCA	cis	rs6479891	1	rs7070052	ENSG00000235816.3	PRELID1P3	-4.87	3.4e-06	0.007	-0.51	-0.4	Arthritis (juvenile idiopathic);	chr10:63144054	chr10:63427297~63427939:+
ESCA	cis	rs394563	0.591	rs237035	ENSG00000231760.4	RP11-350J20.5	4.87	3.4e-06	0.007	0.47	0.4	Dupuytren's disease;	chr6:149389712	chr6:149796151~149826294:-
ESCA	cis	rs1816752	0.87	rs7320102	ENSG00000273628.1	RP11-756A22.7	4.87	3.4e-06	0.007	0.39	0.4	Obesity-related traits;	chr13:24437435	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs7339140	ENSG00000273628.1	RP11-756A22.7	4.87	3.4e-06	0.007	0.39	0.4	Obesity-related traits;	chr13:24437764	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs9511261	ENSG00000273628.1	RP11-756A22.7	4.87	3.4e-06	0.007	0.39	0.4	Obesity-related traits;	chr13:24437880	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs9511262	ENSG00000273628.1	RP11-756A22.7	4.87	3.4e-06	0.007	0.39	0.4	Obesity-related traits;	chr13:24437885	chr13:24933006~24936796:+
ESCA	cis	rs1075232	1	rs9672214	ENSG00000270055.1	CTD-3092A11.2	-4.87	3.4e-06	0.007	-0.94	-0.4	Survival in colorectal cancer (non-distant metastatic);	chr15:31385572	chr15:30487963~30490313:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000250470.1	AP000351.3	-4.87	3.4e-06	0.007	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23976904~23977585:-
ESCA	cis	rs2742234	0.578	rs2742241	ENSG00000273008.1	RP11-351D16.3	-4.87	3.41e-06	0.00701	-0.48	-0.4	Hirschsprung disease;	chr10:43129775	chr10:43136824~43138334:-
ESCA	cis	rs765787	0.53	rs13329228	ENSG00000259520.4	CTD-2651B20.3	4.87	3.41e-06	0.00701	0.45	0.4	Uric acid levels;	chr15:45240819	chr15:45251580~45279251:-
ESCA	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-4.87	3.41e-06	0.00701	-0.54	-0.4	QT interval;	chr16:28857143	chr16:28700294~28701540:-
ESCA	cis	rs2742234	0.541	rs10899786	ENSG00000273008.1	RP11-351D16.3	4.87	3.41e-06	0.00702	0.48	0.4	Hirschsprung disease;	chr10:43249135	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs61845684	ENSG00000273008.1	RP11-351D16.3	4.87	3.41e-06	0.00702	0.48	0.4	Hirschsprung disease;	chr10:43249535	chr10:43136824~43138334:-
ESCA	cis	rs12480328	1	rs73909841	ENSG00000228663.1	PSMD10P1	4.87	3.42e-06	0.00702	0.49	0.4	Prostate cancer;	chr20:50932270	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs73909842	ENSG00000228663.1	PSMD10P1	4.87	3.42e-06	0.00702	0.49	0.4	Prostate cancer;	chr20:50934277	chr20:50913731~50914411:+
ESCA	cis	rs9733	0.65	rs2048558	ENSG00000206931.1	RNU6-1042P	-4.87	3.43e-06	0.00704	-0.48	-0.4	Tonsillectomy;	chr1:150599254	chr1:150701866~150701972:+
ESCA	cis	rs11204677	1	rs11204677	ENSG00000206931.1	RNU6-1042P	-4.87	3.43e-06	0.00704	-0.48	-0.4	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr1:150602219	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.621	rs12746899	ENSG00000206931.1	RNU6-1042P	-4.87	3.43e-06	0.00704	-0.48	-0.4	Tonsillectomy;	chr1:150607202	chr1:150701866~150701972:+
ESCA	cis	rs765787	0.53	rs11636395	ENSG00000259520.4	CTD-2651B20.3	4.86	3.43e-06	0.00705	0.45	0.4	Uric acid levels;	chr15:45243486	chr15:45251580~45279251:-
ESCA	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	4.86	3.44e-06	0.00705	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
ESCA	cis	rs10875746	0.903	rs725454	ENSG00000240399.1	RP1-228P16.1	-4.86	3.44e-06	0.00705	-0.49	-0.4	Longevity (90 years and older);	chr12:48108317	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.729	rs11168357	ENSG00000240399.1	RP1-228P16.1	-4.86	3.45e-06	0.00705	-0.51	-0.4	Longevity (90 years and older);	chr12:48018355	chr12:48054813~48055591:-
ESCA	cis	rs2439831	0.764	rs12324584	ENSG00000249839.1	AC011330.5	-4.86	3.45e-06	0.00706	-0.6	-0.4	Lung cancer in ever smokers;	chr15:43391248	chr15:43663654~43684339:-
ESCA	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	4.86	3.45e-06	0.00707	0.35	0.4	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
ESCA	cis	rs2439831	0.85	rs28504496	ENSG00000205771.5	CATSPER2P1	-4.86	3.47e-06	0.00709	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43724685	chr15:43726918~43747094:-
ESCA	cis	rs2470135	1	rs2470135	ENSG00000205771.5	CATSPER2P1	-4.86	3.47e-06	0.00709	-0.52	-0.4	Diastolic blood pressure;	chr15:43703591	chr15:43726918~43747094:-
ESCA	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-4.86	3.47e-06	0.00709	-0.44	-0.4	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
ESCA	cis	rs875971	0.66	rs10229345	ENSG00000179406.6	LINC00174	-4.86	3.47e-06	0.0071	-0.46	-0.4	Aortic root size;	chr7:66517181	chr7:66376044~66401338:-
ESCA	cis	rs2439831	0.681	rs956391	ENSG00000249839.1	AC011330.5	4.86	3.48e-06	0.00711	0.59	0.4	Lung cancer in ever smokers;	chr15:43325295	chr15:43663654~43684339:-
ESCA	cis	rs2455601	0.786	rs3751064	ENSG00000254860.4	TMEM9B-AS1	4.86	3.49e-06	0.00712	0.62	0.4	Schizophrenia;	chr11:8937356	chr11:8964675~8977527:+
ESCA	cis	rs2439831	0.85	rs10438303	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43724219	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs12441127	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43728977	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.702	rs7171750	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43733660	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs11070408	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43742590	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs28718261	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43751595	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs28595038	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43752661	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs10163054	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43755440	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs7168158	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43758178	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs7174208	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43760484	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs12101756	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43761689	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs12442129	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43763658	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.702	rs7175032	ENSG00000205771.5	CATSPER2P1	-4.86	3.51e-06	0.00716	-0.74	-0.4	Lung cancer in ever smokers;	chr15:43768038	chr15:43726918~43747094:-
ESCA	cis	rs875971	0.66	rs801193	ENSG00000179406.6	LINC00174	4.86	3.53e-06	0.0072	0.44	0.4	Aortic root size;	chr7:66565625	chr7:66376044~66401338:-
ESCA	cis	rs11612508	1	rs11054935	ENSG00000274551.1	RP11-434C1.6	4.86	3.54e-06	0.00722	0.5	0.4	Inflammatory bowel disease;	chr12:12495909	chr12:11516425~11521686:-
ESCA	cis	rs9399137	0.507	rs4896129	ENSG00000232876.1	CTA-212D2.2	-4.86	3.54e-06	0.00722	-0.48	-0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028707	chr6:135055033~135060550:+
ESCA	cis	rs9545047	0.604	rs9545054	ENSG00000227676.3	LINC01068	4.86	3.55e-06	0.00724	0.52	0.4	Schizophrenia;	chr13:79298833	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.547	rs2876739	ENSG00000227676.3	LINC01068	4.86	3.55e-06	0.00724	0.52	0.4	Schizophrenia;	chr13:79299057	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs7988331	ENSG00000227676.3	LINC01068	4.86	3.55e-06	0.00724	0.52	0.4	Schizophrenia;	chr13:79299745	chr13:79566727~79571436:+
ESCA	cis	rs9549260	0.753	rs9549243	ENSG00000229456.1	RLIMP1	4.86	3.56e-06	0.00725	0.5	0.4	Red blood cell count;	chr13:40643068	chr13:40618738~40621348:+
ESCA	cis	rs2455601	0.786	rs2568070	ENSG00000254860.4	TMEM9B-AS1	4.86	3.56e-06	0.00725	0.6	0.4	Schizophrenia;	chr11:8955346	chr11:8964675~8977527:+
ESCA	cis	rs2455601	0.786	rs2568068	ENSG00000254860.4	TMEM9B-AS1	4.86	3.56e-06	0.00725	0.6	0.4	Schizophrenia;	chr11:8956283	chr11:8964675~8977527:+
ESCA	cis	rs9987353	0.519	rs11779181	ENSG00000253981.4	ALG1L13P	4.86	3.56e-06	0.00726	0.5	0.4	Recombination measurement;	chr8:9205517	chr8:8236003~8244667:-
ESCA	cis	rs977987	0.835	rs4888379	ENSG00000261783.1	RP11-252K23.2	-4.86	3.57e-06	0.00727	-0.49	-0.4	Dupuytren's disease;	chr16:75306333	chr16:75379818~75381260:-
ESCA	cis	rs300032	1	rs300032	ENSG00000261175.4	CTD-2015G9.2	4.86	3.57e-06	0.00728	0.68	0.4	IgG glycosylation;	chr16:86647390	chr16:86722091~86741059:+
ESCA	cis	rs6479891	1	rs11818194	ENSG00000235816.3	PRELID1P3	4.86	3.58e-06	0.00728	0.52	0.4	Arthritis (juvenile idiopathic);	chr10:63420692	chr10:63427297~63427939:+
ESCA	cis	rs10875746	0.903	rs4760681	ENSG00000240399.1	RP1-228P16.1	-4.85	3.58e-06	0.00729	-0.5	-0.4	Longevity (90 years and older);	chr12:48111447	chr12:48054813~48055591:-
ESCA	cis	rs6479891	1	rs61855465	ENSG00000235816.3	PRELID1P3	4.85	3.58e-06	0.00729	0.52	0.4	Arthritis (juvenile idiopathic);	chr10:63196847	chr10:63427297~63427939:+
ESCA	cis	rs10875746	0.729	rs11168355	ENSG00000240399.1	RP1-228P16.1	4.85	3.61e-06	0.00734	0.49	0.4	Longevity (90 years and older);	chr12:48017195	chr12:48054813~48055591:-
ESCA	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-4.85	3.61e-06	0.00734	-0.42	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
ESCA	cis	rs9309711	0.623	rs4641971	ENSG00000225234.1	TRAPPC12-AS1	4.85	3.61e-06	0.00735	0.51	0.4	Neurofibrillary tangles;	chr2:3478086	chr2:3481242~3482409:-
ESCA	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-4.85	3.61e-06	0.00735	-0.59	-0.4	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
ESCA	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-4.85	3.61e-06	0.00735	-0.59	-0.4	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
ESCA	cis	rs6951245	0.678	rs4724725	ENSG00000229043.2	AC091729.9	-4.85	3.61e-06	0.00735	-0.59	-0.4	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1175115	chr7:1160374~1165267:+
ESCA	cis	rs28830936	1	rs12441300	ENSG00000250379.1	RP11-23P13.4	4.85	3.62e-06	0.00736	0.47	0.4	Diastolic blood pressure;	chr15:41810647	chr15:41825099~41827936:-
ESCA	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-4.85	3.62e-06	0.00736	-0.68	-0.4	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
ESCA	cis	rs7826238	0.539	rs2945891	ENSG00000253981.4	ALG1L13P	4.85	3.62e-06	0.00736	0.5	0.4	Systolic blood pressure;	chr8:8297953	chr8:8236003~8244667:-
ESCA	cis	rs2505998	1	rs2505998	ENSG00000273008.1	RP11-351D16.3	-4.85	3.63e-06	0.00736	-0.46	-0.4	Hirschsprung disease;	chr10:43075477	chr10:43136824~43138334:-
ESCA	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-4.85	3.63e-06	0.00736	-0.54	-0.4	QT interval;	chr16:28884339	chr16:28700294~28701540:-
ESCA	cis	rs4417704	0.551	rs10173220	ENSG00000235151.1	AC114730.2	-4.85	3.63e-06	0.00737	-0.44	-0.4	Joint mobility (Beighton score);	chr2:240957492	chr2:241844380~241845036:+
ESCA	cis	rs2882667	0.858	rs7724108	ENSG00000253404.1	AC034243.1	-4.85	3.65e-06	0.00739	-0.57	-0.4	Age-related hearing impairment (SNP x SNP interaction);	chr5:139075233	chr5:138744434~138753309:-
ESCA	cis	rs875971	0.638	rs35986979	ENSG00000179406.6	LINC00174	4.85	3.66e-06	0.00742	0.45	0.4	Aortic root size;	chr7:66624003	chr7:66376044~66401338:-
ESCA	cis	rs4792901	0.918	rs12603189	ENSG00000279602.1	CTD-3014M21.1	4.85	3.68e-06	0.00746	0.47	0.4	Dupuytren's disease;	chr17:43541309	chr17:43360041~43361361:-
ESCA	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-4.85	3.69e-06	0.00747	-0.5	-0.4	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
ESCA	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-4.85	3.69e-06	0.00747	-0.81	-0.4	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
ESCA	cis	rs11675119	0.517	rs12619851	ENSG00000225234.1	TRAPPC12-AS1	-4.85	3.69e-06	0.00748	-0.46	-0.4	Neurofibrillary tangles;	chr2:3488976	chr2:3481242~3482409:-
ESCA	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-4.85	3.7e-06	0.00748	-0.67	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
ESCA	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-4.85	3.7e-06	0.00748	-0.67	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
ESCA	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-4.85	3.7e-06	0.00748	-0.67	-0.4	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
ESCA	cis	rs67180937	0.921	rs35700460	ENSG00000272750.1	RP11-378J18.8	-4.85	3.7e-06	0.00749	-0.47	-0.4	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222638065	chr1:222658867~222661512:-
ESCA	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	4.85	3.7e-06	0.00749	0.56	0.4	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	4.85	3.7e-06	0.00749	0.56	0.4	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
ESCA	cis	rs1005277	0.579	rs2749612	ENSG00000263064.2	RP11-291L22.7	4.85	3.71e-06	0.00752	0.54	0.4	Extrinsic epigenetic age acceleration;	chr10:38199682	chr10:38448689~38448949:+
ESCA	cis	rs1075265	0.518	rs13414393	ENSG00000235937.1	AC008280.1	4.85	3.72e-06	0.00752	0.47	0.4	Chronotype;Morning vs. evening chronotype;	chr2:54048025	chr2:54029552~54030682:-
ESCA	cis	rs6785206	0.554	rs4384970	ENSG00000239503.1	MARK2P8	4.85	3.72e-06	0.00753	0.41	0.4	Lymphocyte percentage of white cells;	chr3:128727569	chr3:128748538~128749489:-
ESCA	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	4.85	3.72e-06	0.00753	0.53	0.4	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
ESCA	cis	rs7714584	1	rs10463310	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150881343	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs73284126	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150881745	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7732643	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150881874	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7732945	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150882039	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1820682	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150882580	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2344181	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150883012	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs4560537	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150883024	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11746108	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150885060	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11739619	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150885100	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11167519	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150885845	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11167520	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150886077	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs73284141	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150886524	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs3906527	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150886830	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2345001	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150886956	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs3906528	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150887156	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2344180	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150887795	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2880791	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150887814	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs3857422	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150889047	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.59	rs4352593	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150889770	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7709464	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150889879	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10053750	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150890489	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7714415	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150890730	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7714584	ENSG00000197083.10	ZNF300P1	4.85	3.73e-06	0.00753	0.63	0.4	Crohn's disease;	chr5:150890858	chr5:150930645~150946289:-
ESCA	cis	rs9733	0.65	rs11204680	ENSG00000206931.1	RNU6-1042P	-4.85	3.73e-06	0.00754	-0.48	-0.4	Tonsillectomy;	chr1:150614664	chr1:150701866~150701972:+
ESCA	cis	rs7283707	0.681	rs7277807	ENSG00000269950.1	AP000962.2	-4.84	3.74e-06	0.00756	-0.72	-0.4	QRS complex (12-leadsum);	chr21:15727779	chr21:16574718~16582637:-
ESCA	cis	rs950880	0.71	rs17026974	ENSG00000234389.1	AC007278.3	4.84	3.74e-06	0.00756	0.38	0.4	Serum protein levels (sST2);	chr2:102335900	chr2:102438713~102440475:+
ESCA	cis	rs1538970	0.781	rs12049503	ENSG00000280836.1	AL355480.1	-4.84	3.75e-06	0.00757	-0.51	-0.4	Platelet count;	chr1:45555884	chr1:45581219~45581321:-
ESCA	cis	rs2439831	0.85	rs8042868	ENSG00000205771.5	CATSPER2P1	-4.84	3.75e-06	0.00757	-0.68	-0.4	Lung cancer in ever smokers;	chr15:43647444	chr15:43726918~43747094:-
ESCA	cis	rs1528149	0.856	rs60333130	ENSG00000224683.1	RPL36AP29	4.84	3.75e-06	0.00758	0.5	0.4	Sitting height ratio;	chr7:16059809	chr7:16208945~16209265:+
ESCA	cis	rs61160187	0.61	rs4700399	ENSG00000215032.2	GNL3LP1	4.84	3.76e-06	0.00759	0.51	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60840627	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.75	rs1807017	ENSG00000215032.2	GNL3LP1	4.84	3.76e-06	0.00759	0.53	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60831897	chr5:60891935~60893577:-
ESCA	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	4.84	3.76e-06	0.0076	0.47	0.4	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
ESCA	cis	rs7714584	0.826	rs34005003	ENSG00000197083.10	ZNF300P1	4.84	3.77e-06	0.0076	0.63	0.4	Crohn's disease;	chr5:150845637	chr5:150930645~150946289:-
ESCA	cis	rs2439831	1	rs7173487	ENSG00000249839.1	AC011330.5	-4.84	3.77e-06	0.00761	-0.75	-0.4	Lung cancer in ever smokers;	chr15:43458041	chr15:43663654~43684339:-
ESCA	cis	rs10754283	0.967	rs10801761	ENSG00000231613.1	RP5-943J3.1	4.84	3.8e-06	0.00766	0.43	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89649710	chr1:89788914~89790492:+
ESCA	cis	rs4713675	0.584	rs509539	ENSG00000186328.4	RP11-140K17.2	4.84	3.81e-06	0.00768	0.48	0.4	Plateletcrit;	chr6:33740413	chr6:34715613~34715940:+
ESCA	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	4.84	3.81e-06	0.00768	0.51	0.4	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
ESCA	cis	rs732716	0.785	rs56272533	ENSG00000267980.1	AC007292.6	-4.84	3.82e-06	0.00769	-0.58	-0.4	Mean corpuscular volume;	chr19:4420045	chr19:4363789~4364640:+
ESCA	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-4.84	3.82e-06	0.0077	-0.41	-0.4	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-4.84	3.82e-06	0.0077	-0.41	-0.4	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-4.84	3.82e-06	0.0077	-0.41	-0.4	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
ESCA	cis	rs7829975	1	rs7829975	ENSG00000253981.4	ALG1L13P	-4.84	3.83e-06	0.00771	-0.48	-0.4	Mood instability;	chr8:8690607	chr8:8236003~8244667:-
ESCA	cis	rs4747241	0.739	rs4746116	ENSG00000226163.1	RP11-167P22.3	4.84	3.84e-06	0.00773	0.43	0.4	Heschl's gyrus morphology;	chr10:72312378	chr10:72501746~72502956:+
ESCA	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-4.84	3.85e-06	0.00774	-0.46	-0.4	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
ESCA	cis	rs7267979	0.668	rs4815398	ENSG00000204556.4	CTD-2514C3.1	4.84	3.85e-06	0.00774	0.56	0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:26018832~26020684:+
ESCA	cis	rs9545047	0.604	rs2477397	ENSG00000227676.3	LINC01068	-4.84	3.85e-06	0.00775	-0.52	-0.4	Schizophrenia;	chr13:79428211	chr13:79566727~79571436:+
ESCA	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-4.84	3.86e-06	0.00777	-0.49	-0.4	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
ESCA	cis	rs7829975	0.688	rs6995407	ENSG00000253981.4	ALG1L13P	4.84	3.87e-06	0.00778	0.49	0.4	Mood instability;	chr8:8527137	chr8:8236003~8244667:-
ESCA	cis	rs394563	0.967	rs444784	ENSG00000231760.4	RP11-350J20.5	4.84	3.89e-06	0.00781	0.47	0.4	Dupuytren's disease;	chr6:149477230	chr6:149796151~149826294:-
ESCA	cis	rs9545047	0.604	rs2765078	ENSG00000227676.3	LINC01068	4.83	3.9e-06	0.00784	0.52	0.4	Schizophrenia;	chr13:79420604	chr13:79566727~79571436:+
ESCA	cis	rs1816752	0.719	rs11841989	ENSG00000273628.1	RP11-756A22.7	4.83	3.9e-06	0.00784	0.38	0.4	Obesity-related traits;	chr13:24423560	chr13:24933006~24936796:+
ESCA	cis	rs765787	0.53	rs4775822	ENSG00000259520.4	CTD-2651B20.3	4.83	3.91e-06	0.00785	0.46	0.4	Uric acid levels;	chr15:45234929	chr15:45251580~45279251:-
ESCA	cis	rs6867032	0.958	rs9312970	ENSG00000249731.1	RP11-259O2.3	-4.83	3.91e-06	0.00786	-0.31	-0.4	Gut microbiome composition (winter);	chr5:2002301	chr5:1968094~1969013:+
ESCA	cis	rs6867032	0.917	rs10474733	ENSG00000249731.1	RP11-259O2.3	-4.83	3.91e-06	0.00786	-0.31	-0.4	Gut microbiome composition (winter);	chr5:2004046	chr5:1968094~1969013:+
ESCA	cis	rs765787	0.505	rs1648302	ENSG00000259520.4	CTD-2651B20.3	4.83	3.94e-06	0.0079	0.46	0.4	Uric acid levels;	chr15:45202040	chr15:45251580~45279251:-
ESCA	cis	rs7829975	0.688	rs6601703	ENSG00000253981.4	ALG1L13P	4.83	3.95e-06	0.00792	0.46	0.4	Mood instability;	chr8:8522714	chr8:8236003~8244667:-
ESCA	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	4.83	3.95e-06	0.00792	0.36	0.4	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
ESCA	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	4.83	3.95e-06	0.00792	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
ESCA	cis	rs2505998	0.957	rs2435359	ENSG00000273008.1	RP11-351D16.3	-4.83	3.98e-06	0.00797	-0.46	-0.4	Hirschsprung disease;	chr10:43084567	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.879	rs2435358	ENSG00000273008.1	RP11-351D16.3	-4.83	3.98e-06	0.00797	-0.46	-0.4	Hirschsprung disease;	chr10:43084767	chr10:43136824~43138334:-
ESCA	cis	rs9987353	0.566	rs6998368	ENSG00000253981.4	ALG1L13P	-4.83	3.98e-06	0.00798	-0.51	-0.4	Recombination measurement;	chr8:9212778	chr8:8236003~8244667:-
ESCA	cis	rs732716	0.785	rs62130979	ENSG00000267980.1	AC007292.6	-4.83	3.99e-06	0.00799	-0.55	-0.4	Mean corpuscular volume;	chr19:4432447	chr19:4363789~4364640:+
ESCA	cis	rs28830936	0.934	rs3959569	ENSG00000250379.1	RP11-23P13.4	4.83	4e-06	0.00801	0.47	0.4	Diastolic blood pressure;	chr15:41823549	chr15:41825099~41827936:-
ESCA	cis	rs1005277	0.579	rs2474587	ENSG00000276805.1	RP11-291L22.6	4.83	4e-06	0.00801	0.51	0.4	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474588	ENSG00000276805.1	RP11-291L22.6	4.83	4e-06	0.00801	0.51	0.4	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38451030~38451785:+
ESCA	cis	rs12480328	1	rs76685994	ENSG00000228663.1	PSMD10P1	4.83	4.01e-06	0.00802	0.48	0.4	Prostate cancer;	chr20:50947674	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs73909848	ENSG00000228663.1	PSMD10P1	4.83	4.01e-06	0.00802	0.48	0.4	Prostate cancer;	chr20:50953866	chr20:50913731~50914411:+
ESCA	cis	rs1075265	0.563	rs2692536	ENSG00000235937.1	AC008280.1	4.83	4.01e-06	0.00803	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53788266	chr2:54029552~54030682:-
ESCA	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-4.83	4.02e-06	0.00804	-0.45	-0.4	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
ESCA	cis	rs1075265	0.61	rs6746965	ENSG00000235937.1	AC008280.1	4.83	4.03e-06	0.00806	0.44	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54029552~54030682:-
ESCA	cis	rs6456156	0.811	rs975822	ENSG00000265828.1	MIR3939	4.83	4.03e-06	0.00806	0.45	0.4	Primary biliary cholangitis;	chr6:167102970	chr6:166997807~166997912:-
ESCA	cis	rs4535700	0.501	rs9642405	ENSG00000273720.1	RP11-613E4.4	4.83	4.04e-06	0.00807	0.49	0.4	Macular telangiectasia type 2;	chr7:55910473	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs57251705	ENSG00000273720.1	RP11-613E4.4	4.83	4.04e-06	0.00807	0.49	0.4	Macular telangiectasia type 2;	chr7:55913390	chr7:55743073~55743457:+
ESCA	cis	rs4535700	0.501	rs28828764	ENSG00000273720.1	RP11-613E4.4	4.83	4.04e-06	0.00807	0.49	0.4	Macular telangiectasia type 2;	chr7:55920986	chr7:55743073~55743457:+
ESCA	cis	rs2455601	0.786	rs56680262	ENSG00000254860.4	TMEM9B-AS1	4.83	4.04e-06	0.00808	0.61	0.4	Schizophrenia;	chr11:8950008	chr11:8964675~8977527:+
ESCA	cis	rs2980439	0.525	rs2945238	ENSG00000253981.4	ALG1L13P	4.83	4.06e-06	0.00811	0.49	0.4	Neuroticism;	chr8:8312614	chr8:8236003~8244667:-
ESCA	cis	rs9399137	0.507	rs6923512	ENSG00000232876.1	CTA-212D2.2	4.83	4.06e-06	0.00811	0.48	0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135014130	chr6:135055033~135060550:+
ESCA	cis	rs10875746	0.903	rs11168418	ENSG00000240399.1	RP1-228P16.1	-4.82	4.06e-06	0.00812	-0.49	-0.4	Longevity (90 years and older);	chr12:48121971	chr12:48054813~48055591:-
ESCA	cis	rs2439831	0.85	rs2228368	ENSG00000205771.5	CATSPER2P1	-4.82	4.07e-06	0.00813	-0.72	-0.4	Lung cancer in ever smokers;	chr15:43809812	chr15:43726918~43747094:-
ESCA	cis	rs765787	0.53	rs11854294	ENSG00000259520.4	CTD-2651B20.3	4.82	4.08e-06	0.00814	0.46	0.4	Uric acid levels;	chr15:45235798	chr15:45251580~45279251:-
ESCA	cis	rs7829975	0.511	rs2948286	ENSG00000173295.6	FAM86B3P	4.82	4.08e-06	0.00815	0.48	0.4	Mood instability;	chr8:8272638	chr8:8228595~8244865:+
ESCA	cis	rs977987	0.843	rs10871312	ENSG00000261783.1	RP11-252K23.2	-4.82	4.09e-06	0.00816	-0.49	-0.4	Dupuytren's disease;	chr16:75452304	chr16:75379818~75381260:-
ESCA	cis	rs61160187	0.517	rs7709522	ENSG00000215032.2	GNL3LP1	4.82	4.09e-06	0.00817	0.5	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:61022188	chr5:60891935~60893577:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000250470.1	AP000351.3	-4.82	4.09e-06	0.00817	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23976904~23977585:-
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000250470.1	AP000351.3	-4.82	4.09e-06	0.00817	-0.58	-0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23976904~23977585:-
ESCA	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-4.82	4.1e-06	0.00818	-0.44	-0.4	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
ESCA	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	4.82	4.1e-06	0.00818	0.53	0.4	QT interval;	chr16:28860645	chr16:28700294~28701540:-
ESCA	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	4.82	4.1e-06	0.00819	0.71	0.4	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
ESCA	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-4.82	4.12e-06	0.00821	-0.47	-0.4	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
ESCA	cis	rs7829975	0.688	rs7837587	ENSG00000253981.4	ALG1L13P	4.82	4.12e-06	0.00821	0.47	0.4	Mood instability;	chr8:8521482	chr8:8236003~8244667:-
ESCA	cis	rs4927850	0.723	rs7630825	ENSG00000207650.1	MIR570	4.82	4.12e-06	0.00822	0.41	0.4	Pancreatic cancer;	chr3:196026869	chr3:195699401~195699497:+
ESCA	cis	rs11169552	0.51	rs12231317	ENSG00000200428.1	Y_RNA	4.82	4.13e-06	0.00822	0.49	0.4	Colorectal cancer;	chr12:50647222	chr12:50743568~50743684:+
ESCA	cis	rs2505998	0.833	rs1864403	ENSG00000273008.1	RP11-351D16.3	4.82	4.13e-06	0.00824	0.43	0.4	Hirschsprung disease;	chr10:43109502	chr10:43136824~43138334:-
ESCA	cis	rs17711722	0.653	rs2460421	ENSG00000179406.6	LINC00174	4.82	4.13e-06	0.00824	0.44	0.4	Calcium levels;	chr7:66026136	chr7:66376044~66401338:-
ESCA	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	4.82	4.14e-06	0.00825	0.38	0.4	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
ESCA	cis	rs3820716	0.507	rs16828354	ENSG00000223911.1	AC009480.3	4.82	4.14e-06	0.00826	0.48	0.4	Glomerular filtration rate (creatinine);	chr2:148167009	chr2:147899401~147902956:-
ESCA	cis	rs2221894	0.922	rs2323134	ENSG00000273710.1	Metazoa_SRP	-4.82	4.15e-06	0.00826	-0.47	-0.4	Obesity-related traits;	chr8:28982405	chr8:28915579~28915864:-
ESCA	cis	rs2455601	0.744	rs11042133	ENSG00000254860.4	TMEM9B-AS1	4.82	4.15e-06	0.00827	0.61	0.4	Schizophrenia;	chr11:8944964	chr11:8964675~8977527:+
ESCA	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.82	4.16e-06	0.00828	0.52	0.4	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
ESCA	cis	rs2439831	0.702	rs8033995	ENSG00000205771.5	CATSPER2P1	-4.82	4.16e-06	0.00828	-0.66	-0.4	Lung cancer in ever smokers;	chr15:43721311	chr15:43726918~43747094:-
ESCA	cis	rs7829975	0.5	rs7841082	ENSG00000253981.4	ALG1L13P	-4.82	4.16e-06	0.00828	-0.53	-0.4	Mood instability;	chr8:8311465	chr8:8236003~8244667:-
ESCA	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-4.82	4.16e-06	0.00829	-0.47	-0.4	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
ESCA	cis	rs1816752	0.905	rs7400631	ENSG00000273628.1	RP11-756A22.7	4.82	4.17e-06	0.00829	0.38	0.4	Obesity-related traits;	chr13:24415927	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs8002215	ENSG00000273628.1	RP11-756A22.7	4.82	4.17e-06	0.00829	0.38	0.4	Obesity-related traits;	chr13:24416229	chr13:24933006~24936796:+
ESCA	cis	rs2439831	0.867	rs4075674	ENSG00000249839.1	AC011330.5	-4.82	4.17e-06	0.0083	-0.58	-0.4	Lung cancer in ever smokers;	chr15:43358032	chr15:43663654~43684339:-
ESCA	cis	rs1075232	1	rs1075232	ENSG00000270055.1	CTD-3092A11.2	-4.82	4.17e-06	0.00831	-0.9	-0.4	Survival in colorectal cancer (non-distant metastatic);	chr15:31449013	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs67634762	ENSG00000270055.1	CTD-3092A11.2	-4.82	4.17e-06	0.00831	-0.9	-0.4	Survival in colorectal cancer (non-distant metastatic);	chr15:31455852	chr15:30487963~30490313:+
ESCA	cis	rs2742234	0.541	rs1879310	ENSG00000273008.1	RP11-351D16.3	4.82	4.19e-06	0.00834	0.47	0.4	Hirschsprung disease;	chr10:43239327	chr10:43136824~43138334:-
ESCA	cis	rs6479901	0.557	rs12773283	ENSG00000235816.3	PRELID1P3	-4.82	4.19e-06	0.00834	-0.52	-0.4	Intelligence (multi-trait analysis);	chr10:63298464	chr10:63427297~63427939:+
ESCA	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-4.82	4.19e-06	0.00834	-0.42	-0.4	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
ESCA	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-4.82	4.19e-06	0.00834	-0.42	-0.4	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
ESCA	cis	rs394563	0.901	rs448874	ENSG00000231760.4	RP11-350J20.5	4.82	4.2e-06	0.00835	0.47	0.4	Dupuytren's disease;	chr6:149475831	chr6:149796151~149826294:-
ESCA	cis	rs394563	1	rs394563	ENSG00000231760.4	RP11-350J20.5	4.82	4.2e-06	0.00835	0.47	0.4	Dupuytren's disease;	chr6:149475878	chr6:149796151~149826294:-
ESCA	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-4.82	4.2e-06	0.00836	-0.52	-0.4	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
ESCA	cis	rs765787	0.53	rs1648289	ENSG00000259520.4	CTD-2651B20.3	4.82	4.21e-06	0.00837	0.46	0.4	Uric acid levels;	chr15:45224296	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs1648287	ENSG00000259520.4	CTD-2651B20.3	4.82	4.21e-06	0.00837	0.46	0.4	Uric acid levels;	chr15:45224758	chr15:45251580~45279251:-
ESCA	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-4.82	4.21e-06	0.00837	-0.42	-0.4	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
ESCA	cis	rs9545047	0.584	rs1886494	ENSG00000227676.3	LINC01068	-4.82	4.21e-06	0.00838	-0.53	-0.4	Schizophrenia;	chr13:79403005	chr13:79566727~79571436:+
ESCA	cis	rs6479891	1	rs868798	ENSG00000235816.3	PRELID1P3	4.82	4.22e-06	0.00839	0.5	0.4	Arthritis (juvenile idiopathic);	chr10:63135250	chr10:63427297~63427939:+
ESCA	cis	rs7829975	0.623	rs10087493	ENSG00000173295.6	FAM86B3P	-4.82	4.22e-06	0.00839	-0.47	-0.4	Mood instability;	chr8:8516047	chr8:8228595~8244865:+
ESCA	cis	rs2439831	0.717	rs2470132	ENSG00000249839.1	AC011330.5	-4.82	4.23e-06	0.0084	-0.61	-0.4	Lung cancer in ever smokers;	chr15:43543283	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2251844	ENSG00000249839.1	AC011330.5	-4.82	4.23e-06	0.0084	-0.61	-0.4	Lung cancer in ever smokers;	chr15:43544280	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs486301	ENSG00000249839.1	AC011330.5	-4.82	4.23e-06	0.0084	-0.61	-0.4	Lung cancer in ever smokers;	chr15:43544751	chr15:43663654~43684339:-
ESCA	cis	rs7208859	0.573	rs73267873	ENSG00000263531.1	RP13-753N3.1	4.82	4.23e-06	0.0084	0.59	0.4	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741439	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.561	rs4085382	ENSG00000263531.1	RP13-753N3.1	4.82	4.23e-06	0.0084	0.59	0.4	Body mass index;	chr17:30744184	chr17:30863921~30864940:-
ESCA	cis	rs6479891	1	rs61853336	ENSG00000235816.3	PRELID1P3	4.81	4.24e-06	0.00841	0.5	0.4	Arthritis (juvenile idiopathic);	chr10:63140115	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs4746994	ENSG00000235816.3	PRELID1P3	4.81	4.24e-06	0.00841	0.5	0.4	Arthritis (juvenile idiopathic);	chr10:63145564	chr10:63427297~63427939:+
ESCA	cis	rs61160187	0.582	rs17444495	ENSG00000215032.2	GNL3LP1	4.81	4.24e-06	0.00841	0.5	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:61059457	chr5:60891935~60893577:-
ESCA	cis	rs9462027	0.527	rs6939600	ENSG00000186328.4	RP11-140K17.2	4.81	4.25e-06	0.00843	0.44	0.4	Systemic lupus erythematosus;	chr6:34854399	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.527	rs11755393	ENSG00000186328.4	RP11-140K17.2	4.81	4.25e-06	0.00843	0.44	0.4	Systemic lupus erythematosus;	chr6:34856859	chr6:34715613~34715940:+
ESCA	cis	rs9545047	0.716	rs7333904	ENSG00000227676.3	LINC01068	4.81	4.26e-06	0.00845	0.52	0.4	Schizophrenia;	chr13:79281413	chr13:79566727~79571436:+
ESCA	cis	rs4927850	0.752	rs7624460	ENSG00000207650.1	MIR570	4.81	4.26e-06	0.00845	0.41	0.4	Pancreatic cancer;	chr3:196021659	chr3:195699401~195699497:+
ESCA	cis	rs4927850	0.752	rs7618864	ENSG00000207650.1	MIR570	4.81	4.26e-06	0.00845	0.41	0.4	Pancreatic cancer;	chr3:196022690	chr3:195699401~195699497:+
ESCA	cis	rs453301	0.686	rs6601280	ENSG00000173295.6	FAM86B3P	4.81	4.26e-06	0.00845	0.49	0.4	Joint mobility (Beighton score);	chr8:9051726	chr8:8228595~8244865:+
ESCA	cis	rs394563	0.69	rs237009	ENSG00000231760.4	RP11-350J20.5	4.81	4.27e-06	0.00846	0.5	0.4	Dupuytren's disease;	chr6:149438416	chr6:149796151~149826294:-
ESCA	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	4.81	4.27e-06	0.00846	0.42	0.4	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
ESCA	cis	rs11118620	0.535	rs1389750	ENSG00000272823.1	RP11-295M18.6	4.81	4.28e-06	0.00847	0.46	0.4	Heart failure;	chr1:220866829	chr1:220828676~220829211:-
ESCA	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-4.81	4.29e-06	0.00848	-0.48	-0.4	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-4.81	4.29e-06	0.00848	-0.48	-0.4	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-4.81	4.29e-06	0.00848	-0.48	-0.4	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
ESCA	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	4.81	4.31e-06	0.00853	0.46	0.4	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
ESCA	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-4.81	4.31e-06	0.00853	-0.46	-0.4	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
ESCA	cis	rs2505998	0.719	rs10900296	ENSG00000273008.1	RP11-351D16.3	-4.81	4.31e-06	0.00853	-0.46	-0.4	Hirschsprung disease;	chr10:43077059	chr10:43136824~43138334:-
ESCA	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	4.81	4.33e-06	0.00856	0.62	0.4	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
ESCA	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-4.81	4.34e-06	0.00856	-0.48	-0.4	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
ESCA	cis	rs394563	0.967	rs420099	ENSG00000231760.4	RP11-350J20.5	4.81	4.34e-06	0.00857	0.48	0.4	Dupuytren's disease;	chr6:149473154	chr6:149796151~149826294:-
ESCA	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	4.81	4.34e-06	0.00857	0.62	0.4	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
ESCA	cis	rs6782228	0.848	rs6439140	ENSG00000277250.1	Metazoa_SRP	4.81	4.34e-06	0.00857	0.54	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128673681~128674021:-
ESCA	cis	rs4417704	0.551	rs10179839	ENSG00000235151.1	AC114730.2	-4.81	4.34e-06	0.00858	-0.44	-0.4	Joint mobility (Beighton score);	chr2:240959530	chr2:241844380~241845036:+
ESCA	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	4.81	4.35e-06	0.00859	0.44	0.4	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	4.81	4.35e-06	0.00859	0.44	0.4	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	4.81	4.35e-06	0.00859	0.44	0.4	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	4.81	4.35e-06	0.00859	0.44	0.4	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	4.81	4.35e-06	0.00859	0.44	0.4	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
ESCA	cis	rs4747241	0.739	rs7081608	ENSG00000226163.1	RP11-167P22.3	4.81	4.36e-06	0.0086	0.43	0.4	Heschl's gyrus morphology;	chr10:72313279	chr10:72501746~72502956:+
ESCA	cis	rs8059260	0.668	rs7206753	ENSG00000274038.1	RP11-66H6.4	-4.81	4.36e-06	0.0086	-0.76	-0.4	Alcohol consumption over the past year;	chr16:10974987	chr16:11056556~11057034:+
ESCA	cis	rs6604026	0.656	rs2774945	ENSG00000229052.2	RP11-386I23.1	-4.81	4.36e-06	0.00861	-0.39	-0.4	Multiple sclerosis;	chr1:92880682	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.698	rs2492294	ENSG00000229052.2	RP11-386I23.1	-4.81	4.36e-06	0.00861	-0.39	-0.4	Multiple sclerosis;	chr1:92881009	chr1:92930696~92934098:+
ESCA	cis	rs42490	0.903	rs218902	ENSG00000251136.7	RP11-37B2.1	4.81	4.36e-06	0.00861	0.42	0.4	Leprosy;	chr8:89719986	chr8:89609409~89757727:-
ESCA	cis	rs61160187	0.582	rs3797559	ENSG00000215032.2	GNL3LP1	4.81	4.37e-06	0.00863	0.5	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60927914	chr5:60891935~60893577:-
ESCA	cis	rs9545047	0.604	rs7988784	ENSG00000227676.3	LINC01068	-4.81	4.38e-06	0.00864	-0.52	-0.4	Schizophrenia;	chr13:79335337	chr13:79566727~79571436:+
ESCA	cis	rs2439831	0.85	rs16977798	ENSG00000249839.1	AC011330.5	-4.81	4.4e-06	0.00867	-0.84	-0.4	Lung cancer in ever smokers;	chr15:43859750	chr15:43663654~43684339:-
ESCA	cis	rs61160187	0.549	rs61017995	ENSG00000215032.2	GNL3LP1	4.81	4.42e-06	0.00871	0.51	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60968176	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.556	rs62367862	ENSG00000215032.2	GNL3LP1	4.81	4.42e-06	0.00871	0.51	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60973134	chr5:60891935~60893577:-
ESCA	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	4.8	4.42e-06	0.00872	0.44	0.4	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
ESCA	cis	rs7631605	0.967	rs6550446	ENSG00000272334.1	RP11-129K12.1	-4.8	4.43e-06	0.00873	-0.44	-0.4	Cerebrospinal P-tau181p levels;	chr3:37024882	chr3:36973117~36973672:-
ESCA	cis	rs2921073	0.509	rs2976931	ENSG00000173295.6	FAM86B3P	4.8	4.44e-06	0.00874	0.44	0.4	Parkinson's disease;	chr8:8399807	chr8:8228595~8244865:+
ESCA	cis	rs6604026	0.656	rs2481712	ENSG00000229052.2	RP11-386I23.1	-4.8	4.46e-06	0.00878	-0.39	-0.4	Multiple sclerosis;	chr1:92885920	chr1:92930696~92934098:+
ESCA	cis	rs2742234	1	rs1864399	ENSG00000273008.1	RP11-351D16.3	-4.8	4.46e-06	0.00878	-0.46	-0.4	Hirschsprung disease;	chr10:43115007	chr10:43136824~43138334:-
ESCA	cis	rs9462027	0.562	rs2814946	ENSG00000186328.4	RP11-140K17.2	4.8	4.46e-06	0.00879	0.44	0.4	Systemic lupus erythematosus;	chr6:34683403	chr6:34715613~34715940:+
ESCA	cis	rs1075265	0.811	rs805322	ENSG00000235937.1	AC008280.1	-4.8	4.47e-06	0.0088	-0.42	-0.4	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54029552~54030682:-
ESCA	cis	rs6867032	0.57	rs13166888	ENSG00000249731.1	RP11-259O2.3	-4.8	4.48e-06	0.00882	-0.36	-0.4	Gut microbiome composition (winter);	chr5:1982852	chr5:1968094~1969013:+
ESCA	cis	rs1816752	0.746	rs9511270	ENSG00000273628.1	RP11-756A22.7	4.8	4.48e-06	0.00882	0.39	0.4	Obesity-related traits;	chr13:24444542	chr13:24933006~24936796:+
ESCA	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-4.8	4.49e-06	0.00883	-0.39	-0.4	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
ESCA	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-4.8	4.49e-06	0.00884	-0.47	-0.4	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-4.8	4.49e-06	0.00884	-0.47	-0.4	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-4.8	4.49e-06	0.00884	-0.47	-0.4	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
ESCA	cis	rs9545047	0.604	rs1616547	ENSG00000227676.3	LINC01068	4.8	4.5e-06	0.00886	0.51	0.4	Schizophrenia;	chr13:79411901	chr13:79566727~79571436:+
ESCA	cis	rs732716	0.785	rs62130978	ENSG00000267980.1	AC007292.6	-4.8	4.5e-06	0.00886	-0.57	-0.4	Mean corpuscular volume;	chr19:4429010	chr19:4363789~4364640:+
ESCA	cis	rs11169552	0.51	rs11169515	ENSG00000200428.1	Y_RNA	4.8	4.52e-06	0.00888	0.49	0.4	Colorectal cancer;	chr12:50659732	chr12:50743568~50743684:+
ESCA	cis	rs9549260	0.62	rs9532580	ENSG00000229456.1	RLIMP1	4.8	4.52e-06	0.00888	0.38	0.4	Red blood cell count;	chr13:40670123	chr13:40618738~40621348:+
ESCA	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-4.8	4.52e-06	0.00889	-0.75	-0.4	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
ESCA	cis	rs9399137	0.507	rs4896128	ENSG00000232876.1	CTA-212D2.2	4.8	4.54e-06	0.00893	0.48	0.4	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135028618	chr6:135055033~135060550:+
ESCA	cis	rs9545047	0.604	rs28579970	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79308726	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1980883	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79310629	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9565486	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79317469	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs12875039	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79327449	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9285310	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79328340	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.625	rs9593391	ENSG00000227676.3	LINC01068	-4.8	4.55e-06	0.00893	-0.52	-0.4	Schizophrenia;	chr13:79329168	chr13:79566727~79571436:+
ESCA	cis	rs732716	0.785	rs9973266	ENSG00000267980.1	AC007292.6	-4.8	4.55e-06	0.00893	-0.55	-0.4	Mean corpuscular volume;	chr19:4392718	chr19:4363789~4364640:+
ESCA	cis	rs6604026	0.63	rs2481711	ENSG00000229052.2	RP11-386I23.1	-4.8	4.55e-06	0.00895	-0.39	-0.4	Multiple sclerosis;	chr1:92881015	chr1:92930696~92934098:+
ESCA	cis	rs1075232	0.579	rs58156651	ENSG00000270055.1	CTD-3092A11.2	-4.8	4.56e-06	0.00895	-0.9	-0.4	Survival in colorectal cancer (non-distant metastatic);	chr15:31456864	chr15:30487963~30490313:+
ESCA	cis	rs765787	0.53	rs1706764	ENSG00000259520.4	CTD-2651B20.3	4.8	4.56e-06	0.00895	0.46	0.4	Uric acid levels;	chr15:45232058	chr15:45251580~45279251:-
ESCA	cis	rs4951011	0.572	rs66518790	ENSG00000223505.2	RP11-397P13.7	-4.8	4.57e-06	0.00896	-0.55	-0.4	Breast cancer;	chr1:203896680	chr1:203835585~203835912:-
ESCA	cis	rs1816752	0.87	rs8000215	ENSG00000273628.1	RP11-756A22.7	4.8	4.58e-06	0.00899	0.39	0.4	Obesity-related traits;	chr13:24435648	chr13:24933006~24936796:+
ESCA	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	4.8	4.59e-06	0.00901	0.62	0.4	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	4.8	4.59e-06	0.00901	0.62	0.4	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
ESCA	cis	rs1005277	0.579	rs2474568	ENSG00000276805.1	RP11-291L22.6	4.8	4.59e-06	0.00901	0.52	0.4	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38451030~38451785:+
ESCA	cis	rs9545047	0.584	rs9565485	ENSG00000227676.3	LINC01068	-4.79	4.61e-06	0.00904	-0.52	-0.4	Schizophrenia;	chr13:79307428	chr13:79566727~79571436:+
ESCA	cis	rs11169552	0.51	rs12580051	ENSG00000200428.1	Y_RNA	4.79	4.61e-06	0.00904	0.48	0.4	Colorectal cancer;	chr12:50651289	chr12:50743568~50743684:+
ESCA	cis	rs7267979	0.738	rs2892409	ENSG00000204556.4	CTD-2514C3.1	-4.79	4.62e-06	0.00905	-0.55	-0.4	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:26018832~26020684:+
ESCA	cis	rs1538970	0.774	rs67683090	ENSG00000280836.1	AL355480.1	-4.79	4.62e-06	0.00905	-0.5	-0.4	Platelet count;	chr1:45512131	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.816	rs4633317	ENSG00000280836.1	AL355480.1	-4.79	4.62e-06	0.00905	-0.5	-0.4	Platelet count;	chr1:45519485	chr1:45581219~45581321:-
ESCA	cis	rs1538970	0.781	rs713358	ENSG00000280836.1	AL355480.1	-4.79	4.62e-06	0.00905	-0.5	-0.4	Platelet count;	chr1:45522595	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	4.79	4.62e-06	0.00906	0.43	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
ESCA	cis	rs2221894	1	rs4559202	ENSG00000273710.1	Metazoa_SRP	-4.79	4.63e-06	0.00907	-0.46	-0.4	Obesity-related traits;	chr8:28959335	chr8:28915579~28915864:-
ESCA	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-4.79	4.64e-06	0.00909	-0.47	-0.4	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
ESCA	cis	rs7829975	0.577	rs940030	ENSG00000253981.4	ALG1L13P	-4.79	4.67e-06	0.00914	-0.48	-0.4	Mood instability;	chr8:8689418	chr8:8236003~8244667:-
ESCA	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	4.79	4.67e-06	0.00914	0.51	0.4	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
ESCA	cis	rs10875746	0.859	rs12305511	ENSG00000240399.1	RP1-228P16.1	4.79	4.69e-06	0.00917	0.48	0.4	Longevity (90 years and older);	chr12:48188933	chr12:48054813~48055591:-
ESCA	cis	rs2289700	0.518	rs77362013	ENSG00000279235.1	RP11-16K12.2	-4.79	4.71e-06	0.00921	-0.47	-0.4	Bipolar disorder;	chr15:78874918	chr15:78906127~78906809:+
ESCA	cis	rs6604026	0.656	rs2255723	ENSG00000229052.2	RP11-386I23.1	4.79	4.72e-06	0.00923	0.4	0.4	Multiple sclerosis;	chr1:92902752	chr1:92930696~92934098:+
ESCA	cis	rs2439831	0.702	rs8033995	ENSG00000224677.1	PDIA3P2	-4.79	4.73e-06	0.00923	-0.58	-0.4	Lung cancer in ever smokers;	chr15:43721311	chr15:43649123~43649280:+
ESCA	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-4.79	4.73e-06	0.00924	-0.48	-0.4	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
ESCA	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	4.79	4.73e-06	0.00925	0.55	0.4	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
ESCA	cis	rs1816752	0.905	rs7991450	ENSG00000273628.1	RP11-756A22.7	4.79	4.74e-06	0.00925	0.39	0.4	Obesity-related traits;	chr13:24425898	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.774	rs7986162	ENSG00000273628.1	RP11-756A22.7	4.79	4.74e-06	0.00925	0.39	0.4	Obesity-related traits;	chr13:24425941	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs4769352	ENSG00000273628.1	RP11-756A22.7	4.79	4.74e-06	0.00925	0.39	0.4	Obesity-related traits;	chr13:24426237	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.805	rs4769353	ENSG00000273628.1	RP11-756A22.7	4.79	4.74e-06	0.00925	0.39	0.4	Obesity-related traits;	chr13:24426318	chr13:24933006~24936796:+
ESCA	cis	rs61160187	0.582	rs12652878	ENSG00000215032.2	GNL3LP1	4.79	4.74e-06	0.00926	0.52	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60868949	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.548	rs17392014	ENSG00000215032.2	GNL3LP1	4.79	4.74e-06	0.00926	0.52	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:60869373	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.549	rs12518404	ENSG00000215032.2	GNL3LP1	4.79	4.75e-06	0.00927	0.5	0.4	Educational attainment (years of education);Educational attainment (college completion);	chr5:61046169	chr5:60891935~60893577:-
ESCA	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-4.79	4.75e-06	0.00927	-0.45	-0.4	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
ESCA	cis	rs765787	0.53	rs2668737	ENSG00000259520.4	CTD-2651B20.3	4.79	4.75e-06	0.00928	0.46	0.4	Uric acid levels;	chr15:45230601	chr15:45251580~45279251:-
ESCA	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	4.79	4.75e-06	0.00928	0.57	0.4	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
ESCA	cis	rs1005277	0.541	rs2472177	ENSG00000276805.1	RP11-291L22.6	4.79	4.76e-06	0.00929	0.51	0.4	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38451030~38451785:+
ESCA	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	4.79	4.78e-06	0.00933	0.51	0.4	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
ESCA	cis	rs6479891	1	rs12415984	ENSG00000235816.3	PRELID1P3	4.79	4.78e-06	0.00933	0.5	0.4	Arthritis (juvenile idiopathic);	chr10:63150528	chr10:63427297~63427939:+
ESCA	cis	rs7829975	0.623	rs10092965	ENSG00000253893.2	FAM85B	-4.79	4.78e-06	0.00933	-0.49	-0.4	Mood instability;	chr8:8515975	chr8:8167819~8226614:-
ESCA	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	4.79	4.79e-06	0.00934	0.55	0.4	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
ESCA	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	4.79	4.79e-06	0.00934	0.54	0.4	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
ESCA	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	4.78	4.81e-06	0.00937	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	4.78	4.81e-06	0.00937	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
ESCA	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	4.78	4.82e-06	0.00937	0.47	0.4	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
ESCA	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-4.78	4.82e-06	0.00937	-0.47	-0.4	Height;	chr11:118703185	chr11:118704607~118750263:+
ESCA	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-4.78	4.82e-06	0.00937	-0.47	-0.4	Height;	chr11:118703207	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-4.78	4.82e-06	0.00937	-0.47	-0.4	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
ESCA	cis	rs10754283	0.967	rs10801757	ENSG00000231613.1	RP5-943J3.1	4.78	4.82e-06	0.00938	0.42	0.4	Amyotrophic lateral sclerosis (sporadic);	chr1:89637521	chr1:89788914~89790492:+
ESCA	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	4.78	4.83e-06	0.00939	0.34	0.4	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
ESCA	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-4.78	4.83e-06	0.00939	-0.67	-0.4	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-4.78	4.83e-06	0.00939	-0.67	-0.4	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-4.78	4.83e-06	0.00939	-0.67	-0.4	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
ESCA	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-4.78	4.83e-06	0.00939	-0.67	-0.4	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
ESCA	cis	rs2307394	0.964	rs12053401	ENSG00000223911.1	AC009480.3	4.78	4.83e-06	0.0094	0.47	0.4	Urate levels;	chr2:147999099	chr2:147899401~147902956:-
ESCA	cis	rs2439831	0.681	rs2278859	ENSG00000249839.1	AC011330.5	-4.78	4.83e-06	0.0094	-0.56	-0.4	Lung cancer in ever smokers;	chr15:43340762	chr15:43663654~43684339:-
ESCA	cis	rs2742234	0.666	rs715106	ENSG00000273008.1	RP11-351D16.3	-4.78	4.87e-06	0.00946	-0.47	-0.4	Hirschsprung disease;	chr10:43121303	chr10:43136824~43138334:-
ESCA	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	4.78	4.88e-06	0.00948	0.62	0.4	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
ESCA	cis	rs1816752	0.905	rs7995909	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00954	0.38	0.4	Obesity-related traits;	chr13:24439159	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs6490927	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00954	0.38	0.4	Obesity-related traits;	chr13:24439802	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs6490928	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00954	0.38	0.4	Obesity-related traits;	chr13:24439921	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs6490929	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00954	0.38	0.4	Obesity-related traits;	chr13:24440114	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs3825449	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00954	0.38	0.4	Obesity-related traits;	chr13:24440303	chr13:24933006~24936796:+
ESCA	cis	rs9549260	0.755	rs7335520	ENSG00000229456.1	RLIMP1	4.78	4.92e-06	0.00955	0.36	0.4	Red blood cell count;	chr13:40622270	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.753	rs9549254	ENSG00000229456.1	RLIMP1	4.78	4.92e-06	0.00955	0.49	0.4	Red blood cell count;	chr13:40660626	chr13:40618738~40621348:+
ESCA	cis	rs1816752	0.806	rs3816218	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00955	0.39	0.4	Obesity-related traits;	chr13:24443033	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.666	rs7994022	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00955	0.39	0.4	Obesity-related traits;	chr13:24443092	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.713	rs7336357	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00955	0.39	0.4	Obesity-related traits;	chr13:24443452	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.683	rs7330532	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00955	0.39	0.4	Obesity-related traits;	chr13:24443453	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.59	rs61947036	ENSG00000273628.1	RP11-756A22.7	4.78	4.92e-06	0.00955	0.39	0.4	Obesity-related traits;	chr13:24443544	chr13:24933006~24936796:+
ESCA	cis	rs7829975	0.514	rs2976929	ENSG00000173295.6	FAM86B3P	4.78	4.93e-06	0.00956	0.44	0.4	Mood instability;	chr8:8401202	chr8:8228595~8244865:+
ESCA	cis	rs3747113	1	rs35303215	ENSG00000128262.7	POM121L9P	-4.78	4.94e-06	0.00957	-0.5	-0.4	Gut microbiome composition (summer);	chr22:24405567	chr22:24251828~24265525:+
ESCA	cis	rs5760092	0.618	rs4461358	ENSG00000272787.1	KB-226F1.2	4.78	4.94e-06	0.00958	0.5	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23969211~23969873:+
ESCA	cis	rs2439831	0.85	rs3825783	ENSG00000249839.1	AC011330.5	-4.78	4.94e-06	0.00959	-0.81	-0.4	Lung cancer in ever smokers;	chr15:43810111	chr15:43663654~43684339:-
ESCA	cis	rs765787	0.53	rs28524974	ENSG00000259520.4	CTD-2651B20.3	4.78	4.95e-06	0.00959	0.44	0.4	Uric acid levels;	chr15:45251330	chr15:45251580~45279251:-
ESCA	cis	rs7631605	0.935	rs997588	ENSG00000272334.1	RP11-129K12.1	-4.78	4.95e-06	0.00959	-0.44	-0.4	Cerebrospinal P-tau181p levels;	chr3:37033651	chr3:36973117~36973672:-
ESCA	cis	rs7631605	1	rs6772548	ENSG00000272334.1	RP11-129K12.1	-4.78	4.95e-06	0.00959	-0.44	-0.4	Cerebrospinal P-tau181p levels;	chr3:37034443	chr3:36973117~36973672:-
ESCA	cis	rs765787	0.53	rs2554457	ENSG00000259520.4	CTD-2651B20.3	4.78	4.95e-06	0.00959	0.46	0.4	Uric acid levels;	chr15:45228728	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs10467979	ENSG00000259520.4	CTD-2651B20.3	4.78	4.95e-06	0.00959	0.46	0.4	Uric acid levels;	chr15:45229072	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs2554455	ENSG00000259520.4	CTD-2651B20.3	4.78	4.95e-06	0.00959	0.46	0.4	Uric acid levels;	chr15:45229106	chr15:45251580~45279251:-
ESCA	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	4.78	4.95e-06	0.00959	0.55	0.4	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
ESCA	cis	rs7829975	0.514	rs2920991	ENSG00000173295.6	FAM86B3P	4.78	4.96e-06	0.0096	0.44	0.4	Mood instability;	chr8:8401607	chr8:8228595~8244865:+
ESCA	cis	rs2742234	0.59	rs741968	ENSG00000273008.1	RP11-351D16.3	-4.78	4.96e-06	0.0096	-0.47	-0.4	Hirschsprung disease;	chr10:43116260	chr10:43136824~43138334:-
ESCA	cis	rs6921919	0.848	rs9468350	ENSG00000216901.1	AL022393.7	4.78	4.96e-06	0.00962	0.5	0.4	Autism spectrum disorder or schizophrenia;	chr6:28351330	chr6:28176188~28176674:+
ESCA	cis	rs6750795	0.502	rs11685196	ENSG00000181798.2	LINC00471	-4.78	4.97e-06	0.00962	-0.43	-0.4	Height;	chr2:231516587	chr2:231508426~231514339:-
ESCA	cis	rs732716	0.819	rs12459919	ENSG00000267980.1	AC007292.6	-4.78	4.97e-06	0.00962	-0.56	-0.4	Mean corpuscular volume;	chr19:4434506	chr19:4363789~4364640:+
ESCA	cis	rs394563	0.934	rs384334	ENSG00000231760.4	RP11-350J20.5	4.78	4.97e-06	0.00963	0.47	0.4	Dupuytren's disease;	chr6:149475036	chr6:149796151~149826294:-
ESCA	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	4.78	4.97e-06	0.00963	0.62	0.4	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	4.78	4.97e-06	0.00963	0.62	0.4	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000272787.1	KB-226F1.2	4.78	4.98e-06	0.00963	0.55	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23969211~23969873:+
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000272787.1	KB-226F1.2	4.78	4.98e-06	0.00963	0.55	0.4	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23969211~23969873:+
ESCA	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	4.78	4.98e-06	0.00964	0.45	0.4	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
ESCA	cis	rs9545047	0.604	rs9545048	ENSG00000227676.3	LINC01068	4.78	4.99e-06	0.00965	0.52	0.4	Schizophrenia;	chr13:79285593	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1626333	ENSG00000227676.3	LINC01068	4.78	4.99e-06	0.00965	0.52	0.4	Schizophrenia;	chr13:79286932	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs1856996	ENSG00000227676.3	LINC01068	4.78	4.99e-06	0.00965	0.52	0.4	Schizophrenia;	chr13:79287453	chr13:79566727~79571436:+
ESCA	cis	rs7397814	0.558	rs4764447	ENSG00000256975.1	RP11-525E9.1	-4.78	4.99e-06	0.00966	-0.42	-0.4	IgG glycosylation;	chr12:9426513	chr12:9506347~9508440:-
ESCA	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-4.78	4.99e-06	0.00966	-0.45	-0.4	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
ESCA	cis	rs4835265	0.852	rs4835261	ENSG00000250673.1	RP11-6L6.2	4.78	5e-06	0.00967	0.46	0.4	Gamma glutamyl transpeptidase;	chr4:145860595	chr4:146224557~146229056:+
ESCA	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-4.78	5e-06	0.00968	-0.47	-0.4	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
ESCA	cis	rs858239	0.699	rs1881201	ENSG00000230042.1	AK3P3	4.78	5.01e-06	0.00969	0.44	0.4	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23129178~23129841:+
ESCA	cis	rs2439831	0.717	rs2447198	ENSG00000205771.5	CATSPER2P1	-4.77	5.02e-06	0.00971	-0.69	-0.4	Lung cancer in ever smokers;	chr15:43602920	chr15:43726918~43747094:-
ESCA	cis	rs1075265	0.87	rs7569370	ENSG00000235937.1	AC008280.1	4.77	5.02e-06	0.00971	0.43	0.4	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54029552~54030682:-
ESCA	cis	rs12822507	0.811	rs34946234	ENSG00000275560.1	RP11-180M15.7	-4.77	5.02e-06	0.00971	-0.4	-0.4	Systemic lupus erythematosus;	chr12:12628878	chr12:12718973~12719521:+
ESCA	cis	rs12822507	0.899	rs4763859	ENSG00000275560.1	RP11-180M15.7	-4.77	5.02e-06	0.00971	-0.4	-0.4	Systemic lupus erythematosus;	chr12:12634071	chr12:12718973~12719521:+
ESCA	cis	rs12822507	0.868	rs12830917	ENSG00000275560.1	RP11-180M15.7	-4.77	5.02e-06	0.00971	-0.4	-0.4	Systemic lupus erythematosus;	chr12:12639582	chr12:12718973~12719521:+
ESCA	cis	rs9355610	0.609	rs62436424	ENSG00000265828.1	MIR3939	4.77	5.03e-06	0.00971	0.5	0.4	Graves' disease;	chr6:166960770	chr6:166997807~166997912:-
ESCA	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-4.77	5.03e-06	0.00972	-0.4	-0.4	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
ESCA	cis	rs16828019	0.561	rs12025777	ENSG00000235358.1	RP11-399E6.1	4.77	5.04e-06	0.00974	0.68	0.4	Intelligence (multi-trait analysis);	chr1:41283225	chr1:41242373~41284861:+
ESCA	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-4.77	5.06e-06	0.00978	-0.42	-0.4	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-4.77	5.06e-06	0.00978	-0.42	-0.4	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
ESCA	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-4.77	5.06e-06	0.00978	-0.42	-0.4	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-4.77	5.06e-06	0.00978	-0.42	-0.4	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
ESCA	cis	rs9545047	0.604	rs4885625	ENSG00000227676.3	LINC01068	4.77	5.06e-06	0.00978	0.52	0.4	Schizophrenia;	chr13:79290355	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1324873	ENSG00000227676.3	LINC01068	4.77	5.06e-06	0.00978	0.52	0.4	Schizophrenia;	chr13:79292246	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4573813	ENSG00000227676.3	LINC01068	4.77	5.06e-06	0.00978	0.52	0.4	Schizophrenia;	chr13:79293357	chr13:79566727~79571436:+
ESCA	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	4.77	5.08e-06	0.0098	0.54	0.4	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
ESCA	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	4.77	5.08e-06	0.00981	0.47	0.4	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
ESCA	cis	rs7714584	1	rs7724036	ENSG00000197083.10	ZNF300P1	-4.77	5.09e-06	0.00981	-0.6	-0.4	Crohn's disease;	chr5:150905246	chr5:150930645~150946289:-
ESCA	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	4.77	5.09e-06	0.00981	0.54	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
ESCA	cis	rs8072100	0.934	rs9905583	ENSG00000228782.6	CTD-2026D20.3	4.77	5.1e-06	0.00983	0.43	0.4	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47663650	chr17:47450568~47492492:-
ESCA	cis	rs7829975	0.633	rs2979181	ENSG00000173295.6	FAM86B3P	4.77	5.11e-06	0.00986	0.48	0.4	Mood instability;	chr8:8465578	chr8:8228595~8244865:+
ESCA	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-4.77	5.11e-06	0.00986	-0.58	-0.4	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
ESCA	cis	rs2307394	1	rs1014064	ENSG00000223911.1	AC009480.3	4.77	5.12e-06	0.00987	0.47	0.4	Urate levels;	chr2:147854585	chr2:147899401~147902956:-
ESCA	cis	rs6782228	0.848	rs3935016	ENSG00000277250.1	Metazoa_SRP	4.77	5.13e-06	0.00988	0.53	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.848	rs6439141	ENSG00000277250.1	Metazoa_SRP	4.77	5.13e-06	0.00988	0.53	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128673681~128674021:-
ESCA	cis	rs6782228	0.883	rs6439142	ENSG00000277250.1	Metazoa_SRP	4.77	5.13e-06	0.00988	0.53	0.4	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128673681~128674021:-
ESCA	cis	rs9549260	0.755	rs17061450	ENSG00000229456.1	RLIMP1	4.77	5.13e-06	0.00988	0.36	0.4	Red blood cell count;	chr13:40609579	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.709	rs9549240	ENSG00000229456.1	RLIMP1	4.77	5.13e-06	0.00988	0.36	0.4	Red blood cell count;	chr13:40612507	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.755	rs4429172	ENSG00000229456.1	RLIMP1	4.77	5.13e-06	0.00988	0.36	0.4	Red blood cell count;	chr13:40615006	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.739	rs7330614	ENSG00000229456.1	RLIMP1	4.77	5.13e-06	0.00988	0.36	0.4	Red blood cell count;	chr13:40625284	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.709	rs12585870	ENSG00000229456.1	RLIMP1	4.77	5.13e-06	0.00988	0.36	0.4	Red blood cell count;	chr13:40625350	chr13:40618738~40621348:+
ESCA	cis	rs6479901	0.557	rs7920768	ENSG00000235816.3	PRELID1P3	-4.77	5.14e-06	0.0099	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:63300754	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.512	rs7100372	ENSG00000235816.3	PRELID1P3	-4.77	5.14e-06	0.0099	-0.51	-0.4	Intelligence (multi-trait analysis);	chr10:63304484	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.778	rs7896676	ENSG00000235816.3	PRELID1P3	-4.77	5.14e-06	0.0099	-0.51	-0.4	Arthritis (juvenile idiopathic);	chr10:63305542	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs7896677	ENSG00000235816.3	PRELID1P3	-4.77	5.14e-06	0.0099	-0.51	-0.4	Arthritis (juvenile idiopathic);	chr10:63305545	chr10:63427297~63427939:+
ESCA	cis	rs1048238	0.506	rs7552077	ENSG00000235084.3	CHCHD2P6	-4.77	5.15e-06	0.00991	-0.38	-0.4	Systolic blood pressure;	chr1:15870264	chr1:15604597~15605043:+
ESCA	cis	rs2439831	0.681	rs7168940	ENSG00000249839.1	AC011330.5	-4.77	5.15e-06	0.00991	-0.56	-0.4	Lung cancer in ever smokers;	chr15:43341136	chr15:43663654~43684339:-
ESCA	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-4.77	5.15e-06	0.00992	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
ESCA	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	4.77	5.15e-06	0.00992	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
ESCA	cis	rs6604026	0.656	rs2811598	ENSG00000229052.2	RP11-386I23.1	-4.77	5.16e-06	0.00993	-0.38	-0.39	Multiple sclerosis;	chr1:92871376	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2811597	ENSG00000229052.2	RP11-386I23.1	-4.77	5.16e-06	0.00993	-0.38	-0.39	Multiple sclerosis;	chr1:92875596	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2811596	ENSG00000229052.2	RP11-386I23.1	-4.77	5.16e-06	0.00993	-0.38	-0.39	Multiple sclerosis;	chr1:92875666	chr1:92930696~92934098:+
ESCA	cis	rs765787	0.53	rs11636404	ENSG00000259520.4	CTD-2651B20.3	4.77	5.17e-06	0.00994	0.44	0.39	Uric acid levels;	chr15:45243663	chr15:45251580~45279251:-
ESCA	cis	rs7208859	0.623	rs56325146	ENSG00000263531.1	RP13-753N3.1	4.77	5.19e-06	0.00998	0.58	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824006	chr17:30863921~30864940:-
ESCA	cis	rs2742234	0.955	rs1800861	ENSG00000273008.1	RP11-351D16.3	-4.77	5.21e-06	0.01	-0.45	-0.39	Hirschsprung disease;	chr10:43118395	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.955	rs2075910	ENSG00000273008.1	RP11-351D16.3	-4.77	5.21e-06	0.01	-0.45	-0.39	Hirschsprung disease;	chr10:43118782	chr10:43136824~43138334:-
ESCA	cis	rs1816752	0.905	rs9511266	ENSG00000273628.1	RP11-756A22.7	4.77	5.21e-06	0.01	0.39	0.39	Obesity-related traits;	chr13:24438366	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.817	rs7985394	ENSG00000273628.1	RP11-756A22.7	4.77	5.21e-06	0.01	0.39	0.39	Obesity-related traits;	chr13:24438714	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.789	rs7986037	ENSG00000273628.1	RP11-756A22.7	4.77	5.21e-06	0.01	0.39	0.39	Obesity-related traits;	chr13:24438715	chr13:24933006~24936796:+
ESCA	cis	rs7829975	0.714	rs4840362	ENSG00000253981.4	ALG1L13P	-4.77	5.21e-06	0.01	-0.42	-0.39	Mood instability;	chr8:8812572	chr8:8236003~8244667:-
ESCA	cis	rs61160187	0.582	rs4647150	ENSG00000215032.2	GNL3LP1	4.77	5.22e-06	0.01	0.52	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60874778	chr5:60891935~60893577:-
ESCA	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-4.77	5.22e-06	0.01	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-4.77	5.22e-06	0.01	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
ESCA	cis	rs9549260	0.709	rs4943795	ENSG00000229456.1	RLIMP1	-4.77	5.22e-06	0.01	-0.39	-0.39	Red blood cell count;	chr13:40599296	chr13:40618738~40621348:+
ESCA	cis	rs9389248	0.708	rs7750574	ENSG00000232876.1	CTA-212D2.2	-4.76	5.23e-06	0.01	-0.48	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:135029794	chr6:135055033~135060550:+
ESCA	cis	rs6604026	0.656	rs2811600	ENSG00000229052.2	RP11-386I23.1	-4.76	5.26e-06	0.0101	-0.38	-0.39	Multiple sclerosis;	chr1:92868581	chr1:92930696~92934098:+
ESCA	cis	rs1816752	0.905	rs7571	ENSG00000273628.1	RP11-756A22.7	4.76	5.3e-06	0.0102	0.39	0.39	Obesity-related traits;	chr13:24426479	chr13:24933006~24936796:+
ESCA	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-4.76	5.31e-06	0.0102	-0.54	-0.39	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
ESCA	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-4.76	5.31e-06	0.0102	-0.54	-0.39	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
ESCA	cis	rs12822507	0.831	rs34975957	ENSG00000275560.1	RP11-180M15.7	-4.76	5.31e-06	0.0102	-0.4	-0.39	Systemic lupus erythematosus;	chr12:12633256	chr12:12718973~12719521:+
ESCA	cis	rs1005277	0.579	rs932538	ENSG00000276805.1	RP11-291L22.6	4.76	5.32e-06	0.0102	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38451030~38451785:+
ESCA	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	4.76	5.32e-06	0.0102	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	4.76	5.32e-06	0.0102	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	4.76	5.32e-06	0.0102	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	4.76	5.32e-06	0.0102	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
ESCA	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	4.76	5.33e-06	0.0102	0.59	0.39	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
ESCA	cis	rs9545047	0.604	rs9530891	ENSG00000227676.3	LINC01068	4.76	5.33e-06	0.0102	0.52	0.39	Schizophrenia;	chr13:79284750	chr13:79566727~79571436:+
ESCA	cis	rs7412746	0.658	rs10888397	ENSG00000206931.1	RNU6-1042P	-4.76	5.34e-06	0.0102	-0.49	-0.39	Melanoma;	chr1:150914276	chr1:150701866~150701972:+
ESCA	cis	rs453301	0.571	rs330057	ENSG00000253981.4	ALG1L13P	-4.76	5.34e-06	0.0102	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9232283	chr8:8236003~8244667:-
ESCA	cis	rs9545047	0.716	rs9530920	ENSG00000227676.3	LINC01068	4.76	5.35e-06	0.0102	0.52	0.39	Schizophrenia;	chr13:79423254	chr13:79566727~79571436:+
ESCA	cis	rs9462027	0.883	rs6941110	ENSG00000186328.4	RP11-140K17.2	4.76	5.35e-06	0.0102	0.45	0.39	Systemic lupus erythematosus;	chr6:34823557	chr6:34715613~34715940:+
ESCA	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	4.76	5.35e-06	0.0102	0.54	0.39	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
ESCA	cis	rs6479891	1	rs12416113	ENSG00000235816.3	PRELID1P3	4.76	5.35e-06	0.0103	0.48	0.39	Arthritis (juvenile idiopathic);	chr10:63136717	chr10:63427297~63427939:+
ESCA	cis	rs2439831	0.681	rs7176849	ENSG00000249839.1	AC011330.5	-4.76	5.37e-06	0.0103	-0.59	-0.39	Lung cancer in ever smokers;	chr15:43389229	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.618	rs999026	ENSG00000249839.1	AC011330.5	-4.76	5.37e-06	0.0103	-0.59	-0.39	Lung cancer in ever smokers;	chr15:43398017	chr15:43663654~43684339:-
ESCA	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	4.76	5.38e-06	0.0103	0.54	0.39	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
ESCA	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-4.76	5.38e-06	0.0103	-0.63	-0.39	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
ESCA	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-4.76	5.38e-06	0.0103	-0.51	-0.39	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000272787.1	KB-226F1.2	4.76	5.41e-06	0.0104	0.55	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23969211~23969873:+
ESCA	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	4.76	5.41e-06	0.0104	0.62	0.39	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	4.76	5.41e-06	0.0104	0.62	0.39	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
ESCA	cis	rs765787	0.505	rs11630884	ENSG00000259520.4	CTD-2651B20.3	4.76	5.42e-06	0.0104	0.44	0.39	Uric acid levels;	chr15:45240048	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs11634794	ENSG00000259520.4	CTD-2651B20.3	4.76	5.42e-06	0.0104	0.44	0.39	Uric acid levels;	chr15:45242294	chr15:45251580~45279251:-
ESCA	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-4.76	5.44e-06	0.0104	-0.47	-0.39	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
ESCA	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	4.76	5.44e-06	0.0104	0.46	0.39	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
ESCA	cis	rs2505998	0.833	rs2251674	ENSG00000273008.1	RP11-351D16.3	4.76	5.45e-06	0.0104	0.44	0.39	Hirschsprung disease;	chr10:43109944	chr10:43136824~43138334:-
ESCA	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	4.75	5.47e-06	0.0105	0.68	0.39	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
ESCA	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	4.75	5.48e-06	0.0105	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	4.75	5.48e-06	0.0105	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	4.75	5.48e-06	0.0105	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	4.75	5.48e-06	0.0105	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
ESCA	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-4.75	5.48e-06	0.0105	-0.46	-0.39	Migraine;	chr4:56881195	chr4:56960927~56961373:-
ESCA	cis	rs732716	0.785	rs55660045	ENSG00000267980.1	AC007292.6	-4.75	5.49e-06	0.0105	-0.54	-0.39	Mean corpuscular volume;	chr19:4425308	chr19:4363789~4364640:+
ESCA	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	4.75	5.51e-06	0.0105	0.59	0.39	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
ESCA	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	4.75	5.51e-06	0.0105	0.64	0.39	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
ESCA	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	4.75	5.51e-06	0.0105	0.64	0.39	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
ESCA	cis	rs61160187	0.582	rs4700404	ENSG00000215032.2	GNL3LP1	4.75	5.51e-06	0.0105	0.49	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:61028769	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs28436304	ENSG00000215032.2	GNL3LP1	4.75	5.51e-06	0.0105	0.49	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:61038584	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.548	rs1983484	ENSG00000215032.2	GNL3LP1	4.75	5.51e-06	0.0105	0.49	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:61050998	chr5:60891935~60893577:-
ESCA	cis	rs9549260	0.753	rs9532562	ENSG00000229456.1	RLIMP1	4.75	5.52e-06	0.0105	0.46	0.39	Red blood cell count;	chr13:40579448	chr13:40618738~40621348:+
ESCA	cis	rs4792901	0.722	rs12601849	ENSG00000279602.1	CTD-3014M21.1	-4.75	5.52e-06	0.0105	-0.51	-0.39	Dupuytren's disease;	chr17:43468920	chr17:43360041~43361361:-
ESCA	cis	rs8059260	0.736	rs113433437	ENSG00000274038.1	RP11-66H6.4	-4.75	5.53e-06	0.0106	-0.82	-0.39	Alcohol consumption over the past year;	chr16:10959438	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.736	rs8046423	ENSG00000274038.1	RP11-66H6.4	-4.75	5.53e-06	0.0106	-0.82	-0.39	Alcohol consumption over the past year;	chr16:10964016	chr16:11056556~11057034:+
ESCA	cis	rs7208859	0.725	rs9910051	ENSG00000263531.1	RP13-753N3.1	4.75	5.54e-06	0.0106	0.57	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834184	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.725	rs7210904	ENSG00000263531.1	RP13-753N3.1	4.75	5.54e-06	0.0106	0.57	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843187	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.725	rs9915802	ENSG00000263531.1	RP13-753N3.1	4.75	5.54e-06	0.0106	0.57	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846040	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.725	rs7342938	ENSG00000263531.1	RP13-753N3.1	4.75	5.54e-06	0.0106	0.57	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862812	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.725	rs6505215	ENSG00000263531.1	RP13-753N3.1	4.75	5.54e-06	0.0106	0.57	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862885	chr17:30863921~30864940:-
ESCA	cis	rs2739330	0.731	rs2000468	ENSG00000099984.9	GSTT2	-4.75	5.54e-06	0.0106	-0.47	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23980123~23983911:+
ESCA	cis	rs17027258	0.609	rs4851005	ENSG00000234389.1	AC007278.3	-4.75	5.56e-06	0.0106	-0.34	-0.39	White blood cell types;	chr2:102395092	chr2:102438713~102440475:+
ESCA	cis	rs8059260	0.736	rs7192695	ENSG00000274038.1	RP11-66H6.4	-4.75	5.56e-06	0.0106	-0.71	-0.39	Alcohol consumption over the past year;	chr16:11005395	chr16:11056556~11057034:+
ESCA	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-4.75	5.57e-06	0.0106	-0.47	-0.39	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
ESCA	cis	rs2439831	0.867	rs933941	ENSG00000249839.1	AC011330.5	-4.75	5.57e-06	0.0106	-0.58	-0.39	Lung cancer in ever smokers;	chr15:43340028	chr15:43663654~43684339:-
ESCA	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-4.75	5.58e-06	0.0106	-0.42	-0.39	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
ESCA	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-4.75	5.58e-06	0.0106	-0.62	-0.39	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
ESCA	cis	rs7580717	0.893	rs6714129	ENSG00000201574.1	RNU1-93P	-4.75	5.58e-06	0.0106	-0.44	-0.39	Multiple myeloma;	chr2:231314944	chr2:231133462~231133630:+
ESCA	cis	rs11235843	1	rs72974833	ENSG00000255928.1	RP11-456I15.2	4.75	5.59e-06	0.0106	0.69	0.39	Hand grip strength;	chr11:73664059	chr11:73722349~73722694:+
ESCA	cis	rs9399137	0.507	rs13209780	ENSG00000232876.1	CTA-212D2.2	-4.75	5.6e-06	0.0107	-0.48	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135023657	chr6:135055033~135060550:+
ESCA	cis	rs61160187	0.582	rs976630	ENSG00000215032.2	GNL3LP1	4.75	5.6e-06	0.0107	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60919654	chr5:60891935~60893577:-
ESCA	cis	rs7208859	0.673	rs999797	ENSG00000263531.1	RP13-753N3.1	4.75	5.61e-06	0.0107	0.61	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832311	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11651802	ENSG00000263531.1	RP13-753N3.1	4.75	5.61e-06	0.0107	0.61	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30832642	chr17:30863921~30864940:-
ESCA	cis	rs1075232	1	rs66581165	ENSG00000270055.1	CTD-3092A11.2	-4.75	5.61e-06	0.0107	-0.89	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31451564	chr15:30487963~30490313:+
ESCA	cis	rs2505998	1	rs2435357	ENSG00000273008.1	RP11-351D16.3	-4.75	5.61e-06	0.0107	-0.44	-0.39	Hirschsprung disease;	chr10:43086608	chr10:43136824~43138334:-
ESCA	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-4.75	5.63e-06	0.0107	-0.5	-0.39	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-4.75	5.63e-06	0.0107	-0.5	-0.39	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-4.75	5.63e-06	0.0107	-0.5	-0.39	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
ESCA	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-4.75	5.63e-06	0.0107	-0.5	-0.39	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
ESCA	cis	rs9389248	0.737	rs56358308	ENSG00000232876.1	CTA-212D2.2	-4.75	5.64e-06	0.0107	-0.48	-0.39	High light scatter reticulocyte percentage of red cells;	chr6:134985842	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs11754021	ENSG00000232876.1	CTA-212D2.2	-4.75	5.64e-06	0.0107	-0.48	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134987237	chr6:135055033~135060550:+
ESCA	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	4.75	5.66e-06	0.0107	0.47	0.39	Breast size;	chr12:9232939	chr12:9277235~9313241:+
ESCA	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-4.75	5.67e-06	0.0108	-0.47	-0.39	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
ESCA	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	4.74	5.68e-06	0.0108	0.54	0.39	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
ESCA	cis	rs950880	0.71	rs55927292	ENSG00000234389.1	AC007278.3	-4.74	5.69e-06	0.0108	-0.37	-0.39	Serum protein levels (sST2);	chr2:102348401	chr2:102438713~102440475:+
ESCA	cis	rs6860806	0.507	rs635620	ENSG00000233006.5	AC034220.3	-4.74	5.69e-06	0.0108	-0.38	-0.39	Breast cancer;	chr5:132384571	chr5:132311285~132369916:-
ESCA	cis	rs6860806	0.507	rs635619	ENSG00000233006.5	AC034220.3	-4.74	5.69e-06	0.0108	-0.38	-0.39	Breast cancer;	chr5:132384573	chr5:132311285~132369916:-
ESCA	cis	rs2439831	0.867	rs2920781	ENSG00000249839.1	AC011330.5	-4.74	5.69e-06	0.0108	-0.7	-0.39	Lung cancer in ever smokers;	chr15:43632484	chr15:43663654~43684339:-
ESCA	cis	rs8059260	0.604	rs8052325	ENSG00000274038.1	RP11-66H6.4	-4.74	5.69e-06	0.0108	-0.69	-0.39	Alcohol consumption over the past year;	chr16:11044121	chr16:11056556~11057034:+
ESCA	cis	rs3820716	0.507	rs13032303	ENSG00000223911.1	AC009480.3	4.74	5.7e-06	0.0108	0.47	0.39	Glomerular filtration rate (creatinine);	chr2:148106042	chr2:147899401~147902956:-
ESCA	cis	rs28830936	1	rs112896623	ENSG00000250379.1	RP11-23P13.4	4.74	5.71e-06	0.0108	0.46	0.39	Diastolic blood pressure;	chr15:41709647	chr15:41825099~41827936:-
ESCA	cis	rs11169552	0.51	rs11169493	ENSG00000200428.1	Y_RNA	-4.74	5.72e-06	0.0108	-0.48	-0.39	Colorectal cancer;	chr12:50565643	chr12:50743568~50743684:+
ESCA	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-4.74	5.72e-06	0.0108	-0.56	-0.39	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
ESCA	cis	rs7829975	0.593	rs2979241	ENSG00000173295.6	FAM86B3P	4.74	5.72e-06	0.0108	0.45	0.39	Mood instability;	chr8:8445843	chr8:8228595~8244865:+
ESCA	cis	rs9545047	0.716	rs7140027	ENSG00000227676.3	LINC01068	4.74	5.74e-06	0.0109	0.52	0.39	Schizophrenia;	chr13:79281162	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545076	ENSG00000227676.3	LINC01068	-4.74	5.74e-06	0.0109	-0.51	-0.39	Schizophrenia;	chr13:79335983	chr13:79566727~79571436:+
ESCA	cis	rs3820068	0.577	rs41270271	ENSG00000237301.1	RP4-680D5.2	4.74	5.75e-06	0.0109	0.41	0.39	Systolic blood pressure;	chr1:15587087	chr1:15586136~15603626:-
ESCA	cis	rs4951011	0.572	rs67792495	ENSG00000223505.2	RP11-397P13.7	-4.74	5.75e-06	0.0109	-0.55	-0.39	Breast cancer;	chr1:203896225	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs2096197	ENSG00000223505.2	RP11-397P13.7	-4.74	5.75e-06	0.0109	-0.55	-0.39	Breast cancer;	chr1:203901058	chr1:203835585~203835912:-
ESCA	cis	rs1439620	0.542	rs12900800	ENSG00000271763.1	RP11-386M24.9	4.74	5.76e-06	0.0109	0.42	0.39	Body mass index;	chr15:92969448	chr15:92602910~92620015:+
ESCA	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-4.74	5.76e-06	0.0109	-0.5	-0.39	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
ESCA	cis	rs5760092	0.627	rs6519489	ENSG00000099984.9	GSTT2	4.74	5.77e-06	0.0109	0.57	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23980123~23983911:+
ESCA	cis	rs5760092	0.755	rs11090298	ENSG00000099984.9	GSTT2	4.74	5.77e-06	0.0109	0.57	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23980123~23983911:+
ESCA	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	4.74	5.78e-06	0.0109	0.49	0.39	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
ESCA	cis	rs875971	0.54	rs35510581	ENSG00000179406.6	LINC00174	4.74	5.79e-06	0.011	0.46	0.39	Aortic root size;	chr7:66113790	chr7:66376044~66401338:-
ESCA	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	4.74	5.8e-06	0.011	0.52	0.39	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
ESCA	cis	rs61160187	0.582	rs1021005	ENSG00000215032.2	GNL3LP1	4.74	5.82e-06	0.011	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60895633	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.517	rs6884966	ENSG00000215032.2	GNL3LP1	4.74	5.82e-06	0.011	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60897512	chr5:60891935~60893577:-
ESCA	cis	rs6479901	0.841	rs10465990	ENSG00000235816.3	PRELID1P3	-4.74	5.82e-06	0.011	-0.43	-0.39	Intelligence (multi-trait analysis);	chr10:63200776	chr10:63427297~63427939:+
ESCA	cis	rs2929278	0.589	rs11638972	ENSG00000205771.5	CATSPER2P1	4.74	5.83e-06	0.011	0.5	0.39	Schizophrenia;	chr15:43782493	chr15:43726918~43747094:-
ESCA	cis	rs7283707	0.581	rs2823457	ENSG00000269950.1	AP000962.2	4.74	5.83e-06	0.011	0.68	0.39	QRS complex (12-leadsum);	chr21:15704652	chr21:16574718~16582637:-
ESCA	cis	rs7412746	0.611	rs1889741	ENSG00000206931.1	RNU6-1042P	4.74	5.85e-06	0.0111	0.5	0.39	Melanoma;	chr1:150896569	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs66847267	ENSG00000206931.1	RNU6-1042P	4.74	5.85e-06	0.0111	0.5	0.39	Melanoma;	chr1:150902697	chr1:150701866~150701972:+
ESCA	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-4.74	5.86e-06	0.0111	-0.52	-0.39	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
ESCA	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-4.74	5.86e-06	0.0111	-0.52	-0.39	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
ESCA	cis	rs1075265	0.756	rs805423	ENSG00000235937.1	AC008280.1	4.74	5.86e-06	0.0111	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54029552~54030682:-
ESCA	cis	rs9355610	0.609	rs3756838	ENSG00000265828.1	MIR3939	4.74	5.86e-06	0.0111	0.52	0.39	Graves' disease;	chr6:166957763	chr6:166997807~166997912:-
ESCA	cis	rs9545047	0.604	rs9318641	ENSG00000227676.3	LINC01068	-4.74	5.86e-06	0.0111	-0.52	-0.39	Schizophrenia;	chr13:79426545	chr13:79566727~79571436:+
ESCA	cis	rs1816752	0.712	rs6490932	ENSG00000273628.1	RP11-756A22.7	4.74	5.87e-06	0.0111	0.38	0.39	Obesity-related traits;	chr13:24443313	chr13:24933006~24936796:+
ESCA	cis	rs875971	0.66	rs3764903	ENSG00000179406.6	LINC00174	4.74	5.88e-06	0.0111	0.44	0.39	Aortic root size;	chr7:66633495	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.66	rs1860470	ENSG00000179406.6	LINC00174	4.74	5.88e-06	0.0111	0.44	0.39	Aortic root size;	chr7:66638707	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.577	rs34888281	ENSG00000179406.6	LINC00174	4.74	5.88e-06	0.0111	0.46	0.39	Aortic root size;	chr7:66120784	chr7:66376044~66401338:-
ESCA	cis	rs6860806	0.507	rs183898	ENSG00000233006.5	AC034220.3	-4.74	5.89e-06	0.0111	-0.38	-0.39	Breast cancer;	chr5:132381210	chr5:132311285~132369916:-
ESCA	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	4.74	5.91e-06	0.0112	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	4.74	5.91e-06	0.0112	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
ESCA	cis	rs61160187	0.518	rs62372133	ENSG00000215032.2	GNL3LP1	4.74	5.91e-06	0.0112	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906350	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs62372134	ENSG00000215032.2	GNL3LP1	4.74	5.91e-06	0.0112	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60906420	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs12655603	ENSG00000215032.2	GNL3LP1	4.74	5.91e-06	0.0112	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60908769	chr5:60891935~60893577:-
ESCA	cis	rs11169552	0.51	rs10459235	ENSG00000200428.1	Y_RNA	4.74	5.91e-06	0.0112	0.47	0.39	Colorectal cancer;	chr12:50702400	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10783383	ENSG00000200428.1	Y_RNA	4.74	5.91e-06	0.0112	0.47	0.39	Colorectal cancer;	chr12:50709086	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs4768906	ENSG00000200428.1	Y_RNA	4.74	5.91e-06	0.0112	0.47	0.39	Colorectal cancer;	chr12:50713040	chr12:50743568~50743684:+
ESCA	cis	rs6785206	0.554	rs13075151	ENSG00000239503.1	MARK2P8	-4.74	5.92e-06	0.0112	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128766907	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.502	rs7621587	ENSG00000239503.1	MARK2P8	-4.74	5.92e-06	0.0112	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128774917	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.504	rs9875958	ENSG00000239503.1	MARK2P8	-4.74	5.92e-06	0.0112	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128778249	chr3:128748538~128749489:-
ESCA	cis	rs42490	0.966	rs218936	ENSG00000251136.7	RP11-37B2.1	4.73	5.93e-06	0.0112	0.4	0.39	Leprosy;	chr8:89743186	chr8:89609409~89757727:-
ESCA	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	4.73	5.93e-06	0.0112	0.66	0.39	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
ESCA	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	4.73	5.93e-06	0.0112	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
ESCA	cis	rs7412746	0.503	rs72704639	ENSG00000206931.1	RNU6-1042P	4.73	5.95e-06	0.0112	0.51	0.39	Melanoma;	chr1:150825859	chr1:150701866~150701972:+
ESCA	cis	rs11169552	0.51	rs10783384	ENSG00000200428.1	Y_RNA	4.73	5.95e-06	0.0112	0.47	0.39	Colorectal cancer;	chr12:50724211	chr12:50743568~50743684:+
ESCA	cis	rs150992	0.886	rs161948	ENSG00000248489.1	CTD-2007H13.3	4.73	5.96e-06	0.0112	0.54	0.39	Body mass index;	chr5:98932333	chr5:98929171~98995013:+
ESCA	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-4.73	5.96e-06	0.0112	-0.47	-0.39	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
ESCA	cis	rs2019137	0.776	rs4849183	ENSG00000189223.12	PAX8-AS1	-4.73	5.97e-06	0.0112	-0.52	-0.39	Lymphocyte counts;	chr2:113234797	chr2:113211522~113276581:+
ESCA	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	4.73	6.01e-06	0.0113	0.51	0.39	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
ESCA	cis	rs1816752	0.87	rs7998797	ENSG00000273628.1	RP11-756A22.7	4.73	6.01e-06	0.0113	0.38	0.39	Obesity-related traits;	chr13:24440850	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs7981337	ENSG00000273628.1	RP11-756A22.7	4.73	6.01e-06	0.0113	0.38	0.39	Obesity-related traits;	chr13:24440915	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.87	rs7981480	ENSG00000273628.1	RP11-756A22.7	4.73	6.01e-06	0.0113	0.38	0.39	Obesity-related traits;	chr13:24440966	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.837	rs4769355	ENSG00000273628.1	RP11-756A22.7	4.73	6.01e-06	0.0113	0.38	0.39	Obesity-related traits;	chr13:24441059	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs4770680	ENSG00000273628.1	RP11-756A22.7	4.73	6.01e-06	0.0113	0.38	0.39	Obesity-related traits;	chr13:24441110	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.905	rs9511264	ENSG00000273628.1	RP11-756A22.7	-4.73	6.01e-06	0.0113	-0.38	-0.39	Obesity-related traits;	chr13:24438079	chr13:24933006~24936796:+
ESCA	cis	rs1075265	0.73	rs805392	ENSG00000235937.1	AC008280.1	4.73	6.01e-06	0.0113	0.44	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54029552~54030682:-
ESCA	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	4.73	6.02e-06	0.0113	0.54	0.39	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	4.73	6.02e-06	0.0113	0.54	0.39	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	4.73	6.02e-06	0.0113	0.54	0.39	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
ESCA	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	4.73	6.02e-06	0.0113	0.65	0.39	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
ESCA	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	4.73	6.02e-06	0.0113	0.65	0.39	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
ESCA	cis	rs8059260	0.542	rs11860777	ENSG00000274038.1	RP11-66H6.4	-4.73	6.02e-06	0.0113	-0.72	-0.39	Alcohol consumption over the past year;	chr16:11033718	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.542	rs16957948	ENSG00000274038.1	RP11-66H6.4	-4.73	6.02e-06	0.0113	-0.72	-0.39	Alcohol consumption over the past year;	chr16:11034208	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.542	rs7184915	ENSG00000274038.1	RP11-66H6.4	-4.73	6.02e-06	0.0113	-0.72	-0.39	Alcohol consumption over the past year;	chr16:11034509	chr16:11056556~11057034:+
ESCA	cis	rs10875746	0.859	rs11168371	ENSG00000240399.1	RP1-228P16.1	-4.73	6.03e-06	0.0113	-0.48	-0.39	Longevity (90 years and older);	chr12:48043903	chr12:48054813~48055591:-
ESCA	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	4.73	6.04e-06	0.0114	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
ESCA	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-4.73	6.04e-06	0.0114	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
ESCA	cis	rs559928	0.606	rs61083753	ENSG00000274986.1	MIR6750	4.73	6.04e-06	0.0114	0.66	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64125193	chr11:64898363~64898437:-
ESCA	cis	rs9807368	1	rs9807368	ENSG00000263627.1	PPP4R1-AS1	-4.73	6.05e-06	0.0114	-0.55	-0.39	Platelet distribution width;	chr18:9620161	chr18:9615264~9619363:+
ESCA	cis	rs61160187	0.582	rs7723901	ENSG00000215032.2	GNL3LP1	4.73	6.05e-06	0.0114	0.5	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60977163	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs1471488	ENSG00000215032.2	GNL3LP1	4.73	6.05e-06	0.0114	0.5	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60990270	chr5:60891935~60893577:-
ESCA	cis	rs2221894	0.853	rs11781448	ENSG00000273710.1	Metazoa_SRP	-4.73	6.06e-06	0.0114	-0.42	-0.39	Obesity-related traits;	chr8:28936410	chr8:28915579~28915864:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000272787.1	KB-226F1.2	4.73	6.08e-06	0.0114	0.5	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23969211~23969873:+
ESCA	cis	rs9399137	0.507	rs10484496	ENSG00000232876.1	CTA-212D2.2	-4.73	6.09e-06	0.0114	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978544	chr6:135055033~135060550:+
ESCA	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	4.73	6.1e-06	0.0114	0.44	0.39	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
ESCA	cis	rs2227564	0.672	rs2461864	ENSG00000229990.3	RP11-574K11.8	-4.73	6.11e-06	0.0114	-0.44	-0.39	Crohn's disease;Inflammatory bowel disease;	chr10:73900114	chr10:73841833~73847115:+
ESCA	cis	rs7412746	0.611	rs11204747	ENSG00000206931.1	RNU6-1042P	-4.73	6.12e-06	0.0115	-0.5	-0.39	Melanoma;	chr1:150954676	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.586	rs2864882	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150910561	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs4970984	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150914901	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs72704679	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150925001	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.526	rs6587542	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Tonsillectomy;	chr1:150935225	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs4970931	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150938251	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.503	rs7556451	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Tonsillectomy;	chr1:150940666	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs2271076	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150944181	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs11204748	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150954893	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.621	rs11204749	ENSG00000206931.1	RNU6-1042P	4.73	6.12e-06	0.0115	0.5	0.39	Melanoma;	chr1:150957087	chr1:150701866~150701972:+
ESCA	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-4.73	6.13e-06	0.0115	-0.43	-0.39	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
ESCA	cis	rs61160187	0.582	rs4647132	ENSG00000215032.2	GNL3LP1	4.73	6.13e-06	0.0115	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60886893	chr5:60891935~60893577:-
ESCA	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	4.73	6.14e-06	0.0115	0.65	0.39	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
ESCA	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	4.73	6.15e-06	0.0115	0.49	0.39	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
ESCA	cis	rs938295	0.696	rs867321	ENSG00000206652.1	RNU1-1	4.73	6.15e-06	0.0115	0.7	0.39	Gut microbiota (bacterial taxa);	chr1:15760669	chr1:16514122~16514285:-
ESCA	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-4.73	6.17e-06	0.0115	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
ESCA	cis	rs9399137	0.507	rs6569986	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134990503	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs13197750	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134991242	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs7761964	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134993127	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs11753673	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995338	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs12663447	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134995888	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs4895437	ENSG00000232876.1	CTA-212D2.2	-4.73	6.17e-06	0.0115	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134996216	chr6:135055033~135060550:+
ESCA	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	4.72	6.18e-06	0.0116	0.37	0.39	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
ESCA	cis	rs6921919	0.789	rs6456814	ENSG00000216901.1	AL022393.7	4.72	6.18e-06	0.0116	0.48	0.39	Autism spectrum disorder or schizophrenia;	chr6:28338035	chr6:28176188~28176674:+
ESCA	cis	rs875971	0.577	rs35072105	ENSG00000179406.6	LINC00174	4.72	6.19e-06	0.0116	0.46	0.39	Aortic root size;	chr7:66144830	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-4.72	6.19e-06	0.0116	-0.51	-0.39	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
ESCA	cis	rs6456156	0.792	rs10946213	ENSG00000265828.1	MIR3939	4.72	6.2e-06	0.0116	0.43	0.39	Primary biliary cholangitis;	chr6:167102607	chr6:166997807~166997912:-
ESCA	cis	rs7829975	0.545	rs13261926	ENSG00000253981.4	ALG1L13P	-4.72	6.21e-06	0.0116	-0.47	-0.39	Mood instability;	chr8:8694100	chr8:8236003~8244667:-
ESCA	cis	rs9399137	0.507	rs4580893	ENSG00000232876.1	CTA-212D2.2	-4.72	6.21e-06	0.0116	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134976524	chr6:135055033~135060550:+
ESCA	cis	rs7829975	0.511	rs2955578	ENSG00000173295.6	FAM86B3P	4.72	6.23e-06	0.0116	0.48	0.39	Mood instability;	chr8:8279561	chr8:8228595~8244865:+
ESCA	cis	rs12043259	0.502	rs4951111	ENSG00000229657.2	RP11-494K3.2	-4.72	6.24e-06	0.0116	-0.57	-0.39	Addiction;	chr1:204756518	chr1:204946608~204947169:+
ESCA	cis	rs6604026	0.656	rs2774956	ENSG00000229052.2	RP11-386I23.1	-4.72	6.25e-06	0.0117	-0.39	-0.39	Multiple sclerosis;	chr1:92899169	chr1:92930696~92934098:+
ESCA	cis	rs1075265	0.783	rs805453	ENSG00000235937.1	AC008280.1	4.72	6.25e-06	0.0117	0.42	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.73	rs2111868	ENSG00000235937.1	AC008280.1	4.72	6.25e-06	0.0117	0.42	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54029552~54030682:-
ESCA	cis	rs10759883	0.627	rs690528	ENSG00000175611.10	LINC00476	4.72	6.27e-06	0.0117	0.42	0.39	Nicotine dependence;	chr9:95876006	chr9:95759231~95875977:-
ESCA	cis	rs10759883	0.627	rs689697	ENSG00000175611.10	LINC00476	4.72	6.27e-06	0.0117	0.42	0.39	Nicotine dependence;	chr9:95876560	chr9:95759231~95875977:-
ESCA	cis	rs42490	1	rs13252013	ENSG00000251136.7	RP11-37B2.1	-4.72	6.27e-06	0.0117	-0.41	-0.39	Leprosy;	chr8:89746881	chr8:89609409~89757727:-
ESCA	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-4.72	6.28e-06	0.0117	-0.61	-0.39	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
ESCA	cis	rs1816752	0.805	rs61614647	ENSG00000273628.1	RP11-756A22.7	4.72	6.31e-06	0.0118	0.38	0.39	Obesity-related traits;	chr13:24441829	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.774	rs55888616	ENSG00000273628.1	RP11-756A22.7	4.72	6.31e-06	0.0118	0.38	0.39	Obesity-related traits;	chr13:24441954	chr13:24933006~24936796:+
ESCA	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	4.72	6.32e-06	0.0118	0.62	0.39	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
ESCA	cis	rs7412746	0.611	rs2280627	ENSG00000206931.1	RNU6-1042P	4.72	6.33e-06	0.0118	0.5	0.39	Melanoma;	chr1:150963396	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.646	rs1972060	ENSG00000206931.1	RNU6-1042P	4.72	6.33e-06	0.0118	0.5	0.39	Melanoma;	chr1:150965118	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.611	rs752376	ENSG00000206931.1	RNU6-1042P	4.72	6.33e-06	0.0118	0.5	0.39	Melanoma;	chr1:150968905	chr1:150701866~150701972:+
ESCA	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-4.72	6.34e-06	0.0118	-0.44	-0.39	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
ESCA	cis	rs6479901	0.512	rs4746244	ENSG00000235816.3	PRELID1P3	-4.72	6.34e-06	0.0118	-0.54	-0.39	Intelligence (multi-trait analysis);	chr10:63599941	chr10:63427297~63427939:+
ESCA	cis	rs4951011	0.572	rs56292829	ENSG00000223505.2	RP11-397P13.7	-4.72	6.34e-06	0.0118	-0.55	-0.39	Breast cancer;	chr1:203876646	chr1:203835585~203835912:-
ESCA	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-4.72	6.35e-06	0.0118	-0.46	-0.39	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
ESCA	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	4.72	6.35e-06	0.0118	0.43	0.39	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
ESCA	cis	rs11169552	0.51	rs4768858	ENSG00000200428.1	Y_RNA	4.72	6.37e-06	0.0119	0.48	0.39	Colorectal cancer;	chr12:50646035	chr12:50743568~50743684:+
ESCA	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	4.72	6.37e-06	0.0119	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
ESCA	cis	rs2505998	0.843	rs2506004	ENSG00000273008.1	RP11-351D16.3	-4.72	6.37e-06	0.0119	-0.44	-0.39	Hirschsprung disease;	chr10:43086825	chr10:43136824~43138334:-
ESCA	cis	rs6785206	0.614	rs59241698	ENSG00000239503.1	MARK2P8	-4.72	6.37e-06	0.0119	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128790405	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs7652168	ENSG00000239503.1	MARK2P8	-4.72	6.37e-06	0.0119	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128793452	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs9853945	ENSG00000239503.1	MARK2P8	-4.72	6.37e-06	0.0119	-0.41	-0.39	Lymphocyte percentage of white cells;	chr3:128809787	chr3:128748538~128749489:-
ESCA	cis	rs1061377	1	rs12499266	ENSG00000249685.1	RP11-360F5.3	-4.72	6.38e-06	0.0119	-0.43	-0.39	Uric acid levels;	chr4:39118133	chr4:39133913~39135608:+
ESCA	cis	rs2283792	0.718	rs239918	ENSG00000228050.1	TOP3BP1	4.72	6.38e-06	0.0119	0.5	0.39	Multiple sclerosis;	chr22:21959457	chr22:22223187~22224566:-
ESCA	cis	rs10954779	0.54	rs2725380	ENSG00000253579.1	SUMO2P16	-4.72	6.4e-06	0.0119	-0.42	-0.39	Intelligence (multi-trait analysis);	chr8:31115718	chr8:31131539~31131802:-
ESCA	cis	rs7932354	0.666	rs6485696	ENSG00000271350.1	CTD-2384B9.1	-4.72	6.41e-06	0.0119	-0.46	-0.39	Bone mineral density (hip);Bone mineral density;	chr11:46820494	chr11:47041027~47041945:-
ESCA	cis	rs7932354	0.71	rs10838621	ENSG00000271350.1	CTD-2384B9.1	-4.72	6.41e-06	0.0119	-0.46	-0.39	Bone mineral density (hip);Bone mineral density;	chr11:46829908	chr11:47041027~47041945:-
ESCA	cis	rs6604026	0.656	rs2481713	ENSG00000229052.2	RP11-386I23.1	-4.72	6.42e-06	0.0119	-0.39	-0.39	Multiple sclerosis;	chr1:92889332	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.63	rs2263247	ENSG00000229052.2	RP11-386I23.1	-4.72	6.42e-06	0.0119	-0.39	-0.39	Multiple sclerosis;	chr1:92898510	chr1:92930696~92934098:+
ESCA	cis	rs4345206	0.804	rs11100902	ENSG00000250673.1	RP11-6L6.2	4.72	6.42e-06	0.0119	0.4	0.39	Coronary artery disease;	chr4:145874074	chr4:146224557~146229056:+
ESCA	cis	rs6951245	0.706	rs28685743	ENSG00000229043.2	AC091729.9	-4.72	6.42e-06	0.012	-0.56	-0.39	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1158100	chr7:1160374~1165267:+
ESCA	cis	rs7714584	1	rs7736554	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150878746	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7736873	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150878920	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7716903	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150879012	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11167518	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150879358	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1428552	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150880269	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1428551	ENSG00000197083.10	ZNF300P1	4.71	6.44e-06	0.012	0.61	0.39	Crohn's disease;	chr5:150880270	chr5:150930645~150946289:-
ESCA	cis	rs11118620	0.81	rs1603047	ENSG00000272823.1	RP11-295M18.6	4.71	6.45e-06	0.012	0.48	0.39	Heart failure;	chr1:220849953	chr1:220828676~220829211:-
ESCA	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-4.71	6.46e-06	0.012	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-4.71	6.46e-06	0.012	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-4.71	6.46e-06	0.012	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-4.71	6.46e-06	0.012	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-4.71	6.46e-06	0.012	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
ESCA	cis	rs7829975	0.714	rs12544992	ENSG00000253981.4	ALG1L13P	4.71	6.46e-06	0.012	0.42	0.39	Mood instability;	chr8:8804171	chr8:8236003~8244667:-
ESCA	cis	rs1681630	0.545	rs12790666	ENSG00000280615.1	Y_RNA	-4.71	6.47e-06	0.012	-0.42	-0.39	Height;	chr11:47961925	chr11:47614898~47614994:-
ESCA	cis	rs11169552	0.51	rs7307419	ENSG00000200428.1	Y_RNA	4.71	6.48e-06	0.012	0.46	0.39	Colorectal cancer;	chr12:50613230	chr12:50743568~50743684:+
ESCA	cis	rs8072100	0.967	rs4580230	ENSG00000228782.6	CTD-2026D20.3	4.71	6.48e-06	0.012	0.43	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47661495	chr17:47450568~47492492:-
ESCA	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	4.71	6.49e-06	0.0121	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
ESCA	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	4.71	6.51e-06	0.0121	0.54	0.39	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
ESCA	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-4.71	6.52e-06	0.0121	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
ESCA	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	4.71	6.52e-06	0.0121	0.34	0.39	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
ESCA	cis	rs2439831	0.681	rs526450	ENSG00000249839.1	AC011330.5	-4.71	6.52e-06	0.0121	-0.58	-0.39	Lung cancer in ever smokers;	chr15:43307127	chr15:43663654~43684339:-
ESCA	cis	rs5760092	0.755	rs915589	ENSG00000099984.9	GSTT2	4.71	6.53e-06	0.0121	0.56	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23980123~23983911:+
ESCA	cis	rs11146838	1	rs11146838	ENSG00000276805.1	RP11-291L22.6	4.71	6.54e-06	0.0121	0.52	0.39	Breast cancer;	chr10:38856846	chr10:38451030~38451785:+
ESCA	cis	rs1816752	1	rs9507341	ENSG00000273628.1	RP11-756A22.7	-4.71	6.55e-06	0.0121	-0.38	-0.39	Obesity-related traits;	chr13:24432440	chr13:24933006~24936796:+
ESCA	cis	rs1048238	0.525	rs848214	ENSG00000235084.3	CHCHD2P6	4.71	6.57e-06	0.0121	0.38	0.39	Systolic blood pressure;	chr1:15938927	chr1:15604597~15605043:+
ESCA	cis	rs4535700	0.501	rs6943341	ENSG00000273720.1	RP11-613E4.4	4.71	6.57e-06	0.0122	0.49	0.39	Macular telangiectasia type 2;	chr7:55907489	chr7:55743073~55743457:+
ESCA	cis	rs11118620	0.853	rs12037861	ENSG00000272823.1	RP11-295M18.6	4.71	6.57e-06	0.0122	0.48	0.39	Heart failure;	chr1:220864835	chr1:220828676~220829211:-
ESCA	cis	rs9545047	0.604	rs2763810	ENSG00000227676.3	LINC01068	4.71	6.57e-06	0.0122	0.52	0.39	Schizophrenia;	chr13:79405544	chr13:79566727~79571436:+
ESCA	cis	rs6479901	0.793	rs4450077	ENSG00000235816.3	PRELID1P3	-4.71	6.57e-06	0.0122	-0.44	-0.39	Intelligence (multi-trait analysis);	chr10:63253976	chr10:63427297~63427939:+
ESCA	cis	rs6604026	0.656	rs12066638	ENSG00000229052.2	RP11-386I23.1	-4.71	6.57e-06	0.0122	-0.38	-0.39	Multiple sclerosis;	chr1:92909834	chr1:92930696~92934098:+
ESCA	cis	rs1439620	1	rs1439620	ENSG00000258647.4	LINC00930	4.71	6.6e-06	0.0122	0.46	0.39	Body mass index;	chr15:92886416	chr15:92567818~92572042:-
ESCA	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	4.71	6.61e-06	0.0122	0.36	0.39	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
ESCA	cis	rs28830936	1	rs17677991	ENSG00000250379.1	RP11-23P13.4	4.71	6.61e-06	0.0122	0.46	0.39	Diastolic blood pressure;	chr15:41740185	chr15:41825099~41827936:-
ESCA	cis	rs28830936	1	rs12440747	ENSG00000250379.1	RP11-23P13.4	4.71	6.61e-06	0.0122	0.46	0.39	Diastolic blood pressure;	chr15:41744492	chr15:41825099~41827936:-
ESCA	cis	rs28830936	1	rs17678138	ENSG00000250379.1	RP11-23P13.4	4.71	6.61e-06	0.0122	0.46	0.39	Diastolic blood pressure;	chr15:41750869	chr15:41825099~41827936:-
ESCA	cis	rs11169552	0.51	rs17124930	ENSG00000200428.1	Y_RNA	4.71	6.62e-06	0.0122	0.47	0.39	Colorectal cancer;	chr12:50722152	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs4768907	ENSG00000200428.1	Y_RNA	4.71	6.62e-06	0.0122	0.47	0.39	Colorectal cancer;	chr12:50725524	chr12:50743568~50743684:+
ESCA	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-4.71	6.62e-06	0.0122	-0.55	-0.39	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
ESCA	cis	rs1075265	0.756	rs698854	ENSG00000235937.1	AC008280.1	4.71	6.64e-06	0.0123	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54029552~54030682:-
ESCA	cis	rs11169552	0.51	rs4768903	ENSG00000200428.1	Y_RNA	4.71	6.65e-06	0.0123	0.48	0.39	Colorectal cancer;	chr12:50651666	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10876076	ENSG00000200428.1	Y_RNA	4.71	6.65e-06	0.0123	0.48	0.39	Colorectal cancer;	chr12:50655300	chr12:50743568~50743684:+
ESCA	cis	rs2505998	1	rs2435362	ENSG00000273008.1	RP11-351D16.3	-4.71	6.65e-06	0.0123	-0.45	-0.39	Hirschsprung disease;	chr10:43083331	chr10:43136824~43138334:-
ESCA	cis	rs6604026	0.656	rs2774949	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92886996	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2774950	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92887970	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.63	rs2391177	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92888386	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2774952	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92889689	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2774954	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92897968	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2811591	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92898394	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2811590	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92901609	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs2811589	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92902086	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs949915	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92904217	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs9439948	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92905243	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs9440134	ENSG00000229052.2	RP11-386I23.1	-4.71	6.67e-06	0.0123	-0.39	-0.39	Multiple sclerosis;	chr1:92905256	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs34389767	ENSG00000229052.2	RP11-386I23.1	4.71	6.67e-06	0.0123	0.39	0.39	Multiple sclerosis;	chr1:92908223	chr1:92930696~92934098:+
ESCA	cis	rs7714584	1	rs10078968	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150864711	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1896709	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150865470	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs6862814	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150865697	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7709388	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150866977	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.793	rs7709721	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150867296	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11950957	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150874352	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.793	rs11958146	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150874596	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10061105	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150875623	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs6579803	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150875997	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs6579804	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150876369	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7734778	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150876994	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs7734928	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150877051	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10463240	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150877291	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs9324660	ENSG00000197083.10	ZNF300P1	4.71	6.68e-06	0.0123	0.62	0.39	Crohn's disease;	chr5:150877492	chr5:150930645~150946289:-
ESCA	cis	rs28830936	1	rs28754734	ENSG00000250379.1	RP11-23P13.4	4.71	6.68e-06	0.0123	0.44	0.39	Diastolic blood pressure;	chr15:41800954	chr15:41825099~41827936:-
ESCA	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	4.71	6.69e-06	0.0123	0.54	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
ESCA	cis	rs6781182	0.517	rs11712920	ENSG00000271643.1	RP11-10C24.3	4.71	6.69e-06	0.0123	0.5	0.39	Visceral adipose tissue adjusted for BMI;	chr3:34189441	chr3:33795688~33796950:-
ESCA	cis	rs8072100	0.875	rs4794047	ENSG00000228782.6	CTD-2026D20.3	-4.71	6.69e-06	0.0123	-0.41	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685639	chr17:47450568~47492492:-
ESCA	cis	rs9545047	0.604	rs1752649	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79331980	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1749983	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79332077	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs1752648	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79332124	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1752647	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79332741	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.532	rs1752646	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79332752	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1749988	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79333103	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.588	rs9530894	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79334020	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9530895	ENSG00000227676.3	LINC01068	4.71	6.69e-06	0.0123	0.51	0.39	Schizophrenia;	chr13:79334877	chr13:79566727~79571436:+
ESCA	cis	rs2439831	0.571	rs689883	ENSG00000249839.1	AC011330.5	-4.71	6.7e-06	0.0123	-0.6	-0.39	Lung cancer in ever smokers;	chr15:43520398	chr15:43663654~43684339:-
ESCA	cis	rs7712401	0.765	rs4349713	ENSG00000263432.2	RN7SL689P	4.71	6.7e-06	0.0123	0.55	0.39	Mean platelet volume;	chr5:123055931	chr5:123022487~123022783:-
ESCA	cis	rs2858942	0.575	rs2858011	ENSG00000268836.1	LA16c-OS12.2	4.71	6.7e-06	0.0123	0.41	0.39	Mean corpuscular hemoglobin;	chr16:197939	chr16:185748~186294:-
ESCA	cis	rs2307394	1	rs12464617	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147819077	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs1424944	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147821361	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs11889608	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147821664	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs4972357	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147824809	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13013867	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147827243	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13025589	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147828492	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.89	rs13025219	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147832415	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.963	rs12989083	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147833659	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13004451	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147836024	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs1424954	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147843225	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs12053113	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147844091	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13028411	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147851566	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs10803523	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147858262	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13000597	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147868571	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs929939	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147869959	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs1895693	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147879424	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs11904758	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147882539	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs6711673	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147885690	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.963	rs13033696	ENSG00000223911.1	AC009480.3	4.71	6.7e-06	0.0123	0.46	0.39	Urate levels;	chr2:147887758	chr2:147899401~147902956:-
ESCA	cis	rs394563	0.967	rs369643	ENSG00000231760.4	RP11-350J20.5	4.71	6.71e-06	0.0123	0.46	0.39	Dupuytren's disease;	chr6:149478662	chr6:149796151~149826294:-
ESCA	cis	rs1075232	1	rs56396205	ENSG00000270055.1	CTD-3092A11.2	-4.7	6.72e-06	0.0124	-0.94	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31386182	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs12438318	ENSG00000270055.1	CTD-3092A11.2	-4.7	6.72e-06	0.0124	-0.94	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31388242	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs4450360	ENSG00000270055.1	CTD-3092A11.2	-4.7	6.72e-06	0.0124	-0.94	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31389827	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs72722847	ENSG00000270055.1	CTD-3092A11.2	-4.7	6.72e-06	0.0124	-0.94	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31390143	chr15:30487963~30490313:+
ESCA	cis	rs9399135	0.66	rs4267967	ENSG00000232876.1	CTA-212D2.2	-4.7	6.74e-06	0.0124	-0.45	-0.39	Red blood cell count;	chr6:134951339	chr6:135055033~135060550:+
ESCA	cis	rs6867032	0.527	rs4371796	ENSG00000249731.1	RP11-259O2.3	-4.7	6.75e-06	0.0124	-0.34	-0.39	Gut microbiome composition (winter);	chr5:1977671	chr5:1968094~1969013:+
ESCA	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-4.7	6.76e-06	0.0124	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
ESCA	cis	rs28530618	0.564	rs4911248	ENSG00000230801.1	RP11-243J16.8	4.7	6.76e-06	0.0124	0.44	0.39	Birth weight;	chr20:32626432	chr20:31808503~31808749:-
ESCA	cis	rs11612508	1	rs11612508	ENSG00000274551.1	RP11-434C1.6	4.7	6.78e-06	0.0125	0.48	0.39	Inflammatory bowel disease;	chr12:12504579	chr12:11516425~11521686:-
ESCA	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
ESCA	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-4.7	6.79e-06	0.0125	-0.44	-0.39	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
ESCA	cis	rs10754283	0.967	rs10754285	ENSG00000231613.1	RP5-943J3.1	4.7	6.79e-06	0.0125	0.43	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89651028	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs4658302	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637777	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs7513928	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89639275	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs1317864	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89639889	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs2390763	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89640129	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs2002883	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89640279	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs2185195	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641138	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs6657988	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641186	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs6698273	ENSG00000231613.1	RP5-943J3.1	4.7	6.8e-06	0.0125	0.42	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89641232	chr1:89788914~89790492:+
ESCA	cis	rs6604026	0.656	rs11164843	ENSG00000229052.2	RP11-386I23.1	4.7	6.82e-06	0.0125	0.38	0.39	Multiple sclerosis;	chr1:92950585	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs11164845	ENSG00000229052.2	RP11-386I23.1	4.7	6.82e-06	0.0125	0.38	0.39	Multiple sclerosis;	chr1:92951128	chr1:92930696~92934098:+
ESCA	cis	rs7267979	0.657	rs6107073	ENSG00000204556.4	CTD-2514C3.1	-4.7	6.82e-06	0.0125	-0.53	-0.39	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:26018832~26020684:+
ESCA	cis	rs61160187	0.556	rs4647052	ENSG00000215032.2	GNL3LP1	4.7	6.83e-06	0.0125	0.5	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60939656	chr5:60891935~60893577:-
ESCA	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	4.7	6.83e-06	0.0125	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
ESCA	cis	rs765787	0.53	rs1706834	ENSG00000259520.4	CTD-2651B20.3	4.7	6.85e-06	0.0126	0.45	0.39	Uric acid levels;	chr15:45225656	chr15:45251580~45279251:-
ESCA	cis	rs4792901	0.959	rs12603053	ENSG00000279602.1	CTD-3014M21.1	-4.7	6.85e-06	0.0126	-0.46	-0.39	Dupuytren's disease;	chr17:43550924	chr17:43360041~43361361:-
ESCA	cis	rs10954779	0.567	rs2737335	ENSG00000253579.1	SUMO2P16	-4.7	6.85e-06	0.0126	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:31141607	chr8:31131539~31131802:-
ESCA	cis	rs10954779	0.537	rs1801195	ENSG00000253579.1	SUMO2P16	-4.7	6.85e-06	0.0126	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:31141764	chr8:31131539~31131802:-
ESCA	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-4.7	6.87e-06	0.0126	-0.53	-0.39	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
ESCA	cis	rs10954779	0.567	rs6990131	ENSG00000253579.1	SUMO2P16	4.7	6.88e-06	0.0126	0.43	0.39	Intelligence (multi-trait analysis);	chr8:31138900	chr8:31131539~31131802:-
ESCA	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	4.7	6.89e-06	0.0126	0.56	0.39	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
ESCA	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	4.7	6.89e-06	0.0126	0.32	0.39	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
ESCA	cis	rs10954779	0.51	rs12677943	ENSG00000253579.1	SUMO2P16	4.7	6.89e-06	0.0126	0.43	0.39	Intelligence (multi-trait analysis);	chr8:31139768	chr8:31131539~31131802:-
ESCA	cis	rs61160187	0.673	rs10062240	ENSG00000215032.2	GNL3LP1	-4.7	6.91e-06	0.0127	-0.47	-0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782585	chr5:60891935~60893577:-
ESCA	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	4.7	6.91e-06	0.0127	0.48	0.39	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
ESCA	cis	rs9545047	0.604	rs912639	ENSG00000227676.3	LINC01068	-4.7	6.94e-06	0.0127	-0.51	-0.39	Schizophrenia;	chr13:79409788	chr13:79566727~79571436:+
ESCA	cis	rs2505998	1	rs2435356	ENSG00000273008.1	RP11-351D16.3	4.7	6.94e-06	0.0127	0.45	0.39	Hirschsprung disease;	chr10:43087702	chr10:43136824~43138334:-
ESCA	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-4.7	6.94e-06	0.0127	-0.59	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-4.7	6.94e-06	0.0127	-0.59	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-4.7	6.94e-06	0.0127	-0.59	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-4.7	6.94e-06	0.0127	-0.59	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
ESCA	cis	rs2041895	0.509	rs12368448	ENSG00000260329.1	RP11-412D9.4	4.7	6.95e-06	0.0127	0.41	0.39	Glaucoma (low intraocular pressure);	chr12:106923018	chr12:106954029~106955497:-
ESCA	cis	rs6921919	0.789	rs17301128	ENSG00000216901.1	AL022393.7	4.7	6.96e-06	0.0127	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr6:28340257	chr6:28176188~28176674:+
ESCA	cis	rs9545047	0.604	rs1007569	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79306752	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.584	rs4885626	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79309765	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4885627	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79309786	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs4885628	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79309830	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.554	rs4885629	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79309855	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1927506	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79311350	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1409019	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79312431	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7317343	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79312542	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs6563098	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79313102	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.532	rs1748768	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79313276	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1748767	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79313381	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.567	rs1409018	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79313403	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1410332	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79315171	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545065	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79317034	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs3818563	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79318587	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs3187338	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79320601	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9545068	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79324101	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.625	rs9318621	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79325662	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs7322167	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79325931	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs9285309	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79326707	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.584	rs9545069	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79328065	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.647	rs7317416	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79328400	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.588	rs1408658	ENSG00000227676.3	LINC01068	4.7	6.99e-06	0.0128	0.51	0.39	Schizophrenia;	chr13:79329294	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1853830	ENSG00000227676.3	LINC01068	-4.7	6.99e-06	0.0128	-0.52	-0.39	Schizophrenia;	chr13:79406877	chr13:79566727~79571436:+
ESCA	cis	rs4951011	0.572	rs72745792	ENSG00000223505.2	RP11-397P13.7	-4.69	7e-06	0.0128	-0.55	-0.39	Breast cancer;	chr1:203880341	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs67087079	ENSG00000223505.2	RP11-397P13.7	-4.69	7e-06	0.0128	-0.55	-0.39	Breast cancer;	chr1:203881655	chr1:203835585~203835912:-
ESCA	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	4.69	7e-06	0.0128	0.45	0.39	Migraine;	chr4:56881468	chr4:56960927~56961373:-
ESCA	cis	rs9399137	0.507	rs6940258	ENSG00000232876.1	CTA-212D2.2	-4.69	7.01e-06	0.0128	-0.47	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135044994	chr6:135055033~135060550:+
ESCA	cis	rs2921073	0.605	rs2976933	ENSG00000253981.4	ALG1L13P	4.69	7.02e-06	0.0128	0.5	0.39	Parkinson's disease;	chr8:8397365	chr8:8236003~8244667:-
ESCA	cis	rs2439831	0.85	rs7169988	ENSG00000205771.5	CATSPER2P1	-4.69	7.02e-06	0.0128	-0.69	-0.39	Lung cancer in ever smokers;	chr15:43768237	chr15:43726918~43747094:-
ESCA	cis	rs9987353	0.519	rs13276350	ENSG00000253981.4	ALG1L13P	-4.69	7.03e-06	0.0128	-0.49	-0.39	Recombination measurement;	chr8:9205647	chr8:8236003~8244667:-
ESCA	cis	rs4713675	0.604	rs791902	ENSG00000186328.4	RP11-140K17.2	4.69	7.03e-06	0.0128	0.47	0.39	Plateletcrit;	chr6:33734840	chr6:34715613~34715940:+
ESCA	cis	rs9545047	0.567	rs2296287	ENSG00000227676.3	LINC01068	4.69	7.04e-06	0.0128	0.52	0.39	Schizophrenia;	chr13:79407045	chr13:79566727~79571436:+
ESCA	cis	rs9549260	0.753	rs61963266	ENSG00000229456.1	RLIMP1	4.69	7.06e-06	0.0129	0.46	0.39	Red blood cell count;	chr13:40596899	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.753	rs4943794	ENSG00000229456.1	RLIMP1	4.69	7.06e-06	0.0129	0.46	0.39	Red blood cell count;	chr13:40599271	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.753	rs1986649	ENSG00000229456.1	RLIMP1	4.69	7.06e-06	0.0129	0.46	0.39	Red blood cell count;	chr13:40604687	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.753	rs9549238	ENSG00000229456.1	RLIMP1	4.69	7.06e-06	0.0129	0.46	0.39	Red blood cell count;	chr13:40605184	chr13:40618738~40621348:+
ESCA	cis	rs8062405	0.755	rs55792032	ENSG00000278665.1	RP11-666O2.4	4.69	7.06e-06	0.0129	0.55	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28599241~28601881:-
ESCA	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-4.69	7.06e-06	0.0129	-0.42	-0.39	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-4.69	7.06e-06	0.0129	-0.42	-0.39	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-4.69	7.06e-06	0.0129	-0.42	-0.39	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
ESCA	cis	rs453301	0.686	rs11787026	ENSG00000253981.4	ALG1L13P	4.69	7.07e-06	0.0129	0.49	0.39	Joint mobility (Beighton score);	chr8:9044861	chr8:8236003~8244667:-
ESCA	cis	rs2439831	0.867	rs2278860	ENSG00000249839.1	AC011330.5	4.69	7.07e-06	0.0129	0.54	0.39	Lung cancer in ever smokers;	chr15:43366848	chr15:43663654~43684339:-
ESCA	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-4.69	7.08e-06	0.0129	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-4.69	7.08e-06	0.0129	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-4.69	7.08e-06	0.0129	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-4.69	7.08e-06	0.0129	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
ESCA	cis	rs9399135	0.66	rs4440481	ENSG00000232876.1	CTA-212D2.2	-4.69	7.1e-06	0.0129	-0.45	-0.39	Red blood cell count;	chr6:134955558	chr6:135055033~135060550:+
ESCA	cis	rs858239	0.536	rs6961109	ENSG00000230042.1	AK3P3	-4.69	7.1e-06	0.0129	-0.43	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23129178~23129841:+
ESCA	cis	rs2439831	0.85	rs8032649	ENSG00000249839.1	AC011330.5	4.69	7.11e-06	0.0129	0.78	0.39	Lung cancer in ever smokers;	chr15:43842724	chr15:43663654~43684339:-
ESCA	cis	rs1005277	0.579	rs2472178	ENSG00000276805.1	RP11-291L22.6	4.69	7.11e-06	0.0129	0.5	0.39	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474572	ENSG00000276805.1	RP11-291L22.6	4.69	7.11e-06	0.0129	0.5	0.39	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38451030~38451785:+
ESCA	cis	rs61160187	0.582	rs62372103	ENSG00000215032.2	GNL3LP1	4.69	7.11e-06	0.0129	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60849621	chr5:60891935~60893577:-
ESCA	cis	rs2179367	0.959	rs9390677	ENSG00000216906.2	RP11-350J20.9	4.69	7.13e-06	0.013	0.5	0.39	Dupuytren's disease;	chr6:149389361	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs237034	ENSG00000216906.2	RP11-350J20.9	4.69	7.13e-06	0.013	0.5	0.39	Dupuytren's disease;	chr6:149390726	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs628488	ENSG00000216906.2	RP11-350J20.9	4.69	7.13e-06	0.013	0.5	0.39	Dupuytren's disease;	chr6:149398264	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs544947	ENSG00000216906.2	RP11-350J20.9	4.69	7.13e-06	0.013	0.5	0.39	Dupuytren's disease;	chr6:149402412	chr6:149904243~149906418:+
ESCA	cis	rs6604026	0.616	rs17380789	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92921962	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs34084844	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92922035	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs6698179	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92925157	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.698	rs4420089	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92925486	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs12065253	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92926752	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs6698233	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92931743	chr1:92930696~92934098:+
ESCA	cis	rs6604026	0.656	rs12074608	ENSG00000229052.2	RP11-386I23.1	4.69	7.15e-06	0.013	0.38	0.39	Multiple sclerosis;	chr1:92946224	chr1:92930696~92934098:+
ESCA	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	4.69	7.15e-06	0.013	0.58	0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
ESCA	cis	rs1005277	0.579	rs2983343	ENSG00000276805.1	RP11-291L22.6	4.69	7.16e-06	0.013	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38451030~38451785:+
ESCA	cis	rs2505998	0.833	rs2505533	ENSG00000273008.1	RP11-351D16.3	-4.69	7.17e-06	0.013	-0.43	-0.39	Hirschsprung disease;	chr10:43099005	chr10:43136824~43138334:-
ESCA	cis	rs4713675	0.525	rs622917	ENSG00000186328.4	RP11-140K17.2	4.69	7.18e-06	0.013	0.47	0.39	Plateletcrit;	chr6:33735092	chr6:34715613~34715940:+
ESCA	cis	rs300032	1	rs12600217	ENSG00000261175.4	CTD-2015G9.2	-4.69	7.18e-06	0.013	-0.64	-0.39	IgG glycosylation;	chr16:86647052	chr16:86722091~86741059:+
ESCA	cis	rs3820716	0.507	rs4972332	ENSG00000223911.1	AC009480.3	4.69	7.18e-06	0.013	0.47	0.39	Glomerular filtration rate (creatinine);	chr2:148147366	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs2382211	ENSG00000223911.1	AC009480.3	4.69	7.18e-06	0.013	0.47	0.39	Glomerular filtration rate (creatinine);	chr2:148148931	chr2:147899401~147902956:-
ESCA	cis	rs7829975	0.714	rs59046059	ENSG00000253981.4	ALG1L13P	4.69	7.2e-06	0.0131	0.43	0.39	Mood instability;	chr8:8813226	chr8:8236003~8244667:-
ESCA	cis	rs10954779	0.511	rs4037084	ENSG00000253579.1	SUMO2P16	-4.69	7.2e-06	0.0131	-0.43	-0.39	Intelligence (multi-trait analysis);	chr8:31117276	chr8:31131539~31131802:-
ESCA	cis	rs7829975	0.593	rs2921051	ENSG00000173295.6	FAM86B3P	4.69	7.21e-06	0.0131	0.47	0.39	Mood instability;	chr8:8462594	chr8:8228595~8244865:+
ESCA	cis	rs4951011	0.572	rs6667749	ENSG00000223505.2	RP11-397P13.7	-4.69	7.21e-06	0.0131	-0.55	-0.39	Breast cancer;	chr1:203879980	chr1:203835585~203835912:-
ESCA	cis	rs1005277	0.579	rs2008449	ENSG00000276805.1	RP11-291L22.6	-4.69	7.24e-06	0.0131	-0.49	-0.39	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38451030~38451785:+
ESCA	cis	rs8062405	0.755	rs56209193	ENSG00000278665.1	RP11-666O2.4	4.69	7.25e-06	0.0131	0.56	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28599241~28601881:-
ESCA	cis	rs7714584	1	rs10041072	ENSG00000197083.10	ZNF300P1	4.69	7.25e-06	0.0131	0.6	0.39	Crohn's disease;	chr5:150880080	chr5:150930645~150946289:-
ESCA	cis	rs3820068	0.603	rs59475085	ENSG00000237301.1	RP4-680D5.2	4.69	7.25e-06	0.0131	0.41	0.39	Systolic blood pressure;	chr1:15584636	chr1:15586136~15603626:-
ESCA	cis	rs2439831	1	rs1814538	ENSG00000249839.1	AC011330.5	4.69	7.26e-06	0.0131	0.6	0.39	Lung cancer in ever smokers;	chr15:43467576	chr15:43663654~43684339:-
ESCA	cis	rs2179367	0.959	rs536203	ENSG00000216906.2	RP11-350J20.9	4.69	7.26e-06	0.0131	0.49	0.39	Dupuytren's disease;	chr6:149330128	chr6:149904243~149906418:+
ESCA	cis	rs7829975	0.714	rs60315134	ENSG00000253981.4	ALG1L13P	4.69	7.26e-06	0.0131	0.43	0.39	Mood instability;	chr8:8813089	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.774	rs35431455	ENSG00000253981.4	ALG1L13P	4.69	7.27e-06	0.0131	0.43	0.39	Mood instability;	chr8:8816226	chr8:8236003~8244667:-
ESCA	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-4.69	7.27e-06	0.0131	-0.44	-0.39	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-4.69	7.27e-06	0.0131	-0.44	-0.39	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-4.69	7.27e-06	0.0131	-0.44	-0.39	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-4.69	7.27e-06	0.0131	-0.44	-0.39	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
ESCA	cis	rs2227564	0.729	rs2688611	ENSG00000229990.3	RP11-574K11.8	-4.69	7.27e-06	0.0131	-0.44	-0.39	Crohn's disease;Inflammatory bowel disease;	chr10:73893614	chr10:73841833~73847115:+
ESCA	cis	rs16828019	0.568	rs2236129	ENSG00000235358.1	RP11-399E6.1	4.69	7.27e-06	0.0131	0.72	0.39	Intelligence (multi-trait analysis);	chr1:41152242	chr1:41242373~41284861:+
ESCA	cis	rs2742234	0.59	rs2435377	ENSG00000273008.1	RP11-351D16.3	4.69	7.28e-06	0.0132	0.45	0.39	Hirschsprung disease;	chr10:43188152	chr10:43136824~43138334:-
ESCA	cis	rs7829975	0.714	rs7823757	ENSG00000253981.4	ALG1L13P	4.69	7.29e-06	0.0132	0.43	0.39	Mood instability;	chr8:8812667	chr8:8236003~8244667:-
ESCA	cis	rs2858942	0.818	rs1203979	ENSG00000268836.1	LA16c-OS12.2	-4.68	7.3e-06	0.0132	-0.42	-0.39	Mean corpuscular hemoglobin;	chr16:211867	chr16:185748~186294:-
ESCA	cis	rs10875746	0.729	rs1990028	ENSG00000240399.1	RP1-228P16.1	-4.68	7.3e-06	0.0132	-0.46	-0.39	Longevity (90 years and older);	chr12:48014230	chr12:48054813~48055591:-
ESCA	cis	rs2439831	0.867	rs6493082	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43342610	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs8041132	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43342938	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs7170489	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43344453	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs16957627	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43350459	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs16957630	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43350582	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs16957632	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43350699	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.717	rs7165471	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43352590	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs6493085	ENSG00000249839.1	AC011330.5	-4.68	7.31e-06	0.0132	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43361984	chr15:43663654~43684339:-
ESCA	cis	rs9549260	0.785	rs2253001	ENSG00000229456.1	RLIMP1	4.68	7.31e-06	0.0132	0.37	0.39	Red blood cell count;	chr13:40571193	chr13:40618738~40621348:+
ESCA	cis	rs393155	0.517	rs330050	ENSG00000253981.4	ALG1L13P	-4.68	7.32e-06	0.0132	-0.51	-0.39	Neuroticism;	chr8:9230169	chr8:8236003~8244667:-
ESCA	cis	rs453301	0.571	rs330054	ENSG00000253981.4	ALG1L13P	-4.68	7.32e-06	0.0132	-0.51	-0.39	Joint mobility (Beighton score);	chr8:9230781	chr8:8236003~8244667:-
ESCA	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-4.68	7.32e-06	0.0132	-0.57	-0.39	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
ESCA	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-4.68	7.32e-06	0.0132	-0.57	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-4.68	7.32e-06	0.0132	-0.57	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
ESCA	cis	rs2221894	0.853	rs1976610	ENSG00000273710.1	Metazoa_SRP	-4.68	7.35e-06	0.0132	-0.42	-0.39	Obesity-related traits;	chr8:28926498	chr8:28915579~28915864:-
ESCA	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-4.68	7.36e-06	0.0133	-0.54	-0.39	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
ESCA	cis	rs4747241	0.81	rs10762506	ENSG00000226163.1	RP11-167P22.3	4.68	7.36e-06	0.0133	0.45	0.39	Heschl's gyrus morphology;	chr10:72293993	chr10:72501746~72502956:+
ESCA	cis	rs150992	0.742	rs34495	ENSG00000248489.1	CTD-2007H13.3	4.68	7.37e-06	0.0133	0.54	0.39	Body mass index;	chr5:98930103	chr5:98929171~98995013:+
ESCA	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	4.68	7.38e-06	0.0133	0.53	0.39	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
ESCA	cis	rs3820716	0.507	rs12691776	ENSG00000223911.1	AC009480.3	4.68	7.38e-06	0.0133	0.47	0.39	Glomerular filtration rate (creatinine);	chr2:148118483	chr2:147899401~147902956:-
ESCA	cis	rs10875746	0.669	rs17122812	ENSG00000240399.1	RP1-228P16.1	-4.68	7.38e-06	0.0133	-0.48	-0.39	Longevity (90 years and older);	chr12:48203270	chr12:48054813~48055591:-
ESCA	cis	rs2742234	0.541	rs11238479	ENSG00000273008.1	RP11-351D16.3	4.68	7.39e-06	0.0133	0.47	0.39	Hirschsprung disease;	chr10:43221975	chr10:43136824~43138334:-
ESCA	cis	rs732716	0.719	rs56088814	ENSG00000267980.1	AC007292.6	-4.68	7.4e-06	0.0133	-0.54	-0.39	Mean corpuscular volume;	chr19:4422181	chr19:4363789~4364640:+
ESCA	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-4.68	7.4e-06	0.0133	-0.65	-0.39	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
ESCA	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-4.68	7.4e-06	0.0133	-0.46	-0.39	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
ESCA	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-4.68	7.42e-06	0.0134	-0.46	-0.39	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
ESCA	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-4.68	7.43e-06	0.0134	-0.49	-0.39	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-4.68	7.43e-06	0.0134	-0.49	-0.39	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-4.68	7.43e-06	0.0134	-0.49	-0.39	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
ESCA	cis	rs2307394	0.963	rs13006184	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:147948801	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs12469015	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:147974381	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13003171	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:147991008	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.928	rs72855232	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:147991398	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs12463554	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:147994043	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs7598361	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:148000910	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs2382201	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:148007927	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13033664	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:148012705	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13029038	ENSG00000223911.1	AC009480.3	4.68	7.43e-06	0.0134	0.48	0.39	Urate levels;	chr2:148029739	chr2:147899401~147902956:-
ESCA	cis	rs9462027	0.651	rs13220394	ENSG00000186328.4	RP11-140K17.2	4.68	7.43e-06	0.0134	0.43	0.39	Systemic lupus erythematosus;	chr6:34842395	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs6919654	ENSG00000186328.4	RP11-140K17.2	4.68	7.43e-06	0.0134	0.43	0.39	Systemic lupus erythematosus;	chr6:34842962	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.651	rs7748203	ENSG00000186328.4	RP11-140K17.2	4.68	7.43e-06	0.0134	0.43	0.39	Systemic lupus erythematosus;	chr6:34844277	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469909	ENSG00000186328.4	RP11-140K17.2	4.68	7.43e-06	0.0134	0.43	0.39	Systemic lupus erythematosus;	chr6:34845300	chr6:34715613~34715940:+
ESCA	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	4.68	7.44e-06	0.0134	0.53	0.39	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
ESCA	cis	rs2732480	0.577	rs2634693	ENSG00000258273.1	RP11-370I10.4	-4.68	7.45e-06	0.0134	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48312715	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs2634691	ENSG00000258273.1	RP11-370I10.4	-4.68	7.45e-06	0.0134	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48314476	chr12:48333755~48333901:-
ESCA	cis	rs6452524	0.868	rs1011981	ENSG00000243385.2	CTD-2110K23.1	4.68	7.45e-06	0.0134	0.41	0.39	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.868	rs17284218	ENSG00000243385.2	CTD-2110K23.1	4.68	7.45e-06	0.0134	0.41	0.39	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83201229~83202141:+
ESCA	cis	rs3820716	0.507	rs10497029	ENSG00000223911.1	AC009480.3	4.68	7.45e-06	0.0134	0.46	0.39	Glomerular filtration rate (creatinine);	chr2:148160637	chr2:147899401~147902956:-
ESCA	cis	rs61160187	0.582	rs11740632	ENSG00000215032.2	GNL3LP1	4.68	7.45e-06	0.0134	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60845418	chr5:60891935~60893577:-
ESCA	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.68	7.45e-06	0.0134	-0.49	-0.39	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
ESCA	cis	rs7189233	0.531	rs1861353	ENSG00000279344.1	RP11-44F14.7	4.68	7.45e-06	0.0134	0.34	0.39	Intelligence (multi-trait analysis);	chr16:53418169	chr16:53478957~53481550:-
ESCA	cis	rs2739330	0.796	rs2154594	ENSG00000228039.3	KB-1125A3.10	-4.68	7.47e-06	0.0134	-0.51	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23963780~23964374:+
ESCA	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	4.68	7.47e-06	0.0134	0.54	0.39	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
ESCA	cis	rs12517906	1	rs11249745	ENSG00000280161.1	CTC-205M6.1	-4.68	7.48e-06	0.0134	-0.51	-0.39	Weight;Body mass index;	chr5:180744399	chr5:180810401~180811384:+
ESCA	cis	rs11169552	0.51	rs10506295	ENSG00000200428.1	Y_RNA	4.68	7.48e-06	0.0134	0.47	0.39	Colorectal cancer;	chr12:50691688	chr12:50743568~50743684:+
ESCA	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	4.68	7.48e-06	0.0134	0.53	0.39	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
ESCA	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-4.68	7.49e-06	0.0134	-0.51	-0.39	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
ESCA	cis	rs6781182	0.517	rs11712920	ENSG00000271020.1	RP11-10C24.1	4.68	7.49e-06	0.0134	0.51	0.39	Visceral adipose tissue adjusted for BMI;	chr3:34189441	chr3:33797149~33797681:-
ESCA	cis	rs7208859	0.673	rs79541516	ENSG00000263531.1	RP13-753N3.1	4.68	7.49e-06	0.0134	0.61	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913565	chr17:30863921~30864940:-
ESCA	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	4.68	7.5e-06	0.0134	0.55	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
ESCA	cis	rs5769707	0.967	rs8141807	ENSG00000213279.2	RP1-29C18.9	-4.68	7.52e-06	0.0135	-0.48	-0.39	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49572264~49575426:-
ESCA	cis	rs9462027	0.628	rs9469917	ENSG00000186328.4	RP11-140K17.2	4.68	7.53e-06	0.0135	0.43	0.39	Systemic lupus erythematosus;	chr6:34863592	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs3734264	ENSG00000186328.4	RP11-140K17.2	4.68	7.53e-06	0.0135	0.43	0.39	Systemic lupus erythematosus;	chr6:34864089	chr6:34715613~34715940:+
ESCA	cis	rs1005277	0.579	rs2505198	ENSG00000276805.1	RP11-291L22.6	4.68	7.54e-06	0.0135	0.5	0.39	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38451030~38451785:+
ESCA	cis	rs9457247	0.668	rs2236313	ENSG00000265828.1	MIR3939	-4.68	7.54e-06	0.0135	-0.42	-0.39	Crohn's disease;	chr6:166946901	chr6:166997807~166997912:-
ESCA	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-4.68	7.54e-06	0.0135	-0.51	-0.39	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
ESCA	cis	rs6456156	0.792	rs10946212	ENSG00000265828.1	MIR3939	-4.68	7.56e-06	0.0135	-0.43	-0.39	Primary biliary cholangitis;	chr6:167102459	chr6:166997807~166997912:-
ESCA	cis	rs1155848	0.892	rs28546558	ENSG00000227354.5	RBM26-AS1	4.68	7.57e-06	0.0136	0.88	0.39	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79516024	chr13:79406309~79424328:+
ESCA	cis	rs7829975	0.557	rs7816427	ENSG00000253981.4	ALG1L13P	-4.68	7.57e-06	0.0136	-0.47	-0.39	Mood instability;	chr8:8688374	chr8:8236003~8244667:-
ESCA	cis	rs7829975	0.577	rs940032	ENSG00000253981.4	ALG1L13P	-4.68	7.57e-06	0.0136	-0.47	-0.39	Mood instability;	chr8:8688833	chr8:8236003~8244667:-
ESCA	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	4.68	7.58e-06	0.0136	0.43	0.39	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
ESCA	cis	rs2307394	1	rs13004041	ENSG00000223911.1	AC009480.3	4.67	7.6e-06	0.0136	0.47	0.39	Urate levels;	chr2:147984052	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13012455	ENSG00000223911.1	AC009480.3	4.67	7.6e-06	0.0136	0.47	0.39	Urate levels;	chr2:148030667	chr2:147899401~147902956:-
ESCA	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	4.67	7.6e-06	0.0136	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	4.67	7.6e-06	0.0136	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
ESCA	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	4.67	7.6e-06	0.0136	0.5	0.39	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
ESCA	cis	rs858239	0.796	rs433395	ENSG00000230042.1	AK3P3	-4.67	7.6e-06	0.0136	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23129178~23129841:+
ESCA	cis	rs1816752	0.776	rs7998843	ENSG00000273628.1	RP11-756A22.7	4.67	7.6e-06	0.0136	0.38	0.39	Obesity-related traits;	chr13:24443147	chr13:24933006~24936796:+
ESCA	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-4.67	7.6e-06	0.0136	-0.47	-0.39	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
ESCA	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-4.67	7.61e-06	0.0136	-0.45	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
ESCA	cis	rs42490	0.966	rs2735871	ENSG00000251136.7	RP11-37B2.1	4.67	7.61e-06	0.0136	0.39	0.39	Leprosy;	chr8:89731154	chr8:89609409~89757727:-
ESCA	cis	rs11169552	0.51	rs10876053	ENSG00000200428.1	Y_RNA	4.67	7.63e-06	0.0136	0.48	0.39	Colorectal cancer;	chr12:50541002	chr12:50743568~50743684:+
ESCA	cis	rs2412819	0.571	rs4923965	ENSG00000249839.1	AC011330.5	4.67	7.63e-06	0.0136	0.73	0.39	Lung cancer;	chr15:43790232	chr15:43663654~43684339:-
ESCA	cis	rs2412819	0.571	rs6493090	ENSG00000249839.1	AC011330.5	4.67	7.63e-06	0.0136	0.73	0.39	Lung cancer;	chr15:43792084	chr15:43663654~43684339:-
ESCA	cis	rs10754283	0.935	rs10801756	ENSG00000231613.1	RP5-943J3.1	4.67	7.65e-06	0.0136	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89636273	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.934	rs6684676	ENSG00000231613.1	RP5-943J3.1	4.67	7.65e-06	0.0136	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89636614	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs6428561	ENSG00000231613.1	RP5-943J3.1	4.67	7.65e-06	0.0136	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637060	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs6428562	ENSG00000231613.1	RP5-943J3.1	4.67	7.65e-06	0.0136	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89637106	chr1:89788914~89790492:+
ESCA	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-4.67	7.65e-06	0.0136	-0.45	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
ESCA	cis	rs2179367	0.959	rs480034	ENSG00000216906.2	RP11-350J20.9	-4.67	7.66e-06	0.0137	-0.5	-0.39	Dupuytren's disease;	chr6:149414294	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-4.67	7.67e-06	0.0137	-0.42	-0.39	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
ESCA	cis	rs150992	0.673	rs327792	ENSG00000248489.1	CTD-2007H13.3	4.67	7.68e-06	0.0137	0.57	0.39	Body mass index;	chr5:98909802	chr5:98929171~98995013:+
ESCA	cis	rs7714584	1	rs1896707	ENSG00000197083.10	ZNF300P1	4.67	7.7e-06	0.0137	0.61	0.39	Crohn's disease;	chr5:150865567	chr5:150930645~150946289:-
ESCA	cis	rs7208859	0.673	rs57432042	ENSG00000263531.1	RP13-753N3.1	4.67	7.7e-06	0.0137	0.64	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30914020	chr17:30863921~30864940:-
ESCA	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	4.67	7.71e-06	0.0137	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
ESCA	cis	rs1005277	0.541	rs2472177	ENSG00000263064.2	RP11-291L22.7	4.67	7.72e-06	0.0138	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38095087	chr10:38448689~38448949:+
ESCA	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	4.67	7.72e-06	0.0138	0.45	0.39	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	4.67	7.72e-06	0.0138	0.45	0.39	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
ESCA	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	4.67	7.73e-06	0.0138	0.65	0.39	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
ESCA	cis	rs9399137	0.529	rs7739722	ENSG00000232876.1	CTA-212D2.2	-4.67	7.73e-06	0.0138	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961087	chr6:135055033~135060550:+
ESCA	cis	rs394563	0.591	rs237028	ENSG00000231760.4	RP11-350J20.5	4.67	7.73e-06	0.0138	0.46	0.39	Dupuytren's disease;	chr6:149397514	chr6:149796151~149826294:-
ESCA	cis	rs9987353	0.566	rs34491841	ENSG00000253981.4	ALG1L13P	-4.67	7.74e-06	0.0138	-0.49	-0.39	Recombination measurement;	chr8:9208000	chr8:8236003~8244667:-
ESCA	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	4.67	7.76e-06	0.0138	0.64	0.39	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
ESCA	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-4.67	7.77e-06	0.0138	-0.46	-0.39	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
ESCA	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-4.67	7.77e-06	0.0138	-0.46	-0.39	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
ESCA	cis	rs1005277	0.579	rs2474587	ENSG00000263064.2	RP11-291L22.7	4.67	7.77e-06	0.0138	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38131738	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474588	ENSG00000263064.2	RP11-291L22.7	4.67	7.77e-06	0.0138	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38131942	chr10:38448689~38448949:+
ESCA	cis	rs394563	0.591	rs237029	ENSG00000231760.4	RP11-350J20.5	4.67	7.79e-06	0.0139	0.46	0.39	Dupuytren's disease;	chr6:149396289	chr6:149796151~149826294:-
ESCA	cis	rs2439831	0.867	rs12323999	ENSG00000249839.1	AC011330.5	-4.67	7.8e-06	0.0139	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43390917	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2584702	ENSG00000249839.1	AC011330.5	-4.67	7.8e-06	0.0139	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43392716	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2243434	ENSG00000249839.1	AC011330.5	-4.67	7.8e-06	0.0139	-0.57	-0.39	Lung cancer in ever smokers;	chr15:43397669	chr15:43663654~43684339:-
ESCA	cis	rs10954779	0.728	rs2737333	ENSG00000253579.1	SUMO2P16	4.67	7.82e-06	0.0139	0.44	0.39	Intelligence (multi-trait analysis);	chr8:31135619	chr8:31131539~31131802:-
ESCA	cis	rs7826238	0.594	rs2948285	ENSG00000173295.6	FAM86B3P	4.67	7.82e-06	0.0139	0.47	0.39	Systolic blood pressure;	chr8:8273016	chr8:8228595~8244865:+
ESCA	cis	rs3820716	0.507	rs16828270	ENSG00000223911.1	AC009480.3	4.67	7.83e-06	0.0139	0.46	0.39	Glomerular filtration rate (creatinine);	chr2:148114668	chr2:147899401~147902956:-
ESCA	cis	rs1075265	0.704	rs13417926	ENSG00000235937.1	AC008280.1	4.67	7.84e-06	0.0139	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54029552~54030682:-
ESCA	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-4.67	7.84e-06	0.0139	-0.51	-0.39	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
ESCA	cis	rs2179367	0.959	rs9377212	ENSG00000216906.2	RP11-350J20.9	4.67	7.84e-06	0.0139	0.5	0.39	Dupuytren's disease;	chr6:149383765	chr6:149904243~149906418:+
ESCA	cis	rs10954779	0.537	rs2553278	ENSG00000253579.1	SUMO2P16	4.67	7.85e-06	0.014	0.42	0.39	Intelligence (multi-trait analysis);	chr8:31135859	chr8:31131539~31131802:-
ESCA	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	4.67	7.85e-06	0.014	0.52	0.39	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
ESCA	cis	rs9601248	0.967	rs9545145	ENSG00000227676.3	LINC01068	-4.67	7.86e-06	0.014	-0.5	-0.39	Major depressive disorder;	chr13:79599625	chr13:79566727~79571436:+
ESCA	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	4.67	7.86e-06	0.014	0.43	0.39	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
ESCA	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	4.67	7.87e-06	0.014	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
ESCA	cis	rs28830936	1	rs17678767	ENSG00000250379.1	RP11-23P13.4	4.67	7.87e-06	0.014	0.44	0.39	Diastolic blood pressure;	chr15:41804224	chr15:41825099~41827936:-
ESCA	cis	rs17711722	0.528	rs73138179	ENSG00000164669.11	INTS4P1	-4.67	7.88e-06	0.014	-0.44	-0.39	Calcium levels;	chr7:65829495	chr7:65141225~65234216:+
ESCA	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	4.67	7.88e-06	0.014	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	4.67	7.88e-06	0.014	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	4.67	7.88e-06	0.014	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	4.67	7.88e-06	0.014	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	4.67	7.88e-06	0.014	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
ESCA	cis	rs2179367	0.959	rs540538	ENSG00000216906.2	RP11-350J20.9	4.67	7.9e-06	0.014	0.5	0.39	Dupuytren's disease;	chr6:149326808	chr6:149904243~149906418:+
ESCA	cis	rs2439831	0.867	rs2412778	ENSG00000249839.1	AC011330.5	-4.67	7.91e-06	0.014	-0.56	-0.39	Lung cancer in ever smokers;	chr15:43368784	chr15:43663654~43684339:-
ESCA	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	4.67	7.91e-06	0.014	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	4.67	7.91e-06	0.014	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
ESCA	cis	rs6479901	0.841	rs4469770	ENSG00000235816.3	PRELID1P3	-4.66	7.94e-06	0.0141	-0.43	-0.39	Intelligence (multi-trait analysis);	chr10:63254152	chr10:63427297~63427939:+
ESCA	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	4.66	7.95e-06	0.0141	0.5	0.39	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
ESCA	cis	rs1723838	0.826	rs9651759	ENSG00000255928.1	RP11-456I15.2	4.66	7.97e-06	0.0141	0.9	0.39	Obesity-related traits;	chr11:73891905	chr11:73722349~73722694:+
ESCA	cis	rs1723838	1	rs2886812	ENSG00000255928.1	RP11-456I15.2	4.66	7.97e-06	0.0141	0.9	0.39	Obesity-related traits;	chr11:73894114	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs1531001	ENSG00000255928.1	RP11-456I15.2	4.66	7.97e-06	0.0141	0.9	0.39	Obesity-related traits;	chr11:73895918	chr11:73722349~73722694:+
ESCA	cis	rs2227564	0.7	rs2675677	ENSG00000229990.3	RP11-574K11.8	-4.66	7.99e-06	0.0141	-0.42	-0.39	Crohn's disease;Inflammatory bowel disease;	chr10:73888491	chr10:73841833~73847115:+
ESCA	cis	rs6456156	0.792	rs10946215	ENSG00000265828.1	MIR3939	4.66	7.99e-06	0.0141	0.44	0.39	Primary biliary cholangitis;	chr6:167102693	chr6:166997807~166997912:-
ESCA	cis	rs12744310	0.887	rs12024263	ENSG00000235358.1	RP11-399E6.1	4.66	7.99e-06	0.0141	0.52	0.39	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41355277	chr1:41242373~41284861:+
ESCA	cis	rs10754283	0.905	rs7519969	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89643162	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs7519971	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89643184	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs7546410	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89644256	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs7515375	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89644295	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.901	rs6663526	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89645303	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.934	rs7529653	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89646292	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.87	rs2390764	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647268	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.901	rs4520403	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647281	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs4658130	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89647888	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.934	rs10754284	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648143	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs10801759	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648186	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs10801760	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648265	chr1:89788914~89790492:+
ESCA	cis	rs10754283	0.967	rs7528433	ENSG00000231613.1	RP5-943J3.1	4.66	8.02e-06	0.0142	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89648512	chr1:89788914~89790492:+
ESCA	cis	rs7829975	0.714	rs4841040	ENSG00000253981.4	ALG1L13P	4.66	8.04e-06	0.0142	0.43	0.39	Mood instability;	chr8:8797017	chr8:8236003~8244667:-
ESCA	cis	rs4951011	0.507	rs16852420	ENSG00000223505.2	RP11-397P13.7	-4.66	8.05e-06	0.0142	-0.54	-0.39	Breast cancer;	chr1:203869069	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs56395476	ENSG00000223505.2	RP11-397P13.7	-4.66	8.05e-06	0.0142	-0.54	-0.39	Breast cancer;	chr1:203872905	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.506	rs7550984	ENSG00000223505.2	RP11-397P13.7	-4.66	8.05e-06	0.0142	-0.54	-0.39	Breast cancer;	chr1:203879655	chr1:203835585~203835912:-
ESCA	cis	rs9595066	0.564	rs12869383	ENSG00000227258.4	SMIM2-AS1	-4.66	8.09e-06	0.0143	-0.49	-0.39	Schizophrenia;	chr13:44131305	chr13:44110451~44240517:+
ESCA	cis	rs556990	0.574	rs473598	ENSG00000269125.1	RP11-98F14.11	-4.66	8.11e-06	0.0143	-0.48	-0.39	Blood protein levels;	chr13:113146875	chr13:113165002~113165183:-
ESCA	cis	rs1005277	0.579	rs2472178	ENSG00000263064.2	RP11-291L22.7	4.66	8.12e-06	0.0143	0.52	0.39	Extrinsic epigenetic age acceleration;	chr10:38095822	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474572	ENSG00000263064.2	RP11-291L22.7	4.66	8.12e-06	0.0143	0.52	0.39	Extrinsic epigenetic age acceleration;	chr10:38096388	chr10:38448689~38448949:+
ESCA	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	4.66	8.12e-06	0.0143	0.65	0.39	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
ESCA	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-4.66	8.12e-06	0.0143	-0.38	-0.39	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
ESCA	cis	rs1005277	0.579	rs2474568	ENSG00000263064.2	RP11-291L22.7	4.66	8.14e-06	0.0144	0.53	0.39	Extrinsic epigenetic age acceleration;	chr10:38094219	chr10:38448689~38448949:+
ESCA	cis	rs2412819	0.571	rs528764	ENSG00000249839.1	AC011330.5	4.66	8.16e-06	0.0144	0.67	0.39	Lung cancer;	chr15:43838650	chr15:43663654~43684339:-
ESCA	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs4974998	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39109129	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs7673299	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39109138	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs4974997	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39109151	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs9999327	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39110111	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1036036	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39111104	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1036037	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39111272	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1036038	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39111383	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1560396	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112092	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs1560397	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112265	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs2381285	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112775	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs2163272	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112790	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs2163273	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112835	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs62310332	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39112939	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.965	rs3796510	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39113309	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs10030904	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39113603	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.932	rs6855118	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39114322	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs6829234	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39114586	chr4:39133913~39135608:+
ESCA	cis	rs1061377	1	rs6812540	ENSG00000249685.1	RP11-360F5.3	4.66	8.16e-06	0.0144	0.42	0.39	Uric acid levels;	chr4:39114803	chr4:39133913~39135608:+
ESCA	cis	rs1075265	0.783	rs805450	ENSG00000235937.1	AC008280.1	4.66	8.18e-06	0.0144	0.42	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54029552~54030682:-
ESCA	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	4.66	8.18e-06	0.0144	0.53	0.39	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
ESCA	cis	rs2108622	0.545	rs59140933	ENSG00000267453.5	AC004791.2	-4.66	8.2e-06	0.0144	-0.47	-0.39	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864498	chr19:15851993~15864904:-
ESCA	cis	rs11169552	0.51	rs10876072	ENSG00000200428.1	Y_RNA	4.66	8.2e-06	0.0144	0.46	0.39	Colorectal cancer;	chr12:50619776	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs876079	ENSG00000200428.1	Y_RNA	4.66	8.2e-06	0.0144	0.46	0.39	Colorectal cancer;	chr12:50636926	chr12:50743568~50743684:+
ESCA	cis	rs2505998	0.912	rs2505994	ENSG00000273008.1	RP11-351D16.3	4.66	8.2e-06	0.0144	0.44	0.39	Hirschsprung disease;	chr10:43073439	chr10:43136824~43138334:-
ESCA	cis	rs11169552	0.51	rs10431486	ENSG00000200428.1	Y_RNA	4.66	8.21e-06	0.0145	0.49	0.39	Colorectal cancer;	chr12:50547242	chr12:50743568~50743684:+
ESCA	cis	rs1075265	0.704	rs805405	ENSG00000235937.1	AC008280.1	4.66	8.22e-06	0.0145	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54029552~54030682:-
ESCA	cis	rs2179367	0.959	rs579789	ENSG00000216906.2	RP11-350J20.9	4.66	8.22e-06	0.0145	0.49	0.39	Dupuytren's disease;	chr6:149358235	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs489551	ENSG00000216906.2	RP11-350J20.9	4.66	8.22e-06	0.0145	0.49	0.39	Dupuytren's disease;	chr6:149368321	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs9322178	ENSG00000216906.2	RP11-350J20.9	4.66	8.22e-06	0.0145	0.49	0.39	Dupuytren's disease;	chr6:149372131	chr6:149904243~149906418:+
ESCA	cis	rs2439831	0.85	rs12440573	ENSG00000249839.1	AC011330.5	-4.66	8.23e-06	0.0145	-0.77	-0.39	Lung cancer in ever smokers;	chr15:43816799	chr15:43663654~43684339:-
ESCA	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	4.65	8.26e-06	0.0145	0.32	0.39	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
ESCA	cis	rs1075265	0.783	rs805359	ENSG00000235937.1	AC008280.1	4.65	8.27e-06	0.0145	0.42	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54029552~54030682:-
ESCA	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	4.65	8.27e-06	0.0145	0.48	0.39	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
ESCA	cis	rs61160187	0.582	rs12654306	ENSG00000215032.2	GNL3LP1	4.65	8.27e-06	0.0145	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60889029	chr5:60891935~60893577:-
ESCA	cis	rs1005277	0.579	rs2505198	ENSG00000263064.2	RP11-291L22.7	4.65	8.29e-06	0.0146	0.52	0.39	Extrinsic epigenetic age acceleration;	chr10:38104255	chr10:38448689~38448949:+
ESCA	cis	rs2179367	0.959	rs9373592	ENSG00000216906.2	RP11-350J20.9	4.65	8.3e-06	0.0146	0.49	0.39	Dupuytren's disease;	chr6:149412119	chr6:149904243~149906418:+
ESCA	cis	rs6452524	0.618	rs1478487	ENSG00000243385.2	CTD-2110K23.1	4.65	8.3e-06	0.0146	0.4	0.39	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83201229~83202141:+
ESCA	cis	rs7829975	0.714	rs6994038	ENSG00000253981.4	ALG1L13P	4.65	8.33e-06	0.0146	0.42	0.39	Mood instability;	chr8:8803028	chr8:8236003~8244667:-
ESCA	cis	rs10754283	0.934	rs6428563	ENSG00000231613.1	RP5-943J3.1	4.65	8.33e-06	0.0146	0.41	0.39	Amyotrophic lateral sclerosis (sporadic);	chr1:89646024	chr1:89788914~89790492:+
ESCA	cis	rs2179367	0.959	rs9285519	ENSG00000216906.2	RP11-350J20.9	4.65	8.35e-06	0.0146	0.5	0.39	Dupuytren's disease;	chr6:149371799	chr6:149904243~149906418:+
ESCA	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	4.65	8.35e-06	0.0146	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
ESCA	cis	rs1075265	0.84	rs805309	ENSG00000235937.1	AC008280.1	4.65	8.35e-06	0.0147	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54029552~54030682:-
ESCA	cis	rs7555523	0.779	rs2790049	ENSG00000224358.1	RP11-466F5.8	-4.65	8.36e-06	0.0147	-0.75	-0.39	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165774286	chr1:165768929~165775176:+
ESCA	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-4.65	8.39e-06	0.0147	-0.45	-0.39	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000250470.1	AP000351.3	4.65	8.4e-06	0.0147	0.49	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23976904~23977585:-
ESCA	cis	rs2179367	0.887	rs506268	ENSG00000216906.2	RP11-350J20.9	4.65	8.4e-06	0.0147	0.5	0.39	Dupuytren's disease;	chr6:149364481	chr6:149904243~149906418:+
ESCA	cis	rs10875746	0.624	rs7297298	ENSG00000240399.1	RP1-228P16.1	-4.65	8.45e-06	0.0148	-0.46	-0.39	Longevity (90 years and older);	chr12:48278523	chr12:48054813~48055591:-
ESCA	cis	rs1005277	0.579	rs932538	ENSG00000263064.2	RP11-291L22.7	4.65	8.46e-06	0.0148	0.51	0.39	Extrinsic epigenetic age acceleration;	chr10:38092386	chr10:38448689~38448949:+
ESCA	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-4.65	8.47e-06	0.0148	-0.48	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
ESCA	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	4.65	8.48e-06	0.0148	0.49	0.39	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
ESCA	cis	rs8072100	0.688	rs12602134	ENSG00000228782.6	CTD-2026D20.3	-4.65	8.53e-06	0.0149	-0.42	-0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47504770	chr17:47450568~47492492:-
ESCA	cis	rs9733	0.593	rs10888384	ENSG00000206931.1	RNU6-1042P	-4.65	8.55e-06	0.0149	-0.46	-0.39	Tonsillectomy;	chr1:150601780	chr1:150701866~150701972:+
ESCA	cis	rs9733	0.536	rs10888385	ENSG00000206931.1	RNU6-1042P	-4.65	8.55e-06	0.0149	-0.46	-0.39	Tonsillectomy;	chr1:150601826	chr1:150701866~150701972:+
ESCA	cis	rs7017914	0.503	rs2639935	ENSG00000253173.3	RP11-152C15.1	-4.65	8.56e-06	0.0149	-0.44	-0.39	Bone mineral density;	chr8:70954045	chr8:70103798~70104179:-
ESCA	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	4.65	8.59e-06	0.015	0.51	0.39	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	4.65	8.59e-06	0.015	0.51	0.39	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
ESCA	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-4.65	8.59e-06	0.015	-0.45	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
ESCA	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	4.65	8.59e-06	0.015	0.56	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
ESCA	cis	rs394563	0.839	rs584916	ENSG00000231760.4	RP11-350J20.5	4.64	8.61e-06	0.015	0.46	0.39	Dupuytren's disease;	chr6:149469183	chr6:149796151~149826294:-
ESCA	cis	rs10875746	1	rs10875746	ENSG00000240399.1	RP1-228P16.1	-4.64	8.62e-06	0.015	-0.46	-0.39	Longevity (90 years and older);	chr12:48124481	chr12:48054813~48055591:-
ESCA	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	4.64	8.62e-06	0.015	0.4	0.39	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
ESCA	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-4.64	8.63e-06	0.015	-0.62	-0.39	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
ESCA	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-4.64	8.63e-06	0.015	-0.44	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
ESCA	cis	rs1075265	0.587	rs2542585	ENSG00000235937.1	AC008280.1	4.64	8.64e-06	0.0151	0.42	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54029552~54030682:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000250470.1	AP000351.3	-4.64	8.65e-06	0.0151	-0.51	-0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23976904~23977585:-
ESCA	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	4.64	8.65e-06	0.0151	0.5	0.39	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
ESCA	cis	rs3762637	0.941	rs9810996	ENSG00000272758.4	RP11-299J3.8	-4.64	8.66e-06	0.0151	-0.5	-0.39	LDL cholesterol levels;	chr3:122355540	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.941	rs9810999	ENSG00000272758.4	RP11-299J3.8	-4.64	8.66e-06	0.0151	-0.5	-0.39	LDL cholesterol levels;	chr3:122355544	chr3:122416207~122443180:+
ESCA	cis	rs6456156	0.792	rs10946214	ENSG00000265828.1	MIR3939	-4.64	8.66e-06	0.0151	-0.43	-0.39	Primary biliary cholangitis;	chr6:167102634	chr6:166997807~166997912:-
ESCA	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-4.64	8.66e-06	0.0151	-0.58	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
ESCA	cis	rs2742234	0.541	rs2742235	ENSG00000273008.1	RP11-351D16.3	-4.64	8.68e-06	0.0151	-0.47	-0.39	Hirschsprung disease;	chr10:43120877	chr10:43136824~43138334:-
ESCA	cis	rs5760092	0.618	rs5996631	ENSG00000099984.9	GSTT2	4.64	8.68e-06	0.0151	0.51	0.39	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23980123~23983911:+
ESCA	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-4.64	8.69e-06	0.0151	-0.57	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-4.64	8.69e-06	0.0151	-0.57	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
ESCA	cis	rs1787200	0.517	rs73441552	ENSG00000266696.1	RP11-30L3.2	4.64	8.69e-06	0.0151	0.58	0.39	Height;	chr18:49154006	chr18:49205912~49208781:+
ESCA	cis	rs1787200	0.517	rs73441553	ENSG00000266696.1	RP11-30L3.2	4.64	8.69e-06	0.0151	0.58	0.39	Height;	chr18:49154211	chr18:49205912~49208781:+
ESCA	cis	rs1787200	0.517	rs12608426	ENSG00000266696.1	RP11-30L3.2	4.64	8.69e-06	0.0151	0.58	0.39	Height;	chr18:49155294	chr18:49205912~49208781:+
ESCA	cis	rs1787200	0.517	rs73441559	ENSG00000266696.1	RP11-30L3.2	4.64	8.69e-06	0.0151	0.58	0.39	Height;	chr18:49159931	chr18:49205912~49208781:+
ESCA	cis	rs1787200	0.517	rs57434680	ENSG00000266696.1	RP11-30L3.2	4.64	8.69e-06	0.0151	0.58	0.39	Height;	chr18:49160690	chr18:49205912~49208781:+
ESCA	cis	rs2627019	0.51	rs7574180	ENSG00000223911.1	AC009480.3	4.64	8.69e-06	0.0151	0.47	0.39	Neuroticism;	chr2:148107380	chr2:147899401~147902956:-
ESCA	cis	rs11169552	0.51	rs4768892	ENSG00000200428.1	Y_RNA	4.64	8.7e-06	0.0151	0.48	0.39	Colorectal cancer;	chr12:50566525	chr12:50743568~50743684:+
ESCA	cis	rs6860806	0.531	rs274556	ENSG00000233006.5	AC034220.3	-4.64	8.71e-06	0.0151	-0.38	-0.39	Breast cancer;	chr5:132386383	chr5:132311285~132369916:-
ESCA	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-4.64	8.71e-06	0.0151	-0.48	-0.39	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
ESCA	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	4.64	8.72e-06	0.0151	0.53	0.39	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	4.64	8.72e-06	0.0151	0.53	0.39	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	4.64	8.72e-06	0.0151	0.53	0.39	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
ESCA	cis	rs2412819	0.571	rs7174260	ENSG00000249839.1	AC011330.5	-4.64	8.72e-06	0.0151	-0.73	-0.39	Lung cancer;	chr15:43751988	chr15:43663654~43684339:-
ESCA	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	4.64	8.72e-06	0.0151	0.73	0.39	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
ESCA	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	4.64	8.72e-06	0.0151	0.73	0.39	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
ESCA	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-4.64	8.72e-06	0.0152	-0.57	-0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
ESCA	cis	rs7829975	0.846	rs6601724	ENSG00000173295.6	FAM86B3P	-4.64	8.72e-06	0.0152	-0.43	-0.39	Mood instability;	chr8:8687362	chr8:8228595~8244865:+
ESCA	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	4.64	8.74e-06	0.0152	0.51	0.39	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	4.64	8.74e-06	0.0152	0.51	0.39	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	4.64	8.74e-06	0.0152	0.51	0.39	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	4.64	8.74e-06	0.0152	0.51	0.39	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
ESCA	cis	rs6805251	0.607	rs10511395	ENSG00000276607.2	AC092910.1	-4.64	8.75e-06	0.0152	-0.65	-0.39	HDL cholesterol levels;HDL cholesterol;	chr3:119817712	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.607	rs1054191	ENSG00000276607.2	AC092910.1	-4.64	8.75e-06	0.0152	-0.65	-0.39	HDL cholesterol levels;HDL cholesterol;	chr3:119818050	chr3:120084550~120084657:-
ESCA	cis	rs2307394	0.928	rs1469210	ENSG00000223911.1	AC009480.3	4.64	8.75e-06	0.0152	0.46	0.39	Urate levels;	chr2:147889173	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs2161984	ENSG00000223911.1	AC009480.3	4.64	8.75e-06	0.0152	0.46	0.39	Urate levels;	chr2:147890917	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.964	rs13019809	ENSG00000223911.1	AC009480.3	4.64	8.75e-06	0.0152	0.46	0.39	Urate levels;	chr2:147892904	chr2:147899401~147902956:-
ESCA	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	4.64	8.75e-06	0.0152	0.43	0.39	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
ESCA	cis	rs28830936	1	rs2412622	ENSG00000250379.1	RP11-23P13.4	4.64	8.75e-06	0.0152	0.44	0.39	Diastolic blood pressure;	chr15:41668113	chr15:41825099~41827936:-
ESCA	cis	rs2412819	0.571	rs678084	ENSG00000249839.1	AC011330.5	4.64	8.75e-06	0.0152	0.68	0.39	Lung cancer;	chr15:43828361	chr15:43663654~43684339:-
ESCA	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-4.64	8.76e-06	0.0152	-0.57	-0.39	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
ESCA	cis	rs287982	1	rs112307255	ENSG00000269973.1	RP11-95D17.1	-4.64	8.76e-06	0.0152	-0.5	-0.39	Nonsyndromic cleft lip with cleft palate;	chr2:9842137	chr2:9936360~9939590:+
ESCA	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	4.64	8.78e-06	0.0152	0.4	0.39	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
ESCA	cis	rs6860806	0.507	rs2631364	ENSG00000233006.5	AC034220.3	-4.64	8.8e-06	0.0153	-0.38	-0.39	Breast cancer;	chr5:132371222	chr5:132311285~132369916:-
ESCA	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-4.64	8.8e-06	0.0153	-0.38	-0.39	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
ESCA	cis	rs61160187	0.577	rs34741733	ENSG00000215032.2	GNL3LP1	4.64	8.8e-06	0.0153	0.51	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:60843721	chr5:60891935~60893577:-
ESCA	cis	rs1075232	0.522	rs57924788	ENSG00000270055.1	CTD-3092A11.2	-4.64	8.81e-06	0.0153	-0.77	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31457519	chr15:30487963~30490313:+
ESCA	cis	rs2273156	0.929	rs12050171	ENSG00000241052.1	RP11-173D9.1	-4.64	8.82e-06	0.0153	-0.45	-0.39	Immunoglobulin light chain (AL) amyloidosis;	chr14:34926245	chr14:35144021~35144480:-
ESCA	cis	rs765787	0.53	rs1706837	ENSG00000259520.4	CTD-2651B20.3	4.64	8.82e-06	0.0153	0.45	0.39	Uric acid levels;	chr15:45226838	chr15:45251580~45279251:-
ESCA	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-4.64	8.82e-06	0.0153	-0.5	-0.39	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
ESCA	cis	rs7829975	0.593	rs2921061	ENSG00000253981.4	ALG1L13P	4.64	8.83e-06	0.0153	0.5	0.39	Mood instability;	chr8:8460105	chr8:8236003~8244667:-
ESCA	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-4.64	8.83e-06	0.0153	-0.44	-0.39	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
ESCA	cis	rs3820068	0.705	rs4646063	ENSG00000237301.1	RP4-680D5.2	4.64	8.83e-06	0.0153	0.45	0.39	Systolic blood pressure;	chr1:15503318	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs4645992	ENSG00000237301.1	RP4-680D5.2	4.64	8.83e-06	0.0153	0.45	0.39	Systolic blood pressure;	chr1:15523247	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs72645808	ENSG00000237301.1	RP4-680D5.2	4.64	8.83e-06	0.0153	0.45	0.39	Systolic blood pressure;	chr1:15543623	chr1:15586136~15603626:-
ESCA	cis	rs2439831	0.867	rs2447208	ENSG00000205771.5	CATSPER2P1	-4.64	8.85e-06	0.0153	-0.64	-0.39	Lung cancer in ever smokers;	chr15:43641697	chr15:43726918~43747094:-
ESCA	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-4.64	8.85e-06	0.0153	-0.41	-0.39	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
ESCA	cis	rs4927850	0.752	rs7624460	ENSG00000231464.1	AC024937.4	4.64	8.86e-06	0.0153	0.44	0.39	Pancreatic cancer;	chr3:196021659	chr3:195996738~195998233:+
ESCA	cis	rs4927850	0.752	rs7618864	ENSG00000231464.1	AC024937.4	4.64	8.86e-06	0.0153	0.44	0.39	Pancreatic cancer;	chr3:196022690	chr3:195996738~195998233:+
ESCA	cis	rs950169	0.58	rs17532346	ENSG00000225151.9	GOLGA2P7	-4.64	8.86e-06	0.0154	-0.57	-0.39	Schizophrenia;	chr15:84628264	chr15:84199311~84230136:-
ESCA	cis	rs2439831	0.85	rs12702	ENSG00000224677.1	PDIA3P2	4.64	8.86e-06	0.0154	0.49	0.39	Lung cancer in ever smokers;	chr15:43801729	chr15:43649123~43649280:+
ESCA	cis	rs7535099	0.954	rs6678948	ENSG00000224570.1	RP11-430H12.2	-4.64	8.87e-06	0.0154	-0.61	-0.39	Blood protein levels;	chr1:65571906	chr1:65576129~65578380:-
ESCA	cis	rs636159	0.616	rs301574	ENSG00000213287.3	RP11-680L20.1	-4.64	8.87e-06	0.0154	-0.47	-0.39	Bone ultrasound measurement (velocity of sound);	chr11:87180217	chr11:87258851~87259259:-
ESCA	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	4.64	8.9e-06	0.0154	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
ESCA	cis	rs1723838	0.826	rs1792157	ENSG00000255928.1	RP11-456I15.2	4.64	8.9e-06	0.0154	0.8	0.39	Obesity-related traits;	chr11:73818909	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs2515091	ENSG00000255928.1	RP11-456I15.2	4.64	8.9e-06	0.0154	0.8	0.39	Obesity-related traits;	chr11:73823409	chr11:73722349~73722694:+
ESCA	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	4.64	8.91e-06	0.0154	0.5	0.39	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
ESCA	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	4.64	8.91e-06	0.0154	0.52	0.39	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
ESCA	cis	rs2243480	1	rs958550	ENSG00000222364.1	RNU6-96P	4.64	8.94e-06	0.0155	0.56	0.39	Diabetic kidney disease;	chr7:66170692	chr7:66395191~66395286:+
ESCA	cis	rs28830936	1	rs11632424	ENSG00000250379.1	RP11-23P13.4	4.64	8.95e-06	0.0155	0.43	0.39	Diastolic blood pressure;	chr15:41803153	chr15:41825099~41827936:-
ESCA	cis	rs7412746	0.621	rs7518156	ENSG00000206931.1	RNU6-1042P	4.64	8.96e-06	0.0155	0.49	0.39	Melanoma;	chr1:150973318	chr1:150701866~150701972:+
ESCA	cis	rs9545047	0.604	rs7336581	ENSG00000227676.3	LINC01068	4.63	8.96e-06	0.0155	0.49	0.39	Schizophrenia;	chr13:79385739	chr13:79566727~79571436:+
ESCA	cis	rs1031391	0.716	rs10772416	ENSG00000256274.1	TAS2R64P	-4.63	8.97e-06	0.0155	-0.53	-0.39	Bitter taste perception;	chr12:11017488	chr12:11076769~11079171:-
ESCA	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-4.63	8.97e-06	0.0155	-0.46	-0.39	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
ESCA	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-4.63	8.99e-06	0.0155	-0.46	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-4.63	8.99e-06	0.0155	-0.46	-0.39	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
ESCA	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	4.63	9e-06	0.0156	0.42	0.39	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
ESCA	cis	rs17711722	0.51	rs11767457	ENSG00000164669.11	INTS4P1	-4.63	9e-06	0.0156	-0.44	-0.39	Calcium levels;	chr7:65825628	chr7:65141225~65234216:+
ESCA	cis	rs1075265	0.87	rs1421617	ENSG00000235937.1	AC008280.1	4.63	9.01e-06	0.0156	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54029552~54030682:-
ESCA	cis	rs9549260	0.683	rs35594717	ENSG00000229456.1	RLIMP1	4.63	9.02e-06	0.0156	0.47	0.39	Red blood cell count;	chr13:40666646	chr13:40618738~40621348:+
ESCA	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	4.63	9.03e-06	0.0156	0.64	0.39	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
ESCA	cis	rs2439831	0.867	rs496584	ENSG00000249839.1	AC011330.5	-4.63	9.03e-06	0.0156	-0.58	-0.39	Lung cancer in ever smokers;	chr15:43539725	chr15:43663654~43684339:-
ESCA	cis	rs9399137	0.507	rs13196486	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134962736	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs6918512	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134963701	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs13064	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134966395	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs56164974	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967578	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs35571217	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134969217	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs11757723	ENSG00000232876.1	CTA-212D2.2	-4.63	9.03e-06	0.0156	-0.46	-0.39	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134970155	chr6:135055033~135060550:+
ESCA	cis	rs7208859	0.623	rs9906957	ENSG00000263531.1	RP13-753N3.1	4.63	9.05e-06	0.0156	0.58	0.39	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30830737	chr17:30863921~30864940:-
ESCA	cis	rs71718386	1	rs71718386	ENSG00000229456.1	RLIMP1	4.63	9.06e-06	0.0156	0.36	0.39	Eosinophil counts;	chr13:40650154	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.664	rs1360719	ENSG00000229456.1	RLIMP1	4.63	9.06e-06	0.0156	0.36	0.39	Red blood cell count;	chr13:40651737	chr13:40618738~40621348:+
ESCA	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	4.63	9.11e-06	0.0157	0.32	0.39	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
ESCA	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	4.63	9.11e-06	0.0157	0.53	0.39	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	4.63	9.11e-06	0.0157	0.53	0.39	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
ESCA	cis	rs7829975	0.811	rs7011229	ENSG00000253981.4	ALG1L13P	-4.63	9.12e-06	0.0157	-0.45	-0.39	Mood instability;	chr8:8685814	chr8:8236003~8244667:-
ESCA	cis	rs747650	0.926	rs11039119	ENSG00000271350.1	CTD-2384B9.1	4.63	9.13e-06	0.0157	0.47	0.39	Acne (severe);	chr11:47180373	chr11:47041027~47041945:-
ESCA	cis	rs2019137	0.967	rs902695	ENSG00000189223.12	PAX8-AS1	4.63	9.15e-06	0.0158	0.5	0.39	Lymphocyte counts;	chr2:113197497	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.905	rs2276561	ENSG00000189223.12	PAX8-AS1	4.63	9.15e-06	0.0158	0.5	0.39	Lymphocyte counts;	chr2:113198794	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs2305133	ENSG00000189223.12	PAX8-AS1	4.63	9.15e-06	0.0158	0.5	0.39	Lymphocyte counts;	chr2:113199244	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs12612729	ENSG00000189223.12	PAX8-AS1	4.63	9.15e-06	0.0158	0.5	0.39	Lymphocyte counts;	chr2:113199471	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs731834	ENSG00000189223.12	PAX8-AS1	4.63	9.15e-06	0.0158	0.5	0.39	Lymphocyte counts;	chr2:113199621	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs902696	ENSG00000189223.12	PAX8-AS1	-4.63	9.15e-06	0.0158	-0.5	-0.39	Lymphocyte counts;	chr2:113197302	chr2:113211522~113276581:+
ESCA	cis	rs7829975	0.501	rs2980769	ENSG00000173295.6	FAM86B3P	4.63	9.17e-06	0.0158	0.46	0.39	Mood instability;	chr8:8462781	chr8:8228595~8244865:+
ESCA	cis	rs977987	0.778	rs12930452	ENSG00000261783.1	RP11-252K23.2	-4.63	9.17e-06	0.0158	-0.47	-0.39	Dupuytren's disease;	chr16:75428157	chr16:75379818~75381260:-
ESCA	cis	rs2179367	0.959	rs564961	ENSG00000216906.2	RP11-350J20.9	4.63	9.18e-06	0.0158	0.49	0.39	Dupuytren's disease;	chr6:149336091	chr6:149904243~149906418:+
ESCA	cis	rs2179367	0.959	rs504985	ENSG00000216906.2	RP11-350J20.9	4.63	9.18e-06	0.0158	0.49	0.39	Dupuytren's disease;	chr6:149337842	chr6:149904243~149906418:+
ESCA	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	4.63	9.19e-06	0.0158	0.33	0.39	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
ESCA	cis	rs1075232	1	rs72722829	ENSG00000215302.7	CTD-3092A11.1	-4.63	9.21e-06	0.0159	-0.82	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31346911	chr15:30470779~30507623:+
ESCA	cis	rs1075232	1	rs16956707	ENSG00000215302.7	CTD-3092A11.1	-4.63	9.21e-06	0.0159	-0.82	-0.39	Survival in colorectal cancer (non-distant metastatic);	chr15:31349430	chr15:30470779~30507623:+
ESCA	cis	rs61160187	0.582	rs56025209	ENSG00000215032.2	GNL3LP1	4.63	9.23e-06	0.0159	0.48	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:61053793	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs2049579	ENSG00000215032.2	GNL3LP1	4.63	9.23e-06	0.0159	0.48	0.39	Educational attainment (years of education);Educational attainment (college completion);	chr5:61054838	chr5:60891935~60893577:-
ESCA	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-4.63	9.24e-06	0.0159	-0.66	-0.39	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
ESCA	cis	rs2227564	0.729	rs2675676	ENSG00000229990.3	RP11-574K11.8	-4.63	9.24e-06	0.0159	-0.41	-0.39	Crohn's disease;Inflammatory bowel disease;	chr10:73888529	chr10:73841833~73847115:+
ESCA	cis	rs8072100	1	rs8065437	ENSG00000228782.6	CTD-2026D20.3	4.63	9.25e-06	0.0159	0.42	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644287	chr17:47450568~47492492:-
ESCA	cis	rs8072100	0.967	rs2317826	ENSG00000228782.6	CTD-2026D20.3	4.63	9.25e-06	0.0159	0.42	0.39	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47653533	chr17:47450568~47492492:-
ESCA	cis	rs11612508	1	rs11609905	ENSG00000274551.1	RP11-434C1.6	4.63	9.27e-06	0.0159	0.48	0.39	Inflammatory bowel disease;	chr12:12503826	chr12:11516425~11521686:-
ESCA	cis	rs1075265	0.744	rs2909460	ENSG00000235937.1	AC008280.1	4.63	9.27e-06	0.0159	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.811	rs805308	ENSG00000235937.1	AC008280.1	4.63	9.27e-06	0.0159	0.43	0.39	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54029552~54030682:-
ESCA	cis	rs7283707	0.582	rs9983542	ENSG00000269950.1	AP000962.2	4.63	9.3e-06	0.016	0.66	0.38	QRS complex (12-leadsum);	chr21:15692824	chr21:16574718~16582637:-
ESCA	cis	rs1075265	0.783	rs698858	ENSG00000235937.1	AC008280.1	4.63	9.3e-06	0.016	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.756	rs805367	ENSG00000235937.1	AC008280.1	4.63	9.3e-06	0.016	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54029552~54030682:-
ESCA	cis	rs11169552	0.51	rs7956591	ENSG00000200428.1	Y_RNA	4.63	9.31e-06	0.016	0.47	0.38	Colorectal cancer;	chr12:50555103	chr12:50743568~50743684:+
ESCA	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	4.63	9.32e-06	0.016	0.44	0.38	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
ESCA	cis	rs1005277	0.579	rs2474567	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2472175	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2472176	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474569	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2504143	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.602	rs2504142	ENSG00000276805.1	RP11-291L22.6	4.63	9.33e-06	0.016	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38451030~38451785:+
ESCA	cis	rs2307394	1	rs12473564	ENSG00000223911.1	AC009480.3	4.63	9.33e-06	0.016	0.47	0.38	Urate levels;	chr2:148036161	chr2:147899401~147902956:-
ESCA	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-4.62	9.36e-06	0.0161	-0.55	-0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
ESCA	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-4.62	9.36e-06	0.0161	-0.55	-0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
ESCA	cis	rs2283792	0.687	rs381849	ENSG00000228050.1	TOP3BP1	4.62	9.37e-06	0.0161	0.49	0.38	Multiple sclerosis;	chr22:21951341	chr22:22223187~22224566:-
ESCA	cis	rs858239	0.568	rs6970694	ENSG00000230042.1	AK3P3	-4.62	9.37e-06	0.0161	-0.46	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.601	rs28673077	ENSG00000230042.1	AK3P3	-4.62	9.37e-06	0.0161	-0.46	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23129178~23129841:+
ESCA	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-4.62	9.38e-06	0.0161	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
ESCA	cis	rs12822507	0.929	rs17819158	ENSG00000275560.1	RP11-180M15.7	-4.62	9.38e-06	0.0161	-0.39	-0.38	Systemic lupus erythematosus;	chr12:12620005	chr12:12718973~12719521:+
ESCA	cis	rs7301826	0.651	rs12820597	ENSG00000256250.1	RP11-989F5.1	4.62	9.38e-06	0.0161	0.48	0.38	Plasma plasminogen activator levels;	chr12:130795640	chr12:130810606~130812438:+
ESCA	cis	rs2179367	0.959	rs537354	ENSG00000216906.2	RP11-350J20.9	4.62	9.38e-06	0.0161	0.49	0.38	Dupuytren's disease;	chr6:149344801	chr6:149904243~149906418:+
ESCA	cis	rs7208859	0.725	rs9897673	ENSG00000263531.1	RP13-753N3.1	4.62	9.39e-06	0.0161	0.56	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916348	chr17:30863921~30864940:-
ESCA	cis	rs61160187	0.582	rs67555188	ENSG00000215032.2	GNL3LP1	4.62	9.39e-06	0.0161	0.51	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847401	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs67858932	ENSG00000215032.2	GNL3LP1	4.62	9.39e-06	0.0161	0.51	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:60847424	chr5:60891935~60893577:-
ESCA	cis	rs9399137	0.507	rs13214669	ENSG00000232876.1	CTA-212D2.2	-4.62	9.39e-06	0.0161	-0.47	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134978821	chr6:135055033~135060550:+
ESCA	cis	rs1439620	0.515	rs56245530	ENSG00000271763.1	RP11-386M24.9	4.62	9.4e-06	0.0161	0.4	0.38	Body mass index;	chr15:93006603	chr15:92602910~92620015:+
ESCA	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-4.62	9.41e-06	0.0161	-0.48	-0.38	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
ESCA	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	4.62	9.41e-06	0.0161	0.73	0.38	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
ESCA	cis	rs8059260	0.542	rs7196077	ENSG00000274038.1	RP11-66H6.4	-4.62	9.42e-06	0.0162	-0.71	-0.38	Alcohol consumption over the past year;	chr16:11033198	chr16:11056556~11057034:+
ESCA	cis	rs3820716	0.507	rs12465610	ENSG00000223911.1	AC009480.3	4.62	9.43e-06	0.0162	0.46	0.38	Glomerular filtration rate (creatinine);	chr2:148178611	chr2:147899401~147902956:-
ESCA	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-4.62	9.44e-06	0.0162	-0.57	-0.38	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
ESCA	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	4.62	9.44e-06	0.0162	0.42	0.38	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	4.62	9.44e-06	0.0162	0.42	0.38	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	4.62	9.44e-06	0.0162	0.42	0.38	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
ESCA	cis	rs1005277	0.691	rs2474558	ENSG00000276805.1	RP11-291L22.6	-4.62	9.44e-06	0.0162	-0.54	-0.38	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38451030~38451785:+
ESCA	cis	rs11169552	0.58	rs4768913	ENSG00000200428.1	Y_RNA	4.62	9.45e-06	0.0162	0.48	0.38	Colorectal cancer;	chr12:50742173	chr12:50743568~50743684:+
ESCA	cis	rs2280018	0.963	rs11075255	ENSG00000260735.1	RP11-72I8.1	-4.62	9.46e-06	0.0162	-0.38	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072375	chr16:15094411~15109197:+
ESCA	cis	rs2412819	0.571	rs12900924	ENSG00000249839.1	AC011330.5	-4.62	9.46e-06	0.0162	-0.72	-0.38	Lung cancer;	chr15:43737329	chr15:43663654~43684339:-
ESCA	cis	rs2921036	0.545	rs4840975	ENSG00000253981.4	ALG1L13P	-4.62	9.46e-06	0.0162	-0.5	-0.38	Neuroticism;	chr8:8505748	chr8:8236003~8244667:-
ESCA	cis	rs2505998	0.843	rs2435344	ENSG00000273008.1	RP11-351D16.3	-4.62	9.47e-06	0.0162	-0.42	-0.38	Hirschsprung disease;	chr10:43090426	chr10:43136824~43138334:-
ESCA	cis	rs7829975	0.56	rs6994131	ENSG00000173295.6	FAM86B3P	-4.62	9.47e-06	0.0162	-0.46	-0.38	Mood instability;	chr8:8693448	chr8:8228595~8244865:+
ESCA	cis	rs8059260	0.542	rs11860851	ENSG00000274038.1	RP11-66H6.4	-4.62	9.47e-06	0.0162	-0.71	-0.38	Alcohol consumption over the past year;	chr16:11033893	chr16:11056556~11057034:+
ESCA	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	4.62	9.48e-06	0.0162	0.51	0.38	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
ESCA	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	4.62	9.48e-06	0.0162	0.51	0.38	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
ESCA	cis	rs2179367	0.959	rs514839	ENSG00000216906.2	RP11-350J20.9	4.62	9.49e-06	0.0162	0.49	0.38	Dupuytren's disease;	chr6:149327304	chr6:149904243~149906418:+
ESCA	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	4.62	9.49e-06	0.0162	0.53	0.38	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	4.62	9.49e-06	0.0162	0.47	0.38	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	4.62	9.49e-06	0.0162	0.47	0.38	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
ESCA	cis	rs11955398	0.62	rs6449512	ENSG00000215032.2	GNL3LP1	4.62	9.5e-06	0.0163	0.49	0.38	Intelligence (multi-trait analysis);	chr5:60938415	chr5:60891935~60893577:-
ESCA	cis	rs2439831	0.85	rs8042868	ENSG00000275601.1	AC011330.13	-4.62	9.52e-06	0.0163	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43647444	chr15:43642389~43643023:-
ESCA	cis	rs10256972	0.524	rs6945202	ENSG00000229043.2	AC091729.9	-4.62	9.53e-06	0.0163	-0.4	-0.38	Endometriosis;Longevity;	chr7:1076922	chr7:1160374~1165267:+
ESCA	cis	rs2179367	0.92	rs560051	ENSG00000231760.4	RP11-350J20.5	4.62	9.55e-06	0.0163	0.44	0.38	Dupuytren's disease;	chr6:149345841	chr6:149796151~149826294:-
ESCA	cis	rs9549260	0.755	rs7993233	ENSG00000229456.1	RLIMP1	4.62	9.55e-06	0.0163	0.36	0.38	Red blood cell count;	chr13:40645297	chr13:40618738~40621348:+
ESCA	cis	rs6921919	0.789	rs13210258	ENSG00000216901.1	AL022393.7	4.62	9.55e-06	0.0163	0.47	0.38	Autism spectrum disorder or schizophrenia;	chr6:28340894	chr6:28176188~28176674:+
ESCA	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	4.62	9.56e-06	0.0163	0.43	0.38	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
ESCA	cis	rs2283792	0.812	rs94194	ENSG00000228050.1	TOP3BP1	4.62	9.58e-06	0.0164	0.49	0.38	Multiple sclerosis;	chr22:21933937	chr22:22223187~22224566:-
ESCA	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-4.62	9.59e-06	0.0164	-0.64	-0.38	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
ESCA	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	4.62	9.59e-06	0.0164	0.51	0.38	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	4.62	9.59e-06	0.0164	0.51	0.38	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
ESCA	cis	rs2179367	0.919	rs577001	ENSG00000216906.2	RP11-350J20.9	4.62	9.6e-06	0.0164	0.49	0.38	Dupuytren's disease;	chr6:149325172	chr6:149904243~149906418:+
ESCA	cis	rs9549260	0.755	rs9549236	ENSG00000229456.1	RLIMP1	-4.62	9.6e-06	0.0164	-0.37	-0.38	Red blood cell count;	chr13:40573021	chr13:40618738~40621348:+
ESCA	cis	rs7208859	0.673	rs999798	ENSG00000263531.1	RP13-753N3.1	4.62	9.61e-06	0.0164	0.52	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30831822	chr17:30863921~30864940:-
ESCA	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	4.62	9.63e-06	0.0164	0.66	0.38	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
ESCA	cis	rs11146838	1	rs11146838	ENSG00000263064.2	RP11-291L22.7	4.62	9.64e-06	0.0164	0.52	0.38	Breast cancer;	chr10:38856846	chr10:38448689~38448949:+
ESCA	cis	rs1075265	0.605	rs805373	ENSG00000235937.1	AC008280.1	4.62	9.65e-06	0.0164	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53859458	chr2:54029552~54030682:-
ESCA	cis	rs12480328	1	rs6067584	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50894815	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs6091233	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50895370	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs6091234	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50895780	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs76454304	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50896753	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs4449196	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50905118	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs16995592	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50907914	chr20:50913731~50914411:+
ESCA	cis	rs12480328	0.85	rs16984523	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50908064	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs73909829	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50909760	chr20:50913731~50914411:+
ESCA	cis	rs12480328	1	rs73909831	ENSG00000228663.1	PSMD10P1	4.62	9.66e-06	0.0165	0.45	0.38	Prostate cancer;	chr20:50909948	chr20:50913731~50914411:+
ESCA	cis	rs6479891	0.915	rs10740110	ENSG00000235816.3	PRELID1P3	-4.62	9.66e-06	0.0165	-0.5	-0.38	Arthritis (juvenile idiopathic);	chr10:63283461	chr10:63427297~63427939:+
ESCA	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	4.62	9.67e-06	0.0165	0.43	0.38	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
ESCA	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	4.62	9.68e-06	0.0165	0.51	0.38	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	4.62	9.68e-06	0.0165	0.51	0.38	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	4.62	9.68e-06	0.0165	0.51	0.38	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	4.62	9.68e-06	0.0165	0.51	0.38	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
ESCA	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	4.62	9.68e-06	0.0165	0.42	0.38	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
ESCA	cis	rs7208859	0.623	rs3752019	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30824687	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73271869	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825203	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73271872	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30825210	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55724095	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826040	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs56146117	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30826307	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.568	rs9903854	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Body mass index;	chr17:30826980	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.568	rs9907834	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Body mass index;	chr17:30826995	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs80355557	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827403	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9911173	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827732	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73271887	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30827917	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9898858	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829193	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs55658077	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829501	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9899692	ENSG00000263531.1	RP13-753N3.1	4.62	9.68e-06	0.0165	0.58	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30829921	chr17:30863921~30864940:-
ESCA	cis	rs3093024	0.839	rs968334	ENSG00000265828.1	MIR3939	4.62	9.69e-06	0.0165	0.41	0.38	Rheumatoid arthritis;	chr6:167112608	chr6:166997807~166997912:-
ESCA	cis	rs9462027	0.628	rs9462030	ENSG00000186328.4	RP11-140K17.2	4.62	9.69e-06	0.0165	0.43	0.38	Systemic lupus erythematosus;	chr6:34863503	chr6:34715613~34715940:+
ESCA	cis	rs7826238	0.566	rs2945886	ENSG00000173295.6	FAM86B3P	4.62	9.7e-06	0.0165	0.47	0.38	Systolic blood pressure;	chr8:8290748	chr8:8228595~8244865:+
ESCA	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	4.62	9.7e-06	0.0165	0.65	0.38	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
ESCA	cis	rs559928	0.597	rs2186572	ENSG00000274986.1	MIR6750	4.62	9.71e-06	0.0165	0.67	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64128415	chr11:64898363~64898437:-
ESCA	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-4.62	9.71e-06	0.0165	-0.52	-0.38	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
ESCA	cis	rs1005277	0.579	rs2008449	ENSG00000263064.2	RP11-291L22.7	-4.62	9.72e-06	0.0165	-0.5	-0.38	Extrinsic epigenetic age acceleration;	chr10:38125276	chr10:38448689~38448949:+
ESCA	cis	rs2412819	0.571	rs4644832	ENSG00000249839.1	AC011330.5	4.62	9.72e-06	0.0165	0.73	0.38	Lung cancer;	chr15:43792507	chr15:43663654~43684339:-
ESCA	cis	rs301901	0.581	rs6881383	ENSG00000250155.1	CTD-2353F22.1	4.61	9.73e-06	0.0166	0.38	0.38	Height;	chr5:37545897	chr5:36666214~36725195:-
ESCA	cis	rs11169552	0.51	rs10783381	ENSG00000200428.1	Y_RNA	4.61	9.76e-06	0.0166	0.44	0.38	Colorectal cancer;	chr12:50622667	chr12:50743568~50743684:+
ESCA	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	4.61	9.76e-06	0.0166	0.33	0.38	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
ESCA	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	4.61	9.77e-06	0.0166	0.5	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
ESCA	cis	rs9549260	0.816	rs7324090	ENSG00000229456.1	RLIMP1	4.61	9.78e-06	0.0166	0.37	0.38	Red blood cell count;	chr13:40679821	chr13:40618738~40621348:+
ESCA	cis	rs1005277	0.565	rs2474565	ENSG00000276805.1	RP11-291L22.6	4.61	9.79e-06	0.0166	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38451030~38451785:+
ESCA	cis	rs2227564	0.729	rs2633306	ENSG00000229990.3	RP11-574K11.8	4.61	9.79e-06	0.0166	0.41	0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73892689	chr10:73841833~73847115:+
ESCA	cis	rs1075265	0.587	rs2949812	ENSG00000235937.1	AC008280.1	4.61	9.79e-06	0.0166	0.41	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.621	rs2542593	ENSG00000235937.1	AC008280.1	4.61	9.79e-06	0.0166	0.41	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54029552~54030682:-
ESCA	cis	rs2439831	0.681	rs28578454	ENSG00000249839.1	AC011330.5	-4.61	9.82e-06	0.0167	-0.67	-0.38	Lung cancer in ever smokers;	chr15:43310834	chr15:43663654~43684339:-
ESCA	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-4.61	9.83e-06	0.0167	-0.46	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
ESCA	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-4.61	9.83e-06	0.0167	-0.46	-0.38	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-4.61	9.83e-06	0.0167	-0.46	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
ESCA	cis	rs1005277	0.579	rs2505257	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2472173	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2472174	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474563	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs9418322	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs9299760	ENSG00000276805.1	RP11-291L22.6	4.61	9.85e-06	0.0167	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38451030~38451785:+
ESCA	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-4.61	9.86e-06	0.0167	-0.38	-0.38	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
ESCA	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-4.61	9.86e-06	0.0167	-0.38	-0.38	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
ESCA	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-4.61	9.86e-06	0.0167	-0.38	-0.38	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
ESCA	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-4.61	9.86e-06	0.0167	-0.38	-0.38	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
ESCA	cis	rs7535099	0.954	rs2376016	ENSG00000224570.1	RP11-430H12.2	4.61	9.86e-06	0.0167	0.64	0.38	Blood protein levels;	chr1:65568313	chr1:65576129~65578380:-
ESCA	cis	rs11169552	0.51	rs10506294	ENSG00000200428.1	Y_RNA	-4.61	9.86e-06	0.0167	-0.48	-0.38	Colorectal cancer;	chr12:50676771	chr12:50743568~50743684:+
ESCA	cis	rs2439831	0.717	rs2447198	ENSG00000249839.1	AC011330.5	-4.61	9.86e-06	0.0167	-0.69	-0.38	Lung cancer in ever smokers;	chr15:43602920	chr15:43663654~43684339:-
ESCA	cis	rs28541881	0.536	rs117295911	ENSG00000269553.1	U62631.5	4.61	9.89e-06	0.0168	0.77	0.38	Colorectal cancer;	chr19:34376524	chr19:35330843~35331920:+
ESCA	cis	rs950169	0.922	rs8037078	ENSG00000225151.9	GOLGA2P7	4.61	9.9e-06	0.0168	0.65	0.38	Schizophrenia;	chr15:84150119	chr15:84199311~84230136:-
ESCA	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-4.61	9.92e-06	0.0168	-0.4	-0.38	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
ESCA	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-4.61	9.96e-06	0.0169	-0.43	-0.38	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-4.61	9.96e-06	0.0169	-0.45	-0.38	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
ESCA	cis	rs2227564	0.672	rs10824042	ENSG00000229990.3	RP11-574K11.8	-4.61	9.96e-06	0.0169	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73885870	chr10:73841833~73847115:+
ESCA	cis	rs2227564	0.729	rs2633303	ENSG00000229990.3	RP11-574K11.8	-4.61	9.96e-06	0.0169	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73886124	chr10:73841833~73847115:+
ESCA	cis	rs2227564	0.729	rs2688617	ENSG00000229990.3	RP11-574K11.8	-4.61	9.96e-06	0.0169	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73886389	chr10:73841833~73847115:+
ESCA	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-4.61	9.97e-06	0.0169	-0.46	-0.38	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
ESCA	cis	rs6432860	0.545	rs1841550	ENSG00000232411.1	AC009495.3	-4.61	9.97e-06	0.0169	-0.42	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166057723	chr2:165833048~165839098:-
ESCA	cis	rs9987353	0.544	rs2929469	ENSG00000253981.4	ALG1L13P	4.61	9.98e-06	0.0169	0.49	0.38	Recombination measurement;	chr8:9205146	chr8:8236003~8244667:-
ESCA	cis	rs1005277	0.579	rs2023351	ENSG00000276805.1	RP11-291L22.6	4.61	9.98e-06	0.0169	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38451030~38451785:+
ESCA	cis	rs11169552	0.51	rs10783372	ENSG00000200428.1	Y_RNA	4.61	9.98e-06	0.0169	0.47	0.38	Colorectal cancer;	chr12:50558741	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs11613488	ENSG00000200428.1	Y_RNA	4.61	9.98e-06	0.0169	0.47	0.38	Colorectal cancer;	chr12:50584472	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs4238106	ENSG00000200428.1	Y_RNA	4.61	9.98e-06	0.0169	0.47	0.38	Colorectal cancer;	chr12:50603808	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10876070	ENSG00000200428.1	Y_RNA	4.61	9.98e-06	0.0169	0.47	0.38	Colorectal cancer;	chr12:50608305	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs11169537	ENSG00000200428.1	Y_RNA	4.61	1e-05	0.017	0.47	0.38	Colorectal cancer;	chr12:50733009	chr12:50743568~50743684:+
ESCA	cis	rs36093844	0.626	rs41381550	ENSG00000271318.1	AP000654.5	4.61	1e-05	0.017	0.78	0.38	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85956045	chr11:86821143~86821728:-
ESCA	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	4.61	1.01e-05	0.017	0.41	0.38	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
ESCA	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-4.61	1.01e-05	0.0171	-0.7	-0.38	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.867	rs2447211	ENSG00000205771.5	CATSPER2P1	-4.61	1.01e-05	0.0171	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43644153	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.571	rs2470121	ENSG00000205771.5	CATSPER2P1	-4.61	1.01e-05	0.0171	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43645420	chr15:43726918~43747094:-
ESCA	cis	rs3820068	0.626	rs61103742	ENSG00000237301.1	RP4-680D5.2	4.61	1.01e-05	0.0171	0.4	0.38	Systolic blood pressure;	chr1:15582658	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.626	rs11580170	ENSG00000237301.1	RP4-680D5.2	4.61	1.01e-05	0.0171	0.4	0.38	Systolic blood pressure;	chr1:15583249	chr1:15586136~15603626:-
ESCA	cis	rs2179367	0.959	rs4897125	ENSG00000216906.2	RP11-350J20.9	4.61	1.01e-05	0.0171	0.52	0.38	Dupuytren's disease;	chr6:149445072	chr6:149904243~149906418:+
ESCA	cis	rs2439831	0.867	rs2245715	ENSG00000249839.1	AC011330.5	-4.6	1.01e-05	0.0172	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43525854	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2255440	ENSG00000249839.1	AC011330.5	-4.6	1.01e-05	0.0172	-0.6	-0.38	Lung cancer in ever smokers;	chr15:43538269	chr15:43663654~43684339:-
ESCA	cis	rs12822507	0.965	rs4763858	ENSG00000275560.1	RP11-180M15.7	-4.6	1.02e-05	0.0172	-0.39	-0.38	Systemic lupus erythematosus;	chr12:12624039	chr12:12718973~12719521:+
ESCA	cis	rs12822507	1	rs2284794	ENSG00000275560.1	RP11-180M15.7	-4.6	1.02e-05	0.0172	-0.39	-0.38	Systemic lupus erythematosus;	chr12:12625418	chr12:12718973~12719521:+
ESCA	cis	rs9545047	0.604	rs314695	ENSG00000227676.3	LINC01068	-4.6	1.02e-05	0.0172	-0.5	-0.38	Schizophrenia;	chr13:79432206	chr13:79566727~79571436:+
ESCA	cis	rs9650657	0.665	rs7002117	ENSG00000248896.2	CTD-2135J3.3	4.6	1.02e-05	0.0172	0.48	0.38	Neuroticism;	chr8:10758659	chr8:10729314~10771392:+
ESCA	cis	rs150992	0.962	rs327811	ENSG00000248489.1	CTD-2007H13.3	4.6	1.02e-05	0.0172	0.52	0.38	Body mass index;	chr5:98935471	chr5:98929171~98995013:+
ESCA	cis	rs61160187	0.582	rs1382917	ENSG00000215032.2	GNL3LP1	4.6	1.02e-05	0.0172	0.49	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956668	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.549	rs56031340	ENSG00000215032.2	GNL3LP1	4.6	1.02e-05	0.0172	0.49	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:60958043	chr5:60891935~60893577:-
ESCA	cis	rs1075265	0.783	rs805424	ENSG00000235937.1	AC008280.1	4.6	1.02e-05	0.0172	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54029552~54030682:-
ESCA	cis	rs2439831	0.681	rs11858152	ENSG00000249839.1	AC011330.5	-4.6	1.02e-05	0.0172	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43341998	chr15:43663654~43684339:-
ESCA	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	4.6	1.02e-05	0.0172	0.51	0.38	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	4.6	1.02e-05	0.0172	0.51	0.38	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	4.6	1.02e-05	0.0172	0.51	0.38	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
ESCA	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	4.6	1.02e-05	0.0173	0.53	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	4.6	1.02e-05	0.0173	0.53	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	4.6	1.02e-05	0.0173	0.53	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
ESCA	cis	rs6538678	0.833	rs10859966	ENSG00000258343.1	RP11-536G4.2	4.6	1.02e-05	0.0173	0.42	0.38	Lupus nephritis in systemic lupus erythematosus;	chr12:95859597	chr12:95795345~95858839:-
ESCA	cis	rs9733	0.566	rs11204675	ENSG00000206931.1	RNU6-1042P	-4.6	1.03e-05	0.0173	-0.46	-0.38	Tonsillectomy;	chr1:150598509	chr1:150701866~150701972:+
ESCA	cis	rs2143950	0.749	rs57275892	ENSG00000241052.1	RP11-173D9.1	-4.6	1.03e-05	0.0173	-0.53	-0.38	Atopic dermatitis;	chr14:35278065	chr14:35144021~35144480:-
ESCA	cis	rs2980439	0.525	rs1850511	ENSG00000253981.4	ALG1L13P	4.6	1.03e-05	0.0173	0.47	0.38	Neuroticism;	chr8:8312807	chr8:8236003~8244667:-
ESCA	cis	rs2505998	0.833	rs752977	ENSG00000273008.1	RP11-351D16.3	-4.6	1.03e-05	0.0173	-0.42	-0.38	Hirschsprung disease;	chr10:43092933	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs12767776	ENSG00000273008.1	RP11-351D16.3	-4.6	1.03e-05	0.0173	-0.42	-0.38	Hirschsprung disease;	chr10:43094065	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.796	rs2505537	ENSG00000273008.1	RP11-351D16.3	-4.6	1.03e-05	0.0173	-0.42	-0.38	Hirschsprung disease;	chr10:43096710	chr10:43136824~43138334:-
ESCA	cis	rs2505998	0.833	rs2505535	ENSG00000273008.1	RP11-351D16.3	-4.6	1.03e-05	0.0173	-0.42	-0.38	Hirschsprung disease;	chr10:43097595	chr10:43136824~43138334:-
ESCA	cis	rs1075265	0.73	rs7601692	ENSG00000235937.1	AC008280.1	4.6	1.03e-05	0.0173	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54029552~54030682:-
ESCA	cis	rs2742234	0.541	rs11528481	ENSG00000273008.1	RP11-351D16.3	4.6	1.03e-05	0.0174	0.46	0.38	Hirschsprung disease;	chr10:43242319	chr10:43136824~43138334:-
ESCA	cis	rs2221894	0.922	rs4732657	ENSG00000273710.1	Metazoa_SRP	-4.6	1.03e-05	0.0174	-0.41	-0.38	Obesity-related traits;	chr8:28898471	chr8:28915579~28915864:-
ESCA	cis	rs7829975	0.688	rs7827182	ENSG00000173295.6	FAM86B3P	4.6	1.03e-05	0.0174	0.44	0.38	Mood instability;	chr8:8522961	chr8:8228595~8244865:+
ESCA	cis	rs351365	1	rs351365	ENSG00000234790.1	NUTF2P4	-4.6	1.04e-05	0.0174	-0.53	-0.38	Pancreatic cancer;	chr1:112503773	chr1:112748095~112748475:+
ESCA	cis	rs8072100	1	rs3809868	ENSG00000228782.6	CTD-2026D20.3	-4.6	1.04e-05	0.0175	-0.42	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47673230	chr17:47450568~47492492:-
ESCA	cis	rs8072100	1	rs7210738	ENSG00000228782.6	CTD-2026D20.3	-4.6	1.04e-05	0.0175	-0.42	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47680232	chr17:47450568~47492492:-
ESCA	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-4.6	1.04e-05	0.0175	-0.44	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
ESCA	cis	rs9549260	0.876	rs9549258	ENSG00000229456.1	RLIMP1	4.6	1.04e-05	0.0175	0.48	0.38	Red blood cell count;	chr13:40673889	chr13:40618738~40621348:+
ESCA	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	4.6	1.04e-05	0.0175	0.33	0.38	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	4.6	1.04e-05	0.0175	0.33	0.38	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
ESCA	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	4.6	1.04e-05	0.0175	0.51	0.38	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
ESCA	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	4.6	1.04e-05	0.0175	0.51	0.38	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
ESCA	cis	rs1816752	0.679	rs8181826	ENSG00000273628.1	RP11-756A22.7	-4.6	1.04e-05	0.0175	-0.36	-0.38	Obesity-related traits;	chr13:24396570	chr13:24933006~24936796:+
ESCA	cis	rs13276960	0.553	rs58867349	ENSG00000253385.1	KB-1254G8.1	4.6	1.04e-05	0.0175	0.46	0.38	Schizophrenia;	chr8:102915932	chr8:102854455~102856075:+
ESCA	cis	rs4345206	0.589	rs28590383	ENSG00000250673.1	RP11-6L6.2	-4.6	1.04e-05	0.0175	-0.39	-0.38	Coronary artery disease;	chr4:145882096	chr4:146224557~146229056:+
ESCA	cis	rs559928	0.597	rs2096706	ENSG00000274986.1	MIR6750	4.6	1.05e-05	0.0176	0.7	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64156974	chr11:64898363~64898437:-
ESCA	cis	rs9322193	0.847	rs4870054	ENSG00000231760.4	RP11-350J20.5	4.6	1.05e-05	0.0176	0.44	0.38	Lung cancer;	chr6:149848402	chr6:149796151~149826294:-
ESCA	cis	rs28830936	1	rs4924575	ENSG00000250379.1	RP11-23P13.4	4.6	1.05e-05	0.0176	0.43	0.38	Diastolic blood pressure;	chr15:41804728	chr15:41825099~41827936:-
ESCA	cis	rs1816752	0.776	rs9511268	ENSG00000273628.1	RP11-756A22.7	4.6	1.05e-05	0.0176	0.37	0.38	Obesity-related traits;	chr13:24444182	chr13:24933006~24936796:+
ESCA	cis	rs2439831	0.85	rs3816792	ENSG00000249839.1	AC011330.5	4.6	1.05e-05	0.0176	0.69	0.38	Lung cancer in ever smokers;	chr15:43824788	chr15:43663654~43684339:-
ESCA	cis	rs1075265	0.818	rs12713253	ENSG00000235937.1	AC008280.1	4.6	1.05e-05	0.0176	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54029552~54030682:-
ESCA	cis	rs1723838	1	rs1723838	ENSG00000255928.1	RP11-456I15.2	4.6	1.05e-05	0.0176	0.72	0.38	Obesity-related traits;	chr11:73766000	chr11:73722349~73722694:+
ESCA	cis	rs6805251	0.607	rs11929668	ENSG00000276607.2	AC092910.1	4.6	1.05e-05	0.0176	0.6	0.38	HDL cholesterol levels;HDL cholesterol;	chr3:119816948	chr3:120084550~120084657:-
ESCA	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	4.6	1.05e-05	0.0177	0.51	0.38	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
ESCA	cis	rs394563	0.589	rs1900300	ENSG00000231760.4	RP11-350J20.5	-4.59	1.06e-05	0.0177	-0.45	-0.38	Dupuytren's disease;	chr6:149320491	chr6:149796151~149826294:-
ESCA	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-4.59	1.06e-05	0.0177	-0.74	-0.38	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
ESCA	cis	rs2400997	0.967	rs9707405	ENSG00000258919.1	RP11-1029J19.4	4.59	1.06e-05	0.0177	0.39	0.38	Prostate cancer (SNP x SNP interaction);	chr14:101276857	chr14:101628984~101632530:-
ESCA	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	4.59	1.06e-05	0.0177	0.32	0.38	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	4.59	1.06e-05	0.0177	0.32	0.38	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
ESCA	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	4.59	1.06e-05	0.0177	0.32	0.38	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
ESCA	cis	rs6785206	0.554	rs9867598	ENSG00000239503.1	MARK2P8	-4.59	1.06e-05	0.0177	-0.41	-0.38	Lymphocyte percentage of white cells;	chr3:128741785	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs9831813	ENSG00000239503.1	MARK2P8	-4.59	1.06e-05	0.0177	-0.41	-0.38	Lymphocyte percentage of white cells;	chr3:128759699	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs9841748	ENSG00000239503.1	MARK2P8	-4.59	1.06e-05	0.0177	-0.41	-0.38	Lymphocyte percentage of white cells;	chr3:128761361	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs7631994	ENSG00000239503.1	MARK2P8	-4.59	1.06e-05	0.0177	-0.41	-0.38	Lymphocyte percentage of white cells;	chr3:128762607	chr3:128748538~128749489:-
ESCA	cis	rs7712401	0.765	rs10079941	ENSG00000263432.2	RN7SL689P	4.59	1.06e-05	0.0177	0.54	0.38	Mean platelet volume;	chr5:123045668	chr5:123022487~123022783:-
ESCA	cis	rs11265395	1	rs11265402	ENSG00000215840.3	RP11-122G18.7	4.59	1.06e-05	0.0177	0.45	0.38	Tonsillectomy;	chr1:160443300	chr1:161406068~161407082:+
ESCA	cis	rs8072100	0.846	rs4264433	ENSG00000228782.6	CTD-2026D20.3	-4.59	1.06e-05	0.0178	-0.41	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47659909	chr17:47450568~47492492:-
ESCA	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-4.59	1.06e-05	0.0178	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
ESCA	cis	rs3820068	0.705	rs11583306	ENSG00000237301.1	RP4-680D5.2	-4.59	1.06e-05	0.0178	-0.42	-0.38	Systolic blood pressure;	chr1:15534308	chr1:15586136~15603626:-
ESCA	cis	rs2227564	0.649	rs2948689	ENSG00000229990.3	RP11-574K11.8	-4.59	1.06e-05	0.0178	-0.43	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73898102	chr10:73841833~73847115:+
ESCA	cis	rs7826238	0.564	rs2921053	ENSG00000173295.6	FAM86B3P	4.59	1.06e-05	0.0178	0.44	0.38	Systolic blood pressure;	chr8:8462453	chr8:8228595~8244865:+
ESCA	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	4.59	1.06e-05	0.0178	0.48	0.38	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
ESCA	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	4.59	1.06e-05	0.0178	0.41	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
ESCA	cis	rs28830936	0.966	rs1107858	ENSG00000250379.1	RP11-23P13.4	4.59	1.07e-05	0.0178	0.44	0.38	Diastolic blood pressure;	chr15:41676028	chr15:41825099~41827936:-
ESCA	cis	rs7829975	0.623	rs10092965	ENSG00000173295.6	FAM86B3P	4.59	1.07e-05	0.0178	0.46	0.38	Mood instability;	chr8:8515975	chr8:8228595~8244865:+
ESCA	cis	rs11169552	0.543	rs10876051	ENSG00000200428.1	Y_RNA	4.59	1.07e-05	0.0178	0.47	0.38	Colorectal cancer;	chr12:50538553	chr12:50743568~50743684:+
ESCA	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-4.59	1.07e-05	0.0178	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-4.59	1.07e-05	0.0178	-0.48	-0.38	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	4.59	1.07e-05	0.0178	0.48	0.38	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
ESCA	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	4.59	1.07e-05	0.0178	0.49	0.38	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
ESCA	cis	rs2179367	0.959	rs652807	ENSG00000216906.2	RP11-350J20.9	-4.59	1.07e-05	0.0179	-0.51	-0.38	Dupuytren's disease;	chr6:149416359	chr6:149904243~149906418:+
ESCA	cis	rs8059260	0.542	rs80000109	ENSG00000274038.1	RP11-66H6.4	-4.59	1.07e-05	0.0179	-0.71	-0.38	Alcohol consumption over the past year;	chr16:11031457	chr16:11056556~11057034:+
ESCA	cis	rs2935183	1	rs2935183	ENSG00000228782.6	CTD-2026D20.3	-4.59	1.07e-05	0.0179	-0.41	-0.38	Multiple sclerosis or amyotrophic lateral sclerosis;	chr17:47530206	chr17:47450568~47492492:-
ESCA	cis	rs9545047	0.604	rs1028770	ENSG00000227676.3	LINC01068	-4.59	1.07e-05	0.0179	-0.51	-0.38	Schizophrenia;	chr13:79297346	chr13:79566727~79571436:+
ESCA	cis	rs950169	0.922	rs11635505	ENSG00000225151.9	GOLGA2P7	4.59	1.08e-05	0.0179	0.61	0.38	Schizophrenia;	chr15:84553803	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.922	rs6603022	ENSG00000225151.9	GOLGA2P7	4.59	1.08e-05	0.0179	0.65	0.38	Schizophrenia;	chr15:84161418	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.922	rs11639244	ENSG00000225151.9	GOLGA2P7	-4.59	1.08e-05	0.0179	-0.65	-0.38	Schizophrenia;	chr15:84163898	chr15:84199311~84230136:-
ESCA	cis	rs17361889	0.778	rs1527219	ENSG00000224683.1	RPL36AP29	4.59	1.08e-05	0.0179	0.42	0.38	Pediatric bone mineral content (hip);	chr7:16206127	chr7:16208945~16209265:+
ESCA	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-4.59	1.08e-05	0.0179	-0.46	-0.38	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
ESCA	cis	rs3820068	0.705	rs59502343	ENSG00000237301.1	RP4-680D5.2	4.59	1.08e-05	0.018	0.42	0.38	Systolic blood pressure;	chr1:15546122	chr1:15586136~15603626:-
ESCA	cis	rs1005277	0.541	rs2263163	ENSG00000276805.1	RP11-291L22.6	4.59	1.08e-05	0.018	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38451030~38451785:+
ESCA	cis	rs2505998	0.843	rs2506008	ENSG00000273008.1	RP11-351D16.3	-4.59	1.08e-05	0.018	-0.44	-0.38	Hirschsprung disease;	chr10:43084776	chr10:43136824~43138334:-
ESCA	cis	rs150992	0.638	rs466340	ENSG00000248489.1	CTD-2007H13.3	4.59	1.09e-05	0.018	0.56	0.38	Body mass index;	chr5:98904318	chr5:98929171~98995013:+
ESCA	cis	rs150992	0.673	rs326463	ENSG00000248489.1	CTD-2007H13.3	4.59	1.09e-05	0.018	0.56	0.38	Body mass index;	chr5:98905785	chr5:98929171~98995013:+
ESCA	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-4.59	1.09e-05	0.0181	-0.45	-0.38	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
ESCA	cis	rs1075265	0.575	rs2692531	ENSG00000235937.1	AC008280.1	4.59	1.09e-05	0.0181	0.41	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54029552~54030682:-
ESCA	cis	rs2929278	0.638	rs2016840	ENSG00000205771.5	CATSPER2P1	4.59	1.09e-05	0.0181	0.48	0.38	Schizophrenia;	chr15:43919670	chr15:43726918~43747094:-
ESCA	cis	rs394563	0.619	rs4895787	ENSG00000231760.4	RP11-350J20.5	-4.59	1.09e-05	0.0181	-0.45	-0.38	Dupuytren's disease;	chr6:149325364	chr6:149796151~149826294:-
ESCA	cis	rs7208859	0.623	rs7220999	ENSG00000263531.1	RP13-753N3.1	4.59	1.09e-05	0.0181	0.6	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822280	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55638872	ENSG00000263531.1	RP13-753N3.1	4.59	1.09e-05	0.0181	0.6	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822534	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9899268	ENSG00000263531.1	RP13-753N3.1	4.59	1.09e-05	0.0181	0.6	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30823237	chr17:30863921~30864940:-
ESCA	cis	rs253959	0.545	rs6896147	ENSG00000272265.1	CTD-2287O16.4	-4.59	1.1e-05	0.0182	-0.42	-0.38	Bipolar disorder and schizophrenia;	chr5:116089699	chr5:116078110~116078570:-
ESCA	cis	rs7829975	0.56	rs4841013	ENSG00000173295.6	FAM86B3P	-4.59	1.1e-05	0.0182	-0.45	-0.38	Mood instability;	chr8:8694503	chr8:8228595~8244865:+
ESCA	cis	rs4835265	0.852	rs4835258	ENSG00000250673.1	RP11-6L6.2	-4.58	1.1e-05	0.0182	-0.43	-0.38	Gamma glutamyl transpeptidase;	chr4:145832802	chr4:146224557~146229056:+
ESCA	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	4.58	1.1e-05	0.0183	0.49	0.38	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
ESCA	cis	rs2439831	0.681	rs28653441	ENSG00000249839.1	AC011330.5	-4.58	1.1e-05	0.0183	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43385064	chr15:43663654~43684339:-
ESCA	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	4.58	1.11e-05	0.0183	0.51	0.38	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	4.58	1.11e-05	0.0183	0.51	0.38	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
ESCA	cis	rs7017914	0.652	rs17768191	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70939642	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.629	rs17690181	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70942231	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs13273873	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70942984	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs13280740	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70946286	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs2639911	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70948477	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs2639910	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70949649	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs3098859	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70952797	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.545	rs3110268	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70953933	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.617	rs2732144	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70954384	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.617	rs2639949	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70954781	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.617	rs2639950	ENSG00000253173.3	RP11-152C15.1	-4.58	1.11e-05	0.0183	-0.44	-0.38	Bone mineral density;	chr8:70954823	chr8:70103798~70104179:-
ESCA	cis	rs4927850	1	rs10881563	ENSG00000231464.1	AC024937.4	4.58	1.11e-05	0.0184	0.46	0.38	Pancreatic cancer;	chr3:196023354	chr3:195996738~195998233:+
ESCA	cis	rs9399137	0.507	rs28384513	ENSG00000232876.1	CTA-212D2.2	-4.58	1.11e-05	0.0184	-0.45	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135055071	chr6:135055033~135060550:+
ESCA	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-4.58	1.11e-05	0.0184	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
ESCA	cis	rs9549260	0.755	rs9549241	ENSG00000229456.1	RLIMP1	4.58	1.12e-05	0.0184	0.35	0.38	Red blood cell count;	chr13:40635904	chr13:40618738~40621348:+
ESCA	cis	rs8062405	0.754	rs149299	ENSG00000278665.1	RP11-666O2.4	4.58	1.12e-05	0.0184	0.56	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.721	rs151303	ENSG00000278665.1	RP11-666O2.4	4.58	1.12e-05	0.0184	0.56	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.756	rs151301	ENSG00000278665.1	RP11-666O2.4	4.58	1.12e-05	0.0184	0.56	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28599241~28601881:-
ESCA	cis	rs7412746	0.658	rs4970982	ENSG00000206931.1	RNU6-1042P	4.58	1.12e-05	0.0185	0.48	0.38	Melanoma;	chr1:150892608	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs11204739	ENSG00000206931.1	RNU6-1042P	4.58	1.12e-05	0.0185	0.48	0.38	Melanoma;	chr1:150893284	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs12097963	ENSG00000206931.1	RNU6-1042P	4.58	1.12e-05	0.0185	0.48	0.38	Melanoma;	chr1:150897974	chr1:150701866~150701972:+
ESCA	cis	rs9608946	1	rs17670808	ENSG00000268812.3	RP1-102K2.8	4.58	1.12e-05	0.0185	0.52	0.38	Red cell distribution width;	chr22:30489993	chr22:30246205~30246998:+
ESCA	cis	rs6479901	0.947	rs10761780	ENSG00000235816.3	PRELID1P3	-4.58	1.12e-05	0.0185	-0.45	-0.38	Intelligence (multi-trait analysis);	chr10:63524272	chr10:63427297~63427939:+
ESCA	cis	rs2179367	0.92	rs638407	ENSG00000216906.2	RP11-350J20.9	4.58	1.12e-05	0.0185	0.49	0.38	Dupuytren's disease;	chr6:149417214	chr6:149904243~149906418:+
ESCA	cis	rs11169552	0.51	rs10783370	ENSG00000200428.1	Y_RNA	4.58	1.12e-05	0.0185	0.48	0.38	Colorectal cancer;	chr12:50543366	chr12:50743568~50743684:+
ESCA	cis	rs10954779	0.818	rs3024239	ENSG00000253579.1	SUMO2P16	4.58	1.12e-05	0.0185	0.41	0.38	Intelligence (multi-trait analysis);	chr8:31141606	chr8:31131539~31131802:-
ESCA	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-4.58	1.12e-05	0.0185	-0.41	-0.38	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
ESCA	cis	rs8003054	0.616	rs58333467	ENSG00000258515.1	RP11-203M5.7	4.58	1.12e-05	0.0185	0.35	0.38	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20441405	chr14:20451305~20451918:+
ESCA	cis	rs7951870	0.645	rs10769205	ENSG00000271350.1	CTD-2384B9.1	4.58	1.13e-05	0.0186	0.45	0.38	Schizophrenia;	chr11:46702053	chr11:47041027~47041945:-
ESCA	cis	rs2283792	0.812	rs5995269	ENSG00000228050.1	TOP3BP1	4.58	1.13e-05	0.0186	0.49	0.38	Multiple sclerosis;	chr22:21935025	chr22:22223187~22224566:-
ESCA	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	4.58	1.13e-05	0.0186	0.32	0.38	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
ESCA	cis	rs1075265	0.783	rs718872	ENSG00000235937.1	AC008280.1	4.58	1.13e-05	0.0186	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54029552~54030682:-
ESCA	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-4.58	1.13e-05	0.0186	-0.44	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
ESCA	cis	rs11169552	0.51	rs10876058	ENSG00000200428.1	Y_RNA	4.58	1.13e-05	0.0186	0.47	0.38	Colorectal cancer;	chr12:50562483	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10876061	ENSG00000200428.1	Y_RNA	4.58	1.13e-05	0.0186	0.47	0.38	Colorectal cancer;	chr12:50574902	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10876063	ENSG00000200428.1	Y_RNA	4.58	1.13e-05	0.0186	0.47	0.38	Colorectal cancer;	chr12:50578302	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10783376	ENSG00000200428.1	Y_RNA	4.58	1.13e-05	0.0186	0.47	0.38	Colorectal cancer;	chr12:50587466	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs4768899	ENSG00000200428.1	Y_RNA	4.58	1.13e-05	0.0186	0.47	0.38	Colorectal cancer;	chr12:50606883	chr12:50743568~50743684:+
ESCA	cis	rs9462027	0.628	rs6924898	ENSG00000186328.4	RP11-140K17.2	4.58	1.13e-05	0.0186	0.42	0.38	Systemic lupus erythematosus;	chr6:34843422	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs6457795	ENSG00000186328.4	RP11-140K17.2	4.58	1.13e-05	0.0186	0.42	0.38	Systemic lupus erythematosus;	chr6:34851589	chr6:34715613~34715940:+
ESCA	cis	rs7412746	0.658	rs2272214	ENSG00000206931.1	RNU6-1042P	4.58	1.13e-05	0.0186	0.47	0.38	Melanoma;	chr1:150958986	chr1:150701866~150701972:+
ESCA	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	4.58	1.13e-05	0.0187	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
ESCA	cis	rs5758659	0.904	rs5758653	ENSG00000182057.4	OGFRP1	4.58	1.13e-05	0.0187	0.46	0.38	Cognitive function;	chr22:42217479	chr22:42269753~42275196:+
ESCA	cis	rs9368849	0.527	rs9366881	ENSG00000186328.4	RP11-140K17.2	-4.58	1.14e-05	0.0187	-0.55	-0.38	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35182300	chr6:34715613~34715940:+
ESCA	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	4.58	1.14e-05	0.0187	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
ESCA	cis	rs7829975	0.623	rs7010753	ENSG00000173295.6	FAM86B3P	4.58	1.14e-05	0.0187	0.46	0.38	Mood instability;	chr8:8516446	chr8:8228595~8244865:+
ESCA	cis	rs8059260	0.544	rs34846673	ENSG00000274038.1	RP11-66H6.4	-4.58	1.14e-05	0.0187	-0.67	-0.38	Alcohol consumption over the past year;	chr16:11102829	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.604	rs12929596	ENSG00000274038.1	RP11-66H6.4	-4.58	1.14e-05	0.0187	-0.67	-0.38	Alcohol consumption over the past year;	chr16:11105495	chr16:11056556~11057034:+
ESCA	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	4.58	1.14e-05	0.0187	0.47	0.38	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
ESCA	cis	rs150992	0.673	rs161953	ENSG00000248489.1	CTD-2007H13.3	4.58	1.14e-05	0.0187	0.54	0.38	Body mass index;	chr5:98921201	chr5:98929171~98995013:+
ESCA	cis	rs150992	0.673	rs161952	ENSG00000248489.1	CTD-2007H13.3	4.58	1.14e-05	0.0187	0.54	0.38	Body mass index;	chr5:98921665	chr5:98929171~98995013:+
ESCA	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-4.58	1.14e-05	0.0187	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
ESCA	cis	rs6456156	0.766	rs150112	ENSG00000265828.1	MIR3939	4.58	1.14e-05	0.0188	0.42	0.38	Primary biliary cholangitis;	chr6:167096390	chr6:166997807~166997912:-
ESCA	cis	rs2439831	0.85	rs2957637	ENSG00000275601.1	AC011330.13	-4.58	1.14e-05	0.0188	-0.67	-0.38	Lung cancer in ever smokers;	chr15:43658920	chr15:43642389~43643023:-
ESCA	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-4.58	1.15e-05	0.0188	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
ESCA	cis	rs6479901	0.841	rs10761720	ENSG00000235816.3	PRELID1P3	-4.58	1.15e-05	0.0188	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63139023	chr10:63427297~63427939:+
ESCA	cis	rs1075265	0.54	rs2542587	ENSG00000235937.1	AC008280.1	4.58	1.15e-05	0.0188	0.41	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.563	rs2692537	ENSG00000235937.1	AC008280.1	4.58	1.15e-05	0.0188	0.41	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54029552~54030682:-
ESCA	cis	rs394563	0.602	rs409111	ENSG00000231760.4	RP11-350J20.5	4.57	1.15e-05	0.0188	0.47	0.38	Dupuytren's disease;	chr6:149445724	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.602	rs409099	ENSG00000231760.4	RP11-350J20.5	4.57	1.15e-05	0.0188	0.47	0.38	Dupuytren's disease;	chr6:149445727	chr6:149796151~149826294:-
ESCA	cis	rs9549260	0.755	rs2721066	ENSG00000229456.1	RLIMP1	-4.57	1.15e-05	0.0189	-0.35	-0.38	Red blood cell count;	chr13:40582051	chr13:40618738~40621348:+
ESCA	cis	rs8062405	0.755	rs111693583	ENSG00000278665.1	RP11-666O2.4	4.57	1.15e-05	0.0189	0.55	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28599241~28601881:-
ESCA	cis	rs2742234	0.541	rs10793422	ENSG00000273008.1	RP11-351D16.3	4.57	1.15e-05	0.0189	0.45	0.38	Hirschsprung disease;	chr10:43208426	chr10:43136824~43138334:-
ESCA	cis	rs11235843	0.929	rs12366033	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73667929	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs66481935	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73669278	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs72974840	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73669317	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs3825003	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73678067	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs112650783	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73678883	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.853	rs66556722	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73691994	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs4944856	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73694351	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs4944028	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73696525	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs4944029	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73696558	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs72974866	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73701246	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.866	rs72974869	ENSG00000255928.1	RP11-456I15.2	4.57	1.15e-05	0.0189	0.62	0.38	Hand grip strength;	chr11:73703801	chr11:73722349~73722694:+
ESCA	cis	rs9549260	0.62	rs4325427	ENSG00000229456.1	RLIMP1	4.57	1.15e-05	0.0189	0.35	0.38	Red blood cell count;	chr13:40642397	chr13:40618738~40621348:+
ESCA	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.15e-05	0.0189	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.15e-05	0.0189	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.15e-05	0.0189	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.15e-05	0.0189	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.15e-05	0.0189	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
ESCA	cis	rs1816752	0.669	rs7984513	ENSG00000273628.1	RP11-756A22.7	-4.57	1.15e-05	0.0189	-0.39	-0.38	Obesity-related traits;	chr13:24445117	chr13:24933006~24936796:+
ESCA	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	4.57	1.15e-05	0.0189	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
ESCA	cis	rs2439831	0.681	rs999047	ENSG00000249839.1	AC011330.5	-4.57	1.15e-05	0.0189	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43396718	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.614	rs2467733	ENSG00000249839.1	AC011330.5	-4.57	1.15e-05	0.0189	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43401130	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.681	rs2444036	ENSG00000249839.1	AC011330.5	-4.57	1.15e-05	0.0189	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43401910	chr15:43663654~43684339:-
ESCA	cis	rs300032	1	rs1867486	ENSG00000261175.4	CTD-2015G9.2	4.57	1.15e-05	0.0189	0.63	0.38	IgG glycosylation;	chr16:86647549	chr16:86722091~86741059:+
ESCA	cis	rs42490	1	rs218905	ENSG00000251136.7	RP11-37B2.1	-4.57	1.16e-05	0.0189	-0.39	-0.38	Leprosy;	chr8:89723661	chr8:89609409~89757727:-
ESCA	cis	rs3820716	0.507	rs7580733	ENSG00000223911.1	AC009480.3	4.57	1.16e-05	0.019	0.45	0.38	Glomerular filtration rate (creatinine);	chr2:148196611	chr2:147899401~147902956:-
ESCA	cis	rs3820716	0.507	rs12467336	ENSG00000223911.1	AC009480.3	4.57	1.16e-05	0.019	0.45	0.38	Glomerular filtration rate (creatinine);	chr2:148197883	chr2:147899401~147902956:-
ESCA	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-4.57	1.16e-05	0.019	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
ESCA	cis	rs1075265	0.87	rs17268179	ENSG00000235937.1	AC008280.1	4.57	1.16e-05	0.019	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54029552~54030682:-
ESCA	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	4.57	1.16e-05	0.019	0.48	0.38	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
ESCA	cis	rs858239	0.601	rs6461702	ENSG00000230042.1	AK3P3	-4.57	1.16e-05	0.019	-0.45	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23129178~23129841:+
ESCA	cis	rs2439831	0.867	rs3213990	ENSG00000249839.1	AC011330.5	-4.57	1.16e-05	0.019	-0.56	-0.38	Lung cancer in ever smokers;	chr15:43378028	chr15:43663654~43684339:-
ESCA	cis	rs11169552	0.543	rs11169481	ENSG00000200428.1	Y_RNA	4.57	1.16e-05	0.019	0.46	0.38	Colorectal cancer;	chr12:50532702	chr12:50743568~50743684:+
ESCA	cis	rs2742234	0.91	rs2505511	ENSG00000273008.1	RP11-351D16.3	-4.57	1.16e-05	0.019	-0.44	-0.38	Hirschsprung disease;	chr10:43145581	chr10:43136824~43138334:-
ESCA	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	4.57	1.16e-05	0.019	0.6	0.38	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	4.57	1.16e-05	0.019	0.6	0.38	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
ESCA	cis	rs2179367	0.887	rs506268	ENSG00000231760.4	RP11-350J20.5	4.57	1.16e-05	0.019	0.44	0.38	Dupuytren's disease;	chr6:149364481	chr6:149796151~149826294:-
ESCA	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	4.57	1.16e-05	0.019	0.41	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
ESCA	cis	rs11169552	0.58	rs7134976	ENSG00000200428.1	Y_RNA	4.57	1.16e-05	0.019	0.45	0.38	Colorectal cancer;	chr12:50616309	chr12:50743568~50743684:+
ESCA	cis	rs5758659	1	rs134900	ENSG00000182057.4	OGFRP1	4.57	1.16e-05	0.019	0.44	0.38	Cognitive function;	chr22:42287337	chr22:42269753~42275196:+
ESCA	cis	rs2307394	0.896	rs10186643	ENSG00000223911.1	AC009480.3	4.57	1.17e-05	0.0191	0.46	0.38	Urate levels;	chr2:148046018	chr2:147899401~147902956:-
ESCA	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	4.57	1.17e-05	0.0191	0.37	0.38	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
ESCA	cis	rs10229583	0.527	rs73450923	ENSG00000279078.1	SND1-IT1	4.57	1.17e-05	0.0191	0.44	0.38	Type 2 diabetes;	chr7:127665755	chr7:127997597~128000077:+
ESCA	cis	rs10229583	0.527	rs6943219	ENSG00000279078.1	SND1-IT1	4.57	1.17e-05	0.0191	0.44	0.38	Type 2 diabetes;	chr7:127668332	chr7:127997597~128000077:+
ESCA	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-4.57	1.17e-05	0.0191	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
ESCA	cis	rs2227564	0.729	rs2688615	ENSG00000229990.3	RP11-574K11.8	-4.57	1.17e-05	0.0191	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73891741	chr10:73841833~73847115:+
ESCA	cis	rs2439831	1	rs471229	ENSG00000249839.1	AC011330.5	-4.57	1.17e-05	0.0191	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43441796	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2439841	ENSG00000249839.1	AC011330.5	-4.57	1.17e-05	0.0191	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43442551	chr15:43663654~43684339:-
ESCA	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-4.57	1.17e-05	0.0192	-0.49	-0.38	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
ESCA	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-4.57	1.17e-05	0.0192	-0.49	-0.38	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
ESCA	cis	rs1155848	0.892	rs9565508	ENSG00000227354.5	RBM26-AS1	4.57	1.17e-05	0.0192	0.86	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79482451	chr13:79406309~79424328:+
ESCA	cis	rs11169552	0.51	rs4131769	ENSG00000200428.1	Y_RNA	4.57	1.18e-05	0.0192	0.47	0.38	Colorectal cancer;	chr12:50558239	chr12:50743568~50743684:+
ESCA	cis	rs7412746	0.611	rs7556661	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150919533	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs11581757	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150919768	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs12090215	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150921184	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs72704682	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150925201	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs72704685	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150925211	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs4970986	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150935479	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs59024312	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150936529	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs7521719	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150940658	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs7528773	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150943399	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs3843843	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150945608	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.634	rs2124952	ENSG00000206931.1	RNU6-1042P	4.57	1.18e-05	0.0192	0.48	0.38	Melanoma;	chr1:150951298	chr1:150701866~150701972:+
ESCA	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-4.57	1.18e-05	0.0192	-0.69	-0.38	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
ESCA	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-4.57	1.18e-05	0.0192	-0.43	-0.38	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
ESCA	cis	rs6782228	0.606	rs2253144	ENSG00000277250.1	Metazoa_SRP	4.57	1.18e-05	0.0192	0.43	0.38	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128673681~128674021:-
ESCA	cis	rs6479891	1	rs10761730	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63257293	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs7916282	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63272051	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.915	rs9415682	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63274057	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.778	rs10761735	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63284158	chr10:63427297~63427939:+
ESCA	cis	rs6479891	1	rs9414786	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63284562	chr10:63427297~63427939:+
ESCA	cis	rs6479891	0.822	rs6479892	ENSG00000235816.3	PRELID1P3	-4.57	1.18e-05	0.0192	-0.49	-0.38	Arthritis (juvenile idiopathic);	chr10:63292472	chr10:63427297~63427939:+
ESCA	cis	rs7580717	0.854	rs7589912	ENSG00000201574.1	RNU1-93P	-4.57	1.18e-05	0.0192	-0.43	-0.38	Multiple myeloma;	chr2:231319212	chr2:231133462~231133630:+
ESCA	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	4.57	1.18e-05	0.0192	0.51	0.38	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
ESCA	cis	rs2439831	0.867	rs2470134	ENSG00000249839.1	AC011330.5	4.57	1.18e-05	0.0192	0.67	0.38	Lung cancer in ever smokers;	chr15:43557688	chr15:43663654~43684339:-
ESCA	cis	rs11169552	0.51	rs11169532	ENSG00000200428.1	Y_RNA	4.57	1.18e-05	0.0193	0.46	0.38	Colorectal cancer;	chr12:50726152	chr12:50743568~50743684:+
ESCA	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-4.57	1.18e-05	0.0193	-0.5	-0.38	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
ESCA	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	4.57	1.19e-05	0.0193	0.52	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
ESCA	cis	rs9465539	0.544	rs6910773	ENSG00000228412.5	RP4-625H18.2	-4.57	1.19e-05	0.0193	-0.56	-0.38	Neuroticism;	chr6:19820427	chr6:19802164~19804752:-
ESCA	cis	rs61160187	0.605	rs10068474	ENSG00000215032.2	GNL3LP1	-4.57	1.19e-05	0.0193	-0.48	-0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:60782085	chr5:60891935~60893577:-
ESCA	cis	rs4951011	0.572	rs66616874	ENSG00000223505.2	RP11-397P13.7	-4.57	1.19e-05	0.0193	-0.53	-0.38	Breast cancer;	chr1:203898905	chr1:203835585~203835912:-
ESCA	cis	rs394563	0.591	rs237019	ENSG00000231760.4	RP11-350J20.5	4.57	1.19e-05	0.0193	0.45	0.38	Dupuytren's disease;	chr6:149405928	chr6:149796151~149826294:-
ESCA	cis	rs6479901	0.947	rs10761781	ENSG00000235816.3	PRELID1P3	4.57	1.19e-05	0.0194	0.45	0.38	Intelligence (multi-trait analysis);	chr10:63524843	chr10:63427297~63427939:+
ESCA	cis	rs2280018	0.963	rs4985147	ENSG00000260735.1	RP11-72I8.1	-4.57	1.19e-05	0.0194	-0.38	-0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15074903	chr16:15094411~15109197:+
ESCA	cis	rs2400997	0.967	rs2226074	ENSG00000258919.1	RP11-1029J19.4	4.57	1.19e-05	0.0194	0.4	0.38	Prostate cancer (SNP x SNP interaction);	chr14:101274577	chr14:101628984~101632530:-
ESCA	cis	rs6951245	0.706	rs28522260	ENSG00000229043.2	AC091729.9	-4.57	1.19e-05	0.0194	-0.55	-0.38	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1144328	chr7:1160374~1165267:+
ESCA	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-4.57	1.19e-05	0.0194	-0.55	-0.38	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
ESCA	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-4.57	1.19e-05	0.0194	-0.55	-0.38	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
ESCA	cis	rs9987353	0.566	rs34389718	ENSG00000173295.6	FAM86B3P	-4.57	1.19e-05	0.0194	-0.5	-0.38	Recombination measurement;	chr8:9208015	chr8:8228595~8244865:+
ESCA	cis	rs2742234	0.868	rs2505512	ENSG00000273008.1	RP11-351D16.3	-4.56	1.19e-05	0.0194	-0.43	-0.38	Hirschsprung disease;	chr10:43138148	chr10:43136824~43138334:-
ESCA	cis	rs559928	0.606	rs11605856	ENSG00000274986.1	MIR6750	4.56	1.19e-05	0.0194	0.69	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158056	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs11231710	ENSG00000274986.1	MIR6750	4.56	1.19e-05	0.0194	0.69	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64158271	chr11:64898363~64898437:-
ESCA	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.56	1.19e-05	0.0194	0.54	0.38	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
ESCA	cis	rs7829975	0.511	rs1543238	ENSG00000173295.6	FAM86B3P	4.56	1.19e-05	0.0194	0.47	0.38	Mood instability;	chr8:8277287	chr8:8228595~8244865:+
ESCA	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	4.56	1.2e-05	0.0195	0.63	0.38	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
ESCA	cis	rs8072100	1	rs4375701	ENSG00000228782.6	CTD-2026D20.3	4.56	1.2e-05	0.0196	0.41	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47634852	chr17:47450568~47492492:-
ESCA	cis	rs10754283	0.967	rs10922679	ENSG00000231613.1	RP5-943J3.1	4.56	1.21e-05	0.0196	0.41	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89635366	chr1:89788914~89790492:+
ESCA	cis	rs16975963	1	rs16975963	ENSG00000267152.1	CTD-2528L19.6	4.56	1.21e-05	0.0196	0.39	0.38	Longevity;	chr19:37834896	chr19:37728586~37730643:-
ESCA	cis	rs9545047	0.604	rs1748761	ENSG00000227676.3	LINC01068	4.56	1.21e-05	0.0196	0.51	0.38	Schizophrenia;	chr13:79407491	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs2763809	ENSG00000227676.3	LINC01068	4.56	1.21e-05	0.0196	0.51	0.38	Schizophrenia;	chr13:79407544	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1748762	ENSG00000227676.3	LINC01068	4.56	1.21e-05	0.0196	0.51	0.38	Schizophrenia;	chr13:79407914	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs1748763	ENSG00000227676.3	LINC01068	4.56	1.21e-05	0.0196	0.51	0.38	Schizophrenia;	chr13:79407965	chr13:79566727~79571436:+
ESCA	cis	rs10995505	0.589	rs10822140	ENSG00000235816.3	PRELID1P3	-4.56	1.21e-05	0.0196	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63123267	chr10:63427297~63427939:+
ESCA	cis	rs10995505	0.589	rs2896496	ENSG00000235816.3	PRELID1P3	-4.56	1.21e-05	0.0196	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63123622	chr10:63427297~63427939:+
ESCA	cis	rs7826238	0.72	rs12546760	ENSG00000253981.4	ALG1L13P	-4.56	1.21e-05	0.0196	-0.46	-0.38	Systolic blood pressure;	chr8:8517326	chr8:8236003~8244667:-
ESCA	cis	rs11235843	0.734	rs11235920	ENSG00000255928.1	RP11-456I15.2	4.56	1.21e-05	0.0196	0.65	0.38	Hand grip strength;	chr11:73824841	chr11:73722349~73722694:+
ESCA	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-4.56	1.21e-05	0.0197	-0.45	-0.38	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
ESCA	cis	rs9990333	0.562	rs12632706	ENSG00000242086.7	LINC00969	4.56	1.21e-05	0.0197	0.4	0.38	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196088723	chr3:195658062~195739964:+
ESCA	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-4.56	1.21e-05	0.0197	-0.4	-0.38	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
ESCA	cis	rs10759883	0.627	rs689804	ENSG00000175611.10	LINC00476	4.56	1.21e-05	0.0197	0.42	0.38	Nicotine dependence;	chr9:95868574	chr9:95759231~95875977:-
ESCA	cis	rs1075265	0.62	rs10192626	ENSG00000235937.1	AC008280.1	4.56	1.21e-05	0.0197	0.4	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54029552~54030682:-
ESCA	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	4.56	1.21e-05	0.0197	0.45	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
ESCA	cis	rs10229583	0.527	rs7783478	ENSG00000279078.1	SND1-IT1	4.56	1.22e-05	0.0197	0.44	0.38	Type 2 diabetes;	chr7:127688483	chr7:127997597~128000077:+
ESCA	cis	rs1723838	0.609	rs4944857	ENSG00000255928.1	RP11-456I15.2	-4.56	1.22e-05	0.0197	-0.84	-0.38	Obesity-related traits;	chr11:73706243	chr11:73722349~73722694:+
ESCA	cis	rs10875746	0.669	rs61941003	ENSG00000240399.1	RP1-228P16.1	-4.56	1.22e-05	0.0197	-0.47	-0.38	Longevity (90 years and older);	chr12:48225842	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.579	rs10875778	ENSG00000240399.1	RP1-228P16.1	-4.56	1.22e-05	0.0197	-0.47	-0.38	Longevity (90 years and older);	chr12:48230872	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.669	rs10875779	ENSG00000240399.1	RP1-228P16.1	-4.56	1.22e-05	0.0197	-0.47	-0.38	Longevity (90 years and older);	chr12:48236086	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.669	rs11168487	ENSG00000240399.1	RP1-228P16.1	-4.56	1.22e-05	0.0197	-0.47	-0.38	Longevity (90 years and older);	chr12:48246926	chr12:48054813~48055591:-
ESCA	cis	rs4535700	0.501	rs6943341	ENSG00000226278.1	PSPHP1	4.56	1.22e-05	0.0198	0.5	0.38	Macular telangiectasia type 2;	chr7:55907489	chr7:55764797~55773288:+
ESCA	cis	rs7829975	0.623	rs7010753	ENSG00000253893.2	FAM85B	-4.56	1.22e-05	0.0198	-0.47	-0.38	Mood instability;	chr8:8516446	chr8:8167819~8226614:-
ESCA	cis	rs11169552	0.51	rs3935869	ENSG00000200428.1	Y_RNA	4.56	1.22e-05	0.0198	0.47	0.38	Colorectal cancer;	chr12:50570293	chr12:50743568~50743684:+
ESCA	cis	rs7927771	0.524	rs1056387	ENSG00000280615.1	Y_RNA	4.56	1.22e-05	0.0198	0.45	0.38	Subjective well-being;	chr11:47659818	chr11:47614898~47614994:-
ESCA	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-4.56	1.22e-05	0.0198	-0.49	-0.38	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
ESCA	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-4.56	1.22e-05	0.0198	-0.65	-0.38	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
ESCA	cis	rs2412819	0.571	rs495880	ENSG00000249839.1	AC011330.5	4.56	1.22e-05	0.0198	0.65	0.38	Lung cancer;	chr15:43855067	chr15:43663654~43684339:-
ESCA	cis	rs9987353	0.519	rs11779181	ENSG00000173295.6	FAM86B3P	4.56	1.23e-05	0.0199	0.47	0.38	Recombination measurement;	chr8:9205517	chr8:8228595~8244865:+
ESCA	cis	rs7412746	0.658	rs1546376	ENSG00000206931.1	RNU6-1042P	4.56	1.23e-05	0.0199	0.48	0.38	Melanoma;	chr1:150965185	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs11204750	ENSG00000206931.1	RNU6-1042P	4.56	1.23e-05	0.0199	0.48	0.38	Melanoma;	chr1:150967268	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs6656535	ENSG00000206931.1	RNU6-1042P	4.56	1.23e-05	0.0199	0.48	0.38	Melanoma;	chr1:150967881	chr1:150701866~150701972:+
ESCA	cis	rs2439831	1	rs2444032	ENSG00000249839.1	AC011330.5	-4.56	1.23e-05	0.0199	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43463148	chr15:43663654~43684339:-
ESCA	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-4.56	1.23e-05	0.0199	-0.42	-0.38	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
ESCA	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-4.56	1.23e-05	0.02	-0.41	-0.38	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
ESCA	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	4.56	1.24e-05	0.02	0.49	0.38	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
ESCA	cis	rs11169552	0.51	rs10876073	ENSG00000200428.1	Y_RNA	4.56	1.24e-05	0.02	0.45	0.38	Colorectal cancer;	chr12:50632127	chr12:50743568~50743684:+
ESCA	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	4.56	1.24e-05	0.02	0.5	0.38	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
ESCA	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	4.56	1.24e-05	0.02	0.5	0.38	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
ESCA	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	4.56	1.24e-05	0.02	0.5	0.38	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
ESCA	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	4.56	1.24e-05	0.02	0.5	0.38	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
ESCA	cis	rs6432860	0.545	rs10185885	ENSG00000232411.1	AC009495.3	-4.56	1.24e-05	0.0201	-0.42	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166055152	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs10209560	ENSG00000232411.1	AC009495.3	-4.56	1.24e-05	0.0201	-0.42	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166055175	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs922224	ENSG00000232411.1	AC009495.3	-4.56	1.24e-05	0.0201	-0.42	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166055402	chr2:165833048~165839098:-
ESCA	cis	rs2439831	0.867	rs2255051	ENSG00000249839.1	AC011330.5	-4.55	1.24e-05	0.0201	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43553963	chr15:43663654~43684339:-
ESCA	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-4.55	1.24e-05	0.0201	-0.46	-0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
ESCA	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	4.55	1.25e-05	0.0201	0.49	0.38	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
ESCA	cis	rs9545047	0.604	rs7987193	ENSG00000227676.3	LINC01068	-4.55	1.25e-05	0.0202	-0.51	-0.38	Schizophrenia;	chr13:79408449	chr13:79566727~79571436:+
ESCA	cis	rs2179367	0.92	rs560051	ENSG00000216906.2	RP11-350J20.9	4.55	1.25e-05	0.0202	0.49	0.38	Dupuytren's disease;	chr6:149345841	chr6:149904243~149906418:+
ESCA	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-4.55	1.25e-05	0.0202	-0.45	-0.38	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
ESCA	cis	rs9987353	0.566	rs13260067	ENSG00000253981.4	ALG1L13P	-4.55	1.25e-05	0.0202	-0.48	-0.38	Recombination measurement;	chr8:9213523	chr8:8236003~8244667:-
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000231271.1	AP000350.8	4.55	1.25e-05	0.0202	0.47	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23949918~23954042:+
ESCA	cis	rs7017914	0.605	rs13267098	ENSG00000253173.3	RP11-152C15.1	-4.55	1.26e-05	0.0203	-0.44	-0.38	Bone mineral density;	chr8:70899651	chr8:70103798~70104179:-
ESCA	cis	rs2439831	0.85	rs3816792	ENSG00000205771.5	CATSPER2P1	4.55	1.26e-05	0.0203	0.66	0.38	Lung cancer in ever smokers;	chr15:43824788	chr15:43726918~43747094:-
ESCA	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-4.55	1.26e-05	0.0203	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-4.55	1.26e-05	0.0203	-0.44	-0.38	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
ESCA	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	4.55	1.26e-05	0.0203	0.55	0.38	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
ESCA	cis	rs6479901	0.793	rs4335432	ENSG00000235816.3	PRELID1P3	-4.55	1.26e-05	0.0203	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63226057	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.841	rs6479889	ENSG00000235816.3	PRELID1P3	-4.55	1.26e-05	0.0203	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63228867	chr10:63427297~63427939:+
ESCA	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-4.55	1.26e-05	0.0203	-0.73	-0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
ESCA	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	4.55	1.26e-05	0.0204	0.48	0.38	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
ESCA	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.55	1.27e-05	0.0205	-0.37	-0.38	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
ESCA	cis	rs150992	0.678	rs327793	ENSG00000248489.1	CTD-2007H13.3	4.55	1.27e-05	0.0205	0.55	0.38	Body mass index;	chr5:98913717	chr5:98929171~98995013:+
ESCA	cis	rs11169552	0.51	rs4238108	ENSG00000200428.1	Y_RNA	4.55	1.28e-05	0.0205	0.46	0.38	Colorectal cancer;	chr12:50665908	chr12:50743568~50743684:+
ESCA	cis	rs559928	0.606	rs12419038	ENSG00000274986.1	MIR6750	4.55	1.28e-05	0.0205	0.68	0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145264	chr11:64898363~64898437:-
ESCA	cis	rs2455601	0.882	rs11042118	ENSG00000254860.4	TMEM9B-AS1	4.55	1.28e-05	0.0206	0.6	0.38	Schizophrenia;	chr11:8907244	chr11:8964675~8977527:+
ESCA	cis	rs7829975	0.782	rs6990746	ENSG00000173295.6	FAM86B3P	-4.55	1.28e-05	0.0206	-0.44	-0.38	Mood instability;	chr8:8690301	chr8:8228595~8244865:+
ESCA	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	4.55	1.28e-05	0.0206	0.5	0.38	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
ESCA	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	4.55	1.28e-05	0.0206	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	4.55	1.28e-05	0.0206	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000228039.3	KB-1125A3.10	-4.55	1.28e-05	0.0206	-0.5	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23963780~23964374:+
ESCA	cis	rs11235843	0.929	rs68128239	ENSG00000255928.1	RP11-456I15.2	4.55	1.28e-05	0.0206	0.62	0.38	Hand grip strength;	chr11:73709547	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs67167213	ENSG00000255928.1	RP11-456I15.2	4.55	1.28e-05	0.0206	0.62	0.38	Hand grip strength;	chr11:73711163	chr11:73722349~73722694:+
ESCA	cis	rs1155848	0.892	rs9565509	ENSG00000227354.5	RBM26-AS1	4.55	1.28e-05	0.0206	0.85	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79483696	chr13:79406309~79424328:+
ESCA	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	4.55	1.29e-05	0.0207	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
ESCA	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	4.55	1.29e-05	0.0207	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
ESCA	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	4.55	1.29e-05	0.0207	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
ESCA	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	4.55	1.29e-05	0.0207	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
ESCA	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	4.55	1.29e-05	0.0207	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
ESCA	cis	rs1075265	0.527	rs10167891	ENSG00000235937.1	AC008280.1	4.55	1.29e-05	0.0207	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54029552~54030682:-
ESCA	cis	rs7412746	0.611	rs9661876	ENSG00000206931.1	RNU6-1042P	4.55	1.29e-05	0.0207	0.48	0.38	Melanoma;	chr1:150938435	chr1:150701866~150701972:+
ESCA	cis	rs7208859	0.673	rs11657270	ENSG00000263531.1	RP13-753N3.1	4.55	1.29e-05	0.0207	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887369	chr17:30863921~30864940:-
ESCA	cis	rs1005277	0.579	rs2505194	ENSG00000276805.1	RP11-291L22.6	4.54	1.29e-05	0.0208	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38451030~38451785:+
ESCA	cis	rs9545047	0.604	rs9565487	ENSG00000227676.3	LINC01068	-4.54	1.3e-05	0.0208	-0.5	-0.38	Schizophrenia;	chr13:79332742	chr13:79566727~79571436:+
ESCA	cis	rs2041895	0.565	rs10861679	ENSG00000260329.1	RP11-412D9.4	-4.54	1.3e-05	0.0208	-0.41	-0.38	Glaucoma (low intraocular pressure);	chr12:106929137	chr12:106954029~106955497:-
ESCA	cis	rs1155848	0.892	rs3759438	ENSG00000227354.5	RBM26-AS1	4.54	1.3e-05	0.0209	0.85	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79566863	chr13:79406309~79424328:+
ESCA	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	4.54	1.3e-05	0.0209	0.47	0.38	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
ESCA	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-4.54	1.31e-05	0.021	-0.42	-0.38	Migraine;	chr4:56937339	chr4:56960927~56961373:-
ESCA	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-4.54	1.31e-05	0.021	-0.42	-0.38	Migraine;	chr4:56943905	chr4:56960927~56961373:-
ESCA	cis	rs7208859	0.673	rs73263785	ENSG00000263531.1	RP13-753N3.1	4.54	1.31e-05	0.021	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887790	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs55904046	ENSG00000263531.1	RP13-753N3.1	4.54	1.31e-05	0.021	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888373	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs75142521	ENSG00000263531.1	RP13-753N3.1	4.54	1.31e-05	0.021	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30913519	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9895684	ENSG00000263531.1	RP13-753N3.1	4.54	1.31e-05	0.021	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30915582	chr17:30863921~30864940:-
ESCA	cis	rs6724465	1	rs10445821	ENSG00000272644.1	RP11-33O4.1	4.54	1.31e-05	0.021	0.65	0.38	Height;	chr2:219045058	chr2:219069354~219069809:-
ESCA	cis	rs7812879	0.81	rs2618479	ENSG00000255518.1	RP11-148O21.4	4.54	1.31e-05	0.021	0.47	0.38	Systemic lupus erythematosus;	chr8:11498312	chr8:11556251~11558022:-
ESCA	cis	rs8072100	1	rs11650372	ENSG00000228782.6	CTD-2026D20.3	4.54	1.31e-05	0.021	0.4	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47644429	chr17:47450568~47492492:-
ESCA	cis	rs8072100	1	rs8065669	ENSG00000228782.6	CTD-2026D20.3	4.54	1.31e-05	0.021	0.4	0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47647630	chr17:47450568~47492492:-
ESCA	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	4.54	1.31e-05	0.021	0.51	0.38	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
ESCA	cis	rs858239	0.636	rs7808488	ENSG00000230042.1	AK3P3	-4.54	1.31e-05	0.0211	-0.45	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23129178~23129841:+
ESCA	cis	rs1387259	0.69	rs1601985	ENSG00000258273.1	RP11-370I10.4	-4.54	1.31e-05	0.0211	-0.54	-0.38	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48368131	chr12:48333755~48333901:-
ESCA	cis	rs2019137	0.936	rs4849169	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113196080	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.836	rs4848318	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113196375	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs2241978	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113196429	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs3828188	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113196670	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs3828189	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113196919	chr2:113211522~113276581:+
ESCA	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	4.54	1.32e-05	0.0211	0.52	0.38	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
ESCA	cis	rs28830936	0.966	rs17678552	ENSG00000250379.1	RP11-23P13.4	4.54	1.32e-05	0.0211	0.43	0.38	Diastolic blood pressure;	chr15:41773992	chr15:41825099~41827936:-
ESCA	cis	rs10229583	0.527	rs6979634	ENSG00000279078.1	SND1-IT1	-4.54	1.32e-05	0.0211	-0.43	-0.38	Type 2 diabetes;	chr7:127683911	chr7:127997597~128000077:+
ESCA	cis	rs2742234	0.504	rs7093409	ENSG00000273008.1	RP11-351D16.3	4.54	1.32e-05	0.0211	0.43	0.38	Hirschsprung disease;	chr10:43244619	chr10:43136824~43138334:-
ESCA	cis	rs2019137	0.936	rs3811059	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113204494	chr2:113211522~113276581:+
ESCA	cis	rs2019137	0.936	rs12620738	ENSG00000189223.12	PAX8-AS1	4.54	1.32e-05	0.0211	0.5	0.38	Lymphocyte counts;	chr2:113206162	chr2:113211522~113276581:+
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000231271.1	AP000350.8	4.54	1.32e-05	0.0211	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23949918~23954042:+
ESCA	cis	rs2005	0.502	rs12189669	ENSG00000186328.4	RP11-140K17.2	-4.54	1.32e-05	0.0211	-0.54	-0.38	Obesity-related traits;	chr6:35183023	chr6:34715613~34715940:+
ESCA	cis	rs7535099	0.954	rs6588152	ENSG00000224570.1	RP11-430H12.2	-4.54	1.32e-05	0.0212	-0.6	-0.38	Blood protein levels;	chr1:65573315	chr1:65576129~65578380:-
ESCA	cis	rs61160187	0.582	rs12653132	ENSG00000215032.2	GNL3LP1	4.54	1.32e-05	0.0212	0.49	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:61062881	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs1526896	ENSG00000215032.2	GNL3LP1	4.54	1.32e-05	0.0212	0.49	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:61063883	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs56284222	ENSG00000215032.2	GNL3LP1	4.54	1.32e-05	0.0212	0.49	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:61065723	chr5:60891935~60893577:-
ESCA	cis	rs1075265	0.87	rs6749817	ENSG00000235937.1	AC008280.1	4.54	1.32e-05	0.0212	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54029552~54030682:-
ESCA	cis	rs7412746	0.658	rs8444	ENSG00000206931.1	RNU6-1042P	4.54	1.32e-05	0.0212	0.48	0.38	Melanoma;	chr1:150966095	chr1:150701866~150701972:+
ESCA	cis	rs765787	0.53	rs4775819	ENSG00000259520.4	CTD-2651B20.3	4.54	1.33e-05	0.0212	0.43	0.38	Uric acid levels;	chr15:45233768	chr15:45251580~45279251:-
ESCA	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-4.54	1.33e-05	0.0212	-0.67	-0.38	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
ESCA	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	4.54	1.33e-05	0.0212	0.47	0.38	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
ESCA	cis	rs2283792	0.542	rs9610500	ENSG00000228050.1	TOP3BP1	4.54	1.33e-05	0.0212	0.48	0.38	Multiple sclerosis;	chr22:21866877	chr22:22223187~22224566:-
ESCA	cis	rs7829975	0.846	rs7005216	ENSG00000173295.6	FAM86B3P	-4.54	1.33e-05	0.0212	-0.45	-0.38	Mood instability;	chr8:8689600	chr8:8228595~8244865:+
ESCA	cis	rs1075265	0.588	rs1477258	ENSG00000235937.1	AC008280.1	4.54	1.33e-05	0.0212	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54029552~54030682:-
ESCA	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-4.54	1.33e-05	0.0213	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
ESCA	cis	rs9399137	0.507	rs11154791	ENSG00000232876.1	CTA-212D2.2	-4.54	1.33e-05	0.0213	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135058010	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs7745289	ENSG00000232876.1	CTA-212D2.2	-4.54	1.33e-05	0.0213	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135059189	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs11759062	ENSG00000232876.1	CTA-212D2.2	-4.54	1.33e-05	0.0213	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060110	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs11759077	ENSG00000232876.1	CTA-212D2.2	-4.54	1.33e-05	0.0213	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135060213	chr6:135055033~135060550:+
ESCA	cis	rs9545047	0.604	rs12865187	ENSG00000227676.3	LINC01068	-4.54	1.33e-05	0.0213	-0.5	-0.38	Schizophrenia;	chr13:79316469	chr13:79566727~79571436:+
ESCA	cis	rs2439831	0.867	rs12443102	ENSG00000205771.5	CATSPER2P1	-4.54	1.33e-05	0.0213	-0.64	-0.38	Lung cancer in ever smokers;	chr15:43639905	chr15:43726918~43747094:-
ESCA	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-4.54	1.34e-05	0.0214	-0.72	-0.38	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
ESCA	cis	rs4345206	0.604	rs1979974	ENSG00000250673.1	RP11-6L6.2	-4.54	1.34e-05	0.0214	-0.38	-0.38	Coronary artery disease;	chr4:145879663	chr4:146224557~146229056:+
ESCA	cis	rs10995505	0.589	rs4601646	ENSG00000235816.3	PRELID1P3	-4.54	1.34e-05	0.0214	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63120520	chr10:63427297~63427939:+
ESCA	cis	rs2179367	0.919	rs4897124	ENSG00000216906.2	RP11-350J20.9	4.54	1.34e-05	0.0214	0.52	0.38	Dupuytren's disease;	chr6:149442073	chr6:149904243~149906418:+
ESCA	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	4.54	1.34e-05	0.0214	0.48	0.38	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
ESCA	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-4.54	1.34e-05	0.0215	-0.44	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
ESCA	cis	rs6604026	0.656	rs2811593	ENSG00000229052.2	RP11-386I23.1	4.54	1.34e-05	0.0215	0.38	0.38	Multiple sclerosis;	chr1:92878334	chr1:92930696~92934098:+
ESCA	cis	rs1075265	0.84	rs2884254	ENSG00000235937.1	AC008280.1	4.54	1.35e-05	0.0215	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54029552~54030682:-
ESCA	cis	rs747650	0.892	rs1976143	ENSG00000271350.1	CTD-2384B9.1	-4.53	1.35e-05	0.0216	-0.46	-0.38	Acne (severe);	chr11:47203983	chr11:47041027~47041945:-
ESCA	cis	rs747650	0.892	rs1976142	ENSG00000271350.1	CTD-2384B9.1	-4.53	1.35e-05	0.0216	-0.46	-0.38	Acne (severe);	chr11:47204143	chr11:47041027~47041945:-
ESCA	cis	rs2739330	0.892	rs4822455	ENSG00000272787.1	KB-226F1.2	-4.53	1.35e-05	0.0216	-0.44	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23969211~23969873:+
ESCA	cis	rs2439831	0.867	rs2255042	ENSG00000249839.1	AC011330.5	4.53	1.36e-05	0.0216	0.59	0.38	Lung cancer in ever smokers;	chr15:43542120	chr15:43663654~43684339:-
ESCA	cis	rs2307394	1	rs13027200	ENSG00000223911.1	AC009480.3	4.53	1.36e-05	0.0216	0.47	0.38	Urate levels;	chr2:147952084	chr2:147899401~147902956:-
ESCA	cis	rs10954779	0.764	rs2725365	ENSG00000253579.1	SUMO2P16	-4.53	1.36e-05	0.0217	-0.42	-0.38	Intelligence (multi-trait analysis);	chr8:31142727	chr8:31131539~31131802:-
ESCA	cis	rs2505998	0.833	rs1800858	ENSG00000273008.1	RP11-351D16.3	-4.53	1.36e-05	0.0217	-0.41	-0.38	Hirschsprung disease;	chr10:43100520	chr10:43136824~43138334:-
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000272787.1	KB-226F1.2	4.53	1.36e-05	0.0218	0.5	0.38	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23969211~23969873:+
ESCA	cis	rs9549260	0.617	rs9549266	ENSG00000229456.1	RLIMP1	4.53	1.37e-05	0.0218	0.51	0.38	Red blood cell count;	chr13:40704273	chr13:40618738~40621348:+
ESCA	cis	rs950169	0.922	rs4586394	ENSG00000225151.9	GOLGA2P7	4.53	1.37e-05	0.0218	0.64	0.38	Schizophrenia;	chr15:84153633	chr15:84199311~84230136:-
ESCA	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	4.53	1.37e-05	0.0218	0.4	0.38	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
ESCA	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-4.53	1.37e-05	0.0218	-0.41	-0.38	Migraine;	chr4:56940917	chr4:56960927~56961373:-
ESCA	cis	rs7412746	0.634	rs4451553	ENSG00000206931.1	RNU6-1042P	4.53	1.37e-05	0.0218	0.48	0.38	Melanoma;	chr1:150964853	chr1:150701866~150701972:+
ESCA	cis	rs1048238	0.506	rs10927866	ENSG00000235084.3	CHCHD2P6	-4.53	1.37e-05	0.0218	-0.36	-0.38	Systolic blood pressure;	chr1:15848822	chr1:15604597~15605043:+
ESCA	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-4.53	1.37e-05	0.0219	-0.45	-0.38	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
ESCA	cis	rs2739330	0.76	rs1002286	ENSG00000224205.1	AP000351.4	-4.53	1.37e-05	0.0219	-0.41	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23987320~23991421:-
ESCA	cis	rs7580717	0.529	rs6739959	ENSG00000201574.1	RNU1-93P	-4.53	1.38e-05	0.0219	-0.41	-0.38	Multiple myeloma;	chr2:231183605	chr2:231133462~231133630:+
ESCA	cis	rs2307394	1	rs4972320	ENSG00000223911.1	AC009480.3	4.53	1.38e-05	0.0219	0.47	0.38	Urate levels;	chr2:148027001	chr2:147899401~147902956:-
ESCA	cis	rs7267979	0.789	rs6076347	ENSG00000204556.4	CTD-2514C3.1	4.53	1.38e-05	0.0219	0.5	0.38	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:26018832~26020684:+
ESCA	cis	rs2688482	0.512	rs2177336	ENSG00000207650.1	MIR570	4.53	1.38e-05	0.022	0.54	0.38	Lung disease severity in cystic fibrosis;	chr3:195790007	chr3:195699401~195699497:+
ESCA	cis	rs2688482	0.512	rs1106502	ENSG00000207650.1	MIR570	4.53	1.38e-05	0.022	0.54	0.38	Lung disease severity in cystic fibrosis;	chr3:195790387	chr3:195699401~195699497:+
ESCA	cis	rs2688482	0.512	rs1104760	ENSG00000207650.1	MIR570	4.53	1.38e-05	0.022	0.54	0.38	Lung disease severity in cystic fibrosis;	chr3:195790450	chr3:195699401~195699497:+
ESCA	cis	rs2439831	0.681	rs1549525	ENSG00000249839.1	AC011330.5	-4.53	1.38e-05	0.022	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43335657	chr15:43663654~43684339:-
ESCA	cis	rs7017914	0.652	rs56352991	ENSG00000253173.3	RP11-152C15.1	-4.53	1.38e-05	0.022	-0.44	-0.38	Bone mineral density;	chr8:70655843	chr8:70103798~70104179:-
ESCA	cis	rs8072100	0.934	rs8067286	ENSG00000228782.6	CTD-2026D20.3	-4.53	1.38e-05	0.022	-0.4	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47517224	chr17:47450568~47492492:-
ESCA	cis	rs8072100	0.875	rs62073966	ENSG00000228782.6	CTD-2026D20.3	-4.53	1.38e-05	0.022	-0.4	-0.38	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47522647	chr17:47450568~47492492:-
ESCA	cis	rs2742234	0.911	rs3004214	ENSG00000273008.1	RP11-351D16.3	-4.53	1.39e-05	0.022	-0.45	-0.38	Hirschsprung disease;	chr10:43136250	chr10:43136824~43138334:-
ESCA	cis	rs6432860	0.527	rs11690959	ENSG00000232411.1	AC009495.3	-4.53	1.39e-05	0.0221	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166047515	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs13403426	ENSG00000232411.1	AC009495.3	-4.53	1.39e-05	0.0221	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166049798	chr2:165833048~165839098:-
ESCA	cis	rs6432852	0.581	rs1903439	ENSG00000232411.1	AC009495.3	-4.53	1.39e-05	0.0221	-0.41	-0.38	Diabetic kidney disease;	chr2:166050559	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.527	rs10221756	ENSG00000232411.1	AC009495.3	-4.53	1.39e-05	0.0221	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166050877	chr2:165833048~165839098:-
ESCA	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-4.53	1.39e-05	0.0221	-0.73	-0.38	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
ESCA	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	4.53	1.39e-05	0.0221	0.51	0.38	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	4.53	1.39e-05	0.0221	0.51	0.38	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	4.53	1.39e-05	0.0221	0.51	0.38	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	4.53	1.39e-05	0.0221	0.51	0.38	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
ESCA	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	4.53	1.39e-05	0.0221	0.51	0.38	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
ESCA	cis	rs9399137	0.507	rs12664898	ENSG00000232876.1	CTA-212D2.2	-4.53	1.39e-05	0.0221	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134967525	chr6:135055033~135060550:+
ESCA	cis	rs9399137	0.507	rs12663810	ENSG00000232876.1	CTA-212D2.2	-4.53	1.39e-05	0.0221	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134968644	chr6:135055033~135060550:+
ESCA	cis	rs6452524	0.935	rs7736296	ENSG00000243385.2	CTD-2110K23.1	-4.53	1.39e-05	0.0221	-0.39	-0.38	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83201229~83202141:+
ESCA	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	4.53	1.39e-05	0.0221	0.64	0.38	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
ESCA	cis	rs9399137	0.507	rs4289677	ENSG00000232876.1	CTA-212D2.2	-4.53	1.39e-05	0.0221	-0.46	-0.38	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954347	chr6:135055033~135060550:+
ESCA	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-4.53	1.39e-05	0.0221	-0.49	-0.38	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
ESCA	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-4.53	1.39e-05	0.0221	-0.72	-0.38	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-4.53	1.39e-05	0.0221	-0.72	-0.38	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
ESCA	cis	rs9309711	0.643	rs10188449	ENSG00000225234.1	TRAPPC12-AS1	-4.53	1.4e-05	0.0221	-0.46	-0.38	Neurofibrillary tangles;	chr2:3476595	chr2:3481242~3482409:-
ESCA	cis	rs1005277	0.579	rs2474571	ENSG00000276805.1	RP11-291L22.6	4.53	1.4e-05	0.0222	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38451030~38451785:+
ESCA	cis	rs7283707	0.681	rs389270	ENSG00000269950.1	AP000962.2	4.53	1.4e-05	0.0222	0.53	0.38	QRS complex (12-leadsum);	chr21:15923413	chr21:16574718~16582637:-
ESCA	cis	rs7714584	1	rs60134818	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150881481	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs6579806	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150891522	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs4958848	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150891560	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1863998	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150892191	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11167521	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150892223	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10057988	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150892500	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs10052606	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150892655	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs57001853	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150892890	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs2217266	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150893059	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs1816256	ENSG00000197083.10	ZNF300P1	4.53	1.4e-05	0.0222	0.6	0.38	Crohn's disease;	chr5:150893291	chr5:150930645~150946289:-
ESCA	cis	rs6432860	0.545	rs2217199	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166053185	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs1972445	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166053699	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs6432864	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166053850	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs7606654	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166053924	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs1461203	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166056247	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs10192608	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166057168	chr2:165833048~165839098:-
ESCA	cis	rs6432852	0.702	rs2195143	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Diabetic kidney disease;	chr2:166057400	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.527	rs7564306	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166058385	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.527	rs7609055	ENSG00000232411.1	AC009495.3	-4.53	1.4e-05	0.0222	-0.41	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166059743	chr2:165833048~165839098:-
ESCA	cis	rs7829975	0.624	rs7823056	ENSG00000173295.6	FAM86B3P	4.53	1.4e-05	0.0222	0.46	0.38	Mood instability;	chr8:8525195	chr8:8228595~8244865:+
ESCA	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-4.53	1.4e-05	0.0222	-0.46	-0.38	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
ESCA	cis	rs2439831	1	rs690436	ENSG00000249839.1	AC011330.5	-4.52	1.41e-05	0.0223	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43469007	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs561863	ENSG00000249839.1	AC011330.5	-4.52	1.41e-05	0.0223	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43469154	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs689596	ENSG00000249839.1	AC011330.5	-4.52	1.41e-05	0.0223	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43469519	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs689616	ENSG00000249839.1	AC011330.5	-4.52	1.41e-05	0.0223	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43469703	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs689647	ENSG00000249839.1	AC011330.5	-4.52	1.41e-05	0.0223	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43469998	chr15:43663654~43684339:-
ESCA	cis	rs1005277	0.579	rs2472183	ENSG00000276805.1	RP11-291L22.6	4.52	1.41e-05	0.0223	0.5	0.38	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.691	rs2474558	ENSG00000263064.2	RP11-291L22.7	-4.52	1.41e-05	0.0223	-0.54	-0.38	Extrinsic epigenetic age acceleration;	chr10:38197213	chr10:38448689~38448949:+
ESCA	cis	rs4835265	0.631	rs4835260	ENSG00000250673.1	RP11-6L6.2	-4.52	1.41e-05	0.0224	-0.42	-0.38	Gamma glutamyl transpeptidase;	chr4:145844408	chr4:146224557~146229056:+
ESCA	cis	rs36093844	0.527	rs72949443	ENSG00000271318.1	AP000654.5	-4.52	1.41e-05	0.0224	-0.85	-0.38	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85944402	chr11:86821143~86821728:-
ESCA	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	4.52	1.41e-05	0.0224	0.44	0.38	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
ESCA	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-4.52	1.42e-05	0.0224	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
ESCA	cis	rs1075232	1	rs72722861	ENSG00000270055.1	CTD-3092A11.2	-4.52	1.42e-05	0.0224	-0.86	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30487963~30490313:+
ESCA	cis	rs1075232	0.826	rs12438813	ENSG00000270055.1	CTD-3092A11.2	-4.52	1.42e-05	0.0224	-0.86	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30487963~30490313:+
ESCA	cis	rs1075232	1	rs34959140	ENSG00000270055.1	CTD-3092A11.2	-4.52	1.42e-05	0.0224	-0.86	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30487963~30490313:+
ESCA	cis	rs7283707	0.681	rs75443279	ENSG00000269950.1	AP000962.2	4.52	1.42e-05	0.0224	0.76	0.38	QRS complex (12-leadsum);	chr21:15727165	chr21:16574718~16582637:-
ESCA	cis	rs7283707	0.581	rs7282314	ENSG00000269950.1	AP000962.2	4.52	1.42e-05	0.0224	0.76	0.38	QRS complex (12-leadsum);	chr21:15727370	chr21:16574718~16582637:-
ESCA	cis	rs453301	0.686	rs17702602	ENSG00000253981.4	ALG1L13P	-4.52	1.42e-05	0.0224	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9051086	chr8:8236003~8244667:-
ESCA	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	4.52	1.42e-05	0.0224	0.47	0.38	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
ESCA	cis	rs9309711	0.621	rs11127428	ENSG00000225234.1	TRAPPC12-AS1	-4.52	1.42e-05	0.0224	-0.47	-0.38	Neurofibrillary tangles;	chr2:3467375	chr2:3481242~3482409:-
ESCA	cis	rs1723838	0.826	rs6592528	ENSG00000255928.1	RP11-456I15.2	4.52	1.42e-05	0.0224	0.88	0.38	Obesity-related traits;	chr11:73666305	chr11:73722349~73722694:+
ESCA	cis	rs6867032	0.527	rs4246752	ENSG00000249731.1	RP11-259O2.3	-4.52	1.42e-05	0.0225	-0.33	-0.38	Gut microbiome composition (winter);	chr5:1975461	chr5:1968094~1969013:+
ESCA	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	4.52	1.42e-05	0.0225	0.42	0.38	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
ESCA	cis	rs4948102	0.595	rs10255049	ENSG00000275875.1	RP11-613E4.5	-4.52	1.42e-05	0.0225	-0.45	-0.38	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55741525~55741869:+
ESCA	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-4.52	1.42e-05	0.0225	-0.4	-0.38	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
ESCA	cis	rs3820068	0.581	rs34453754	ENSG00000237301.1	RP4-680D5.2	4.52	1.42e-05	0.0225	0.43	0.38	Systolic blood pressure;	chr1:15666713	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs35509554	ENSG00000237301.1	RP4-680D5.2	4.52	1.42e-05	0.0225	0.43	0.38	Systolic blood pressure;	chr1:15667019	chr1:15586136~15603626:-
ESCA	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-4.52	1.43e-05	0.0226	-0.37	-0.38	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
ESCA	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-4.52	1.43e-05	0.0226	-0.37	-0.38	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
ESCA	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-4.52	1.43e-05	0.0226	-0.37	-0.38	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
ESCA	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-4.52	1.43e-05	0.0226	-0.37	-0.38	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
ESCA	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	4.52	1.43e-05	0.0226	0.51	0.38	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
ESCA	cis	rs8062405	0.755	rs4149398	ENSG00000278665.1	RP11-666O2.4	4.52	1.43e-05	0.0226	0.53	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28599241~28601881:-
ESCA	cis	rs6456156	0.846	rs9364891	ENSG00000265828.1	MIR3939	4.52	1.44e-05	0.0226	0.43	0.38	Primary biliary cholangitis;	chr6:167102831	chr6:166997807~166997912:-
ESCA	cis	rs10754283	0.934	rs1934043	ENSG00000231613.1	RP5-943J3.1	4.52	1.44e-05	0.0227	0.41	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89641086	chr1:89788914~89790492:+
ESCA	cis	rs8062405	0.755	rs4788073	ENSG00000278665.1	RP11-666O2.4	4.52	1.44e-05	0.0227	0.54	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28599241~28601881:-
ESCA	cis	rs6805251	0.594	rs6769435	ENSG00000276607.2	AC092910.1	-4.52	1.44e-05	0.0227	-0.45	-0.38	HDL cholesterol levels;HDL cholesterol;	chr3:119965560	chr3:120084550~120084657:-
ESCA	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-4.52	1.44e-05	0.0227	-0.74	-0.38	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
ESCA	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	4.52	1.44e-05	0.0227	0.44	0.38	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
ESCA	cis	rs7829975	0.511	rs1401390	ENSG00000173295.6	FAM86B3P	4.52	1.44e-05	0.0227	0.46	0.38	Mood instability;	chr8:8278888	chr8:8228595~8244865:+
ESCA	cis	rs1005277	0.579	rs2472181	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474574	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2504140	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474575	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2472182	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2021649	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2505197	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2505196	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.541	rs2505193	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474580	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2504148	ENSG00000276805.1	RP11-291L22.6	4.52	1.44e-05	0.0227	0.49	0.38	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38451030~38451785:+
ESCA	cis	rs7017914	0.652	rs3098858	ENSG00000253173.3	RP11-152C15.1	-4.52	1.44e-05	0.0227	-0.43	-0.38	Bone mineral density;	chr8:70951038	chr8:70103798~70104179:-
ESCA	cis	rs2739330	0.703	rs5760112	ENSG00000224205.1	AP000351.4	4.52	1.44e-05	0.0227	0.41	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23987320~23991421:-
ESCA	cis	rs6432860	0.545	rs1461201	ENSG00000232411.1	AC009495.3	-4.52	1.44e-05	0.0227	-0.43	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166061184	chr2:165833048~165839098:-
ESCA	cis	rs2179367	0.959	rs2262617	ENSG00000216906.2	RP11-350J20.9	4.52	1.45e-05	0.0228	0.52	0.38	Dupuytren's disease;	chr6:149438590	chr6:149904243~149906418:+
ESCA	cis	rs12480328	1	rs16995568	ENSG00000228663.1	PSMD10P1	-4.52	1.45e-05	0.0228	-0.36	-0.38	Prostate cancer;	chr20:50884357	chr20:50913731~50914411:+
ESCA	cis	rs7017914	0.628	rs12156041	ENSG00000253173.3	RP11-152C15.1	-4.52	1.45e-05	0.0228	-0.44	-0.38	Bone mineral density;	chr8:70914690	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.628	rs1389198	ENSG00000253173.3	RP11-152C15.1	-4.52	1.45e-05	0.0228	-0.44	-0.38	Bone mineral density;	chr8:70921872	chr8:70103798~70104179:-
ESCA	cis	rs9532580	0.71	rs9577090	ENSG00000229456.1	RLIMP1	4.52	1.45e-05	0.0228	0.36	0.38	Mean corpuscular hemoglobin;	chr13:40651091	chr13:40618738~40621348:+
ESCA	cis	rs9532580	0.553	rs9549250	ENSG00000229456.1	RLIMP1	4.52	1.45e-05	0.0228	0.36	0.38	Mean corpuscular hemoglobin;	chr13:40651092	chr13:40618738~40621348:+
ESCA	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	4.52	1.45e-05	0.0228	0.52	0.38	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
ESCA	cis	rs1439620	1	rs11074115	ENSG00000258647.4	LINC00930	4.52	1.45e-05	0.0228	0.45	0.38	Body mass index;	chr15:92887933	chr15:92567818~92572042:-
ESCA	cis	rs1864400	0.645	rs2249005	ENSG00000273008.1	RP11-351D16.3	-4.52	1.45e-05	0.0228	-0.45	-0.38	Hirschsprung disease;	chr10:43131832	chr10:43136824~43138334:-
ESCA	cis	rs7829975	0.626	rs907183	ENSG00000253981.4	ALG1L13P	-4.52	1.45e-05	0.0229	-0.45	-0.38	Mood instability;	chr8:8872251	chr8:8236003~8244667:-
ESCA	cis	rs453301	0.571	rs330048	ENSG00000253981.4	ALG1L13P	-4.52	1.45e-05	0.0229	-0.48	-0.38	Joint mobility (Beighton score);	chr8:9229768	chr8:8236003~8244667:-
ESCA	cis	rs1075265	0.73	rs4413193	ENSG00000235937.1	AC008280.1	4.52	1.46e-05	0.0229	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54029552~54030682:-
ESCA	cis	rs61160187	0.582	rs888799	ENSG00000215032.2	GNL3LP1	4.52	1.46e-05	0.0229	0.48	0.38	Educational attainment (years of education);Educational attainment (college completion);	chr5:61049363	chr5:60891935~60893577:-
ESCA	cis	rs611744	0.87	rs634216	ENSG00000253754.1	RP11-35G22.1	-4.52	1.46e-05	0.023	-0.35	-0.38	Dupuytren's disease;	chr8:108162574	chr8:108226200~108227544:+
ESCA	cis	rs11169552	0.51	rs10876056	ENSG00000200428.1	Y_RNA	4.52	1.46e-05	0.023	0.47	0.38	Colorectal cancer;	chr12:50554734	chr12:50743568~50743684:+
ESCA	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-4.51	1.46e-05	0.023	-0.63	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
ESCA	cis	rs2823455	0.681	rs17241395	ENSG00000269950.1	AP000962.2	4.51	1.47e-05	0.023	0.76	0.38	Panic disorder;	chr21:15694200	chr21:16574718~16582637:-
ESCA	cis	rs9462027	0.628	rs2477508	ENSG00000186328.4	RP11-140K17.2	-4.51	1.47e-05	0.0231	-0.42	-0.38	Systemic lupus erythematosus;	chr6:34735918	chr6:34715613~34715940:+
ESCA	cis	rs150992	1	rs150992	ENSG00000248489.1	CTD-2007H13.3	4.51	1.47e-05	0.0231	0.54	0.38	Body mass index;	chr5:98939493	chr5:98929171~98995013:+
ESCA	cis	rs1075265	0.656	rs2542574	ENSG00000235937.1	AC008280.1	4.51	1.47e-05	0.0231	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54029552~54030682:-
ESCA	cis	rs7702057	0.53	rs17138879	ENSG00000271918.1	CTD-2287O16.5	-4.51	1.47e-05	0.0231	-0.65	-0.38	Amyotrophic lateral sclerosis;	chr5:116089730	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs17138866	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116088914	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs59429923	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116089241	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs1129495	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116092684	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs61105089	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116096514	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs2136213	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116098716	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs4921060	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116109004	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs58510083	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116109101	chr5:116083807~116085416:-
ESCA	cis	rs7702057	0.53	rs61672521	ENSG00000271918.1	CTD-2287O16.5	4.51	1.47e-05	0.0231	0.65	0.38	Amyotrophic lateral sclerosis;	chr5:116112548	chr5:116083807~116085416:-
ESCA	cis	rs6456156	0.846	rs10946211	ENSG00000265828.1	MIR3939	4.51	1.47e-05	0.0231	0.43	0.38	Primary biliary cholangitis;	chr6:167102001	chr6:166997807~166997912:-
ESCA	cis	rs6456156	0.846	rs7749827	ENSG00000265828.1	MIR3939	4.51	1.47e-05	0.0231	0.43	0.38	Primary biliary cholangitis;	chr6:167102136	chr6:166997807~166997912:-
ESCA	cis	rs7535099	1	rs7524458	ENSG00000224570.1	RP11-430H12.2	-4.51	1.47e-05	0.0231	-0.6	-0.38	Blood protein levels;	chr1:65585217	chr1:65576129~65578380:-
ESCA	cis	rs7535099	1	rs7535099	ENSG00000224570.1	RP11-430H12.2	-4.51	1.47e-05	0.0231	-0.6	-0.38	Blood protein levels;	chr1:65585314	chr1:65576129~65578380:-
ESCA	cis	rs7535099	0.954	rs11208680	ENSG00000224570.1	RP11-430H12.2	-4.51	1.47e-05	0.0231	-0.6	-0.38	Blood protein levels;	chr1:65587380	chr1:65576129~65578380:-
ESCA	cis	rs1005277	0.579	rs2505248	ENSG00000276805.1	RP11-291L22.6	4.51	1.47e-05	0.0231	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38451030~38451785:+
ESCA	cis	rs4927850	1	rs10881563	ENSG00000207650.1	MIR570	4.51	1.47e-05	0.0231	0.42	0.38	Pancreatic cancer;	chr3:196023354	chr3:195699401~195699497:+
ESCA	cis	rs42490	1	rs2735870	ENSG00000251136.7	RP11-37B2.1	4.51	1.48e-05	0.0232	0.38	0.38	Leprosy;	chr8:89730456	chr8:89609409~89757727:-
ESCA	cis	rs42490	1	rs218907	ENSG00000251136.7	RP11-37B2.1	-4.51	1.48e-05	0.0232	-0.38	-0.38	Leprosy;	chr8:89728164	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.966	rs218908	ENSG00000251136.7	RP11-37B2.1	-4.51	1.48e-05	0.0232	-0.38	-0.38	Leprosy;	chr8:89728886	chr8:89609409~89757727:-
ESCA	cis	rs42490	1	rs218913	ENSG00000251136.7	RP11-37B2.1	-4.51	1.48e-05	0.0232	-0.38	-0.38	Leprosy;	chr8:89732206	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.966	rs218914	ENSG00000251136.7	RP11-37B2.1	-4.51	1.48e-05	0.0232	-0.38	-0.38	Leprosy;	chr8:89733130	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.934	rs218925	ENSG00000251136.7	RP11-37B2.1	-4.51	1.48e-05	0.0232	-0.38	-0.38	Leprosy;	chr8:89737352	chr8:89609409~89757727:-
ESCA	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-4.51	1.48e-05	0.0232	-0.45	-0.38	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
ESCA	cis	rs4835265	0.852	rs10004928	ENSG00000250673.1	RP11-6L6.2	-4.51	1.48e-05	0.0232	-0.43	-0.38	Gamma glutamyl transpeptidase;	chr4:145856157	chr4:146224557~146229056:+
ESCA	cis	rs4835265	0.852	rs10008626	ENSG00000250673.1	RP11-6L6.2	-4.51	1.48e-05	0.0232	-0.43	-0.38	Gamma glutamyl transpeptidase;	chr4:145857672	chr4:146224557~146229056:+
ESCA	cis	rs8062405	0.755	rs12447461	ENSG00000278665.1	RP11-666O2.4	4.51	1.48e-05	0.0232	0.54	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28599241~28601881:-
ESCA	cis	rs950169	0.922	rs4842940	ENSG00000225151.9	GOLGA2P7	4.51	1.48e-05	0.0232	0.64	0.38	Schizophrenia;	chr15:84162473	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.922	rs4842941	ENSG00000225151.9	GOLGA2P7	4.51	1.48e-05	0.0232	0.64	0.38	Schizophrenia;	chr15:84162560	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.922	rs12911223	ENSG00000225151.9	GOLGA2P7	4.51	1.48e-05	0.0232	0.64	0.38	Schizophrenia;	chr15:84162919	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.845	rs4106951	ENSG00000225151.9	GOLGA2P7	-4.51	1.48e-05	0.0232	-0.64	-0.38	Schizophrenia;	chr15:84164642	chr15:84199311~84230136:-
ESCA	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-4.51	1.48e-05	0.0232	-0.38	-0.38	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
ESCA	cis	rs7631605	0.967	rs6550458	ENSG00000272334.1	RP11-129K12.1	-4.51	1.48e-05	0.0232	-0.42	-0.38	Cerebrospinal P-tau181p levels;	chr3:37146827	chr3:36973117~36973672:-
ESCA	cis	rs7924176	0.643	rs1908339	ENSG00000236900.1	TIMM9P1	4.51	1.48e-05	0.0232	0.51	0.38	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74083342	chr10:74344550~74344805:-
ESCA	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-4.51	1.48e-05	0.0232	-0.51	-0.38	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
ESCA	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	4.51	1.48e-05	0.0232	0.67	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
ESCA	cis	rs2742234	0.554	rs1254963	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43200638	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs1254962	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43201544	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.554	rs1270015	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43202792	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs1254960	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43204209	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs1254959	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43205531	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs1254958	ENSG00000273008.1	RP11-351D16.3	4.51	1.48e-05	0.0232	0.45	0.38	Hirschsprung disease;	chr10:43206695	chr10:43136824~43138334:-
ESCA	cis	rs9549260	0.755	rs9549255	ENSG00000229456.1	RLIMP1	4.51	1.48e-05	0.0232	0.35	0.38	Red blood cell count;	chr13:40661076	chr13:40618738~40621348:+
ESCA	cis	rs11169552	0.51	rs11169507	ENSG00000200428.1	Y_RNA	-4.51	1.49e-05	0.0233	-0.45	-0.38	Colorectal cancer;	chr12:50621726	chr12:50743568~50743684:+
ESCA	cis	rs858239	0.831	rs7796541	ENSG00000226816.2	AC005082.12	4.51	1.49e-05	0.0233	0.46	0.38	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23206013~23208045:+
ESCA	cis	rs6432860	0.545	rs4667502	ENSG00000232411.1	AC009495.3	-4.51	1.49e-05	0.0233	-0.42	-0.38	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166060846	chr2:165833048~165839098:-
ESCA	cis	rs7208859	0.614	rs73265646	ENSG00000263531.1	RP13-753N3.1	4.51	1.49e-05	0.0234	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917005	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs58908911	ENSG00000263531.1	RP13-753N3.1	4.51	1.49e-05	0.0234	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30917540	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs28588622	ENSG00000263531.1	RP13-753N3.1	4.51	1.49e-05	0.0234	0.59	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30918681	chr17:30863921~30864940:-
ESCA	cis	rs1538970	0.816	rs9727262	ENSG00000280836.1	AL355480.1	-4.51	1.5e-05	0.0234	-0.47	-0.38	Platelet count;	chr1:45532907	chr1:45581219~45581321:-
ESCA	cis	rs2179367	0.887	rs6570965	ENSG00000216906.2	RP11-350J20.9	4.51	1.5e-05	0.0234	0.49	0.38	Dupuytren's disease;	chr6:149396340	chr6:149904243~149906418:+
ESCA	cis	rs2439831	1	rs689826	ENSG00000249839.1	AC011330.5	-4.51	1.5e-05	0.0234	-0.59	-0.38	Lung cancer in ever smokers;	chr15:43457718	chr15:43663654~43684339:-
ESCA	cis	rs42490	0.966	rs218932	ENSG00000251136.7	RP11-37B2.1	-4.51	1.5e-05	0.0234	-0.38	-0.38	Leprosy;	chr8:89740725	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.966	rs2735878	ENSG00000251136.7	RP11-37B2.1	-4.51	1.5e-05	0.0234	-0.38	-0.38	Leprosy;	chr8:89742720	chr8:89609409~89757727:-
ESCA	cis	rs1075232	1	rs12439239	ENSG00000215302.7	CTD-3092A11.1	-4.51	1.5e-05	0.0234	-0.8	-0.38	Survival in colorectal cancer (non-distant metastatic);	chr15:31359515	chr15:30470779~30507623:+
ESCA	cis	rs1048238	0.506	rs698889	ENSG00000235084.3	CHCHD2P6	4.51	1.5e-05	0.0234	0.36	0.38	Systolic blood pressure;	chr1:15940545	chr1:15604597~15605043:+
ESCA	cis	rs4742903	0.545	rs7039927	ENSG00000270332.1	SMC2-AS1	4.51	1.5e-05	0.0234	0.43	0.38	Breast cancer;High-grade serous ovarian cancer;	chr9:104224523	chr9:104080024~104093073:-
ESCA	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	4.51	1.5e-05	0.0234	0.59	0.38	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11951694	ENSG00000197083.10	ZNF300P1	4.51	1.5e-05	0.0234	0.59	0.38	Crohn's disease;	chr5:150874776	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11955172	ENSG00000197083.10	ZNF300P1	4.51	1.5e-05	0.0234	0.59	0.38	Crohn's disease;	chr5:150874816	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.793	rs11955174	ENSG00000197083.10	ZNF300P1	4.51	1.5e-05	0.0234	0.59	0.38	Crohn's disease;	chr5:150874829	chr5:150930645~150946289:-
ESCA	cis	rs9549260	0.755	rs9577091	ENSG00000229456.1	RLIMP1	4.51	1.5e-05	0.0234	0.35	0.38	Red blood cell count;	chr13:40653728	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.755	rs7328677	ENSG00000229456.1	RLIMP1	4.51	1.5e-05	0.0234	0.35	0.38	Red blood cell count;	chr13:40655768	chr13:40618738~40621348:+
ESCA	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	4.51	1.5e-05	0.0235	0.5	0.38	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
ESCA	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	4.51	1.5e-05	0.0235	0.54	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
ESCA	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	4.51	1.5e-05	0.0235	0.51	0.38	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
ESCA	cis	rs11169552	0.51	rs10747587	ENSG00000200428.1	Y_RNA	4.51	1.51e-05	0.0235	0.45	0.38	Colorectal cancer;	chr12:50711517	chr12:50743568~50743684:+
ESCA	cis	rs2227564	0.729	rs2675675	ENSG00000229990.3	RP11-574K11.8	-4.51	1.51e-05	0.0235	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73889290	chr10:73841833~73847115:+
ESCA	cis	rs1723838	0.826	rs1880643	ENSG00000255928.1	RP11-456I15.2	4.51	1.51e-05	0.0235	0.73	0.38	Obesity-related traits;	chr11:73701969	chr11:73722349~73722694:+
ESCA	cis	rs2439831	0.867	rs8039638	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43342207	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs28415933	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43343602	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs12324572	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43344002	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2412780	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43363596	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2412779	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43363729	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2899082	ENSG00000249839.1	AC011330.5	-4.51	1.51e-05	0.0235	-0.54	-0.38	Lung cancer in ever smokers;	chr15:43363845	chr15:43663654~43684339:-
ESCA	cis	rs1075265	0.749	rs805375	ENSG00000235937.1	AC008280.1	4.51	1.51e-05	0.0235	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54029552~54030682:-
ESCA	cis	rs1075265	0.749	rs805380	ENSG00000235937.1	AC008280.1	4.51	1.51e-05	0.0235	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54029552~54030682:-
ESCA	cis	rs150992	0.673	rs692832	ENSG00000248489.1	CTD-2007H13.3	4.51	1.51e-05	0.0236	0.54	0.38	Body mass index;	chr5:98856761	chr5:98929171~98995013:+
ESCA	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-4.51	1.51e-05	0.0236	-0.45	-0.38	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
ESCA	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	4.51	1.51e-05	0.0236	0.51	0.38	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	4.51	1.51e-05	0.0236	0.51	0.38	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	4.51	1.51e-05	0.0236	0.51	0.38	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
ESCA	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	4.51	1.51e-05	0.0236	0.52	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	4.51	1.51e-05	0.0236	0.52	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	4.51	1.51e-05	0.0236	0.52	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
ESCA	cis	rs9601248	0.874	rs9545154	ENSG00000227676.3	LINC01068	4.51	1.52e-05	0.0236	0.47	0.38	Major depressive disorder;	chr13:79617682	chr13:79566727~79571436:+
ESCA	cis	rs9601248	0.874	rs9545155	ENSG00000227676.3	LINC01068	4.51	1.52e-05	0.0236	0.47	0.38	Major depressive disorder;	chr13:79617738	chr13:79566727~79571436:+
ESCA	cis	rs9601248	0.874	rs9545158	ENSG00000227676.3	LINC01068	4.51	1.52e-05	0.0236	0.47	0.38	Major depressive disorder;	chr13:79618771	chr13:79566727~79571436:+
ESCA	cis	rs7829975	0.56	rs56094035	ENSG00000173295.6	FAM86B3P	-4.51	1.52e-05	0.0236	-0.45	-0.38	Mood instability;	chr8:8694112	chr8:8228595~8244865:+
ESCA	cis	rs7829975	0.539	rs4841012	ENSG00000173295.6	FAM86B3P	-4.51	1.52e-05	0.0236	-0.45	-0.38	Mood instability;	chr8:8694200	chr8:8228595~8244865:+
ESCA	cis	rs1075265	0.756	rs2160931	ENSG00000235937.1	AC008280.1	4.51	1.52e-05	0.0236	0.42	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54029552~54030682:-
ESCA	cis	rs8059260	0.668	rs76212701	ENSG00000274038.1	RP11-66H6.4	-4.51	1.52e-05	0.0236	-0.69	-0.38	Alcohol consumption over the past year;	chr16:11023634	chr16:11056556~11057034:+
ESCA	cis	rs977987	0.771	rs12929673	ENSG00000261783.1	RP11-252K23.2	-4.51	1.52e-05	0.0236	-0.46	-0.38	Dupuytren's disease;	chr16:75436397	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.836	rs35209155	ENSG00000261783.1	RP11-252K23.2	-4.51	1.52e-05	0.0236	-0.46	-0.38	Dupuytren's disease;	chr16:75436598	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.836	rs8055974	ENSG00000261783.1	RP11-252K23.2	-4.51	1.52e-05	0.0236	-0.46	-0.38	Dupuytren's disease;	chr16:75437088	chr16:75379818~75381260:-
ESCA	cis	rs4407350	0.682	rs135624	ENSG00000228807.1	MRPS18CP6	4.51	1.52e-05	0.0237	0.42	0.38	Intelligence (multi-trait analysis);	chr22:44494805	chr22:44483495~44483717:-
ESCA	cis	rs2227564	0.597	rs2633305	ENSG00000229990.3	RP11-574K11.8	-4.5	1.53e-05	0.0237	-0.41	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73892365	chr10:73841833~73847115:+
ESCA	cis	rs6509942	0.626	rs420286	ENSG00000242100.2	RPL9P32	4.5	1.53e-05	0.0238	0.66	0.38	Antibody status in Tripanosoma cruzi seropositivity;	chr19:29922281	chr19:29956369~29956988:-
ESCA	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	4.5	1.53e-05	0.0238	0.42	0.38	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
ESCA	cis	rs2742234	0.59	rs2742237	ENSG00000273008.1	RP11-351D16.3	-4.5	1.53e-05	0.0238	-0.45	-0.38	Hirschsprung disease;	chr10:43125875	chr10:43136824~43138334:-
ESCA	cis	rs7535099	0.954	rs10889562	ENSG00000224570.1	RP11-430H12.2	-4.5	1.53e-05	0.0238	-0.61	-0.38	Blood protein levels;	chr1:65564762	chr1:65576129~65578380:-
ESCA	cis	rs7535099	0.909	rs72681384	ENSG00000224570.1	RP11-430H12.2	-4.5	1.53e-05	0.0238	-0.61	-0.38	Blood protein levels;	chr1:65566256	chr1:65576129~65578380:-
ESCA	cis	rs2742234	0.518	rs2505514	ENSG00000273008.1	RP11-351D16.3	-4.5	1.53e-05	0.0238	-0.44	-0.38	Hirschsprung disease;	chr10:43137800	chr10:43136824~43138334:-
ESCA	cis	rs6479901	0.793	rs10761725	ENSG00000235816.3	PRELID1P3	-4.5	1.53e-05	0.0238	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63214777	chr10:63427297~63427939:+
ESCA	cis	rs6805251	0.594	rs334535	ENSG00000276607.2	AC092910.1	4.5	1.53e-05	0.0238	0.47	0.38	HDL cholesterol levels;HDL cholesterol;	chr3:120073457	chr3:120084550~120084657:-
ESCA	cis	rs2221894	0.922	rs4732890	ENSG00000273710.1	Metazoa_SRP	-4.5	1.53e-05	0.0238	-0.4	-0.38	Obesity-related traits;	chr8:28893864	chr8:28915579~28915864:-
ESCA	cis	rs9987353	0.566	rs6998368	ENSG00000173295.6	FAM86B3P	-4.5	1.53e-05	0.0238	-0.48	-0.38	Recombination measurement;	chr8:9212778	chr8:8228595~8244865:+
ESCA	cis	rs12744310	0.887	rs17362424	ENSG00000235358.1	RP11-399E6.1	-4.5	1.53e-05	0.0238	-0.55	-0.38	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41328731	chr1:41242373~41284861:+
ESCA	cis	rs2439831	1	rs2467743	ENSG00000249839.1	AC011330.5	-4.5	1.53e-05	0.0238	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43458148	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2245176	ENSG00000249839.1	AC011330.5	-4.5	1.53e-05	0.0238	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43458564	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2245054	ENSG00000249839.1	AC011330.5	-4.5	1.53e-05	0.0238	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43459711	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs2264876	ENSG00000249839.1	AC011330.5	-4.5	1.53e-05	0.0238	-0.58	-0.38	Lung cancer in ever smokers;	chr15:43465221	chr15:43663654~43684339:-
ESCA	cis	rs9399135	0.636	rs7749106	ENSG00000232876.1	CTA-212D2.2	-4.5	1.53e-05	0.0238	-0.44	-0.38	Red blood cell count;	chr6:134947004	chr6:135055033~135060550:+
ESCA	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	4.5	1.53e-05	0.0238	0.48	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
ESCA	cis	rs7535099	1	rs1938489	ENSG00000224570.1	RP11-430H12.2	-4.5	1.53e-05	0.0239	-0.63	-0.38	Blood protein levels;	chr1:65582939	chr1:65576129~65578380:-
ESCA	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-4.5	1.54e-05	0.0239	-0.49	-0.38	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
ESCA	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	4.5	1.54e-05	0.0239	0.42	0.38	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
ESCA	cis	rs6781182	0.517	rs11712920	ENSG00000271324.1	RP11-10C24.2	4.5	1.54e-05	0.0239	0.48	0.38	Visceral adipose tissue adjusted for BMI;	chr3:34189441	chr3:33793644~33794145:-
ESCA	cis	rs765787	0.53	rs2899378	ENSG00000259520.4	CTD-2651B20.3	-4.5	1.54e-05	0.0239	-0.43	-0.38	Uric acid levels;	chr15:45245386	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs12903149	ENSG00000259520.4	CTD-2651B20.3	-4.5	1.54e-05	0.0239	-0.43	-0.38	Uric acid levels;	chr15:45246878	chr15:45251580~45279251:-
ESCA	cis	rs765787	0.53	rs3759892	ENSG00000259520.4	CTD-2651B20.3	-4.5	1.54e-05	0.0239	-0.43	-0.38	Uric acid levels;	chr15:45250511	chr15:45251580~45279251:-
ESCA	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	4.5	1.54e-05	0.0239	0.5	0.38	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	4.5	1.54e-05	0.0239	0.5	0.38	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	4.5	1.54e-05	0.0239	0.5	0.38	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
ESCA	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	4.5	1.54e-05	0.0239	0.45	0.38	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
ESCA	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.5	1.54e-05	0.0239	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-4.5	1.54e-05	0.0239	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-4.5	1.54e-05	0.0239	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-4.5	1.54e-05	0.0239	-0.67	-0.38	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
ESCA	cis	rs301901	0.581	rs10941343	ENSG00000250155.1	CTD-2353F22.1	4.5	1.54e-05	0.0239	0.38	0.38	Height;	chr5:37543239	chr5:36666214~36725195:-
ESCA	cis	rs301901	0.573	rs12652433	ENSG00000250155.1	CTD-2353F22.1	4.5	1.54e-05	0.0239	0.38	0.38	Height;	chr5:37543358	chr5:36666214~36725195:-
ESCA	cis	rs765787	0.53	rs2554456	ENSG00000259520.4	CTD-2651B20.3	4.5	1.54e-05	0.024	0.45	0.38	Uric acid levels;	chr15:45228940	chr15:45251580~45279251:-
ESCA	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	4.5	1.55e-05	0.024	0.41	0.38	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
ESCA	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-4.5	1.55e-05	0.024	-0.42	-0.38	Migraine;	chr4:56957291	chr4:56960927~56961373:-
ESCA	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	4.5	1.55e-05	0.024	0.6	0.38	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	4.5	1.55e-05	0.024	0.6	0.38	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
ESCA	cis	rs2439831	0.717	rs9806227	ENSG00000249839.1	AC011330.5	-4.5	1.55e-05	0.024	-0.55	-0.38	Lung cancer in ever smokers;	chr15:43387917	chr15:43663654~43684339:-
ESCA	cis	rs6452524	0.868	rs1564379	ENSG00000243385.2	CTD-2110K23.1	4.5	1.55e-05	0.024	0.39	0.38	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83201229~83202141:+
ESCA	cis	rs2439831	0.85	rs7163245	ENSG00000249839.1	AC011330.5	-4.5	1.55e-05	0.024	-0.55	-0.38	Lung cancer in ever smokers;	chr15:43379096	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs28729853	ENSG00000249839.1	AC011330.5	-4.5	1.55e-05	0.024	-0.55	-0.38	Lung cancer in ever smokers;	chr15:43381482	chr15:43663654~43684339:-
ESCA	cis	rs2227564	0.7	rs2688612	ENSG00000229990.3	RP11-574K11.8	-4.5	1.55e-05	0.024	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73893447	chr10:73841833~73847115:+
ESCA	cis	rs7829975	0.688	rs7817376	ENSG00000253981.4	ALG1L13P	-4.5	1.55e-05	0.0241	-0.45	-0.38	Mood instability;	chr8:8523020	chr8:8236003~8244667:-
ESCA	cis	rs75804782	0.625	rs11889723	ENSG00000265215.1	MIR4269	4.5	1.55e-05	0.0241	0.57	0.38	Chronotype;Morning vs. evening chronotype;	chr2:238562828	chr2:239305462~239305545:+
ESCA	cis	rs12534093	0.662	rs11767307	ENSG00000234286.1	AC006026.13	4.5	1.55e-05	0.0241	0.53	0.38	Infant length;Height;	chr7:23544877	chr7:23680195~23680786:-
ESCA	cis	rs2439831	1	rs527921	ENSG00000249839.1	AC011330.5	4.5	1.56e-05	0.0241	0.68	0.38	Lung cancer in ever smokers;	chr15:43478218	chr15:43663654~43684339:-
ESCA	cis	rs2307394	1	rs2113793	ENSG00000223911.1	AC009480.3	4.5	1.56e-05	0.0241	0.45	0.38	Urate levels;	chr2:147865884	chr2:147899401~147902956:-
ESCA	cis	rs1816752	0.819	rs7316961	ENSG00000273628.1	RP11-756A22.7	4.5	1.56e-05	0.0241	0.37	0.38	Obesity-related traits;	chr13:24411039	chr13:24933006~24936796:+
ESCA	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	4.5	1.56e-05	0.0242	0.5	0.38	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	4.5	1.56e-05	0.0242	0.5	0.38	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
ESCA	cis	rs1005277	0.579	rs1985707	ENSG00000276805.1	RP11-291L22.6	4.5	1.56e-05	0.0242	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38451030~38451785:+
ESCA	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	4.5	1.56e-05	0.0242	0.43	0.38	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
ESCA	cis	rs9914544	0.564	rs1859083	ENSG00000264885.1	RP11-815I9.4	4.5	1.56e-05	0.0242	0.41	0.38	Educational attainment (years of education);	chr17:18939993	chr17:18667629~18669461:-
ESCA	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-4.5	1.56e-05	0.0242	-0.47	-0.38	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-4.5	1.56e-05	0.0242	-0.47	-0.38	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
ESCA	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-4.5	1.56e-05	0.0242	-0.47	-0.38	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
ESCA	cis	rs113872281	1	rs113872281	ENSG00000279277.1	RP11-861A13.3	4.5	1.56e-05	0.0242	0.44	0.38	Pelvic organ prolapse (moderate/severe);	chr3:108934985	chr3:108036718~108038445:-
ESCA	cis	rs3820068	0.705	rs41486146	ENSG00000237301.1	RP4-680D5.2	-4.5	1.56e-05	0.0242	-0.44	-0.38	Systolic blood pressure;	chr1:15574022	chr1:15586136~15603626:-
ESCA	cis	rs11169552	0.51	rs4768852	ENSG00000200428.1	Y_RNA	4.5	1.57e-05	0.0243	0.46	0.38	Colorectal cancer;	chr12:50566506	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs10876060	ENSG00000200428.1	Y_RNA	4.5	1.57e-05	0.0243	0.46	0.38	Colorectal cancer;	chr12:50571847	chr12:50743568~50743684:+
ESCA	cis	rs11169552	0.51	rs55877451	ENSG00000200428.1	Y_RNA	4.5	1.57e-05	0.0243	0.46	0.38	Colorectal cancer;	chr12:50593595	chr12:50743568~50743684:+
ESCA	cis	rs2439831	0.764	rs2447193	ENSG00000205771.5	CATSPER2P1	-4.5	1.57e-05	0.0243	-0.63	-0.38	Lung cancer in ever smokers;	chr15:43637535	chr15:43726918~43747094:-
ESCA	cis	rs1864400	0.69	rs2565200	ENSG00000273008.1	RP11-351D16.3	-4.5	1.57e-05	0.0243	-0.45	-0.38	Hirschsprung disease;	chr10:43127485	chr10:43136824~43138334:-
ESCA	cis	rs3820716	0.507	rs7595286	ENSG00000223911.1	AC009480.3	4.5	1.57e-05	0.0243	0.46	0.38	Glomerular filtration rate (creatinine);	chr2:148146093	chr2:147899401~147902956:-
ESCA	cis	rs7535099	0.909	rs3790432	ENSG00000224570.1	RP11-430H12.2	-4.5	1.57e-05	0.0243	-0.6	-0.38	Blood protein levels;	chr1:65570056	chr1:65576129~65578380:-
ESCA	cis	rs9549260	0.755	rs1413482	ENSG00000229456.1	RLIMP1	4.5	1.57e-05	0.0243	0.35	0.38	Red blood cell count;	chr13:40644314	chr13:40618738~40621348:+
ESCA	cis	rs28830936	0.966	rs1918310	ENSG00000250379.1	RP11-23P13.4	4.5	1.58e-05	0.0244	0.43	0.38	Diastolic blood pressure;	chr15:41773055	chr15:41825099~41827936:-
ESCA	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-4.5	1.58e-05	0.0244	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-4.5	1.58e-05	0.0244	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-4.5	1.58e-05	0.0244	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-4.5	1.58e-05	0.0244	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-4.5	1.58e-05	0.0244	-0.46	-0.38	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
ESCA	cis	rs1697137	0.585	rs2545387	ENSG00000249364.4	RP11-434D9.1	4.5	1.58e-05	0.0244	0.51	0.38	Carotid atherosclerosis in HIV infection;	chr5:67092571	chr5:67379378~67805238:+
ESCA	cis	rs2739330	0.652	rs2000469	ENSG00000228039.3	KB-1125A3.10	4.5	1.58e-05	0.0244	0.49	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23963780~23964374:+
ESCA	cis	rs2280018	1	rs2280017	ENSG00000260735.1	RP11-72I8.1	4.5	1.58e-05	0.0245	0.38	0.38	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15057504	chr16:15094411~15109197:+
ESCA	cis	rs1816752	0.905	rs7995492	ENSG00000273628.1	RP11-756A22.7	4.5	1.58e-05	0.0245	0.37	0.38	Obesity-related traits;	chr13:24438885	chr13:24933006~24936796:+
ESCA	cis	rs1005277	0.557	rs1854563	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2505237	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474599	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2505240	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.54	rs2224248	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474608	ENSG00000276805.1	RP11-291L22.6	4.5	1.58e-05	0.0245	0.48	0.38	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38451030~38451785:+
ESCA	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	4.49	1.58e-05	0.0245	0.64	0.38	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
ESCA	cis	rs8099594	0.64	rs487767	ENSG00000266696.1	RP11-30L3.2	4.49	1.59e-05	0.0245	0.45	0.38	Height;	chr18:49291622	chr18:49205912~49208781:+
ESCA	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	4.49	1.59e-05	0.0245	0.5	0.38	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
ESCA	cis	rs150992	0.673	rs331934	ENSG00000248489.1	CTD-2007H13.3	-4.49	1.59e-05	0.0245	-0.57	-0.38	Body mass index;	chr5:98804016	chr5:98929171~98995013:+
ESCA	cis	rs9309711	0.621	rs7586472	ENSG00000225234.1	TRAPPC12-AS1	-4.49	1.59e-05	0.0245	-0.45	-0.38	Neurofibrillary tangles;	chr2:3469899	chr2:3481242~3482409:-
ESCA	cis	rs4407350	0.756	rs6519877	ENSG00000228807.1	MRPS18CP6	-4.49	1.59e-05	0.0246	-0.41	-0.38	Intelligence (multi-trait analysis);	chr22:44494312	chr22:44483495~44483717:-
ESCA	cis	rs6479901	0.789	rs10822146	ENSG00000235816.3	PRELID1P3	-4.49	1.59e-05	0.0246	-0.41	-0.38	Intelligence (multi-trait analysis);	chr10:63191707	chr10:63427297~63427939:+
ESCA	cis	rs736408	0.562	rs2072390	ENSG00000242797.3	GLYCTK-AS1	-4.49	1.59e-05	0.0246	-0.33	-0.38	Bipolar disorder;	chr3:52746493	chr3:52288580~52299067:-
ESCA	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	4.49	1.59e-05	0.0246	0.66	0.38	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
ESCA	cis	rs2439831	0.681	rs825740	ENSG00000249839.1	AC011330.5	-4.49	1.6e-05	0.0246	-0.57	-0.38	Lung cancer in ever smokers;	chr15:43300210	chr15:43663654~43684339:-
ESCA	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	4.49	1.6e-05	0.0247	0.52	0.38	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
ESCA	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	4.49	1.6e-05	0.0248	0.46	0.38	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
ESCA	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-4.49	1.61e-05	0.0248	-0.46	-0.38	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
ESCA	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	4.49	1.61e-05	0.0248	0.52	0.38	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
ESCA	cis	rs61990749	0.597	rs9323650	ENSG00000239272.1	RPL21P10	4.49	1.61e-05	0.0248	0.44	0.38	Fibroblast growth factor basic levels;	chr14:77683993	chr14:77683202~77683989:-
ESCA	cis	rs875971	0.862	rs1860469	ENSG00000179406.6	LINC00174	4.49	1.61e-05	0.0248	0.45	0.38	Aortic root size;	chr7:66641888	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.862	rs4718383	ENSG00000179406.6	LINC00174	4.49	1.61e-05	0.0248	0.45	0.38	Aortic root size;	chr7:66643422	chr7:66376044~66401338:-
ESCA	cis	rs2227564	0.83	rs2633322	ENSG00000229990.3	RP11-574K11.8	-4.49	1.61e-05	0.0248	-0.42	-0.38	Crohn's disease;Inflammatory bowel disease;	chr10:73934174	chr10:73841833~73847115:+
ESCA	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	4.49	1.62e-05	0.0249	0.65	0.38	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
ESCA	cis	rs9545047	0.604	rs943712	ENSG00000227676.3	LINC01068	4.49	1.62e-05	0.0249	0.5	0.38	Schizophrenia;	chr13:79282671	chr13:79566727~79571436:+
ESCA	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	4.49	1.62e-05	0.0249	0.5	0.38	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
ESCA	cis	rs2742234	0.59	rs2505557	ENSG00000273008.1	RP11-351D16.3	-4.49	1.62e-05	0.0249	-0.44	-0.38	Hirschsprung disease;	chr10:43170568	chr10:43136824~43138334:-
ESCA	cis	rs9545047	0.604	rs943711	ENSG00000227676.3	LINC01068	4.49	1.62e-05	0.025	0.5	0.38	Schizophrenia;	chr13:79282886	chr13:79566727~79571436:+
ESCA	cis	rs9545047	0.604	rs943709	ENSG00000227676.3	LINC01068	4.49	1.62e-05	0.025	0.5	0.38	Schizophrenia;	chr13:79282990	chr13:79566727~79571436:+
ESCA	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-4.49	1.62e-05	0.025	-0.76	-0.38	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
ESCA	cis	rs7283707	0.681	rs61130783	ENSG00000269950.1	AP000962.2	4.49	1.63e-05	0.0251	0.54	0.38	QRS complex (12-leadsum);	chr21:15909874	chr21:16574718~16582637:-
ESCA	cis	rs9921338	0.54	rs2868410	ENSG00000263080.1	RP11-485G7.5	4.49	1.63e-05	0.0251	0.45	0.38	Vein graft stenosis in coronary artery bypass grafting;	chr16:11334244	chr16:11341809~11345211:-
ESCA	cis	rs2739330	0.734	rs2000467	ENSG00000231271.1	AP000350.8	-4.49	1.63e-05	0.0251	-0.48	-0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23949918~23954042:+
ESCA	cis	rs2921036	0.529	rs2979192	ENSG00000253981.4	ALG1L13P	4.49	1.63e-05	0.0251	0.5	0.38	Neuroticism;	chr8:8480637	chr8:8236003~8244667:-
ESCA	cis	rs1439620	0.542	rs12900800	ENSG00000258647.4	LINC00930	4.49	1.63e-05	0.0251	0.48	0.38	Body mass index;	chr15:92969448	chr15:92567818~92572042:-
ESCA	cis	rs5769707	0.777	rs8138399	ENSG00000213279.2	RP1-29C18.9	-4.49	1.64e-05	0.0251	-0.45	-0.38	Monocyte percentage of white cells;Monocyte count;	chr22:49651176	chr22:49572264~49575426:-
ESCA	cis	rs3820068	0.655	rs59605679	ENSG00000237301.1	RP4-680D5.2	4.49	1.64e-05	0.0251	0.41	0.38	Systolic blood pressure;	chr1:15537301	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs58424111	ENSG00000237301.1	RP4-680D5.2	4.49	1.64e-05	0.0251	0.41	0.38	Systolic blood pressure;	chr1:15541975	chr1:15586136~15603626:-
ESCA	cis	rs2412819	0.545	rs3862143	ENSG00000249839.1	AC011330.5	4.49	1.64e-05	0.0252	0.71	0.38	Lung cancer;	chr15:43779282	chr15:43663654~43684339:-
ESCA	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	4.49	1.64e-05	0.0252	0.49	0.38	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	4.49	1.64e-05	0.0252	0.49	0.38	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
ESCA	cis	rs2179367	0.959	rs562428	ENSG00000216906.2	RP11-350J20.9	4.49	1.64e-05	0.0252	0.49	0.38	Dupuytren's disease;	chr6:149326389	chr6:149904243~149906418:+
ESCA	cis	rs6456156	0.792	rs2039321	ENSG00000265828.1	MIR3939	-4.49	1.64e-05	0.0252	-0.42	-0.38	Primary biliary cholangitis;	chr6:167102811	chr6:166997807~166997912:-
ESCA	cis	rs3762637	0.941	rs74467988	ENSG00000272758.4	RP11-299J3.8	-4.49	1.64e-05	0.0252	-0.47	-0.38	LDL cholesterol levels;	chr3:122364293	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.882	rs9818537	ENSG00000272758.4	RP11-299J3.8	-4.49	1.64e-05	0.0252	-0.47	-0.38	LDL cholesterol levels;	chr3:122367610	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.941	rs9863712	ENSG00000272758.4	RP11-299J3.8	-4.49	1.64e-05	0.0252	-0.47	-0.38	LDL cholesterol levels;	chr3:122381059	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.941	rs28679619	ENSG00000272758.4	RP11-299J3.8	-4.49	1.64e-05	0.0252	-0.47	-0.38	LDL cholesterol levels;	chr3:122381502	chr3:122416207~122443180:+
ESCA	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	4.49	1.64e-05	0.0252	0.47	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	4.49	1.64e-05	0.0252	0.47	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	4.49	1.64e-05	0.0252	0.47	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	4.49	1.64e-05	0.0252	0.47	0.38	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
ESCA	cis	rs287982	1	rs72780999	ENSG00000269973.1	RP11-95D17.1	-4.49	1.64e-05	0.0252	-0.48	-0.37	Nonsyndromic cleft lip with cleft palate;	chr2:9841841	chr2:9936360~9939590:+
ESCA	cis	rs3762637	1	rs7645862	ENSG00000272758.4	RP11-299J3.8	-4.49	1.65e-05	0.0252	-0.45	-0.37	LDL cholesterol levels;	chr3:122502292	chr3:122416207~122443180:+
ESCA	cis	rs17826219	0.5	rs1985572	ENSG00000263531.1	RP13-753N3.1	4.49	1.65e-05	0.0253	0.66	0.37	Body mass index;	chr17:30735725	chr17:30863921~30864940:-
ESCA	cis	rs42490	1	rs13279023	ENSG00000251136.7	RP11-37B2.1	-4.49	1.65e-05	0.0253	-0.39	-0.37	Leprosy;	chr8:89748816	chr8:89609409~89757727:-
ESCA	cis	rs10759883	0.627	rs689986	ENSG00000175611.10	LINC00476	4.49	1.65e-05	0.0253	0.42	0.37	Nicotine dependence;	chr9:95866867	chr9:95759231~95875977:-
ESCA	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	4.49	1.65e-05	0.0253	0.49	0.37	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	4.49	1.65e-05	0.0253	0.49	0.37	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	4.49	1.65e-05	0.0253	0.49	0.37	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	4.49	1.65e-05	0.0253	0.49	0.37	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	4.49	1.65e-05	0.0253	0.49	0.37	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-4.49	1.65e-05	0.0253	-0.49	-0.37	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
ESCA	cis	rs6805251	0.562	rs9879992	ENSG00000276607.2	AC092910.1	-4.48	1.65e-05	0.0253	-0.45	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:119993874	chr3:120084550~120084657:-
ESCA	cis	rs2439831	0.702	rs2467402	ENSG00000249839.1	AC011330.5	4.48	1.65e-05	0.0253	0.65	0.37	Lung cancer in ever smokers;	chr15:43732292	chr15:43663654~43684339:-
ESCA	cis	rs4747241	0.81	rs7088870	ENSG00000226163.1	RP11-167P22.3	4.48	1.65e-05	0.0253	0.44	0.37	Heschl's gyrus morphology;	chr10:72293555	chr10:72501746~72502956:+
ESCA	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	4.48	1.65e-05	0.0253	0.43	0.37	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
ESCA	cis	rs8072100	0.754	rs8081717	ENSG00000228782.6	CTD-2026D20.3	-4.48	1.66e-05	0.0254	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47576555	chr17:47450568~47492492:-
ESCA	cis	rs950880	0.553	rs2241116	ENSG00000234389.1	AC007278.3	-4.48	1.66e-05	0.0254	-0.4	-0.37	Serum protein levels (sST2);	chr2:102386805	chr2:102438713~102440475:+
ESCA	cis	rs2439831	0.867	rs4583210	ENSG00000249839.1	AC011330.5	-4.48	1.66e-05	0.0254	-0.54	-0.37	Lung cancer in ever smokers;	chr15:43368727	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.867	rs28461955	ENSG00000249839.1	AC011330.5	-4.48	1.66e-05	0.0254	-0.54	-0.37	Lung cancer in ever smokers;	chr15:43369261	chr15:43663654~43684339:-
ESCA	cis	rs8072100	0.935	rs12150231	ENSG00000228782.6	CTD-2026D20.3	-4.48	1.66e-05	0.0255	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47639725	chr17:47450568~47492492:-
ESCA	cis	rs8072100	1	rs11870935	ENSG00000228782.6	CTD-2026D20.3	-4.48	1.66e-05	0.0255	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47655239	chr17:47450568~47492492:-
ESCA	cis	rs6901004	0.805	rs354532	ENSG00000271789.1	RP5-1112D6.7	-4.48	1.66e-05	0.0255	-0.35	-0.37	Blood metabolite levels;	chr6:111227610	chr6:111297126~111298510:+
ESCA	cis	rs7283707	0.581	rs10154118	ENSG00000269950.1	AP000962.2	4.48	1.67e-05	0.0255	0.54	0.37	QRS complex (12-leadsum);	chr21:15910266	chr21:16574718~16582637:-
ESCA	cis	rs9326248	0.569	rs10047459	ENSG00000254851.1	RP11-109L13.1	-4.48	1.67e-05	0.0255	-0.56	-0.37	Blood protein levels;	chr11:116851110	chr11:117135528~117138582:+
ESCA	cis	rs7208859	0.673	rs78799101	ENSG00000263531.1	RP13-753N3.1	4.48	1.67e-05	0.0255	0.59	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30888142	chr17:30863921~30864940:-
ESCA	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	4.48	1.67e-05	0.0255	0.48	0.37	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
ESCA	cis	rs2439831	0.85	rs12442297	ENSG00000205771.5	CATSPER2P1	-4.48	1.67e-05	0.0255	-0.77	-0.37	Lung cancer in ever smokers;	chr15:43876272	chr15:43726918~43747094:-
ESCA	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	4.48	1.67e-05	0.0255	0.4	0.37	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
ESCA	cis	rs2439831	0.85	rs3816792	ENSG00000275601.1	AC011330.13	4.48	1.67e-05	0.0255	0.64	0.37	Lung cancer in ever smokers;	chr15:43824788	chr15:43642389~43643023:-
ESCA	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	4.48	1.67e-05	0.0255	0.45	0.37	Breast size;	chr12:9219433	chr12:9277235~9313241:+
ESCA	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	4.48	1.67e-05	0.0255	0.45	0.37	Breast size;	chr12:9220266	chr12:9277235~9313241:+
ESCA	cis	rs1816752	0.783	rs7317439	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24410939	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.819	rs7317504	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24411287	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.783	rs7317712	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24411365	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.783	rs7139527	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24411374	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.819	rs9511240	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24411768	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.819	rs7988388	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24412675	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.875	rs7993132	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24412903	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.792	rs7330956	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24413174	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.777	rs6490915	ENSG00000273628.1	RP11-756A22.7	4.48	1.67e-05	0.0255	0.36	0.37	Obesity-related traits;	chr13:24413724	chr13:24933006~24936796:+
ESCA	cis	rs2858942	0.78	rs2858014	ENSG00000268836.1	LA16c-OS12.2	4.48	1.67e-05	0.0256	0.39	0.37	Mean corpuscular hemoglobin;	chr16:198358	chr16:185748~186294:-
ESCA	cis	rs2858942	0.818	rs2685123	ENSG00000268836.1	LA16c-OS12.2	4.48	1.67e-05	0.0256	0.39	0.37	Mean corpuscular hemoglobin;	chr16:198419	chr16:185748~186294:-
ESCA	cis	rs11148252	0.508	rs6561671	ENSG00000235660.1	LINC00345	-4.48	1.67e-05	0.0256	-0.42	-0.37	Lewy body disease;	chr13:52608179	chr13:52484161~52484680:-
ESCA	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-4.48	1.68e-05	0.0256	-0.38	-0.37	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
ESCA	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-4.48	1.68e-05	0.0256	-0.5	-0.37	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
ESCA	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	4.48	1.68e-05	0.0256	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
ESCA	cis	rs3820716	0.507	rs4972334	ENSG00000223911.1	AC009480.3	4.48	1.68e-05	0.0256	0.45	0.37	Glomerular filtration rate (creatinine);	chr2:148185637	chr2:147899401~147902956:-
ESCA	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-4.48	1.68e-05	0.0256	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
ESCA	cis	rs9399137	0.507	rs6940878	ENSG00000232876.1	CTA-212D2.2	-4.48	1.68e-05	0.0256	-0.45	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135045171	chr6:135055033~135060550:+
ESCA	cis	rs6785206	0.554	rs35653243	ENSG00000239503.1	MARK2P8	-4.48	1.68e-05	0.0257	-0.39	-0.37	Lymphocyte percentage of white cells;	chr3:128777567	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.504	rs34992870	ENSG00000239503.1	MARK2P8	-4.48	1.68e-05	0.0257	-0.39	-0.37	Lymphocyte percentage of white cells;	chr3:128784209	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs12054283	ENSG00000239503.1	MARK2P8	-4.48	1.68e-05	0.0257	-0.39	-0.37	Lymphocyte percentage of white cells;	chr3:128786986	chr3:128748538~128749489:-
ESCA	cis	rs6785206	0.554	rs3772158	ENSG00000239503.1	MARK2P8	-4.48	1.68e-05	0.0257	-0.39	-0.37	Lymphocyte percentage of white cells;	chr3:128797299	chr3:128748538~128749489:-
ESCA	cis	rs6452524	0.836	rs62372713	ENSG00000243385.2	CTD-2110K23.1	4.48	1.68e-05	0.0257	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.868	rs62372714	ENSG00000243385.2	CTD-2110K23.1	4.48	1.68e-05	0.0257	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.868	rs17205699	ENSG00000243385.2	CTD-2110K23.1	4.48	1.68e-05	0.0257	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.868	rs10057303	ENSG00000243385.2	CTD-2110K23.1	4.48	1.68e-05	0.0257	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.868	rs2386235	ENSG00000243385.2	CTD-2110K23.1	4.48	1.68e-05	0.0257	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83201229~83202141:+
ESCA	cis	rs11169552	0.51	rs7138604	ENSG00000200428.1	Y_RNA	4.48	1.69e-05	0.0257	0.45	0.37	Colorectal cancer;	chr12:50559014	chr12:50743568~50743684:+
ESCA	cis	rs9355610	0.609	rs9366076	ENSG00000265828.1	MIR3939	4.48	1.69e-05	0.0258	0.46	0.37	Graves' disease;	chr6:166960220	chr6:166997807~166997912:-
ESCA	cis	rs8040855	0.931	rs11855471	ENSG00000259295.5	CSPG4P12	-4.48	1.69e-05	0.0258	-0.59	-0.37	Bulimia nervosa;	chr15:85175976	chr15:85191438~85213905:+
ESCA	cis	rs12712135	0.709	rs4140786	ENSG00000234389.1	AC007278.3	-4.48	1.69e-05	0.0258	-0.33	-0.37	Blood protein levels;	chr2:102471716	chr2:102438713~102440475:+
ESCA	cis	rs7849270	1	rs3124512	ENSG00000268707.1	RP11-247A12.7	4.48	1.69e-05	0.0258	0.43	0.37	Blood metabolite ratios;	chr9:129141602	chr9:129170434~129170940:+
ESCA	cis	rs7829975	0.688	rs13270194	ENSG00000253981.4	ALG1L13P	4.48	1.69e-05	0.0258	0.43	0.37	Mood instability;	chr8:8520592	chr8:8236003~8244667:-
ESCA	cis	rs6860806	0.507	rs270608	ENSG00000233006.5	AC034220.3	4.48	1.69e-05	0.0258	0.37	0.37	Breast cancer;	chr5:132312713	chr5:132311285~132369916:-
ESCA	cis	rs6558530	0.73	rs10097891	ENSG00000253982.1	CTD-2336O2.1	4.48	1.69e-05	0.0258	0.46	0.37	Systolic blood pressure;	chr8:1778643	chr8:1761990~1764502:-
ESCA	cis	rs9368849	0.527	rs3800403	ENSG00000186328.4	RP11-140K17.2	-4.48	1.69e-05	0.0258	-0.54	-0.37	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35170473	chr6:34715613~34715940:+
ESCA	cis	rs9368849	0.527	rs942375	ENSG00000186328.4	RP11-140K17.2	-4.48	1.69e-05	0.0258	-0.54	-0.37	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35173084	chr6:34715613~34715940:+
ESCA	cis	rs9368849	0.527	rs942374	ENSG00000186328.4	RP11-140K17.2	-4.48	1.69e-05	0.0258	-0.54	-0.37	Airway responsiveness in chronic obstructive pulmonary disease;	chr6:35176115	chr6:34715613~34715940:+
ESCA	cis	rs6456156	0.967	rs150108	ENSG00000265828.1	MIR3939	-4.48	1.69e-05	0.0258	-0.42	-0.37	Primary biliary cholangitis;	chr6:167099665	chr6:166997807~166997912:-
ESCA	cis	rs12682352	0.652	rs1567398	ENSG00000253981.4	ALG1L13P	-4.48	1.7e-05	0.0259	-0.43	-0.37	Neuroticism;	chr8:8869294	chr8:8236003~8244667:-
ESCA	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-4.48	1.7e-05	0.0259	-0.48	-0.37	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
ESCA	cis	rs394563	0.69	rs237010	ENSG00000231760.4	RP11-350J20.5	4.48	1.7e-05	0.0259	0.47	0.37	Dupuytren's disease;	chr6:149437614	chr6:149796151~149826294:-
ESCA	cis	rs2412819	0.545	rs35822148	ENSG00000249839.1	AC011330.5	-4.48	1.7e-05	0.0259	-0.73	-0.37	Lung cancer;	chr15:43808084	chr15:43663654~43684339:-
ESCA	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-4.48	1.7e-05	0.0259	-0.46	-0.37	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
ESCA	cis	rs7829975	0.902	rs777707	ENSG00000253981.4	ALG1L13P	4.48	1.7e-05	0.0259	0.42	0.37	Mood instability;	chr8:8726834	chr8:8236003~8244667:-
ESCA	cis	rs11235843	0.929	rs11235864	ENSG00000255928.1	RP11-456I15.2	-4.48	1.7e-05	0.0259	-0.55	-0.37	Hand grip strength;	chr11:73697227	chr11:73722349~73722694:+
ESCA	cis	rs61160187	0.582	rs12652830	ENSG00000215032.2	GNL3LP1	4.48	1.7e-05	0.0259	0.48	0.37	Educational attainment (years of education);Educational attainment (college completion);	chr5:60956655	chr5:60891935~60893577:-
ESCA	cis	rs61160187	0.582	rs4700402	ENSG00000215032.2	GNL3LP1	4.48	1.7e-05	0.0259	0.48	0.37	Educational attainment (years of education);Educational attainment (college completion);	chr5:60966220	chr5:60891935~60893577:-
ESCA	cis	rs3820068	0.705	rs57971278	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15512109	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.655	rs11587521	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15512711	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs16851727	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15531423	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs74054769	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15533652	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs72645803	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15541737	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs72645804	ENSG00000237301.1	RP4-680D5.2	4.48	1.71e-05	0.026	0.41	0.37	Systolic blood pressure;	chr1:15541892	chr1:15586136~15603626:-
ESCA	cis	rs11235843	0.853	rs11235925	ENSG00000255928.1	RP11-456I15.2	4.48	1.71e-05	0.026	0.63	0.37	Hand grip strength;	chr11:73841598	chr11:73722349~73722694:+
ESCA	cis	rs8003054	0.616	rs12050102	ENSG00000258515.1	RP11-203M5.7	4.48	1.71e-05	0.026	0.34	0.37	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20442073	chr14:20451305~20451918:+
ESCA	cis	rs8040855	0.825	rs4843021	ENSG00000259295.5	CSPG4P12	-4.48	1.71e-05	0.026	-0.6	-0.37	Bulimia nervosa;	chr15:85151317	chr15:85191438~85213905:+
ESCA	cis	rs7208859	0.573	rs56031503	ENSG00000263531.1	RP13-753N3.1	4.48	1.71e-05	0.026	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748647	chr17:30863921~30864940:-
ESCA	cis	rs1005277	0.579	rs2983343	ENSG00000263064.2	RP11-291L22.7	4.48	1.71e-05	0.026	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38094404	chr10:38448689~38448949:+
ESCA	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	4.48	1.71e-05	0.026	0.48	0.37	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
ESCA	cis	rs9399137	0.507	rs61738647	ENSG00000232876.1	CTA-212D2.2	-4.48	1.71e-05	0.026	-0.45	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134961597	chr6:135055033~135060550:+
ESCA	cis	rs9399135	0.527	rs61738492	ENSG00000232876.1	CTA-212D2.2	-4.48	1.71e-05	0.026	-0.45	-0.37	Red blood cell count;	chr6:134961633	chr6:135055033~135060550:+
ESCA	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-4.48	1.71e-05	0.026	-0.46	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
ESCA	cis	rs7208859	0.614	rs9914534	ENSG00000263531.1	RP13-753N3.1	4.48	1.71e-05	0.0261	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30875646	chr17:30863921~30864940:-
ESCA	cis	rs8003054	0.616	rs17277375	ENSG00000258515.1	RP11-203M5.7	4.47	1.72e-05	0.0262	0.34	0.37	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20441313	chr14:20451305~20451918:+
ESCA	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-4.47	1.72e-05	0.0262	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
ESCA	cis	rs10954779	0.764	rs2725364	ENSG00000253579.1	SUMO2P16	-4.47	1.73e-05	0.0262	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:31142496	chr8:31131539~31131802:-
ESCA	cis	rs7301016	0.846	rs17732182	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62632351	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs11174575	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62632612	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs11174576	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62632656	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs12367878	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62633703	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs73126024	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62633984	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs12369751	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62637353	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs7296573	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62639261	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs7297093	ENSG00000257568.1	RP11-863H1.1	4.47	1.73e-05	0.0263	0.48	0.37	IgG glycosylation;	chr12:62639607	chr12:62482349~62484932:-
ESCA	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	4.47	1.73e-05	0.0263	0.44	0.37	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
ESCA	cis	rs2742234	0.955	rs2435385	ENSG00000273008.1	RP11-351D16.3	-4.47	1.73e-05	0.0263	-0.43	-0.37	Hirschsprung disease;	chr10:43170302	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.955	rs2503849	ENSG00000273008.1	RP11-351D16.3	-4.47	1.73e-05	0.0263	-0.43	-0.37	Hirschsprung disease;	chr10:43177328	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.955	rs2435384	ENSG00000273008.1	RP11-351D16.3	-4.47	1.73e-05	0.0263	-0.43	-0.37	Hirschsprung disease;	chr10:43178283	chr10:43136824~43138334:-
ESCA	cis	rs7535099	1	rs3790426	ENSG00000224570.1	RP11-430H12.2	-4.47	1.73e-05	0.0263	-0.56	-0.37	Blood protein levels;	chr1:65577336	chr1:65576129~65578380:-
ESCA	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-4.47	1.74e-05	0.0264	-0.41	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
ESCA	cis	rs4345206	0.604	rs17020769	ENSG00000250673.1	RP11-6L6.2	4.47	1.74e-05	0.0264	0.38	0.37	Coronary artery disease;	chr4:145879770	chr4:146224557~146229056:+
ESCA	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	4.47	1.74e-05	0.0265	0.5	0.37	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
ESCA	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	4.47	1.75e-05	0.0265	0.57	0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
ESCA	cis	rs12022452	0.908	rs4660423	ENSG00000229901.1	RP11-399E6.4	4.47	1.75e-05	0.0265	0.45	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40554632	chr1:41375004~41375669:-
ESCA	cis	rs9462027	0.54	rs9366863	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34721169	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs10947521	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34721600	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9380455	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34723001	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs6929567	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34724958	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs10807141	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34725334	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs10738078	ENSG00000186328.4	RP11-140K17.2	-4.47	1.75e-05	0.0265	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34726140	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.606	rs4513788	ENSG00000186328.4	RP11-140K17.2	4.47	1.75e-05	0.0265	0.41	0.37	Systemic lupus erythematosus;	chr6:34727002	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.54	rs2814951	ENSG00000186328.4	RP11-140K17.2	4.47	1.75e-05	0.0265	0.41	0.37	Systemic lupus erythematosus;	chr6:34727304	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.675	rs13206387	ENSG00000186328.4	RP11-140K17.2	4.47	1.75e-05	0.0265	0.41	0.37	Systemic lupus erythematosus;	chr6:34729015	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814953	ENSG00000186328.4	RP11-140K17.2	4.47	1.75e-05	0.0265	0.41	0.37	Systemic lupus erythematosus;	chr6:34729990	chr6:34715613~34715940:+
ESCA	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	4.47	1.75e-05	0.0265	0.49	0.37	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
ESCA	cis	rs11235843	0.929	rs4944032	ENSG00000255928.1	RP11-456I15.2	-4.47	1.75e-05	0.0265	-0.61	-0.37	Hand grip strength;	chr11:73702076	chr11:73722349~73722694:+
ESCA	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	4.47	1.75e-05	0.0266	0.46	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
ESCA	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	4.47	1.76e-05	0.0266	0.43	0.37	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
ESCA	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-4.47	1.76e-05	0.0267	-0.43	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
ESCA	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	4.47	1.76e-05	0.0267	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	4.47	1.76e-05	0.0267	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	4.47	1.76e-05	0.0267	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	4.47	1.76e-05	0.0267	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
ESCA	cis	rs2439831	0.681	rs484029	ENSG00000249839.1	AC011330.5	-4.47	1.76e-05	0.0267	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43327362	chr15:43663654~43684339:-
ESCA	cis	rs1075265	0.655	rs13432632	ENSG00000235937.1	AC008280.1	4.47	1.76e-05	0.0267	0.42	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54029552~54030682:-
ESCA	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0267	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0267	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
ESCA	cis	rs394563	0.591	rs805026	ENSG00000231760.4	RP11-350J20.5	4.47	1.77e-05	0.0268	0.44	0.37	Dupuytren's disease;	chr6:149407118	chr6:149796151~149826294:-
ESCA	cis	rs394563	0.591	rs237012	ENSG00000231760.4	RP11-350J20.5	4.47	1.77e-05	0.0268	0.44	0.37	Dupuytren's disease;	chr6:149408062	chr6:149796151~149826294:-
ESCA	cis	rs8062405	0.723	rs113208333	ENSG00000278665.1	RP11-666O2.4	4.47	1.77e-05	0.0268	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.691	rs743590	ENSG00000278665.1	RP11-666O2.4	4.47	1.77e-05	0.0268	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28599241~28601881:-
ESCA	cis	rs11235843	0.929	rs11235844	ENSG00000255928.1	RP11-456I15.2	4.47	1.77e-05	0.0268	0.59	0.37	Hand grip strength;	chr11:73668030	chr11:73722349~73722694:+
ESCA	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0268	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0268	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0268	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0268	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	4.47	1.77e-05	0.0268	0.45	0.37	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
ESCA	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	4.47	1.77e-05	0.0268	0.67	0.37	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
ESCA	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	4.47	1.77e-05	0.0268	0.67	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
ESCA	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	4.47	1.77e-05	0.0268	0.67	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
ESCA	cis	rs2455601	0.882	rs11042115	ENSG00000254860.4	TMEM9B-AS1	4.47	1.78e-05	0.0269	0.59	0.37	Schizophrenia;	chr11:8905132	chr11:8964675~8977527:+
ESCA	cis	rs2455601	0.882	rs11042116	ENSG00000254860.4	TMEM9B-AS1	4.47	1.78e-05	0.0269	0.59	0.37	Schizophrenia;	chr11:8906925	chr11:8964675~8977527:+
ESCA	cis	rs9399137	0.507	rs6904897	ENSG00000232876.1	CTA-212D2.2	-4.47	1.78e-05	0.0269	-0.46	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135061842	chr6:135055033~135060550:+
ESCA	cis	rs11235843	0.778	rs4944861	ENSG00000255928.1	RP11-456I15.2	4.47	1.78e-05	0.0269	0.61	0.37	Hand grip strength;	chr11:73719460	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.929	rs67488767	ENSG00000255928.1	RP11-456I15.2	4.47	1.78e-05	0.0269	0.61	0.37	Hand grip strength;	chr11:73721644	chr11:73722349~73722694:+
ESCA	cis	rs7017914	0.628	rs2380691	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70872942	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs6998354	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70873934	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.644	rs12156377	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70875457	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs1908032	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70876735	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs7003788	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70876889	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.628	rs13272343	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70882272	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs6984618	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70883334	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.69	rs12675094	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70884968	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.628	rs12675116	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70885056	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs13252230	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70886081	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs6996049	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70887771	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.629	rs35762981	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70889405	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs7841286	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70890908	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs13271286	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.44	-0.37	Bone mineral density;	chr8:70894364	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs7814774	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.43	-0.37	Bone mineral density;	chr8:70934881	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs62506898	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.43	-0.37	Bone mineral density;	chr8:70935267	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs17689989	ENSG00000253173.3	RP11-152C15.1	-4.47	1.79e-05	0.027	-0.43	-0.37	Bone mineral density;	chr8:70936769	chr8:70103798~70104179:-
ESCA	cis	rs2005	0.582	rs9394287	ENSG00000186328.4	RP11-140K17.2	4.46	1.79e-05	0.027	0.65	0.37	Obesity-related traits;	chr6:35248963	chr6:34715613~34715940:+
ESCA	cis	rs9987353	0.519	rs13276350	ENSG00000173295.6	FAM86B3P	-4.46	1.79e-05	0.027	-0.47	-0.37	Recombination measurement;	chr8:9205647	chr8:8228595~8244865:+
ESCA	cis	rs10027350	0.757	rs4459977	ENSG00000271172.1	RP11-660M5.1	4.46	1.79e-05	0.027	0.41	0.37	Childhood ear infection;	chr4:25183937	chr4:25220403~25220913:+
ESCA	cis	rs6867032	0.695	rs3902820	ENSG00000249731.1	RP11-259O2.3	-4.46	1.79e-05	0.027	-0.3	-0.37	Gut microbiome composition (winter);	chr5:2000216	chr5:1968094~1969013:+
ESCA	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	4.46	1.8e-05	0.0271	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
ESCA	cis	rs4345206	0.639	rs1507928	ENSG00000250673.1	RP11-6L6.2	-4.46	1.8e-05	0.0271	-0.38	-0.37	Coronary artery disease;	chr4:145866883	chr4:146224557~146229056:+
ESCA	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	4.46	1.8e-05	0.0271	0.52	0.37	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	4.46	1.8e-05	0.0271	0.52	0.37	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
ESCA	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	4.46	1.8e-05	0.0271	0.63	0.37	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
ESCA	cis	rs4664293	0.801	rs7590595	ENSG00000226266.5	AC009961.3	-4.46	1.8e-05	0.0271	-0.45	-0.37	Monocyte percentage of white cells;	chr2:159715198	chr2:159670708~159712435:-
ESCA	cis	rs4664293	0.801	rs6432552	ENSG00000226266.5	AC009961.3	-4.46	1.8e-05	0.0271	-0.45	-0.37	Monocyte percentage of white cells;	chr2:159717613	chr2:159670708~159712435:-
ESCA	cis	rs4664293	0.801	rs7589771	ENSG00000226266.5	AC009961.3	-4.46	1.8e-05	0.0271	-0.45	-0.37	Monocyte percentage of white cells;	chr2:159727621	chr2:159670708~159712435:-
ESCA	cis	rs12712135	0.709	rs11676236	ENSG00000234389.1	AC007278.3	-4.46	1.8e-05	0.0271	-0.33	-0.37	Blood protein levels;	chr2:102465235	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.677	rs11687013	ENSG00000234389.1	AC007278.3	-4.46	1.8e-05	0.0271	-0.33	-0.37	Blood protein levels;	chr2:102465261	chr2:102438713~102440475:+
ESCA	cis	rs1577917	0.687	rs13197828	ENSG00000203875.9	SNHG5	-4.46	1.8e-05	0.0271	-0.52	-0.37	Response to antipsychotic treatment;	chr6:86095912	chr6:85660950~85678736:-
ESCA	cis	rs4345206	0.589	rs10003835	ENSG00000250673.1	RP11-6L6.2	-4.46	1.8e-05	0.0271	-0.38	-0.37	Coronary artery disease;	chr4:145888839	chr4:146224557~146229056:+
ESCA	cis	rs4345206	0.589	rs10006310	ENSG00000250673.1	RP11-6L6.2	-4.46	1.8e-05	0.0271	-0.38	-0.37	Coronary artery disease;	chr4:145888846	chr4:146224557~146229056:+
ESCA	cis	rs9549260	0.755	rs9532579	ENSG00000229456.1	RLIMP1	4.46	1.8e-05	0.0272	0.35	0.37	Red blood cell count;	chr13:40669321	chr13:40618738~40621348:+
ESCA	cis	rs1005277	0.579	rs2472183	ENSG00000263064.2	RP11-291L22.7	4.46	1.8e-05	0.0272	0.51	0.37	Extrinsic epigenetic age acceleration;	chr10:38103567	chr10:38448689~38448949:+
ESCA	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-4.46	1.81e-05	0.0272	-0.37	-0.37	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
ESCA	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-4.46	1.81e-05	0.0272	-0.38	-0.37	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
ESCA	cis	rs7208859	0.573	rs55661352	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30718610	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs8075357	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Body mass index;	chr17:30730179	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs59447372	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30730567	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs61643715	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Body mass index;	chr17:30730744	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.636	rs8080829	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Body mass index;	chr17:30731712	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8079891	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30731845	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73267858	ENSG00000263531.1	RP13-753N3.1	4.46	1.81e-05	0.0272	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732719	chr17:30863921~30864940:-
ESCA	cis	rs4535700	0.501	rs10245725	ENSG00000273720.1	RP11-613E4.4	-4.46	1.81e-05	0.0272	-0.45	-0.37	Macular telangiectasia type 2;	chr7:55908855	chr7:55743073~55743457:+
ESCA	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	4.46	1.81e-05	0.0272	0.51	0.37	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
ESCA	cis	rs7120118	0.517	rs12575157	ENSG00000271557.1	YPEL5P2	4.46	1.81e-05	0.0273	0.63	0.37	HDL cholesterol;	chr11:47251195	chr11:47841324~47841682:+
ESCA	cis	rs11118620	0.853	rs11118622	ENSG00000272823.1	RP11-295M18.6	4.46	1.81e-05	0.0273	0.44	0.37	Heart failure;	chr1:220868833	chr1:220828676~220829211:-
ESCA	cis	rs2227564	0.729	rs2675674	ENSG00000229990.3	RP11-574K11.8	-4.46	1.82e-05	0.0273	-0.41	-0.37	Crohn's disease;Inflammatory bowel disease;	chr10:73892924	chr10:73841833~73847115:+
ESCA	cis	rs6479891	1	rs9415680	ENSG00000235816.3	PRELID1P3	-4.46	1.82e-05	0.0273	-0.49	-0.37	Arthritis (juvenile idiopathic);	chr10:63261130	chr10:63427297~63427939:+
ESCA	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-4.46	1.82e-05	0.0274	-0.46	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
ESCA	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-4.46	1.82e-05	0.0274	-0.46	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
ESCA	cis	rs9462027	0.651	rs9469870	ENSG00000186328.4	RP11-140K17.2	4.46	1.82e-05	0.0274	0.41	0.37	Systemic lupus erythematosus;	chr6:34776572	chr6:34715613~34715940:+
ESCA	cis	rs6867032	0.834	rs4526149	ENSG00000249731.1	RP11-259O2.3	-4.46	1.83e-05	0.0275	-0.3	-0.37	Gut microbiome composition (winter);	chr5:1990052	chr5:1968094~1969013:+
ESCA	cis	rs394563	0.726	rs6922130	ENSG00000231760.4	RP11-350J20.5	-4.46	1.83e-05	0.0275	-0.43	-0.37	Dupuytren's disease;	chr6:149351239	chr6:149796151~149826294:-
ESCA	cis	rs7208859	0.673	rs9912122	ENSG00000263531.1	RP13-753N3.1	4.46	1.83e-05	0.0275	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813698	chr17:30863921~30864940:-
ESCA	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-4.46	1.83e-05	0.0275	-0.41	-0.37	Migraine;	chr4:56950140	chr4:56960927~56961373:-
ESCA	cis	rs7412746	0.658	rs6677420	ENSG00000206931.1	RNU6-1042P	4.46	1.83e-05	0.0275	0.47	0.37	Melanoma;	chr1:150974014	chr1:150701866~150701972:+
ESCA	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	4.46	1.83e-05	0.0275	0.41	0.37	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
ESCA	cis	rs3136516	0.696	rs10838611	ENSG00000271350.1	CTD-2384B9.1	-4.46	1.84e-05	0.0276	-0.42	-0.37	Venous thromboembolism;	chr11:46675649	chr11:47041027~47041945:-
ESCA	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-4.46	1.84e-05	0.0276	-0.48	-0.37	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
ESCA	cis	rs9399135	0.622	rs3817776	ENSG00000232876.1	CTA-212D2.2	4.46	1.84e-05	0.0276	0.42	0.37	Red blood cell count;	chr6:134935618	chr6:135055033~135060550:+
ESCA	cis	rs2439831	0.681	rs528517	ENSG00000249839.1	AC011330.5	-4.46	1.84e-05	0.0276	-0.54	-0.37	Lung cancer in ever smokers;	chr15:43320727	chr15:43663654~43684339:-
ESCA	cis	rs765787	0.53	rs2899379	ENSG00000259520.4	CTD-2651B20.3	-4.46	1.84e-05	0.0276	-0.43	-0.37	Uric acid levels;	chr15:45242601	chr15:45251580~45279251:-
ESCA	cis	rs2221894	0.511	rs11782284	ENSG00000273710.1	Metazoa_SRP	-4.46	1.84e-05	0.0276	-0.4	-0.37	Obesity-related traits;	chr8:28888807	chr8:28915579~28915864:-
ESCA	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-4.46	1.84e-05	0.0276	-0.43	-0.37	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
ESCA	cis	rs7826238	0.601	rs2976907	ENSG00000173295.6	FAM86B3P	4.46	1.84e-05	0.0276	0.48	0.37	Systolic blood pressure;	chr8:8487658	chr8:8228595~8244865:+
ESCA	cis	rs7826238	0.601	rs2979206	ENSG00000173295.6	FAM86B3P	4.46	1.84e-05	0.0276	0.48	0.37	Systolic blood pressure;	chr8:8488071	chr8:8228595~8244865:+
ESCA	cis	rs394563	0.726	rs366905	ENSG00000231760.4	RP11-350J20.5	4.46	1.84e-05	0.0276	0.43	0.37	Dupuytren's disease;	chr6:149413961	chr6:149796151~149826294:-
ESCA	cis	rs1723838	0.826	rs1670560	ENSG00000255928.1	RP11-456I15.2	4.46	1.84e-05	0.0277	0.86	0.37	Obesity-related traits;	chr11:73889122	chr11:73722349~73722694:+
ESCA	cis	rs17826219	0.585	rs8064302	ENSG00000212190.1	RNU6-298P	-4.46	1.85e-05	0.0277	-0.74	-0.37	Body mass index;	chr17:30397920	chr17:30861843~30861938:+
ESCA	cis	rs11169552	0.51	rs10876043	ENSG00000200428.1	Y_RNA	-4.46	1.85e-05	0.0277	-0.59	-0.37	Colorectal cancer;	chr12:50510361	chr12:50743568~50743684:+
ESCA	cis	rs6724465	0.852	rs12471419	ENSG00000272644.1	RP11-33O4.1	4.46	1.85e-05	0.0277	0.63	0.37	Height;	chr2:219043903	chr2:219069354~219069809:-
ESCA	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	4.46	1.85e-05	0.0277	0.44	0.37	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
ESCA	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	4.46	1.85e-05	0.0277	0.44	0.37	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
ESCA	cis	rs7208859	0.673	rs2470251	ENSG00000263531.1	RP13-753N3.1	4.46	1.85e-05	0.0277	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30768043	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11652370	ENSG00000263531.1	RP13-753N3.1	4.46	1.85e-05	0.0277	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770205	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs56846352	ENSG00000263531.1	RP13-753N3.1	4.46	1.85e-05	0.0277	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792170	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs7211776	ENSG00000263531.1	RP13-753N3.1	4.46	1.85e-05	0.0277	0.53	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793178	chr17:30863921~30864940:-
ESCA	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	4.46	1.85e-05	0.0277	0.52	0.37	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
ESCA	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	4.46	1.85e-05	0.0277	0.63	0.37	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
ESCA	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	4.46	1.86e-05	0.0278	0.61	0.37	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
ESCA	cis	rs10954779	0.515	rs1425296	ENSG00000253579.1	SUMO2P16	-4.46	1.86e-05	0.0278	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:31114472	chr8:31131539~31131802:-
ESCA	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-4.46	1.86e-05	0.0278	-0.45	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
ESCA	cis	rs12480328	0.681	rs73909843	ENSG00000228663.1	PSMD10P1	4.45	1.86e-05	0.0278	0.43	0.37	Prostate cancer;	chr20:50938227	chr20:50913731~50914411:+
ESCA	cis	rs12480328	0.681	rs6096198	ENSG00000228663.1	PSMD10P1	4.45	1.86e-05	0.0278	0.43	0.37	Prostate cancer;	chr20:50941708	chr20:50913731~50914411:+
ESCA	cis	rs12480328	0.681	rs56165102	ENSG00000228663.1	PSMD10P1	4.45	1.86e-05	0.0278	0.43	0.37	Prostate cancer;	chr20:50942889	chr20:50913731~50914411:+
ESCA	cis	rs7208859	0.673	rs11656462	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30833682	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs17826219	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30834827	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11655623	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30835155	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs61223749	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30836729	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs3764420	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837136	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11654331	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30837999	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs3764421	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30840635	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11651858	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30843700	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs36056619	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30845266	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9909497	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30846210	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11080135	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30849463	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs73277960	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30850423	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73277964	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30852183	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9894876	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855002	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11652409	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30855689	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73277967	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30857148	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs60020217	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30858036	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9896095	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30860479	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs73277974	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30862851	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73277978	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864431	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs58920731	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30864728	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs9905827	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Body mass index;	chr17:30865150	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11657391	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30867269	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73277984	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869115	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73277986	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869179	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs58089675	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30869746	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs12103588	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30870442	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73263755	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30871954	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9899349	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30873104	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs4131618	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30877783	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11652358	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30878462	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11656845	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30879146	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs11658344	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30880727	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9891179	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881142	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9891413	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881191	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9900144	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30881371	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs73263776	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30884313	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11650271	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30886925	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs11656121	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887025	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11650973	ENSG00000263531.1	RP13-753N3.1	4.45	1.86e-05	0.0278	0.58	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30887027	chr17:30863921~30864940:-
ESCA	cis	rs2991971	0.747	rs2492841	ENSG00000280836.1	AL355480.1	-4.45	1.86e-05	0.0278	-0.4	-0.37	High light scatter reticulocyte count;	chr1:45429219	chr1:45581219~45581321:-
ESCA	cis	rs172639	0.812	rs2776288	ENSG00000263969.2	RN7SL678P	4.45	1.87e-05	0.0278	0.41	0.37	Urinary electrolytes (magnesium/calcium ratio);	chr21:36446573	chr21:37215605~37215903:+
ESCA	cis	rs4835265	0.929	rs7658706	ENSG00000250673.1	RP11-6L6.2	-4.45	1.87e-05	0.0278	-0.47	-0.37	Gamma glutamyl transpeptidase;	chr4:145884190	chr4:146224557~146229056:+
ESCA	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	4.45	1.87e-05	0.0279	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
ESCA	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	4.45	1.87e-05	0.0279	0.62	0.37	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
ESCA	cis	rs6479901	0.894	rs7098614	ENSG00000235816.3	PRELID1P3	-4.45	1.87e-05	0.0279	-0.41	-0.37	Intelligence (multi-trait analysis);	chr10:63355667	chr10:63427297~63427939:+
ESCA	cis	rs28830936	0.966	rs2303518	ENSG00000250379.1	RP11-23P13.4	4.45	1.87e-05	0.0279	0.42	0.37	Diastolic blood pressure;	chr15:41817777	chr15:41825099~41827936:-
ESCA	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-4.45	1.88e-05	0.0279	-0.45	-0.37	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
ESCA	cis	rs2439831	0.85	rs7169988	ENSG00000224677.1	PDIA3P2	-4.45	1.88e-05	0.0279	-0.58	-0.37	Lung cancer in ever smokers;	chr15:43768237	chr15:43649123~43649280:+
ESCA	cis	rs950880	0.553	rs3755272	ENSG00000234389.1	AC007278.3	-4.45	1.88e-05	0.028	-0.4	-0.37	Serum protein levels (sST2);	chr2:102417365	chr2:102438713~102440475:+
ESCA	cis	rs950880	0.553	rs2293225	ENSG00000234389.1	AC007278.3	-4.45	1.88e-05	0.028	-0.4	-0.37	Serum protein levels (sST2);	chr2:102419429	chr2:102438713~102440475:+
ESCA	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	4.45	1.88e-05	0.028	0.5	0.37	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	4.45	1.88e-05	0.028	0.5	0.37	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
ESCA	cis	rs42490	1	rs2735873	ENSG00000251136.7	RP11-37B2.1	4.45	1.88e-05	0.028	0.38	0.37	Leprosy;	chr8:89737748	chr8:89609409~89757727:-
ESCA	cis	rs42490	0.966	rs2644033	ENSG00000251136.7	RP11-37B2.1	4.45	1.88e-05	0.028	0.38	0.37	Leprosy;	chr8:89739196	chr8:89609409~89757727:-
ESCA	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-4.45	1.88e-05	0.028	-0.4	-0.37	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
ESCA	cis	rs4881147	1	rs4881147	ENSG00000278419.1	RP11-298E9.7	-4.45	1.88e-05	0.028	-0.47	-0.37	Scalp hair shape;	chr10:3300582	chr10:3134566~3145166:+
ESCA	cis	rs2227564	0.729	rs2633304	ENSG00000229990.3	RP11-574K11.8	-4.45	1.88e-05	0.028	-0.41	-0.37	Crohn's disease;Inflammatory bowel disease;	chr10:73890892	chr10:73841833~73847115:+
ESCA	cis	rs2227564	0.729	rs2688616	ENSG00000229990.3	RP11-574K11.8	-4.45	1.88e-05	0.028	-0.41	-0.37	Crohn's disease;Inflammatory bowel disease;	chr10:73890894	chr10:73841833~73847115:+
ESCA	cis	rs2688482	0.512	rs882605	ENSG00000207650.1	MIR570	4.45	1.89e-05	0.0281	0.53	0.37	Lung disease severity in cystic fibrosis;	chr3:195790682	chr3:195699401~195699497:+
ESCA	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-4.45	1.89e-05	0.0281	-0.35	-0.37	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
ESCA	cis	rs10875746	0.625	rs2898065	ENSG00000240399.1	RP1-228P16.1	-4.45	1.89e-05	0.0281	-0.45	-0.37	Longevity (90 years and older);	chr12:48250836	chr12:48054813~48055591:-
ESCA	cis	rs2098713	0.569	rs56264101	ENSG00000250155.1	CTD-2353F22.1	4.45	1.89e-05	0.0281	0.42	0.37	Telomere length;	chr5:37540792	chr5:36666214~36725195:-
ESCA	cis	rs2098713	0.569	rs55716037	ENSG00000250155.1	CTD-2353F22.1	4.45	1.89e-05	0.0281	0.42	0.37	Telomere length;	chr5:37540805	chr5:36666214~36725195:-
ESCA	cis	rs4927850	1	rs7625570	ENSG00000231464.1	AC024937.4	4.45	1.9e-05	0.0282	0.45	0.37	Pancreatic cancer;	chr3:196020527	chr3:195996738~195998233:+
ESCA	cis	rs4927850	0.881	rs7624638	ENSG00000231464.1	AC024937.4	4.45	1.9e-05	0.0282	0.45	0.37	Pancreatic cancer;	chr3:196021858	chr3:195996738~195998233:+
ESCA	cis	rs4927850	1	rs10881564	ENSG00000231464.1	AC024937.4	4.45	1.9e-05	0.0282	0.45	0.37	Pancreatic cancer;	chr3:196023455	chr3:195996738~195998233:+
ESCA	cis	rs10875746	0.551	rs11168536	ENSG00000240399.1	RP1-228P16.1	-4.45	1.9e-05	0.0282	-0.46	-0.37	Longevity (90 years and older);	chr12:48351268	chr12:48054813~48055591:-
ESCA	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	4.45	1.9e-05	0.0282	0.42	0.37	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
ESCA	cis	rs9462027	0.628	rs2814957	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34734912	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2477507	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34735822	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2764197	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34737278	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2492860	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34737753	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814959	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34738170	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2764198	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34738351	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814961	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34739174	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.539	rs2814963	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34741131	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9462006	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34742550	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs6906759	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34775213	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.63	rs9469871	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34777230	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs11759151	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34779826	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9462020	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34783488	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.651	rs34493158	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34785562	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.651	rs9469885	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34790939	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469887	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34791163	chr6:34715613~34715940:+
ESCA	cis	rs2764208	0.576	rs6457791	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34792177	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs7752060	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34792548	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs7752522	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34792806	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs998278	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34797807	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469892	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34801324	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs6921363	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34803043	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469894	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34806948	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs66506671	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34809372	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.675	rs9296132	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34809754	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2038839	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34810014	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs1543558	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34816594	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.651	rs7752390	ENSG00000186328.4	RP11-140K17.2	4.45	1.9e-05	0.0282	0.41	0.37	Systemic lupus erythematosus;	chr6:34822847	chr6:34715613~34715940:+
ESCA	cis	rs6479901	0.947	rs10740123	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63404755	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10995530	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63419654	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.841	rs72837019	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63427258	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10761764	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63429143	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10761767	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63432671	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.846	rs7917169	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63433181	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10761768	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63434369	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.895	rs10822172	ENSG00000235816.3	PRELID1P3	-4.45	1.9e-05	0.0282	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63455478	chr10:63427297~63427939:+
ESCA	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-4.45	1.9e-05	0.0282	-0.45	-0.37	Height;	chr11:118791319	chr11:118704607~118750263:+
ESCA	cis	rs611744	0.816	rs626211	ENSG00000253754.1	RP11-35G22.1	-4.45	1.9e-05	0.0282	-0.35	-0.37	Dupuytren's disease;	chr8:108177219	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs650925	ENSG00000253754.1	RP11-35G22.1	-4.45	1.9e-05	0.0282	-0.35	-0.37	Dupuytren's disease;	chr8:108184496	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs2212703	ENSG00000253754.1	RP11-35G22.1	-4.45	1.9e-05	0.0282	-0.35	-0.37	Dupuytren's disease;	chr8:108186172	chr8:108226200~108227544:+
ESCA	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-4.45	1.91e-05	0.0282	-0.48	-0.37	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
ESCA	cis	rs2742234	0.541	rs7073849	ENSG00000273008.1	RP11-351D16.3	4.45	1.91e-05	0.0283	0.43	0.37	Hirschsprung disease;	chr10:43245026	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs7098236	ENSG00000273008.1	RP11-351D16.3	4.45	1.91e-05	0.0283	0.43	0.37	Hirschsprung disease;	chr10:43245060	chr10:43136824~43138334:-
ESCA	cis	rs1864400	0.69	rs7098237	ENSG00000273008.1	RP11-351D16.3	4.45	1.91e-05	0.0283	0.43	0.37	Hirschsprung disease;	chr10:43245065	chr10:43136824~43138334:-
ESCA	cis	rs9462027	0.506	rs6934662	ENSG00000186328.4	RP11-140K17.2	4.45	1.91e-05	0.0283	0.41	0.37	Systemic lupus erythematosus;	chr6:34792107	chr6:34715613~34715940:+
ESCA	cis	rs2882667	0.638	rs2351905	ENSG00000253404.1	AC034243.1	4.45	1.91e-05	0.0283	0.5	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139135641	chr5:138744434~138753309:-
ESCA	cis	rs1538970	0.816	rs61788356	ENSG00000280836.1	AL355480.1	-4.45	1.91e-05	0.0283	-0.46	-0.37	Platelet count;	chr1:45541003	chr1:45581219~45581321:-
ESCA	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	4.45	1.92e-05	0.0284	0.7	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
ESCA	cis	rs2688482	0.512	rs3103954	ENSG00000207650.1	MIR570	4.45	1.92e-05	0.0284	0.57	0.37	Lung disease severity in cystic fibrosis;	chr3:195789759	chr3:195699401~195699497:+
ESCA	cis	rs3820068	0.705	rs11577225	ENSG00000237301.1	RP4-680D5.2	4.45	1.92e-05	0.0284	0.41	0.37	Systolic blood pressure;	chr1:15537747	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs72643701	ENSG00000237301.1	RP4-680D5.2	4.45	1.92e-05	0.0284	0.41	0.37	Systolic blood pressure;	chr1:15539724	chr1:15586136~15603626:-
ESCA	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	4.45	1.92e-05	0.0284	0.38	0.37	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
ESCA	cis	rs3093024	1	rs3093023	ENSG00000265828.1	MIR3939	4.45	1.92e-05	0.0284	0.39	0.37	Rheumatoid arthritis;	chr6:167120802	chr6:166997807~166997912:-
ESCA	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	4.45	1.92e-05	0.0284	0.49	0.37	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
ESCA	cis	rs4535700	0.501	rs10245725	ENSG00000226278.1	PSPHP1	-4.45	1.92e-05	0.0285	-0.47	-0.37	Macular telangiectasia type 2;	chr7:55908855	chr7:55764797~55773288:+
ESCA	cis	rs9601248	0.874	rs4141825	ENSG00000227676.3	LINC01068	4.45	1.93e-05	0.0285	0.46	0.37	Major depressive disorder;	chr13:79616713	chr13:79566727~79571436:+
ESCA	cis	rs875971	0.545	rs13311962	ENSG00000179406.6	LINC00174	4.45	1.93e-05	0.0285	0.51	0.37	Aortic root size;	chr7:66603142	chr7:66376044~66401338:-
ESCA	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	4.45	1.93e-05	0.0285	0.51	0.37	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
ESCA	cis	rs1048238	0.506	rs6668183	ENSG00000235084.3	CHCHD2P6	-4.45	1.93e-05	0.0285	-0.35	-0.37	Systolic blood pressure;	chr1:15847319	chr1:15604597~15605043:+
ESCA	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	4.45	1.93e-05	0.0285	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
ESCA	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	4.45	1.93e-05	0.0285	0.47	0.37	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
ESCA	cis	rs10875746	0.669	rs10875772	ENSG00000240399.1	RP1-228P16.1	-4.45	1.93e-05	0.0286	-0.47	-0.37	Longevity (90 years and older);	chr12:48215770	chr12:48054813~48055591:-
ESCA	cis	rs2307394	0.964	rs2161983	ENSG00000223911.1	AC009480.3	4.45	1.93e-05	0.0286	0.45	0.37	Urate levels;	chr2:147891817	chr2:147899401~147902956:-
ESCA	cis	rs28830936	1	rs17677199	ENSG00000250379.1	RP11-23P13.4	4.45	1.94e-05	0.0286	0.42	0.37	Diastolic blood pressure;	chr15:41662415	chr15:41825099~41827936:-
ESCA	cis	rs28830936	1	rs11637341	ENSG00000250379.1	RP11-23P13.4	4.45	1.94e-05	0.0286	0.42	0.37	Diastolic blood pressure;	chr15:41663627	chr15:41825099~41827936:-
ESCA	cis	rs7412746	0.566	rs11204743	ENSG00000206931.1	RNU6-1042P	4.45	1.94e-05	0.0286	0.47	0.37	Melanoma;	chr1:150917930	chr1:150701866~150701972:+
ESCA	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	4.45	1.94e-05	0.0286	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	4.45	1.94e-05	0.0286	0.46	0.37	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
ESCA	cis	rs6860806	0.507	rs272880	ENSG00000233006.5	AC034220.3	4.44	1.94e-05	0.0287	0.36	0.37	Breast cancer;	chr5:132334485	chr5:132311285~132369916:-
ESCA	cis	rs7829975	0.682	rs7013471	ENSG00000253981.4	ALG1L13P	-4.44	1.94e-05	0.0287	-0.42	-0.37	Mood instability;	chr8:8829815	chr8:8236003~8244667:-
ESCA	cis	rs9549260	0.755	rs2755216	ENSG00000229456.1	RLIMP1	4.44	1.94e-05	0.0287	0.35	0.37	Red blood cell count;	chr13:40582801	chr13:40618738~40621348:+
ESCA	cis	rs2439831	0.681	rs7175434	ENSG00000249839.1	AC011330.5	-4.44	1.94e-05	0.0287	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43336344	chr15:43663654~43684339:-
ESCA	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-4.44	1.94e-05	0.0287	-0.41	-0.37	Migraine;	chr4:56956882	chr4:56960927~56961373:-
ESCA	cis	rs7267979	0.789	rs6083810	ENSG00000204556.4	CTD-2514C3.1	4.44	1.94e-05	0.0287	0.5	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:26018832~26020684:+
ESCA	cis	rs7267979	0.789	rs6083820	ENSG00000204556.4	CTD-2514C3.1	4.44	1.94e-05	0.0287	0.5	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:26018832~26020684:+
ESCA	cis	rs7267979	0.789	rs62213729	ENSG00000204556.4	CTD-2514C3.1	4.44	1.94e-05	0.0287	0.5	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:26018832~26020684:+
ESCA	cis	rs7267979	0.789	rs6083841	ENSG00000204556.4	CTD-2514C3.1	4.44	1.94e-05	0.0287	0.5	0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:26018832~26020684:+
ESCA	cis	rs7267979	0.789	rs2260197	ENSG00000204556.4	CTD-2514C3.1	-4.44	1.94e-05	0.0287	-0.5	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:26018832~26020684:+
ESCA	cis	rs7267979	0.753	rs404148	ENSG00000204556.4	CTD-2514C3.1	-4.44	1.94e-05	0.0287	-0.5	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:26018832~26020684:+
ESCA	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	4.44	1.95e-05	0.0287	0.47	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
ESCA	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.44	1.95e-05	0.0287	-0.56	-0.37	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
ESCA	cis	rs2439831	0.85	rs3862142	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43772608	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.702	rs2788	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43772688	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs2277531	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43776871	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs28891769	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43780662	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs28578398	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43782848	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs60883262	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43784305	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs8023458	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43788741	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs16963953	ENSG00000224677.1	PDIA3P2	-4.44	1.95e-05	0.0287	-0.61	-0.37	Lung cancer in ever smokers;	chr15:43789521	chr15:43649123~43649280:+
ESCA	cis	rs858239	0.512	rs55788996	ENSG00000230042.1	AK3P3	-4.44	1.95e-05	0.0287	-0.43	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23153230	chr7:23129178~23129841:+
ESCA	cis	rs7829975	0.871	rs7829826	ENSG00000253981.4	ALG1L13P	-4.44	1.95e-05	0.0288	-0.43	-0.37	Mood instability;	chr8:8720610	chr8:8236003~8244667:-
ESCA	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	4.44	1.96e-05	0.0288	0.59	0.37	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
ESCA	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	4.44	1.96e-05	0.0288	0.59	0.37	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
ESCA	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	4.44	1.96e-05	0.0288	0.59	0.37	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
ESCA	cis	rs8059260	0.604	rs2160042	ENSG00000274038.1	RP11-66H6.4	-4.44	1.96e-05	0.0288	-0.72	-0.37	Alcohol consumption over the past year;	chr16:11064375	chr16:11056556~11057034:+
ESCA	cis	rs6951245	0.542	rs28460147	ENSG00000229043.2	AC091729.9	-4.44	1.96e-05	0.0288	-0.57	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1177556	chr7:1160374~1165267:+
ESCA	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-4.44	1.96e-05	0.0288	-0.44	-0.37	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
ESCA	cis	rs2742234	0.59	rs1254965	ENSG00000273008.1	RP11-351D16.3	4.44	1.96e-05	0.0288	0.44	0.37	Hirschsprung disease;	chr10:43194405	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.518	rs1254967	ENSG00000273008.1	RP11-351D16.3	4.44	1.96e-05	0.0288	0.44	0.37	Hirschsprung disease;	chr10:43194943	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.503	rs1254968	ENSG00000273008.1	RP11-351D16.3	4.44	1.96e-05	0.0288	0.44	0.37	Hirschsprung disease;	chr10:43196243	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.578	rs2435354	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43156997	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2257767	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43162363	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2503864	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43171319	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2503863	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43171950	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2503848	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43177337	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2435383	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43180223	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs1059484	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43184352	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2505553	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43185803	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2435376	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43189515	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.579	rs2503881	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43190578	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2115817	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0288	-0.44	-0.37	Hirschsprung disease;	chr10:43191104	chr10:43136824~43138334:-
ESCA	cis	rs3820068	0.581	rs59684759	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15593398	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645861	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15593819	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.532	rs72645862	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15593871	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.532	rs78917815	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15594326	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645864	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15594658	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.554	rs60233444	ENSG00000237301.1	RP4-680D5.2	4.44	1.96e-05	0.0289	0.42	0.37	Systolic blood pressure;	chr1:15594835	chr1:15586136~15603626:-
ESCA	cis	rs765787	0.53	rs12442533	ENSG00000259520.4	CTD-2651B20.3	-4.44	1.96e-05	0.0289	-0.43	-0.37	Uric acid levels;	chr15:45237433	chr15:45251580~45279251:-
ESCA	cis	rs2742234	0.59	rs2435337	ENSG00000273008.1	RP11-351D16.3	-4.44	1.96e-05	0.0289	-0.44	-0.37	Hirschsprung disease;	chr10:43166388	chr10:43136824~43138334:-
ESCA	cis	rs2439831	0.681	rs540031	ENSG00000249839.1	AC011330.5	-4.44	1.96e-05	0.0289	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43316657	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.681	rs1095386	ENSG00000249839.1	AC011330.5	-4.44	1.96e-05	0.0289	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43317311	chr15:43663654~43684339:-
ESCA	cis	rs9549260	0.755	rs2721071	ENSG00000229456.1	RLIMP1	4.44	1.97e-05	0.029	0.35	0.37	Red blood cell count;	chr13:40570370	chr13:40618738~40621348:+
ESCA	cis	rs6558530	0.73	rs10100341	ENSG00000253982.1	CTD-2336O2.1	4.44	1.97e-05	0.029	0.45	0.37	Systolic blood pressure;	chr8:1775583	chr8:1761990~1764502:-
ESCA	cis	rs2227564	0.7	rs2688613	ENSG00000229990.3	RP11-574K11.8	-4.44	1.97e-05	0.029	-0.42	-0.37	Crohn's disease;Inflammatory bowel disease;	chr10:73893287	chr10:73841833~73847115:+
ESCA	cis	rs8040855	1	rs8040855	ENSG00000259295.5	CSPG4P12	-4.44	1.98e-05	0.029	-0.6	-0.37	Bulimia nervosa;	chr15:85155976	chr15:85191438~85213905:+
ESCA	cis	rs2688482	0.557	rs2550236	ENSG00000207650.1	MIR570	4.44	1.98e-05	0.029	0.56	0.37	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195699401~195699497:+
ESCA	cis	rs2439831	0.85	rs3862142	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43772608	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.702	rs2788	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43772688	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs2277531	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43776871	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs28891769	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43780662	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs28578398	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43782848	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs60883262	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43784305	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs8023458	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43788741	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.85	rs16963953	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.029	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43789521	chr15:43726918~43747094:-
ESCA	cis	rs10954779	0.511	rs1800392	ENSG00000253579.1	SUMO2P16	-4.44	1.98e-05	0.029	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:31116441	chr8:31131539~31131802:-
ESCA	cis	rs6998967	0.54	rs7817124	ENSG00000272518.1	RP11-26J3.3	-4.44	1.98e-05	0.0291	-0.55	-0.37	Late-onset myasthenia gravis;	chr8:80491773	chr8:79956465~79957381:-
ESCA	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	4.44	1.98e-05	0.0291	0.65	0.37	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
ESCA	cis	rs2439831	0.85	rs16965120	ENSG00000205771.5	CATSPER2P1	-4.44	1.98e-05	0.0291	-0.64	-0.37	Lung cancer in ever smokers;	chr15:43808144	chr15:43726918~43747094:-
ESCA	cis	rs12712135	0.677	rs11678721	ENSG00000234389.1	AC007278.3	-4.44	1.99e-05	0.0291	-0.33	-0.37	Blood protein levels;	chr2:102456778	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs11677555	ENSG00000234389.1	AC007278.3	-4.44	1.99e-05	0.0291	-0.33	-0.37	Blood protein levels;	chr2:102456833	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs6705498	ENSG00000234389.1	AC007278.3	-4.44	1.99e-05	0.0291	-0.33	-0.37	Blood protein levels;	chr2:102460210	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs6719196	ENSG00000234389.1	AC007278.3	-4.44	1.99e-05	0.0291	-0.33	-0.37	Blood protein levels;	chr2:102460428	chr2:102438713~102440475:+
ESCA	cis	rs1005277	0.565	rs2474565	ENSG00000263064.2	RP11-291L22.7	4.44	1.99e-05	0.0292	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38091900	chr10:38448689~38448949:+
ESCA	cis	rs9462027	0.628	rs7745097	ENSG00000186328.4	RP11-140K17.2	4.44	1.99e-05	0.0292	0.41	0.37	Systemic lupus erythematosus;	chr6:34826657	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.606	rs7768759	ENSG00000186328.4	RP11-140K17.2	4.44	1.99e-05	0.0292	0.41	0.37	Systemic lupus erythematosus;	chr6:34827908	chr6:34715613~34715940:+
ESCA	cis	rs847851	0.63	rs9469905	ENSG00000186328.4	RP11-140K17.2	4.44	1.99e-05	0.0292	0.41	0.37	Colonoscopy-negative controls vs population controls;	chr6:34829970	chr6:34715613~34715940:+
ESCA	cis	rs1005277	0.579	rs2505241	ENSG00000276805.1	RP11-291L22.6	4.44	1.99e-05	0.0292	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38153493	chr10:38451030~38451785:+
ESCA	cis	rs7301826	0.651	rs7956851	ENSG00000256250.1	RP11-989F5.1	-4.44	2e-05	0.0292	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810606~130812438:+
ESCA	cis	rs9462027	0.628	rs9368832	ENSG00000186328.4	RP11-140K17.2	-4.44	2e-05	0.0292	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34711810	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.606	rs12201281	ENSG00000186328.4	RP11-140K17.2	-4.44	2e-05	0.0292	-0.41	-0.37	Systemic lupus erythematosus;	chr6:34713314	chr6:34715613~34715940:+
ESCA	cis	rs4927850	1	rs7625570	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.41	0.37	Pancreatic cancer;	chr3:196020527	chr3:195699401~195699497:+
ESCA	cis	rs4927850	0.881	rs7624638	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.41	0.37	Pancreatic cancer;	chr3:196021858	chr3:195699401~195699497:+
ESCA	cis	rs4927850	1	rs10881564	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.41	0.37	Pancreatic cancer;	chr3:196023455	chr3:195699401~195699497:+
ESCA	cis	rs4927850	1	rs7627706	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.4	0.37	Pancreatic cancer;	chr3:196026482	chr3:195699401~195699497:+
ESCA	cis	rs4927850	0.881	rs7630489	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.4	0.37	Pancreatic cancer;	chr3:196026530	chr3:195699401~195699497:+
ESCA	cis	rs4927850	1	rs7627868	ENSG00000207650.1	MIR570	4.44	2e-05	0.0293	0.4	0.37	Pancreatic cancer;	chr3:196026602	chr3:195699401~195699497:+
ESCA	cis	rs8072100	0.905	rs8077106	ENSG00000228782.6	CTD-2026D20.3	-4.44	2.01e-05	0.0294	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47575925	chr17:47450568~47492492:-
ESCA	cis	rs2665103	0.589	rs2134046	ENSG00000278603.1	RP13-608F4.5	4.44	2.01e-05	0.0294	0.47	0.37	Intelligence (multi-trait analysis);	chr15:82232203	chr15:82472203~82472426:+
ESCA	cis	rs2303759	0.67	rs45549132	ENSG00000269814.1	CTC-273B12.10	-4.44	2.01e-05	0.0295	-0.51	-0.37	Multiple sclerosis;	chr19:49290771	chr19:48513207~48513660:-
ESCA	cis	rs9487094	0.644	rs13201430	ENSG00000260273.1	RP11-425D10.10	4.44	2.01e-05	0.0295	0.45	0.37	Height;	chr6:109634847	chr6:109382795~109383666:+
ESCA	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	4.44	2.01e-05	0.0295	0.48	0.37	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
ESCA	cis	rs9977672	0.689	rs9982724	ENSG00000231713.2	AF064860.7	-4.43	2.02e-05	0.0295	-0.39	-0.37	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr21:39089452	chr21:39727755~39730680:+
ESCA	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-4.43	2.02e-05	0.0295	-0.44	-0.37	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
ESCA	cis	rs7535099	0.954	rs3790431	ENSG00000224570.1	RP11-430H12.2	-4.43	2.02e-05	0.0295	-0.58	-0.37	Blood protein levels;	chr1:65570345	chr1:65576129~65578380:-
ESCA	cis	rs2439831	0.85	rs28590651	ENSG00000249839.1	AC011330.5	-4.43	2.02e-05	0.0295	-0.7	-0.37	Lung cancer in ever smokers;	chr15:43820818	chr15:43663654~43684339:-
ESCA	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.43	2.02e-05	0.0295	-0.42	-0.37	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
ESCA	cis	rs2742234	0.955	rs2075913	ENSG00000273008.1	RP11-351D16.3	-4.43	2.02e-05	0.0296	-0.43	-0.37	Hirschsprung disease;	chr10:43126920	chr10:43136824~43138334:-
ESCA	cis	rs11148252	0.508	rs11148260	ENSG00000235660.1	LINC00345	-4.43	2.02e-05	0.0296	-0.42	-0.37	Lewy body disease;	chr13:52588508	chr13:52484161~52484680:-
ESCA	cis	rs6860806	0.507	rs274570	ENSG00000233006.5	AC034220.3	-4.43	2.02e-05	0.0296	-0.36	-0.37	Breast cancer;	chr5:132377534	chr5:132311285~132369916:-
ESCA	cis	rs8003054	0.589	rs4465523	ENSG00000258515.1	RP11-203M5.7	4.43	2.03e-05	0.0296	0.34	0.37	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445364	chr14:20451305~20451918:+
ESCA	cis	rs9608946	1	rs1001409	ENSG00000268812.3	RP1-102K2.8	4.43	2.03e-05	0.0296	0.52	0.37	Red cell distribution width;	chr22:30522838	chr22:30246205~30246998:+
ESCA	cis	rs2412819	0.545	rs654276	ENSG00000249839.1	AC011330.5	4.43	2.03e-05	0.0296	0.71	0.37	Lung cancer;	chr15:43798656	chr15:43663654~43684339:-
ESCA	cis	rs6452524	0.534	rs10061690	ENSG00000243385.2	CTD-2110K23.1	4.43	2.03e-05	0.0296	0.4	0.37	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83201229~83202141:+
ESCA	cis	rs61990749	0.597	rs11623088	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77671392	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs11624101	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77671716	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs1048147	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77673645	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs13379065	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77674952	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs17106157	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77680535	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs2267758	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77681086	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs2267759	ENSG00000239272.1	RPL21P10	-4.43	2.03e-05	0.0296	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77681272	chr14:77683202~77683989:-
ESCA	cis	rs2118674	1	rs2118674	ENSG00000239467.4	AC007405.6	-4.43	2.03e-05	0.0296	-0.72	-0.37	Palmitoleic acid (16:1n-7) levels;	chr2:170462384	chr2:170771113~170778148:+
ESCA	cis	rs6805251	0.594	rs7652172	ENSG00000276607.2	AC092910.1	-4.43	2.03e-05	0.0296	-0.43	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120045239	chr3:120084550~120084657:-
ESCA	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	4.43	2.03e-05	0.0296	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
ESCA	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	4.43	2.03e-05	0.0296	0.55	0.37	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
ESCA	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.43	2.03e-05	0.0296	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
ESCA	cis	rs2283231	1	rs2283231	ENSG00000166492.9	FAM86GP	4.43	2.03e-05	0.0297	0.5	0.37	Gout;	chr11:2895485	chr11:3410352~3422496:-
ESCA	cis	rs2098713	0.534	rs6867424	ENSG00000250155.1	CTD-2353F22.1	4.43	2.03e-05	0.0297	0.42	0.37	Telomere length;	chr5:37534771	chr5:36666214~36725195:-
ESCA	cis	rs7208859	0.615	rs216462	ENSG00000263531.1	RP13-753N3.1	-4.43	2.03e-05	0.0297	-0.63	-0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30568879	chr17:30863921~30864940:-
ESCA	cis	rs2439831	0.85	rs16965120	ENSG00000249839.1	AC011330.5	-4.43	2.03e-05	0.0297	-0.66	-0.37	Lung cancer in ever smokers;	chr15:43808144	chr15:43663654~43684339:-
ESCA	cis	rs6601530	0.565	rs6601518	ENSG00000248896.2	CTD-2135J3.3	-4.43	2.04e-05	0.0298	-0.49	-0.37	Carotid intima media thickness;	chr8:10747724	chr8:10729314~10771392:+
ESCA	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-4.43	2.04e-05	0.0298	-0.58	-0.37	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
ESCA	cis	rs12744310	0.836	rs12048808	ENSG00000235358.1	RP11-399E6.1	4.43	2.04e-05	0.0298	0.56	0.37	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41348636	chr1:41242373~41284861:+
ESCA	cis	rs1048238	0.506	rs698890	ENSG00000235084.3	CHCHD2P6	4.43	2.04e-05	0.0298	0.36	0.37	Systolic blood pressure;	chr1:15940876	chr1:15604597~15605043:+
ESCA	cis	rs9584850	0.794	rs72655609	ENSG00000231194.1	FARP1-AS1	4.43	2.04e-05	0.0298	0.46	0.37	Neuroticism;	chr13:98476368	chr13:98435405~98435840:-
ESCA	cis	rs559928	0.606	rs56207008	ENSG00000274986.1	MIR6750	4.43	2.05e-05	0.0298	0.68	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64115743	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs17773078	ENSG00000274986.1	MIR6750	4.43	2.05e-05	0.0298	0.68	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64138752	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs60394481	ENSG00000274986.1	MIR6750	4.43	2.05e-05	0.0298	0.68	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64141563	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.556	rs734762	ENSG00000274986.1	MIR6750	4.43	2.05e-05	0.0298	0.68	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64144717	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs12417635	ENSG00000274986.1	MIR6750	4.43	2.05e-05	0.0298	0.68	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64145256	chr11:64898363~64898437:-
ESCA	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-4.43	2.05e-05	0.0299	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
ESCA	cis	rs7829975	0.714	rs11777085	ENSG00000253981.4	ALG1L13P	4.43	2.05e-05	0.0299	0.4	0.37	Mood instability;	chr8:8814919	chr8:8236003~8244667:-
ESCA	cis	rs7301016	0.846	rs17732089	ENSG00000257568.1	RP11-863H1.1	-4.43	2.06e-05	0.0299	-0.47	-0.37	IgG glycosylation;	chr12:62629878	chr12:62482349~62484932:-
ESCA	cis	rs1816752	0.819	rs6490917	ENSG00000273628.1	RP11-756A22.7	4.43	2.06e-05	0.03	0.36	0.37	Obesity-related traits;	chr13:24423119	chr13:24933006~24936796:+
ESCA	cis	rs42648	0.837	rs3761804	ENSG00000225498.1	AC002064.5	4.43	2.06e-05	0.03	0.33	0.37	Homocysteine levels;	chr7:90286024	chr7:90312496~90322592:+
ESCA	cis	rs977987	0.806	rs11862684	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75427848	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.815	rs11861810	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75427931	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11149832	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75428815	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12448947	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75429056	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs4888420	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75429100	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12449170	ENSG00000261783.1	RP11-252K23.2	-4.43	2.06e-05	0.03	-0.45	-0.37	Dupuytren's disease;	chr16:75429114	chr16:75379818~75381260:-
ESCA	cis	rs1439620	0.686	rs4778061	ENSG00000271763.1	RP11-386M24.9	4.43	2.06e-05	0.03	0.41	0.37	Body mass index;	chr15:92958168	chr15:92602910~92620015:+
ESCA	cis	rs5769707	0.967	rs2071904	ENSG00000213279.2	RP1-29C18.9	-4.43	2.06e-05	0.03	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49572264~49575426:-
ESCA	cis	rs5769707	0.846	rs5770610	ENSG00000213279.2	RP1-29C18.9	-4.43	2.06e-05	0.03	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49572264~49575426:-
ESCA	cis	rs7829975	0.502	rs11785183	ENSG00000253981.4	ALG1L13P	-4.43	2.06e-05	0.03	-0.47	-0.37	Mood instability;	chr8:8708447	chr8:8236003~8244667:-
ESCA	cis	rs11169552	0.51	rs10876047	ENSG00000200428.1	Y_RNA	4.43	2.06e-05	0.03	0.45	0.37	Colorectal cancer;	chr12:50531502	chr12:50743568~50743684:+
ESCA	cis	rs10954779	0.728	rs2252480	ENSG00000253579.1	SUMO2P16	-4.43	2.07e-05	0.03	-0.42	-0.37	Intelligence (multi-trait analysis);	chr8:31132594	chr8:31131539~31131802:-
ESCA	cis	rs9601248	1	rs9601248	ENSG00000227676.3	LINC01068	-4.43	2.07e-05	0.03	-0.49	-0.37	Major depressive disorder;	chr13:79594869	chr13:79566727~79571436:+
ESCA	cis	rs12712135	0.651	rs12712150	ENSG00000234389.1	AC007278.3	-4.43	2.07e-05	0.0301	-0.33	-0.37	Blood protein levels;	chr2:102458353	chr2:102438713~102440475:+
ESCA	cis	rs9545047	0.625	rs1408657	ENSG00000227676.3	LINC01068	4.43	2.07e-05	0.0301	0.49	0.37	Schizophrenia;	chr13:79329315	chr13:79566727~79571436:+
ESCA	cis	rs9328448	0.58	rs2743993	ENSG00000217746.1	RP1-303A1.1	-4.43	2.07e-05	0.0302	-0.44	-0.37	Coronary artery calcification;	chr6:8054180	chr6:7938430~7939322:-
ESCA	cis	rs6432860	0.545	rs10930195	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166045896	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs10194956	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166046065	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs6432861	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166046718	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs13383628	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166047150	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.51	rs1542484	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166048865	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.527	rs1542483	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166049062	chr2:165833048~165839098:-
ESCA	cis	rs6432860	0.545	rs6755433	ENSG00000232411.1	AC009495.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166049443	chr2:165833048~165839098:-
ESCA	cis	rs8072100	0.935	rs78551919	ENSG00000228782.6	CTD-2026D20.3	-4.43	2.07e-05	0.0302	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47548636	chr17:47450568~47492492:-
ESCA	cis	rs2303759	0.626	rs12982246	ENSG00000269814.1	CTC-273B12.10	-4.43	2.08e-05	0.0302	-0.49	-0.37	Multiple sclerosis;	chr19:49297912	chr19:48513207~48513660:-
ESCA	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	4.43	2.08e-05	0.0302	0.5	0.37	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
ESCA	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-4.43	2.08e-05	0.0302	-0.37	-0.37	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
ESCA	cis	rs2439831	0.85	rs28590651	ENSG00000205771.5	CATSPER2P1	-4.43	2.08e-05	0.0302	-0.67	-0.37	Lung cancer in ever smokers;	chr15:43820818	chr15:43726918~43747094:-
ESCA	cis	rs977987	0.872	rs4887825	ENSG00000261783.1	RP11-252K23.2	-4.43	2.08e-05	0.0302	-0.46	-0.37	Dupuytren's disease;	chr16:75438524	chr16:75379818~75381260:-
ESCA	cis	rs7186831	1	rs7186831	ENSG00000261783.1	RP11-252K23.2	-4.43	2.08e-05	0.0302	-0.46	-0.37	Chronic obstructive pulmonary disease;	chr16:75439257	chr16:75379818~75381260:-
ESCA	cis	rs5758659	1	rs5758659	ENSG00000182057.4	OGFRP1	4.43	2.08e-05	0.0302	0.43	0.37	Cognitive function;	chr22:42225997	chr22:42269753~42275196:+
ESCA	cis	rs1048238	0.506	rs7547314	ENSG00000235084.3	CHCHD2P6	-4.43	2.08e-05	0.0302	-0.35	-0.37	Systolic blood pressure;	chr1:15860227	chr1:15604597~15605043:+
ESCA	cis	rs2739330	0.752	rs2330634	ENSG00000272787.1	KB-226F1.2	-4.43	2.08e-05	0.0302	-0.44	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23969211~23969873:+
ESCA	cis	rs6788895	1	rs41372346	ENSG00000244265.1	SIAH2-AS1	4.43	2.08e-05	0.0303	0.71	0.37	Breast cancer;	chr3:150771329	chr3:150761937~150762538:+
ESCA	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	4.43	2.08e-05	0.0303	0.66	0.37	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
ESCA	cis	rs11169552	0.51	rs11169487	ENSG00000200428.1	Y_RNA	4.43	2.09e-05	0.0303	0.47	0.37	Colorectal cancer;	chr12:50543322	chr12:50743568~50743684:+
ESCA	cis	rs8072100	0.84	rs11079774	ENSG00000228782.6	CTD-2026D20.3	4.43	2.09e-05	0.0303	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402340	chr17:47450568~47492492:-
ESCA	cis	rs2019137	0.868	rs6755639	ENSG00000189223.12	PAX8-AS1	-4.43	2.09e-05	0.0303	-0.48	-0.37	Lymphocyte counts;	chr2:113224233	chr2:113211522~113276581:+
ESCA	cis	rs12712135	0.709	rs11465728	ENSG00000234389.1	AC007278.3	-4.43	2.09e-05	0.0303	-0.33	-0.37	Blood protein levels;	chr2:102448051	chr2:102438713~102440475:+
ESCA	cis	rs4713675	0.546	rs791903	ENSG00000186328.4	RP11-140K17.2	4.43	2.09e-05	0.0304	0.46	0.37	Plateletcrit;	chr6:33734868	chr6:34715613~34715940:+
ESCA	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	4.43	2.09e-05	0.0304	0.51	0.37	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	4.43	2.09e-05	0.0304	0.51	0.37	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
ESCA	cis	rs1048238	0.506	rs12023422	ENSG00000235084.3	CHCHD2P6	-4.43	2.1e-05	0.0304	-0.35	-0.37	Systolic blood pressure;	chr1:15861130	chr1:15604597~15605043:+
ESCA	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	4.43	2.1e-05	0.0304	0.5	0.37	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	4.43	2.1e-05	0.0304	0.5	0.37	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	4.43	2.1e-05	0.0304	0.5	0.37	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
ESCA	cis	rs611744	0.87	rs685358	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108149184	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.81	rs672161	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108151953	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.839	rs672552	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108151994	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs613261	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108153720	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs613179	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108153777	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.839	rs638238	ENSG00000253754.1	RP11-35G22.1	-4.42	2.1e-05	0.0304	-0.34	-0.37	Dupuytren's disease;	chr8:108156923	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs596703	ENSG00000253754.1	RP11-35G22.1	4.42	2.1e-05	0.0304	0.34	0.37	Dupuytren's disease;	chr8:108147917	chr8:108226200~108227544:+
ESCA	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	4.42	2.1e-05	0.0305	0.53	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
ESCA	cis	rs8059260	0.668	rs7198089	ENSG00000274038.1	RP11-66H6.4	-4.42	2.1e-05	0.0305	-0.68	-0.37	Alcohol consumption over the past year;	chr16:11027199	chr16:11056556~11057034:+
ESCA	cis	rs6452524	0.905	rs7736289	ENSG00000243385.2	CTD-2110K23.1	4.42	2.1e-05	0.0305	0.38	0.37	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83201229~83202141:+
ESCA	cis	rs7503807	0.837	rs9915667	ENSG00000278200.1	RP13-766D20.4	-4.42	2.11e-05	0.0305	-0.39	-0.37	Obesity;	chr17:80780540	chr17:81480523~81481570:-
ESCA	cis	rs8059260	0.604	rs12102345	ENSG00000274038.1	RP11-66H6.4	-4.42	2.11e-05	0.0305	-0.67	-0.37	Alcohol consumption over the past year;	chr16:11053863	chr16:11056556~11057034:+
ESCA	cis	rs5758659	0.845	rs5758645	ENSG00000182057.4	OGFRP1	4.42	2.11e-05	0.0305	0.43	0.37	Cognitive function;	chr22:42202945	chr22:42269753~42275196:+
ESCA	cis	rs5769707	0.935	rs9616332	ENSG00000213279.2	RP1-29C18.9	-4.42	2.11e-05	0.0305	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49572264~49575426:-
ESCA	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.42	2.11e-05	0.0305	0.36	0.37	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
ESCA	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-4.42	2.11e-05	0.0305	-0.66	-0.37	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
ESCA	cis	rs7535099	1	rs12059300	ENSG00000224570.1	RP11-430H12.2	-4.42	2.11e-05	0.0306	-0.62	-0.37	Blood protein levels;	chr1:65581389	chr1:65576129~65578380:-
ESCA	cis	rs7535099	0.954	rs12067730	ENSG00000224570.1	RP11-430H12.2	-4.42	2.11e-05	0.0306	-0.62	-0.37	Blood protein levels;	chr1:65583339	chr1:65576129~65578380:-
ESCA	cis	rs2638953	0.815	rs10843188	ENSG00000247934.4	RP11-967K21.1	-4.42	2.11e-05	0.0306	-0.41	-0.37	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Height;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Hip circumference adjusted for BMI;	chr12:28504200	chr12:28163298~28190738:-
ESCA	cis	rs11039131	0.929	rs1685404	ENSG00000271350.1	CTD-2384B9.1	-4.42	2.11e-05	0.0306	-0.42	-0.37	Schizophrenia;	chr11:47222114	chr11:47041027~47041945:-
ESCA	cis	rs2439831	1	rs2264239	ENSG00000249839.1	AC011330.5	-4.42	2.12e-05	0.0306	-0.57	-0.37	Lung cancer in ever smokers;	chr15:43473335	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2251538	ENSG00000249839.1	AC011330.5	-4.42	2.12e-05	0.0306	-0.57	-0.37	Lung cancer in ever smokers;	chr15:43475011	chr15:43663654~43684339:-
ESCA	cis	rs1364044	0.909	rs13153094	ENSG00000251062.1	CTD-2218G20.1	-4.42	2.12e-05	0.0306	-0.43	-0.37	Stroke (pediatric);	chr5:33858940	chr5:32887990~32888145:-
ESCA	cis	rs1364044	0.909	rs10941108	ENSG00000251062.1	CTD-2218G20.1	-4.42	2.12e-05	0.0306	-0.43	-0.37	Stroke (pediatric);	chr5:33867314	chr5:32887990~32888145:-
ESCA	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	4.42	2.12e-05	0.0307	0.52	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
ESCA	cis	rs1439620	0.686	rs4778061	ENSG00000260337.3	RP11-386M24.6	4.42	2.13e-05	0.0307	0.48	0.37	Body mass index;	chr15:92958168	chr15:92592574~92596462:-
ESCA	cis	rs3820068	0.581	rs16849152	ENSG00000237301.1	RP4-680D5.2	4.42	2.13e-05	0.0307	0.41	0.37	Systolic blood pressure;	chr1:15595279	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs58425551	ENSG00000237301.1	RP4-680D5.2	4.42	2.13e-05	0.0307	0.41	0.37	Systolic blood pressure;	chr1:15596023	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs16851841	ENSG00000237301.1	RP4-680D5.2	4.42	2.13e-05	0.0307	0.41	0.37	Systolic blood pressure;	chr1:15596218	chr1:15586136~15603626:-
ESCA	cis	rs8099594	0.64	rs9789092	ENSG00000266696.1	RP11-30L3.2	-4.42	2.13e-05	0.0307	-0.44	-0.37	Height;	chr18:49303096	chr18:49205912~49208781:+
ESCA	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	4.42	2.13e-05	0.0308	0.51	0.37	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	4.42	2.13e-05	0.0308	0.51	0.37	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	4.42	2.13e-05	0.0308	0.51	0.37	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	4.42	2.13e-05	0.0308	0.51	0.37	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
ESCA	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	4.42	2.13e-05	0.0308	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	4.42	2.13e-05	0.0308	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	4.42	2.13e-05	0.0308	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	4.42	2.13e-05	0.0308	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
ESCA	cis	rs2179367	0.959	rs521845	ENSG00000216906.2	RP11-350J20.9	-4.42	2.14e-05	0.0308	-0.48	-0.37	Dupuytren's disease;	chr6:149350562	chr6:149904243~149906418:+
ESCA	cis	rs7829975	0.511	rs2976906	ENSG00000173295.6	FAM86B3P	4.42	2.14e-05	0.0308	0.46	0.37	Mood instability;	chr8:8484905	chr8:8228595~8244865:+
ESCA	cis	rs1075232	0.826	rs12437800	ENSG00000215302.7	CTD-3092A11.1	-4.42	2.14e-05	0.0309	-0.82	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31379229	chr15:30470779~30507623:+
ESCA	cis	rs3820068	0.603	rs7536654	ENSG00000237301.1	RP4-680D5.2	4.42	2.14e-05	0.0309	0.42	0.37	Systolic blood pressure;	chr1:15662646	chr1:15586136~15603626:-
ESCA	cis	rs12480328	1	rs73909823	ENSG00000228663.1	PSMD10P1	4.42	2.14e-05	0.0309	0.44	0.37	Prostate cancer;	chr20:50880508	chr20:50913731~50914411:+
ESCA	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	4.42	2.14e-05	0.0309	0.52	0.37	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	4.42	2.14e-05	0.0309	0.52	0.37	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	4.42	2.14e-05	0.0309	0.52	0.37	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
ESCA	cis	rs2742234	0.91	rs2505513	ENSG00000273008.1	RP11-351D16.3	-4.42	2.14e-05	0.0309	-0.42	-0.37	Hirschsprung disease;	chr10:43138089	chr10:43136824~43138334:-
ESCA	cis	rs4888378	0.6	rs729109	ENSG00000261783.1	RP11-252K23.2	4.42	2.15e-05	0.0309	0.54	0.37	Coronary artery disease;	chr16:75282176	chr16:75379818~75381260:-
ESCA	cis	rs11219122	0.619	rs7948443	ENSG00000254976.1	OR8B7P	-4.42	2.15e-05	0.0309	-0.47	-0.37	Immunoglobulin light chain (AL) amyloidosis;	chr11:123365164	chr11:124324871~124325789:-
ESCA	cis	rs9462027	0.583	rs6937784	ENSG00000186328.4	RP11-140K17.2	4.42	2.16e-05	0.0309	0.41	0.37	Systemic lupus erythematosus;	chr6:34676499	chr6:34715613~34715940:+
ESCA	cis	rs9549260	0.755	rs17061503	ENSG00000229456.1	RLIMP1	-4.42	2.16e-05	0.0309	-0.34	-0.37	Red blood cell count;	chr13:40672621	chr13:40618738~40621348:+
ESCA	cis	rs9549367	0.588	rs9549360	ENSG00000269125.1	RP11-98F14.11	-4.42	2.16e-05	0.0309	-0.47	-0.37	Platelet distribution width;	chr13:113238718	chr13:113165002~113165183:-
ESCA	cis	rs2179367	0.959	rs4895789	ENSG00000216906.2	RP11-350J20.9	4.42	2.16e-05	0.0309	0.5	0.37	Dupuytren's disease;	chr6:149443518	chr6:149904243~149906418:+
ESCA	cis	rs7208859	0.623	rs56018041	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30732967	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs56095789	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733152	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11656844	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733579	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11652533	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733583	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11652631	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30733748	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs79505916	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30735308	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs77498725	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30736968	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs73267865	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737186	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs57698184	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30737900	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs59923796	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30737901	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs57005940	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30739311	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs73267872	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30740189	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs9893922	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30741407	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs56812022	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30741715	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs57670615	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30742480	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs2874724	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30745415	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.568	rs9898097	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30745654	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs9891256	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30745674	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9911490	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30745995	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7503542	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746812	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7503335	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30746944	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs11656278	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30748170	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs6505207	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30749553	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs7223803	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750175	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55814012	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30750679	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs2449749	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30751280	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9894709	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751436	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9896603	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30751494	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.636	rs4055314	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30752751	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7219361	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753375	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.636	rs7221463	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30753533	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7219712	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753552	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs8078656	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30753953	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8080882	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30754128	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs28556733	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30756927	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs28452421	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30756962	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs28433704	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757267	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs28779471	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30757351	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.5	rs61685770	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30758695	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs57486336	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758713	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs55764512	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30758740	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs73988172	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759314	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs12103440	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759639	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs12103508	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30759763	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs11653605	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30761367	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11657777	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30764767	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269913	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765165	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7217984	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30765748	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269916	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30769308	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs60114476	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30770649	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs8065744	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30772431	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs8071236	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30772984	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.636	rs2449770	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30774046	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs59913838	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774545	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs56163556	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30774850	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8067035	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775170	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8067338	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775327	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs4055105	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775532	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7220289	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30776744	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8081299	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777278	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8068645	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777324	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55811708	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30777713	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs2322197	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30778787	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.562	rs8078897	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779239	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8075163	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30779292	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs8075107	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30779631	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7223209	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780202	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7223404	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780345	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9916725	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780453	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9916727	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780454	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9914499	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30780570	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269945	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781741	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9897728	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30781786	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs1054400	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30782936	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs1054397	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783178	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9890558	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783337	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9912283	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783355	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs12006	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30783634	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs3752021	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784025	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs3752020	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784107	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9890855	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784689	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9893422	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784697	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9891166	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30784884	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269974	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785366	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs34756112	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30785998	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs60724269	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786255	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs76633166	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30786347	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs1061346	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787211	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs1061343	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787258	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs1061342	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30787445	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55938328	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30789992	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269988	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30791127	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs55961983	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792268	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs7222803	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30792879	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9899525	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30793278	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.568	rs7213925	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30794616	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs11653098	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795483	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11658945	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30795491	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11657990	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797182	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9911784	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797562	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9911997	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30797630	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9890862	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30798432	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs78071511	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30801136	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11650982	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30802937	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs2035494	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803375	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs3794796	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30803862	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs9915546	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805126	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs28469200	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30806554	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs8064686	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30807821	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs8070182	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30808576	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs11657369	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809450	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs8075341	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809547	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73271842	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30810137	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9895815	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811015	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs7214313	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30811578	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs8077116	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813144	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs28760584	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30813999	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.706	rs73271850	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30815122	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.636	rs79565452	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Body mass index;	chr17:30815823	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7208088	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816649	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7212991	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816731	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs7208441	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30816845	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs28627615	ENSG00000263531.1	RP13-753N3.1	4.42	2.16e-05	0.0309	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30818799	chr17:30863921~30864940:-
ESCA	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	4.42	2.16e-05	0.0309	0.48	0.37	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
ESCA	cis	rs7829975	0.522	rs6601689	ENSG00000173295.6	FAM86B3P	4.42	2.16e-05	0.0309	0.48	0.37	Mood instability;	chr8:8314761	chr8:8228595~8244865:+
ESCA	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	4.42	2.17e-05	0.031	0.49	0.37	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
ESCA	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	4.42	2.17e-05	0.031	0.49	0.37	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
ESCA	cis	rs11051970	0.879	rs2651362	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32434917	chr12:32477382~32477471:-
ESCA	cis	rs11051970	0.879	rs950080	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32435569	chr12:32477382~32477471:-
ESCA	cis	rs11051970	0.879	rs950079	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32435686	chr12:32477382~32477471:-
ESCA	cis	rs11051970	0.877	rs2651360	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32435986	chr12:32477382~32477471:-
ESCA	cis	rs11051970	0.879	rs1500874	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32436473	chr12:32477382~32477471:-
ESCA	cis	rs11051970	0.877	rs2728671	ENSG00000253063.1	RNU6-494P	-4.42	2.17e-05	0.031	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32436781	chr12:32477382~32477471:-
ESCA	cis	rs4927850	0.958	rs1975582	ENSG00000207650.1	MIR570	4.42	2.17e-05	0.031	0.41	0.37	Pancreatic cancer;	chr3:196024568	chr3:195699401~195699497:+
ESCA	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	4.42	2.17e-05	0.031	0.5	0.37	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
ESCA	cis	rs7829975	0.774	rs13259216	ENSG00000253981.4	ALG1L13P	4.42	2.17e-05	0.031	0.42	0.37	Mood instability;	chr8:8816091	chr8:8236003~8244667:-
ESCA	cis	rs7631605	0.935	rs2241031	ENSG00000272334.1	RP11-129K12.1	-4.42	2.17e-05	0.031	-0.38	-0.37	Cerebrospinal P-tau181p levels;	chr3:37048783	chr3:36973117~36973672:-
ESCA	cis	rs17711722	0.583	rs11768292	ENSG00000226824.5	RP4-756H11.3	4.42	2.18e-05	0.0311	0.41	0.37	Calcium levels;	chr7:66009814	chr7:66654538~66669855:+
ESCA	cis	rs7951870	1	rs7951579	ENSG00000271350.1	CTD-2384B9.1	4.42	2.18e-05	0.0311	0.47	0.37	Schizophrenia;	chr11:46448350	chr11:47041027~47041945:-
ESCA	cis	rs7951870	1	rs61882743	ENSG00000271350.1	CTD-2384B9.1	4.42	2.18e-05	0.0311	0.47	0.37	Schizophrenia;	chr11:46527204	chr11:47041027~47041945:-
ESCA	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	4.42	2.18e-05	0.0311	0.49	0.37	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
ESCA	cis	rs2439831	0.702	rs495175	ENSG00000249839.1	AC011330.5	-4.42	2.18e-05	0.0311	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43506486	chr15:43663654~43684339:-
ESCA	cis	rs1976403	0.633	rs1780324	ENSG00000234397.3	RP11-415K20.1	-4.42	2.18e-05	0.0311	-0.39	-0.37	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:22322840~22323331:-
ESCA	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	4.42	2.18e-05	0.0312	0.48	0.37	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-4.42	2.18e-05	0.0312	-0.48	-0.37	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
ESCA	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-4.42	2.18e-05	0.0312	-0.48	-0.37	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
ESCA	cis	rs17691453	0.66	rs4260028	ENSG00000175746.6	C15orf54	4.42	2.18e-05	0.0312	0.47	0.37	Metabolite levels (Dihydroxy docosatrienoic acid);	chr15:39306816	chr15:39250684~39254845:+
ESCA	cis	rs7208859	0.623	rs9915566	ENSG00000263531.1	RP13-753N3.1	4.42	2.18e-05	0.0312	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30805140	chr17:30863921~30864940:-
ESCA	cis	rs3820068	0.581	rs12385690	ENSG00000237301.1	RP4-680D5.2	4.41	2.19e-05	0.0312	0.4	0.37	Systolic blood pressure;	chr1:15606437	chr1:15586136~15603626:-
ESCA	cis	rs7829975	0.846	rs1879957	ENSG00000173295.6	FAM86B3P	-4.41	2.19e-05	0.0312	-0.43	-0.37	Mood instability;	chr8:8687298	chr8:8228595~8244865:+
ESCA	cis	rs1005277	0.579	rs2474567	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38093564	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2472175	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38093973	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2472176	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38093993	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474569	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38094563	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2504143	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38094778	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.602	rs2504142	ENSG00000263064.2	RP11-291L22.7	4.41	2.19e-05	0.0312	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38094865	chr10:38448689~38448949:+
ESCA	cis	rs1062177	1	rs892006	ENSG00000253921.1	CTB-113P19.3	-4.41	2.19e-05	0.0312	-0.49	-0.37	Preschool internalizing problems;	chr5:151801329	chr5:151753992~151767247:+
ESCA	cis	rs8072100	0.84	rs9895746	ENSG00000228782.6	CTD-2026D20.3	4.41	2.19e-05	0.0312	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47401733	chr17:47450568~47492492:-
ESCA	cis	rs4742903	0.527	rs9776198	ENSG00000270332.1	SMC2-AS1	4.41	2.19e-05	0.0312	0.43	0.37	Breast cancer;High-grade serous ovarian cancer;	chr9:104215335	chr9:104080024~104093073:-
ESCA	cis	rs28830936	0.966	rs890498	ENSG00000250379.1	RP11-23P13.4	4.41	2.2e-05	0.0313	0.42	0.37	Diastolic blood pressure;	chr15:41819100	chr15:41825099~41827936:-
ESCA	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-4.41	2.2e-05	0.0313	-0.38	-0.37	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
ESCA	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-4.41	2.2e-05	0.0313	-0.44	-0.37	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
ESCA	cis	rs7829975	0.511	rs2921028	ENSG00000173295.6	FAM86B3P	4.41	2.2e-05	0.0314	0.46	0.37	Mood instability;	chr8:8482967	chr8:8228595~8244865:+
ESCA	cis	rs7829975	0.511	rs2976902	ENSG00000173295.6	FAM86B3P	4.41	2.2e-05	0.0314	0.46	0.37	Mood instability;	chr8:8483595	chr8:8228595~8244865:+
ESCA	cis	rs4330281	0.692	rs8179891	ENSG00000233133.1	AC104451.2	-4.41	2.2e-05	0.0314	-0.42	-0.37	Schizophrenia;	chr3:17685886	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.669	rs12634893	ENSG00000233133.1	AC104451.2	-4.41	2.2e-05	0.0314	-0.42	-0.37	Schizophrenia;	chr3:17688200	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.669	rs10510478	ENSG00000233133.1	AC104451.2	-4.41	2.2e-05	0.0314	-0.42	-0.37	Schizophrenia;	chr3:17688790	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.63	rs4408889	ENSG00000233133.1	AC104451.2	-4.41	2.2e-05	0.0314	-0.42	-0.37	Schizophrenia;	chr3:17688926	chr3:17706058~17706233:-
ESCA	cis	rs7179228	0.918	rs11072006	ENSG00000260657.2	RP11-315D16.4	-4.41	2.21e-05	0.0315	-0.62	-0.37	Systolic blood pressure;	chr15:68327293	chr15:68267792~68277994:-
ESCA	cis	rs12480328	1	rs17790938	ENSG00000228663.1	PSMD10P1	4.41	2.21e-05	0.0315	0.43	0.37	Prostate cancer;	chr20:50892647	chr20:50913731~50914411:+
ESCA	cis	rs10229583	0.527	rs7778413	ENSG00000279078.1	SND1-IT1	4.41	2.22e-05	0.0315	0.41	0.37	Type 2 diabetes;	chr7:127717662	chr7:127997597~128000077:+
ESCA	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-4.41	2.22e-05	0.0315	-0.31	-0.37	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
ESCA	cis	rs7584099	0.59	rs12105745	ENSG00000223911.1	AC009480.3	4.41	2.22e-05	0.0316	0.41	0.37	Response to statin therapy;	chr2:147916093	chr2:147899401~147902956:-
ESCA	cis	rs9462027	0.628	rs7739003	ENSG00000186328.4	RP11-140K17.2	4.41	2.22e-05	0.0316	0.41	0.37	Systemic lupus erythematosus;	chr6:34832552	chr6:34715613~34715940:+
ESCA	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-4.41	2.23e-05	0.0317	-0.43	-0.37	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
ESCA	cis	rs7208859	0.673	rs2433	ENSG00000263531.1	RP13-753N3.1	4.41	2.23e-05	0.0317	0.56	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30899210	chr17:30863921~30864940:-
ESCA	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	4.41	2.23e-05	0.0317	0.48	0.37	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	4.41	2.23e-05	0.0317	0.48	0.37	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	4.41	2.23e-05	0.0317	0.48	0.37	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
ESCA	cis	rs6432860	0.545	rs3812718	ENSG00000232411.1	AC009495.3	4.41	2.23e-05	0.0317	0.4	0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166053034	chr2:165833048~165839098:-
ESCA	cis	rs6479901	0.894	rs9919452	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63488812	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10740128	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63490783	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10761776	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63491217	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs7910662	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63493940	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.624	rs10822175	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63495414	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs9971294	ENSG00000235816.3	PRELID1P3	-4.41	2.23e-05	0.0317	-0.44	-0.37	Intelligence (multi-trait analysis);	chr10:63503108	chr10:63427297~63427939:+
ESCA	cis	rs9399137	0.507	rs4520025	ENSG00000232876.1	CTA-212D2.2	-4.41	2.23e-05	0.0317	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957481	chr6:135055033~135060550:+
ESCA	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-4.41	2.23e-05	0.0318	-0.63	-0.37	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
ESCA	cis	rs1048238	0.506	rs10927867	ENSG00000235084.3	CHCHD2P6	-4.41	2.24e-05	0.0318	-0.35	-0.37	Systolic blood pressure;	chr1:15850790	chr1:15604597~15605043:+
ESCA	cis	rs61990749	0.597	rs1008988	ENSG00000239272.1	RPL21P10	4.41	2.24e-05	0.0318	0.44	0.37	Fibroblast growth factor basic levels;	chr14:77794452	chr14:77683202~77683989:-
ESCA	cis	rs611744	0.781	rs656406	ENSG00000253754.1	RP11-35G22.1	-4.41	2.24e-05	0.0318	-0.34	-0.37	Dupuytren's disease;	chr8:108161614	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs633794	ENSG00000253754.1	RP11-35G22.1	-4.41	2.24e-05	0.0318	-0.34	-0.37	Dupuytren's disease;	chr8:108162473	chr8:108226200~108227544:+
ESCA	cis	rs9399137	0.507	rs4594969	ENSG00000232876.1	CTA-212D2.2	-4.41	2.25e-05	0.0319	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134964448	chr6:135055033~135060550:+
ESCA	cis	rs2688482	0.512	rs3103953	ENSG00000207650.1	MIR570	-4.41	2.25e-05	0.0319	-0.57	-0.37	Lung disease severity in cystic fibrosis;	chr3:195793726	chr3:195699401~195699497:+
ESCA	cis	rs6998967	0.54	rs1051920	ENSG00000272518.1	RP11-26J3.3	-4.41	2.25e-05	0.0319	-0.56	-0.37	Late-onset myasthenia gravis;	chr8:80526185	chr8:79956465~79957381:-
ESCA	cis	rs9462027	0.675	rs7755926	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34754797	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469859	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34755125	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.63	rs7341267	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34759254	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.606	rs7759227	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34760453	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs7741437	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34769776	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9469863	ENSG00000186328.4	RP11-140K17.2	4.41	2.25e-05	0.0319	0.41	0.37	Systemic lupus erythematosus;	chr6:34771872	chr6:34715613~34715940:+
ESCA	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	4.41	2.25e-05	0.0319	0.5	0.37	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	4.41	2.25e-05	0.0319	0.5	0.37	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
ESCA	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	4.41	2.25e-05	0.0319	0.5	0.37	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
ESCA	cis	rs7301826	0.651	rs10848209	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
ESCA	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-4.41	2.25e-05	0.0319	-0.42	-0.37	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
ESCA	cis	rs7924176	0.601	rs1874152	ENSG00000236900.1	TIMM9P1	-4.41	2.26e-05	0.032	-0.48	-0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);Permanent tooth development;	chr10:74076361	chr10:74344550~74344805:-
ESCA	cis	rs950169	0.881	rs72750843	ENSG00000225151.9	GOLGA2P7	-4.41	2.26e-05	0.032	-0.58	-0.37	Schizophrenia;	chr15:84592552	chr15:84199311~84230136:-
ESCA	cis	rs2108622	0.727	rs7251296	ENSG00000267453.5	AC004791.2	-4.41	2.26e-05	0.032	-0.46	-0.37	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872926	chr19:15851993~15864904:-
ESCA	cis	rs6860806	0.507	rs270606	ENSG00000233006.5	AC034220.3	4.41	2.26e-05	0.032	0.36	0.37	Breast cancer;	chr5:132315174	chr5:132311285~132369916:-
ESCA	cis	rs4835265	0.852	rs7685277	ENSG00000250673.1	RP11-6L6.2	4.41	2.27e-05	0.0321	0.4	0.37	Gamma glutamyl transpeptidase;	chr4:145854148	chr4:146224557~146229056:+
ESCA	cis	rs2273156	0.929	rs4573843	ENSG00000241052.1	RP11-173D9.1	-4.41	2.27e-05	0.0321	-0.43	-0.37	Immunoglobulin light chain (AL) amyloidosis;	chr14:34922563	chr14:35144021~35144480:-
ESCA	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-4.41	2.27e-05	0.0322	-0.43	-0.37	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
ESCA	cis	rs1005277	0.579	rs176886	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.557	rs176887	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474584	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs1548255	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474586	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs2474594	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38451030~38451785:+
ESCA	cis	rs1005277	0.579	rs11011461	ENSG00000276805.1	RP11-291L22.6	4.41	2.27e-05	0.0322	0.48	0.37	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38451030~38451785:+
ESCA	cis	rs9987353	0.519	rs2929465	ENSG00000253981.4	ALG1L13P	-4.4	2.27e-05	0.0322	-0.47	-0.37	Recombination measurement;	chr8:9206492	chr8:8236003~8244667:-
ESCA	cis	rs4330281	0.647	rs56059241	ENSG00000233133.1	AC104451.2	-4.4	2.28e-05	0.0322	-0.42	-0.37	Schizophrenia;	chr3:17690681	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.608	rs11128842	ENSG00000233133.1	AC104451.2	-4.4	2.28e-05	0.0322	-0.42	-0.37	Schizophrenia;	chr3:17693853	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.647	rs7613953	ENSG00000233133.1	AC104451.2	-4.4	2.28e-05	0.0322	-0.42	-0.37	Schizophrenia;	chr3:17701658	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.669	rs7650617	ENSG00000233133.1	AC104451.2	-4.4	2.28e-05	0.0322	-0.42	-0.37	Schizophrenia;	chr3:17701768	chr3:17706058~17706233:-
ESCA	cis	rs7208859	0.725	rs9891656	ENSG00000263531.1	RP13-753N3.1	4.4	2.28e-05	0.0323	0.52	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30916337	chr17:30863921~30864940:-
ESCA	cis	rs977987	0.778	rs12929908	ENSG00000261783.1	RP11-252K23.2	-4.4	2.28e-05	0.0323	-0.45	-0.37	Dupuytren's disease;	chr16:75428173	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.742	rs12928898	ENSG00000261783.1	RP11-252K23.2	-4.4	2.28e-05	0.0323	-0.45	-0.37	Dupuytren's disease;	chr16:75428183	chr16:75379818~75381260:-
ESCA	cis	rs636159	0.727	rs2511095	ENSG00000213287.3	RP11-680L20.1	-4.4	2.29e-05	0.0323	-0.44	-0.37	Bone ultrasound measurement (velocity of sound);	chr11:87192421	chr11:87258851~87259259:-
ESCA	cis	rs636159	0.727	rs301576	ENSG00000213287.3	RP11-680L20.1	-4.4	2.29e-05	0.0323	-0.44	-0.37	Bone ultrasound measurement (velocity of sound);	chr11:87193854	chr11:87258851~87259259:-
ESCA	cis	rs1816752	0.819	rs7400583	ENSG00000273628.1	RP11-756A22.7	4.4	2.29e-05	0.0323	0.36	0.37	Obesity-related traits;	chr13:24415916	chr13:24933006~24936796:+
ESCA	cis	rs7017914	0.69	rs13263370	ENSG00000253173.3	RP11-152C15.1	-4.4	2.29e-05	0.0323	-0.43	-0.37	Bone mineral density;	chr8:71057299	chr8:70103798~70104179:-
ESCA	cis	rs3820068	0.581	rs72645895	ENSG00000237301.1	RP4-680D5.2	4.4	2.29e-05	0.0324	0.42	0.37	Systolic blood pressure;	chr1:15605214	chr1:15586136~15603626:-
ESCA	cis	rs7631605	0.967	rs6806487	ENSG00000272334.1	RP11-129K12.1	-4.4	2.29e-05	0.0324	-0.4	-0.37	Cerebrospinal P-tau181p levels;	chr3:37079601	chr3:36973117~36973672:-
ESCA	cis	rs10954779	0.764	rs6994361	ENSG00000253579.1	SUMO2P16	-4.4	2.3e-05	0.0324	-0.4	-0.37	Intelligence (multi-trait analysis);	chr8:31161169	chr8:31131539~31131802:-
ESCA	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	4.4	2.3e-05	0.0324	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	4.4	2.3e-05	0.0324	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	4.4	2.3e-05	0.0324	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	4.4	2.3e-05	0.0324	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
ESCA	cis	rs11169552	0.943	rs10876096	ENSG00000200428.1	Y_RNA	-4.4	2.3e-05	0.0324	-0.45	-0.37	Colorectal cancer;	chr12:50810170	chr12:50743568~50743684:+
ESCA	cis	rs5758659	0.714	rs133373	ENSG00000182057.4	OGFRP1	4.4	2.3e-05	0.0325	0.45	0.37	Cognitive function;	chr22:42069784	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs5758574	ENSG00000182057.4	OGFRP1	-4.4	2.3e-05	0.0325	-0.45	-0.37	Cognitive function;	chr22:42085396	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs2284087	ENSG00000182057.4	OGFRP1	-4.4	2.3e-05	0.0325	-0.45	-0.37	Cognitive function;	chr22:42089667	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs5758578	ENSG00000182057.4	OGFRP1	-4.4	2.3e-05	0.0325	-0.45	-0.37	Cognitive function;	chr22:42094288	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs5758589	ENSG00000182057.4	OGFRP1	-4.4	2.3e-05	0.0325	-0.45	-0.37	Cognitive function;	chr22:42122378	chr22:42269753~42275196:+
ESCA	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	4.4	2.3e-05	0.0325	0.48	0.37	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
ESCA	cis	rs5769707	0.967	rs9616713	ENSG00000213279.2	RP1-29C18.9	-4.4	2.3e-05	0.0325	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49572264~49575426:-
ESCA	cis	rs1005277	0.579	rs2474571	ENSG00000263064.2	RP11-291L22.7	4.4	2.3e-05	0.0325	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38095711	chr10:38448689~38448949:+
ESCA	cis	rs5769707	0.935	rs739239	ENSG00000213279.2	RP1-29C18.9	-4.4	2.3e-05	0.0325	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49572264~49575426:-
ESCA	cis	rs8099594	0.64	rs1539965	ENSG00000266696.1	RP11-30L3.2	4.4	2.31e-05	0.0325	0.45	0.37	Height;	chr18:49327971	chr18:49205912~49208781:+
ESCA	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-4.4	2.31e-05	0.0325	-0.48	-0.37	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
ESCA	cis	rs1005277	0.579	rs2505257	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38083736	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2472173	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38085710	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2472174	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38086454	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474563	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38087010	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs9418322	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38088368	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs9299760	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38088992	chr10:38448689~38448949:+
ESCA	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-4.4	2.31e-05	0.0326	-0.44	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
ESCA	cis	rs1005277	0.579	rs2023351	ENSG00000263064.2	RP11-291L22.7	4.4	2.31e-05	0.0326	0.49	0.37	Extrinsic epigenetic age acceleration;	chr10:38089886	chr10:38448689~38448949:+
ESCA	cis	rs1439620	0.686	rs7167859	ENSG00000271763.1	RP11-386M24.9	4.4	2.31e-05	0.0326	0.41	0.37	Body mass index;	chr15:92957805	chr15:92602910~92620015:+
ESCA	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-4.4	2.32e-05	0.0327	-0.44	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
ESCA	cis	rs6479901	0.895	rs7082066	ENSG00000235816.3	PRELID1P3	-4.4	2.32e-05	0.0327	-0.42	-0.37	Intelligence (multi-trait analysis);	chr10:63239211	chr10:63427297~63427939:+
ESCA	cis	rs11308613	1	rs11308613	ENSG00000223685.4	LINC00571	-4.4	2.32e-05	0.0327	-0.54	-0.37	Mild influenza (H1N1) infection;	chr13:37983874	chr13:38050817~38143232:-
ESCA	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-4.4	2.32e-05	0.0327	-0.37	-0.37	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
ESCA	cis	rs5758659	1	rs5758660	ENSG00000182057.4	OGFRP1	4.4	2.32e-05	0.0327	0.43	0.37	Cognitive function;	chr22:42227712	chr22:42269753~42275196:+
ESCA	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-4.4	2.32e-05	0.0327	-0.44	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
ESCA	cis	rs4407350	0.756	rs131155	ENSG00000228807.1	MRPS18CP6	-4.4	2.33e-05	0.0328	-0.41	-0.37	Intelligence (multi-trait analysis);	chr22:44495367	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.721	rs131156	ENSG00000228807.1	MRPS18CP6	-4.4	2.33e-05	0.0328	-0.41	-0.37	Intelligence (multi-trait analysis);	chr22:44495490	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.721	rs105248	ENSG00000228807.1	MRPS18CP6	-4.4	2.33e-05	0.0328	-0.41	-0.37	Intelligence (multi-trait analysis);	chr22:44495519	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.721	rs131157	ENSG00000228807.1	MRPS18CP6	-4.4	2.33e-05	0.0328	-0.41	-0.37	Intelligence (multi-trait analysis);	chr22:44495842	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.756	rs131158	ENSG00000228807.1	MRPS18CP6	-4.4	2.33e-05	0.0328	-0.41	-0.37	Intelligence (multi-trait analysis);	chr22:44495993	chr22:44483495~44483717:-
ESCA	cis	rs1075265	0.508	rs12621225	ENSG00000235937.1	AC008280.1	4.4	2.33e-05	0.0328	0.41	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53710040	chr2:54029552~54030682:-
ESCA	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	4.4	2.33e-05	0.0328	0.48	0.37	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
ESCA	cis	rs1005277	0.579	rs2472181	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38097836	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474574	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38098367	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2504140	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38098651	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474575	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38098973	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2472182	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38099937	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2021649	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38103194	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2505197	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38104382	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2505196	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38104635	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.541	rs2505193	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38105710	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474580	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38109785	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2504148	ENSG00000263064.2	RP11-291L22.7	4.4	2.33e-05	0.0328	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38111860	chr10:38448689~38448949:+
ESCA	cis	rs2439831	0.867	rs3213991	ENSG00000249839.1	AC011330.5	-4.4	2.33e-05	0.0328	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43378082	chr15:43663654~43684339:-
ESCA	cis	rs7412746	0.587	rs3849279	ENSG00000206931.1	RNU6-1042P	4.4	2.33e-05	0.0328	0.48	0.37	Melanoma;	chr1:150972231	chr1:150701866~150701972:+
ESCA	cis	rs67180937	0.582	rs71524942	ENSG00000272750.1	RP11-378J18.8	-4.4	2.33e-05	0.0328	-0.45	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222689650	chr1:222658867~222661512:-
ESCA	cis	rs7017914	0.652	rs13250391	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0328	-0.43	-0.37	Bone mineral density;	chr8:70885537	chr8:70103798~70104179:-
ESCA	cis	rs3820068	0.581	rs1547031	ENSG00000237301.1	RP4-680D5.2	4.4	2.34e-05	0.0329	0.41	0.37	Systolic blood pressure;	chr1:15592465	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs1547033	ENSG00000237301.1	RP4-680D5.2	4.4	2.34e-05	0.0329	0.41	0.37	Systolic blood pressure;	chr1:15592493	chr1:15586136~15603626:-
ESCA	cis	rs2098713	0.534	rs11952015	ENSG00000250155.1	CTD-2353F22.1	4.4	2.34e-05	0.0329	0.41	0.37	Telomere length;	chr5:37539402	chr5:36666214~36725195:-
ESCA	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0329	0.51	0.37	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
ESCA	cis	rs7017914	0.652	rs2017035	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70929571	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs10504487	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70931364	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs34366597	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70932658	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs7839977	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70933067	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs1493199	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70934269	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.616	rs17689943	ENSG00000253173.3	RP11-152C15.1	-4.4	2.34e-05	0.0329	-0.43	-0.37	Bone mineral density;	chr8:70936145	chr8:70103798~70104179:-
ESCA	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	4.4	2.34e-05	0.0329	0.5	0.37	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
ESCA	cis	rs11779988	0.545	rs208753	ENSG00000253671.1	RP11-806O11.1	-4.4	2.35e-05	0.033	-0.42	-0.37	Breast cancer;	chr8:17957406	chr8:17808941~17820868:+
ESCA	cis	rs10229583	0.527	rs6943385	ENSG00000279078.1	SND1-IT1	-4.4	2.35e-05	0.033	-0.43	-0.37	Type 2 diabetes;	chr7:127668374	chr7:127997597~128000077:+
ESCA	cis	rs10246939	0.511	rs62475469	ENSG00000228775.6	WEE2-AS1	4.4	2.35e-05	0.033	0.4	0.37	Bitter taste perception;	chr7:141864846	chr7:141704338~141738346:-
ESCA	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	4.4	2.36e-05	0.0331	0.48	0.37	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	4.4	2.36e-05	0.0331	0.48	0.37	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	4.4	2.36e-05	0.0331	0.48	0.37	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
ESCA	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	4.4	2.36e-05	0.0331	0.48	0.37	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
ESCA	cis	rs8072100	1	rs4794048	ENSG00000228782.6	CTD-2026D20.3	4.4	2.36e-05	0.0331	0.39	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47685707	chr17:47450568~47492492:-
ESCA	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	4.4	2.36e-05	0.0331	0.41	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
ESCA	cis	rs10954779	0.764	rs2553280	ENSG00000253579.1	SUMO2P16	-4.4	2.36e-05	0.0332	-0.41	-0.37	Intelligence (multi-trait analysis);	chr8:31137345	chr8:31131539~31131802:-
ESCA	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	4.4	2.37e-05	0.0332	0.62	0.37	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
ESCA	cis	rs10754283	0.756	rs17441836	ENSG00000231613.1	RP5-943J3.1	4.39	2.37e-05	0.0332	0.42	0.37	Amyotrophic lateral sclerosis (sporadic);	chr1:89669874	chr1:89788914~89790492:+
ESCA	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	4.39	2.37e-05	0.0332	0.36	0.37	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
ESCA	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	4.39	2.37e-05	0.0332	0.36	0.37	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
ESCA	cis	rs2717559	0.542	rs2717586	ENSG00000253716.4	RP13-582O9.5	-4.39	2.37e-05	0.0332	-0.39	-0.37	Urinary tract infection frequency;	chr8:142816466	chr8:143280161~143281690:-
ESCA	cis	rs1501911	0.53	rs161941	ENSG00000248489.1	CTD-2007H13.3	-4.39	2.37e-05	0.0332	-0.52	-0.37	Lung function (FEV1/FVC);	chr5:98863500	chr5:98929171~98995013:+
ESCA	cis	rs10229583	0.563	rs7801118	ENSG00000279078.1	SND1-IT1	4.39	2.37e-05	0.0333	0.4	0.37	Type 2 diabetes;	chr7:127623832	chr7:127997597~128000077:+
ESCA	cis	rs7951870	0.504	rs3740973	ENSG00000271350.1	CTD-2384B9.1	4.39	2.37e-05	0.0333	0.42	0.37	Schizophrenia;	chr11:46400687	chr11:47041027~47041945:-
ESCA	cis	rs7932354	0.528	rs10838654	ENSG00000271350.1	CTD-2384B9.1	-4.39	2.38e-05	0.0333	-0.44	-0.37	Bone mineral density (hip);Bone mineral density;	chr11:47073960	chr11:47041027~47041945:-
ESCA	cis	rs4345206	0.639	rs7662070	ENSG00000250673.1	RP11-6L6.2	-4.39	2.38e-05	0.0334	-0.35	-0.37	Coronary artery disease;	chr4:145887865	chr4:146224557~146229056:+
ESCA	cis	rs7582403	0.789	rs1597406	ENSG00000223911.1	AC009480.3	-4.39	2.38e-05	0.0334	-0.39	-0.37	Neuroticism;	chr2:148119429	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.844	rs2890922	ENSG00000223911.1	AC009480.3	-4.39	2.38e-05	0.0334	-0.39	-0.37	Neuroticism;	chr2:148129393	chr2:147899401~147902956:-
ESCA	cis	rs9549260	0.755	rs3900833	ENSG00000229456.1	RLIMP1	4.39	2.38e-05	0.0334	0.34	0.37	Red blood cell count;	chr13:40614155	chr13:40618738~40621348:+
ESCA	cis	rs9549260	0.62	rs12583418	ENSG00000229456.1	RLIMP1	4.39	2.38e-05	0.0334	0.34	0.37	Red blood cell count;	chr13:40621274	chr13:40618738~40621348:+
ESCA	cis	rs9462027	0.628	rs2764206	ENSG00000186328.4	RP11-140K17.2	4.39	2.38e-05	0.0334	0.41	0.37	Systemic lupus erythematosus;	chr6:34745123	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814969	ENSG00000186328.4	RP11-140K17.2	4.39	2.38e-05	0.0334	0.41	0.37	Systemic lupus erythematosus;	chr6:34745622	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814970	ENSG00000186328.4	RP11-140K17.2	4.39	2.38e-05	0.0334	0.41	0.37	Systemic lupus erythematosus;	chr6:34745723	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.583	rs912716	ENSG00000186328.4	RP11-140K17.2	4.39	2.38e-05	0.0334	0.41	0.37	Systemic lupus erythematosus;	chr6:34747984	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9462009	ENSG00000186328.4	RP11-140K17.2	4.39	2.38e-05	0.0334	0.41	0.37	Systemic lupus erythematosus;	chr6:34748553	chr6:34715613~34715940:+
ESCA	cis	rs7709377	0.723	rs1820053	ENSG00000272265.1	CTD-2287O16.4	4.39	2.38e-05	0.0334	0.52	0.37	Metabolite levels  (X-11787);	chr5:116212651	chr5:116078110~116078570:-
ESCA	cis	rs7709377	0.723	rs7723648	ENSG00000272265.1	CTD-2287O16.4	4.39	2.38e-05	0.0334	0.52	0.37	Metabolite levels  (X-11787);	chr5:116212738	chr5:116078110~116078570:-
ESCA	cis	rs9386630	0.583	rs7741724	ENSG00000224987.1	RP1-191J18.65	-4.39	2.39e-05	0.0334	-0.51	-0.37	Coffee consumption;	chr6:107216905	chr6:107985089~107985690:-
ESCA	cis	rs9386630	0.656	rs6568479	ENSG00000224987.1	RP1-191J18.65	-4.39	2.39e-05	0.0335	-0.51	-0.37	Coffee consumption;	chr6:107225876	chr6:107985089~107985690:-
ESCA	cis	rs35146811	0.555	rs2527898	ENSG00000201913.1	Y_RNA	-4.39	2.4e-05	0.0336	-0.45	-0.37	Coronary artery disease;	chr7:99936407	chr7:100330777~100330877:-
ESCA	cis	rs7412746	0.611	rs10888398	ENSG00000206931.1	RNU6-1042P	-4.39	2.4e-05	0.0336	-0.46	-0.37	Melanoma;	chr1:150914306	chr1:150701866~150701972:+
ESCA	cis	rs2221894	1	rs6558085	ENSG00000273710.1	Metazoa_SRP	-4.39	2.4e-05	0.0336	-0.43	-0.37	Obesity-related traits;	chr8:28945415	chr8:28915579~28915864:-
ESCA	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	4.39	2.41e-05	0.0337	0.62	0.37	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	4.39	2.41e-05	0.0337	0.62	0.37	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
ESCA	cis	rs11051970	0.879	rs2728669	ENSG00000253063.1	RNU6-494P	-4.39	2.41e-05	0.0337	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32437717	chr12:32477382~32477471:-
ESCA	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-4.39	2.41e-05	0.0337	-0.44	-0.37	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-4.39	2.41e-05	0.0337	-0.44	-0.37	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
ESCA	cis	rs7819412	0.668	rs2409714	ENSG00000248896.2	CTD-2135J3.3	-4.39	2.42e-05	0.0338	-0.48	-0.37	Triglycerides;	chr8:11152608	chr8:10729314~10771392:+
ESCA	cis	rs12022452	0.73	rs2297755	ENSG00000229901.1	RP11-399E6.4	4.39	2.42e-05	0.0338	0.44	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40547343	chr1:41375004~41375669:-
ESCA	cis	rs4330281	0.58	rs9310519	ENSG00000233133.1	AC104451.2	4.39	2.42e-05	0.0338	0.42	0.37	Schizophrenia;	chr3:17535013	chr3:17706058~17706233:-
ESCA	cis	rs4330281	0.58	rs9310520	ENSG00000233133.1	AC104451.2	4.39	2.42e-05	0.0338	0.42	0.37	Schizophrenia;	chr3:17535884	chr3:17706058~17706233:-
ESCA	cis	rs7017914	0.69	rs12674838	ENSG00000253173.3	RP11-152C15.1	-4.39	2.42e-05	0.0338	-0.37	-0.37	Bone mineral density;	chr8:71078045	chr8:70103798~70104179:-
ESCA	cis	rs4927850	0.957	rs4927851	ENSG00000207650.1	MIR570	4.39	2.42e-05	0.0338	0.4	0.37	Pancreatic cancer;	chr3:196024982	chr3:195699401~195699497:+
ESCA	cis	rs4927850	0.918	rs4361313	ENSG00000207650.1	MIR570	4.39	2.42e-05	0.0338	0.4	0.37	Pancreatic cancer;	chr3:196025389	chr3:195699401~195699497:+
ESCA	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-4.39	2.43e-05	0.0339	-0.51	-0.37	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
ESCA	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-4.39	2.43e-05	0.0339	-0.51	-0.37	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
ESCA	cis	rs6805251	0.639	rs6775397	ENSG00000276607.2	AC092910.1	-4.39	2.43e-05	0.0339	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:119942526	chr3:120084550~120084657:-
ESCA	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	4.39	2.43e-05	0.0339	0.48	0.37	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
ESCA	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	4.39	2.43e-05	0.0339	0.49	0.37	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
ESCA	cis	rs72759215	1	rs72759215	ENSG00000215032.2	GNL3LP1	4.39	2.43e-05	0.0339	0.47	0.37	Intelligence (multi-trait analysis);	chr5:61056756	chr5:60891935~60893577:-
ESCA	cis	rs875971	0.545	rs6950988	ENSG00000179406.6	LINC00174	-4.39	2.43e-05	0.0339	-0.52	-0.37	Aortic root size;	chr7:66511428	chr7:66376044~66401338:-
ESCA	cis	rs9608946	1	rs9606735	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30488844	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs9606736	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30490590	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs17738527	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30492507	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs17738540	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30492540	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs8137718	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30492972	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs9606739	ENSG00000268812.3	RP1-102K2.8	4.39	2.44e-05	0.034	0.5	0.37	Red cell distribution width;	chr22:30495307	chr22:30246205~30246998:+
ESCA	cis	rs7017914	0.628	rs55740254	ENSG00000253173.3	RP11-152C15.1	-4.39	2.44e-05	0.034	-0.43	-0.37	Bone mineral density;	chr8:70928325	chr8:70103798~70104179:-
ESCA	cis	rs2179367	0.887	rs2789488	ENSG00000216906.2	RP11-350J20.9	-4.39	2.44e-05	0.034	-0.46	-0.37	Dupuytren's disease;	chr6:149404154	chr6:149904243~149906418:+
ESCA	cis	rs7212590	0.618	rs7217337	ENSG00000263820.1	AC005702.2	-4.39	2.44e-05	0.034	-0.61	-0.37	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59946056	chr17:60042805~60042882:-
ESCA	cis	rs7212590	0.655	rs16943969	ENSG00000263820.1	AC005702.2	-4.39	2.44e-05	0.034	-0.61	-0.37	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59953792	chr17:60042805~60042882:-
ESCA	cis	rs7212590	0.618	rs7219051	ENSG00000263820.1	AC005702.2	-4.39	2.44e-05	0.034	-0.61	-0.37	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59955349	chr17:60042805~60042882:-
ESCA	cis	rs7212590	0.618	rs59767604	ENSG00000263820.1	AC005702.2	-4.39	2.44e-05	0.034	-0.61	-0.37	Monocyte count;Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr17:59963978	chr17:60042805~60042882:-
ESCA	cis	rs2439831	1	rs2439831	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43492277	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2467736	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43492719	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2444250	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43492853	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs101094	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43495124	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs689781	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43499899	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2584725	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43500937	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2253708	ENSG00000249839.1	AC011330.5	-4.39	2.44e-05	0.0341	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43505075	chr15:43663654~43684339:-
ESCA	cis	rs7829975	0.688	rs6995407	ENSG00000173295.6	FAM86B3P	4.39	2.45e-05	0.0341	0.45	0.37	Mood instability;	chr8:8527137	chr8:8228595~8244865:+
ESCA	cis	rs67981189	0.542	rs1012725	ENSG00000269945.1	RP6-91H8.5	4.39	2.45e-05	0.0342	0.47	0.37	Schizophrenia;	chr14:71138994	chr14:71219100~71222724:+
ESCA	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-4.39	2.45e-05	0.0342	-0.4	-0.37	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
ESCA	cis	rs7714584	1	rs11747270	ENSG00000197083.10	ZNF300P1	-4.39	2.46e-05	0.0342	-0.55	-0.37	Crohn's disease;	chr5:150879305	chr5:150930645~150946289:-
ESCA	cis	rs7718446	0.622	rs2400215	ENSG00000250343.1	CTC-255N20.1	4.39	2.46e-05	0.0342	0.49	0.37	Migraine without aura;	chr5:146400790	chr5:147180204~147234859:-
ESCA	cis	rs8072100	1	rs4794016	ENSG00000228782.6	CTD-2026D20.3	-4.39	2.46e-05	0.0343	-0.4	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47648565	chr17:47450568~47492492:-
ESCA	cis	rs9309711	0.666	rs6723126	ENSG00000225234.1	TRAPPC12-AS1	-4.38	2.47e-05	0.0343	-0.45	-0.37	Neurofibrillary tangles;	chr2:3480729	chr2:3481242~3482409:-
ESCA	cis	rs17826219	0.568	rs2626985	ENSG00000263531.1	RP13-753N3.1	4.38	2.47e-05	0.0343	0.57	0.37	Body mass index;	chr17:30750419	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.568	rs59858012	ENSG00000263531.1	RP13-753N3.1	4.38	2.47e-05	0.0344	0.58	0.37	Body mass index;	chr17:30751564	chr17:30863921~30864940:-
ESCA	cis	rs1075265	0.633	rs7591431	ENSG00000235937.1	AC008280.1	4.38	2.47e-05	0.0344	0.42	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54029552~54030682:-
ESCA	cis	rs9584850	1	rs9584850	ENSG00000231194.1	FARP1-AS1	4.38	2.48e-05	0.0344	0.46	0.37	Neuroticism;	chr13:98449172	chr13:98435405~98435840:-
ESCA	cis	rs508487	0.537	rs5072	ENSG00000254851.1	RP11-109L13.1	-4.38	2.48e-05	0.0344	-0.78	-0.37	Cardiovascular disease risk factors;Triglyceride levels;	chr11:116836867	chr11:117135528~117138582:+
ESCA	cis	rs9462027	0.606	rs6906129	ENSG00000186328.4	RP11-140K17.2	4.38	2.48e-05	0.0345	0.4	0.37	Systemic lupus erythematosus;	chr6:34833383	chr6:34715613~34715940:+
ESCA	cis	rs61990749	0.597	rs2267761	ENSG00000239272.1	RPL21P10	-4.38	2.48e-05	0.0345	-0.44	-0.37	Fibroblast growth factor basic levels;	chr14:77681506	chr14:77683202~77683989:-
ESCA	cis	rs858239	0.965	rs156429	ENSG00000230042.1	AK3P3	-4.38	2.48e-05	0.0345	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23129178~23129841:+
ESCA	cis	rs7631605	0.905	rs9822082	ENSG00000272334.1	RP11-129K12.1	-4.38	2.48e-05	0.0345	-0.4	-0.37	Cerebrospinal P-tau181p levels;	chr3:37044713	chr3:36973117~36973672:-
ESCA	cis	rs9462027	0.628	rs2814942	ENSG00000186328.4	RP11-140K17.2	4.38	2.48e-05	0.0345	0.4	0.37	Systemic lupus erythematosus;	chr6:34676484	chr6:34715613~34715940:+
ESCA	cis	rs7582403	0.778	rs6727415	ENSG00000223911.1	AC009480.3	-4.38	2.48e-05	0.0345	-0.39	-0.37	Neuroticism;	chr2:148135838	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.816	rs7558404	ENSG00000223911.1	AC009480.3	-4.38	2.48e-05	0.0345	-0.39	-0.37	Neuroticism;	chr2:148137738	chr2:147899401~147902956:-
ESCA	cis	rs4927850	1	rs7630875	ENSG00000207650.1	MIR570	4.38	2.48e-05	0.0345	0.4	0.37	Pancreatic cancer;	chr3:196026895	chr3:195699401~195699497:+
ESCA	cis	rs8062405	0.723	rs762633	ENSG00000278665.1	RP11-666O2.4	4.38	2.49e-05	0.0345	0.52	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28599241~28601881:-
ESCA	cis	rs7582403	0.844	rs1234416	ENSG00000223911.1	AC009480.3	4.38	2.49e-05	0.0346	0.39	0.37	Neuroticism;	chr2:148035896	chr2:147899401~147902956:-
ESCA	cis	rs2742234	0.59	rs2435338	ENSG00000273008.1	RP11-351D16.3	-4.38	2.49e-05	0.0346	-0.43	-0.37	Hirschsprung disease;	chr10:43146667	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2435339	ENSG00000273008.1	RP11-351D16.3	-4.38	2.49e-05	0.0346	-0.43	-0.37	Hirschsprung disease;	chr10:43146725	chr10:43136824~43138334:-
ESCA	cis	rs1538970	0.816	rs34673142	ENSG00000280836.1	AL355480.1	-4.38	2.49e-05	0.0346	-0.47	-0.37	Platelet count;	chr1:45519889	chr1:45581219~45581321:-
ESCA	cis	rs7208859	0.573	rs8078182	ENSG00000263531.1	RP13-753N3.1	4.38	2.49e-05	0.0346	0.52	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30822646	chr17:30863921~30864940:-
ESCA	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	4.38	2.49e-05	0.0346	0.52	0.37	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
ESCA	cis	rs28830936	1	rs11629678	ENSG00000250379.1	RP11-23P13.4	4.38	2.49e-05	0.0346	0.43	0.37	Diastolic blood pressure;	chr15:41640332	chr15:41825099~41827936:-
ESCA	cis	rs2303759	0.666	rs66967196	ENSG00000269814.1	CTC-273B12.10	-4.38	2.49e-05	0.0346	-0.49	-0.37	Multiple sclerosis;	chr19:49305637	chr19:48513207~48513660:-
ESCA	cis	rs253959	0.564	rs4921064	ENSG00000272265.1	CTD-2287O16.4	4.38	2.49e-05	0.0346	0.42	0.37	Bipolar disorder and schizophrenia;	chr5:116111637	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.532	rs10045890	ENSG00000272265.1	CTD-2287O16.4	4.38	2.49e-05	0.0346	0.42	0.37	Bipolar disorder and schizophrenia;	chr5:116112188	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.595	rs11241361	ENSG00000272265.1	CTD-2287O16.4	4.38	2.49e-05	0.0346	0.42	0.37	Bipolar disorder and schizophrenia;	chr5:116112611	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.545	rs11241362	ENSG00000272265.1	CTD-2287O16.4	4.38	2.49e-05	0.0346	0.42	0.37	Bipolar disorder and schizophrenia;	chr5:116112630	chr5:116078110~116078570:-
ESCA	cis	rs2470578	0.792	rs2733496	ENSG00000233133.1	AC104451.2	4.38	2.49e-05	0.0346	0.39	0.37	Schizophrenia;	chr3:17239838	chr3:17706058~17706233:-
ESCA	cis	rs8003054	0.589	rs999692	ENSG00000258515.1	RP11-203M5.7	-4.38	2.5e-05	0.0347	-0.33	-0.37	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20449506	chr14:20451305~20451918:+
ESCA	cis	rs997781	0.611	rs7217887	ENSG00000267184.1	RP1-200G19.1	4.38	2.5e-05	0.0347	0.43	0.37	MGMT methylation in smokers;	chr17:69200211	chr17:69707193~69707373:-
ESCA	cis	rs10771431	1	rs11611670	ENSG00000212440.1	SNORA75	4.38	2.5e-05	0.0347	0.46	0.37	Breast size;	chr12:9232939	chr12:9286673~9286822:-
ESCA	cis	rs1005277	0.579	rs2505194	ENSG00000263064.2	RP11-291L22.7	4.38	2.5e-05	0.0347	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38104953	chr10:38448689~38448949:+
ESCA	cis	rs1864400	0.696	rs2742239	ENSG00000273008.1	RP11-351D16.3	-4.38	2.5e-05	0.0347	-0.44	-0.37	Hirschsprung disease;	chr10:43126264	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.59	rs2075912	ENSG00000273008.1	RP11-351D16.3	-4.38	2.5e-05	0.0347	-0.44	-0.37	Hirschsprung disease;	chr10:43126769	chr10:43136824~43138334:-
ESCA	cis	rs3820068	0.581	rs58567918	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15599328	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645871	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15599647	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs74054797	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15599722	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645874	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15599743	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs111699992	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15600663	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645877	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15601611	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645879	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15601704	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645881	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15601708	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs56128111	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15602453	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs16851851	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15603133	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs72645887	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15603410	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645888	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15603427	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645889	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15603756	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645890	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15604107	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs16851855	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15604374	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs72645893	ENSG00000237301.1	RP4-680D5.2	4.38	2.5e-05	0.0347	0.41	0.37	Systolic blood pressure;	chr1:15604448	chr1:15586136~15603626:-
ESCA	cis	rs7618915	0.547	rs34017441	ENSG00000242797.3	GLYCTK-AS1	-4.38	2.5e-05	0.0347	-0.33	-0.37	Bipolar disorder;	chr3:52708397	chr3:52288580~52299067:-
ESCA	cis	rs28830936	1	rs2004162	ENSG00000250379.1	RP11-23P13.4	4.38	2.51e-05	0.0347	0.42	0.37	Diastolic blood pressure;	chr15:41673344	chr15:41825099~41827936:-
ESCA	cis	rs5763662	1	rs4823057	ENSG00000237015.1	CTA-984G1.5	-4.38	2.51e-05	0.0348	-0.71	-0.37	LDL cholesterol levels;LDL cholesterol;	chr22:29845072	chr22:29260889~29262037:+
ESCA	cis	rs9326248	0.569	rs11216161	ENSG00000254851.1	RP11-109L13.1	-4.38	2.51e-05	0.0348	-0.54	-0.37	Blood protein levels;	chr11:116850485	chr11:117135528~117138582:+
ESCA	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	4.38	2.52e-05	0.0349	0.49	0.37	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
ESCA	cis	rs975752	0.764	rs11190456	ENSG00000230224.1	PHBP9	-4.38	2.52e-05	0.0349	-0.55	-0.37	Schizophrenia;	chr10:100292006	chr10:100248271~100249095:+
ESCA	cis	rs9601248	0.874	rs2093621	ENSG00000227676.3	LINC01068	4.38	2.52e-05	0.0349	0.45	0.37	Major depressive disorder;	chr13:79613953	chr13:79566727~79571436:+
ESCA	cis	rs9601248	0.874	rs2093620	ENSG00000227676.3	LINC01068	4.38	2.52e-05	0.0349	0.45	0.37	Major depressive disorder;	chr13:79613954	chr13:79566727~79571436:+
ESCA	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-4.38	2.53e-05	0.0349	-0.41	-0.37	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
ESCA	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	4.38	2.53e-05	0.0349	0.57	0.37	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
ESCA	cis	rs2307394	1	rs12987286	ENSG00000223911.1	AC009480.3	4.38	2.53e-05	0.0349	0.44	0.37	Urate levels;	chr2:147905999	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs6729997	ENSG00000223911.1	AC009480.3	4.38	2.53e-05	0.0349	0.44	0.37	Urate levels;	chr2:147907988	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs13008497	ENSG00000223911.1	AC009480.3	4.38	2.53e-05	0.0349	0.44	0.37	Urate levels;	chr2:147909192	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs723681	ENSG00000223911.1	AC009480.3	4.38	2.53e-05	0.0349	0.44	0.37	Urate levels;	chr2:147910940	chr2:147899401~147902956:-
ESCA	cis	rs2307394	1	rs3764955	ENSG00000223911.1	AC009480.3	4.38	2.53e-05	0.0349	0.44	0.37	Urate levels;	chr2:147917228	chr2:147899401~147902956:-
ESCA	cis	rs6724465	1	rs12470505	ENSG00000272644.1	RP11-33O4.1	-4.38	2.53e-05	0.035	-0.64	-0.37	Height;	chr2:219043647	chr2:219069354~219069809:-
ESCA	cis	rs6452524	0.618	rs4266384	ENSG00000243385.2	CTD-2110K23.1	4.38	2.53e-05	0.035	0.38	0.37	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83201229~83202141:+
ESCA	cis	rs4330281	0.647	rs4435673	ENSG00000233133.1	AC104451.2	-4.38	2.54e-05	0.0351	-0.41	-0.37	Schizophrenia;	chr3:17707633	chr3:17706058~17706233:-
ESCA	cis	rs1538970	0.851	rs61788285	ENSG00000280836.1	AL355480.1	-4.38	2.54e-05	0.0351	-0.49	-0.37	Platelet count;	chr1:45453562	chr1:45581219~45581321:-
ESCA	cis	rs72387598	1	rs72387598	ENSG00000280836.1	AL355480.1	-4.38	2.54e-05	0.0351	-0.49	-0.37	Platelet distribution width;	chr1:45457307	chr1:45581219~45581321:-
ESCA	cis	rs6487679	0.543	rs7979115	ENSG00000111788.10	RP11-22B23.1	4.38	2.54e-05	0.0351	0.77	0.37	Non-alcoholic fatty liver disease histology (AST);	chr12:9212684	chr12:9277235~9313241:+
ESCA	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	4.38	2.55e-05	0.0351	0.47	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
ESCA	cis	rs7017914	0.652	rs6994814	ENSG00000253173.3	RP11-152C15.1	-4.38	2.55e-05	0.0352	-0.43	-0.37	Bone mineral density;	chr8:70656903	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.628	rs7830515	ENSG00000253173.3	RP11-152C15.1	-4.38	2.55e-05	0.0352	-0.43	-0.37	Bone mineral density;	chr8:70657999	chr8:70103798~70104179:-
ESCA	cis	rs9549260	0.755	rs9532571	ENSG00000229456.1	RLIMP1	4.38	2.55e-05	0.0352	0.34	0.37	Red blood cell count;	chr13:40644533	chr13:40618738~40621348:+
ESCA	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	4.38	2.55e-05	0.0352	0.69	0.37	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
ESCA	cis	rs11235843	0.853	rs11235922	ENSG00000255928.1	RP11-456I15.2	4.38	2.55e-05	0.0352	0.62	0.37	Hand grip strength;	chr11:73825653	chr11:73722349~73722694:+
ESCA	cis	rs875971	0.528	rs801213	ENSG00000179406.6	LINC00174	4.38	2.55e-05	0.0352	0.52	0.37	Aortic root size;	chr7:66549931	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs801212	ENSG00000179406.6	LINC00174	4.38	2.55e-05	0.0352	0.52	0.37	Aortic root size;	chr7:66550643	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs73152714	ENSG00000179406.6	LINC00174	-4.38	2.55e-05	0.0352	-0.52	-0.37	Aortic root size;	chr7:66534641	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs4718364	ENSG00000179406.6	LINC00174	-4.38	2.55e-05	0.0352	-0.52	-0.37	Aortic root size;	chr7:66536353	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs6961853	ENSG00000179406.6	LINC00174	-4.38	2.55e-05	0.0352	-0.52	-0.37	Aortic root size;	chr7:66537035	chr7:66376044~66401338:-
ESCA	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	4.38	2.55e-05	0.0352	0.5	0.37	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
ESCA	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	4.38	2.56e-05	0.0353	0.49	0.37	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
ESCA	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	4.38	2.56e-05	0.0353	0.43	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
ESCA	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-4.37	2.57e-05	0.0353	-0.44	-0.37	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
ESCA	cis	rs1075265	0.749	rs805434	ENSG00000235937.1	AC008280.1	4.37	2.57e-05	0.0353	0.4	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54029552~54030682:-
ESCA	cis	rs1005277	0.541	rs2263163	ENSG00000263064.2	RP11-291L22.7	4.37	2.57e-05	0.0354	0.5	0.37	Extrinsic epigenetic age acceleration;	chr10:38100959	chr10:38448689~38448949:+
ESCA	cis	rs7631605	0.905	rs4678944	ENSG00000272334.1	RP11-129K12.1	-4.37	2.57e-05	0.0354	-0.41	-0.37	Cerebrospinal P-tau181p levels;	chr3:37173194	chr3:36973117~36973672:-
ESCA	cis	rs7631605	1	rs9854956	ENSG00000272334.1	RP11-129K12.1	-4.37	2.57e-05	0.0354	-0.41	-0.37	Cerebrospinal P-tau181p levels;	chr3:37177097	chr3:36973117~36973672:-
ESCA	cis	rs9987353	0.544	rs2929470	ENSG00000253981.4	ALG1L13P	-4.37	2.57e-05	0.0354	-0.47	-0.37	Recombination measurement;	chr8:9204980	chr8:8236003~8244667:-
ESCA	cis	rs9584850	0.874	rs9168	ENSG00000231194.1	FARP1-AS1	4.37	2.57e-05	0.0354	0.47	0.37	Neuroticism;	chr13:98449329	chr13:98435405~98435840:-
ESCA	cis	rs1075232	1	rs72722861	ENSG00000215302.7	CTD-3092A11.1	-4.37	2.57e-05	0.0354	-0.8	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31412085	chr15:30470779~30507623:+
ESCA	cis	rs1075232	0.826	rs12438813	ENSG00000215302.7	CTD-3092A11.1	-4.37	2.57e-05	0.0354	-0.8	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31413710	chr15:30470779~30507623:+
ESCA	cis	rs1075232	1	rs34959140	ENSG00000215302.7	CTD-3092A11.1	-4.37	2.57e-05	0.0354	-0.8	-0.37	Survival in colorectal cancer (non-distant metastatic);	chr15:31433020	chr15:30470779~30507623:+
ESCA	cis	rs7829975	0.714	rs11784052	ENSG00000173295.6	FAM86B3P	4.37	2.58e-05	0.0355	0.4	0.37	Mood instability;	chr8:8814452	chr8:8228595~8244865:+
ESCA	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	4.37	2.58e-05	0.0355	0.41	0.37	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
ESCA	cis	rs2439831	1	rs690002	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43437151	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs537115	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43437750	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2245908	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43439256	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2444029	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43445286	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs690316	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43445682	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2467739	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43447998	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs28666488	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43448892	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2245790	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43452259	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs2467740	ENSG00000249839.1	AC011330.5	-4.37	2.58e-05	0.0355	-0.55	-0.37	Lung cancer in ever smokers;	chr15:43454594	chr15:43663654~43684339:-
ESCA	cis	rs611744	0.87	rs640068	ENSG00000253754.1	RP11-35G22.1	-4.37	2.58e-05	0.0355	-0.34	-0.37	Dupuytren's disease;	chr8:108145773	chr8:108226200~108227544:+
ESCA	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	4.37	2.58e-05	0.0355	0.7	0.37	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
ESCA	cis	rs9549260	0.848	rs966968	ENSG00000229456.1	RLIMP1	-4.37	2.59e-05	0.0356	-0.34	-0.37	Red blood cell count;	chr13:40673900	chr13:40618738~40621348:+
ESCA	cis	rs980000	0.744	rs7166772	ENSG00000273792.1	RP11-554D20.2	4.37	2.59e-05	0.0356	0.7	0.37	Menarche (age at onset);	chr15:60580669	chr15:60847757~60849068:-
ESCA	cis	rs12534093	0.701	rs67056093	ENSG00000234286.1	AC006026.13	-4.37	2.59e-05	0.0356	-0.48	-0.37	Infant length;Height;	chr7:23486450	chr7:23680195~23680786:-
ESCA	cis	rs8059260	0.611	rs34143079	ENSG00000274038.1	RP11-66H6.4	-4.37	2.59e-05	0.0356	-0.67	-0.37	Alcohol consumption over the past year;	chr16:11069069	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.541	rs7195452	ENSG00000274038.1	RP11-66H6.4	-4.37	2.59e-05	0.0356	-0.67	-0.37	Alcohol consumption over the past year;	chr16:11069469	chr16:11056556~11057034:+
ESCA	cis	rs9309711	0.666	rs11127429	ENSG00000225234.1	TRAPPC12-AS1	-4.37	2.6e-05	0.0357	-0.45	-0.37	Neurofibrillary tangles;	chr2:3481453	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.666	rs11127430	ENSG00000225234.1	TRAPPC12-AS1	-4.37	2.6e-05	0.0357	-0.45	-0.37	Neurofibrillary tangles;	chr2:3481471	chr2:3481242~3482409:-
ESCA	cis	rs1816752	0.712	rs2862898	ENSG00000273628.1	RP11-756A22.7	4.37	2.6e-05	0.0357	0.35	0.37	Obesity-related traits;	chr13:24414323	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.652	rs2902356	ENSG00000273628.1	RP11-756A22.7	4.37	2.6e-05	0.0357	0.35	0.37	Obesity-related traits;	chr13:24414333	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.819	rs4770664	ENSG00000273628.1	RP11-756A22.7	4.37	2.6e-05	0.0357	0.35	0.37	Obesity-related traits;	chr13:24414695	chr13:24933006~24936796:+
ESCA	cis	rs61990749	0.597	rs28534379	ENSG00000239272.1	RPL21P10	-4.37	2.6e-05	0.0357	-0.43	-0.37	Fibroblast growth factor basic levels;	chr14:77705797	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs176943	ENSG00000239272.1	RPL21P10	-4.37	2.6e-05	0.0357	-0.43	-0.37	Fibroblast growth factor basic levels;	chr14:77709454	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs176944	ENSG00000239272.1	RPL21P10	-4.37	2.6e-05	0.0357	-0.43	-0.37	Fibroblast growth factor basic levels;	chr14:77709868	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs176946	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77712096	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs176952	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77714393	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs176955	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77714877	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs2544566	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77715395	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs2544567	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77715396	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs176962	ENSG00000239272.1	RPL21P10	4.37	2.6e-05	0.0357	0.43	0.37	Fibroblast growth factor basic levels;	chr14:77719167	chr14:77683202~77683989:-
ESCA	cis	rs10875746	0.587	rs9788082	ENSG00000240399.1	RP1-228P16.1	-4.37	2.6e-05	0.0357	-0.49	-0.37	Longevity (90 years and older);	chr12:48358273	chr12:48054813~48055591:-
ESCA	cis	rs6432860	0.545	rs13398150	ENSG00000232411.1	AC009495.3	-4.37	2.6e-05	0.0357	-0.4	-0.37	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;	chr2:166060447	chr2:165833048~165839098:-
ESCA	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-4.37	2.6e-05	0.0358	-0.45	-0.37	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
ESCA	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	4.37	2.61e-05	0.0358	0.48	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
ESCA	cis	rs9584850	0.874	rs4584	ENSG00000231194.1	FARP1-AS1	4.37	2.61e-05	0.0358	0.46	0.37	Neuroticism;	chr13:98449615	chr13:98435405~98435840:-
ESCA	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	4.37	2.61e-05	0.0358	0.48	0.37	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
ESCA	cis	rs6479901	0.841	rs10995505	ENSG00000235816.3	PRELID1P3	4.37	2.61e-05	0.0358	0.41	0.37	Intelligence (multi-trait analysis);	chr10:63331399	chr10:63427297~63427939:+
ESCA	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-4.37	2.61e-05	0.0359	-0.48	-0.37	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
ESCA	cis	rs1075265	0.622	rs4671529	ENSG00000235937.1	AC008280.1	4.37	2.61e-05	0.0359	0.41	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53697167	chr2:54029552~54030682:-
ESCA	cis	rs11051970	0.879	rs2088807	ENSG00000253063.1	RNU6-494P	-4.37	2.63e-05	0.036	-0.36	-0.37	Response to tocilizumab in rheumatoid arthritis;	chr12:32439167	chr12:32477382~32477471:-
ESCA	cis	rs9399137	0.561	rs11753985	ENSG00000232876.1	CTA-212D2.2	-4.37	2.63e-05	0.036	-0.43	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134959300	chr6:135055033~135060550:+
ESCA	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	4.37	2.63e-05	0.036	0.46	0.37	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
ESCA	cis	rs6479891	0.722	rs4746951	ENSG00000235816.3	PRELID1P3	4.37	2.63e-05	0.036	0.43	0.37	Arthritis (juvenile idiopathic);	chr10:63123839	chr10:63427297~63427939:+
ESCA	cis	rs4742903	0.527	rs10991156	ENSG00000270332.1	SMC2-AS1	-4.37	2.64e-05	0.0362	-0.43	-0.37	Breast cancer;High-grade serous ovarian cancer;	chr9:104192328	chr9:104080024~104093073:-
ESCA	cis	rs10229583	0.527	rs10239440	ENSG00000279078.1	SND1-IT1	4.37	2.64e-05	0.0362	0.41	0.37	Type 2 diabetes;	chr7:127765995	chr7:127997597~128000077:+
ESCA	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	4.37	2.64e-05	0.0362	0.36	0.37	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
ESCA	cis	rs8040855	0.965	rs6496766	ENSG00000259295.5	CSPG4P12	-4.37	2.64e-05	0.0362	-0.59	-0.37	Bulimia nervosa;	chr15:85159144	chr15:85191438~85213905:+
ESCA	cis	rs8040855	1	rs6496768	ENSG00000259295.5	CSPG4P12	-4.37	2.64e-05	0.0362	-0.59	-0.37	Bulimia nervosa;	chr15:85159701	chr15:85191438~85213905:+
ESCA	cis	rs1439620	0.686	rs7167859	ENSG00000260337.3	RP11-386M24.6	4.37	2.65e-05	0.0362	0.47	0.37	Body mass index;	chr15:92957805	chr15:92592574~92596462:-
ESCA	cis	rs5758659	0.714	rs133376	ENSG00000182057.4	OGFRP1	4.37	2.65e-05	0.0363	0.44	0.37	Cognitive function;	chr22:42070901	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.653	rs133383	ENSG00000182057.4	OGFRP1	4.37	2.65e-05	0.0363	0.44	0.37	Cognitive function;	chr22:42077599	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs6002607	ENSG00000182057.4	OGFRP1	-4.37	2.65e-05	0.0363	-0.44	-0.37	Cognitive function;	chr22:42100502	chr22:42269753~42275196:+
ESCA	cis	rs5758659	0.714	rs5751220	ENSG00000182057.4	OGFRP1	-4.37	2.65e-05	0.0363	-0.44	-0.37	Cognitive function;	chr22:42120201	chr22:42269753~42275196:+
ESCA	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.37	2.65e-05	0.0363	-0.51	-0.37	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
ESCA	cis	rs5769707	0.967	rs9616333	ENSG00000213279.2	RP1-29C18.9	-4.37	2.65e-05	0.0363	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49657199	chr22:49572264~49575426:-
ESCA	cis	rs5769707	0.874	rs9616714	ENSG00000213279.2	RP1-29C18.9	-4.37	2.65e-05	0.0363	-0.46	-0.37	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49572264~49575426:-
ESCA	cis	rs11317778	1	rs11317778	ENSG00000248489.1	CTD-2007H13.3	4.37	2.65e-05	0.0363	0.55	0.37	Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr5:98905525	chr5:98929171~98995013:+
ESCA	cis	rs150992	0.711	rs2617507	ENSG00000248489.1	CTD-2007H13.3	4.37	2.65e-05	0.0363	0.55	0.37	Body mass index;	chr5:98912548	chr5:98929171~98995013:+
ESCA	cis	rs1723838	0.826	rs1670561	ENSG00000255928.1	RP11-456I15.2	-4.37	2.65e-05	0.0363	-0.77	-0.37	Obesity-related traits;	chr11:73890114	chr11:73722349~73722694:+
ESCA	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-4.37	2.66e-05	0.0363	-0.71	-0.37	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-4.37	2.66e-05	0.0363	-0.71	-0.37	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
ESCA	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.61	-0.37	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.68	-0.37	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.68	-0.37	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
ESCA	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.68	-0.37	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
ESCA	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.65	-0.37	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
ESCA	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-4.37	2.66e-05	0.0364	-0.65	-0.37	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
ESCA	cis	rs7267979	0.702	rs449801	ENSG00000204556.4	CTD-2514C3.1	-4.37	2.66e-05	0.0364	-0.49	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:26018832~26020684:+
ESCA	cis	rs8062405	0.754	rs151179	ENSG00000278665.1	RP11-666O2.4	4.37	2.66e-05	0.0364	0.54	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.756	rs151182	ENSG00000278665.1	RP11-666O2.4	4.37	2.66e-05	0.0364	0.54	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28599241~28601881:-
ESCA	cis	rs62388641	1	rs62388641	ENSG00000272279.1	RP11-157J24.2	4.37	2.66e-05	0.0364	0.69	0.37	Daytime sleep phenotypes;	chr6:1539849	chr6:1528364~1528911:-
ESCA	cis	rs847851	0.612	rs7768189	ENSG00000186328.4	RP11-140K17.2	4.36	2.67e-05	0.0365	0.4	0.37	Colonoscopy-negative controls vs population controls;	chr6:34774673	chr6:34715613~34715940:+
ESCA	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	4.36	2.67e-05	0.0365	0.49	0.37	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
ESCA	cis	rs2179367	0.887	rs6570965	ENSG00000231760.4	RP11-350J20.5	4.36	2.67e-05	0.0365	0.42	0.37	Dupuytren's disease;	chr6:149396340	chr6:149796151~149826294:-
ESCA	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-4.36	2.67e-05	0.0365	-0.53	-0.37	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
ESCA	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-4.36	2.67e-05	0.0365	-0.53	-0.37	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
ESCA	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-4.36	2.67e-05	0.0365	-0.35	-0.37	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
ESCA	cis	rs17608059	0.611	rs62052300	ENSG00000141028.6	CDRT15P1	-4.36	2.67e-05	0.0365	-0.36	-0.37	Temperament;	chr17:14013482	chr17:14024514~14025488:+
ESCA	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	4.36	2.68e-05	0.0366	0.51	0.37	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
ESCA	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	4.36	2.68e-05	0.0366	0.51	0.37	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
ESCA	cis	rs7017914	0.69	rs55915640	ENSG00000253173.3	RP11-152C15.1	-4.36	2.68e-05	0.0366	-0.42	-0.37	Bone mineral density;	chr8:71052423	chr8:70103798~70104179:-
ESCA	cis	rs7826238	0.535	rs2979179	ENSG00000173295.6	FAM86B3P	4.36	2.68e-05	0.0366	0.43	0.37	Systolic blood pressure;	chr8:8462519	chr8:8228595~8244865:+
ESCA	cis	rs11235843	1	rs2272248	ENSG00000255928.1	RP11-456I15.2	4.36	2.68e-05	0.0366	0.6	0.37	Hand grip strength;	chr11:73660897	chr11:73722349~73722694:+
ESCA	cis	rs11235843	1	rs4944852	ENSG00000255928.1	RP11-456I15.2	4.36	2.68e-05	0.0366	0.6	0.37	Hand grip strength;	chr11:73661062	chr11:73722349~73722694:+
ESCA	cis	rs7709377	0.723	rs2416434	ENSG00000272265.1	CTD-2287O16.4	4.36	2.69e-05	0.0367	0.5	0.37	Metabolite levels  (X-11787);	chr5:116172655	chr5:116078110~116078570:-
ESCA	cis	rs2179367	0.959	rs9377212	ENSG00000231760.4	RP11-350J20.5	4.36	2.69e-05	0.0367	0.42	0.37	Dupuytren's disease;	chr6:149383765	chr6:149796151~149826294:-
ESCA	cis	rs2281558	0.517	rs16987966	ENSG00000125804.12	FAM182A	-4.36	2.69e-05	0.0367	-0.46	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25662778	chr20:26054655~26086917:+
ESCA	cis	rs2281558	0.583	rs11087526	ENSG00000125804.12	FAM182A	-4.36	2.69e-05	0.0367	-0.46	-0.37	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;	chr20:25667380	chr20:26054655~26086917:+
ESCA	cis	rs7951870	1	rs7951870	ENSG00000271350.1	CTD-2384B9.1	4.36	2.69e-05	0.0367	0.47	0.37	Schizophrenia;	chr11:46351761	chr11:47041027~47041945:-
ESCA	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	4.36	2.69e-05	0.0368	0.55	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
ESCA	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-4.36	2.69e-05	0.0368	-0.46	-0.37	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
ESCA	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-4.36	2.69e-05	0.0368	-0.42	-0.37	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
ESCA	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	4.36	2.7e-05	0.0368	0.35	0.37	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
ESCA	cis	rs72672639	0.831	rs10956909	ENSG00000245080.5	RP11-320N21.1	-4.36	2.7e-05	0.0368	-0.63	-0.37	Carotid plaque burden;	chr8:94265439	chr8:95066808~95073182:-
ESCA	cis	rs4407350	0.729	rs9819	ENSG00000228807.1	MRPS18CP6	4.36	2.7e-05	0.0368	0.4	0.37	Intelligence (multi-trait analysis);	chr22:44493506	chr22:44483495~44483717:-
ESCA	cis	rs9987353	0.518	rs4841110	ENSG00000173295.6	FAM86B3P	4.36	2.7e-05	0.0368	0.45	0.37	Recombination measurement;	chr8:9228513	chr8:8228595~8244865:+
ESCA	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	4.36	2.7e-05	0.0369	0.51	0.37	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
ESCA	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	4.36	2.7e-05	0.0369	0.51	0.37	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
ESCA	cis	rs7208859	0.673	rs11653955	ENSG00000263531.1	RP13-753N3.1	4.36	2.7e-05	0.0369	0.57	0.37	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30706274	chr17:30863921~30864940:-
ESCA	cis	rs1426063	0.748	rs6534607	ENSG00000248165.1	RP11-44F21.2	4.36	2.7e-05	0.0369	0.47	0.37	QT interval;	chr4:75106366	chr4:74993877~75034824:-
ESCA	cis	rs4511180	0.9	rs2361422	ENSG00000249007.1	RP11-510N19.5	-4.36	2.7e-05	0.0369	-0.32	-0.37	Post-traumatic stress disorder;	chr1:202189542	chr1:202011370~202015657:+
ESCA	cis	rs3100127	1	rs3100127	ENSG00000249007.1	RP11-510N19.5	-4.36	2.7e-05	0.0369	-0.32	-0.37	Post-traumatic stress disorder;	chr1:202191842	chr1:202011370~202015657:+
ESCA	cis	rs6805251	0.594	rs9289138	ENSG00000276607.2	AC092910.1	-4.36	2.71e-05	0.0369	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120020450	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.594	rs7613197	ENSG00000276607.2	AC092910.1	-4.36	2.71e-05	0.0369	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120022093	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.594	rs6770314	ENSG00000276607.2	AC092910.1	-4.36	2.71e-05	0.0369	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120023874	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.594	rs6802301	ENSG00000276607.2	AC092910.1	-4.36	2.71e-05	0.0369	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120034477	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.594	rs9859778	ENSG00000276607.2	AC092910.1	-4.36	2.71e-05	0.0369	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120044760	chr3:120084550~120084657:-
ESCA	cis	rs9987353	0.566	rs34491841	ENSG00000173295.6	FAM86B3P	-4.36	2.71e-05	0.0369	-0.47	-0.37	Recombination measurement;	chr8:9208000	chr8:8228595~8244865:+
ESCA	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	4.36	2.71e-05	0.0369	0.41	0.37	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	4.36	2.71e-05	0.0369	0.41	0.37	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	4.36	2.71e-05	0.0369	0.41	0.37	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
ESCA	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	4.36	2.71e-05	0.0369	0.41	0.37	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
ESCA	cis	rs12022452	1	rs12031278	ENSG00000229901.1	RP11-399E6.4	4.36	2.71e-05	0.0369	0.45	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40511246	chr1:41375004~41375669:-
ESCA	cis	rs12022452	1	rs75936657	ENSG00000229901.1	RP11-399E6.4	4.36	2.71e-05	0.0369	0.45	0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536017	chr1:41375004~41375669:-
ESCA	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-4.36	2.71e-05	0.0369	-0.43	-0.37	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
ESCA	cis	rs5760092	0.755	rs4585126	ENSG00000099984.9	GSTT2	4.36	2.71e-05	0.0369	0.5	0.37	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23980123~23983911:+
ESCA	cis	rs3820068	0.506	rs17448966	ENSG00000237301.1	RP4-680D5.2	4.36	2.72e-05	0.037	0.41	0.37	Systolic blood pressure;	chr1:15664488	chr1:15586136~15603626:-
ESCA	cis	rs6748734	0.516	rs4605365	ENSG00000235151.1	AC114730.2	-4.36	2.73e-05	0.0371	-0.38	-0.37	Urinary metabolites;	chr2:240952592	chr2:241844380~241845036:+
ESCA	cis	rs2742234	0.59	rs2293020	ENSG00000273008.1	RP11-351D16.3	4.36	2.73e-05	0.0371	0.43	0.37	Hirschsprung disease;	chr10:43197439	chr10:43136824~43138334:-
ESCA	cis	rs8072100	0.869	rs4439799	ENSG00000228782.6	CTD-2026D20.3	4.36	2.73e-05	0.0371	0.42	0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704233	chr17:47450568~47492492:-
ESCA	cis	rs7829975	0.902	rs485107	ENSG00000253981.4	ALG1L13P	-4.36	2.73e-05	0.0371	-0.42	-0.37	Mood instability;	chr8:8723898	chr8:8236003~8244667:-
ESCA	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-4.36	2.73e-05	0.0372	-0.64	-0.37	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
ESCA	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.36	2.73e-05	0.0372	0.64	0.37	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
ESCA	cis	rs7631605	1	rs6789043	ENSG00000272334.1	RP11-129K12.1	-4.36	2.74e-05	0.0372	-0.41	-0.37	Cerebrospinal P-tau181p levels;	chr3:36984376	chr3:36973117~36973672:-
ESCA	cis	rs10875746	0.551	rs3751273	ENSG00000240399.1	RP1-228P16.1	-4.36	2.74e-05	0.0372	-0.45	-0.37	Longevity (90 years and older);	chr12:48345655	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.551	rs10875799	ENSG00000240399.1	RP1-228P16.1	-4.36	2.74e-05	0.0372	-0.45	-0.37	Longevity (90 years and older);	chr12:48347096	chr12:48054813~48055591:-
ESCA	cis	rs8062405	0.755	rs2077031	ENSG00000278665.1	RP11-666O2.4	4.36	2.75e-05	0.0372	0.51	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.723	rs35175818	ENSG00000278665.1	RP11-666O2.4	4.36	2.75e-05	0.0372	0.51	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.723	rs62031562	ENSG00000278665.1	RP11-666O2.4	4.36	2.75e-05	0.0372	0.51	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.69	rs762634	ENSG00000278665.1	RP11-666O2.4	4.36	2.75e-05	0.0372	0.51	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28599241~28601881:-
ESCA	cis	rs875971	0.545	rs801199	ENSG00000179406.6	LINC00174	4.36	2.75e-05	0.0372	0.52	0.37	Aortic root size;	chr7:66560286	chr7:66376044~66401338:-
ESCA	cis	rs2439831	0.867	rs2447196	ENSG00000205771.5	CATSPER2P1	4.36	2.75e-05	0.0373	0.63	0.37	Lung cancer in ever smokers;	chr15:43601620	chr15:43726918~43747094:-
ESCA	cis	rs2439831	0.681	rs1549523	ENSG00000249839.1	AC011330.5	-4.36	2.75e-05	0.0373	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43331991	chr15:43663654~43684339:-
ESCA	cis	rs3820068	0.581	rs16851848	ENSG00000237301.1	RP4-680D5.2	4.36	2.75e-05	0.0373	0.41	0.37	Systolic blood pressure;	chr1:15601203	chr1:15586136~15603626:-
ESCA	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	4.36	2.75e-05	0.0373	0.47	0.37	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
ESCA	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	4.36	2.76e-05	0.0373	0.44	0.37	Breast size;	chr12:9220132	chr12:9277235~9313241:+
ESCA	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	4.36	2.76e-05	0.0374	0.5	0.37	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
ESCA	cis	rs997154	0.608	rs8007089	ENSG00000279656.1	RP11-298I3.6	4.36	2.76e-05	0.0374	0.52	0.37	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22922704	chr14:23023083~23024217:-
ESCA	cis	rs9677476	0.587	rs62197354	ENSG00000201574.1	RNU1-93P	-4.36	2.76e-05	0.0374	-0.43	-0.37	Food antigen IgG levels;	chr2:231304014	chr2:231133462~231133630:+
ESCA	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	4.36	2.76e-05	0.0374	0.49	0.37	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
ESCA	cis	rs3820068	0.705	rs72643694	ENSG00000237301.1	RP4-680D5.2	4.36	2.76e-05	0.0374	0.4	0.37	Systolic blood pressure;	chr1:15533690	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs16851731	ENSG00000237301.1	RP4-680D5.2	4.36	2.76e-05	0.0374	0.4	0.37	Systolic blood pressure;	chr1:15533745	chr1:15586136~15603626:-
ESCA	cis	rs17108533	1	rs17108533	ENSG00000274818.1	RP1-292L20.3	-4.36	2.76e-05	0.0374	-0.59	-0.37	Response to antipsychotic treatment in schizophrenia (reasoning);	chr14:70783085	chr14:70906657~70907111:-
ESCA	cis	rs8072100	1	rs8072100	ENSG00000228782.6	CTD-2026D20.3	-4.36	2.76e-05	0.0374	-0.39	-0.37	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47597321	chr17:47450568~47492492:-
ESCA	cis	rs2439831	0.85	rs28504496	ENSG00000224677.1	PDIA3P2	-4.36	2.77e-05	0.0374	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43724685	chr15:43649123~43649280:+
ESCA	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	4.36	2.77e-05	0.0374	0.36	0.37	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
ESCA	cis	rs2742234	0.955	rs2503865	ENSG00000273008.1	RP11-351D16.3	-4.36	2.77e-05	0.0374	-0.41	-0.37	Hirschsprung disease;	chr10:43164088	chr10:43136824~43138334:-
ESCA	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	4.36	2.77e-05	0.0374	0.48	0.37	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
ESCA	cis	rs6437061	0.835	rs2853361	ENSG00000263641.1	MIR4777	-4.35	2.78e-05	0.0375	-0.34	-0.37	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);	chr2:232256213	chr2:231362708~231362793:+
ESCA	cis	rs6717918	0.517	rs2853362	ENSG00000263641.1	MIR4777	-4.35	2.78e-05	0.0375	-0.34	-0.37	Height;	chr2:232257702	chr2:231362708~231362793:+
ESCA	cis	rs2439831	0.681	rs2278858	ENSG00000275601.1	AC011330.13	-4.35	2.78e-05	0.0376	-0.6	-0.37	Lung cancer in ever smokers;	chr15:43340557	chr15:43642389~43643023:-
ESCA	cis	rs9399137	0.507	rs4451150	ENSG00000232876.1	CTA-212D2.2	-4.35	2.78e-05	0.0376	-0.44	-0.37	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134957925	chr6:135055033~135060550:+
ESCA	cis	rs6805251	0.594	rs16830689	ENSG00000276607.2	AC092910.1	-4.35	2.78e-05	0.0376	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120052424	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.594	rs6779828	ENSG00000276607.2	AC092910.1	-4.35	2.78e-05	0.0376	-0.44	-0.37	HDL cholesterol levels;HDL cholesterol;	chr3:120056300	chr3:120084550~120084657:-
ESCA	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	4.35	2.78e-05	0.0376	0.59	0.37	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
ESCA	cis	rs11038871	1	rs7949371	ENSG00000271350.1	CTD-2384B9.1	4.35	2.79e-05	0.0376	0.4	0.37	Immunoglobulin A;	chr11:46500754	chr11:47041027~47041945:-
ESCA	cis	rs11038871	1	rs7949282	ENSG00000271350.1	CTD-2384B9.1	4.35	2.79e-05	0.0376	0.4	0.37	Immunoglobulin A;	chr11:46500756	chr11:47041027~47041945:-
ESCA	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	4.35	2.79e-05	0.0377	0.5	0.37	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
ESCA	cis	rs4407350	0.748	rs131170	ENSG00000228807.1	MRPS18CP6	-4.35	2.79e-05	0.0377	-0.4	-0.37	Intelligence (multi-trait analysis);	chr22:44505721	chr22:44483495~44483717:-
ESCA	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	4.35	2.79e-05	0.0377	0.39	0.37	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
ESCA	cis	rs150992	0.673	rs331549	ENSG00000248489.1	CTD-2007H13.3	-4.35	2.79e-05	0.0377	-0.55	-0.37	Body mass index;	chr5:98805731	chr5:98929171~98995013:+
ESCA	cis	rs150992	0.673	rs992775	ENSG00000248489.1	CTD-2007H13.3	-4.35	2.79e-05	0.0377	-0.55	-0.37	Body mass index;	chr5:98807754	chr5:98929171~98995013:+
ESCA	cis	rs150992	0.673	rs331545	ENSG00000248489.1	CTD-2007H13.3	-4.35	2.79e-05	0.0377	-0.55	-0.37	Body mass index;	chr5:98810402	chr5:98929171~98995013:+
ESCA	cis	rs10229583	0.563	rs10270127	ENSG00000279078.1	SND1-IT1	4.35	2.79e-05	0.0377	0.4	0.37	Type 2 diabetes;	chr7:127621956	chr7:127997597~128000077:+
ESCA	cis	rs6785206	0.554	rs35439439	ENSG00000239503.1	MARK2P8	-4.35	2.8e-05	0.0377	-0.39	-0.37	Lymphocyte percentage of white cells;	chr3:128756450	chr3:128748538~128749489:-
ESCA	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	4.35	2.8e-05	0.0377	0.54	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
ESCA	cis	rs12712135	0.709	rs12469887	ENSG00000234389.1	AC007278.3	-4.35	2.8e-05	0.0377	-0.32	-0.37	Blood protein levels;	chr2:102470298	chr2:102438713~102440475:+
ESCA	cis	rs61160187	0.582	rs17332824	ENSG00000215032.2	GNL3LP1	-4.35	2.8e-05	0.0377	-0.47	-0.37	Educational attainment (years of education);Educational attainment (college completion);	chr5:60870360	chr5:60891935~60893577:-
ESCA	cis	rs858239	0.536	rs6956974	ENSG00000230042.1	AK3P3	4.35	2.8e-05	0.0377	0.39	0.37	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23129178~23129841:+
ESCA	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-4.35	2.8e-05	0.0377	-0.48	-0.37	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
ESCA	cis	rs9977672	0.625	rs35819975	ENSG00000231713.2	AF064860.7	-4.35	2.8e-05	0.0378	-0.39	-0.37	Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;	chr21:39087606	chr21:39727755~39730680:+
ESCA	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	4.35	2.8e-05	0.0378	0.45	0.37	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
ESCA	cis	rs1075265	0.722	rs805374	ENSG00000235937.1	AC008280.1	4.35	2.8e-05	0.0378	0.4	0.37	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54029552~54030682:-
ESCA	cis	rs2439831	1	rs690263	ENSG00000249839.1	AC011330.5	-4.35	2.81e-05	0.0378	-0.56	-0.37	Lung cancer in ever smokers;	chr15:43412267	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.681	rs498837	ENSG00000249839.1	AC011330.5	-4.35	2.81e-05	0.0378	-0.53	-0.37	Lung cancer in ever smokers;	chr15:43315826	chr15:43663654~43684339:-
ESCA	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	4.35	2.81e-05	0.0378	0.65	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
ESCA	cis	rs2688482	0.557	rs3103952	ENSG00000207650.1	MIR570	4.35	2.81e-05	0.0378	0.56	0.37	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195699401~195699497:+
ESCA	cis	rs9462027	0.54	rs4282407	ENSG00000186328.4	RP11-140K17.2	4.35	2.81e-05	0.0378	0.41	0.37	Systemic lupus erythematosus;	chr6:34862385	chr6:34715613~34715940:+
ESCA	cis	rs9608946	1	rs737942	ENSG00000268812.3	RP1-102K2.8	4.35	2.82e-05	0.0379	0.49	0.37	Red cell distribution width;	chr22:30480848	chr22:30246205~30246998:+
ESCA	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	4.35	2.82e-05	0.038	0.52	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
ESCA	cis	rs853679	0.769	rs17720293	ENSG00000204709.4	LINC01556	4.35	2.82e-05	0.038	0.83	0.37	Depression;	chr6:28246920	chr6:28943877~28944537:+
ESCA	cis	rs2243480	1	rs4718317	ENSG00000222364.1	RNU6-96P	4.35	2.82e-05	0.038	0.55	0.37	Diabetic kidney disease;	chr7:66183914	chr7:66395191~66395286:+
ESCA	cis	rs3762637	1	rs12630576	ENSG00000272758.4	RP11-299J3.8	-4.35	2.82e-05	0.038	-0.47	-0.37	LDL cholesterol levels;	chr3:122420670	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs55853677	ENSG00000272758.4	RP11-299J3.8	-4.35	2.82e-05	0.038	-0.47	-0.37	LDL cholesterol levels;	chr3:122421769	chr3:122416207~122443180:+
ESCA	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	4.35	2.82e-05	0.038	0.5	0.37	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
ESCA	cis	rs2764208	0.77	rs112283401	ENSG00000186328.4	RP11-140K17.2	4.35	2.83e-05	0.038	0.4	0.37	Systemic lupus erythematosus;	chr6:34829979	chr6:34715613~34715940:+
ESCA	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	4.35	2.83e-05	0.0381	0.69	0.37	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
ESCA	cis	rs2439831	0.85	rs28413881	ENSG00000224677.1	PDIA3P2	-4.35	2.83e-05	0.0381	-0.68	-0.37	Lung cancer in ever smokers;	chr15:43881901	chr15:43649123~43649280:+
ESCA	cis	rs3136516	0.504	rs10838610	ENSG00000271350.1	CTD-2384B9.1	-4.35	2.83e-05	0.0381	-0.4	-0.37	Venous thromboembolism;	chr11:46664710	chr11:47041027~47041945:-
ESCA	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	4.35	2.83e-05	0.0381	0.39	0.37	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
ESCA	cis	rs8099594	0.64	rs504246	ENSG00000266696.1	RP11-30L3.2	4.35	2.83e-05	0.0381	0.44	0.37	Height;	chr18:49332619	chr18:49205912~49208781:+
ESCA	cis	rs7584099	0.501	rs7587464	ENSG00000223911.1	AC009480.3	-4.35	2.83e-05	0.0381	-0.39	-0.37	Response to statin therapy;	chr2:148181010	chr2:147899401~147902956:-
ESCA	cis	rs7584099	0.554	rs11676430	ENSG00000223911.1	AC009480.3	-4.35	2.83e-05	0.0381	-0.39	-0.37	Response to statin therapy;	chr2:148181764	chr2:147899401~147902956:-
ESCA	cis	rs9608946	1	rs7284873	ENSG00000268812.3	RP1-102K2.8	4.35	2.84e-05	0.0382	0.5	0.37	Red cell distribution width;	chr22:30518486	chr22:30246205~30246998:+
ESCA	cis	rs7283707	0.681	rs73346766	ENSG00000269950.1	AP000962.2	4.35	2.84e-05	0.0382	0.59	0.37	QRS complex (12-leadsum);	chr21:15815002	chr21:16574718~16582637:-
ESCA	cis	rs6479891	1	rs9414788	ENSG00000235816.3	PRELID1P3	-4.35	2.84e-05	0.0382	-0.46	-0.37	Arthritis (juvenile idiopathic);	chr10:63296952	chr10:63427297~63427939:+
ESCA	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-4.35	2.84e-05	0.0382	-0.53	-0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-4.35	2.84e-05	0.0382	-0.53	-0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-4.35	2.84e-05	0.0382	-0.53	-0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
ESCA	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-4.35	2.84e-05	0.0382	-0.53	-0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
ESCA	cis	rs1816752	0.603	rs9551099	ENSG00000273628.1	RP11-756A22.7	-4.35	2.84e-05	0.0382	-0.38	-0.37	Obesity-related traits;	chr13:24410978	chr13:24933006~24936796:+
ESCA	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	4.35	2.85e-05	0.0383	0.42	0.37	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
ESCA	cis	rs2179367	0.959	rs4895788	ENSG00000216906.2	RP11-350J20.9	4.35	2.85e-05	0.0383	0.47	0.36	Dupuytren's disease;	chr6:149426955	chr6:149904243~149906418:+
ESCA	cis	rs875971	0.597	rs11771318	ENSG00000179406.6	LINC00174	4.35	2.85e-05	0.0383	0.43	0.36	Aortic root size;	chr7:66597493	chr7:66376044~66401338:-
ESCA	cis	rs2179367	0.959	rs564961	ENSG00000231760.4	RP11-350J20.5	4.35	2.85e-05	0.0383	0.41	0.36	Dupuytren's disease;	chr6:149336091	chr6:149796151~149826294:-
ESCA	cis	rs2179367	0.959	rs504985	ENSG00000231760.4	RP11-350J20.5	4.35	2.85e-05	0.0383	0.41	0.36	Dupuytren's disease;	chr6:149337842	chr6:149796151~149826294:-
ESCA	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	4.35	2.86e-05	0.0383	0.64	0.36	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
ESCA	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	4.35	2.86e-05	0.0383	0.64	0.36	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
ESCA	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	4.35	2.86e-05	0.0383	0.64	0.36	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
ESCA	cis	rs10048158	0.51	rs3785617	ENSG00000229330.2	AC006947.1	-4.35	2.86e-05	0.0383	-0.39	-0.36	&beta2-Glycoprotein I (β2-GPI) plasma levels;	chr17:66222897	chr17:66676372~66677404:+
ESCA	cis	rs7301016	0.846	rs11174568	ENSG00000257568.1	RP11-863H1.1	4.35	2.86e-05	0.0383	0.47	0.36	IgG glycosylation;	chr12:62627377	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs11174569	ENSG00000257568.1	RP11-863H1.1	4.35	2.86e-05	0.0383	0.47	0.36	IgG glycosylation;	chr12:62627381	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.846	rs11174571	ENSG00000257568.1	RP11-863H1.1	4.35	2.86e-05	0.0383	0.47	0.36	IgG glycosylation;	chr12:62628549	chr12:62482349~62484932:-
ESCA	cis	rs7301016	0.802	rs11613011	ENSG00000257568.1	RP11-863H1.1	4.35	2.86e-05	0.0383	0.47	0.36	IgG glycosylation;	chr12:62629298	chr12:62482349~62484932:-
ESCA	cis	rs9907295	0.818	rs9303692	ENSG00000270894.1	AC015849.13	4.35	2.86e-05	0.0384	0.41	0.36	Fibroblast growth factor basic levels;	chr17:35861492	chr17:35818399~35823713:+
ESCA	cis	rs394563	0.591	rs237016	ENSG00000231760.4	RP11-350J20.5	4.35	2.86e-05	0.0384	0.44	0.36	Dupuytren's disease;	chr6:149423723	chr6:149796151~149826294:-
ESCA	cis	rs11779988	0.545	rs409217	ENSG00000253671.1	RP11-806O11.1	-4.35	2.87e-05	0.0385	-0.42	-0.36	Breast cancer;	chr8:17959088	chr8:17808941~17820868:+
ESCA	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	4.35	2.87e-05	0.0385	0.36	0.36	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
ESCA	cis	rs274567	0.501	rs272855	ENSG00000233006.5	AC034220.3	4.35	2.87e-05	0.0385	0.36	0.36	Blood metabolite levels;	chr5:132351482	chr5:132311285~132369916:-
ESCA	cis	rs8072100	0.967	rs12452315	ENSG00000228782.6	CTD-2026D20.3	-4.35	2.87e-05	0.0385	-0.4	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402080	chr17:47450568~47492492:-
ESCA	cis	rs6452524	0.935	rs6896953	ENSG00000243385.2	CTD-2110K23.1	-4.35	2.87e-05	0.0385	-0.38	-0.36	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83201229~83202141:+
ESCA	cis	rs9608946	1	rs13750	ENSG00000268812.3	RP1-102K2.8	4.35	2.88e-05	0.0386	0.5	0.36	Red cell distribution width;	chr22:30489113	chr22:30246205~30246998:+
ESCA	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	4.35	2.88e-05	0.0386	0.39	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
ESCA	cis	rs858239	0.665	rs858306	ENSG00000230042.1	AK3P3	-4.35	2.88e-05	0.0386	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.633	rs858300	ENSG00000230042.1	AK3P3	-4.35	2.88e-05	0.0386	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.698	rs858295	ENSG00000230042.1	AK3P3	-4.35	2.88e-05	0.0386	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.73	rs858290	ENSG00000230042.1	AK3P3	-4.35	2.88e-05	0.0386	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23129178~23129841:+
ESCA	cis	rs858239	0.73	rs858289	ENSG00000230042.1	AK3P3	-4.35	2.88e-05	0.0386	-0.42	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23129178~23129841:+
ESCA	cis	rs4951011	0.572	rs7552670	ENSG00000223505.2	RP11-397P13.7	-4.34	2.88e-05	0.0386	-0.51	-0.36	Breast cancer;	chr1:203799200	chr1:203835585~203835912:-
ESCA	cis	rs11992186	0.57	rs17628941	ENSG00000253981.4	ALG1L13P	-4.34	2.89e-05	0.0387	-0.45	-0.36	Neuroticism;	chr8:8730024	chr8:8236003~8244667:-
ESCA	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	4.34	2.89e-05	0.0387	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	4.34	2.89e-05	0.0387	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-4.34	2.89e-05	0.0387	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-4.34	2.89e-05	0.0387	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
ESCA	cis	rs2179367	0.959	rs521845	ENSG00000231760.4	RP11-350J20.5	-4.34	2.9e-05	0.0388	-0.42	-0.36	Dupuytren's disease;	chr6:149350562	chr6:149796151~149826294:-
ESCA	cis	rs3758785	0.565	rs598645	ENSG00000255893.1	RP11-685N10.1	4.34	2.9e-05	0.0388	0.41	0.36	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94338579	chr11:94472908~94473570:-
ESCA	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-4.34	2.9e-05	0.0389	-0.42	-0.36	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
ESCA	cis	rs6724465	0.778	rs12471418	ENSG00000272644.1	RP11-33O4.1	4.34	2.9e-05	0.0389	0.62	0.36	Height;	chr2:219043901	chr2:219069354~219069809:-
ESCA	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	4.34	2.91e-05	0.0389	0.55	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	4.34	2.91e-05	0.0389	0.55	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	4.34	2.91e-05	0.0389	0.55	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	4.34	2.91e-05	0.0389	0.55	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
ESCA	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	4.34	2.91e-05	0.0389	0.55	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
ESCA	cis	rs6604026	0.63	rs35807969	ENSG00000229052.2	RP11-386I23.1	4.34	2.91e-05	0.0389	0.37	0.36	Multiple sclerosis;	chr1:92993512	chr1:92930696~92934098:+
ESCA	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-4.34	2.91e-05	0.0389	-0.46	-0.36	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
ESCA	cis	rs7714584	1	rs13361189	ENSG00000197083.10	ZNF300P1	4.34	2.91e-05	0.0389	0.56	0.36	Crohn's disease;	chr5:150843825	chr5:150930645~150946289:-
ESCA	cis	rs4927850	0.957	rs4927851	ENSG00000231464.1	AC024937.4	4.34	2.92e-05	0.039	0.44	0.36	Pancreatic cancer;	chr3:196024982	chr3:195996738~195998233:+
ESCA	cis	rs4927850	0.918	rs4361313	ENSG00000231464.1	AC024937.4	4.34	2.92e-05	0.039	0.44	0.36	Pancreatic cancer;	chr3:196025389	chr3:195996738~195998233:+
ESCA	cis	rs1439620	1	rs1439621	ENSG00000258647.4	LINC00930	4.34	2.92e-05	0.039	0.43	0.36	Body mass index;	chr15:92898677	chr15:92567818~92572042:-
ESCA	cis	rs17711722	0.565	rs73372653	ENSG00000164669.11	INTS4P1	-4.34	2.92e-05	0.039	-0.42	-0.36	Calcium levels;	chr7:65977808	chr7:65141225~65234216:+
ESCA	cis	rs7582403	0.737	rs6430287	ENSG00000223911.1	AC009480.3	-4.34	2.92e-05	0.039	-0.4	-0.36	Neuroticism;	chr2:148091849	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.844	rs6430288	ENSG00000223911.1	AC009480.3	-4.34	2.92e-05	0.039	-0.4	-0.36	Neuroticism;	chr2:148091855	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.844	rs12615059	ENSG00000223911.1	AC009480.3	-4.34	2.92e-05	0.039	-0.4	-0.36	Neuroticism;	chr2:148092920	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.807	rs1449958	ENSG00000223911.1	AC009480.3	-4.34	2.92e-05	0.039	-0.4	-0.36	Neuroticism;	chr2:148095707	chr2:147899401~147902956:-
ESCA	cis	rs4927850	0.958	rs1975582	ENSG00000231464.1	AC024937.4	4.34	2.92e-05	0.0391	0.44	0.36	Pancreatic cancer;	chr3:196024568	chr3:195996738~195998233:+
ESCA	cis	rs2742234	0.91	rs2503866	ENSG00000273008.1	RP11-351D16.3	-4.34	2.93e-05	0.0391	-0.41	-0.36	Hirschsprung disease;	chr10:43150813	chr10:43136824~43138334:-
ESCA	cis	rs10875746	0.669	rs10783244	ENSG00000240399.1	RP1-228P16.1	-4.34	2.93e-05	0.0391	-0.43	-0.36	Longevity (90 years and older);	chr12:48271206	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.669	rs9634261	ENSG00000240399.1	RP1-228P16.1	-4.34	2.93e-05	0.0391	-0.43	-0.36	Longevity (90 years and older);	chr12:48293088	chr12:48054813~48055591:-
ESCA	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	4.34	2.93e-05	0.0391	0.52	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
ESCA	cis	rs4951011	0.572	rs7540041	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203800404	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.515	rs6662925	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203803661	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs7532505	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203805665	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs6685918	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203808181	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs7546400	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203808671	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.515	rs61827262	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203810246	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs3753590	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203818362	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs12403727	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203819225	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs12403366	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203821113	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs12402315	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203821149	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs12403365	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203823454	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs6673230	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203826569	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs61559537	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203826798	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs6689679	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203837325	chr1:203835585~203835912:-
ESCA	cis	rs4951011	0.572	rs10494847	ENSG00000223505.2	RP11-397P13.7	-4.34	2.94e-05	0.0392	-0.51	-0.36	Breast cancer;	chr1:203850312	chr1:203835585~203835912:-
ESCA	cis	rs7208859	0.673	rs9915963	ENSG00000263531.1	RP13-753N3.1	4.34	2.94e-05	0.0392	0.6	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30692625	chr17:30863921~30864940:-
ESCA	cis	rs6710503	0.546	rs13020772	ENSG00000271936.1	RP11-443B20.1	4.34	2.94e-05	0.0392	0.39	0.36	Lung cancer in ever smokers;Breast cancer;	chr2:24638406	chr2:24825610~24826717:+
ESCA	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
ESCA	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
ESCA	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-4.34	2.94e-05	0.0392	-0.37	-0.36	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
ESCA	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	4.34	2.95e-05	0.0393	0.6	0.36	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
ESCA	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-4.34	2.95e-05	0.0393	-0.44	-0.36	Height;	chr11:118761813	chr11:118704607~118750263:+
ESCA	cis	rs9462027	0.628	rs6937314	ENSG00000186328.4	RP11-140K17.2	4.34	2.95e-05	0.0393	0.41	0.36	Systemic lupus erythematosus;	chr6:34831531	chr6:34715613~34715940:+
ESCA	cis	rs1062177	1	rs6890099	ENSG00000253921.1	CTB-113P19.3	-4.34	2.95e-05	0.0393	-0.47	-0.36	Preschool internalizing problems;	chr5:151772401	chr5:151753992~151767247:+
ESCA	cis	rs453301	0.606	rs6601279	ENSG00000253981.4	ALG1L13P	-4.34	2.95e-05	0.0393	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9050721	chr8:8236003~8244667:-
ESCA	cis	rs453301	0.606	rs6981060	ENSG00000253981.4	ALG1L13P	-4.34	2.95e-05	0.0393	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9050725	chr8:8236003~8244667:-
ESCA	cis	rs2739330	0.685	rs4822453	ENSG00000224205.1	AP000351.4	4.34	2.95e-05	0.0393	0.41	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23987320~23991421:-
ESCA	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0393	0.53	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
ESCA	cis	rs7709377	0.638	rs13163088	ENSG00000272265.1	CTD-2287O16.4	-4.34	2.96e-05	0.0393	-0.53	-0.36	Metabolite levels  (X-11787);	chr5:116187682	chr5:116078110~116078570:-
ESCA	cis	rs9399137	0.507	rs7748708	ENSG00000232876.1	CTA-212D2.2	-4.34	2.96e-05	0.0393	-0.43	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:134954004	chr6:135055033~135060550:+
ESCA	cis	rs7618915	0.547	rs11130317	ENSG00000242797.3	GLYCTK-AS1	-4.34	2.96e-05	0.0394	-0.33	-0.36	Bipolar disorder;	chr3:52697467	chr3:52288580~52299067:-
ESCA	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	4.34	2.96e-05	0.0394	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
ESCA	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
ESCA	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
ESCA	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
ESCA	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-4.34	2.96e-05	0.0394	-0.38	-0.36	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
ESCA	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	4.34	2.96e-05	0.0394	0.42	0.36	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
ESCA	cis	rs9545047	0.604	rs1324868	ENSG00000227676.3	LINC01068	-4.34	2.96e-05	0.0394	-0.76	-0.36	Schizophrenia;	chr13:79380040	chr13:79566727~79571436:+
ESCA	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	4.34	2.96e-05	0.0394	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
ESCA	cis	rs6717918	0.517	rs2633263	ENSG00000263641.1	MIR4777	-4.34	2.97e-05	0.0394	-0.34	-0.36	Height;	chr2:232262743	chr2:231362708~231362793:+
ESCA	cis	rs6717918	0.517	rs2633262	ENSG00000263641.1	MIR4777	-4.34	2.97e-05	0.0394	-0.34	-0.36	Height;	chr2:232265874	chr2:231362708~231362793:+
ESCA	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	4.34	2.97e-05	0.0395	0.46	0.36	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
ESCA	cis	rs858239	0.614	rs10229956	ENSG00000226816.2	AC005082.12	-4.34	2.97e-05	0.0395	-0.39	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23206013~23208045:+
ESCA	cis	rs10875746	0.669	rs10431526	ENSG00000240399.1	RP1-228P16.1	-4.34	2.97e-05	0.0395	-0.43	-0.36	Longevity (90 years and older);	chr12:48296360	chr12:48054813~48055591:-
ESCA	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	4.34	2.98e-05	0.0395	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	4.34	2.98e-05	0.0395	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	4.34	2.98e-05	0.0395	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
ESCA	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	4.34	2.98e-05	0.0395	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
ESCA	cis	rs3820068	0.559	rs6675334	ENSG00000237301.1	RP4-680D5.2	4.34	2.98e-05	0.0395	0.41	0.36	Systolic blood pressure;	chr1:15597085	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs61056912	ENSG00000237301.1	RP4-680D5.2	4.34	2.98e-05	0.0395	0.41	0.36	Systolic blood pressure;	chr1:15599801	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs67806552	ENSG00000237301.1	RP4-680D5.2	4.34	2.98e-05	0.0395	0.41	0.36	Systolic blood pressure;	chr1:15600643	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs6692461	ENSG00000237301.1	RP4-680D5.2	4.34	2.98e-05	0.0395	0.41	0.36	Systolic blood pressure;	chr1:15601954	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs6692489	ENSG00000237301.1	RP4-680D5.2	4.34	2.98e-05	0.0395	0.41	0.36	Systolic blood pressure;	chr1:15602022	chr1:15586136~15603626:-
ESCA	cis	rs2742234	0.955	rs2503841	ENSG00000273008.1	RP11-351D16.3	-4.34	2.98e-05	0.0396	-0.41	-0.36	Hirschsprung disease;	chr10:43180273	chr10:43136824~43138334:-
ESCA	cis	rs12712135	0.709	rs12463588	ENSG00000234389.1	AC007278.3	-4.34	2.98e-05	0.0396	-0.32	-0.36	Blood protein levels;	chr2:102468797	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs2310302	ENSG00000234389.1	AC007278.3	-4.34	2.98e-05	0.0396	-0.32	-0.36	Blood protein levels;	chr2:102469589	chr2:102438713~102440475:+
ESCA	cis	rs8072100	0.539	rs36043200	ENSG00000228782.6	CTD-2026D20.3	-4.34	2.98e-05	0.0396	-0.38	-0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47552040	chr17:47450568~47492492:-
ESCA	cis	rs2439831	0.867	rs2920781	ENSG00000205771.5	CATSPER2P1	-4.34	2.98e-05	0.0396	-0.63	-0.36	Lung cancer in ever smokers;	chr15:43632484	chr15:43726918~43747094:-
ESCA	cis	rs1364044	0.909	rs12656358	ENSG00000251062.1	CTD-2218G20.1	-4.34	2.99e-05	0.0396	-0.43	-0.36	Stroke (pediatric);	chr5:33872238	chr5:32887990~32888145:-
ESCA	cis	rs7429990	0.965	rs319689	ENSG00000224895.1	VPS26BP1	-4.34	2.99e-05	0.0397	-0.3	-0.36	Educational attainment (years of education);	chr3:47886677	chr3:47960327~47961081:-
ESCA	cis	rs1439620	1	rs4778055	ENSG00000258647.4	LINC00930	4.34	2.99e-05	0.0397	0.43	0.36	Body mass index;	chr15:92890706	chr15:92567818~92572042:-
ESCA	cis	rs1439620	1	rs2119011	ENSG00000258647.4	LINC00930	4.34	2.99e-05	0.0397	0.43	0.36	Body mass index;	chr15:92891019	chr15:92567818~92572042:-
ESCA	cis	rs1439620	1	rs12900342	ENSG00000258647.4	LINC00930	4.34	2.99e-05	0.0397	0.43	0.36	Body mass index;	chr15:92893259	chr15:92567818~92572042:-
ESCA	cis	rs1439620	1	rs1992283	ENSG00000258647.4	LINC00930	4.34	2.99e-05	0.0397	0.43	0.36	Body mass index;	chr15:92895379	chr15:92567818~92572042:-
ESCA	cis	rs1439620	1	rs10775257	ENSG00000258647.4	LINC00930	4.34	2.99e-05	0.0397	0.43	0.36	Body mass index;	chr15:92896256	chr15:92567818~92572042:-
ESCA	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	4.34	2.99e-05	0.0397	0.47	0.36	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
ESCA	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	4.34	2.99e-05	0.0397	0.41	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
ESCA	cis	rs6452524	0.868	rs11746977	ENSG00000243385.2	CTD-2110K23.1	4.34	2.99e-05	0.0397	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83201229~83202141:+
ESCA	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	4.34	3e-05	0.0397	0.61	0.36	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
ESCA	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	4.34	3e-05	0.0397	0.61	0.36	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
ESCA	cis	rs1005277	0.579	rs176880	ENSG00000276805.1	RP11-291L22.6	-4.33	3e-05	0.0398	-0.47	-0.36	Extrinsic epigenetic age acceleration;	chr10:38112489	chr10:38451030~38451785:+
ESCA	cis	rs7631605	0.78	rs6550459	ENSG00000272334.1	RP11-129K12.1	-4.33	3e-05	0.0398	-0.4	-0.36	Cerebrospinal P-tau181p levels;	chr3:37182244	chr3:36973117~36973672:-
ESCA	cis	rs5758659	1	rs134869	ENSG00000182057.4	OGFRP1	4.33	3e-05	0.0398	0.42	0.36	Cognitive function;	chr22:42256068	chr22:42269753~42275196:+
ESCA	cis	rs732716	0.785	rs11666453	ENSG00000267980.1	AC007292.6	-4.33	3e-05	0.0398	-0.5	-0.36	Mean corpuscular volume;	chr19:4368800	chr19:4363789~4364640:+
ESCA	cis	rs732716	0.785	rs56033249	ENSG00000267980.1	AC007292.6	-4.33	3e-05	0.0398	-0.5	-0.36	Mean corpuscular volume;	chr19:4369450	chr19:4363789~4364640:+
ESCA	cis	rs10875746	0.859	rs4760622	ENSG00000240399.1	RP1-228P16.1	-4.33	3.01e-05	0.0399	-0.43	-0.36	Longevity (90 years and older);	chr12:48198177	chr12:48054813~48055591:-
ESCA	cis	rs559928	0.606	rs56311067	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164135	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.548	rs11231713	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164377	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.556	rs11607903	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64164668	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs55942618	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168533	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs76653616	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64168667	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.593	rs112275221	ENSG00000274986.1	MIR6750	4.33	3.01e-05	0.0399	0.66	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64169522	chr11:64898363~64898437:-
ESCA	cis	rs875971	0.545	rs2420612	ENSG00000179406.6	LINC00174	-4.33	3.02e-05	0.04	-0.52	-0.36	Aortic root size;	chr7:66536825	chr7:66376044~66401338:-
ESCA	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	4.33	3.02e-05	0.04	0.51	0.36	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	4.33	3.02e-05	0.04	0.51	0.36	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
ESCA	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	4.33	3.02e-05	0.04	0.52	0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
ESCA	cis	rs6479901	0.895	rs10733788	ENSG00000235816.3	PRELID1P3	-4.33	3.02e-05	0.04	-0.41	-0.36	Intelligence (multi-trait analysis);	chr10:63158105	chr10:63427297~63427939:+
ESCA	cis	rs3820068	0.532	rs72647105	ENSG00000237301.1	RP4-680D5.2	4.33	3.02e-05	0.04	0.41	0.36	Systolic blood pressure;	chr1:15608743	chr1:15586136~15603626:-
ESCA	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	4.33	3.02e-05	0.04	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
ESCA	cis	rs1048238	0.506	rs848212	ENSG00000235084.3	CHCHD2P6	4.33	3.03e-05	0.0401	0.35	0.36	Systolic blood pressure;	chr1:15936957	chr1:15604597~15605043:+
ESCA	cis	rs8059260	0.544	rs35347079	ENSG00000274038.1	RP11-66H6.4	-4.33	3.03e-05	0.0401	-0.64	-0.36	Alcohol consumption over the past year;	chr16:11099696	chr16:11056556~11057034:+
ESCA	cis	rs8059260	0.604	rs12928945	ENSG00000274038.1	RP11-66H6.4	-4.33	3.03e-05	0.0401	-0.64	-0.36	Alcohol consumption over the past year;	chr16:11106309	chr16:11056556~11057034:+
ESCA	cis	rs6724465	0.866	rs56411706	ENSG00000272644.1	RP11-33O4.1	4.33	3.03e-05	0.0401	0.62	0.36	Height;	chr2:219030826	chr2:219069354~219069809:-
ESCA	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	4.33	3.04e-05	0.0401	0.54	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
ESCA	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.33	3.04e-05	0.0402	-0.63	-0.36	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
ESCA	cis	rs9677476	0.587	rs6710104	ENSG00000201574.1	RNU1-93P	-4.33	3.04e-05	0.0402	-0.43	-0.36	Food antigen IgG levels;	chr2:231306482	chr2:231133462~231133630:+
ESCA	cis	rs7283707	0.681	rs76491942	ENSG00000269950.1	AP000962.2	4.33	3.04e-05	0.0402	0.71	0.36	QRS complex (12-leadsum);	chr21:15799018	chr21:16574718~16582637:-
ESCA	cis	rs7283707	0.505	rs80178255	ENSG00000269950.1	AP000962.2	4.33	3.04e-05	0.0402	0.71	0.36	QRS complex (12-leadsum);	chr21:15800224	chr21:16574718~16582637:-
ESCA	cis	rs7283707	0.681	rs77563426	ENSG00000269950.1	AP000962.2	4.33	3.04e-05	0.0402	0.71	0.36	QRS complex (12-leadsum);	chr21:15800703	chr21:16574718~16582637:-
ESCA	cis	rs7283707	0.681	rs77592989	ENSG00000269950.1	AP000962.2	4.33	3.04e-05	0.0402	0.71	0.36	QRS complex (12-leadsum);	chr21:15802062	chr21:16574718~16582637:-
ESCA	cis	rs7283707	0.681	rs77351677	ENSG00000269950.1	AP000962.2	4.33	3.04e-05	0.0402	0.71	0.36	QRS complex (12-leadsum);	chr21:15802418	chr21:16574718~16582637:-
ESCA	cis	rs11779988	0.545	rs436506	ENSG00000253671.1	RP11-806O11.1	4.33	3.04e-05	0.0402	0.42	0.36	Breast cancer;	chr8:17940734	chr8:17808941~17820868:+
ESCA	cis	rs3820068	0.603	rs17448778	ENSG00000237301.1	RP4-680D5.2	4.33	3.04e-05	0.0402	0.41	0.36	Systolic blood pressure;	chr1:15658811	chr1:15586136~15603626:-
ESCA	cis	rs611744	0.81	rs619227	ENSG00000253754.1	RP11-35G22.1	-4.33	3.05e-05	0.0403	-0.34	-0.36	Dupuytren's disease;	chr8:108202871	chr8:108226200~108227544:+
ESCA	cis	rs611744	0.87	rs635941	ENSG00000253754.1	RP11-35G22.1	-4.33	3.05e-05	0.0403	-0.34	-0.36	Dupuytren's disease;	chr8:108223228	chr8:108226200~108227544:+
ESCA	cis	rs2179367	0.959	rs537354	ENSG00000231760.4	RP11-350J20.5	4.33	3.05e-05	0.0403	0.41	0.36	Dupuytren's disease;	chr6:149344801	chr6:149796151~149826294:-
ESCA	cis	rs9584850	0.874	rs3742137	ENSG00000231194.1	FARP1-AS1	4.33	3.05e-05	0.0403	0.45	0.36	Neuroticism;	chr13:98450195	chr13:98435405~98435840:-
ESCA	cis	rs875971	0.545	rs1638724	ENSG00000179406.6	LINC00174	4.33	3.05e-05	0.0403	0.5	0.36	Aortic root size;	chr7:66575494	chr7:66376044~66401338:-
ESCA	cis	rs875971	0.545	rs1267814	ENSG00000179406.6	LINC00174	4.33	3.05e-05	0.0403	0.5	0.36	Aortic root size;	chr7:66579422	chr7:66376044~66401338:-
ESCA	cis	rs11867129	1	rs11867129	ENSG00000279901.1	CTD-2270P14.2	-4.33	3.05e-05	0.0403	-0.5	-0.36	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2315287	chr16:2683106~2684764:+
ESCA	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-4.33	3.06e-05	0.0404	-0.46	-0.36	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-4.33	3.06e-05	0.0404	-0.46	-0.36	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
ESCA	cis	rs7702057	0.53	rs7703978	ENSG00000271918.1	CTD-2287O16.5	4.33	3.07e-05	0.0405	0.69	0.36	Amyotrophic lateral sclerosis;	chr5:116085951	chr5:116083807~116085416:-
ESCA	cis	rs17256082	0.715	rs1023837	ENSG00000224638.1	AC106900.6	-4.33	3.07e-05	0.0405	-0.43	-0.36	Glycated hemoglobin levels;	chr2:174418322	chr2:173880865~173899428:-
ESCA	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-4.33	3.07e-05	0.0405	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
ESCA	cis	rs4407350	0.756	rs3827401	ENSG00000228807.1	MRPS18CP6	-4.33	3.07e-05	0.0405	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44494738	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.721	rs3827402	ENSG00000228807.1	MRPS18CP6	-4.33	3.07e-05	0.0405	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44494771	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.756	rs135622	ENSG00000228807.1	MRPS18CP6	-4.33	3.07e-05	0.0405	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44494778	chr22:44483495~44483717:-
ESCA	cis	rs2243480	1	rs1499614	ENSG00000222364.1	RNU6-96P	-4.33	3.07e-05	0.0405	-0.56	-0.36	Diabetic kidney disease;	chr7:66265811	chr7:66395191~66395286:+
ESCA	cis	rs2306032	0.669	rs10838622	ENSG00000271350.1	CTD-2384B9.1	-4.33	3.08e-05	0.0406	-0.43	-0.36	Total body bone mineral density;	chr11:46834985	chr11:47041027~47041945:-
ESCA	cis	rs75804782	0.521	rs55915157	ENSG00000265215.1	MIR4269	4.33	3.08e-05	0.0406	0.76	0.36	Chronotype;Morning vs. evening chronotype;	chr2:238515632	chr2:239305462~239305545:+
ESCA	cis	rs11051970	0.879	rs2088806	ENSG00000253063.1	RNU6-494P	-4.33	3.09e-05	0.0406	-0.36	-0.36	Response to tocilizumab in rheumatoid arthritis;	chr12:32439191	chr12:32477382~32477471:-
ESCA	cis	rs6710503	0.546	rs1372817	ENSG00000271936.1	RP11-443B20.1	4.33	3.09e-05	0.0407	0.39	0.36	Lung cancer in ever smokers;Breast cancer;	chr2:24512638	chr2:24825610~24826717:+
ESCA	cis	rs875971	0.545	rs1796222	ENSG00000179406.6	LINC00174	4.33	3.1e-05	0.0408	0.51	0.36	Aortic root size;	chr7:66592167	chr7:66376044~66401338:-
ESCA	cis	rs62034325	0.697	rs710410	ENSG00000278665.1	RP11-666O2.4	4.33	3.11e-05	0.0409	0.51	0.36	Body mass index;	chr16:28592021	chr16:28599241~28601881:-
ESCA	cis	rs2742234	0.59	rs2565201	ENSG00000273008.1	RP11-351D16.3	-4.33	3.11e-05	0.0409	-0.44	-0.36	Hirschsprung disease;	chr10:43123036	chr10:43136824~43138334:-
ESCA	cis	rs7412746	0.658	rs897815	ENSG00000206931.1	RNU6-1042P	-4.33	3.11e-05	0.0409	-0.43	-0.36	Melanoma;	chr1:150906625	chr1:150701866~150701972:+
ESCA	cis	rs9399137	0.507	rs11758774	ENSG00000232876.1	CTA-212D2.2	-4.33	3.12e-05	0.041	-0.45	-0.36	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;Glycated hemoglobin levels;Platelet count;Hematology traits;F-cell distribution;HbA2 levels;	chr6:135062651	chr6:135055033~135060550:+
ESCA	cis	rs9389248	0.737	rs12664956	ENSG00000232876.1	CTA-212D2.2	-4.33	3.12e-05	0.041	-0.45	-0.36	High light scatter reticulocyte percentage of red cells;	chr6:135063050	chr6:135055033~135060550:+
ESCA	cis	rs28830936	0.967	rs9672671	ENSG00000250379.1	RP11-23P13.4	4.33	3.12e-05	0.041	0.42	0.36	Diastolic blood pressure;	chr15:41624877	chr15:41825099~41827936:-
ESCA	cis	rs28830936	0.966	rs17733613	ENSG00000250379.1	RP11-23P13.4	4.33	3.12e-05	0.041	0.42	0.36	Diastolic blood pressure;	chr15:41625387	chr15:41825099~41827936:-
ESCA	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	4.32	3.12e-05	0.041	0.47	0.36	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
ESCA	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	4.32	3.13e-05	0.0411	0.5	0.36	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
ESCA	cis	rs10927875	0.619	rs7537101	ENSG00000235084.3	CHCHD2P6	4.32	3.13e-05	0.0411	0.34	0.36	Dilated cardiomyopathy;	chr1:15823889	chr1:15604597~15605043:+
ESCA	cis	rs2179367	0.959	rs536203	ENSG00000231760.4	RP11-350J20.5	4.32	3.13e-05	0.0411	0.41	0.36	Dupuytren's disease;	chr6:149330128	chr6:149796151~149826294:-
ESCA	cis	rs1710354	0.897	rs1710353	ENSG00000279676.1	CTB-147C22.6	-4.32	3.13e-05	0.0411	-0.45	-0.36	Blood protein levels;	chr19:51299396	chr19:50962197~50962781:-
ESCA	cis	rs9584850	0.834	rs3783005	ENSG00000231194.1	FARP1-AS1	-4.32	3.13e-05	0.0411	-0.44	-0.36	Neuroticism;	chr13:98459083	chr13:98435405~98435840:-
ESCA	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.32	3.13e-05	0.0411	0.65	0.36	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
ESCA	cis	rs79149102	0.579	rs7342591	ENSG00000260274.1	RP11-817O13.8	-4.32	3.13e-05	0.0411	-0.54	-0.36	Lung cancer;	chr15:75014522	chr15:75368155~75369584:+
ESCA	cis	rs12022452	1	rs12034162	ENSG00000229901.1	RP11-399E6.4	4.32	3.13e-05	0.0411	0.45	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40498933	chr1:41375004~41375669:-
ESCA	cis	rs7474896	0.616	rs2474561	ENSG00000263064.2	RP11-291L22.7	4.32	3.13e-05	0.0412	0.54	0.36	Obesity (extreme);	chr10:38084616	chr10:38448689~38448949:+
ESCA	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-4.32	3.13e-05	0.0412	-0.43	-0.36	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-4.32	3.13e-05	0.0412	-0.43	-0.36	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-4.32	3.13e-05	0.0412	-0.43	-0.36	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-4.32	3.13e-05	0.0412	-0.43	-0.36	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
ESCA	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-4.32	3.13e-05	0.0412	-0.43	-0.36	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
ESCA	cis	rs10954779	0.764	rs2162071	ENSG00000253579.1	SUMO2P16	-4.32	3.14e-05	0.0412	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:31163739	chr8:31131539~31131802:-
ESCA	cis	rs6456156	0.819	rs7765739	ENSG00000265828.1	MIR3939	-4.32	3.14e-05	0.0412	-0.4	-0.36	Primary biliary cholangitis;	chr6:167104984	chr6:166997807~166997912:-
ESCA	cis	rs2412819	0.571	rs11070411	ENSG00000249839.1	AC011330.5	4.32	3.15e-05	0.0413	0.68	0.36	Lung cancer;	chr15:43766436	chr15:43663654~43684339:-
ESCA	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-4.32	3.15e-05	0.0413	-0.53	-0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
ESCA	cis	rs950169	0.922	rs4842939	ENSG00000225151.9	GOLGA2P7	4.32	3.15e-05	0.0413	0.57	0.36	Schizophrenia;	chr15:84159214	chr15:84199311~84230136:-
ESCA	cis	rs3762637	1	rs9882100	ENSG00000272758.4	RP11-299J3.8	-4.32	3.15e-05	0.0413	-0.46	-0.36	LDL cholesterol levels;	chr3:122451061	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs9968189	ENSG00000272758.4	RP11-299J3.8	-4.32	3.15e-05	0.0413	-0.46	-0.36	LDL cholesterol levels;	chr3:122456289	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.941	rs60222267	ENSG00000272758.4	RP11-299J3.8	-4.32	3.15e-05	0.0413	-0.46	-0.36	LDL cholesterol levels;	chr3:122460785	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.882	rs56074178	ENSG00000272758.4	RP11-299J3.8	-4.32	3.15e-05	0.0413	-0.46	-0.36	LDL cholesterol levels;	chr3:122461164	chr3:122416207~122443180:+
ESCA	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	4.32	3.15e-05	0.0413	0.41	0.36	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
ESCA	cis	rs7829975	0.535	rs4841005	ENSG00000253981.4	ALG1L13P	-4.32	3.15e-05	0.0413	-0.43	-0.36	Mood instability;	chr8:8643720	chr8:8236003~8244667:-
ESCA	cis	rs42490	0.934	rs218947	ENSG00000251136.7	RP11-37B2.1	4.32	3.16e-05	0.0414	0.36	0.36	Leprosy;	chr8:89705148	chr8:89609409~89757727:-
ESCA	cis	rs8059260	0.736	rs77599345	ENSG00000274038.1	RP11-66H6.4	-4.32	3.16e-05	0.0414	-0.74	-0.36	Alcohol consumption over the past year;	chr16:10964707	chr16:11056556~11057034:+
ESCA	cis	rs10954779	0.764	rs2737338	ENSG00000253579.1	SUMO2P16	-4.32	3.16e-05	0.0414	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:31155614	chr8:31131539~31131802:-
ESCA	cis	rs10954779	0.764	rs2737341	ENSG00000253579.1	SUMO2P16	-4.32	3.16e-05	0.0414	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:31156409	chr8:31131539~31131802:-
ESCA	cis	rs7582403	0.844	rs6753116	ENSG00000223911.1	AC009480.3	-4.32	3.17e-05	0.0415	-0.39	-0.36	Neuroticism;	chr2:148094946	chr2:147899401~147902956:-
ESCA	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-4.32	3.17e-05	0.0415	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-4.32	3.17e-05	0.0415	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
ESCA	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-4.32	3.17e-05	0.0415	-0.45	-0.36	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
ESCA	cis	rs12744310	0.887	rs12032040	ENSG00000235358.1	RP11-399E6.1	4.32	3.17e-05	0.0416	0.5	0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41352635	chr1:41242373~41284861:+
ESCA	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	4.32	3.18e-05	0.0416	0.46	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	4.32	3.18e-05	0.0416	0.46	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	4.32	3.18e-05	0.0416	0.46	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
ESCA	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	4.32	3.18e-05	0.0416	0.46	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
ESCA	cis	rs6805251	0.672	rs6790751	ENSG00000276607.2	AC092910.1	4.32	3.18e-05	0.0416	0.43	0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119842753	chr3:120084550~120084657:-
ESCA	cis	rs6539247	0.509	rs2374584	ENSG00000257890.1	RP11-114F10.2	-4.32	3.18e-05	0.0416	-0.41	-0.36	Attention function in attention deficit hyperactive disorder;	chr12:106052210	chr12:106050961~106058254:-
ESCA	cis	rs10875746	0.537	rs4760625	ENSG00000240399.1	RP1-228P16.1	-4.32	3.18e-05	0.0417	-0.43	-0.36	Longevity (90 years and older);	chr12:48279960	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.669	rs11168510	ENSG00000240399.1	RP1-228P16.1	-4.32	3.18e-05	0.0417	-0.43	-0.36	Longevity (90 years and older);	chr12:48291772	chr12:48054813~48055591:-
ESCA	cis	rs8059260	0.604	rs16958021	ENSG00000274038.1	RP11-66H6.4	-4.32	3.19e-05	0.0417	-0.66	-0.36	Alcohol consumption over the past year;	chr16:11076190	chr16:11056556~11057034:+
ESCA	cis	rs1816752	0.721	rs7399656	ENSG00000273628.1	RP11-756A22.7	4.32	3.19e-05	0.0417	0.35	0.36	Obesity-related traits;	chr13:24415708	chr13:24933006~24936796:+
ESCA	cis	rs7208859	0.623	rs11658022	ENSG00000263531.1	RP13-753N3.1	4.32	3.19e-05	0.0417	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30758341	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs73269923	ENSG00000263531.1	RP13-753N3.1	4.32	3.19e-05	0.0417	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30775553	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.573	rs11654035	ENSG00000263531.1	RP13-753N3.1	4.32	3.19e-05	0.0417	0.57	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30809408	chr17:30863921~30864940:-
ESCA	cis	rs7618915	0.547	rs8906	ENSG00000242797.3	GLYCTK-AS1	-4.32	3.19e-05	0.0417	-0.33	-0.36	Bipolar disorder;	chr3:52705504	chr3:52288580~52299067:-
ESCA	cis	rs2221894	0.6	rs76071566	ENSG00000273710.1	Metazoa_SRP	4.32	3.19e-05	0.0417	0.47	0.36	Obesity-related traits;	chr8:28928468	chr8:28915579~28915864:-
ESCA	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-4.32	3.19e-05	0.0417	-0.52	-0.36	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
ESCA	cis	rs2273156	1	rs2383688	ENSG00000241052.1	RP11-173D9.1	-4.32	3.19e-05	0.0417	-0.44	-0.36	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934245	chr14:35144021~35144480:-
ESCA	cis	rs2273156	1	rs2383689	ENSG00000241052.1	RP11-173D9.1	-4.32	3.19e-05	0.0417	-0.44	-0.36	Immunoglobulin light chain (AL) amyloidosis;	chr14:34934814	chr14:35144021~35144480:-
ESCA	cis	rs470089	1	rs138099	ENSG00000234735.1	AL022237.3	4.32	3.19e-05	0.0417	0.42	0.36	Type 2 diabetes (dietary heme iron intake interaction);	chr22:43855972	chr22:43092167~43092524:+
ESCA	cis	rs1061377	0.748	rs12649085	ENSG00000249685.1	RP11-360F5.3	4.32	3.19e-05	0.0418	0.4	0.36	Uric acid levels;	chr4:39106459	chr4:39133913~39135608:+
ESCA	cis	rs9584850	0.915	rs7983438	ENSG00000231194.1	FARP1-AS1	4.32	3.2e-05	0.0418	0.46	0.36	Neuroticism;	chr13:98451063	chr13:98435405~98435840:-
ESCA	cis	rs8072100	0.807	rs2175290	ENSG00000228782.6	CTD-2026D20.3	4.32	3.2e-05	0.0418	0.38	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47402551	chr17:47450568~47492492:-
ESCA	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-4.32	3.2e-05	0.0418	-0.5	-0.36	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
ESCA	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-4.32	3.2e-05	0.0418	-0.5	-0.36	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
ESCA	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-4.32	3.2e-05	0.0418	-0.5	-0.36	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
ESCA	cis	rs9807989	0.507	rs11465721	ENSG00000234389.1	AC007278.3	4.32	3.2e-05	0.0418	0.35	0.36	Asthma;	chr2:102446780	chr2:102438713~102440475:+
ESCA	cis	rs8059260	0.736	rs16957854	ENSG00000274038.1	RP11-66H6.4	-4.32	3.2e-05	0.0419	-0.73	-0.36	Alcohol consumption over the past year;	chr16:10976466	chr16:11056556~11057034:+
ESCA	cis	rs6867032	0.527	rs1017924	ENSG00000249731.1	RP11-259O2.3	4.32	3.2e-05	0.0419	0.3	0.36	Gut microbiome composition (winter);	chr5:1976073	chr5:1968094~1969013:+
ESCA	cis	rs7618915	0.547	rs62255371	ENSG00000242797.3	GLYCTK-AS1	-4.32	3.2e-05	0.0419	-0.32	-0.36	Bipolar disorder;	chr3:52713305	chr3:52288580~52299067:-
ESCA	cis	rs10954779	0.846	rs11574388	ENSG00000253579.1	SUMO2P16	4.32	3.2e-05	0.0419	0.39	0.36	Intelligence (multi-trait analysis);	chr8:31163872	chr8:31131539~31131802:-
ESCA	cis	rs10954779	0.846	rs10954780	ENSG00000253579.1	SUMO2P16	4.32	3.2e-05	0.0419	0.39	0.36	Intelligence (multi-trait analysis);	chr8:31164201	chr8:31131539~31131802:-
ESCA	cis	rs7730934	1	rs11742271	ENSG00000227908.3	FLJ31104	4.32	3.2e-05	0.0419	0.49	0.36	Blood protein levels;	chr5:55967454	chr5:55995167~56003649:+
ESCA	cis	rs7017914	0.652	rs13262205	ENSG00000253173.3	RP11-152C15.1	-4.32	3.22e-05	0.042	-0.43	-0.36	Bone mineral density;	chr8:70659690	chr8:70103798~70104179:-
ESCA	cis	rs1075232	1	rs12437749	ENSG00000270055.1	CTD-3092A11.2	-4.32	3.22e-05	0.0421	-0.81	-0.36	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30487963~30490313:+
ESCA	cis	rs847845	0.535	rs67385931	ENSG00000186328.4	RP11-140K17.2	4.32	3.23e-05	0.0421	0.81	0.36	Non-small cell lung cancer;	chr6:35018729	chr6:34715613~34715940:+
ESCA	cis	rs8072100	0.837	rs62074055	ENSG00000228782.6	CTD-2026D20.3	4.32	3.23e-05	0.0421	0.4	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47694567	chr17:47450568~47492492:-
ESCA	cis	rs2742234	0.59	rs2505506	ENSG00000273008.1	RP11-351D16.3	-4.32	3.23e-05	0.0421	-0.43	-0.36	Hirschsprung disease;	chr10:43150406	chr10:43136824~43138334:-
ESCA	cis	rs4835265	1	rs4835265	ENSG00000250673.1	RP11-6L6.2	-4.32	3.23e-05	0.0421	-0.46	-0.36	Gamma glutamyl transpeptidase;	chr4:145900258	chr4:146224557~146229056:+
ESCA	cis	rs4345206	0.639	rs7662069	ENSG00000250673.1	RP11-6L6.2	-4.32	3.23e-05	0.0421	-0.35	-0.36	Coronary artery disease;	chr4:145887864	chr4:146224557~146229056:+
ESCA	cis	rs875971	0.66	rs1860468	ENSG00000179406.6	LINC00174	4.32	3.23e-05	0.0421	0.41	0.36	Aortic root size;	chr7:66642265	chr7:66376044~66401338:-
ESCA	cis	rs6969780	0.524	rs12530948	ENSG00000233429.8	HOTAIRM1	-4.32	3.24e-05	0.0422	-0.72	-0.36	Diastolic blood pressure;Systolic blood pressure;Hypertension;Blood pressure traits (multi-trait analysis);	chr7:27161639	chr7:27095647~27100265:+
ESCA	cis	rs2408955	0.515	rs10875742	ENSG00000240399.1	RP1-228P16.1	-4.32	3.24e-05	0.0422	-0.39	-0.36	Glycated hemoglobin levels;	chr12:48099591	chr12:48054813~48055591:-
ESCA	cis	rs6604026	0.698	rs10874744	ENSG00000229052.2	RP11-386I23.1	-4.32	3.24e-05	0.0422	-0.34	-0.36	Multiple sclerosis;	chr1:92840760	chr1:92930696~92934098:+
ESCA	cis	rs61160187	0.667	rs7722373	ENSG00000215032.2	GNL3LP1	4.32	3.24e-05	0.0422	0.48	0.36	Educational attainment (years of education);Educational attainment (college completion);	chr5:60951988	chr5:60891935~60893577:-
ESCA	cis	rs1723838	0.623	rs2008722	ENSG00000255928.1	RP11-456I15.2	-4.32	3.24e-05	0.0422	-0.88	-0.36	Obesity-related traits;	chr11:73655501	chr11:73722349~73722694:+
ESCA	cis	rs6724465	1	rs10445823	ENSG00000272644.1	RP11-33O4.1	4.32	3.25e-05	0.0423	0.58	0.36	Height;	chr2:219045442	chr2:219069354~219069809:-
ESCA	cis	rs6724465	1	rs13398523	ENSG00000272644.1	RP11-33O4.1	4.32	3.25e-05	0.0423	0.58	0.36	Height;	chr2:219045730	chr2:219069354~219069809:-
ESCA	cis	rs6724465	1	rs13412036	ENSG00000272644.1	RP11-33O4.1	4.32	3.25e-05	0.0423	0.58	0.36	Height;	chr2:219045732	chr2:219069354~219069809:-
ESCA	cis	rs7107356	1	rs7107356	ENSG00000280615.1	Y_RNA	4.31	3.25e-05	0.0423	0.39	0.36	Neuroticism (multi-trait analysis);Neuroticism;	chr11:47654618	chr11:47614898~47614994:-
ESCA	cis	rs2439831	0.681	rs825739	ENSG00000249839.1	AC011330.5	-4.31	3.25e-05	0.0423	-0.54	-0.36	Lung cancer in ever smokers;	chr15:43300230	chr15:43663654~43684339:-
ESCA	cis	rs9608946	0.956	rs9608955	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30504842	chr22:30246205~30246998:+
ESCA	cis	rs9608946	0.784	rs9608959	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30505990	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs7292573	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30510317	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs2023967	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30511181	chr22:30246205~30246998:+
ESCA	cis	rs9608946	0.956	rs13054004	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30513237	chr22:30246205~30246998:+
ESCA	cis	rs9608946	1	rs9608968	ENSG00000268812.3	RP1-102K2.8	4.31	3.25e-05	0.0423	0.5	0.36	Red cell distribution width;	chr22:30516902	chr22:30246205~30246998:+
ESCA	cis	rs7582403	0.844	rs1234410	ENSG00000223911.1	AC009480.3	4.31	3.26e-05	0.0424	0.39	0.36	Neuroticism;	chr2:148082938	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.771	rs1238800	ENSG00000223911.1	AC009480.3	-4.31	3.26e-05	0.0424	-0.39	-0.36	Neuroticism;	chr2:148086129	chr2:147899401~147902956:-
ESCA	cis	rs7582403	0.844	rs1234413	ENSG00000223911.1	AC009480.3	-4.31	3.26e-05	0.0424	-0.39	-0.36	Neuroticism;	chr2:148086800	chr2:147899401~147902956:-
ESCA	cis	rs7709377	0.671	rs10478286	ENSG00000272265.1	CTD-2287O16.4	-4.31	3.26e-05	0.0424	-0.5	-0.36	Metabolite levels  (X-11787);	chr5:116160166	chr5:116078110~116078570:-
ESCA	cis	rs2307394	0.748	rs11900506	ENSG00000223911.1	AC009480.3	4.31	3.26e-05	0.0424	0.44	0.36	Urate levels;	chr2:147806102	chr2:147899401~147902956:-
ESCA	cis	rs7951870	1	rs7108770	ENSG00000271350.1	CTD-2384B9.1	4.31	3.26e-05	0.0424	0.47	0.36	Schizophrenia;	chr11:46626882	chr11:47041027~47041945:-
ESCA	cis	rs2739330	0.796	rs1006771	ENSG00000231271.1	AP000350.8	4.31	3.27e-05	0.0424	0.42	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23949918~23954042:+
ESCA	cis	rs17691453	0.686	rs1371963	ENSG00000175746.6	C15orf54	4.31	3.27e-05	0.0424	0.46	0.36	Metabolite levels (Dihydroxy docosatrienoic acid);	chr15:39305932	chr15:39250684~39254845:+
ESCA	cis	rs17691453	0.686	rs4429266	ENSG00000175746.6	C15orf54	4.31	3.27e-05	0.0424	0.46	0.36	Metabolite levels (Dihydroxy docosatrienoic acid);	chr15:39306642	chr15:39250684~39254845:+
ESCA	cis	rs17691453	0.66	rs8027538	ENSG00000175746.6	C15orf54	4.31	3.27e-05	0.0424	0.46	0.36	Metabolite levels (Dihydroxy docosatrienoic acid);	chr15:39307617	chr15:39250684~39254845:+
ESCA	cis	rs12712135	0.652	rs11465727	ENSG00000234389.1	AC007278.3	-4.31	3.27e-05	0.0425	-0.32	-0.36	Blood protein levels;	chr2:102448043	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs11465729	ENSG00000234389.1	AC007278.3	-4.31	3.27e-05	0.0425	-0.32	-0.36	Blood protein levels;	chr2:102448052	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.709	rs11465730	ENSG00000234389.1	AC007278.3	-4.31	3.27e-05	0.0425	-0.32	-0.36	Blood protein levels;	chr2:102450398	chr2:102438713~102440475:+
ESCA	cis	rs12712135	0.677	rs6705385	ENSG00000234389.1	AC007278.3	-4.31	3.27e-05	0.0425	-0.32	-0.36	Blood protein levels;	chr2:102460109	chr2:102438713~102440475:+
ESCA	cis	rs9462027	0.628	rs7771778	ENSG00000186328.4	RP11-140K17.2	-4.31	3.27e-05	0.0425	-0.4	-0.36	Systemic lupus erythematosus;	chr6:34692547	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs7742652	ENSG00000186328.4	RP11-140K17.2	-4.31	3.27e-05	0.0425	-0.4	-0.36	Systemic lupus erythematosus;	chr6:34699298	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9348950	ENSG00000186328.4	RP11-140K17.2	-4.31	3.27e-05	0.0425	-0.4	-0.36	Systemic lupus erythematosus;	chr6:34705901	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs9357181	ENSG00000186328.4	RP11-140K17.2	-4.31	3.27e-05	0.0425	-0.4	-0.36	Systemic lupus erythematosus;	chr6:34706056	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2395598	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34672909	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.651	rs2395599	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34673638	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.63	rs2744943	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34675402	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.606	rs2744941	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34679140	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.628	rs2814945	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34680201	chr6:34715613~34715940:+
ESCA	cis	rs9462027	0.583	rs2814947	ENSG00000186328.4	RP11-140K17.2	4.31	3.27e-05	0.0425	0.4	0.36	Systemic lupus erythematosus;	chr6:34685491	chr6:34715613~34715940:+
ESCA	cis	rs2470578	0.792	rs2596641	ENSG00000233133.1	AC104451.2	4.31	3.28e-05	0.0425	0.4	0.36	Schizophrenia;	chr3:17249802	chr3:17706058~17706233:-
ESCA	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	4.31	3.28e-05	0.0425	0.5	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
ESCA	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-4.31	3.28e-05	0.0426	-0.36	-0.36	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
ESCA	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	4.31	3.29e-05	0.0426	0.5	0.36	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
ESCA	cis	rs6479901	0.843	rs9414802	ENSG00000235816.3	PRELID1P3	4.31	3.3e-05	0.0427	0.44	0.36	Intelligence (multi-trait analysis);	chr10:63391622	chr10:63427297~63427939:+
ESCA	cis	rs7631605	1	rs2302507	ENSG00000272334.1	RP11-129K12.1	-4.31	3.3e-05	0.0427	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37103044	chr3:36973117~36973672:-
ESCA	cis	rs7631605	0.935	rs6550455	ENSG00000272334.1	RP11-129K12.1	-4.31	3.3e-05	0.0427	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37105867	chr3:36973117~36973672:-
ESCA	cis	rs2439831	0.85	rs68079546	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43844759	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs56909447	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43845420	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28476182	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43847445	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28696802	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43848197	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28413704	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43856229	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.702	rs16977724	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43859101	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.702	rs9989313	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43860619	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28858500	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43864744	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs3742982	ENSG00000275601.1	AC011330.13	-4.31	3.3e-05	0.0427	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43884483	chr15:43642389~43643023:-
ESCA	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-4.31	3.3e-05	0.0427	-0.66	-0.36	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
ESCA	cis	rs977987	0.806	rs11149833	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75430104	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs11641587	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75430521	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12930768	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75430602	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.778	rs12445726	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75431677	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.843	rs11644741	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75432535	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs12917651	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75432798	chr16:75379818~75381260:-
ESCA	cis	rs977987	0.806	rs35787595	ENSG00000261783.1	RP11-252K23.2	-4.31	3.3e-05	0.0427	-0.44	-0.36	Dupuytren's disease;	chr16:75432949	chr16:75379818~75381260:-
ESCA	cis	rs6456156	0.526	rs1854853	ENSG00000265828.1	MIR3939	4.31	3.3e-05	0.0427	0.38	0.36	Primary biliary cholangitis;	chr6:167119574	chr6:166997807~166997912:-
ESCA	cis	rs7618915	0.571	rs6778844	ENSG00000242797.3	GLYCTK-AS1	4.31	3.3e-05	0.0427	0.33	0.36	Bipolar disorder;	chr3:52562382	chr3:52288580~52299067:-
ESCA	cis	rs7208859	0.673	rs73263981	ENSG00000263531.1	RP13-753N3.1	4.31	3.3e-05	0.0427	0.56	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593484	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.524	rs73263982	ENSG00000263531.1	RP13-753N3.1	4.31	3.3e-05	0.0427	0.56	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30593606	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.623	rs216433	ENSG00000263531.1	RP13-753N3.1	4.31	3.3e-05	0.0427	0.56	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30594842	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs216435	ENSG00000263531.1	RP13-753N3.1	4.31	3.3e-05	0.0427	0.56	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30595719	chr17:30863921~30864940:-
ESCA	cis	rs11169552	0.51	rs11169479	ENSG00000200428.1	Y_RNA	4.31	3.31e-05	0.0428	0.43	0.36	Colorectal cancer;	chr12:50528553	chr12:50743568~50743684:+
ESCA	cis	rs3820068	0.705	rs4646031	ENSG00000237301.1	RP4-680D5.2	4.31	3.31e-05	0.0428	0.4	0.36	Systolic blood pressure;	chr1:15508153	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs4646022	ENSG00000237301.1	RP4-680D5.2	4.31	3.31e-05	0.0428	0.4	0.36	Systolic blood pressure;	chr1:15512617	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.705	rs4645983	ENSG00000237301.1	RP4-680D5.2	4.31	3.31e-05	0.0428	0.4	0.36	Systolic blood pressure;	chr1:15524108	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.677	rs72643691	ENSG00000237301.1	RP4-680D5.2	4.31	3.31e-05	0.0428	0.4	0.36	Systolic blood pressure;	chr1:15529756	chr1:15586136~15603626:-
ESCA	cis	rs2439831	0.85	rs524417	ENSG00000249839.1	AC011330.5	-4.31	3.31e-05	0.0428	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43480176	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs2439832	ENSG00000249839.1	AC011330.5	-4.31	3.31e-05	0.0428	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43487488	chr15:43663654~43684339:-
ESCA	cis	rs36093844	0.527	rs1596739	ENSG00000271318.1	AP000654.5	-4.31	3.32e-05	0.0429	-0.73	-0.36	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85922325	chr11:86821143~86821728:-
ESCA	cis	rs7208859	0.623	rs8082537	ENSG00000263531.1	RP13-753N3.1	4.31	3.32e-05	0.0429	0.59	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30688914	chr17:30863921~30864940:-
ESCA	cis	rs17826219	0.561	rs11655876	ENSG00000263531.1	RP13-753N3.1	4.31	3.32e-05	0.0429	0.59	0.36	Body mass index;	chr17:30690132	chr17:30863921~30864940:-
ESCA	cis	rs7208859	0.673	rs9907197	ENSG00000263531.1	RP13-753N3.1	4.31	3.32e-05	0.0429	0.59	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30691245	chr17:30863921~30864940:-
ESCA	cis	rs4664293	0.801	rs7607143	ENSG00000226266.5	AC009961.3	-4.31	3.32e-05	0.043	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159728250	chr2:159670708~159712435:-
ESCA	cis	rs4664293	0.833	rs10170336	ENSG00000226266.5	AC009961.3	-4.31	3.32e-05	0.043	-0.44	-0.36	Monocyte percentage of white cells;	chr2:159732832	chr2:159670708~159712435:-
ESCA	cis	rs6558530	0.836	rs7461600	ENSG00000253982.1	CTD-2336O2.1	4.31	3.33e-05	0.043	0.47	0.36	Systolic blood pressure;	chr8:1766476	chr8:1761990~1764502:-
ESCA	cis	rs9462027	0.628	rs1998702	ENSG00000186328.4	RP11-140K17.2	4.31	3.33e-05	0.043	0.4	0.36	Systemic lupus erythematosus;	chr6:34774140	chr6:34715613~34715940:+
ESCA	cis	rs253959	0.545	rs7734133	ENSG00000272265.1	CTD-2287O16.4	4.31	3.34e-05	0.0431	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116096418	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.545	rs10072350	ENSG00000272265.1	CTD-2287O16.4	4.31	3.34e-05	0.0431	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116097829	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.545	rs10072417	ENSG00000272265.1	CTD-2287O16.4	4.31	3.34e-05	0.0431	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116097906	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.576	rs1588268	ENSG00000272265.1	CTD-2287O16.4	4.31	3.34e-05	0.0431	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116101091	chr5:116078110~116078570:-
ESCA	cis	rs253959	0.545	rs2416425	ENSG00000272265.1	CTD-2287O16.4	4.31	3.34e-05	0.0431	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116101727	chr5:116078110~116078570:-
ESCA	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	4.31	3.34e-05	0.0431	0.62	0.36	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
ESCA	cis	rs11235843	0.853	rs1869433	ENSG00000255928.1	RP11-456I15.2	4.31	3.34e-05	0.0431	0.59	0.36	Hand grip strength;	chr11:73828498	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.853	rs12365080	ENSG00000255928.1	RP11-456I15.2	4.31	3.34e-05	0.0431	0.59	0.36	Hand grip strength;	chr11:73836914	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.715	rs12421900	ENSG00000255928.1	RP11-456I15.2	4.31	3.34e-05	0.0431	0.59	0.36	Hand grip strength;	chr11:73840111	chr11:73722349~73722694:+
ESCA	cis	rs11235843	0.853	rs4537782	ENSG00000255928.1	RP11-456I15.2	4.31	3.34e-05	0.0431	0.59	0.36	Hand grip strength;	chr11:73852846	chr11:73722349~73722694:+
ESCA	cis	rs7829975	0.688	rs7826654	ENSG00000173295.6	FAM86B3P	4.31	3.34e-05	0.0431	0.43	0.36	Mood instability;	chr8:8521596	chr8:8228595~8244865:+
ESCA	cis	rs7829975	0.688	rs7826660	ENSG00000173295.6	FAM86B3P	4.31	3.34e-05	0.0431	0.43	0.36	Mood instability;	chr8:8521597	chr8:8228595~8244865:+
ESCA	cis	rs2439831	0.85	rs10438303	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43724219	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs12441127	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43728977	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.702	rs7171750	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43733660	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs11070408	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43742590	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs28718261	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43751595	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs28595038	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43752661	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs10163054	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43755440	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs7168158	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43758178	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs7174208	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43760484	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs12101756	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43761689	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.85	rs12442129	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43763658	chr15:43649123~43649280:+
ESCA	cis	rs2439831	0.702	rs7175032	ENSG00000224677.1	PDIA3P2	-4.31	3.34e-05	0.0431	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43768038	chr15:43649123~43649280:+
ESCA	cis	rs7618915	0.501	rs3733039	ENSG00000242797.3	GLYCTK-AS1	-4.31	3.34e-05	0.0431	-0.32	-0.36	Bipolar disorder;	chr3:52685072	chr3:52288580~52299067:-
ESCA	cis	rs8059260	0.604	rs11863415	ENSG00000274038.1	RP11-66H6.4	-4.31	3.35e-05	0.0432	-0.62	-0.36	Alcohol consumption over the past year;	chr16:11053237	chr16:11056556~11057034:+
ESCA	cis	rs8072100	0.967	rs9894905	ENSG00000228782.6	CTD-2026D20.3	4.31	3.35e-05	0.0432	0.39	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47408616	chr17:47450568~47492492:-
ESCA	cis	rs9584850	0.874	rs3742136	ENSG00000231194.1	FARP1-AS1	4.31	3.36e-05	0.0433	0.46	0.36	Neuroticism;	chr13:98450353	chr13:98435405~98435840:-
ESCA	cis	rs11084753	1	rs435942	ENSG00000277013.1	CTC-526N19.1	4.31	3.36e-05	0.0433	0.34	0.36	Body mass index;	chr19:33831192	chr19:33906352~33908391:+
ESCA	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	4.31	3.36e-05	0.0433	0.71	0.36	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
ESCA	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	4.31	3.36e-05	0.0433	0.35	0.36	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
ESCA	cis	rs453301	0.658	rs3855900	ENSG00000253981.4	ALG1L13P	-4.31	3.36e-05	0.0433	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9044411	chr8:8236003~8244667:-
ESCA	cis	rs3820068	0.603	rs7537618	ENSG00000237301.1	RP4-680D5.2	4.31	3.36e-05	0.0433	0.42	0.36	Systolic blood pressure;	chr1:15651187	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs7529759	ENSG00000237301.1	RP4-680D5.2	4.31	3.36e-05	0.0433	0.42	0.36	Systolic blood pressure;	chr1:15651382	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.581	rs6693694	ENSG00000237301.1	RP4-680D5.2	4.31	3.36e-05	0.0433	0.42	0.36	Systolic blood pressure;	chr1:15653640	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs72647138	ENSG00000237301.1	RP4-680D5.2	4.31	3.36e-05	0.0433	0.42	0.36	Systolic blood pressure;	chr1:15654434	chr1:15586136~15603626:-
ESCA	cis	rs453301	0.682	rs2929451	ENSG00000253981.4	ALG1L13P	4.31	3.37e-05	0.0434	0.46	0.36	Joint mobility (Beighton score);	chr8:9227785	chr8:8236003~8244667:-
ESCA	cis	rs7267979	0.789	rs6050472	ENSG00000204556.4	CTD-2514C3.1	-4.31	3.37e-05	0.0434	-0.5	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:26018832~26020684:+
ESCA	cis	rs8059260	0.604	rs35715760	ENSG00000274038.1	RP11-66H6.4	-4.31	3.37e-05	0.0434	-0.64	-0.36	Alcohol consumption over the past year;	chr16:11102091	chr16:11056556~11057034:+
ESCA	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-4.31	3.37e-05	0.0434	-0.54	-0.36	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.922	rs11633534	ENSG00000225151.9	GOLGA2P7	-4.31	3.37e-05	0.0434	-0.57	-0.36	Schizophrenia;	chr15:84581411	chr15:84199311~84230136:-
ESCA	cis	rs950169	0.65	rs12902052	ENSG00000225151.9	GOLGA2P7	-4.31	3.37e-05	0.0434	-0.57	-0.36	Schizophrenia;	chr15:84582607	chr15:84199311~84230136:-
ESCA	cis	rs2439831	0.85	rs9944216	ENSG00000275601.1	AC011330.13	4.31	3.37e-05	0.0434	0.68	0.36	Lung cancer in ever smokers;	chr15:43868575	chr15:43642389~43643023:-
ESCA	cis	rs2810114	0.834	rs36559	ENSG00000269945.1	RP6-91H8.5	-4.31	3.37e-05	0.0434	-0.44	-0.36	Alcohol dependence;	chr14:70888232	chr14:71219100~71222724:+
ESCA	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	4.31	3.38e-05	0.0434	0.54	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
ESCA	cis	rs1075265	0.749	rs805436	ENSG00000235937.1	AC008280.1	4.3	3.38e-05	0.0435	0.4	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54029552~54030682:-
ESCA	cis	rs2742234	0.541	rs1317214	ENSG00000273008.1	RP11-351D16.3	4.3	3.38e-05	0.0436	0.43	0.36	Hirschsprung disease;	chr10:43238083	chr10:43136824~43138334:-
ESCA	cis	rs2742234	0.541	rs871763	ENSG00000273008.1	RP11-351D16.3	4.3	3.38e-05	0.0436	0.43	0.36	Hirschsprung disease;	chr10:43238740	chr10:43136824~43138334:-
ESCA	cis	rs7631605	0.816	rs7640224	ENSG00000272334.1	RP11-129K12.1	-4.3	3.39e-05	0.0436	-0.4	-0.36	Cerebrospinal P-tau181p levels;	chr3:37143652	chr3:36973117~36973672:-
ESCA	cis	rs7582403	0.844	rs10928374	ENSG00000223911.1	AC009480.3	-4.3	3.39e-05	0.0436	-0.39	-0.36	Neuroticism;	chr2:148094466	chr2:147899401~147902956:-
ESCA	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-4.3	3.39e-05	0.0436	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-4.3	3.39e-05	0.0436	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
ESCA	cis	rs2303759	0.709	rs2278405	ENSG00000269814.1	CTC-273B12.10	4.3	3.41e-05	0.0438	0.49	0.36	Multiple sclerosis;	chr19:49309146	chr19:48513207~48513660:-
ESCA	cis	rs7829975	0.539	rs940031	ENSG00000253981.4	ALG1L13P	-4.3	3.41e-05	0.0438	-0.44	-0.36	Mood instability;	chr8:8689338	chr8:8236003~8244667:-
ESCA	cis	rs1816752	0.633	rs8002387	ENSG00000273628.1	RP11-756A22.7	4.3	3.41e-05	0.0438	0.35	0.36	Obesity-related traits;	chr13:24416306	chr13:24933006~24936796:+
ESCA	cis	rs61990749	0.597	rs1477262	ENSG00000239272.1	RPL21P10	4.3	3.41e-05	0.0438	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77760310	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs1978416	ENSG00000239272.1	RPL21P10	4.3	3.41e-05	0.0438	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77761558	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs3759728	ENSG00000239272.1	RPL21P10	4.3	3.41e-05	0.0438	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77763816	chr14:77683202~77683989:-
ESCA	cis	rs7927771	0.524	rs10838774	ENSG00000280615.1	Y_RNA	4.3	3.41e-05	0.0439	0.39	0.36	Subjective well-being;	chr11:47834562	chr11:47614898~47614994:-
ESCA	cis	rs12534093	0.662	rs7799435	ENSG00000234286.1	AC006026.13	-4.3	3.41e-05	0.0439	-0.5	-0.36	Infant length;Height;	chr7:23545083	chr7:23680195~23680786:-
ESCA	cis	rs2251069	0.517	rs61986116	ENSG00000258503.1	RP11-368P15.1	4.3	3.41e-05	0.0439	0.58	0.36	Optic cup area;	chr14:53454939	chr14:53011971~53012267:+
ESCA	cis	rs7615952	0.605	rs11708269	ENSG00000272840.1	RP11-379B18.6	4.3	3.41e-05	0.0439	0.6	0.36	Blood pressure (smoking interaction);	chr3:125613306	chr3:125774714~125797953:+
ESCA	cis	rs3762637	1	rs72960431	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122509814	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs28434553	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122510668	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.941	rs9837149	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122511998	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs9867429	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122513821	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.943	rs72960447	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122516258	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.943	rs6762156	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122517178	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.823	rs59569049	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122519941	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.943	rs9872708	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122523960	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.823	rs9849013	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122531758	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.943	rs28403550	ENSG00000272758.4	RP11-299J3.8	-4.3	3.42e-05	0.0439	-0.47	-0.36	LDL cholesterol levels;	chr3:122532991	chr3:122416207~122443180:+
ESCA	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-4.3	3.42e-05	0.044	-0.37	-0.36	Height;	chr2:231516587	chr2:231501990~231502201:-
ESCA	cis	rs11971779	0.68	rs6965212	ENSG00000273391.1	RP11-634H22.1	4.3	3.42e-05	0.044	0.48	0.36	Diisocyanate-induced asthma;	chr7:139341719	chr7:139359032~139359566:-
ESCA	cis	rs1364044	0.909	rs13184475	ENSG00000251062.1	CTD-2218G20.1	-4.3	3.43e-05	0.044	-0.42	-0.36	Stroke (pediatric);	chr5:33842641	chr5:32887990~32888145:-
ESCA	cis	rs1364044	0.909	rs35147918	ENSG00000251062.1	CTD-2218G20.1	-4.3	3.43e-05	0.044	-0.42	-0.36	Stroke (pediatric);	chr5:33844996	chr5:32887990~32888145:-
ESCA	cis	rs1364044	0.909	rs13187545	ENSG00000251062.1	CTD-2218G20.1	-4.3	3.43e-05	0.044	-0.42	-0.36	Stroke (pediatric);	chr5:33852997	chr5:32887990~32888145:-
ESCA	cis	rs1364044	0.909	rs13155761	ENSG00000251062.1	CTD-2218G20.1	-4.3	3.43e-05	0.044	-0.42	-0.36	Stroke (pediatric);	chr5:33854635	chr5:32887990~32888145:-
ESCA	cis	rs35324223	1	rs35324223	ENSG00000271350.1	CTD-2384B9.1	4.3	3.43e-05	0.044	0.47	0.36	Autism spectrum disorder or schizophrenia;	chr11:46381302	chr11:47041027~47041945:-
ESCA	cis	rs2742234	0.541	rs10899782	ENSG00000273008.1	RP11-351D16.3	4.3	3.43e-05	0.044	0.43	0.36	Hirschsprung disease;	chr10:43240913	chr10:43136824~43138334:-
ESCA	cis	rs7412746	0.658	rs6658066	ENSG00000206931.1	RNU6-1042P	4.3	3.43e-05	0.044	0.45	0.36	Melanoma;	chr1:150946461	chr1:150701866~150701972:+
ESCA	cis	rs11038871	1	rs1317826	ENSG00000271350.1	CTD-2384B9.1	4.3	3.43e-05	0.0441	0.4	0.36	Immunoglobulin A;	chr11:46366318	chr11:47041027~47041945:-
ESCA	cis	rs765787	0.53	rs12904265	ENSG00000259520.4	CTD-2651B20.3	-4.3	3.44e-05	0.0441	-0.42	-0.36	Uric acid levels;	chr15:45234515	chr15:45251580~45279251:-
ESCA	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-4.3	3.44e-05	0.0441	-0.41	-0.36	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
ESCA	cis	rs9584850	0.834	rs2031239	ENSG00000231194.1	FARP1-AS1	4.3	3.44e-05	0.0441	0.45	0.36	Neuroticism;	chr13:98459306	chr13:98435405~98435840:-
ESCA	cis	rs2307394	0.896	rs1424949	ENSG00000223911.1	AC009480.3	4.3	3.44e-05	0.0441	0.45	0.36	Urate levels;	chr2:147785394	chr2:147899401~147902956:-
ESCA	cis	rs1426063	0.668	rs6534595	ENSG00000248165.1	RP11-44F21.2	4.3	3.45e-05	0.0442	0.46	0.36	QT interval;	chr4:75104432	chr4:74993877~75034824:-
ESCA	cis	rs3762637	1	rs9843165	ENSG00000272758.4	RP11-299J3.8	-4.3	3.46e-05	0.0443	-0.46	-0.36	LDL cholesterol levels;	chr3:122412264	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs16845530	ENSG00000272758.4	RP11-299J3.8	-4.3	3.46e-05	0.0443	-0.46	-0.36	LDL cholesterol levels;	chr3:122423600	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs3762637	ENSG00000272758.4	RP11-299J3.8	-4.3	3.46e-05	0.0443	-0.46	-0.36	LDL cholesterol levels;	chr3:122426477	chr3:122416207~122443180:+
ESCA	cis	rs3762637	1	rs9833415	ENSG00000272758.4	RP11-299J3.8	-4.3	3.46e-05	0.0443	-0.46	-0.36	LDL cholesterol levels;	chr3:122440993	chr3:122416207~122443180:+
ESCA	cis	rs3762637	0.882	rs72958418	ENSG00000272758.4	RP11-299J3.8	-4.3	3.46e-05	0.0443	-0.46	-0.36	LDL cholesterol levels;	chr3:122441526	chr3:122416207~122443180:+
ESCA	cis	rs3820068	0.532	rs6701009	ENSG00000237301.1	RP4-680D5.2	4.3	3.46e-05	0.0443	0.41	0.36	Systolic blood pressure;	chr1:15609119	chr1:15586136~15603626:-
ESCA	cis	rs877426	0.591	rs56188498	ENSG00000264539.1	MIR548AR	4.3	3.46e-05	0.0443	0.43	0.36	Facial morphology (factor 14, intercanthal width);	chr13:114062329	chr13:114244505~114244561:+
ESCA	cis	rs1005277	0.579	rs2505248	ENSG00000263064.2	RP11-291L22.7	4.3	3.46e-05	0.0443	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38170169	chr10:38448689~38448949:+
ESCA	cis	rs253959	0.607	rs1396497	ENSG00000272265.1	CTD-2287O16.4	4.3	3.46e-05	0.0443	0.4	0.36	Bipolar disorder and schizophrenia;	chr5:116091719	chr5:116078110~116078570:-
ESCA	cis	rs7179228	0.918	rs2414997	ENSG00000260657.2	RP11-315D16.4	-4.3	3.46e-05	0.0443	-0.56	-0.36	Systolic blood pressure;	chr15:68323181	chr15:68267792~68277994:-
ESCA	cis	rs1061377	0.748	rs11096977	ENSG00000249685.1	RP11-360F5.3	4.3	3.46e-05	0.0443	0.41	0.36	Uric acid levels;	chr4:39106186	chr4:39133913~39135608:+
ESCA	cis	rs1061377	0.748	rs6810770	ENSG00000249685.1	RP11-360F5.3	4.3	3.46e-05	0.0443	0.41	0.36	Uric acid levels;	chr4:39106545	chr4:39133913~39135608:+
ESCA	cis	rs28830936	1	rs11070343	ENSG00000250379.1	RP11-23P13.4	4.3	3.47e-05	0.0444	0.42	0.36	Diastolic blood pressure;	chr15:41647948	chr15:41825099~41827936:-
ESCA	cis	rs3820068	0.603	rs932602	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15659592	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs3766163	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15660052	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs10492986	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15662207	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs41270279	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15662383	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs998032	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15663423	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.603	rs927207	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15664057	chr1:15586136~15603626:-
ESCA	cis	rs3820068	0.529	rs79570154	ENSG00000237301.1	RP4-680D5.2	4.3	3.47e-05	0.0444	0.42	0.36	Systolic blood pressure;	chr1:15664417	chr1:15586136~15603626:-
ESCA	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.47e-05	0.0444	-0.45	-0.36	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.689	rs4535075	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.47e-05	0.0444	-0.45	-0.36	Neurofibrillary tangles;	chr2:3477945	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.666	rs6767	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.47e-05	0.0444	-0.45	-0.36	Neurofibrillary tangles;	chr2:3479434	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.623	rs7569694	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.47e-05	0.0444	-0.45	-0.36	Neurofibrillary tangles;	chr2:3479619	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.666	rs6723101	ENSG00000225234.1	TRAPPC12-AS1	-4.3	3.47e-05	0.0444	-0.45	-0.36	Neurofibrillary tangles;	chr2:3480672	chr2:3481242~3482409:-
ESCA	cis	rs12744310	0.887	rs6660265	ENSG00000235358.1	RP11-399E6.1	-4.3	3.48e-05	0.0445	-0.46	-0.36	Intelligence;Cognitive ability (multi-trait analysis);Cognitive ability;	chr1:41353004	chr1:41242373~41284861:+
ESCA	cis	rs17826219	0.636	rs12946563	ENSG00000263531.1	RP13-753N3.1	4.3	3.48e-05	0.0445	0.57	0.36	Body mass index;	chr17:30776148	chr17:30863921~30864940:-
ESCA	cis	rs1816752	0.819	rs4770665	ENSG00000273628.1	RP11-756A22.7	4.3	3.48e-05	0.0445	0.35	0.36	Obesity-related traits;	chr13:24414810	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.749	rs77832754	ENSG00000273628.1	RP11-756A22.7	4.3	3.48e-05	0.0445	0.35	0.36	Obesity-related traits;	chr13:24416016	chr13:24933006~24936796:+
ESCA	cis	rs1816752	0.819	rs7985478	ENSG00000273628.1	RP11-756A22.7	4.3	3.48e-05	0.0445	0.35	0.36	Obesity-related traits;	chr13:24417135	chr13:24933006~24936796:+
ESCA	cis	rs3820068	0.532	rs1547034	ENSG00000237301.1	RP4-680D5.2	4.3	3.48e-05	0.0445	0.39	0.36	Systolic blood pressure;	chr1:15592554	chr1:15586136~15603626:-
ESCA	cis	rs237743	1	rs238150	ENSG00000222365.1	SNORD12B	-4.3	3.48e-05	0.0445	-0.51	-0.36	Height;	chr20:49235382	chr20:49280319~49280409:+
ESCA	cis	rs35146811	0.555	rs1981549	ENSG00000201913.1	Y_RNA	-4.3	3.48e-05	0.0445	-0.44	-0.36	Coronary artery disease;	chr7:99944013	chr7:100330777~100330877:-
ESCA	cis	rs35146811	0.555	rs1981550	ENSG00000201913.1	Y_RNA	-4.3	3.48e-05	0.0445	-0.44	-0.36	Coronary artery disease;	chr7:99944329	chr7:100330777~100330877:-
ESCA	cis	rs17256082	0.81	rs6433473	ENSG00000179997.8	AC010894.4	4.3	3.48e-05	0.0445	0.43	0.36	Glycated hemoglobin levels;	chr2:174357690	chr2:174501952~174502312:+
ESCA	cis	rs7709377	0.723	rs73780896	ENSG00000272265.1	CTD-2287O16.4	4.3	3.49e-05	0.0446	0.51	0.36	Metabolite levels  (X-11787);	chr5:116215206	chr5:116078110~116078570:-
ESCA	cis	rs7709377	0.723	rs7735094	ENSG00000272265.1	CTD-2287O16.4	4.3	3.49e-05	0.0446	0.51	0.36	Metabolite levels  (X-11787);	chr5:116215207	chr5:116078110~116078570:-
ESCA	cis	rs6805251	0.672	rs1719889	ENSG00000276607.2	AC092910.1	4.3	3.49e-05	0.0446	0.42	0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119859941	chr3:120084550~120084657:-
ESCA	cis	rs61041384	0.661	rs74240781	ENSG00000256092.2	RP13-942N8.1	-4.3	3.49e-05	0.0446	-0.65	-0.36	Schizophrenia;	chr12:123308154	chr12:123363868~123366113:+
ESCA	cis	rs7829975	0.501	rs4840353	ENSG00000253981.4	ALG1L13P	-4.3	3.49e-05	0.0446	-0.45	-0.36	Mood instability;	chr8:8723060	chr8:8236003~8244667:-
ESCA	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	4.3	3.5e-05	0.0447	0.47	0.36	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
ESCA	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-4.3	3.5e-05	0.0447	-0.47	-0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
ESCA	cis	rs9549260	0.577	rs6563841	ENSG00000229456.1	RLIMP1	4.3	3.5e-05	0.0447	0.34	0.36	Red blood cell count;	chr13:40665041	chr13:40618738~40621348:+
ESCA	cis	rs10894147	1	rs10750422	ENSG00000281097.1	LINC01395	4.3	3.5e-05	0.0447	0.6	0.36	Obesity-related traits;	chr11:129822685	chr11:129612116~129617269:-
ESCA	cis	rs2179367	0.959	rs585022	ENSG00000216906.2	RP11-350J20.9	4.3	3.51e-05	0.0448	0.47	0.36	Dupuytren's disease;	chr6:149432168	chr6:149904243~149906418:+
ESCA	cis	rs9549260	0.709	rs2721072	ENSG00000229456.1	RLIMP1	4.3	3.51e-05	0.0448	0.34	0.36	Red blood cell count;	chr13:40570782	chr13:40618738~40621348:+
ESCA	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-4.3	3.51e-05	0.0448	-0.44	-0.36	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
ESCA	cis	rs11169552	0.51	rs4768853	ENSG00000200428.1	Y_RNA	4.29	3.51e-05	0.0448	0.44	0.36	Colorectal cancer;	chr12:50588002	chr12:50743568~50743684:+
ESCA	cis	rs10875746	0.669	rs11168499	ENSG00000240399.1	RP1-228P16.1	-4.29	3.51e-05	0.0448	-0.43	-0.36	Longevity (90 years and older);	chr12:48268887	chr12:48054813~48055591:-
ESCA	cis	rs2108622	0.711	rs113059233	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866558	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.683	rs111388185	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866604	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.683	rs112571591	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866635	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.647	rs111427692	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15866669	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs12609468	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867004	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs12610967	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867119	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.711	rs12609820	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867247	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.668	rs62106153	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867697	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs12611242	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867754	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs12611308	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867776	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs12610189	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15867831	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.711	rs113343664	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868183	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.701	rs118144071	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15868384	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs8102532	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869250	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs62106156	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869614	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs7253873	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870090	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
ESCA	cis	rs2108622	0.727	rs55954696	ENSG00000267453.5	AC004791.2	-4.29	3.51e-05	0.0448	-0.45	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870995	chr19:15851993~15864904:-
ESCA	cis	rs6456156	0.875	rs55802221	ENSG00000265828.1	MIR3939	4.29	3.52e-05	0.0449	0.4	0.36	Primary biliary cholangitis;	chr6:167103832	chr6:166997807~166997912:-
ESCA	cis	rs4506170	0.668	rs73336742	ENSG00000253929.1	CASC21	-4.29	3.52e-05	0.0449	-0.56	-0.36	Prostate cancer;	chr8:127336158	chr8:127339274~127392631:+
ESCA	cis	rs4506170	0.668	rs16902118	ENSG00000253929.1	CASC21	-4.29	3.52e-05	0.0449	-0.56	-0.36	Prostate cancer;	chr8:127336372	chr8:127339274~127392631:+
ESCA	cis	rs7631605	1	rs6550450	ENSG00000272334.1	RP11-129K12.1	-4.29	3.53e-05	0.045	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37081608	chr3:36973117~36973672:-
ESCA	cis	rs7631605	1	rs1990492	ENSG00000272334.1	RP11-129K12.1	-4.29	3.53e-05	0.045	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37083129	chr3:36973117~36973672:-
ESCA	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	4.29	3.53e-05	0.045	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
ESCA	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	4.29	3.53e-05	0.045	0.42	0.36	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
ESCA	cis	rs1678618	1	rs1245574	ENSG00000226163.1	RP11-167P22.3	4.29	3.53e-05	0.045	0.38	0.36	Smoking behavior;	chr10:72048709	chr10:72501746~72502956:+
ESCA	cis	rs2439831	0.681	rs511673	ENSG00000249839.1	AC011330.5	-4.29	3.54e-05	0.0451	-0.52	-0.36	Lung cancer in ever smokers;	chr15:43326665	chr15:43663654~43684339:-
ESCA	cis	rs7301826	0.557	rs7953184	ENSG00000256250.1	RP11-989F5.1	4.29	3.54e-05	0.0451	0.4	0.36	Plasma plasminogen activator levels;	chr12:130800307	chr12:130810606~130812438:+
ESCA	cis	rs6479891	0.63	rs10995447	ENSG00000235816.3	PRELID1P3	4.29	3.55e-05	0.0451	0.42	0.36	Arthritis (juvenile idiopathic);	chr10:63119761	chr10:63427297~63427939:+
ESCA	cis	rs2303759	0.709	rs3760667	ENSG00000269814.1	CTC-273B12.10	-4.29	3.55e-05	0.0452	-0.48	-0.36	Multiple sclerosis;	chr19:49311575	chr19:48513207~48513660:-
ESCA	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	4.29	3.55e-05	0.0452	0.48	0.36	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
ESCA	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	4.29	3.55e-05	0.0452	0.48	0.36	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
ESCA	cis	rs7631605	0.905	rs9876116	ENSG00000272334.1	RP11-129K12.1	-4.29	3.55e-05	0.0452	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37042249	chr3:36973117~36973672:-
ESCA	cis	rs6061231	0.837	rs6121558	ENSG00000273619.1	RP5-908M14.9	-4.29	3.55e-05	0.0452	-0.48	-0.36	Colorectal cancer;	chr20:62386309	chr20:62386303~62386970:-
ESCA	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	4.29	3.56e-05	0.0452	0.39	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
ESCA	cis	rs9601248	0.841	rs9545146	ENSG00000227676.3	LINC01068	-4.29	3.56e-05	0.0452	-0.47	-0.36	Major depressive disorder;	chr13:79601471	chr13:79566727~79571436:+
ESCA	cis	rs10875746	0.669	rs2279464	ENSG00000240399.1	RP1-228P16.1	-4.29	3.56e-05	0.0452	-0.43	-0.36	Longevity (90 years and older);	chr12:48296626	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.669	rs10875792	ENSG00000240399.1	RP1-228P16.1	-4.29	3.56e-05	0.0452	-0.43	-0.36	Longevity (90 years and older);	chr12:48303640	chr12:48054813~48055591:-
ESCA	cis	rs10875746	0.623	rs10875793	ENSG00000240399.1	RP1-228P16.1	-4.29	3.56e-05	0.0452	-0.43	-0.36	Longevity (90 years and older);	chr12:48303647	chr12:48054813~48055591:-
ESCA	cis	rs300890	0.585	rs542555	ENSG00000250326.1	RP11-284M14.1	4.29	3.56e-05	0.0452	0.44	0.36	Nasopharyngeal carcinoma;	chr4:143264803	chr4:142933195~143184861:-
ESCA	cis	rs6710503	0.546	rs11680192	ENSG00000271936.1	RP11-443B20.1	4.29	3.56e-05	0.0452	0.38	0.36	Lung cancer in ever smokers;Breast cancer;	chr2:24516518	chr2:24825610~24826717:+
ESCA	cis	rs7709377	0.723	rs7707191	ENSG00000272265.1	CTD-2287O16.4	4.29	3.56e-05	0.0452	0.51	0.36	Metabolite levels  (X-11787);	chr5:116209382	chr5:116078110~116078570:-
ESCA	cis	rs7709377	0.723	rs6866773	ENSG00000272265.1	CTD-2287O16.4	4.29	3.56e-05	0.0452	0.51	0.36	Metabolite levels  (X-11787);	chr5:116209619	chr5:116078110~116078570:-
ESCA	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	4.29	3.56e-05	0.0452	0.43	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
ESCA	cis	rs9462027	0.517	rs2744973	ENSG00000186328.4	RP11-140K17.2	4.29	3.56e-05	0.0453	0.41	0.36	Systemic lupus erythematosus;	chr6:34612444	chr6:34715613~34715940:+
ESCA	cis	rs3762637	1	rs7615673	ENSG00000272758.4	RP11-299J3.8	-4.29	3.56e-05	0.0453	-0.47	-0.36	LDL cholesterol levels;	chr3:122406697	chr3:122416207~122443180:+
ESCA	cis	rs9584850	0.834	rs12463	ENSG00000231194.1	FARP1-AS1	4.29	3.57e-05	0.0453	0.45	0.36	Neuroticism;	chr13:98453048	chr13:98435405~98435840:-
ESCA	cis	rs9584850	0.834	rs8481	ENSG00000231194.1	FARP1-AS1	4.29	3.57e-05	0.0453	0.45	0.36	Neuroticism;	chr13:98453141	chr13:98435405~98435840:-
ESCA	cis	rs9584850	0.794	rs9630321	ENSG00000231194.1	FARP1-AS1	4.29	3.57e-05	0.0453	0.45	0.36	Neuroticism;	chr13:98454725	chr13:98435405~98435840:-
ESCA	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-4.29	3.57e-05	0.0453	-0.47	-0.36	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
ESCA	cis	rs1387259	0.759	rs7960122	ENSG00000258273.1	RP11-370I10.4	4.29	3.57e-05	0.0453	0.51	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48383217	chr12:48333755~48333901:-
ESCA	cis	rs6452524	0.534	rs9293328	ENSG00000243385.2	CTD-2110K23.1	4.29	3.57e-05	0.0453	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83201229~83202141:+
ESCA	cis	rs6452524	0.534	rs11746747	ENSG00000243385.2	CTD-2110K23.1	4.29	3.57e-05	0.0453	0.42	0.36	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83201229~83202141:+
ESCA	cis	rs7951870	0.504	rs7484125	ENSG00000271350.1	CTD-2384B9.1	4.29	3.57e-05	0.0453	0.4	0.36	Schizophrenia;	chr11:46566717	chr11:47041027~47041945:-
ESCA	cis	rs11038871	0.815	rs6485686	ENSG00000271350.1	CTD-2384B9.1	4.29	3.57e-05	0.0453	0.4	0.36	Immunoglobulin A;	chr11:46635880	chr11:47041027~47041945:-
ESCA	cis	rs858239	0.863	rs466225	ENSG00000230042.1	AK3P3	-4.29	3.57e-05	0.0453	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23129178~23129841:+
ESCA	cis	rs2439831	1	rs2584726	ENSG00000249839.1	AC011330.5	-4.29	3.57e-05	0.0453	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43423184	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs565007	ENSG00000249839.1	AC011330.5	-4.29	3.57e-05	0.0453	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43424443	chr15:43663654~43684339:-
ESCA	cis	rs2439831	1	rs550239	ENSG00000249839.1	AC011330.5	-4.29	3.57e-05	0.0453	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43427999	chr15:43663654~43684339:-
ESCA	cis	rs2439831	0.85	rs558656	ENSG00000249839.1	AC011330.5	-4.29	3.57e-05	0.0453	-0.55	-0.36	Lung cancer in ever smokers;	chr15:43431316	chr15:43663654~43684339:-
ESCA	cis	rs7412746	0.658	rs4970987	ENSG00000206931.1	RNU6-1042P	4.29	3.57e-05	0.0453	0.45	0.36	Melanoma;	chr1:150977206	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.634	rs12562939	ENSG00000206931.1	RNU6-1042P	4.29	3.57e-05	0.0453	0.45	0.36	Melanoma;	chr1:150978976	chr1:150701866~150701972:+
ESCA	cis	rs7412746	0.658	rs12067685	ENSG00000206931.1	RNU6-1042P	4.29	3.57e-05	0.0453	0.45	0.36	Melanoma;	chr1:150980441	chr1:150701866~150701972:+
ESCA	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.29	3.58e-05	0.0454	0.48	0.36	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
ESCA	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	4.29	3.58e-05	0.0454	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	4.29	3.58e-05	0.0454	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	4.29	3.58e-05	0.0454	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	4.29	3.58e-05	0.0454	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	4.29	3.58e-05	0.0454	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
ESCA	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	4.29	3.58e-05	0.0454	0.49	0.36	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
ESCA	cis	rs453301	0.606	rs7462373	ENSG00000253981.4	ALG1L13P	-4.29	3.58e-05	0.0454	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9041808	chr8:8236003~8244667:-
ESCA	cis	rs636159	0.702	rs607616	ENSG00000213287.3	RP11-680L20.1	-4.29	3.59e-05	0.0455	-0.44	-0.36	Bone ultrasound measurement (velocity of sound);	chr11:87149505	chr11:87258851~87259259:-
ESCA	cis	rs636159	0.702	rs476832	ENSG00000213287.3	RP11-680L20.1	-4.29	3.59e-05	0.0455	-0.44	-0.36	Bone ultrasound measurement (velocity of sound);	chr11:87149621	chr11:87258851~87259259:-
ESCA	cis	rs10229583	0.527	rs10249616	ENSG00000279078.1	SND1-IT1	4.29	3.59e-05	0.0455	0.4	0.36	Type 2 diabetes;	chr7:127759446	chr7:127997597~128000077:+
ESCA	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	4.29	3.59e-05	0.0455	0.53	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
ESCA	cis	rs9309711	0.544	rs9309712	ENSG00000225234.1	TRAPPC12-AS1	-4.29	3.59e-05	0.0455	-0.4	-0.36	Neurofibrillary tangles;	chr2:3487556	chr2:3481242~3482409:-
ESCA	cis	rs36093844	0.626	rs11234492	ENSG00000271318.1	AP000654.5	-4.29	3.59e-05	0.0455	-0.74	-0.36	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);	chr11:85953768	chr11:86821143~86821728:-
ESCA	cis	rs7017914	0.628	rs2279128	ENSG00000253173.3	RP11-152C15.1	-4.29	3.59e-05	0.0455	-0.43	-0.36	Bone mineral density;	chr8:70669324	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.583	rs1477943	ENSG00000253173.3	RP11-152C15.1	-4.29	3.59e-05	0.0455	-0.43	-0.36	Bone mineral density;	chr8:70670528	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs62533063	ENSG00000253173.3	RP11-152C15.1	-4.29	3.59e-05	0.0455	-0.43	-0.36	Bone mineral density;	chr8:70673824	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs12681420	ENSG00000253173.3	RP11-152C15.1	-4.29	3.59e-05	0.0455	-0.43	-0.36	Bone mineral density;	chr8:70680963	chr8:70103798~70104179:-
ESCA	cis	rs8059260	0.604	rs34573672	ENSG00000274038.1	RP11-66H6.4	-4.29	3.59e-05	0.0455	-0.64	-0.36	Alcohol consumption over the past year;	chr16:11111882	chr16:11056556~11057034:+
ESCA	cis	rs7283707	0.581	rs412155	ENSG00000269950.1	AP000962.2	4.29	3.59e-05	0.0455	0.52	0.36	QRS complex (12-leadsum);	chr21:15927450	chr21:16574718~16582637:-
ESCA	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	4.29	3.6e-05	0.0455	0.43	0.36	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
ESCA	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	4.29	3.6e-05	0.0455	0.43	0.36	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
ESCA	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	4.29	3.6e-05	0.0455	0.43	0.36	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
ESCA	cis	rs5758659	0.967	rs5758670	ENSG00000182057.4	OGFRP1	4.29	3.61e-05	0.0457	0.42	0.36	Cognitive function;	chr22:42240681	chr22:42269753~42275196:+
ESCA	cis	rs7712401	0.623	rs7723798	ENSG00000263432.2	RN7SL689P	4.29	3.61e-05	0.0457	0.5	0.36	Mean platelet volume;	chr5:123034022	chr5:123022487~123022783:-
ESCA	cis	rs2019137	0.901	rs4849176	ENSG00000189223.12	PAX8-AS1	4.29	3.61e-05	0.0457	0.47	0.36	Lymphocyte counts;	chr2:113220359	chr2:113211522~113276581:+
ESCA	cis	rs12022452	1	rs3738471	ENSG00000229901.1	RP11-399E6.4	4.29	3.61e-05	0.0457	0.45	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40540873	chr1:41375004~41375669:-
ESCA	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.29	3.62e-05	0.0457	0.34	0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
ESCA	cis	rs6805251	0.594	rs334559	ENSG00000276607.2	AC092910.1	-4.29	3.62e-05	0.0458	-0.46	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:120090758	chr3:120084550~120084657:-
ESCA	cis	rs7618915	0.57	rs11714088	ENSG00000242797.3	GLYCTK-AS1	-4.29	3.62e-05	0.0458	-0.32	-0.36	Bipolar disorder;	chr3:52724926	chr3:52288580~52299067:-
ESCA	cis	rs7618915	0.547	rs34610878	ENSG00000242797.3	GLYCTK-AS1	-4.29	3.62e-05	0.0458	-0.32	-0.36	Bipolar disorder;	chr3:52725153	chr3:52288580~52299067:-
ESCA	cis	rs7618915	0.547	rs11130323	ENSG00000242797.3	GLYCTK-AS1	-4.29	3.62e-05	0.0458	-0.32	-0.36	Bipolar disorder;	chr3:52736261	chr3:52288580~52299067:-
ESCA	cis	rs7618915	0.547	rs2268026	ENSG00000242797.3	GLYCTK-AS1	-4.29	3.62e-05	0.0458	-0.32	-0.36	Bipolar disorder;	chr3:52744331	chr3:52288580~52299067:-
ESCA	cis	rs765787	0.53	rs12440321	ENSG00000259520.4	CTD-2651B20.3	-4.29	3.62e-05	0.0458	-0.42	-0.36	Uric acid levels;	chr15:45237187	chr15:45251580~45279251:-
ESCA	cis	rs7283707	0.681	rs28627435	ENSG00000269950.1	AP000962.2	4.29	3.62e-05	0.0458	0.63	0.36	QRS complex (12-leadsum);	chr21:15736906	chr21:16574718~16582637:-
ESCA	cis	rs8040855	0.965	rs4843027	ENSG00000259295.5	CSPG4P12	-4.29	3.63e-05	0.0458	-0.56	-0.36	Bulimia nervosa;	chr15:85171892	chr15:85191438~85213905:+
ESCA	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	4.29	3.63e-05	0.0459	0.47	0.36	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
ESCA	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	4.29	3.63e-05	0.0459	0.44	0.36	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
ESCA	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-4.29	3.63e-05	0.0459	-0.43	-0.36	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
ESCA	cis	rs150992	0.512	rs161954	ENSG00000248489.1	CTD-2007H13.3	4.29	3.63e-05	0.0459	0.51	0.36	Body mass index;	chr5:98920833	chr5:98929171~98995013:+
ESCA	cis	rs9926664	0.584	rs8046526	ENSG00000274134.1	MIR6774	4.29	3.63e-05	0.0459	0.48	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr16:85918029	chr16:85918347~85918416:+
ESCA	cis	rs9926664	0.584	rs8058904	ENSG00000274134.1	MIR6774	4.29	3.63e-05	0.0459	0.48	0.36	Neutrophil count;Sum basophil neutrophil counts;	chr16:85918076	chr16:85918347~85918416:+
ESCA	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	4.29	3.63e-05	0.0459	0.43	0.36	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
ESCA	cis	rs7582403	0.844	rs1375859	ENSG00000223911.1	AC009480.3	-4.29	3.63e-05	0.0459	-0.39	-0.36	Neuroticism;	chr2:148134786	chr2:147899401~147902956:-
ESCA	cis	rs9549260	0.755	rs9566553	ENSG00000229456.1	RLIMP1	4.29	3.63e-05	0.0459	0.34	0.36	Red blood cell count;	chr13:40600094	chr13:40618738~40621348:+
ESCA	cis	rs7631605	0.816	rs1500794	ENSG00000272334.1	RP11-129K12.1	-4.29	3.64e-05	0.0459	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37124051	chr3:36973117~36973672:-
ESCA	cis	rs7829975	0.658	rs907181	ENSG00000253981.4	ALG1L13P	4.29	3.64e-05	0.046	0.38	0.36	Mood instability;	chr8:8845365	chr8:8236003~8244667:-
ESCA	cis	rs11038871	1	rs3802890	ENSG00000271350.1	CTD-2384B9.1	4.29	3.64e-05	0.046	0.39	0.36	Immunoglobulin A;	chr11:46512996	chr11:47041027~47041945:-
ESCA	cis	rs2980439	0.517	rs712253	ENSG00000253981.4	ALG1L13P	-4.29	3.64e-05	0.046	-0.5	-0.36	Neuroticism;	chr8:8246260	chr8:8236003~8244667:-
ESCA	cis	rs1723838	0.536	rs4944858	ENSG00000255928.1	RP11-456I15.2	-4.29	3.64e-05	0.046	-0.81	-0.36	Obesity-related traits;	chr11:73708012	chr11:73722349~73722694:+
ESCA	cis	rs2439831	0.85	rs28509275	ENSG00000275601.1	AC011330.13	-4.29	3.64e-05	0.046	-0.69	-0.36	Lung cancer in ever smokers;	chr15:43805907	chr15:43642389~43643023:-
ESCA	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-4.29	3.64e-05	0.046	-0.39	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
ESCA	cis	rs7932354	0.528	rs4752952	ENSG00000271350.1	CTD-2384B9.1	-4.29	3.65e-05	0.0461	-0.43	-0.36	Bone mineral density (hip);Bone mineral density;	chr11:47061307	chr11:47041027~47041945:-
ESCA	cis	rs7932354	0.528	rs7946709	ENSG00000271350.1	CTD-2384B9.1	-4.29	3.65e-05	0.0461	-0.43	-0.36	Bone mineral density (hip);Bone mineral density;	chr11:47079245	chr11:47041027~47041945:-
ESCA	cis	rs11169552	0.51	rs4768893	ENSG00000200428.1	Y_RNA	4.29	3.65e-05	0.0461	0.44	0.36	Colorectal cancer;	chr12:50566697	chr12:50743568~50743684:+
ESCA	cis	rs5760092	0.572	rs738806	ENSG00000228039.3	KB-1125A3.10	4.28	3.65e-05	0.0461	0.46	0.36	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23963780~23964374:+
ESCA	cis	rs1005277	0.579	rs1985707	ENSG00000263064.2	RP11-291L22.7	4.28	3.65e-05	0.0462	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38145170	chr10:38448689~38448949:+
ESCA	cis	rs7709377	0.723	rs7730943	ENSG00000272265.1	CTD-2287O16.4	4.28	3.66e-05	0.0462	0.5	0.36	Metabolite levels  (X-11787);	chr5:116208934	chr5:116078110~116078570:-
ESCA	cis	rs535066	0.56	rs17597014	ENSG00000260878.1	RP11-320H14.1	-4.28	3.66e-05	0.0462	-0.4	-0.36	Epilepsy;	chr4:46130958	chr4:46243548~46244215:-
ESCA	cis	rs535066	0.504	rs6827659	ENSG00000260878.1	RP11-320H14.1	-4.28	3.66e-05	0.0462	-0.4	-0.36	Epilepsy;	chr4:46146219	chr4:46243548~46244215:-
ESCA	cis	rs801193	0.66	rs2659897	ENSG00000251451.1	GS1-124K5.6	4.28	3.66e-05	0.0462	0.31	0.36	Aortic root size;	chr7:66722728	chr7:66407288~66409239:-
ESCA	cis	rs6805251	0.672	rs7617372	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119900483	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.672	rs28516957	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119901906	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.672	rs1579031	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119911074	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.672	rs13314595	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119912251	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.672	rs4072520	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119916546	chr3:120084550~120084657:-
ESCA	cis	rs6805251	0.672	rs7620750	ENSG00000276607.2	AC092910.1	-4.28	3.66e-05	0.0462	-0.42	-0.36	HDL cholesterol levels;HDL cholesterol;	chr3:119924334	chr3:120084550~120084657:-
ESCA	cis	rs2412488	1	rs2090117	ENSG00000250930.4	LNX1-AS1	4.28	3.66e-05	0.0462	0.41	0.36	DNA methylation (variation);	chr4:53434424	chr4:53496400~53549578:+
ESCA	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	4.28	3.66e-05	0.0462	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
ESCA	cis	rs2412819	0.571	rs514255	ENSG00000249839.1	AC011330.5	-4.28	3.67e-05	0.0463	-0.62	-0.36	Lung cancer;	chr15:43893134	chr15:43663654~43684339:-
ESCA	cis	rs7283707	0.581	rs57737796	ENSG00000269950.1	AP000962.2	4.28	3.67e-05	0.0463	0.77	0.36	QRS complex (12-leadsum);	chr21:15705163	chr21:16574718~16582637:-
ESCA	cis	rs287982	1	rs287975	ENSG00000269973.1	RP11-95D17.1	-4.28	3.67e-05	0.0463	-0.46	-0.36	Nonsyndromic cleft lip with cleft palate;	chr2:9829346	chr2:9936360~9939590:+
ESCA	cis	rs1005277	0.557	rs1854563	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38146033	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2505237	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38149970	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474599	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38150011	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2505240	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38153491	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.54	rs2224248	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38162958	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474608	ENSG00000263064.2	RP11-291L22.7	4.28	3.67e-05	0.0463	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38168181	chr10:38448689~38448949:+
ESCA	cis	rs2455799	0.545	rs7647752	ENSG00000227578.1	RPS3AP53	4.28	3.67e-05	0.0463	0.53	0.36	Mean platelet volume;	chr3:15750967	chr3:15141380~15142157:+
ESCA	cis	rs2455799	0.586	rs4684260	ENSG00000227578.1	RPS3AP53	4.28	3.67e-05	0.0463	0.53	0.36	Mean platelet volume;	chr3:15754892	chr3:15141380~15142157:+
ESCA	cis	rs1426063	0.748	rs7654088	ENSG00000248165.1	RP11-44F21.2	-4.28	3.67e-05	0.0463	-0.45	-0.36	QT interval;	chr4:75107103	chr4:74993877~75034824:-
ESCA	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	4.28	3.67e-05	0.0463	0.38	0.36	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
ESCA	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-4.28	3.67e-05	0.0463	-0.38	-0.36	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
ESCA	cis	rs9487094	0.666	rs1074765	ENSG00000260273.1	RP11-425D10.10	-4.28	3.67e-05	0.0463	-0.45	-0.36	Height;	chr6:109360458	chr6:109382795~109383666:+
ESCA	cis	rs1062177	1	rs973529	ENSG00000253921.1	CTB-113P19.3	-4.28	3.67e-05	0.0463	-0.48	-0.36	Preschool internalizing problems;	chr5:151808597	chr5:151753992~151767247:+
ESCA	cis	rs17691453	0.686	rs1530219	ENSG00000175746.6	C15orf54	4.28	3.67e-05	0.0463	0.45	0.36	Metabolite levels (Dihydroxy docosatrienoic acid);	chr15:39310179	chr15:39250684~39254845:+
ESCA	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	4.28	3.67e-05	0.0463	0.46	0.36	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
ESCA	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	4.28	3.67e-05	0.0463	0.46	0.36	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
ESCA	cis	rs10954779	0.728	rs2725359	ENSG00000253579.1	SUMO2P16	-4.28	3.69e-05	0.0465	-0.4	-0.36	Intelligence (multi-trait analysis);	chr8:31134232	chr8:31131539~31131802:-
ESCA	cis	rs2455799	0.559	rs2654653	ENSG00000227578.1	RPS3AP53	4.28	3.69e-05	0.0465	0.53	0.36	Mean platelet volume;	chr3:15746333	chr3:15141380~15142157:+
ESCA	cis	rs7283707	0.681	rs74774121	ENSG00000269950.1	AP000962.2	4.28	3.7e-05	0.0465	0.71	0.36	QRS complex (12-leadsum);	chr21:15802579	chr21:16574718~16582637:-
ESCA	cis	rs9608946	0.956	rs35841307	ENSG00000268812.3	RP1-102K2.8	4.28	3.7e-05	0.0466	0.49	0.36	Red cell distribution width;	chr22:30519771	chr22:30246205~30246998:+
ESCA	cis	rs441810	1	rs449043	ENSG00000275439.1	AP001619.1	4.28	3.7e-05	0.0466	0.47	0.36	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers;	chr21:41328483	chr21:41922177~41922274:-
ESCA	cis	rs560713	0.887	rs509342	ENSG00000272189.1	RP3-325F22.5	4.28	3.7e-05	0.0466	0.32	0.36	Intraocular pressure;	chr6:136160253	chr6:136550661~136552554:+
ESCA	cis	rs4881147	0.962	rs9787505	ENSG00000278419.1	RP11-298E9.7	-4.28	3.7e-05	0.0466	-0.47	-0.36	Scalp hair shape;	chr10:3298620	chr10:3134566~3145166:+
ESCA	cis	rs17711722	0.503	rs453835	ENSG00000164669.11	INTS4P1	4.28	3.71e-05	0.0466	0.41	0.36	Calcium levels;	chr7:66046172	chr7:65141225~65234216:+
ESCA	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-4.28	3.71e-05	0.0466	-0.43	-0.36	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
ESCA	cis	rs7829975	0.564	rs2921057	ENSG00000173295.6	FAM86B3P	4.28	3.71e-05	0.0467	0.45	0.36	Mood instability;	chr8:8461157	chr8:8228595~8244865:+
ESCA	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	4.28	3.71e-05	0.0467	0.5	0.36	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
ESCA	cis	rs7932354	0.655	rs6485690	ENSG00000271350.1	CTD-2384B9.1	-4.28	3.72e-05	0.0467	-0.42	-0.36	Bone mineral density (hip);Bone mineral density;	chr11:46777081	chr11:47041027~47041945:-
ESCA	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	4.28	3.72e-05	0.0467	0.48	0.36	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
ESCA	cis	rs7618915	0.547	rs1561337	ENSG00000242797.3	GLYCTK-AS1	-4.28	3.72e-05	0.0468	-0.32	-0.36	Bipolar disorder;	chr3:52625947	chr3:52288580~52299067:-
ESCA	cis	rs11235843	0.706	rs10898949	ENSG00000255928.1	RP11-456I15.2	-4.28	3.72e-05	0.0468	-0.59	-0.36	Hand grip strength;	chr11:73870627	chr11:73722349~73722694:+
ESCA	cis	rs5758659	0.967	rs5751250	ENSG00000182057.4	OGFRP1	4.28	3.72e-05	0.0468	0.42	0.36	Cognitive function;	chr22:42243639	chr22:42269753~42275196:+
ESCA	cis	rs5758659	1	rs5758677	ENSG00000182057.4	OGFRP1	4.28	3.72e-05	0.0468	0.42	0.36	Cognitive function;	chr22:42247033	chr22:42269753~42275196:+
ESCA	cis	rs11867129	1	rs11859337	ENSG00000279901.1	CTD-2270P14.2	-4.28	3.72e-05	0.0468	-0.49	-0.36	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr16:2315703	chr16:2683106~2684764:+
ESCA	cis	rs1005277	0.579	rs176886	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38115046	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.557	rs176887	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38117166	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474584	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38127461	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs1548255	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38128265	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474586	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38129954	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs2474594	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38137733	chr10:38448689~38448949:+
ESCA	cis	rs1005277	0.579	rs11011461	ENSG00000263064.2	RP11-291L22.7	4.28	3.72e-05	0.0468	0.48	0.36	Extrinsic epigenetic age acceleration;	chr10:38142499	chr10:38448689~38448949:+
ESCA	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	4.28	3.72e-05	0.0468	0.56	0.36	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
ESCA	cis	rs10875746	0.669	rs11168508	ENSG00000240399.1	RP1-228P16.1	-4.28	3.72e-05	0.0468	-0.43	-0.36	Longevity (90 years and older);	chr12:48289728	chr12:48054813~48055591:-
ESCA	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	4.28	3.73e-05	0.0468	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
ESCA	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	4.28	3.73e-05	0.0468	0.4	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
ESCA	cis	rs8072100	0.807	rs4561509	ENSG00000228782.6	CTD-2026D20.3	4.28	3.73e-05	0.0468	0.41	0.36	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr17:47704433	chr17:47450568~47492492:-
ESCA	cis	rs7829975	0.5	rs7841082	ENSG00000173295.6	FAM86B3P	-4.28	3.73e-05	0.0468	-0.48	-0.36	Mood instability;	chr8:8311465	chr8:8228595~8244865:+
ESCA	cis	rs4407350	0.756	rs131154	ENSG00000228807.1	MRPS18CP6	-4.28	3.73e-05	0.0469	-0.39	-0.36	Intelligence (multi-trait analysis);	chr22:44494965	chr22:44483495~44483717:-
ESCA	cis	rs7829975	0.577	rs17684466	ENSG00000253981.4	ALG1L13P	-4.28	3.73e-05	0.0469	-0.45	-0.36	Mood instability;	chr8:8687723	chr8:8236003~8244667:-
ESCA	cis	rs2179367	0.959	rs9285519	ENSG00000231760.4	RP11-350J20.5	4.28	3.73e-05	0.0469	0.42	0.36	Dupuytren's disease;	chr6:149371799	chr6:149796151~149826294:-
ESCA	cis	rs2470578	0.792	rs1449885	ENSG00000233133.1	AC104451.2	4.28	3.73e-05	0.0469	0.4	0.36	Schizophrenia;	chr3:17220264	chr3:17706058~17706233:-
ESCA	cis	rs4345206	0.677	rs13124853	ENSG00000250673.1	RP11-6L6.2	-4.28	3.74e-05	0.0469	-0.36	-0.36	Coronary artery disease;	chr4:145863622	chr4:146224557~146229056:+
ESCA	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	4.28	3.74e-05	0.047	0.46	0.36	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
ESCA	cis	rs9545047	0.584	rs12871015	ENSG00000227676.3	LINC01068	-4.28	3.75e-05	0.047	-0.47	-0.36	Schizophrenia;	chr13:79333564	chr13:79566727~79571436:+
ESCA	cis	rs8062405	0.755	rs17640009	ENSG00000278665.1	RP11-666O2.4	4.28	3.75e-05	0.047	0.52	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28599241~28601881:-
ESCA	cis	rs7829975	0.577	rs7816329	ENSG00000253981.4	ALG1L13P	-4.28	3.75e-05	0.047	-0.44	-0.36	Mood instability;	chr8:8686333	chr8:8236003~8244667:-
ESCA	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
ESCA	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
ESCA	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-4.28	3.76e-05	0.0471	-0.37	-0.36	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
ESCA	cis	rs4407350	0.715	rs3827400	ENSG00000228807.1	MRPS18CP6	-4.28	3.76e-05	0.0472	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44494724	chr22:44483495~44483717:-
ESCA	cis	rs4407350	0.655	rs135623	ENSG00000228807.1	MRPS18CP6	-4.28	3.76e-05	0.0472	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44494792	chr22:44483495~44483717:-
ESCA	cis	rs7310309	0.943	rs7297808	ENSG00000257564.1	RP11-123M21.2	4.28	3.76e-05	0.0472	0.6	0.36	Classic bladder exstrophy;	chr12:79559977	chr12:78793526~78794114:-
ESCA	cis	rs28541881	0.536	rs7255455	ENSG00000269553.1	U62631.5	4.28	3.77e-05	0.0472	0.71	0.36	Colorectal cancer;	chr19:34339584	chr19:35330843~35331920:+
ESCA	cis	rs9987353	0.544	rs2929469	ENSG00000173295.6	FAM86B3P	4.28	3.77e-05	0.0472	0.46	0.36	Recombination measurement;	chr8:9205146	chr8:8228595~8244865:+
ESCA	cis	rs1681630	0.848	rs1631174	ENSG00000280615.1	Y_RNA	-4.28	3.78e-05	0.0473	-0.44	-0.36	Height;	chr11:47952821	chr11:47614898~47614994:-
ESCA	cis	rs1723838	0.702	rs4944859	ENSG00000255928.1	RP11-456I15.2	-4.28	3.79e-05	0.0475	-0.81	-0.36	Obesity-related traits;	chr11:73713090	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs4944860	ENSG00000255928.1	RP11-456I15.2	-4.28	3.79e-05	0.0475	-0.81	-0.36	Obesity-related traits;	chr11:73716081	chr11:73722349~73722694:+
ESCA	cis	rs1723838	0.826	rs1404975	ENSG00000255928.1	RP11-456I15.2	-4.28	3.79e-05	0.0475	-0.81	-0.36	Obesity-related traits;	chr11:73722089	chr11:73722349~73722694:+
ESCA	cis	rs1062177	1	rs2347596	ENSG00000253921.1	CTB-113P19.3	-4.27	3.8e-05	0.0475	-0.46	-0.36	Preschool internalizing problems;	chr5:151799638	chr5:151753992~151767247:+
ESCA	cis	rs1062177	0.95	rs892005	ENSG00000253921.1	CTB-113P19.3	-4.27	3.8e-05	0.0475	-0.46	-0.36	Preschool internalizing problems;	chr5:151801060	chr5:151753992~151767247:+
ESCA	cis	rs7179228	1	rs4777037	ENSG00000260657.2	RP11-315D16.4	-4.27	3.8e-05	0.0475	-0.56	-0.36	Systolic blood pressure;	chr15:68327798	chr15:68267792~68277994:-
ESCA	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	4.27	3.8e-05	0.0476	0.52	0.36	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
ESCA	cis	rs17155006	0.676	rs4730287	ENSG00000273055.1	CTB-13F3.1	-4.27	3.8e-05	0.0476	-0.35	-0.36	Pneumococcal bacteremia;	chr7:108130179	chr7:107942116~107942740:+
ESCA	cis	rs3820068	0.581	rs68052904	ENSG00000237301.1	RP4-680D5.2	4.27	3.8e-05	0.0476	0.4	0.36	Systolic blood pressure;	chr1:15590219	chr1:15586136~15603626:-
ESCA	cis	rs7631605	0.905	rs6550445	ENSG00000272334.1	RP11-129K12.1	-4.27	3.81e-05	0.0476	-0.39	-0.36	Cerebrospinal P-tau181p levels;	chr3:37024878	chr3:36973117~36973672:-
ESCA	cis	rs6604026	0.74	rs10782945	ENSG00000229052.2	RP11-386I23.1	-4.27	3.81e-05	0.0476	-0.34	-0.36	Multiple sclerosis;	chr1:92838715	chr1:92930696~92934098:+
ESCA	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-4.27	3.81e-05	0.0477	-0.37	-0.36	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-4.27	3.81e-05	0.0477	-0.37	-0.36	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-4.27	3.81e-05	0.0477	-0.37	-0.36	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
ESCA	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-4.27	3.81e-05	0.0477	-0.37	-0.36	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
ESCA	cis	rs10759883	0.627	rs816684	ENSG00000175611.10	LINC00476	-4.27	3.81e-05	0.0477	-0.4	-0.36	Nicotine dependence;	chr9:95822707	chr9:95759231~95875977:-
ESCA	cis	rs10759883	0.627	rs816683	ENSG00000175611.10	LINC00476	-4.27	3.81e-05	0.0477	-0.4	-0.36	Nicotine dependence;	chr9:95822819	chr9:95759231~95875977:-
ESCA	cis	rs9311474	0.508	rs2878628	ENSG00000242797.3	GLYCTK-AS1	4.27	3.81e-05	0.0477	0.32	0.36	Electroencephalogram traits;	chr3:52550699	chr3:52288580~52299067:-
ESCA	cis	rs4664293	0.769	rs10171236	ENSG00000226266.5	AC009961.3	-4.27	3.81e-05	0.0477	-0.45	-0.36	Monocyte percentage of white cells;	chr2:159729752	chr2:159670708~159712435:-
ESCA	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-4.27	3.82e-05	0.0477	-0.45	-0.36	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
ESCA	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	4.27	3.82e-05	0.0477	0.46	0.36	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
ESCA	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	4.27	3.82e-05	0.0477	0.46	0.36	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
ESCA	cis	rs7981781	1	rs35369009	ENSG00000232587.1	EEF1A1P3	-4.27	3.82e-05	0.0477	-0.3	-0.36	Fasting plasma glucose;	chr13:27916373	chr13:28214513~28215897:+
ESCA	cis	rs10954779	0.764	rs16877794	ENSG00000253579.1	SUMO2P16	4.27	3.82e-05	0.0477	0.4	0.36	Intelligence (multi-trait analysis);	chr8:31158766	chr8:31131539~31131802:-
ESCA	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	4.27	3.82e-05	0.0478	0.49	0.36	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
ESCA	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	4.27	3.82e-05	0.0478	0.42	0.36	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
ESCA	cis	rs7631605	1	rs4647277	ENSG00000272334.1	RP11-129K12.1	-4.27	3.82e-05	0.0478	-0.4	-0.36	Cerebrospinal P-tau181p levels;	chr3:37017018	chr3:36973117~36973672:-
ESCA	cis	rs2108622	0.628	rs11086005	ENSG00000267453.5	AC004791.2	-4.27	3.83e-05	0.0478	-0.47	-0.36	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15864286	chr19:15851993~15864904:-
ESCA	cis	rs6921919	0.638	rs7772827	ENSG00000204709.4	LINC01556	4.27	3.84e-05	0.0479	0.47	0.36	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28943877~28944537:+
ESCA	cis	rs7618915	0.547	rs6976	ENSG00000242797.3	GLYCTK-AS1	-4.27	3.84e-05	0.048	-0.33	-0.36	Bipolar disorder;	chr3:52694788	chr3:52288580~52299067:-
ESCA	cis	rs9608946	1	rs7289828	ENSG00000268812.3	RP1-102K2.8	4.27	3.84e-05	0.048	0.5	0.36	Red cell distribution width;	chr22:30525262	chr22:30246205~30246998:+
ESCA	cis	rs11675119	0.501	rs12994811	ENSG00000225234.1	TRAPPC12-AS1	-4.27	3.85e-05	0.048	-0.45	-0.36	Neurofibrillary tangles;	chr2:3490530	chr2:3481242~3482409:-
ESCA	cis	rs9309711	0.518	rs9752314	ENSG00000225234.1	TRAPPC12-AS1	-4.27	3.85e-05	0.048	-0.45	-0.36	Neurofibrillary tangles;	chr2:3490551	chr2:3481242~3482409:-
ESCA	cis	rs71327718	1	rs71327718	ENSG00000272840.1	RP11-379B18.6	4.27	3.85e-05	0.048	0.57	0.36	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125774714~125797953:+
ESCA	cis	rs2439831	0.867	rs3809481	ENSG00000275601.1	AC011330.13	-4.27	3.85e-05	0.048	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43370631	chr15:43642389~43643023:-
ESCA	cis	rs2041895	0.527	rs10861681	ENSG00000260329.1	RP11-412D9.4	-4.27	3.85e-05	0.048	-0.39	-0.36	Glaucoma (low intraocular pressure);	chr12:106940484	chr12:106954029~106955497:-
ESCA	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-4.27	3.86e-05	0.0481	-0.69	-0.36	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
ESCA	cis	rs2430307	0.556	rs3930019	ENSG00000186645.7	AC114737.6	-4.27	3.86e-05	0.0481	-0.45	-0.36	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index;	chr7:76912293	chr7:77024691~77030572:-
ESCA	cis	rs4511180	0.932	rs7525555	ENSG00000249007.1	RP11-510N19.5	4.27	3.86e-05	0.0482	0.31	0.36	Post-traumatic stress disorder;	chr1:202170575	chr1:202011370~202015657:+
ESCA	cis	rs12517906	1	rs12514728	ENSG00000280161.1	CTC-205M6.1	-4.27	3.86e-05	0.0482	-0.5	-0.36	Weight;Body mass index;	chr5:180750377	chr5:180810401~180811384:+
ESCA	cis	rs12517906	1	rs61608105	ENSG00000280161.1	CTC-205M6.1	-4.27	3.86e-05	0.0482	-0.5	-0.36	Weight;Body mass index;	chr5:180752380	chr5:180810401~180811384:+
ESCA	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	4.27	3.86e-05	0.0482	0.43	0.36	Breast size;	chr12:9228263	chr12:9277235~9313241:+
ESCA	cis	rs7208859	0.673	rs216424	ENSG00000263531.1	RP13-753N3.1	4.27	3.86e-05	0.0482	0.56	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30616046	chr17:30863921~30864940:-
ESCA	cis	rs7829975	0.564	rs2921060	ENSG00000173295.6	FAM86B3P	-4.27	3.87e-05	0.0482	-0.45	-0.36	Mood instability;	chr8:8460307	chr8:8228595~8244865:+
ESCA	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	4.27	3.87e-05	0.0482	0.47	0.36	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
ESCA	cis	rs74435620	0.759	rs17618877	ENSG00000240698.1	RPS2P39	-4.27	3.88e-05	0.0483	-0.58	-0.36	Interleukin-1-receptor antagonist levels;	chr11:108509147	chr11:108690289~108690956:-
ESCA	cis	rs42490	1	rs218929	ENSG00000251136.7	RP11-37B2.1	-4.27	3.88e-05	0.0483	-0.36	-0.36	Leprosy;	chr8:89739091	chr8:89609409~89757727:-
ESCA	cis	rs7618915	0.508	rs13065851	ENSG00000242797.3	GLYCTK-AS1	-4.27	3.89e-05	0.0484	-0.33	-0.36	Bipolar disorder;	chr3:52610820	chr3:52288580~52299067:-
ESCA	cis	rs7618915	0.547	rs11709448	ENSG00000242797.3	GLYCTK-AS1	-4.27	3.89e-05	0.0484	-0.33	-0.36	Bipolar disorder;	chr3:52613433	chr3:52288580~52299067:-
ESCA	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	4.27	3.9e-05	0.0485	0.56	0.36	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
ESCA	cis	rs61990749	0.597	rs12896026	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77778093	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs12435761	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77779734	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs2112136	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77782609	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs759808	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77784502	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs4903643	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77788448	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs717683	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77789110	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs1477259	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77789795	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs1477260	ENSG00000239272.1	RPL21P10	4.27	3.9e-05	0.0485	0.43	0.36	Fibroblast growth factor basic levels;	chr14:77790475	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.544	rs7151211	ENSG00000239272.1	RPL21P10	-4.27	3.9e-05	0.0485	-0.43	-0.36	Fibroblast growth factor basic levels;	chr14:77685558	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs2364584	ENSG00000239272.1	RPL21P10	-4.27	3.9e-05	0.0485	-0.43	-0.36	Fibroblast growth factor basic levels;	chr14:77685943	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs72685264	ENSG00000239272.1	RPL21P10	-4.27	3.9e-05	0.0485	-0.43	-0.36	Fibroblast growth factor basic levels;	chr14:77686655	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs7147516	ENSG00000239272.1	RPL21P10	-4.27	3.9e-05	0.0485	-0.43	-0.36	Fibroblast growth factor basic levels;	chr14:77687637	chr14:77683202~77683989:-
ESCA	cis	rs61990749	0.597	rs10136053	ENSG00000239272.1	RPL21P10	-4.27	3.9e-05	0.0485	-0.43	-0.36	Fibroblast growth factor basic levels;	chr14:77688862	chr14:77683202~77683989:-
ESCA	cis	rs2273156	0.517	rs7159324	ENSG00000241052.1	RP11-173D9.1	4.27	3.9e-05	0.0486	0.48	0.36	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:35144021~35144480:-
ESCA	cis	rs1075265	0.722	rs13414216	ENSG00000235937.1	AC008280.1	4.27	3.9e-05	0.0486	0.4	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53699166	chr2:54029552~54030682:-
ESCA	cis	rs67981189	0.501	rs3829954	ENSG00000269945.1	RP6-91H8.5	-4.27	3.91e-05	0.0486	-0.43	-0.36	Schizophrenia;	chr14:70988823	chr14:71219100~71222724:+
ESCA	cis	rs1075265	0.73	rs805391	ENSG00000235937.1	AC008280.1	-4.27	3.91e-05	0.0487	-0.39	-0.36	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54029552~54030682:-
ESCA	cis	rs7829975	0.688	rs7837587	ENSG00000173295.6	FAM86B3P	4.27	3.92e-05	0.0487	0.42	0.36	Mood instability;	chr8:8521482	chr8:8228595~8244865:+
ESCA	cis	rs4407350	0.756	rs131168	ENSG00000228807.1	MRPS18CP6	-4.27	3.92e-05	0.0487	-0.4	-0.36	Intelligence (multi-trait analysis);	chr22:44500345	chr22:44483495~44483717:-
ESCA	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	4.27	3.92e-05	0.0487	0.51	0.36	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
ESCA	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	4.27	3.92e-05	0.0487	0.51	0.36	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
ESCA	cis	rs3820068	0.581	rs16851819	ENSG00000237301.1	RP4-680D5.2	-4.27	3.92e-05	0.0487	-0.41	-0.36	Systolic blood pressure;	chr1:15592244	chr1:15586136~15603626:-
ESCA	cis	rs1538970	0.781	rs10890330	ENSG00000280836.1	AL355480.1	-4.27	3.93e-05	0.0488	-0.5	-0.36	Platelet count;	chr1:45454734	chr1:45581219~45581321:-
ESCA	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	4.27	3.93e-05	0.0488	0.36	0.36	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
ESCA	cis	rs7017914	0.652	rs12674694	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70658599	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs35863913	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70661024	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.617	rs34917985	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70662426	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs6993326	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70663365	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs10504480	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70666012	chr8:70103798~70104179:-
ESCA	cis	rs7017914	0.652	rs11987501	ENSG00000253173.3	RP11-152C15.1	-4.27	3.93e-05	0.0488	-0.43	-0.36	Bone mineral density;	chr8:70666283	chr8:70103798~70104179:-
ESCA	cis	rs66823261	0.778	rs2906332	ENSG00000253166.2	RP11-585F1.6	-4.27	3.93e-05	0.0488	-0.52	-0.36	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:202660~202897:-
ESCA	cis	rs559928	0.597	rs11600667	ENSG00000274986.1	MIR6750	4.27	3.93e-05	0.0488	0.6	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208711	chr11:64898363~64898437:-
ESCA	cis	rs2810114	0.916	rs2810099	ENSG00000269945.1	RP6-91H8.5	4.27	3.93e-05	0.0488	0.43	0.36	Alcohol dependence;	chr14:70965704	chr14:71219100~71222724:+
ESCA	cis	rs6456156	1	rs7761159	ENSG00000265828.1	MIR3939	-4.27	3.94e-05	0.0489	-0.39	-0.36	Primary biliary cholangitis;	chr6:167106419	chr6:166997807~166997912:-
ESCA	cis	rs2307394	0.896	rs2382110	ENSG00000223911.1	AC009480.3	4.27	3.94e-05	0.0489	0.44	0.36	Urate levels;	chr2:147817242	chr2:147899401~147902956:-
ESCA	cis	rs2307394	0.929	rs13012991	ENSG00000223911.1	AC009480.3	4.27	3.94e-05	0.0489	0.44	0.36	Urate levels;	chr2:147817913	chr2:147899401~147902956:-
ESCA	cis	rs7179228	0.876	rs8042664	ENSG00000260657.2	RP11-315D16.4	-4.27	3.94e-05	0.0489	-0.55	-0.36	Systolic blood pressure;	chr15:68330522	chr15:68267792~68277994:-
ESCA	cis	rs2470578	0.792	rs1449887	ENSG00000233133.1	AC104451.2	4.27	3.94e-05	0.0489	0.4	0.36	Schizophrenia;	chr3:17230736	chr3:17706058~17706233:-
ESCA	cis	rs2470578	0.792	rs1449888	ENSG00000233133.1	AC104451.2	4.27	3.94e-05	0.0489	0.4	0.36	Schizophrenia;	chr3:17230784	chr3:17706058~17706233:-
ESCA	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-4.27	3.94e-05	0.0489	-0.44	-0.36	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
ESCA	cis	rs2836974	0.583	rs9981884	ENSG00000232608.1	TIMM9P2	-4.27	3.94e-05	0.0489	-0.39	-0.36	Cognitive function;	chr21:39213707	chr21:39216624~39217506:+
ESCA	cis	rs6479901	0.947	rs7083823	ENSG00000235816.3	PRELID1P3	-4.27	3.94e-05	0.0489	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63510912	chr10:63427297~63427939:+
ESCA	cis	rs4345206	0.806	rs13128814	ENSG00000250673.1	RP11-6L6.2	4.26	3.95e-05	0.049	0.36	0.36	Coronary artery disease;	chr4:145879850	chr4:146224557~146229056:+
ESCA	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-4.26	3.95e-05	0.049	-0.45	-0.36	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
ESCA	cis	rs453301	0.571	rs2929453	ENSG00000253981.4	ALG1L13P	-4.26	3.96e-05	0.0491	-0.47	-0.36	Joint mobility (Beighton score);	chr8:9226831	chr8:8236003~8244667:-
ESCA	cis	rs997154	0.655	rs8015121	ENSG00000279656.1	RP11-298I3.6	4.26	3.96e-05	0.0491	0.51	0.36	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22906042	chr14:23023083~23024217:-
ESCA	cis	rs2439831	0.702	rs2467402	ENSG00000205771.5	CATSPER2P1	4.26	3.96e-05	0.0491	0.6	0.36	Lung cancer in ever smokers;	chr15:43732292	chr15:43726918~43747094:-
ESCA	cis	rs2098713	0.569	rs62359006	ENSG00000250155.1	CTD-2353F22.1	4.26	3.97e-05	0.0492	0.4	0.36	Telomere length;	chr5:37510947	chr5:36666214~36725195:-
ESCA	cis	rs2098713	0.569	rs35624889	ENSG00000250155.1	CTD-2353F22.1	4.26	3.97e-05	0.0492	0.4	0.36	Telomere length;	chr5:37514162	chr5:36666214~36725195:-
ESCA	cis	rs2098713	0.569	rs36186847	ENSG00000250155.1	CTD-2353F22.1	4.26	3.97e-05	0.0492	0.4	0.36	Telomere length;	chr5:37514268	chr5:36666214~36725195:-
ESCA	cis	rs2098713	0.534	rs12515702	ENSG00000250155.1	CTD-2353F22.1	4.26	3.97e-05	0.0492	0.4	0.36	Telomere length;	chr5:37520773	chr5:36666214~36725195:-
ESCA	cis	rs2098713	0.537	rs36190855	ENSG00000250155.1	CTD-2353F22.1	4.26	3.97e-05	0.0492	0.4	0.36	Telomere length;	chr5:37528407	chr5:36666214~36725195:-
ESCA	cis	rs2221894	0.511	rs10503836	ENSG00000273710.1	Metazoa_SRP	4.26	3.97e-05	0.0492	0.38	0.36	Obesity-related traits;	chr8:29027953	chr8:28915579~28915864:-
ESCA	cis	rs1787200	0.517	rs12606288	ENSG00000266696.1	RP11-30L3.2	4.26	3.97e-05	0.0492	0.56	0.36	Height;	chr18:49162231	chr18:49205912~49208781:+
ESCA	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	4.26	3.97e-05	0.0492	0.49	0.36	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
ESCA	cis	rs2439831	0.867	rs2447211	ENSG00000275601.1	AC011330.13	-4.26	3.97e-05	0.0492	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43644153	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.571	rs2470121	ENSG00000275601.1	AC011330.13	-4.26	3.97e-05	0.0492	-0.59	-0.36	Lung cancer in ever smokers;	chr15:43645420	chr15:43642389~43643023:-
ESCA	cis	rs12022452	1	rs12048678	ENSG00000229901.1	RP11-399E6.4	4.26	3.97e-05	0.0492	0.44	0.36	Age-related hearing impairment (SNP x SNP interaction);	chr1:40482096	chr1:41375004~41375669:-
ESCA	cis	rs2251069	0.517	rs61986118	ENSG00000258503.1	RP11-368P15.1	4.26	3.97e-05	0.0492	0.57	0.36	Optic cup area;	chr14:53456453	chr14:53011971~53012267:+
ESCA	cis	rs4835265	0.852	rs1027841	ENSG00000250673.1	RP11-6L6.2	-4.26	3.98e-05	0.0492	-0.4	-0.36	Gamma glutamyl transpeptidase;	chr4:145847922	chr4:146224557~146229056:+
ESCA	cis	rs858239	0.799	rs10279941	ENSG00000226816.2	AC005082.12	4.26	3.98e-05	0.0492	0.47	0.36	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23206013~23208045:+
ESCA	cis	rs1816752	0.905	rs2000153	ENSG00000273628.1	RP11-756A22.7	4.26	3.98e-05	0.0493	0.34	0.36	Obesity-related traits;	chr13:24405752	chr13:24933006~24936796:+
ESCA	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-4.26	3.99e-05	0.0493	-0.52	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
ESCA	cis	rs7283707	0.681	rs59084861	ENSG00000269950.1	AP000962.2	4.26	3.99e-05	0.0494	0.69	0.36	QRS complex (12-leadsum);	chr21:15810990	chr21:16574718~16582637:-
ESCA	cis	rs559928	0.606	rs11600628	ENSG00000274986.1	MIR6750	4.26	4e-05	0.0494	0.59	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64208555	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs78038516	ENSG00000274986.1	MIR6750	4.26	4e-05	0.0494	0.59	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64210595	chr11:64898363~64898437:-
ESCA	cis	rs559928	0.606	rs11231726	ENSG00000274986.1	MIR6750	4.26	4e-05	0.0494	0.59	0.36	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr11:64219867	chr11:64898363~64898437:-
ESCA	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	4.26	4e-05	0.0495	0.54	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
ESCA	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-4.26	4.01e-05	0.0496	-0.46	-0.36	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
ESCA	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-4.26	4.01e-05	0.0496	-0.35	-0.36	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
ESCA	cis	rs8003054	0.572	rs11626277	ENSG00000258515.1	RP11-203M5.7	4.26	4.01e-05	0.0496	0.33	0.36	Facial morphology (factor 1, breadth of lateral portion of upper face);	chr14:20445990	chr14:20451305~20451918:+
ESCA	cis	rs1061377	0.71	rs12503506	ENSG00000249685.1	RP11-360F5.3	4.26	4.02e-05	0.0496	0.39	0.36	Uric acid levels;	chr4:39082553	chr4:39133913~39135608:+
ESCA	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	4.26	4.02e-05	0.0497	0.52	0.36	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
ESCA	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-4.26	4.02e-05	0.0497	-0.7	-0.36	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
ESCA	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	4.26	4.03e-05	0.0498	0.51	0.36	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
ESCA	cis	rs1723838	1	rs1723846	ENSG00000255928.1	RP11-456I15.2	4.26	4.03e-05	0.0498	0.71	0.36	Obesity-related traits;	chr11:73788869	chr11:73722349~73722694:+
ESCA	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	4.26	4.03e-05	0.0498	0.42	0.36	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
ESCA	cis	rs453301	0.686	rs6601281	ENSG00000253981.4	ALG1L13P	-4.26	4.03e-05	0.0498	-0.46	-0.36	Joint mobility (Beighton score);	chr8:9053494	chr8:8236003~8244667:-
ESCA	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	4.26	4.03e-05	0.0498	0.47	0.36	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
ESCA	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-4.26	4.03e-05	0.0498	-0.39	-0.36	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
ESCA	cis	rs2186369	1	rs3177243	ENSG00000244425.3	RN7SL268P	-4.26	4.03e-05	0.0498	-0.5	-0.36	IgG N-glycosylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG glycosylation;IgG fucosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);	chr22:23837735	chr22:23879493~23879790:-
ESCA	cis	rs2307394	1	rs13017754	ENSG00000223911.1	AC009480.3	4.26	4.03e-05	0.0498	0.44	0.36	Urate levels;	chr2:147837786	chr2:147899401~147902956:-
ESCA	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-4.26	4.03e-05	0.0498	-0.46	-0.36	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
ESCA	cis	rs2439831	0.85	rs3736180	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43814426	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28684672	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43815464	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs7183809	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43828670	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs3759790	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43828832	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs7179388	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43831747	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28524541	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43832633	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28564774	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43833277	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs12441984	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43834087	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs7169322	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43838816	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs28707214	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43839425	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs61390361	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43867644	chr15:43642389~43643023:-
ESCA	cis	rs2439831	0.85	rs11856795	ENSG00000275601.1	AC011330.13	-4.26	4.04e-05	0.0498	-0.68	-0.36	Lung cancer in ever smokers;	chr15:43868384	chr15:43642389~43643023:-
ESCA	cis	rs7631605	1	rs7631605	ENSG00000272334.1	RP11-129K12.1	-4.26	4.04e-05	0.0499	-0.4	-0.36	Cerebrospinal P-tau181p levels;	chr3:37193098	chr3:36973117~36973672:-
ESCA	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	4.26	4.05e-05	0.0499	0.53	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
ESCA	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	4.26	4.05e-05	0.0499	0.53	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
ESCA	cis	rs1075232	1	rs12437749	ENSG00000215302.7	CTD-3092A11.1	-4.26	4.05e-05	0.0499	-0.76	-0.36	Survival in colorectal cancer (non-distant metastatic);	chr15:31357685	chr15:30470779~30507623:+
ESCA	cis	rs867371	0.502	rs8025964	ENSG00000278603.1	RP13-608F4.5	4.26	4.05e-05	0.0499	0.43	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82229429	chr15:82472203~82472426:+
ESCA	cis	rs867371	0.502	rs1846908	ENSG00000278603.1	RP13-608F4.5	4.26	4.05e-05	0.0499	0.43	0.36	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82230185	chr15:82472203~82472426:+
ESCA	cis	rs2665103	0.655	rs1501367	ENSG00000278603.1	RP13-608F4.5	4.26	4.05e-05	0.0499	0.43	0.36	Intelligence (multi-trait analysis);	chr15:82230475	chr15:82472203~82472426:+
ESCA	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-4.26	4.05e-05	0.0499	-0.51	-0.36	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
ESCA	cis	rs6479901	0.947	rs7074735	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63459519	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.802	rs7075205	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63459834	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10995540	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63460170	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10159609	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63461168	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.894	rs1061259	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63465484	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs10995541	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63473575	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.894	rs10761773	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63480322	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.894	rs2393978	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63482050	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.895	rs10822173	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63483842	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs7915680	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63484544	chr10:63427297~63427939:+
ESCA	cis	rs6479901	0.947	rs7085862	ENSG00000235816.3	PRELID1P3	-4.26	4.05e-05	0.05	-0.43	-0.36	Intelligence (multi-trait analysis);	chr10:63486687	chr10:63427297~63427939:+
ESCA	cis	rs8040855	0.894	rs4843023	ENSG00000259295.5	CSPG4P12	-4.26	4.06e-05	0.05	-0.55	-0.36	Bulimia nervosa;	chr15:85162641	chr15:85191438~85213905:+
ESCA	trans	rs13177918	0.677	rs57890152	ENSG00000224114.1	RP11-343H5.4	16.4	9.8e-33	1.44e-23	1.11	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.686	rs12654827	ENSG00000224114.1	RP11-343H5.4	16.4	9.8e-33	1.44e-23	1.11	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13160685	ENSG00000224114.1	RP11-343H5.4	16.4	9.8e-33	1.44e-23	1.11	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13161099	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.629	rs13161261	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13161417	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13161156	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13181401	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs4541646	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs3900644	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs2070844	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs2073472	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.629	rs2070842	ENSG00000224114.1	RP11-343H5.4	16.36	1.19e-32	1.44e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13171800	ENSG00000224114.1	RP11-343H5.4	16.31	1.55e-32	1.71e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs2070841	ENSG00000224114.1	RP11-343H5.4	16.31	1.55e-32	1.71e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13177951	ENSG00000224114.1	RP11-343H5.4	16.31	1.55e-32	1.71e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13177970	ENSG00000224114.1	RP11-343H5.4	16.31	1.55e-32	1.71e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13164105	ENSG00000224114.1	RP11-343H5.4	16.31	1.55e-32	1.71e-23	1.1	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.75	rs58256223	ENSG00000224114.1	RP11-343H5.4	16.21	2.55e-32	2.67e-23	1.11	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.75	rs59354956	ENSG00000224114.1	RP11-343H5.4	16.21	2.55e-32	2.67e-23	1.11	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs4841	ENSG00000224114.1	RP11-343H5.4	16.12	4.18e-32	4.01e-23	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13183077	ENSG00000224114.1	RP11-343H5.4	16.12	4.18e-32	4.01e-23	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs3797622	ENSG00000224114.1	RP11-343H5.4	16.12	4.18e-32	4.01e-23	1.1	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	15.95	1.01e-31	8.94e-23	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	15.95	1.01e-31	8.94e-23	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	15.95	1.01e-31	8.94e-23	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	15.95	1.01e-31	8.94e-23	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	15.95	1.01e-31	8.94e-23	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	15.93	1.1e-31	9.39e-23	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	15.93	1.1e-31	9.39e-23	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	15.93	1.1e-31	9.39e-23	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	15.83	1.84e-31	1.48e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	15.83	1.84e-31	1.48e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	15.83	1.84e-31	1.48e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	15.83	1.86e-31	1.48e-22	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	15.83	1.86e-31	1.48e-22	1.17	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-15.78	2.36e-31	1.86e-22	-1.2	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	15.68	3.98e-31	2.79e-22	1.16	0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.677	rs3857421	ENSG00000224114.1	RP11-343H5.4	-15.65	4.86e-31	3.35e-22	-1.12	-0.82	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	15.13	7.47e-30	3.53e-21	1.15	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	14.8	4.38e-29	1.94e-20	1.21	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.626	rs13175436	ENSG00000224114.1	RP11-343H5.4	13.96	3.94e-27	1.65e-18	1.03	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.626	rs67026795	ENSG00000224114.1	RP11-343H5.4	13.96	3.94e-27	1.65e-18	1.03	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.603	rs10447222	ENSG00000224114.1	RP11-343H5.4	13.96	3.94e-27	1.65e-18	1.03	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.603	rs13175992	ENSG00000224114.1	RP11-343H5.4	13.92	4.92e-27	2.05e-18	1.02	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	13.85	7.2e-27	2.86e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	13.85	7.2e-27	2.86e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	13.85	7.2e-27	2.86e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	13.85	7.24e-27	2.86e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	13.85	7.24e-27	2.86e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	13.79	9.99e-27	3.92e-18	1.09	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.578	rs35919198	ENSG00000224114.1	RP11-343H5.4	13.72	1.46e-26	5.64e-18	1.03	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	13.71	1.53e-26	5.85e-18	1.08	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.626	rs3819332	ENSG00000224114.1	RP11-343H5.4	13.71	1.56e-26	5.95e-18	1.02	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.626	rs13170300	ENSG00000224114.1	RP11-343H5.4	13.71	1.56e-26	5.95e-18	1.02	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:206695837~206696269:-
ESCA	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	13.5	4.87e-26	1.77e-17	0.94	0.77	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	13.5	4.87e-26	1.77e-17	0.94	0.77	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	13.5	4.87e-26	1.77e-17	0.94	0.77	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	13.5	4.87e-26	1.77e-17	0.94	0.77	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-13.26	1.78e-25	6.18e-17	-0.92	-0.77	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	13.23	2.15e-25	7.33e-17	0.94	0.77	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	13.23	2.15e-25	7.33e-17	0.94	0.77	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	13.23	2.15e-25	7.33e-17	0.94	0.77	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	13.04	6e-25	1.98e-16	0.93	0.76	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.559	rs10447224	ENSG00000224114.1	RP11-343H5.4	13.04	6.22e-25	2.03e-16	0.98	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.559	rs10447225	ENSG00000224114.1	RP11-343H5.4	13.04	6.22e-25	2.03e-16	0.98	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:206695837~206696269:-
ESCA	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	13.03	6.49e-25	2.11e-16	0.93	0.76	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
ESCA	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	12.94	1.05e-24	3.4e-16	0.93	0.76	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	12.93	1.14e-24	3.65e-16	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	12.93	1.14e-24	3.65e-16	1.04	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
ESCA	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	12.89	1.39e-24	4.4e-16	0.93	0.76	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	12.88	1.47e-24	4.59e-16	0.93	0.76	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	12.88	1.47e-24	4.59e-16	0.93	0.76	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	12.88	1.47e-24	4.59e-16	0.93	0.76	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	12.84	1.85e-24	5.58e-16	0.93	0.76	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	12.84	1.85e-24	5.58e-16	0.93	0.76	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	12.84	1.85e-24	5.58e-16	0.93	0.76	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	12.84	1.85e-24	5.58e-16	0.93	0.76	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	12.84	1.85e-24	5.58e-16	0.93	0.76	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	12.77	2.65e-24	7.94e-16	0.93	0.76	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	12.77	2.65e-24	7.94e-16	0.93	0.76	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	12.76	2.79e-24	8.29e-16	0.92	0.75	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	12.76	2.79e-24	8.29e-16	0.92	0.75	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	12.74	3.24e-24	9.52e-16	0.92	0.75	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	12.66	4.96e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	12.66	4.99e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	12.66	4.99e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	12.66	4.99e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	12.66	4.99e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	12.66	4.99e-24	1.43e-15	0.92	0.75	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	12.61	6.38e-24	1.77e-15	0.91	0.75	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	12.61	6.38e-24	1.77e-15	0.91	0.75	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	12.61	6.38e-24	1.77e-15	0.91	0.75	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	12.61	6.38e-24	1.77e-15	0.91	0.75	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	12.61	6.38e-24	1.77e-15	0.91	0.75	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	12.6	7.08e-24	1.93e-15	0.93	0.75	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
ESCA	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	12.57	8.39e-24	2.25e-15	0.91	0.75	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	12.56	8.46e-24	2.26e-15	0.92	0.75	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
ESCA	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	12.53	1e-23	2.65e-15	0.91	0.75	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	12.52	1.1e-23	2.88e-15	0.92	0.75	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	12.51	1.12e-23	2.92e-15	0.91	0.75	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	12.46	1.5e-23	3.72e-15	1	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
ESCA	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	12.43	1.74e-23	4.24e-15	0.92	0.75	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	12.43	1.74e-23	4.24e-15	0.92	0.75	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	12.43	1.74e-23	4.24e-15	0.92	0.75	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	12.43	1.74e-23	4.24e-15	0.92	0.75	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	12.43	1.76e-23	4.27e-15	0.91	0.75	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.559	rs12109637	ENSG00000224114.1	RP11-343H5.4	12.4	2.13e-23	5.14e-15	0.94	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:206695837~206696269:-
ESCA	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	12.38	2.35e-23	5.64e-15	0.91	0.74	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	12.35	2.8e-23	6.72e-15	0.91	0.74	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	12.34	2.91e-23	6.93e-15	0.9	0.74	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
ESCA	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-12.34	2.96e-23	7.05e-15	-0.91	-0.74	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	12.3	3.65e-23	8.59e-15	0.9	0.74	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	12.26	4.49e-23	1.04e-14	0.9	0.74	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	12.26	4.49e-23	1.04e-14	0.9	0.74	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	12.26	4.49e-23	1.04e-14	0.9	0.74	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	12.26	4.59e-23	1.06e-14	0.9	0.74	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.906	rs12652032	ENSG00000224114.1	RP11-343H5.4	12.23	5.3e-23	1.21e-14	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:206695837~206696269:-
ESCA	trans	rs13177918	1	rs13161334	ENSG00000224114.1	RP11-343H5.4	12.23	5.3e-23	1.21e-14	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:206695837~206696269:-
ESCA	trans	rs13177918	1	rs35007082	ENSG00000224114.1	RP11-343H5.4	12.19	6.82e-23	1.55e-14	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:206695837~206696269:-
ESCA	trans	rs13177918	1	rs13177918	ENSG00000224114.1	RP11-343H5.4	12.19	6.82e-23	1.55e-14	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:206695837~206696269:-
ESCA	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	12.16	8.11e-23	1.82e-14	0.88	0.74	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	12.16	8.11e-23	1.82e-14	0.88	0.74	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
ESCA	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	12.13	9.48e-23	2.1e-14	1.06	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
ESCA	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	12.13	9.48e-23	2.1e-14	1.06	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
ESCA	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	12.11	1.03e-22	2.26e-14	0.88	0.74	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	12.1	1.12e-22	2.43e-14	0.88	0.74	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	12.07	1.32e-22	2.82e-14	0.87	0.74	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	12.06	1.41e-22	2.99e-14	0.88	0.74	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	12.06	1.41e-22	2.99e-14	0.88	0.74	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	12.03	1.62e-22	3.41e-14	0.89	0.74	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	12.01	1.87e-22	3.94e-14	0.89	0.73	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	12	1.97e-22	4.09e-14	0.89	0.73	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	11.96	2.4e-22	4.92e-14	1.05	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
ESCA	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	11.96	2.4e-22	4.92e-14	1.05	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
ESCA	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	11.85	4.38e-22	8.45e-14	0.89	0.73	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	11.85	4.38e-22	8.45e-14	0.89	0.73	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	11.85	4.38e-22	8.45e-14	0.89	0.73	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	11.85	4.42e-22	8.49e-14	0.87	0.73	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	11.84	4.61e-22	8.56e-14	0.88	0.73	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	11.77	7.03e-22	1.28e-13	0.87	0.73	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	11.77	7.03e-22	1.28e-13	0.87	0.73	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	11.77	7.03e-22	1.28e-13	0.87	0.73	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	11.76	7.38e-22	1.34e-13	0.87	0.73	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	11.75	7.79e-22	1.4e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	11.75	7.79e-22	1.4e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	11.75	7.79e-22	1.4e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	11.75	7.79e-22	1.4e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	11.75	7.79e-22	1.4e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	11.75	7.9e-22	1.41e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	11.75	7.9e-22	1.41e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	11.75	7.9e-22	1.41e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
ESCA	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	11.74	8.04e-22	1.43e-13	1.25	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
ESCA	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	11.74	8.14e-22	1.43e-13	0.87	0.73	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	11.71	9.5e-22	1.64e-13	0.88	0.73	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	11.71	9.97e-22	1.71e-13	0.88	0.73	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	11.7	1.05e-21	1.75e-13	0.9	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
ESCA	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	11.62	1.58e-21	2.57e-13	0.88	0.72	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	11.62	1.6e-21	2.6e-13	0.87	0.72	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
ESCA	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	11.56	2.24e-21	3.57e-13	1.27	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
ESCA	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	11.55	2.36e-21	3.72e-13	0.89	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	11.55	2.36e-21	3.72e-13	0.89	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	11.55	2.36e-21	3.72e-13	0.89	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	11.55	2.37e-21	3.72e-13	0.9	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	11.55	2.37e-21	3.72e-13	0.9	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
ESCA	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	11.45	4.09e-21	6.25e-13	0.87	0.72	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-11.37	6.64e-21	1.01e-12	-0.92	-0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
ESCA	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	11.32	8.53e-21	1.28e-12	1.25	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	11.3	9.73e-21	1.46e-12	1.34	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	11.3	9.73e-21	1.46e-12	1.34	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	11.26	1.2e-20	1.77e-12	1.26	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	11.26	1.22e-20	1.79e-12	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	11.26	1.22e-20	1.79e-12	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	11.26	1.22e-20	1.79e-12	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	11.26	1.22e-20	1.79e-12	1.27	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	11.25	1.24e-20	1.81e-12	1.31	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	11.25	1.24e-20	1.81e-12	1.31	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	11.16	2.11e-20	3.07e-12	1.25	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	11.15	2.21e-20	3.19e-12	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	11.15	2.21e-20	3.19e-12	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	11.15	2.21e-20	3.19e-12	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	11.15	2.21e-20	3.19e-12	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	11.05	3.84e-20	5.43e-12	1.24	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	11.01	4.94e-20	6.9e-12	1.24	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	11.01	4.94e-20	6.9e-12	1.24	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	10.98	5.76e-20	7.99e-12	1.23	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	10.98	5.76e-20	7.99e-12	1.23	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	10.98	5.76e-20	7.99e-12	1.23	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	10.96	6.47e-20	8.88e-12	1.26	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	10.96	6.47e-20	8.88e-12	1.26	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
ESCA	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-10.94	7.3e-20	9.99e-12	-0.96	-0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
ESCA	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-10.93	7.59e-20	1.03e-11	-0.84	-0.7	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
ESCA	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	10.92	7.91e-20	1.08e-11	1.26	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	10.9	8.79e-20	1.2e-11	1.27	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	-10.87	1.08e-19	1.46e-11	-1.22	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	10.78	1.74e-19	2.34e-11	1.26	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	10.78	1.78e-19	2.39e-11	1.25	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	10.76	1.95e-19	2.61e-11	1.31	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	10.72	2.43e-19	3.22e-11	1.25	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	10.72	2.43e-19	3.22e-11	1.25	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	10.72	2.43e-19	3.22e-11	1.25	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
ESCA	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	10.67	3.26e-19	4.31e-11	0.92	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	10.66	3.4e-19	4.49e-11	0.85	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-10.63	3.94e-19	5.2e-11	-1	-0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	10.56	6.13e-19	8.03e-11	0.84	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	10.51	7.8e-19	1.02e-10	0.73	0.69	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
ESCA	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	-10.5	8.55e-19	1.11e-10	-1.26	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	-10.47	9.98e-19	1.29e-10	-1.2	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	-10.47	1.01e-18	1.29e-10	-1.25	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
ESCA	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	10.43	1.21e-18	1.54e-10	1.06	0.69	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	10.43	1.21e-18	1.54e-10	1.06	0.69	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	10.43	1.21e-18	1.54e-10	1.06	0.69	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	10.43	1.21e-18	1.54e-10	1.06	0.69	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	10.43	1.21e-18	1.54e-10	1.06	0.69	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
ESCA	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	10.42	1.31e-18	1.65e-10	0.83	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	10.42	1.31e-18	1.65e-10	0.83	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	10.42	1.31e-18	1.65e-10	0.83	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
ESCA	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	-10.35	1.88e-18	2.36e-10	-1.25	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
ESCA	trans	rs11098499	0.954	rs4309825	ENSG00000279072.1	RP13-580B18.4	-10.33	2.16e-18	2.68e-10	-0.76	-0.68	Corneal astigmatism;	chr4:119393726	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	10.31	2.38e-18	2.95e-10	0.83	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	10.31	2.38e-18	2.95e-10	0.83	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
ESCA	trans	rs11098499	0.865	rs11098513	ENSG00000279072.1	RP13-580B18.4	10.3	2.53e-18	3.13e-10	0.76	0.68	Corneal astigmatism;	chr4:119394920	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	10.25	3.34e-18	4.09e-10	1.25	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
ESCA	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	10.23	3.86e-18	4.7e-10	1.05	0.68	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
ESCA	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	10.21	4.2e-18	5.11e-10	0.96	0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	10.2	4.35e-18	5.29e-10	0.68	0.68	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
ESCA	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-10.2	4.54e-18	5.51e-10	-1.21	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
ESCA	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	10.14	6.32e-18	7.65e-10	0.83	0.67	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
ESCA	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	10.12	7.01e-18	8.44e-10	1.23	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
ESCA	trans	rs11098499	0.954	rs11729521	ENSG00000279072.1	RP13-580B18.4	10.11	7.26e-18	8.72e-10	0.78	0.67	Corneal astigmatism;	chr4:119495633	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs11944880	ENSG00000279072.1	RP13-580B18.4	-10.1	7.76e-18	9.27e-10	-0.77	-0.67	Corneal astigmatism;	chr4:119238179	chr7:56809214~56848800:-
ESCA	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	10.1	7.98e-18	9.41e-10	1.05	0.67	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	10.1	7.98e-18	9.41e-10	1.05	0.67	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
ESCA	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-10.09	8.06e-18	9.41e-10	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
ESCA	trans	rs11098499	0.618	rs28491261	ENSG00000279072.1	RP13-580B18.4	10.08	8.72e-18	1e-09	0.76	0.67	Corneal astigmatism;	chr4:119373745	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs59394118	ENSG00000279072.1	RP13-580B18.4	10.08	8.72e-18	1e-09	0.76	0.67	Corneal astigmatism;	chr4:119374396	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs9996417	ENSG00000279072.1	RP13-580B18.4	10.08	8.72e-18	1e-09	0.76	0.67	Corneal astigmatism;	chr4:119374707	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-10.07	9.45e-18	1.09e-09	-1.26	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
ESCA	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-10.05	1.04e-17	1.18e-09	-1.21	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
ESCA	trans	rs11098499	0.865	rs1112817	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119376645	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs10016060	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119377257	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10005644	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119377322	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs10016448	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119377690	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.657	rs9996569	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119377849	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs11723757	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119378514	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs11723839	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119378518	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs11729050	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119378911	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs28429722	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119378938	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10014845	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119379922	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs12506546	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119380463	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs7674500	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119382438	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs4507344	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119386330	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs4373140	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119386543	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs13113483	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119387884	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.542	rs10440343	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119388632	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28668716	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119388720	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs10011097	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119389204	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs7699346	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119389387	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.542	rs7677836	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119389483	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs10002083	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119389997	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10024844	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119390373	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs7437420	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119391748	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs4345162	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119391804	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.657	rs4463052	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119392103	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs4560394	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119392280	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs13151285	ENSG00000279072.1	RP13-580B18.4	10.03	1.14e-17	1.18e-09	0.75	0.67	Corneal astigmatism;	chr4:119393586	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs13435802	ENSG00000279072.1	RP13-580B18.4	-10.03	1.15e-17	1.2e-09	-0.76	-0.67	Corneal astigmatism;	chr4:119256805	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs59866101	ENSG00000279072.1	RP13-580B18.4	10.02	1.19e-17	1.22e-09	0.75	0.67	Corneal astigmatism;	chr4:119375436	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.618	rs6858383	ENSG00000279072.1	RP13-580B18.4	10.02	1.19e-17	1.22e-09	0.75	0.67	Corneal astigmatism;	chr4:119375617	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs6832410	ENSG00000279072.1	RP13-580B18.4	10.02	1.19e-17	1.22e-09	0.75	0.67	Corneal astigmatism;	chr4:119375645	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-10.01	1.31e-17	1.35e-09	-0.81	-0.67	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.691	rs9996644	ENSG00000279072.1	RP13-580B18.4	9.99	1.42e-17	1.45e-09	0.76	0.67	Corneal astigmatism;	chr4:119317722	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs9996494	ENSG00000279072.1	RP13-580B18.4	9.99	1.42e-17	1.45e-09	0.76	0.67	Corneal astigmatism;	chr4:119317725	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.663	rs9996501	ENSG00000279072.1	RP13-580B18.4	9.99	1.42e-17	1.45e-09	0.76	0.67	Corneal astigmatism;	chr4:119317763	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs28458294	ENSG00000279072.1	RP13-580B18.4	9.99	1.42e-17	1.45e-09	0.76	0.67	Corneal astigmatism;	chr4:119317769	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.663	rs28369503	ENSG00000279072.1	RP13-580B18.4	9.99	1.42e-17	1.45e-09	0.76	0.67	Corneal astigmatism;	chr4:119317770	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	9.99	1.44e-17	1.47e-09	0.71	0.67	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
ESCA	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	9.98	1.49e-17	1.52e-09	1	0.67	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
ESCA	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-9.98	1.55e-17	1.58e-09	-1.25	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
ESCA	trans	rs11098499	0.908	rs7696649	ENSG00000279072.1	RP13-580B18.4	9.96	1.71e-17	1.74e-09	0.77	0.67	Corneal astigmatism;	chr4:119401022	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28884220	ENSG00000279072.1	RP13-580B18.4	9.92	2.18e-17	2.19e-09	0.75	0.67	Corneal astigmatism;	chr4:119386056	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28793658	ENSG00000279072.1	RP13-580B18.4	9.92	2.18e-17	2.19e-09	0.75	0.67	Corneal astigmatism;	chr4:119386059	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	9.88	2.71e-17	2.68e-09	0.79	0.67	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	9.88	2.71e-17	2.68e-09	0.79	0.67	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	9.88	2.71e-17	2.68e-09	0.79	0.67	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.754	rs9991959	ENSG00000279072.1	RP13-580B18.4	-9.87	2.74e-17	2.7e-09	-0.76	-0.66	Corneal astigmatism;	chr4:119332618	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-9.87	2.87e-17	2.82e-09	-0.7	-0.66	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
ESCA	trans	rs11098499	0.954	rs28572238	ENSG00000279072.1	RP13-580B18.4	9.85	3.1e-17	3.02e-09	0.74	0.66	Corneal astigmatism;	chr4:119395531	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28714195	ENSG00000279072.1	RP13-580B18.4	9.85	3.1e-17	3.02e-09	0.74	0.66	Corneal astigmatism;	chr4:119395795	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs12508173	ENSG00000279072.1	RP13-580B18.4	9.85	3.1e-17	3.02e-09	0.74	0.66	Corneal astigmatism;	chr4:119397371	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs12504149	ENSG00000279072.1	RP13-580B18.4	9.85	3.1e-17	3.02e-09	0.74	0.66	Corneal astigmatism;	chr4:119397422	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.58	rs12509234	ENSG00000279072.1	RP13-580B18.4	9.83	3.44e-17	3.32e-09	0.75	0.66	Corneal astigmatism;	chr4:119398279	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs10014719	ENSG00000279072.1	RP13-580B18.4	9.83	3.44e-17	3.32e-09	0.75	0.66	Corneal astigmatism;	chr4:119399560	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10017543	ENSG00000279072.1	RP13-580B18.4	9.83	3.44e-17	3.32e-09	0.75	0.66	Corneal astigmatism;	chr4:119400265	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	9.83	3.47e-17	3.35e-09	0.79	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	9.83	3.47e-17	3.35e-09	0.79	0.66	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
ESCA	trans	rs11098499	0.821	rs10032151	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119470473	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs10032158	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119470477	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6838814	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119471288	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs13107475	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119471856	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs7436506	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119472614	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs12499324	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119472631	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10008459	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119473076	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs2127821	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119473380	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs9998585	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119475647	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10034623	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119476674	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs6842762	ENSG00000279072.1	RP13-580B18.4	9.82	3.68e-17	3.48e-09	0.75	0.66	Corneal astigmatism;	chr4:119477081	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs1511018	ENSG00000279072.1	RP13-580B18.4	9.82	3.78e-17	3.56e-09	0.77	0.66	Corneal astigmatism;	chr4:119240425	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs1397608	ENSG00000279072.1	RP13-580B18.4	9.82	3.78e-17	3.56e-09	0.77	0.66	Corneal astigmatism;	chr4:119240589	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs7684942	ENSG00000279072.1	RP13-580B18.4	9.82	3.78e-17	3.56e-09	0.77	0.66	Corneal astigmatism;	chr4:119241046	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	9.81	3.9e-17	3.66e-09	0.67	0.66	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
ESCA	trans	rs1552244	1	rs12152515	ENSG00000230342.2	FANCD2P2	9.8	4.11e-17	3.83e-09	1.18	0.66	Alzheimer's disease;	chr3:10102292	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.954	rs10031483	ENSG00000279072.1	RP13-580B18.4	9.8	4.13e-17	3.83e-09	0.76	0.66	Corneal astigmatism;	chr4:119501481	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10031665	ENSG00000279072.1	RP13-580B18.4	9.8	4.13e-17	3.83e-09	0.76	0.66	Corneal astigmatism;	chr4:119501697	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3733519	ENSG00000279072.1	RP13-580B18.4	9.8	4.13e-17	3.83e-09	0.76	0.66	Corneal astigmatism;	chr4:119502293	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3733523	ENSG00000279072.1	RP13-580B18.4	9.8	4.13e-17	3.83e-09	0.76	0.66	Corneal astigmatism;	chr4:119502564	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3733524	ENSG00000279072.1	RP13-580B18.4	9.8	4.13e-17	3.83e-09	0.76	0.66	Corneal astigmatism;	chr4:119502574	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs1480931	ENSG00000279072.1	RP13-580B18.4	9.79	4.3e-17	3.98e-09	0.73	0.66	Corneal astigmatism;	chr4:119474654	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-9.79	4.37e-17	4.04e-09	-0.66	-0.66	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.908	rs7695996	ENSG00000279072.1	RP13-580B18.4	9.79	4.46e-17	4.1e-09	0.75	0.66	Corneal astigmatism;	chr4:119400878	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-9.78	4.57e-17	4.19e-09	-0.65	-0.66	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-9.78	4.57e-17	4.19e-09	-0.65	-0.66	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
ESCA	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-9.78	4.66e-17	4.24e-09	-1.02	-0.66	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
ESCA	trans	rs1816752	0.679	rs7999480	ENSG00000237917.1	PARP4P1	-9.78	4.71e-17	4.24e-09	-0.81	-0.66	Obesity-related traits;	chr13:24397865	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs11935596	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119491302	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs12507964	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119491906	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs11098530	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119491999	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6834796	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119493538	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs11734241	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119495717	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs17006190	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119497683	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs28685688	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119499179	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs7687843	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119500056	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs2306455	ENSG00000279072.1	RP13-580B18.4	9.78	4.72e-17	4.24e-09	0.76	0.66	Corneal astigmatism;	chr4:119500814	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs9849434	ENSG00000230342.2	FANCD2P2	-9.77	4.88e-17	4.38e-09	-1.06	-0.66	Alzheimer's disease;	chr3:10092026	chr3:11859674~11891172:+
ESCA	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	9.77	4.91e-17	4.4e-09	0.56	0.66	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.954	rs11098525	ENSG00000279072.1	RP13-580B18.4	9.77	4.93e-17	4.4e-09	0.75	0.66	Corneal astigmatism;	chr4:119468997	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs11098526	ENSG00000279072.1	RP13-580B18.4	9.77	4.93e-17	4.4e-09	0.75	0.66	Corneal astigmatism;	chr4:119469204	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.826	rs4472123	ENSG00000279072.1	RP13-580B18.4	9.76	5.12e-17	4.57e-09	0.76	0.66	Corneal astigmatism;	chr4:119315475	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	9.76	5.29e-17	4.71e-09	0.79	0.66	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	9.75	5.44e-17	4.82e-09	0.72	0.66	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
ESCA	trans	rs11098499	0.955	rs11931312	ENSG00000279072.1	RP13-580B18.4	9.75	5.6e-17	4.96e-09	0.77	0.66	Corneal astigmatism;	chr4:119237868	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.632	rs34481394	ENSG00000279072.1	RP13-580B18.4	9.74	5.9e-17	5.07e-09	0.75	0.66	Educational attainment;	chr4:119327219	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.666	rs35231872	ENSG00000279072.1	RP13-580B18.4	9.74	5.9e-17	5.07e-09	0.75	0.66	Educational attainment;	chr4:119327221	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.7	rs35653026	ENSG00000279072.1	RP13-580B18.4	9.74	5.9e-17	5.07e-09	0.75	0.66	Educational attainment;	chr4:119327223	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs11941899	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119461603	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs7681978	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119462620	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.821	rs28665282	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119463031	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.738	rs10026493	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119463039	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs10026736	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119463167	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs7681214	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119464165	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs28559989	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465472	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs28499576	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465522	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28632018	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465575	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs71614449	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465900	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs35063680	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465947	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs34858317	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119465955	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs17046116	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119466104	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs17046118	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119466341	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs7654587	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.74	0.66	Corneal astigmatism;	chr4:119467251	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs938056	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.75	0.66	Corneal astigmatism;	chr4:119316298	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs878376	ENSG00000279072.1	RP13-580B18.4	9.74	5.93e-17	5.07e-09	0.75	0.66	Corneal astigmatism;	chr4:119316547	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.913	rs10010696	ENSG00000279072.1	RP13-580B18.4	9.73	6.09e-17	5.2e-09	0.77	0.66	Corneal astigmatism;	chr4:119243148	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000233778.3	RP11-777J24.1	9.73	6.18e-17	5.26e-09	0.61	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.954	rs7681544	ENSG00000279072.1	RP13-580B18.4	9.73	6.19e-17	5.26e-09	0.75	0.66	Corneal astigmatism;	chr4:119490100	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs17005535	ENSG00000279072.1	RP13-580B18.4	9.73	6.19e-17	5.26e-09	0.75	0.66	Corneal astigmatism;	chr4:119490407	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs11940028	ENSG00000279072.1	RP13-580B18.4	9.73	6.19e-17	5.26e-09	0.75	0.66	Corneal astigmatism;	chr4:119490752	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	9.72	6.37e-17	5.4e-09	0.61	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
ESCA	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	9.72	6.43e-17	5.42e-09	0.79	0.66	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	9.72	6.43e-17	5.42e-09	0.79	0.66	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	9.72	6.43e-17	5.42e-09	0.79	0.66	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	9.72	6.43e-17	5.42e-09	0.79	0.66	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs10518328	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119480624	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6822679	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119481547	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs4577559	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119482888	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs7656252	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119483113	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs28845498	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119484031	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs28753180	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119484212	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs56270433	ENSG00000279072.1	RP13-580B18.4	9.71	6.68e-17	5.57e-09	0.75	0.66	Corneal astigmatism;	chr4:119484875	chr7:56809214~56848800:-
ESCA	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	9.71	6.69e-17	5.58e-09	0.78	0.66	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs6848389	ENSG00000279072.1	RP13-580B18.4	9.7	7.41e-17	6.13e-09	0.76	0.66	Corneal astigmatism;	chr4:119481467	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1546503	ENSG00000279072.1	RP13-580B18.4	9.69	7.84e-17	6.44e-09	0.75	0.66	Corneal astigmatism;	chr4:119320012	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.708	rs1546506	ENSG00000279072.1	RP13-580B18.4	9.69	7.84e-17	6.44e-09	0.75	0.66	Corneal astigmatism;	chr4:119320085	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.789	rs9991166	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119316696	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.708	rs10005237	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119316742	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs878372	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119317625	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs10213267	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119317919	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs10212775	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119318089	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs9999724	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119318789	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs2964	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119318976	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1511025	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119319083	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12711071	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119319779	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12510269	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119320491	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12506610	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119320504	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.743	rs10003567	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119320519	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs10006259	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119320990	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs28652763	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119321157	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs714899	ENSG00000279072.1	RP13-580B18.4	9.68	8.04e-17	6.5e-09	0.75	0.66	Corneal astigmatism;	chr4:119321880	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.662	rs13108589	ENSG00000279072.1	RP13-580B18.4	9.68	8.25e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119346947	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs10213554	ENSG00000279072.1	RP13-580B18.4	-9.67	8.41e-17	6.6e-09	-0.75	-0.66	Corneal astigmatism;	chr4:119339630	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.575	rs907204	ENSG00000279072.1	RP13-580B18.4	9.67	8.62e-17	6.6e-09	0.75	0.66	Corneal astigmatism;	chr4:119317499	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.575	rs907205	ENSG00000279072.1	RP13-580B18.4	9.67	8.62e-17	6.6e-09	0.75	0.66	Corneal astigmatism;	chr4:119317509	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10006525	ENSG00000279072.1	RP13-580B18.4	9.67	8.69e-17	6.6e-09	0.75	0.66	Corneal astigmatism;	chr4:119487776	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6849171	ENSG00000279072.1	RP13-580B18.4	9.67	8.69e-17	6.6e-09	0.75	0.66	Corneal astigmatism;	chr4:119488394	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs13116504	ENSG00000279072.1	RP13-580B18.4	9.66	8.85e-17	6.6e-09	0.77	0.66	Corneal astigmatism;	chr4:119288257	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28555550	ENSG00000279072.1	RP13-580B18.4	9.66	8.85e-17	6.6e-09	0.77	0.66	Corneal astigmatism;	chr4:119289885	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs28419773	ENSG00000279072.1	RP13-580B18.4	9.66	8.85e-17	6.6e-09	0.77	0.66	Corneal astigmatism;	chr4:119289906	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	9.66	8.88e-17	6.6e-09	0.79	0.66	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs10518331	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119402440	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs13133522	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119403269	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs35091806	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119404374	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs35165976	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119404475	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs2389802	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119404577	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6846442	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119405168	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs4001305	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119438081	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs67265404	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119438115	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs71614422	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119438185	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.738	rs34566984	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119440115	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.738	rs34965784	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119440431	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs17009122	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119441248	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.505	rs75122014	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119441271	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs9685777	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119444810	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs9759478	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119446843	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs71614438	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119450097	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs66506550	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119450290	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs7659501	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119450397	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs71629403	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119451412	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs73842633	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119454309	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs80242894	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119454597	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs28495013	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119454676	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28571712	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119454825	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.738	rs28408407	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119454875	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs1809406	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119455967	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs2389809	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119456244	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.657	rs71614442	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119458191	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs2892848	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119460186	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs9994730	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119460409	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs9994810	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119460435	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs10020027	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119460724	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs7356491	ENSG00000279072.1	RP13-580B18.4	9.66	9.18e-17	6.6e-09	0.74	0.66	Corneal astigmatism;	chr4:119460819	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6849561	ENSG00000279072.1	RP13-580B18.4	-9.65	9.47e-17	6.79e-09	-0.71	-0.66	Corneal astigmatism;	chr4:119488539	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs10020034	ENSG00000279072.1	RP13-580B18.4	9.65	9.64e-17	6.91e-09	0.75	0.66	Corneal astigmatism;	chr4:119373176	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3733520	ENSG00000279072.1	RP13-580B18.4	9.64	1.01e-16	7.22e-09	0.77	0.66	Corneal astigmatism;	chr4:119502325	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs1511019	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119244852	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.913	rs11098496	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119246311	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs35197422	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119248159	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs35434465	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119248223	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs1511015	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119249318	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs10029750	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119251388	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs6837898	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119257999	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs28374891	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119262395	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs35643470	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119263793	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs12506395	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119263939	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs7659194	ENSG00000279072.1	RP13-580B18.4	9.63	1.04e-16	7.26e-09	0.76	0.66	Corneal astigmatism;	chr4:119285992	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs11732087	ENSG00000279072.1	RP13-580B18.4	9.63	1.05e-16	7.31e-09	0.74	0.66	Corneal astigmatism;	chr4:119318676	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs6807846	ENSG00000230342.2	FANCD2P2	9.63	1.08e-16	7.42e-09	1.13	0.66	Alzheimer's disease;	chr3:10092807	chr3:11859674~11891172:+
ESCA	trans	rs10028773	0.7	rs7671797	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Educational attainment;	chr4:119327002	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs7672594	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119327388	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs7672778	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119327430	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs2036860	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119327779	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs2036857	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119328085	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs2036856	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119328133	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs4443261	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119328146	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12513083	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119328457	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12509621	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119328505	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1511017	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119329650	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.789	rs12498994	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119329663	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs12507565	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119329966	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.826	rs12511640	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119330093	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1980026	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119330488	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.722	rs28713555	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119330840	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.743	rs11098501	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119330862	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs11098502	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119330908	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.708	rs11732686	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119331175	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs11724409	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119331206	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.789	rs1980024	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119331892	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs34425882	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119332022	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs4107728	ENSG00000279072.1	RP13-580B18.4	9.63	1.09e-16	7.42e-09	0.75	0.66	Corneal astigmatism;	chr4:119332755	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs72676074	ENSG00000279072.1	RP13-580B18.4	9.62	1.1e-16	7.48e-09	0.74	0.66	Corneal astigmatism;	chr4:119438686	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs1552244	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10093893	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7610821	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10094466	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs2272124	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10096505	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs55882090	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10097398	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7622963	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10098141	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7622966	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10098149	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs34179822	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10098333	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.938	rs7647987	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10099012	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs3826	ENSG00000230342.2	FANCD2P2	9.62	1.11e-16	7.5e-09	1.11	0.66	Alzheimer's disease;	chr3:10099381	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.909	rs10017335	ENSG00000279072.1	RP13-580B18.4	-9.62	1.12e-16	7.55e-09	-0.73	-0.66	Corneal astigmatism;	chr4:119460368	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	9.62	1.15e-16	7.73e-09	0.69	0.66	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
ESCA	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-9.61	1.2e-16	8.02e-09	-0.83	-0.65	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.955	rs7685268	ENSG00000279072.1	RP13-580B18.4	9.61	1.22e-16	8.11e-09	0.77	0.65	Corneal astigmatism;	chr4:119241033	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs9995234	ENSG00000279072.1	RP13-580B18.4	9.61	1.22e-16	8.11e-09	0.74	0.65	Corneal astigmatism;	chr4:119400672	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	9.6	1.23e-16	8.18e-09	1.14	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-9.6	1.24e-16	8.2e-09	-0.68	-0.65	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-9.6	1.24e-16	8.2e-09	-0.68	-0.65	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
ESCA	trans	rs11098499	0.954	rs12502423	ENSG00000279072.1	RP13-580B18.4	9.6	1.25e-16	8.25e-09	0.74	0.65	Corneal astigmatism;	chr4:119503017	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-9.6	1.25e-16	8.28e-09	-0.74	-0.65	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
ESCA	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	9.6	1.28e-16	8.45e-09	1.01	0.65	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
ESCA	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-9.59	1.33e-16	8.79e-09	-0.79	-0.65	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.865	rs28634456	ENSG00000279072.1	RP13-580B18.4	9.59	1.34e-16	8.82e-09	0.74	0.65	Corneal astigmatism;	chr4:119454623	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs12508504	ENSG00000279072.1	RP13-580B18.4	9.59	1.36e-16	8.96e-09	0.74	0.65	Corneal astigmatism;	chr4:119489452	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs66900435	ENSG00000279072.1	RP13-580B18.4	9.57	1.46e-16	9.52e-09	0.74	0.65	Corneal astigmatism;	chr4:119328270	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs17595608	ENSG00000279072.1	RP13-580B18.4	9.57	1.46e-16	9.52e-09	0.74	0.65	Corneal astigmatism;	chr4:119329351	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1980027	ENSG00000279072.1	RP13-580B18.4	9.57	1.46e-16	9.52e-09	0.74	0.65	Corneal astigmatism;	chr4:119330422	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-9.57	1.46e-16	9.52e-09	-0.81	-0.65	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
ESCA	trans	rs11098499	1	rs11098499	ENSG00000279072.1	RP13-580B18.4	9.57	1.49e-16	9.69e-09	0.76	0.65	Corneal astigmatism;	chr4:119266456	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs11726229	ENSG00000279072.1	RP13-580B18.4	9.57	1.52e-16	9.87e-09	0.76	0.65	Corneal astigmatism;	chr4:119290425	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	9.56	1.55e-16	1e-08	0.67	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.954	rs10017371	ENSG00000279072.1	RP13-580B18.4	9.56	1.55e-16	1e-08	0.74	0.65	Corneal astigmatism;	chr4:119372621	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs11098500	ENSG00000279072.1	RP13-580B18.4	9.56	1.56e-16	1.01e-08	0.76	0.65	Corneal astigmatism;	chr4:119298084	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs3749591	ENSG00000279072.1	RP13-580B18.4	9.56	1.6e-16	1.03e-08	0.77	0.65	Corneal astigmatism;	chr4:119292875	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3890049	ENSG00000279072.1	RP13-580B18.4	9.55	1.7e-16	1.08e-08	0.73	0.65	Corneal astigmatism;	chr4:119405128	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	9.55	1.7e-16	1.08e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
ESCA	trans	rs13177918	0.734	rs6579790	ENSG00000224114.1	RP11-343H5.4	9.54	1.74e-16	1.1e-08	0.83	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.734	rs6579791	ENSG00000224114.1	RP11-343H5.4	9.54	1.74e-16	1.1e-08	0.83	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:206695837~206696269:-
ESCA	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	9.54	1.79e-16	1.13e-08	0.78	0.65	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
ESCA	trans	rs1552244	0.935	rs11926481	ENSG00000230342.2	FANCD2P2	9.53	1.87e-16	1.18e-08	1.16	0.65	Alzheimer's disease;	chr3:10100418	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs12152512	ENSG00000230342.2	FANCD2P2	9.53	1.87e-16	1.18e-08	1.16	0.65	Alzheimer's disease;	chr3:10102086	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000233778.3	RP11-777J24.1	9.51	2.1e-16	1.31e-08	0.61	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:92144088~92144435:-
ESCA	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	9.51	2.12e-16	1.32e-08	0.65	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	9.51	2.12e-16	1.32e-08	0.65	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	9.51	2.12e-16	1.32e-08	0.65	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	9.51	2.12e-16	1.32e-08	0.65	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
ESCA	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	9.5	2.23e-16	1.38e-08	0.79	0.65	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs9993199	ENSG00000279072.1	RP13-580B18.4	-9.49	2.28e-16	1.41e-08	-0.74	-0.65	Corneal astigmatism;	chr4:119471718	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1980025	ENSG00000279072.1	RP13-580B18.4	-9.49	2.33e-16	1.44e-08	-0.72	-0.65	Corneal astigmatism;	chr4:119331651	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs7672372	ENSG00000279072.1	RP13-580B18.4	9.49	2.33e-16	1.44e-08	0.74	0.65	Corneal astigmatism;	chr4:119327251	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.535	rs7671759	ENSG00000279072.1	RP13-580B18.4	9.48	2.39e-16	1.47e-08	0.74	0.65	Corneal astigmatism;	chr4:119326939	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	9.48	2.51e-16	1.54e-08	0.79	0.65	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
ESCA	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	9.47	2.53e-16	1.55e-08	1.1	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
ESCA	trans	rs11098499	0.954	rs10006706	ENSG00000279072.1	RP13-580B18.4	9.47	2.54e-16	1.56e-08	0.74	0.65	Corneal astigmatism;	chr4:119487997	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs13319597	ENSG00000230342.2	FANCD2P2	-9.47	2.62e-16	1.6e-08	-1.01	-0.65	Alzheimer's disease;	chr3:10084628	chr3:11859674~11891172:+
ESCA	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	9.46	2.73e-16	1.66e-08	0.58	0.65	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	9.46	2.73e-16	1.66e-08	0.59	0.65	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.697	rs28655325	ENSG00000279072.1	RP13-580B18.4	9.45	2.84e-16	1.73e-08	0.74	0.65	Corneal astigmatism;	chr4:119451844	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-9.45	2.97e-16	1.8e-08	-0.67	-0.65	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-9.45	2.97e-16	1.8e-08	-0.67	-0.65	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
ESCA	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	9.44	2.97e-16	1.8e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.618	rs35265692	ENSG00000279072.1	RP13-580B18.4	9.44	3.07e-16	1.86e-08	0.74	0.65	Corneal astigmatism;	chr4:119403980	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs1546502	ENSG00000279072.1	RP13-580B18.4	9.44	3.1e-16	1.88e-08	0.75	0.65	Corneal astigmatism;	chr4:119314743	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs1546504	ENSG00000279072.1	RP13-580B18.4	9.43	3.27e-16	1.97e-08	0.75	0.65	Corneal astigmatism;	chr4:119320024	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs11098527	ENSG00000279072.1	RP13-580B18.4	9.42	3.33e-16	2e-08	0.74	0.65	Corneal astigmatism;	chr4:119478751	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs2272125	ENSG00000230342.2	FANCD2P2	9.42	3.41e-16	2.04e-08	1.17	0.65	Alzheimer's disease;	chr3:10096385	chr3:11859674~11891172:+
ESCA	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	9.42	3.42e-16	2.04e-08	0.66	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
ESCA	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	9.42	3.49e-16	2.08e-08	0.76	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
ESCA	trans	rs11098499	0.954	rs12510138	ENSG00000279072.1	RP13-580B18.4	9.41	3.54e-16	2.11e-08	0.74	0.65	Corneal astigmatism;	chr4:119502780	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.61	rs199529	ENSG00000263503.1	RP11-707O23.5	9.41	3.59e-16	2.14e-08	1.21	0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45600869~45602340:-
ESCA	trans	rs11098499	0.954	rs878373	ENSG00000279072.1	RP13-580B18.4	9.41	3.67e-16	2.17e-08	0.75	0.65	Corneal astigmatism;	chr4:119316329	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10006877	ENSG00000279072.1	RP13-580B18.4	9.41	3.67e-16	2.17e-08	0.75	0.65	Corneal astigmatism;	chr4:119321638	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs12505469	ENSG00000279072.1	RP13-580B18.4	9.41	3.67e-16	2.17e-08	0.75	0.65	Corneal astigmatism;	chr4:119328430	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs2017057	ENSG00000279072.1	RP13-580B18.4	9.41	3.67e-16	2.17e-08	0.75	0.65	Corneal astigmatism;	chr4:119336556	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-9.39	3.96e-16	2.34e-08	-0.67	-0.65	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	9.39	4.04e-16	2.38e-08	0.6	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.909	rs78332141	ENSG00000279072.1	RP13-580B18.4	9.38	4.17e-16	2.45e-08	0.74	0.65	Corneal astigmatism;	chr4:119454627	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs2389803	ENSG00000279072.1	RP13-580B18.4	-9.37	4.43e-16	2.58e-08	-0.72	-0.65	Corneal astigmatism;	chr4:119472356	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs6815725	ENSG00000279072.1	RP13-580B18.4	9.37	4.45e-16	2.58e-08	0.77	0.65	Corneal astigmatism;	chr4:119237255	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs1551	ENSG00000279072.1	RP13-580B18.4	9.37	4.45e-16	2.58e-08	0.77	0.65	Corneal astigmatism;	chr4:119237345	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs11722183	ENSG00000279072.1	RP13-580B18.4	9.37	4.49e-16	2.59e-08	0.73	0.65	Corneal astigmatism;	chr4:119359442	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-9.37	4.59e-16	2.65e-08	-0.64	-0.65	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
ESCA	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	9.36	4.66e-16	2.69e-08	0.65	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.954	rs10008392	ENSG00000279072.1	RP13-580B18.4	9.36	4.74e-16	2.73e-08	0.74	0.64	Corneal astigmatism;	chr4:119397684	chr7:56809214~56848800:-
ESCA	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	9.36	4.81e-16	2.76e-08	0.81	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
ESCA	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	9.36	4.81e-16	2.76e-08	0.81	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
ESCA	trans	rs11098499	0.754	rs10518300	ENSG00000279072.1	RP13-580B18.4	-9.35	5.13e-16	2.94e-08	-0.75	-0.64	Corneal astigmatism;	chr4:119328344	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.908	rs1002152	ENSG00000279072.1	RP13-580B18.4	9.34	5.22e-16	2.98e-08	0.73	0.64	Corneal astigmatism;	chr4:119352232	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs1022145	ENSG00000279072.1	RP13-580B18.4	9.34	5.23e-16	2.98e-08	0.75	0.64	Corneal astigmatism;	chr4:119309824	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs11722872	ENSG00000279072.1	RP13-580B18.4	9.34	5.23e-16	2.98e-08	0.75	0.64	Corneal astigmatism;	chr4:119311875	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs17049949	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119334135	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs10213221	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119334771	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs7689729	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119335037	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.7	rs7690338	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Educational attainment;	chr4:119335313	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.865	rs3956464	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119335609	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.619	rs28502463	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119335868	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.648	rs2002047	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119336073	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.775	rs2002049	ENSG00000279072.1	RP13-580B18.4	9.33	5.57e-16	3.14e-08	0.72	0.64	Corneal astigmatism;	chr4:119336262	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-9.33	5.65e-16	3.18e-08	-0.65	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
ESCA	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	9.33	5.68e-16	3.18e-08	0.57	0.64	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	9.33	5.68e-16	3.18e-08	0.57	0.64	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.754	rs28643450	ENSG00000279072.1	RP13-580B18.4	9.32	5.77e-16	3.22e-08	0.75	0.64	Corneal astigmatism;	chr4:119324087	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.738	rs72918577	ENSG00000279072.1	RP13-580B18.4	9.32	5.86e-16	3.26e-08	0.74	0.64	Corneal astigmatism;	chr4:119405546	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	9.32	5.89e-16	3.27e-08	0.81	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
ESCA	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	9.32	5.89e-16	3.27e-08	0.81	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-9.32	5.96e-16	3.31e-08	-0.68	-0.64	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
ESCA	trans	rs11098499	0.754	rs10212714	ENSG00000279072.1	RP13-580B18.4	9.31	6.14e-16	3.39e-08	0.72	0.64	Corneal astigmatism;	chr4:119333147	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.789	rs10212719	ENSG00000279072.1	RP13-580B18.4	9.31	6.14e-16	3.39e-08	0.72	0.64	Corneal astigmatism;	chr4:119333282	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-9.31	6.35e-16	3.5e-08	-1.01	-0.64	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.754	rs1849457	ENSG00000279072.1	RP13-580B18.4	9.29	6.86e-16	3.78e-08	0.72	0.64	Corneal astigmatism;	chr4:119333200	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	9.29	7.12e-16	3.91e-08	0.65	0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	9.29	7.12e-16	3.91e-08	0.7	0.64	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
ESCA	trans	rs11098499	1	rs6849889	ENSG00000279072.1	RP13-580B18.4	9.29	7.16e-16	3.92e-08	0.76	0.64	Corneal astigmatism;	chr4:119265193	chr7:56809214~56848800:-
ESCA	trans	rs11098499	1	rs58601355	ENSG00000279072.1	RP13-580B18.4	9.29	7.16e-16	3.92e-08	0.76	0.64	Corneal astigmatism;	chr4:119265212	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.717	rs6874318	ENSG00000224114.1	RP11-343H5.4	-9.27	7.71e-16	4.21e-08	-0.81	-0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:206695837~206696269:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-9.24	9.07e-16	4.84e-08	-0.68	-0.64	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-9.24	9.07e-16	4.84e-08	-0.68	-0.64	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
ESCA	trans	rs916888	0.821	rs199499	ENSG00000263503.1	RP11-707O23.5	9.22	1.03e-15	5.09e-08	1.28	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:45600869~45602340:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-9.21	1.1e-15	5.43e-08	-0.69	-0.64	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
ESCA	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-9.19	1.22e-15	5.97e-08	-1	-0.64	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	9.18	1.25e-15	6.12e-08	0.74	0.64	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
ESCA	trans	rs11098499	0.954	rs1546505	ENSG00000279072.1	RP13-580B18.4	9.18	1.3e-15	6.36e-08	0.74	0.64	Corneal astigmatism;	chr4:119320069	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-9.17	1.33e-15	6.47e-08	-0.65	-0.64	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	9.17	1.37e-15	6.66e-08	0.67	0.64	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
ESCA	trans	rs1552244	1	rs4269070	ENSG00000230342.2	FANCD2P2	9.16	1.4e-15	6.76e-08	1.12	0.64	Alzheimer's disease;	chr3:10084399	chr3:11859674~11891172:+
ESCA	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-9.15	1.49e-15	7.14e-08	-0.55	-0.64	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	9.14	1.61e-15	7.67e-08	0.65	0.64	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
ESCA	trans	rs11098499	0.955	rs13129661	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119231754	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs56386062	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119233980	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs4145951	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119234662	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs35916640	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119234697	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs13113112	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119234885	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.955	rs13114751	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119235462	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.913	rs35271032	ENSG00000279072.1	RP13-580B18.4	9.14	1.64e-15	7.76e-08	0.78	0.64	Corneal astigmatism;	chr4:119235504	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs9811771	ENSG00000230342.2	FANCD2P2	9.12	1.74e-15	8.1e-08	1.08	0.64	Alzheimer's disease;	chr3:10092265	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032414	ENSG00000230342.2	FANCD2P2	9.11	1.85e-15	8.56e-08	1.14	0.63	Alzheimer's disease;	chr3:10116618	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032299	ENSG00000230342.2	FANCD2P2	9.1	1.94e-15	8.99e-08	1.38	0.63	Alzheimer's disease;	chr3:10045954	chr3:11859674~11891172:+
ESCA	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	9.1	2.03e-15	9.39e-08	0.64	0.63	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.722	rs17595727	ENSG00000279072.1	RP13-580B18.4	-9.09	2.1e-15	9.67e-08	-0.7	-0.63	Corneal astigmatism;	chr4:119340919	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs17517414	ENSG00000279072.1	RP13-580B18.4	9.09	2.1e-15	9.67e-08	0.7	0.63	Corneal astigmatism;	chr4:119340946	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6820115	ENSG00000279072.1	RP13-580B18.4	9.09	2.11e-15	9.7e-08	0.7	0.63	Corneal astigmatism;	chr4:119477027	chr7:56809214~56848800:-
ESCA	trans	rs1552244	0.808	rs17032306	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10049715	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.872	rs7646073	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10055721	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs3895942	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10067061	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.938	rs66915020	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10068490	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.81	rs4019706	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10071178	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.872	rs6771931	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10071724	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9824585	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10073118	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6782602	ENSG00000230342.2	FANCD2P2	9.09	2.13e-15	9.72e-08	1.24	0.63	Alzheimer's disease;	chr3:10074857	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-9.09	2.16e-15	9.84e-08	-0.97	-0.63	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
ESCA	trans	rs1552244	1	rs113134644	ENSG00000230342.2	FANCD2P2	9.08	2.17e-15	9.88e-08	1.23	0.63	Alzheimer's disease;	chr3:10044602	chr3:11859674~11891172:+
ESCA	trans	rs10028773	0.666	rs12498657	ENSG00000279072.1	RP13-580B18.4	9.05	2.58e-15	1.16e-07	0.7	0.63	Educational attainment;	chr4:119341711	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.722	rs10006192	ENSG00000279072.1	RP13-580B18.4	9.05	2.58e-15	1.16e-07	0.7	0.63	Corneal astigmatism;	chr4:119341867	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.615	rs28551750	ENSG00000279072.1	RP13-580B18.4	9.05	2.58e-15	1.16e-07	0.7	0.63	Corneal astigmatism;	chr4:119343746	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs9995716	ENSG00000279072.1	RP13-580B18.4	9.05	2.58e-15	1.16e-07	0.7	0.63	Corneal astigmatism;	chr4:119343841	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs11098524	ENSG00000279072.1	RP13-580B18.4	9.04	2.71e-15	1.21e-07	0.73	0.63	Corneal astigmatism;	chr4:119468877	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.697	rs35280960	ENSG00000279072.1	RP13-580B18.4	9.04	2.77e-15	1.23e-07	0.73	0.63	Corneal astigmatism;	chr4:119335904	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.661	rs10015965	ENSG00000279072.1	RP13-580B18.4	9.04	2.84e-15	1.27e-07	0.7	0.63	Corneal astigmatism;	chr4:119347082	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1383532	ENSG00000279072.1	RP13-580B18.4	-9.03	2.99e-15	1.33e-07	-0.71	-0.63	Corneal astigmatism;	chr4:119513249	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6847248	ENSG00000279072.1	RP13-580B18.4	9.02	3.12e-15	1.38e-07	0.74	0.63	Corneal astigmatism;	chr4:119304800	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1010740	ENSG00000279072.1	RP13-580B18.4	-9.01	3.21e-15	1.42e-07	-0.7	-0.63	Corneal astigmatism;	chr4:119542254	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.69	rs34818745	ENSG00000279072.1	RP13-580B18.4	9	3.46e-15	1.51e-07	0.73	0.63	Corneal astigmatism;	chr4:119335900	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.818	rs55825515	ENSG00000279072.1	RP13-580B18.4	8.99	3.61e-15	1.58e-07	0.72	0.63	Corneal astigmatism;	chr4:119565247	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1552092	ENSG00000279072.1	RP13-580B18.4	8.99	3.61e-15	1.58e-07	0.72	0.63	Corneal astigmatism;	chr4:119567341	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs6804473	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10018741	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.938	rs7652951	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10022079	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7611218	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10022276	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.872	rs6803517	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10023742	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9834980	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10023844	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7651058	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10025280	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9845756	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10025864	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs33917318	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10026113	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032268	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10026288	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs3846177	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10026888	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs35515831	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10029678	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9881859	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10031130	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6442146	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10031860	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6442148	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10036605	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs2160869	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10037571	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9875081	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10042251	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9879080	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10042540	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9809061	ENSG00000230342.2	FANCD2P2	8.98	3.8e-15	1.63e-07	1.21	0.63	Alzheimer's disease;	chr3:10043446	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-8.98	3.82e-15	1.64e-07	-0.64	-0.63	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-8.97	4.01e-15	1.72e-07	-0.7	-0.63	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
ESCA	trans	rs11098499	0.691	rs17009144	ENSG00000279072.1	RP13-580B18.4	-8.97	4.07e-15	1.74e-07	-0.69	-0.63	Corneal astigmatism;	chr4:119349640	chr7:56809214~56848800:-
ESCA	trans	rs1552244	0.938	rs7625049	ENSG00000230342.2	FANCD2P2	8.97	4.14e-15	1.76e-07	1.23	0.63	Alzheimer's disease;	chr3:10073935	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.863	rs58452170	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119538519	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs7678400	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119540802	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1480936	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119541706	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11098531	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119543846	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs28718422	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119545149	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs12498539	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119547215	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.818	rs12498599	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119547348	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10009626	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119548850	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3822194	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119550493	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3822195	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119550505	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775854	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119550816	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs2306456	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119551267	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11947234	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119553704	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6853998	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119554705	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6858777	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119554811	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11933966	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119555560	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs36040693	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119556461	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11731756	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119557541	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs34308924	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119560276	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs2170276	ENSG00000279072.1	RP13-580B18.4	8.97	4.18e-15	1.76e-07	0.71	0.63	Corneal astigmatism;	chr4:119564669	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-8.96	4.36e-15	1.83e-07	-0.71	-0.63	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-8.96	4.36e-15	1.83e-07	-0.71	-0.63	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-8.96	4.36e-15	1.83e-07	-0.62	-0.63	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-8.96	4.36e-15	1.83e-07	-0.62	-0.63	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-8.94	4.69e-15	1.97e-07	-0.65	-0.63	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
ESCA	trans	rs11098499	0.863	rs1480940	ENSG00000279072.1	RP13-580B18.4	8.93	4.97e-15	2.08e-07	0.7	0.63	Corneal astigmatism;	chr4:119536527	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-8.92	5.35e-15	2.22e-07	-0.71	-0.63	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
ESCA	trans	rs11098499	0.863	rs13134665	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119505275	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775843	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119506689	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775844	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119506878	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3822190	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119506943	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3822191	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119506946	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs7664986	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119508797	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.818	rs10008791	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119510314	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11736416	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119510506	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775845	ENSG00000279072.1	RP13-580B18.4	8.92	5.35e-15	2.22e-07	0.71	0.63	Corneal astigmatism;	chr4:119511292	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10030660	ENSG00000279072.1	RP13-580B18.4	8.92	5.48e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119515549	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs13149407	ENSG00000279072.1	RP13-580B18.4	8.92	5.48e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119516670	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10004484	ENSG00000279072.1	RP13-580B18.4	8.92	5.48e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119521273	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1155576	ENSG00000279072.1	RP13-580B18.4	8.92	5.48e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119529004	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1383533	ENSG00000279072.1	RP13-580B18.4	8.92	5.51e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119513421	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs2291185	ENSG00000279072.1	RP13-580B18.4	8.92	5.51e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119513678	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3822192	ENSG00000279072.1	RP13-580B18.4	8.92	5.51e-15	2.27e-07	0.71	0.63	Corneal astigmatism;	chr4:119524565	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-8.91	5.54e-15	2.28e-07	-0.63	-0.63	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-8.91	5.54e-15	2.28e-07	-0.63	-0.63	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
ESCA	trans	rs11098499	0.722	rs7673476	ENSG00000279072.1	RP13-580B18.4	8.9	6.1e-15	2.51e-07	0.7	0.63	Corneal astigmatism;	chr4:119327528	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs34868248	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119521275	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3733525	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119525893	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775847	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119526487	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775848	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119526569	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10013305	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119529269	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775849	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119529753	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.818	rs7688802	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119530513	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs7695620	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119531621	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs12502389	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119533036	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.821	rs3775852	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119533401	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.82	rs6534140	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119534156	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs7657849	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119534339	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10034450	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119534494	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1480939	ENSG00000279072.1	RP13-580B18.4	8.89	6.34e-15	2.57e-07	0.7	0.63	Corneal astigmatism;	chr4:119535772	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-8.88	6.53e-15	2.65e-07	-0.97	-0.63	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.909	rs79026312	ENSG00000279072.1	RP13-580B18.4	8.88	6.71e-15	2.71e-07	0.7	0.62	Corneal astigmatism;	chr4:119519522	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs35111518	ENSG00000279072.1	RP13-580B18.4	8.88	6.71e-15	2.71e-07	0.7	0.62	Corneal astigmatism;	chr4:119519527	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000235459.5	RPS26P31	8.87	6.89e-15	2.78e-07	0.58	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.82	rs6829903	ENSG00000279072.1	RP13-580B18.4	8.87	6.98e-15	2.82e-07	0.71	0.62	Corneal astigmatism;	chr4:119585729	chr7:56809214~56848800:-
ESCA	trans	rs8081395	0.741	rs180532	ENSG00000187870.7	RNFT1P3	8.86	7.3e-15	2.94e-07	0.72	0.62	White blood cell count;	chr17:59925936	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.741	rs180530	ENSG00000187870.7	RNFT1P3	8.85	7.66e-15	3.08e-07	0.72	0.62	White blood cell count;	chr17:59926233	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.741	rs2645462	ENSG00000187870.7	RNFT1P3	8.85	7.98e-15	3.19e-07	0.72	0.62	White blood cell count;	chr17:59906198	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.711	rs1292034	ENSG00000187870.7	RNFT1P3	8.85	7.98e-15	3.19e-07	0.72	0.62	White blood cell count;	chr17:59912499	chr17:20743333~20754501:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-8.85	8.08e-15	3.22e-07	-0.66	-0.62	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-8.85	8.08e-15	3.22e-07	-0.66	-0.62	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-8.84	8.09e-15	3.22e-07	-0.72	-0.62	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
ESCA	trans	rs10028773	0.6	rs4001390	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Educational attainment;	chr4:119344628	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs2136911	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119344704	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.554	rs2175381	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119344812	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.599	rs3864142	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119345036	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.605	rs6833140	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119345667	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs6815934	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119346155	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.568	rs6838457	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Educational attainment;	chr4:119346212	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.535	rs10005542	ENSG00000279072.1	RP13-580B18.4	8.84	8.22e-15	3.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119347147	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	8.84	8.3e-15	3.29e-07	0.58	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
ESCA	trans	rs1552244	0.935	rs28815328	ENSG00000230342.2	FANCD2P2	8.82	9.17e-15	3.61e-07	1.19	0.62	Alzheimer's disease;	chr3:10020543	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs28684871	ENSG00000230342.2	FANCD2P2	8.82	9.17e-15	3.61e-07	1.19	0.62	Alzheimer's disease;	chr3:10030951	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6414438	ENSG00000230342.2	FANCD2P2	8.82	9.17e-15	3.61e-07	1.19	0.62	Alzheimer's disease;	chr3:10032140	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6442147	ENSG00000230342.2	FANCD2P2	8.82	9.17e-15	3.61e-07	1.19	0.62	Alzheimer's disease;	chr3:10036563	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.863	rs9997631	ENSG00000279072.1	RP13-580B18.4	8.81	9.83e-15	3.84e-07	0.7	0.62	Corneal astigmatism;	chr4:119548840	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs10018280	ENSG00000279072.1	RP13-580B18.4	8.81	9.83e-15	3.84e-07	0.7	0.62	Corneal astigmatism;	chr4:119556984	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6534141	ENSG00000279072.1	RP13-580B18.4	8.81	9.83e-15	3.84e-07	0.7	0.62	Corneal astigmatism;	chr4:119564068	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs2127823	ENSG00000279072.1	RP13-580B18.4	8.81	9.83e-15	3.84e-07	0.7	0.62	Corneal astigmatism;	chr4:119564515	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs3775858	ENSG00000279072.1	RP13-580B18.4	8.81	9.83e-15	3.84e-07	0.7	0.62	Corneal astigmatism;	chr4:119564873	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-8.8	1.01e-14	3.96e-07	-0.61	-0.62	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.863	rs13140391	ENSG00000279072.1	RP13-580B18.4	8.8	1.05e-14	4.08e-07	0.71	0.62	Corneal astigmatism;	chr4:119582282	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs13140409	ENSG00000279072.1	RP13-580B18.4	8.8	1.05e-14	4.08e-07	0.71	0.62	Corneal astigmatism;	chr4:119582305	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6833334	ENSG00000279072.1	RP13-580B18.4	8.8	1.05e-14	4.08e-07	0.71	0.62	Corneal astigmatism;	chr4:119583072	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs12510133	ENSG00000279072.1	RP13-580B18.4	8.8	1.05e-14	4.08e-07	0.69	0.62	Corneal astigmatism;	chr4:119350189	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs9820598	ENSG00000230342.2	FANCD2P2	8.79	1.08e-14	4.18e-07	1.21	0.62	Alzheimer's disease;	chr3:10076228	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs57631744	ENSG00000230342.2	FANCD2P2	8.79	1.08e-14	4.18e-07	1.21	0.62	Alzheimer's disease;	chr3:10077278	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.872	rs6792951	ENSG00000230342.2	FANCD2P2	8.79	1.08e-14	4.18e-07	1.21	0.62	Alzheimer's disease;	chr3:10077919	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs6805869	ENSG00000230342.2	FANCD2P2	8.79	1.08e-14	4.18e-07	1.21	0.62	Alzheimer's disease;	chr3:10078233	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs9827740	ENSG00000230342.2	FANCD2P2	8.79	1.08e-14	4.18e-07	1.21	0.62	Alzheimer's disease;	chr3:10078847	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.863	rs3775841	ENSG00000279072.1	RP13-580B18.4	8.79	1.11e-14	4.25e-07	0.7	0.62	Corneal astigmatism;	chr4:119504622	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6858592	ENSG00000279072.1	RP13-580B18.4	8.79	1.11e-14	4.26e-07	0.69	0.62	Corneal astigmatism;	chr4:119537537	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	8.79	1.12e-14	4.29e-07	0.62	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
ESCA	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	8.79	1.12e-14	4.29e-07	0.62	0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.863	rs10019674	ENSG00000279072.1	RP13-580B18.4	-8.78	1.16e-14	4.42e-07	-0.7	-0.62	Corneal astigmatism;	chr4:119522334	chr7:56809214~56848800:-
ESCA	trans	rs8081395	0.711	rs11368	ENSG00000187870.7	RNFT1P3	8.77	1.2e-14	4.58e-07	0.72	0.62	White blood cell count;	chr17:59954051	chr17:20743333~20754501:-
ESCA	trans	rs11098499	0.754	rs12506487	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350206	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs12502524	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350259	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs28396837	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350386	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.629	rs28369518	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350475	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.722	rs10025925	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350589	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.731	rs10015579	ENSG00000279072.1	RP13-580B18.4	8.77	1.22e-14	4.64e-07	0.69	0.62	Corneal astigmatism;	chr4:119350647	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.82	rs13128602	ENSG00000279072.1	RP13-580B18.4	-8.77	1.25e-14	4.75e-07	-0.7	-0.62	Corneal astigmatism;	chr4:119538211	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs59732491	ENSG00000279072.1	RP13-580B18.4	8.76	1.29e-14	4.87e-07	0.7	0.62	Corneal astigmatism;	chr4:119568433	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11723090	ENSG00000279072.1	RP13-580B18.4	8.76	1.29e-14	4.87e-07	0.7	0.62	Corneal astigmatism;	chr4:119569437	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-8.76	1.31e-14	4.95e-07	-0.67	-0.62	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.644	rs10050092	ENSG00000279072.1	RP13-580B18.4	8.76	1.32e-14	4.97e-07	0.7	0.62	Corneal astigmatism;	chr4:119610930	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1814813	ENSG00000279072.1	RP13-580B18.4	-8.75	1.37e-14	5.18e-07	-0.68	-0.62	Corneal astigmatism;	chr4:119337052	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs56270432	ENSG00000230342.2	FANCD2P2	8.75	1.39e-14	5.25e-07	1.29	0.62	Alzheimer's disease;	chr3:10045833	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-8.74	1.46e-14	5.51e-07	-0.97	-0.62	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-8.74	1.46e-14	5.51e-07	-0.97	-0.62	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-8.74	1.46e-14	5.51e-07	-0.97	-0.62	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-8.74	1.46e-14	5.51e-07	-0.97	-0.62	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-8.74	1.46e-14	5.51e-07	-0.97	-0.62	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.863	rs7669520	ENSG00000279072.1	RP13-580B18.4	8.73	1.49e-14	5.59e-07	0.7	0.62	Corneal astigmatism;	chr4:119594123	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs6789156	ENSG00000230342.2	FANCD2P2	8.73	1.49e-14	5.59e-07	1.08	0.62	Alzheimer's disease;	chr3:10082436	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.82	rs11737395	ENSG00000279072.1	RP13-580B18.4	8.72	1.6e-14	5.98e-07	0.7	0.62	Corneal astigmatism;	chr4:119599549	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-8.72	1.63e-14	6.09e-07	-0.65	-0.62	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-8.72	1.63e-14	6.09e-07	-0.65	-0.62	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	8.71	1.68e-14	6.26e-07	0.72	0.62	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
ESCA	trans	rs11098499	0.863	rs6534139	ENSG00000279072.1	RP13-580B18.4	-8.71	1.72e-14	6.39e-07	-0.72	-0.62	Corneal astigmatism;	chr4:119528301	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-8.7	1.83e-14	6.78e-07	-0.63	-0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-8.7	1.83e-14	6.78e-07	-0.63	-0.62	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-8.69	1.87e-14	6.9e-07	-0.63	-0.62	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
ESCA	trans	rs1552244	1	rs4260416	ENSG00000230342.2	FANCD2P2	8.69	1.89e-14	6.96e-07	1.13	0.62	Alzheimer's disease;	chr3:10083599	chr3:11859674~11891172:+
ESCA	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	8.69	1.91e-14	7.07e-07	0.79	0.62	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-8.69	1.92e-14	7.1e-07	-0.6	-0.62	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
ESCA	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-8.68	2.03e-14	7.5e-07	-0.51	-0.62	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
ESCA	trans	rs13177918	0.734	rs6579790	ENSG00000213058.3	RP4-765C7.2	8.67	2.05e-14	7.57e-07	0.83	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr1:178411616~178411972:+
ESCA	trans	rs13177918	0.734	rs6579791	ENSG00000213058.3	RP4-765C7.2	8.67	2.05e-14	7.57e-07	0.83	0.62	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr1:178411616~178411972:+
ESCA	trans	rs1552244	1	rs6781811	ENSG00000230342.2	FANCD2P2	-8.67	2.16e-14	7.93e-07	-1.08	-0.62	Alzheimer's disease;	chr3:10080238	chr3:11859674~11891172:+
ESCA	trans	rs916888	0.821	rs199499	ENSG00000280022.1	RP11-707O23.1	8.66	2.18e-14	8e-07	1.2	0.62	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788132	chr17:45592621~45593369:+
ESCA	trans	rs8081395	0.576	rs1292032	ENSG00000187870.7	RNFT1P3	8.66	2.24e-14	8.2e-07	0.69	0.62	White blood cell count;	chr17:59914982	chr17:20743333~20754501:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	8.66	2.28e-14	8.34e-07	0.57	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
ESCA	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-8.65	2.32e-14	8.49e-07	-0.97	-0.62	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	8.65	2.32e-14	8.49e-07	0.97	0.62	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	8.65	2.32e-14	8.49e-07	0.97	0.62	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	8.65	2.32e-14	8.49e-07	0.97	0.62	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	8.65	2.38e-14	8.68e-07	0.61	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	8.65	2.39e-14	8.73e-07	0.61	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.644	rs3986377	ENSG00000279072.1	RP13-580B18.4	8.64	2.46e-14	8.95e-07	0.69	0.61	Corneal astigmatism;	chr4:119339115	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.556	rs4473640	ENSG00000279072.1	RP13-580B18.4	8.64	2.46e-14	8.95e-07	0.69	0.61	Educational attainment;	chr4:119339282	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs7699064	ENSG00000279072.1	RP13-580B18.4	-8.63	2.6e-14	9.46e-07	-0.71	-0.61	Corneal astigmatism;	chr4:119507154	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs1552095	ENSG00000279072.1	RP13-580B18.4	8.63	2.61e-14	9.48e-07	0.72	0.61	Corneal astigmatism;	chr4:119539151	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000196656.7	AC004057.1	8.63	2.67e-14	9.69e-07	0.66	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr4:113214046~113217170:-
ESCA	trans	rs11098499	0.82	rs28394116	ENSG00000279072.1	RP13-580B18.4	8.62	2.75e-14	9.95e-07	0.7	0.61	Corneal astigmatism;	chr4:119603128	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs61077902	ENSG00000230342.2	FANCD2P2	8.62	2.79e-14	1.01e-06	1.13	0.61	Alzheimer's disease;	chr3:10084469	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	8.62	2.83e-14	1.02e-06	0.66	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
ESCA	trans	rs1552244	0.748	rs9862221	ENSG00000230342.2	FANCD2P2	8.61	2.86e-14	1.04e-06	1.26	0.61	Alzheimer's disease;	chr3:10017974	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6791810	ENSG00000230342.2	FANCD2P2	-8.61	2.99e-14	1.08e-06	-1.08	-0.61	Alzheimer's disease;	chr3:10082760	chr3:11859674~11891172:+
ESCA	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-8.6	3.06e-14	1.11e-06	-0.72	-0.61	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000196656.7	AC004057.1	8.6	3.1e-14	1.12e-06	0.66	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-8.6	3.12e-14	1.12e-06	-0.64	-0.61	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
ESCA	trans	rs1816752	0.875	rs59531061	ENSG00000237917.1	PARP4P1	8.59	3.26e-14	1.18e-06	0.77	0.61	Obesity-related traits;	chr13:24507297	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.863	rs9884402	ENSG00000279072.1	RP13-580B18.4	8.59	3.28e-14	1.18e-06	0.69	0.61	Corneal astigmatism;	chr4:119568827	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.731	rs9995026	ENSG00000279072.1	RP13-580B18.4	8.59	3.28e-14	1.18e-06	0.69	0.61	Corneal astigmatism;	chr4:119569344	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs11098532	ENSG00000279072.1	RP13-580B18.4	8.59	3.28e-14	1.18e-06	0.69	0.61	Corneal astigmatism;	chr4:119569571	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.82	rs28535956	ENSG00000279072.1	RP13-580B18.4	-8.59	3.3e-14	1.18e-06	-0.69	-0.61	Corneal astigmatism;	chr4:119615703	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	8.59	3.33e-14	1.19e-06	0.61	0.61	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
ESCA	trans	rs11098499	0.863	rs17050695	ENSG00000279072.1	RP13-580B18.4	8.58	3.37e-14	1.21e-06	0.67	0.61	Corneal astigmatism;	chr4:119568372	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs6835635	ENSG00000279072.1	RP13-580B18.4	8.58	3.37e-14	1.21e-06	0.69	0.61	Corneal astigmatism;	chr4:119537712	chr7:56809214~56848800:-
ESCA	trans	rs8081395	0.737	rs4968401	ENSG00000187870.7	RNFT1P3	-8.58	3.4e-14	1.22e-06	-0.71	-0.61	White blood cell count;	chr17:59963369	chr17:20743333~20754501:-
ESCA	trans	rs11098499	0.863	rs2306457	ENSG00000279072.1	RP13-580B18.4	8.58	3.51e-14	1.25e-06	0.71	0.61	Corneal astigmatism;	chr4:119551684	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	8.57	3.62e-14	1.29e-06	0.97	0.61	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	8.57	3.62e-14	1.29e-06	0.97	0.61	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	8.57	3.62e-14	1.29e-06	0.97	0.61	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
ESCA	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-8.57	3.67e-14	1.31e-06	-0.77	-0.61	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
ESCA	trans	rs11098499	0.691	rs10010355	ENSG00000279072.1	RP13-580B18.4	8.57	3.67e-14	1.31e-06	0.68	0.61	Corneal astigmatism;	chr4:119339888	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.691	rs9307471	ENSG00000279072.1	RP13-580B18.4	8.57	3.67e-14	1.31e-06	0.68	0.61	Corneal astigmatism;	chr4:119340107	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs2389880	ENSG00000279072.1	RP13-580B18.4	8.56	3.82e-14	1.36e-06	0.69	0.61	Corneal astigmatism;	chr4:119638715	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.675	rs11098534	ENSG00000279072.1	RP13-580B18.4	8.56	3.83e-14	1.36e-06	0.69	0.61	Corneal astigmatism;	chr4:119635617	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	8.56	3.93e-14	1.39e-06	0.77	0.61	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
ESCA	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-8.54	4.24e-14	1.5e-06	-0.92	-0.61	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.57	rs6832740	ENSG00000279072.1	RP13-580B18.4	8.54	4.28e-14	1.51e-06	0.7	0.61	Corneal astigmatism;	chr4:119624981	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs6855918	ENSG00000279072.1	RP13-580B18.4	8.54	4.28e-14	1.51e-06	0.7	0.61	Corneal astigmatism;	chr4:119625144	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs55822690	ENSG00000230342.2	FANCD2P2	8.54	4.3e-14	1.52e-06	1.12	0.61	Alzheimer's disease;	chr3:10086319	chr3:11859674~11891172:+
ESCA	trans	rs8081395	0.741	rs180519	ENSG00000187870.7	RNFT1P3	8.54	4.33e-14	1.53e-06	0.71	0.61	White blood cell count;	chr17:59938910	chr17:20743333~20754501:-
ESCA	trans	rs11098499	0.731	rs6846966	ENSG00000279072.1	RP13-580B18.4	8.52	4.79e-14	1.68e-06	0.68	0.61	Corneal astigmatism;	chr4:119372053	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs6847778	ENSG00000279072.1	RP13-580B18.4	8.52	4.79e-14	1.68e-06	0.68	0.61	Corneal astigmatism;	chr4:119372427	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-8.51	4.93e-14	1.73e-06	-0.64	-0.61	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
ESCA	trans	rs11098499	0.866	rs3756156	ENSG00000279072.1	RP13-580B18.4	8.5	5.22e-14	1.83e-06	0.69	0.61	Corneal astigmatism;	chr4:119603686	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	8.5	5.29e-14	1.85e-06	0.95	0.61	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	8.5	5.35e-14	1.87e-06	0.96	0.61	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.874	rs13139045	ENSG00000279072.1	RP13-580B18.4	8.49	5.45e-14	1.91e-06	0.69	0.61	Corneal astigmatism;	chr4:119247433	chr7:56809214~56848800:-
ESCA	trans	rs1552244	0.935	rs35586456	ENSG00000230342.2	FANCD2P2	8.49	5.58e-14	1.95e-06	1.19	0.61	Alzheimer's disease;	chr3:10075254	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-8.49	5.74e-14	2e-06	-0.6	-0.61	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
ESCA	trans	rs11098499	0.866	rs10518329	ENSG00000279072.1	RP13-580B18.4	8.48	6.03e-14	2.09e-06	0.67	0.61	Corneal astigmatism;	chr4:119480680	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs7665125	ENSG00000279072.1	RP13-580B18.4	8.47	6.1e-14	2.12e-06	0.67	0.61	Corneal astigmatism;	chr4:119480924	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.615	rs59867181	ENSG00000279072.1	RP13-580B18.4	-8.47	6.38e-14	2.21e-06	-0.7	-0.61	Corneal astigmatism;	chr4:119635312	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-8.46	6.59e-14	2.27e-06	-0.62	-0.61	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-8.46	6.59e-14	2.27e-06	-0.62	-0.61	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
ESCA	trans	rs11098499	0.644	rs7693919	ENSG00000279072.1	RP13-580B18.4	8.46	6.6e-14	2.27e-06	0.69	0.61	Corneal astigmatism;	chr4:119619416	chr7:56809214~56848800:-
ESCA	trans	rs8081395	0.707	rs1024637	ENSG00000187870.7	RNFT1P3	-8.45	6.78e-14	2.33e-06	-0.7	-0.61	White blood cell count;	chr17:59961532	chr17:20743333~20754501:-
ESCA	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	8.45	6.8e-14	2.34e-06	0.61	0.61	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
ESCA	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	8.45	6.82e-14	2.34e-06	0.97	0.61	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	8.45	6.84e-14	2.35e-06	0.59	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
ESCA	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	8.45	6.89e-14	2.37e-06	0.96	0.61	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.82	rs2389885	ENSG00000279072.1	RP13-580B18.4	8.45	6.92e-14	2.37e-06	0.68	0.61	Corneal astigmatism;	chr4:119612776	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs34835603	ENSG00000279072.1	RP13-580B18.4	8.45	7.08e-14	2.43e-06	0.69	0.61	Corneal astigmatism;	chr4:119632273	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.615	rs28850368	ENSG00000279072.1	RP13-580B18.4	8.45	7.08e-14	2.43e-06	0.69	0.61	Corneal astigmatism;	chr4:119633158	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs28787668	ENSG00000279072.1	RP13-580B18.4	8.45	7.08e-14	2.43e-06	0.69	0.61	Corneal astigmatism;	chr4:119633532	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs7676296	ENSG00000279072.1	RP13-580B18.4	8.45	7.08e-14	2.43e-06	0.69	0.61	Corneal astigmatism;	chr4:119634532	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000204652.6	RPS26P8	8.43	7.74e-14	2.65e-06	0.59	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr17:45608571~45608918:+
ESCA	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	8.43	7.81e-14	2.65e-06	0.96	0.61	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
ESCA	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	8.42	8.02e-14	2.71e-06	0.61	0.6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
ESCA	trans	rs8081395	0.729	rs12453125	ENSG00000187870.7	RNFT1P3	-8.42	8.27e-14	2.8e-06	-0.73	-0.6	White blood cell count;	chr17:59968715	chr17:20743333~20754501:-
ESCA	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-8.42	8.3e-14	2.81e-06	-0.68	-0.6	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
ESCA	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	8.42	8.31e-14	2.81e-06	0.96	0.6	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	8.42	8.33e-14	2.81e-06	0.66	0.6	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
ESCA	trans	rs11098499	0.644	rs3806808	ENSG00000279072.1	RP13-580B18.4	8.4	8.89e-14	2.99e-06	0.69	0.6	Corneal astigmatism;	chr4:119629930	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.698	rs4422403	ENSG00000279072.1	RP13-580B18.4	8.4	9.04e-14	3.04e-06	0.66	0.6	Corneal astigmatism;	chr4:119337039	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.569	rs10023641	ENSG00000279072.1	RP13-580B18.4	8.4	9.04e-14	3.04e-06	0.66	0.6	Corneal astigmatism;	chr4:119337255	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	8.4	9.08e-14	3.05e-06	0.57	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
ESCA	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-8.4	9.13e-14	3.07e-06	-0.72	-0.6	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.644	rs10012252	ENSG00000279072.1	RP13-580B18.4	8.39	9.5e-14	3.2e-06	0.68	0.6	Corneal astigmatism;	chr4:119637984	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	8.39	9.62e-14	3.23e-06	0.97	0.6	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.954	rs6857105	ENSG00000279072.1	RP13-580B18.4	8.39	9.74e-14	3.26e-06	0.72	0.6	Corneal astigmatism;	chr4:119301143	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000233278.1	RPS26P2	8.38	1.01e-13	3.37e-06	0.68	0.6	Cognitive function;	chr12:56076841	chr9:30831878~30832225:-
ESCA	trans	rs1552244	0.872	rs115331527	ENSG00000230342.2	FANCD2P2	8.38	1.02e-13	3.4e-06	1.27	0.6	Alzheimer's disease;	chr3:10112820	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs67852463	ENSG00000230342.2	FANCD2P2	8.38	1.02e-13	3.4e-06	1.27	0.6	Alzheimer's disease;	chr3:10115521	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.588	rs2389874	ENSG00000279072.1	RP13-580B18.4	-8.37	1.05e-13	3.5e-06	-0.7	-0.6	Corneal astigmatism;	chr4:119633836	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.562	rs13101722	ENSG00000279072.1	RP13-580B18.4	-8.37	1.05e-13	3.5e-06	-0.7	-0.6	Corneal astigmatism;	chr4:119634820	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.78	rs10013652	ENSG00000279072.1	RP13-580B18.4	8.37	1.09e-13	3.64e-06	0.67	0.6	Corneal astigmatism;	chr4:119371101	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.82	rs28578366	ENSG00000279072.1	RP13-580B18.4	-8.36	1.11e-13	3.69e-06	-0.67	-0.6	Corneal astigmatism;	chr4:119615750	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-8.36	1.13e-13	3.77e-06	-0.67	-0.6	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
ESCA	trans	rs8081395	0.741	rs1292056	ENSG00000187870.7	RNFT1P3	8.36	1.15e-13	3.81e-06	0.69	0.6	White blood cell count;	chr17:59881686	chr17:20743333~20754501:-
ESCA	trans	rs11098499	0.691	rs10028773	ENSG00000279072.1	RP13-580B18.4	-8.34	1.24e-13	4.1e-06	-0.66	-0.6	Corneal astigmatism;	chr4:119344104	chr7:56809214~56848800:-
ESCA	trans	rs8081395	0.741	rs180520	ENSG00000187870.7	RNFT1P3	8.34	1.26e-13	4.19e-06	0.7	0.6	White blood cell count;	chr17:59937788	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.775	rs2526355	ENSG00000187870.7	RNFT1P3	8.33	1.29e-13	4.29e-06	0.67	0.6	White blood cell count;	chr17:59875872	chr17:20743333~20754501:-
ESCA	trans	rs1292048	1	rs1292048	ENSG00000187870.7	RNFT1P3	8.33	1.29e-13	4.29e-06	0.67	0.6	Red cell distribution width;	chr17:59877710	chr17:20743333~20754501:-
ESCA	trans	rs13177918	0.717	rs6874318	ENSG00000213058.3	RP4-765C7.2	-8.32	1.39e-13	4.53e-06	-0.81	-0.6	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150462836	chr1:178411616~178411972:+
ESCA	trans	rs11098499	0.738	rs28687057	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119359657	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.775	rs67281037	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119360002	chr7:56809214~56848800:-
ESCA	trans	rs10028773	0.506	rs12374346	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Educational attainment;	chr4:119360550	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs12374244	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119360817	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs12374352	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119360822	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.775	rs10021601	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119361408	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs6857892	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119361541	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.909	rs28581362	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119362393	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.82	rs12503082	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119363162	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs12499602	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119363232	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.774	rs11098505	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119363472	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs11098506	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119363816	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs13105020	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119364533	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs6824111	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119364813	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.779	rs10857066	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119365441	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.775	rs10029303	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119365600	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs9995136	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119365690	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.687	rs71610270	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119366281	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs13125526	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119366864	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs12513310	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119366884	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.564	rs11098507	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119367131	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs12510451	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119367988	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.774	rs73842616	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119369528	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.645	rs72676059	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119369673	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.569	rs55845118	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119369758	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs7677068	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119370549	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.866	rs9991221	ENSG00000279072.1	RP13-580B18.4	8.32	1.39e-13	4.53e-06	0.66	0.6	Corneal astigmatism;	chr4:119370952	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.644	rs10009566	ENSG00000279072.1	RP13-580B18.4	8.32	1.41e-13	4.57e-06	0.67	0.6	Corneal astigmatism;	chr4:119637453	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	8.32	1.43e-13	4.65e-06	0.65	0.6	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
ESCA	trans	rs8081395	0.741	rs1292055	ENSG00000187870.7	RNFT1P3	8.3	1.53e-13	4.95e-06	0.69	0.6	White blood cell count;	chr17:59881707	chr17:20743333~20754501:-
ESCA	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-8.29	1.61e-13	5.21e-06	-0.93	-0.6	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
ESCA	trans	rs1552244	1	rs35741213	ENSG00000230342.2	FANCD2P2	8.29	1.63e-13	5.27e-06	1.29	0.6	Alzheimer's disease;	chr3:10045977	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.78	rs7692994	ENSG00000279072.1	RP13-580B18.4	8.29	1.64e-13	5.3e-06	0.66	0.6	Corneal astigmatism;	chr4:119506334	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.562	rs2389879	ENSG00000279072.1	RP13-580B18.4	-8.28	1.71e-13	5.5e-06	-0.68	-0.6	Corneal astigmatism;	chr4:119636529	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.588	rs6534149	ENSG00000279072.1	RP13-580B18.4	-8.28	1.71e-13	5.5e-06	-0.68	-0.6	Corneal astigmatism;	chr4:119638137	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-8.27	1.84e-13	5.9e-06	-0.93	-0.6	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-8.27	1.88e-13	6.05e-06	-0.94	-0.6	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-8.27	1.88e-13	6.05e-06	-0.94	-0.6	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000204652.6	RPS26P8	8.26	1.9e-13	6.09e-06	0.58	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:45608571~45608918:+
ESCA	trans	rs1552244	1	rs7626117	ENSG00000230342.2	FANCD2P2	8.26	1.92e-13	6.15e-06	1	0.6	Alzheimer's disease;	chr3:10098987	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	8.26	1.95e-13	6.24e-06	0.59	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
ESCA	trans	rs1552244	1	rs2272123	ENSG00000230342.2	FANCD2P2	8.26	1.99e-13	6.37e-06	1.15	0.6	Alzheimer's disease;	chr3:10098431	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs58275763	ENSG00000230342.2	FANCD2P2	8.26	1.99e-13	6.37e-06	1.15	0.6	Alzheimer's disease;	chr3:10101590	chr3:11859674~11891172:+
ESCA	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	8.25	2.09e-13	6.65e-06	0.95	0.6	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-8.23	2.3e-13	7.3e-06	-0.93	-0.6	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-8.23	2.3e-13	7.3e-06	-0.93	-0.6	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	8.23	2.34e-13	7.43e-06	0.64	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
ESCA	trans	rs11098499	1	rs1011054	ENSG00000279072.1	RP13-580B18.4	-8.22	2.47e-13	7.83e-06	-0.69	-0.6	Corneal astigmatism;	chr4:119281232	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-8.21	2.6e-13	8.23e-06	-0.59	-0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
ESCA	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	8.2	2.61e-13	8.23e-06	0.76	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
ESCA	trans	rs1552244	1	rs6764068	ENSG00000230342.2	FANCD2P2	8.2	2.61e-13	8.23e-06	1.24	0.59	Alzheimer's disease;	chr3:10112158	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs113522867	ENSG00000230342.2	FANCD2P2	8.2	2.61e-13	8.23e-06	1.24	0.59	Alzheimer's disease;	chr3:10112819	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs113153120	ENSG00000230342.2	FANCD2P2	8.2	2.61e-13	8.23e-06	1.24	0.59	Alzheimer's disease;	chr3:10114714	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs112509186	ENSG00000230342.2	FANCD2P2	8.2	2.61e-13	8.23e-06	1.24	0.59	Alzheimer's disease;	chr3:10114849	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-8.2	2.65e-13	8.35e-06	-0.92	-0.59	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.562	rs58583086	ENSG00000279072.1	RP13-580B18.4	-8.2	2.7e-13	8.5e-06	-0.68	-0.59	Corneal astigmatism;	chr4:119635207	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-8.19	2.81e-13	8.82e-06	-0.61	-0.59	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-8.19	2.81e-13	8.82e-06	-0.61	-0.59	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	8.19	2.81e-13	8.83e-06	0.6	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
ESCA	trans	rs1552244	1	rs12374115	ENSG00000230342.2	FANCD2P2	-8.19	2.86e-13	8.99e-06	-1.09	-0.59	Alzheimer's disease;	chr3:10093082	chr3:11859674~11891172:+
ESCA	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	8.18	2.96e-13	9.26e-06	0.51	0.59	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
ESCA	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-8.17	3.08e-13	9.65e-06	-0.94	-0.59	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-8.17	3.08e-13	9.65e-06	-0.94	-0.59	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
ESCA	trans	rs8081395	0.741	rs1292051	ENSG00000187870.7	RNFT1P3	8.16	3.29e-13	1.03e-05	0.68	0.59	White blood cell count;	chr17:59886562	chr17:20743333~20754501:-
ESCA	trans	rs1552244	0.938	rs9873794	ENSG00000230342.2	FANCD2P2	8.16	3.3e-13	1.03e-05	1.14	0.59	Alzheimer's disease;	chr3:10032469	chr3:11859674~11891172:+
ESCA	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	8.15	3.45e-13	1.07e-05	0.49	0.59	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.863	rs13136462	ENSG00000279072.1	RP13-580B18.4	8.15	3.53e-13	1.1e-05	0.68	0.59	Corneal astigmatism;	chr4:119622018	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs67006488	ENSG00000230342.2	FANCD2P2	8.15	3.57e-13	1.11e-05	1.25	0.59	Alzheimer's disease;	chr3:10111309	chr3:11859674~11891172:+
ESCA	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	8.14	3.66e-13	1.14e-05	0.72	0.59	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
ESCA	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	8.14	3.72e-13	1.15e-05	0.76	0.59	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-8.14	3.73e-13	1.16e-05	-0.67	-0.59	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-8.14	3.73e-13	1.16e-05	-0.67	-0.59	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
ESCA	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	8.14	3.79e-13	1.17e-05	0.75	0.59	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
ESCA	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-8.12	4.23e-13	1.3e-05	-0.93	-0.59	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
ESCA	trans	rs1552244	1	rs13433680	ENSG00000230342.2	FANCD2P2	8.11	4.23e-13	1.3e-05	1.15	0.59	Alzheimer's disease;	chr3:10094706	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032396	ENSG00000230342.2	FANCD2P2	-8.11	4.34e-13	1.33e-05	-1.27	-0.59	Alzheimer's disease;	chr3:10111875	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-8.11	4.41e-13	1.35e-05	-0.62	-0.59	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.82	rs13122709	ENSG00000279072.1	RP13-580B18.4	8.09	4.82e-13	1.47e-05	0.67	0.59	Corneal astigmatism;	chr4:119634201	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-8.09	4.84e-13	1.48e-05	-0.89	-0.59	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-8.09	4.85e-13	1.48e-05	-0.65	-0.59	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
ESCA	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-8.09	4.9e-13	1.49e-05	-0.91	-0.59	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-8.09	4.9e-13	1.49e-05	-0.91	-0.59	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-8.08	5.01e-13	1.53e-05	-0.93	-0.59	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
ESCA	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	8.08	5.08e-13	1.55e-05	0.59	0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-8.07	5.33e-13	1.62e-05	-0.68	-0.59	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
ESCA	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-8.06	5.64e-13	1.71e-05	-0.93	-0.59	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-8.06	5.77e-13	1.75e-05	-0.92	-0.59	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
ESCA	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-8.05	5.95e-13	1.8e-05	-0.58	-0.59	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
ESCA	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	8.05	6.08e-13	1.84e-05	0.62	0.59	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
ESCA	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	8.05	6.13e-13	1.85e-05	0.91	0.59	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	8.04	6.22e-13	1.88e-05	0.96	0.59	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	8.04	6.48e-13	1.95e-05	0.64	0.59	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
ESCA	trans	rs1552244	1	rs6772315	ENSG00000230342.2	FANCD2P2	8.03	6.54e-13	1.97e-05	1.28	0.59	Alzheimer's disease;	chr3:10071960	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-8.03	6.54e-13	1.97e-05	-0.92	-0.59	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.603	rs9551099	ENSG00000237917.1	PARP4P1	-8.03	6.55e-13	1.97e-05	-0.77	-0.59	Obesity-related traits;	chr13:24410978	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-8.03	6.8e-13	2.04e-05	-0.59	-0.59	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
ESCA	trans	rs11098499	0.78	rs12504773	ENSG00000279072.1	RP13-580B18.4	8.02	6.91e-13	2.07e-05	0.67	0.59	Corneal astigmatism;	chr4:119640994	chr7:56809214~56848800:-
ESCA	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	8.02	7.04e-13	2.11e-05	0.54	0.59	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
ESCA	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	8.02	7.05e-13	2.12e-05	0.77	0.59	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
ESCA	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-8.01	7.28e-13	2.17e-05	-0.92	-0.59	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
ESCA	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	8.01	7.34e-13	2.18e-05	0.59	0.59	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
ESCA	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-8	7.8e-13	2.31e-05	-0.92	-0.59	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-8	7.8e-13	2.31e-05	-0.92	-0.59	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
ESCA	trans	rs1552244	0.938	rs34750074	ENSG00000230342.2	FANCD2P2	7.99	8.2e-13	2.42e-05	1.28	0.58	Alzheimer's disease;	chr3:10050056	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-7.99	8.29e-13	2.45e-05	-0.9	-0.58	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
ESCA	trans	rs1552244	0.872	rs35988239	ENSG00000230342.2	FANCD2P2	7.99	8.31e-13	2.45e-05	1.44	0.58	Alzheimer's disease;	chr3:10032461	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs7649243	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10047786	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7615646	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10048089	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs7652190	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10063466	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7619340	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10066494	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6793396	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10069243	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs7621551	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10072521	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6764168	ENSG00000230342.2	FANCD2P2	7.99	8.36e-13	2.46e-05	1.27	0.58	Alzheimer's disease;	chr3:10082121	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	7.98	8.57e-13	2.52e-05	0.56	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
ESCA	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
ESCA	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	7.97	8.99e-13	2.62e-05	0.95	0.58	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.78	rs7680914	ENSG00000279072.1	RP13-580B18.4	7.97	9.1e-13	2.66e-05	0.67	0.58	Corneal astigmatism;	chr4:119641898	chr7:56809214~56848800:-
ESCA	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-7.97	9.18e-13	2.68e-05	-0.63	-0.58	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
ESCA	trans	rs66887589	0.616	rs11098497	ENSG00000279072.1	RP13-580B18.4	7.97	9.39e-13	2.73e-05	0.67	0.58	Diastolic blood pressure;	chr4:119265913	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs11098498	ENSG00000279072.1	RP13-580B18.4	7.97	9.39e-13	2.73e-05	0.67	0.58	Diastolic blood pressure;	chr4:119265964	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs10032299	ENSG00000279072.1	RP13-580B18.4	7.97	9.39e-13	2.73e-05	0.67	0.58	Diastolic blood pressure;	chr4:119285264	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs7659403	ENSG00000279072.1	RP13-580B18.4	7.97	9.39e-13	2.73e-05	0.67	0.58	Diastolic blood pressure;	chr4:119286099	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000234513.1	AC073072.7	7.96	9.49e-13	2.75e-05	0.56	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:22773646~22773993:-
ESCA	trans	rs11098499	0.954	rs13145352	ENSG00000279072.1	RP13-580B18.4	-7.96	9.59e-13	2.78e-05	-0.69	-0.58	Corneal astigmatism;	chr4:119488808	chr7:56809214~56848800:-
ESCA	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	7.96	9.65e-13	2.8e-05	0.78	0.58	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-7.96	9.72e-13	2.82e-05	-0.63	-0.58	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
ESCA	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	7.96	9.85e-13	2.85e-05	0.9	0.58	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	7.96	9.85e-13	2.85e-05	0.9	0.58	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	7.96	9.85e-13	2.85e-05	0.9	0.58	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	7.96	9.93e-13	2.87e-05	0.56	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
ESCA	trans	rs1552244	1	rs35993975	ENSG00000230342.2	FANCD2P2	7.95	1e-12	2.9e-05	1.35	0.58	Alzheimer's disease;	chr3:10026110	chr3:11859674~11891172:+
ESCA	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	7.95	1.03e-12	2.97e-05	0.57	0.58	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
ESCA	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-7.95	1.05e-12	3.02e-05	-0.74	-0.58	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
ESCA	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	7.94	1.06e-12	3.04e-05	0.93	0.58	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	7.94	1.06e-12	3.04e-05	0.93	0.58	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.73	rs78971550	ENSG00000279072.1	RP13-580B18.4	7.94	1.07e-12	3.06e-05	0.65	0.58	Corneal astigmatism;	chr4:119359886	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.645	rs78422072	ENSG00000279072.1	RP13-580B18.4	7.94	1.07e-12	3.06e-05	0.65	0.58	Corneal astigmatism;	chr4:119359887	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.603	rs2343806	ENSG00000213058.3	RP4-765C7.2	7.94	1.08e-12	3.1e-05	0.76	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:178411616~178411972:+
ESCA	trans	rs11098499	0.863	rs1010739	ENSG00000279072.1	RP13-580B18.4	7.93	1.12e-12	3.2e-05	0.64	0.58	Corneal astigmatism;	chr4:119542316	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.626	rs2748240	ENSG00000224114.1	RP11-343H5.4	7.93	1.12e-12	3.22e-05	0.69	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:206695837~206696269:-
ESCA	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	7.93	1.13e-12	3.23e-05	0.76	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
ESCA	trans	rs1552244	0.938	rs67667957	ENSG00000230342.2	FANCD2P2	7.93	1.13e-12	3.25e-05	1.11	0.58	Alzheimer's disease;	chr3:10125580	chr3:11859674~11891172:+
ESCA	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-7.93	1.14e-12	3.26e-05	-0.49	-0.58	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
ESCA	trans	rs1552244	1	rs17032295	ENSG00000230342.2	FANCD2P2	7.93	1.14e-12	3.28e-05	1.05	0.58	Alzheimer's disease;	chr3:10044996	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	7.93	1.15e-12	3.3e-05	0.92	0.58	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
ESCA	trans	rs8081395	0.741	rs1292053	ENSG00000187870.7	RNFT1P3	-7.92	1.2e-12	3.42e-05	-0.64	-0.58	White blood cell count;	chr17:59886176	chr17:20743333~20754501:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-7.92	1.21e-12	3.44e-05	-0.66	-0.58	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
ESCA	trans	rs1552244	0.81	rs7612908	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10047464	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.81	rs6809572	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10058461	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs112847840	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10059968	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs722509	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10060693	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs35198334	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10062869	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6786638	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10076391	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs6442150	ENSG00000230342.2	FANCD2P2	7.91	1.29e-12	3.65e-05	1.26	0.58	Alzheimer's disease;	chr3:10080891	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	7.9	1.35e-12	3.79e-05	0.62	0.58	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
ESCA	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-7.9	1.36e-12	3.81e-05	-0.89	-0.58	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
ESCA	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	7.9	1.37e-12	3.84e-05	0.55	0.58	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
ESCA	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-7.89	1.43e-12	4.02e-05	-0.49	-0.58	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-7.89	1.44e-12	4.03e-05	-0.49	-0.58	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
ESCA	trans	rs66887589	0.616	rs11731675	ENSG00000279072.1	RP13-580B18.4	7.88	1.45e-12	4.05e-05	0.66	0.58	Diastolic blood pressure;	chr4:119291359	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs1052633	ENSG00000279072.1	RP13-580B18.4	7.88	1.45e-12	4.05e-05	0.66	0.58	Diastolic blood pressure;	chr4:119294159	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.592	rs2175383	ENSG00000279072.1	RP13-580B18.4	7.88	1.45e-12	4.05e-05	0.66	0.58	Diastolic blood pressure;	chr4:119294681	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs6822808	ENSG00000279072.1	RP13-580B18.4	7.88	1.45e-12	4.05e-05	0.66	0.58	Diastolic blood pressure;	chr4:119296210	chr7:56809214~56848800:-
ESCA	trans	rs1552244	1	rs7648104	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10031627	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs113771705	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10034299	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs111392584	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10034307	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032276	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10035291	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032277	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10035339	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs17032278	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10036271	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs66797209	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10036842	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7631678	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10037132	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7637888	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10039038	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7615764	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10040908	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs35220123	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10041485	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs4441636	ENSG00000230342.2	FANCD2P2	7.88	1.47e-12	4.09e-05	1.26	0.58	Alzheimer's disease;	chr3:10042192	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	7.88	1.48e-12	4.1e-05	0.93	0.58	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
ESCA	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	7.88	1.49e-12	4.12e-05	0.75	0.58	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
ESCA	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	7.88	1.49e-12	4.12e-05	0.75	0.58	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
ESCA	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	7.88	1.49e-12	4.12e-05	0.75	0.58	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
ESCA	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	7.88	1.49e-12	4.12e-05	0.75	0.58	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
ESCA	trans	rs8081395	0.801	rs2665404	ENSG00000187870.7	RNFT1P3	7.88	1.52e-12	4.21e-05	0.69	0.58	White blood cell count;	chr17:59798035	chr17:20743333~20754501:-
ESCA	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	7.87	1.53e-12	4.23e-05	0.58	0.58	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000233278.1	RPS26P2	7.87	1.56e-12	4.31e-05	0.6	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr9:30831878~30832225:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000233278.1	RPS26P2	7.87	1.56e-12	4.31e-05	0.6	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:30831878~30832225:-
ESCA	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-7.86	1.62e-12	4.46e-05	-0.49	-0.58	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-7.86	1.62e-12	4.46e-05	-0.49	-0.58	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-7.85	1.7e-12	4.68e-05	-0.63	-0.58	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
ESCA	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	7.85	1.75e-12	4.82e-05	0.92	0.58	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-7.85	1.77e-12	4.86e-05	-0.62	-0.58	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
ESCA	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-7.84	1.81e-12	4.97e-05	-0.63	-0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
ESCA	trans	rs13177918	0.603	rs2748241	ENSG00000224114.1	RP11-343H5.4	7.84	1.87e-12	5.12e-05	0.69	0.58	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:206695837~206696269:-
ESCA	trans	rs8081395	0.836	rs2150879	ENSG00000187870.7	RNFT1P3	-7.83	1.89e-12	5.17e-05	-0.7	-0.58	White blood cell count;	chr17:59781849	chr17:20743333~20754501:-
ESCA	trans	rs66887589	0.616	rs6843509	ENSG00000279072.1	RP13-580B18.4	7.83	1.91e-12	5.23e-05	0.66	0.58	Diastolic blood pressure;	chr4:119299041	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000243403.1	RP11-330L19.1	7.83	1.96e-12	5.37e-05	0.55	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr15:64592979~64593326:+
ESCA	trans	rs66887589	0.72	rs11724758	ENSG00000279072.1	RP13-580B18.4	7.82	2e-12	5.46e-05	0.65	0.58	Diastolic blood pressure;	chr4:119318723	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	7.81	2.19e-12	5.98e-05	0.86	0.58	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000233278.1	RPS26P2	7.81	2.2e-12	6.01e-05	0.6	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:30831878~30832225:-
ESCA	trans	rs8081395	0.801	rs2777895	ENSG00000187870.7	RNFT1P3	-7.79	2.36e-12	6.42e-05	-0.69	-0.57	White blood cell count;	chr17:59802249	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.769	rs12449331	ENSG00000187870.7	RNFT1P3	-7.79	2.36e-12	6.42e-05	-0.69	-0.57	White blood cell count;	chr17:59806285	chr17:20743333~20754501:-
ESCA	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-7.78	2.48e-12	6.73e-05	-0.89	-0.57	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-7.78	2.48e-12	6.73e-05	-0.89	-0.57	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-7.77	2.6e-12	7.05e-05	-0.58	-0.57	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
ESCA	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	7.77	2.62e-12	7.1e-05	0.72	0.57	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	7.77	2.64e-12	7.17e-05	0.54	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
ESCA	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	7.75	2.89e-12	7.81e-05	0.75	0.57	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
ESCA	trans	rs1816752	0.669	rs9553309	ENSG00000237917.1	PARP4P1	-7.75	2.9e-12	7.85e-05	-0.75	-0.57	Obesity-related traits;	chr13:24471476	chrY:26594851~26634652:-
ESCA	trans	rs8081395	0.801	rs12938273	ENSG00000187870.7	RNFT1P3	-7.75	3.02e-12	8.14e-05	-0.7	-0.57	White blood cell count;	chr17:59824291	chr17:20743333~20754501:-
ESCA	trans	rs8081395	0.836	rs1292061	ENSG00000187870.7	RNFT1P3	-7.75	3.02e-12	8.14e-05	-0.7	-0.57	White blood cell count;	chr17:59833869	chr17:20743333~20754501:-
ESCA	trans	rs66887589	0.72	rs2036858	ENSG00000279072.1	RP13-580B18.4	7.75	3.03e-12	8.17e-05	0.64	0.57	Diastolic blood pressure;	chr4:119328082	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.73	rs12505735	ENSG00000279072.1	RP13-580B18.4	7.74	3.05e-12	8.23e-05	0.65	0.57	Corneal astigmatism;	chr4:119611801	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.566	rs7664440	ENSG00000279072.1	RP13-580B18.4	7.74	3.12e-12	8.4e-05	0.66	0.57	Corneal astigmatism;	chr4:119657385	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.604	rs12642411	ENSG00000279072.1	RP13-580B18.4	7.74	3.12e-12	8.4e-05	0.66	0.57	Corneal astigmatism;	chr4:119659370	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000233278.1	RPS26P2	-7.74	3.14e-12	8.44e-05	-0.64	-0.57	Cognitive function;	chr12:56080024	chr9:30831878~30832225:-
ESCA	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-7.74	3.15e-12	8.46e-05	-0.49	-0.57	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-7.74	3.15e-12	8.46e-05	-0.49	-0.57	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-7.74	3.15e-12	8.46e-05	-0.49	-0.57	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-7.74	3.15e-12	8.46e-05	-0.49	-0.57	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000233278.1	RPS26P2	-7.73	3.24e-12	8.7e-05	-0.63	-0.57	Cognitive function;	chr12:56084218	chr9:30831878~30832225:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000233278.1	RPS26P2	-7.73	3.24e-12	8.7e-05	-0.63	-0.57	Cognitive function;	chr12:56084874	chr9:30831878~30832225:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-7.73	3.26e-12	8.74e-05	-0.72	-0.57	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
ESCA	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	7.73	3.32e-12	8.89e-05	0.89	0.57	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.954	rs1480931	ENSG00000276997.3	RP11-378J18.9	7.72	3.52e-12	9.41e-05	0.65	0.57	Corneal astigmatism;	chr4:119474654	chr1:222477252~222504622:-
ESCA	trans	rs2950393	0.777	rs7966391	ENSG00000121089.4	NACA3P	7.72	3.54e-12	9.47e-05	0.48	0.57	Platelet distribution width;	chr12:56745272	chr4:164943290~164943937:+
ESCA	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	7.71	3.56e-12	9.49e-05	0.6	0.57	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
ESCA	trans	rs11098499	0.604	rs2389886	ENSG00000279072.1	RP13-580B18.4	7.71	3.63e-12	9.69e-05	0.64	0.57	Corneal astigmatism;	chr4:119649267	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000243403.1	RP11-330L19.1	7.71	3.64e-12	9.7e-05	0.54	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr15:64592979~64593326:+
ESCA	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-7.7	3.78e-12	1e-04	-0.87	-0.57	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-7.7	3.78e-12	1e-04	-0.87	-0.57	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-7.7	3.78e-12	1e-04	-0.87	-0.57	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-7.7	3.78e-12	1e-04	-0.87	-0.57	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
ESCA	trans	rs13177918	0.603	rs2343806	ENSG00000224114.1	RP11-343H5.4	7.7	3.78e-12	0.000101	0.7	0.57	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr1:206695837~206696269:-
ESCA	trans	rs66887589	0.592	rs28580295	ENSG00000279072.1	RP13-580B18.4	7.7	3.85e-12	0.000102	0.63	0.57	Diastolic blood pressure;	chr4:119357718	chr7:56809214~56848800:-
ESCA	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	7.69	4.07e-12	0.000108	0.76	0.57	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.722	rs1814814	ENSG00000279072.1	RP13-580B18.4	7.69	4.11e-12	0.000109	0.62	0.57	Corneal astigmatism;	chr4:119336969	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	7.68	4.28e-12	0.000113	0.55	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
ESCA	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	7.67	4.39e-12	0.000116	0.75	0.57	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	7.67	4.44e-12	0.000117	0.61	0.57	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-7.67	4.56e-12	0.00012	-0.64	-0.57	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
ESCA	trans	rs8081395	0.801	rs2665405	ENSG00000187870.7	RNFT1P3	-7.67	4.6e-12	0.000121	-0.68	-0.57	White blood cell count;	chr17:59797931	chr17:20743333~20754501:-
ESCA	trans	rs2950393	0.804	rs3214051	ENSG00000121089.4	NACA3P	7.66	4.66e-12	0.000122	0.47	0.57	Platelet distribution width;	chr12:56725452	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs2035081	ENSG00000121089.4	NACA3P	7.66	4.66e-12	0.000122	0.47	0.57	Platelet distribution width;	chr12:56732095	chr4:164943290~164943937:+
ESCA	trans	rs1552244	0.935	rs66493421	ENSG00000230342.2	FANCD2P2	7.66	4.82e-12	0.000126	1.27	0.57	Alzheimer's disease;	chr3:10050885	chr3:11859674~11891172:+
ESCA	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-7.66	4.85e-12	0.000127	-0.54	-0.57	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.604	rs2389887	ENSG00000279072.1	RP13-580B18.4	7.65	5e-12	0.000131	0.66	0.57	Corneal astigmatism;	chr4:119649489	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.604	rs34278750	ENSG00000279072.1	RP13-580B18.4	7.65	5e-12	0.000131	0.66	0.57	Corneal astigmatism;	chr4:119649981	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.604	rs10022185	ENSG00000279072.1	RP13-580B18.4	7.65	5e-12	0.000131	0.66	0.57	Corneal astigmatism;	chr4:119650610	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.616	rs11732621	ENSG00000279072.1	RP13-580B18.4	7.65	5.03e-12	0.000132	0.64	0.57	Diastolic blood pressure;	chr4:119291728	chr7:56809214~56848800:-
ESCA	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	7.64	5.18e-12	0.000135	0.79	0.57	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
ESCA	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	7.64	5.18e-12	0.000135	0.79	0.57	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
ESCA	trans	rs2950393	0.804	rs2958127	ENSG00000121089.4	NACA3P	7.64	5.2e-12	0.000136	0.49	0.57	Platelet distribution width;	chr12:56720523	chr4:164943290~164943937:+
ESCA	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-7.64	5.26e-12	0.000137	-0.71	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
ESCA	trans	rs1816752	0.669	rs3783072	ENSG00000237917.1	PARP4P1	-7.64	5.33e-12	0.000139	-0.73	-0.57	Obesity-related traits;	chr13:24493258	chrY:26594851~26634652:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000212829.8	RPS26P3	7.64	5.36e-12	0.00014	0.55	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr9:9090898~9091245:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	7.63	5.43e-12	0.000141	0.63	0.57	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
ESCA	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-7.63	5.54e-12	0.000144	-0.48	-0.57	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
ESCA	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-7.63	5.54e-12	0.000144	-0.48	-0.57	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	7.63	5.56e-12	0.000145	0.55	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
ESCA	trans	rs8081395	0.836	rs2063353	ENSG00000187870.7	RNFT1P3	-7.63	5.57e-12	0.000145	-0.68	-0.57	White blood cell count;	chr17:59811831	chr17:20743333~20754501:-
ESCA	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	7.63	5.6e-12	0.000145	0.78	0.57	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000212829.8	RPS26P3	7.62	5.75e-12	0.000149	0.56	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr9:9090898~9091245:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-7.62	5.88e-12	0.000152	-0.62	-0.57	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
ESCA	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-7.61	6.13e-12	0.000159	-0.7	-0.57	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
ESCA	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	7.6	6.37e-12	0.000165	0.91	0.57	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	7.6	6.37e-12	0.000165	0.91	0.57	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
ESCA	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	7.6	6.38e-12	0.000165	0.73	0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-7.6	6.45e-12	0.000167	-0.61	-0.57	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.913	rs10006304	ENSG00000279072.1	RP13-580B18.4	7.59	6.81e-12	0.000175	0.69	0.56	Corneal astigmatism;	chr4:119203150	chr7:56809214~56848800:-
ESCA	trans	rs11332131	1	rs11332131	ENSG00000187870.7	RNFT1P3	7.58	7.07e-12	0.000181	0.69	0.56	Platelet distribution width;	chr17:59849031	chr17:20743333~20754501:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-7.58	7.17e-12	0.000183	-0.59	-0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000242206.2	RPS26P35	7.58	7.22e-12	0.000185	0.59	0.56	Cognitive function;	chr12:56076841	chr8:118761856~118762201:-
ESCA	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	7.57	7.79e-12	0.000199	0.74	0.56	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
ESCA	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	7.56	7.88e-12	0.000201	0.74	0.56	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
ESCA	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	7.56	7.88e-12	0.000201	0.74	0.56	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	7.56	8.06e-12	0.000206	0.57	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
ESCA	trans	rs2950393	0.804	rs10783796	ENSG00000121089.4	NACA3P	7.56	8.14e-12	0.000207	0.47	0.56	Platelet distribution width;	chr12:56733387	chr4:164943290~164943937:+
ESCA	trans	rs1552244	1	rs76041173	ENSG00000230342.2	FANCD2P2	7.55	8.41e-12	0.000214	1.24	0.56	Alzheimer's disease;	chr3:10037011	chr3:11859674~11891172:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-7.55	8.43e-12	0.000215	-0.6	-0.56	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.954	rs6849561	ENSG00000276997.3	RP11-378J18.9	-7.55	8.67e-12	0.000221	-0.63	-0.56	Corneal astigmatism;	chr4:119488539	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	7.54	8.9e-12	0.000226	0.54	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000244604.1	RP11-713H12.1	7.54	9.02e-12	0.000229	0.54	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr17:8561230~8561576:+
ESCA	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	7.54	9.02e-12	0.000229	0.88	0.56	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
ESCA	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	7.53	9.22e-12	0.000234	0.44	0.56	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
ESCA	trans	rs1552244	1	rs56394721	ENSG00000230342.2	FANCD2P2	7.53	9.36e-12	0.000237	1.23	0.56	Alzheimer's disease;	chr3:10109111	chr3:11859674~11891172:+
ESCA	trans	rs7930295	0.505	rs34303332	ENSG00000236257.1	EI24P2	7.53	9.38e-12	0.000237	0.96	0.56	Schizophrenia;	chr11:125544288	chr1:158454198~158455273:+
ESCA	trans	rs2950393	0.804	rs2958130	ENSG00000121089.4	NACA3P	7.53	9.43e-12	0.000238	0.48	0.56	Platelet distribution width;	chr12:56746722	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000233278.1	RPS26P2	-7.53	9.52e-12	0.000241	-0.61	-0.56	Cognitive function;	chr12:56083910	chr9:30831878~30832225:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-7.53	9.53e-12	0.000241	-0.66	-0.56	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.913	rs56122576	ENSG00000279072.1	RP13-580B18.4	7.51	1.03e-11	0.000259	0.68	0.56	Corneal astigmatism;	chr4:119208181	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.913	rs13126596	ENSG00000279072.1	RP13-580B18.4	7.51	1.03e-11	0.000259	0.68	0.56	Corneal astigmatism;	chr4:119219574	chr7:56809214~56848800:-
ESCA	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	7.5	1.08e-11	0.000271	0.77	0.56	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
ESCA	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	7.5	1.08e-11	0.000271	0.77	0.56	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
ESCA	trans	rs1552244	1	rs61052895	ENSG00000230342.2	FANCD2P2	7.5	1.11e-11	0.000278	1.14	0.56	Alzheimer's disease;	chr3:10105832	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs67569278	ENSG00000230342.2	FANCD2P2	7.5	1.11e-11	0.000278	1.14	0.56	Alzheimer's disease;	chr3:10108209	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs68067759	ENSG00000230342.2	FANCD2P2	7.5	1.11e-11	0.000278	1.14	0.56	Alzheimer's disease;	chr3:10108851	chr3:11859674~11891172:+
ESCA	trans	rs1816752	0.646	rs750390	ENSG00000237917.1	PARP4P1	-7.5	1.13e-11	0.000282	-0.72	-0.56	Obesity-related traits;	chr13:24461603	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs4309825	ENSG00000276997.3	RP11-378J18.9	-7.49	1.14e-11	0.000285	-0.65	-0.56	Corneal astigmatism;	chr4:119393726	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000223416.3	RPS26P15	7.48	1.21e-11	0.000301	0.56	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:58056133~58056480:-
ESCA	trans	rs1816752	0.624	rs2096093	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24472753	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs750389	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24461677	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs750388	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24461690	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs2902359	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24461783	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs2862902	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24461965	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs734715	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462041	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs730030	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462509	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs7992667	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462821	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs7995958	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462895	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs8002741	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462918	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs7998198	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462979	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs7998203	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24462989	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7998600	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463222	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511279	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463348	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511280	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463364	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511281	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463441	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.624	rs9511282	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463597	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.583	rs9511283	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463656	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.583	rs9511284	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24463660	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9507351	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24465118	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs4770688	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466007	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs4770689	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466008	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs12431171	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466380	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs12854523	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466460	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9578740	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466692	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.631	rs4769358	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466940	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.608	rs4769359	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24466966	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.608	rs4769360	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24467016	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.608	rs9511290	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24467189	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511291	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24467609	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511292	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24467623	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511296	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24467962	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9634401	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468072	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.624	rs9634402	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468119	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9634403	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468211	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9581064	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468251	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs4770692	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468689	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs4769361	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468834	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs4770693	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468835	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs4770694	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468891	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.609	rs4770695	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24468895	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.624	rs9507354	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24469227	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7337981	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24469245	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7328391	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24470325	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs4480642	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24471358	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9551108	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24471434	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.603	rs4238178	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24472344	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs2862903	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24473169	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7319207	ENSG00000237917.1	PARP4P1	-7.48	1.25e-11	0.000305	-0.73	-0.56	Obesity-related traits;	chr13:24473220	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511293	ENSG00000237917.1	PARP4P1	-7.47	1.26e-11	0.000306	-0.73	-0.56	Obesity-related traits;	chr13:24467747	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511294	ENSG00000237917.1	PARP4P1	-7.47	1.26e-11	0.000306	-0.73	-0.56	Obesity-related traits;	chr13:24467773	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511295	ENSG00000237917.1	PARP4P1	-7.47	1.26e-11	0.000306	-0.73	-0.56	Obesity-related traits;	chr13:24467794	chrY:26594851~26634652:-
ESCA	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-7.47	1.26e-11	0.000306	-0.9	-0.56	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
ESCA	trans	rs66887589	0.592	rs62320740	ENSG00000279072.1	RP13-580B18.4	7.47	1.27e-11	0.000309	0.63	0.56	Diastolic blood pressure;	chr4:119358331	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-7.47	1.28e-11	0.000309	-0.7	-0.56	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
ESCA	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	7.47	1.3e-11	0.000316	0.56	0.56	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
ESCA	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-7.47	1.31e-11	0.000319	-0.54	-0.56	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	7.46	1.33e-11	0.000321	0.56	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
ESCA	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	7.46	1.33e-11	0.000321	0.86	0.56	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	7.46	1.34e-11	0.000322	0.89	0.56	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000242206.2	RPS26P35	-7.46	1.35e-11	0.000324	-0.57	-0.56	Cognitive function;	chr12:56084218	chr8:118761856~118762201:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000242206.2	RPS26P35	-7.46	1.35e-11	0.000324	-0.57	-0.56	Cognitive function;	chr12:56084874	chr8:118761856~118762201:-
ESCA	trans	rs11098499	0.739	rs10031033	ENSG00000279072.1	RP13-580B18.4	7.46	1.35e-11	0.000326	0.65	0.56	Corneal astigmatism;	chr4:119230297	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.624	rs9553312	ENSG00000237917.1	PARP4P1	-7.45	1.42e-11	0.000341	-0.74	-0.56	Obesity-related traits;	chr13:24474055	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.913	rs68128210	ENSG00000279072.1	RP13-580B18.4	7.45	1.45e-11	0.000345	0.68	0.56	Corneal astigmatism;	chr4:119216664	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-7.45	1.45e-11	0.000345	-0.69	-0.56	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
ESCA	trans	rs1552244	0.882	rs113268531	ENSG00000230342.2	FANCD2P2	7.45	1.46e-11	0.000347	1.05	0.56	Alzheimer's disease;	chr3:10125385	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.938	rs56274701	ENSG00000230342.2	FANCD2P2	7.45	1.46e-11	0.000347	1.05	0.56	Alzheimer's disease;	chr3:10126106	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-7.45	1.46e-11	0.000347	-0.59	-0.56	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000234192.1	RP11-57C13.5	-7.44	1.49e-11	0.000352	-0.67	-0.56	Cognitive function;	chr12:56080595	chr10:87642607~87642954:+
ESCA	trans	rs8081395	0.834	rs11650106	ENSG00000187870.7	RNFT1P3	-7.44	1.51e-11	0.000356	-0.68	-0.56	White blood cell count;	chr17:59772890	chr17:20743333~20754501:-
ESCA	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	7.43	1.61e-11	0.000379	0.78	0.56	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
ESCA	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	7.42	1.64e-11	0.000385	0.75	0.56	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
ESCA	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-7.42	1.65e-11	0.000388	-0.89	-0.56	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
ESCA	trans	rs8081395	0.836	rs1295926	ENSG00000187870.7	RNFT1P3	-7.42	1.65e-11	0.000389	-0.68	-0.56	White blood cell count;	chr17:59832012	chr17:20743333~20754501:-
ESCA	trans	rs1816752	0.583	rs9553311	ENSG00000237917.1	PARP4P1	-7.42	1.65e-11	0.000389	-0.73	-0.56	Obesity-related traits;	chr13:24474016	chrY:26594851~26634652:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	7.42	1.69e-11	0.000396	0.6	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
ESCA	trans	rs2950393	0.804	rs1131514	ENSG00000121089.4	NACA3P	-7.42	1.69e-11	0.000396	-0.45	-0.56	Platelet distribution width;	chr12:56739356	chr4:164943290~164943937:+
ESCA	trans	rs1552244	0.935	rs41520445	ENSG00000230342.2	FANCD2P2	-7.42	1.69e-11	0.000397	-1.09	-0.56	Alzheimer's disease;	chr3:10111457	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-7.42	1.7e-11	0.000399	-0.89	-0.56	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-7.42	1.7e-11	0.000399	-0.89	-0.56	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-7.42	1.7e-11	0.000399	-0.89	-0.56	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	7.42	1.72e-11	0.000402	0.54	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
ESCA	trans	rs1552244	0.935	rs35148833	ENSG00000230342.2	FANCD2P2	7.41	1.76e-11	0.000411	1.22	0.56	Alzheimer's disease;	chr3:10075253	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.81	rs35711405	ENSG00000230342.2	FANCD2P2	7.41	1.76e-11	0.000411	1.22	0.56	Alzheimer's disease;	chr3:10075255	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	7.41	1.76e-11	0.000412	0.6	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
ESCA	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-7.41	1.79e-11	0.000419	-0.85	-0.56	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.954	rs59866101	ENSG00000276997.3	RP11-378J18.9	7.4	1.85e-11	0.000431	0.64	0.56	Corneal astigmatism;	chr4:119375436	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.618	rs6858383	ENSG00000276997.3	RP11-378J18.9	7.4	1.85e-11	0.000431	0.64	0.56	Corneal astigmatism;	chr4:119375617	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs6832410	ENSG00000276997.3	RP11-378J18.9	7.4	1.85e-11	0.000431	0.64	0.56	Corneal astigmatism;	chr4:119375645	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-7.39	1.91e-11	0.000445	-0.68	-0.55	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-7.39	1.91e-11	0.000445	-0.68	-0.55	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
ESCA	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-7.39	1.92e-11	0.000447	-0.58	-0.55	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
ESCA	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-7.39	1.94e-11	0.000451	-0.86	-0.55	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.646	rs3783073	ENSG00000237917.1	PARP4P1	-7.39	1.95e-11	0.000452	-0.73	-0.55	Obesity-related traits;	chr13:24493222	chrY:26594851~26634652:-
ESCA	trans	rs7930295	0.687	rs7117500	ENSG00000236257.1	EI24P2	7.39	1.98e-11	0.00046	0.99	0.55	Schizophrenia;	chr11:125504232	chr1:158454198~158455273:+
ESCA	trans	rs8081395	0.801	rs2645479	ENSG00000187870.7	RNFT1P3	7.39	1.98e-11	0.00046	0.68	0.55	White blood cell count;	chr17:59843171	chr17:20743333~20754501:-
ESCA	trans	rs66887589	0.777	rs10015883	ENSG00000279072.1	RP13-580B18.4	7.38	2.03e-11	0.000472	0.6	0.55	Diastolic blood pressure;	chr4:119346991	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs10017371	ENSG00000276997.3	RP11-378J18.9	7.38	2.07e-11	0.00048	0.65	0.55	Corneal astigmatism;	chr4:119372621	chr1:222477252~222504622:-
ESCA	trans	rs1552244	1	rs7628448	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10105144	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs66838678	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10108666	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.935	rs7618815	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10109361	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs7652935	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10109454	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs67134728	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10109747	chr3:11859674~11891172:+
ESCA	trans	rs1552244	1	rs68045038	ENSG00000230342.2	FANCD2P2	7.37	2.16e-11	5e-04	1.2	0.55	Alzheimer's disease;	chr3:10110144	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-7.37	2.2e-11	0.000509	-0.89	-0.55	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-7.35	2.4e-11	0.000551	-0.85	-0.55	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-7.35	2.4e-11	0.000551	-0.85	-0.55	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	7.35	2.41e-11	0.000552	0.53	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	7.35	2.43e-11	0.000557	0.59	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	7.34	2.51e-11	0.000574	0.59	0.55	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000244604.1	RP11-713H12.1	7.34	2.55e-11	0.000583	0.54	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr17:8561230~8561576:+
ESCA	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-7.33	2.65e-11	0.000605	-0.92	-0.55	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
ESCA	trans	rs66887589	0.748	rs28439855	ENSG00000279072.1	RP13-580B18.4	7.31	2.96e-11	0.000672	0.59	0.55	Diastolic blood pressure;	chr4:119341101	chr7:56809214~56848800:-
ESCA	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	7.31	2.99e-11	0.000679	0.54	0.55	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	7.31	3.03e-11	0.000687	0.69	0.55	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
ESCA	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	7.3	3.2e-11	0.000724	0.94	0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
ESCA	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	7.29	3.25e-11	0.000734	0.61	0.55	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
ESCA	trans	rs3749237	1	rs1317140	ENSG00000197582.5	GPX1P1	7.29	3.32e-11	0.000751	0.77	0.55	Resting heart rate;	chr3:49841219	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.604	rs2389882	ENSG00000279072.1	RP13-580B18.4	7.28	3.41e-11	0.000769	0.62	0.55	Corneal astigmatism;	chr4:119645578	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs1546503	ENSG00000276997.3	RP11-378J18.9	7.28	3.55e-11	0.000799	0.64	0.55	Corneal astigmatism;	chr4:119320012	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.708	rs1546506	ENSG00000276997.3	RP11-378J18.9	7.28	3.55e-11	0.000799	0.64	0.55	Corneal astigmatism;	chr4:119320085	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000233278.1	RPS26P2	7.27	3.57e-11	0.000805	0.58	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:30831878~30832225:-
ESCA	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	7.27	3.61e-11	0.000812	0.76	0.55	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
ESCA	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-7.26	3.77e-11	0.000847	-0.69	-0.55	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-7.26	3.79e-11	0.000851	-0.57	-0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	7.26	3.81e-11	0.000856	0.58	0.55	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
ESCA	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	-7.25	4.09e-11	0.000916	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	-7.25	4.09e-11	0.000916	-0.7	-0.55	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
ESCA	trans	rs2950393	0.804	rs898609	ENSG00000121089.4	NACA3P	7.25	4.12e-11	0.000921	0.47	0.55	Platelet distribution width;	chr12:56713026	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs4902	ENSG00000121089.4	NACA3P	7.25	4.12e-11	0.000921	0.47	0.55	Platelet distribution width;	chr12:56714419	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs2290894	ENSG00000121089.4	NACA3P	7.25	4.12e-11	0.000921	0.47	0.55	Platelet distribution width;	chr12:56714911	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs2926748	ENSG00000121089.4	NACA3P	7.25	4.12e-11	0.000921	0.47	0.55	Platelet distribution width;	chr12:56715628	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.777	rs2926747	ENSG00000121089.4	NACA3P	7.25	4.12e-11	0.000921	0.47	0.55	Platelet distribution width;	chr12:56716147	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs2926752	ENSG00000121089.4	NACA3P	7.24	4.21e-11	0.00094	0.48	0.55	Platelet distribution width;	chr12:56710144	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.777	rs2958148	ENSG00000121089.4	NACA3P	7.24	4.21e-11	0.00094	0.48	0.55	Platelet distribution width;	chr12:56710153	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-7.24	4.28e-11	0.000953	-0.59	-0.55	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-7.24	4.28e-11	0.000953	-0.59	-0.55	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
ESCA	trans	rs8081395	0.805	rs1295927	ENSG00000187870.7	RNFT1P3	7.24	4.28e-11	0.000954	0.65	0.55	White blood cell count;	chr17:59852174	chr17:20743333~20754501:-
ESCA	trans	rs1816752	0.624	rs2862901	ENSG00000237917.1	PARP4P1	-7.24	4.37e-11	0.000971	-0.71	-0.55	Obesity-related traits;	chr13:24461101	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	7.23	4.41e-11	0.000981	0.59	0.55	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
ESCA	trans	rs11098499	0.618	rs28491261	ENSG00000276997.3	RP11-378J18.9	7.22	4.62e-11	0.00103	0.64	0.55	Corneal astigmatism;	chr4:119373745	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs59394118	ENSG00000276997.3	RP11-378J18.9	7.22	4.62e-11	0.00103	0.64	0.55	Corneal astigmatism;	chr4:119374396	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs9996417	ENSG00000276997.3	RP11-378J18.9	7.22	4.62e-11	0.00103	0.64	0.55	Corneal astigmatism;	chr4:119374707	chr1:222477252~222504622:-
ESCA	trans	rs1816752	0.608	rs4770690	ENSG00000237917.1	PARP4P1	-7.21	4.96e-11	0.0011	-0.71	-0.55	Obesity-related traits;	chr13:24467049	chrY:26594851~26634652:-
ESCA	trans	rs1552244	0.748	rs113890152	ENSG00000230342.2	FANCD2P2	7.21	4.98e-11	0.0011	1.18	0.55	Alzheimer's disease;	chr3:10044302	chr3:11859674~11891172:+
ESCA	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	7.2	5.16e-11	0.00114	0.99	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	7.2	5.16e-11	0.00114	0.99	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
ESCA	trans	rs66887589	0.616	rs13113885	ENSG00000279072.1	RP13-580B18.4	7.2	5.23e-11	0.00115	0.62	0.54	Diastolic blood pressure;	chr4:119300021	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.592	rs11731571	ENSG00000279072.1	RP13-580B18.4	7.19	5.57e-11	0.00123	0.62	0.54	Diastolic blood pressure;	chr4:119300030	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs6820115	ENSG00000276997.3	RP11-378J18.9	7.19	5.64e-11	0.00124	0.62	0.54	Corneal astigmatism;	chr4:119477027	chr1:222477252~222504622:-
ESCA	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	7.18	5.73e-11	0.00125	0.75	0.54	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-7.18	5.73e-11	0.00125	-0.64	-0.54	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
ESCA	trans	rs11098499	0.865	rs1112817	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119376645	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs10016060	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119377257	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10005644	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119377322	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs10016448	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119377690	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.657	rs9996569	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119377849	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs11723757	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119378514	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs11723839	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119378518	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs11729050	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119378911	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs28429722	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119378938	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10014845	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119379922	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs12506546	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119380463	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs7674500	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119382438	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs4507344	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119386330	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs4373140	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119386543	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs13113483	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119387884	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.542	rs10440343	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119388632	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs28668716	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119388720	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs10011097	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119389204	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs7699346	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119389387	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.542	rs7677836	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119389483	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10002083	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119389997	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10024844	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119390373	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs7437420	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119391748	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs4345162	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119391804	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.657	rs4463052	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119392103	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs4560394	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119392280	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs13151285	ENSG00000276997.3	RP11-378J18.9	7.18	5.77e-11	0.00125	0.63	0.54	Corneal astigmatism;	chr4:119393586	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-7.18	5.84e-11	0.00126	-0.57	-0.54	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000234192.1	RP11-57C13.5	-7.18	5.91e-11	0.00128	-0.6	-0.54	Cognitive function;	chr12:56080024	chr10:87642607~87642954:+
ESCA	trans	rs877636	0.74	rs705698	ENSG00000204652.6	RPS26P8	7.17	6.14e-11	0.00132	0.58	0.54	Cognitive function;	chr12:55990903	chr17:45608571~45608918:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-7.17	6.25e-11	0.00135	-0.61	-0.54	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
ESCA	trans	rs11098499	0.865	rs11098513	ENSG00000276997.3	RP11-378J18.9	7.16	6.38e-11	0.00137	0.63	0.54	Corneal astigmatism;	chr4:119394920	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	7.16	6.4e-11	0.00138	0.69	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
ESCA	trans	rs7930295	0.556	rs6590146	ENSG00000236257.1	EI24P2	7.16	6.44e-11	0.00139	0.93	0.54	Schizophrenia;	chr11:125479933	chr1:158454198~158455273:+
ESCA	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	7.15	6.72e-11	0.00143	0.56	0.54	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	7.15	6.75e-11	0.00144	0.53	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
ESCA	trans	rs1816752	0.646	rs7997248	ENSG00000237917.1	PARP4P1	-7.15	6.78e-11	0.00145	-0.7	-0.54	Obesity-related traits;	chr13:24507050	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	7.14	7.11e-11	0.00151	0.53	0.54	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	7.14	7.11e-11	0.00151	0.53	0.54	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	7.14	7.11e-11	0.00151	0.53	0.54	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
ESCA	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	7.14	7.11e-11	0.00151	0.53	0.54	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.954	rs9993199	ENSG00000276997.3	RP11-378J18.9	-7.14	7.18e-11	0.00153	-0.64	-0.54	Corneal astigmatism;	chr4:119471718	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-7.14	7.2e-11	0.00153	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	7.14	7.26e-11	0.00154	0.69	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	7.14	7.26e-11	0.00154	0.69	0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
ESCA	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-7.14	7.27e-11	0.00154	-0.98	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
ESCA	trans	rs11098499	0.909	rs1546504	ENSG00000276997.3	RP11-378J18.9	7.14	7.27e-11	0.00154	0.64	0.54	Corneal astigmatism;	chr4:119320024	chr1:222477252~222504622:-
ESCA	trans	rs1816752	0.669	rs2862906	ENSG00000237917.1	PARP4P1	-7.13	7.39e-11	0.00157	-0.7	-0.54	Obesity-related traits;	chr13:24494482	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs12508504	ENSG00000276997.3	RP11-378J18.9	7.12	7.86e-11	0.00166	0.63	0.54	Corneal astigmatism;	chr4:119489452	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	7.12	8.06e-11	0.0017	0.55	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000242206.2	RPS26P35	-7.11	8.15e-11	0.00172	-0.54	-0.54	Cognitive function;	chr12:56083910	chr8:118761856~118762201:-
ESCA	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-7.11	8.32e-11	0.00175	-0.94	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
ESCA	trans	rs2950393	0.929	rs10876916	ENSG00000121089.4	NACA3P	7.11	8.45e-11	0.00178	0.47	0.54	Platelet distribution width;	chr12:56692728	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.74	rs705698	ENSG00000233778.3	RP11-777J24.1	7.11	8.48e-11	0.00178	0.54	0.54	Cognitive function;	chr12:55990903	chr8:92144088~92144435:-
ESCA	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-7.1	8.77e-11	0.00184	-0.55	-0.54	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.821	rs10032151	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119470473	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs10032158	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119470477	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs6838814	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119471288	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs13107475	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119471856	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs7436506	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119472614	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs12499324	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119472631	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10008459	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119473076	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs2127821	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119473380	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs9998585	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119475647	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10034623	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119476674	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs6842762	ENSG00000276997.3	RP11-378J18.9	7.09	9.02e-11	0.00189	0.63	0.54	Corneal astigmatism;	chr4:119477081	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	7.09	9.04e-11	0.00189	0.53	0.54	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
ESCA	trans	rs1552244	0.882	rs7633769	ENSG00000230342.2	FANCD2P2	7.09	9.14e-11	0.00191	0.88	0.54	Alzheimer's disease;	chr3:9978938	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.751	rs12715665	ENSG00000230342.2	FANCD2P2	7.09	9.14e-11	0.00191	0.88	0.54	Alzheimer's disease;	chr3:9979917	chr3:11859674~11891172:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-7.09	9.31e-11	0.00194	-0.66	-0.54	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	7.08	9.52e-11	0.00199	0.63	0.54	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
ESCA	trans	rs1552244	1	rs17032283	ENSG00000230342.2	FANCD2P2	7.08	9.59e-11	0.002	1.1	0.54	Alzheimer's disease;	chr3:10039861	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-7.08	9.94e-11	0.00207	-0.86	-0.54	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.624	rs7330766	ENSG00000237917.1	PARP4P1	-7.07	1.01e-10	0.00211	-0.7	-0.54	Obesity-related traits;	chr13:24495579	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.603	rs7984094	ENSG00000237917.1	PARP4P1	-7.07	1.01e-10	0.00211	-0.7	-0.54	Obesity-related traits;	chr13:24496212	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs1361578	ENSG00000237917.1	PARP4P1	-7.07	1.04e-10	0.00217	-0.71	-0.54	Obesity-related traits;	chr13:24491117	chrY:26594851~26634652:-
ESCA	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	7.07	1.04e-10	0.00217	0.56	0.54	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	7.06	1.06e-10	0.0022	0.55	0.54	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.731	rs6846966	ENSG00000276997.3	RP11-378J18.9	7.06	1.07e-10	0.00222	0.62	0.54	Corneal astigmatism;	chr4:119372053	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.866	rs6847778	ENSG00000276997.3	RP11-378J18.9	7.06	1.07e-10	0.00222	0.62	0.54	Corneal astigmatism;	chr4:119372427	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000242206.2	RPS26P35	-7.06	1.08e-10	0.00224	-0.56	-0.54	Cognitive function;	chr12:56080024	chr8:118761856~118762201:-
ESCA	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	7.06	1.09e-10	0.00226	0.74	0.54	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
ESCA	trans	rs1816752	0.646	rs6490937	ENSG00000237917.1	PARP4P1	-7.06	1.1e-10	0.00227	-0.69	-0.54	Obesity-related traits;	chr13:24475834	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.608	rs7326664	ENSG00000237917.1	PARP4P1	-7.06	1.1e-10	0.00227	-0.69	-0.54	Obesity-related traits;	chr13:24475868	chrY:26594851~26634652:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-7.05	1.1e-10	0.00228	-0.57	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
ESCA	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	7.05	1.11e-10	0.00228	0.85	0.54	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.524	rs7996445	ENSG00000237917.1	PARP4P1	-7.05	1.12e-10	0.00231	-0.69	-0.54	Obesity-related traits;	chr13:24475329	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7995190	ENSG00000237917.1	PARP4P1	-7.05	1.12e-10	0.00231	-0.69	-0.54	Obesity-related traits;	chr13:24475709	chrY:26594851~26634652:-
ESCA	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	7.04	1.18e-10	0.00242	0.63	0.54	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
ESCA	trans	rs66887589	0.777	rs4643791	ENSG00000279072.1	RP13-580B18.4	-7.04	1.21e-10	0.00248	-0.57	-0.54	Diastolic blood pressure;	chr4:119344464	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.692	rs2282409	ENSG00000237917.1	PARP4P1	-7.03	1.22e-10	0.0025	-0.69	-0.54	Obesity-related traits;	chr13:24512388	chrY:26594851~26634652:-
ESCA	trans	rs7930295	0.556	rs9704355	ENSG00000236257.1	EI24P2	7.03	1.27e-10	0.0026	0.92	0.54	Schizophrenia;	chr11:125478435	chr1:158454198~158455273:+
ESCA	trans	rs1816752	0.716	rs1539096	ENSG00000237917.1	PARP4P1	-7.03	1.27e-10	0.0026	-0.7	-0.54	Obesity-related traits;	chr13:24501721	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs1546505	ENSG00000276997.3	RP11-378J18.9	7.02	1.29e-10	0.00261	0.65	0.54	Corneal astigmatism;	chr4:119320069	chr1:222477252~222504622:-
ESCA	trans	rs1552244	0.882	rs13100734	ENSG00000230342.2	FANCD2P2	7.02	1.29e-10	0.00262	0.88	0.54	Alzheimer's disease;	chr3:9981194	chr3:11859674~11891172:+
ESCA	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-7.02	1.3e-10	0.00263	-0.93	-0.54	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
ESCA	trans	rs1552244	0.832	rs73024591	ENSG00000230342.2	FANCD2P2	7.02	1.32e-10	0.00267	1.15	0.53	Alzheimer's disease;	chr3:10161510	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-7.02	1.32e-10	0.00267	-0.86	-0.53	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-7.02	1.32e-10	0.00267	-0.86	-0.53	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
ESCA	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	7.02	1.32e-10	0.00268	0.7	0.53	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
ESCA	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	7.02	1.33e-10	0.0027	0.61	0.53	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
ESCA	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	7.02	1.34e-10	0.00271	0.57	0.53	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
ESCA	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	7.02	1.35e-10	0.00273	0.47	0.53	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.526	rs10026625	ENSG00000279072.1	RP13-580B18.4	7.01	1.36e-10	0.00274	0.61	0.53	Corneal astigmatism;	chr4:119358981	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-7.01	1.37e-10	0.00276	-0.57	-0.53	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
ESCA	trans	rs11098499	0.69	rs34818745	ENSG00000276997.3	RP11-378J18.9	7.01	1.37e-10	0.00276	0.64	0.53	Corneal astigmatism;	chr4:119335900	chr1:222477252~222504622:-
ESCA	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	7.01	1.37e-10	0.00277	0.46	0.53	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
ESCA	trans	rs2950393	0.804	rs11171951	ENSG00000121089.4	NACA3P	7.01	1.37e-10	0.00277	0.46	0.53	Platelet distribution width;	chr12:56718853	chr4:164943290~164943937:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000234192.1	RP11-57C13.5	-7.01	1.41e-10	0.00285	-0.63	-0.53	Cognitive function;	chr12:56080696	chr10:87642607~87642954:+
ESCA	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	7.01	1.42e-10	0.00285	0.53	0.53	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.789	rs9991166	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119316696	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.708	rs10005237	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119316742	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs878372	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119317625	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs10213267	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119317919	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs10212775	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119318089	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs9999724	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119318789	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs2964	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119318976	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs1511025	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119319083	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12711071	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119319779	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12510269	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119320491	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12506610	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119320504	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.743	rs10003567	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119320519	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs10006259	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119320990	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs28652763	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119321157	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs714899	ENSG00000276997.3	RP11-378J18.9	7.01	1.42e-10	0.00285	0.63	0.53	Corneal astigmatism;	chr4:119321880	chr1:222477252~222504622:-
ESCA	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-7	1.43e-10	0.00287	-0.86	-0.53	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-7	1.43e-10	0.00287	-0.86	-0.53	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-7	1.43e-10	0.00287	-0.86	-0.53	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
ESCA	trans	rs13177918	0.75	rs58256223	ENSG00000226396.1	RP5-1056L3.3	7	1.45e-10	0.00291	0.52	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.75	rs59354956	ENSG00000226396.1	RP5-1056L3.3	7	1.45e-10	0.00291	0.52	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:19608114~19608568:+
ESCA	trans	rs2950393	0.777	rs12828563	ENSG00000121089.4	NACA3P	7	1.46e-10	0.00293	0.46	0.53	Platelet distribution width;	chr12:56709378	chr4:164943290~164943937:+
ESCA	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-7	1.47e-10	0.00295	-0.97	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
ESCA	trans	rs1816752	0.646	rs9507355	ENSG00000237917.1	PARP4P1	6.99	1.5e-10	0.00301	0.67	0.53	Obesity-related traits;	chr13:24476819	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-6.99	1.51e-10	0.00302	-0.6	-0.53	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
ESCA	trans	rs13177918	0.626	rs2748240	ENSG00000239528.1	RPS14P8	6.99	1.52e-10	0.00303	0.59	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr5:116562562~116562930:+
ESCA	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-6.99	1.54e-10	0.00308	-0.81	-0.53	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.646	rs4770700	ENSG00000237917.1	PARP4P1	-6.99	1.55e-10	0.00309	-0.7	-0.53	Obesity-related traits;	chr13:24494796	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.754	rs11732087	ENSG00000276997.3	RP11-378J18.9	6.99	1.56e-10	0.00312	0.63	0.53	Corneal astigmatism;	chr4:119318676	chr1:222477252~222504622:-
ESCA	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-6.98	1.59e-10	0.00317	-0.84	-0.53	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-6.98	1.62e-10	0.00322	-0.58	-0.53	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
ESCA	trans	rs11098499	0.662	rs13108589	ENSG00000276997.3	RP11-378J18.9	6.98	1.63e-10	0.00324	0.62	0.53	Corneal astigmatism;	chr4:119346947	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-6.98	1.65e-10	0.00329	-0.57	-0.53	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
ESCA	trans	rs1816752	0.624	rs4770701	ENSG00000237917.1	PARP4P1	-6.97	1.69e-10	0.00336	-0.69	-0.53	Obesity-related traits;	chr13:24508806	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.702	rs773108	ENSG00000233778.3	RP11-777J24.1	6.97	1.7e-10	0.00338	0.53	0.53	Cognitive function;	chr12:55976127	chr8:92144088~92144435:-
ESCA	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	-6.97	1.73e-10	0.00343	-0.68	-0.53	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
ESCA	trans	rs11098499	0.754	rs938056	ENSG00000276997.3	RP11-378J18.9	6.97	1.73e-10	0.00344	0.63	0.53	Corneal astigmatism;	chr4:119316298	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs878376	ENSG00000276997.3	RP11-378J18.9	6.97	1.73e-10	0.00344	0.63	0.53	Corneal astigmatism;	chr4:119316547	chr1:222477252~222504622:-
ESCA	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-6.96	1.77e-10	0.00352	-0.66	-0.53	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	6.96	1.78e-10	0.00353	0.57	0.53	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
ESCA	trans	rs11098499	0.954	rs10518328	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119480624	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs6822679	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119481547	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs4577559	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119482888	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs7656252	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119483113	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs28845498	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119484031	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs28753180	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119484212	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs56270433	ENSG00000276997.3	RP11-378J18.9	6.96	1.79e-10	0.00355	0.63	0.53	Corneal astigmatism;	chr4:119484875	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs11098525	ENSG00000276997.3	RP11-378J18.9	6.96	1.83e-10	0.00361	0.62	0.53	Corneal astigmatism;	chr4:119468997	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs11098526	ENSG00000276997.3	RP11-378J18.9	6.96	1.83e-10	0.00361	0.62	0.53	Corneal astigmatism;	chr4:119469204	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-6.95	1.87e-10	0.00369	-0.64	-0.53	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
ESCA	trans	rs11098499	0.575	rs907204	ENSG00000276997.3	RP11-378J18.9	6.95	1.88e-10	0.00371	0.62	0.53	Corneal astigmatism;	chr4:119317499	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.575	rs907205	ENSG00000276997.3	RP11-378J18.9	6.95	1.88e-10	0.00371	0.62	0.53	Corneal astigmatism;	chr4:119317509	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.74	rs705698	ENSG00000212994.5	RPS26P6	6.95	1.91e-10	0.00376	0.58	0.53	Cognitive function;	chr12:55990903	chr8:100895771~100896118:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000224553.1	AC008065.1	6.94	1.95e-10	0.00382	0.52	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr2:171374931~171375278:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-6.94	1.98e-10	0.00389	-0.58	-0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-6.94	2.03e-10	0.00397	-0.57	-0.53	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
ESCA	trans	rs11707813	0.649	rs9816826	ENSG00000278598.1	MIR6775	6.93	2.07e-10	0.00404	1.15	0.53	Lip morphology;	chr3:61158895	chr16:87834592~87834660:-
ESCA	trans	rs11098499	0.863	rs3736115	ENSG00000279072.1	RP13-580B18.4	-6.93	2.07e-10	0.00405	-0.6	-0.53	Corneal astigmatism;	chr4:119567548	chr7:56809214~56848800:-
ESCA	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-6.93	2.08e-10	0.00406	-0.85	-0.53	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-6.93	2.08e-10	0.00406	-0.85	-0.53	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-6.93	2.08e-10	0.00406	-0.85	-0.53	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
ESCA	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	6.93	2.11e-10	0.00412	0.91	0.53	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	6.93	2.14e-10	0.00416	0.52	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
ESCA	trans	rs1816752	0.716	rs9553330	ENSG00000237917.1	PARP4P1	-6.92	2.17e-10	0.00423	-0.68	-0.53	Obesity-related traits;	chr13:24516018	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs28572238	ENSG00000276997.3	RP11-378J18.9	6.92	2.2e-10	0.00427	0.61	0.53	Corneal astigmatism;	chr4:119395531	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs28714195	ENSG00000276997.3	RP11-378J18.9	6.92	2.2e-10	0.00427	0.61	0.53	Corneal astigmatism;	chr4:119395795	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs12508173	ENSG00000276997.3	RP11-378J18.9	6.92	2.2e-10	0.00427	0.61	0.53	Corneal astigmatism;	chr4:119397371	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs12504149	ENSG00000276997.3	RP11-378J18.9	6.92	2.2e-10	0.00427	0.61	0.53	Corneal astigmatism;	chr4:119397422	chr1:222477252~222504622:-
ESCA	trans	rs13177918	0.677	rs4841	ENSG00000226396.1	RP5-1056L3.3	6.92	2.2e-10	0.00428	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13183077	ENSG00000226396.1	RP5-1056L3.3	6.92	2.2e-10	0.00428	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs3797622	ENSG00000226396.1	RP5-1056L3.3	6.92	2.2e-10	0.00428	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.626	rs3819332	ENSG00000226396.1	RP5-1056L3.3	6.92	2.2e-10	0.00428	0.5	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.626	rs13170300	ENSG00000226396.1	RP5-1056L3.3	6.92	2.2e-10	0.00428	0.5	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:19608114~19608568:+
ESCA	trans	rs1552244	1	rs6768102	ENSG00000230342.2	FANCD2P2	6.92	2.22e-10	0.00431	1.09	0.53	Alzheimer's disease;	chr3:10107696	chr3:11859674~11891172:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-6.92	2.23e-10	0.00433	-0.65	-0.53	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
ESCA	trans	rs13177918	0.677	rs13161099	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.629	rs13161261	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13161417	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13161156	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13181401	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs4541646	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs3900644	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs2070844	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs2073472	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.629	rs2070842	ENSG00000226396.1	RP5-1056L3.3	6.91	2.36e-10	0.00456	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:19608114~19608568:+
ESCA	trans	rs66887589	0.627	rs3872807	ENSG00000279072.1	RP13-580B18.4	6.9	2.43e-10	0.00467	0.55	0.53	Diastolic blood pressure;	chr4:119439096	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.56	rs9684327	ENSG00000279072.1	RP13-580B18.4	6.9	2.43e-10	0.00467	0.55	0.53	Diastolic blood pressure;	chr4:119444286	chr7:56809214~56848800:-
ESCA	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-6.9	2.43e-10	0.00468	-0.63	-0.53	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
ESCA	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	6.89	2.5e-10	0.0048	0.61	0.53	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
ESCA	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	6.89	2.5e-10	0.0048	0.61	0.53	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
ESCA	trans	rs11098499	0.909	rs28884220	ENSG00000276997.3	RP11-378J18.9	6.89	2.51e-10	0.00482	0.61	0.53	Corneal astigmatism;	chr4:119386056	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs28793658	ENSG00000276997.3	RP11-378J18.9	6.89	2.51e-10	0.00482	0.61	0.53	Corneal astigmatism;	chr4:119386059	chr1:222477252~222504622:-
ESCA	trans	rs2950393	0.804	rs7980317	ENSG00000121089.4	NACA3P	6.89	2.57e-10	0.00493	0.44	0.53	Platelet distribution width;	chr12:56764399	chr4:164943290~164943937:+
ESCA	trans	rs13177918	0.677	rs57890152	ENSG00000226396.1	RP5-1056L3.3	6.89	2.61e-10	0.00499	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.686	rs12654827	ENSG00000226396.1	RP5-1056L3.3	6.89	2.61e-10	0.00499	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13160685	ENSG00000226396.1	RP5-1056L3.3	6.89	2.61e-10	0.00499	0.51	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:19608114~19608568:+
ESCA	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	6.89	2.62e-10	0.00501	0.67	0.53	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
ESCA	trans	rs13177918	0.677	rs3857421	ENSG00000226396.1	RP5-1056L3.3	-6.88	2.62e-10	0.00502	-0.52	-0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:19608114~19608568:+
ESCA	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-6.88	2.64e-10	0.00506	-0.6	-0.53	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.954	rs7681544	ENSG00000276997.3	RP11-378J18.9	6.88	2.66e-10	0.00507	0.62	0.53	Corneal astigmatism;	chr4:119490100	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs17005535	ENSG00000276997.3	RP11-378J18.9	6.88	2.66e-10	0.00507	0.62	0.53	Corneal astigmatism;	chr4:119490407	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs11940028	ENSG00000276997.3	RP11-378J18.9	6.88	2.66e-10	0.00507	0.62	0.53	Corneal astigmatism;	chr4:119490752	chr1:222477252~222504622:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-6.88	2.66e-10	0.00508	-0.59	-0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.562	rs2389879	ENSG00000276997.3	RP11-378J18.9	-6.88	2.75e-10	0.00524	-0.62	-0.53	Corneal astigmatism;	chr4:119636529	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.588	rs6534149	ENSG00000276997.3	RP11-378J18.9	-6.88	2.75e-10	0.00524	-0.62	-0.53	Corneal astigmatism;	chr4:119638137	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.739	rs9996382	ENSG00000279072.1	RP13-580B18.4	6.87	2.76e-10	0.00527	0.6	0.53	Corneal astigmatism;	chr4:119229857	chr7:56809214~56848800:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000224553.1	AC008065.1	6.87	2.78e-10	0.0053	0.52	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr2:171374931~171375278:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	6.87	2.79e-10	0.00531	0.57	0.53	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000233278.1	RPS26P2	-6.87	2.79e-10	0.00533	-0.64	-0.53	Cognitive function;	chr12:56080595	chr9:30831878~30832225:-
ESCA	trans	rs66887589	0.777	rs1814815	ENSG00000279072.1	RP13-580B18.4	6.87	2.82e-10	0.00536	0.57	0.53	Diastolic blood pressure;	chr4:119336936	chr7:56809214~56848800:-
ESCA	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	6.87	2.84e-10	0.00541	0.55	0.53	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
ESCA	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-6.86	2.92e-10	0.00555	-0.79	-0.53	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	6.86	2.94e-10	0.00559	0.54	0.53	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
ESCA	trans	rs66887589	0.777	rs2017058	ENSG00000279072.1	RP13-580B18.4	6.86	2.97e-10	0.00564	0.57	0.53	Diastolic blood pressure;	chr4:119336584	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs878373	ENSG00000276997.3	RP11-378J18.9	6.86	2.99e-10	0.00568	0.63	0.53	Corneal astigmatism;	chr4:119316329	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10006877	ENSG00000276997.3	RP11-378J18.9	6.86	2.99e-10	0.00568	0.63	0.53	Corneal astigmatism;	chr4:119321638	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs12505469	ENSG00000276997.3	RP11-378J18.9	6.86	2.99e-10	0.00568	0.63	0.53	Corneal astigmatism;	chr4:119328430	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs2017057	ENSG00000276997.3	RP11-378J18.9	6.86	2.99e-10	0.00568	0.63	0.53	Corneal astigmatism;	chr4:119336556	chr1:222477252~222504622:-
ESCA	trans	rs1552244	0.688	rs7645137	ENSG00000230342.2	FANCD2P2	6.86	3.01e-10	0.00571	0.86	0.53	Alzheimer's disease;	chr3:9978865	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.954	rs12502423	ENSG00000276997.3	RP11-378J18.9	6.86	3.01e-10	0.00571	0.62	0.53	Corneal astigmatism;	chr4:119503017	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10020034	ENSG00000276997.3	RP11-378J18.9	6.85	3.14e-10	0.00594	0.62	0.53	Corneal astigmatism;	chr4:119373176	chr1:222477252~222504622:-
ESCA	trans	rs13177918	0.603	rs2748241	ENSG00000239528.1	RPS14P8	6.85	3.14e-10	0.00595	0.58	0.53	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr5:116562562~116562930:+
ESCA	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	6.85	3.16e-10	0.00597	0.63	0.53	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
ESCA	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-6.84	3.25e-10	0.00614	-0.86	-0.53	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	6.84	3.31e-10	0.00624	0.53	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
ESCA	trans	rs1552244	0.882	rs13063098	ENSG00000230342.2	FANCD2P2	6.84	3.32e-10	0.00625	0.88	0.52	Alzheimer's disease;	chr3:9968235	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.832	rs3732968	ENSG00000230342.2	FANCD2P2	6.83	3.38e-10	0.00636	0.85	0.52	Alzheimer's disease;	chr3:9971589	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs67762674	ENSG00000230342.2	FANCD2P2	6.83	3.38e-10	0.00636	0.85	0.52	Alzheimer's disease;	chr3:9972801	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000196933.5	RPS26P11	6.83	3.4e-10	0.00641	0.53	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:72044545~72044892:+
ESCA	trans	rs11098499	0.954	rs11935596	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119491302	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs12507964	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119491906	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs11098530	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119491999	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs6834796	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119493538	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs11734241	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119495717	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs17006190	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119497683	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs28685688	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119499179	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs7687843	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119500056	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs2306455	ENSG00000276997.3	RP11-378J18.9	6.83	3.45e-10	0.00648	0.62	0.52	Corneal astigmatism;	chr4:119500814	chr1:222477252~222504622:-
ESCA	trans	rs1552244	0.882	rs67631672	ENSG00000230342.2	FANCD2P2	6.83	3.46e-10	0.00649	0.85	0.52	Alzheimer's disease;	chr3:9963084	chr3:11859674~11891172:+
ESCA	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-6.83	3.46e-10	0.0065	-0.58	-0.52	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
ESCA	trans	rs1552244	0.816	rs13059144	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9968513	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs66559400	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9970867	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs68153882	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9971426	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs35056669	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9972487	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs3732967	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9973753	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs3732966	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9974056	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs13062917	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9975348	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.816	rs13076197	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9978089	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs34779351	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9980117	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs13077641	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9981251	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs13074282	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9983015	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs68080705	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9984059	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.882	rs67895180	ENSG00000230342.2	FANCD2P2	6.83	3.55e-10	0.00661	0.85	0.52	Alzheimer's disease;	chr3:9984395	chr3:11859674~11891172:+
ESCA	trans	rs11098499	0.954	rs10006525	ENSG00000276997.3	RP11-378J18.9	6.82	3.56e-10	0.00664	0.62	0.52	Corneal astigmatism;	chr4:119487776	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs6849171	ENSG00000276997.3	RP11-378J18.9	6.82	3.56e-10	0.00664	0.62	0.52	Corneal astigmatism;	chr4:119488394	chr1:222477252~222504622:-
ESCA	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-6.82	3.61e-10	0.00671	-0.67	-0.52	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
ESCA	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-6.82	3.61e-10	0.00671	-0.67	-0.52	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
ESCA	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-6.82	3.61e-10	0.00671	-0.67	-0.52	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
ESCA	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-6.82	3.61e-10	0.00671	-0.67	-0.52	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
ESCA	trans	rs13177918	0.603	rs2343806	ENSG00000239528.1	RPS14P8	6.82	3.69e-10	0.00687	0.59	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452422	chr5:116562562~116562930:+
ESCA	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	6.81	3.74e-10	0.00694	0.67	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
ESCA	trans	rs2950393	0.804	rs2958132	ENSG00000121089.4	NACA3P	6.81	3.74e-10	0.00695	0.44	0.52	Platelet distribution width;	chr12:56750749	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-6.81	3.77e-10	0.007	-0.55	-0.52	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-6.81	3.77e-10	0.007	-0.55	-0.52	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-6.81	3.81e-10	0.00707	-0.55	-0.52	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-6.81	3.81e-10	0.00707	-0.55	-0.52	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
ESCA	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-6.81	3.86e-10	0.00715	-0.6	-0.52	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.562	rs58583086	ENSG00000276997.3	RP11-378J18.9	-6.81	3.87e-10	0.00717	-0.62	-0.52	Corneal astigmatism;	chr4:119635207	chr1:222477252~222504622:-
ESCA	trans	rs13177918	0.677	rs13171800	ENSG00000226396.1	RP5-1056L3.3	6.81	3.9e-10	0.00721	0.5	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs2070841	ENSG00000226396.1	RP5-1056L3.3	6.81	3.9e-10	0.00721	0.5	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13177951	ENSG00000226396.1	RP5-1056L3.3	6.81	3.9e-10	0.00721	0.5	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13177970	ENSG00000226396.1	RP5-1056L3.3	6.81	3.9e-10	0.00721	0.5	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.677	rs13164105	ENSG00000226396.1	RP5-1056L3.3	6.81	3.9e-10	0.00721	0.5	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:19608114~19608568:+
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000196933.5	RPS26P11	6.8	4.03e-10	0.00743	0.53	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:72044545~72044892:+
ESCA	trans	rs11098499	0.661	rs10015965	ENSG00000276997.3	RP11-378J18.9	6.8	4.07e-10	0.00751	0.6	0.52	Corneal astigmatism;	chr4:119347082	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-6.8	4.1e-10	0.00754	-0.51	-0.52	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
ESCA	trans	rs11098499	0.954	rs6848389	ENSG00000276997.3	RP11-378J18.9	6.79	4.21e-10	0.00773	0.63	0.52	Corneal astigmatism;	chr4:119481467	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs1002152	ENSG00000276997.3	RP11-378J18.9	6.79	4.25e-10	0.00781	0.61	0.52	Corneal astigmatism;	chr4:119352232	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs11941899	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119461603	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs7681978	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119462620	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.821	rs28665282	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119463031	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.738	rs10026493	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119463039	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10026736	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119463167	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs7681214	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119464165	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs28559989	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465472	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs28499576	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465522	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs28632018	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465575	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.908	rs71614449	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465900	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs35063680	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465947	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs34858317	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119465955	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs17046116	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119466104	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs17046118	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119466341	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs7654587	ENSG00000276997.3	RP11-378J18.9	6.79	4.31e-10	0.00786	0.61	0.52	Corneal astigmatism;	chr4:119467251	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs11729521	ENSG00000276997.3	RP11-378J18.9	6.78	4.48e-10	0.00814	0.62	0.52	Corneal astigmatism;	chr4:119495633	chr1:222477252~222504622:-
ESCA	trans	rs1816752	0.646	rs9511301	ENSG00000237917.1	PARP4P1	-6.78	4.54e-10	0.00824	-0.67	-0.52	Obesity-related traits;	chr13:24477034	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7332220	ENSG00000237917.1	PARP4P1	-6.78	4.54e-10	0.00824	-0.67	-0.52	Obesity-related traits;	chr13:24477081	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.624	rs11149109	ENSG00000237917.1	PARP4P1	-6.78	4.54e-10	0.00824	-0.67	-0.52	Obesity-related traits;	chr13:24477290	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs9511302	ENSG00000237917.1	PARP4P1	-6.78	4.54e-10	0.00824	-0.67	-0.52	Obesity-related traits;	chr13:24477580	chrY:26594851~26634652:-
ESCA	trans	rs7930295	0.556	rs35904963	ENSG00000236257.1	EI24P2	6.78	4.54e-10	0.00824	0.89	0.52	Schizophrenia;	chr11:125476956	chr1:158454198~158455273:+
ESCA	trans	rs1552244	0.882	rs3755782	ENSG00000230342.2	FANCD2P2	6.78	4.56e-10	0.00828	0.85	0.52	Alzheimer's disease;	chr3:9987621	chr3:11859674~11891172:+
ESCA	trans	rs1816752	0.692	rs6490944	ENSG00000237917.1	PARP4P1	-6.78	4.57e-10	0.00829	-0.68	-0.52	Obesity-related traits;	chr13:24513866	chrY:26594851~26634652:-
ESCA	trans	rs2404476	0.819	rs13149393	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154699345	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs13149801	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154699457	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs4527457	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154701302	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs276177	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154707304	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs276175	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154711034	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs10517600	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154711806	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs1394725	ENSG00000239959.1	ENPP7P2	-6.77	4.58e-10	0.0083	-0.48	-0.52	Interleukin-6 levels;	chr4:154714357	chr3:75446769~75491202:-
ESCA	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-6.77	4.63e-10	0.00837	-0.66	-0.52	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.691	rs9996644	ENSG00000276997.3	RP11-378J18.9	6.77	4.75e-10	0.00859	0.61	0.52	Corneal astigmatism;	chr4:119317722	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs9996494	ENSG00000276997.3	RP11-378J18.9	6.77	4.75e-10	0.00859	0.61	0.52	Corneal astigmatism;	chr4:119317725	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.663	rs9996501	ENSG00000276997.3	RP11-378J18.9	6.77	4.75e-10	0.00859	0.61	0.52	Corneal astigmatism;	chr4:119317763	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs28458294	ENSG00000276997.3	RP11-378J18.9	6.77	4.75e-10	0.00859	0.61	0.52	Corneal astigmatism;	chr4:119317769	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.663	rs28369503	ENSG00000276997.3	RP11-378J18.9	6.77	4.75e-10	0.00859	0.61	0.52	Corneal astigmatism;	chr4:119317770	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.826	rs4472123	ENSG00000276997.3	RP11-378J18.9	6.77	4.76e-10	0.00859	0.62	0.52	Corneal astigmatism;	chr4:119315475	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs11722183	ENSG00000276997.3	RP11-378J18.9	6.76	4.84e-10	0.00872	0.61	0.52	Corneal astigmatism;	chr4:119359442	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.615	rs59867181	ENSG00000276997.3	RP11-378J18.9	-6.76	4.85e-10	0.00875	-0.62	-0.52	Corneal astigmatism;	chr4:119635312	chr1:222477252~222504622:-
ESCA	trans	rs13177918	0.603	rs13175992	ENSG00000226396.1	RP5-1056L3.3	6.76	4.96e-10	0.00893	0.49	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:19608114~19608568:+
ESCA	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-6.76	5.01e-10	0.00902	-0.62	-0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
ESCA	trans	rs11098499	0.754	rs1980025	ENSG00000276997.3	RP11-378J18.9	-6.76	5.03e-10	0.00905	-0.6	-0.52	Corneal astigmatism;	chr4:119331651	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	6.76	5.04e-10	0.00905	0.54	0.52	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	6.76	5.04e-10	0.00905	0.54	0.52	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	6.76	5.04e-10	0.00905	0.54	0.52	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	6.76	5.04e-10	0.00905	0.54	0.52	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
ESCA	trans	rs877636	1	rs877636	ENSG00000234192.1	RP11-57C13.5	-6.75	5.11e-10	0.00917	-0.59	-0.52	Cognitive function;	chr12:56086799	chr10:87642607~87642954:+
ESCA	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-6.75	5.16e-10	0.00927	-0.62	-0.52	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
ESCA	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-6.75	5.31e-10	0.00946	-0.69	-0.52	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	6.74	5.39e-10	0.00958	0.66	0.52	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	6.74	5.39e-10	0.00958	0.66	0.52	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	6.74	5.39e-10	0.00958	0.66	0.52	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
ESCA	trans	rs13177918	0.626	rs13175436	ENSG00000226396.1	RP5-1056L3.3	6.74	5.44e-10	0.00966	0.49	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.626	rs67026795	ENSG00000226396.1	RP5-1056L3.3	6.74	5.44e-10	0.00966	0.49	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:19608114~19608568:+
ESCA	trans	rs13177918	0.603	rs10447222	ENSG00000226396.1	RP5-1056L3.3	6.74	5.44e-10	0.00966	0.49	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:19608114~19608568:+
ESCA	trans	rs11098499	0.954	rs11098524	ENSG00000276997.3	RP11-378J18.9	6.74	5.54e-10	0.00984	0.62	0.52	Corneal astigmatism;	chr4:119468877	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs10212714	ENSG00000276997.3	RP11-378J18.9	6.73	5.6e-10	0.00992	0.6	0.52	Corneal astigmatism;	chr4:119333147	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.789	rs10212719	ENSG00000276997.3	RP11-378J18.9	6.73	5.6e-10	0.00992	0.6	0.52	Corneal astigmatism;	chr4:119333282	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs705696	ENSG00000234192.1	RP11-57C13.5	6.73	5.64e-10	0.00998	0.59	0.52	Cognitive function;	chr12:56086864	chr10:87642607~87642954:+
ESCA	trans	rs1552244	0.572	rs6442154	ENSG00000230342.2	FANCD2P2	6.73	5.66e-10	0.01	1.05	0.52	Alzheimer's disease;	chr3:10127101	chr3:11859674~11891172:+
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-6.73	5.7e-10	0.0101	-0.6	-0.52	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
ESCA	trans	rs11098499	0.954	rs10031483	ENSG00000276997.3	RP11-378J18.9	6.73	5.71e-10	0.0101	0.61	0.52	Corneal astigmatism;	chr4:119501481	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10031665	ENSG00000276997.3	RP11-378J18.9	6.73	5.71e-10	0.0101	0.61	0.52	Corneal astigmatism;	chr4:119501697	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs3733519	ENSG00000276997.3	RP11-378J18.9	6.73	5.71e-10	0.0101	0.61	0.52	Corneal astigmatism;	chr4:119502293	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs3733523	ENSG00000276997.3	RP11-378J18.9	6.73	5.71e-10	0.0101	0.61	0.52	Corneal astigmatism;	chr4:119502564	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs3733524	ENSG00000276997.3	RP11-378J18.9	6.73	5.71e-10	0.0101	0.61	0.52	Corneal astigmatism;	chr4:119502574	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs1849457	ENSG00000276997.3	RP11-378J18.9	6.73	5.85e-10	0.0103	0.6	0.52	Corneal astigmatism;	chr4:119333200	chr1:222477252~222504622:-
ESCA	trans	rs1816752	0.646	rs8002599	ENSG00000237917.1	PARP4P1	-6.72	5.96e-10	0.0105	-0.67	-0.52	Obesity-related traits;	chr13:24478486	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7322323	ENSG00000237917.1	PARP4P1	-6.72	5.96e-10	0.0105	-0.67	-0.52	Obesity-related traits;	chr13:24479189	chrY:26594851~26634652:-
ESCA	trans	rs1816752	0.646	rs7322329	ENSG00000237917.1	PARP4P1	-6.72	5.96e-10	0.0105	-0.67	-0.52	Obesity-related traits;	chr13:24479193	chrY:26594851~26634652:-
ESCA	trans	rs877636	0.74	rs705698	ENSG00000196656.7	AC004057.1	6.72	6e-10	0.0106	0.6	0.52	Cognitive function;	chr12:55990903	chr4:113214046~113217170:-
ESCA	trans	rs11098499	0.754	rs17049949	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119334135	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs10213221	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119334771	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs7689729	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119335037	chr1:222477252~222504622:-
ESCA	trans	rs10028773	0.7	rs7690338	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Educational attainment;	chr4:119335313	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs3956464	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119335609	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.619	rs28502463	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119335868	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.648	rs2002047	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119336073	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.775	rs2002049	ENSG00000276997.3	RP11-378J18.9	6.72	6.07e-10	0.0107	0.6	0.52	Corneal astigmatism;	chr4:119336262	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs12510133	ENSG00000276997.3	RP11-378J18.9	6.71	6.18e-10	0.0108	0.59	0.52	Corneal astigmatism;	chr4:119350189	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-6.71	6.22e-10	0.0109	-0.55	-0.52	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
ESCA	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	6.71	6.27e-10	0.011	0.66	0.52	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	6.71	6.27e-10	0.011	0.66	0.52	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	6.71	6.27e-10	0.011	0.66	0.52	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.908	rs11098527	ENSG00000276997.3	RP11-378J18.9	6.7	6.53e-10	0.0113	0.61	0.52	Corneal astigmatism;	chr4:119478751	chr1:222477252~222504622:-
ESCA	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-6.7	6.53e-10	0.0113	-0.6	-0.52	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.697	rs35280960	ENSG00000276997.3	RP11-378J18.9	6.7	6.59e-10	0.0114	0.62	0.52	Corneal astigmatism;	chr4:119335904	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	6.7	6.67e-10	0.0116	0.61	0.52	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
ESCA	trans	rs11098499	0.588	rs2389874	ENSG00000276997.3	RP11-378J18.9	-6.69	6.94e-10	0.012	-0.62	-0.52	Corneal astigmatism;	chr4:119633836	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.562	rs13101722	ENSG00000276997.3	RP11-378J18.9	-6.69	6.94e-10	0.012	-0.62	-0.52	Corneal astigmatism;	chr4:119634820	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1010740	ENSG00000276997.3	RP11-378J18.9	-6.69	6.97e-10	0.012	-0.6	-0.52	Corneal astigmatism;	chr4:119542254	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12506487	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350206	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs12502524	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350259	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs28396837	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350386	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.629	rs28369518	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350475	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.722	rs10025925	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350589	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.731	rs10015579	ENSG00000276997.3	RP11-378J18.9	6.69	6.97e-10	0.012	0.59	0.52	Corneal astigmatism;	chr4:119350647	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-6.69	6.99e-10	0.012	-0.54	-0.52	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-6.69	6.99e-10	0.012	-0.54	-0.52	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
ESCA	trans	rs11098499	0.754	rs7672372	ENSG00000276997.3	RP11-378J18.9	6.69	7.07e-10	0.0122	0.61	0.52	Corneal astigmatism;	chr4:119327251	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000227887.1	RPS26P13	6.69	7.13e-10	0.0123	0.51	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:208697369~208697698:-
ESCA	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	6.69	7.15e-10	0.0123	0.63	0.52	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
ESCA	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-6.69	7.17e-10	0.0123	-0.84	-0.52	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	6.68	7.3e-10	0.0125	0.57	0.52	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.954	rs3890049	ENSG00000276997.3	RP11-378J18.9	6.68	7.34e-10	0.0126	0.6	0.52	Corneal astigmatism;	chr4:119405128	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	6.68	7.34e-10	0.0126	0.55	0.52	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
ESCA	trans	rs11098499	0.908	rs7695996	ENSG00000276997.3	RP11-378J18.9	6.68	7.41e-10	0.0127	0.6	0.52	Corneal astigmatism;	chr4:119400878	chr1:222477252~222504622:-
ESCA	trans	rs66887589	0.774	rs9307477	ENSG00000279072.1	RP13-580B18.4	6.68	7.43e-10	0.0127	0.55	0.52	Diastolic blood pressure;	chr4:119500654	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	-6.68	7.44e-10	0.0128	-0.66	-0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
ESCA	trans	rs10028773	0.6	rs4001390	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Educational attainment;	chr4:119344628	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs2136911	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119344704	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.554	rs2175381	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119344812	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.599	rs3864142	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119345036	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.605	rs6833140	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119345667	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs6815934	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119346155	chr1:222477252~222504622:-
ESCA	trans	rs10028773	0.568	rs6838457	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Educational attainment;	chr4:119346212	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.535	rs10005542	ENSG00000276997.3	RP11-378J18.9	6.68	7.47e-10	0.0128	0.59	0.52	Corneal astigmatism;	chr4:119347147	chr1:222477252~222504622:-
ESCA	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	6.68	7.49e-10	0.0128	0.66	0.52	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.644	rs2389880	ENSG00000276997.3	RP11-378J18.9	6.67	7.63e-10	0.013	0.6	0.52	Corneal astigmatism;	chr4:119638715	chr1:222477252~222504622:-
ESCA	trans	rs66887589	0.807	rs9799664	ENSG00000279072.1	RP13-580B18.4	6.67	7.68e-10	0.0131	0.54	0.52	Diastolic blood pressure;	chr4:119405523	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.575	rs9996586	ENSG00000279072.1	RP13-580B18.4	6.67	7.68e-10	0.0131	0.54	0.52	Corneal astigmatism;	chr4:119405787	chr7:56809214~56848800:-
ESCA	trans	rs13177918	0.578	rs35919198	ENSG00000226396.1	RP5-1056L3.3	6.67	7.69e-10	0.0131	0.49	0.52	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:19608114~19608568:+
ESCA	trans	rs941207	0.542	rs1903370	ENSG00000121089.4	NACA3P	-6.67	7.71e-10	0.0131	-0.42	-0.52	Platelet count;	chr12:56812900	chr4:164943290~164943937:+
ESCA	trans	rs11098499	0.754	rs66900435	ENSG00000276997.3	RP11-378J18.9	6.67	7.85e-10	0.0134	0.61	0.52	Corneal astigmatism;	chr4:119328270	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs17595608	ENSG00000276997.3	RP11-378J18.9	6.67	7.85e-10	0.0134	0.61	0.52	Corneal astigmatism;	chr4:119329351	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs1980027	ENSG00000276997.3	RP11-378J18.9	6.67	7.85e-10	0.0134	0.61	0.52	Corneal astigmatism;	chr4:119330422	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	6.66	7.95e-10	0.0135	0.9	0.52	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
ESCA	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	6.66	8.09e-10	0.0137	0.53	0.51	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
ESCA	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	6.66	8.11e-10	0.0137	0.9	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	6.66	8.11e-10	0.0137	0.9	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	6.66	8.11e-10	0.0137	0.9	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
ESCA	trans	rs11098499	0.739	rs9884728	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119205924	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.739	rs7441137	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119212066	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.71	rs6851130	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119212557	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.739	rs4833612	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119226441	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.739	rs10013032	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119228264	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.739	rs951570	ENSG00000279072.1	RP13-580B18.4	-6.66	8.11e-10	0.0137	-0.6	-0.51	Corneal astigmatism;	chr4:119229312	chr7:56809214~56848800:-
ESCA	trans	rs1816752	0.646	rs2862905	ENSG00000237917.1	PARP4P1	-6.65	8.43e-10	0.0142	-0.67	-0.51	Obesity-related traits;	chr13:24485142	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.754	rs1814813	ENSG00000276997.3	RP11-378J18.9	-6.65	8.47e-10	0.0143	-0.59	-0.51	Corneal astigmatism;	chr4:119337052	chr1:222477252~222504622:-
ESCA	trans	rs66887589	0.807	rs13134517	ENSG00000279072.1	RP13-580B18.4	6.65	8.61e-10	0.0145	0.54	0.51	Diastolic blood pressure;	chr4:119484107	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.807	rs7694483	ENSG00000279072.1	RP13-580B18.4	6.65	8.61e-10	0.0145	0.54	0.51	Diastolic blood pressure;	chr4:119484774	chr7:56809214~56848800:-
ESCA	trans	rs66887589	0.837	rs6534135	ENSG00000279072.1	RP13-580B18.4	6.65	8.61e-10	0.0145	0.54	0.51	Diastolic blood pressure;	chr4:119485147	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.754	rs10518300	ENSG00000276997.3	RP11-378J18.9	-6.64	8.78e-10	0.0145	-0.62	-0.51	Corneal astigmatism;	chr4:119328344	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	6.64	8.79e-10	0.0145	0.94	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
ESCA	trans	rs11098499	0.954	rs10518331	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119402440	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs13133522	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119403269	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs35091806	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119404374	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs35165976	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119404475	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs2389802	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119404577	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs6846442	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119405168	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs4001305	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119438081	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs67265404	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119438115	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs71614422	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119438185	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.738	rs34566984	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119440115	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.738	rs34965784	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119440431	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs17009122	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119441248	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.505	rs75122014	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119441271	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs9685777	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119444810	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs9759478	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119446843	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs71614438	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119450097	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs66506550	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119450290	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs7659501	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119450397	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs71629403	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119451412	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs73842633	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119454309	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs80242894	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119454597	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs28495013	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119454676	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs28571712	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119454825	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.738	rs28408407	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119454875	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs1809406	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119455967	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs2389809	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119456244	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.657	rs71614442	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119458191	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs2892848	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119460186	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.865	rs9994730	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119460409	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs9994810	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119460435	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.697	rs10020027	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119460724	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.779	rs7356491	ENSG00000276997.3	RP11-378J18.9	6.64	8.81e-10	0.0145	0.6	0.51	Corneal astigmatism;	chr4:119460819	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs6858592	ENSG00000276997.3	RP11-378J18.9	6.64	8.83e-10	0.0145	0.59	0.51	Corneal astigmatism;	chr4:119537537	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	6.64	8.86e-10	0.0145	0.9	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
ESCA	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-6.64	9.01e-10	0.0148	-0.54	-0.51	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000227887.1	RPS26P13	6.64	9.02e-10	0.0148	0.5	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr1:208697369~208697698:-
ESCA	trans	rs11098499	0.954	rs10006706	ENSG00000276997.3	RP11-378J18.9	6.64	9.18e-10	0.015	0.6	0.51	Corneal astigmatism;	chr4:119487997	chr1:222477252~222504622:-
ESCA	trans	rs2404476	0.819	rs276167	ENSG00000239959.1	ENPP7P2	-6.63	9.25e-10	0.0151	-0.48	-0.51	Interleukin-6 levels;	chr4:154696774	chr3:75446769~75491202:-
ESCA	trans	rs10028773	0.7	rs7671797	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Educational attainment;	chr4:119327002	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs7672594	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119327388	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs7672778	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119327430	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs2036860	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119327779	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs2036857	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119328085	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs2036856	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119328133	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs4443261	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119328146	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12513083	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119328457	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12509621	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119328505	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs1511017	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119329650	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.789	rs12498994	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119329663	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs12507565	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119329966	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.826	rs12511640	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119330093	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs1980026	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119330488	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.722	rs28713555	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119330840	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.743	rs11098501	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119330862	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs11098502	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119330908	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.708	rs11732686	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119331175	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs11724409	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119331206	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.789	rs1980024	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119331892	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs34425882	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119332022	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs4107728	ENSG00000276997.3	RP11-378J18.9	6.63	9.49e-10	0.0154	0.61	0.51	Corneal astigmatism;	chr4:119332755	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	6.63	9.52e-10	0.0155	0.51	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
ESCA	trans	rs877636	0.74	rs705698	ENSG00000243403.1	RP11-330L19.1	6.63	9.53e-10	0.0155	0.53	0.51	Cognitive function;	chr12:55990903	chr15:64592979~64593326:+
ESCA	trans	rs11098499	0.58	rs12509234	ENSG00000276997.3	RP11-378J18.9	6.63	9.54e-10	0.0155	0.6	0.51	Corneal astigmatism;	chr4:119398279	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10014719	ENSG00000276997.3	RP11-378J18.9	6.63	9.54e-10	0.0155	0.6	0.51	Corneal astigmatism;	chr4:119399560	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.954	rs10017543	ENSG00000276997.3	RP11-378J18.9	6.63	9.54e-10	0.0155	0.6	0.51	Corneal astigmatism;	chr4:119400265	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	6.63	9.57e-10	0.0155	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	6.63	9.57e-10	0.0155	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	6.63	9.57e-10	0.0155	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	6.63	9.57e-10	0.0155	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
ESCA	trans	rs11098499	0.908	rs7696649	ENSG00000276997.3	RP11-378J18.9	6.62	9.88e-10	0.016	0.61	0.51	Corneal astigmatism;	chr4:119401022	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.644	rs10050092	ENSG00000276997.3	RP11-378J18.9	6.62	1.01e-09	0.0162	0.6	0.51	Corneal astigmatism;	chr4:119610930	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-6.62	1.02e-09	0.0164	-0.87	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
ESCA	trans	rs11098499	0.954	rs2389803	ENSG00000276997.3	RP11-378J18.9	-6.61	1.04e-09	0.0168	-0.59	-0.51	Corneal astigmatism;	chr4:119472356	chr1:222477252~222504622:-
ESCA	trans	rs10028773	0.632	rs34481394	ENSG00000276997.3	RP11-378J18.9	6.6	1.08e-09	0.0174	0.6	0.51	Educational attainment;	chr4:119327219	chr1:222477252~222504622:-
ESCA	trans	rs10028773	0.666	rs35231872	ENSG00000276997.3	RP11-378J18.9	6.6	1.08e-09	0.0174	0.6	0.51	Educational attainment;	chr4:119327221	chr1:222477252~222504622:-
ESCA	trans	rs10028773	0.7	rs35653026	ENSG00000276997.3	RP11-378J18.9	6.6	1.08e-09	0.0174	0.6	0.51	Educational attainment;	chr4:119327223	chr1:222477252~222504622:-
ESCA	trans	rs2733310	0.79	rs16977278	ENSG00000204556.4	CTD-2514C3.1	6.6	1.09e-09	0.0174	0.63	0.51	Mean platelet volume;	chr15:57180013	chr20:26018832~26020684:+
ESCA	trans	rs2404476	0.783	rs276173	ENSG00000239959.1	ENPP7P2	-6.6	1.1e-09	0.0176	-0.48	-0.51	Interleukin-6 levels;	chr4:154694450	chr3:75446769~75491202:-
ESCA	trans	rs727153	0.515	rs276172	ENSG00000239959.1	ENPP7P2	-6.6	1.1e-09	0.0176	-0.48	-0.51	Alzheimer's disease;	chr4:154694769	chr3:75446769~75491202:-
ESCA	trans	rs877636	0.702	rs773108	ENSG00000204652.6	RPS26P8	6.6	1.12e-09	0.0179	0.53	0.51	Cognitive function;	chr12:55976127	chr17:45608571~45608918:+
ESCA	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-6.6	1.12e-09	0.0179	-0.53	-0.51	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
ESCA	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-6.6	1.12e-09	0.0179	-0.53	-0.51	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
ESCA	trans	rs66887589	0.775	rs6843229	ENSG00000279072.1	RP13-580B18.4	6.6	1.12e-09	0.0179	0.54	0.51	Diastolic blood pressure;	chr4:119502932	chr7:56809214~56848800:-
ESCA	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	6.59	1.13e-09	0.018	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
ESCA	trans	rs10028773	0.546	rs13117947	ENSG00000279072.1	RP13-580B18.4	6.59	1.13e-09	0.0181	0.56	0.51	Educational attainment;	chr4:119335905	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.535	rs7671759	ENSG00000276997.3	RP11-378J18.9	6.59	1.18e-09	0.0188	0.6	0.51	Corneal astigmatism;	chr4:119326939	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs4759229	ENSG00000233278.1	RPS26P2	-6.58	1.19e-09	0.0189	-0.61	-0.51	Cognitive function;	chr12:56080696	chr9:30831878~30832225:-
ESCA	trans	rs11098499	0.954	rs12510138	ENSG00000276997.3	RP11-378J18.9	6.58	1.2e-09	0.0191	0.6	0.51	Corneal astigmatism;	chr4:119502780	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.644	rs17517414	ENSG00000276997.3	RP11-378J18.9	6.58	1.21e-09	0.0193	0.58	0.51	Corneal astigmatism;	chr4:119340946	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.722	rs17595727	ENSG00000276997.3	RP11-378J18.9	-6.58	1.21e-09	0.0193	-0.58	-0.51	Corneal astigmatism;	chr4:119340919	chr1:222477252~222504622:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-6.58	1.22e-09	0.0194	-0.56	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
ESCA	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	6.58	1.22e-09	0.0195	0.89	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
ESCA	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	6.57	1.24e-09	0.0198	0.56	0.51	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	6.57	1.25e-09	0.0198	0.5	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
ESCA	trans	rs11098499	0.644	rs7693919	ENSG00000276997.3	RP11-378J18.9	6.57	1.29e-09	0.0204	0.6	0.51	Corneal astigmatism;	chr4:119619416	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-6.57	1.31e-09	0.0206	-0.56	-0.51	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
ESCA	trans	rs9356181	1	rs1010549	ENSG00000251962.1	AL591668.1	6.56	1.31e-09	0.0207	0.52	0.51	Mean corpuscular volume;	chr6:164071351	chrX:134403298~134403382:-
ESCA	trans	rs9356181	1	rs3846781	ENSG00000251962.1	AL591668.1	6.56	1.31e-09	0.0207	0.52	0.51	Mean corpuscular volume;	chr6:164074381	chrX:134403298~134403382:-
ESCA	trans	rs11098499	0.908	rs9995234	ENSG00000276997.3	RP11-378J18.9	6.56	1.31e-09	0.0208	0.59	0.51	Corneal astigmatism;	chr4:119400672	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10017335	ENSG00000276997.3	RP11-378J18.9	-6.56	1.32e-09	0.0208	-0.58	-0.51	Corneal astigmatism;	chr4:119460368	chr1:222477252~222504622:-
ESCA	trans	rs4820294	0.77	rs7285699	ENSG00000247925.2	RP3-510L9.1	-6.56	1.32e-09	0.0208	-0.49	-0.51	Fat distribution (HIV);	chr22:37670549	chr6:11173452~11259099:+
ESCA	trans	rs11098499	0.909	rs1546502	ENSG00000276997.3	RP11-378J18.9	6.56	1.32e-09	0.0208	0.61	0.51	Corneal astigmatism;	chr4:119314743	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-6.56	1.34e-09	0.0211	-0.56	-0.51	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-6.56	1.35e-09	0.0213	-0.55	-0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
ESCA	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-6.56	1.36e-09	0.0215	-0.86	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
ESCA	trans	rs11098499	0.865	rs28634456	ENSG00000276997.3	RP11-378J18.9	6.56	1.37e-09	0.0215	0.59	0.51	Corneal astigmatism;	chr4:119454623	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1480940	ENSG00000276997.3	RP11-378J18.9	6.55	1.39e-09	0.0219	0.59	0.51	Corneal astigmatism;	chr4:119536527	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.754	rs9991959	ENSG00000276997.3	RP11-378J18.9	-6.55	1.4e-09	0.0219	-0.6	-0.51	Corneal astigmatism;	chr4:119332618	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.866	rs10518329	ENSG00000276997.3	RP11-378J18.9	6.55	1.4e-09	0.0219	0.58	0.51	Corneal astigmatism;	chr4:119480680	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1383532	ENSG00000276997.3	RP11-378J18.9	-6.55	1.42e-09	0.0222	-0.59	-0.51	Corneal astigmatism;	chr4:119513249	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-6.55	1.43e-09	0.0223	-0.85	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-6.55	1.43e-09	0.0223	-0.85	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-6.55	1.43e-09	0.0223	-0.85	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-6.55	1.43e-09	0.0223	-0.85	-0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
ESCA	trans	rs1563304	1	rs1563304	ENSG00000263503.1	RP11-707O23.5	6.54	1.48e-09	0.0232	0.93	0.51	Neuroticism;	chr17:46797087	chr17:45600869~45602340:-
ESCA	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	6.54	1.5e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
ESCA	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	6.53	1.52e-09	0.0233	0.65	0.51	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
ESCA	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	6.53	1.53e-09	0.0235	0.92	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
ESCA	trans	rs11098499	0.754	rs10213554	ENSG00000276997.3	RP11-378J18.9	-6.53	1.53e-09	0.0235	-0.6	-0.51	Corneal astigmatism;	chr4:119339630	chr1:222477252~222504622:-
ESCA	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	6.53	1.54e-09	0.0236	0.56	0.51	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
ESCA	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	6.53	1.54e-09	0.0237	0.58	0.51	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
ESCA	trans	rs1816752	0.716	rs1441058	ENSG00000237917.1	PARP4P1	-6.53	1.55e-09	0.0238	-0.65	-0.51	Obesity-related traits;	chr13:24516275	chrY:26594851~26634652:-
ESCA	trans	rs1879734	1	rs4927027	ENSG00000260144.1	RP11-361M10.3	-6.53	1.57e-09	0.0241	-0.61	-0.51	Mitral valve prolapse;	chr1:53675601	chr15:72605183~72612326:+
ESCA	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	6.53	1.58e-09	0.0242	0.56	0.51	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
ESCA	trans	rs1816752	0.716	rs7995304	ENSG00000237917.1	PARP4P1	-6.53	1.59e-09	0.0244	-0.65	-0.51	Obesity-related traits;	chr13:24514284	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.954	rs10008392	ENSG00000276997.3	RP11-378J18.9	6.52	1.6e-09	0.0244	0.6	0.51	Corneal astigmatism;	chr4:119397684	chr1:222477252~222504622:-
ESCA	trans	rs2404476	0.819	rs13142641	ENSG00000239959.1	ENPP7P2	-6.52	1.6e-09	0.0245	-0.48	-0.51	Interleukin-6 levels;	chr4:154691288	chr3:75446769~75491202:-
ESCA	trans	rs11098499	0.909	rs79026312	ENSG00000276997.3	RP11-378J18.9	6.52	1.61e-09	0.0245	0.59	0.51	Corneal astigmatism;	chr4:119519522	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs35111518	ENSG00000276997.3	RP11-378J18.9	6.52	1.61e-09	0.0245	0.59	0.51	Corneal astigmatism;	chr4:119519527	chr1:222477252~222504622:-
ESCA	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
ESCA	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
ESCA	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
ESCA	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
ESCA	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
ESCA	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	6.52	1.63e-09	0.0248	0.84	0.51	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
ESCA	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	6.52	1.63e-09	0.0249	0.63	0.51	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
ESCA	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-6.52	1.65e-09	0.025	-0.59	-0.51	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
ESCA	trans	rs13205180	0.55	rs1970193	ENSG00000230020.1	NHS-AS1	6.52	1.65e-09	0.025	0.63	0.51	Diastolic blood pressure;	chr6:52125300	chrX:17552349~17557387:-
ESCA	trans	rs11098499	0.644	rs10012252	ENSG00000276997.3	RP11-378J18.9	6.52	1.65e-09	0.025	0.59	0.51	Corneal astigmatism;	chr4:119637984	chr1:222477252~222504622:-
ESCA	trans	rs66887589	0.837	rs7661498	ENSG00000279072.1	RP13-580B18.4	6.51	1.68e-09	0.0255	0.53	0.51	Diastolic blood pressure;	chr4:119486953	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs34868248	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119521275	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3733525	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119525893	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3775847	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119526487	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3775848	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119526569	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs10013305	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119529269	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3775849	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119529753	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.818	rs7688802	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119530513	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs7695620	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119531621	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs12502389	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119533036	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.821	rs3775852	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119533401	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.82	rs6534140	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119534156	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs7657849	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119534339	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs10034450	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119534494	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1480939	ENSG00000276997.3	RP11-378J18.9	6.51	1.7e-09	0.0257	0.59	0.51	Corneal astigmatism;	chr4:119535772	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	6.51	1.73e-09	0.0261	0.66	0.51	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
ESCA	trans	rs10028773	0.666	rs12498657	ENSG00000276997.3	RP11-378J18.9	6.51	1.74e-09	0.0262	0.58	0.51	Educational attainment;	chr4:119341711	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.722	rs10006192	ENSG00000276997.3	RP11-378J18.9	6.51	1.74e-09	0.0262	0.58	0.51	Corneal astigmatism;	chr4:119341867	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.615	rs28551750	ENSG00000276997.3	RP11-378J18.9	6.51	1.74e-09	0.0262	0.58	0.51	Corneal astigmatism;	chr4:119343746	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.691	rs9995716	ENSG00000276997.3	RP11-378J18.9	6.51	1.74e-09	0.0262	0.58	0.51	Corneal astigmatism;	chr4:119343841	chr1:222477252~222504622:-
ESCA	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	6.51	1.74e-09	0.0262	0.6	0.51	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	6.51	1.74e-09	0.0262	0.6	0.51	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.739	rs2203039	ENSG00000279072.1	RP13-580B18.4	-6.51	1.74e-09	0.0262	-0.6	-0.51	Corneal astigmatism;	chr4:119211192	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.954	rs3733520	ENSG00000276997.3	RP11-378J18.9	6.51	1.75e-09	0.0263	0.61	0.51	Corneal astigmatism;	chr4:119502325	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	6.5	1.79e-09	0.0269	0.5	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
ESCA	trans	rs11098499	0.754	rs28643450	ENSG00000276997.3	RP11-378J18.9	6.5	1.8e-09	0.027	0.61	0.51	Corneal astigmatism;	chr4:119324087	chr1:222477252~222504622:-
ESCA	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	6.5	1.81e-09	0.0271	0.57	0.51	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
ESCA	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-6.5	1.82e-09	0.0273	-0.52	-0.51	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
ESCA	trans	rs877636	1	rs2292239	ENSG00000234192.1	RP11-57C13.5	6.5	1.82e-09	0.0274	0.57	0.51	Cognitive function;	chr12:56088396	chr10:87642607~87642954:+
ESCA	trans	rs11098499	0.691	rs17009144	ENSG00000276997.3	RP11-378J18.9	-6.5	1.83e-09	0.0275	-0.58	-0.51	Corneal astigmatism;	chr4:119349640	chr1:222477252~222504622:-
ESCA	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	6.49	1.85e-09	0.0277	0.63	0.51	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	6.49	1.85e-09	0.0277	0.63	0.51	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	6.49	1.85e-09	0.0277	0.63	0.51	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
ESCA	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	6.49	1.87e-09	0.028	0.88	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
ESCA	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	6.49	1.87e-09	0.028	0.88	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
ESCA	trans	rs13205180	0.55	rs12661793	ENSG00000230020.1	NHS-AS1	6.49	1.93e-09	0.0288	0.63	0.5	Diastolic blood pressure;	chr6:52122088	chrX:17552349~17557387:-
ESCA	trans	rs2950393	0.804	rs898611	ENSG00000121089.4	NACA3P	-6.48	1.95e-09	0.029	-0.43	-0.5	Platelet distribution width;	chr12:56769532	chr4:164943290~164943937:+
ESCA	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	6.48	1.97e-09	0.0293	0.53	0.5	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
ESCA	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	6.48	1.97e-09	0.0293	0.53	0.5	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
ESCA	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	6.48	1.97e-09	0.0293	0.53	0.5	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
ESCA	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	6.48	1.97e-09	0.0293	0.53	0.5	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
ESCA	trans	rs2950393	0.804	rs7967600	ENSG00000121089.4	NACA3P	6.48	1.97e-09	0.0293	0.43	0.5	Platelet distribution width;	chr12:56768208	chr4:164943290~164943937:+
ESCA	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	6.48	1.99e-09	0.0295	0.61	0.5	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
ESCA	trans	rs1816752	0.716	rs9553331	ENSG00000237917.1	PARP4P1	-6.48	1.99e-09	0.0296	-0.66	-0.5	Obesity-related traits;	chr13:24516030	chrY:26594851~26634652:-
ESCA	trans	rs11098499	0.738	rs72918577	ENSG00000276997.3	RP11-378J18.9	6.48	1.99e-09	0.0296	0.6	0.5	Corneal astigmatism;	chr4:119405546	chr1:222477252~222504622:-
ESCA	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	6.48	2.01e-09	0.0298	0.53	0.5	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000234192.1	RP11-57C13.5	6.48	2.03e-09	0.0301	0.52	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr10:87642607~87642954:+
ESCA	trans	rs1531228	0.831	rs75711040	ENSG00000200528.1	RNU6-1331P	6.47	2.05e-09	0.0303	0.8	0.5	Barrett's esophagus;	chr12:13469732	chr8:53914719~53914824:+
ESCA	trans	rs11098499	0.955	rs11944880	ENSG00000276997.3	RP11-378J18.9	-6.47	2.05e-09	0.0304	-0.6	-0.5	Corneal astigmatism;	chr4:119238179	chr1:222477252~222504622:-
ESCA	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-6.47	2.06e-09	0.0304	-0.78	-0.5	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
ESCA	trans	rs1816752	0.603	rs9511278	ENSG00000237917.1	PARP4P1	-6.47	2.07e-09	0.0305	-0.7	-0.5	Obesity-related traits;	chr13:24455766	chrY:26594851~26634652:-
ESCA	trans	rs995030	0.528	rs10858738	ENSG00000261121.1	RP11-496D24.2	-6.47	2.1e-09	0.0309	-0.77	-0.5	Testicular germ cell tumor;	chr12:88447451	chr4:24659856~24671568:+
ESCA	trans	rs66887589	0.967	rs1480933	ENSG00000279072.1	RP13-580B18.4	6.47	2.1e-09	0.0309	0.53	0.5	Diastolic blood pressure;	chr4:119512093	chr7:56809214~56848800:-
ESCA	trans	rs11098499	0.863	rs9997631	ENSG00000276997.3	RP11-378J18.9	6.47	2.11e-09	0.031	0.59	0.5	Corneal astigmatism;	chr4:119548840	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs10018280	ENSG00000276997.3	RP11-378J18.9	6.47	2.11e-09	0.031	0.59	0.5	Corneal astigmatism;	chr4:119556984	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs6534141	ENSG00000276997.3	RP11-378J18.9	6.47	2.11e-09	0.031	0.59	0.5	Corneal astigmatism;	chr4:119564068	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs2127823	ENSG00000276997.3	RP11-378J18.9	6.47	2.11e-09	0.031	0.59	0.5	Corneal astigmatism;	chr4:119564515	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3775858	ENSG00000276997.3	RP11-378J18.9	6.47	2.11e-09	0.031	0.59	0.5	Corneal astigmatism;	chr4:119564873	chr1:222477252~222504622:-
ESCA	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	6.46	2.15e-09	0.0316	0.62	0.5	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
ESCA	trans	rs7312770	0.637	rs705699	ENSG00000242206.2	RPS26P35	6.46	2.16e-09	0.0317	0.49	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:118761856~118762201:-
ESCA	trans	rs1563304	1	rs1563304	ENSG00000280022.1	RP11-707O23.1	6.46	2.17e-09	0.0318	0.9	0.5	Neuroticism;	chr17:46797087	chr17:45592621~45593369:+
ESCA	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	6.46	2.17e-09	0.0319	0.64	0.5	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	6.46	2.18e-09	0.0319	0.62	0.5	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	6.46	2.18e-09	0.0319	0.62	0.5	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
ESCA	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-6.46	2.23e-09	0.0326	-0.66	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
ESCA	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-6.46	2.24e-09	0.0328	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-6.46	2.24e-09	0.0328	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-6.46	2.24e-09	0.0328	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
ESCA	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-6.46	2.25e-09	0.0329	-0.79	-0.5	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-6.46	2.25e-09	0.0329	-0.52	-0.5	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
ESCA	trans	rs9309245	0.501	rs62138438	ENSG00000227722.1	RP5-1059H15.1	6.45	2.26e-09	0.0331	0.67	0.5	Type 2 diabetes;	chr2:53157933	chr1:168369054~168369601:+
ESCA	trans	rs11098499	0.863	rs10030660	ENSG00000276997.3	RP11-378J18.9	6.45	2.26e-09	0.0331	0.59	0.5	Corneal astigmatism;	chr4:119515549	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs13149407	ENSG00000276997.3	RP11-378J18.9	6.45	2.26e-09	0.0331	0.59	0.5	Corneal astigmatism;	chr4:119516670	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs10004484	ENSG00000276997.3	RP11-378J18.9	6.45	2.26e-09	0.0331	0.59	0.5	Corneal astigmatism;	chr4:119521273	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1155576	ENSG00000276997.3	RP11-378J18.9	6.45	2.26e-09	0.0331	0.59	0.5	Corneal astigmatism;	chr4:119529004	chr1:222477252~222504622:-
ESCA	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	6.45	2.28e-09	0.0333	0.62	0.5	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.644	rs10009566	ENSG00000276997.3	RP11-378J18.9	6.45	2.3e-09	0.0336	0.58	0.5	Corneal astigmatism;	chr4:119637453	chr1:222477252~222504622:-
ESCA	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	-6.45	2.31e-09	0.0337	-0.65	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
ESCA	trans	rs1879734	1	rs55888542	ENSG00000260144.1	RP11-361M10.3	-6.45	2.31e-09	0.0337	-0.6	-0.5	Mitral valve prolapse;	chr1:53678624	chr15:72605183~72612326:+
ESCA	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-6.45	2.32e-09	0.0338	-0.62	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
ESCA	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-6.45	2.32e-09	0.0338	-0.62	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
ESCA	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-6.45	2.32e-09	0.0338	-0.62	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
ESCA	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	6.45	2.32e-09	0.0338	0.84	0.5	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
ESCA	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-6.45	2.34e-09	0.0341	-0.59	-0.5	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
ESCA	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-6.45	2.34e-09	0.0341	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
ESCA	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-6.45	2.34e-09	0.0341	-0.85	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
ESCA	trans	rs1816752	0.524	rs1965154	ENSG00000237917.1	PARP4P1	-6.45	2.36e-09	0.0343	-0.68	-0.5	Obesity-related traits;	chr13:24498062	chrY:26594851~26634652:-
ESCA	trans	rs13177918	0.734	rs6579790	ENSG00000239528.1	RPS14P8	6.44	2.4e-09	0.0349	0.59	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464379	chr5:116562562~116562930:+
ESCA	trans	rs13177918	0.734	rs6579791	ENSG00000239528.1	RPS14P8	6.44	2.4e-09	0.0349	0.59	0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150464440	chr5:116562562~116562930:+
ESCA	trans	rs2404476	0.792	rs4696601	ENSG00000239959.1	ENPP7P2	-6.44	2.44e-09	0.0353	-0.47	-0.5	Interleukin-6 levels;	chr4:154690919	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs13125372	ENSG00000239959.1	ENPP7P2	-6.44	2.44e-09	0.0353	-0.47	-0.5	Interleukin-6 levels;	chr4:154692022	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs924902	ENSG00000239959.1	ENPP7P2	-6.44	2.44e-09	0.0353	-0.47	-0.5	Interleukin-6 levels;	chr4:154692185	chr3:75446769~75491202:-
ESCA	trans	rs2404476	0.819	rs276174	ENSG00000239959.1	ENPP7P2	-6.44	2.44e-09	0.0353	-0.47	-0.5	Interleukin-6 levels;	chr4:154692421	chr3:75446769~75491202:-
ESCA	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	6.44	2.44e-09	0.0353	0.57	0.5	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	6.44	2.44e-09	0.0353	0.57	0.5	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	6.44	2.44e-09	0.0353	0.57	0.5	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
ESCA	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	6.44	2.44e-09	0.0353	0.57	0.5	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
ESCA	trans	rs11098499	0.866	rs72676074	ENSG00000276997.3	RP11-378J18.9	6.44	2.46e-09	0.0356	0.59	0.5	Corneal astigmatism;	chr4:119438686	chr1:222477252~222504622:-
ESCA	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-6.44	2.47e-09	0.0357	-0.66	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
ESCA	trans	rs1879734	1	rs7543166	ENSG00000260144.1	RP11-361M10.3	-6.44	2.47e-09	0.0357	-0.6	-0.5	Mitral valve prolapse;	chr1:53677750	chr15:72605183~72612326:+
ESCA	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	6.44	2.48e-09	0.0357	0.59	0.5	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
ESCA	trans	rs7106204	0.534	rs16912285	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24230982	chr1:174892417~174893155:+
ESCA	trans	rs16912285	0.786	rs76326641	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr11:24231526	chr1:174892417~174893155:+
ESCA	trans	rs7106204	0.534	rs74650605	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24231868	chr1:174892417~174893155:+
ESCA	trans	rs7106204	0.534	rs75297923	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24231984	chr1:174892417~174893155:+
ESCA	trans	rs7106204	0.534	rs76397001	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24232642	chr1:174892417~174893155:+
ESCA	trans	rs16912285	0.892	rs80332091	ENSG00000237249.1	RP1-102G20.2	-6.43	2.49e-09	0.0358	-0.61	-0.5	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr11:24233702	chr1:174892417~174893155:+
ESCA	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-6.43	2.51e-09	0.0361	-0.82	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
ESCA	trans	rs11098499	0.604	rs2389886	ENSG00000276997.3	RP11-378J18.9	6.43	2.55e-09	0.0366	0.58	0.5	Corneal astigmatism;	chr4:119649267	chr1:222477252~222504622:-
ESCA	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-6.42	2.66e-09	0.0379	-0.4	-0.5	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
ESCA	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-6.42	2.66e-09	0.038	-0.74	-0.5	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
ESCA	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-6.42	2.68e-09	0.0383	-0.52	-0.5	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
ESCA	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-6.42	2.7e-09	0.0385	-0.59	-0.5	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
ESCA	trans	rs2351088	0.764	rs17652822	ENSG00000248409.1	KB-1269D1.8	6.42	2.71e-09	0.0386	1.01	0.5	Tonsillectomy;	chr22:45765349	chr22:23392771~23393839:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000242206.2	RPS26P35	6.42	2.71e-09	0.0386	0.48	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:118761856~118762201:-
ESCA	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-6.41	2.75e-09	0.0391	-0.84	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
ESCA	trans	rs1552244	0.882	rs7636817	ENSG00000230342.2	FANCD2P2	6.41	2.77e-09	0.0394	0.77	0.5	Alzheimer's disease;	chr3:9973192	chr3:11859674~11891172:+
ESCA	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	6.41	2.84e-09	0.0403	0.59	0.5	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
ESCA	trans	rs4820294	0.669	rs35662099	ENSG00000247925.2	RP3-510L9.1	-6.4	2.92e-09	0.0413	-0.48	-0.5	Fat distribution (HIV);	chr22:37657902	chr6:11173452~11259099:+
ESCA	trans	rs66887589	0.72	rs11724758	ENSG00000276997.3	RP11-378J18.9	6.4	2.93e-09	0.0415	0.58	0.5	Diastolic blood pressure;	chr4:119318723	chr1:222477252~222504622:-
ESCA	trans	rs1552244	0.832	rs17050674	ENSG00000230342.2	FANCD2P2	6.4	2.93e-09	0.0415	0.83	0.5	Alzheimer's disease;	chr3:9985574	chr3:11859674~11891172:+
ESCA	trans	rs1552244	0.765	rs17050675	ENSG00000230342.2	FANCD2P2	6.4	2.93e-09	0.0415	0.83	0.5	Alzheimer's disease;	chr3:9986002	chr3:11859674~11891172:+
ESCA	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	6.4	2.96e-09	0.0417	0.62	0.5	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	6.4	2.96e-09	0.0417	0.62	0.5	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	6.4	2.96e-09	0.0417	0.62	0.5	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	6.4	2.96e-09	0.0417	0.62	0.5	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
ESCA	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	6.4	2.96e-09	0.0417	0.62	0.5	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
ESCA	trans	rs7106204	0.534	rs75335266	ENSG00000237249.1	RP1-102G20.2	-6.4	2.98e-09	0.042	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24234849	chr1:174892417~174893155:+
ESCA	trans	rs7106204	0.534	rs78539127	ENSG00000237249.1	RP1-102G20.2	-6.4	2.98e-09	0.042	-0.61	-0.5	Response to Homoharringtonine (cytotoxicity);	chr11:24235152	chr1:174892417~174893155:+
ESCA	trans	rs12957516	0.576	rs7236205	ENSG00000229994.1	RPL5P4	-6.4	3e-09	0.0422	-0.42	-0.5	Educational attainment (college completion);	chr18:37696727	chr1:35350722~35351607:+
ESCA	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-6.4	3.01e-09	0.0424	-0.57	-0.5	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
ESCA	trans	rs9356181	1	rs206729	ENSG00000251962.1	AL591668.1	6.4	3.01e-09	0.0424	0.51	0.5	Mean corpuscular volume;	chr6:164080703	chrX:134403298~134403382:-
ESCA	trans	rs13205180	0.55	rs9382070	ENSG00000230020.1	NHS-AS1	-6.4	3.02e-09	0.0424	-0.63	-0.5	Diastolic blood pressure;	chr6:52123098	chrX:17552349~17557387:-
ESCA	trans	rs4820294	0.669	rs1894532	ENSG00000247925.2	RP3-510L9.1	-6.4	3.02e-09	0.0424	-0.48	-0.5	Fat distribution (HIV);	chr22:37663743	chr6:11173452~11259099:+
ESCA	trans	rs1552244	0.882	rs6443276	ENSG00000230342.2	FANCD2P2	6.39	3.05e-09	0.0428	0.77	0.5	Alzheimer's disease;	chr3:9967221	chr3:11859674~11891172:+
ESCA	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-6.39	3.08e-09	0.043	-0.77	-0.5	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
ESCA	trans	rs11098499	0.866	rs7665125	ENSG00000276997.3	RP11-378J18.9	6.39	3.1e-09	0.0434	0.57	0.5	Corneal astigmatism;	chr4:119480924	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000242206.2	RPS26P35	6.39	3.13e-09	0.0437	0.48	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:118761856~118762201:-
ESCA	trans	rs916888	0.61	rs199452	ENSG00000264057.1	RP11-583F2.1	6.39	3.15e-09	0.0439	0.54	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:64927634~64934203:+
ESCA	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
ESCA	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	6.39	3.15e-09	0.0439	0.58	0.5	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
ESCA	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	6.39	3.15e-09	0.0439	0.51	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
ESCA	trans	rs4820294	0.669	rs12628135	ENSG00000247925.2	RP3-510L9.1	-6.38	3.18e-09	0.0443	-0.48	-0.5	Fat distribution (HIV);	chr22:37669648	chr6:11173452~11259099:+
ESCA	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	6.38	3.2e-09	0.0445	0.57	0.5	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
ESCA	trans	rs916888	0.647	rs199449	ENSG00000264057.1	RP11-583F2.1	6.38	3.21e-09	0.0447	0.54	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:64927634~64934203:+
ESCA	trans	rs1552244	0.882	rs13063929	ENSG00000230342.2	FANCD2P2	6.38	3.22e-09	0.0447	0.76	0.5	Alzheimer's disease;	chr3:9968624	chr3:11859674~11891172:+
ESCA	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	6.38	3.22e-09	0.0447	0.51	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
ESCA	trans	rs11098499	0.675	rs11098534	ENSG00000276997.3	RP11-378J18.9	6.38	3.23e-09	0.0449	0.59	0.5	Corneal astigmatism;	chr4:119635617	chr1:222477252~222504622:-
ESCA	trans	rs7312770	0.637	rs705700	ENSG00000234192.1	RP11-57C13.5	6.38	3.23e-09	0.0449	0.51	0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr10:87642607~87642954:+
ESCA	trans	rs10779169	0.511	rs10863023	ENSG00000279645.1	RP11-759A24.1	-6.38	3.25e-09	0.0451	-0.5	-0.5	Nose size;	chr12:85623135	chr15:96285068~96289265:-
ESCA	trans	rs11098499	0.863	rs58452170	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119538519	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs7678400	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119540802	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs1480936	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119541706	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs11098531	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119543846	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs28718422	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119545149	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs12498539	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119547215	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.818	rs12498599	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119547348	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs10009626	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119548850	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3822194	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119550493	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3822195	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119550505	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs3775854	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119550816	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs2306456	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119551267	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs11947234	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119553704	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs6853998	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119554705	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs6858777	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119554811	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs11933966	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119555560	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs36040693	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119556461	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs11731756	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119557541	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs34308924	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119560276	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.863	rs2170276	ENSG00000276997.3	RP11-378J18.9	6.38	3.27e-09	0.0452	0.59	0.5	Corneal astigmatism;	chr4:119564669	chr1:222477252~222504622:-
ESCA	trans	rs11098499	0.739	rs6534130	ENSG00000279072.1	RP13-580B18.4	-6.38	3.32e-09	0.0458	-0.58	-0.5	Corneal astigmatism;	chr4:119210184	chr7:56809214~56848800:-
ESCA	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-6.38	3.32e-09	0.0459	-0.56	-0.5	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
ESCA	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-6.37	3.34e-09	0.0461	-0.84	-0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
ESCA	trans	rs11098499	0.863	rs7669520	ENSG00000276997.3	RP11-378J18.9	6.37	3.43e-09	0.0473	0.59	0.5	Corneal astigmatism;	chr4:119594123	chr1:222477252~222504622:-
ESCA	trans	rs2404476	0.819	rs276168	ENSG00000239959.1	ENPP7P2	6.37	3.47e-09	0.0477	0.45	0.5	Interleukin-6 levels;	chr4:154696508	chr3:75446769~75491202:-
ESCA	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-6.37	3.48e-09	0.0479	-0.52	-0.5	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
ESCA	trans	rs11786458	0.529	rs12548376	ENSG00000261649.4	GOLGA6L7P	6.36	3.57e-09	0.049	0.53	0.5	Inattentive symptoms;	chr8:40449689	chr15:28842235~28848675:-
ESCA	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	6.36	3.61e-09	0.0493	0.62	0.5	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
ESCA	trans	rs11098499	0.697	rs28655325	ENSG00000276997.3	RP11-378J18.9	6.36	3.63e-09	0.0495	0.59	0.5	Corneal astigmatism;	chr4:119451844	chr1:222477252~222504622:-